### MINUTES OF 317th MEETING OF REGISTRATION BOARD HELD ON $16^{th}$ & $17^{th}$ MAY, 2022 \*=\*=\*=\*

Item No.	Detail of Item	Pages
I.	Confirmation of Minutes of Registration Board	03
II.	Division of Pharmaceutical Evaluation & Registration	04
	Registration-I Section	04
	Registration-II Section	115
	Post Registration-I Section	144
	Post Registration-II Section	156
	Import & Vet-II Section	157
	Registration-I Section	167
	RRR Section	229
	Pharmaceutical Evaluation Cell (PEC)	273
III.	Division of Biological Evaluation & Research	820
IV.	Division of Quality Assurance & Laboratory Testing	872
V.	Any Other Item with the permission of Chair	883-894

Drug Regulatory Authority of Pakistan T.F. Complex, Mauve Area, G-9/4 Islamabad.

317<sup>th</sup> meeting of Registration Board was held on 16<sup>th</sup>- 17<sup>th</sup> May, 2022 in the Committee Room of Drug Regulatory Authority of Pakistan, G-9/4, Islamabad. The meeting was scheduled up to 18<sup>th</sup> May, 2022 but was concluded on 17<sup>th</sup> May, 2022. The meeting was chaired by Dr. Obaidullah, Director, Pharmaceutical Evaluation & Registration Division, DRAP. The meeting started with recitation of the Holy Verses.

The meeting was attended by the following: -

1.	Dr. Rafeeq Alam Khan, Meritorious Professor,	Member
	Faculty of Pharmacy, Ziauddin University, Karachi.	
2.	Dr. Qurban Ali, Former Director General,	Member
	National Veterinary Laboratories, Islamabad	
3.	Dr. Ali Ahmed Agha, Director,	Member
	Drugs Testing Laboratory, Quetta. Government of Balochistan	
4.	Syed Adnan Rizvi, Director,	Member
	Drugs Testing Laboratory, Karachi Government of Sindh	
5.	Dr. Imranullah Khan, Director,	Member
	Drugs Testing Laboratory, Peshawar Government of KPK	
6.	Mr. Muhammad Aslam, Deputy Draftsman-II,	Member
	Representative of Ministry of Law & Justice, Islamabad	
7.	Mr. Ghulam Mujtaba, Deputy Director,	Member
	Representative of IPO, Islamabad.	
8.	Ch. Zeeshan Nazir, Additional Director,	Member
	Representative of Biological Evaluation & Research Division, DRAP	
9.	Mst. Mahvash Ansari, Deputy Director,	Member
	Representative of QA< Division, DRAP	
10.	Mr. Abdullah,	Member/
	Additional Director (PE&R), DRAP.	Secretary

Mr. Muneeb Ahmed Cheema DD, Mr. Asif Jalil, Incharge PEC, Hafiz M. Ali Tayyab AD, Noor-ul-Ain Arshia AD, Sana Kanwal AD, M. Sarfraz Nawaz AD and respective Assistant Directors of PE&R attended the meeting to present the agenda of PE&R Division. M. Zubair Masood AD, M. Kashif AD & Mr. Saadat Ali Khan AD attended the meeting to present agenda of DBER. Deputy Director, QA&LT was assisted by respective Assistant Directors to present the agenda of QA&LT Division.

Mr. Jalal Ud Din Zaffar & Mr. Hamid Raza (PPMA); Mr. Nadeem Alamgir (Pharma Bureau) and Mr. Zia-ul-Haq & Mr. Saif-ur-Rehman (PC&DA) attended the meeting as observers.

Item No. I: Confirmation of Minutes of 316th meetings of Registration Board.

316th meeting of Registration Board was held on 15th March to 18th March, 2022. The draft minutes of

Registration Board were circulated among the members of Board on 25th April, 2022 with the request for

perusal/approval/comments (if any) till 28th April, 2022 at 10:00am. All members agreed the draft minutes.

While compiling the minutes of meeting, the additional agenda of Registration-I and Post Registration-

I Section of PE&R Division was missed which was incorporated in the final minutes.

Accordingly, fair minutes were processed to Chairman, Registration Board for perusal/approval. After

approval from Chairman Registration Board, fair minutes of 316th meeting of Registration Board were

circulated among concerned divisions/sections for implementation.

Decision: Registration Board confirmed the minutes of 316th meeting.

### **Registration-I Section**

### Case No.1. Personal Hearing Notices Issued to Registration Holders of Diclofenac Potassium 75mg & 100mg Tablet/ Capsule.

- 1. Registration Board, in its various meetings considered the case regarding "Registration Status of Formulations (Diclofenac Potassium 75mg & 100mg and Famotidine 10mg/5ml) not approved by Reference Regulatory Authorities & Previous Decisions Taken by the Registration Board in its 250<sup>th</sup> & 258<sup>th</sup> Meeting".
- **2.** With respect to "Diclofenac Potassium", complete record including proceedings & decisions of Registration Board and relevant decisions of DRAP's Authority have been reproduced as under:

Sr.	Formulation	Ref. Meeting	Decision/Remarks
No.		No. of RB	
1.	Diclofenac Potassium 75mg & 100mg	M-258 (held on 25 <sup>th</sup> - 26 <sup>th</sup> April, 2016)	Decision: Diclofenac Potassium is not registered in any reference country in dose more than 50mg, thus Registration Board decided to issue show cause notices to manufacturers of Diclofenac Potassium (75 and 100mg) for de-registration of these products.

### 3. Current Status of WP No 1695/2017

M/s. Quaper Pharmaceuticals (Pvt) Limited, Sargodha has filed a Writ Petition in Islamabad High Court Islamabad v/s Federation of Pakistan, Drugs Registration Board etc against issuance of show cause notice in the case of Diclofenec Potassium 75mg Tablets. The case was heard on 30-05-2017and adjourned. The Islamabad High Court, Islamabad dismissed the application of M/s. Quper Pharma, Sargodha vide its orders dated 29-01-2020 being without merit.

### 4. Decision of M-288 held on 14th-15th Feb, 2019:

Registration Board decided that all registration holders of "Diclofenac Potassium 75mg & 100mg" shall be called for personal hearing.

### 5. Decision taken by DRAP's Authority in its 70<sup>th</sup> meeting held on 05<sup>th</sup> Sep, 2019:

For formulations containing "drugs" which were previously registered by the Registration Board and have proof of availability and prescription of last 10 years but are not available in the Reference Regulatory Authorities shall continue to be considered/registered as drugs until and unless withdrawn on Safety, Efficacy and Quality reasons.

### 6. <u>Decision of M-296 held on 08<sup>th</sup>-10<sup>th</sup> Sep, 2020:</u>

Registration Board deliberated the case in the light of above stated facts / opinions and decided as under:

- i. Since, all such formulations which are not approved by the Reference Regulatory Authorities; the safety and efficacy profile cannot be established in the absence of a well-established system for reporting of adverse events, so a reference shall be forwarded to DRAP's Authority with the request to review the decision taken in its 70<sup>th</sup> meeting held on 05-09-2019. In this regard, PE&R Division shall prepare a comprehensive document/agenda for consideration of Authority, keeping in view the practices adopted by RRA for all such formulations;
- ii. For all those formulations which are registered/applied in strengths, different from those approved by reference regulatory authorities, the registration holders/applicants shall standardize their formulations (by submitting registration application with requisite fee, provided that the firm did not have same registration) in line with those approved by reference regulatory authorities. In this regard, recommendation shall be forwarded to DRAP's Authority to exempt all such cases/applications for standardization of formulation to be submitted on Form-5F/CTD format as notified vide SRO 713(I)/2018 dated 09-06-2018.

- iii. Drug products withdrawn from RRA due to any commercial reason shall be considered for registration by Registration Board.
- iv. Vitamin-mineral formulations will be considered as per vitamin policy approved by Policy Board and further adopted by Registration Board in its 295<sup>th</sup> meeting.

Keeping in view the point (i) and in order to proceed further for effective implementation/execution of point (ii) to (iv) of the above-mentioned decision, the Authority was requested to review the decision taken vide its 70<sup>th</sup> meeting held on 05-09-2019.

### 7. Decision of DRAP Authority in its 125th meeting held on 03rd Nov. 2021:

The Authority deferred the agenda item for detailed deliberations keeping in view the therapeutic categories etc. of such formulations.

### 8. Proceedings of M-313:

- i. The concept of reliance on the decisions of reference regulatory authorities adopted by the Registration Board in its 275<sup>th</sup> meeting was reiterated as deliberated during proceedings of 296<sup>th</sup> meeting with respect to instant case.
- ii. Furthermore, Registration Board was apprised that a policy of reliance on reference regulatory authorities has also been approved by the Authority in its 73<sup>rd</sup> meeting held on 06-11-2019.
- iii. Registration Board was also informed regarding court case (CP No.1545/2017) filed by M/s Cibex (Pvt.) Ltd., Karachi vs DRAP & others i.e, sub-judiced before the hon'ble Sindh High Court and written statement/updated registration status of such formulations on behalf of DRAP is required to be furnished.
- iv. It was further deliberated that relevant registration holders/ manufacturers shall be provided with an opportunity to submit their response regarding (a) evidence for approval status of such formulation in reference regulatory authorities (b) product development data and relevant studies with respect to quality, safety and efficacy of these formulations.

### 9. Decision of M-313 held on 16th-18th Nov. 2021:

Keeping in view the detailed deliberations during proceedings of its 296<sup>th</sup> and 313<sup>th</sup> meeting, Registration Board decided as under:

- i. To issue show cause notices to all registration holders/ manufacturers (including those listed in above tables) of below mentioned formulations under Section 7 (11)(d) of the Drug Act, 1976 that why the registration of their products may not be cancelled in the public interest. In this regard, the Board advised relevant registration sections to review the above-mentioned lists for correctness and issue notices accordingly. Moreover, any registration holder not included in above lists shall also be issued show cause notice after approval of Chairman Registration Board.
- ii. Furthermore, management of these firms shall also be given the opportunity of personal hearing in the forthcoming meeting of the Board under section 42 of the Drugs Act, 1976.

S. No.	Formulations
1.	Diclofenac Potassium Tablets/ Capsules in strengths greater than 50mg
2.	Famotidine Suspension in strength/dosage form other than 40mg/5ml Powder
	for Oral Suspension.

iii. The Board also advised to share the updated status with hon'ble Sindh High Court if required.

### 10. Decision of 128th meeting of Authority held on 14th Dec, 2021:

- I. The Authority endorsed the recommendations of Registration Board and made following decisions:-
  - A. Partially reviewed its earlier decision taken in its 70<sup>th</sup> meeting held on 05-09-2019, consolidated amended decision is reproduced as under:

- 1. For molecules falling in the grey areas or overlapping between PE&R and H&OTC division:
  - a. Formulations/molecules already registered as "drugs" by Registration Board shall continue to be considered/registered as drugs irrespective of their status in Reference Regulatory Authorities until and unless withdrawn on Safety, Efficacy and Quality reasons.
  - b. If any such formulation was also enlisted by H&OTC Division, it will be un-enlisted. The applicants shall be advised to approach PE&R Division for processing of application for registration. For such un-enlisted applications, a separate queue shall be prepared by the PE&R Division in order to avoid discomfort to the applicants and assurance of availability of such formulations for patients.
  - c. This decision shall not apply to those formulations / molecules covered under Vitamin-Policy as approved by the Policy Board.
- 2. New formulations/molecules other than those which were already registered by Registration Board will be considered on the basis of their status in Reference Regulatory Authorities. If in the RRA, these are considered as drugs, these will be dealt by the PE&R Division while otherwise will be dealt by Health & OTC Division.
- 3. Endorsed the Reference Regulatory Authorities as adopted by the Registration Board from time to time and the criteria being opted to adopt RRAs. Registration Board was advised to issue a notification of adopted RRAs and comprehensive selection criteria for information and easy understanding of all relevant stakeholders.
- 4. Drug formulations/strengths which were previously registered by the Registration Board but are not available in any Reference Regulatory Authorities, shall be reviewed and disposed off keeping in view of safety and efficacy evidence / data in the Reference Regulatory Authorities.
- B. Registration Board may decide and dispose off such formulations as and when identified/reported.
- II. The Authority further advised Registration Board to review existing RRAs for veterinary drugs and submit its recommendations to the Authority for its consideration.
- 11. In line with the decision taken by the Board in its 313<sup>th</sup> meeting, show-cause/personal hearing notices were issued to 162 registration holders for hearing before the Registration Board on 1<sup>st</sup> February, 2022 at 10 a.m. (for Diclofenac Potassium) & 2.30 p.m (for Famotidine). However, due to prevailing cases of COVID-19, personal hearings have been postponed (vide letter issued dated 27-01-2022).

## 12. <u>Current Status of CP No.1545/2017 filed by M/s Cibex in SHC [Catafen 100 Tablet (Diclofenac Potassium 100mg) Reg. No.039198:</u>

M/s Cibex (Pvt.) Ltd., Karachi has also filed a court case against DRAP and others for issuance of letter [regarding change in registration status of Catafen Tablet 100mg (Diclofenac Potassium; R#039198) from M/s Macter to M/s Cibex]. The last date of hearing was Friday, 28th January, 2022 wherein "Syed Hakim Masood, Federal Inspector Drugs, DRAP, Karachi present and undertakes that the Petitioner's grievance including the other items will be considered in the forthcoming meeting which will probably be held on or about 01.02.2022. In the wake of above, the matter is adjourned to 04.03.2022."

## 13. Writ Petition No. 365/2022 filed by M/s Siza International Private Limited, Lahore [Rheumatin-K Tablet (Diclofenac Potassium: 75me) Reg. No. 024049]:

Operative part of court order dated 07-01-2022 is reproduced as under:

"Subject to notice in the meanwhile proceedings under the impugned show cause notice dated 29<sup>th</sup> of December, 2021 shall continue but the final decision shall not be made till the next date of hearing"

## 14. Writ Petition No. 4168/2022 filed by M/s Shrooq Pharmaceuticals (Pvt) Ltd., Lahore [Pointer 75 Capsule (Diclofenac Potassium (Pellets): 75mg) Reg. No. 064791 & Moven-75mg Tablet (Diclofenac Potassium: 75mg) Reg. No. 040304]:

Operative part of court order dated 24-01-2022 is reproduced as under:

"At the outset learned proxy counsel submits that since identical matter (W.P. No. 365/2022) is pending adjudication before my learned brother Shahid Waheed. J. this petition be also referred to the said learned Bench.

In view of above, office is directed to place this petition before the said learned Bench after soliciting orders from the Hon'ble Chief Justice."

# 15. Writ Petition No. 4345/2022 filed by M/s Davis Pharmaceuticals Laboratories, Lahore [Mobil-K-75mg Tablet (Diclofenac Potassium: 75me) Reg. No. 041945 & Mobil-K 100mg Tablet (Diclofenac Potassium: 100mg) Reg. No. 063176]:

Operative part of court order dated 25-01-2022 is reproduced as under:

"Subject to notice in the meanwhile proceedings under the impugned show cause notice dated 29<sup>th</sup> of December, 2021 shall continue but the final decision shall not be made till the next date of hearing"

## 16. Writ Petition No. 23797/2022 filed by M/s Sapient Pharma, Lahore [Zainex 75mg Tablets (Diclofenac Potassium: 75mg) Reg. No. 069281]:

Operative part of court order dated 19-04-2022 is reproduced as under:

"Since interim relief has already been granted in connected petition, subject to notice and in the meanwhile proceedings under the impugned show cause notice dated 06.04.2022 shall continue but the final decision shall not be made till the next date of hearing"

## 17. Writ Petition No. 25530/2022 filed by M/s Pakheim International Pharma (Pvt) Ltd., Lahore [Fen-K SR Tablet 100mg (Diclofenac Potassium: 100mg) Reg. No. 023973]:

## 18. Writ Petition No. 23797/2022 filed by M/s Paramount Pharmaceuticals, Islamabad [Ronset SR Tablet 100mg (Diclofenac Potassium: 100mg) Reg. No. 052727]:

Operative part of court order dated 21-04-2022 is reproduced as under:

"Subject to notice, in the meanwhile proceedings under the impugned show cause notice shall continue but the final decision shall not be made till the next date of hearing"

All the firms have challenged the Show Cause Notices issued for cancellation of their drugs stating violation of the decision taken in 70<sup>th</sup> Meeting of the DRAP Authority held on the 05-09-2019.

However, the decision taken in 70<sup>th</sup> Meeting of the DRAP Authority, has been reviewed in the 128<sup>th</sup> Meeting held on 14-12-2021, whereby Registration Board was allowed to review and dispose of registration of drugs keeping in view their safety and efficacy.

### 19. Writ Petition No. 9832 of 2022 filed by Quaper Pvt. Ltd. Vs. FoP and others.

In instant case, the Petitioner has challenged the decision taken by the Registration Board of the Drug Regulatory Authority of Pakistan in its 313<sup>th</sup> Meeting held on the 16<sup>th</sup>, 17<sup>th</sup> and 18<sup>th</sup> November, 2021, whereby the Petitioner has not been allowed to resume manufacturing of a drug by the name of 'Kaymax Tablets' (as its registration had been suspended after its declaration as sub-standard by the Drugs Testing Laboratory) till the determination of its safety and efficacy in accordance with the applicable law. Next date of hearing is 25-04-2022.

### 20. <u>Decision of M-315 held on 01<sup>st</sup> Feb, 2022:</u>

Registration Board noted the information and advised to provide the opportunity of personal hearing in the next meeting of Registration Board.

- **21.** While planning for 317<sup>th</sup> meeting of Registration Board, Division of PE&R has once again gone through a process of reviewing Diclofenac Potassium 75mg & 100mg Tablets based on all available facts and findings which have been summarized as under:
  - i. Diclofenac potassium is approved by various reference regulatory authorities in 12.5mg, 25mg and 50mg tablet strengths. As per the review of databases of all reference regulatory authorities (RRAs) approved by the Registration Board in its 275<sup>th</sup> meeting, it was observed that the maximum strength of diclofenac potassium in any dosage form is 50mg.
  - ii. However, in Pakistan diclofenac potassium 75 and 100mg are also available. Since DRAP is in process of reviewing the rationale, safety and efficacy of various approved formulations, therefore the formulation of diclofenac potassium 75 and 100mg tablets were also reviewed.
  - iii. Product monographs and SmPC of innovator's and generic versions of Diclofenac Potassium tablets approved by various RRAs have been reviewed, which depicts that the daily dose of diclofenac potassium is from 75-200mg in divided doses, whereas the maximum strength of available diclofenac potassium tablet is 50mg. Detailed recommendations regarding dosage as extracted from official websites of various RRAs have been reproduced as under:

S/N	RRA/	Recommended Dosage
3/14	Product Detail	Recommended Dosage
1.	USFDA/ Cataflam 50mg	Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals.
	Tablet	<ul> <li>For treatment of pain or primary dysmenorrhea the recommended dosage is 50 mg three times a day. With experience, physicians may find that in some patients an initial dose of 100 mg of CATAFLAM, followed by 50 mg doses, will provide better relief.</li> <li>For the relief of osteoarthritis, the recommended dosage is 100-150 mg/day in divided doses, 50 mg twice a day or three times a day.</li> <li>For the relief of rheumatoid arthritis, the recommended dosage is 150-200 mg/day in divided doses, 50 mg three times a day or four times a day.</li> </ul>
		• Furthermore, USFDA under the heading of 'warning' states as under:
		"Long-term administration of NSAIDs has resulted in renal papillary necrosis and other renal injury. Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. In these patients, administration of an NSAID may cause a dose-dependent reduction in prostaglandin formation and, secondarily, in renal
		blood flow, which may precipitate overt renal decompensation.  Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE-inhibitors or ARBs, and the elderly. Discontinuation of NSAID therapy is usually followed by recovery to the pretreatment state.
		No information is available from controlled clinical studies regarding the use of CATAFLAM in patients with advanced renal disease. The renal effects of CATAFLAM may hasten the progression of renal dysfunction in patients with pre-existing renal disease (USFDA)."
2.	MHRA/ Diclofenac Potassium 50mg	Undesirable effects may be minimized by using the lowest effective dose for the shortest duration necessary to control symptoms.

		The recommended daily dose is 100-150mg in two or three divided		
		<ul> <li>The recommended daily dose is 100-150mg in two or three divided doses. For milder cases, 75-100mg daily in two or three divided doses is usually sufficient.</li> </ul>		
		• In migraine an initial dose of 50mg should be taken at the first signs of an impending attack. In cases where relief 2 hours after the first dose is not sufficient, a further dose of 50mg may be taken. If needed, further doses of 50mg may be taken at intervals of 4-6 hours, not exceeding a total dose of 200mg per day.		
3.	TGA/ Voltaren Rapid 50mg Tablet	After assessing the risk/benefit ratio in each individual patient, the lowest effective dose for the shortest possible duration should be used. Adverse effects may be minimized by using the lowest effective dose for the shortest duration necessary to control symptoms.		
		Acute pain states with an inflammatory component:		
		As a rule, the initial daily dosage for adults is 100 to 150 mg. In milder cases, as well as for children over 14 years of age, 75 to 100 mg daily is usually sufficient. The total daily dosage should generally be prescribed in 2 or 3 fractional doses. Treatment is to continue for a maximum of 7 days. If the pain has not resolved satisfactorily after 7 days' treatment, the patient should be instructed to return for review by the doctor.		
		<u>Acute migraine</u>		
		In migraine, an initial dose of 50 mg should be taken at the first signs of an impending attack. If the pain is not relieved within 2 hours of this initial dose, a further dose of 50 mg may be taken. If needed, further doses of 50 mg may be taken at intervals of 4-6 hours. The total dose to treat an acute migraine should not exceed 200 mg. The total daily dose should not exceed 200 mg.		
		Diclofenac potassium should not be used for migraine prophylaxis.		
		Symptomatic treatment of primary dysmenorrhoea		
		In primary dysmenorrhoea, initially a dose of 50 or 100 mg should be given followed by 50 mg three times daily for 3 days. Treatment should be started upon appearance of the first symptoms and, depending on their duration and severity, continued for up to three days. If the pain has not resolved satisfactorily after 3 days' treatment, the patient should be instructed to return for review by the doctor.		
4.	Health Canada/ Pms-Diclofenac K	As a general recommendation, the dose should be individually adjusted. Adverse effects may be minimized by using the lowest effective dose for the shortest duration necessary to control symptoms.		
		<ul> <li>The recommended daily dose for pms-DICLOFENAC K is one 50 mg tablet, every 6-8 hours as required for a total daily maximum amount of 100 mg.</li> <li>For primary dysmenorrhea, treatment may be initiated on the first day with a loading dose of 100 mg, followed by 50 mg every six to eight hours after the initial dose if needed, for a maximum dose of 200 mg only on the first day.</li> <li>Patients should be maintained on the lowest effective dose.</li> </ul>		
5.	Swedish Medical Products	Voltaren T treatment should be initiated at the lowest presumed effective dose, in order to be able to adjusted for therapy responses and possible side effects.		
	Agency/ Voltaren T 50 mg Tablet	Side effects can be minimized by using the lowest effective dose for the shortest possible duration of treatment that is necessary to control symptoms. In long-term treatment, a low dose is sought.		
		For Adults:		
		• 50 mg up to 3 times per day. The maximum recommended daily dose is 150 mg.		

		•	In migraines, 50 mg is initially given at the first sign of a seizure. If relief is not achieved within the 2 hours, given an additional 50 mg. This can be repeated at intervals of 4-6 hours, with a maximum 150 mg per day.
6.	BNF/ Voltarol Rapid 50mg Tablet	•	Pain and inflammation in rheumatic disease and other musculoskeletal disorders Adult: 75–150 mg daily in 2–3 divided doses
		•	Acute gout Adult: 75–150 mg daily in 2–3 divided doses  Postoperative pain
		•	Adult: 75–150 mg daily in 2–3 divided doses  Migraine Adult: 50 mg, to be given at onset of migraine, then 50 mg after 2 hours if required, then 50 mg after 4–6 hours; maximum 200 mg per day.

- iv. Keeping in view the above-mentioned information, it can be concluded that maximum daily dose range of Diclofenac Potassium is categorically described in available literature. However, 2-3 divided/fractional doses are recommended for administration which raise question regarding calculation of maximum single dose. In other words, clarity is required whether Diclofenac Potassium in strengths higher than 50mg can be administered as a single dose.
- v. It is also pertinent to mention that "use of lowest effective dose for the shortest duration" has been emphasized. Furthermore, even for indications where 100mg is recommended, the same is mentioned as either initial dose or loading dose, requirement of which may be fulfilled by taking two tablets of 50mg.
- **22.** Based upon the above review, following two questions were framed and were communicated for guidance to various RRA's including USFDA, Health Canada, MHRA UK, Sweden, TGA Australia and BNF.
  - a. Whether diclofenac potassium 75mg or 100mg tablet can be administered twice a day to achieve a maximum daily dose of 150 200mg
  - b. Any relevant clinical data which shows that administration of a single dose of 75 or 100mg diclofenac potassium is safe.
- **23.** Response received from various RRAs is presented as under:

RRA	Correspondent Name/ Designation/	Contact Detail	Date of response
	e-mail		
USFDA	Tisha Washington	U.S. Food and Drug	24-02-2022
	<ul> <li>International Program Strategic Initiatives OCD</li> <li>Center for Drug Evaluation and Research</li> <li>CDERINTLEXEC@fda.hhs.gov</li> </ul>	Administration Tel: 301-796-1019 Tisha.Washington@fda.hhs.gov	

- According to the Orange Book, diclofenac potassium is available in 25mg and 50mg tablets only, whereas diclofenac sodium is also available in 75mg and 100mg delayed release and extended release tablets.
- To provide you with insight on the dosing and dose limitation, the dosing information for Diclofenac sodium enteric-coated tablets of 25 mg, 50 mg, and 75 mg can be found below: https://www.accessdata.fda.gov/drugsatfda\_docs/label/2006/019201s035lbl.pdf
- And for Diclofenac potassium immediate-release tablets of 50 mg below https://www.accessdata.fda.gov/drugsatfda\_docs/label/2011/020142s021s022lbl.pdf
- The relevant page of the label of Diclofenac potassium immediate-release tablets of 50 mg is placed below:

#### DOSAGE AND ADMINISTRATION

Carefully consider the potential benefits and risks of Cataflam® (diclofenac potassium immediate-release tablets) and other treatment options before deciding to use Cataflam. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS).

After observing the response to initial therapy with Cataflam, the dose and frequency should be adjusted to suit an individual patient's needs.

For treatment of pain or primary dysmenorrhea the recommended dosage is 50 mg t.i.d. With experience, physicians may find that in some patients an initial dose of 100 mg of Cataflam, followed by 50-mg doses, will provide better relief.

For the relief of osteoarthritis the recommended dosage is 100-150 mg/day in divided doses, 50 mg b.i.d. or t.i.d.

For the relief of rheumatoid arthritis the recommended dosage is 150-200 mg/day in divided doses, 50 mg t.i.d. or q.i.d.

Different formulations of diclofenac [Voltaren\* (diclofenac sodium enteric-coated tablets); Voltaren\*-XR (diclofenac sodium extended-release tablets); Cataflam\* (diclofenac potassium immediate-release tablets)] are not necessarily bioequivalent even if the milligram strength is the same.

#### **HOW SUPPLIED**

Cataflam<sup>®</sup> (diclofenac potassium immediate-release tablets)

50 mg – light brown, round, biconvex, sugar-coated tablets (imprinted Cataflam on one side and 50 on the other side in black ink)

Bottles of 100......NDC 0078-0436-05

Do not store above 30°C (86°F). Dispense in tight container (USP).

RRA	Correspondent Name/ Designation/ e-mail	Contact Detail	Date of response
Swedish Medical Products Agency	Ingrid Landberg     Head of department Efficacy and Safety 1     ingrid.landberg@lakemedelsv erket.se	P.O.Box 26, SE-751 03 Uppsala, Sweden  Visiting address: Dag Hammarskjölds väg 42 Phone: +46 (0)18-17 46 00, Direct: +46 (0)18 174272 ingrid.landberg@lakemed elsverket.se www.lakemedelsverket.s  e	28-02-2022

- In Sweden the maximum diclofenac potassium dosage is in general 150 mg per 24 hours, and the recommended dosage is depending on the indication.
- This dosage can in general be divided into several doses.
- Unfortunately, we cannot provide any further data or support to address the two questions asked in your email, since these questions must be answered by the respective MAH for the respective medical product.
- Several issues needs to be considered for each case, for example diclofenac formulation, indication and patient population.

RRA	Correspondent Name/ Designation/ e-mail	Contact Detail	Date of response
Health Canada	bcansenquiries@hc-sc.gc.ca	Bureau of Cardiology, Allergy and Neurological Sciences BCANS Enquiries / Government of Canada bcans.enquiries@hc- sc.gc.ca	10-03-2022

Bureau de cardiologie,	
allergologie et sciences	
neurologiques	
Enquêtes BCASN /	
Gouvernement du Canada	
bcans.enquiries@hc-	
sc.gc.ca	

- The Therapeutic Products Directorate (TPD) is the Canadian federal authority that regulates pharmaceutical drugs for human use. Prior to being given market authorization, a manufacturer must present substantive scientific evidence of a product's safety, efficacy and quality as required by the Food and Drugs Act and Regulations.
- Health Canada has not authorized a 75 mg or 100 mg tablet of diclofenac potassium. Only the 50 mg diclofenac potassium tablet is available.
- Generally speaking the recommended daily dose is one 50 mg tablet, every 6-8 hours as required for a total daily maximum amount of 100 mg.
- For primary dysmenorrhea, treatment may be initiated on the first day with a loading dose of 100 mg, followed by 50 mg every six to eight hours after the initial dose if needed, for a maximum dose of 200 mg only on the first day.
- Patients should be maintained on the lowest effective dose.
- More detailed information is available for <u>diclofenac potassium</u> products through the Health Canada's Drug Product Database.
- A 50mg powder/sachet formulation of diclofenac potassium is also available, <u>CAMBIA®</u> (diclofenac <u>potassium</u>). CAMBIA® (diclofenac potassium) is indicated for the acute treatment of migraine attacks with or without aura in adults 18 years and older. The maximum recommended daily dose is one sachet (50 mg).
- Health Canada is committed to transparency, and maintains many publicly available sources of information which you may find useful:
  - **The Drug Product Database:** <a href="https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/drug-product-database.html">https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/drug-product-database.html</a>
  - The Drug Product Register: <a href="https://hpr-rps.hres.ca/">https://hpr-rps.hres.ca/</a> for Summary Basis of Decision reports
  - The Public Release of Clinical Information portal: <a href="https://clinical-information.canada.ca/search/circ">https://clinical-information.canada.ca/search/circ</a>
- As Health Canada has not authorized a 75 mg or 100 mg tablet of diclofenac potassium, we therefore suggest that to receive the information you are requesting, you contact manufacturers of these products directly, especially those with marketing authorizations in your country.

RRA	Correspondent Name/ Designation/ e-mail	Contact Detail	Date of response
UK MHRA  (Medicines and Healthcare products Regulatory Agency)	Annabelle     MHRA Customer     Experience Centre     Communications and engagement team     Medicines and Healthcare products Regulatory Agency     RIS.NA@mhra.gov.uk	10 South Colonnade, Canary Wharf, London E14 4PU Telephone 020 3080 6000 gov.uk/mhra	22-03-2022

- In the UK, the recommended maximum daily dose of diclofenac is 150 mg.
- The maximum approved strength of diclofenac potassium in the UK is 50 mg as an immediate release tablet formulation.
- We have no data to support the efficacy or safety of 75 mg or 100 mg strength diclofenac potassium tablets.
- We have approved some products containing 75 mg or 100 mg of diclofenac but as oral modified release formulations. These contain alternative diclofenac salts e.g. diclofenac sodium.

RRA	Correspondent Name/	Contact Detail	Date of response
	Designation/ e-mail		
TGA Australia	• Liam	Phone: 1800 020	07-04-2022
(Therapeutic Goods Administration)	TGA Contact Centre     Regulatory Assistance	653 Fax: 02 6203 1605 Email: <u>info@tga.gov.au</u>	

Section	Therapeutic Goods	
Regulatory	Administration	
Engagement Branch	Department of Health	
<ul><li>info@tga.gov.au</li></ul>	PO Box 100	
	Woden ACT 2606	
	<u>www.tga.gov</u> .au	

- Whether diclofenac potassium 75mg or 100mg tablet can be administered twice a day to achieve a maximum daily dose of 150 – 200mg
  - In Australia, this product is only registered as a 25mg or 50mg product, so cannot directly comment on this query. The repository of PIs is available <a href="https://www.tga.gov.au/picmi-search-facility">https://www.tga.gov.au/picmi-search-facility</a>
- Any relevant clinical data which shows that administration of a single dose of 75 or 100mg diclofenac potassium is safe.
  - Noting the response to the above, the Product Information would be the source of truth in terms of recommended dosing. The TGA cannot provide any data that was submitted by Australian sponsors for the purpose of evaluations to other parties, including overseas regulators without the sponsor's express permission.
- We would suggest contacting the Australian sponsors directly if they would be willing to share any data that would assist.
  - **24.** In line with the decision of 315<sup>th</sup> meeting of Registration Board, following registration holders were issued show cause & personal hearing notices stating:

"Diclofenac Potassium in strengths higher than 50mg have not been approved by any of the reference regulatory authorities (RRAs) adopted by the Registration Board in its 275<sup>th</sup> meeting and the safety & efficacy in strengths higher than 50mg are not established by any RRA. The above information provokes the provisions of Section 7 (1 l)(d) and 42 of the Drugs Act, 1976. Accordingly, registration holders are required to show cause as to why the registration of their products may not be cancelled with immediate effect."

Diclofenac Potassium  Date & Time of Hearing: 16 <sup>th</sup> May, 2022 at 10:00A.M.			
Sr. No.	Reg No	Brand Name & composition	Registration Holder
1.	64588	Daikin Tablets 75mg Diclofenac Potassium 75mg	3S Pharmaceuticals (Pvt) Ltd., 5- Km, Off Raiwind Manga Road, Lahore. , Lahore
2.	58146	Zulfenec –P 75mg Tablet Diclofenac Potassium75 mg	M/s Adamjee Pharmaceuticals (Pvt.) Ltd., Plot 39, Sector 15, Korangi Industrial Area, Karachi.
3.	58147	Zulfenec –P 100mg Tablet Diclofenac Potassium100 mg	M/s Adamjee Pharmaceuticals (Pvt.) Ltd., Plot 39, Sector 15, Korangi Industrial Area, Karachi.
4.	76892	Dicgesic-K Tablets 75 mg Diclofenac Potassium: 75mg	M/s. Alen Pharmaceuticals (Pvt) Ltd., 138 Nowshera Industrial Estate, Risalpur.
5.	57517	Lyon Tablet Diclofenac Potassium 75mg	Alfalah Pharma (Pvt) Ltd., 12-Km, Sheikhupura Road, Lahore. , Lahore
6.	50330	Kemipan Plus Tablet Diclofenac Potassium75mg	M/s. Alkemy Pharmaceutical Laboratories (Pvt) Ltd, Hyderabad, P-9 SITE, Hyderabad.

7.	54702	D-Fine P 75mg Tab Diclofenac Potassium75mg	M/s Alliance Pharmaceuticals (Pvt) Ltd, Plot # 112-A, Hayatabad, Industrial Estate, Peshawar.
8.	52438	Xion Tablets 75mg Diclofenac Potassium 75mg	Allmed (Pvt) Ltd., Plot No. 590 Sundar Industrial Estate Lahore. , Lahore
9.	36326	Aldal Tablets Diclofenac Potassium75mg	M/s. Alson Pharmaceuticals, 169, Road No.7-B, Industrial Estate Hayatabad, Peshawar.
10.	37849	Phenpal Capsule Each capsule contains:- Diclofenac Potassium 75mg	M/s. Alson Pharmaceuticals, 169, Road No.7-B, Industrial Estate, Hayatabad, Peshawar.
11.	57784	Demsum 75 mg Tablet Diclofenac Potasium75mg	Amarant Pharamceuticals (Pvt) Ltd., 158-D Den Toro Gadap Road Super Highway Karachi., Karachi Previous Title: Lexicon Pharmaceuticals Pvt. Ltd. Karachi
12.	54527	Ariflam 75mg Capsule Diclofenac Potassium enteric coated pellets equivalent to75mg	M/s. Aries Pharmaceuticals (Pvt) Ltd, 1-W, Industrial Estate, Hayatabad, Peshawar.
13.	60292	Ariflam 100mg SR Capsule Diclofenac Potassium enteric coated pellets equivalent to Diclofenac Potassium100mg	M/s. Aries Pharmaceuticals (Pvt) Ltd, 1-W, Industrial Estate, Hayatabad, Peshawar.
14.	74198	Peflam Tab Diclofenac Potassium 75mg	Arsons Pharmaceutical Industries (Pvt) Ltd., 22-Km Multan Road Off 2.5-KM Defence Road, Lahore., Lahore
15.	59625	Nostif-K Tablet Diclofenac Potassium 75mg	Axis Pharmaceuticals, 3-B Value Addition City 1.5 Km Khurrianwala – Sahanwala Road Faisalabad., Faisalabad
16.	30959	Artimov-K Tablets 75mg Diclofenac Potassium75mg	M/s Barrett Hodgson Pakistan (Pvt) Ltd. F/423, S.I.T.E., Karachi.
17.	30960	Artimov-K Tablets 100mg Diclofenac Potassium100mg	M/s Barrett Hodgson Pakistan (Pvt) Ltd. F/423, S.I.T.E., Karachi.
18.	77028	Basocap -75mg Capsule Diclofenac Potassium 75mg	Basel Pharmaceuticals, 227-Phase-II Multan Industrial Estate Multan, Multan
19.	31128	Beflam Tablets 75mg Diclofenac Potassium 75mg	Batala Pharmaceuticals, 23/B Small Industrial Estate No. 2 Near Wapda Town, Khiali Bypass Gujranwala, Gujranwala
20.	21577	Keygesic Tablet 75mg Diclofenac Potassium 75mg	Benson Pharmaceuticals, Plot No.119 Street No.8, I-10/3 Industrial Area Islamabad. , Islamabad
21.	62591	Diclotal K Tablet 75mg Diclofenac Potassium 75mg	Berlex Lab. International, 10-Km Nangshah Chowk Karachi Road Multan, Multan

22.	38342	Osti-P Tablet Diclofenac Potassium 75mg	Bio Fine Pharmaceuticals (Pvt) Ltd., 74 Industrial Estate Multan., Multan
23.	65195	Biodic-P Diclofenac Potassium 75mg	Biorex Pharmaceuticals, Plot No.292 Industrial Triangle Kahuta Road Islamabad., Islamabad
24.	74501	Caldic 75mg Tablet Diclofenac Potassium75mg	M/s Caliph Pharmaceuticals (Pvt) Ltd, Plot No. 17 Industrial Estate, Risalpur, Khyber Pakhtunkhwa.
25.	24333	Kalfen Tablet 75mg Diclofenac Potassium 75mg	Candid Pharmaceuticals, Opp Pasrur Sugar Mills Sialkot Road, Pasrur., Pasrur
26.	50019	Carafenac-P Tablets 75mg Diclofenac Potassium 75mg	Caraway Pharmaceuticals, Plot No. 12 Street No. N-3 National Industrial Zone (RCCI) Rawat Islamabad., Islamabad
27.	54325	Fapa 100mg SR Tablet Diclofenac Potassium 75mg	Caylex Pharmaceuticals (Pvt) Ltd., 27-Km Mian Raiwind Road Lahore., Lahore
28.	48383	Deflam Tablet 75mg Diclofenac Potassium 75mg	CCL Pharmaceuticals (Pvt) Ltd., 62 Industrial Estate Kot Lakhpat Lahore, Lahore
29.	36727	Confenac-K Tablets Diclofenac Potassium75mg	M/s. Convell Laboratories, Saidu Sharif, Swat.
30.	37887	Diclorel Tablets Diclofenac Potassium75mg	M/s. Convell Laboratories, Saidu Sharif, Swat.
31.	66480	Frisky Tablet Diclofenac Potassium 75mg	Crest Pharmaceuticals, Plot No. 43 Industrial Triangle Kahuta Road Islamabad., Islamabad
32.	56377	Dlf-K Diclofenac Potassium 75mg	Crown Pharmaceuticals, 286 Kahuta Industrial Triangle Islamabad., Islamabad
33.	41945	Mobil K 75mg Tablet Diclofenac Potassium 75mg	Davis Pharmaceutical Laboratories, Plot No. 121 Industrial Triangle Kahuta Road Islamabad., Islamabad
34.	63176	Mobil-K 100mg Tablets Diclofenac Potassium100mg	Davis Pharmaceutical Laboratories , Plot No. 121 Industrial Triangle Kahuta Road Islamabad., Islamabad
35.	32102	Dicfin 75mg Tablets Each tablet contains:- Diclofenac Potassium 75mg	M/s Dr. Raza Pharma, Plot No. 44-C, Industrial Estate, Hayatabad, Peshawar.
36.	51172	Engrol 75mg Capsules Diclofenac Potassium 75mg	English Pharmaceutical Industries, Indus Link Katarband Road Thokar Niaz Beg, Multan Road Lahore., Lahore

37.	23811	Ardi-K Tablets Diclofenac Potassium 75mg	English Pharmaceutical Industries, Indus Link Katarband Road Thokar
			Niaz Beg, Multan Road Lahore., Lahore
38.	46215	Brisc 75mg Tablet Diclofenac Potassium 75mg	Envoy Pharmaceuticals (Pvt) Ltd., 27-Km Multan Road Maraka Lahore , Lahore
39.	58420	Eplopot Tablet Diclofenac Potassium75 mg	M/s E-Pharm Laboratories, A-40, S.I.T.E. Super Highway Industrial Area North, Karachi.
40.	56720	Dilo-K 75mg Capsule Diclofenac Potassium75mg	M/s Farm Aid Group, Plot # 3/2, Phase I & II, Hattar Industrial Estate, Haripur.
41.	60923	Flexura 75mg Tablet Diclofenac Potassium75mg	M/s. Fassgen Pharmaceuticals, Plot No. 67/1-A, Phase-III, Industrial Estate, Hattar.
42.	38169	Synoflam- 75Mg Tablets Diclofenac PotassiumUSP75mg	M/s Fedro Pharmaceutical Labs (Pvt) Ltd., 149-Industrial Estate, Jamrud Road, Hayatabad.
43.	49839	D-K Tablet 75mg Diclofenac Potassium 75mg	Ferroza International Pharmaceuticals (Pvt) Ltd., 33-Km Ferozepur Road Lahore., Lahore
44.	46893	Feflam-75 Tablets Diclofenac Potassium 75mg	Festal Laboratories, Jinnah Industries Link Kattar Band Road Thokar Niaz Baig Lahore., Lahore
45.	36772	Pofen 75Mg Tablets Diclofenac Potassium75mg	M/s Fozan Pharmaceutical Industrial (Pvt) Ltd.,36- A, Industrial Estate, Hayatabad, Peshawar.
46.	54195	Frendic-P Tablet 75mg Diclofenac Potassium 75mg	Friends Pharma (Pvt) Ltd., 31-Km Ferozepur Road Lahore., Lahore
47.	49013	Caveron Tab 75mg Diclofenac Potassium 75mg	FYNK Pharmaceuticals, 19-Km Ferozepur Road G.T. Road Kala shah Kaku Lahore. , Lahore
48.	46175	Reform Capsules 75mg. Diclofenac Potassium75mg	M/s Genome Pharmaceuticals (Pvt.) Ltd. Plot # 16/I-Phase IV, Industrial Estate, Hattar, Haripur Previous Title: Silver Oak Corporation, Plot No.16/1-Phase IV, Industrial Estate, Hattar
49.	63038	Arthopot Capsule Diclofenac Potassium75mg	M/s. Gillman Pharmaceuticals, 14/2-A. Phase I & II, Industrial Estate, Hattar.
50.	38553	Glift-K 75mg Tablet Diclofenac Potassium 75mg	Glitz Pharma, Plot No 265 Industrial Triangle Kahuta Road Islamadad. , Islamabad
51.	54918	Artinil-K SR 100mg Tab Diclofenac Potassium100mg	Global Pharmaceuticals, Plot No 204-205 Kahuta Triangle Industrial Area Islamabad., Islamabad
52.	21634	Artinil-K 75mg Tab Diclofenac Potassium 75mg	Global Pharmaceuticals, Plot No 204-205 Kahuta Triangle Industrial Area Islamabad., Islamabad

53.	56183	Potafin Diclofenac Potassium 75mg	Goodman Laboratories, Plot No.5 St: No. S-5 National Industrial Zone Rawat Islamabad., Islamabad
54.	54273	Muskel 75mg Tablets Diclofenac Potassium 75mg	Hamaz Pharmaceuticals (Pvt) Ltd., 13-Km Lutafabad Bosan Road Multan., Multan
55.	59883	Zofen-K Tablets 75mg Each tablet contains:- Diclofenac Potassium 75mg	Harmann Pharmaceutical Laboratories (Pvt) Ltd., 16-Km Multan Road Lahore. , Lahore
56.	50107	Diclokam-K Tablets 75mg Diclofenac Potassium 75mg	Harrison Pharmaceuticals, 10-Km Lahore Road Sargodha., Sargodha
57.	60366	Harrifan-K 100mg Tablet Diclofenac Potassium100mg	Harrison Pharmaceuticals, 10-Km Lahore Road Sargodha. , Sargodha
58.	68362	Rxoflam Tablets 75mg. Diclofenac Potassium75mg	M/s. Healer Laboratories (Pvt) Ltd., 96/102-C SIE Kohat Road, Peshawar.
59.	41483	Getab tablet Diclofenic Potassium 75mg	M/s Hicon Pharmaceuticals. 131-Industrial Estate, Hayatabad, Peshawar.
60.	55997	Qufen -K 75mg Tablet Diclofenac Potassium75mg	M/s High-Q Pharmaceuticals, Plot No.224, Sector 23, Korangi Industrial Area, Karachi.
61.	22543	Maxit 75 mg Tablet Diclofenac potassium 75 mg	M/s Hilton Pharma (Pvt.) limited, Plot # 13-14, Sector 15, Korangi Industrial Area, Karachi.
62.	62476	Kaynac Capsule 75mg Diclofenac Potassium 75mg	Hoover Pharmaceuticals (Pvt) Ltd., Plot No.16 Zain Park Industrial Area Saggain By Pass Road Lahore., Lahore
63.	31800	Ketagesic-75 Tablet Diclofenac Potassium 75mg	Hygeia Pharmaceuticals, Plot No. 295 Industrial Triangle Kahuta Road Islamabad., Islamabad
64.	69285	Denum K Tablets Diclofenac Potassium 75mg	Irza Pharma (Pvt) Ltd., 10.2-Km Lahore Sheikhupura Road P.O Kot Abdul Malik District Sheikhupura., Sheikhupura
2021) reconseque	egarding "Cancel ent to the "With	I/s Leads Pharma Pvt. Ltd., Islamabad has llation of Registration of Drugs" regis drawal/ Voluntary Surrender of Licens communicated vide Licensing Division's	stered under Tablet (General) Section ed Sections (including Tablet General
65.	50953	Diclosoft- K Tablets 75mg Diclofenac Potassium 75mg	Leads Pharma (Pvt) Ltd., Plot No. 81-A Street No. 6 I-10/3 Islamabad., Islamabad
66.	74597	Nexfen Tablets 75 mg. Diclofenac Potassium75 mg	M/s. Libra (Pvt) Ltd, 77-Peshawar Industrial Estate, Hayatabad, Peshawar.

Linofenac-P 75mg Tablet Diclofenac Potassium ... 75mg

67.

65234

Linear Pharma, Plot No. 18 S. No. S-4 National Industrial Zone (RCCI) Rawat Islamabad., Islamabad

68.	63262	Diclotus-K Diclofenac Potassium 75mg	Lotus Pharmaceutials (Pvt) Ltd., Plot No.118-A Street No. 8, I-10/3 Industrial Area Islamabad., Islamabad
69.	39198	Catafen 100 Tablets Diclofenac Potassium.100mg	M/s Macter International Limited. F-216, S.I.T.E, Karachi.
70.	38450	Kaldic Diclofenac Potassium100mg	Mass Pharma (Pvt) Ltd., 17 Km Ferozpur Road Lahore., Lahore
71.	28866	Inflaban-75 Tablet Diclofenac Potassium 75mg	Medera Pharmaceuticals (Pvt) Ltd., 249-A Industrial Triangle Kahuta Road Islamabad., Islamabad
72.	53260	Defenac 100mg Tablet Diclofenac Potassium :100mg	M/s Mediate Pharmaceuticals (Pvt) Limited, Plot 150-151, Sector 24, Korangi Industrial Area, Karachi.
73.	73586	Defenac 75mg Capsule Diclofenac Potassium: 75mg	M/s Mediate Pharmaceuticals (Pvt) Limited, Plot 150-151, Sector 24, Korangi Industrial Area, Karachi.
74.	61574	Dicsod-K Tablet Each tablet contains:- Diclofenac potassium 75 mg	M/s Medicaids (Pvt) Limited, Plot No. 10, Sector-27, Korangi Industrial Area, Karachi.
75.	31178	Mediflam SR 100mg Tablets Diclofenac Potassium 75mg	Mediceena Pharma (Pvt) Ltd., 27 Km Raiwind Road Lahore, Lahore
76.	73273	Anti-Pain 100mg Capsules Diclofenac Potassium Pellets eq. to Diclofenac Potassium: 100mg	M/s. Medicraft Pharmaceuticals (Pvt.) Ltd., 126-B Industrial Estate Hayatabad, Peshawar.
77.	64022	Anti-Pain 75mg Capsule Diclofenac Potassium Pellets equivalent to Diclofenac Potassium75mg	M/s. Medicraft Pharmaceuticals (Pvt.) Ltd., 126-B Industrial Estate Hayatabad, Peshawar.
78.	64026	DP-Med 100mg Tablet Diclofenac Potassium100mg	M/s. Medicraft Pharmaceuticals (Pvt.) Ltd., 126-B Industrial Estate Hayatabad, Peshawar.
79.	69004	Kenac Tablet 75mg Diclofenac Potassium 75mg	Medisave Pharmaceuticals, Plot No.578-579 Sundar Industrial Estate Lahore., Lahore
80.	73124	Kalium 75mg Tablet Diclofenac Potassium 75mg	Medisynth Pharmaceuticals, Plot No. 55 Street No. S-5 National Industrial Zone Rawat Islamabad., Islamabad
81.	68456	Volmed-K Capsule Diclofenac Potassium75mg	M/s. Meditech Pharmaceuticals, 15-D Industrial Estate, Jamrud Road, Peshawar
82.	66670	Qrelif-75 Tablets Diclofenac Potassium 75mg	Medizan Laboratories (Pvt) Ltd., Plot No 313 Industrial Triangle Kahuta Road Islamabad., Islamabad
83.	59535	D-Fenac Tablets Diclofenac Potassium 75mg	Medley Pharmaceuticals, 41/A Punjab Small Industries Estate Jhang Bahtar Road Wah Cantt., Wah Cantonment

84.	43655	Marinac-P 75 tablet	Miracle Pharmaceuticals (Pvt) Ltd.,
		Diclofenac Potassium 75mg	Plot No-8 Street No-5 National Industrial Zone Rawat, Islamabad, Islamabad
85.	62636	Diclofil P Tablet Diclofenac Potassium 75mg	Murfy Pharmaceuticals (Pvt) Ltd., 8- Km Raiwind Road Lahore., Lahore
86.	43908	Digam Tablets 75mg Diclofenac Potassium: 75mg	M/s. Navegal Laboratories, Plot No. 41/1-A-2,Phase-I Industrial Estate Hattar, Haripur.
87.	68239	Naveflam Capsules 75mg. Diclofenac Potassium75mg	M/s. Navegal Laboratories, Plot No. 41/1-A-2,Phase-I Industrial Estate Hattar, Haripur.
88.	38016	Dicloned-k 75mg tablet Diclofenac Potassium USP75mg	M/s Nenza Pharmaceuticals Pvt Ltd 33-A, Industrial Estate Hayatabad, Peshawar
89.	42984	Movom-P Capsules 75mg Diclofenac Potassium (enteric coated granules): 75mg	M/s Nenza Pharmaceuticals Pvt Ltd 33-A, Industrial Estate Hayatabad, Peshawar
90.	42985	Movom-P Capsules 100mg Diclofenac Potassium (enteric coated granules): 100mg	M/s Nenza Pharmaceuticals Pvt Ltd 33-A, Industrial Estate Hayatabad, Peshawar
91.	43982	Neofenik-75 Tablets Diclofenac Potassium 75mg	M/s Neomedix Plot No. 5/N-5 National Industrial Zone, Rawat Islamabad.
92.	39800	Noafilm Tablet 100mg Diclofenac Potassium100mg (Anti-rheumaticsystemic)	M/s Noa Hemis Pharmaceuticals, Plot #154, Sector 23, Korangi Industrial Area, Karachi.
93.	42123	Noafilm-75 Tablet 75mg Diclofenac Potassium75mg (Anti-rheumaticsystemic)	M/s Noa Hemis Pharmaceuticals, Plot #154, Sector 23, Korangi Industrial Area, Karachi.
94.	43605	Declam Tablets 75mg Diclofenac Potassium 75mg	NovaMed Pharmaceuticals (Pvt) Ltd., 28-Km Ferozepur Road Lahore, Lahore
95.	64842	Declam Tablet 100mg Diclofenac Potassium100mg	NovaMed Pharmaceuticals (Pvt) Ltd., 28-Km Ferozepur Road Lahore, Lahore
96.	56250	Dipolive 75mg Tablet Diclofenac Potassium 75mg	Olive Laboratories, Plot No.52-S-6 National Industrial Zone Rawat Rawalpindi., Rawalpindi
97.	56977	Olitass Diclofenac Potassium 75mg	Olive Laboratories, Plot No.52-S-6 National Industrial Zone Rawat Rawalpindi., Rawalpindi
98.	23973	Fen-K SR Tablet 100mg Diclofenac Potassium 10mg	Pakheim International Pharma (Pvt) Ltd., 28 Km Ferozepur Road Lahore., Lahore
99.	52552	Tasilex Tablets 75mg Diclofenac Potassium 75mg	Panacea Pharmaceuticals, Plot No.4 Street No.S-6 National Industrial Zone Rawat Islamabad., Islamabad

100.	52803	Tasium Capsule 75mg Diclofenac Potassium 75mg	Panacea Pharmaceuticals, Plot No.4 Street No.S-6 National Industrial Zone Rawat Islamabad., Islamabad
			Zone Rawat Islamabad., Islamabad
101.	52727	Ronset SR Tablets Diclofenac Potassium100mg	Paramount Pharmaceuticals, 36 Industrial Triangle, Kahuta Road Islamabad., Islamabad
102.	38437	Phlodic-K Tablet Diclofenac Potassium 75mg	Pearl Pharmaceuticals, Plot No 204 Street No. 1 I-10/3 Industrial Area Islamabad., Islamabad
103.	32086	Tonek Tablet 75mg Diclofenac Potassium75mg	M/s. Polyfine Chempharma, 51 Industrial Estate, Hayatabad, Peshawar.
104.	59971	Reuqin-75mg Tablet Diclofenac Potassium 75mg	Qintar Pharmaceuticals, 14-A Small Industrial Estate Lahore Road Sargodha., Sargodha
105.	46202	Kaymax Tablet Diclofenac Potassium 75mg	Quaper (Pvt) Ltd., 26-A S.I.E. Lahore Road Sargodha., Sargodha
106.	40187	Relsex 75mg Tablet Diclofenac Potassium 75mg	Rasco Pharma (Pvt) Ltd., 5.5 Km Raiwind Road Ali Razabad Lahore., Lahore
107.	58263	Velflex 100mg Tablet Diclofenac Potassium100 mg	M/s Ray Pharma (Pvt) Ltd., S-58, S.I.T.E, Karachi.
108.	58262	Velflex 75 mg tablet Diclofenac Potassium75 mg	M/s Ray Pharma (Pvt) Ltd.,S-58, S.I.T.E Karachi.
109.	60445	Relic Tablet 75mg Diclofenac Potassium 75mg	M/s Raymond Pharmaceuticals Lahore (Formerly Home Chemical Industries), 16-KM Multan Road Lahore.
110.	66886	Regopyrin Tablet 75mg Diclofenac Potassium: 75mg	M/s. Regent Laboratories, C-20, S.I.T.E Super Highway, Karachi.
111.	65134	Ronac Tablets 75mg Diclofenac Potassium 75mg	Rogen Pharmaceuticals, Plot No. 30 S-4 National Industrial Zone Rawat Islamabad, Islamabad
112.	65135	Ronac SR Tablets 100mg Diclofenac Potassium100mg	Rogen Pharmaceuticals, Plot No. 30 S-4 National Industrial Zone Rawat Islamabad, Islamabad
113.	56701	Volden Fort K 75mg Tablet Diclofenac Potassium 75mg	Rotex Pharma (Pvt) Ltd., Plot No. 206-207 Industrial Triangle Khuta Road Islamabad, Islamabad
114.	62985	Diclosaf-P 75mg Tablets Diclofenac Potassium75mg	M/s. Saaaf Pharmaceutical Industries, Plot No. 15, Nowshera Industrial Estate, Risalpur.
115.	64198	Diclosaf-P SR 100mg Tablets Diclofenac Potassium100mg	M/s. Saaaf Pharmaceutical Industries, Plot No. 15, Nowshera Industrial Estate, Risalpur.
116.	55109	Dyfe-P 100mg SR Tablet Diclofenac Potassium100mg	M/s Safe Pharmaceuticals (Pvt.) Ltd., Plot C-I-20, Sector 6-B, North Karachi Industrial Area, Karachi.

117.	55108	Dyfe-P 75mg Tablet Diclofenac Potassium75mg	M/s Safe Pharmaceuticals (Pvt.) Ltd.,Plot C-I-20, Sector 6-B, North Karachi Industrial Area, Karachi.
118.	69281	Zainex 75mg Tablets Diclofenac Potassium 75mg	Sapient Pharma, 123-S Industrial Area Kot Lakhpat Lahore., Lahore
119.	36815	Dic-P 75Mg Tablets Diclofenic Potassium75mg	M/s Shaheen Pharmaceuticals. 3 km, Murghzar Road, Saidu Sharif, Swat.
120.	49385	Lofen 75mg Tablet Diclofenac Potassium 75mg	Shawan Pharmaceuticals, Plot No. 37 Road NS-1 National Industrial Zone Rawat Rawalpindi.
121.	64791	Pointer 75 Capsule Diclofenac Potassium 75mg	Shrooq Pharmaceuticals (Pvt) Ltd, 21-Km Ferozepur Road, Lahore., Lahore
122.	40304	Moven 75mg Tablet Diclofenac Potassium 75mg	Shrooq Pharmaceuticals (Pvt) Ltd, 21-Km Ferozepur Road, Lahore., Lahore
123.	72136	Siclo 75mg Tablet Diclofenac Potassium 75mg	Siam Pharmaceuticals, Plot No. 217 Industrial Triangle Kahuta Road Islamabad., Islamabad
124.	24049	Rheumatin-K Tablet 75mg Diclofenac Potassium 75mg	Siza International (Pvt) Ltd., 18-Km Main Ferozepur Road Lahore, Lahore
125.	57612	Detran-P 75mg Tablet Diclofenac Potassium 75mg	Sunshine Pharmaceuticals, Emanabad, G.T. Road, Gujranwala, Gujranwala
126.	60965	Diclowan-P 75mg Tablet Diclofenac Potassium 75mg	Swan Pharmaceutical (Pvt) Ltd., 11- E Industrial Triangle Kahuta Road Islamabad.
127.	23822	Klic-F 75mg tablet Diclofenac Potassium: 75mg	M/s Tabros Pharma (Pvt) limited, L-20/B, Sector-22, Federal B Industrial Area, Karachi.
128.	65546	Theradic-P Tablet 100mg Diclofenac Potassium100mg	Theramed Pharmaceuticals (Pvt) Ltd., 45-Km Multan Road Lahore., Lahore
129.	70233	Triclo-K 75mg Capsules Diclofenac Potassium 75mg	Trison Research Labortories (Pvt) Ltd., 27-A Punjab SIE Sargodha., Sargodha
130.	52707	Unifin Tablet 75mg Diclofenac Potassium 75mg	Unison Chemical Works, 15 Km Raiwind Road Lahore., Lahore
131.	47294	Dic-P 100mg Tablets Diclofenac Potassium: 100mg	M/s Unitech Pharmaceuticals (Pvt) Ltd. Plot No. 4/116, Sector 21, Korangi Industrial Area, Karachi.

132.	27876	Signa 75mg Tablet Diclofenac Potassium 75mg	Valor Pharmaceuticals, 124/A Kahuta Triangle Industrial Area Islamabad., Islamabad
133.	78831	VALRON-P 75 Tablets Diclofenac Potassium 75mg	Venus Pharma, 23 Km Multan Road Lahore. , Lahore
134.	37574	Diclovis-K 75Mg Tablets Diclofenac Potassium 75mg	Vision Pharmaceuticals, Plot No. 22- 23 Industrial Triangle Kahuta Road Islamabad, Islamabad
135.	56845	Detaflam Tablet 75mg Diclofenac Potassium 75mg	Webros Pharmaceuticals, Plot No. 1 Street No. 10 National Industrial Zone Rawat Islamabad., Islamabad
136.	65126	Relpain Diclofenac Potassium 75mg	Well & Well Pharma (Pvt) Ltd., Plot No.7 Street S-8 National Industrial Zone RCCI Rawat Islamabad., Islamabad
137.	68326	Dolwel 75mg Tablet Diclofenac Potassium75mg	M/s Welmark Pharmaceuticals, Plot #122, Block B, Phase 5, Industrial State, Hattar.
138.	24273	Antiflam Tabelts Diclofenac Potassium 75mg	Wilshire Laboratories (Pvt) Ltd ., 124/1 Industial Estate Kot Lakhpat Lahore. , Lahore
139.	72983	Declowin 75mg Tablet Diclofenac Potassium 75mg	Winilton Pharmaceuticals (Pvt) Ltd., Plot No. 45 Street No. S-5 National Industrial Zone Rawat Rawalpindi., Rawalpindi
140.	47860	Achex Diclofenac Potassium 75mg	Wise Pharmaceuticals, Plot No. 3-A Street S-1 National Industrial Zone, Rawat Islamabad.
141.	56529	Pofac 75mg tablet Diclofenac Potassium75mg	M/s. Wnsfeild Pharmaceuticals, Plot.No.122, Block-A, Phase- V,Industrial Estate Hattar, Haripur.
142.	57985	Painogin 75mg Tablet Diclofenac Potassium75mg	M/s Zanctok Pharmaceuticals Laboratories, F-5 S.I.T.E Area,Hyderabad.
143.	58404	Corom-P 75mg Tablet Diclofenac Potassium75 mg	M/s Zephyr Pharmatec (Pvt.) Ltd, A-39, SITE II, Super Highway, Karachi.
144.	35988	Quikrel 75mg Tablet Each tablet contains:- Diclofenac Potassium 75mg	M/s. Z-Jans Pharmaceuticals (Pvt) Ltd., 148-A, Industrial Estate Hayatabad, Peshawar.
145.	054273	Muskel 75mg Tablet Each tablet contains:- Diclofenac Potassium 75mg	Hamaz Pharmaceuticals (Pvt) Ltd., 13-Km Lutafabad Bosan Road Multan.
146.	057662	K-Lam 75mg Tablet Each tablet contains:- Diclofenac Potassium 75mg	DrugPharm (Pvt) Ltd. 28-Km, Sheikhupura Road, Lahore

**25.** Furthermore, following responses have been received against the show cause notices:

S.NO	COMPANY NAME	RESPONSE
1.	M/s Rotex Pharma Pvt Ltd, Islamabad	In response to your letter No. F.5-6/2021 - Reg-11 (M-313) (Misc.) date 29/12/2021, we would like to inform you that the registration of the subject Product i.e. Volden Fort K 75mg Tablet may not be cancelled with immediate effect, because we have the following inventory in hand;
		<ul> <li>i. Finished Goods in warehouse 38,893 packs</li> <li>ii. Diclofenac Potassium (API) in inventory 308kg</li> <li>iii. Diclofenac Potassium (API) LC opened (See attached)</li> <li>1000kg</li> </ul>
		Therefore, it is requested that we may please be allowed to consume above stock before cancellation of Registration.
2.	M/s Alfalah Pharma (Pvt) Ltd, Lahore	With reference to your letter no. F.5-6/2021-Reg-II(M-313)(Misc), dated 29-12-2021, we M/s Alfalah Pharma (Pvt.) Ltd., 12 Km Sheikhupura Road, Lahore, had received a show cause notice regarding the
		Cancellation of Registration of our product "LYON 75MG TABLET (Diclofenac potassium)" having registration no. 057517.
		We honor the board decision and it is so correct that there is no approved reference from any RRAs, but it is humbly requested in you honor that we have registered this product since dated 04-06-2009 (copy of registration letter is attached) and we are selling it on doctor's prescription.
		We have a huge market regarding its use. We had never any complaint from any doctor or patient regarding its use. We had done stability study of three different batches on both Accelerated (40°C 2°C and 75% + 5% RH) and Real time (30°C 2°C and 65% + 5% RH) at different intervals, the
		results of that are satisfactory (copy attached).  Kindly allow us to continue quality production of "LYON 75MG TABLET (Diclofenac potassium)".  Your decision is highly appreciated.
3.	M/s Candid Pharma,	Please refer your letter No.F.5-6/2021-Reg-II(M-313)(Misc) dated
	Lahore	29.12.2021 regarding the subject cited above.
		We, Candid Pharmaceuticals, hereby submit that any decision taken up by the Drug Registration Board in interest of general public regarding fate of
		Diclofenac potassium 75mg will be acceptable to us.
4.	M/s Lotus Pahrmaceuticals (Pvt)	With reference to your letter No F.5-6/2021-Reg-II (M-313) (Misc) dated 29th December 2021, it is stated that we are not manufacturing
	Ltd, Islamabad	Diclofenac Potassium (Diclotus-K 75mg) since July-2021 Furthermore,
	35/ 13 1	we have no intention to manufacture above mentioned product in future.
5.	M/s Adamjee Pharaceuticals Pvt	We reference to your letter no. F-3-6/2021 Reg-1 (M313) Misc dated 7 <sup>th</sup> January 2022, we have objection to cancellation of Zulfenac-P 75mg and
	Ltd	Zulfenac-P 100mg tablet. We will utilize our raw material to manufacture
		Adafenac-P 50mg tablets (diclofenac Potassium 50mg Registration No. 58145.
6.	M/s Novamed	With reference to your show cause notice No.F.5-6/2021-Reg-II(M-
	<u>Pharmaceuticals Pvt</u> <u>Ltd</u>	313)(Misc) dated 29-12-2021 and 07-01-2022 and personal hearing Notice No.F.3-2/2022-Reg-I (M-317)(Misc) dated 06-04-2022 on the
	<u> </u>	subject cited above, we want to explain our narrative for our registered drug Declam Tablet 75mg (Diclofenac Potassium 75mg) and Declam
		Tablet 100mg (Diclofenac Potassium 100mg) having registration
		No.064842 & 043605.  Declam Tablet 75mg and Declam Tablet 100mg, both the strength are
		registered with the DRAP since 13-06-2006 and 10-08-2010 respectively
		and are being marketed since registration. However, during this period of
		12 years no adverse event has been reported till date. When there is a concern of efficacy and safety of drug, pharmacovigilance department of the competent authority is requested to conduct a risk based study
		associated with efficacy and safety pf questioned strengths of said drugs and accordingly advise the companies.
		Need your kind advice and guidance over the matter. Kindly consider this written reply as appearance in Personal Hearing
		scheduled on 19-04-2022. Assuring you for our utmost cooperation in this regard.
		Thanking you in anticipation.

7.	M/s Nenza	With reference to your letter No.F.3-2/2022-Reg-I (M-317)(Misc) dated
,.	Pharmaceutical Pvt	06-04-2022. Kindly note that our products Dicloned-k 75mg, Movom-p
	Ltd	caps 75mg and 100mg have never been in any reported safety and efficacy
		issue in the country since its production and providing relief to number of
		patients since its launch for decades.
		Furthermore, we have inventory of raw and packaging material along with
		finished stock for sale to market, therefore we request to kindly provide
		an appropriate time line to consume the inventory of the stated products.
8.	M/s Shrooq	In reference to your letter No. Nil dated 6 <sup>th</sup> April, 2022, it is hereby noted
	Pharmaceuticals Pvt	that I have received show cause notices for cancellation of registration of
	<u>Ltd</u>	the products mentioned above. In many defense, I would like to state the
		following:
		1. Diclofenac Potassium in 50mg is registered in Reference Regulatory Authorities while 75mg is not registered. This does not
		mean that 75mg is unsafe in any way.
		2. As discussed earlier in a meeting with DRAP, regarding this
		matter it was said that 75mg dose is nephrotoxic while a 75mg
		Ampoule of Diclofenac Sodium is registered in RRAs.
		3. We obtained the registration of said products in 2015 and it has
		been in use by patients all over Pakistan ever since. We have not
		received a single complaint till this day for any adverse reaction
		occurring.
		For the safety of patients, it is requested; please conduct multicenter
		clinical trials for this dosage form. If there is any evidence of adverse
		effects, we will happily withdraw these products from the market and you
9.	M/g Fogggon	may de-register.  With reference to your letter No E 2 6/2021 Pag I (M 212) (Miss) details
9.	<u>M/s Fassgen</u> Pharmaceuticals	With reference to your letter No.F.3-6/2021-Reg-I (M-313)(Misc) dated 7 <sup>th</sup> Jauray, 2022 on received 14 <sup>th</sup> January, 2022, show cause and personal
	1 Hai Hiaccuticais	hearing notice regarding cancellation of registration of Flexura 75mg
		(Diclofenac Potassium) tablets.
		Worldwide research recommended dosage of Diclofenac Potassium is
		150mg.day which provide better relief to patient. So, our product is 75mg
		it can be divided doses 75mg twice a day.
		Whereas DRAP earlier decided that, molecules being established since 10
		years reported no safety issues should be granted permission to continue
		for marketing. Furthermore, in our opinion that, letter contents should
		have been for new manufacturers and not mandatory for every
		manufacturer.  And if the DRAP consider that the permission has to be given according
		to the international standards and if everyone's registration above 50mg
		in Pakistan has to be cancelled then it is humble requested you to kindly
		grant us alternate new product registration.
		Your cooperation will highly be appreciated.
10.	M/s Trison Research	Kindly refer to your letter No.F.5-3/2022-Reg-II(M-317)(Misc) received
	Laboratories Pvt Ltd	by us on 23-04-2022 regarding the subject captioned above. It is stated
		that decision of the registration board regarding cancellation of the
		registration of our product TRICLO K 75ng Capsule and the subsequent
		personal hearing notice cannot be justified on the basis of Reference
		Regulatory Authority of the said strengths.
		Many of the pharmaceuticals industries including us in Pakistan are
		holding the registration of Diclofenac Potassium formulations above 50mg strengths. They are manufacturing the strengths of Diclofenac
		Potassium above 50mg from their date of registration, no health
		threatening ADR's relating its safety and efficacy have been observed
		since then.
		Moreover, strengths above 50mg are also registered and manufactured in
		countries like India, China and Bangladesh. Clinical trials have been
		conducted; its clinical safety and efficacy have been found satisfactory in
		these countries. Its safety and efficacy in strengths above 50mg cannot be
		justified by their presence or absence in RRA.
		So, it is requested to give us exception to personnel hearing notice in the
1		light of the above.

11.	M/s Caliph	With due respect, It is stated with reference to your letter subjected above
	<b>Pharmaceuticals</b>	we M/s Caliph Pharmaceuticals do herby state that the subject Drug
	(Pvt.) Ltd, KPK	diclofenac Potassium 75mg is being sold in Pakistan for more than 10
	(I Vt.) Ltu, KI K	
		years and our product Caldic 75mg is also being regularly prescribed by
		doctors around Pakistan since our registration.
		We therefore request the honorable Registration board to allow the sale of
		drug in Pakistan.
		· ·
		In Case of refusal of this request, we shall apply for Standardization of
		Formulation as or Strength as per the procedure available in 283 <sup>rd</sup> meeting
		of Registration Board, till then we shall be allowed to manufacture this
		drug till we get the approval for diclofenac potassium 50mg which is
		available in reference Regulatory Authority.
		We are available for any further information regarding this matter.
10	NA TINA DI	
12.	M/s Hilton Pharma	We have received your letter No. F 3-6/2021 Reg-1 (M-313) Mis dated
	(Pvt.) Ltd, Karachi	29 <sup>th</sup> December, 2021, referring the subject product case is fixed for
		personal hearing dated 10 <sup>th</sup> January 2022 at 10. 00am
		This is to inform you that due to short notice of hearing and paucity of
		time, we request you to kindly grant an adjournment which is fixed on date
1.0	36/36 31	cited above so that, we can some with proper hearing.
13.	M/s Mediate	With reference to your letter No. F 3-6/2021 Reg -1 (M-313) Misc dated
	Pharmaceutical (Pvt.)	the 29 <sup>th</sup> December 2021 received on 05 <sup>th</sup> January 2021 regarding the
	Ltd Karachi	captioned subject.
		As per your direction regarding cancelation of the already registered drugs
		contains Diclofenac Potassium in strength higher than 50mg for our
		products diclofenac potassium 100mg with registration No 053260 and
		diclofenac potassium 75mg with registration No. 073586.
		Kindly note that we are manufacturing 50mg and 100mg of tablets from
		2009, we have note receive we have not received any complain regarding
		dosage of this product.
		Furthermore, we have not manufactured Defenac 75mg capsule yet, But
		any how whatever DRAP have decided for all we accept the decision
		accordingly.
14.	M/s Zanctok	In reference to the above mentioned subject i.e the issued by
	<b>Pharamceutixcals</b>	DRAP on 29 <sup>th</sup> December 2021 regarding Registration status of
	Laboratories Karachi	formulation (Diclofenac Potassium 75mg and famotidine 10mg/5ml)
		which nullifies the registration of these drugs by regulatory authority.
1		
1		It is stated that, our product "Painogin 75mg" was registered by
		DRAP on 31st July 2009 under section 7 of the drug Act 1976 and Rules
1		28, 29 and 30 of the Drug (Licensing Registration and Advertising) Rules,
		1976 and was recently granted renewal of registration on 24 <sup>th</sup> June 2019
1		(Ref Paid Challan No. 1936384) and endorsed by Assistant Director
		Revenue (B&A) DRAP, on 2 <sup>nd</sup> July 2019,
1		
1		In the period of 2009-2021, a total of 91 batches of painogin
1		(Diclofenac Potassium 75mg) were manufactured and marketed
1		throughout the country. During this marketed period, not even a single
		significant complaint clinical complication, contraindication, product
1		recall or patient relate adverse event was reported. The product is being
1		continually use by the customers with fulfillment of standard safety and
1		dosage requirements.
		Keeping in view all the above mentioned facts, it is requested to
		the authority that kindly, as per Registration Board policy, revise the
1		decision of immediate cancellation of registration for this product, and do
1		allow us its manufacturing and marketing on continue basis.
		ano n ao no manatactaring and marketing on continue basis.

### **Proceedings during 317th Meeting:**

1. The instant proceedings have been undertaken in pursuance of decision taken by the Registration Board in its 313<sup>th</sup> Meeting wherein Show Cause Notices were issued to all registration holders of Diclofenac Potassium 75mg and 100mg under Section 7(11)(d) of the Drugs Act, 1976 for suspension or cancellation of registration of the aforementioned registered drug products in the public interest. Show Cause to registration holders of the drug

in question were also issued personal hearing notices under Section 42 of the Drugs Act, 1976 and were heard at length.

- 2. A list of pharmaceutical companies which did not attend the meeting is at Annexure-A; a list of pharmaceutical manufacturers who have shown satisfaction on instant proceedings undertaken by the Registration Board, without raising any challenge to the show cause notice and consented to accepting the decision of the Registration Board is at Annexure-B; a list of pharmaceutical companies who either attended personal hearing or responded through written arguments is at Annexure-C; a list of pharmaceutical companies who have filed Writ Petitions before the Hon'ble Lahore High Court, Lahore is at Annexure-D.
- 3. For the sake of brevity and to avoid repetition, all arguments advanced by the registration holders are amalgamated. The arguments raised in brief in replies to the notice as well as during personal hearing were that the Board in its 313<sup>th</sup> Meeting without conducting any proper fact finding enquiry decided to issue show cause notices by disregarding that many registrations of the drug had subsisted for more than a decade without any reported adverse effects; similarly, the show cause notice and personal hearing notices were also devoid of reasons and hence the same are void ab initio. The Board had granted registration of drug after satisfying itself of its safety and efficacy and cannot now take a somersault. Non-registration or unavailability of a drug in Reference Regulatory Authorities is an irrational ground for questioning the safety and efficacy of drugs since these have proved effective in the domestic market for years; furthermore, the aforementioned ground is alien to the drug laws and cannot be invoked for any regulatory action. Reference was made to an email by the Denmark Regulatory Authority which expressed its consent to potentially granting registration of diclofenac potassium of dosage above 50mg, to argue that the drug is available in Reference Regulatory Authorities. Reference was also made to British National Formulary as well as other literature to argue that the dosage and administration regime of the Diclofenac Potassium is more than 100 to 150mg and the drug in question falls within the said range. Lastly, it was argued that discontinuation of the drug would adversely affect the patients along with incurring immense financial loss upon the registration holders.
- 4. Record has been perused with the able assistance of the representatives of the registration holders and arguments have been heard. Since common questions of law and facts are involved, therefore, all notices are decided through a common order.
- 5. Succinctly stated the facts of the matter are that the Registration Board in its various meetings considered the cases of, *inter alia*, Diclofenac Potassium Tablets/ Capsules in strengths greater than 50mg i.e. the drugs in question. It was concluded that from the available record and review of information available from the Reference Regulatory Authorities ('**RRAs**') that no clinical data regarding their safety and efficacy is available in the above strengths/dosage forms. Hence, continuing registration of the formulations was not considered justifiable keeping in view safety and efficacy parameters which are mandatorily required for continuing with registration of any drug. Therefore, it was decided in the 288<sup>th</sup> Meeting of the Board dated 14<sup>th</sup>-15<sup>th</sup> February, 2019 to issue Show Cause Notices to the registration holders in accordance with the law explained above, to seek response as to why the registrations should not be cancelled or suspended.
- 6. In the meanwhile, DRAP Authority in its 70<sup>th</sup> Meeting held on 05-09-2019 decided the following:

"For formulations containing "drugs" which were previously registered by the Registration Board and have proof of availability and prescription of last 10 years but are not available in the Reference Regulatory Authorities shall continue to be

considered/ registered as drugs until and unless withdrawn on Safety, Efficacy and Quality reasons."

7. Subsequently, Registration Board in its 296<sup>th</sup> Meeting held on the 8<sup>th</sup>-10<sup>th</sup> September, 2020, decided to request the DRAP Authority to review its above mentioned decision in the following words:

"Since, all such formulations which are not approved by the Reference Regulatory Authorities; the safety and efficacy profile cannot be established in the absence of a well-established system for reporting of adverse events, so a reference shall be forwarded to DRAP's Authority with the request to review the decision taken in its 70th meeting held on 05-09-2019. In this regard, PE&R Division shall prepare a comprehensive document/agenda for consideration of Authority, keeping in view the practices adopted by RRA for all such formulations;"

8. The DRAP Authority in its 128<sup>th</sup> Meeting held on 14-12-2021 was pleased to accept the request the Registration Board and reviewed its 70<sup>th</sup> Minutes in the following words:

The Authority endorsed the recommendation of Registration Board and made following decisions:-

A. Partially reviewed its earlier decision taken in its 70<sup>th</sup> meeting held on 05-09-019, consolidated amended decision is reproduced as under:

[...]

- 4. Drug formulations/ strengths which are previously registered by the Registration Board but are not available in any Reference Regulatory Authorities, shall be reviewed and disposed of keeping in view of safety and efficacy evidence/ data in the reference Regulatory Authorities."
- 9. In pursuance of the above mentioned, Registration Board in 313<sup>th</sup> Meeting decided to issue Show Cause Notice to all registration holders of Diclofenac Potassium 75mg and 100mg under Section 7(11)(d) of the Drugs Act, 1976 for cancellation or suspension of registration of the aforementioned in the public interest. Therefore, the instant proceedings are being undertaken in light of permission granted by the DRAP Authority in its 128<sup>th</sup> Meeting.
- 10. It is to be noted at the outset that registration or licensing has been held by the Superior Courts to be a privilege not a right which can always be cancelled or suspended in accordance with the law. It has argued at length that the Registration Board granted registration after determining safety, efficacy and quality of drugs which was renewed over time, therefore, the Board cannot after passing of many years re-assess the safety and efficacy of drugs. The argument is fallacious as Rule 27 of the Drugs (Licensing, Registration and Licensing) Rules, 1976 ('Rules, 1976') while providing the duration of drug registration also added that the registration can always be cancelled or suspended earlier as well. The grounds on which the drug registration can be suspended or cancelled are provided in Section 7 (11) of the Drugs Act, 1976, and therefore, the argument that registration once granted will continue in perpetuity is against the law. Furthermore, Section 21 of the General Clauses Act, 1897, grants the Board the power to rescind any drug registration in accordance with the grounds provided in Section 7 (11) of the Drugs Act, 1976. The argument in discussion is also fallacious for the reason that scientific pharmaceutical knowledge is always in the process of evolution and decision based on knowledge available at one point of time cannot be used to defeat the just and fair decision to be taken in future with the broadening of knowledge. This principle has

been encapsulated in Rule 30 (12) of the Rules, 1976, which grants the Board power to seek any information at any point in time post-registration regarding the safety, efficacy and quality of drugs. The Board has ample powers under Rule 30 (2) to rescind, vary or modify any decision taken by it in the larger public interest to perform its statutory regulatory duty of ensuring the provision of safe and efficacious drugs and medicines to the public at large.

- 11. The primary ground which has prevailed with the Board for initiating the instant proceedings is that the drug in question (Diclofenac Potassium 75mg and 100mg) is neither approved by any of RRAs nor any data regarding their safety and efficacy is available. To better appreciate the argument, it is important to understand the scheme of the law which allows for placing reliance on RRAs as well as its importance for performing the statutory regulatory duties.
- 12. Applicant companies are generic drug product manufacturers. The generic drug product is pharmaceutically equivalent to the innovator's drug product as it contains the identical medicinal ingredients in the same amount/strength and dosage form and it must have same pharmacokinetics, pharmacodynamics, indications, contraindications, side effects etc. A generic drug product must work in the same way as that of innovator's drug product and, therefore, it can be interchanged with the innovator's drug product. Diclofenac Potassium, in 75mg and 100mg, has no innovator and applicant companies have neither conducted nor provided any safety and efficacy study to establish the aforementioned points (i.e., pharmacokinetics, pharmacodynamics, indications, contraindications, side effects etc.).
- 13. Criteria for grant of registration of any drug product is safety, efficacy and quality parameters and the onus for provision of relevant data to establish aforementioned parameters under the applicable law is upon the applicant/registration holder. For this purpose, applicant either needs to provide sufficient data to satisfy the aforementioned parameters by themselves, or provide reference to approval of registration granted by any Reference Regulatory Authorities ('RRAs'); this serves the purpose for determining safety and efficacy of the drugs. RRAs are regulatory authorities of developed countries which have stringent regulatory regimen and have developed robust mechanisms for determining drug safety, efficacy and quality and their decisions are supported by the rapid advances in sciences as well as empirical studies. Even WHO supports the reliance by developing countries on decisions of the Stringent Regulatory Authorities to ensure availability of quality assured, safe and effective health products and to avoid redundancy, global harmonization of standards and wastage of limited regulatory and financial resources. This reliance enables Registration Board and DRAP to have evidence for robust, accurate and evidence based decision-making, considering that the products registered and sold in the countries of RRAs have already been strenuously evaluated to fulfil the harmonized standards of safety, efficacy and quality as adopted by WHO, ICH, etc. This reliance also enables DRAP being the national regulatory authority in undertaking post marketing surveillance, particularly of matters related to safety and efficacy of drug. RRAs have stronger reporting and information sharing system, which can be used by DRAP as a national regulatory authority as a useful tool for surveillance, new available treatments and new indications or contra-indications.
- 14. It is pertinent to mention that since adoption of RRA, DRAP has approved only those drug products which are either approved by RRAs based on their safety and efficacy assessment or after provision by the applicant pharmaceutical concern of relevant data regarding their safety, efficacy and quality. Moreover, DRAP has also started review process of already registered drugs to ensure availability of quality assured safe and effective therapeutic goods to ailing patients in the larger public interest.

- 15. The Registration Board in accordance with the global best practices, in its 275<sup>th</sup> Meeting held on 25<sup>th</sup> to 27<sup>th</sup> October, 2017, decided to adopt the RRAs and their decisions "as reference for molecules/ formulations as reference for molecules/ formulations (in same dosage form and strengths) along with clinical trials for human purpose"; this decision was also upheld by the DRAP Authority in its 128<sup>th</sup> meeting. The aforementioned decision has since been applied by the Registration Board and also been followed by all pharmaceutical concerns for registration of their products without any caveat. Currently, all registered formulations and dosage of drugs and medicines in Pakistan are now required to comply with the details/ specifications as approved by RRAs or provide sufficient data for assessing safety, efficacy and quality of the drug product. Aforementioned decision has been taken to ensure availability of quality assured safe and effective medicines to ailing patients as it is matter of prime public health concern.
- 16. The adoption of RRAs allows the performance of the statutory duty to "adopt [...] standards and guidelines to ensure safety, efficacy, and quality of therapeutic goods" as ordained under Section 7 (t) of the DRAP Act, 2012. Therefore, the DRAP Authority [created under Section 2 (iv) and Section 7 of the DRAP Act, 2012] also approved the policy of reliance on RRAs in its 73<sup>rd</sup> Meeting held on 06-11-2019. Hence, the argument that reliance on RRAs is alien to the drug laws and without any basis for determining safety and efficacy of drugs is baseless. Furthermore, as all pharmaceutical concerns are effectively complying with decision by the Board regarding reliance on RRAs in approval of their drug products and have never raised any objection or caveat to it, therefore, they are restrained and estopped by their own conduct from challenging it in the instant proceedings.
- 17. As the legality of reliance on RRAs has been detailed above, the Board has undertaken a thorough inquiry of the registration and availability of Diclofenac Potassium 75mg and 100mg Tablets in RRAs. The findings of the inquiry are summarized below:
  - a. Diclofenac potassium is approved by various RRAs in 12.5mg, 25mg and 50mg tablet strengths. As per the review of databases of all RRAs approved by the Registration Board in its 275<sup>th</sup> meeting, it was observed that the maximum strength of diclofenac potassium in any dosage form is 50mg.
  - b. Product monographs and SmPC of innovator's and generic versions of Diclofenac Potassium tablets approved by various RRAs have been reviewed, which depicts that the daily dose of diclofenac potassium is from 75-200mg in divided doses, whereas the maximum strength of available diclofenac potassium tablet is 50mg.
  - c. Detailed recommendations of diclofenac potassium regarding dosage as available in the official print and online media of various RRAs have been reproduced as under:

S/N	RRA/	Recommended Dosage
	Product Detail	
1.	USFDA/	Use the lowest effective dose for the shortest duration
	Cataflam	consistent with individual patient treatment goals.
	50mg Tablet	<ul> <li>For treatment of pain or primary dysmenorrhea the recommended dosage is 50 mg three times a day. With experience, physicians may find that in some patients an initial dose of 100 mg of CATAFLAM, followed by 50 mg doses, will provide better relief.</li> <li>For the relief of osteoarthritis, the recommended dosage is 100-150 mg/day in divided doses, 50 mg twice a day or three times a day.</li> </ul>

		For the relief of rheumatoid arthritis, the recommended dosage
		is 150-200 mg/day in divided doses, 50 mg three times a day or four times a day.
		• Furthermore, USFDA under the heading of 'warning' states as under:
		"Long-term administration of NSAIDs has resulted in renal papillary necrosis and other renal injury. Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. In these patients, administration of an NSAID may cause a dose-dependent reduction in prostaglandin formation and, secondarily, in renal blood flow, which may precipitate overt renal decompensation. Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE-inhibitors or ARBs, and the elderly. Discontinuation of NSAID therapy is usually followed by recovery to the pretreatment state.
		No information is available from controlled clinical studies regarding the use of CATAFLAM in patients with advanced renal disease. The renal effects of CATAFLAM may hasten the progression of renal dysfunction in patients with preexisting renal disease (USFDA)."
2.	MHRA/ Diclofenac Potassium	Undesirable effects may be minimized by using the lowest effective dose for the shortest duration necessary to control symptoms.
	50mg	<ul> <li>The recommended daily dose is 100-150mg in two or three divided doses. For milder cases, 75-100mg daily in two or three divided doses is usually sufficient.</li> <li>In migraine an initial dose of 50mg should be taken at the first signs of an impending attack. In cases where relief 2 hours after the first dose is not sufficient, a further dose of 50mg may be taken. If needed, further doses of 50mg may be taken at intervals of 4-6 hours, not exceeding a total dose of 200mg per day.</li> </ul>
3.	TGA/ Voltaren	After assessing the risk/benefit ratio in each individual patient, the lowest effective dose for the shortest possible
	Rapid 50mg	duration should be used. Adverse effects may be minimized
	Tablet	by using the lowest effective dose for the shortest duration
		necessary to control symptoms.
		Acute pain states with an inflammatory component:

As a rule, the initial daily dosage for adults is 100 to 150 mg. In milder cases, as well as for children over 14 years of age, 75 to 100 mg daily is usually sufficient. The total daily dosage should generally be prescribed in 2 or 3 fractional doses. Treatment is to continue for a maximum of 7 days. If the pain has not resolved satisfactorily after 7 days' treatment, the patient should be instructed to return for review by the doctor. Acute migraine In migraine, an initial dose of 50 mg should be taken at the first signs of an impending attack. If the pain is not relieved within 2 hours of this initial dose, a further dose of 50 mg may be taken. If needed, further doses of 50 mg may be taken at intervals of 4-6 hours. The total dose to treat an acute migraine should not exceed 200 mg. The total daily dose should not exceed 200 mg. Diclofenac potassium should not be used for migraine prophylaxis. Symptomatic treatment of primary dysmenorrhoea In primary dysmenorrhoea, initially a dose of 50 or 100 mg should be given followed by 50 mg three times daily for 3 days. Treatment should be started upon appearance of the first symptoms and, depending on their duration and severity, continued for up to three days. If the pain has not resolved satisfactorily after 3 days' treatment, the patient should be instructed to return for review by the doctor. As a general recommendation, the dose should be Canada/ individually adjusted. Adverse effects may be minimized by using the lowest effective dose for the shortest duration Diclofenac K necessary to control symptoms. The recommended daily dose for pms-DICLOFENAC K is one 50 mg tablet, every 6-8 hours as required for a total daily maximum amount of 100 mg. For primary dysmenorrhea, treatment may be initiated on the first day with a loading dose of 100 mg, followed by 50 mg every six to eight hours after the initial dose if needed, for a maximum dose of 200 mg only on the first day. Patients should be maintained on the lowest effective dose. **Swedish** Voltaren T treatment should be initiated at the lowest Medical presumed effective dose, in order to be able to adjusted for **Products** therapy responses and possible side effects. Agency/

4.

5.

Health

Pms-

	Voltaren T 50	Side affects can be minimized by using the lawast affective			
		Side effects can be minimized by using the lowest effective			
	mg Tablet	dose for the shortest possible duration of treatment that is			
		necessary to control symptoms. In long-term treatment, a			
		low dose is sought.			
		For Adults:			
		• 50 mg up to 3 times per day. The maximum recommended daily dose is 150 mg.			
		• In migraines, 50 mg is initially given at the first sign of a seizure. If relief is not achieved within the 2 hours, given an additional 50 mg. This can be repeated at intervals of 4-6 hours, with a maximum 150 mg per day.			
6.	BNF/	Pain and inflammation in rheumatic disease and other			
	Voltarol	musculoskeletal disorders			
	Rapid 50mg	Adult: 75–150 mg daily in 2–3 divided doses			
	Tablet	Acute gout			
	Tubict				
		Adult: 75–150 mg daily in 2–3 divided doses			
		Postoperative pain			
		Adult: 75–150 mg daily in 2–3 divided doses			
		• Migraine			
		Adult: 50 mg, to be given at onset of migraine, then 50 mg			
		after 2 hours if required, then 50 mg after 4-6 hours;			
		maximum 200 mg per day.			

- 18. A study of the above amply demonstrates that the Registration Board had conducted a thorough inquiry before initiation of the instant proceedings. Based upon the above review and inquiry, following two questions were framed and were communicated for guidance by the Board to various RRA's including USFDA, Health Canada, MHRA UK, Swedish Medical Products Agency Sweden, TGA Australia and BNF:
  - c. Whether diclofenac potassium 75mg or 100mg tablet can be administered twice a day to achieve a maximum daily dose of 150-200mg;
  - d. Any relevant clinical data which shows that administration of a single dose of 75 or 100mg diclofenac potassium is safe.

19. Above regulatory authorities through their official replies concurred with the findings of the Board in its inquiry and their replies are summarized as under:

Regulatory	Correspondent Name/	Contact Detail	Date of
Authority	Designation/ e-mail		response
USFDA	Tisha Washington	U.S. Food and Drug	24-02-2022
	• International Program Strategic	Administration	
	Initiatives OCD	Tel: 301-796-1019	
	• Center for Drug Evaluation and	Tisha.Washington@fda.hh	
	Research	<u>s.gov</u>	
	• CDERINTLEXEC@fda.hhs.g		
	<u>ov</u>		

- According to the Orange Book, diclofenac potassium is available in 25mg and 50mg tablets only, whereas diclofenac sodium is also available in 75mg and 100mg delayed release and extended release tablets.
- To provide you with insight on the dosing and dose limitation, the dosing information for Diclofenac sodium enteric-coated tablets of 25 mg, 50 mg, and 75 mg can be found below: <a href="https://www.accessdata.fda.gov/drugsatfda\_docs/label/2006/019201s035lbl.pdf">https://www.accessdata.fda.gov/drugsatfda\_docs/label/2006/019201s035lbl.pdf</a>
- And for Diclofenac potassium immediate-release tablets of 50 mg below https://www.accessdata.fda.gov/drugsatfda\_docs/label/2011/020142s021s022lbl.pdf
- The relevant page of the label of Diclofenac potassium immediate-release tablets of 50 mg is placed below:

### DOSAGE AND ADMINISTRATION

Carefully consider the potential benefits and risks of Cataflam® (diclofenae potassium immediate-release tablets) and other treatment options before deciding to use Cataflam. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS).

After observing the response to initial therapy with Cataflam, the dose and frequency should be adjusted to suit an individual patient's needs.

For treatment of pain or primary dysmenorrhea the recommended dosage is 50 mg t.i.d. With experience, physicians may find that in some patients an initial dose of 100 mg of Cataflam, followed by 50-mg doses, will provide better relief.

For the relief of osteoarthritis the recommended dosage is 100-150 mg/day in divided doses, 50 mg b.i.d. or t.i.d.

For the relief of rheumatoid arthritis the recommended dosage is 150-200 mg/day in divided doses, 50 mg t.i.d. or q.i.d.

Different formulations of diclofenac [Voltaren® (diclofenac sodium enteric-coated tablets); Voltaren®-XR (diclofenac sodium extended-release tablets); Cataflam® (diclofenac potassium immediate-release tablets)] are not necessarily bioequivalent even if the milligram strength is the same.

### **HOW SUPPLIED**

Cataflam<sup>®</sup> (diclofenac potassium immediate-release tablets)

50 mg – light brown, round, biconvex, sugar-coated tablets (imprinted Cataflam on one side and 50 on the other side in black ink)

Bottles of 100..........NDC 0078-0436-05

Do not store above 30°C (86°F). Dispense in tight container (USP).

Regulatory	Correspondent Name/	Contact Detail	Date of
Authority	Designation/ e-mail		response
<b>Swedish Medical</b>	Ingrid Landberg	P.O.Box 26, SE-751 03	28-02-2022
<b>Products Agency</b>	Head of department	Uppsala, Sweden	
	Efficacy and Safety 1		
	• ingrid.landberg@lakeme	Visiting address: Dag	
	delsverket.se	Hammarskjölds väg 42	
		Phone: +46 (0)18-17	
		46 00, Direct: +46	
		(0)18 174272	
		ingrid.landberg@lakem	
		<u>edelsverket.se</u>	
		www.lakemedelsverket	
		<u>.se</u>	

• In Sweden the maximum diclofenac potassium dosage is in general 150 mg per 24 hours, and the recommended dosage is depending on the indication.

- This dosage can in general be divided into several doses.
- Unfortunately, we cannot provide any further data or support to address the two questions
  asked in your email, since these questions must be answered by the respective MAH for the
  respective medical product.
- Several issues needs to be considered for each case, for example diclofenac formulation, indication and patient population.

Regulatory	Correspondent Name/	Contact Detail	Date of
Authority	Designation/ e-mail		response
<b>Health Canada</b>	bcansenquiries@hc-	Bureau of Cardiology,	10-03-2022
	sc.gc.ca	Allergy and	
		Neurological Sciences	
		BCANS Enquiries /	
		Government of Canada	
		bcans.enquiries@hc-	
		sc.gc.ca	
		Bureau de cardiologie,	
		allergologie et sciences	
		neurologiques	
		Enquêtes BCASN /	
		Gouvernement du	
		Canada	
		bcans.enquiries@hc-	
		sc.gc.ca	

- The Therapeutic Products Directorate (TPD) is the Canadian federal authority that regulates pharmaceutical drugs for human use. Prior to being given market authorization, a manufacturer must present substantive scientific evidence of a product's safety, efficacy and quality as required by the Food and Drugs Act and Regulations.
- Health Canada has not authorized a 75 mg or 100 mg tablet of diclofenac potassium. Only the 50 mg diclofenac potassium tablet is available.
- Generally speaking the recommended daily dose is one 50 mg tablet, every 6-8 hours as required for a total daily maximum amount of 100 mg.
- For primary dysmenorrhea, treatment may be initiated on the first day with a loading dose of 100 mg, followed by 50 mg every six to eight hours after the initial dose if needed, for a maximum dose of 200 mg only on the first day.
- Patients should be maintained on the lowest effective dose.
- More detailed information is available for <u>diclofenac potassium</u> products through the Health Canada's Drug Product Database.
- A 50mg powder/sachet formulation of diclofenac potassium is also available, <u>CAMBIA®</u> (<u>diclofenac potassium</u>). CAMBIA® (<u>diclofenac potassium</u>) is indicated for the acute treatment of migraine attacks with or without aura in adults 18 years and older. The maximum recommended daily dose is one sachet (50 mg).
- Health Canada is committed to transparency, and maintains many publicly available sources of information which you may find useful:
  - **The Drug Product Database:** <a href="https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/drug-product-database.html">https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/drug-product-database.html</a>
  - **The Drug Product Register:** <a href="https://hpr-rps.hres.ca/">https://hpr-rps.hres.ca/</a> for Summary Basis of Decision reports

- The Public Release of Clinical Information portal: <a href="https://clinical-information.canada.ca/search/ci-rc">https://clinical-information.canada.ca/search/ci-rc</a>
- As Health Canada has not authorized a 75 mg or 100 mg tablet of diclofenac potassium, we therefore suggest that to receive the information you are requesting, you contact manufacturers of these products directly, especially those with marketing authorizations in your country.

• MHRA Customer  • Medicines and  (Medicines and  (Medicines and)  • MHRA Customer  Experience Centre   Canary Wharf, London  E14 4PU	Regulatory Authority	Correspondent Name/ Designation/ e-mail	Contact Detail	Date of response
Healthcare products Regulatory Agency)  • Communications and engagement team • Medicines and Healthcare products Regulatory Agency • RIS.NA@mhra.gov.uk  • Telephone 020 3080 6000	UK MHRA  (Medicines and Healthcare products	<ul> <li>Annabelle</li> <li>MHRA Customer     Experience Centre</li> <li>Communications and     engagement team</li> <li>Medicines and     Healthcare products     Regulatory Agency</li> </ul>	Canary Wharf, London E14 4PU Telephone 020 3080 6000	22-03-2022

- In the UK, the recommended maximum daily dose of diclofenac is 150 mg.
- The maximum approved strength of diclofenac potassium in the UK is 50 mg as an immediate release tablet formulation.
- We have no data to support the efficacy or safety of 75 mg or 100 mg strength diclofenac potassium tablets.
- We have approved some products containing 75 mg or 100 mg of diclofenac but as oral modified release formulations. These contain alternative diclofenac salts e.g. diclofenac sodium.

Regulatory Authority	Correspondent Name/ Designation/ e-mail	Contact Detail	Date of response
TGA Australia  (Therapeutic Goods Administration)	<ul> <li>Liam</li> <li>TGA Contact Centre         Regulatory Assistance         Section         Regulatory         Engagement Branch</li> <li>info@tga.gov.au</li> </ul>	Phone: 1800 020 653 Fax: 02 6203 1605 Email: info@tga.gov.a  u  Therapeutic Goods Administration Department of Health PO Box 100 Woden ACT 2606  www.tga.gov.au	07-04-2022

- Whether diclofenac potassium 75mg or 100mg tablet can be administered twice a day to achieve a maximum daily dose of 150 200mg
  - In Australia, this product is only registered as a 25mg or 50mg product, so cannot directly comment on this query. The repository of PIs is available <a href="https://www.tga.gov.au/picmi-search-facility">https://www.tga.gov.au/picmi-search-facility</a>
- Any relevant clinical data which shows that administration of a single dose of 75 or 100mg diclofenac potassium is safe.

- Noting the response to the above, the Product Information would be the source of truth in terms of recommended dosing. The TGA cannot provide any data that was submitted by Australian sponsors for the purpose of evaluations to other parties, including overseas regulators without the sponsor's express permission.
- We would suggest contacting the Australian sponsors directly if they would be willing to share any data that would assist.
  - 20. A review of the above clearly shows that various RRAs acknowledged the unavailability of any data regarding the safety and efficacy of Diclofenac Potassium above 50mg. The reference to an email by the Denmark Regulatory Authority in which it allegedly argued that registration of the drug in not banned, is also misplaced: the said Regulatory Authority merely expressed its willingness to register it subject to the availability of data regarding its safety and efficacy including clinical trial studies. Had the drug been freely available in Denmark or any other regulatory jurisdiction, the already existing registration status of any drug must have been shared with the Board during the hearing. Reference was also made to the registration of the drug in China, India, Egypt and Kenya. However, these jurisdictions are not comparable to RRAs and thus, their decisions cannot be safely relied on for safety, efficacy and quality parameters as their regulatory authorities are not stringent regulatory bodies. Moreover, none of registration holder were able to share any clinical data on the basis of which these regulatory authorities (China, India, Egypt and Kenya) had purportedly approved the drug. In taking high risk decisions such as determining the safety and efficacy of drugs, the globally accepted principle is to err on the side of caution and adopt the most stringent standards in the largest public interest. The Superior Courts in Pakistan have in various pronouncements held matters related to safety and efficacy of drugs to be directly affecting the constitutionally protected right to life of the people for which highest care and caution is to be adopted by the regulatory authority. It has also been held by the Hon'ble Court that in matters which affect the life and health of the people at large, precautionary principle is to be mandatorily adopted wherein the larger public interest must always give way to narrow corporate interests.
  - 21. It is to be noted that data regarding safety and efficacy of Diclofenac Potassium above 50mg has not been provided by the registration holders in spite of the fact that under the law i.e. Rule 30 (12) of the Rules, 1976, the burden of proof is upon the person seeking to continue registration of the drug to advance data regarding its safety and efficacy. It has been argued that the said drug has been freely available in the domestic market for years without any adverse effect being reported, which is proof enough of its safety and efficacy. However, no applicant was able to share evidence of any functional adverse drug reporting system (pharmacovigilance system) to collect such data by their company. In such a situation when the pharmaceutical concerns do not even operate any system to receive and act upon adverse effects of the drugs, the absence of data regarding adverse effects might be the result of lack of reporting rather than an evidence of drug's safety and efficacy. Even otherwise, the absence of any adverse effects at one point of time is not a guarantee that they might not arise in the future and the statutory task of the regulator is to pre-emptively deter such a situation from ever occurring by applying the pre-cautionary principle.
  - 22. It is also to be noted that pharmacovigilance data or even stability studies data is not the substitute of positive data regarding the safety and efficacy of drugs which has been universally accepted to arise only from valid clinical trials to be performed in accordance with the Bio-Study Rules, 2017. In light of the above discussed, allowing the registration of Diclofenac Potassium above 50mg to continue shall not be in the public interest as statutory intent of enacting the drug laws is the provision of safe and efficacious drugs and medicines

to the people at large without any compromise. The task of the regulator is to curb any potential future menace from adversely affecting the public at large rather than responding belatedly to public health crisis which could have been mitigated by applying the precautionary principle.

- 23. It was also argued with reference to British National Formulary as well as other literature that the maximum daily dosage and administration regime of the Diclofenac Potassium is between 100 to 150mg and the drugs in question falls within the said range. The argument cannot sustain as the literature emphasizes the "use of lowest effective dose for the shortest duration". Indications where 100mg is recommended are only dysmenorrhea or pain, and even in such cases the same is mentioned as either initial dose or loading dose (meaning that 1 dose only and no subsequent dose intake); such requirement can be met by taking two tablets of 50mg and it is for this reason that the RRAs have not approved Diclofenac Potassium in dosage above 50mg. Therefore, there is no medical necessity for Diclofenac Potassium above 50mg. Furthermore, in case of suspension of registration, there will be ample supply of registered 50mg dosage form to meet the patient needs.
- 24. Representative of M/s Hilton Pharma, Karachi during arguments relied upon an academic study titled "Diclofenac Potassium in Acute Postoperative pain and Dysmenorrhoea results from comprehensive Clinical Trial Reports". However, a basic review of the article shows that it is neither published in a peer reviewed academic journal of repute nor is there any evidence that any RRA across the world has endorsed its contents while making its regulatory decision. Furthermore, the article does not have any data regarding safety and efficacy of Diclofenac Potassium above 50mg. Therefore, safe reliance cannot be made on it.
- 25. M/s Pakheim Lahore, in their written response, submitted that their product Fen-K SR is a sustained release tablet unique release profile that extends upto 10 hours and during clinical trials on different volunteers it has been recorded that ratio of diclofenac potassium in blood stream do not rise above 5.5 after 8 hours of ingestion which is within the normal range and safe (Data of clinical trials will be submitted if desired). The firm further offered DRAP to conduct clinical trials from any of the DRAP recommended laboratory. However, the firm has neither submitted any information regarding protocols of the study conducted by them nor any detail stating that the clinical trials have been performed in compliance with the Bio Study Rules, 2017. In the absence of such information, legitimacy of the so called clinical trials cannot be established rather these are in-vitro and in-vivo studies of the product and don't depict any safety and efficacy profile of the product in any way.
- 26. M/s Alfalah Pharma, Lahore, in their written response, submitted that they have conducted stability studies on three different batches at both accelerated ( $40^{\circ}\text{C} \pm 2^{\circ}\text{C}$  and 75% + 5% RH) and real time ( $30^{\circ}\text{C} \pm 2^{\circ}\text{C}$  and 65% + 5% RH) conditions with satisfactory results achieved. Stability studies can be used as one of the tool/parameter to determine quality of a drug product but are not relevant to establish safety and efficacy of the product.
- 27. The Board noted that evidence based regulatory decisions are being taken in the larger public interest and only against registration of Diclofenac Potassium above 50mg (75mg and 100mg) due to lack of its safety and efficacy data and pharmaceutical firms can obtain registration of Diclofenac Potassium for 50mg, 25mg and 12.5mg Tablet and 50mg Sachet after completion of legal formalities. This will preserve them from any financial loss as they can serve the patients in dosage forms with evidence based safety and efficacy profile of drug products.

28. Director DTL Karachi dissented with the decision taken by the Board and opined not to suspend registration of these products.

### **Decision:**

In light of the foregoing discussions, risk-benefit analysis and public health impact of Diclofenac Potassium 75mg and 100mg, the Board made following decisions:

- i. Suspended all drug registrations of Diclofenac Potassium 75mg and 100mg under Section 7 (11) (d) read with Section 42 of the Drugs Act, 1976 in the larger public interest, with immediate effect as these are neither approved by any Reference Regulatory Authority nor any safety and efficacy data regarding them is available with any registration holder. Period of suspension will be for one (01) year or till demonstration of its safety and efficacy by conducting indigenous clinical trials in accordance with the Bio Study Rules, 2017 or its approval by the Reference Regulatory Authorities, whichever is earlier. After provision of aforementioned data, cases of such pharmaceutical firms shall be considered on merit by Registration Board.
- ii. Suspended manufacturing and import of these drug products immediately and directed to withdraw available stocks from the market in the larger public interest. QA&LT Division, DRAP will monitor and implement the decision in coordination with the respective provincial governments.
- iii. Recommended Licensing Division, DRAP for approval of Qualified person for Pharmacovigilance (QPPV) / Local Safety Officer (LSO) whichever is applicable in licensed pharmaceutical units and advised PE&R and BE&R Divisions for implementing similar action for importers of finished drug products as required under Pharmacovigilance Rules, 2022.
- iv. Final decision regarding pharmaceutical firms who have obtained interim relief from the Hon'ble Lahore High Court, Lahore shall be announced after decision and direction by the Hon'ble Court. Legal Affairs Division is requested to place the instant decision before the Hon'ble Court and seek expeditious disposal of the matter in the larger public interest.
- v. Recommended DRAP Authority for out of queue consideration of registration applications of Diclofenac Potassium 50mg, 25mg and 12.5mg Tablet and 50mg Sachet in order to facilitate the registration holders affected by the instant decision.

	Non-Attendees Affile Xui e-A	
G 37		
Sr. No.	Registration Holder	
1.	3S Pharmaceuticals (Pvt) Ltd., 5-Km, Off Raiwind Manga Road, Lahore.	
2.	M/s. Alen Pharmaceuticals (Pvt) Ltd., 138 Nowshera Industrial Estate, Risalpur.	
3.	M/s. Alkemy Pharmaceutical Laboratories (Pvt) Ltd, Hyderabad, P-9 SITE, Hyderabad.	
4.	M/s Alliance Pharmaceuticals (Pvt) Ltd, Plot # 112-A, Hayatabad, Industrial Estate,	
	Peshawar.	
5.	M/s. Alson Pharmaceuticals, 169, Road No.7-B, Industrial Estate Hayatabad, Peshawar.	
6.	Amarant Pharamceuticals (Pvt) Ltd., 158-D Den Toro Gadap Road Super Highway	
	Karachi., Karachi	
	Previous Title:	
	Lexicon Pharmaceuticals Pvt. Ltd. Karachi	
7.	Arsons Pharmaceutical Industries (Pvt) Ltd., 22-Km Multan Road Off 2.5-KM Defence	
	Road, Lahore.	
8.	Basel Pharmaceuticals, 227-Phase-II Multan Industrial Estate Multan, Multan	
9.	Berlex Lab. International, 10-Km Nangshah Chowk Karachi Road Multan, Multan	
10.	Bio Fine Pharmaceuticals (Pvt) Ltd., 74 Industrial Estate Multan.	
11.	Caylex Pharmaceuticals (Pvt) Ltd., 27-Km Mian Raiwind Road Lahore.	
12.	M/s. Convell Laboratories, Saidu Sharif, Swat.	
13.	Crest Pharmaceuticals, Plot No. 43 Industrial Triangle Kahuta Road Islamabad.	
14.	Crown Pharmaceuticals, 286 Kahuta Industrial Triangle Islamabad.	
15.	M/s Dr. Raza Pharma, Plot No. 44-C, Industrial Estate, Hayatabad, Peshawar.	
16.	English Pharmaceutical Industries, Indus Link Katarband Road Thokar Niaz Beg, Multan	
1.7	Road Lahore.	
17.	Envoy Pharmaceuticals (Pvt) Ltd., 27-Km Multan Road Maraka Lahore.	
18.	E-Pharm Laboratories, A-40, S.I.T.E. Super Highway Industrial Area North, Karachi.	
19.	M/s Farm Aid Group, Plot # 3/2, Phase I & II, Hattar Industrial Estate, Haripur.	
20.	Ferroza International Pharmaceuticals (Pvt) Ltd., 33-Km Ferozepur Road Lahore.	
21.	Festal Laboratories, Jinnah Industries Link Kattar Band Road Thokar Niaz Baig Lahore.	
22.	M/s Fozan Pharmaceutical Industrial (Pvt) Ltd.,36- A, Industrial Estate, Hayatabad, Peshawar.	
23.	Friends Pharma (Pvt) Ltd., 31-Km Ferozepur Road Lahore.	
24.	M/s Genome Pharmaceuticals (Pvt.) Ltd. Plot # 16/I-Phase IV, Industrial Estate, Hattar,	
24.	Haripur	
	Previous Title:	
	Silver Oak Corporation, Plot No.16/1-Phase IV, Industrial Estate, Hattar	
25.	Harmann Pharmaceutical Laboratories (Pvt) Ltd., 16-Km Multan Road Lahore., Lahore	
26.	M/s. Healer Laboratories (Pvt) Ltd., 96/102-C SIE Kohat Road, Peshawar.	
27.	M/s High-Q Pharmaceuticals, Plot No.224, Sector 23, Korangi Industrial Area, Karachi.	
28.	Hoover Pharmaceuticals (Pvt) Ltd., Plot No.16 Zain Park Industrial Area Saggain By Pass	
	Road Lahore., Lahore	
29.	Hygeia Pharmaceuticals, Plot No. 295 Industrial Triangle Kahuta Road Islamabad.	
30.	Irza Pharma (Pvt) Ltd., 10.2-Km Lahore Sheikhupura Road P.O Kot Abdul Malik District	
	Sheikhupura.	
31.	M/s. Libra (Pvt) Ltd, 77-Peshawar Industrial Estate, Hayatabad, Peshawar.	
32.	Mass Pharma (Pvt) Ltd., 17 Km Ferozpur Road Lahore., Lahore	
33.	M/s Medicaids (Pvt) Limited, Plot No. 10, Sector-27, Korangi Industrial Area, Karachi.	
34.	Mediceena Pharma (Pvt) Ltd., 27 Km Raiwind Road Lahore.	
35.	Medicraft Pharmaceuticals (Pvt.) Ltd., 126-B Industrial Estate Hayatabad, Peshawar.	
36.	Medisynth Pharmaceuticals, Plot No. 55 Street No. S-5 National Industrial Zone Rawat	
	Islamabad.	
37.	M/s. Meditech Pharmaceuticals, 15-D Industrial Estate, Jamrud Road, Peshawar	
38.	Murfy Pharmaceuticals (Pvt) Ltd., 8-Km Raiwind Road Lahore.	
39.	M/s. Navegal Laboratories, Plot No. 41/1-A-2, Phase-I Industrial Estate, Hattar, Haripur.	

M/s Neomedix, Plot No. 5/N-5 National Industrial Zone, Rawat Islamabad.
M/s Noa Hemis Pharmaceuticals, Plot #154, Sector 23, Korangi Industrial Area, Karachi.
M/s. Polyfine Chempharma, 51 Industrial Estate, Hayatabad, Peshawar.
Rasco Pharma (Pvt) Ltd., 5.5 Km Raiwind Road Ali Razabad Lahore.
M/s Ray Pharma (Pvt) Ltd., S-58, S.I.T.E, Karachi.
M/s Raymond Pharmaceuticals Lahore (Formerly Home Chemical Industries), 16-KM
Multan Road Lahore.
M/s. Regent Laboratories, C-20, S.I.T.E Super Highway, Karachi.
M/s Safe Pharmaceuticals (Pvt.) Ltd., Plot C-I-20, Sector 6-B, North Karachi Industrial
Area, Karachi.
Shawan Pharmaceuticals, Plot No. 37 Road NS-1 National Industrial Zone Rawat
Rawalpindi.
Theramed Pharmaceuticals (Pvt) Ltd., 45-Km Multan Road Lahore., Lahore
Venus Pharma, 23 Km Multan Road Lahore. , Lahore
Wilshire Laboratories (Pvt) Ltd., 124/1 Industial Estate Kot Lakhpat Lahore.

### Annexure-B

Attendees Having Agreement with RB Decision			Amicaure-B
Sr. No.	Registration Holder	Statement of Agreement	Name & Designation of Representative (Attendees)
1.	Allmed (Pvt) Ltd., Plot No. 590 Sundar Industrial Estate Lahore.	<ul><li>i. Registered for 10 years.</li><li>ii. They agree with the decision of Registration Board for all registration holders.</li></ul>	Mr. Feroze Ahmad Manager Regulatory Affairs
2.	Axis Pharmaceuticals, 3-B Value Addition City 1.5 Km Khurrianwala – Sahanwala Road Faisalabad.	<ul><li>i. Registered for 10 years.</li><li>ii. They agree with the decision of Registration Board for all registration holders.</li></ul>	Rana Fakhar Hayat GM Quality, regulatory
3.	CCL Pharmaceuticals (Pvt) Ltd., 62 Industrial Estate Kot Lakhpat Lahore.	They agree with the decision of Registration Board for all registration holders.	Mr. Babar Imran Babar SMCA
4.	M/s Fedro Pharmaceutical Labs (Pvt) Ltd., 149-Industrial Estate, Jamrud Road, Hayatabad.	They agree with the decision of RB and requested to convert their already registered strengths to 50mg.	Mr. Shakeel Ahmad Production Manager
5.	Global Pharmaceuticals, Plot No 204-205 Kahuta Triangle Industrial Area Islamabad.	They agree with the decision of Registration Board for all registration holders.	Mr. Suleman
6.	Medizan Laboratories (Pvt) Ltd., Plot No 313 Industrial Triangle Kahuta Road Islamabad.	They agree with the decision of Registration Board for all registration holders.	Mr. Khalid Mahmood
7.	Qintar Pharmaceuticals, 14-A Small Industrial Estate Lahore Road Sargodha.	They agree with the decision of Registration Board for all registration holders.	Mr. Sufian Sarfraz
8.	Rogen Pharmaceuticals, Plot No. 30 S-4 National Industrial Zone Rawat Islamabad.	They agree with the decision of RB and requested to convert their already registered strengths to 50mg.	Mr. Muhammad Aqil QCM
9.	Siam Pharmaceuticals, Plot No. 217 Industrial Triangle Kahuta Road Islamabad.	<ul> <li>i. They agree with the decision of Registration Board for all registration holders.</li> <li>ii. Interpretation of data may be required from multinational company producing said product before final decision.</li> </ul>	Mr. Noor Faraz QCM
10.	Swan Pharmaceutical (Pvt) Ltd., 11-E Industrial Triangle Kahuta Road Islamabad.	They agree with the decision of Registration Board for all registration holders	Mr. Awar
11.	M/s Unitech Pharmaceuticals (Pvt) Ltd. Plot No. 4/116, Sector 21, Korangi Industrial Area, Karachi.	They agree with the decision of Registration Board for all registration holders.	Mr. Ikram Habib
12.	Valor Pharmaceuticals, 124/A Kahuta Triangle Industrial Area Islamabad.	They agree with the decision of Registration Board for all registration holders.	Mr. Faisal

13.	Vision Pharmaceuticals, Plot No. 22-23 Industrial Triangle Kahuta Road Islamabad.	They agree with the decision of Registration Board for all registration holders.	Mr. Iftikhar Tarar
14.	Winilton Pharmaceuticals (Pvt) Ltd., Plot No. 45 Street No. S-5 National Industrial Zone Rawat Rawalpindi.	They agree with the decision of RB and requested to convert their already registered strengths to 50mg.	Mr. Amir Afzal Admin
15.	M/s Zanctok Pharmaceuticals Laboratories, F-5 S.I.T.E Area, Hyderabad.	<ul> <li>i.The product has already been discontinued on the bases of CDL report.</li> <li>ii.They agree with the decision of Registration Board for all registration holders.</li> </ul>	Mr. Ghulam Abbas

Annexure-C

	Amexure-C			
	Attendees Having Disagreement/ Varying Stance			
Sr. No.	Registration Holder	Statement/ Stance	Name & Designation of Representative (Attendees)	
1.	M/s. Aries Pharmaceuticals (Pvt) Ltd, 1-W, Industrial Estate, Hayatabad, Peshawar.	<ul> <li>i. Their product is registered since 2005. They are marketing 60,000 packs per month and no ADRs are reported till now.</li> <li>ii. Reference was made to the decision of 70<sup>th</sup> meeting of Authority regarding 10 years policy.</li> <li>iii. In response to question asked it was replied that no QPPV has been appointed. Safety efficacy data is not available with the firm.</li> </ul>	Mr. Yasar Siddique	
2.	Batala Pharmaceuticals, 23/B Small Industrial Estate No. 2 Near Wapda Town, Khiali Bypass Gujranwala.	<ul> <li>i. Their product is registered since 2003 and no ADRs are reported till now.</li> <li>ii. It covers 60-70% of total market of firm and in case of cancellation their market will badly suffer.</li> <li>iii. In response to question asked it was replied that no QPPV has been appointed. Safety efficacy data is not available with the firm.</li> </ul>	Mr. Yousaf CEO	
3.	Benson Pharmaceuticals, Plot No.119 Street No.8, I-10/3 Industrial Area Islamabad.	A System for Clinical trials should be established and trials be conducted from CRF otherwise firms may be allowed to continue the production.	Mr. Javid Iqbal CEO	
4.	Biorex Pharmaceuticals, Plot No.292 Industrial Triangle Kahuta Road Islamabad.	<ul> <li>i. Their product is registered since 2010 and no ADRs are reported till now.</li> <li>ii. Reference was made to the decision of 70<sup>th</sup> meeting of Authority regarding 10 years policy.</li> <li>iii. Reference was made to BNF.</li> </ul>	Mr. Muhammad Ramzan QCM	
5.	Caraway Pharmaceuticals, Plot No. 12 Street No. N-3 National Industrial Zone (RCCI) Rawat Islamabad.	Registered for 15years and no ADRs are reported till now.	Dr. Sayed Tauqeer Ali Chief Operating Officer	
6.	M/s. Gillman Pharmaceuticals, 14/2-A. Phase I & II, Industrial Estate, Hattar.	<ul> <li>i. Their product is registered since 2010 and no ADRs are reported till now.</li> <li>ii. In case of cancellation their institutional business will suffer.</li> </ul>	Mr. Rauf Regulatory Manager	
7.	Glitz Pharma, Plot No 265 Industrial Triangle Kahuta Road Islamabad.	<ul> <li>i. In USFDA officially this strength is not banned</li> <li>ii. Converted in 2015 from OTC to perception only medicine.</li> <li>iii. Higher doses more effective</li> </ul>	Miss. Arifa Hibba QA	

		iv. Novartis replied that only due to
		due to commercial reasons these
		strengths are not manufactured.
8.	Goodman Laboratories, Plot	i. Same products are registered in Mr. Zubair Saeed
0.	No.5 St: No. S-5 National	1 &
	Industrial Zone Rawat	India and Kenya. Production Incharge
		ii. DRAP should conduct clinical
	Islamabad.	trials for safety efficacy of
	II DI II I DI	Diclofenac Potassium.
9.	Hamaz Pharmaceuticals (Pvt)	i. Their product is registered since Mr. Atif Shah
	Ltd., 13-Km Lutafabad Bosan	2009 and no ADRs are reported Regulatory Manager
	Road Multan.	till now.
		ii. In response to question asked it
		was replied that no QPPV has
		been appointed. Safety efficacy
		data is not available with the
		firm.
		iii. They have submitted that
		personal hearing letter has no
		legal value as there is no
		violation of provision of Section
		7(11).
		iv. Main component is diclofenac in
		both formulations which is
		available in 75mg and 100mg in
		salt form of sodium.
		v. In China, India, Egypt
		diclofenac potassium is available
		in strengths above 50mg which
		covers 38% of world population.
		No ADRs were also reported in
		these countries nor any clinical
		trial data is available in these
		countries.
		vi. They have also consulted
		following RRAs regarding
		registration of Diclofenac
		potassium above 50mg and their
		responses are as under;
		vii.Sweden: application for
		registration of said product is
		welcomed.
		viii. Japan: They can register
		said product on the basis of
		Clinical Trials Data.
		ix. Denmark: Formulation is not
		banned for registration due to
		any health and safety reasons.
		x. In Martindale both salt forms of
		Diclofenac have same doses.
		xi. In BNF recommended daily dose
		is 75-150mg in two to three
		divided doses and therefore both
		strengths 75mg and 100mg can
		fall under this dosage regimen.
		xii.Since, the product has not been
		proven either safe or unsafe,
		therefore the matter should be
L		meretore the matter should be

	1		1
10.	M/s Hicon Pharmaceuticals.	investigated on the basis of scientific grounds.  xiii. Non-availability of said products in RRAs does not establish that the product is unsafe or toxic.  xiv. Hence, the said product may not be cancelled and showcause may be revoked.  i. There is minor difference in	Mr. Umair Aslam
	131-Industrial Estate, Hayatabad, Peshawar.	strengths of 50 mg and 75mg. 50mg can be taken four times daily and 75mg can be taken three times daily. ii. Both strengths have different efficacy while toxicity profile is same for both. iii. In Ireland max. daily dose is 225mg.	GM Mr. Sahams-Ul-Islam QCM
11.	M/s Hilton Pharma (Pvt.) limited, Plot # 13-14, Sector 15, Korangi Industrial Area, Karachi.	i. With experience, physicians may find that in some patients and initial dose of 100mg of CTAFLAM, followed by 50mg doses, will provide better relief. Hence innovator brand has evaluated a single dose of up to 100mg as safe & well tolerated. ii. In prolonged use for more than 6 months of Diclofenac Potassium, Hepatic Issues are reported.  Following review article was shared by the firm: i. Title: Diclofenac Potassium in Acute Postoperative Pain and Dysmennorhoea: Results from Comprehensive Clinical Trial Reports ii. Published dated 17-01-2018 iii. Journal: "Pain Research & Management" (Impact factor: 3.037) iv. Publisher: Hindawi v. Study: Efficacy of Diclofenac Potassium in unpublished clinical study reports (CSRs) and published reports was compared to examine publication bias, industry bias and comprehensiveness. vi. Discussion & Results: There was no clinically important difference in efficacy between 50mg and 100mg doses of diclofenac potassium. vii. Conclusion: As indicated in results the review article does	Dr. Imtiaz Ahmad General Manager Medical Affairs

12.	Linear Pharma, Plot No. 18 S. No. S-4 National Industrial Zone (RCCI) Rawat, Islamabad.	not provide any sufficient data/ evidence supporting safety and efficacy of diclofenac potassium in strengths above 50mg especially when it has been recommended by various RRAs "to use the lowest effective dose for shortest duration necessary to control symptoms."  Registered since 2010. Same dose for Diclofenac Sodium and Potassium in BNF.	Mr. Zahoor Ahmad QCM
13.	M/s Macter International Limited. F-216, S.I.T.E, Karachi.	<ul> <li>i. M/s. Cibex on behalf of M/s. Macter. Representative of M/s. Cibex was advised to submit authority letter otherwise your presence cannot be considered.</li> <li>ii. They have sent an email to Denmark and they have replied that Diclofenac Potassium is not banned for registration due to any health and safety reasons.</li> <li>iii. In China, India and Bangladesh, diclofenac potassium is available in strengths above 50mg which covers half of world population. No ADRs were also reported in these countries nor any clinical trial data is available in these countries.</li> <li>iv. In USFDA, the recommended daily dose is 50mg three times a day [up to 150mg daily for the treatment of pain and primary dysmenorrhea. In some patients an initial dose of 100mg followed by 50mg three times a day will provide better relief.</li> <li>v. In BNF recommended daily dose is 75-150mg in two to three divided doses and therefore both strengths 75mg and 100mg can fall under this dosage regimen.</li> <li>vi. Non-availability of said products in RRAs does not establish that the product is unsafe or toxic.</li> <li>vii. They have also submitted that personal hearing letter has no legal value as there is no violation of provision of Section 7(11).</li> <li>viii. Hence, the said product may not be cancelled and showcause may be revoked.</li> </ul>	Representative of M/s. Cibex Mr. Malik Zamir appeared on behalf of M/s. Macter. Representative of M/s. Cibex was advised to submit authority letter otherwise your presence cannot be considered but he has not submitted authority letter.

1.4	M - 11 D1 1 - 41/A	. The in our least is not in our least at the	Mr. Assal Massler
14.	Punjab Small Industries Estate Jhang Bahtar Road Wah Cantt., Wah Cantonment	<ul> <li>i. Their product is registered since 2009 and no ADRs are reported till now.</li> <li>ii. Reference was made of BNF.</li> <li>iii. In response to question asked it was replied that no QPPV has been appointed and no ADRs has been reported for any other product.</li> </ul>	Mr. Asad Mughal Production Manager
15.	Miracle Pharmaceuticals (Pvt) Ltd., Plot No-8 Street No-5 National Industrial Zone Rawat, Islamabad.	They are marketing this product since long and due to cancellation of said product their market will suffer.	Mr. Aftab Safdar Procurement Officer Mr. Naveed Ahamd QCM
16.	Panacea Pharmaceuticals, Plot No.4 Street No. S-6 National Industrial Zone Rawat Islamabad.	<ul> <li>i. Their product is registered since 2006 and no ADRs are reported till now.</li> <li>ii. Market survey shall be conducted before final decision.</li> </ul>	Representative of firm
17.	Pearl Pharmaceuticals, Plot No 204 Street No. 1 I-10/3 Industrial Area Islamabad.	<ul> <li>i. Their product is registered since 2005. They are marketing 60,000 packs per month and no ADRs are reported till now.</li> <li>ii. Reference was made to the decision of 70<sup>th</sup> meeting of Authority regarding 10 years policy.</li> <li>iii. In response to question asked it was replied that no QPPV has been appointed. Safety efficacy data is not available with the firm.</li> <li>iv. Reference was made to BNF and registrations in India and China.</li> </ul>	Mr. Ilyas Jalal Mr. Fayaz
18.	M/s. Saaaf Pharmaceutical Industries, Plot No. 15, Nowshera Industrial Estate, Risalpur.	Their product is registered since 2005 and no ADRs are reported till now.	Mr. Fayaz Khan
19.	M/s Shaheen Pharmaceuticals 3 km, Murghzar Road, Saidu Sharif, Swat.	<ul> <li>i. Their product is registered since 2005 and no ADRs are reported till now.</li> <li>ii. In response to question asked it was replied that no QPPV has been appointed and no ADRs has been reported.</li> </ul>	Mr. Akbar Zeb QCM
20.	Sunshine Pharmaceuticals, Emanabad, G.T. Road, Gujranwala.	Clinical Trails shall be conducted in collaboration with DRAP.	Adv. Usman Saleem Director Mr. Adil Zaman
21.	M/s Tabros Pharma (Pvt) limited, L-20/B, Sector-22, Federal B Industrial Area, Karachi.	<ul> <li>i. In Drugs.com 100mg oral dose is recommended as initial dose.</li> <li>ii. In EMC 100-150mg is recommended in two divided doses.</li> </ul>	Mr. Aurangzeb SMRA
22.	Well & Well Pharma (Pvt) Ltd., Plot No.7 Street S-8 National Industrial Zone RCCI Rawat Islamabad.		Mr. Sher Afsar Kahan

23.	Wise Pharmaceuticals, Plot No. 3-A Street S-1 National Industrial Zone, Rawat Islamabad.  M/s Zephyr Pharmatec (Pvt.) Ltd, A-39, SITE II, Super Highway, Karachi.	i. Their product is registered since 2007 and they are bearing market expenses. ii. Reference was made of BNF. iii. It was requested to allow them to continue production till the establishment of scientific grounds for cancellation.  Scientific study is required to establish safety and efficacy as no ADRs and clinical trial data is available.  Mr. Syed Mohsin Ali QCM  Mr. Asif Khitab Sr. Manager regulatory
	Firms Re	esponded through Written Arguments
Sr. No.	Registration Holder	Written Statement
25.	M/s. Wnsfeild Pharmaceuticals, Plot.No.122, Block-A, Phase-V,Industrial Estate Hattar, Haripur.	<ul> <li>i. In China, India, Kenya diclofenac potassium is available in strengths above 50mg which covers 38% of world population. No ADRs were also reported in these countries nor any clinical trial data is available in these countries.</li> <li>ii. They have also consulted following RRAs regarding registration of Diclofenac potassium above 50mg and their responses are as under;</li> <li>iii. Sweden: application for registration of said product is welcomed.</li> <li>iv. Japan: They can register said product on the basis of Clinical Trials Data.</li> <li>v. Denmark: Formulation is not banned for registration due to any health and safety reasons.</li> <li>vi. In USFDA, the recommended daily dose is 50mg three times a day [up to 150mg daily for the treatment of pain and primary dysmenorrhea. In some patients an initial dose of 100mg followed by 50mg three times a day will provide better relief.</li> <li>vii. In Martindale both salt forms of Diclofenac have same doses.</li> <li>viii.In BNF recommended daily dose is 75-150mg in two to three divided doses and therefore both strengths 75mg and 100mg can fall under this dosage regimen.</li> <li>ix. Since, the product has not been proven either safe or unsafe, therefore the matter should be investigated on the basis of scientific grounds.</li> <li>x. Non-availability of said products in RRAs does not establish that the product is unsafe or toxic.</li> <li>xi. They have also submitted that personal hearing letter has no legal value as there is no violation of provision of Section 7(11).</li> <li>xii. Hence, the said product may not be cancelled and show-cause may be revoked.</li> </ul>
26.	M/s Barrett Hodgson Pakistan (Pvt) Ltd., F/423, S.I.T.E., Karachi.	Our technical person who will participate in case and know all the relevant facts is on leave. Therefore, we urge and request you to kindly defer and grant us an adjournment to a next date of hearing wherein we shall make sure to participate with full facts and evidence of the case under discussion.
27.	M/s Welmark Pharmaceuticals, Plot #122, Block B, Phase 5, Industrial State, Hattar.	<ol> <li>In China, India, Kenya diclofenac potassium is available in strengths above 50mg which covers 38% of world population. No ADRs were also reported in these countries nor any clinical trial data is available in these countries.</li> </ol>

		<ul> <li>ii. They have also consulted following RRAs regarding registration of Diclofenac potassium above 50mg and their responses are as under;</li> <li>iii. Sweden: application for registration of said product is welcomed.</li> <li>iv. Japan: They can register said product on the basis of Clinical Trials Data.</li> <li>v. Denmark: Formulation is not banned for registration due to any health and safety reasons.</li> <li>vi. In USFDA, the recommended daily dose is 50mg three times a day [up to 150mg daily for the treatment of pain and primary dysmenorrhea. In some patients an initial dose of 100mg followed by 50mg three times a day will provide better relief.</li> <li>vii. In Martindale both salt forms of Diclofenac have same doses.</li> <li>viii.In BNF recommended daily dose is 75-150mg in two to three divided doses and therefore both strengths 75mg and 100mg can fall under this dosage regimen.</li> <li>ix. Since, the product has not been proven either safe or unsafe, therefore the matter should be investigated on the basis of</li> </ul>
		scientific grounds.  x. Non-availability of said products in RRAs does not establish that the product is unsafe or toxic.  xi. They have also submitted that personal hearing letter has no legal value as there is no violation of provision of Section 7(11).  xii. Hence, the said product may not be cancelled and show-cause may be revoked.
28.	M/s NovaMed Pharmaceuticals (Pvt) Ltd., 28-Km Ferozepur Road Lahore, Lahore	Registered with the DRAP since 13-06-2006 and 10-08-2010 and are being marketed since registration. However, during this period of 12 years no adverse event has been reported till date. When there is a concern of efficacy and safety of drug, pharmacovigilance department of the competent authority is requested to conduct a risk based study associated with efficacy and safety pf questioned strengths of said drugs and accordingly advise the companies. In Denmark formulation is not banned for registration due to any health and safety reasons.
29.	Medera Pharmaceuticals (Pvt) Ltd., 249-A Industrial Triangle Kahuta Road Islamabad., Islamabad	i.Available in India, China, Kenya and Denmark. ii.Our product holds 30% of the market.
30.	Webros Pharmaceuticals, Plot No. 1 Street No. 10 National Industrial Zone Rawat Islamabad.	<ul> <li>i. In China, India, Kenya diclofenac potassium is available in strengths above 50mg which covers 38% of world population. No ADRs were also reported in these countries nor any clinical trial data is available in these countries.</li> <li>ii. They have also consulted following RRAs regarding registration of Diclofenac potassium above 50mg and their responses are as under;</li> <li>iii. Sweden: application for registration of said product is welcomed.</li> <li>iv. Japan: They can register said product on the basis of Clinical Trials Data.</li> <li>v. Denmark: Formulation is not banned for registration due to any health and safety reasons.</li> <li>vi. In USFDA, the recommended daily dose is 50mg three times a day [up to 150mg daily for the treatment of pain and primary dysmenorrhea. In some patients an initial dose of 100mg followed by 50mg three times a day will provide better relief.</li> <li>vii. In Martindale both salt forms of Diclofenac have same doses.</li> </ul>

31.	M/s Adamjee Pharmaceuticals (Pvt.) Ltd., Plot 39, Sector 15, Korangi Industrial Area,	<ul> <li>viii. In BNF recommended daily dose is 75-150mg in two to three divided doses and therefore both strengths 75mg and 100mg can fall under this dosage regimen.</li> <li>ix. Since, the product has not been proven either safe or unsafe, therefore the matter should be investigated on the basis of scientific grounds.</li> <li>x. Non-availability of said products in RRAs does not establish that the product is unsafe or toxic.</li> <li>xi. They have also submitted that personal hearing letter has no legal value as there is no violation of provision of Section 7(11).</li> <li>xii. Hence, the said product may not be cancelled and show-cause may be revoked.</li> <li>Firm has requested to cancel their products after utilization of packing material of said products.</li> </ul>
32.	Karachi.  Alfalah Pharma (Pvt) Ltd., 12-Km, Sheikhupura Road, Lahore.	<ul> <li>i. We honor the board decision and it is so correct that there is no approved reference from any RRAs, but it is humbly requested in you honor that we have registered this product since dated 04-06-2009 (copy of registration letter is attached) and we are selling it on doctor's prescription.</li> <li>ii. We have a huge market regarding its use. We had never any complaint from any doctor or patient regarding its use. We had done stability study of three different batches on both Accelerated (40°C 2°C and 75% + 5% RH) and Real time (30°C 2°C and 65% + 5% RH) at different intervals, the results of that are satisfactory (copy attached).</li> <li>iii. Kindly allow us to continue quality production of "LYON 75MG TABLET (Diclofenac potassium)".</li> <li>iv. Your decision is highly appreciated.</li> </ul>
33.	M/s Caliph Pharmaceuticals (Pvt) Ltd, Plot No. 17 Industrial Estate, Risalpur, Khyber Pakhtunkhwa.	<ul> <li>i.With due respect, It is stated with reference to your letter subjected above we M/s Caliph Pharmaceuticals do herby state that the subject Drug diclofenac Potassium 75mg is being sold in Pakistan for more than 10 years and our product Caldic 75mg is also being regularly prescribed by doctors around Pakistan since our registration.</li> <li>ii.We therefore request the honorable Registration board to allow the sale of drug in Pakistan.</li> <li>iii.In Case of refusal of this request, we shall apply for Standardization of Formulation as or Strength as per the procedure available in 283rd meeting of Registration Board, till then we shall be allowed to manufacture this drug till we get the approval for diclofenac potassium 50mg which is available in reference Regulatory Authority.</li> <li>iv.We are available for any further information regarding this matter.</li> </ul>
34.	Candid Pharmaceuticals, Opp Pasrur Sugar Mills Sialkot Road, Pasrur.	We, Candid Pharmaceuticals, hereby submit that any decision taken up by the Drug Registration Board in interest of general public regarding fate of Diclofenac potassium 75mg will be acceptable to us.
35.	M/s. Fassgen Pharmaceuticals,, Plot No. 67/1-A, Phase-III, Industrial Estate, Hattar.	i.Worldwide research recommended dosage of Diclofenac Potassium is 150mg.day which provide better relief to patient. So, our product is 75mg it can be divided doses 75mg twice a day. ii.Whereas DRAP earlier decided that, molecules being established since 10 years reported no safety issues should be granted permission to continue for marketing. Furthermore, in our opinion

	T	
36.	Lotus Pharmaceutials (Pvt)	that, letter contents should have been for new manufacturers and not mandatory for every manufacturer.  iii.And if the DRAP consider that the permission has to be given according to the international standards and if everyone's registration above 50mg in Pakistan has to be cancelled then it is humble requested you to kindly grant us alternate new product registration.  iv.Your cooperation will highly be appreciated.  We have no intention to manufacture above mentioned product in
30.	Ltd., Plot No.118-A Street No. 8, I-10/3 Industrial Area Islamabad.	future.
37.	Mediate Pharmaceutical (Pvt) Ltd. Plot No. 150-151 Sector 24 Korangi Industrial Area Karachi.	i.As per your direction regarding cancelation of the already registered drugs contains Diclofenac Potassium in strength higher than 50mg for our products diclofenac potassium 100mg with registration No 053260 and diclofenac potassium 75mg with registration No. 073586.  ii.Kindly note that we are manufacturing 50mg and 100mg of tablets from 2009, we have note receive we have not received any complain regarding dosage of this product.  iii.Furthermore, we have not manufactured Defenac 75mg capsule yet, But any how whatever DRAP have decided for all we accept the decision accordingly.
38.	Nenza Pharmaceuticals (Pvt) Ltd., 33-A Hayatabad Industrial Estate Peshawar.	i.Our products have never been in any reported safety and efficacy issue in the country since its production and providing relief to number of patients since its launch for decades.  ii.Furthermore, we have inventory of raw and packaging material along with finished stock for sale to market, therefore we request to kindly provide an appropriate time line to consume the inventory of the stated products.
39.	Rotex Pharma (Pvt) Ltd., Plot No. 206-207 Industrial Triangle Kahuta Road Islamabad,	we would like to inform you that the registration of the subject Product i.e. Volden Fort K 75mg Tablet may not be cancelled with immediate effect, because we have the following inventory in hand; iv. Finished Goods in warehouse 38,893 packs v. Diclofenac Potassium (API) in inventory 308kg vi. Diclofenac Potassium (API) LC opened (See attached) 1000kg Therefore, it is requested that we may please be allowed to consume above stock before cancellation of Registration.
40.	Trison Research Labortories (Pvt) Ltd., 27-A Punjab SIE Sargodha.	<ul> <li>i. It is stated that decision of the registration board regarding cancellation of the registration of our product TRICLO K 75ng Capsule and the subsequent personal hearing notice cannot be justified on the basis of Reference Regulatory Authority of the said strengths.</li> <li>ii. Many of the pharmaceuticals industries including us in Pakistan are holding the registration of Diclofenac Potassium formulations above 50mg strengths. They are manufacturing the strengths of Diclofenac Potassium above 50mg from their date of registration, no health threatening ADR's relating its safety and efficacy have been observed since then.</li> <li>iii. Moreover, strengths above 50mg are also registered and manufactured in countries like India, China and Bangladesh. Clinical trials have been conducted; its clinical safety and efficacy have been found satisfactory in these countries. Its safety and efficacy in strengths above 50mg cannot be justified by their presence or absence in RRA.</li> </ul>

		iv. So, it is requested to give us exception to personnel hearing
		notice in the light of the above.
41.	M/s. Z-Jans Pharmaceuticals (Pvt) Ltd., 148-A, Industrial Estate Hayatabad, Peshawar.	It is stated that as per the study submitted by the PPMA to the honorable board our stance will be the same as per PPMA and we will be agreed with collective decision of the honorable board regarding our afore said product if the decision was for all the manufacturer in Pakistan.
42.	Unison Chemical Works, 15 Km Raiwind Road Lahore., Lahore	<ul> <li>i. Non-availability of said products in RRAs does not establish that the product is unsafe or toxic</li> <li>ii. They have submitted that personal hearing letter has no legal value as there is no violation of provision of Section 7(11).</li> <li>iii. Their product is registered and being marketed since many years and no ADRs are reported till to date which establishes that product is safe and effective.</li> <li>iv. Hence, the said product may not be cancelled and show-cause may be revoked.</li> </ul>
43.	Medisave Pharmaceuticals, Plot No.578-579 Sundar Industrial Estate Lahore., Lahore	<ul> <li>i. In China, India and Bangladesh, diclofenac potassium is available in strengths above 50mg which covers half of world population. No ADRs were also reported in these countries nor any clinical trial data is available in these countries.</li> <li>ii. In USFDA, the recommended daily dose is 50mg three times a day [up to 150mg daily for the treatment of pain and primary dysmenorrhea. In some patients an initial dose of 100mg followed by 50mg three times a day will provide better relief.</li> <li>iii. In BNF recommended daily dose is 75-150mg in two to three divided doses and therefore both strengths 75mg and 100mg can fall under this dosage regimen.</li> <li>iv. Non-availability of said products in RRAs does not establish that the product is unsafe or toxic.</li> <li>v. They have also submitted that personal hearing letter has no legal value as there is no violation of provision of Section 7(11).</li> <li>vi. Hence, the said product may not be cancelled and show-cause may be revoked.</li> </ul>
44.	Harrison Pharmaceuticals, 10-Km Lahore Road Sargodha.	<ul> <li>i. In China, India and Bangladesh, diclofenac potassium is available in strengths above 50mg which covers half of world population. No ADRs were also reported in these countries nor any clinical trial data is available in these countries.</li> <li>ii. In USFDA, the recommended daily dose is 50mg three times a day [up to 150mg daily for the treatment of pain and primary dysmenorrhea. In some patients an initial dose of 100mg followed by 50mg three times a day will provide better relief.</li> <li>iii. In BNF recommended daily dose is 75-150mg in two to three divided doses and therefore both strengths 75mg and 100mg can fall under this dosage regimen.</li> <li>iv. Non-availability of said products in RRAs does not establish that the product is unsafe or toxic.</li> <li>v. They have also submitted that personal hearing letter has no legal value as there is no violation of provision of Section 7(11).</li> <li>vi. Hence, the said product may not be cancelled and show-cause may be revoked.</li> </ul>
45.	FYNK Pharmaceuticals, 19- Km Ferozepur Road G.T. Road Kala shah Kaku Lahore	i. In China, India and Bangladesh, diclofenac potassium is available in strengths above 50mg which covers half of world population. No ADRs were also reported in these countries nor
		any clinical trial data is available in these countries.  ii. In USFDA, the recommended daily dose is 50mg three times a day [up to 150mg daily for the treatment of pain and primary

		dysmenorrhea. In some patients an initial dose of 100mg followed by 50mg three times a day will provide better relief.  iii. In BNF recommended daily dose is 75-150mg in two to three divided doses and therefore both strengths 75mg and 100mg can fall under this dosage regimen.  iv. Non-availability of said products in RRAs does not establish that the product is unsafe or toxic.  v. They have also submitted that personal hearing letter has no legal value as there is no violation of provision of Section 7(11).  vi. Hence, the said product may not be cancelled and show-cause may be revoked.
46.	Epharm Laboratories, A-40, Road No. 1, S.I.T.E. Super Highway Industrial Area, North Zone, Karachi	<ul> <li>i. In China, India and Bangladesh, diclofenac potassium is available in strengths above 50mg which covers half of world population. No ADRs were also reported in these countries nor any clinical trial data is available in these countries.</li> <li>ii. In USFDA, the recommended daily dose is 50mg three times a day [up to 150mg daily for the treatment of pain and primary dysmenorrhea. In some patients an initial dose of 100mg followed by 50mg three times a day will provide better relief.</li> <li>iii. In BNF recommended daily dose is 75-150mg in two to three divided doses and therefore both strengths 75mg and 100mg can fall under this dosage regimen.</li> <li>iv. Non-availability of said products in RRAs does not establish that the product is unsafe or toxic.</li> <li>v. They have also submitted that personal hearing letter has no legal value as there is no violation of provision of Section 7(11).</li> <li>vi. Hence, the said product may not be cancelled and show-cause may be revoked.</li> </ul>

	Atte	Amicaure	
Sr.No.	Registration Holder	Statement/ Stance	Name & Designation of Representative (Attendees)
1.	Paramount Pharmaceuticals, 36 Industrial Triangle, Kahuta Road Islamabad.	<ul> <li>i. They are marketing their product since 1998 and this is favourite product of Physicians. This prescribing data shall be collected and shared with RRAs.</li> <li>i. The product may be marketed with a precautionary statement on its label regarding duration of use.</li> </ul>	Mr. Nasir M. Qureshi CEO
2.	Siza International (Pvt) Ltd, 18 KM, Main Ferozepur Road, Lahore	<ul> <li>i. Registered for 20 years and no ADRs are reported till now.</li> <li>ii. In response to question asked it was replied that no QPPV has been appointed. Safety efficacy data is not available with the firm.</li> <li>iii. No system is established regarding ADRs reporting.</li> <li>iv. No clinical trial data is available with the firm.</li> </ul>	M. Saddiq Malik GM Regulatory Affairs
3.	Davis Pharmaceutical Laboratories, Plot No. 121 Industrial Triangle Kahuta Road Islamabad.	<ul> <li>i. Main component is diclofenac in both formulations which is available in 75mg and 100mg in salt form of sodium.</li> <li>ii. In China, India, Egypt diclofenac potassium is available in strengths above 50mg which covers 38% of world population. No ADRs were also reported in these countries nor any clinical trial data is available in these countries.</li> <li>iii. They have also consulted following RRAs regarding registration of Diclofenac potassium above 50mg and their responses are as under;</li> <li>a. Sweden: application for registration of said product is welcomed.</li> <li>b. Japan: They can register said product on the basis of Clinical Trials Data.</li> <li>c. Denmark: Formulation is not banned for registration due to any health and safety reasons.</li> <li>iv. In Martindale both salt forms of Diclofenac have same doses.</li> <li>v. In BNF recommended daily dose is 75-150mg in two to three divided doses and therefore both strengths 75mg and 100mg can fall under this dosage regimen.</li> <li>vi. Since, the product has not been proven either safe or unsafe, therefore the matter should be investigated on the basis of scientific grounds.</li> <li>vii. Non-availability of said products in RRAs does not establish that the product is unsafe or toxic.</li> <li>viii. Hence, the said product may not be cancelled and show-cause may be revoked.</li> </ul>	Mr. AmanULLAH Sheikh CEO

	T	T			
4.	Quaper (Pvt) Ltd., 26-A S.I.E.			decision of Registration	Mr. Iftikhar
	Lahore Road Sargodha.	Board for all reg	_		Director
5.	Shrooq Pharmaceuticals (Pvt)			g of Authority it was	Dr. Riaz Ahmed
	Ltd, 21-Km Ferozepur Road, Lahore.			uate all the products, allable in RRAs, on the	CEO
	Lanore.	bases of safe			
				nails to many RRAs for	
				Diclofenac Potassium	
				no RRAs has given any	
				eclaring strengths above	
		50mg as uns			
				et falls in grey area.	
				SmPC and Leaflets of	
				ets, DRAP has itself	
			abov	arity is required weather e 50mg may be	
				single dose for longer	
				ther reiterates our point	
		of view.		r	
			was	asked by member	
				ard regarding problem	
				on of 200mg daily in	
				50mg instead of 75 or	
				replied that in existing bing it is not mentioned	
				be administered after	
		every 8 hour			
		vi. Thus, in ord	der to	maintain steady state	
				the half-life of product	
				ropriate and safer to	
	Non At	administer hit tendees who hav			
Sr.No.	Registration Holder	tenuces who hav		Written Respo	nse (if any)
6.	Pakheim International Pharma (	Pvt) Ltd., 28	i.		R is a sustained release
	Km Ferozepur Road Lahore., La				nical trials on different
				volunteers we have four	nd that ratio of diclofenac
					am do not rise above 5.5
					ion which is within the
					. (Data of clinical trials
			ii.	will be submitted if des	regarding following in-
			11.		their product which can
				be verified from dissolu	
				25-35% is released in fi	
				35-45% is released in 2	-4 hours.
				45-55% is released in 4	-6 hours.
				And NLT 80% is releas	
			iii.	We offer DRAP to cond	
	G : . D	1 4		any DRAP recommende	ed laboratory.
7.	Sapient Pharma, 123-S Industria	ıı Area Kot		-	
8.	Lakhpat Lahore., Lahore M/s. Cibex (Pvt) Ltd. F-405 S.I.	T E Karachi			
0.	000784	1.L Ixaracili		-	
			1		

### Case No.2. Personal Hearing Notices Issued to Registration Holders of Famotidine 10mg/5ml Liquid/Dry Suspension.

- 1. Registration Board, in its various meetings considered the case regarding "Registration Status of Formulations (Diclofenac Potassium 75mg & 100mg and Famotidine 10mg/5ml) not approved by Reference Regulatory Authorities & Previous Decisions Taken by the Registration Board in its 250<sup>th</sup> & 258<sup>th</sup> Meeting".
- **2.** With respect to Famotidine Suspension, complete record including proceedings & decisions of Registration Board and relevant decisions of DRAP's Authority have been reproduced as under:

Sr.	Formulation	Ref. Meeting	Decision/Remarks	
No.		No. of RB		
1.	Famotidine	M-250	Remarks:	
	10mg/5ml	(held on 09 <sup>th</sup>	Not approved by reference drug regulatory agencies.	
	Suspension	10 <sup>th</sup> July,	Internationally available formulation is dry powder for	
		2015)	suspension in the strength of 40 mg/5 ml.	
			(Ref: US FDA)	
			<u>Decision:</u>	
			i. Applicants shall revise their formulation as per innovator	
			(new registration application with complete fee) within six	
			months if manufacturing facility is approved by CLB.	
			ii. For already registered drugs, same procedure as mentioned	
			above (at Sr. No. i) shall be adopted. Otherwise show cause	
			notice shall be issued for de-registration of registered drugs	
			in this formulation.	
			iii. All such application shall be processed on priority basis.	

### 3. Decision taken by DRAP's Authority in its 70<sup>th</sup> meeting held on 05<sup>th</sup> Sep, 2019:

For formulations containing "drugs" which were previously registered by the Registration Board and have proof of availability and prescription of last 10 years but are not available in the Reference Regulatory Authorities shall continue to be considered/registered as drugs until and unless withdrawn on Safety, Efficacy and Quality reasons.

### 4. Decision of M-296 held on 08th-10th Sep, 2020:

Registration Board deliberated the case in the light of above stated facts / opinions and decided as under:

- i. Since, all such formulations which are not approved by the Reference Regulatory Authorities; the safety and efficacy profile cannot be established in the absence of a well-established system for reporting of adverse events, so a reference shall be forwarded to DRAP's Authority with the request to review the decision taken in its 70<sup>th</sup> meeting held on 05-09-2019. In this regard, PE&R Division shall prepare a comprehensive document/agenda for consideration of Authority, keeping in view the practices adopted by RRA for all such formulations;
- ii. For all those formulations which are registered/applied in strengths, different from those approved by reference regulatory authorities, the registration holders/applicants shall standardize their formulations (by submitting registration application with requisite fee, provided that the firm did not have same registration) in line with those approved by reference regulatory authorities. In this regard, recommendation shall be forwarded to DRAP's Authority to exempt all such cases/applications for standardization of formulation to be submitted on Form-5F/CTD format as notified vide SRO 713(I)/2018 dated 09-06-2018.
- iii. Drug products withdrawn from RRA due to any commercial reason shall be considered for registration by Registration Board.
- iv. Vitamin-mineral formulations will be considered as per vitamin policy approved by Policy Board and further adopted by Registration Board in its 295<sup>th</sup> meeting.

Keeping in view the point (i) and in order to proceed further for effective implementation/execution of point (ii) to (iv) of the above-mentioned decision, the Authority was requested to review the decision taken vide its 70<sup>th</sup> meeting held on 05-09-2019.

### 5. Decision of DRAP Authority in its 125th meeting held on 03rd Nov. 2021:

The Authority deferred the agenda item for detailed deliberations keeping in view the therapeutic categories etc. of such formulations.

### 6. Proceedings of M-313:

- The concept of reliance on the decisions of reference regulatory authorities adopted by the Registration Board in its 275<sup>th</sup> meeting was reiterated as deliberated during proceedings of 296<sup>th</sup> meeting with respect to instant case.
- ii. Furthermore, Registration Board was apprised that a policy of reliance on reference regulatory authorities has also been approved by the Authority in its 73<sup>rd</sup> meeting held on 06-11-2019.
- iii. Registration Board was also informed regarding court case (CP No.1545/2017) filed by M/s Cibex (Pvt.) Ltd., Karachi vs DRAP & others i.e, sub-judiced before the hon'ble Sindh High Court and written statement/updated registration status of such formulations on behalf of DRAP is required to be furnished.
- iv. It was further deliberated that relevant registration holders/ manufacturers shall be provided with an opportunity to submit their response regarding (a) evidence for approval status of such formulation in reference regulatory authorities (b) product development data and relevant studies with respect to quality, safety and efficacy of these formulations.

#### 7. <u>Decision of M-313 held on 16th-18th Nov, 2021:</u>

Keeping in view the detailed deliberations during proceedings of its 296<sup>th</sup> and 313<sup>th</sup> meeting, Registration Board decided as under:

- i. To issue show cause notices to all registration holders/ manufacturers (including those listed in above tables) of below mentioned formulations under Section 7 (11)(d) of the Drug Act, 1976 that why the registration of their products may not be cancelled in the public interest. In this regard, the Board advised relevant registration sections to review the above-mentioned lists for correctness and issue notices accordingly. Moreover, any registration holder not included in above lists shall also be issued show cause notice after approval of Chairman Registration Board.
- ii. Furthermore, management of these firms shall also be given the opportunity of personal hearing in the forthcoming meeting of the Board under section 42 of the Drugs Act, 1976.

L	S. No.	Formulations
	1.	Diclofenac Potassium Tablets/ Capsules in strengths greater than 50mg
Ī	2.	Famotidine Suspension in strength/dosage form other than 40mg/5ml Powder
		for Oral Suspension.

iii. The Board also advised to share the updated status with hon'ble Sindh High Court if required.

#### 8. Decision of 128th meeting of Authority held on 14th Dec, 2021:

- I. The Authority endorsed the recommendations of Registration Board and made following decisions:-
  - A. Partially reviewed its earlier decision taken in its 70<sup>th</sup> meeting held on 05-09-2019, consolidated amended decision is reproduced as under:
    - 1. For molecules falling in the grey areas or overlapping between PE&R and H&OTC division:
      - a. Formulations/molecules already registered as "drugs" by Registration Board shall continue to be considered / registered as drugs irrespective of their status in Reference Regulatory Authorities until and unless withdrawn on Safety, Efficacy and Quality reasons.

- b. If any such formulation was also enlisted by H&OTC Division, it will be unenlisted. The applicants shall be advised to approach PE&R Division for processing of application for registration. For such unenlisted applications, a separate queue shall be prepared by the PE&R Division in order to avoid discomfort to the applicants and assurance of availability of such formulations for patients.
- c. This decision shall not apply to those formulations / molecules covered under Vitamin-Policy as approved by the Policy Board.
- 2. New formulations/molecules other than those which were already registered by Registration Board will be considered on the basis of their status in Reference Regulatory Authorities. If in the RRA, these are considered as drugs, these will be dealt by the PE&R Division while otherwise will be dealt by Health & OTC Division.
- 3. Endorsed the Reference Regulatory Authorities as adopted by the Registration Board from time to time and the criteria being opted to adopt RRAs. Registration Board was advised to issue a notification of adopted RRAs and comprehensive selection criteria for information and easy understanding of all relevant stakeholders.
- 4. Drug formulations/strengths which were previously registered by the Registration Board but are not available in any Reference Regulatory Authorities, shall be reviewed and disposed off keeping in view of safety and efficacy evidence / data in the Reference Regulatory Authorities.
- B. Registration Board may decide and dispose off such formulations as and when identified/reported.
- II. The Authority further advised Registration Board to review existing RRAs for veterinary drugs and submit its recommendations to the Authority for its consideration.
- **9.** In line with the decision taken by the Board in its 313<sup>th</sup> meeting, show-cause/personal hearing notices were issued to **162** registration holders for hearing before the Registration Board on 1<sup>st</sup> February, 2022 at 10 a.m. (for Diclofenac Potassium) & 2.30 p.m (for Famotidine). However, due to prevailing cases of COVID-19, personal hearings have been postponed (vide letter issued dated 27-01-2022).

# 10. <u>Current Status of CP No.1545/2017 filed by M/s Cibex in SHC [Famobex Suspension (Famotidine 10mg/5ml) Reg.No. 027108]</u>

M/s Cibex (Pvt.) Ltd., Karachi has also filed a court case against DRAP and others for issuance of letter [regarding change in registration status of Famobex Suspension (Famotidine 10mg/5ml; R#027108) from M/s Macter to M/s Cibex]. The last date of hearing was Friday, 28th January, 2022 wherein "Syed Hakim Masood, Federal Inspector Drugs, DRAP, Karachi present and undertakes that the Petitioner's grievance including the other items will be considered in the forthcoming meeting which will probably be held on or about 01.02.2022. In the wake of above, the matter is adjourned to 04.03.2022."

## 11. Writ Petition No. 365/2022 filed by M/s Siza International Private Limited, Lahore [Ulcenil l0mg/5ml Suspension (Famotidine 10mg) Reg. No. 025568]:

Operative part of court order dated 07-01-2022 is reproduced as under:

"Subject to notice in the meanwhile proceedings under the impugned show cause notice dated 29<sup>th</sup> of December, 2021 shall continue but the final decision shall not be made till the next date of hearing"

# 12. Writ Petition No. 4168/2022 filed by M/s Shrooq Pharmaceuticals (Pvt) Ltd., Lahore [Fomen 10mg/5ml Suspension (Famotidine l0mg) Reg. No. 040312]:

Operative part of court order dated 24-01-2022 is reproduced as under:

"At the outset learned proxy counsel submits that since identical matter (W.P. No. 365/2022) is pending adjudication before my learned brother Shahid Waheed. J. this petition be also referred to the said learned Bench.

In view of above, office is directed to place this petition before the said learned Bench after soliciting orders from the Hon'ble Chief Justice."

### 13. Writ Petition No. 4409/2022 filed by M/s Pakistan Pharmaceuticals Products Pvt. Ltd., Karachi [Famdin Suspension (Famotidine 10mg) Reg. No. 055103]:

Operative part of court order dated 28-01-2022 is reproduced as under:

"Subject to notice in the meanwhile proceedings under the impugned show cause notice dated 29<sup>th</sup> of December, 2021 shall continue but the final decision shall not be made till the next date of hearing"

## 14. Writ Petition No. 24000/2022 filed by M/s Paramount Pharmaceuticals, Islamabad [Pepton 10 Suspension (Famotidine: 10mg) Reg. No. 033996]:

Operative part of court order dated 21-04-2022 is reproduced as under:

"Subject to notice, in the meanwhile proceedings under the impugned show cause notice shall continue but the final decision shall not be made till the next date of hearing"

All the firms have challenged the Show Cause Notices issued for cancellation of their drugs stating violation of the decision taken in 70<sup>th</sup> Meeting of the DRAP Authority held on the 05-09-2019.

However, the decision taken in 70<sup>th</sup> Meeting of the DRAP Authority, has been reviewed in the 128<sup>th</sup> Meeting held on 14-12-2021, whereby Registration Board was allowed to review and dispose of registration of drugs keeping in view their safety and efficacy.

#### 15. <u>Decision of M-315 held on 01<sup>st</sup> Feb, 2022:</u>

Registration Board noted the information and advised to provide the opportunity of personal hearing in the next meeting of Registration Board.

**16.** In line with the decision of 315<sup>th</sup> meeting of Registration Board, following registration holders were issued show cause & personal hearing notices stating:

"Famotidine Suspension in strength/ dosage form other than 40mg/5ml Powder for Oral Suspension has not been approved by any of the reference regulatory authorities (RRAs) adopted by the Registration Board in its 275<sup>th</sup> meeting and the safety & efficacy in strength/ dosage form other than 40mg/5ml Powder for Oral Suspension are not established by any RRA. The above information provokes the provisions of Section 7 (11)(d) and 42 of the Drugs Act, 1976. Accordingly, registration holders are required to show cause as to why the registration of their products may not be cancelled with immediate effect."

	Famotidine Date & Time of Hearing: 17 <sup>th</sup> May, 2022 at 10:00 A.M.					
Sr. No.	Reg No	Brand Name & composition	Registration Holder			
1	58152	Trump 10mg/5ml Suspension Famotidine10 mg	M/s Adamjee Pharmaceuticals (Pvt.) Ltd., Plot 39, Sector 15, Korangi Industrial Area, Karachi.			
2	35275	Ge Pep Suspension Each 5ml contains:- Famotidine 10mg	Akson Pharmaceuticals Co. (Pvt.) Ltd.			

3	78725	Al-Famot Oral Liquid Suspension 60ml Famotidine 10mg	Ali Industries, Plot No.239/C Sundar Industrial Estate Raiwind Road Lahore.,
4	54717	Afomit Susp Famotidine10mg	M/s Alliance Pharmaceuticals (Pvt) Ltd, Plot # 112-A, Hayatabad, Industrial Estate, Peshawar.
5	43409	Sypep Suspension Famotidine10 mg	M/s. Alson Pharmaceutical, 169, Road No. 7-B, Industrial Estate Hayatabad, Peshawar.
6	40816	Fambria Suspension Famotidine 10mg	Ambrosia Pharmaceuticals,, Plot No.18, St. No.9, National Industrial Zone, Rawat, Islamabad.,
7	60333	Famodex Suspension Famotidine 10mg	Ameer Pharma (Pvt) Ltd, , 23-KM, Sheikhupura Road, Lahore.,
8	47354	Zebid Suspension Famotidine10mg	M/s Atco Laboratories Ltd, B-18, S.I.T.E, Karachi.
9	77070	Feptid Oral Suspension Famotidine: 10mg	Axis Pharmaceuticals , 3-B Value Addition City 1.5 Km Khurrianwala – Sahanwala Road Faisalabad
10	24255	Acicon Suspension Each 5ml contains:- Famotidine USP10mg	M/s Barrett Hodgson Pakistan (Pvt) Ltd., F/423, S.I.T.E., Karachi.
11	70711	Acicon 10mg/5ml Dry Suspension Famotidine10 mg	M/s Barrett Hodgson Pakistan (Pvt) Ltd., F/423, S.I.T.E., Karachi.
12	25469	Kamcid Suspension Each 5Ml Contains:- Famotidine10mg	M/s Bloom Pharmaceuticals Pvt. Ltd, Plot # 30, Phase I & II, Industrial Estate, Hattar.
13	30082	Nulcer Suspension Famotidine10mg	M/s. Brookes Pharma (Pvt) Ltd., Plot No. 58-59, Sector No. 15, Korangi Industrial Area, Karachi.
14	69070	Femcare Suspension Famotidine10mg	Care Pharmaceuticals, 8-KM Thokar, Raiwind Road, Lahore.,
15	45470	Pharmotidin Suspension Famotidine 10 mg	M/s. E-Pharm Laboratories, A-40 S.I.T.E Super Highway North Karachi, Karachi.
16	59498	Fedcid Suspension Each 5ml contains:- Famotidine 10mg	M/s Fedro Pharmaceutical Labs (Pvt) Ltd., 149-Industrial Estate, Jamrud Road, Hayatabad.
17	46936	H2foz Suspension Famotidine10mg	M/s Fozan Pharmaceutical Industrial (Pvt) Ltd., 36- A, Industrial Estate, Hayatabad, Peshawar
18	62698	NO-UL Suspension Famotidine10mg	Fynk Pharmaceuticals,, 19 K.M. G.T. Road, Kala Shah Kaku, Lahore.,
19	25149	Fadiphine Suspension Each 5ml contains Famotidine10mg	Global Pharmaceuticals, Plot No 204- 205, Kahuta Triangle, Industrial Area, Islamabad
20	33340	Fagastril Syrup Famotidine10mg	Gray's Pharma, Islamabd,

21	75050	Dinex Suspension Each 5 ml contians:- Famotidine 10 mg	Gulf Pharmaceuticals, Plot No.4, St.No.S-6, National Industrial Zone, Rawat,
22	59947	Gaster Suspension Famotidin 10mg	Hamaz Pharmaceuticals (Pvt) Ltd., 22 Km Lutafabad Road, Multan.,
23	59885	Gestrodine Suspension Each 5ml contains:- Famotidine10mg	Harmann Pharmaceutical Labs (Pvt) Ltd,, 16 -Km Multan Road, Lahore.,
24	30273	Cantil Suspension Famotidine10mg	Helicon Pharmaceutek, Pakistan (Pvt) Ltd,, Model Town Road, Faisalabad,
25	31233	Peprid Suspension Famotidine10mg	M/s. Helix Pharma Pvt. Ltd., A-56, Manghopir Road S.I.T.E., Karachi.
26	41472	Hifame Suspension Famotidine 10mg	M/s Hicon Pharmaceuticals. 131-Industrial Estate, Hayatabad Peshawar.
27	47829	Famonil Suspension 60ml Famotidine10mg	M/s. Hisun Pharmaceutical Industry, 37-A R-02 Industrial Estate Gadoon Amazai, District Swabi.
28	54455	Famosib Suspnesion Famotidine 10mg	Irza Pharma (Pvt) Ltd, 10/2 Km Sheikhupura Road, P.O. Kot Abdul Malik, Sheikhupura.
29	54287	Stomachcare Susp Each 5ml contains:- Famotidine 10mg	Jawa Pharmaceuticals (Pvt.) Ltd.,
30	61758	Kohiton Suspension Famotidine10mg	M/s. Kohs Pharmaceuticals (Pvt) Ltd., Plot No. P/8 S.I.T.E, Hyderabad.
31	71168	Famotidine 10mg/5ml Suspension Famotidine 10mg	Lawrence Pharma (Pvt.) Ltd, , 10.5Km Sheikhupura Road, Lahore.,
32	54223	Myolif Suspension Famotidine10mg	Life Pharmaceutical Company, 24-III, Industrial Estate, Multan
33	56653	Nogacid Suspension Famotidine10mg	M/s Lowitt Pharma (Pvt) Ltd.,Plot No.24-Industrial Estate, Hayatabad, Peshawar.
34	58116	Atodine Suspension 10mg/5ml Famotidine10 mg	M/s Macquin's International, F-2/H, PTC Industrial Complex S.I.T.E, Karachi.
35	27108	Famobex Suspension Each 5Ml Contains:- Famotidine10.000mg	M/s Macter International Limited. F-216, S.I.T.E, Karachi.
36	63004	Famoday Suspension Each 5ml contains:- Famotidine 10mg	Max Pharmaceuticals, Rawalpindi
37	27115	Famorex Suspension Each 5Ml Contains:- Famotidine10mg	Mediceena Pharma (Pvt) Ltd, , 27-K.M, Raiwind Road, Lahore

38	63081	Pepcimed Suspension 10mg/5ml Famotidine10mg	M/s. Medicraft Pharmaceuticals (Pvt.) Ltd.,126-B Industrial Estate Hayatabad, Peshawar.
39	33684	Acidrol Suspension Famotidine10mg	Medisearch Pharmacal, Lahore.
40	54613	Efdine Suspension Famotidine10mg	M/s. Meditech Pharmaceuticals, 15-D Industrial Estate, Jamrud Road, Peshawar,
41	59540	Motidin Suspension Famotidine10mg	Medley Pharmaceutical,, 41-A P.S.I.E Jhang Bahtar Road, Wah Cantt,
42	75259	Modin Suspension Famotidine: 10mg	Metro Pharmaceuticals, Plot No. 14 St. No. SS-2 National Industrial Zone (RCCI) Rawat Islamabad, Islamabad
43	66298	Maripep Each 5ml contains:- Famotidine 10mg	Miracle Pharmaceuticals (Pvt.) Ltd., Islamabad,
44	33704	Neofam Suspension Famotidine10mg	Neomedix , Plot No.5, N-5 National Industrial Zone Rawat (Islamabad), ,
45	38876	Neutidin Suspension 10mg/5ml Famotidine10mg	Neutro Pharma (Pvt) Ltd, 9.5Km,SheikhupuraLahore,
46	31646	Capcid Suspension Famotidine10mg	Olive Laboratories,, Plot # 52-S6, National Industrial Zone ,
47	77441	Famonyx 10 Suspension Famotidine: 10mg	M/s. Onyx Pharmaceuticals Industries, 30-A Industrial Estate Mansehra.
48	55103	Famdin Suspension Famotidine10mg	M/s Pakistan Pharmaceutical Products (Pvt) Ltd., D-122, Sindh Industrial Trading Estate, Karachi.
49	33996	Pepton Suspension Famotidine10mg	Paramount Pharma, Islamabad, 36, Industrial Triangle Kahuta Road, Islamabad,
50	25565	Reducid Suspension Famotidine10mg	M/s Platinum Pharmaceuticals (Pvt) limited, A-20 North Western Industrial Zone, Bin Qasim, Karachi
51	41619	Servipep Susp. Famotidine10mg	M/s. Polyfine Chempharma, 51 Industrial Estate, Hayatabad, Peshawar.
52	41444	Famo Rains Suspension Famotidine10 mg	Previous Address: Mac & Rains Pharmaceuticals (Pvt) Ltd, 1.5 KM, Manga Raiwind Road, Manga Mandi, Lahore. Current Address: M/s Searle IV Solutions (Pvt) Ltd, 1.5 KM, Manga Raiwind Road, Manga Mandi, Lahore.

53	52452	Fam-PH Suspension. Famotidine10mg	Previous Address: Evergreen Pharmaceuticals (Pvt) Ltd, Plot No. 590, Sundar Industrial Estate, Lahore. Current Address: M/s Allmed (Pvt) Ltd, Plot No. 590 Sundar Industrial Estate, Lahore
54	64891	Famoprime Suspension 10mg Famotidine10mg	Prime Labs (Pvt) Ltd, 9.5 Km Sheikhupura Road, Lahore.,
55	27550	Loacid Suspension 10mg/5ml Famotidine 10mg	Raazee Therapeutics (Pvt) Ltd., 48-Km Lahore Kasur Road Kasur., Kasur, , Pakistan
56	69396	Famtac Suspension Famotidine10mg	Rasco Pharma,, 5.5 KM Raiwind Road Ali Razabad, Lahore,
57	30124	Recid Syp Famotidine10mg	M/s. Regent Laboratories C-20, S.I.T.E Super Highway, Karachi
58	64293	S.Famers 10mg Syrup Famotidine10mg	M/s Sayyed Pharmaceutical (Pvt) Ltd.,Plot No. 67/2, Phase 3, Industrial Estate, Hattar. Haripur.
59	28254	Famoscot Oral Suspension 10mg Famotidine10 mg	Scotmann Pharmaceuticals, 5D, I-10/3 Industrial Area, Islamabad
60	55282	Almadine Suspension 10mg/5ml Famotidine10mg	Selomore Pharmaceuticals (Pvt) Ltd.,35 KM, Multan Raod, lahore
61	25952	Famoat Suspension 10mg/5ml Famotidine 10mg	Shaigan Pharmaceutical (Pvt) Ltd., 14- Km Adyala Road Post Office Dahgal Rawalpindi, Rawalpindi, , Pakistan
62	40312	Fomen Suspension 10mg Famotidine10mg	Shrooq Pharmaceutical (Pvt) Ltd, 21-KM, Feroze Pur Road, Lahore
63	25568	Ulcenil Suspneion Each 5Ml Contains:- Famotidine10mg	Siza International (Pvt) Ltd, 18 KM, Main Ferozepur Road, Lahore
64	34789	Gastridine Suspension Famotidine10mg	M/s T.G. Pharma, E-30 Sector 15, Korangi Industrial Area, Karachi. [Previous Title: M/s. Unicorn Pharma] Karachi
65	65555	Therafame Suspension 10mg/5ml Famotidine10mg	Theramed Pharmaceutical, , 331-J-1 Johar Town Lahore,
66	42764	Fastine Suspension Famotidine10mg	Trigon Pharmaceutical (Pvt) Limited, 18 Km Raiwind Road, Lahore
67	67940	Gdicd Suspension Famotidine10mg	Unison Chemical Works, Lahore,
68	25037	Peptiban Suspension Each 5ml contains Famotidine10mg	Werrick Pharmaceuticals, 216-217, I-10/3, Industrial Area, Islamabad.,
69	65677	Famid 10mg Suspension Famotidine10mg	Wilshire Laboratories,, 124/A, Kotlakhpat, Indus. Area, Township Scheme, Lahore.,

70	65956	Famotop Suspension Famotidine10mg	Xenon Pharma, Lahore.
71	57740	Famtaza Dry Suspension Famotidine10mg	M/s. Zafa Pharmaceutical Laboratories (Pvt.) Ltd., L-1/B Block 22 Federal B Industrial Area, Karachi
72	61150	Flut Suspension Famotidine10mg	M/s Zephyr Pharmatec (Pvt.) Ltd, A-39, SITE II, Super Highway, Karachi
73	43731	Ulcare.Suspension.10mg. Famotidine10mg	M/s. Z-Jans Pharmaceuticals (Pvt) Ltd., 148-A, Industrial Estate Hayatabad, Peshawar.
74	038876	Neutidin Suspension 10mg/5ml Famotidine10mg	Neutro Pharma (Pvt) Ltd, 9.5Km,Sheikhupura Lahore.
75	044794	Famofit Suspension 10mg/5ml Famotidine10mg	Synchro Pharmaceuticals, 77-Industrial Estate Kot Lakhpat Lahore.

21. It is also pertinent to mention here that subsequent to the decision of 250<sup>th</sup> meeting of Registration Board regarding "Famotidine Suspension", following registration holders applied for revision of their registered/approved products in line with the reference product approved by RRA:

S/	Reg Holder	Previously Approved/	Revised formulation
N		Registered formulation	
1.	M/s. Bryon	Nocer 10 suspension	Nocer 40 Dry Suspension
	Pharmaceuticals	Each 5ml contains:	Each 5ml contains:
	(Pvt) Ltd., 48	Famotidine10mg	Famotidine40mg
	Hayatabad	(R#042966)	(R#087998)
	Industrial Estate		
	Peshawar.		
2.	M/s Astellas	Famos Dry Suspension 10mg/5ml	Famallas Dry Suspension 40mg/5ml
	Pharmaceutical	Each 5ml contains:	Each 5ml contains:
	(Pvt) Ltd.	Famotidine10mg	Famotidine40mg
	Industrial Estate,	(Approved in M-272, Reg. letter	(R#108745)
	Hayatabad,	not issued)	
	Peshawar.		
3.	M/s Pharmix	Ulcofin Suspension 10mg	Ulcofin Dry Powder Suspension
	Laboratories	Each 5ml contains:	40mg/5ml
	(Pvt) Ltd. 21-	Famotidine10mg	Each 5ml contains:
	Km Ferozepur	(USP Specification)	Famotidine40mg
	Road Lahore	(R#053752)	(R&I date: 29-11-2022,
			Fee of Rs.20000/-)
			(Under process of evaluation)

**22.** Furthermore, following responses have been received against the show cause notices:

S.NO	COMPANY NAME	RESPONSE
1.	M/s Helicon	Reference to your letter no. F.5-6/2021-Reg-11 (M-313)(Misc) dated
	<u>Pharmaceutiek</u> Pakistan (Pvt) Ltd	29th December 2021 & F.5-3/2022-Reg-11 (M-317)(Misc) dated
	<del></del>	06 <sup>th</sup> April, 2022.
		This drug was registered on 09.08.2003. Thus has a prescriber doctor's
		confidence in the brand. It is very long procedure for new registration.

		Whereas we also have been granted (	Cantil 40mg tablet (Famotidine) under
	registration no. 016854. The patients who could not take tablet and		s who could not take tablet and have
		to choose take suspension according to the doctor's prescription.	
		Therefore in the interest of patients a	• •
		for substituting the formulation from 10mg/5ml to 40mg/5ml in	
		suspension form.	i romgo i i i i i i i i i i i i i i i i i i i
		_	be granted for complying with the
			eculiar circumstances of our case of
		change of strength of our registered formulation namely Cantil Suspension	
		registration no. 030273 from 10mg/5ml to 40mg/5ml. We follow the	
		SOP's in this regard.	
2.	M/s Lotus Pahrmaceuticals (Pvt)	With reference to your letter No F.5	
	Ltd, Islamabad	dated 29th December 2021, it is state	_
		Famotidine 10mg/5ml (Pepdine Syru	up) since Oct-2019.
		Furthermore, we have no intention to	o manufacture above mentioned
		product in future.	
3.	M/s Adamjee	With reference to your letter	We reference to your letter No. F 3-
	Pharaceuticals Pvt Ltd	No.F.3-2/2022-Reg-I (M-	6/2021-Reg -1 (M-313) Misc. dated
		317)(Misc) dated 06 <sup>th</sup> April, 2022	7 <sup>th</sup> January 2022, we have no
		we have no objection to	objection to cancellation of trump
		cancellation of Trump 10mg/5ml	10mg/5ml Suspension We will
		Suspension. Please cancel the said	utilize our raw Material to
		products after complete utilization	manufacture Trump 40mg and
		of the packaging materials of the	20mg tablets (Famotidine 40mg and
		said products.	20mg) Registration No. 58151 and
			58150 respectively,
4.	M/s Sayyed	Reference to your letter no. F 3-6/2	2021-Reg-1 (M-313 (Mis) dated 29 <sup>th</sup>
	Pharmaceuticals	December, 2021, regarding cancellat	tion of registration of S-Famers 10mg
	(Pvt.) Ltd, Hattar,	Syrup (Famotidine 10mg /5ml) regi	stration no. 064293, we M/s Sayyed
			se 3 Industrial Estate, Haripur hereby
		submit that,	, 1
		In Martindale 38 <sup>th</sup> edition volume 2, Page 1842 famotidine is licensed for	
		_	
		use in children in some countries, including the USA, It is used to inhibit	
		gastric acid secretion and may be given orally in the management of gastro esophageal reflux disease, the following initial oral doses of famotidine	
		are suggested, according to age,	wing initial oral doses of famoudille
			once doily
		Under 3 month: 500 micrograms/kg	
		3 month up to year: 500 microgram/kg twice daily.	
			ce daily up to 40mg twice daily may
		also be given.	

		In the management of peptic ulcers, famotidine may be given to children from 1 to 16 years in an initial oral dose of 500 micrograms/kg daily either in a single dose at night or in 2 divided doses  However we will apply to change our drug product from S-famers 10mg  Syrup (Famotidine 10mg/5ml) Reg No. 064293 to famotidine 40mg 5ml dry powder for Suspension as per decision of the honorable registration board.
5.	M/s Macquin's International Karachi	Kindly refer to your letter No. F 3-6/2021-Reg-1 (M-313) Misc date 29 December 2021, the above subject, it is respectfully submitted that our CEO is suffering from Covid 19 he will be available as per doctor Prescription in mid-February,  It is therefore humble requested he may please be allowed to appear before the Registration Board for Personal hearing by 10 February 2022. We shall be remain grateful in anticipation for granted us one month time on medical ground.

### **Proceedings During 317th Meeting:**

- 1. The instant proceedings have been undertaken in pursuance of decision taken by the Registration Board in its 313<sup>th</sup> Meeting wherein Show Cause Notices were issued to all registration holders of Famotidine in strength/ dosage form other than 40mg/5ml Powder for Oral Suspension *viz.* Famotidine 10mg/5ml and 40mg/5ml Liquid Suspension under Section 7(11)(d) of the Drugs Act, 1976 for cancellation or suspension of registration of the aforementioned registered drug products in the public interest. The Show Caused registration holders of the drug in question were also issued personal hearing notices under Section 42 of the Drugs Act, 1976 and were heard at length.
- 2. A list of pharmaceutical companies which did not attend the meeting is at Annexure-A; a list of pharmaceutical manufacturers who have shown satisfaction on instant proceedings undertaken by the Registration Board, without raising any challenge to the show cause notice and consented to accepting the decision of the Registration Board is at Annexure-B; a list of pharmaceutical companies who either attended personal hearing or responded through written arguments is at Annexure-C; a list of pharmaceutical companies who have filed Writ Petitions before the Hon'ble Lahore High Court, Lahore is at Annexure-D.
- 3. For the sake of brevity and to avoid repetition, all arguments advanced by the registration holders are amalgamated. The arguments raised in brief in replies to the notice as well as during personal hearing were that the Board in its 313<sup>th</sup> Meeting without conducting any proper fact finding enquiry decided to issue show cause notices by disregarding that many registrations of the drug had subsisted for more than a decade without any reported adverse

effects; similarly, the show cause notice and personal hearing notices were also devoid of reasons and hence the same are *void ab initio*. The Board had granted registration of drug after satisfying itself of its safety and efficacy and cannot now take a somersault. Non-registration or unavailability of a drug in Reference Regulatory Authorities is an irrational ground for questioning the safety and efficacy of drugs since these have proved effective in the domestic market for years; furthermore, the aforementioned ground is alien to the drug laws and cannot be invoked for any regulatory action. Lastly, it was argued that discontinuation of the drug would adversely affect the patients along with incurring immense financial loss upon the registration holders.

- 4. Record has been perused with the able assistance of the representatives of the registration holders and arguments have been heard. Since common questions of law and facts are involved, therefore, all notices are decided through a common order.
- 5. Succinctly stated the facts of the matter are that the Registration Board in its various meetings considered the cases of, *inter alia*, Famotidine in strength/ dosage form other than 40mg/5ml Powder for Oral Suspension i.e. the drugs in question. It was concluded that from the available record and reviewing of information available from the Reference Regulatory Authorities ('RRAs') that no data regarding efficacy of Famotidine in strength/ dosage form other than 40mg/5ml Powder for Oral Suspension is available, so continuity of the formulations was not considered justifiable. With regards to the drug in question, decision has already been taken in the 250th Meeting of the Board dated 09th and 10th of July, 2015, which is reproduced as hereunder:

### "Decision:

- i. Applicants shall revise their formulation as per innovator (new registration application with complete fee) within six months if manufacturing facility is approved by CLB.
- ii. For already registered drugs, same procedure as mentioned above (at Sr. No. i) shall be adopted. Otherwise show cause notice shall be issued for de-registration of registered drugs in this formulation.
- iii. All such application shall be processed on priority basis.".
- 6. In the meanwhile, DRAP Authority in its 70<sup>th</sup> Meeting held on 05-09-2019 decided the following:

"For formulations containing "drugs" which were previously registered by the Registration Board and have proof of availability and prescription of last 10 years but are not available in the Reference Regulatory Authorities shall continue to be considered/registered as drugs until and unless withdrawn on Safety, Efficacy and Quality reasons."

7. Subsequently, Registration Board in its 296<sup>th</sup> Meeting held on the 8<sup>th</sup>-10<sup>th</sup> September, 2020, decided to request the DRAP Authority to review its above mentioned decision in the following words:

"Since, all such formulations which are not approved by the Reference Regulatory Authorities; the safety and efficacy profile cannot be established in the absence of a well-established system for reporting of adverse events, so a reference shall be forwarded to DRAP's Authority with the request to review the decision taken in its 70th meeting held on 05-09-2019. In this regard, PE&R Division shall prepare a comprehensive document/agenda for consideration of Authority, keeping in view the practices adopted by RRA for all such formulations;"

8. The DRAP Authority in its 128<sup>th</sup> Meeting held on 14-12-2021 was pleased to accept the request the Registration Board and reviewed its 70<sup>th</sup> Minutes in the following words:

The Authority endorsed the recommendation of Registration Board and made following decisions:-

A. Partially reviewed its earlier decision taken in its 70<sup>th</sup> meeting held on 05-09-019, consolidated amended decision is reproduced as under:

[...]

- 4. Drug formulations/ strengths which are previously registered by the Registration Board but are not available in any Reference Regulatory Authorities, shall be reviewed and disposed of keeping in view of safety and efficacy evidence/ data in the reference Regulatory Authorities."
- 9. In pursuance of the above mentioned, Registration Board in 313<sup>th</sup> Meeting decided to issue Show Cause Notice to the Petitioner and other pharmaceutical concerns to all registration holders of Famotidine in strength/ dosage form other than 40mg/5ml Powder for Oral Suspension under Section 7(11)(d) of the Drugs Act, 1976 for cancellation or suspension of registration of the aforementioned in the public interest. Therefore, in pursuance of the decision by the DRAP Authority taken in its 128<sup>th</sup> Meeting, the instant proceedings are being undertaken.
- 10. It is to be noted at the outset that registration or licensing has been held by the Superior Courts to be a privilege not a right which can always be cancelled or suspended in accordance with the law. It has argued at length that the Registration Board granted registration after determining safety, efficacy and quality of drugs which was renewed over time, therefore, the Board cannot after passing of many years re-assess the safety, efficacy and quality of drugs. The argument is fallacious as Rule 27 of the Drugs (Licensing, Registration and Licensing) Rules, 1976 ('Rules, 1976') while providing the duration of drug registration also added that

the registration can always be cancelled or suspended earlier as well. The grounds on which the drug registration can be suspended or cancelled are provided in Section 7 (11) of the Drugs Act, 1976, and therefore, the argument that registration once granted will continue in perpetuity is against the law. Furthermore, Section 21 of the General Clauses Act, 1897, grants the Board the power to rescind any drug registration in accordance with the grounds provided in Section 7 (11) of the Drugs Act, 1976. The argument in discussion is also fallacious for the reason that scientific pharmaceutical knowledge is always in the process of evolution and decision based on knowledge available at one point of time cannot be used to defeat the just and fair decision to be taken in future with the broadening of knowledge. This principle has been encapsulated in Rule 30 (12) of the Rules, 1976, which grants the Board power to seek any information at any point in time post-registration regarding the safety, efficacy and quality of drugs. The Board has ample powers under Rule 30 (2) to rescind, vary or modify any decision taken by it in the larger public interest to perform its statutory regulatory duty of ensuring the provision of safe and efficacious drugs and medicines to the public at large.

- 11. The primary ground which has prevailed with the Board for initiating the instant proceedings is that the drug in question (Famotidine in strength/ dosage form other than 40mg/5ml Powder for Oral Suspension) is neither approved by any of RRAs nor any data regarding its efficacy is available. To better appreciate the argument, it is important to understand the scheme of the law which allows for placing reliance on RRAs as well as its importance for performing the statutory regulatory duties.
- 12. Applicant companies are generic drug product manufacturers. The generic drug product is pharmaceutically equivalent to the innovator's drug product as it contains the identical medicinal ingredients in the same amount/strength and dosage form and it must have same pharmacokinetics, pharmacodynamics, indications, contraindications, side effects etc. A generic drug product must work in the same way as that of innovator's drug product and, therefore, it can be interchanged with the innovator's drug product. Famotidine Liquid Suspension has no innovator and applicant companies have neither conducted nor provided any efficacy study to establish the aforementioned points (i.e., pharmacokinetics, pharmacodynamics, indications, contraindications, side effects etc.).
- 13. Criteria for grant of registration of any drug product is safety, efficacy and quality parameters and the onus for provision of relevant data to establish aforementioned parameters under the applicable law is upon the applicant/registration holder. For this purpose, applicant either needs to provide sufficient data to satisfy the aforementioned parameters by themselves, or

provide reference to approval of registration granted by any Reference Regulatory Authorities ('RRAs'); this serves the purpose for determining safety and efficacy of the drugs. RRAs are regulatory authorities of developed countries which have stringent regulatory regimen and have developed robust mechanisms for determining drug safety, efficacy and quality and their decisions are supported by the rapid advances in sciences as well as empirical studies. Even WHO supports the reliance by developing countries on decisions of the Stringent Regulatory Authorities to ensure availability of quality assured, safe and effective health products and to avoid redundancy, global harmonization of standards and wastage of limited regulatory and financial resources. This reliance enables Registration Board and DRAP to have evidence for robust, accurate and evidence based decision-making, considering that the products registered and sold in the countries of RRAs have already been strenuously evaluated to fulfil the harmonized standards of safety, efficacy and quality as adopted by WHO, ICH, etc. This reliance also enables DRAP being the national regulatory authority in undertaking post marketing surveillance, particularly of matters related to safety and efficacy of drug. RRAs have stronger reporting and information sharing system, which can be used by DRAP as a national regulatory authority as a useful tool for surveillance, new available treatments and new indications or contra-indications.

- 14. It is pertinent to mention that since adoption of RRA, DRAP has approved only those drug products which are either approved by RRAs based on their safety and efficacy assessment or after provision by the applicant pharmaceutical concern of relevant data regarding their safety, efficacy and quality. Moreover, DRAP has also started review process of already registered drugs to ensure availability of quality assured safe and effective therapeutic goods to ailing patients in the larger public interest.
- 15. The Registration Board in accordance with the global best practices, in its 275<sup>th</sup> Meeting held on 25<sup>th</sup> to 27<sup>th</sup> of October, 2017, decided to adopt the RRAs and their decisions "as reference for molecules/ formulations (in same dosage form and strengths) along with clinical trials for human purpose"; this decision was also upheld by the DRAP Authority in its 128<sup>th</sup> meeting. The aforementioned decision has since been applied by the Registration Board and also been followed by all pharmaceutical concerns for registration of their products without any caveat. Currently, all registered formulations and dosage of drugs and medicines in Pakistan are now required to comply with the details/ specifications as approved by RRAs or provide sufficient data for assessing safety, efficacy and quality of the drug product. Aforementioned decision has been taken to ensure availability

- of quality assured safe and effective medicines to ailing patients as it is matter of prime public health concern.
- 16. The adoption of RRAs allows the performance of the statutory duty to "adopt [...] standards and guidelines to ensure safety, efficacy, and quality of therapeutic goods" as ordained under Section 7 (t) of the DRAP Act, 2012. Therefore, the DRAP Authority [created under Section 2 (iv) and Section 7 of the DRAP Act, 2012] also approved the policy of reliance on RRAs in its 73<sup>rd</sup> Meeting held on 06-11-2019. Hence, the argument that reliance on RRAs is alien to the drug laws and without any basis for determining safety and efficacy of drugs is baseless. Furthermore, as all pharmaceutical concerns are effectively complying with decision by the Board regarding reliance on RRAs in approval of their drug products and have never raised any objection or caveat to it, therefore, they are restrained and estopped by their own conduct from challenging it in the instant proceedings.
- 17. As the legality of reliance on RRAs has been detailed above, the Board has undertaken a thorough inquiry of the registration and availability of Famotidine in strength/ dosage form other than 40mg/5ml Powder for Oral Suspension in RRAs. It was found that famotidine is registered only in the form of Dry Suspension with strength of 40mg/5ml. There is no evidence of approval of Famotidine liquid suspension in strengths of 10mg/5ml and 40mg/5ml in RRAs.
- 18. It is to be noted that data regarding efficacy of famotidine liquid suspension with strength of 10mg/5ml and 40mg/5ml has not been provided by the registration holders as under the law i.e. Rule 30 (12) of the Rules, 1976, the burden of proof is upon the person seeking to continue registration to advance data regarding the safety and efficacy of the drugs. It has been argued that the said drug has been freely available in the domestic market for years without any adverse effect being reported, which is proof enough of its safety and efficacy. However, no applicant can share any authentic clinical data regarding efficacy of famotidine liquid suspension with strength of 10mg/5ml and 40mg/5ml in their company rather argued that till data no adverse event has been reported after use of these formulations and argued that the absence of such data serve as an evidence for drug's safety and efficacy.
- 18. It is also to be noted that pharmacovigilance data or even stability studies data is not the substitute of positive data regarding the efficacy of drugs which has been universally accepted to arise only from valid clinical trials to be performed in accordance with the Bio-Study Rules, 2017. In light of the above discussed, allowing the registration of Famotidine in strength/dosage form other than 40mg/5ml Powder for Oral Suspension to continue shall not be in the public

- interest as statutory intent of enacting the drug laws is the provision of safe and efficacious drugs and medicines to the people at large without any compromise. The task of the regulator is to curb any potential future menace from advent of sub-therapeutic use of drug and thus adversely affecting the public at large rather than responding belatedly to public health crisis which could have been mitigated by applying the pre-cautionary principle.
- 19. The Board noted that regulatory action was being taken only against registration of Famotidine in strength/ dosage form other than 40mg/5ml Powder for Oral Suspension for lack of its efficacy data; all pharmaceutical concerns were still free to obtain registration of Famotidine 40mg/5ml Powder for Oral Suspension after completion of legal formalities. Therefore, the registration holders can still maintain the market share of their respective brand of the drug in question and hence, bear no financial or reputational loss. This observation was posed to all the registration holders during personal hearings, but no satisfactory reply was given by them for their insistence on maintaining registration of Famotidine in strength/ dosage form other than 40mg/5ml Powder for Oral Suspension which lacks data regarding its efficacy, rather than accepting registration of Famotidine 40mg/5ml Powder for Oral Suspension which is both safe and efficacious and also serves the same medical use. This will preserve them from any financial loss as they can serve the patients in dosage forms with evidence based efficacy profile of drug product.
- 20. It was argued by the representative of M/s Scotmann, Islamabad that Famotidine 10mg is approved in dispersible tablet dosage form in USFDA and is safe in patients with compromised renal clearance. Secondly, in patients with renal impairment, USFDA recommends dosage regimen of "20mg every other day" or an alternate regimen of "10 mg once daily (Since 20 mg or 40 mg tablet strength cannot be used for this dosage regimen, use an alternate famotidine formulation)". However, above recommendation is specific for patients of renal impairment. Furthermore, alternate famotidine formulation may not necessarily be 'famotidine 10mg/5ml suspension' as 'famotidine 10mg chewable tablet' is also approved by USFDA. It was also contended that dose adjustment is easy in 10mg/5ml as compared to 40mg/5ml. However, in response to a question raised by Registration Board it was responded that neither any approval has been granted by RRA which supports that both 10mg Tablet and liquid Suspension have same efficacy profile nor any document confirming efficacy of 10mg/5ml suspension is available with them for sharing with Registration Board.
- 21. Director DTL Karachi dissented with the decision taken by the Board and opined not to suspend registration of these products.

#### **Decision:**

In light of the foregoing discussions, risk-benefit analysis and public health impact of Famotidine 10mg/5ml and 40mg/5ml, the Board made following decisions:

- i. Suspended all drug registrations of Famotidine 10mg/5ml and 40mg/5ml Liquid Suspension under Section 7(11)(d) read with Section 42 of the Drugs Act, 1976 in the larger public interest, with immediate effect as neither approved by any Reference Regulatory Authorities nor efficacy data is available with any registration holder. Period of suspension will be for one (01) year or till demonstration of efficacy by conducting indigenous clinical trials in accordance with Bio Study Rules, 2017 or approval by Reference Regulatory Authorities whichever is earlier. After provision of aforementioned data, cases of such pharmaceutical firms shall be considered on merit by the Registration Board
- ii. Suspended manufacturing and import of these drug products immediately and directed to withdraw available stocks from the market in the larger public interest. QA&LT Division, DRAP will monitor and implement the decision in coordination with the respective provincial governments.
- iii. Final decision regarding pharmaceutical concerns who have obtained interim relief from the Hon'ble Lahore High Court, Lahore shall be announced after decision and direction by the Hon'ble Court. Legal Affairs Division is requested to place the instant decision before the Hon'ble Court and seek expeditious disposal of the matter in the larger public interest.
- iv. Recommended DRAP Authority for out of queue consideration of registration applications of Famotidine 40mg/5ml Dry Suspension in order to facilitate the registration holders affected by the instant decision.

	Non-Attendees
S.	Registration Holder
No.	Registration Holder
1.	Ali Industries, Plot No.239/C Sundar Industrial Estate Raiwind Road Lahore.,
2.	M/s Alliance Pharmaceuticals (Pvt) Ltd, Plot # 112-A, Hayatabad, Industrial Estate, Peshawar.
3.	M/s. Alson Pharmaceutical, 169, Road No. 7-B, Industrial Estate Hayatabad, Peshawar.
4.	Ameer Pharma (Pvt) Ltd, 23-KM, Sheikhupura Road, Lahore.,
5.	Axis Pharmaceuticals, 3-B Value Addition City 1.5 Km Khurrianwala – Sahanwala Road Faisalabad
6.	Care Pharmaceuticals, 8-KM Thokar, Raiwind Road, Lahore.
7.	M/s. E-Pharm Laboratories, A-40 S.I.T.E Super Highway North Karachi, Karachi.
8.	M/s Fedro Pharmaceutical Labs (Pvt) Ltd., 149-Industrial Estate, Jamrud Road, Hayatabad.
9.	M/s Fozan Pharmaceutical Industrial (Pvt) Ltd., 36- A, Industrial Estate, Hayatabad, Peshawar
10.	Fynk Pharmaceuticals, 19 K.M. G.T. Road, Kala Shah Kaku, Lahore.,
11.	Gray's Pharmaceuticals Plot No.02 Street No 03 National Industrial Zone,
	Rawat Islamabad
	(Previous Address: Gray's Pharmaceuticals, Plot No. 442, Street No. 7, I-9/2, Industrial Area,
	Islamabad.
12.	Harmann Pharmaceutical Labs (Pvt) Ltd., 16 -Km Multan Road, Lahore.,
13.	M/s Hicon Pharmaceuticals. 131-Industrial Estate, Hayatabad, Peshawar.
14.	M/s. Hisun Pharmaceutical Industry, 37-A R-02 Industrial Estate Gadoon Amazai, District Swabi.
15.	Irza Pharma (Pvt) Ltd, 10/2 Km Sheikhupura Road, P.O. Kot Abdul Malik, Sheikhupura.
16.	M/s. Kohs Pharmaceuticals (Pvt) Ltd., Plot No. P/8 S.I.T.E, Hyderabad.
17.	Life Pharmaceutical Company, 24-III, Industrial Estate, Multan
18.	Mediceena Pharma (Pvt) Ltd, , 27-K.M, Raiwind Road, Lahore
19.	M/s. Medicraft Pharmaceuticals (Pvt.) Ltd.,126-B Industrial Estate Hayatabad, Peshawar.
20.	Metro Pharmaceuticals, Plot No. 14 St. No. SS-2 National Industrial Zone (RCCI) Rawat Islamabad.
21.	Neomedix, Plot No.5, N-5 National Industrial Zone Rawat (Islamabad).
22.	Olive Laboratories Plot No.52-S-6 National Industrial Zone Rawat Rawalpindi.
23.	M/s. Onyx Pharmaceuticals Industries, 30-A Industrial Estate Mansehra.
24.	Previous Address:
	Mac & Rains Pharmaceuticals (Pvt) Ltd, 1.5 KM, Manga Raiwind Road, Manga Mandi, Lahore.
	<u>Current Address:</u>
	M/s Searle IV Solutions (Pvt) Ltd,
	1.5 KM, Manga Raiwind Road, Manga Mandi, Lahore.
25.	Rasco Pharma, 5.5 KM Raiwind Road Ali Razabad, Lahore,
26.	M/s. Regent Laboratories C-20, S.I.T.E Super Highway, Karachi
27.	Selomore Pharmaceuticals (Pvt) Ltd.,35 KM, Multan Raod, lahore
28.	M/s T.G. Pharma, E-30 Sector 15, Korangi Industrial Area, Karachi.
	[Previous Title: M/s. Unicorn Pharma] Karachi
29.	Theramed Pharmaceutical, 331-J-1 Johar Town Lahore,
30.	Wilshire Laboratories, 124/A, Kotlakhpat, Indus. Area, Township Scheme, Lahore.,
31.	M/s. Synchro Pharmaceuticals 77-Industrial Estate Kot Lakhpat Lahore.

## Annexure-B

	Attendees Having Agreement with RB Decision						
Sr. No.	Registration Holder	Statement of Agreement	Name & Designation of Representative (Attendees)				
1.	Akson Pharmaceuticals Co. (Pvt.) Ltd.	The firm agreed with the decision of Registration Board for all registration holders.	Mr. M. Azeem Q.C.M				
2.	M/s Atco Laboratories Ltd, B-18, S.I.T.E, Karachi.	The firm agreed with the decision of Registration Board for all registration holders. Further they have submitted that in USFDA 10mg Tablet is also registered but they have not provided any data confirming that both 10mg Tablet and Suspension have same efficacy profile or any document regarding efficacy of 10mg suspension.	Mr. Amjad Butt & Mr. Azhar Zaidi				
3.	M/s Bloom Pharmaceuticals Pvt. Ltd, Plot # 30, Phase I & II, Industrial Estate, Hattar.	The firm agreed with the decision of Registration Board for all registration holders.	Mr. Farhan Liaqat Manager Regulatory Affairs				
4.	M/s. Brookes Pharma (Pvt) Ltd., Plot No. 58-59, Sector No. 15, Korangi Industrial Area, Karachi.	<ul> <li>i. They have stated that 10mg/5ml is used as an Antacid by Doctors and 40mg/5ml is used as anti-Ulcer.</li> <li>ii. The firm agreed with the decision of Registration Board for all registration holders.</li> </ul>	Mr. Arshad M.Awan				
5.	Global Pharmaceuticals, Plot No 204-205, Kahuta Triangle, Industrial Area, Islamabad	<ul> <li>i. The firm agreed with the decision of Registration Board for all registration holders.</li> <li>ii. They also wanted to convert to 40mg/5ml dry suspension.</li> </ul>	Mr. M. Suleman Regulatory Manager				
6.	Gulf Pharmaceuticals, Plot No.4, St.No. S-6, National Industrial Zone, Rawat,	The firm agreed with the decision of Registration Board for all registration holders. However, firm has requested to give time to utilize the existing stock of finished products.	Mr. Shuja-ul- Hassan M. Khalique				
7.	M/s. Helix Pharma Pvt. Ltd., A-56, Manghopir Road S.I.T.E., Karachi.	The firm agreed with the decision of Registration Board for all registration holders.	Syed Shehzad Regulatory Manager				
8.	Max Pharmaceuticals, Rawalpindi	The firm agreed with the decision of Registration Board for all registration holders.	Waqar Muhammad Project Manager				
9.	M/s. Meditech Pharmaceuticals, 15-D Industrial Estate, Jamrud Road, Peshawar,	The firm agreed with the decision of Registration Board for all registration holders.	Faisal				
10.	M/s. Polyfine Chempharma, 51 Industrial Estate, Hayatabad, Peshawar.	The firm agreed with the decision of Registration Board for all registration holders.	Faisal				

11.	Previous Address: Mac & Rains Pharmaceuticals (Pvt) Ltd, 1.5 KM, Manga Raiwind Road, Manga Mandi, Lahore. Current Address: M/s Searle IV Solutions (Pvt) Ltd, 1.5 KM, Manga Raiwind Road, Manga Mandi, Lahore.	The firm agreed with the decision of Registration Board for all registration holders.	Yasir Yaqoob DM Regulatory
12.	Trigon Pharmaceutical (Pvt) Limited, 18 Km Raiwind Road, Lahore	The firm agreed with the decision of Registration Board for all registration holders.	Asad Khan Regulatory Manager
13.	Xenon Pharma, Lahore.	The firm agreed with the decision of Registration Board for all registration holders.	Adeel Shaikh Assistant Regulatory Manager
14.	M/s. Zafa Pharmaceutical Laboratories (Pvt.) Ltd., L-1/B Block 22 Federal B Industrial Area, Karachi	The firm agreed with the decision of Registration Board for all registration holders.	Irfan Habib QRM
15.	Werrick Pharmaceuticals, 216-217, I-10/3, Industrial Area, Islamabad.,	The firm informed that they are switching over to standard formulation i.e. Famotidine 40mg/5ml Dry suspension.	M. Tauqeer QCM

Annexure-C

			Aimexure-C
	Attendees 1	Having Disagreement/ Varying Stance	
Sr. No.	Registration Holder	Statement/ Stance	Name & Designation of Representative (Attendees)
1.	Ambrosia Pharmaceuticals, Plot No.18, St. No.9, National Industrial Zone, Rawat, Islamabad.,	<ul> <li>i. Available in China which covers 3.6 billion of total population and also available in India.</li> <li>ii. Firm was asked to provide data on which basis approvals were granted in India then firm replied that they have no data.</li> <li>iii. No ADRs are reported till now.</li> <li>iv. Firm has asked the Board that on which basis Board has issued notice to the firm. Board replied that the bases are Section 7 (11) (d) of the Drugs Act, 1976.</li> </ul>	Mr. Jaafar
2.	Hamaz Pharmaceuticals (Pvt) Ltd,, 22 Km Lutafabad Road, Multan.,	<ul> <li>i. Non-availability of said products in RRAs does not establish that the product is unsafe or toxic</li> <li>ii. They have submitted that personal hearing letter has no legal value as there is no violation of provision of Section 7(11).</li> <li>iii. Their product is registered and being marketed since many years and no ADRs are reported till to date which establishes that product is safe and effective.</li> <li>iv. Hence, the said product may not be cancelled and show-cause may be revoked.</li> </ul>	Mr. Atif Shah Regulatory Manager
3.	Jawa Pharmaceuticals (Pvt.) Ltd.,	<ul> <li>iv. It's an old registration.</li> <li>v. Doctors are satisfied</li> <li>vi. No market complaint has been reported till to date.</li> <li>vii. In response to question asked it was replied that no efficacy data is not available with the firm.</li> </ul>	Muhammad Ali Assistant Manager QC
4.	Lawrence Pharma (Pvt.) Ltd, 10.5Km Sheikhupura Road, Lahore.,	Firm informed that Technical person is not available and they will submit written response which is not received till now.	Kashif Adnan
5.	M/s Lowitt Pharma (Pvt) Ltd.,Plot No.24-Industrial Estate, Hayatabad, Peshawar.	<ul> <li>i. Registered for 10 to 11 years.</li> <li>ii. Preferred by Doctors.</li> <li>iii. No market complaint has been reported till to date.</li> <li>iv. In response to question asked it was replied that no efficacy data is not available with the firm.</li> <li>v. Dose calculation and administration in easy in 10mg/5ml.</li> </ul>	Syed Zahir Ali Plant Manager
6.	M/s Macter International Limited. F-216, S.I.T.E, Karachi.	i. Representative of M/s. Cibex Mr. Malik Zamir appeared and he was asked to submit registration letter	Representative of M/s. Cibex Mr. Malik Zamir appeared on behalf of

		of product registered in the name of M/s. Cibex.  ii. Non-availability of said products in RRAs does not establish that the product is unsafe or toxic  iii. They have submitted that personal hearing letter has no legal value as there is no violation of provision of Section 7(11).  iv. Their product is registered and being marketed since many years and no ADRs are reported till to date which establishes that product is safe and effective.  v. Hence, the said product may not be cancelled and show-cause may be revoked.	M/s. Macter. Representative of M/s. Cibex was advised to submit authority letter otherwise your presence cannot be considered but he has not submitted authority letter.
7.	Medisearch Pharmacal, Lahore.	<ul> <li>i. Their product is registered since 2004 and no ADRs are reported till now as product is safe and effective.</li> <li>ii. Firm was asked question to submit data regarding efficacy of said product and firm replied that they have no data.</li> <li>iii. This product is largely used in India and China.</li> </ul>	Farhan Khalid
8.	Medley Pharmaceutical, 41-A P.S.I.E Jhang Bahtar Road, Wah Cantt,	Registered since, August, 2009 and no ADRs are reported till now as product is safe and effective. Firm has no clinical data regarding its efficacy.	Asad Mughal Production Manager
9.	Miracle Pharmaceuticals (Pvt.) Ltd., Islamabad,	With the cancellation of 10mg/5ml product's market will be affected. The firm has relevant section & may revise their formulation as per RRA.	Muhamamd Naveed QCM Aftab Safdar Procurement
10.	Neutro Pharma (Pvt) Ltd, 9.5Km,SheikhupuraLahore,	<ul> <li>i. In China, India Famotidine 10mg is available which covers 38% of world population. It is also available in USA.</li> <li>ii. No ADRs were also reported in these countries nor any clinical trial data is available in these countries.</li> <li>iii. Their product is registered and being marketed since many years and no ADRs are reported till to date which establishes that product is safe and effective.</li> <li>iv. In BNF recommended daily dose is 10mg.</li> <li>v. In Drugs.com, recommended dose in Hyper-acidity is 10mg followed by 20mg and In Dyspepsia, Heart Burn, recommended dose is in divided doses of 10mg twice daily.</li> </ul>	Nazia

		vi. Non-availability of said products	
11	M/s Platinum Pharma aguti sala	in RRAs does not establish that the product is unsafe or toxic. vii. Hence, the said product may not be cancelled and show-cause may be revoked. viii.Further they have requested to consider application for conversion on For-5 instead of CTD.	Fahim Lakhani
11.	M/s Platinum Pharmaceuticals (Pvt) limited, A-20 North Western Industrial Zone, Bin Qasim, Karachi	Although no efficacy data is available with the firm. However, MRP of Famotidine 40mg/5ml Dry Suspension is not viable.	Plant Manager
12.	Previous Address: Evergreen Pharmaceuticals (Pvt) Ltd, Plot No. 590, Sundar Industrial Estate, Lahore. Current Address: M/s Allmed (Pvt) Ltd, Plot No. 590 Sundar Industrial Estate, Lahore	i.Registered since 14 years.  ii.No efficacy data is available.  iii.Reference was made to 70 <sup>th</sup> meeting of Authority.	Feroz Ahmad Manager Regulatory Affairs
13.	Scotmann Pharmaceuticals, 5D, I-10/3 Industrial Area, Islamabad	<ul> <li>i. They have already applied fresh application for registration of 40mg/5ml dry suspension.</li> <li>ii. Dose of 10mg is also safe in patients having compromised renal clearance.</li> <li>iii. 10mg is also available in dispersible tablet dosage form in USFDA.</li> <li>iv. Dose adjustment is easy in 10mg/5ml as compared to 40mg/5ml.</li> </ul>	Muhammad Amir DGM Tipu Sultan Akram GM Muhamamd Bilal DMRA
14.	Shaigan Pharmaceutical (Pvt) Ltd., 14-Km Adyala Road Post Office Dahgal Rawalpindi, Pakistan	Registered since 2000. No ADRs are reported.	Dr. Musarat Zulfiqar
15.	Raazee Therapeutics (Pvt) Ltd., 48-Km Lahore Kasur Road Kasur., Kasur, , Pakistan	<ul> <li>i. Their product is in market for 20 years and no ADRs are reported till now for this product nor for any other product as ADRs reporting system is available with the firm.</li> <li>ii. In BNF recommended dose is 10 mg.</li> <li>iii. In USFDA 10 mg Tablet is also registered.</li> <li>iv. In case of Hyper-acidity recommended dose 10 mg followed by 20 mg.</li> <li>v. In Dyspepsia, Heart Burn, recommended dose is in divided doses of 10 mg twice daily.</li> <li>vi. A question was raised that do you have any data confirming that both</li> </ul>	M. Saddiq Malik GM Regulatory Affairs

		10mg Tablet and Suspension have same efficacy profile or any document regarding efficacy of 10mg suspension. Then firm has replied that no data is available and time may be given for clinical trials.  vii. They will also apply for registration of dry suspension dosage form.				
- 0		esponded through Written Arguments				
Sr. No.	Registration Holder	Written Argument/ Statement				
16.	M/s Barrett Hodgson Pakistan (Pvt) Ltd. F/423, S.I.T.E., Karachi.	Our technical person who will participate in case and know all the relevant facts is on leave. Therefore, we urge and request you to kindly defer and grant us an adjournment to a next date of hearing wherein we shall make sure to participate with full facts and evidence of the case under discussion.				
17.	M/s. Prime Labs (Pvt) Ltd, 9.5 Km Sheikhupura Road, Lahore.,	evidence of the case under discussion.  Their product is available in market since last 17 years and no ADRs have been reported till now. They have quoted the reference of 70th meeting of Authority				
18.	M/s Adamjee Pharmaceuticals (Pvt.) Ltd., Plot 39, Sector 15, Korangi Industrial Area, Karachi.	Please cancel the said products after complete utilization of the packaging materials of the said products.				
19.	Helicon Pharmaceutek, Pakistan (Pvt) Ltd., Model Town Road, Faisalabad,	<ul> <li>i. This drug was registered on 09.08.2003. Thus, has a prescriber doctor's confidence in the brand. It is very long procedure for new registration.</li> <li>ii. Whereas we also have been granted Cantil 40mg tablet (Famotidine) under registration no. 016854. The patients who could not take tablet and have to choose take suspension according to the doctor's prescription.</li> <li>iii. Therefore, in the interest of patients and prescribing doctors we request for substituting the formulation from 10mg/5ml to 40mg/5ml in suspension form.</li> <li>iv. Necessary approvals may kindly be granted for complying with the decision of Registration Board in peculiar circumstances of our case of change of strength of our registered formulation namely Cantil Suspension registration no. 030273 from 10mg/5ml to 40mg/5ml. We follow the SOP's in this regard.</li> </ul>				
20.	M/s Macquin's International, F-2/H, PTC Industrial Complex S.I.T.E, Karachi.	<ul> <li>i. It is respectfully submitted that our CEO is suffering from Covid 19 he will be available as per doctor Prescription in mid-February,</li> <li>ii. It is therefore humble requested he may please be allowed to appear before the Registration Board for Personal hearing by 10 February 2022. We shall remain grateful in anticipation for granted us one month time on medical ground.</li> </ul>				
21.	M/s Sayyed Pharmaceutical (Pvt) Ltd.,Plot No. 67/2, Phase 3, Industrial Estate, Hattar. Haripur	<ul> <li>i. In Martindale 38<sup>th</sup> edition volume 2, Page 1842 famotidine is licensed for use in children in some countries, including the USA, It is used to inhibit gastric acid secretion and may be given orally in the management of gastro esophageal reflux disease, the following initial oral doses of famotidine are suggested, according to age,</li> <li>Under 3 months: 500 micrograms/kg once daily.</li> <li>3 months up to year: 500 microgram/kg twice daily.</li> <li>1-16 Years: 500 micrograms/kg twice daily up to 40mg twice daily may also be given.</li> </ul>				

		<ul> <li>i. In the management of peptic ulcers, famotidine may be given to children from 1 to 16 years in an initial oral dose of 500 micrograms/kg daily either in a single dose at night or in 2 divided doses</li> <li>ii. However, we will apply to change our drug product from S-famers</li> </ul>
		10mg Syrup (Famotidine 10mg/5ml) Reg No. 064293 to famotidine 40mg 5ml dry powder for Suspension as per decision of the honorable registration board.
22.	M/s. Z-Jans Pharmaceuticals (Pvt) Ltd., 148-A, Industrial Estate Hayatabad, Peshawar.	<ul> <li>i. It is stated that we will be agree with collective decision of the honorable board regarding our afore said product if the decision was for all the manufacturer in Pakistan.</li> <li>ii. You are hereby requested that grant us registration of the same product in Dry Suspension 40mg/5ml in mutual.</li> </ul>
23.	Unison Chemical Works, 15 Km Raiwind Road Lahore., Lahore	<ul> <li>v. Non-availability of said products in RRAs does not establish that the product is unsafe or toxic</li> <li>vi. They have submitted that personal hearing letter has no legal value as there is no violation of provision of Section 7(11).</li> <li>vii. Their product is registered and being marketed since many years and no ADRs are reported till to date which establishes that product is safe and effective.</li> <li>viii. Hence, the said product may not be cancelled and show-cause may be revoked.</li> </ul>
24.	Fynk Pharmaceuticals, 19 K.M. G.T. Road, Kala Shah Kaku, Lahore	<ul> <li>i. Non-availability of said products in RRAs does not establish that the product is unsafe or toxic</li> <li>ii. They have submitted that personal hearing letter has no legal value as there is no violation of provision of Section 7(11).</li> <li>iii. Their product is registered and being marketed since many years and no ADRs are reported till to date which establishes that product is safe and effective.</li> <li>iv. Hence, the said product may not be cancelled and show-cause may be revoked.</li> </ul>
25.	Epharm Laboratories, A-40, Road No. 1, S.I.T.E. Super Highway Industrial Area, North Zone, Karachi	<ul> <li>i. Non-availability of said products in RRAs does not establish that the product is unsafe or toxic</li> <li>ii. They have submitted that personal hearing letter has no legal value as there is no violation of provision of Section 7(11).</li> <li>iii. Their product is registered and being marketed since many years and no ADRs are reported till to date which establishes that product is safe and effective.</li> <li>iv. Hence, the said product may not be cancelled and show-cause may be revoked.</li> </ul>

	Attendees who have filled Court cases					
Sr. No.	Registration Holder	Statement/ Stance	Name & Designation of Representative (Attendees)			
1.	Paramount Pharma, 36, Industrial Triangle Kahuta Road, Islamabad,	<ul> <li>ii. It's an old registration.</li> <li>iii. Doctors are satisfied</li> <li>iv. No market complaint has been reported till to date.</li> <li>v. In response to question asked it was replied that no efficacy data is not available with the firm.</li> </ul>	Tasleem Ul Haq Manager Regulatory Affairs			
2.	Siza International (Pvt) Ltd, 18 KM, Main Ferozepur Road, Lahore	<ul> <li>i. Their product is in market for 20years and no ADRs are reported till now for this product nor for any other product as ADRs reporting system is available with the firm.</li> <li>ii. In BNF recommended dose is 10mg.</li> <li>iii. In USFDA 10mg Tablet is also registered.</li> <li>iv. In case of Hyper-acidity recommended dose 10mg followed by 20mg.</li> <li>v. In Dyspepsia, Heart Burn, recommended dose is in divided doses of 10mg twice daily.</li> <li>vi. A question was raised that do you have any data confirming that both 10mg Tablet and Suspension have same efficacy profile or any document regarding efficacy of 10mg suspension. Then firm has replied that no data is available and time may be given for clinical trials.</li> <li>vii. They will also apply for registration of dry suspension dosage form.</li> </ul>	M. Saddiq Malik GM Regulatory Affairs			
G N		Non-Attendees who have filled Court cases				
Sr. No.	Registration Holder		1' F			
4.		tical Products (Pvt) Ltd., D-122, Sindh Industrial Tr	rading Estate, Karachi.			
5.		Pvt) Ltd, 21-KM, Feroze Pur Road, Lahore				
6.	M/s. Cibex (Pvt) Ltd. F-4	405 S.I.T.E Karachi 000784				

# Case No.3. Personal Hearing Notices issued to the Registration Holders of Irrational combination - Paracetamol 500mg, Thioridazine 3mg and Caffeine 70mg.

Registration Board in its various meetings considered the subject mentioned case and finally in its 313<sup>th</sup> meeting held on 16<sup>th</sup>-18<sup>th</sup> Nov, 2021 decided to provide the opportunity of personal hearing to the following registration holders:

S.No.	Reg. No.	Product Name & Composition	Registration Holders
1.	015654	Diagesic-P Tablet	M/s Wilson's Pharmaceuticals,
		Each tablet contains:	387-388 Sector I-9 Industrial Area
		Paracetamol500mg	Islamabad.
		Thioridazine3mg	
		Caffeine70mg	
2.	063092	Pregesic Tablet	Existing Title: M/s ICI Pakistan Ltd.,
		Each tablet contains:	[Previous Title: M/s Cirin
		Paracetamol500mg	Pharmaceuticals (Pvt.) Ltd.]
		Thioridazine3mg	32/2A, Phase III, Industrial Estate, <u>Hattar.</u>
		Caffeine70mg	

Complete record of the case including previous proceedings and decisions of Registration Board have been reproduced as under:

### 1. Proceedings of M-263 held on 29th -30th Nov., 2016:

A combination of Paracetamol 500mg, Thioridazine 3mg and Caffeine is registered in Pakistan by the name of tablet Diagesic P of Wilson's Pharmaceutical Islamabad Registration no. 015654 and tablet Pregesic of Cirin Pharmaceutical Hattar Registration no.063092. The said combination is routinely prescribed by the physicians as analgesic and also is sold as OTC medicine by the pharmacies and medical store.

Thioridazine, a conventional anti-psychotic drug which was used in Schizophrenia and was discontinued in most of the western countries. Novartis had issued dear health care professional letter in July, 2000 for its research product Mallaril (thioridazine) regarding black box warning of QTc interval prolongation, arrhythmia (abnormal heart rhythm that can lead to sudden cardiac arrest), sudden death and limit its use only for schizophrenic patients who fail to show an acceptable response to adequate courses of treatment with other anti-psychotic drugs. In 2005 Novartis announced to discontinue all form of Thioridazine worldwide due to its questionable benefit risk profile. Moreover, the said combination is not registered in any stringent regulatory authorities (Canada, EU, FDA, PMDA, TGA and MHRA).

Rule 30(10)[a] of Drug (Licensing, Registering & Advertising), 1976 in respect of registered drugs shall be complied with the following provisions of the rule, stated as under:

"30(10). If a drug or any of its ingredients, which is imported or manufactured by a company in Pakistan is also approved for registration and free sale by its subsidiary, sister concern, associate or parent company in the country where it was originally developed or in any of the countries namely, U.S.A, European Union Countries, Canada, Japan, Australia and—

a. if that drug at any time, for safety reasons is withdrawn or banned or certain restrictions are imposed in any of the said countries, then it shall be the responsibility of the manufacturer in Pakistan or the case may be, the inventors, to immediately withdraw the drug from the market in Pakistan or, as the case may be to impose similar restriction and to inform the Registration Board within fourteen days of such an information having come to his knowledge and having taken the necessary action. The Registration Board after getting the said intimation shall take similar action for the same drugs available from other sources with the shortest possible time;"

The case was placed in 263<sup>rd</sup> meeting of Registration Board and Board decided as under;

### 2. Decision of M-263 held on 29th -30th Nov., 2016:

- i. The combination (Paracetamol 500mg, Thioridazine 3mg and Caffeine 70mg) is not available in any of the reference regulatory authorities as approved by the Board i.e. FDA, TGA, EMA, PMDA, MHRA, Health Canada, Germany, France, Switzerland, Sweden, Norway, Denmark, Austria and Netherland. Since, it is reported vide WHO newsletter no.1, 2005 about voluntary withdrawn of Thioridazine worldwide by the brand leader Novartis, hence all irrational combinations containing Thioridazine, which are also not existent worldwide be also withdrawn throughout the country.
- ii. Show cause notice will be served by the concerned Registration section to Wilson's Pharmaceutical Islamabad and Cirin Pharmaceutical Hattar for de-registration of drug.
- iii. Advised PE & R Division to confirm/status of registration of the said combination (other than two brands i.e. Diagesic-P and Pregesic) and inform Registration Board to initiate process for deregistration of products.

### 3. Proceedings of M-293 held on 06<sup>th</sup>-08<sup>th</sup> Jan, 2020:

The Board was informed that show cause notices were served to M/s. Wilson Pharmaceutical, Islamabad and M/s. Cirin pharmaceutical, Hattar regarding cancellation of registration under Drugs Act 1976 and rules framed there under. Later on, M/s. Wilson Pharmaceutical, Islamabad filed a case in the Court of Senior Civil Judge (West) Islamabad. The Court vide their order dated 01-11-2018 rejected plaint under order VII rule 11 of CPC.

It is pertinent to mention here that Provincial Drug Inspector, Nowshera has informed that the Registration Board in its  $263^{rd}$  meeting decided regarding the registration of Tablet Diagesic-P of M/s. Wilson Pharmaceuticals, Islamabad on account of safety and efficacy concerns. He has seized the said drug product from multiple sales outlets at district Nowshera and then served show cause notice to M/s. Wilson, Islamabad. In response, Mr. Tepu Sultan Akram, General Manager of M/s. Wilson Pharmaceuticals Islamabad replied him that registration of Diagesic-P Tablet (Reg.No.015654) is still intact and renewed regularly from the DRAP and no proceeding regarding the cancellation/de-registration of Diagesic-P Tablet is initiated by DRAP. He has therefore, requested for final decision by DRAP in the case to further proceed in the matter.

#### 4. Decision of M-293 held on 06th-08th Jan, 2020:

Registration Board deliberated on the matter in details and decided to give an opportunity of personal hearing as per Drug Act, 1976 and Rules framed there under to both the firms i.e M/s. Wilson Pharmaceuticals, Islamabad & M/s. Cirin Pharmaceuticals, Hattar in forthcoming meeting of Registration Board.

### 5. Reference received from Shifa International Hospital dated 18th Oct, 2021:

'Thioridazine' originally marketed by the brand name of Melliril by Novartis, was voluntarily recalled due to serious cardiac side effects and later many other countries suspended its usage/ registration or imposed restrictions for use. However, in Pakistan this medicine is still available by the name 'Diagesic-P' tablets (manufactured by Wilson Pharmaceuticals). Pharmacovigilance system in Pakistan is in rudimentary stage and how many patients have suffered/ are suffering due to this medicine is unknown. So in the best interes of patient safety it is requested that company is to be directed by DAP to remove this medicine Thioridazine from its combination product Diagesic-P.

### 6. <u>Decision of M-313 held on 16<sup>th</sup>-18<sup>th</sup> Nov, 2021:</u>

Registration Board discussed that as show-cause notices have already been issued to M/s Wilson Pharmaceuticals, Islamabad and M/s Cirin Pharmaceuticals (New Title: ICI Pakistan Ltd.), Hattar, therefore, Registration Board decided that management of above-mentioned firms shall be given the opportunity of personal hearing in the forthcoming meeting of the Board under section 42 of the Drugs Act, 1976.

Accordingly, notices have been issued to registration holders of "Diagesic-P" & "Pregesic" Tablet for personal hearing before the Registration Board on 17<sup>th</sup> May, 2022 at 10:00 A.M.

### **Proceedings During 317th Meeting:**

- 1. The instant proceedings have been undertaken in pursuance of decision taken by the Registration Board in its 263<sup>rd</sup> wherein Show Cause were issued to all registration holders of fixed dose combination containing Paracetamol 500mg, Thioridazine 3mg and Caffeine 70mg under Section 7(11) (b, c & d) and Rule 30(10)(a) of Drugs (Licensing, Registering & Advertising) Rules, 1976 for cancellation or suspension of registration of the aforementioned in the public interest. The Show Caused registration holders of the drug in question were also issued personal hearing notices under Section 42 of the Drugs Act, 1976 and were heard at length.
- 2. Despite of show cause notice issued to the two companies which hold registration of above-mentioned formulation, M/s Cirin Pharmaceuticals (Pvt.) Ltd. (Existing Title: ICI Pakistan), 32/2A, Phase III, Industrial Estate, Hattar did not avail the opportunity of personal hearing while, M/s Wilson's Pharmaceuticals, 387-388 Sector I-9 Industrial Area Islamabad appeared before Registration Board and presented their case.
- 3. The arguments raised in brief in reply to the notice as well as during personal hearing were that the registration reference for their product "Diagesic-P Tablets" was "Optagesic Tablets (containing the same ingredients)" which was marketed by Sandoz Pakistan in 1994 and widely prescribed by doctors and freely available in the global market. Later on, Novartis came into being after the merger of Sandoz and Ciba Geigy in 1996. The marketing portfolio of the newly established Novartis did not contain Optagesic. The marketing of Optagesic was therefore discontinued due to commercial reasons. The Board in its 263<sup>rd</sup> Meeting without conducting any proper fact finding enquiry decided to issue show cause notices by

disregarding that the drug had subsisted over a period of last 26 years without any reported adverse effects. While referring to the minutes of 296<sup>th</sup> meeting, the firm has stated that system for recording evidence of ADRs and their evaluation is not well established till to date, therefore, the absence of such data in itself is a stopple for any proceeding whatsoever for deregistration of Diagesic-P Tablet. Furthermore, the firm has contended that until now since the first show cause served in 2017, the drug has not been evaluated considering scientific grounds, therapeutic equivalencies and pharmacodynamic aspects as deliberated by the Board vide the same 296<sup>th</sup> meeting with respect to those products which have been withdrawn by the Reference Regulatory Authorities due to marketing/ commercial reasons. Therefore, the present exercise of issuance of show cause notice is uncalled for & premature. Moreover, grounds of show-cause are also baseless as 3mg Thioridazine in Diagesic-P Tablet is being compared with Mellaril (Thioridazine) which is available in strengths of 10mg to 200mg.

- 4. Record has been perused with the able assistance of the representatives of the registration holder and arguments have been heard.
- 5. As per USFDA, Thioridazine Hydrochloride tablets (10mg-200mg) are indicated for the management of schizophrenic patients who fail to respond adequately to treatment with other antipsychotic drugs. Due to the risk of significant, potentially life threatening, proarrhythmic effects with thioridazine treatment, thioridazine hydrochloride tablets should be used only in patients who have failed to respond adequately to treatment with appropriate courses of other antipsychotic drugs, either because of insufficient effectiveness or the inability to achieve an effective dose due to intolerable adverse effects from those drugs. The usual starting dose for adult schizophrenic patients is 50 mg to 100 mg three times a day, with a gradual increment to a maximum of 800 mg daily if necessary. Considering one of the arguments that Diagesic-P (Paracetamol 500mg, Thioridazine 3mg and Caffeine 70mg) contains only 3mg of thioridazine which may not be associated with the aforementioned ADRs, it is to be noted that data supporting safety and efficacy of 3mg thioridazine in a formulation which also contains 'Caffeine' and 'Paracetamol' is not available in any RRA nor any safety and efficacy data submitted by the pharmaceutical firms.
- 6. Succinctly stated the facts of the matter are that the Registration Board in its various meetings considered the case of, *inter alia*, fixed dose combination containing Paracetamol 500mg, Thioridazine 3mg and Caffeine 70mg i.e. the drug product in question. Although, the concern initially raised when it was reported vide WHO newsletter no.1, 2005 about voluntary withdrawn of Thioridazine worldwide by the brand leader Novartis. Later on, it was concluded that from the available record and reviewing of information available from the Reference Regulatory Authorities ('RRAs') that although generic versions of Thioridazine Tablets

(10mg-200mg) are approved and still available in RRAs in comparison to which the fixed dose combination of Diagesic-P (Paracetamol 500mg, Thioridazine 3mg and Caffeine 70mg) contains far less quantity/strength of thioridazine. However, data regarding safety and efficacy of the instant combination (Paracetamol 500mg, Thioridazine 3mg and Caffeine 70mg) is neither available in RRAs nor any data to establish safety and efficacy has been submitted by any pharmaceutical concern. Hence, continuing registration of the formulations was not considered justifiable keeping in view safety and efficacy parameters which are mandatorily required for continuing with registration of any drug. Therefore, it was decided in the 263<sup>rd</sup> Meeting dated 29<sup>th</sup> and 30<sup>th</sup> February, 2016 to issue Show Cause Notices to the registration holders in accordance with the law explained above, to seek response as to why the registrations should not be cancelled.

7. In the meanwhile, DRAP Authority in its 70<sup>th</sup> Meeting held on 05-09-2019 decided the following:

"For formulations containing "drugs" which were previously registered by the Registration Board and have proof of availability and prescription of last 10 years but are not available in the Reference Regulatory Authorities shall continue to be considered/registered as drugs until and unless withdrawn on Safety, Efficacy and Quality reasons."

8. Subsequently, Registration Board in its 296<sup>th</sup> Meeting held on the 8<sup>th</sup>-10<sup>th</sup> September, 2020, decided to request the DRAP Authority to review its above mentioned decision in the following words:

"Since, all such formulations which are not approved by the Reference Regulatory Authorities; the safety and efficacy profile cannot be established in the absence of a well-established system for reporting of adverse events, so a reference shall be forwarded to DRAP's Authority with the request to review the decision taken in its 70th meeting held on 05-09-2019. In this regard, PE&R Division shall prepare a comprehensive document/agenda for consideration of Authority, keeping in view the practices adopted by RRA for all such formulations;"

9. The DRAP Authority in its 128<sup>th</sup> Meeting held on 14-12-2021 was pleased to accept the request the Registration Board and reviewed its 70<sup>th</sup> Minutes in the following words:

The Authority endorsed the recommendation of Registration Board and made following decisions:-

A. Partially reviewed its earlier decision taken in its 70<sup>th</sup> meeting held on 05-09-019, consolidated amended decision is reproduced as under:

[...]

- 4. Drug formulations/ strengths which are previously registered by the Registration Board but are not available in any Reference Regulatory Authorities, shall be reviewed and disposed of keeping in view of safety and efficacy evidence/ data in the reference Regulatory Authorities."
- 10. In pursuance of the above mentioned, Registration Board in 313<sup>th</sup> Meeting decided to issue Personal Hearing Notice to all registration holders of fixed dose combination containing Paracetamol 500mg, Thioridazine 3mg and Caffeine 70mg under Section 42 of the Drugs Act, 1976 for cancellation or suspension of registration of the aforementioned in the public interest. Therefore, in pursuance of the decision by the DRAP Authority taken in its 128<sup>th</sup> Meeting, the instant proceedings are being undertaken.
- 11. It is to be noted at the outset that registration or licensing has been held by the Superior Courts to be a privilege not a right which can always be cancelled or suspended in accordance with the law. It has argued at length that the Registration Board granted registration after determining safety and efficacy of drugs which was renewed over time, therefore, the Board cannot after passing of many years re-assess the safety and efficacy of drugs. The argument is fallacious as Rule 27 of the Drugs (Licensing, Registration and Licensing) Rules, 1976 ('Rules, 1976') while providing the duration of drug registration also added that the registration can always be cancelled or suspended earlier as well. The grounds on which the drug registration can be suspended or cancelled are provided in Section 7 (11) of the Drugs Act, 1976, and therefore, the argument that registration once granted will continue forever on the basis of its market life is against the law. Furthermore, Section 21 of the General Clauses Act, 1897, grants the Board the power to rescind any drug registration so made in accordance with the grounds provided in Section 7 (11) of the Drugs Act, 1976. The argument in discussion is also fallacious for the reason that scientific pharmaceutical knowledge is always in the process of evolution and decision based on knowledge available at one point of time cannot be used to defeat the just and fair decision to be taken in future with the broadening of knowledge. This principle has been encapsulated in Rule 30 (12) of the Rules, 1976, which grants the Board power to seek any information at any point in time post-registration regarding the safety and efficacy of drugs. The Board has ample powers under Rule 30 (2) to rescind, vary or modify any decision taken by it in the larger public interest to perform its statutory regulatory duty of ensuring the provision of safe and efficacious drugs and medicines to the public at large.
- 12. Applicant companies are generic drug product manufacturers. The generic drug product is pharmaceutically equivalent to the innovator's drug product as it contains the identical

medicinal ingredients in the same amount/strength and dosage form and it must have same pharmacokinetics, pharmacodynamics, indications, contraindications, side effects etc. A generic drug product must work in the same way as that of innovator's drug product and, therefore, it can be interchanged with the innovator's drug product. As status of innovator's drug product 'Optagesic Tablet (as claimed by M/s Wilson, Islamabad)' is not accessible and M/s Wilson, Islamabad has not submitted any data supporting safety, efficacy and the then approval status in RRAs of "Optagesic Tablet". Furthermore, applicant companies have neither conducted nor provided any safety and efficacy study to establish the aforementioned points (i.e., pharmacokinetics, pharmacodynamics, indications, contraindications, side effects etc.).

- 13. The primary ground which has prevailed with the Board for initiating the instant proceedings is that the drug in question is neither approved by any of RRAs nor any data regarding safety and efficacy of fixed dose combination containing Paracetamol 500mg, Thioridazine 3mg and Caffeine 70mg is available. Furthermore, in this regard, the firm's stance stating withdrawal of aforementioned combination is due to commercial reasons could neither be verified from any source nor M/s Wilson was able to provide any document to substantiate their claim. To better appreciate the argument, it is important to understand the scheme of the law which allows for placing reliance on RRAs as well as its importance for performing the statutory regulatory duties.
- 14. Criteria for grant of registration of any drug product is safety, efficacy and quality parameters and the onus for provision of relevant data onus for provision of relevant data to establish aforementioned parameters under the applicable law is upon the applicant/registration holder. For this purpose, applicant either needs to provide sufficient data to satisfy the aforementioned parameters by themselves, or provide reference to approval of registration granted by any Reference Regulatory Authorities ('RRAs'); this serves the purpose for determining safety and efficacy of the drugs. Reference Regulatory Authorities ('RRAs') are regulatory authorities of developed countries which have stringent regulatory regimen. They have developed robust mechanisms for determining drug safety, efficacy and quality and their decisions are supported by the rapid advances in sciences as well as empirical studies. Even WHO supports the reliance by developing countries on decisions of the Stringent Regulatory Authorities, to avoid redundancy, global harmonization of standards and wastage of limited regulatory and financial resources. This reliance enables Registration Board to have evidence for robust and accurate decision-making, considering that the products registered and sold in the countries of reference regulatory authorities have already been strenuously evaluated to fulfil the harmonized standards of safety, efficacy and quality as adopted by WHO, ICH, etc.

- This reliance also enables DRAP being the national regulatory authority in undertaking post marketing surveillance, particularly of matters related to safety and efficacy of drug. RRAs have stronger reporting and information sharing system, which can be used by DRAP as a national regulatory authority as a useful tool for surveillance, new available treatments and new indications or contra-indications.
- 15. It is pertinent to mention that since adoption of RRA, DRAP has approved only those drug products which are either approved by RRAs based on their safety and efficacy assessment or after provision by the applicant pharmaceutical concern of relevant data regarding their safety, efficacy and quality. Moreover, DRAP has also started review process of already registered drugs to ensure availability of quality assured safe and effective therapeutic goods to ailing patients in the larger public interest.
- 16. The Registration Board in accordance with the global best practices, in its 275<sup>th</sup> Meeting held on 25<sup>th</sup> to 27<sup>th</sup> of October, 2017, decided to adopt the RRAs and their decisions "as reference for molecules/ formulations as reference for molecules/ formulations (in same dosage form and strengths) along with clinical trials for human purpose." The aforementioned decision has since been applied by the Registration Board and also been followed by all pharmaceutical concerns without any caveat. Currently, all registered formulations and dosage of drugs and medicines in Pakistan are now required to comply with the details/ specifications as approved by RRAs or provide sufficient data for assessing safety, efficacy and quality of the drug product. Aforementioned decision has been taken to ensure availability of quality assured safe and effective medicines to ailing patients as it is matter of prime public health concern.
- 17. The adoption of RRAs allows the performance of the statutory duty to "adopt [...] standards and guidelines to ensure safety, efficacy, and quality of therapeutic goods" as ordained under Section 7 (t) of the DRAP Act, 2012. Therefore, the DRAP Authority [created under Section 2 (iv) and Section 7 of the DRAP Act, 2012] also approved the policy of reliance on RRAs in its 73<sup>rd</sup> Meeting held on 06-11-2019. Hence, the argument that reliance on RRAs is without any basis for determining safety and efficacy of the drug which is not available in RRAs and, therefore, data regarding its ADRs is lacking. Furthermore, as all pharmaceutical concerns are effectively complying with decision by the Board regarding reliance on RRAs in approval of their drug products and have never raised any objection or caveat to it, therefore, they are restrained and estopped by their own conduct from challenging the reliance on RRAs.
- 18. As the legality of reliance on RRAs has been detailed above, the Board has initiated instant proceedings after conducting thorough inquiry of the registration and availability of the fixed dose combination (Paracetamol 500mg, Thioridazine 3mg and Caffeine 70mg) in RRAs.

  Minutes of 317<sup>th</sup> meeting of Registration Board (16-17 May, 2022)

Although, WHO newsletter No.1, 2005 (about voluntary withdrawn of Thioridazine worldwide by the brand leader Novartis) was one of the prime reasons for initiating proceedings of show cause notice issued in 2017. However, responding to one of the arguments raised by M/s Wilson i.e., 3mg of Thioridazine in 'Diagesic-P Tablet' is being irrationally compared with higher strengths (10mg-200mg) of Thioridazine in 'Mellaril' which was commercially withdrawn, it is acknowledged that although generic versions of Thioridazine Tablets (10mg-200mg) are approved and still available in RRAs. Furthermore, the fixed dose combination of Diagesic-P (Paracetamol 500mg, Thioridazine 3mg and Caffeine 70mg) contains far less quantity/strength of thioridazine. However, it is reiterated that the instant combination (Paracetamol 500mg, Thioridazine 3mg and Caffeine 70mg) has neither been approved by RRAs nor any pharmaceutical concern has submitted data supporting its safety and efficacy, both of which are ultimate grounds for initiating instant proceedings.

- 19. In taking high risk decisions such as determining the safety and efficacy of drugs, the globally accepted principle is to err on the side of caution and adopt the most stringent standards in the largest public interest. The Superior Courts in Pakistan have in various pronouncements held matters related to safety and efficacy of drugs to be directly affecting the constitutionally protected right to life of the people for which highest care and caution is to be adopted by the regulatory authority. It has also been held by the Hon'ble Court that in matters which affect the life and health of the people at large, precautionary principle is to be mandatorily adopted wherein the larger public interest must always give way to narrow corporate interests.
- 20. It is to be noted that data regarding safety and efficacy of the combination (Paracetamol 500mg, Thioridazine 3mg and Caffeine 70mg) has not been provided by the registration holders as under the law i.e. Rule 30 (12) of the Rules, 1976, the burden of proof is upon the person seeking to continue registration to advance data regarding the safety and efficacy of the drugs. It has been argued that the said drug has been freely available in the domestic market for years without any adverse effect being reported, which is proof enough of its safety and efficacy. However, the applicant could not share any adverse drug reporting system (pharmacovigilance system) in their company and the absence of such data might be the result of lack of reporting rather than serve as an evidence regarding the drug's safety and efficacy. Even otherwise, the absence of any adverse effects at one point of time is not a guarantee that it will not arise in the future and the statutory task of the regulator is to pre-emptively deter such a situation from ever occurring by applying the pre-cautionary principle.

- 21. It is also to be noted that pharmacovigilance data or even stability studies data is not the substitute of positive data regarding the safety and efficacy of drugs which has been universally accepted to arise only from valid clinical trials to be performed in accordance with the Bio-Study Rules, 2017. In light of the above discussed, allowing the registration of the combination (Paracetamol 500mg, Thioridazine 3mg and Caffeine 70mg) to continue shall not be in the public interest as statutory intent of enacting the drug laws is the provision of safe and efficacious drugs and medicines to the people at large without any compromise. The task of the regulator is to curb any potential future menace from adversely affecting the public at large rather than responding belatedly to public health crisis which could have been mitigated by applying the pre-cautionary principle.
- 22. Director DTL Karachi dissented with the decision taken by the Board and opined not to suspend registration of these products.

### **Decision:**

In light of the foregoing discussions, risk-benefit analysis and public health impact of the combination (Paracetamol 500mg, Thioridazine 3mg and Caffeine 70mg), the Board made following decisions:

- i. Suspended all drug registrations of the combination (Paracetamol 500mg, Thioridazine 3mg and Caffeine 70mg) under Section 7 (11) (b, c & d) read with Section 42 of the Drugs Act, 1976 in the larger public interest, with immediate effect as neither approved by any Reference Regulatory Authorities nor safety and efficacy data is available with any registration holder. Period of suspension will be for 1 year or till sharing of safety and efficacy data either by conducting clinical trials (to establish safety and efficacy) in accordance with the Bio-Study Rules, 2017 or approval by Reference Regulatory Authorities whichever is earlier. After provision of aforementioned data, cases of such pharmaceutical firms shall be considered on merit by the Registration Board.
- ii. Suspended manufacturing and import of these drug products immediately and directed to withdraw available stocks from the market. QA&LT Division, DRAP will monitor and implement the decision in coordination with the respective provincial governments.
- iii. Recommended Licensing Division, DRAP for approval of Qualified person for Pharmacovigilance (QPPV) / Local Safety Officer (LSO) whichever is applicable in licensed pharmaceutical units and advised PE&R and BE&R Divisions for similar action for importers of finished drug products as required under Pharmacovigilance Rules, 2022.

#### Case No.4. Review of Apremilast Tablet Range

Registration Board in its different meetings considered applications submitted for registration of different strengths of Apremilast Tablets. Detail is as under:

		Status of Apremilast Tablets Considered by the RB							
S/N	Meeting Reference	Name of Applicant			Registration Status				
1.	M-272	M/s Crystolite Pharma, Islamabad	Apremist Tablet 30mg	Approved	Registration issued dated 22-12-2021 (R#111052)				
2.	M-293	M/s S. J & G Fazul Ellahi (Pvt.) Ltd. Karachi	Ezla Tablet 10mg, 20mg & 30mg	Rejected	N/A				
3.	M-296	M/s Navegal Laboratories, Hattar	Aprem Tablet 10mg & 30mg	Deferred for Submission of application on Form-5D along-with differential fee & submission of stability study data as per guidelines provided in 293rd meeting of Registration Board.	N/A				
4.	M-307	M/s Tabros Pharma, Karachi	Pixel Tablet 10mg, 20mg & 30mg	Approved	Not yet issued.				

In this regard, MRP of Apremilast 30mg tablet has been fixed @Rs.3,559/4x14's vide S.R.O. 1582(I)/2021 dated 09-12-2021.

Following information regarding "Apremilast Tablet" has been extracted from SmPC/ product monographs available on official web-sites of various RRAs:

Apremilast is a phosphodiesterase 4 (PDE4) inhibitor i.e. indicated as a selective immunosuppressant for the treatment of Psoriatic Arthritis, Psoriasis and oral ulcers associated with Behçet's disease.


It has been approved by various reference regulatory authorities (RRAs) including USFDA, UK MHRA and TGA Australia in strengths of 10mg, 20mg and 30mg.

However, as per information available in RRAs, the recommended dosage and method of administration state that the treatment with Apremilast should be initiated by specialists experienced in the diagnosis and treatment of psoriasis, psoriatic arthritis or Behçet's disease.

Furthermore, the recommended dose of Apremilast is 30 mg taken orally twice daily, approximately 12 hours apart (morning and evening), with no food restrictions. In order to reduce the risk of GI symptoms, an initial titration schedule is required as shown below. No re-titration is required after initial titration.

Dose Titration Schedule										
Day 1         Day 2         Day 3         Day 4         Day 5         Day 6 8							6 &			
									thereafter	
AM	AM	PM	AM	PM	AM	PM	AM	PM	AM	PM
10mg	10mg	10mg	10mg	20mg	20mg	20mg	20mg	30mg	30mg	30mg

Accordingly, USFDA states that the product will be packaged as bottles containing 60 tablets of 30mg strength for regular use and as a blister pack containing 10mg, 20mg and 30mg strengths as a 2-week starter pack for proper titration. Similarly, initial starter packs/ titration blister packs have been approved by different RRAs. One of such example from USFDA has been placed as under:



Keeping in view the dosing/ titration schedule recommended by RRAs, instant case has been placed before the Registration Board for review of all previously granted approvals of Apremilast tablets.

#### **Decision:**

Keeping in view the reference product approved by RRAs which is available as "a blister pack containing Apremilast 10mg (4 Tablet), Apremilast 20mg (4 Tablets) and Apremilast 30mg (19 Tablets) as a 2-week starter pack for proper titration and a bottle containing 60 tablets of Apremilast 30mg for regular use", Registration Board made following decisions:

- i. Show Cause notice shall be issued to M/s Crystolite Pharmaceuticals, Plot No. 1 & 2, Street No. S-2 RCCI Industrial Estate, Rawat Islamabad under section 7(11)(d) of the Drugs Act, 1976 that why the registration of their product Apremist (Apremilast) Tablet 30mg (Reg.No.111052) may not be cancelled. The management of the firm shall also be given the opportunity of personal hearing in the forthcoming meeting of the Board under section 42 of the Drugs Act, 1976."
- ii. M/s Tabros Pharma (Pvt) Ltd. Plot No. L-20/B, Karachi Industrial Area, Sector-22, Federal B Area, Karachi shall be directed to revise/ standardize their applications of "Pixel Tablet 10mg, 20mg & 30mg" in line with the reference product approved by RRAs for further consideration of Registration Board.
- iii. A reference shall be forwarded to DRAP's Authority regarding out of que consideration of fresh applications received in context with point (i) and (ii) above.

# Case No.5. Request of M/s Sayyed Pharmaceutical (Pvt) Ltd., Hattar for import of Triazolam Working Standard.

Registration Board in its 313th meeting approved the following products of M/s Sayyed

Pharmaceutical (Pvt) Ltd,67/2, Phase 3, Industrial Estate, Hattar, Haripur:

I	II	III	IV
Sr #	Applied Brand Name with Composition and FPP Specifications	Demanded MRP, Pack Size	Decision of M-313
1.	Zolnex 0.5mg tablet Each tablet contains: Alprazolam0.5mg USP	3×10's As per SRO	<ul> <li>Approved.</li> <li>Firm shall submit content uniformity test data as per USP monograph before issuance of letter.</li> </ul>
2.	Zolnex 1 mg tablet Each tablet contains: Alprazolam1 mg USP	3×10's As per SRO	Manufacturer will place first three production batches on long term stability studies through out proposed shelf life and on accelerated studies for six months as per the
3.	Zolnex 0.25 mg tablet Each tablet contains: Alprazolam0.25 mg USP	3×10's As per SRO	commitment submitted in the registration application.  • Manufacturer will perform process validation of first three batches as per the commitment submitted in the registration application.

In line with the decision taken by the Registration Board, the firm submitted reports of content uniformity test. However, as per submitted detail, the test was not conducted in conformance with USP monograph of Alprazolam Tablet, which states addition of internal standard "Triazolam" in standard and sample preparation for analysis of content uniformity. Accordingly, vide letter dated 18-03-2022, the firm was requested to comply with the USP monograph of Alprazolam Tablet for assessment of content uniformity of dosage units and submit report/data in line with the decision taken by the Registration Board in its 313<sup>th</sup> meeting.

In response, the firm stated that the manufacturer of controlled drug substance "Alprazolam" has informed that the internal standard "Triazolam" will be provided with commercial stock only. In this context, the firm submitted an undertaking stating that data of content uniformity will be submitted prior to market the commercial batch.

Accordingly, registration of above-mentioned products was issued (vide letter dated 29-03-2022) with following additional condition:

"Before marketing of the above-mentioned products, the firm shall submit data of content uniformity test as per updated USP monograph of Alprazolam Tablet."

Later on, the firm requested for import of controlled drug substance "Triazolam working standard" for performance of content uniformity test. Break-up of required quantity as submitted by the firm is detailed as under:

Product Name	Quantity Required	Source		
Triazolam Working Standard	600mg	Cambrex Profarmaco Millano S.R.L. via		
		Curiel, 34-20067 Paullo Milano, Italy.		

For every 0.25 mg of alprazolam contained in the tablet, add 10 ml of internal standard solution to the container (Ref. USP 44)

Strength of tablets	Quantity required for preparation of stock internal standard solution	Dilution from stock internal standard solution	Final concentration	
0.25mg 0.5mg 1.0mg	66.6 mg (to be dissolved in 100ml of acetonitrile)	48/1000	0.032 mg/ml	

Volume of internal standard solution required for each strength	Stability Study (Time points)	Required Quantity of Triazolam
0.25 mg (10 ml x  10  Tablets = 100 ml)	Accelerated (initial, 3 <sup>rd</sup> and 6 <sup>th</sup> )	66.6 mg x  3 = 199.8 mg
0.5mg (20ml x 10 Tablets = 200ml) 1.0mg (40ml x 10 Tablets = 400ml)	Real (3 <sup>rd</sup> , 6 <sup>th</sup> , 9 <sup>th</sup> , 12 <sup>th</sup> , 18 <sup>th</sup> and 24 <sup>th</sup> )	66.6mg x 6 = 399.6mg
	Total	599.4 mg = 600 mg

In this regard, it is further informed that in 316<sup>th</sup> meeting (held on 15<sup>th</sup> -18<sup>th</sup> March, 2022), the Registration Board while deliberating a case regarding import of Innovator's Sample for FPP development, Pharmaceutical Equivalence and CDP Studies, decided to delegate power to the Chairman for deciding all those cases where approval/recommendation of Registration Board is required for import of controlled drug substance/innovator product's pack. While, minutes of 316<sup>th</sup> meeting were under process of finalization, instant request of M/s Sayyed, Hattar was received. Accordingly, keeping in view the condition of registration regarding "submission of data of content uniformity test as per updated USP monograph of Alprazolam Tablet before marketing of the ALP-SYD Tablet Range" letter communicating approval for procurement of required quantity was issued to Controlled Drugs Division, DRAP.

Submitted for information/ endorsement by the Registration Board.

**Decision:** 

Registration Board endorsed/ noted the information regarding recommendation forwarded to the Controlled Drugs Division, DRAP vide letter dated 21-04-2022 for procurement of 600mg of Triazolam working standard by M/s Sayyed Pharmaceutical (Pvt) Ltd,67/2, Phase 3, Industrial Estate, Hattar, Haripur.

Case No.6.

Request for Change in Registration Status of Panadol Extend Tablet (Reg. No.097070) from M/s GlaxoSmithKline Pakistan Limited, F-268, S.I.TE. Karachi to M/s GSK Consumer Healthcare Pakistan Limited, Petaro Road Jamshoro.

M/s GSK Consumer Healthcare Pakistan Limited, Petaro Road Jamshoro has requested for change in registration status of Panadol Extend Tablet (Reg. No.097070) from M/s GlaxoSmithKline Pakistan Limited, F-268, S.I.TE. Karachi to their name.

The product is currently registered for bulk import (of tablets) from Glaxo Welcome Spain and local repacking along-with quality control release at M/s GSK Consumer Healthcare Pakistan Limited, Petaro Road Jamshoro.

The applicant initially applied for change in registration status from M/s GlaxoSmithKline Pakistan Limited, F-268, S.I.TE. Karachi to their name along-with end to end local manufacturing (Dy.No.33338/R&I dated 21-12-2021). However, the firm vide their letter No.REF/DRAP/Reg-003/0322 received dated10-03-2022 (Dy.No.6669) revised their request by informing that **there is no change in manufacturing site (abroad) and repacking site (local)**. Detail is as under:

# Administrative Documents Submitted in the light of SOP approved by the Registration Board in its 283<sup>rd</sup> meeting

- i. Copy of GMP certificate on the basis of inspection conducted on 15-09-2020.
- ii. Copy of DML (000010) of M/s GSK Consumer Healthcare Pakistan Limited, Petaro Road Jamshoro renewed w.e.f. 31-03-2020.
- iii. Approval of "Tablet (General) Section" confirmed from Licensing Division's letter dated 27-01-2022.
- iv. NOC (dated 13-01-2022) issued by M/s. GlaxoSmithKline Pakistan Limited in the light of De-Merger order of Sindh High Court.
- v. Relevant undertakings & commitments.

Ι	II	III	IV	${f v}$
---	----	-----	----	---------

S.No.	Reg. No.	<b>Product Name &amp; Composition</b>	Registration Trail	Remarks
1.	097070	Panadol Extend Tablet Each modified release tablet contains: Paracetamol	Initial Reg. Date:  08-07-2019  Change of Source of Bulk Tablets dated 12- 03-2021: From M/s GlaxoSmithKline Australia Pty Limited, Consumer Healthcare Division, 82 Hughes Avenue, Ermington NSW 2115, Australia to M/s Glaxo Welcome, S.A. Avda. Extremadura, 3, Pol. Ind. Allendeduero, Arvanda de Duero, 09400 Burgos, Spain  Change of Local Repacking Site dated 26- 10-2021: From M/s GlaxoSmithKline Pakistan Limited, F-268, S.I.TE. Karachi to M/s GSK Consumer Healthcare Pakistan Limited, Petaro Road Jamshoro	Dy.No.33338/R&I     Dated 21-12-2021 Rs.30,000/- (Challan .No. 231886180613)     &     Dy.No.6669     10-03-2022

Since, the CTD application regarding change in local repacking site of instant product was considered by the Registration Board in its 312<sup>th</sup> meeting, accordingly same evaluation report has been reproduced below for record:

#### **Extract Taken from M-312**

# i. Application for Change of Local Repacking Site of Registered Product of M/s GSK Pakistan Limited, Karachi on Bulk Import & Local Repacking basis.

The firm has applied for change of local repacking site of the product already registered on Bulk Import & Local Repacking basis. The product to be repacked at GSK consumer Healthcare Pakistan Limited Petaro Road, Jamshoro (on contract manufacturing basis) and imported from M/s Glaxo Welcome, S.A. Avda. Extremadura, 3, Pol. Ind. Allendeduero, Arvanda de Duero, 09400 Burgos, Spain. Previously this product has been approved to be locally repacked at M/s GlaxoSmithKline Pakistan Limited. F-268, S.I.T.E. Karachi. The details are as under;

1.	Name, address of Applicant / Marketing Authorization Holder	M/s GlaxoSmithKline Pakistan Limited, F-268, S.I.T.E., Karachi
	Name, address of Manufacturing site.	Bulk Imported from:  M/s Glaxo Welcome, S.A. Avda. Extremadura, 3, Pol. Ind.  Allendeduero, Aranda de Duero, 09400 Burgos, Spain.  Local Repacking & Quality Release of tablet:  M/s GlaxoSmithKline Consumer Healthcare (Pakistan) Limited, Petaro Road, Jamshoro
	Status of the applicant	<ul><li>☐ Manufacturer</li><li>☑ Importer (Bulk import and local repack)</li></ul>

	☐ Is involved in none of the above (contract giver)
Status of application	<b>⊠</b> New Drug Product (NDP)
	☐ Generic Drug Product (GDP) Source change
Intended use of pharmaceutical	
product	Export sale
	☐ Domestic and Export sales
Dy. No. and date of submission	Dy. No. 10113(R&I) dated 31-03-2021
Details of fee submitted	PKR 50,000/ 15-02-2021
The proposed proprietary name / brand name	Panadol Extend Tablets (Reg. No. 097070)
Strength/concentration of drug of	
Active Pharmaceutical ingredient (API) per unit	Paracetamol665mg"
Pharmaceutical form of applied drug	Oral
Pharmacotherapeutic Group of (API)	Analgesics and antipyretics anilide
	Paracetamol (Acetaminophen)
	ATC code: N02B E01
Reference to Finished product specifications	USP
Status in reference regulatory authorities	Approved in TGA Australia
For generic drugs (me-too status)	Panadol Extend Tablets (Reg. No. 097070)
Name and address of API manufacturer.	Novacyl, Wuxi Pharmaceutical Co. Ltd. 8 Guang Shi-Xi Road China-214185, Wuxi ,Jiangsu province.
Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS –PD template. Firm has summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturer, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation/reference, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
Module-III Drug Substance:	Firm has submitted detailed drug substance data related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation/reference, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
Stability Studies of Drug Substance (Conditions & duration of Stability studies)	Firm has submitted stability data of 3 batches of API at accelerated ( $40^{\circ}$ C $\pm 2^{\circ}$ C/75% $\pm 5\%$ RH) and real time ( $25^{\circ}$ C $\pm 2^{\circ}$ C / $60\% \pm 5\%$ RH) conditions
Module-III Drug Product:	Firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols, control of excipients, control of drug product, specifications, analytical procedures, Reference/validation of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.
Pharmaceutical Equivalence	Firm has submitted that Bulk imported product is innovator/ reference product & already approved by Spanish Agency of Medicines & Medical Devices so requirement for pharmaceutical equivalence not needed.

	Analytical method validation/ verification of product			Firm has submitted analytical method verification data.				
	Stability studies	Firm has submitted stability studies data of three batches at both accelerated and long-term conditions.						
STA	BILITY STUDY DATA							
Man	ufacturer of API	Novacyl, V Jiangsu pr		macei	utical Co. Ltd.	8 Guang	Shi-Xi Road	China-214185, Wuxi,
API	Bulk tablet Lot No.	1501, 150	2 & 1503					
	cription of Pack ntainer closure system)	a laminate	of opaque	e PVC		PVDC se	aled with an	ck of 10's comprising aluminium foil. After
Stab	ility Storage Condition				5% ± 5%RH 75% ± 5%RH	[		
Time	e Period (for Bulk tablet)	Real time: Accelerate						
Time prod	`	Real time: Accelerate						
Freq	uency	Accelerate Real Time			ths) 18, 24 (Month	ns)		
Batc	eh No	FF5U		FF5	V		FF5W	
Batc	h Size	5001 table	ets	5003	3 tablets		5505 tablets	
Man	ufacturing Date	04-2020		05-2	2020		04-2020	
DO	CUMENTS / DATA PROV	IDED BY	THE APP	PLICA	ANT			
Sr.#	Documents To Be Pro	vided	Status					
1.	COA of API		Yes					
2.	Approval of API by authority of country of origin certificate of API manufacture by regulatory authority of origin.	in or GMP arer issued	Copy of certificate of suitability No. R1-CEP 2002-214-Rev 03 issued by the European Directorate for the Quality of Medicines & Healthcare in the name of Novacyl, Wuxi Pharmaceutical Co. Ltd. 8 Guang Shi-Xi Road China-214185, Wuxi ,Jiangsu province. dated 19 July 2018.					
3.	Protocols followed for constability study and details of		Yes					
4. Data of 03 batches will be supported by attested respective documents like chromatograms, laboratory reports, data sheets etc.		ments like	Yes					
5. Documents confirming import of Bulk tablets etc.			Copy of i	tch	e attested by A		DRAP, Karac ty Imported.	hi.  Date of approval  by DRAP
			6H6E 3B5L XX21	}	05/20 dated 03.06.2020	Panadol tablet 60 15509 t	65mg bulk int.	17-06-2020
6. All provided documents will be attested (name, sign & stamp) for ensuring authenticity of data/documents.		Yes						
7. Commitment to continue real time stability study till assigned shelf life of the product.		Yes						

8. Commitment to follow Drug Specification Rules, 1978.

### REMARKS OF EVALUATOR

- Firm has submitted stability data of API at accelerated  $(40^{\circ}\text{C} \pm 2^{\circ}\text{C} / 75\% \pm 5\%\text{RH})$  and real time  $(25^{\circ}\text{C} \pm 2^{\circ}\text{C} / 60\% \pm 5\%\text{RH})$  conditions that justification submitted by the firm as follows:
  - Panadol Extend Tablets are manufactured in Spain for bulk export and local packaging in Pakistan therefore subject stability on raw material was performed in Spain. Where stringent window of ambient temperature is supportive and endorsed that raw material is stable even at 25°C. Kindly note that it is also supported by ICH Q1A (R2) Stability Testing of New Drug Substances and Products, which allow applicant to decide whether long term stability studies are performed at  $25^{\circ}\text{C} \pm 2^{\circ}\text{C} / 60\% \pm 5\% \text{RH}$ ) conditions. Rest accelerated conditions are same in each case. Besides we have also submitted bulk and finished tablets stability studies for Zone IVa, required for end products in Pakistan market.
- Firm has submitted copy of Eudra GMP certificate for the manufacturing site of bulk product i.e., M/s Glaxo Welcome, S.A. Avda. Extremadura, 3, Pol. Ind. Allendeduero, Aranda de Duero, 09400 Burgos, Spain, issued on the basis of inspection conducted on 03-09-2019.
- Following is a list of the processes performed at different sites:

S.No.	Activity	SITE Name	SITE Name
1.	Bulk tablet Manufacturing	Glaxo Welcome, Spain	
2.	Packaging		GSK, Pakistan
3.	Process validation	Glaxo Welcome, Spain	
4.	Bulk tablet product testing	Glaxo Welcome, Spain	
5.	Raw material testing/control	Glaxo Welcome, Spain	
6.	Manufacturing process control	Glaxo Welcome, Spain	
7.	FG testing/control		GSK, Pakistan
8.	FG Stability studies Zone IV		GSK, Pakistan
9.	Analytical method verification		GSK, Pakistan

The firm has also submitted the following documents;

- i. Application on Form-5F.
- ii. Copies of initial registration letter (08-Jul-19).
- iii. Copies of DML & last inspection report (15<sup>th</sup> Sep 2020) of M/s GSK consumer Healthcare Pakistan Limited Petaro Road, Jamshoro
- iv. Original & legalized CoPP of manufacturer of source (Certificate No.31334/2020 dated 06-May-2020 issued by Spanish Agency of Medicines & Medical Devices) valid for TWO YEARS.
- v. Contract manufacturing agreement between M/s GSK consumer Healthcare Pakistan Limited Petaro Road, Jamshoro & M/s GlaxoSmithKline Pakistan Limited, Karachi (registered office) 35 Dockyard Road, West Wharf, Karachi-74000. Dated 11.07.2019.
- vi. Undertaking.

### **Decision of 63-PRVC:**

The Committee referred the case to Registration Board since Chairman is not authorized for the grant of contract manufacturing permission.

### **Decision of M-312:**

Registration Board acceded to request of firm for change of local repacking (blistering and secondary packaging) site of above registered product from M/s Glaxosmithkline Pakistan Limited. F-268, S.I.T.E. Karachi to M/s Glaxosmithkline Consumer Healthcare (Pakistan) Limited, Petaro Road, Jamshoro on contract manufacturing basis for the period of five years. Quality control testing and release will also be performed at M/s Glaxosmithkline Consumer Healthcare (Pakistan) Limited, Petaro Road, Jamshoro.

Decision: Registration Board deferred the case for submission of updated approval status of the applied formulation alogwith safety and efficacy profile in reference regulatory authorities adopted by the Board in its 275<sup>th</sup> meeting. Moreover, the Board further advised to submit valid and legalized CoPP of the product as existing has been expired.

# Case No.7. Request for Change in Registration Status of Product from M/s Novartis Pharma Pakistan Ltd, 15 West Wharf Dockyard Road, Karachi to M/s Novartis Pharma Pakistan Ltd, C-21, S.I.T.E Area Karachi

M/s Novartis Pharma Pakistan Ltd, C-21, S.I.T.E Area Karachi (DML # 000003) has requested for change in registration status of following product from M/s Novartis Pharma Pakistan Ltd, 15 West Wharf Dockyard Road, Karachi (DML # 000193) to their name. The product was registered on 13-02-2020 through contract manufacturing basis from M/s. GlaxoSmithKline Consumer Healthcare Pakistan Ltd., Petaro Road Jamshoro Sindh (DML 000010) for the period of 30months:

Koac	d Jamshoro Sindh (DML 000010) for the period of 30months:
	Administrative Documents Submitted in the light of SOP approved by the Registration Board in
	its 283 <sup>rd</sup> meeting
i	Acknowledgement copy of application for issuance GMP certificate dated 24-06-2021
ii.	Copy of DML of M/s Novartis Pharma Pakistan Ltd, C-21, S.I.T.E Area Karachi (DML # 000003) w.e.f.
	18-09-2020.
iii.	Copy of Tablet (General) section approval letter dated 28-12-2021 issued by Licensing Division in the
	name of M/s Novartis Pharma Pakistan Ltd, C-21, S.I.T.E Area Karachi (DML # 000003)
iv.	NOC (dated 11-03-2022) from M/s Novartis Pharma Pakistan Ltd, 15 West Wharf Dockyard Road,
	Karachi (DML # 000193).
v.	Relevant undertakings & commitments.

The case was referred to Pharmaceutical Evaluation Cell/ QMS for scrutinization/evaluation. Detail of submitted documents remarks of evaluators have been mentioned as under:

Ι	II	III	IV	V	
S/N	Reg. No.	Product Name & Composition (As per Registration letter)	Registration Trail	Dy. No./ Fee/ Date Remarks	
1.	024660	Annuva Dispersible Tablets Each tablet contains: Diclofenac free acid 46.50 eq. to diclofenac sodium50mg (Manufacturer's Specification)	Initial Reg. Date: 13-02-2020	Dy. No.32512 29-11-2021 DS#16208384382 Rs.30,000/- 25-11-2021	
		lress of Applicant / Marketing tion Holder	M/s. Novartis Ph S.I.T.E. Area, Ka	arma (Pakistan) Limited, C-21, rachi	
	Name, add	lress of Manufacturing site.	M/s. Novartis Pharma (Pakistan) Limited, C-21, S.I.T.E. Area, Karachi		
	Status of the applicant  Status of application  Intended use of pharmaceutical product  Evidence of availability of manufacturing facility		<ul><li>☑ Manufacturer</li><li>☐ Importer</li><li>☐ Is involved in none of the above (contract giver)</li></ul>		
			☐ New Drug Prod ☐ Generic Drug P Application is for	` '	
			<ul><li>☑ Domestic sale</li><li>☐ Export sale</li><li>☐ Domestic and Export sales</li></ul>		
			Firm has submitted copy of letter from Assist Director Licensing dated 3-01-2021 for "Approva Regularization of Layout plan" including tal section (General)		
	The propo	sed proprietary name / brand name	Annuva Dispersibl	le Tablet	

Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each tablet contains: Diclofenac free acid 46.50 eq. to diclofenac sodium 50mg
Pharmaceutical form of applied drug	Dispersible Tablet
Pharmacotherapeutic Group of (API)	Analgesic, Anti-inflammatory
Reference to Finished product specifications	Manufacturer's specification
Proposed Pack size	Product already registered
Proposed unit price	Product already registered
The status in reference regulatory authorities	Voltaren Dispersible tablet of M/s Novartis approved by Germany.
For generic drugs (me-too status)	Not Applicable
GMP status of the Finished product manufacturer	Firm has submitted copy of an application submitted in the office of Additional Director (E&M) DRAF Karachi for the issuance of GMP certificate dated 24-06-2021.
Name and address of API manufacturer.	Amoli Organics Private Limited, Plot N 322/4, Shed Area, G.I.D.C., Vapi, District – Valsad, Stat Gujarat, INDIA PIN – 396
Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS- template. Summarized information related nomenclature, structure, general property solubilities, physical form, manufacture description of manufacturing process and control impurities, specifications, analytical procedures a its verification, batch analysis and justification specification, reference standard, container clos system and stability studies of drug substance a drug product is submitted.
Module III (Drug Substance)	Firm has submitted detailed drug substance description of manufacturing process and control impurities, specifications, analytical procedures a its validation, batch analysis and justification specification, reference standard, container close system and stability studies of drug substance.
Stability studies	Firm containing API has submitted 66 months r time stability data at 25±2 Degree C and 60±5 perc RH for batches DA/0606/0027A, DA/0607/0028 DA/0606/0029A.
Module-III (Drug Product):	The firm has submitted detail of manufacture description of manufacturing process and control impurities, specifications, analytical procedu (including dissolution testing at acidic and buff medium) and its verification studies, batch analy and justification of specification, reference standar container closure system and stability studies of disproduct.

	Pharmaceutical equivalence and comparative dissolution profile			Firm has stated that it is not Applicable since Novartis Pharma is the Innovator of Annuva Dispersible		
	aissolution prome			Tablets		
	Analytical method validation/verification of product			Method validation studies have submitted including Precision of instrument, Specificity, Accuracy, Linearity & Range, Repeatability, Intermediate Precision, Robustness, Stability of solution.		
		STABILIT	ΓY S	STUDY DATA		
Man	ufacturer of API	Amoli Organics Priv	vate	Limited		
API	Lot No.	DA/2103/0013B				
	cription of Pack ntainer closure em)	Alu-PVC blister pack carton box, Pack Size			mation leaflet in a unit folding	
Stab Cone	ility Storage dition	Real time: 30°C / 65% Accelerated: 40°C / 75				
Time	e Period	Real time: 6 months Accelerated: 6 months	S			
Freq	uency	Accelerated: 0, 1, 2, 3 Real Time: 0, 3, 6 (Me				
Batc	h No.	BAA156		BAA245	BAA246	
Batc	h Size	225 Kg		225 Kg	225 Kg	
Man	ufacturing Date	05-2021		06-2021	06-2021	
Date	of Initiation	02-2021		02-2021	02-2021	
No.	of Batches			03		
		Admini	stra	rative Portion		
1.		s approval of applicati ata of the firm (if any)	ons	The firm has not submitted any document.		
2.	. Approval of API/ DML/GMP certificate of Al manufacturer issued by concerned regulator authority of country of origin.					
3.	Documents for the paperoval from DRAP	procurement of API w (in case of import).	vith	h Submitted		
4.	Data of stability batches will be supported attested respective documents lichromatograms, Raw data sheets, COA, summary data sheets en			e		
5.	Compliance Record of HPLC software 21CFl & audit trail reports on product testing		FR	R N/A		
6.	6. Record of Digital data logger for temperature and humidity monitoring of stability chamber (real time and accelerated)				N/A	
	arks		т.			
	servations S.7.3: Stability studies o	f drug substance as per	Firm's response Submitted as per Zone-IV-b conditions.			
Zon 3.2.	Zone IV a shall be submitted.  3.2.S.4.1: Drug substance specifications and analytical procedures applied by Novartis Pharma			Submitted.		
	shall be submitted.					

Submitted invoice is of the subsequent date to that of date of manufacturing.	Firm has submitted copy of commercial invoice attested by AD DRAP I&E Karachi dated 14-05-2020 (Invoice no.
or date of manufacturing.	MVP2021/GEP00086)

### Decision Registration Board decided as under:

i. Cancelled registration of following product from the name of M/s Novartis Pharma Pakistan Ltd, 15 West Wharf Dockyard Road, Karachi (DML # 000193)

S. No.	Reg. No.	Product Name & Composition
1.	024660	Annuva Dispersible Tablets
		Each tablet contains:
		Diclofenac free acid 46.50 eq. to diclofenac
		sodium50mg
		(Manufacturer's Specifications)

- ii. Approved registration of following product in the name of M/s Novartis Pharma Pakistan Ltd, C-21, S.I.T.E Area Karachi (DML # 000003) with same registration numbers in the light of legal opinion furnished by Legal Affairs Division, DRAP vide letter F.No. 11-1/2018/DD(LA)-Vol-I dated 05-10-2021.
  - a) Manufacturer will place first three production batches of both products on long term stability studies throughout proposed shelf life and on accelerated studies for six months as per the commitment submitted in the registration application.

b) Manufacturer will perform process validation of first three batches of both products as per the commitment submitted in the registration application.

S. No.	Product Name & Composition
1.	Annuva Dispersible Tablets Each dispersible tablet contains: Diclofenac free acid 46.50 eq. to diclofenac sodium 50mg (Manufacturer's Specifications)

- iii. Reference will be sent to Costing and Pricing Division for confirmation of maximum retail price (MRP).
- iv. The firm shall submit fee of Rs. 7500/- for correction/pre-approval change in product specifications as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021.
- v. Registration letter will be issued after submission of CDP and pharmaceutical equivalence performed against the innovator's product i.e., Voltaren Dispersible tablet of M/s Novartis approved by Germany.

#### Case No.8. Correction in Minutes of 316th Meeting of Registration Board

Registration Board in its 316<sup>th</sup> meeting held on 15<sup>th</sup>-18<sup>th</sup> March, 2022 approved cases regarding change in registration status of following products from M/s Novartis Pharma Pakistan Ltd, 15 West Wharf Dockyard Road, Karachi (DML # 000193) to M/s Novartis Pharma Pakistan Ltd, C-21, S.I.T.E Area Karachi (DML # 000003). The products were registered on 22-01-2020 through contract manufacturing basis from M/s. GlaxoSmithKline Consumer Healthcare Pakistan Ltd., Petaro Road Jamshoro Sindh (DML 000010) for the period of 30months. Detail is reproduced as under:

# Administrative Documents Submitted in the light of SOP approved by the Registration Board in its 283<sup>rd</sup> meeting

- i. Acknowledgement copy of application for issuance GMP certificate dated 24-06-2021
- ii. Copy of DML of M/s Novartis Pharma Pakistan Ltd, C-21, S.I.T.E Area Karachi (DML # 000003) w.e.f. 18-09-2020.
- iii. Copy of Tablet (General) section approval letter dated 28-12-2021 issued by Licensing Division in the name of M/s Novartis Pharma Pakistan Ltd, C-21, S.I.T.E Area Karachi (DML # 000003)
- iv. NOC (dated 11-03-2022) from M/s Novartis Pharma Pakistan Ltd, 15 West Wharf Dockyard Road, Karachi (DML # 000193).

### v. Relevant undertakings & commitments.

The cases were referred to Pharmaceutical Evaluation Cell/ QMS for scrutinization/evaluation. Detail of submitted documents remarks of evaluators have been mentioned as under:

I	II	Ш	IV	V	
S/N	Reg. No.	Product Name & Composition (As per Registration letter)	Registration Trail	Dy. No./ Fee/ Date Remarks	
1.	013209	Lamisil 250mg Tablet Each tablet contains: Terbinafine250mg (Manufacturer's Specifications)	Initial Reg. Date: 22-01-2020	Dy.No.32946, 32947 dated 03-12-2021 & Dy. No. 26590 dated 24-09-2021 DS#53861318 Rs.30,000/-14-09-2021	
		lress of Applicant / Marketing tion Holder	M/s. Novartis Pharma Area, Karachi	(Pakistan) Limited, C-21, S.I.T.E.	
	Name, add	lress of Manufacturing site.	M/s. Novartis Pharma (P Karachi	akistan) Limited, C-21, S.I.T.E. Area,	
	Status of t	he applicant	<ul> <li>☑ Manufacturer</li> <li>☐ Importer</li> <li>☐ Is involved in none of the above (contract giver)</li> </ul>		
	Status of a	pplication	<ul> <li>□ New Drug Product (NDP)</li> <li>□ Generic Drug Product (GDP)</li> <li>Application is for Change of Manufacturing site</li> </ul>		
Intended use of pharmaceutical product		se of pharmaceutical product	<ul><li>☑ Domestic sale</li><li>☐ Export sale</li><li>☐ Domestic and Export sales</li></ul>		
	The proposed proprietary name / brand name		Lamisil 250mg Tablet		
Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit		•	Each Enteric, film coated controlled released tablet contains: 281.25mg terbinafine Hydrochloride equivalent to 250mg terbinafine		
	Pharmacei	atical form of applied drug	_	nite Biconvex, Round, beveled edged g it scored tablet from one side while n other side.	
	Pharmaco	therapeutic Group of (API)	Antifungals		
	Reference	to Finished product specifications	BP		
	Proposed 1	Pack size	1×10's		
	Proposed	anit price	Product already registered		
	The status	in reference regulatory authorities	Lamisil has been appr authorities such as Belgi	oved in many stringent regulatory um, Canada Australia.	
	For generi	c drugs (me-too status)	Not Applicable		
	GMP status of the Finished product manufacturer		GMP Inspection of the site has been carried out wit satisfactory report, waiting for DRAP to issue the GM Certificate		
	Name and	address of API manufacturer.	Novartis Pharma AG, Lichtstrasse 35, 4056 Basel		
	Module-II (Quality Overall Summary)		Firm has submitted QOS as per WHO QOS-PD template Summarized information related to nomenclature, structure general properties, solubilities, physical form, manufacturers		

		specifications, analytical analysis and justification	ring process and controls, impurities, procedures and its verification, batch of specification, reference standard, and stability studies of drug substance itted.	
		nomenclature, structure physical form, manufact process and controls, i procedures and its valida	niled drug substance data related to , general properties, solubilities, turers, description of manufacturing mpurities, specifications, analytical ation, batch analysis and justification e standard, container closure system ug substance.	
Stability studies		Degree C and 60 perce 830923C0063, 830923C0		
		along with degradation	submitted 6 months real time stability studies of finished pharmaceutical API stability studies is not as per Zone	
Module-III (Drug Product):		The firm has submitted detail of manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedure (including dissolution testing at acidic and buffer medium) and its verification studies, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug product.		
Pharmaceutical equival dissolution profile	ence and comparative	Not applicable since Novartis Pharma is the Innovator of Lamisil Tablets		
		Method verification studies have submitted including Precision of instrument, Specificity, Accuracy, Linearity & Range, Repeatability, Intermediate Precision, Robustness, Stability of solution.		
	STABILI	TY STUDY DATA		
Manufacturer of API	M/S Novartis Pharma	AG, Lichtstrasse 35, 4056	6 Basel	
API Lot No.	C0237			
Description of Pack (Container closure system)	Alu-PVC blister packet box, Pack Size: 10 tal	•	mation leaflet in a unit folding carton	
Stability Storage Condition	Real time: 30°C / 65% Accelerated: 40°C / 75			
Time Period	Time Period Real time: 6 months		Accelerated: 6 months	
Frequency Accelerated: 0, 1, 2, 3 Real Time: 0, 3, 6 (Mo				
Batch No. BAA079		BAA083	BAA086	
Batch Size 100000 tab		100000 tab	100000 tab	
Manufacturing Date 04-2021		4-2021	04-2021	
Date of Initiation 01-2021		01-2021	01-2021	
No. of Batches		03		
	Admini	istrative Portion		
1. Reference of previous a with stability study data		The firm has not submitted	ed any document.	

2.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.		Copy of GMP certificate No. GMP-CH-1002421 06/08/2021 issued by Swissmedic valid till 06/08/2024.		
3.	Documents for the procurement of API with approval from DRAP (in case of import).		API Invoice and Packing List (Invoice Ref No. 2001624613) submitted along with Form 3 and Form 7.		
4.	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.			Submitted	
5.		Record of HPLC software 21CFR reports on product testing		Submitted	
6.	and humidit	Digital data logger for temperature y monitoring of stability chambers and accelerated)		Submitted	
Ι	II	III	IV	V	
S/N	Reg. No.	Product Name & Composition (As per Registration letter)	Registration Trail	Dy. No./ Fee/ Date Remarks	
2.	013208	Lamisil 125mg Tablet Each tablet contains: Terbinafine125mg (Manufacturer's Specifications)	Initial Reg. Date: 22-01-2020	Dy.No.32946, 32947 dated 03-12-2021 & Dy. No. 26590 dated 24-09-2021 DS#49808661696 Rs.30,000/-14-09-2021	
	Name, address of Applicant / Marketing Authorization Holder Name, address of Manufacturing site.		M/s. Novartis Pharma (Pakistan) Limited, C-21, S.I.T.E. Area, Karachi  M/s. Novartis Pharma (Pakistan) Limited, C-21, S.I.T.E. Area, Karachi		
	Status of the applicant		<ul> <li>☑ Manufacturer</li> <li>☐ Importer</li> <li>☐ Is involved in none of the above (contract giver)</li> </ul>		
	Status of ap	plication	<ul> <li>□ New Drug Product (NDP)</li> <li>□ Generic Drug Product (GDP)</li> <li>Application is for Change of Manufacturing site</li> </ul>		
	Intended use of pharmaceutical product		<ul><li>☑ Domestic sale</li><li>☐ Export sale</li><li>☐ Domestic and Export</li></ul>	sales	
	The propose	ed proprietary name / brand name	Lamisil 125mg Tablet		
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit		Each Enteric, film coated controlled released tablet contains: 240.622mg terbinafine Hydrochloride equivalent to 125mg terbinafine		
	Pharmaceutical form of applied drug		Whitish to yellowish white Biconvex, Round, beveled edged having bisect line making it scored tablet from one side while LAMISIL 125 written on other side.		
	Pharmacoth	erapeutic Group of (API)	Antifungals		
	Reference to	o Finished product specifications	BP		
	Proposed Pack size		1×10's		
	Proposed ur	nit price	Product already registered		

	The status	in reference regulatory authorities	Lamisil has been approved in many stringent regulatory authorities such as UK, Canada, Austria, and Australia.
	For generi	c drugs (me-too status)	Not Applicable
	GMP status of the Finished product manufacturer		GMP Inspection has been carried out with satisfactory report, waiting for DRAP to issue the GMP Certificate
	Name and	address of API manufacturer.	Novartis Pharma AG, Lichtstrasse 35, 4056 Basel
	Module-II (Quality Overall Summary)		Firm has submitted QOS as per WHO QOS-PD template. Summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product is submitted.
	Module III (Drug Substance)  Stability studies  Module-III (Drug Product):		Firm has submitted detailed drug substance data related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
			Firm has submitted 48 months real time stability data at 25 Degree C and 60 percent RH for batches 830923C0121, 830923C0063, 830923C0027.  Moreover, the firm also submitted 6 months real time stability along with degradation studies of finished pharmaceutical product since submitted API stability studies is not as per Zone IVA.
			The firm has submitted detail of manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedure (including dissolution testing at acidic and buffer medium) and its verification studies, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug product.
	Pharmaceu dissolution	ntical equivalence and comparative profile	Not Applicable since Novartis Pharma is the Innovator of Lamisil Tablets
	Analytical method validation/verification of product		Method validation studies have submitted including Precision of instrument, Specificity, Accuracy, Linearity & Range, Repeatability, Intermediate Precision, Robustness, Stability of solution.
		STABILI	TY STUDY DATA
	Manufacturer of API M/S Novartis Pharma AG, Lichtstras		sse 35, 4056 Basel
API L	API Lot No. C0235		
Pack (Cont	Description of Pack (Container closure system)  Alu-PVC blister packed along with patient information leaflet in a unit folding carton box, Pack 1: 10 tablets (1 x 10's).		patient information leaflet in a unit folding carton box, Pack Size

Stability Storage Condition		Real time: 30°C / 65% RH Accelerated: 40°C / 75% RH				
Time Period Real time: 6 months Accelerated: 6 months						
Frequ	iency	Accelerated: 0, 1, 2, 3, 6 (Months) Real Time: 0, 3, 6 (Months)				
Batch	No.	BAA124	BAA125		BAA126	
Batch	Size	180000 tab	180000 tab		180000 tab	
Manu Date	ıfacturinş	g 05-2021	05-2021		05-2021	
No. o	f Batche	s	0	3		
		Admini	istrative Port	ion		
1.		ce of previous approval of applications bility study data of the firm (if any)	The firm has	not submitted any o	document.	
2.	manufa	al of API/ DML/GMP certificate of API cturer issued by concerned regulatory y of country of origin.		IP certificate No. Grissmedic valid till (	GMP-CH-1002421 06/08/2021 06/08/2024.	
3.		ents for the procurement of API with all from DRAP (in case of import).	API Invoice attested by AD DRAP I&E Karachi dated November 2020 and Packing List (Invoice Ref No. 2001602337) submitted along with Form 3 and Form 7.			
4. Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.		respective documents like tograms,				
5.		ance Record of HPLC software 21CFR trail reports on product testing	Submitted			
6.	and hun	of Digital data logger for temperature nidity monitoring of stability chambers ne and accelerated)			itted	
Rema	arks of E	Evaluator:				
Sect	ion# (	Observations		Firm's response		
	r /. F	procedures used for routine testing of the Dr Active Pharmaceutical Ingredient by M Pharma (Pakistan) Limited is required.	ies of the Drug substance specifications and analytical redures used for routine testing of the Drug substance ive Pharmaceutical Ingredient by M/s. Novartis (Pakistan) Limited is required.		copies of the Drug substance nalytical procedures	
	f r	Submitted analytical method verification studies are not for the titration method applied for the Assay test in BP monograph of Terbinafine HCl.		submitted for the monograph.	verification studies have been titration method as per BP	
3.2. P.5.3 ICH Q2 guidelines recommend that "accura assessed using a minimum of 9 determina minimum of 3 concentration levels covering range (e.g., 3 concentrations/3 replicates each analytical procedure)."  Whereas submitted method verification reperformance of accuracy parameter determinations only.		the specified th of the total port includes		method verification studies for f accuracy parameter as per f ICH Q2 guidelines.		

### **Decision of M-316:**

Registration Board decided as under:

i. Cancelled registration of following products from the name of M/s Novartis Pharma Pakistan Ltd. 15 West Wharf Dockyard Road. Karachi (DML # 000193)

Pakisian I	Lia, 15 wesi wharj	Dockyara Roda, Karacni (DML # 000195)
S. No.	Reg. No.	Product Name & Composition

1.	013209	Lamisil 250mg Tablet
		Each tablet contains:
		Terbinafine250mg
		(Manufacturer's Specifications)
2.	013208	Lamisil 125mg Tablet
		Each tablet contains:
		Terbinafine125mg
		(Manufacturer's Specifications)

- ii. Approved registration of following products in the name of M/s Novartis Pharma Pakistan Ltd, C-21, S.I.T.E Area Karachi (DML # 000003) with same registration numbers in the light of legal opinion furnished by Legal Affairs Division, DRAP vide letter F.No. 11-1/2018/DD(LA)-Vol-I dated 05-10-2021.
  - a) Manufacturer will place first three production batches of both products on long term stability studies throughout proposed shelf life and on accelerated studies for six months as per the commitment submitted in the registration application.

b) Manufacturer will perform process validation of first three batches of both products as per the commitment submitted in the registration application.

S. No.	Product Name & Composition
1.	Lamisil 250mg Tablet
	Each Enteric, film coated controlled released tablet contains: 281.25mg terbinafine Hydrochloride equivalent to 250mg terbinafine (BP Specifications)
2.	Lamisil 125mg Tablet  Each Enteric, film coated controlled released tablet contains: 240.622mg terbinafine Hydrochloride equivalent to 125mg terbinafine (BP Specifications)

iii. Reference will be sent to Costing and Pricing Division for confirmation of maximum retail price (MRP).

However, the firm has now requested for correction in composition of both the products stating that their applied composition is as under:

S. No.	Product Name & Composition
1.	Lamisil 250mg Tablet
	Each tablet contains: 281.25mg Terbinafine Hydrochloride Equivalent to 250mg Terbinafine (BP Specifications)
2.	Lamisil 125mg Tablet  Each tablet contains: 140.622mg Terbinafine Hydrochloride Equivalent to 125mg Terbinafine (BP Specifications)

#### **Decision:** Registration Board decided as under:

i. Approved correction in minutes of 316<sup>th</sup> meeting, regarding composition of the above-mentioned products, as per following detail:

S. No.	Product Name & Composition
1.	Lamisil 250mg Tablet
	Each tablet contains: 281.25mg Terbinafine Hydrochloride Equivalent to 250mg Terbinafine (BP Specifications)

2.	Lamisil 125mg Tablet
	Each tablet contains: 140.622mg Terbinafine Hydrochloride Equivalent to 125mg Terbinafine (BP Specifications)

ii. Registration letter will be issued after submission of CDP and pharmaceutical equivalence performed against the innovator's product approved by reference regulatory authorities.

## Case No.9. Request of M/s Epharm Laboratories, Karachi for Correction/ Change in Strength/Composition of Approved Product.

Registration Board in its 284<sup>th</sup> meeting held on 31<sup>st</sup> July, 2018 – 01<sup>st</sup> August, 2018 approved the following product, however, registration letter could not be issued as different strengths were mentioned in composition and alongside the brand name. Detail is as under:

M/S. Epharm Laboratories, A-40, Road No. 1,		
S.I.T.E, Super Highway Industrial Area, North Karachi		
Nepapharm 1mg/ml ophthalmic Suspension		
Each <b>ml</b> contains:		
Nepafenac3mg		
Dy.No.17996; 12 -10-2017; Rs.20,000/- (12-10-2017)		
NSAID		
Form 5		
Manufacturers specification		
5ml; As per SRO		
NEVANAC of USFDA approved		
Barinep Ophthalmic Suspension of M/S Barret		
Hodgson		
The last GMP inspection conducted on 01-03-2018 and		
report concludes that current level of compliance was		
noted as satisfactory.		
Decision: Approved with innovator's specification.		

Reference/standard product approved by RRA is available in strengths of both 0.3% (3mg/ml) & 0.1% (1mg/ml) and likewise for generic products registered for local manufacturing. However, the firm has now submitted fee of Rs.30,000/-(Invoice #.8161814841) for change in label claim as per following details:

"Each ml contains:

Nepafenac .....1mg

(As per Innovator Specifications)"

Decision: Registration Board approved correction in composition of the above-mentioned product

as per following detail:

"Each ml contains:

Nepafenac ......1mg

(As per Innovator's Specifications)"

## Case No.10. Correction in Composition of Mirofer Injection of M/s Epharm Laboratories, Karachi.

Registration Board in its  $278^{th}$  meeting approved the following product of Epharm Laboratories, A-40, Road No. 1, S.I.T.E, Super Highway Industrial Area, North , Karachi as per below mentioned details:

Name and address of manufacturer /	M/s. Epharm Laboratories, A-40, Road No. 1, S.I.T.E, Super		
Applicant	Highway Industrial Area, North, Karachi		
Brand Name +Dosage Form + Strength	Mirofer Injection		
Composition	Each 5ml contains:		

	Iron-III Hydroxide <b>Polymaltose</b> Complex eq. to elemental			
	Iron100mg			
Diary No. Date of R& I & fee	Dy. No. 289, 25-08-2015, Rs. 20,000/- (24-08-2015)			
Pharmacological Group	Haematinic			
Type of Form	Form 5			
Finished product Specifications	USP			
Pack size & Demanded Price	5mlx5, Ampoule As per SRO			
Approval status of product in Reference	USFDA approved			
Regulatory Authorities				
Me-too status	Venofer by Gastro care			
GMP status	Last inspection conducted on 15-09-2016, "Good".			
Remarks of the Evaluator	<ul> <li>Method of sterilization of product is filtration rather than terminal sterilization. Firm has not justified on the basis of scientific data.</li> </ul>			
	Pharmacotherapeutic group: Anti-anaemic preparation, iron, parenteral preparation. (MHRA)			
Previous Decision	Deferred in 274 <sup>th</sup> meeting for the submission of GMP inspection report within the period of last one year.			
Evaluation by PEC	The firm has submitted copy of panel inspection on 27-4-2017 recommending grant of GMP certificate to the site.			
Decision: Approved				

#### **Proceedings of M-295:**

M/s Epharm, Karachi later on submitted clarification regarding their applied product i.e., Iron (III) Hydroxide Sucrose Complex eq. to Elemental Iron" instead of "Iron (III) Hydroxide Polymaltose Complex eq. to Elemental Iron" (mentioned in minutes of 278<sup>th</sup> meeting). Original dossier couldn't be retrieved, however, the firm submitted DRAP's endorsed receipt (25-08-2015) & copy of form-5 stating "Iron Sucrose Eq. to Iron 100mg/5ml Injection".

Accordingly, the case regarding correction in composition along-with standardization of label claim was submitted for consideration of Registration Board in its 295<sup>th</sup> meeting held on 08<sup>th</sup>-11<sup>th</sup> June, 2020.

#### **Decision of M-295:**

Registration Board deferred the case for verification of applied composition from original dossier submitted by the firm at the time of initial application.

Now, the firm has submitted fresh application along-with fee of Rs. 30000/- (Slip No.9147088401 verified from https://fee.dra.gov.pk/) for correction in composition/ label claim as per following detail:

#### "Each 5ml contains:

Iron (III) Hydroxide Sucrose Complex Eq. to Elemental Iron......100mg"

### **Decision:**

Registration Board approved correction in composition of the above-mentioned product as per following detail along-with change in brand name.

"Each ml contains:

Iron (III) Hydroxide Sucrose Complex eq. to Elemental Iron......20mg

(USP Specifications)
Pack size: 5mlx5's"

## Case No.11. Correction in Composition/ Pack size of Approved Products of M/s Welmed Pharmaceuticals Industries (Pvt) Ltd., Swabi

Registration Board in its 289<sup>th</sup> meeting approved the following products of M/s Welmed Pharmaceuticals Industries (Pvt) Ltd., 108, R:2 Industrial Estate, Gadoon, District Swabi as per below mentioned details:

mentioned details:			
Case No. 11(a)	1.00 vv. 1.00		
Name and address of manufacturer /	M/S Welmed Pharmaceuticals Industries (Pvt) Ltd., 108, R:2		
Applicant	Industrial Estat, Gadoon, District Swabi, Pakistan Contract		
	manufactured by: Previous: M/S Biolabs (Pvt) Ltd, Plot # 145,		
	Industrial Triangle, Kahuta Road Islamabad.		
	Now: Winthrox Laboratories (Pvt) Ltd K-219-A, SITE highway,		
	phase-II Karachi, Pakistan		
Brand Name +Dosage Form + Strength	Welrose injection		
Composition	Each ml contains: Iron sucrose complex eq. to elemental		
	Iron100mg		
Diary No. Date of R& I & fee	Dy.No.10649; 01-08-2017; Rs.50,000/- (01-08-2017)		
Pharmacological Group	Anti anaemics		
Type of Form	Form 5		
Finished product Specifications	BP		
Pack size & Demanded Price	As per SRO		
Approval status of product in Reference	Venofer Injection by Vifor (MHRA Approved)		
Regulatory Authorities			
Me-too status	Venofer injection by Gastrocare,		
GMP status	Last GMP inspection of Welwrd conducted on 12-07-2018 and		
	the report concludes		
	"All the observations in the inspection were discussed with the		
	firm management and technical persons. They were committed		
	to rectify all the observations. The firm may be considerd to be		
	operating in satisfactory level of cGMP compliance subject to		
	fulfillment of observations mentioned in the inspection report."		
	&		
	Last inspection of Bio-Labs conducted on 05-12-2017 & 06-12-		
	2017 and report concludes that firm is found at fair level of GMP		
Remarks of the Evaluator	compliance		
Remarks of the Evaluator	• Number of sections of applicant approved by Licensing Board:06		
	Number of products already registered/approved on contract		
	manufacturing in the name of applicant: 12		
Previous Decision(s) (M-285)	Deferred for following reasons:		
( ) ( ) /	Registration Board decided to defer all applied products of		
	contract manufacturing from M/s Bio Labs (Pvt) Ltd. of		
	Cephalosporin facility, Ampoule general section and infusion		
	(Non-Antibiotic and Antibiotic) section till the finalization of		
	inspection report for assessment and confirmation of		
	manufacturing capacity of M/s Bio Labs (Pvt) Ltd(M-285)		
Evaluation by PEC	Change manufacturing facility from M/S Biolabs to M/S Winthrox.		
Previous Decision(s) (M-288)	Deferred for following reasons		
	Deferred for updated status of GMP of the firm "Winthrox form QA		
	& LT division as inspection report was not submitted by firm (M-288)		
Evaluation by PEC	Last inspection of Winthrox conducted on 09-10-2018 and report		
	concludes that overall GMP compliance is rated as good.		
Decision: Approved			

Registration letter could not be issued as the reference product approved by RRA contains "Iron (III) Hydroxide Sucrose Complex eq. to Elemental Iron 20mg/ml or 100mg/5ml".

However, the firm has submitted fee of Rs.7500/- & Rs.30000/-(Invoice # 59422840201 & 5976072531 respectively, verified from <a href="https://fee.dra.gov.pk/">https://fee.dra.gov.pk/</a>) for correction in composition/ label claim in line with that of the reference product approved by RRA i.e., as under:

## "Each ml contains: Iron (III) Hydroxide Sucrose Complex eq. to Elemental Iron......20mg"

Case No. 11(b)	
Name and address of manufacturer / Applicant	M/S Welmed Pharmaceuticals Industries (Pvt) Ltd., 108, R:2 Industrial Estat, Gadoon, District Swabi, Pakistan Contract manufactured by: Previous: M/S Biolabs (Pvt) Ltd, Plot # 145, Industrial Triangle, Kahuta Road Islamabad.
	Now: Winthrox Laboratories (Pvt) Ltd K-219-A, SITE highway, phase-II Karachi, Pakistan
Brand Name +Dosage Form + Strength	Mecowel 500mcg injection
Composition	Each ml contains: Mecobalamine500mcg
Diary No. Date of R& I & fee	Dy.No.10651; 01-08-2017; Rs.50,000/- (01-08-2017)
Pharmacological Group	Co-enzyme-type vitamin B12
Type of Form	Form 5
Finished product Specifications	Manufacture's specification
Pack size & Demanded Price	5ml x 5's ; As per SRO
Approval status of product in Reference Regulatory Authorities	PMDA approved
Me-too status	Wycomin 500 mcg Injection by Wnsfeild Pharmaceutical,
Remarks of the Evaluator	Last GMP inspection of Welwrd conducted on 12-07-2018 and the report concludes  "All the observations in the inspection were discussed with the firm management and technical persons. They were committed to rectify all the observations. The firm may be considerd to be operating in satisfactory level of cGMP compliance subject to fulfillment of observations mentioned in the inspection report."  & Last inspection of Bio-Labs conducted on 05-12-2017 & 06-12-2017 and report concludes that firm is found at fair level of GMP compliance.  • Number of sections of applicant approved by Licensing Board:06
	<ul> <li>Number of products already registered/approved on contract manufacturing in the name of applicant: 12</li> </ul>
Previous Decision(s) (M-285)	Deferred for following reasons: Registration Board decided to defer all applied products of contract manufacturing from M/s Bio Labs (Pvt) Ltd. of Cephalosporin facility, Ampoule general section and infusion (Non-Antibiotic and Antibiotic) section till the finalization of inspection report for assessment and confirmation of manufacturing capacity of M/s Bio Labs (Pvt) Ltd(M-285)
Evaluation by PEC	Change manufacturing facility from M/S Biolabs to M/S Winthrox.
Previous Decision(s) (M-288)	Deferred for following reasons Deferred for updated status of GMP of the firm "Winthrox form QA & LT division as inspection report was not submitted by firm (M-288)
Evaluation by PEC	Last inspection of Winthrox conducted on 09-10-2018 and report concludes that overall GMP compliance is rated as good.

#### Decision: Approved with innovator's specification.

Registration letter could not be issued as the reference product approved by RRA has a pack size/volume per injection of 1ml containing 500mcg.

However, the firm has submitted fee of Rs.7500/- & Rs.30000/-(Invoice # 92451072834 & 8802685145 respectively, verified from <a href="https://fee.dra.gov.pk/">https://fee.dra.gov.pk/</a>) for correction in demanded pack size from "5mlx5's" to "1mlx10's".

#### **Decision:**

#### Registration Board decided as under:

i. For Case No. 11(a), approved correction in composition of the product as per following detail:

"Each ml contains:

(USP Specifications)
Pack size: 5mlx5's"

ii. For Case No. 11(b), approved correction in pack size of the product from "5mlx5's" to "1mlx10's".

#### Case No. 01: Availability of Paracetamol Containing Drug Products

1. DRAP, Lahore has forwarded a letter dated 17-12-2021 in which he has stated that Application No. 51/21 regarding Paracetamol availability was fixed in Drug Court Lahore on 16-12-2021. A comprehensive report regarding API Production by 04 firm located in Punjab and paracetamol tablet / respective dosage forms manufacturing status by firms and respective distribution record were submitted to the Honorable Drug Court, Lahore, in compliance of Orders dated 08-12-2021. The Order dated 08.12.201 is reproduced as under:

Dr Zia Hussain Federal Drug Inspector and Shahrukh Ali Assistant Director, DRAP Lahore are present before the court and request for submitting the complete report and need some more time. In the interest of justice, request is allowed and both the officers are directed to produce the complete report regarding the responsibility of shortage of tablet Paracetamol.

A direction is issued to the Additional Director DRAP Lahore to ensure the compliance of the order of this court and produce comprehensive report on 16-12-2021. In case on non-compliance of order of this court, the Additional Director DRAP shall appear in person before this court on the next date.

2. The cases of manufacturers had been forwarded by DRAP, Lahore to Registration Board under section 19(7) of Drugs Act, 1976 due to non-manufacturing of product in violation of condition of registration under Drugs (L, R &A) Rules, 1976. The learned Chairman Drug Court Lahore on dated 16.12.2021 passed following orders is reproduced as under:

Majida Mujahid Additional Director, Shahrukh Ali Assistant Director DRAP Lahore, Abdul Rasheed Sheikh, Syed Zia Hussain FIDs submit their report, according to that list 17 companies are issued notices regarding provision of production and distribution record of Paracetamol Tablet and other respective dosage. They have requested for some time to furnish the comprehensive report as they have already referred the matter to Director, Drug Registration Board and Board has to issue show cause etc and Director Board will pass appropriate order to the manufacturing companies, therefore sometime may be given in this regard. In the interest of justice, request is allowed and the case is adjourned to for 12-01-2022.

Director, Drug Registration Board DRAP Islamabad is directed to submit his report before the court on the date already fixed. Additional Director, Assistant Director DRAP & Federal Drug Inspectors Lahore are also directed to pursue the matter and submit their comprehensive report regarding the manufacturing and raw material of Paracetamol on the said date.

3. DRAP Lahore had forwarded the list of following firms, which are registration holders of Paracetamol Tablets 500mg / respective dosage forms and are not manufacturing the product. Details are as under:

Sr. No	Name of Manufacturer	Registration	Brand Name
		No.	
1.	M/s Sunshine Pharmaceuticals,	057610	Sunmol 500mg Tablets
	Emanabad, G.T. Road, Gujranwala,		Paracetamol 500mg
	Gujranwala		
2.	M/s Batala Pharmaceuticals 23/B	026306	Bamol 500mg Tablet
	Small Industrial Estate No. 2 Nea		Paracetamol 500mg
	Wapda Town, Khiali Bypass		
	Gujranwala		
3.	M/s Theramed Pharmaceuticals (Pvt)	065561	Therapol 500mg Tablet
	Ltd., 45-Km Multan Road Lahore.,		Paracetamol 500mg
	Lahore		

4.	M/s Allmed (Pvt) Ltd., Plot No. 590	054407	Everpol 500mg Tablets
	Sundar Industrial Estate Lahore.	00	Paracetamol 500mg
	Lahore		
5.	M/s Medisearch Pharmacal (Pvt) Ltd. 5	033688	Favasaf Suspension
	Km Raiwind Manga Road, Lahore.		Each 5ml contains:
			Paracetamol 120mg
6.	M/s NovaMed Pharmaceuticals (Pvt)	099847	Supamol 500mg Tablet
	Ltd., 28-Km Ferozepur Road Lahore,		Paracetamol 500mg
	Lahore		1 unuversition to the second
7.	M/s Pharmacare Laboratories (Pvt)	008233	Paracetamol 500mg Tablet
	Ltd. 129/1 Indus Estate Township		Paracetamol 500mg
	Lahore		1 unu cummi v v v mg
8.	M/s Medipak Ltd., Plot No 132	027706	Panafin 500mg Tablet
0.	Industrial Estate Kot Lakhpat Lahore.	027700	Paracetamol 500mg
9.	M/s Pulse Pharmaceuticals (Pvt) Ltd.	050864	Pyrecaf 500mg Tablets
<i>)</i> .	Mozay Badoke Raiwind Road (Sua	050001	Paracetamol 500mg
	Asil Road) Lahore		Taraccamor 500mg
10.	M/s Standpharm Pakistan (Pvt) Ltd.,	064623	Stanpol 500mg Tablet
10.	20 Km Ferozepur Road Lahore	001023	Paracetamol 500mg
11.	M/s Munawar Pharma Pvt Ltd, 31,	016577	Munapol 500mg Tablet
11.	Km, Ferozepur Road, Lahore.	010377	Paracetamol 500mg
12.	M/s CCL Pharmaceuticals (Pvt) Ltd.	023982	Epinol CF Tablet
12.	62 Industrial Estate Kot Lakhpat	023702	Paracetamol500mg
	Lahore		Pseudoephedrine Hcl 60mg
	Lanore		Chorpheniramine Maleate 4mg
	M/s CCL Pharmaceuticals (Pvt) Ltd.	099765	Trapadol Tablet
	62 Industrial Estate Kot Lakhpat	077703	Tramadol HCl: 37.5mg; Paracetamol:
	Lahore		325mg
13.	M/s Himont Pharmaceuticals (Pvt) Ltd.	105964	Himodol-P 37.5mg/325mg Tablet
13.	17-Km Ferozepur Road Lahore.	103701	Tramadol HCl: 37.5mg; Paracetamol:
	Tr Tim Terozepar Road Editore.		325mg
14.	M/s Pharma Lord (Pvt) Ltd., 12-Km	090132	Paralord 500mg Tablets
	Lahore Road Layyah.	., J. <b></b>	Paracetamol 500mg
15.	M/s. Magns Pharmaceuticals Plot No.	095680	Xaradol 325mg/37.5mg Tablet
	7B, Value Addition City, Sahianwala	0,2000	Tramadol HCl: 37.5mg; Paracetamol:
	Road, Khurrianwala, Faisalabad		325mg
	M/s. Magns Pharmaceuticals Plot No.	103383	Maggesic 450/35mg Tablet
	7B, Value Addition City, Sahianwala	-00000	Paracetamol: 450mg;
	Road, Khurrianwala, Faisalabad		Orphenadrine citrate: 35mg
16.	M/s Axis Pharmaceuticals, 3-B Value	060768	Axamol 500mg Tablet
10.	Addition City 1.5 Km Khurrianwala –	500700	Paracetamol 500mg
	Sahanwala Road Faisalabad.		
17.	M/s Lawrence Pharma (Pvt) Ltd. 10.5	059871	Lawramol Suspension
-/-	Km Sheidkupura Road Lahore.	007011	Each 5ml contains: -
	Tim bilotakapara Road Lanore.		Paracetamol 120mg
18.	M/s Xenon Pharmaceuticals (Pvt) Ltd.	011710	Paracetamol 500mg Tablet
10.	9.5-Km Sheikhupura Road Lahore	011/10	Paracetamol 500mg
19.	M/s Raazee Therapeutics (Pvt) Ltd.	030888	Tocor Forte Tablet
1).	48-Km Lahore Kasur Road Kasur.	050000	Codeine Phosphate15mg
	To-Kiii Lanoie Kasui Kuau Kasui.		_
			Paracetamol500mg

4. In a joint discussion of PE&R Division with Legal Affair's Division along with Legal Counsel regarding orders of Drug Court Lahore, it was discussed that field office, DRAP, Lahore has forwarded data of companies which are only in the area of Punjab. Hence, manufacturing status of Paracetamol Tablet 500mg

should also be obtained from all other manufacturers having registration of said product. Accordingly, letter was communicated to 120 companies (List attached at para 8 below) for provision of production and distribution data of paracetamol containing drug products.

- 5. In compliance of above orders of Drug Court Lahore dated 16-12-2021, a report was submitted in Drug Court Lahore. Chairman, Drug Court was concerned about the completion of legal proceedings against already referred cases and directed to complete it before next date of hearing i.e. 27-01-2022.
- 6. Case was forwarded to Legal Affair's Division for their opinion and opinion of said Division is reproduced as under;
  - a) "Rule 30 of the Drugs (Licensing, Registering and advertising) Rules, 1976 stipulates the conditions of Registration of Drug. Sub-rule (4) and (5) of the said rule states that "every drug shall be produced in sufficient quantity so as to ensure its regular and adequate supply in the market" and that "the manufacture of any drug shall not, without the prior approval of the Registration Board, be discontinued for period which may result in its shortage".
  - b) If any manufacturer violates the abovementioned condition of registration of drug, the Registration Board has the power under section 7(11)(c) and 7(11)(d) of the Drugs Act, 1976 to cancel or suspend the registration or specify any further conditions to which the registration shall be subject, after issuing Show Cause Notice to the manufacturer.
  - c) Before making any decision regarding cancellation or suspension of drug for contravening the Drug Act, 1976 or rules made thereunder, the Registration Board is required to give personal hearing to the person (manufacturer)
  - d) Foregoing in view, the Registration Board may issue Show Cause Notice to the manufacturers of paracetamol who are violating the conditions of registration by not producing in sufficient quantity so as to ensure its regular and adequate supply in the market or who have discontinued it manufacturing for period which resulted in its shortage under section 7(11) (c) and 7(11) (d) of the Drugs Act 1976 read with rule 30(4) and 30(5) of the Drugs (Licensing, Registering and advertising) Rules, 1976, as the case may be."
- 7. Accordingly, Show Cause notices have been issued to all the firms referred by Honorable Drug Court Lahore. And report was submitted in the Honorable Drug Court Lahore. Honorable Chairman, Drug Court Lahore has shown serious concern as to why legal proceedings had not yet been completed and directed to provide complete report within one week and case is relisted for 03-02-2022.
- 8. Detail of 120 firms for which letters were issued for provision of data regarding manufacturing and distribution of Paracetamol Tablet 500mg is as under;

Sr.	Reg No	Brand Name	Registration Holder / Manufacturer	
No.				
1.	001786	Pedrol 500mg Tablet Stanley Pharmaceuticals (Pvt) Ltd., Plot No.		
			Industrial Estate Jamrud Road Peshawar.	
2.	002119	Paracetamol Tablets 500mg	Orta Laboratories (Pvt) Ltd., 24-Km Multan Road	
			Off. Defence Road Mohalanwal (Near Bahria Town	
			Bridge) Lahore.	
3.	002140	Paracetamol 500mg Tablet	Sharex Laboratories (Pvt) Ltd., KLP Road Sharex	
			Colony, P.O Box No. 11, Sadiqabad District Rahim	
			Yar Khan, Rahim Yar Khan	
4.	002728	Paracetamol 500mg Tablet	Nabiqasim Industries (Pvt) Ltd., 17/24 Korangi	
			Industrial Area Karachi.	
5.	002773	Parapol Tablet 500mg	Lisko Pakistan (Pvt) Ltd., L-10/D Block 21 Federal B	
			Industrial Area Karachi.	
6.	002870	Paracetamol 500mg Tablet	Ferozsons Laboratories Ltd., Amangarh Nowshehra.	

7.	002950	Paracetamol Tablet	Tabros Pharma (Pvt) Ltd., Plot No. L-20/B Karachi
	000011		Industrial Area Sector-22 Federal B Area Karachi.
8.	003216	Paracetamol 500mg Tablet	Medicaids (Pvt) Ltd., Plot No 10 Sector 37 Korangi
	002220	D . 1.17.1	Industrial Area Karachi.
9.	003220	Paracetamol Tab	Ahson Drug Co. T/1 SITE Tando Adam
10.	003665	PARACETAMOL 500MG TAB	Harmann Pharmaceutical Laboratories (Pvt) Ltd., 16- Km Multan Road Lahore.
11.	003670	Paracetamol Tab	Irza Pharma (Pvt) Ltd., 10.2-Km Lahore Sheikhupura
			Road P.O Kot Abdul Malik District Sheikhupura.
12.	003684	Paracetamol Tab	Nawabsons Laboratories (Pvt) Ltd., Jia Bagga off Raiwind Road Lahore.
13.	004268	Cekamol Tablet 500mg	CKD Pharmaceuticals Pakistan (Pvt) Ltd., 50/28 Korangi Industrial Area Karachi.
14.	004294	PARACETAMOL TAB	Eros Pharmaceuticals (Pvt) Ltd, 94 Korangi Industries Area Sector 23 Karachi.
15.	004430	Paracetamol 500mg Tab	Unexo Labs (Pvt) Ltd., 9.5-Km Sheikhupura Road
15.	004430	Taracctanior 500mg Tab	Lahore.
16.	005083	PARACETAMOL TAB	S. Fazalilahi & Sons (Pvt) Ltd., 1.5-Km Sunder Road
10.	003003		Raiwind Lahore.
17.	005627	PARACETAMOL 500MG TAB	Geofman Pharmaceuticals, 20-23 Korangi Industrial
	000027		Area Karachi.
18.	005704	PARACETAMOL 500MG	Ideal Pharma Industries, 18-Km Ferozepur Road
		TABLET	Lahore.
19.	006593	Paracetamol Tab	Soma Laboratories Plot No. 43-D Sundar Industrial
			Estate Raiwind Road Lahore.
20.	006918	Paracetamol Tablet 500mg	Mediate Pharmaceutical (Pvt) Ltd. Plot No. 150-151
			Sector 24 Korangi Industrial Area Karachi.
21.	007697	Paramac Tablet 500mg	Macter International Ltd. E-40 SITE Karachi.
22.	008233	Paracetamol tablet	Pharmacare Laboratories (Pvt) Ltd. 129/1 Indus
			Estate Township Lahore.
23.	008391	Paracetamol Tablet 500mg	Regent Laboratories, C-20 SITE Super Highway Karachi.
24.	008731	PARACETAMOL 500MG TAB	Siza International (Pvt) Ltd., 18-Km Main Ferozepur
			Road Lahore.
25.	008882	Paracetamol Tablet	Standard Drug Company, E-6-A SITE Hyderabad.
26.	009013	Paracetamol 500mg Tablets	Zanctok Pharmaceutical Laboratories, F/5 SITE
			Hyderabad.
27.	010555	PARACETAMOL TAB Each	Pliva Pakistan (Pvt) Ltd. Plot No. B-77 Hub Industrial
		tablet contains:-	Trading Estate Hub Chowki Balochistan.
		PARACETAMOL 500MG	
28.	010838	Tylomol Tablets 500mg	Popular Chemical Works (Pvt) Ltd. 9-Km Lahore
6.0	011500	D	Sheikhupura Road Lahore.
29.	011710	Paracetamol 500mg Tablet	Xenon Pharamaceuticals (Pvt) Ltd. 9.5-Km
20	012217	EEDDINOL SOOMC TARE	Sheikhupura Road Lahore.
30.	012217	FEBRINOL 500MG TAB Each	PharmaWise Labs (Pvt) Ltd 25-M Industrial Area Kot
		tablet contains:- PARACETAMOL 500mg	Lakhpat Lahore.
31.	012593	Paracetamol 500mg Tablet	Spectrum Laboratories (Pvt) Ltd, Tariq Street, Al-
31.	012373	1 aracetanioi Joonig 1 abiet	Mumtaz Road, Samanabad, Lahore.
32.	013941	Acetosol Tablet	Shaigan Pharmaceutical (Pvt) Ltd., 14-Km Adyala
32.	013771	12000501 1 00100	Road Post Office Dahgal Rawalpindi.
33.	013946	DEEPOL TAB Each tablet	Delux Chemical Industries, Plot No. 26-A1 Landhi
		contains:- PARACETAMOL	Karachi.
		500mg	
	•	•	•

34.	014000	Sidramol Tablet	Bio Fine Pharmaceuticals (Pvt) Ltd. 74 Industrial Estate Multan.	
35.	020224	Fevamol Tablet	Swiss Pharmaceuticals (Pvt) Ltd., A-159 SITE North Karachi Scheme No. 33 Karachi.	
36.	020357	Paracetamol Tablets	Paramount Pharmaceuticals, 36 Industrial Triangle, Kahuta Road Islamabad.	
37.	020524	Alinadol Tablet	Alina Combine Pharmaceuticals (Pvt) Ltd., Plot No. A-127 SITE Super Highway Karachi.	
38.	023779	Tempol Tablet 500mg	W.Woodward Pakistan Ltd., F-275 SITE Karachi.	
39.	023962	Wyladol 500mg Tablet	Usawa Pharmaceuticals, 146-Special Industrial Zone Risalpur Nowshera.	
40.	027706	Panafin 500mg Tablet	Medipak Ltd., Plot No 132 Industrial Estate Kot Lakhpat Lahore.	
41.	027881	Namic Tablet	Valor Pharmaceuticals, 124/A Kahuta Triangle Industrial Area Islamabad.	
42.	028276	Scot's Paracetamol Tablets 500mg	Scotmann Pharmaceuticals, Plot No. E-5, Sector I-10/3, Islamabad.	
43.	029574	Paracetamol Tab 500mg	Wilson's Pharmaceuticals, 387-388 Sector I-9 Industrial Area Islamabad.	
44.	030002	Colbex Tab	Pearl Pharmaceuticals, Plot No 204 Street No. 1 I-10/3 Industrial Area Islamabad.	
45.	030265	Medinol Tablets	Polyfine Chempharma, 51 Industrial Estate Hayatabad Peshawar.	
46.	030432	Vell Extra Tab	Convell Laboratories, Saidu Sharif Swat.	
47.	031246	Lotemp Tablets	IPP, 34 Industrial Triangle Kahuta Road Islamabad.	
48.	032252	Paigone Tablets	FYNK Pharmaceuticals, 19-Km Ferozepur Road G.T. Road Kala shah Kaku Lahore.	
49.	033081	Racet Tablet	Welmed Pharmaceutical Industries (Pvt) Ltd., 108- R:2 Industrial Estate Gadoon District Sawabi.	
50.	033569	Facemol Tablets 500mg	Farm Aid Group, Plot No. 3/2,Phase I&II, Hattar Industrial Area, Hattar., Haripur	
51.	034307	Fevadol Tablet	Pharmatec Pakistan (Pvt) Ltd., D-86/A SITE Karachi.	
52.	035276	Aksopol Tablet	Akson Pharmaceuticals (Pvt) Ltd., Plot No. 9B-1 & Sector D-1 Old Industrial Estate Mirpur Azad Kashmir., Mirpur	
53.	036069	Fedramol Plus Tablets	Fedro Pharmaceutical Labs (Pvt) Ltd., 149-Industrial Estate Jamrud Road Peshawar.	
54.	036976	Advil 500mg Tablet	Aries Pharmaceuticals (Pvt) Ltd., 1-W Industrial Estate Hayatabad Peshawar.	
55.	038569	Pracmol Tablet 500mg	Glitz Pharma, Plot No 265 Industrial Triangle Kahuta Road Islamadad.	
56.	038734	Jetamol	Jinnah Pharmaceuticals (Pvt) Ltd., 13-Km Lahore Road Multan.	
57.	042029	Jolzet Tablet	Amarant Pharamceuticals (Pvt) Ltd. 158-D Den Toro Gadap Road Super Highway Karachi.	
58.	042761	Benamol Tablet 500mg	Trigon Pharmaceuticals (Pvt) Ltd., 8- Km Thoker Raiwind Road Lahore.	
59.	043763	Chilpol Tablet 500mg	Alliance Pharmaceuticals (Pvt) Ltd., 112-A Hayatabad Industrial Estate Peshawar.	
60.	043875	Paractamol-500 Tablet	Miracle Pharmaceuticals (Pvt) Ltd., Plot No-8 Street No-5 National Industrial Zone Rawat, Islamabad.	
61.	046404	Tamil Tablet	Aneeb Pharmaceuticals (Pvt) Ltd., 24-Km, Badian Road, Lahore Cantt.	

62.	048684	Potradol 500mg Tablet	Medimarker's Pharmaceuticals (Pvt) Ltd., Plot No. A-	
			104 S.I.T.E Area Hyderabad.	
63.	049344	Normidol Tablets.	Shaheen Pharmaceuticals, 3-Km Murghzar Road Saidu Sharif Swat.,	
64.	074579	Nodal 500mg Tablet	Shaheen Pharmaceuticals, 3-Km Murghzar Road	
04.	074379	Nodai 300ing Tablet	Saidu Sharif Swat.	
65.	049862	Acetamol 500mg Tablet	Legacy Pharmaceuticals (Ptv) Ltd., Plot No. 111-A	
			Industrial Estate Hayatabad Peshawar.	
66.	051106	Tempnil Tablet 500mg	Neomedix, Plot No. 5/N-5 National Industrial Zone,	
			Rawat Islamabad.	
67.	054235	Friendomol Tablets	Friends Pharma (Pvt) Ltd., 31-Km Ferozepur Road	
			Lahore.	
68.	054259	Saptamol 500mg Tablets	Sapient Pharma, 123-S Industrial Area Kot Lakhpat	
			Lahore.	
69.	058121	Xamol 500mg Tablet	Macquin's International, F-2/H, P.T.C, S.I.T.E	
0).	030121	Admor 500mg Tablet	Karachi.	
70.	058218	Cepol CF Tablet	Safe Pharmaceuticals (Pvt) Ltd., Plot No C-I, 20,	
			Sector 6-B, North Karachi Industrial Area, Karachi.	
71.	059340	Xendol 500mg Tablet	Nenza Pharmaceuticals (Pvt) Ltd., 33-A Hayatabad	
/1.	037310	rendor soonig rubiet	Industrial Estate Peshawar.	
72.	059421	Paracetol 500mg Tablet	Roryan Pharmaceutical industries (Pvt) Ltd., 85-B	
12.	039421	Faracetor 500mg Tablet		
	0.50556	0 111 511	Hayatabad Industrial Estate Peshawar.	
73.	059556	Optidol Tablets	Medley Pharmaceuticals, 41/A Punjab Small	
			Industries Estate Jhang Bahtar Road Wah Cantt.	
74.	059916	Flutabs Tablets	Jawa Pharmaceuticals (Pvt) Ltd., 112/10 Quaid-e-	
			Azam Industrial Estate Kot Lakhpat Lahore.	
75.	060768	Axamol Tablet	Axis Pharmaceuticals, 3-B Value Addition City 1.5	
			Km Khurrianwala – Sahanwala Road Faisalabad.	
76.	062382	Parari tablet	Lawari International, Gulkada Saidu Sharif Swat.	
77.	063278	Cetapol	Lotus Pharmaceutials (Pvt) Ltd., Plot No.118-A	
			Street No. 8, I-10/3 Industrial Area Islamabad.	
78.	063338	Taramol	Trison Research Labortories (Pvt) Ltd., 27-A Punjab	
,			SIE Sargodha.	
79.	064623	Stanpol 500mg Tablet	Standpharm Pakistan (Pvt) Ltd., 20 Km Ferozepur	
1).	004023	Stampor 500mg Tablet	Road Lahore.	
80.	064863	Primemol Tablets 500mg	Prime Laboratories (Pvt) Ltd., 9.5 Km Sheikhupura	
80.	004603	Filmemor rablets 300mg	Road Lahore.	
0.1	065561	TEL 1 TE 11 4 700		
81.	065561	Therapol Tablet 500mg	Theramed Pharmaceuticals (Pvt) Ltd., 45-Km Multan	
			Road Lahore.	
82.	067511	Doliprane 500mg Tablet	Sanofi-Aventis Pakistan Ltd., Plot No. 23 Sector 22	
			Korangi Industrial Area Karachi.	
83.	068340	Parasol Tablets	Z-Jans Pharmaceutical (Pvt) Ltd., 148-A Industrial	
			Estate Hayatabad Peshawar.	
84.	068387	Tlemol Tablets	Fassgen Pharmaceuticals, Plot No. 67/1 Block-A	
			Phase-III Industrial Estate Hattar.	
85.	068530	Fermol Tablet 500mg	Caraway Pharmaceuticals, Plot No. 12 Street No. N-3	
			National Industrial Zone (RCCI) Rawat Islamabad.	
86.	068626	Nedol Tablets 500mg	Ambrosia Pharmaceuticals, Plot No.18 St: No. 09	
50.	000020	The state of the s	National Industrial Zone Rawat Islamabad.	
87.	069731	Oveedal Tablets	Healer Laboratories (Pvt) Ltd., 96/102-C SIE Kohat	
٥/.	009/31	Ovecual Tablets		
			Road Peshawar.	
00	07000	3.6 1.175.11.		
88.	070306	Menadol Tablets	Medicon Pharmaceutical Industries (Pvt) Ltd., B-1/11, Industrial Estate, Hayatabad Peshawar.	

90. 071109 Vidol Tablets Venus Pharma, 23 Km Multan Road I 91. 073328 Pansetol Swan Pharmaceutical (Pvt) Ltd., 11-E Triangle Kahuta Road Islamabad.  92. 076689 Feveren Tablet 500mg Asian Continental (Pvt) Ltd., D/32 SI Highway Karachi.  93. 081680 Weladol 500mg Tablet Well & Well Pharma (Pvt) Ltd., Plot N National Industrial Zone RCCI Rawat  94. 084484 Paramax Tablet Next Pharmaceutical Products (Pvt) L 41A-B, Sundar Industrial Estate, Laho 95. 085511 Parcol Tablet 500mg Arsons Pharmaceutical Industries (Pvt)	TE Super No.7 Street S-8 Islamabad. Idd., Plot No. ore. It) Ltd., 22-Km oad, Lahore.	
Triangle Kahuta Road Islamabad.  92. 076689 Feveren Tablet 500mg Asian Continental (Pvt) Ltd., D/32 SI Highway Karachi.  93. 081680 Weladol 500mg Tablet Well & Well Pharma (Pvt) Ltd., Plot National Industrial Zone RCCI Rawat  94. 084484 Paramax Tablet Next Pharmaceutical Products (Pvt) L 41A-B, Sundar Industrial Estate, Laho	TE Super No.7 Street S-8 Islamabad. td., Plot No. ore. t) Ltd., 22-Km oad, Lahore.	
92. 076689 Feveren Tablet 500mg Asian Continental (Pvt) Ltd., D/32 ST Highway Karachi.  93. 081680 Weladol 500mg Tablet Well & Well Pharma (Pvt) Ltd., Plot National Industrial Zone RCCI Rawat  94. 084484 Paramax Tablet Next Pharmaceutical Products (Pvt) L 41A-B, Sundar Industrial Estate, Laho	No.7 Street S-8 Islamabad.  td., Plot No. ore. t) Ltd., 22-Km oad, Lahore.	
Highway Karachi.  93. 081680 Weladol 500mg Tablet Well & Well Pharma (Pvt) Ltd., Plot National Industrial Zone RCCI Rawat  94. 084484 Paramax Tablet Next Pharmaceutical Products (Pvt) L 41A-B, Sundar Industrial Estate, Laho	No.7 Street S-8 Islamabad.  td., Plot No. ore. t) Ltd., 22-Km oad, Lahore.	
93. 081680 Weladol 500mg Tablet Well & Well Pharma (Pvt) Ltd., Plot National Industrial Zone RCCI Rawat  94. 084484 Paramax Tablet Next Pharmaceutical Products (Pvt) L 41A-B, Sundar Industrial Estate, Laho	tslamabad. td., Plot No. ore. t) Ltd., 22-Km oad, Lahore.	
94. 084484 Paramax Tablet Next Pharmaceutical Products (Pvt) L 41A-B, Sundar Industrial Estate, Laho	tslamabad. td., Plot No. ore. t) Ltd., 22-Km oad, Lahore.	
41A-B, Sundar Industrial Estate, Laho	ore. t) Ltd., 22-Km oad, Lahore.	
	t) Ltd., 22-Km oad, Lahore.	
95. 085511 Parcol Tablet 500mg Arsons Pharmaceutical Industries (Pvi	oad, Lahore.	
Multan Road Off 2.5-KM Defence Ro		
96. 086961 Adol 500mg Tablet Akhai Pharmaceuticals (Pvt) Ltd., A-2	248 & A-256 to	
A-259 Hub Industrial Trading Estate I	Lasbella	
Balochistan.		
97. 090132 Paralord 500mg Tablets Pharma Lord (Pvt) Ltd., 12-Km Lahor	• • •	
98. 091838 Evathro Tablet 500mg Effort Pharmaceuticals (Pvt) Ltd, 28 k	Cm Ferozepur	
Road Lahore.	*** 1	
99. 089231 Mytomol 500mg Tablet Mafins Pharma, Plot No. A-5 SITE Su Industrial Area Karachi.	iper Highway	
100. 095370 Acetadol 500mg Tablet Evolution Pharmaceuticals (Pvt) Ltd.,	Dlot No. 25 %	
	26, Street No. S-3, RCCI Industrial Estate, Rawat Islamabad.	
101. 095430 Setamol 500mg Tablets Olive Laboratories, Plot No.52-S-6 Na	ational	
Industrial Zone Rawat Rawalpindi.	ational	
102. 091941 Danidol 500mg tablets Danas Pharmaceuticals (Pvt) Ltd., Plo	ot No. 312-	
Industrial Triangle Kahuta Road Islam		
103. 083005 Parazol 500mg Tablet Indus Pharma (Pvt) Ltd., Plot No. 26,		
66 & 67 Sector 27 Korangi Industrial	Area Karachi.	
104. 003469 Paracetamol 500mg Tablet Davis Pharmaceutical Laboratories, F	Plot No. 121	
Industrial Triangle Kahuta Road Islam	nabad.	
105. 005154 Esatdol Tablet 500mg Hamaz Pharmaceuticals (Pvt) Ltd., 13	3-Km Lutafabad	
Bosan Road Multan.		
106. 016577 Munapol 500mg Tablet Munawar Pharma Pvt Ltd, 31, Km, Fe Lahore,	erozepur Road,	
107. 019630 PM-500 Tablet Tagma Pharma (Pvt) Ltd., 12.5 Km La	ahore Raiwind	
Road Lahore.		
108. 019840 Unidol Tablets 500mg Unipharma (Pvt) Ltd., 4.5 KM Manag	a Raiwind Road	
Raiwind Lahore.		
109. 019900 CC Don 500mg Tablet Saydon Pharmaceutical Industries (Pv	·	
Hayatabad Industrial Estate Peshawar		
110. 027961 Medimol 500mg Tablet Mediceena Pharma (Pvt) Ltd., 27 Km	Raiwind Road	
Lahore.  111. 032420 Rascodol Tablet 500mg Rasco Pharma (Pvt) Ltd., 5.5 Km Raiv	wind Road Ali	
Razabad Lahore.	wind Road All	
112. 032887 Megapol Tablet 500mg Mega Pharmaceuticals Ltd., 27 Km Ra	aiwind Road	
Lahore.		
113. 098506 Mismol Tablet 500mg Mission Pharmaceuticals, Plot No. A-	94, S.I.T.E	
Super Highway Karachi.		
114. 095217 Cepmol Tablet 500mg Caliph Pharmaceuticals (Pvt) Ltd., Plo	ot No. 17	
115. 099847 Supamol Tablet 500mg NovaMed Pharmaceuticals (Pvt) Ltd.,	28-Km	
Ferozepur Road Lahore.	20 Km	

116.	100672	Timol 500mg Tablets	Arreta Pharmaceuticals (Pvt) Ltd, , Plot No.13-A, St.	
			No. N-5, RCCI, Rawat, Rawalpindi.	
117.	101172	Puma Tablet 500mg	Rock Pharmaceutical Laboratories (Pvt) Ltd., Plot No.	
			134-B 135-B Nowshera Industrial Estate Risalpur.	
118.	106443	Racitol 500mg Tablet	Linta Pharmaceuticals (Pvt) Ltd., Plot No. 3 Street	
			No. S-5, National Industrial zone Rawat Islamabad.	
119.	108840	Provas Tablet 500mg	Sami Pharmaceuticals (Pvt) Ltd., F-95 Off Hub River	
			Road, SITE Karachi.	
120.	109330	Junimol Tablets	3S Pharmaceuticals (Pvt) Ltd., 5-Km, Off Raiwind	
			Manga Road, Lahore.	

## 9. Reply of 45 firms out of 120 is received which is as under;

Sr.	Name of Firm	Reply	
No.			
		nanufacturing Paracetamol Tablet 500mg	
1.	Mega Pharmaceuticals Ltd. 27	They have manufactured Paracetamol Tablets in the months of	
	Km Raiwind Road Lahore	January and November 2021.	
2.	Macquin's International F-2/H,	They have manufactured Paracetamol Tablets in the month of July,	
	P.T.C, S.I.T.E Karachi	2021.	
3.	Delux Chemical Industries Plot	They have manufactured Paracetamol Tablet in the months of	
	No. 26-A1 Landhi Karachi.	February, May, July and October 2021.	
4.	Harmann Pharmaceutical	They have manufactured Paracetamol Tablet in the months of	
	Laboratories (Pvt) Ltd. 16-Km	January, April, and December 2021.	
	Multan Road Lahore.		
5.	Nenza Pharmaceuticals (Pvt) Ltd.,	They are manufacturing Paracetamol Tablet and they have also	
	33-A Hayatabad Industrial Estate	submitted data of year 2021 regarding manufacturing of Paracetamol	
	Peshawar.	Tablet 500mg.	
6.	Medicon Pharmaceutical	They have procured 10 tons of Paracetamol and consumed all the	
	Industries (Pvt) Ltd., B-1/11,	year of 2021.	
	Industrial Estate, Hayatabad		
	Peshawar.		
7.	Zanctok Pharmaceutical	They are manufacturing Paracetamol Tablet and they have also	
	Laboratories, F/5 SITE	submitted data of year 2021 regarding manufacturing of Paracetamol	
0	Hyderabad.	Tablet 500mg.	
8.	Venus Pharma, 23 Km Multan	They are manufacturing Paracetamol Tablet and they have also	
	Road Lahore.	submitted data of year 2021 regarding manufacturing of Paracetamol	
0	Dool Dhamas antical Laboratoria	Tablet 500mg.	
9.	Rock Pharmaceutical Laboratories	They have manufactured Paracetamol Tablet in the months of	
	(Pvt) Ltd., Plot No. 134-B 135-B Nowshera Industrial Estate	January and May, 2021.	
	Nowshera Industrial Estate Risalpur.		
10.	Irza Pharma (Pvt) Ltd., 10.2-Km	They are manufacturing Paracetamol Tablet and they have also	
10.	Lahore Sheikhupura Road P.O Kot	submitted data of year 2021 regarding manufacturing of Paracetamol	
	Abdul Malik District Sheikhupura.	Tablet 500mg.	
11.	Caliph Pharmaceuticals (Pvt) Ltd.,	They have manufactured Paracetamol Tablet in the months of April,	
11.	Plot No. 17 Industrial Estate	2021.	
	Risalpur.	2021.	
12.	CKD Pharmaceuticals Pakistan	They have manufactured Paracetamol Tablet in the months of	
12.	(Pvt) Ltd., 50/28 Korangi	February, March, April, and May 2021.	
	Industrial Area Karachi.	1 2010mily, manuficially mine many mount	
13.	Jawa Pharmaceuticals (Pvt) Ltd.,	They are manufacturing Paracetamol Tablet and they have also	
10.	112/10 Quaid-e-Azam Industrial	submitted data of year 2021 regarding manufacturing of Paracetamol	
	Estate Kot Lakhpat Lahore.	Tablet 500mg.	
		1	

14.	Effort Pharmaceuticals (Pvt) Ltd, 28 Km Ferozepur Road Lahore.	They have manufactured Paracetamol Tablet in the months of January, 2021.
15.	Eros Pharmaceuticals (Pvt) Ltd, 94	They are manufacturing Paracetamol Tablet and they have also
15.	Korangi Industries Area Sector 23	submitted data of year 2021 regarding manufacturing of Paracetamol
	Karachi.	Tablet 500mg.
16		
16.	Hamaz Pharmaceuticals (Pvt) Ltd.,	They are manufacturing Paracetamol Tablet and they have also
	13-Km Lutafabad Bosan Road	submitted data of year 2021 regarding manufacturing of Paracetamol
	Multan.	Tablet 500mg.
17.	Rasco Pharma (Pvt) Ltd., 5.5 Km	They are manufacturing Paracetamol Tablet and they have also
	Raiwind Road Ali Razabad	submitted data of year 2021 regarding manufacturing of Paracetamol
	Lahore.	Tablet 500mg.
		They have further submitted that due to Lower MRP, Tablets were
		produced in limited quantity.
18.	Shaheen Pharmaceuticals, 3-Km	They are manufacturing Paracetamol Tablet and they have also
	Murghzar Road Saidu Sharif,	submitted data of year 2021 regarding manufacturing of Paracetamol
	Swat.	Tablet 500mg
19.	Pliva Pakistan (Pvt) Ltd. Plot No.	They have manufactured Paracetamol Tablet in the months of
17.	B-77 Hub Industrial Trading	January, March, April, and December 2021.
		January, March, April, and December 2021.
20	Estate Hub Chowki Balochistan.	The same of the Board of the Bo
20.	Unexo Labs (Pvt) Ltd., 9.5-Km	They are manufacturing Paracetamol Tablet and they have also
	Sheikhupura Road Lahore.	submitted data of year 2021 regarding manufacturing of Paracetamol
		Tablet 500mg.
21.	Stanley Pharmaceuticals (Pvt)	They are manufacturing Paracetamol Tablet and they have also
	Ltd., Plot No. 84-B Industrial	submitted data of year 2021 regarding manufacturing of Paracetamol
	Estate Jamrud Road Peshawar.	Tablet 500mg.
22.	Axis Pharmaceuticals, 3-B Value	Firm has submitted manufacturing data for the month of January-
	Addition City 1.5 Km	May and November and distribution data of January to December.
	Khurrianwala – Sahanwala Road	
	Faisalabad.,	
23.	Convell Laboratories, Saidu Sharif	They are manufacturing Paracetamol Tablet and they have also
23.	Swat	submitted data of year 2021 regarding manufacturing of Paracetamol
	Swat	Tablet 500mg.
24	Navighana Laboratorias (Dut)	<u> </u>
24.	Nawabsons Laboratories (Pvt)	They are manufacturing Paracetamol Tablet and they have also
	Ltd. Jia Bagga off Raiwind Road	submitted data of year 2021 regarding manufacturing of Paracetamol
	Lahore	Tablet 500mg.
		manufacturing Paracetamol 500mg Tablet
25.	Medipak Ltd. Plot No 132	This is to inform that regarding the shortage of Paracetamol Tablet
	Industrial Estate Kot Lakhpat	500mg in the market, we have already placed an order to purchase
	Lahore.	Paracetamol from Pharmagen Limited on dated 06- 12-2021
		(purchase order # 722467 attached) and tentative schedule for
		delivery of quoted quantity is 2 <sup>nd</sup> week of February.
		Despite above information, during the shortage of Paracetamol
		Tablet 500mg a very critical points were also highlighted by the
		Paracetamol Tablet 500mg manufacturing companies which are:
		Non-availability of Paracetamol API
		2. High Prices of Paracetamol API
		3. Very low approved prices of Paracetamol tablet 500mg.
		The details are as given:
		i. Currently following API manufacturer are providing the
		Paracetamol Tablet grade API to all the Paracetamol Tablet
		manufacturers:
		a. Zafa Pharma, Karachi Rs. 3,200.00 per Kg
		b. Drug Pharma, Karachi Rs. 3,000.00 per Kg
		c. Saakh Pharma, Karachi Rs. 3,000.00 per Kg
		d. Zeenat Chemicals Rs. 3,000.00 per Kg

		,
		e. Carryfor Pharma, Karachi Rs. 2,950.00 per Kg
		f. Pharmagen Limited Rs. 2,500.00 per Kg
		ii. If we consider the cost calculation then 1000gm of API 2000
		tablets (theoretical) can be manufactured, so per tablet API cost is
		Rs.1.25 and if we calculate per tablet MRP of DRAP granted so it is
		Rs. 0.91 (Rs.181.12/200's).
		iii. It is because of the above drastic gap in between MRP fixed by
		DRAP and cost of Paracetamol API, all packaging that it is neither
		feasible nor possible for any manufacturer to market the aforesaid
		drug at above to MRP fixed by DRAP.
		Nonetheless there is huge loss in manufacturing of Panafin
		Tablet 500mg but considering the shortage of Paracetamol in the
		market and interest of the patients we hereby assure that once
		we will receive the API from the supplier we will-, instantly
		produce the batches and intimate you according to the
		prescribed format as given in aforesaid letter.
26.	Xenon Pharamaceuticals (Pvt)	As per data submitted by the firm, firm is not manufacturing
۷٠.	Ltd. 9.5-Km Sheikhupura Road	Paracetamol Tablet in year 2021.
	Lahore.	Taraccianion Lautei in year 2021.
27.	Pharma Lord (Pvt) Ltd., 12-Km	M/c Dharma Lard cannot manufacture this medicat Decayed Diller of
21.		M/s Pharma Lord cannot manufacture this product Because Price of
	Lahore Road Layyah.	API is high and M.R.P given is low which do not meet the product
		costing requirements. We are interested to produce this product if
		you grant M.R.P of this product according to the raw material prices.
		Accordingly, we can start production and market easily.
28.	Standpharm Pakistan (Pvt) Ltd.,	It is to bring into your kind notice that we are not marketing
	20 Km Ferozepur Road Lahore.	Paracetamol Tablet.
29.	M/s Pharmacare Laboratories	We did not manufacture Paracetamol Tablet due to demand of
	(Pvt) Ltd. 129/1 Indus Estate	Panadol only, Inflated rate/ unavailability of API & Lack of demand
	Township Lahore	of our product.
30.	Well & Well Pharma (Pvt) Ltd.	They have not manufactured Paracetamol Tablet due to high cost of
	Plot No.7 Street S-8 National	Raw Material. The product manufacturing cost is more than its MRP
	Industrial Zone RCCI Rawat	due to which they are unable to produce and market this product.
	Islamabad.	
31.	Trigon Pharmaceuticals (Pvt) Ltd.	They have issued purchase order to M/s. Zenith Chemicals for
	8- Km Thoker Raiwind Road	Paracetamol material the payment of Rs.50,000/- in advance on 04-
	Lahore.	11-2021 but till the date they cannot get the material.
		They have manufactured Paracetamol in 2020. At the moment
		material is short in market. If material will be available then they will
		manufacture it immediately to fulfill the market demand.
32.	Spectrum Laboratories (Pvt) Ltd,	Keeping in view the limited availability of raw material during the
	Tariq Street, Al-Mumtaz Road,	year 2021, we could not manufacture Paracetamol Tablet 500mg.
	Samanabad, Lahore,	jum = 521, 110 to said not mandrate transcention fuotet 500mg.
33.	Usawa Pharmaceuticals, 146-	Since 2002 they did not manufacture this product due to very low
23.	Special Industrial Zone Risalpur	MRP.
	Nowshera	The materials cost is very high and It is not possible for us to
	TOWSHOIA	manufacture it in this very low MRP.
21	Suring Dharmanauticals (Dat) I (1	-
34.	Swiss Pharmaceuticals (Pvt) Ltd.,	We wish to inform you that previously, we had manufactured
	A-159 SITE North Karachi	FEVAMOL 500mg Tablet but due to
	Scheme No. 33 Karachi.	1. Low availability of API (Paracetamol) in market
		2 Low Product Cost in Pakistan market
		We have stopped the manufacturing but we wish to continue the
		manufacturing of the said product if these matters resolved.
35.	Fassgen Pharmaceuticals, Plot No.	It is pertinent to mention here that we Fassgen Pharmaceuticals did
	67/1 Block-A Phase-III Industrial	not marketed Tlemol directly rather it was delivered to three different
	Estate Hattar.	companies for trading purpose.

	I	
		The contract with company, was signed in 2019, and was cancelled due to Covid -19.
		The main reasons for cancellation of said agreement in as under:-
		1. Unavailability of raw materials
		II. Remaining raw materials were very expansive
		III. Company incurred huge losses since then
		New Agreement of Tlemol 500 mg signed with other company in
		2022. And hopefully market gap will soon be filled after marketing.
		And of course, if we do not continue the production and sale of said product. We will definitely get its permission as per Rule 30 of the
		Drug (Licensing, Registration and Advertising) rules, 1976 from
		Registration Board.
36.	Linta Pharmaceuticals (Pvt) Ltd.,	It is stated that this product was registered on 11 <sup>th</sup> December 2020
	Plot No. 3 Street No. S-5, National	but till then we have not manufactured any batch of said product as
	Industrial zone Rawat Islamabad.	MRP of it is low and is not falling in our costing range. Therefore,
		the said product is not in our manufacturing plan yet.
37.	Tabros Pharma (Pvt) Ltd., Plot No.	We would like to inform you that marketing of Paracetamol tablet is
	L-20/B Karachi Industrial Area	not feasible due to shortage & high price of its API.
38.	Sector-22 Federal B Area Karachi. Fedro Pharmaceutical Labs (Pvt)	As per submitted data, firm is not manufacturing Paracetamol Tablet
30.	Ltd., 149-Industrial Estate Jamrud	in year 2021.
	Road Peshawar.	III year 2021.
39.	Trison Research Laboratories	1. Due to increased requirement/demand of Paracetamol API,
	(Pvt) Ltd., 27-A Punjab SIE	especially during the recent period of the spread of dengue and
	Sargodha.	Covid-19, Paracetamol API is acute short and easily not available in
		Pakistan, as the local manufacturers of Paracetamol API are not able
		to supply Paracetamol to meet the demands of manufacturers by way
		of formulation. Even after exhaustive efforts, we have not been able
		to arrange/procure of Paracetamol API
		2. According to Paracetamol API manufacturers they are unable to produce Paracetamol due to non-availability of intermediates, which
		were imported from China and India etc. used in the manufacturing
		process of Paracetamol API
		3. Similarly shutdown of worldwide many industries producing
		intermediates used in the production of Paracetamol is another factor
		contributing the shortage of API.
		4. Unfortunately due to heavy custom duties imposed on imported
		Paracetamol and sky-high prices of locally produced Paracetamol
		and the rising value of USS dollar against Pakistani rupees is also contributed in this regard.
		5. Furthermore, the granted price of our aforementioned registered
		drug product is very low i.e 246.10/200s, so it's not feasible for us to
		produce sufficient quantity so as to
		ensure the regular and adequate supply in the market at the granted
		price.
40.	Lotus Pharmaceuticals (Pvt) Ltd.,	We have not made this product since last year because the material
	Plot No.118-A Street No. 8, I-10/3	was very expensive and give too much production cost
41	Industrial Area Islamabad.	We the Asian Continued (D.) Italy
41.	Asian Continental (Pvt) Ltd., D/32 SITE Super Highway Karachi.	We, the Asian Continental (Pvt.) Ltd. are not producing and marketing the product as the product is not viable to us to
	STIL Super Highway Karaciii.	manufacture and market due to high cost of API (Paracetamol) and
		other overheads.
		It is also pertinent to mention here that the unavailability/ shortage
		of API (Paracetamol) in local as well as international market is

		another reason due to which we are unable to produce and market the product.
		We, in our best, assure you that after the availability of the API (Paracetamol), and reasonable price is awarded to us by DRAP, we
		will produce and market the product in compliance of the condition
		of the drug registration and Rule 30 of the Drug (Licensing,
		Registration and Advertisement Rules, 1976 and the data required by
		your good self will be submitted accordingly.
42.	Olive Laboratories, Plot No.52-S-	we are not marketing the product because of the high prices of the
	6 National Industrial Zone Rawat	Paracetamol (API) and not feasible to market the product in awarded
	Rawalpindi.	MRP by the DRAP.
43.	IPP, 34 Industrial Triangle Kahuta	This is to inform you that the Retail Price of our product is low and
	Road Islamabad.	as you know that the prices of Raw Material (Paracetamol) had
		increased many folds and it does not meet our costing.
44.	Sami Pharmaceuticals (Pvt) Ltd.,	Our product PROVAS (Paracetamol) 500mg Tablet was registered
	F-95 Off Hub River Road, SITE	on 30"July 2021, validation studies for it are underway; so soon as
	Karachi.	these are conducted and development work satisfactorily completed,
		we will launch the said product
45.	Sanofi-Aventis Pakistan Ltd., Plot	Firm has submitted that Doliprane (Paracetamol)500mg Tablet is not
	No. 23 Sector 22 Korangi	being marketed nor been launched since its registration and they have
	Industrial Area Karachi.	submitted the application regarding deregistration on 19 <sup>th</sup> December,
		2016.

9. As per orders of the Drug Court Lahore, Show-Cause Notices had also been issued to referred firms (details as in para-3 above). M/s. Medipak and M/s. Magns has replied, which is as under:

#### i. M/s. Medipak Ltd., Plot No 132 Industrial Estate Kot Lakhpat Lahore.

"In the certain circumstances of Paracetamol Tablet 500mg shortage and despite the high cost of the Paracetamol (The API), we have processed to purchase Paracetamol raw material to ensure the availability of Panafin Tablets 500mg in the market soonest possible.

In the meanwhile, this is to inform that we have been approved MRP of Panafin Tablets for 200's (packaging) vide letter no. F.9-8/2020-DD (P) dated 22-10-2021 @ Rs.181.12/200's.

#### Cost Calculation is as given:

It is because of the above drastic gap in between MRP fixed by DRAP and cost of Paracetamol API, all packaging that it is neither feasible nor possible for us to manufacture and market the aforesaid drug at above to MRP fixed by DRAP.

Nonetheless there is huge loss in manufacturing of Panafin Tablet 500mg but considering the shortage of Paracetamol in the market and interest of the patients we hereby assure that once we will receive the API from the supplier we will instantly produce the batches and intimate you according to the prescribed format as given in aforesaid letter

Keeping in view of above, it is requested to refer our product for price revision to Pricing Division rather to suspend / cancel as Medipak Limited since almost last 04-decade manufacturing quality and cost-effective medicines in Pakistan by pioneering the local manufacturing in infusion therapy."

## ii. M/s. Magns Pharmaceuticals Plot No. 7B, Value Addition City, Sahianwala Road, Khurrianwala, Faisalabad.

Month wise Paracetamol Purchased by the firm w.e.f 1st January to 26th January, 2022	Month wise Paracetamol	Purchased by the	firm w.e.f 1st Januar	y to 26 <sup>th</sup> January, 2022
--	------------------------	------------------	-----------------------	-------------------------------------

Month	Quantity of	Name of Manufacturer /	Invoice No.	Date of Purchse
	Paracetamol API	supplier of Paracetamol		
	Purchased	API		
April, 2021	1000Kg	Saakh Pharma	PRT/2021/0108	13-04-2021
October,	1000Kg	Pharmagen Ltd.	679	15-10-2021
2021				
November,	1000Kg	Pharmagen Ltd.	830	02-11-2021
2021				

Firm has not submitted month wise production & distribution record. However consolidated data of regarding utilization of Paracetamol API for different dosage forms from 1<sup>st</sup> January, 2021 to 26<sup>th</sup> January, 2022 is submitted. Detail is as under;

Name of dosage form manufactured having Paracetamol as API as combination	Reg. No.	Quantity of finished formulation manufactured for said period	Quantity of Paracetamol API used for respective dosage form
Xaradol 325mg/37.5mg Tablet	095680	48,00,000 Tablets	1601.5751 Kg
Tramadol HCl: 37.5mg; Paracetamol:		(16 Batches)	
325mg			
Maggesic 450/35mg Tablet	103383	42,00,000 Tablets	1913.499 Kg
Paracetamol: 450mg;		(21 Batches)	
Orphenadrine citrate: 35mg			

They have submitted that in light of above data they have not discontinued / suspended their production and supply of Paracetamol containing products. They are manufacturing and selling their product continuously without any break or discontinuation. Firm has also submitted sale record of their products.

10. In respectful deference and compliance with the directions and orders by the Honorable Drug Court, Lahore, Personal Hearing Notice has been issued to all the companies referred by the Honorable Drug Court, Lahore. The Companies have been given strict instructions to ensure their presence in the specially convened meeting. The Companies have been warned that no adjournment on any cost shall be given and if they fail to appear, their right of personal hearing shall be struck of and the Board shall take appropriate decision in light of the Order by the Honorable Drug Court, Lahore.

#### **Proceeding of the 315<sup>th</sup> Meeting of Registration Board:**

1. The instant Case is being considered on the directions issued by the Honorable Drug Court, Lahore, which has taken cognizance of the matter regarding the shortage and unavailability of Paracetamol Tablet 500mg in the market which had caused immense stress and issues for the patients. Honorable Drug Court, Lahore, took cognizance of the matter through Application No. 51/21 and *vide* Order dated 08-12-2021 directed the field staff at the DRAP Office, Lahore, to investigate and identify the causes for the shortage of the drug in the market. The field staff of DRAP, Lahore, undertook detailed investigation and solicited replies from the registration holders of Paracetamol 500mg. It was uncovered in ensuing investigation that 17 drug registration holders of Paracetamol 500mg had discontinued its manufacturing for considerable time. The report was presented before the Honorable Drug Court, Lahore, which noted with dismay the practice of

discontinuation of manufacturing of an essential drug by the registration holders which infringed right of the people to have access to drugs and medicines. The Honorable Drug Court, Lahore, through Orders dated 12-01-2022 and 27-01-2022 was graciously pleased to direct the Registration Board to expeditiously conclude proceedings under the law against firms which had discontinued production of Paracetamol 500mg.

- 2. Registration Board in compliance of and deference to the Order of the Honorable Drug Court issued Show Cause Notice dated 20-01-2022 under Section 7 (11) (c) and (d) of the Drugs Act, 1976, to all companies which were identified by DRAP's Lahore office to have discontinued production of Paracetamol 500mg. Despite urgency of the matter, apart from M/s Medipak and M/s. Magns no other company filed reply to the Show Cause Notices. The Registration Board on 28-01-2022 issued personal hearing notices to all the companies which were served by the area Federal Inspector of Drugs. The companies were given a chance of personal hearing on 1st February, 2021 at 3.30 P.M.
- 3. Replies of the 10 firms out of 17 for which Show Cause notices have been issued are as under;

#### i. M/s. Medipak Ltd., Plot No 132 Industrial Estate Kot Lakhpat Lahore.

Mr. Anzaar Ahmed and Mr. Usman appeared on behalf of the firm. In their reply of Show Cause and during personal hearing firm has submitted that the price of Active Pharmaceutical Ingredient of Paracetamol has increased many folds, due to which it is not economically feasible for them to manufacture Paracetamol 500mg at the prices determined under the law. They have already placed an order to purchase Paracetamol from M/s. Pharmagen Limited on dated 06- 12-2021 (purchase order # 722467) and tentative schedule for delivery of quoted quantity is 2<sup>nd</sup> week of February. They have also assured that once they will receive the API from the supplier, they will instantly produce the batches and intimate DRAP according to the prescribed format.

#### ii. M/s. Magns Pharmaceuticals Plot No. 7B, Value Addition City, Sahianwala Road, Khurrianwala, Faisalabad.

Mr. Asghar Ali appeared on behalf of the firm. In their reply of Show Cause and during personal hearing firm has submitted that they have procured 1000kg of Paracetamol API each in April, October and November, 2021 and they have manufactured 16 batches (48,00,000 Tablets) of Xaradol 325mg/37.5mg Tablet Reg. # 095680 and 21 batches (42,00,000 Tablets) of Maggesic 450/35mg Tablet Reg. # 103383 from 1st January, 2021 to 26th January, 2022. Firm has further submitted that they have submitted that in light of above data they have not discontinued / suspended their production and supply of Paracetamol containing products. They are manufacturing and selling their product continuously without any break or discontinuation. Firm has also submitted sale record of their products.

#### iii. M/s. Batala Pharmaceuticals 23/B Small Industrial Estate No. 2 Near Wapda Town, Khiali Bypass Gujranwala.

No one appear on behalf of the firm. In the reply of Show Cause firm has submitted that due to high price of API & shortage of material world over, they could not find raw material on time which caused shortage of Paracetamol Tablet in the open market. Moreover, demand suddenly raised which also caused shortage. However, after initial show cause notice from PQCB Lahore, they have supplied more than I Lac tablets urgently in the market in order to meet the demand in the market. Meanwhile they have l 128

ordered 1-ton Paracetamol API from M/s. Pharmagen in order to produce sufficient quantity of product in the best interest of patient. They will start production as soon as we get the raw material.

#### iv. M/s. Himont Pharmaceuticals (Pvt) Ltd. 17-Km Ferozepur Road Lahore.

No one appear on behalf of the firm. In the reply of Show Cause firm has submitted that their only product which contains Paracetamol under the brand name Himodol-P 37.5mg/325mg Tablet Reg. # 105964 is combination product which contains Tramadol HCl and Paracetamol. The MRP given to them by DRAP is not justified and their price increase case is already in process vide letter dated 15th June, 2021. As soon as they get a favorable price, they will launch it in the market.

#### v. M/s. Xenon Pharmaceuticals (Pvt) Ltd. 9.5-Km Sheikhupura Road Lahore.

Mr. Adeel Sheikh appeared on behalf of the firm. In their reply of Show Cause and during personal hearing firm has submitted that the reason they did not manufacture paracetamol is that the raw material was in shortage and was very expensive. The suppliers kept pointing towards the supply chain issues due to COVID-19, as the reason for this. Moreover, the MRP given to them by the DRAP was too low and hence they were incapable to make this product in loss. In the latest Drug Pricing Committee, they have approved a higher price for this product. The recommendation of the DPC is currently pending in the Cabinet they are expecting that once the Cabinet approves their recommendation, they will be able to manufacture this product once again and make it readily available in the market and they should be able to market this product as per demand of market after these issues are resolved

#### vi. M/s. Standpharm Pakistan (Pvt) Ltd., 20 Km Ferozepur Road Lahore.

Mr. Abdullah Kiyani appeared on behalf of the firm. In their reply of Show Cause and during personal hearing firm has submitted that the price of Active Raw Material (Paracetamol) is increasing day by day. From last 2 years, it has been increased more than 400% but there is no increase in MRP from DRAP. If pricing division considers the revision of MRP, they shall be able to start its manufacturing and marketing.

#### vii. M/s. Pharmacare Laboratories (Pvt) Ltd. 129/1 Indus Estate Township Lahore.

Mr. Sayed Ali Raza appeared on behalf of the firm. In the reply of Show Cause and during personal hearing firm has submitted that resumption of production was allowed 279<sup>th</sup> meeting of CLB, the letter for resumption was received on 16-03-2021. They have purchased Paracetamol 100kgs on 30-06-2021 & 75kg on 19-07-2021 for their registered product Skeldrin (Paracetamol.450mg, Orphenadrine Citrate.35mg) sold to distributors. Regarding Paracetamol 500mg Tablet Reg. # 008233 production, they didn't manufacture due to demand of Panadol only, inflated rate/ unavailability of API & lack of demand for their product, but they have now purchased the API and will manufacture Paracetamol according to their market demand. Hence, it is requested to not suspend / cancel their product Paracetamol Tablet 500mg Reg. # 008233.

#### viii. M/s. Theramed Pharmaceuticals (Pvt) Ltd., 45-Km Multan Road Lahore.

No one appear on behalf of the firm. In the reply of Show Cause firm has submitted that they are currently in process of manufacturing Therapol 500mg Tablet Reg. No.065561. The price of Paracetamol API was raised from Rs.800/kg to Rs.2700/kg which result in increased costing of product which was not feasible. The Paracetamol API was short in market now it is available and they are ordering Minutes of 317<sup>th</sup> meeting of Registration Board (16-17 May, 2022) | 129

Paracetamol API. their pack size was 20 tablets per pack which is not workable. They need to get additional packs of 100 tablets per pack, 200 tablets per pack & 1000 tablets per pack. They are in a condition of producing Therapol 500mg tablet stocks for market use.

# ix. M/s. Axis Pharmaceuticals, 3-B Value Addition City 1.5 Km Khurrianwala – Sahanwala Road Faisalabad.

Mr. Ghulam Murtaza (Plant Manager) appeared on behalf of the firm. In the reply of Show Cause and during personal hearing that they are continually manufacturing the subjected drug and not discontinue the manufacturing & marketing of this product. Actually, in last few months this product was not manufactured due to non-availability of API i.e. Paracetamol. On availability of API (Paracetamol), manufacturing of said product has already been re-initiated. Although prices of API are still quite high and but they are continually manufacturing this drug as per their customer demand. Furthermore, they have already requested to costing and pricing division of DRAP to revise MRP of this product as a hardship case.

#### x. M/s. Pharma Lord (Pvt) Ltd., 12-Km Lahore Road Layyah.

Mr. Ghulam Muhammad appeared on behalf of the firm. In the reply of Show Cause and during personal hearing firm has apologized that they have not manufactured Paralord 500mg Tablet Reg. No. 090132 due to higher price of API and MRP was not granted according to the API price. For continue the registration of this product they are deciding that they make some batches and spread in the market on loss until the normalization of the pandemic situation. And this is their humble request that please review this MRP and grant to them according to the current API and Packing Material Cost for manufacturing and marketing on regular basis.

#### xi. M/s. Lawrence Pharma (Pvt) Ltd. 10.5 Km Sheikhupura Road Lahore.

Mr. Kashif appeared on behalf of the firm. In the reply of Show Cause and during personal hearing firm has submitted that as they are generic manufacture, there is no law in our country which bounds prescribers to prescribe generic medicines to patients. Almost all the prescribers prescribe branded medicines which creates a huge demand for such products results in low market demand or no demand for generic products at times where its brands are available in markets, in comparison. Since pandemic (COVID-19) started, the consumption of paracetamol (mostly in solid dosage form) has been soared remarkably across the world and nationwide because of covid- 19 and dengue as well. It has resulted in shortage of raw material worldwide. Most of raw materials are being imported from CHINA. Many manufacturing units stopped working in CHINA during this pandemic due to high infectious rate. As many units were also shut down previously there, because of global warming. As the demand-supply chain has been badly affected during this pandemic across the worldwide resulted in shortage of APIs and inactive material which are being used to produce the finished products and increase of price to many folds and delayed or no delivery from suppliers. As demand was raised periodically but due to disruption in supplies, it was delayed with no positive reply. Due to unstable economy and fluctuation in dollar rate, as price of API, inactive materials, packaging materials and utilities has been increased. It results in increase production cost than M.R.P. They have further stated that they will try their best to ensure the availability in future.

- Furthermore M/s Sunshine Gujranwala, M/s Allmed Lahore, M/s Medisearch Lahore, M/s NovaMed Lahore, M/s Pulse Lahore and M/s Munawar Lahore neither appeared nor they have submitted reply of Show Cause notice
- 4. All drug registration holders are required to ensure continuous and adequate supply of the drug to meet its demand in the market in compliance with the 'Conditions for Registration of Drug' under Rule 30 (4) and (5) of the Drugs (Licensing, Registration and Advertising) Rules, 1976. The said Rule forbids the discontinuation of production for a period which might result in its shortage without "prior approval of the Registration Board".
- 5. The companies complaining of unfeasibility of prices to recover the costs of production were enquired as to if they had filed 'Hardship Cases' under Para. 9 of the Drug Pricing Policy, 2018. It is to be noted that the Policy, 2018, was formulated under directions by the Hon'ble Supreme Court which catered to the eventualities complained of by the registration holders. However, mere filing of 'Hardship Case' or even appearance of any cause of action of unfeasibility of prices did not grant the registration holders a right to discontinue production. However, the Registration Board will not comment on the merits of the claim lest it prejudice the case of the companies before the Drug Pricing Committee, which has sole jurisdiction to decide the same.
- 6. The Registration Board noted with dismay the discontinuation of production of Paracetamol 500mg by the companies which is violation of the Drugs (Licensing, Registration and Advertising) Rules, 1976.

#### 11. Decision of 315<sup>th</sup> meeting of DRB:

Keeping in view the urgent need to fulfill the market needs of the suffering patients and to ameliorate the shortage, the Registration Board in the larger public interest decided the following:

- a. By exercising restraint, a strict and stern warning is issued under Section 7 (11) of the Drugs Act, 1976, to following registration holders of Paracetamol 500mg who have been Show Caused and not manufacturing paracetamol containing products are hereby ordered to immediately and forthwith commence production in adequate quantities. Non-compliance of these orders shall be dealt strictly under the relevant law.
  - i. M/s. Medipak Ltd., Plot No 132 Industrial Estate Kot Lakhpat Lahore.
  - ii. M/s. Xenon Pharamaceuticals (Pvt) Ltd. 9.5-Km Sheikhupura Road Lahore.
  - iii. M/s. Pharma Lord (Pvt) Ltd., 12-Km Lahore Road Layyah.
  - iv. M/s. Standpharm Pakistan (Pvt) Ltd., 20 Km Ferozepur Road Lahore.
  - v. M/s Pharmacare Laboratories (Pvt) Ltd. 129/1 Indus Estate Township Lahore.
  - vi. M/s Batala Pharmaceuticals 23/B Small Industrial Estate No. 2 Near Wapda Town, Khiali Bypass Gujranwala.
  - vii. M/s Sunshine Pharmaceuticals, Emanabad, G.T. Road, Gujranwala.
  - viii. M/s Theramed Pharmaceuticals (Pvt) Ltd., 45-Km Multan Road Lahore.
  - ix. M/s Allmed (Pvt) Ltd., Plot No. 590 Sundar Industrial Estate Lahore.
  - x. M/s Medisearch Pharmacal (Pvt) Ltd. 5 Km Raiwind Manga Road, Lahore.
  - xi. M/s NovaMed Pharmaceuticals (Pvt) Ltd., 28-Km Ferozepur Road Lahore, Lahore.

- xii. M/s Pulse Pharmaceuticals (Pvt) Ltd. Mozay Badoke Raiwind Road (Sua Asil Road) Lahore.
- xiii. M/s Munawar Pharma Pvt Ltd, 31, Km, Ferozepur Road, Lahore.
- xiv. M/s Himont Pharmaceuticals (Pvt) Ltd. 17-Km Ferozepur Road Lahore.
- xv. M/s Lawrence Pharma (Pvt) Ltd. 10.5 Km Sheikhupura Road Lahore.
- b. Following registration holders of Paracetamol 500mg who have been Show Caused and are manufacturing paracetamol containing products are hereby advised to increase their production as per market demand on priority.
  - i. M/s Axis Pharmaceuticals, 3-B Value Addition City 1.5 Km Khurrianwala –
     Sahanwala Road Faisalabad.
  - ii. M/s. Magns Pharmaceuticals Plot No. 7B, Value Addition City, Sahianwala Road, Khurrianwala, Faisalabad.
- c. Starting from March, 2022, manufacturers of both above categories are directed to submit monthly production and distribution data to DRAP, Lahore office by 7<sup>th</sup> of every month for onward submission to Drug Court, Lahore after its evaluation. Any unexplained delay or submission of false and forged data shall be dealt strictly under the relevant law.
- d. All other companies who have not been issued Show Cause Notice or Personal Hearing Notice but are registration holders of Paracetamol 500mg, are hereby directed to immediately start / increase production of the same and ensure continuous supply the same in the market. Any such firm may at any point in time be required to share data regarding production and supply of Paracetamol 500mg to verify compliance with the instant directions.
- e. To issue directions to following API manufacturers of Paracetamol drug substance for adequate production to meet emergent national needs.
  - i. M/s Citi Pharma (Pvt) Ltd., 3.5-Km Head Balloki Road, Phool Nagar Kasur.
  - ii. M/s Pharmagen Ltd., Kot Nabi Baksh Wala 34-Km, Ferozpur Road Lahore.
  - iii. M/s Zenith Chemical Industries (Pvt) Ltd., Moza Dondey Gia Daga, Raiwind Road Lahore.
  - iv. M/s Zafa Chemie, Raiwind Manga Bypass Near Sundar Industrial Estate Mouza Bahikot Tehsil & District Lahore.
  - v. M/s Saakh Pharma (Pvt) Ltd., Plot No. C-7/1, North Western Industrial Zone Post Qasim, Karachi.
  - vi. M/s Carryfor Pharmaceutical (Pvt) Ltd, Plot No. E-81, North Western Industrial Zone, Port Qasim, Karachi.
  - vii. M/s Drug Pharma Chemicals (Pvt) Ltd, Plot No. 226, Sector 23, Korangi Industrial Area, Karachi.
  - viii. M/s Unichem Pakistan Pharmaceuticals (Pvt) Ltd., Plot No.310, Industrial Triangle Kahuta Road, Islamabad.

- f. Quality Assurance Division, DRAP is directed to advise Provincial Health Departments to check and ensure the continuous distribution of paracetamol containing products through authorized distributors of manufacturers and to curb the menace of hoarding.
- g. Legal Affair Division to look into possibility to include penal provision for hoarding of registered drug products by manufacturer / importer / distributer / wholesaler / retailer.
- 12. As per above decision of 315<sup>th</sup> meeting of Registration Board letters were communicated to all the firms and submitted in Honorable Drug Court Lahore. Drug Court Lahore called Chairman Registration Board in person before the Court on next date of Hearing dated 08-03-2022.
- 13. Warning letters were issued to fifteen (15) out of seventeen (17) registration holders for not manufacturing the paracetamol tablet and letter and rest of two (02) were issued letter to increase production as they have already started production of paracetamol containing drug products. Manufacturing status of 15 registration holders is as under;

Sr.	Name of	Registration	Brand Name	Status	
No	Manufacturer	No.			
	FIRMS WHO HAVE STARTED PRODUCTION OF PARACETAMOL TABLETS				
1.	M/s Sunshine	057610	Sunmol 500mg Tablets	Firm has started production of	
	Pharmaceuticals,		Paracetamol 500mg	Paracetamol Tablet 500mg.	
	Emanabad, G.T.			Also submitted data regarding	
	Road, Gujranwala.			its production	
2.	M/s Batala	026306	Bamol 500mg Tablet	Firm has started production of	
	Pharmaceuticals 23/B		Paracetamol 500mg	Paracetamol Tablet 500mg.	
	Small Industrial			Also submitted data regarding	
	Estate No. 2,			its production	
	Gujranwala				
3.	M/s Medipak Ltd.,	027706	Panafin 500mg Tablet	Firm has started production of	
	Plot No 132 Industrial		Paracetamol 500mg	Paracetamol Tablet 500mg.	
	Estate Kot Lakhpat			Also submitted data regarding	
4	Lahore.	0.64622	G. 1500 T.11	its production	
4.	M/s Standpharm	064623	Stanpol 500mg Tablet	Firm has started production of	
	Pakistan (Pvt) Ltd., 20		Paracetamol 500mg	Paracetamol Tablet 500mg.	
	Km Ferozepur Road Lahore			Also submitted data regarding	
5.	M/s Xenon	011710	Paracetamol 500mg	its production  Firm has started production of	
<i>J</i> .	Pharmaceuticals (Pvt)	011710	Tablet	Paracetamol Tablet 500mg.	
	Ltd. 9.5-Km		Paracetamol 500mg	Also submitted data regarding	
	Sheikhupura Road		Turuccumor 500mg	its production	
	Lahore			ns production	
6.	M/s Pharmacare	008233	Paracetamol 500mg	Firm has submitted that they	
	Laboratories (Pvt)		Tablet	have started manufacturing of	
	Ltd. 129/1 Indus		Paracetamol 500mg	Paracetamol Tablet batch No.	
	Estate Township			1030 having batch size of	
	Lahore			100000 Tablets.	
7.	M/s Theramed	065561	Therapol 500mg Tablet	Firm has submitted only invoice	
	Pharmaceuticals (Pvt)		Paracetamol 500mg	of 50kg of Paracetamol API	
	Ltd., 45-Km Multan			from Citi Pharma. Firm has	
	Road Lahore.			submitted that they have	
				manufactured Paracetamol	
				Tablet Batch No. 750 having	
				batch size of 100000 Tablets.	
	FIRMS WHO HAVE	SUBMITTED 1	PURCHASE ORDERS OF	F PARACETAMOL API	

8.	M/s NovaMed Pharmaceuticals (Pvt) Ltd., 28-Km Ferozepur Road	099847	Supamol 500mg Tablet Paracetamol 500mg	Firm has submitted only Purchase Order for 100kg of Paracetamol API
9.	Lahore, Lahore M/s Lawrence Pharma (Pvt) Ltd.	059871	Lawramol Suspension Each 5ml contains: -	Firm has submitted only Purchase Order for 25kg of
	10.5 Km Sheikhupura Road Lahore.		Paracetamol 120mg	Paracetamol API
	FIRMS WHO A	RE NOT MAN	UFACTURING PARACE	TAMOL TABLET
10.	M/s Allmed (Pvt) Ltd., Plot No. 590 Sundar Industrial Estate Lahore.	054407	Everpol 500mg Tablets Paracetamol 500mg	Not Manufacturing
11.	M/s Medisearch Pharmacal (Pvt) Ltd. 5-Km Raiwind Manga Road, Lahore.	033688	Favasaf Suspension Each 5ml contains: Paracetamol 120mg	Not manufacturing
12.	M/s Pulse Pharmaceuticals (Pvt) Ltd. Mozay Badoke Raiwind Road (Sua Asil Road) Lahore	050864	Pyrecaf 500mg Tablets Paracetamol 500mg	Not manufacturing
13.	M/s Munawar Pharma Pvt Ltd, 31, Km, Ferozepur Road, Lahore.	016577	Munapol 500mg Tablet Paracetamol 500mg	Not manufacturing
14.	M/s Himont Pharmaceuticals (Pvt) Ltd. 17-Km Ferozepur Road Lahore.	105964	Himodol-P 37.5mg/325mg Tablet Tramadol HCl 37.5mg Paracetamol 325mg	Not manufacturing
15.	M/s Pharma Lord (Pvt) Ltd., 12-Km Lahore Road Layyah.	090132	Paralord 500mg Tablets Paracetamol 500mg	Not manufacturing

14. Same has also been submitted in Drug Court Lahore on 08-03-2022 and orders of the Court is as under;

Chairman Registration Board present in person and submit his report regarding the shortage of Paracetamol and after this that action taken by the Board against the manufacturing units.

After going through the decision of the Board which is submitted by the law officer, the Board issued warning under section 7(11) of Drugs Act, 1976 but after going through the said section 7(11) of the Drugs Act, 1976 there is no provision that the Board has a power to issue a warning.

On this point Chairman Drug Regulatory Authority seeks some more time to assist the court. Let this case be adjourned for 21.03.2022.

### **Proceeding of the 316<sup>th</sup> Meeting of Registration Board:**

The matter came up for hearing in 315<sup>th</sup> Meeting of the Drug Registration Board held on the 1<sup>st</sup> of February, 2022, wherein the Board after going through the replies submitted by the show caused companies decided to issue stern warning to the same to immediately start production; the companies were also directed to provide data of the same to ensure their compliance with decision of the Registration Board. The decision was placed before the Hon'ble Drug Court, Lahore, which through Order 08-03-2022 ordered as follows;

"Chairman Registration Board present in person and submit his report regarding the shortage of Paracetamol and after this that action taken by the Board against the manufacturing units.

After going through the decision of the Board which is submitted by the law officer, the Board issued warning under section 7(11) of Drugs Act, 1976 but after going through the said section 7(11) of the Drugs Act, 1976 there is no provision that the Board has a power to issue a warning.

On this point Chairman Drug Regulatory Authority seeks some more time to assist the court. Let this case be adjourned for 21.03.2022"

The matter was again discussed by the members of the Drug Registration Board. The Drug Registration Board studied Section 7 (11) of the Drugs Act, 1976, and observed the following:

- i. The actions proposed to be taken by the Board i.e. cancellation, suspension of registration or imposition of some additional condition to registration, are mandatorily linked to the pre-condition of issuance show cause to the accused person seeking their defense. The Board can only order any action against the person if they are unable to provide defense to the allegations raised in the Show Cause Notice. It was also noted that under Article 10A of the Constitution of the Islamic Republic of Pakistan, 1973, as interpreted by the superior courts, every person has a right of presenting his defense before any decision is taken which adversely affects them;
- ii. The Legislature in its wisdom has predicated the statutory power of the Board to impose sanction with the word '*may*' thereby granting it the discretion to decide whether to impose the sanction or not. However, as per the admitted principles of administrative law, exercise of such discretion must be backed by reason and logic.

The Registration Board discussed the matter again, keeping in view the above and Order by the Honorable Drug Court. The Registration Board noted that the companies had raised the defense of lack of availability of raw material in the market and its inflated costs, which temporarily caused a hiatus in their production. The defense presented by the companies was found to be plausible, which is further bolstered by the fact that the companies have since the last meeting started production. The Board did not find any evidence of intentional stoppage of production by the companies for a continued period of time; the temporarily stoppage of production was directly linked to conditions of *force majeure*, due to the presence of which there was no *mens rea* or criminal intention which would necessitate taking any punitive penal action against the companies.

The Board further deliberated that suspension or cancellation of registration of paracetamol would exacerbate the shortage of drug. Therefore, the only option which remained with the Board was to stipulate additional condition of registration for the companies to provide data of their production of paracetamol to ensure that such a shortage would not occur in future. The issuance of 'warning' was merely a part of the discretionary decision of the Registration Board whereby it imposed the condition on companies to provide data regarding production and sale of paracetamol. It was noted that warning issued was not the stand alone decision as it was a part of the decision which imposed conditions of registration and hence, the complete decision has to be read as a whole rather than disjunctively.

However, Mr. Syed Adnan Rizvi, Director, Drugs Testing Laboratory, Karachi, Sindh (Member Registration Board) disagreed with opinion by rest of the members of the Registration Board and opined that the stoppage of production by the companies of paracetamol was a violation of the conditions of registration for which their cases should be registered in the Drug Court by the concerned Federal Drug Inspector after proper investigation against the violators.

#### **Decision of 316<sup>th</sup> meeting:**

Keeping in view the discussion, the Registration Board decided to uphold its previous decision taken in 315<sup>th</sup> Meeting of the Drug Registration Board held on the 1<sup>st</sup> of February, 2022, as issuance of 'warning' was merely a part of the discretionary decision of the Registration Board whereby it imposed the condition on companies to provide data regarding production and sale of paracetamol. It was also decided that warning issued was not the stand alone decision as it was a part of the decision which imposed conditions of registration and hence, the complete decision has to be read as a whole rather than disjunctively;

The Registration Board further decided to take up the matter again in light of the decision and guidance by the Honorable Drug Court, Lahore. The Board expressed its respectful deference to any decision by the Honorable Court.

Same was also submitted in Drug Court Lahore on 21-04-2022 and case was adjourned for 05-2022.

As per decision of 315<sup>th</sup> meeting of Registration Board compliance report regarding production of Paracetamol Tablet be submitted in Drug Court Lahore by 7<sup>th</sup> of every month starting from March, 2022. Accordingly, a report regarding manufacturing and marketing status of Paracetamol Tablet has also been submitted in Drug Court Lahore on 05-04-2022 and court decided as under;

A comprehensive report regarding the production and supply of Paracetamol submitted by the DRAP which has been perused in which representative of DRAP ensures the court that the manufacturing and supply of said Paracetamol is being done and is available in the different cities in Province. Keeping in view the said report, this application is disposed of.

**Decision:** Registration Board noted the information.

## Case No 02: Allocation of Quota for Control Substances Ephedrine HCl for the year 2017 to M/s. Sharex Laboratories, Sadiqabad.

The case of M/s. Sharex Laboratories, Sadiqabad was considered in 275<sup>th</sup> and 286<sup>th</sup> meeting of Registration Board as per detailed below:-

#### 2. Proceedings of 275<sup>th</sup> Meeting of Registration Board:

The instant case was presented based on the letter received from Assistant Director (CD) (Dated 21<sup>st</sup> Sep, 2017) wherein it has been stated that M/s Sharex Laboratories, sadiqabad applied for quota allocation of product Tracodil syrup (Reg. 003158). The case was presented before 43rd meeting of committee on allocation of controlled drug held on 26<sup>th</sup> July, 2017, the committee deferred the case for issuance of show cause by DRAP for manufacturing of Tracodil syrup (Reg. 003158) 60ml, 400ml pack without approval. It was requested to verify the status of product registration of Tracodil syrup (Reg. 003158) 400ml pack size. The approved pack sizes of product Tracodil Syrup (Reg. No. 003158) have been verified as per available record i.e 120ml, 450ml (National Formulary 1981) and 60ml (dated 27th October 1988).

#### 3. Decision of 275th meeting of Registration Board:

Registration decided to call M/s Sharex Laboratories, Sadiqabad for personal hearing and for deliberating above mentioned matter before the Registration Board.

#### 4. **Proceedings of 286<sup>th</sup> meeting of Registration Board:**

Mr. Muhammad Ishfaq, production pharmacist, appeared before Registration Board and apologized on behalf of the firm for applying quota of 400ml pack size of product Tracodil syrup (Reg.003158) without approval.

#### 5. Decision of 286th meeting of Registration Board:

Registration Board in its 286<sup>th</sup> meeting decided to refer the case to Legal Affair division for legal opinion.

- 6. Accordingly, the case was refer to Legal Affairs, Division and in response, Legal Affairs, Division has provided following opinion:
- i. That M/s. Sharex Laboratory applied for the quota allocation of product Tracodil Syrup (Reg.No.003158).
- ii. That the Committee on Allocation of Controlled Drugs held on 26.07.2017 deferred the case for issuance of show cause by DRAP for manufacturing of "Tracodil Syrup" (Reg.No.003158) 60ml, 400ml pack without approval. It was requested to verify the status of product registration of "Tracodil Syrup" (Reg.No.003158) and 60ml (dated 27th October, 1988).
- iii. That the approved pack size of the product "Tracodil Syrup" (Reg.No.003158) have been verified as per available record i.e 120ml, 450ml (National Formulary 1981) and 60ml (dated 27th October, 1988).
- iv. That Mr. Muhammad Ishfaq production pharmacist, appeared in 286<sup>th</sup> meeting before Board and apologized on behalf of the firm for applying quota of 400ml pack size of product "Tracodil Syrup" (Reg.No.003158) without approval.

- v. That the Registration Board in 286<sup>th</sup> meeting referred the case to Legal Affairs, Division for legal opinion.
- vi. Drug Regulatory Authority of Pakistan Act, 2012 in Schedule-II A(1) (a) (vii) prohibits export, import or manufacture and sale or sell of any therapeutic goods which is not registered or is not in accordance with conditions of registration as disclosed in the registration dossier and that has undergone pharmaceutical evaluation. Furthermore, Schedule-II(A)(c) prohibits to sell any therapeutic goods except under, and in accordance with the conditions of a license issued under this Act. In addition, Schedule-II A(a)(f) prohibit to supply an incorrect, incomplete or misleading information when required to furnish any information under this Act or the rules.
- vii. In this regard, DRAP Act, 2012 under section 27 read with schedule-III (6) provides penalty for violating the prohibitions mentioned above.

#### 7. Decision of 289<sup>th</sup> meeting of Registration Board:

In light of the opinion of Legal Affair's Division on the matter, Registration Board deliberated the case and decided to issue show cause notice to M/s Sharex Laboratories, Sadiqabad for violation of condition of drug registration, as follows:

- Cancellation of registration.
- Suspension of registration.
- Prosecution in Drug Court
- 8. Accordingly, show cause notice was served to M/s. Sharex Laboratories, Sadiqabad.
- 9. Registration Board in its 295<sup>th</sup> meeting deliberated on the matter in details and decided to give an opportunity of personal hearing as per Drug Act, 1976 and Rules framed there under to M/s. Sharex Laboratories, Sadiqabad in forthcoming meeting of Registration Board.
- 10. In 296<sup>th</sup> meeting M/s. Sharex Laboratories, Sadiqabad was called for personal hearing. Mr. Muhammad Ishfaq, production pharmacist, appeared before Registration Board and apologized on behalf of the firm and stated that firm was unaware about the approval of pack sizes of Tracodil Syrup (Reg.No.003158) as on initial registration letter no pack size was written. He has further stated that firm will submit all the relevant documents / approvals granted by DRAP regarding said product.
- 11. Registration Board in 296<sup>th</sup> meeting deferred the case for further deliberation after submission of documents as stated by representative of the firm.

In compliance with 296th meeting of Registration Board firm has submitted following documents;

- i. Initial registration letter of Ammonium Chloride Syrup Reg. No. 003158 dated 06-11-1977 in which Pack size & MRP are not mentioned.
- Change of brand name letter from Ammonium Chloride Syrup to Tracodil Cough Syrup dated 16-08-1979
- iii. Price revision of locally manufactured / fixation of prices of additional packs letter dated 27-10-1988 in which Pack sizes along with MRPs are mentioned with following details;

Sr. No.	Reg. No.	Name of Drug	Packing	MRP
1.	003158	Tracodil Cough Syrup	120ml	8.00
			60ml	5.00
			450ml	18.50

12. **Decision of 308th Meeting of registration Board:** 

Registration Board after through deliberation decided as follows:

- > Referred the case to Costing & Pricing Division for proceeding as per rules for overcharging of MRP.
- Manufacturing of product as per approval granted by relevant forums.
- 13. Accordingly, above decision of Registration Board was communicated to Costing & Pricing Division and reply of said Division is as under;

"In light of opinion of the Legal Division, the matter is of selling of an un-approved pack size which may fall under violation of the conditions of Registration. Moreover, no evidence of

overpricing has been provided. Therefore, Division of PE&R may proceed in accordance with the opinion of the Legal Division."

- 14. Opinion of Legal Affair's Division is as under;
  - i. Drug Regulatory Authority of Pakistan Act, 2012 in Schedule-II A(1) (a) (vii) prohibits export, import or manufacture and sale or sell of any therapeutic goods which is not registered or is not in accordance with conditions of registration as disclosed in the registration dossier and that has undergone pharmaceutical evaluation. Furthermore, Schedule-II(A)(c) prohibits to sell any therapeutic goods except under, and in accordance with the conditions of a license issued under this Act. In addition, Schedule-II A(a)(f) prohibit to supply an incorrect, incomplete or misleading information when required to furnish any information under this Act or the rules.
  - ii. In this regard, DRAP Act, 2012 under section 27 read with schedule-III (6) provides penalty for violating the prohibitions mentioned above.

Decision: Registration Board deliberated the matter in details and decided to have opinion from Legal Affair Division regarding need of another opportunity of personal hearing as per Drug Act, 1976 and Rules framed there under.

## Case No.03: <u>Cancellation Registration of Drugs in lieu of cancellation of DML/Surrender of Sections</u>

a. Central Licensing Board in its 284<sup>th</sup> meeting held on 16-12-2021 cancelled Drug manufacturing licenses of following firms. Detail is as under;

Sr. No.	Name of Firm	Decision of CLB
1.	M/s. Jasons Pharmaceuticals Plot No. 26 Street No. SS-2 National Industrial Zone Rawat Islamabad. 000727	The Board decided to cancel the Drug Manufacturing License <b>No. 000727</b> by way of formulation in the name of M/s. Jasons Pharmaceuticals Plot No. 26 Street No. SS-2 National Industrial Zone Rawat Islamabad as the Drug Manufacturing License No. 000727 is no more valid as under Rule 5 (6) of The Drugs (L, R & A) Rules, 1976. However, firm may file an application afresh under Rule 5 of The Drugs (Licensing, Registering and Advertising) Rules, 1976. [( <b>No.F.1-21/2007-Lic (Vol-I) dated 27-12-2021</b> ]
2.	M/s. Ceicil Labs (Pvt) Ltd. 21 km Ferozpur Road Lahore. 000384	The Board decided to cancel the Drug Manufacturing License <b>No. 000384</b> by way of formulation in the name of M/s. Ceicil Labs (Pvt) Ltd. 21 km Ferozpur Road Lahore as the Drug Manufacturing License No. 000384 is no more valid as under Rule 5 (6) of The Drugs (L, R & A) Rules, 1976. However, firm may file an application afresh under Rule 5 of The Drugs (Licensing, Registering and Advertising) Rules, 1976. [( <b>No.F.1-10/93-Lic (Vol-I) dated 27-12-2021</b> ]
3.	M/s, Soma Laboratories Plot No. 43-D Sundar Industrial Estate Raiwind Road Lahore. 000225	The Central Licensing Board considered the request of firm for surrendered the Drug Manufacturing License No. 000225 by way formulation of M/s, Soma Laboratories Plot No. 43-D Sundar Industrial Estate Raiwind Road Lahore and decided that the said Manufacturing License stands cancelled with immediate effect under the Drugs Act, 1976 and rules framed there under. Manufacturing of Drugs in the name of said license and at said premises is prohibited and punishable offence under section 23 and 27 of the Drugs Act 1976 and rules framed there under. [(No.F.1-65/2005-Lic (Vol-I) dated 14-01-2022]

b. Central Licensing Board has also acceded to request of the firms regarding voluntary withdrawal /surrender of licensed sections by following firms. Detail is as under;

Sr. No.	Name of Firm	Decision of CLB
1.	M/s. The Schazoo	The central Licensing Board in its 284 <sup>th</sup> meeting held on 16 <sup>th</sup> December, 2021,
	Pharmaceutical	has considered the request of firm for withdrawal / voluntary surrendering the
	Laboratories (Pvt)	licensed sections and acceded the request for the following licensed sections
	Ltd. Kalalwala	of M/s. The Schazoo Pharmaceutical Laboratories (Pvt) Ltd. Kalalwala Stop,
	Stop, 20-Km	20-Km Lahore Jaranwala Road District Sheikhupura under DML No. 000019
	Lahore Jaranwala	(Formulation
	Road District	Tablet (Cephalosporin)
	Sheikhupura.	2. Capsule (Cephalosporin)
	000019	3. Dry Powder Suspension (Cephalosporin)
2.	M/s. Akson	The central Licensing Board in its 283 <sup>th</sup> meeting held on 28 <sup>th</sup> October, 2021,
	Pharmaceuticals	considered the facts on the record and after threadbare deliberation acceded
	(Pvt) Ltd. Plot No.	the request of M/s. Akson Pharmaceuticals (Pvt) Ltd. Plot No. 9B-1 & 2
	9B-1 & 2 Sector D-	Sector D-1 Old Industrial Estate Mirpur Azad Kashmir with the direction to
	1 Old Industrial	intimate future utilization of withdrawn facility. Therefor following licensed
	Estate Mirpur Azad	sections of M/s. Akson Pharmaceuticals (Pvt) Ltd. Plot No. 9B-1 & 2 Sector
	Kashmir.	D-1 Old Industrial Estate Mirpur Azad Kashmir stands withdrawn with
	000486	immediate effect;
		1. Capsule (Cephalosporin)
		2. Dry Powder Suspension (Cephalosporin)
		3. Injectable Powder (Cephalosporin)

Registration Board in its 307<sup>th</sup> meeting has authorized its Chairman for issuance of show cause notice for cancellation of registration after cancellation of DML. Accordingly, above mentioned firms were issued show cause notices.

M/s. Akson Pharmaceuticals, Azad Kashmir in reply of show cause submitted that they had applied for contract manufacturing of their 22 registered products from M/s. Gray's Pharmaceuticals, Islamabad before surrender of the sections. Date of surrender is 14-12-2021 and their CTD applications R&I submission is in September, 2021. Detail of products is as under;

Sr.	Reg No.	Brand Name	Composition
No.			
1	037621	Endopime 500mg Injection	Cefipime 500mg Injection
2	037622	Endopime 1gm Injection	Cefipime 1 gm Injection
3	029937	Aksoxime 100mg Suspension	Cefixime 100mg Suspension
4	056274	Aksoxime 400mg Capsule	Cefixime 400mg Capsule
5	056276	Aksoxime 200mg Suspension	Cefixime 200mg Suspension
6	064447	Kerazon plus 1 gm Injection	Cefoperazone + sulbactum 1gm Injection
7	064448	Kerazon plus 2 gm Injection	Cefoperazone + sulbactum 2gm Injection
8	023741	Jaycil 500mg Capsule	Cefadroxil 500 mg Capsule
9	023742	Jaycil 125 mg Suspension	Cefadroxil 125 mg Suspension
10	023743	Jaycil 250mg Suspension	Cefadroxil 250 mg Suspension
11	023739	Aksosef 250 Capsule	Cephradine 250mg Capsule
12	023740	Aksosef 500 Capsule	Cephradine 500mg Capsule
13	027724	Aksosef 125 Suspension	Cephradine 125mg Suspension
14	027725	Aksosef 250 Suspension	Cephradine 250mg Suspension
15	036599	Trophin 500mg IV Injection	Ceftriaxone 500mg Injection
16	036607	Onexin 250mg IM/IV Injection	Cefotaxime 250mg Injection
17	036608	Onexin 500mg IM/IV Injection	Cefotaxime 500mg Injection
18	036609	Onexin 1g IM/IV Injection	Cefotaxime 1gm Injection

19	030580	Trophin 250mg IV Injection	Ceftriaxone 250mg Injection
20	030581	Trophin 1gm IV/IM Injection	Ceftriaxone 1 gm Injection
21	052413	Trophin 500mg IM Injection	Ceftriaxone 500mg Injection
22	052414	Trophin 250mg IM Injection	Ceftriaxone 250mg Injection

## **Decision of 316<sup>th</sup> meeting of Registration Board:**

## Registration Board decided to call above mentioned firms for personal hearing.

Accordingly, all the firm have called for personal hearing at 12.30 P.M

M/s. Akson was not called for personal hearing as firm has applied for transfer of registration on contract manufacturing before surrender of section.

**Proceedings and Decision of 317th meeting of Registration Board:** 

Sr.	Name of Firms	Proceedings of 313th meeting	Decision of 313th meeting of
No.	- 100000 00	of Registration Board	Registration Board
1.	M/s. Jasons Pharmaceuticals Plot No. 26 Street No. SS-2 National Industrial Zone Rawat Islamabad. 000727	The firm was issued showcause and personal hearing notices to appear before the Registration Board. No one appeared before 317th meeting of Registration Board.	Keeping in view the decision taken by the Central Licensing Board in its 284th meeting regarding cancellation of DML, Registration Board cancelled the registration of all products registered in the name of M/s. Jasons Pharmaceuticals Plot No. 26 Street No. SS-2 National Industrial Zone Rawat Islamabad w.e.f cancellation of their DML.
2.	M/s. Ceicil Labs (Pvt) Ltd. 21 km Ferozpur Road Lahore. 000384	The firm was issued showcause and personal hearing notices to appear before the Registration Board. No one appeared before 317 <sup>th</sup> meeting of Registration Board.	Keeping in view the decision taken by the Central Licensing Board in its 284th meeting regarding cancellation of DML, Registration Board cancelled the registration of all products registered in the name of M/s. Ceicil Labs (Pvt) Ltd. 21 km Ferozpur Road Lahore w.e.f cancellation of their DML.
3.	M/s, Soma Laboratories Plot No. 43-D Sundar Industrial Estate Raiwind Road Lahore. 000225	The firm was issued showcause and personal hearing notices to appear before the Registration Board. No one appeared before 317 <sup>th</sup> meeting of Registration Board. However, Firm has telephonically replied that they have no objection to cancel the registrations of their products.	Keeping in view the decision taken by the Central Licensing Board in its 284th meeting regarding cancellation of DML, Registration Board cancelled the registration of all products registered in the name of M/s, Soma Laboratories Plot No. 43-D Sundar Industrial Estate Raiwind Road Lahore w.e.f cancellation of their DML.
4.	M/s. The Schazoo Pharmaceutical Laboratories (Pvt) Ltd. Kalalwala Stop, 20- Km Lahore Jaranwala Road District Sheikhupura. 000019	The firm was issued showcause and personal hearing notices to appear before the Registration Board. Mr. Sayed Mushtaq Malik, Executive Director Marketing, appeared on behalf of firm has submitted that they want to transfer following three products on contract	a. Keeping in view the decision taken by the Central Licensing Board in its 284th Meeting regarding withdrawal of licensed sections, the Registration Board deliberated and cancelled all drug products registered under following sections of M/s. The Schazoo Pharmaceutical Laboratories

manufacturing. Detail	of (Pvt) Ltd. Kalalwala Stop, 20-
products are as under;	Km Lahore Jaranwala Road
Eficaz 400mg Capsu	le District Sheikhupura w.e.f
(Cefixime) Reg. No. 069408	decision of the Central Licensing
. Eficaz Dry Powder Suspensi	Doord arrest made at a ct CN a b
	i Tablet (Cenhalosporin)
100mg (Cefixime) Reg. N	ii. Capsule (Cephalosporin)
071432	iii. Dry Powder Suspension
i. Eficaz DS Dry Powe	er (Cephalosporin).
Suspension (Cefixime) Re	b. Acceded to request of firm for
No. 071434	contract manufacturing of
	following 3 products and advised
	ro submit application
	accordibgly.
	i. Eficaz 400mg Capsule
	(Cefixime) Reg. No. 069408
	ii. Eficaz Dry Powder
	Suspension 100mg (Cefixime)
	Reg. No. 071432
	iii. Eficaz DS Dry Powder
	Suspension (Cefixime) Reg. No.
	071434

## Case No.04: Complaint from Pakistan Citizen's Portal Regarding Manufacturing of Same Product with Two Different Brand Names.

A complaint has been received from Prime Minister's Performance Delivery Unit (PMDU), Pakistan Citizen's Portal that M/s. Pacific Pharmaceuticals 30Km Multan Road, Lahore is manufacturing a product by two names and the firm also marketing the products with two different MRPs i.e Rs.355.56 for Plasezyme & Rs.227.13 for Plasil with Enzyme. The details are given as under:-

Sr.#	Reg. No.	Product Name and Composition
1.	021646	Plasenzym Tablet
		Each tablet contains: -
		Metoclopramide HCl 6mg
		Sodium dehydrochlolate 20mg
		Bromelain Proteolytic unit 35,000
		Pancreatin FIP Proteolytic unit 210
		Simethicon 50mg
2.	012130	Plasil with Enzyme Tablet
		Each tablet contains: -
		Metoclopramide HCl 6mg
		Sodium dehydrochlolate 20mg
		Bromelain Proteolytic unit 35,000
		Pancreatin FIP Proteolytic unit 210
		Simethicon 50mg

M/s. Pacific Pharmaceutical Lahore has submitted following documents:-

- i. Copy of registration letter of Plasil with Enzyme Tablet (Reg.No.012130) dated 02-01-1991 registered in the name of M/s. Pacific Phamraceuticals Ltd; 29th Km Multan Road, Lahore. Previously this drug was registered in the name of M/s. Mars Phamra, Lahore in finished import under the brand name Plasil Enzymatico (Reg.No.002659) manufactured by M/s. Lepitit Millan Italy and transferred to M/s. Isman Drug House, 26 Comercial Building Shahra-e-Quaid-e-Azam Road, Lahore dated 18th November, 1978
- ii. Copy of registration letter of **Plasenzym Tablet** (**Reg.No.021646**) **dated 20-05-1998** registered in the name of M/s. Pacific Phamraceuticals Ltd; 29th Km Multan Road, Lahore.

It is submitted that the firm has not provided any evidence regarding change of registration status from M/s. Isman Drug House Lahore to M/s. Pacific Pharmaceutical, Lahore. Now firm contains two registrations of

same formulation with two different brand names in local manufacturing and marketing with two different MRPs as complained stated above.

Registration Board in 297<sup>th</sup> meeting decided to issue show cause to M/s. Pacific Pharmaceutical, Lahore. Accordingly show cause notice has been issued to the firm and firm has submitted a reply which is as under:

- 1. This is in regards to the Show Cause Notice received by Pacific Pharmaceuticals (Private) Limited's (the "Company") dated 21<sup>st</sup> October 2021 in regards to the registration of two different brand names for the same product.
- 2. That the Plasil with Enzyme bearing Registration No. 012130 was a registered product of Isman Drug House, a parent company of the Company, whereby the same was being imported by the Isman Drug House at that time, which was later on transferred to the Company for manufacturing locally. Furthermore, the Plasenzym bearing Registration No. 021646 is a product registered by the Company itself, since, one of the old products was transferred to our Company, we started using both names to avoid disrupting the market. That both products are owned and are being manufactured by the Company not to defraud the public but in order to help them carry on with the product name they are comfortable with and have been using for decades.
- 3. It is pertinent to mention here that; several other companies are following the same market practice in order to cater to different segments or regions of the market. Please see below the similar products of only one company, Global Pharmaceutical, marketing its medicines under several brand names.

Sr. No.	Product Name	Generic	Registration Holder	
1.	Norbac injection 250mg IV	Ceftrixone	M/s. Global Pharmaceuticals (Pvt) Ltd., Plot No 204-205 Kahuta Triangle Industrial Area Islamabad	
2.	Norbac injection 500mg IV	Ceftrixone	M/s. Global Pharmaceuticals (Pvt) Ltd., Plot No 204-205 Kahuta Triangle Industrial Area Islamabad	
3.	Aczon I.M Injection 500mg	Ceftrixone	M/s. Vision Pharmaceuticals (Pvt) Ltd., Plot No. 22-23 Industrial Triangle Kahuta Road Islamabad	
4.	Amizone 250mg Injection	Ceftrixone	M/s. Aims Pharmaceuticals, Industrial triangle Kahuta Road, Islamabad Contract Manufactured By: M/s. Global Pharmaceuticals (Pvt) Ltd., Plot No 204-205 Kahuta Triangle Industrial Area Islamabad	
5.	Nafcin 500mg Tablet	Ciprofloxacin HCl eq. to Ciprofloxacin500mg	M/s. Global Pharmaceuticals (Pvt) Ltd., Plot No 204-205 Kahuta Triangle Industrial Area Islamabad	
6.	Artinil-K 50mg Tablet	Diclofenac Potassium	M/s. Global Pharmaceuticals (Pvt) Ltd., Plot No 204-205 Kahuta Triangle Industrial Area Islamabad	
7.	Ostinac 50mg Tablet	Diclofenac Sodium	M/s. Global Pharmaceuticals (Pvt) Ltd., Plot No 204-205 Kahuta Triangle Industrial Area Islamabad	
8.	Ostinac 75mg Tablet	Diclofenac Sodium	M/s. Global Pharmaceuticals (Pvt) Ltd., Plot No 204-205 Kahuta Triangle Industrial Area Islamabad	
9.	Zoycin 2.25gm Injection	Piperacillin (as Piperacillin Sodium): 2gm Tazobactam (as Tazobactam Sodium): 0.25gm	M/s. Global Pharmaceuticals (Pvt) Ltd., Plot No 204-205 Kahuta Triangle Industrial Area Islamabad	
10.	Zoycin 4.5gm Injection	Piperacillin (as Piperacillin Sodium): 4gm Tazobactam (as Tazobactam Sodium): 0.50gm	M/s. Global Pharmaceuticals (Pvt) Ltd., Plot No 204-205 Kahuta Triangle Industrial Area Islamabad	
11.	Tazpin 2.25gm Injection	Piperacillin (as Piperacillin Sodium): 2gm Tazobactam (as Tazobactam Sodium): 0.25gm	M/s. Vision Pharmaceuticals (Pvt) Ltd., Plot No. 22-23 Industrial Triangle Kahuta Road Islamabad Contract Manufactured By:	

			M/s. Global Pharmaceuticals (Pvt) Ltd., Plot No 204-205 Kahuta Triangle Industrial Area Islamabad	
12.	Tazpin 4.5gm	Piperacillin (as Piperacillin	M/s. Vision Pharmaceuticals (Pvt) Ltd., Plot No.	
	Injection	Sodium): 4gm	22-23 Industrial Triangle Kahuta Road Islamabad	
		Tazobactam (as Tazobactam	Contract Manufactured By:	
		Sodium): 0.50gm	M/s. Global Pharmaceuticals (Pvt) Ltd., Plot No	
			204-205 Kahuta Triangle Industrial Area	
			Islamabad	
13.	Bestoxil 500Mg	Cefadroxil	M/s. Vision Pharmaceuticals (Pvt) Ltd., Plot No.	
	Capsules		22-23 Industrial Triangle Kahuta Road Islamabad	
14.	Ceroxil Cap 500 mg	Cefadroxil	M/s. Global Pharmaceuticals (Pvt) Ltd., Plot No	
			204-205 Kahuta Triangle Industrial Area	
			Islamabad	

- 4. Furthermore, the above-mentioned products belong to one single company who is marketing several of its products under different brand names having similar salts. There are several other companies involved in the same practice in order to cater different demands and regions.
- 5. This practice does not constitute to any sort of violation; hence, it is respectfully prayed that the Authority may kindly suspend the working of its Show Cause Notice dated 21<sup>st</sup> October 2021.

As per above reply of the firm, stance of the firm is not justified as all above stated products are not registered products of M/s. Global.

### **Decision of 316<sup>th</sup> meeting of registration Board:**

Registration Board decided to call M/s. Pacific Pharmaceuticals Limited, Lahore for personal hearing for cancellation of one of above-mentioned products registered in their name.

Accordingly, firm has been called for personal hearing at 12.30 P.M.

## **Proceedings of 317th Meeting**

Mr. Gazi Mustansar Riaz appeared on behalf of firm and requested to re-schedule the hearing as their technical head is on medical leave.

Decision: Registration Board considered the request of the firm and decided to give another opportunity of personal hearing in forthcoming meeting of the Board.

### A. Post Registration Variations:

### **Deferred case of 74th PRVC**

### Case No.01: Abbott Laboratories (Pakistan) Ltd., Karachi (Page No. 650 – 703/C):

Dy.No.636-37 & 827 (PR-I) dated: 26-May & 23-Jun-2021

M/s Abbott Laboratories (Pakistan) Limited, Opp.Radio Pakistan Transmission Centre, Hyaderabad Road, Landhi, Karachi has requested for retaining of manufacturer's specification of their following already registered drugs being manufactured by M/s Highnoon Laboratories Limited, 17.5-Km, Multan Road, Lahore on contract manufacturing basis having

validity till 17-August-2021. The details are as under;

Sr. No.	Reg. No.	Name of Drug(s) with Composition & Existing Specification	Document Submitted by the firm
1.	011468	Faverin 50mg Tablets Each tablet contains: Fluvoxamine Maleate50mg (Manufacturer's Specification)	<ul> <li>Fee of Rs.7,500/- (21-May-21) &amp; Differential fee of Rs.2,500/- (21-June-21) for each product.</li> <li>Copy of initial registration letter.</li> <li>Analytical reports/ comparison in tabulated</li> </ul>
2.	011469	Faverin 100mg Tablets Each tablet contains: Fluvoxamine Maleate100mg (Manufacturer's Specification)	form.  > Undertaking.

The following are comparisons in tabulated form;

1. Faverin 50mg Tablets (Reg.No. 011468):

Test Parameters	Abbott	BP - 2021	JP - 17	USP- 2020
rest Farameters	(Specification)	(Specification)	(Specification)	(Specification)
Monograph Name	Fluvoxamine Maleate tablets	Fluvoxamine Maleate tablets	Fluvoxamine Maleate Tablets	Fluvoxamine Maleate Tablets
Appearance	Round, plain, biconvex, white film coated tablets			
Identification	1. By HPLC 2. By UV	A. BY HPLC B. By Infrared Absorption spectrum	By UV	1. By HPLC 2. By UV
Average Weight	258 mg ± 3%			
Weight Variation	18/20 ± 5% [245 271mg], 02/20 ± 10% [232284mg]	Included as per General Chapters of compendia	Included as per General Chapters of compendia	Included as per General Chapters of compendia
Disintegration	Not more than 30 minutes. Meet the BP requirements			
Dissolution	NLT 80% in water for 20 minutes	NLT 75% (Q) in 20 minutes	NLT 80% for 20 mins	NLT 80% (Q) of the labeled amount
Assay	92.5 – 105.0%	92.5-105.0%	95.0 – 105.0%	90.0-110.0%
Content Uniformity (By HPLC and UV)	85.00 – 115.00 %	Meets the BP requirements	Meet the JP requirements	Meet the USP requirements
Microbiological Quality	TAMC: ≤10 <sup>3</sup> CFU/g TYMC: ≤10 <sup>2</sup> CFU/g E. Coli: Absent/g	Meets the BP requirements	Meets JP requirements	Meets the USP requirements

2. Faverin 100mg Tablets (Reg.No. 011469):

Test Parameters	Abbott	BP - 2021	JP - 17	USP- 2020
rest Farameters	(Specification)	(Specification)	(Specification)	(Specification)
Monograph Name	Fluvoxamine Maleate tablets	Fluvoxamine Maleate tablets	Fluvoxamine Maleate Tablets	Fluvoxamine Maleate Tablets

Appearance	Oval, biconvex, scored, white film coated tablets.			
Identification	1. By HPLC 2. By UV	A. BY HPLC B. By Infrared Absorption spectrum	By UV	1. By HPLC 2. By UV
Average Weight	510 mg	Included as per general chapters of compendia	Included as per general chapters of compendia	Included as per general chapters of compendia
Weight Variation	18/20 + 5% [485 – 536mg], 02/20 + 10% [459 – 561mg]			
Disintegration	Not more than 30 minutes.	Meet the BP requirements		
Dissolution	NLT 80% in water for 20 minutes	NLT 75% (Q) in 20 minutes	NLT 80% for 20 mins	NLT 80% (Q) of the labeled amount
Assay	92.5 – 105.0%	92.5-105.0%	95.0 – 105.0%	90.0%-110.0%
Content Uniformity (By HPLC & UV)	85.00 – 115.00 %			Meet the USP requirements
Microbiological Quality	TAMC: ≤10 <sup>3</sup> CFU/g TYMC: ≤10 <sup>2</sup> CFU/g E. Coli: Absent/g	Meets the BP requirements	Meets JP requirements	Meets the USP requirements

#### **Remarks:**

Firm has not submitted comparison of acceptance criteria for impurity testing in Faverin (fluvoxamine) 50mg and 100mg tablet.

#### **65-PRVC Decision:**

The Committee considered the case and deferred the request of firm regarding Faverin (fluvoxamine) 50mg & 100mg tablet for submission of acceptance criteria for impurities since acceptance criteria for impurities are provided in official monographs BP, USP & JP.

The firm also resubmitted the comparison in tabulated form as under;

Sr.	Test Parameters	Faverin 50mg Tablet	BP - 2021	JP - 17	USP- 2020
No.		(Specification)	(Specification)	(Specification)	(Specification)
1	Monograph Name	Fluvoxamine Maleate Tablets	Fluvoxamine Maleate Tablets	Fluvoxamine Maleate Tablets	Fluvoxamine Maleate Tablets
2	Appearance	Round, plain, biconvex, white film coated tablets			
3	Identification	1. By HPLC 2. By UV	A. BY HPLC B. By Infrared Absorption spectrum	By UV	1. By HPLC 2. By UV
4	Average Weight	258 mg ± 5%			
5	Weight Variation	18/20 ± 5% [245 271mg], 02/20 ± 10% [232284mg]			
6	Dissolution	NLT 80% (Q) in water for 20 minutes	NLT 75% in water for 20 minutes	NLT 80% in water for 20 mins	NLT 80% (Q) in water for 30 min
7	Assay	92.5 – 105.0%	92.5 - 105%	95.0 – 105.0%	90.0%-110.0%
8	Content Uniformity (By HPLC) Content	Meets the USP / BP requirements	Meets the BP requirements	Meet the JP requirements	Meet the USP requirements
	Uniformity (By UV)	,	,	,	,

		Impurity C: NMT 3%	Impurity C: NMT 3%	NA	Imp: Succinyl fluvoxamine: NMT 0.8%
		impurity B: NMT 0.5%	impurity B: NMT 0.5%	NA	Z-Isomer (Imp B): NMT 0.5%
	Organic	Impurity D: NMT 0.8%	Impurity D: NMT 0.8%	NA	Valerophenone analog (Imp D): NMT 0.2%
	Impurities Test	Unspecified impurities each: NMT 0.2%	Unspecified impurities each: NMT 0.2%	NA	Unspecified impurities each: NMT 0.1%
		Sum of impurities (Excluding impurity C & impurity D): NMT 1.0%	Sum of impurities (Excluding impurity C & impurity D): NMT 1.0%	NA	Total Impurities: NMT 1.8%
		NA	NA	NA	Fluvoxamine Maleamide (Imp C): NMT 0.2%
		NA	NA	NA	Aminoethyl fluvoxamine: NMT 0.2%
		NA	NA	NA	Aminoethyl desmethoxy fluvoxamine: NMT 0.2%
9		NA	NA	NA	Dealkyl benzyl fluvoxamine: NMT 0.2%
		NA	NA	NA	Desmethoxy fluvoxamine: NMT 0.2%
		NA	NA	NA	Fluvoxamine oxime: NMT 0.2%
	TEST 2 (Alternate test in USP)	NA	NA	NA	Desfluoro Fluvoxamine: NMT 0.2% Imp: Succinyl fluvoxamine: NMT 1.2% Aminoethyl fluvoxamine: NMT 0.2% Z-Isomer (Imp B): NMT 0.5% Desmethoxy fluvoxamine: NMT 0.2% Fluvoxamine oxime: NMT 0.2% Valerophenone analog (Imp D): NMT 0.2% Unspecified impurities each: NMT 0.2% Total Impurities: NMT 1.5%
10	Microbiological Quality	TAMC: ≤10³ CFU/g TYMC: ≤10² CFU/g E. Coli: Absent/g	Meets the BP requirements	Meets JP requirements	Meets the USP requirements

Faverin 100mg Tablet

Sr.	Test Parameters	Faverin 100mg Tablet	BP - 2021	JP - 17	USP- 2020
No.		(Specification)	(Specification)	(Specification)	(Specification)
1	Monograph Name	Fluvoxamine Maleate tablets	Fluvoxamine Maleate tablets	Fluvoxamine Maleate Tablets	Fluvoxamine Maleate Tablets

2	Appearance	Oval, plain, biconvex, scored, white film coated tablets.			
3	Identification	1. By HPLC 2. By UV	A. BY HPLC B. By Infrared Absorption spectrum	By UV	1. By HPLC 2. By UV
4	Average Weight	510 mg ± 5%			
5	Weight Variation	18/20 + 5% [485 – 536mg], 02/20 + 10% [459 – 561mg]			
6	Dissolution	NLT 80% (Q) in water for 20 minutes	NLT 75% in water for 20 minutes	NLT 80% in water for 20 mins	NLT 80% (Q) in water for 30 min
7	Assay	92.5 – 105.0%	92.5 - 105%	95.0 – 105.0%	90.0%-110.0%
8	Content Uniformity (By HPLC) Content	Meets the USP / BP requirements	Meets the BP	Meet the JP	Meet the USP
	Uniformity (By UV)	requirements	requirements	requirements	requirements
		Impurity C: NMT 3%	Impurity C: NMT 3%	NA	Imp: Succinyl fluvoxamine: NMT 0.8%
		impurity B: NMT 0.5%	impurity B: NMT 0.5%	NA	Z-Isomer (Imp B): NMT 0.5%
	Organic Impurities Test 1	Impurity D: NMT 0.8%	Impurity D: NMT 0.8%	NA	Valerophenone analog (Imp D): NMT <b>0.2%</b>
	impunites rest i	Unspecified impurities each: NMT 0.2%	Unspecified impurities each: NMT 0.2%	NA	Unspecified impurities each: NMT 0.1%
		Sum of impurities (Excluding impurity C & impurity D): NMT 1.0%	Sum of impurities (Excluding impurity C & impurity D): NMT 1.0%	NA	Total Impurities: NMT 1.8%
		NA	NA	NA	Fluvoxamine Maleamide (Imp C): NMT 0.2%
9		NA	NA	NA	Aminoethyl fluvoxamine: NMT 0.2%
		NA	NA	NA	Aminoethyl desmethoxy fluvoxamine: NMT 0.2%
		NA	NA	NA	Dealkyl benzyl fluvoxamine: NMT 0.2%
		NA	NA	NA	Desmethoxy fluvoxamine: NMT 0.2%
		NA	NA	NA	Fluvoxamine oxime: NMT 0.2%
	TEST 2 (Alternate test in	NA	NA	NA	Desfluoro Fluvoxamine: NMT 0.2%
	ÙSP)				Imp: Succinyl fluvoxamine: NMT 1.2%

					Aminoethyl fluvoxamine: NMT 0.2%  Z-Isomer (Imp B): NMT 0.5%  Desmethoxy fluvoxamine: NMT 0.2%  Fluvoxamine oxime: NMT 0.2%  Valerophenone analog (Imp D): NMT 0.2%  Unspecified impurities each: NMT 0.2%  Total Impurities: NMT 1.5%
10	Microbiological Quality	TAMC: ≤10 <sup>3</sup> CFU/g TYMC: ≤10 <sup>2</sup> CFU/g E. Coli: Absent/g	Meets the BP requirements	Meets JP requirements	Meets the USP requirements

**Remarks:** Acceptance limits of impurities mentioned in USP are more stringent than acceptance limit of impurities as per manufacturer's specification.

Decision 74<sup>th</sup> PRVC: The committee considered the case and deferred the request of firm for submission of clarification regarding acceptance limits of impurities which are more stringent in USP than manufacturer's specification.

### **Updated Submission:**

The comparison of specifications mainly impurities has been further deliberated in following table:

Impurity Name (common	Manufacturer	BP	JP		SP ication nits	Remarks
/chemical)	Specifications Limits	Specification Limits	Specification Limits	As per Test 1	As per Test 2	The same
Impurity-C or Addition Product or ((E)-N- [2[[[α-(4-methoxybutyl)-4'- (trifluoromethyl)benzylidene] amino]oxy]ethyl]aspartic acid)	≤3.0%	≤3.0%	NA	≤0.8%	≤1.2%	impurity has two different limits within a monograph. This happens when impurity methods
Impurity-D or Fluvoxketone or (5-Methoxy-4'-trifluoromethylvalerophenone)	≤0.8%	≤0.8%	NA	≤0.2%	≤0.2%	are submitted by two different companies. Differing

Impurity D as per BP						synthetic routes and the unique chemical environments of different drug product formulations mean that impurity profiles may differ for different manufacturers' products.
Z-isomer or Impurity-B as per BP	≤0.5%	≤0.5%	NA	≤0.5%	≤0.5%	Equivalent to USP.
Fluvoxamine oxime	≤0.2%	NA	NA	≤0.2%	≤0.2%	Equivalent to
Desmethoxy fluvoxamine	≤0.2%	NA	NA	≤0.2%	≤0.2%	USP. Covered under
Desfluoro fluvoxamine*	≤0.2%	NA	NA	NA	≤0.2%	unspecified impurity in
Aminoethyl fluvoxamine	≤0.2%	NA	NA	≤0.2%	≤0.2%	Manufacturer specification.
Unspecified Impurities each	≤0.2%	≤0.2%	NA	≤0.1%	≤0.2%	Equivalent to USP
Sum of Impurities (excluding Impurities C & D (As per Abbott)/as per BP	≤1.0%	≤1.0%	NA	NA	NA	
Total degradation product (as per USP)	NA	NA	NA	≤1.8%	NA	
Total degradation product (as per USP)	NA	NA	NA	NA	≤1.5%	

Regarding difference in impurity acceptance limit (mainly Impurity C and D which is more stringent in USP than BP) in different monographs i.e USP and BP has been justified by firm in the light of remarks from relevant Pharmacopeia (USP &BP).

"This situation happens often, i.e., where the same impurity has two different limits within a monograph. This happens when impurity methods are submitted by two different companies"

Furthermore, it has been clarified that *The impurity profile presented in a monograph is based on available information representing one or more articles of commerce. The impurity profile in the monograph may not be applicable to all approved products due to differing synthetic routes and/or drug product formulations.* 

Differing synthetic routes and the unique chemical environments of different drug product formulations mean that impurity profiles may differ for different manufacturers' products.

#### Safety and Toxicological evaluation data:

#### Addition Product (Impurity C) / Succinyl fluvoxamine

#### Fluvoxketone (Impurity -D) / Valerophenone analogue

- **a.** 14-day Repeated dose oral toxicity study in rats
- b. Embryo-foetal development toxicity study in rats
- c. Juvenile toxicity study in rats
- d. Genotoxicity studies

#### **Conclusion:**

Fluvoxamine maleate Addition Product impurity (impurity C) and Fluvoxketone impurity (impurity D) at the specifications of 3.0% and 0.8% in fluvoxamine maleate tablets are of no potential toxicological concern.

#### **References:**

- 1. Sl 14.7.006: Fluvoxamine maleate spiked with 10% addition product, 4% Z-lsomer, 3% fluvoxketone, 1 % difluoro and I% hydroxy: Oral (gavage) comparative study of embryofoetal developmental in rats
- 2. Study S 114.7 .002: Fluvoxamine maleate spiked with 2% Z-isomer, 4% Addition product, I% Dimer, 1 % Difluoro and 1 % Hydroxy: 21 Day oral (gavage) administration rangefinding study in the rat (3 weeks of age at commencement)
- 3.Sl 14.4.005: Fluvoxamine maleate spiked with 4% Addition product, 1% Dimer, 1%Ditluoro and 1 % Hydroxy: Reverse Mutation in five Histidine-requiring strains of Salmonella typhimurium
- 4. S 114.4.006: Fluvoxamine maleate spiked with 2% Z-isomer, 4% Addition product, I%Dimer, I% Ditluoro and I % Hydroxy: Mutation at the Thymidine Kinase (tk) Locus of Mouse Lymphoma L5178Y Cells (MLA) using Microtiter® Fluctuation Technique
- 5. ICH Harmonized Tripartite Guideline -Impurities: guidelines for residual solvents (Q3C(R6)), October 2016
- 6. In vitro mammalian chromosome aberration test, 5-methoxy-4'-(trifluoromethyl)valerophenone (FI u

voxketone) https://echa.europa.eu/reg istration-doss i er/-/registereddossier/3127 /7 /7 /2, accessed on 01.08.2019.

#### Decision 78th PRVC: The Committee referred the case to Registration Board.

Decision: Registration Board considered the case and acceded to request of firm for grant of innovator's specification being equivalent/more stringent to BP in all parameters.

#### Case No.02: Referred case by PRVC:

i. Change of Finished Product Specifications of Registered Drugs.

#### **Decision of 290<sup>th</sup> Meeting of Registration Board:**

The Registration Board authorized Chairman, Registration Board for approval of change/correction of finished product specifications in different scenarios discussed as under:

- i. Products registered with manufacturer specifications but formulation exist in official monograph (as decided by Registration Board in 267<sup>th</sup> meeting)
- ii. Products registered with any pharmacopoeial specification (e.g. USP) but formulation do not exist in that particular pharmacopeia but another pharmacopeia (e.g. BP).

However, when firm request to change finished product specification from one pharmacopeia to another pharmacopeia (e.g. BP to USP) and formulation exist in both existing and proposed pharmacopeias (e.g. BP & USP) and shifting to manufacturer's specifications, such cases shall be

discussed in Registration Board considering comparison between equipment/technology, acceptance criteria, Assay protocol and tests etc.

#### **Decision of 296th Meeting of Registration Board:**

Registration Board authorized its Chairman to grant approval for change of finished product specification from one pharmacopeia to another pharmacopeia.

The following firms have submitted applications for the change finished product

specifications		

Sr. No.	Reg. No.	Name of Drug(s) with Composition & Existing Specification	Date of initial Reg. & renewal status	Proposed Specification	Documents submitted / Remarks (if any)
Ι	II	III	IV	V	VI
i.	M/s Atco	Laboratories Limited, 17/24, Korang	i Industrial	Area, Karachi.	
Do	cuments a	s per SOPs submitted as under;			
	a.	Fee of Rs.10,000/- (21-Dec-21) for	each produ	ct.	
	b.	Copies of initial Registration letters	& last rene	wal status for e	each product.
	c.	Copies of Official monographs of e	ach formula	ations.	_
	d.	Undertaking.			
1.	013888	Tanakan 40mg Tablets Each tablet contains: Ginkgo Biloba Extract40mg Dy.No.01 (PR-I) dated: 3-Jan-22	15-Dec-92 29-Nov-17	As per Innovator's Specifications	3
<u>79-</u>	79-PRVC Decision: The Committee referred the case to Registration Board.				

Decision: Registration Board considered the case and referred it to the committee constituted in 74<sup>th</sup> meeting of DRAP to decide the placement of therapeutic goods likely to be in various categories.

#### **78-PRVC:**

ii. Extension in Permission of Bulk Import & Local Repacking and Change of Name of Manufacturing Site (Page No.196–211/C).

Dy.No.282 (PR-I) dated: 8-Feb-22.

M/s Sanofi-aventis Pakistan Limited, Plot No.23, Sector 22, Korangi Industrial Area, Karachi has intimated that the name and address of manufacturer of product being imported in bulk and locally repacked along-with extension in permission of their following drug as per details give below;

Reg.	Name of Drug with Composition with Date	Existing Manufacturer	Proposed Manufacturer
No.	of Initial Reg. & last renewal		
023617	Telfast D Tablets	Sanofi Winthrop	Opella Healthcare
	Each tablet contains:	Industries, 56 Route de	International SAS,
	Fexofenadine HCl60mg	choisy-au-Bac Compiegne	56 route de Choisy,
	Pseudoephedrine HCl120mg	60205, France.	Compiegne, 60200,
			France.
	Grant of Permission for Bulk Import: 9-Feb-17		

In this regard, the firm has submitted the following:

- a. Fee of Rs.150,000/- (4-Feb-22) + Rs.10,000/- (3-Feb-22).
- b. Copies of initial registration letter (12-May-99), Transfer of Registration dated 28-Jul-06 and last renewal status (28-Jun-21).
- c. Original & Legalized GMP of proposed manufacturer issued by National Agency for The Safety of Medicine and Health Products, vide Certificate No.2020/HPF/FR/068/NT dated 21-September, 2021.

### d. Undertaking.78-PRVC Decision:

The Committee referred the case to Registration Board

Decision: Registration Board acceded to request of firm as follows:

- a. Consideration of renewal status of the product from registration of product in name of  $\,$  M/s Sanofi-aventis Pakistan Limited.
- b. Change in address of manufacturer from Sanofi Winthrop Industries, 56 Route de choisy-au-Bac Compiegne 60205, France to Opella Healthcare International SAS, 56 route de Choisy, Compiegne, 60200, France (site will remain same)

#### B. Registration of Drugs for Export Purpose Only.

Case No.01: Registration of Drug(s) of M/s Medisure Laboratories Pakistan (Pvt.) Ltd., A-115, SITE., Super Highway, Karachi Exclusively for Export Purpose.

Firm has applied for registration of drug(s) only for export purpose as per following details:

Requirements as Per SOP	<b>Submitted Documents</b>
Application on Form-5/ Form 5-D with required fee as per relevant SRO.	Form-5; Fee <b>Rs.30,000/-</b> (03.03.2022)+ <b>Rs.45,000/-</b> (16.03.2022)
Copy of DML (Renewal status) along with approval of relevant sections verified by licensing Division or inspection report for renewal of DML before 2005.	Copy of DML provided. Approval of Liquid Injectables (Ampoules & Vials) Section confirmed vide letter dated 19-July-2012.
GMP Status. Copy of Inspection report/GMP certificate.	GMP inspection conducted on 7-Sep-2021.
Undertakings that applied product is exclusively for export purpose and proposed names/ label/ color do not resemble with already registered brands in importing country.	

Detail of the products is given below:

Sr.#	Name of Drug(s) with composition	Generic/RRA Status	Dy.No.(EFD)
Ι	II	III	IV
1.	Neurocoline 250mg/ml Injection (4ml)	Purchase Order of: M/s Medisure	Dy. No.7497/22 (28.03.2022)
	Each ml contains:	Biiotech Co., Ltd., Yangon.	
	Citicoline250mg		
		Remarks: The formulation registered	
		in Pakistan as under:	
		Citicoline 250mg/2ml (125mg/ml) by	
		M/s Hilton Pharma	

Decision: Registration Board approved above mentioned product of M/s Medisure Laboratories Pakistan (Pvt.) Ltd., A-115, SITE., Super Highway, Karachi. Since applied formulation is neither registered for local use nor approved by any RRA (as adopted by Registration Board in 275th meeting) hence manufacturer and importing country shall be responsible for safety, efficacy and quality of drug product

Case No.02: Registration of Drug(s) of M/s Medicraft Pharmaceuticals (Pvt.) Ltd., 126-B, Industrial Estate, Hayatabad, Peshawar Exclusively for Export Purposes.

Firm has applied for registration of drug(s) only for export purpose as per following details:

Requirements As Per SOP	<b>Submitted Documents</b>
Application on Form-5/ Form 5-D with required fee as per relevant SRO.	Form-5; Fee <b>Rs.75,000/-</b> (03.03.2022)
Copy of DML (Renewal status) along with approval of relevant sections verified by licensing Division or inspection report for renewal of DML before 2005.  GMP Status. Copy of Inspection report/GMP certificate.	Copy of DML provided. Approval of Tablet (General) Section confirmed from renewal of DML vide letter dated 17-September-2021.  GMP inspection conducted on 22-April-2021.
Undertakings that applied product is exclusively for export purpose and proposed names/ label/ colour do not resemble with already registered brands in importing country.	*

Detail of the products is given below:

Sr.#	Name of Drug(s) with composition	Generic/RRA Status/ Purchase Order by	Dy.No.(EFD)
I	II	III	IV
1.	Tremomed 250mg Tablets	Copy of Purchase Order	Dy. No.7555/22 (01.04.2022)
	Each film coated tablet contains:	by: M/s STE 2SA SARL,	
	Tramadol HCl250mg	West Africa.	

Decision: Registration Board approved above mentioned product of M/s Medicraft Pharmaceuticals (Pvt.) Ltd., 126-B, Industrial Estate, Hayatabad, Peshawar. Since applied formulation is neither registered for local use nor approved by any RRA (as adopted by Registration Board in 275th meeting) hence manufacturer and importing country shall be responsible for safety, efficacy and quality of drug product

Case No.03: Registration of Drug(s) of M/s Albro Pharmaceuticals (Pvt.) Ltd., 340-S, Industrial Area, Kot Lakhpat, Lahore Exclusively for Export Purposes.

Firm has applied for registration of drug(s) only for export purpose as per following details:

Requirements as Per SOP	Submitted Documents
Application on Form-5/ Form 5-D with required fee as per	Form-5; Fee <b>Rs.30,000/-</b> (09.Feb.2022) +
relevant SRO.	<b>Rs.45,000</b> /-(12-Apr-2022)
Copy of DML (Renewal status) along with approval of	Copy of DML provided. Approval of Tablet (General)
relevant sections verified by licensing Division or	Section confirmed from inspection report of DML
inspection report for renewal of DML before 2005.	conducted on 6-Dec-17 (P.No/C).
GMP Status. Copy of Inspection report/GMP certificate.	GMP inspection conducted on 12-August-2020.
Undertakings that applied product is exclusively for export	Provided.
purpose and proposed names/ label/ colour do not resemble	
with already registered brands in importing country.	

Detail of the products is given below:

Sr.#	Name of Drug(s) with composition	Generic/RRA Status/ Purchase Order by	Dy.No.(EFD)
I	II	III	IV
1.	Amsil 200mg/200mg Chewable Tablets	Copy of Purchase Order by:	Dy. No.7594/22 (14.04.2022)
	Each chewable tablet contains:	M/s Wais Rahman Mohmand	
	Dried Aluminium Hydroxide200mg	Ltd. Co. Kabul, Afghanistan.	
	Magnesium Trisilicate200mg		
2.	Ferin Plus 65mg/400mcg tablet	Copy of Purchase Order by:	Dy. No. 7595 (14.04.2022)
	Dried Ferrous Sulphate 200mg eq to ferrous	M/s Wais Rahman Mohmand	
	iron65mg	Ltd. Co. Kabul, Afghanistan.	
	Folic Acid400mcg	-	

Decision: Registration Board approved above mentioned product of M/s Albro Pharmaceuticals (Pvt.) Ltd., 340-S, Industrial Area, Kot Lakhpat, Lahore. Since applied formulation is neither registered for local use nor approved by any RRA (as

# adopted by Registration Board in 275th meeting) hence manufacturer and importing country shall be responsible for safety, efficacy and quality of drug product

Case No.04: Registration of Drug (s) of M/s Star Laboratories (Pvt.) Ltd, 23-Km Multan Road (Chung) Lahore, for export purposes only (for Veterinary use).

Firm has applied for registration of drug(s) only for export purpose as per following details:

Requirements As Per SOP	<b>Submitted Documents</b>
Application on Form-5/ Form 5-D with required fee	Form5;
as per relevant SRO.	
Copy of DML (Renewal status) along with approval	Copy of DML provided
of relevant sections verified by licensing Division or	Approval of relevant section verified from
inspection report for renewal of DML before 2005.	Inspection report renewal of DML dated 14-
	12/2015
GMP Status. Copy of Inspection report/GMP	GMP status verified from GMP certificate based /
certificate.	on inspection dated 24-01-2020
Undertakings that the applied product is exclusively	Provided
for export purpose and the proposed names/ label/	
colour do not resemble with already registered brands	
in importing country.	

Detail of the products is given below:

Sr.#	Name of Drug(s) with composition	Generic/RRA Status	Dy.No.(EFD)/Fee with date
I	II	III	IV
1.	Macrolin 1000 WS Powder	Purchase order	Dy. No. 7733 (13.05.2022)
	Each gram contains:	Uzbekistan	Rs.75,000/- (11.05.2022)
	Tylosin as tartrate1000mg		
2.	Ascorbic - C 1000 WS Powder	Purchase order	Dy. No. 7734 (13.05.2022)
	Each gram contains:	Uzbekistan	Rs.75,000/- (06.05.2022)
	Vitamin C1000mg		
3.	Oxy-1000 WS Powder	Purchase order	Dy. No. 7735 (13.05.2022)
	Each gram contains:	Uzbekistan	Rs.75,000/- (06.05.2022)
	Oxytetracycline HCl1000mg		

Decision: Registration Board approved above mentioned products of M/s Star Laboratories (Pvt.) Ltd, 23-Km Multan Road (Chung) Lahore. Since applied formulation is neither registered for local use nor approved by any RRA (as adopted by Registration Board in 275th meeting) hence manufacturer and importing country shall be responsible for safety, efficacy and quality of drug product

Case No.05: Referred Cases by PRVCs.

#### **50-PRVC:**

i. Registration of Drug (s) of M/s Maxitech Pharma (Pvt) Ltd. Plot No. E-178, S.I.T.E Super Highway, Phase-II Karachi for Export Purpose Only.

Firm has applied for registration of drug(s) only for export purpose as per following details:

Requirements As Per SOP	Submitted Documents
Application on Form-5/ Form 5-D with required fee as per relevant SRO.	Form5; (Pages 324-330/C)
Copy of DML (Renewal status) along with approval of relevant sections verified by licensing Division or inspection report for renewal of DML before 2005.	Copy of DML provided (Page-399/C). Approval of relevant section verified from Licensing section letter No.F.2-12/2012-Lic dated 25.11.16 (Pages. 334/C).
GMP Status. Copy of Inspection report/GMP certificate.	GMP status verified from GMP inspection dated 05.08.20 (Pages. 335-336/C).

Undertakings that the applied product is exclusively	Provided (Pages.332-333/C)
for export purpose and the proposed names/ label/	
colour do not resemble with already registered brands	
in importing country.	

Detail of the products is given below:

Sr.#	Name of Drug(s) with Composition	Generic/RRA Status	Dy.No.(EFD)/date & Remarks
Ι	II	III	IV
1.	Melanocyl 1% Lotion Each ml contains: Methoxsalen	Generic product to be confirmed	Dy. No.2437/20- 11.11.2020. Rs. 20,000/- dated 23.10.2020
	(antipsoriatics)		

#### **50-PRVC Decision:**

The Committee deferred the product for confirmation of generic product.

<u>Updated Submission (Page No. – /C):</u> Dy.No.158 (PR-I) dated: 26-Jan-22

Now, the firm has intimated that the above mentioned formulation does not exist in Pakistan. In this regard, they have submitted differential fee of Rs.55,000/- dated 24<sup>th</sup> November, 2022 alongwith purchase order of M/s Medisure Biotech Co., Ltd., Yangon.

78-PRVC Decision: The Committee referred the case to Registration Board.

Decision: Registration Board approved above mentioned product of M/s Maxitech Pharma (Pvt) Ltd. Plot No. E-178, S.I.T.E Super Highway, Phase-II Karachi. Since applied formulation is neither registered for local use nor approved by any RRA (as adopted by Registration Board in 275th meeting) hence manufacturer and importing country shall be responsible for safety, efficacy and quality of drug product

#### Referred case of 78th PRVC

#### Case No.01: Similarity of Brand Names

M/s. CCL Pharmaceuticals, has intimated about brand name resemblance with Glitz Pharma, Islamabad which was discussed in 30th PRVC and decided to direct M/s. Glitz Pharma, Islamabad for submission of alternate brand names.

M/s. CCL Pharmaceuticals, Lahore				
Sr.	Reg. No.	Name of Product (s) of	Name of Drug (s)	Name of Firm having
No.		M/s. CCL	having similarity.	similar Brand name
		Pharmaceuticals, Lahore		
1	068112	Dasirox tablet 100mg	Desirox 250mg tablet	M/s. Glitz Pharma,
2	068113	Dasirox tablet 400mg	Reg. No. 091954	Islamabad

Accordingly, letters were written to firm (dated 23-07-2019 & 28-02-2022) but the firm hasn't submitted any brand name.

#### Reply submitted by the firm:

M/s. Glitz Pharma, Rawalpindi has submitted the reply with reference letter F. No. 3-1/2022 Deficiency (PR-II) dated 28-02-2022 Reminder-II stated that the brand name "Desirox 250mg & 500mg" both are our market running products from long time & the name Desirox is the Trade Mark of Glitz Pharma in Class:5 under No. 524145 dated 20-02-2019 in respect of pharmaceuticals preparations.

They also requested to direct the CCL Pharmaceuticals to change their brand name.

Again the case was presented in 78th PRVC and decided as follows:

The committee considered the case and decided to seek legal opinion from Legal Affairs division, DRAP and referred it to Registration Board.

Decision: Registration Board considered the case and decided to advise M/s. Glitz Pharma, Islamabad again to apply for change of brand name. In case of non- compliance within 30 days of issuance of aforementioned letter, the Board authorized its Chairman for approval for issuance of issue show cause notice to the firm for suspension/cancellation of registered drug product.

#### **HUMAN IMPORT**

#### Case. No. 01: COMPLIANCE WITH PHARMACOPEIAL SPECIFICATION.

1. Registration Board in 197<sup>th</sup> meeting held on 3-4<sup>th</sup> May, 2006 deliberated matter of specification of pharmaceutical products and following decision was taken and communicated vide letter No.F.3-2/2006-Reg.II (South) dated 05.06.2006.

"All the firms shall adopt the specification intentioned in the official pharmacopeias for all the formulation except those drugs not included in the official pharmacopoeias. For these drugs manufacturers may adopt their own specification till the inclusion of the formulation in the official pharmacopoeias. After this decision firms will not be allowed to adopt their own specifications for the drugs, which are included in any of the official pharmacopoeias, listed in the Section 3 of Drugs Act, 1976".

- 2. Matter was again deliberated in 290<sup>th</sup> meeting of Registration Board held on 04.7.2019 and *Inter alia* the Board decided as follows (communicated vide letter No.F.03-37/2019-QC (290<sup>th</sup> RB) dated 26.09.2019
  - The Drug Testing Laboratories should conduct testing as per specifications mentioned on the label of the product and product is manufactured as per Pharmacopoeal specifications specified in any of the official pharmacopeias.
  - If the product is not labeled but included in any of the official pharmacopeia, it should be tested as per that pharmacopeia and the product should also be declared as Misbranded (for not mentioning the specifications).
  - If the product is not included in any of the official pharmacopeia, and the manufacturer/or is asked by the DTL's of any province OR DRAP, the same should be supplied within seven days positively.
  - If the product registration holder fails to provide the product specifications within seven days, it is violation of the condition for registration, and it will lead to the suspension/Cancellation of product registration once it has been reported to the DRAP even if the specifications are provided to the concerned testing laboratories because testing of drugs is time limit case and labs have no option to keep the testing of samples in pendency.
  - Once the product has been included in the official pharmacopeias mentioned in the Drug act, 1976 & DRAP Act, 2012 and rules framed there under, it is not permitted to opt any other specifications.
- 3. Pharma Bureau has written two letters on 15.12.2020 and 11.01.2021 on the subject matter and highlighted following points:
  - i. All the firm's shall adopt the specifications mentioned in the official pharmacopoeias for all the formulations except those drugs not included in the official pharmacopoeias, for these drugs manufacturers may adopt their own specifications till the inclusion of that formulation in the official pharmacopoeias. This practice continued up to September 2019.
  - ii. In September 2019 DRAP issued an instruction to its field inspectors across the country wherein it instructed them to ensure compliance of the 2006DRB decision.
  - iii. Drug Testing Lab declared mis-branded all the products which are labelled with the companies' specifications. All these products are registered with the same specifications in multiple SRA's which, as per the law in Pakistan, are the benchmark for determining quality, safety and efficacy standards. Innovator companies follow and use their own specifications as these specifications are registered in different countries and in most cases are more stringent than those set out in different pharmacopoeia.
  - iv. The regulator in Pakistan is also aware of the fact that product specifications cannot be changed for any one country.
  - v. In the event that this issue is not resolved in the next DRB we can look forward to all the things the government doesn't want to have to deal with, and that too in the midst of a global pandemic, like a massive shortage of life-saving drugs these include oncology, cardiac and immune-suppressants. Submitted for consideration of Registration Board.
- 4. Director DTL Faisalabad send a reference to DRAP dated 08-01-2021 and sought following guidance as per DRAP's letter No.F.3-2/2006-Reg.II (South) dated 05.06.2006.

1	1.	All the firms shall adopt the specifications mentioned in the official pharmacopeias for all formulations except those drugs not included in official pharmacopoeias. For these drugs manufacturer may adopt their own specifications till the inclusion of that formulation in the official pharmacopoeias. After this decision firms will not be allowed to adopt their own specifications for the drugs which are included in any of the official pharmacopoeias,	List of the manufacturer specifications after necessary approval is requested to be provided to DTL Faisalabad. As mentioned in para 3 of the said letter.
		listed I section 3 of drugs Act 1976.	
2	2.	In para 3 "the manufacturer specifications mentioned in para 2 after necessary approval would be circulated to all the drugs testing laboratories (DTLs), which will be treated as reference specification for the finished drugs for which these are approved"	If no such list is available this lab may please be guided whether to declare misbrand those drugs whose labels still mention "manufacturers specifications". Even after inclusion of monographs in any pharmacopeias as mentioned in the section 3 of drugs act 1976.

5. Registration Board was apprised that some products have been declared mis-branded as their official monographs have been included in pharmacopeia and registration holders are still mentioning manufacturer's specifications on unit cartons. However, their specifications are more stringent to Pharmacopeial specifications for all parameters.

#### **Decision of 297<sup>th</sup> meeting of RB:**

Keeping in view the above, Registration Board deliberated the matter in detail and decided as follows:

- All registration holders shall follow official Pharmacopeial specifications for all such formulations for which official monographs of drug product is available in the most recent edition of such pharmacopeia.
- The manufacturers/importers having stringent product specifications for all parameters than official Pharmacopeial specifications, shall apply to Registration Board for its approval.
- The Board allowed timeline of six month to the manufacturer/importer for implementation of above decision.
- 6. Above decision circular issued by DRAP dated 27<sup>th</sup> January 2021 after that Pharma Bureau submit a letter which is reproduced as under:
  - It was decided in the 197<sup>th</sup> meeting of DRB, held on May 3-4,2006, that all the firms shall adopt the specification mentioned in the official pharmacopeia for all the formulation except the drugs not included in Pharmacopeia. Innovator companies continued to follow their own specifications, usually more stringent that the Pharmacopeia, and DRAP had no objection to the same. This practice continued until DRAP issued a letter in September 2019 to field inspectors to ensure compliance of the 2006 decision. It should be noted that the Ministry of Health and DRAP had no issue until this point for innovator drug to use own specifications as these are developed and validated by innovator's company and later published in Pharmacopeia generally for standardization of specification for generic products.
  - DTL testing is required before the supply of these products to Government institutes. As a result of this decision, innovator products are being declared as misbranded by the DTL. Provincial inspector restricts stocks for utilization and forward cases to PQCB which then takes 2 to 3 months to decide the matter and not necessarily positively. This will lead to a reputational loss of these global brands.
  - As global organization our products are manufactured at different sites in Europe and UD from where products are supplied to countries, across the world, whereby similar company specifications are used.
  - In the case of local manufacturing a thorough technology transfer process is established whereby all established protocol are provided to local manufacturing sites and testing procedure as established as per internationally acceptable standards and guidelines.
  - It is impossible to change the same for one country which has no additional benefit related to quality of products. Rather in many cases we are more stringent in terms of specifications.
  - These specification and Testing Methods have always been provided to DRAP at the time of products registrations, variations and any update therein. Till date, the same submitted specification are considered as registered by DRAP and are mentioned on product packaging material. Thus, claiming such submitted registered specification as 'misbranded' by the provincial testing laboratories in incorrect and causes of concern for our member companies at both the local and international level.
  - If this issue persist MNC's may not able to quote their products in Governments tenders especially if firm continue to receive misbranding letter form the DTL for these globally renowned brands. This

- will result shortages of life-saving drugs, all in the midst of COVID-19. It should also be noted that for many drugs there are no alternative available.
- The Pharma Bureau (PB) has made several verbal and writer communications on this topic. In its written communication to DRAP, before the DRAP meeting in January, PB requested DRAP to allow use company specification, in line with international country regulation requirement without any further delay considering the importance of this issue.
- At the DRB meeting (January 12to15) DRAP agreed to give 6 month time to either comply with regulation or share comparison to get an approval of company specification if same is stringent. We know that the decision was made with the intention to address industry concerns. And we greatly appreciate the fact that the DRB has made and effort to address the matter vide its circular of January 27,2021. However, while this important in the context international practices. It is therefore, important that DRAP review its decision immediately to resolve this issue.
- The operational Challenge, which were anticipated after the decision are already being faced by firm as drugs are continuing to be declared misbranded after notification of this decision. by DRAP, despite a 6 month grace period provided by DRAP.

Given the above and the critical nature of the matter we propose the following:

- 1. DRAP immediately communicates the decision of the DRB to all field inspectors so as to ensure the no medicine is declared misbranded.
- 2. DRAP review its decision that innovators companies must provide comparisons with the Pharmacopoeia as the same is not aligned with international practices.
- 7. These specifications are developed by innovator campaniles and therefore, cannot be compared with generic and other products which come out later and are derived from innovator specification. Furthermore, there are several other parameters which include sensitivity of equipment used and concept of Quality bye Design which allows for several test to be skipped. All these are science base decisions which, perhaps, had not been considered while making this decision and ignoring them can lead to companies facing serious challenges. As these specifications are already approved by stringent regulatory Authorities we see not additional value of comparing exercise without any additional value on the quality and safety of products.

#### 8. Decision of 307<sup>th</sup> meeting of Registration Board:

Keeping in view the above, Registration Board deliberated the matter in detail and decided as follows:

- All registration holders shall follow official Pharmacopeial specifications for all such formulations for which official monographs of drug product is available in the most recent edition of such pharmacopeia.
- The manufacturers/importers having stringent product specifications for all parameters than official Pharmacopeial specifications, shall apply to Registration Board for its approval.
- The Board allowed timeline of further six months (wef 27<sup>th</sup> July 2021) to the manufacturer/importer for implementation of above decision.
- 9. Case was again presented before Registration Board in its 309<sup>th</sup> meeting with new proposals.

Decision of M-307 on specification	New proposal	
All registration holders shall follow official	Same	
Pharmacopeial specifications for all such		
formulations for which official monographs of		
drug product is available in the most recent edition		
of such pharmacopeia.		
The manufacturers/importers having stringent	The manufacturers/importers having stringent/	
product specifications for all parameters than	<b>equivalent</b> product specifications for all	
official Pharmacopeial specifications, shall apply	parameters than official Pharmacopeial	
to Registration Board for its approval.	specifications, shall apply to Registration Board for	
	its approval.	
The Board allowed timeline of further six months	Same	
(wef 27 <sup>th</sup> July 2021) to the manufacturer/importer		
for implementation of above decision.		

#### **Decision of 309th meeting of Registration Board:**

Keeping in view the above, Registration Board deliberated the matter in detail and decided as follows:

- All registration holders shall follow official Pharmacopeial specifications for all such formulations for which official monographs of drug product is available in the most recent edition of such pharmacopeia.
- The manufacturers/importers having stringent/equivalent product specifications for all parameters than official Pharmacopeial specifications, shall apply to Registration Board for its approval.
- The Board allowed timeline of further six months (w.e.f 27<sup>th</sup> July 2021) to the manufacturer/importer for implementation of above decision.
- 10. Above decision circular issued by DRAP dated 26<sup>th</sup> July 2021.

#### **Report of submitted cases:**

	Total received	Approval letter issued	Deficiency/clarification letter issued	Under Process
Local	3204	1875	721	608
Imported	125	58	07	60

- 11. Pharma Bureau submit a letter which is reproduced as under:
  - As stated earlier many of our member firms have submitted applications for retaining in house specification for their innovator drugs. While many of these applications have been disposed of many are still under process of evaluation and await final approval for using manufacturer specifications for their innovator products and few are currently undergoing validation / stability studies in compliance to DRAP guideline.
  - ➤ The Covid pandemic has as you are aware, created many logistical and other issues, including supply chain issues and printing issues. As a result, it has not been possible to meet the deadlines for printing of packs and other product information.
  - ➤ In addition, the Pharma Bureau had also requested vide our letter of May 5<sup>th</sup> 2021, for an amendment in the Drug Specification Rules 1978, to include innovator specification in Drug Specification Rules, to resolve these issues in the long run.
  - In view of the foregoing, we request you for further extension of six months in timeline the process of amendment in the Drug Specification Rules 1978 to capture innovator specifications.
- 12. PPMA has also submitted a letter in which they have state as under;

The exception period for implementation of Drug Registration Board's decision regarding adopting and writing of pharmacopeia specifications on all generic drugs will expire on January 25, 2022. Huge number of applications for approval are still pending at DRAP for change of specifications. Even if the approvals are given before the deadline, developing printing and replacing labels of drugs with approved specification will take at-least 6 months to 1 year. In the consequences, DTL's may start misbranding the products and many prosecutions are likely to be launched against PPMA companies for misbranded products. Since the meeting of 315<sup>th</sup> DRB is postpone for February, therefore extension in period of exemption can't be presented for DRB approval

They have requested to take up this issue for minimum 6 months further extension.

Decision of 315<sup>th</sup> meeting of RB: The Board allowed timeline of further three months (w.e.f 27<sup>th</sup> January, 2022) to the manufacturer/importer for implementation of above decision of 309<sup>th</sup> meeting of Registration Board circulated vide Circular No. F.3-5/2020-I&V-II(M-297) dated 26<sup>th</sup> July, 2021.

Pharma Bureau emailed which is reproduced as under:

This is with reference to your letter No.F.3-5/2020-I&V-II (M-297) dated July 26<sup>th</sup>, 2021 regarding extension of six-month time for compliance with pharmacopeial specifications.

As you are no doubt aware, many of our member firms have submitted applications for retaining in-house specification for their innovator drugs. The majority of these applications are under process of evaluation and await final approval for using manufacturer specification for their innovator products and few are currently undergoing validation / stability studies in compliance to DRAP guideline.

In addition, Pharma Bureau has also requested vide letter dated May 5<sup>th</sup>, 2021, for an amendment in the Drug Specification Rules 1978, to include innovator specification in Drug Specification Rules, to resolve these issues in the long run.

In view of the foregoing, we request you for further extension of six months in timeline, from January 27<sup>th</sup>, 2022, for compliance with pharmacopeial specification and expedite the process of amendment in the Drug Specification Rules 1978 to capture innovator specifications.

#### Remarks:

Registration Board in its 315<sup>th</sup> meeting further extent the time line for three months.

#### **Decision:**

Registration Board observed that initially in 297<sup>th</sup> meeting, timeline of six months was allowed to the manufacturer/importer for implementation of above decision w.e.f. 27<sup>th</sup> January 2021. Later, Registration Board extended time lines twice in its 307<sup>th</sup> meeting and 315<sup>th</sup> meeting respectively which ended on 26<sup>th</sup>April 2022. During this period, PE&R Division has also decided cases of specifications. Keeping in view aforementioned position, the Board decided not to further extend time lines.

# Case No.2 PROPOSAL TO CONSIDER THE RELIANCE PATHWAY FOR THE REGISTRATION OF INNOVATOR PRODUCTS MANUFACTURED OUTSIDE THE UNTED STATES

Pharma Bureau submit a letter on subject cited above which is reproduced as under:

Pharma Bureau member companies involved in the import of state-of-the-art drugs from the First World countries in general and the United States of America in particular.

As you are aware of, USFDA is usually the first authority to register any new drug or therapy for the use of its patients and at times, the difference between the initial approval-time from the USFDA to the next SRA (especially EU) can take anywhere from 6 months to 1 year. Due to this fundamental reason, most of the markets in the world relied on the USFDA approval, and proceeded with their local registrations accordingly with the US CPP.

There has, however, there is a policy change in within the USFDA regarding the Foreign Export (FE) CPP program for products not manufactured nor exported from the US, and eventually, they relinquished their foreign exported CPPs program due to lack of legal authority from the US Congress, which is notified as follows on their official website:

"The FDA Center for Drug Evaluation and Research (CDER) previously issued foreign exported CPPs for FDA-approved drugs and biologics that were exported from a country other than the United States. Now CDER does not issue foreign exported CPPs given the other resources available for stakeholders to verify whether a drug or biologic is FDA approved and to view FDA's classifications of its inspections of manufacturing facilities."

(Source link: <a href="https://www.fda.gov/drugs/guidance-compliance-regulatory-information/human-drug-exports">https://www.fda.gov/drugs/guidance-compliance-regulatory-information/human-drug-exports</a>)

However, the US FDA has undertaken a number of transparency initiatives in recent years. These initiatives and associated documents below can serve as valid alternatives to an FE CPP, which are as follows:

- 1) USFDA approval letter present on FDA website.
- 2) The "90-Day Decisional e-mail" from FDA, which includes as an attachment a copy of the narrative portion of the Establishment Inspection Report (EIR), along with the FDA Market Authorization Letter which satisfies the intent of the FE CPP. Decisional email represents the manufacturing site along with its DUNS (Data Universal Numbering System). The DUNS can be traced on the official website for the full information about the manufacturing site on the following link:
  - https://www.accessdata.fda.gov/scripts/cder/drls/default.cfm
  - Hence, the manufacturing site of the product can also be verified from the FDA website.
- 3) National Drug Code (NDC) Directory of FDA is updated on a daily basis and is a key resource to verify the different attributes of products such as proprietary name, strength, dosage form, route of administration, marketing date, etc. It serves as a universal product identifier for the drugs approved by FDA. FDA publishes the listed NDC numbers with a current list of all drugs manufactured, prepared, propagated, compounded, or processed by it for commercial distribution. Following is the website link for the NDC Directory:
  - https://www.accessdata.fda.gov/scripts/cder/ndc/index.cfm
- 4) Further resources of information to verify miscellaneous attributes of the product along with its marketing status are the ORANGE BOOK for small molecules/chemical drugs and the PURPLE BOOK for biologicals. Following are the links for the said databases:

ORANGE BOOK: <a href="https://www.accessdata.fda.gov/scripts/cder/ob/index.cfm">https://www.accessdata.fda.gov/scripts/cder/ob/index.cfm</a> PURPLE BOOK: <a href="https://purplebooksearch.fda.gov/">https://purplebooksearch.fda.gov/</a>

In the light of above facts and information, we are confident that we have enough alternate resources to validate the necessary information, which is included in a CPP.

Considering the said details, we request you to exercise flexibility by accepting this alternate pathway for the new drugs manufactured outside the US, and make the registration of innovator drugs top priority in order to meet the unmet needs of the patients of Pakistan.

#### **Decision of 316<sup>th</sup> meeting of RB:**

#### Registration Board considered and decided to defer the case for further deliberation.

Following data submitted by Pharma Bureau to check registration status of Drug in USA:

#### Discontinuation of Foreign Export CPP by US FDA

The FDA Center for Drug Evaluation and Research (CDER) previously issued foreign exported CPPs for FDA-approved drugs and biologics that were exported from a country other than the United States. Now CDER does not issue foreign exported CPPs given the other resources available for stakeholders to verify whether a drug or biologic is FDA approved and to view FDA's classifications of its inspections of manufacturing facilities. Link of the above information is as follows:

https://www.fda.gov/drugs/guidance-compliance-regulatory-information/human-drug-exports

#### Alternatives Documents to US FE CPP

FDA has published resources that enable stakeholders to verify whether a drug or biologic is FDA approved and to view FDA's classifications of its inspections of foreign facilities.

#### A. License Approval Letter

US FDA approval letter present on FDA website, https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm

Enter the Product Name in the search bar, click the on the "letter" option in "Approval Date(s) and History, Letters, Labels, Reviews.

#### **B.** GMP Status

• If FDA conduct PLI (pre-license inspection), the following document can be used to support the GMP status:

"90-Day Decisional Letter" from FDA to the applicant, which includes as an attachment a copy of the narrative portion of the Establishment Inspection Report

If FDA doesn't conduct PLI, GMP certificate issued by another SRA (e.g. Switzerland, Germany, etc.) recognized by DRAP can be used to support the GMP status

• FDA Application Review Report contains a summary of FDA's assessment on the manufacturing facility including the inspection outcome (if applicable) or the reason for waiving inspection.

https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm

#### C. Marketing Status

National Drug Code (NDC) Directory of FDA is updated on a daily basis and is a key resource to verify the different attributes of products such as proprietary name, strength, dosage form, route of administration, marketing date.

https://www.accessdata.fda.gov/scripts/cder/ndc/index.cfm

In order to verify Marketing status, please go on following link of FDA database:

https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm

Type "Product Name" in search bar, then product details will open. Marketing status can be found as "Prescription" which means that product is available is market as a prescription medicine.

In addition as per Glossary of US FDA site Status means

#### Status

Status indicates how a biological product is sold in the United States, Prescription (Rx), Over the Counter (OTC), Discontinued (Disc).

This reconfirms that product is available in US.

Further it can be checked as follows as quoted on FDA site <a href="https://purplebooksearch.fda.gov/userguide">https://purplebooksearch.fda.gov/userguide</a>

To view the current label, click on the 'Product Label' icon/link on a product card. This will bring up a new window with the product's landing page within Drugs@FDA for CDER regulated products or the National Library of Medicine's DailyMed website for CBER regulated products. For products where a label is not available (e.g., revoked products), the 'Product Label' icon/link will not be active.

#### D. Manufacturing Site

- 1. Please go to "Product Quality Review" under section "FDA application review files. <a href="https://www.accessdata.fda.gov/drugsatfda">https://www.accessdata.fda.gov/drugsatfda</a> docs/nda/2020/761170Orig1s000TOC.cfm
  - 2. The 90-day Decisional Letter contains manufacturing site information along with its DUNS (Data Universal Numbering System) and FEI (Facility Establishment Identifier). The DUNS and FEI can be traced on the official website for the full information about the manufacturing site on the following link:

https://www.accessdata.fda.gov/scripts/cder/drls/default.cfm

#### Other supportive resources on FDA websites

- US FDA Orange book (small molecule) and Purple book (large molecule) provide product approval and marketing status information.
- ORANGE BOOK: <a href="https://www.accessdata.fda.gov/scripts/cder/ob/index.cfm">https://www.accessdata.fda.gov/scripts/cder/ob/index.cfm</a>
- PURPLE BOOK: <a href="https://purplebooksearch.fda.gov/">https://purplebooksearch.fda.gov/</a>

#### Modernization of CPP Scheme & eCPP

**EMA:** EMA eCPPs can be validated using the eCPP validation webpage. EMA issues, upon request, a letter that informs who are those authorized to sign the CPPs.

To assure the authenticity of EMA electronic certificates, each certificate contains an advanced electronic signature from a trusted provider fully compliant with the eIDAS Regulation (Regulation (EU) N°910/2014) that guarantees the unique link to the signatory and the full authenticity and integrity of the document. The Agency is using a certificate from a provider within the EU List of eIDAS Trusted Lists (LOTL).

The advanced electronic signature meets the following requirements: it is uniquely linked to the signatory; it is capable of identifying the signatory; it is created using electronic signature creation data that the signatory can, with a high level of confidence, use under his sole control; and it is linked to the data signed therewith in such a way that any subsequent change in the data is detectable. By certifying the PDF file, the electronic certificates are being "locked down" to detect unauthorized manipulation. The EMA's electronic certificates and the electronic signature have been tested using Adobe Acrobat Reader. However, they are designed to **be** 

#### compatible with other PDF compliant applications

#### Valid electronic certificate & signature

When opening the signed electronic certificate with Adobe Acrobat Reader, a 'Signature panel' ribbon will appear on the on top of the document with the message: "Signed and all signatures are valid." Clicking on the electronic signature itself, a pop-up window will appear confirming that the signature is valid stating the name and email address of the signing person; that the document has not been modified since it was signed and that the signer's identity is valid.

When clicking on the 'Signature properties' button, a pop-up window will confirm that the signature includes an embedded timestamp, that the signature was validated as of the secure (timestamp time) and that a path from the signers' certificate to the issuer's certificate was successfully established. This window also confirms the validity of the signer certificate.

#### Example of a non-valid electronic certificate including a signature from an untrusted source

When opening a signed electronic certificate where the signature is from an untrusted source with Adobe Acrobat Reader or equivalent software, a 'Signature panel' ribbon will appear on top of the document with the message: "At least one signature has problems". Clicking on the electronic signature itself, a pop-up window will appear alerting that the validity of the signature is unknown.

**In case** of doubt, how can I confirm the authenticity or integrity of the electronic certificate issued by **EMA**? In case of any doubt on the authenticity or integrity of electronic certificates issued by EMA, regulatory authorities of importing countries, MAHs or any interested party can verify their authenticity in the verification system published on EMA website.

https://www.ema.europa.eu/en/human-regulatory/post-authorisation/certifying-medicinal-products/authenticity-verification-electronic-certificates

Upon inclusion of the unique numbers for the certificate and the request -both located in the first page of the electronic certificates issued by EMA-, the online verification tool will confirm its validity and display some details of the certificate (e.g. country of importation, medicinal product and pharmaceutical form, issuing date, signatory person).

#### **US-FDA Online Verification of eCPPs**

Starting on Dec. 3, 2021, CDER has started issuing electronic Certificates of Pharmaceutical Product (eCPPs) and will no longer issue or mail paper CPPs.

Effective March 25, 2022, electronic Certificates of Pharmaceutical Product (eCPPs) issued by the U.S. Food and Drug Administration Centre for Drug Evaluation will include a unique Quick Response (QR) code. This change will allow for quicker and easier verification of the authenticity of eCPPs. Anyone, including foreign governments that receives an eCPP for human drug products exported from the U.S. FDA may verify the authenticity of these certificates using following link.

#### https://www.access.fda.gov/fecv/searchCderCertificate

The regulators can download the eCPP from FDA portal.

Decision: Registration Board considered and deferred for further confirmation of CoPP requirement as per law. The Board further directed to send an email to USFDA for clarification on CoPP issuance in above scenario.

### Case No. 3 REQUEST OF M/S. CHIESI PHARMACEUTICALS (PVT) LTD, LAHORE. FOR APPROVAL OF MANUFACTURER SPECIFICATIONS

The firm has submitted request with a fee of Rs.7500/- dated 07-06-2021 for **PEYONA SOLUTION FOR INFUSION (079619)** 

Sr#	Tests	Specifications			
		Chiesi	USP		
1.	Appearance of solution visual inspection	clear solution free of visible particles	Free of haze, obvious turbidity and precipitate		
2.	Colour of solution visual inspection	colourless	colourless		
3.	Extractable volume (ml) Ph. Eur.	≥ 1.0	NA		
4.	pH Ph. Eur./ pH meter	4.2 - 5.2	4.2 - 5.2		
5.	Caffeine citrate				
6.	Identification:				
7.	- HPLC Rt	positive	Positive		
8.	- TLC spot	positive	Positive		
9.	Content (mg/1 ml) HPLC	20.0 ± 5% (19.0-21.0)	$100 \pm 10$		
10.	Uniformity of dosage units Ph. Eur., 2.9.40 (by mass variation)	$AV: \le 15 (L1)^{(2)}$	NA		
11.	Degradation products (1) (% area): HPLC				
12.	a) Any unspecified:	≤ 0.1	≤ 0.1		
13.	b) Total:	≤ 0.5	≤ 0.1		
14.	Sterility Ph. Eur.	sterile	Sterile		
15.	Bacterial endotoxins (EU/ml) (LAL test) Ph. Eur.	≤ 5	≤ 0.25		

16.	Particulate contamination:	≥25 ≤ 600	NMT 150 particles
	Sub-visible particles (µm) Ph. Eur.	part./ampoule	≥10um
		$\geq 10 \leq 6,000$	NMT
		part./ampoule	25particles25um/ampoul
			e
17.	Final packaging	complies with	
	visual inspection	standard sample	

#### Decision 73rd PRVC

The Committee evaluated the cases and Chairman Registration Board, on the recommendations of the committee, decided to deferred the case for following clarification as <u>Degradation products</u>, <u>Bacterial endotoxin and Particulate contamination limits</u> of Chiesi specs are less stringent than USP Specs and applicable fee per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021 Other terms and conditions will remain the same.

#### Firm reply:

Please be so kind to note that the product is innovation of Chiesi and the limits were set in compliance with general monographs of European Pharmacopoeia. However in order to be compliant with DRAP specification rules, working has already been initiated to equal the limits to that stated in USP. We humbly request to please give us time period of 8 months in order to be compliant with the USP limits of these particular tests.

#### Decision 78rd PRVC

The Committee evaluated the cases and Chairman Registration Board, on the recommendations of the committee, decided to refer the case to Registration Board.

Decision: Registration Board considered and deferred the case for scientific justification of seeking 8 months' time period for compliance of specifications.

## Case no. 4 REQUEST OF M/S. CHIESI PHARMACEUTICALS (PVT) LTD, LAHORE. FOR APPROVAL OF MANUFACTURER SPECIFICATIONS

The firm has submitted request with a fee of Rs.5,000/- for **Atem NEBULISER SOLUTION (033167)** 

Sr#	Test	Manufacturer Specifications	BP Specs
1.	Appearance Visual	Clear and colorless solution	NA
2.	Acidity (pH) EP 2-2.3 "Potenziometric Determination of PH"	4.5 – 6.5	3.0 – 4.0
3.	Identification	Positive By HPLC	A) IR B) B) Colour after reaction
4.	Assay HPLC	0.475 - 0.525mg/2ml (95 – 105%)	95-110%
5.	Related Susbtances HPLC Tropic Acid (Impurity C) Apo-Ipratropium Bromide (F) Any other Total	≤1.0% ≤0.2% ≤0.2% ≤1.5%	Any impurity $\leq 0.5\%$ Tota; $\leq 1.5\%$
6.	Extractable Volume Graduated Cylinder	2.0-2.3	NA
7.	Sterility EP 2.6.1 "Sterility"	Sterile	NA
8.	Osmolality	NA	245-299 mOsm/kg Available in BP 2015 but excluded in BP 2020

#### **Decision 73rd PRVC**

The Committee evaluated the cases and Chairman Registration Board, on the recommendations of the committee, decided to deferred the case for following clarification as <u>pH range of Chiesi specs are less stringent</u> than BP Specs.

#### Firm reply:

Please note that as the product is innovation of Chiesi and PH limit was set during research and development of this product in accordance with the PH range specified in European Pharmacopoeia Monograph for "Liquid Preparations for Nebulization" which states that "The PH of liquid preparations for Nebulization is not lower than 3 and not higher than 10". However, to be compliant with the DRAP Rules, we have initiated working on re-formulation of the product in order to set the PH limit as per BP, for which certain time period is required in order to re-fix the formulation on specific PH range and to carry out certain group of analysis and to do stability studies in order to stabilize the product over the particular PH. We humbly request to please grant us time of 1.5 year to complete working on re-formulation and to get approval from DRAP after re-formulation and setting the product to particular PH. As the product is on import from Italy, therefore it will take time to receive updated stocks.

#### Decision 78rd PRVC

The Committee evaluated the cases and Chairman Registration Board, on the recommendations of the committee, decided to refer the case to Registration Board.

Decision: Registration Board considered and deferred the case for scientific justification of seeking 1.5 year's time period for compliance of specifications.

# Case No.1. Request for Change in Registration Status of Products from M/s Novartis Pharma (Pakistan) Limited, Karachi to M/s AGP Limited B-23-C, S.I.T.E. Karachi (DML No. 000348)

M/s AGP Limited B-23-C, S.I.T.E. Karachi (DML No. 000348) has requested for change in registration status of following products from M/s Novartis Pharma (Pakistan) Limited, 15- West Wharf, Dockyard Road, Karachi (DML # 000193) to their name. The products were registered on 13-02-2020 through contract manufacturing basis at M/s GlaxoSmithKline Consumer Healthcare, Pakistan Ltd., Petaro Road Jamshoro for a period of 30months.

Administrative Documents Submitted in the light of SOP approved by the Registration Board in its 283 <sup>rd</sup> meeting
i. Copy of GMP certificate on the basis of inspection conducted on 03-06-2021.
ii. Copy of DML of M/s AGP B-23-C, S.I.T.E. Karachi renewed w.e.f. 06-02-2020.
iii. Copy of approval letter issued dated 30-06-2020 by Licensing Division confirming "Tablet (General) Section, Capsule (General) Section & Oral Liquid (General) Section"
iv. NOC from M/s. Novartis Pharma (Pakistan) Limited, 15- West Wharf, Dockyard Road, Karachi dated 09-08-2021.
v. Relevant undertakings & commitments.

The cases were referred to Pharmaceutical Evaluation Cell/QMS for scrutinization/evaluation. Detail of submitted documents remarks of evaluators have been mentioned as under:

I	II	Ш	IV	V
S.No.	Reg. No.	Product Name & Composition (As per Registration letter)	Registration Trail	Dy. No./ Fee/ Date Remarks
1.	023374	Quvasc tablet 10mg Each tablet contains: Amlodipine (as Besylate)10mg (Manufacturer's Specifications)	Initial Reg. Date: 13-02-2020	Dy.No.3468 R&I Dated 04-02-2022. Rs.30,000/- Challan.No. 9803516133
		dress of Applicant / Marketing ation Holder	M/s AGP Limited, B-23	-C, S.I.T.E, Karachi
	Name, add	dress of Manufacturing site.	M/s AGP Limited, B-23-	C, S.I.T.E, Karachi
	Status of t	he applicant	Firm has applied for tra	the above (contract giver) ansfer of product from M/s AGP Limited. NOC by M/s
	GMP state	us of the firm	17 <sup>th</sup> June-2021. Copy of a panel inspection	on report dated 03-06-2021 is panel has recommended eate.
	Evidence of approval of manufacturing facility		The firm has submitted copy of DML (Renewed) dated 06-02-2020. The firm has also submitted renewal letter dated 30 <sup>th</sup> June, 2020, indicating presence of Tablet (General) Section. DML# 000348	

Pharmaceutical form of applied drug Pharmacotherapeutic Group of (API) Reference to Finished product specifications Proposed Pack size Proposed unit price The status in reference regulatory authorities For generic drugs (me-too status) Name and address of API manufacturer.  Module-II (Quality Overall Summary)  Module-III Drug Substance:  Module-III Drug Substance (Conditions & duration of Stability studies)  Stability Studies of Drug Substance (Conditions & duration of Stability studies)  Module-III Drug Product:  White or almost White powder Calcium Channel Blocker  BP Specifications BP Specification Submarded As per SRO Norvasc by Pfizer,  Malladi Drugs & Pharmaceuticals Limited Unit-3 7B & 7C SIPCOT Industrial Complex, Ranipet Vellore District, Tamil Nadu India.  Firm has submitted QOS as per WHO QOS-PI template. Firm has submitted QOS as per WHO QOS-PI template. Firm has submitted procedures and controls, impurities specification, analytical procedures and it validation, batch analysis and justification of specification of manufacturer, structure general properties, solubilities, physical form manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard container closure system and stability studies of drug substance.  Stability Studies of Drug Substance (Conditions & duration of Stability studies)  Firm has submitted stability data of 3 batches od drug substance at both accelerated as well as real time conditions. The accelerated stability data is conducted at 40°C± 2°C / 75% ± 5% RH for 6 months. The rea time stability data is conducted at 25°C ± 2°C / 60% ± 5% RH for 60 months. Cone II)  Module-III Drug Product:  Firm has submitted data of drug product including its		
Domestic sale   Export sale   Domestic sale   Export sale   Domestic and Export sales   Domestic and Export sales   Dy. No. and date of submission   Dy. No. 3468: 04-02-2022	Status of application	. ,
Dy. No. and date of submission  Dy. No. 3468: 04-02-2022  The proposed proprietary name / brand name  Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit  Pharmaceutical ingredient (API) per unit  Pharmaceutical form of applied drug  Pharmacotherapeutic Group of (API)  Reference to Finished product specifications  Proposed Pack size  Proposed Pack size  Proposed Pack size  Proposed unit price  The status in reference regulatory authorities  For generic drugs (me-too status)  Name and address of API manufacturer.  Module-II (Quality Overall Summary)  Module-II (Quality Overall Summary)  Module-III Drug Substance:  Module-III Drug Substance:  Stability Studies of Drug Substance  (Conditions & duration of Stability studies)  Module-III Orug Product:  Firm has submitted detailed data for both drug substance and drug product.  Firm has submitted detailed data for both drug substance and upstance and stability studies of drug substance and upstance.  Stability Studies of Drug Substance  (Conditions & duration of Stability studies)  Module-III Drug Product:  Firm has submitted stability study data is conducted at 25°C ± 2°C / 60% ± 5% RH for 66 months. (Zone II)  Firm has submitted data of drug product including its firm has submitted data of drug product including its firm has submitted data of drug product at 40°C ± 2°C / 75% ± 5% RH for 6 months. The rea time stability data is conducted at 25°C ± 2°C / 60% ± 5% RH for 66 months. (Zone II)  Firm has submitted data of drug product including its firm has submitted data of drug product at 40°C ± 2°C / 60% ± 5% RH for 66 months. The rea time stability data is conducted at 25°C ± 2°C / 60% ± 5% RH for 66 months. (Zone II)  Firm has submitted data of drug product including its firm has submitted data of drug product including its firm has submitted data of drug product including its firm has submitted data of drug product including its firm has submitted data of drug product including its firm has submitted data of drug product including i	Intended use of pharmaceutical product	□ Domestic sale
Dy. No. and date of submission   Dy. No. 3468: 04-02-2022     Details of fee submitted   PKR 30,000/-: 01-02-2022     The proposed proprietary name / brand name     Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit     Pharmaceutical form of applied drug   Each Tablet Contains: Amlodipine Besilate equivalent to 10 mg amlodipine     Pharmacotherapeutic Group of (API)   Calcium Channel Blocker     Reference to Finished product   Specifications     Proposed Pack size   2 x 10's     Proposed unit price   As per SRO     The status in reference regulatory authorities     For generic drugs (me-too status)   Lodopine by Martin Dow Marker Ltd     Malladi Drugs & Pharmaceuticals Limited Unit-3   7B & 7C SIPCOT Industrial Complex, Ranipet Vellore District, Tamil Nadu India.     Module-III (Quality Overall Summary)     Firm has submitted QOS as per WHO QOS-PI template. Firm has summarized information related to nomenclature, structure, general proporties solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities specification, reference standard, container closure system and stability studies of drug substance and drug product.		•
Details of fee submitted  PKR 30,000/-: 01-02-2022  The proposed proprietary name / brand name  Pharmaceutical ingredient (API) per unit  Pharmaceutical form of applied drug  Pharmacotherapeutic Group of (API)  Reference to Finished product specifications  Proposed Pack size  Proposed unit price  As per SRO  The status in reference regulatory authorities  For generic drugs (me-too status)  Name and address of API manufacturer.  Module-II (Quality Overall Summary)  Module-III (Drug Substance:  Module-III Drug Substance:  Stability Studies of Drug Substance  Conditions & duration of Stability studies)  Module-III Orug Product:  Firm has submitted data of drug product including its time stability data is conducted at 25°C ± 2°C / 60% 5 5% RH for 66 months. (Zone II)  Firm has submitted data of drug product including its image submitted data of drug product including its image submitted data of drug product including its image submitted at a for grup substance and the conditions. The accelerated stability statud is conducted at 25°C ± 2°C / 60% 5 5% RH for 66 months. (Zone II)  Firm has submitted data of drug product including its Firm has submitted data of drug product including its firm as submitted data of drug product including its firm as submitted at a for grup conduct at 40°C ± 2°C / 75% ± 5% RH for 6 months. The rea time stability data is conducted at 25°C ± 2°C / 60% 5 5% RH for 60 months. (Zone II)  Module-III Drug Product:  Firm has submitted data of drug product including its procedure and its validation, betch analysis and justification. The accelerated stability data is conducted at 25°C ± 2°C / 60% 5 5% RH for 60 months. (Zone II)  Firm has submitted data of drug product including its procedure and its validation, betch analysis and justification. The accelerated stability data is conducted at 25°C ± 2°C / 60% 5 5% RH for 60 months. (Zone II)  Firm has submitted data of drug product including its procedure and its validation, batch analysis and justification. The accelerated stability data is conduct	Dy. No. and date of submission	
Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit Pharmaceutical form of applied drug White or almost White powder Pharmacotherapeutic Group of (API) Calcium Channel Blocker  Reference to Finished product specifications  Proposed Pack size 2 x 10's  Proposed Pack size As per SRO  Norvasc by Pfizer,  authorities  For generic drugs (me-too status)  Name and address of API manufacturer.  Module-II (Quality Overall Summary)  Firm has submitted QOS as per WHO QOS-PI template. Firm has submitted data for both drug substance and drug product.  Module-III Drug Substance:  Module-III Drug Substance:  Stability Studies of Drug Substance  Conditions & duration of Stability studies of drug substance and drug product:  Module-III Drug Product:  Firm has submitted data of drug product including its form of the color than allowed as a conducted at 25°C ± 2°C / 60% : 5% RH for 60 months. (Zone II)  Module-III Drug Product:  Firm has submitted data of drug product including its form of the color than allowed and the conducted at 25°C ± 2°C / 60% : 5% RH for 60 months. (Zone II)  Module-III Drug Product:  Firm has submitted data of drug product including its form of the color than allowed and the colo	•	
Pharmaceutical form of applied drug Pharmaceutical form of applied drug Pharmacotherapeutic Group of (API) Reference to Finished product specifications Proposed Pack size Proposed unit price As per SRO The status in reference regulatory authorities For generic drugs (me-too status) Name and address of API manufacturer.  Module-II (Quality Overall Summary)  Module-II (Quality Overall Summary)  Firm has submitted QOS as per WHO QOS-PI template. Firm has submitted detailed data for both drug substance and drug product.  Module-III Drug Substance:  Module-III Drug Substance:  Stability Studies of Drug Substance  Conditions & duration of Stability studies)  Module-III Drug Product:  Firm has submitted data of drug product including its thin the read itm stability study data of 3 batches of drug substance at the Son RH for 60 months. CZone II)  Module-III Drug Product:  Firm has submitted data of drug product including its thin the submitted data of drug product including its time stability study data of 3 batches of drug substance at the Son RH for 60 months. CZone II)  Module-III Drug Product:  Firm has submitted data of drug product including its submitted data of drug product including its substance at Son RH for 60 months. CZone II)  Module-III Drug Product:  Firm has submitted data of drug product including its submitted data of drug product including its submitted data of drug product.		Quvasc Tablet 10 mg
Pharmacotherapeutic Group of (API)  Reference to Finished product specifications  Proposed Pack size  Proposed unit price  As per SRO  The status in reference regulatory authorities  For generic drugs (me-too status)  Norvasc by Pfizer,  authorities  As per SRO  Norvasc by Pfizer,  authorities  For generic drugs (me-too status)  Lodopine by Martin Dow Marker Ltd  Malladi Drugs & Pharmaceuticals Limited Unit-3  7B & 7C SIPCOT Industrial Complex, Ranipet Vellore District, Tamil Nadu India.  Firm has submitted QOS as per WHO QOS-PI template. Firm has summarized information related to nomenclature, structure, general properties solubilities, physical form, manufacturers and it validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product.  Module-III Drug Substance:  Firm has submitted detailed data for both drug substance data related to nomenclature, structure general properties, solubilities, physical form manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard container closure system and stability studies of drug substance.  Stability Studies of Drug Substance  (Conditions & duration of Stability studies)  Firm has submitted stability study data of 3 batches of drug substance at both accelerated as well as real time conditions. The accelerated stability data is conducted at 40°C ± 2°C / 75% ± 5% RH for 6 months. The rea time stability data is conducted at 25°C ± 2°C / 60% ± 5% RH for 60 months. (Zone II)  Module-III Drug Product:  Firm has submitted data of drug product including its		Each Tablet Contains: Amlodipine Besilate equivalent to 10 mg amlodipine
Reference to Finished product specifications  Proposed Pack size  Proposed unit price  As per SRO  Norvasc by Pfizer, authorities  For generic drugs (me-too status)  Name and address of API manufacturer.  Module-II (Quality Overall Summary)  Firm has submitted QOS as per WHO QOS-PE template. Firm has submitted gord procedures and it validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and controls, impurities.  Module-III Drug Substance:  Stability Studies of Drug Substance  (Conditions & duration of Stability studies)  Module-III Drug Product:  Firm has submitted data of drug product including its than submitted stability study data of 3 batches of drug substance at 40°C ± 2°C / 75% ± 5% RH for 60 months. (Zone II)  Firm has submitted data of drug product including its firm has submitted data of drug product including its stability data is conducted at 25°C ± 2°C / 60% = 5% RH for 60 months. (Zone II)  Firm has submitted data of drug product including its firm has submitted data of drug product including its firm has submitted data of drug product including its firm has submitted data of drug product including its firm has submitted data of drug product including its firm has submitted data of drug product including its firm has submitted data of drug product including its firm has submitted data of drug product including its firm has submitted data of drug product including its firm has submitted data of drug product including its firm has submitted data of drug product including its firm has submitted data of drug product including its firm has submitted data of drug product including its firm has submitted data of drug product including its firm has submitted data of drug product including its firm has submitted data of drug product including its firm has submitted data of drug product including its firm has submitted data of drug product including its firm has submitted data of drug product including its firm has	Pharmaceutical form of applied drug	White or almost White powder
Proposed Pack size  Proposed unit price  As per SRO  The status in reference regulatory authorities  For generic drugs (me-too status)  Name and address of API manufacturer.  Malladi Drugs & Pharmaceuticals Limited Unit-3  TB & 7C SIPCOT Industrial Complex, Ranipet Vellore District, Tamil Nadu India.  Module-II (Quality Overall Summary)  Firm has submitted QOS as per WHO QOS-PI template. Firm has summarized information related to nomenclature, structure, general properties solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities specification, reference standard, container closure system and stability studies of drug substance and drug product.  Module-III Drug Substance:  Module-III Drug Substance:  Firm has submitted detailed data for both drug substance data related to nomenclature, structure general properties, solubilities, physical form manufacturing process and controls, impurities specification, reference standard, container closure system and stability studies of drug substance and drug product.  Firm has submitted detailed data for both drug substance data related to nomenclature, structure general properties, solubilities, physical form manufacturers, description of manufacturing process and controls, impurities, specifications, analytica procedures and its validation, batch analysis and justification of specifications analytica procedures and its validation, batch analysis and justification of specifications, analytica procedures and its validation, batch analysis and justification of specifications, analytica procedures and its validation, batch analysis and controls, impurities, specifications, analytica procedures and its validation, batch analysis and controls, impurities, specifications, analytica procedures and its validation, batch analysis and pr	Pharmacotherapeutic Group of (API)	Calcium Channel Blocker
Proposed unit price  The status in reference regulatory authorities  For generic drugs (me-too status)  Name and address of API manufacturer.  Malladi Drugs & Pharmaceuticals Limited Unit-3 7B & 7C SIPCOT Industrial Complex, Ranipet Vellore District, Tamil Nadu India.  Firm has submitted QOS as per WHO QOS-PI template, Firm has submitted QOS as per WHO QOS-PI template, Firm has summarized information related to nomenclature, structure, general properties solubilities, physical form, manufacturers, description of maufacturing process and controls, impurities specification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product.  Module-III Drug Substance:  Firm has submitted detailed data for both drug substance data related to nomenclature, structure general properties, solubilities, physical form manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard container closure system and stability studies of drug substance.  Stability Studies of Drug Substance (Conditions & duration of Stability studies)  Firm has submitted stability study data of 3 batches of drug substance at both accelerated as well as real time conditions. The accelerated stability data is conducted at 40°C ± 2°C / 75% ± 5% RH for 60 months. The rea time stability data is conducted at 25°C ± 2°C / 60% = 5% RH for 60 months. (Zone II)		BP Specifications
The status in reference regulatory authorities  For generic drugs (me-too status)  Lodopine by Martin Dow Marker Ltd  Malladi Drugs & Pharmaceuticals Limited Unit-3 7B & 7C SIPCOT Industrial Complex, Ranipet Vellore District, Tamil Nadu India.  Module-II (Quality Overall Summary)  Firm has submitted QOS as per WHO QOS-PI template. Firm has summarized information related to nomenclature, structure, general properties solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities specification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product.  Module-III Drug Substance:  Firm has submitted detailed data for both drug substance data related to nomenclature, structure general properties, solubilities, physical form manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard container closure system and stability studies of drug substance.  Stability Studies of Drug Substance (Conditions & duration of Stability studies)  Firm has submitted stability study data of 3 batches of drug substance at both accelerated as well as real time conditions. The accelerated stability data is conducted at 40°C ± 2°C / 75% ± 5% RH for 60 months. The rea time stability data is conducted at 25°C ± 2°C / 60% = 5% RH for 60 months. (Zone II)	Proposed Pack size	2 x 10's
authorities  For generic drugs (me-too status)  Name and address of API manufacturer.  Malladi Drugs & Pharmaceuticals Limited Unit-3 7B & 7C SIPCOT Industrial Complex, Ranipet Vellore District, Tamil Nadu India.  Module-II (Quality Overall Summary)  Firm has submitted QOS as per WHO QOS-PT template. Firm has submitted QOS as per WHO QOS-PT template. Firm has submitted properties solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities specifications, analytical procedures and it validation, batch analysis and justification o specification, reference standard, container closure system and stability studies of drug substance and drug product.  Module-III Drug Substance:  Firm has submitted detailed data for both drug substance data related to nomenclature, structure general properties, solubilities, physical form manufacturers, description of manufacturing process and controls, impurities, specification, analytical procedures and its validation, batch analysis and justification of specification, reference standard container closure system and stability studies of drug substance.  Stability Studies of Drug Substance (Conditions & duration of Stability studies)  Firm has submitted stability study data of 3 batches of drug substance at both accelerated as well as real time conditions. The accelerated stability data is conducted at 40°C ± 2°C / 75% ± 5% RH for 6 months. The reatime stability data is conducted at 40°C ± 2°C / 55% RH for 6 months. The reatime stability data is conducted at 40°C ± 2°C / 60% ± 5% RH for 6 months. The reatime stability data is conducted at 40°C ± 2°C / 60% ± 5% RH for 6 months. The reatime stability data is conducted at 40°C ± 2°C / 60% ± 5% RH for 6 months. The reatime stability data is conducted at 40°C ± 2°C / 60% ± 5% RH for 6 months. The reatime stability data is conducted at 40°C ± 2°C / 60% ± 5% RH for 6 months. The reatime stability data is conducted at 40°C ± 2°C / 60% ± 5% RH for 6 months. The reatime stability data is conducted	Proposed unit price	As per SRO
Malladi Drugs & Pharmaceuticals Limited Unit-3 7B & 7C SIPCOT Industrial Complex, Ranipet Vellore District, Tamil Nadu India.  Module-II (Quality Overall Summary)  Firm has submitted QOS as per WHO QOS-PI template. Firm has summarized information related to nomenclature, structure, general properties solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities specification, reference standard, container closure system and stability studies of drug substance and drug product.  Module-III Drug Substance:  Firm has submitted detailed data for both drug substance data related to nomenclature, structure general properties, solubilities, physical form manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard container closure system and stability studies of drug substance.  Stability Studies of Drug Substance (Conditions & duration of Stability studies)  Firm has submitted stability study data of 3 batches of drug substance at both accelerated as well as real time conditions. The accelerated stability data is conducted at 40°C ± 2°C / 75% ± 5% RH for 6 months. The rea time stability data is conducted at 25°C ± 2°C / 60% = 5% RH for 60 months. (Zone II)  Module-III Drug Product:  Firm has submitted data of drug product including its		Norvasc by Pfizer,
TB & 7C SIPCOT Industrial Complex, Ranipet Vellore District, Tamil Nadu India.  Module-II (Quality Overall Summary)  Firm has submitted QOS as per WHO QOS-PE template. Firm has summarized information related to nomenclature, structure, general properties solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities specifications, analytical procedures and it validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product.  Module-III Drug Substance:  Firm has submitted detailed data for both drug substance data related to nomenclature, structure general properties, solubilities, physical form manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard container closure system and stability studies of drug substance.  Stability Studies of Drug Substance (Conditions & duration of Stability studies)  Firm has submitted stability study data of 3 batches of drug substance at both accelerated as well as real time conditions. The accelerated as well as real time conditions. The accelerated as well as real time conditions. The accelerated as well as conducted at 40°C ± 2°C / 75% ± 5% RH for 6 months. The rea time stability data is conducted at 25°C ± 2°C / 60% ± 5% RH for 60 months. (Zone II)	For generic drugs (me-too status)	Lodopine by Martin Dow Marker Ltd
template. Firm has summarized information related to nomenclature, structure, general properties solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities specifications, analytical procedures and it validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product.  Module-III Drug Substance:  Firm has submitted detailed data for both drug substance data related to nomenclature, structure general properties, solubilities, physical form manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard container closure system and stability studies of drug substance.  Stability Studies of Drug Substance  (Conditions & duration of Stability studies)  Firm has submitted stability study data of 3 batches of drug substance at both accelerated as well as real time conditions. The accelerated stability data is conducted at 40°C ± 2°C / 75% ± 5% RH for 6 months. The real time stability data is conducted at 25°C ± 2°C / 60% = 5% RH for 60 months. (Zone II)	Name and address of API manufacturer.	7B & 7C SIPCOT Industrial Complex, Ranipet,
substance data related to nomenclature, structure general properties, solubilities, physical form manufacturers, description of manufacturing process and controls, impurities, specifications, analytica procedures and its validation, batch analysis and justification of specification, reference standard container closure system and stability studies of drug substance.  Stability Studies of Drug Substance (Conditions & duration of Stability studies)  Firm has submitted stability study data of 3 batches o drug substance at both accelerated as well as real time conditions. The accelerated stability data is conducted at $40^{\circ}\text{C} \pm 2^{\circ}\text{C} / 75\% \pm 5\%$ RH for 6 months. The real time stability data is conducted at $25^{\circ}\text{C} \pm 2^{\circ}\text{C} / 60\% \pm 5\%$ RH for 60 months. (Zone II)  Module-III Drug Product:	Module-II (Quality Overall Summary)	solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and
(Conditions & duration of Stability studies) drug substance at both accelerated as well as real time conditions. The accelerated stability data is conducted at $40^{\circ}\text{C} \pm 2^{\circ}\text{C} / 75\% \pm 5\%$ RH for 6 months. The real time stability data is conducted at $25^{\circ}\text{C} \pm 2^{\circ}\text{C} / 60\% \pm 5\%$ RH for 60 months. (Zone II)  Module-III Drug Product: Firm has submitted data of drug product including its	Module-III Drug Substance:	Firm has submitted detailed data for both drug substance data related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
7	· -	Firm has submitted stability study data of 3 batches of drug substance at both accelerated as well as real time conditions. The accelerated stability data is conducted at $40^{\circ}\text{C} \pm 2^{\circ}\text{C}  /  75\% \pm 5\%$ RH for 6 months. The real time stability data is conducted at $25^{\circ}\text{C} \pm 2^{\circ}\text{C}  /  60\% \pm 5\%$ RH for 60 months. (Zone II)
	Module-III Drug Product:	Firm has submitted data of drug product including its description, composition, pharmaceutical

	Comparative Dissolut	ion Profile	and con spectanal spectana	process control, process control, process control, process control, process control of excipients, confications, analytical pytical procedures, batchedications, reference tainer closure system and has submitted registrated in the comparator i.e. by Marker Ltd  In has submitted report of hod for the drug substant has submitted report of the drug substant has submitted re	sults of pharmaceutical by tests for their product Lodopine tablet by Martin of verification of analytical nee.
		STABILITY ST	1	hod for the drug produc	t.
Manuf	acturer of API	Malladi Drugs & Pha	rmac	euticals Limited Unit-3	ellore District, Tamil Nadu
API Lo	ot No.	4501520			
	ption of Pack iiner closure system)	Blisters of Alu/PVC V	White	e Opaque 2x10's and pa	cked in printed unit carton
Stabilit	ty Storage Condition	Real time : $30^{\circ}\text{C} \pm 2^{\circ}\text{C}$ Accelerated: $40^{\circ}\text{C} \pm 2$			
Time F	Period	Real time: 6 months Accelerated: 6 month	S		
Freque	ency	Accelerated: 0, 3, 6 (Real Time: 0, 3, 6 (M			
Batch 1	No.	21/001-STB/AML TAB/01	,-	21/002-STB/AML- TAB/02	21/003-STB/AML- TAB/03
Batch	Size	2500 tabs		2500 tabs	2500 tabs
Manuf	acturing Date	06-2021		06-2021	06-2021
Date of	f Initiation	15-06-2021		15-06-2021	15-06-2021
No. of	Batches			03	
	DOCUMENTS / DATA	TO BE PROVIDED A	LO	NG WITH STABILIT	Y STUDY DATA
1.	Reference of previous approval of applications with stability study data of the firm (if any)		A panel inspection was conducted on the directions of the Board on 26 <sup>th</sup> September,2018, to investigate the stability data and stability studies. The panel concluded that the authenticity of data was verifiable to satisfactory level.		
2.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.		y 10287/D1/4/2020 issued by Department of Food		by Department of Food Control Administration, 1, dated 15-04-2021. The
3.	Documents for the procurement of API with approval from DRAP (in case of import).		Firm has submitted copy of commercial invoice specifying import of 3.80 Kg Amlodipine Besilate dated 12-02-2021. The invoice is cleared by AD (I&E) DRAP.		

4.		Firm has submitted complete record of testing of all batches along with chromatograms, raw data sheets, COA and summary data sheets.
5.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	Firm has submitted the Compliance certificate for HPLC
6.		Firm has submitted record of digital data logger for temperature and humidity monitoring of real time and accelerated stability chambers.

### **Evaluation by PEC:**

Shortcomings communicated	Response by the firm
There are two API manufacturing sites mentioned in the dossiers (i.e Dr Reddy's and Malladi Drugs.) However GMP certificate of only Malladi Drugs is provided. Although the current invoice is of the Batch produced by Malladi Drugs, clarification is required if Dr Redyy's batches will also be used and their GMP certificate is required.	Firm clarified that Malladi Drugs is the Manufacturing site, and submitted a declaration.
Analytical process verification studies of API by M/s AGP not provided	Submitted
Long term stability of API by API Manufacturer is conducted on Zone 2 conditions 25 degrees Celsius at 60% humidity. Justify.	As per decision of board, the following documents are submitted:  1. Degradation studies  2. Data of data logger during storage in the ware house.  3. Declaration that 1 year stability studies will be provided, as the studies are on going right now.  (Initiated in September 2021)
Clarify if Granulation is involved in manufacturing or not (Since process flow chart and excipients indicate direct compression process, however granulation is mentioned as a step in validation protocols and also specification of intermediate granules are provided)	Clarified that it was a typo error. The tablets are manufactured by direct compression,
Finished product stability studies provided of 6 months.(Both Accelerated and real time)	6 month stability provided.

I	II	III		IV	V
S.No.	Reg. No.	Product Name & Composition (As per Registration letter)	on	Registration Trail	Dy. No./ Fee/ Date Remarks
2.	023373	Quvasc Tablet 5mg Each tablet contains: Amlodipine (as Besylate)5mg (Manufacturer's Specifications)		Initial Reg. Date: 13-02-2020	Dy.No.3467/R&I 04-02-2022 Rs.30,000/- Challan.No. 0823258305
	Name, addres Authorization	s of Applicant / Marketing a Holder	M/s	AGP Limited, B-23-0	C, S.I.T.E, Karachi
	Name, address	lress of Manufacturing site. Manufacturing site.		M/s AGP Limited, B-23-C, S.I.T.E, Karachi	
	Status of the a	pplicant		lanufacturer nporter	

	☐ Is involved in none of the above (contract giver) Firm has applied for transfer of product from M/s Novartis Pharma to M/s AGP Limited. NOC by M/s Novartis attached.
GMP status of the firm	Firm has submitted copy of GMP certificate, dated 17 <sup>th</sup> June-2021. Copy of a panel inspection report dated 03-06-2021 is attached in which the panel has recommended issuance of GMP Certificate.
Evidence of approval of manufacturing facility	The firm has submitted copy of DML (Renewed) dated 06-02-2020. The firm has also submitted renewal letter dated 30 <sup>th</sup> June, 2020, indicating presence of Tablet (General) Section. DML# 000348
Status of application	☐ New Drug Product (NDP) ☐ Generic Drug Product (GDP)
Intended use of pharmaceutical product	<ul><li>□ Domestic sale</li><li>□ Export sale</li><li>⊠ Domestic and Export sales</li></ul>
Dy. No. and date of submission	Dy. No. 3467: 04-02-2022
Details of fee submitted	PKR 30,000/-: 01-02-2022
The proposed proprietary name / brand name	Quvasc Tablet 5 mg
Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each Tablet Contains: Amlodipine Besilate equivalent to 5 mg amlodipine
Pharmaceutical form of applied drug	White or almost White powder
Pharmacotherapeutic Group of (API)	Calcium Channel Blocker
Reference to Finished product specifications	BP Specifications
Proposed Pack size	2 x 10's
Proposed unit price	As per SRO
The status in reference regulatory authorities	Norvasc by Pfizer,
For generic drugs (me-too status)	Lodopine by Martin Dow Marker Ltd
Name and address of API manufacturer.	Malladi Drugs & Pharmaceuticals Limited Unit-3 7B & 7C SIPCOT Industrial Complex, Ranipet, Vellore District, Tamil Nadu India.
Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Firm has summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product.
Module-III Drug Substance:	Firm has submitted detailed data for both drug substance data related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing

			analytical procedures a analysis and justification	impurities, specifications, and its validation, batch of specification, reference sure system and stability s.
	(Conditions & duration of Stability studies)		of drug substance at both time conditions. The acconducted at $40^{\circ}\text{C} \pm 2^{\circ}\text{m}$ months. The real time sta	lity study data of 3 batches accelerated as well as real celerated stability data is C / 75% ± 5% RH for 6 ability data is conducted at RH for 60 months. (Zone
	Module-III Drug Product:		its description, comp development, manufactu and process control, pro- control of excipients, of specifications, analytical analytical procedures, ba	of drug product including position, pharmaceutical re, manufacturing process ocess validation protocols, control of drug product, procedures, validation of atch analysis, justification nee standard or materials, and stability.
	Pharmaceutical Equivalence and Comparative Dissolution Profile		Firm has submitted results of pharmaceutical equivalence for the quality tests for their product against the comparator i.e. Lodopine tablet by Martin Dow Marker Ltd	
	Analytical method validation/verification of product		Firm has not submitted report of verification of analytical method for the drug substance by AGP. Firm has submitted report of verification of analytical method for the drug product.	
		STABILITY STU	DY DATA	
Manufactur	rer of API		aceuticals Limited Unit-3 rial Complex, Ranipet, Vo	ellore District, Tamil Nadu
API Lot No	).	4501520		
Description (Container	of Pack closure system)	Blisters of Alu/PVC Wh	ite Opaque 2x10's and pa	cked in printed unit carton
Stability Sta	orage Condition	Real time : $30^{\circ}\text{C} \pm 2^{\circ}\text{C}$ / Accelerated: $40^{\circ}\text{C} \pm 2^{\circ}\text{C}$		
		Real time: 6 months Accelerated: 6 months		
		Accelerated: 0, 3, 6 (More Real Time: 0, 3, 6 (More	-	
Batch No.		21/005-STB/AML- TAB/05	21/006-STB/AML- TAB/06	21/004-STB/AML- TAB/04
Batch Size		2,000 tabs	2,000 tabs	2,000 tabs
Manufactur	ring Date	06-2021	06-2021	06-2021
Date of Init	iation	17-06-2021	17-06-2021	17-06-2021
No. of Batc	hes		03	
DO	CUMENTS / DATA	TO BE PROVIDED ALC	ONG WITH STABILIT	Y STUDY DATA

1.	Reference of previous approval of applications with stability study data of the firm (if any)	A panel inspection was conducted on the directions of the Board on 26 <sup>th</sup> September,2018, to investigate the stability data. And stability studies. The panel concluded that the authenticity of data was verifiable to satisfactory level.
2.		Firm has submitted copy of GMP certificate (No. 10287/D1/4/2020 issued by Department of Food Safety and Drugs Control Administration, Government of Tamilnadu, dated 15-04-2021. The certificate is valid till 31-12-2023
3.	Documents for the procurement of API with approval from DRAP (in case of import).	Firm has submitted copy of commercial invoice specifying import of 3.80 Kg Amlodipine Besilate dated 12-02-2021. The invoice is cleared by AD (I&E) DRAP.
4.	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Firm has submitted complete record of testing of all batches along with chromatograms, raw data sheets, COA and summary data sheets.
5.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	Firm has submitted the Compliance certificate for HPLC
6.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Firm has submitted record of digital data logger for temperature and humidity monitoring of real time and accelerated stability chambers.

### **Evaluation by PEC:**

Shortcomings communicated	Response by the firm
There are two API manufacturing sites mentioned in the dossiers (i.e Dr Reddy's and Malladi Drugs.) However GMP certificate of only Malladi Drugs is provided. Although the current invoice is of the Batch produced	Firm clarified that Malladi Drugs is the Manufacturing site, and submitted a declaration.
by Malladi Drugs, clarification is required if Dr Redyy's batches will also be used and their GMP certificate is required.	
Analytical process verification studies of API by M/s AGP not provided	Submitted
Long term stability of API by API Manufacturer is conducted on Zone 2 conditions 25 degrees Celsius at	As per decision of board, the following documents are submitted:
60% humidity. Justify.	<ol> <li>Degradation studies</li> <li>Data of data logger during storage in the ware house.</li> <li>Declaration that 1 year stability studies will be provided, as the studies are on going right now.</li> <li>(Initiated in September 2021)</li> </ol>
Clarify if Granulation is involved in manufacturing or not (Since process flow chart and excipients indicate direct compression process, however granulation is mentioned as a step in validation protocols and also specification of intermediate granules are provided)	Clarified that it was a typo error. The tablets are manufactured by direct compression,
Finished product stability studies provided of 6 months.(Both Accelerated and real time)	6 month stability provided.

I	II	Ш	IV	V

S.No.	Reg. No.	Product Name & Compositi (As per Registration letter)	ion	Registration Trail	Dy. No./ Fee/ Date Remarks
3.	023372	Quvasc Tablet 2.5mg Each tablet contains: Amlodipine (as Besylate)2.5mg (Manufacturer's Specification			Dated 04-02-2022 Rs.30,000/- Challan.No.
	Name, address of Authorization I	of Applicant / Marketing Holder	M/s	AGP Limited, B-23-0	C, S.I.T.E, Karachi
	Name, address o	f Manufacturing site.	M/s	AGP Limited, B-23-C	, S.I.T.E, Karachi
	Status of the app	licant	□ In □ Is Firm	has applied for trans	ne above (contract giver) fer of product from M/s GP Limited. NOC by M/s
	GMP status of th	ne firm	17 <sup>th</sup> . Copy is at	June-2021.  y of a panel inspection	of GMP certificate, dated report dated 03-06-2021 panel has recommended te.
	Evidence of appr	roval of manufacturing facility	dated rene prese	d 06-02-2020. The f	opy of DML (Renewed) irm has also submitted June, 2020, indicating al) Section.
	Status of applica	tion		ew Drug Product (ND eneric Drug Product (	
	Intended use of p	pharmaceutical product	□ E:	omestic sale xport sale omestic and Export sa	les
	Dy. No. and date	e of submission	Dy.	No. 3466: 04-02-2022	
	Details of fee sul	bmitted	PKR	30,000/-: 01-02-2022	
	The proposed pro	oprietary name / brand name	Quv	asc Tablet 2.5 mg	
	_	ntration of drug of Active ngredient (API) per unit	Aml	n Tablet Contains: odipine Besilate ed odipine	quivalent to 2.5 mg
	Pharmaceutical f	Form of applied drug	Whi	te or almost White pov	wder
	Pharmacotherape	eutic Group of (API)	Calc	ium Channel Blocker	
	Reference to Fin	ished product specifications	BP S	Specifications	
	Proposed Pack s	ize	2 x 1	.0's	
	Proposed unit pr	ice	As p	er SRO	
	The status in refe	erence regulatory authorities	Norv	asc by Pfizer,	
	For generic drug	s (me-too status)	Lode	opine by Martin Dow	Marker Ltd
	Name and addre	ss of API manufacturer.	Mall	adi Drugs & Pharmac	euticals Limited Unit-3

			7B & 7C SIPCOT Industrial Complex, Ranipet, Vellore District, Tamil Nadu India.
	Module-II (Quality Over	rall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Firm has summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product.
	Module-III Drug Substa	nce:	Firm has submitted detailed data for both drug substance data related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Stability Studies of Drug (Conditions & duration of		Firm has submitted stability study data of 3 batches of drug substance at both accelerated as well as real time conditions. The accelerated stability data is conducted at $40^{\circ}\text{C} \pm 2^{\circ}\text{C}$ / $75\% \pm 5\%$ RH for 6 months. The real time stability data is conducted at $25^{\circ}\text{C} \pm 2^{\circ}\text{C}$ / $60\% \pm 5\%$ RH for 60 months. (Zone II)
	Module-III Drug Produc	ot:	Firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.
	Pharmaceutical Equivalence and Comparative Dissolution Profile		Firm has submitted results of pharmaceutical equivalence for the quality tests for their product against the comparator i.e. Lodopine tablet by Martin Dow Marker Ltd
	Analytical method validation/verification of product		Firm has not submitted report of verification of analytical method for the drug substance by AGP. Firm has submitted report of verification of analytical method for the drug product.
		STABILITY STU	DY DATA
Manufact			aceuticals Limited Unit-3 trial Complex, Ranipet, Vellore District, Tamil Nadu
API Lot N	No.	4501520	
	on of Pack er closure system)		ite Opaque 2x10's and packed in printed unit carton
Stability Storage Condition Real time : 30		Real time : $30^{\circ}\text{C} \pm 2^{\circ}\text{C}$ /	$65\% \pm 5\% RH$

		Accelerated: 40°C	$C \pm 2^{\circ}C$ /	75% ± 5%RH	
Time	e Period	Real time: 3 mon Accelerated: 3 m			
Freq	Frequency Accelerated: 0, 3 (M Real Time: 0, 3 (Mo		*	s)	
Batc	h No.	21/015-STB/A TAB/10		21/015-STB/AML- TAB/11	21/015-STB/AML- TAB/12
Batc	h Size	5,000 tab	s	5,000 tabs	5,000 tabs
Man	ufacturing Date	09-2021		09-2021	09-2021
Date	of Initiation	17-09-202	21	17-09-2021	17-09-2021
No.	of Batches			03	
	DOCUMENTS / DATA	TO BE PROVID	ED ALO	NG WITH STABILIT	Y STUDY DATA
1.	Reference of previous approval of applications with stability study data of the firm (if any)		o tl c	A panel inspection was conducted on the directions of the Board on 26 <sup>th</sup> September,2018, to investigate the stability data. And stability studies. The panel concluded that the authenticity of data was verifiable to satisfactory level.	
2.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.		latory 1 S	0287/D1/4/2020 issued afety and Drugs	by Department of Food Control Administration, lu, dated 15-04-2021. The
3.	Documents for the procurement of API with approval from DRAP (in case of import).		s <sub>j</sub>	pecifying import of 3.80	y of commercial invoice O Kg Amlodipine Besilate nvoice is cleared by AD
4.	Data of stability batches will be supported by attested respective documents like chromatograms. Raw data sheets, COA, summary data sheets etc.		grams, b		lete record of testing of all atograms, raw data sheets, heets.
5.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing			irm has submitted the OPLC.	Compliance certificate for
6.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)		s (real to		y monitoring of real time
Eval	uation by PEC:		•		
			_	1 11 01	
	rtcomings communicated re are two API manufacturing site	. 11		se by the firm	1 1/ 6

Shortcomings communicated	Response by the firm
There are two API manufacturing sites mentioned in the	Firm clarified that Malladi Drugs is the Manufacturing
dossiers (i.e Dr Reddy's and Malladi Drugs.) However	site, and submitted a declaration.
GMP certificate of only Malladi Drugs is provided.	
Although the current invoice is of the Batch produced	
by Malladi Drugs, clarification is required if Dr	
Redyy's batches will also be used and their GMP	
certificate is required.	
Analytical process verification studies of API by M/s	Submitted
AGP not provided	
Long term stability of API by API Manufacturer is	As per decision of board, the following documents are
conducted on Zone 2 conditions 25 degrees Celsius at	submitted:
60% humidity. Justify.	1. Degradation studies
	2. Data of data logger during storage in the ware house.
	3. Declaration that 1 year stability studies will be
	provided, as the studies are on going right now.
	(Initiated in September 2021)

Clarify if Granulation is involved in manufacturing or	Clarified that it was a typo error. The tablets are	
not (Since process flow chart and excipients indicate	manufactured by direct compression,	
direct compression process, however granulation is		
mentioned as a step in validation protocols and also		
specification of intermediate granules are provided)		
Finished product stability studies provided of 3	6 month stability provided.	
months.(Both Accelerated and real time)		

#### **Decision** Registration Board decided as under:

 Cancelled registration of following products from the name of M/s Novartis Pharma (Pakistan) Limited, 15- West Wharf, Dockyard Road, Karachi (DML No. 000193)

S. No.	Reg. No.	Product Name & Composition
1.	023374	Quvasc tablet 10mg
		Each tablet contains:
		Amlodipine (as Besylate)10mg
		(Manufacturer's Specifications)
2.	023373	Quvasc Tablet 5mg
		Each tablet contains:
		Amlodipine (as Besylate)5mg
		(Manufacturer's Specifications)
3.	023372	Quvasc Tablet 2.5mg
		Each tablet contains:
		Amlodipine (as Besylate)2.5mg
		(Manufacturer's Specifications)

- ii. Approved registration of following products in the name of M/s AGP Ltd., B-23-C S.I.T.E. Karachi (DML No. 000348).
  - a) Manufacturer will place first three production batches of both products on long term stability studies throughout proposed shelf life and on accelerated studies for six months as per the commitment submitted in the registration application.

b) Manufacturer will perform process validation of first three batches of both products as per the commitment submitted in the registration application.

S. No.	Product Name & Composition
1.	Quvasc Tablet 10mg
	each tablet contains:
	Amlodipine Besilate Equivalent to 10mg Amlodipine
	(BP Specifications)
2.	Quvasc Tablet 5mg
	each tablet contains:
	Amlodipine Besilate equivalent to 5 mg Amlodipine
	(BP Specifications)
3.	Quvasc Tablet 2.5mg
	Each tablet contains:
	Amlodipine Besilate equivalent to 2.5 mg Amlodipine
	(BP Specifications)

iii. Reference will be sent to Costing and Pricing Division for confirmation of maximum retail price (MRP).

## Case No.2. Request for Change in Registration Status of Product from M/s OBS Pakistan (Pvt.) Ltd., Karachi to M/s Aspin Pharma (Pvt.) Ltd., Karachi

Registration Board in its 307<sup>th</sup> meeting held on 08<sup>th</sup> – 10<sup>th</sup> June, 2021 deferred the request of M/s. Aspin Pharma (Pvt.) Ltd; Plot No. 10 & 25, Sector 20, Korangi Industrial Area Karachi-74900 for change of registration status of following product from M/s. OBS Pakistan (Pvt.) Ltd; Karachi to their name as per following details:

The cases were referred to Pharmaceutical Evaluation Cell/QMS for scrutinization/evaluation. Detail of submitted documents remarks of evaluators have been mentioned as under:

#### Administrative Documents in the light of SOP approved by the Registration Board in its 283rd meeting

- vi. Copy of last GMP inspection report dated 01-06-2020 (Good Level of Compliance).
- vii. Panel Inspection report for renewal of DML dated 26-01-2021.
- viii. Section approval of M/s Aspin verified from Licensing Division's letter for renewal of DML (dated 09<sup>th</sup> June, 2016) confirming following sections;
  - ➤ Tablet (General)
  - Capsule (General)
  - Liquid Syrup
  - Ointment/ Cream.
- ix. NOC from M/s. OBS Pakistan (Pvt.) Ltd; Karachi dated 10-12-2020, 07-01-2021 & 16-03-2021.
- x. Relevant undertakings & commitments.

Ι	II	III	Γ	V	V	VI
S/N	Reg. No.	Name of drug(s) & Composition	Registration Trail		Remarks	Status in Previous RB meeting
1.	026397	Mezeron 30mg Tablet Each tablet contains: Mirtazapine30mg	Initial Reg. in to of M/s C Kara 25-09 Renew Regists 28-04 Trans Registr MSD of Kar 13-12 Trans Registr Ol 09-07 Change Na 26-08 Last R	date of the name Organon, achi. 1-2001 wal of tration 1-2006 after of tration to Pakistan, achi 1-2008 after of tration to BS 1-2009 of Brand	Dy.No. 357/DDC(Reg-I) 18-04-2019 Rs.20,000/- Standard formulation approved by RRA is "Film coated"	Stability Studies: Initiated in September-2019; 3 Months Completed CDP: Performed at OBS. Product is transferring from OBS site to Aspin site through Tech Transfer with same formulation and manufacturing process. Therefore CDP report of OBS site will remain applicable at Aspin site until any change in process or formulation.
	Name, address of Applicant / Marketing Authorization Holder				Aspin Pharma (F 10&25 Korangi Industrial	Pvt) Ltd, Karachi. Area, Karachi-Pakistan
	Name, address of Manufacturing site.  Status of the applicant			M/s Aspin Pharma (Pvt) Ltd, Karachi. Plot No. 10&25 Korangi Industrial Area, Karachi-Pakistan. (DML 000045) (Transfer of Registration from M/s OBS Pakistan Pvt. Ltd Karachi, [NOC attached dated 07-01-2021]		
				<ul><li>☑Manufacturer</li><li>☐ Importer</li><li>☐ Is involved in none of the above (contract giver)</li></ul>		
	GMP status of the firm		For transfer of registration:			

	GMP certificate of M/s Aspin Pharma (Pvt) Ltd. Plot No. 10&25 Korangi Industrial Area, Karachi dated 18.06.2020.		
Evidence of approval of manufacturing facility	Applicant has provided copies of renewal of DML letter, and GMP certificates of manufacturing site mentioning Capsule (General) among Formulation sections.		
Status of application	☐ New Drug Product (NDP) ☐ Generic Drug Product (GDP)		
Intended use of pharmaceutical product	<ul><li>☑ Domestic sale</li><li>☐ Export sale</li><li>☐ Domestic and Export sales</li></ul>		
Dy. No. and date of submission	Dy. No. 38/AD (Reg-I) 07—01-2021, Dy.No 928-(RI)/ 06-01-2021, 17047-R&I/14-07-2020		
Details of fee submitted	For transfer of registration: PKR 20,000/-: 18-04-2019		
The proposed proprietary name / brand name	Mezeron 30mg Tablets (Reg.No. 026397)		
Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each film coated tablet contains: Mirtazapine 30mg		
Pharmaceutical form of applied drug	Tan colored, oval shape, film coated tablets, upper side plain & score line on lower side.		
Pharmacotherapeutic Group of (API)	Other antidepressants		
Reference to Finished product specifications	USP Specification		
Proposed Pack size	1x10's		
Proposed unit price	-		
The status in reference regulatory authorities	Remeron 30mg Tablet, Organon		
For generic drugs (me-too status)	Valta 30mg Tablet, Getz Pharma, Karachi (Reg# 044074)		
Name and address of API manufacturer.	M/s Zhejiang Liaoyuan Pharmaceutical Co. Ltd, Linhai City, China		
1.5.11-Proposed Label	Not submitted		
Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Firm has summarized information related to general properties, physical form, specification, impurities and degradation products, specifications, analytical procedures, batch analysis, working standard, container closure system and stability studies of drug substance and drug product. Following points may need consideration DS solubilities are not disclosed aiming its part of restricted DMF. However, spectrophotometry techniques are described for character elucidation. Firm has used secondary reference standard provided by Drug Substance manufacturer. Firm has insufficiently summarized development of formulation and manufacturing process under 2.3.P.2.2.1 and 2.3.P.2.3		
Module-III Drug Substance:	Firm has submitted data for drug substance related to nomenclature, structure, general properties, solubilities,		

		I	Т		
Man	ufacturing Date	08-2019		08-2019	08-2019
Date of Initiation 08-2019			08-2019	08-2019	
No.	of Batches	03			
DOG	CUMENTS / DATA TO BE P	PROVIDED AL	ONG W	ITH STABILITY ST	UDY DATA
1.	Reference of previous approve with stability study data of the		ıs -		
2.	Approval of API/ DML/GMP manufacturer issued by concauthority of country of origin.	cerned regulator	y Zhejia China	ng Liaoyuan Pharm	f GMP certificate issued to Maceutical Co. Ltd, Linhai Co. EI/49148-10/2017, issued on Gy.
3.	Documents for the procurement of API with approval from DRAP (in case of import).			o Huafei Bio-Tech Co DBS Pakistan, Karac	of commercial invoice form Mode, Ltd, China (Vendor/Supplier) thi, specifying import of 20 (F)-180602M) dated 31-08-201
4.					of testing of all batches along washeets, COA and summary d
5.	Compliance Record of HPLC & audit trail reports on produc		R Firm I compl	•	ate for HPLC system as 21 C
6.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)				
Eval	uation Remarks:				
	Shortcomings communicated R			e by the firm	
maı Ltd	manufacturing site i.e M/s Aspin Pharma (Pvt) ac			s provided Stability ed and real time curing site.	data of 3 batches at conditions at new
Pro	Comparative Dissolution Profile  Process validation protocols and Analytical Fi method validation/ verification			provided analytical m	ethod verification report.

#### **Decision of M-307:**

Deferred the request with respect to following products due to reasons mentioned alongside the case:

S. No.	Reg. No.	<b>Product Name</b>		Reasons
i.	026397	Mezeron	30mg	Deferred for submission of
		Tablet		stability studies of active
				substance (API) as per
				conditions of Zone IV-A
				or/otherwise submission of
				requisite information/ documents
				as already decided by the Board
				in its 290 <sup>th</sup> meeting under
				"Requirement of The Storage
				Conditions for The API Stability
				and FPP Stability".

The firm vide letter no. ASP/RAL/04/03 dated April 05, 2022 has now submitted that:-

<sup>&</sup>quot;This is with reference to the subject stated above. We Aspin Pharma (Pvt.) Ltd. would like to bring into your knowledge that the stability data of API i.e. Mirtazapine used in one of our products. Mezeron Tablet 30mg is according to zone II as provided by the API manufacturer.

We do understand that the requirement of submission of API long term stability data is 30°C±2C/65%RH±5%RH. However, API is stored in our warehouse under controlled conditions till it is processed into finished product.

Besides that, API manufacturer has performed accelerated stability at 40'C±2"C/75%RH±5%RH for a total of six consecutive batches and tested for up to 6 months. the results of which are unchanged from the initial testing which shows the stable nature of API and its controlled manufacturing process

As WHO and ICH recommended the stability study storage condition for FPP to be determined according to climate zone and on that basis. Pakistan falls under zone IVA On the other hand, we are performing stability study on more stringent conditions i.e.  $30^{\circ}\text{C}\pm2\text{C}/75\%\text{RH}\pm5\%\text{RH}$  and the results of accelerated and long term data shows that the product is stable. Please further note that the product is tested according to USP monograph and the results of assay is indicating the potency of API w1th1n the defined limit in Pharmacopoeia.

Therefore. we request the honorable DRAP to accept the stability study provided for API for climate condition 25°C±2 C/60%RH±5%RH along with its six months accelerated stability at 40°C±2°C/75%RHx5%RH and the FPP stability on the recommended storage condition in the country of origin as an evidence that product is stable and in compliance with the specification and have no impact on product's quality parameters

We have already completed our stability studies for finished product for  $21\$  months at  $30^{\circ}C\pm2^{\circ}C$  75%RH $\pm5\%$ RH as well as six months accelerated stability study at  $40^{\circ}C\pm2^{\circ}C$  and 75%RH $\pm5\%$ RH. The results of which are satisfactory.

We commit & assure that we will follow the required storage condition of API throughout its transportation till its use in the finished product for all the future shipments.

In the view of above-mentioned justification, we do hope acceptance of the stability data of API and our Finished Product further for registration process."

As per the decision of the Regisatrion Board aforementioned, The firm was required to submit followings information in accordance to the decision of the 290<sup>th</sup> meeting of the Registration Board:-

- I. Data logger for the storage condition through the transportation of the API of Mezeron 30mg tablets imported in August, 2018 from M/s Zhejiang Liaoyuan Pharmaceutical Co. Ltd, Linhai City, China
- II. Real time stability studies of the Mezeron 30mg Tab performed by the M/s Aspin Pharma, Karachi along with the degradation studies.

The firm has submitted stability data sheets for the real time stability studies performed for two years at  $30^{\circ}\text{C}\pm2^{\circ}\text{C}$ ,  $75\%\text{RH}\pm5\%$  as well as accelerated stability of 6 months performed at  $40^{\circ}\text{C}\pm2^{\circ}\text{C}$  and  $75\%\text{RH}\pm5\%\text{RH}$ . However, the degradation studies data is not provided.

## **Decision:**

Registration Board deferred the case for submission of stability studies of active substance (API) as per conditions of Zone IV-A or/otherwise submission of following information/ documents as already decided by the Board in its 290<sup>th</sup> meeting under "Requirement of The Storage Conditions for The API Stability and FPP Stability":

- i. Record of the data logger for the storage condition throughout the transportation of the API of Mezeron 30mg tablets imported in August, 2018 from M/s Zhejiang Liaoyuan Pharmaceutical Co. Ltd, Linhai City, China
- ii. Real time stability studies of the Mezeron 30mg Tablet performed for atleast 01 year along with the degradation studies by M/s Aspin Pharma, Karachi.

# Case No.3. Request for Change in Registration Status of Products from M/s OBS Pakistan (Pvt.) Ltd., Karachi to M/s Aspin Pharma (Pvt.) Ltd., Karachi

Registration Board in its 307<sup>th</sup> meeting held on 8<sup>th</sup> – 10<sup>th</sup> June, 2021 deferred the request of M/s. Aspin Pharma (Pvt.) Ltd; Plot No. 10 & 25, Sector 20, Korangi Industrial Area Karachi-74900 for change of registration status of following products from M/s. OBS Pakistan (Pvt.) Ltd; Karachi to their name as per following details:

# The cases were referred to Pharmaceutical Evaluation Cell/ QMS for scrutinization/evaluation. Detail of submitted documents remarks of evaluators have been mentioned as under:

# Administrative Documents in the light of SOP approved by the Registration Board in its 283<sup>rd</sup> meeting

- i. Copy of last GMP inspection report dated 01-06-2020 (**Good** Level of Compliance).
- ii. Panel Inspection report for renewal of DML dated 26-01-2021.
- iii. Section approval of M/s Aspin verified from Licensing Division's letter for renewal of DML (dated 09<sup>th</sup> June, 2016) confirming following sections;
  - Tablet (General)
  - Capsule (General)
  - Liquid Syrup
  - Ointment/ Cream.
- iv. NOC from M/s. OBS Pakistan (Pvt.) Ltd; Karachi dated 10-12-2020, 07-01-2021 & 16-03-2021.
- v. Relevant undertakings & commitments.

I	II	III	IV	V	VI	
S.No.	Name of Drug	(s) Reg. No.	Registration History	Remarks	Status in 293 <sup>rd</sup> Meeting	
1.	Anvol 2.5mg Tablet Each tab contains: Nebiv (as HCl)2.5 (Manufacturer's Specifications)	olol mg	Initial date of Reg. 21- 04-2014 Last Renewal 22- 02-2019 with fee of Rs.10,000/-	Dy.No.3311 (R&I) 11- 04.2019 Rs.20,000/-	Stability Studies: To be initiated in January2020 CDP: Performed at OBS. Product is transferring from OBS site to Aspin site through Tech Transfer with same formulation and manufacturing process. Therefore CDP report of OBS site will remain applicable at Aspin site until any change in process or formulation.	
	nse of the Firm su pility Data	bmitted vide R&I	Dy.No. 3851 da	ted 02-02-2021		
Manuf	acturer of API	CADILA PHARMACEUTICALS LIMITED				
API lo	t no.	18NV022				
	ption of Pack ner closure )	ALU-ALU bliste	er in unit carton			
	ty Storage	$30 \pm 2$ oC/75 $\pm 5$ %				
Condit	ion	$40 \pm 2$ oC/75 $\pm 5$ °	%			
Time F	Period	Real time: 24 months Accelerated: 06 months				
Freque	ncy	Initial, 03 & 06 1	nonth			
Batch		180DS04	180DS05	5	180DS06	
Batch	Size	2500 Tablets	2500 Tal	olets	2500 Tablets	
Manuf	acturing Date	01-2020	01-2020		01-2020	
	f Initiation	01-2020	01-2020		01-2020	
No of 1	Batches	03	•			
Remarks of Evaluator Firm has sub Summary Re			t of each batch, A	Analytical Test Re	mission sheet, Stability eport of each time point for on sample information	

		1		<u> </u>	1 4 41		. TT C' 1 1	
			•			9	te. However, firm has only a at the time of submission.	
2. Com	parative Dissolut			10115 1	cur time s	tability stadies date	a at the time of submission.	
	ks of Evaluator			d CDI	P of Anvo	l 10 mg tablets.		
3. Proce	ss Validation Pr	otoc	ol					
Remarl	ks of Evaluator						laining process design and	
							idation approach on three	
							s identified Critical	
							trols (IPC) outlined in	
						e 3. Sampling and t ave been defined.	esting plan with statistical	
4. Analy	vtical method val				vianons na	ive been defined.		
	ks of Evaluator				lytical me	thod validation of	their own developed	
							laint RSD values. Firm	
					•	1	rity, Accuracy Precision,	
		Inte	rmediate prec		Robustne	1		
I	II		III	IV		V	VI	
S.No.	Name of Drug(	s)	Reg. No.	_	stration	Remarks	Status in 293 <sup>rd</sup> Meeting	
2.	Anyol 5mg Tah	lat	081069	Hist	<b>ory</b> ial date	Dy.No.2910	Stability Studies: To be	
۷.	Anvol 5mg Tab Each tablet	ici	081009		Reg. 22-	(R&I) 08-	initiated in January-2020	
	contains: Nebiv	olol			5-2016	04.2019	CDP: Performed at	
	(as HCl)5m				2010	Rs.20,000/-	Aspin site and report has	
	(Manufacturer's					,	been submitted	
	Specifications)							
•	nse of the Firm su	bmit	ted vide R&I	Dy.No	o. 3852 da	ted 02-02-2021		
	oility Data		DW 4 DW 4 D			a i n amen		
	acturer of API	CADILA PHARMACEUTICALS LIMITED						
API lot	otion of Pack		18NV022					
	er closure system)	ALU-ALU blister in unit carton						
	y Storage	$30 \pm 2$ oC/ $75 \pm 5$ %						
Conditi	ion	$40 \pm 2 \circ \text{C} / 75 \pm 5 \%$						
Time P	Period	Real time: 24 months						
			elerated: 06 n		S			
Freque			ial, 03 & 06 n	nonth			T	
Batch I			DS04		181DS0:		181DS06	
Batch S			0 Tablets		2500 Tal	biets	2500 Tablets	
	acturing Date  f Initiation		2020 2020		01-2020 01-2020		01-2020 01-2020	
	Batches	03	2020		01-2020		01-2020	
	ks of Evaluator		n has submit	ted s	tability p	rotocols sample s	submission sheet, Stability	
1 Ciliari	as of Litaration				• •		eport of each time point for	
							ution sample information	
		chr	omatograms p	erfori	ned at the	ir manufacturing si	ite. However, firm has only	
				nths R	teal time s	tability studies data	a at the time of submission.	
	parative Dissolut			1.00	D C :	1.10		
	ks of Evaluator			d CDI	of Anvo	l 10 mg tablets.		
	ess Validation Pr			od see	20000 1201:	lation protocol a	laining process decises and	
Keinari	ks of Evaluator			•			plaining process design and alidation approach on three	
							s identified Critical Process	
							IPC) outlined in QOS and	
							lan with statistical process	
			trol and devia				1	
	tical method val							

Remarks of Evaluator	Firm has submitted analytical method validation of their own developed
	method of analysis for Nebivolol tablets with complaint RSD values. Firm
	has performed system suitability, specificity, Linearity, Accuracy Precision,
	Intermediate precision, Robustness.

## Decision of M-307:

Deferred the request with respect to following products due to reasons mentioned alongside each:

S. No.	Reg. No.	Product Name	Reasons
ii.	081780	Anvol 2.5mg Tablet	Deferred for submission of CDP.
iii.	081069	Anvol 5mg Tablet	Deferred for submission of CDP.

The firm has submitted the CDP for above mentioned product as per following details:

## i. **Anvol 5 mg Tablet:-**

## **Comparative Dissolution Profile**

The comparative dissolution profile was performed for Anvol Tablet 5 mg against the Nebilet Tablet 5 mg (Manufactured by Menarini International Operations Luxembourg). Comparison was performed in HCl buffer (pH 1.2), Acetate buffer (pH 4.5) and phosphate buffer solution (pH 6.8) using 12 samples at 10, 15,20, 30, and 45, minutes.

Sr	Buffer	Time interval	Anvol Tablet 5 mg	Nebilet Tablet 5 mg
		10 min	104.724 %	90.304 %
		15 min	101.786 %	97.594%
	HCl buffer	20 min	102.171%	100.401%
i	(pH 1.2)	30 min	101.004%	99.198%
	(pm 1.2)	45 min	98.560%	97.826%
			f1 = 4.334	
			f2 = 59.787	
	Acetate buffer	10 min	14.989%	16.591%
		15 min	20.345%	24.168%
		20 min	25.247%	29.447%
ii		30 min	33.378%	37.338%
	(pH 4.5)	45 min	40.299%	45.062%
			f1 = 11.357	
			f2= 69.297	
		10 min	16.903%	27.300%
		15 min	25.203%	25.738%
	phosphate	20 min	30.454%	31.536%
iii	buffer	30 min	41.340%	45.225%
	(pH 6.8)	45 min	52.297%	61.029%
			f1 = 12.790	
			f2= 58.200	

Calculation of value revealed that dissimilarity factor f1 and similarity factor f2 fall under acceptable criteria at pH 1.2 and pH 4.5, and pH 6.8.

#### ii. Anvol 2.5 mg Tablets:-

### **Comparative Dissolution Profile**

The comparative dissolution profile was performed for Anvol Tablet 2.5 mg against the Bystolic Tablet 2.5 mg (Manufactured by Allergan). Comparison was performed in HCl buffer (pH 1.2), Acetate buffer (pH 4.5) and phosphate buffer solution (pH 6.8) using 12 samples at 10, 15,20, 30, and 45, minutes.

Sr	Buffer	Time interval	Anvol Tablet 5 mg	Bystolic Tablet 5 mg
		10 min	104.776 %	108.433 %
		15 min	102.862 %	101.536%
	HCl buffer	20 min	102.170%	101.593%
i	(pH 1.2)	30 min	97.618%	105.785%
	(pii 1.2)	45 min	99.772%	97.935%
			f1 = 3.574	
			f2 = 65.351	
	Acetate buffer	10 min	94.045%	96.498%
		15 min	96.004%	94.615%
		20 min	88.317%	96.279%
ii		30 min	92.572%	97.499%
	(pH 4.5)	45 min	94.698%	100.328%
			f1 = 7.056	
			f2 = 55.804	
		10 min	97.181%	102.384%
		15 min	97.334%	105.562%
	phosphate	20 min	97.511%	97.951%
ii	buffer	30 min	88.666%	103.244%
	(pH 6.8)	45 min	103.745%	101.560%
			f1 = 5.767	·
			f2 = 56.268	

Calculation of value revealed that dissimilarity factor f1 and similarity factor f2 fall under acceptable criteria at pH 1.2 and pH 4.5, and pH 6.8.

Decision: Registration Board deferred the case for submission of justification regarding un-even trends of dissolution profile of both the products i.e., Anvol Tablet 5mg & 2.5mg.

Case No.4. Request for Change in Registration Status of Products from M/s Getz Pharma (Pvt) Ltd, 29-30, Sector 27, Korangi Industrial Area, Karachi to M/s Getz Pharma (Pvt) Ltd, Plot No.01, Sector 25, Korangi Industrial Area, Karachi

M/s Getz Pharma (Pvt) Ltd, Plot No.01, Sector 25, Korangi Industrial Area, Karachi (**DML No. 000933**) has requested for change in registration status of following products from M/s Getz Pharma (Pvt) Ltd, 29-30, Sector 27, Korangi Industrial Area, Karachi (**DML No. 000284**) to their name. Detail is given as under:

I	II	III	IV
S.No.	Reg.	Name of Drug(s)	Initial date of registration/
	No.		Remarks of RRR Section
			regarding Renewal Status
1.	029437	Getryl Tablets 1mg	14/12/2002
		Each tablet contains:-	Renewal is granted till
		Glimepiride1mg	20.03.2023 vide letter dated
			22.05.2018
2.	019877	Claritek Tablets 250mg	30/09/1996
		Each tablet contains:-	Renewal application received
		Clarithromycin USP250mg	within time
3.	010640	Claritek Tablets 500mg	16/05/1997
		Each tablet contains:-	Renewal application received
		Clarithromycin500mg	within time
4.	086937	Vilget-M Tablet 50mg/500mg	19/02/2018
		Each film coated tablet contains:	Renewal not due yet
		Vildagliptin50mg	
		Metformin HCl USP500mg	

		(As per Innovator's Specifications)	
5.	073875	Vilget-M Tablet 50mg+850mg	27/03/2013
		Each film coated tablet contains:	Renewal is granted till
		Vildagliptin50mg	26.03.2023 vide letter dated
		Metformin HCl850mg	10.07.2018
		(Manufacturer's Specifications)	
6.	073876	Vilget-M Tablet 50mg+1000mg	27/03/2013
		Each film coated tablet contains:	Renewal is granted till
		Vildagliptin50mg	26.03.2023 vide letter dated
		Metformin HCl1000mg	10.07.2018
		(Manufacturer's Specifications)	
7.	053120	Zetro 500mg Tablets	14/11/2008
		Each tablet contains:-	Renewal application received
		Azithromycin (as Dihydrate)500mg	within time
		(Manufacturer's Specification)	
8.	108570	Vonozan Tablet 10mg	26/05/2021
		Each film coated tablet contains:	Renewal not due yet
		Vonoprazan as Fumarate10mg	
		(As per *Innovator's Specifications)	
9.	108571	Vonozan Tablet 20mg	26/05/2021
		Each film coated tablet contains:	Renewal not due yet
		Vonoprazan as Fumarate20mg	
		(As per *Innovator's Specifications)	
10.	045471	HCQ 200 Tablets	28-07-2007
		Each film coated tablet contains:-	Renewal application received
		Hydroxychloroquine Sulphate200mg	within time

## Administrative Documents in the light of SOP approved by the Registration Board in its 283<sup>rd</sup> meeting

- i. Copy of DML No. 000933 issued w.e.f. 25-05-2021
- ii. Copy of Last Inspection report dated 17-11-2021.
- iii. Approved sections verified from Licensing Division's letter for issuance of DML (dated 07th June, 2021):
  - > Tablet (General)
  - Capsule (General)
- Dry Powder Suspension (General)
- iv. NOC from M/s Getz Pharma (Pvt) Ltd, 29-30, Sector 27, Korangi Industrial Area, Karachi dated 26-01-2022
- v. Relevant undertakings & commitments.

In the light of SOP approved by the Board in it 283<sup>rd</sup> meeting, after screening for administrative documents, the applications were forwarded to Pharmaceutical Evaluation Cell for scrutinization/evaluation. Detail of submitted documents & remarks of evaluator have been mentioned as under:

1.	Name, address of Applicant /	M/s Getz Pharma (Pvt.) Ltd. Plot No. 01, Sector 25, Korangi Industrial
	Marketing Authorization Holder.	Area, Karachi Pakistan
	Name, address of Manufacturing	M/s Getz Pharma (Pvt.) Ltd. Plot No. 01, Sector 25, Korangi
	site.	Industrial Area, Karachi Pakistan
	Status of the applicant	Manufacturer
		☐ Importer
		$\square$ Is involved in none of the above (contract giver)
	GMP Status of the firm	Firm has been granted Drug Manufacturing License (DML 000933)
		by way of formulation dated 25-05-2021.
	Evidence of approval of	Firm has been granted Drug Manufacturing License (DML 000933)
	manufacturing facility	by way of formulation dated 25-05-2021, with approved Tablets,
		Capsules & Dry Powder Suspension sections.
	Status of application	☐ New Drug Product (NDP)
		☐ Generic Drug Product (GDP)

Intended use of pharmaceutical product	☐ Domestic sale
product	☐ Export sale
	☑ Domestic and Export sales
Dy. No. and date of submission	Dy. No. 5424/R&I dated 25-02-2022
Details of fee submitted	PKR 30,000/-: 28-01-2022
The proposed proprietary name / brand name	Getryl Tablets 1mg
Strength / concentration of drug of Active Pharmaceutical ingredient	Each tablet contains: Glimepiride 1mg
(API) per unit Pharmaceutical form of applied	Tablets
drug Pharmacotherapeutic Group of	Salfonylureas
(API) Reference to Finished product	USP Specifications
specifications	OSF Specifications
Proposed Pack size	2x10's (20's) & 3x10's (30's)
Proposed unit price	Rs.159.11/- (20's) & Rs. 238.65/- (30's)
The status in reference regulatory authorities	"Amaryl Tablets 1mg" Approved by US-FDA manufactured by Sanot Aventis US.
For generic drugs (me-too status)	Getryl Tablets 1mg (Reg. No.: 029437) manufactured by M/s Get Pharma (Pvt.) Limited Plot No. 29 -30, Sector 27, Korangi Industria Area, Karachi.
Name and address of API manufacturer	Shandong Xinhua Pharmaceutical Company Limited, Hutian Chemical Industrial Zone, Zibo, Shandong, P.R. China
Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Firm has summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications analytical procedures and its validation, batch analysis an justification of specification, reference standard, container closure system and stability studies of drug substance and drug product.
Module-III Drug Substance:	Firm has submitted data for drug substance related to nomenclature structure, general properties, solubilities, physical form manufacturers, description of manufacturing process, impurities specifications, analytical procedures and its validation, batch analyst and justification of specification, reference standard, container closure system and stability studies of both drug substances.
Stability Studies of Drug	Firm has submitted stability study data of 3 batches of drug substance
Substance	at both accelerated as well as real time conditions. The accelerate
(Conditions & duration of Stability	stability data is conducted at $40^{\circ}\text{C} \pm 2^{\circ}\text{C} / 75\% \pm 5\%$ RH for 6 months. The real time stability data is conducted at $30^{\circ}\text{C} \pm 2^{\circ}\text{C} / 65 \pm 5\%$ RI
studies)	for 60 months.
Module-III Drug Product:	Firm has submitted data of drug product including its description composition, pharmaceutical development, manufacture manufacturing process and process control, process validation, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis justification of specifications, reference standard or materials container closure system and stability studies.
Pharmaceutical Equivalence and Comparative Dissolution Profile	Getz Pharma (Pvt) Limited Plot no. 29 – 30, sector 27 Korang Industrial Area, Karachi Pharmaceutical Equivalence Studies & Comparative Dissolution Profile studies of Getryl Tablets 1mg against the reference product Amaryl Tablets 1mg, in three dissolution mediums has been submitted with acceptable level of f2 results.
	Getz Pharma (Pvt) Limited Plot No. 01, Sector 25 Korang Industrial Area, Karachi Firm has also submitted the Comparative Dissolution Profile studie of Getryl Tablets 1mg against the reference product Amaryl Tablet

		1mg, in Routine Release Medium wherein more than 85% of drug is released in 15 minutes.					
	Analytical method validation / verification of product			ication st	tudies of the d	rug substance & d	drug
	Stability studies	Firm has submi accelerated and	long-terr two ba	n conditi atches ti	ions from exist 11 3 <sup>rd</sup> month	three batches at betting site and stabetime interval (basite.	ility
	STABILITY STUDY DATA (PI					ea, Karachi)	
Mar	nufacturer of APIs	M/s Glenmark Plot No. 141-143 Mohol – 413213	3, 160-16	55, 170-1	72, Chandram	ouli Industrial Est dia	tate,
	Lot No.	0000113348, 000	0011247	7			
	cription of Pack ntainer closure system)	Alu-Alu blister					
Stab	ility Storage Condition	Real time: 30°C : Accelerated: 40°	C ± 2°C				
Tim	e Period	Accelerated: 6 m Real time: 48 mg					
Free	luency	Accelerated: 0, 3 Real Time: 0, 3,		,	 86 & 48 (Mont	hs)	_
	ch No.	212T10			3T10	214T10	
	eh Size	760,000 Table	ets		0 Tablets	760,000 Table	ts
	ufacturing Date	15.02.2016			3.2016	08.03.2016	
	e of initiation	16.03.2016			4.2016	13.04.2016	
No.	of Batches	PROVIDED ALONG WITH STABILITY STUDY DATA					
1.	Reference of previous approval of					f their product Es	tima
2.	applications with stability study data of the firm (if any)  Approval of API/ DML/GMP	<ul> <li>2019 and was presented in 289<sup>th</sup> meeting of Registration Board held on 14<sup>th</sup> -16<sup>th</sup> May, 2019. According to the report following points were confirmed.</li> <li>The firm has 21 CFR compliant HPLC software</li> <li>The firm has audit trail reports available.</li> <li>The firm possesses stability chambers with digital data loggers.</li> </ul>					
2.	certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Glimepiride: Firm has submitt Food & Drug Ac				o. 6076982) issued e, India.	d by
3.	Documents for the procurement of API with approval from DRAP (in case	Firm has submit DRAP, Karachi.	ted copy	of comr	nercial invoice	e attested by AD l	I&E
	of import).	Batch No.	Invoid	ee No.	Quantity Imported	Date of approval by DRAP	
		0000113348	20080	00659	50 KG	12-01-2016	
		0000112477	20080	00612	50 KG	29-12-2015	]
4.	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Firm has submitted data of stability batches along with attested respective documents like chromatograms, Raw data sheets, COA,					
5.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing.						
6.	Record of Digital data logger for temperature & humidity monitoring of stability chambers (real time and accelerated)	humidity monito	ring of s	tability c	hambers (real	er for temperatur	
	STABILITY STUDY DATA (	Piot No. 01, Secto	r 25 Ko	rangi In	dustrial Area	, Karachi)	

		1					
Mar	nufacturer of APIs				ited situated at Hu	tian	
ΛDI	Lot No.	Chemical Industri	al Zone, Zibo, S	nandong, P.R	. China		
		2003203					
	cription of Pack ntainer closure system)	Alu-Alu blister					
Stab	pility Storage Condition	Real time: $30^{\circ}\text{C} \pm 2^{\circ}\text{C} / 75\% \pm 5\%\text{RH}$ Accelerated: $40^{\circ}\text{C} \pm 2^{\circ}\text{C} / 75\% \pm 5\%\text{RH}$					
Tim	ne Period	Real time: 0, 3 mg		7,01411			
1 1111	ic i ciioù	Accelerated: 0, 3					
Fred	quency	Accelerated: 0, 3,					
	<u> </u>	Real Time: 0, 3, 6					
	ch No.	030ES01		ES02	-		
	ch Size	10,000 Tablets	10,000	Tablets	-		
Mar	nufacturing Date	16.09.2021	16.0	9.2021	-		
Date	e of initiation	04.10.2021	04.1	0.2021	-		
No.	of Batches		(	)2			
	DOCUMENTS / DATA TO BE	PROVIDED ALC	NG WITH STA	BILITY ST	UDY DATA		
1.	Reference of previous approval of						
	applications with stability study data						
	of						
	the firm (if any)						
2.	Approval of API/ DML/GMP	Firm has subm	itted copy of	GMP certi	ficate (Certificate	e #	
	certificate of API manufacturer	SD20190969) iss	ued by Shandor	g Food and	Drug Administrati	ion,	
	issued by concerned regulatory	valid till 01-08-20	)24.				
	authority of country of origin.						
3.	Documents for the procurement of	Firm has submit	ted copy of inv	oice attested	by AD I&E DR	AP,	
	API	Karachi.					
	with approval from DRAP (in case						
	of			Dat	e of approval		
	import).	Batch No.	Invoice No.		by DRAP		
		2003203	JC202011002-	-1 2	28/01/2021		
				•		_	
4.	Data of stability batches will be						
	supported by attested respective	Firm has submit	ted data of stal	oility batches	along with attes	sted	
	documents like chromatograms,				w data sheets, Co		
	Raw data sheets, COA, summary	summary data she		6		,	
	data sheets etc.	Summary data sin					
5.	Compliance Record of HPLC						
٥.							
	I SOHWARE ZICEK & AHOH HAH FEDORIS	Firm has submitted method audit trail reports from 2018 onwards.					
	software 21CFR & audit trail reports	Firm has submitte	ed method audit t	ran reports ir	om 2018 onwards.		
6	on product testing.	Firm has submitte	ed method audit t	ran reports ir	om 2018 onwards.		
6.	on product testing.  Record of Digital data logger for						
6.	on product testing.  Record of Digital data logger for temperature & humidity monitoring	Firm has submitt	ed record of dig	ital data logg	ger for temperature	e &	
6.	on product testing.  Record of Digital data logger for	Firm has submitt	ed record of dig	ital data logg		e &	

## Miscellaneous Data:

The firm has submitted the following documents as per WHO TRS 981,2013 (47<sup>th</sup> report, Annex 3) and SOP for approval of post-registration variations approved in 283<sup>rd</sup> DRB meeting:

- Stability Data of 3 batches till shelf life manufactured at their existing facility located at Plot No. 29 30, Sector 27, Korangi Industrial Area.
- Stability Data of 2 stability batches (till 3<sup>rd</sup> month time point) from new facility located at Plot No. 01, Sector 25, Korangi Industrial Area as per Guidance Document for Submission of Application on Form 5-F (CTD) for registration of pharmaceutical drug products for human use issued in October, 2020.
- Comparative Dissolution Profile and Pharmaceutical Equivalence studies of the product with the innovator from existing manufacturing facility & also submitted Comparative Dissolution Profile against innovator from new manufacturing facility.
- Comparative batch analysis data on two batches from the new facility and comparative data on the last three batches from the existing facility.
- Executed Production document of stability batch.
- Process Validation Protocol from new site.
- Undertakings in accordance with SOP for approval of post-registration variations by DRAP.
- Analytical Method Verification studies of API & Finished product.

•	Valid GMP Certificate of the API ma	anufacturer.
2.	Name, address of Applicant /	M/s Getz Pharma (Pvt.) Ltd.
	Marketing Authorization Holder.	Plot No. 01, Sector 25, Korangi Industrial Area, Karachi Pakistan
	Name, address of Manufacturing	M/s Getz Pharma (Pvt.) Ltd.
	site.	Plot No. 01, Sector 25, Korangi Industrial Area, Karachi Pakistan
	Status of the applicant	⊠ Manufacturer
		☐ Importer
		☐ Is involved in none of the above (contract giver)
	GMP Status of the firm	Firm has been granted Drug Manufacturing License (DML 000933) by
	Givir Status of the min	way of formulation dated 25-05-2021.
	Evidence of approval of	Firm has been granted Drug Manufacturing License (DML 000933) by
	manufacturing facility	way of formulation dated 25-05-2021, with approved Tablets, Capsules
	Z ,	& Dry Powder Suspension sections.
	Status of application	□ New Drug Product (NDP)
		☑ Generic Drug Product (GDP)
	Intended use of pharmaceutical	□ Domestic sale
	product	
	product	Export sale
		☑ Domestic and Export sales
	Dy. No. and date of submission	Dy. No.: 5427/R&I dated 25-02-2022
	Details of fee submitted	PKR 30,000/-: 28-01-2022
	The proposed proprietary name / brand name	Claritek Tablets 250mg
	Strength / concentration of drug of	
	Active Pharmaceutical ingredient	Each film coated tablet contains:
	(API) per unit	Clarithromycin USP250mg
	71	, and g
	Pharmaceutical form of applied	Film-coated Tablets
	drug	Timi-coated Tablets
	Pharmacotherapeutic Group of (API)	Antibacterial for systemic use : Macrolides
	Reference to Finished product specifications	USP Specifications
	Proposed Pack size	10's and 14's
	Proposed unit price	388.38 for 10's and 689.91 for 14's
	Claimed shelf life	3 years
	The status in reference regulatory authorities	Klaricid Tablets 250mg approved by MHRA marketed by Mylan Products Ltd., UK
	For generic drugs (me-too status)	Claritek Tablets 250mg (Reg. No.: 019877) manufactured by M/s Getz Pharma (Pvt.) Limited Plot No. 29-30, Sector 27, Korangi Industrial Area, Karachi
	Name and address of API manufacturer.	M/s. Zhejiang Guobang Pharmaceutical Co., Ltd. located at No. 6, Weiwu Road, Hangzhou Gulf Shangyu Economic and Technological Development Zone, Zhejiang, P. R. China.
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Firm has summarized information related to nomenclature, structure, general
	Jannary)	properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product.
	Module-III Drug Substance:	Firm has submitted detailed data for drug substance data related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Stability Studies of Drug	Firm has submitted stability study data of 3 batches of drug substance
	Substance	at both accelerated as well as real time conditions. The accelerated
	(Conditions & duration of	stability data is conducted at $40^{\circ}\text{C} \pm 2^{\circ}\text{C} / 75\% \pm 5\%$ RH for 6 months.
	Stability	The real time stability data is conducted at $30^{\circ}\text{C} \pm 2^{\circ}\text{C} / 75 \pm 5\%$ RH

	studies)	for 48 months.				
	Module-III Drug Product:  Pharmaceutical Equivalence and Comparative Dissolution Profile	Firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.  Getz Pharma (Pvt) Limited  Plot no. 29 – 30, sector 27 Korangi Industrial Area, Karachi				
		(Existing Facility) Pharmaceutical Equiva Profile studies of Clarite	alence Studies & Con ek Tablets 250mg against ng, in three dissolution	nparative Dissolution the reference product		
		Getz Pharma (Pvt) Limited Plot No. 01, Sector 25 Korangi Industrial Area, Karachi (New Facility) Firm has also submitted the Comparative Dissolution Profile studies of Claritek Tablets 250mg against the reference product Klaricid Tablets 250mg in routine release Medium with acceptable level of f2 results.				
	Analytical method validation/		fication studies of the dr			
	verification of product	product.	incation stadies of the un	as substance and drug		
	Stability studies	accelerated and long te studies data of two bate	ability studies data of the conditions from existence at initial and 3 <sup>rd</sup> more conditions) from new	ting site and stability of the time interval (both		
	STABILITY STUDY DATA (P					
Man	ufacturer of APIs	M/s. Zhejiang Guobang Pharmaceutical Co., Ltd. located at No. 6, Weiwu Road, Hangzhou Gulf Shangyu Economic and Technological Development Zone, Zhejiang, P. R. China.				
API	Lot No.	0000052046, 0000052047, 0000052049				
	cription of Pack	Alu-PVC blister				
(Coı	ntainer closure system)					
Stab	ility Storage Condition	Real time: 30°C ± 2°C / 75% ± 5%RH Accelerated: 40°C ± 2°C / 75% ± 5%RH				
Tim	e Period	Real time: 24 months for batch# 238F01, 18 months for batch # 239F01 & 240F01 Accelerated: 6 months				
E	WAR AND	Accelerated: 0, 3, 6 (Months)				
	uency	Real Time: 0, 3, 6, 9, 12				
	h No.	238F01	239F01	240F01		
	h Size	750,000 Tablets 10-2019	750,000 Tablets 12-2019	750,000 Tablets		
	ufacturing Date of initiation	08.01.2013	10.01.2013	12-2019 22.02.2013		
	of Batches	00.01.2013	03	22.02.2013		
	DOCUMENTS / DATA TO BE	PROVIDED ALONG		UDY DATA		
1.	Reference of previous approval of applications with stability study data of the firm (if any)	Firm has referred to onsite inspection report of their product Estine (Ebastine) tablets 10mg & 20mg which was conducted on 06 <sup>th</sup> May, 2019 and was presented in 289 <sup>th</sup> meeting of Registration Board held on 14 <sup>th</sup> -16 <sup>th</sup> May, 2019. According to the report following points were confirmed.  • The firm has 21 CFR compliant HPLC software  • The firm has audit trail reports available.  • The firm possesses stability chambers with digital data loggers.				
2.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.		e issued by State Food & and Copy of DML issued a valid till 08-12-2024.			

3.	Documents for the procurement of API with approval from DRAP (in case	Karachi, has been submitted.					
	of import).	Ba	tch No.	Inv	oice No.	Quantity Imported	Date of approval by DRAP
		128-1	90378-1	JC201	905019-1	650 Kg	15-07-2019
			90475-1		1904007-1	650 Kg	23.07.2019
		128-1	90573-1	JC201	1904008-1	650 Kg	26.08.2019
4.	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	respect		ents lik			long with attested data sheets, COA,
5.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing.	Firm h	as submitted	d audit t	rail reports.		
6.	Record of Digital data logger for temperature & humidity monitoring of stability chambers (real time and accelerated)		ailable.				
	STABILITY STUDY DATA						
	sufacturer of APIs	Weiwt Develo	Road, Har	ıgzhou		yu Economic	. located at No. 6, and Technological
	Lot No.	128-20	1272-1				
	cription of Pack ntainer closure system)	Alu-PVC blister					
	ility Storage Condition	Real time: $30^{\circ}\text{C} \pm 2^{\circ}\text{C} / 75\% \pm 5\%\text{RH}$ Accelerated: $40^{\circ}\text{C} \pm 2^{\circ}\text{C} / 75\% \pm 5\%\text{RH}$					
Tim	e Period	Accelerated: 0, 3 (Months) Real Time: 0, 3 (Months)					
	uency	Accelerated: Initial, 3 & 6 months Real Time: Initial, 3, 6, 9, 12, 18, 24 & 36 months					
	ch No.		028ES01		028ES		-
	ch Size nufacturing Date		000 Tablets 5.09.2021		10,000 T 15.09.2		-
	e of initiation		1.10.2021		01.10.2		-
	of Batches		1.10.2021		02	.021	
	DOCUMENTS / DATA TO BE	PROV	IDED ALO	NG W	ITH STAB	ILITY STUI	DY DATA
1.	Reference of previous approval of applications with stability study data of the firm (if any)						
2.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	is valid Produc	till 04-09-2 ets Administ	2023 an ration v	d Copy of D valid till 08-	OML issued by 12-2024.	orug Administration y Zhejiang Medical
3.	Documents for the procurement of API with approval from DRAP (in case of	Plot no	0.29 - 30, se	ector 27			Limited Karachi attested by
	import).		Batch N		Invoice JC2020110		Date of approval by DRAP 0.03.2021
	Date of stability both 1 21 1	<u> </u>	120 20127	_ 1	0 C 2 O 2 O 1 T (	<i>525</i> 1   50	.03.2021
4.	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	respect		ents lik			long with attested data sheets, COA,

5.	Compliance Record of HPLC	
	software 21CFR & audit trail	Firm has submitted audit trail reports.
	reports on product testing.	
6.	Record of Digital data logger for	
	temperature & humidity	N/A
	monitoring of stability chambers	IV/A
	(real time and accelerated)	

The firm has submitted the following documents as per WHO TRS 981,2013 (47<sup>th</sup> report, Annex 3) and SOP guidelines stated in 283<sup>rd</sup> DRB meeting minutes:

- Stability Data of 3 batches till shelf life manufactured at their existing facility located at Plot No. 29 30, Sector 27, Korangi Industrial Area.
- Stability Data of 2 stability batches at 0 and 3<sup>rd</sup> point have also been submitted by manufacturer from new facility located at Plot No. 01, Sector 25, Korangi Industrial Area as per Guidance Document for Submission of Application on Form 5-F (CTD) for registration of pharmaceutical drug products for human use issued in October, 2021.
- Comparative Dissolution Profile and Pharmaceutical Equivalence studies of the product with the innovator from existing manufacturing facility & also submitted Comparative Dissolution Profile against innovator from new manufacturing facility.
- Comparative batch analysis data on two batches from the new facility and comparative data on the last three batches from the existing facility.
- Firm has submitted Executed Production document of stability batch.
- Firm has submitted Process Validation Protocol.
- Firm has submitted undertakings that process validation, accelerated and real time stability studies on 03 commercial batches at new manufacturing facility will be conducted & in case of any quality complaint / OOS result as a result of this change, the same shall be reported to registration board and all the stock shall be recalled from the market immediately.
- Analytical Method Verification / validation studies of API & Finished product.
- Valid GMP/DML of the API manufacturer submitted.

#### Remarks of Evaluator:

• Firm has submitted two sets of stability data from existing plant i.e., M/s Getz Pharma (Pvt) Limited Plot no. 29 – 30, sector 27 Korangi Industrial Area, Karachi., briefed as below:

I. Stability data with analytical record, i.e., chromatograms, raw data sheets etc.....

Batch No.	238F01	239F01	240F01
Batch Size	750,000 Tablets	750,000 Tablets	750,000 Tablets
<b>Manufacturing Date</b>	10-2019	12-2019	12-2019
<b>Duration of Long-</b>	24 months	18 months	18 months
term stability			

II. Stability data without analytical record, i.e., chromatograms, raw data sheets etc.....

Batch No.	087F01	088F01	088F01
Batch Size	300,000 Tablets	300,000 Tablets	300,000 Tablets
<b>Manufacturing Date</b>	16.11.2012	10.12.2012	19.01.2013
<b>Duration of Long-</b>	36 months	36 months	36 months
term stability			

• Firm has claimed 36 months shelf life, on the basis of above referred stability data.

	min has claimed so months shen me	i, on the busis of above felerica stability acta.
3.	Name, address of Applicant /	M/s Getz Pharma (Pvt.) Ltd. Plot No. 01, Sector 25, Korangi
	Marketing Authorization Holder.	Industrial Area, Karachi Pakistan
	Name, address of Manufacturing	M/s Getz Pharma (Pvt.) Ltd. Plot No. 01, Sector 25, Korangi
	site.	Industrial Area, Karachi Pakistan
	Status of the applicant	
		□ Importer
		☐ Is involved in none of the above (contract giver)
	GMP Status of the firm	Firm has been granted Drug Manufacturing License (DML 000933) by
		way of formulation dated 25-05-2021.

Evidence of approval of manufacturing facility	Firm has been granted Drug Manufacturing License (DML 000933) way of formulation dated 25-05-2021, with approved Tablets, Capsu & Dry Powder Suspension sections.
Status of application	•
Status of application	□ New Drug Product (NDP)
	☑ Generic Drug Product (GDP)
Intended use of pharmaceutical	☐ Domestic sale
product	☐ Export sale
	□ Domestic and Export sales
Dy. No. and date of submission	Dy. No.: 5428/R&I dated 25-02-2022
Details of fee submitted	PKR 30,000/-: 28-01-2022
The proposed proprietary name / brand name	Claritek Tablets 500mg
Strength / concentration of drug of	
Active Pharmaceutical ingredient	Each film-coated tablet contains:
(API) per unit	Clarithromycin500mg
(AFI) per unit	Clarithroniyen500mg
Pharmaceutical form of applied	
drug	Film-coated Tablets
Pharmacotherapeutic Group of (API)	Antibacterial for systemic use : Macrolides
Reference to Finished product specifications	USP
Proposed Pack size	10's
Proposed unit price	767.12 for 10's
The status in reference regulatory	Klaricid Tablets 500mg approved by MHRA marketed by My
authorities	Products Ltd., UK
For generic drugs (me-too status)	Claritek Tablets 500mg (Reg. No.: 010640) manufactured by M/s C
Tor generic drugs (inc-too status)	Pharma (Pvt.) Limited Plot No. 29-30, Sector 27, Korangi Indust Area, Karachi
Name and address of API	M/s. Zhejiang Guobang Pharmaceutical Co., Ltd. located at No
manufacturer.	Weiwu Road, Hangzhou Gulf Shangyu Economic and Technolog Development Zone, Zhejiang, P. R. China.
Module-II (Quality Overall	Firm has submitted QOS as per WHO QOS-PD template. Firm
Summary)	summarized information related to nomenclature, structure, generation
Summary)	properties, solubilities, physical form, manufacturers, description
	manufacturing process and controls, impurities, specification
	analytical procedures and its validation, batch analysis and justificat
	of specification, reference standard, container closure system
	•
Modulo III Daug Cubatanasi	stability studies of drug substance and drug product.
Module-III Drug Substance:	Firm has submitted detailed data for drug substance data related
	nomenclature, structure, general properties, solubilities, physical fo
	manufacturers, description of manufacturing process and contributions and if a solidary
	impurities, specifications, analytical procedures and its validati
	batch analysis and justification of specification, reference stands
Gutilly Gutil CD	container closure system and stability studies of drug substance.
Stability Studies of Drug	Firm has submitted stability study data of 3 batches of drug substa
Substance	at both accelerated as well as real time conditions. The accelerated at both accelerated as well as real time conditions. The accelerated at both accelerated as well as real time conditions.
(Conditions & duration of	stability data is conducted at $40^{\circ}\text{C} \pm 2^{\circ}\text{C} / 75\% \pm 5\%$ RH for 6 mon
Stability	The real time stability data is conducted at $30^{\circ}\text{C} \pm 2^{\circ}\text{C} / 75 \pm 5\%$
studies)	for 48 months.
Module-III Drug Product:	Firm has submitted data of drug product including its description
	composition, pharmaceutical development, manufactu
	manufacturing process and process control, process validate
	protocols, control of excipients, control of drug product, specification
į	analytical procedures, validation of analytical procedures, ba
	analysis, justification of specifications, reference standard or materi
	analysis, justification of specifications, reference standard or materic container closure system and stability.
Pharmaceutical Equivalence and	• •
Pharmaceutical Equivalence and Comparative Dissolution Profile	

		Profile studies of C Klaricid Tablets	Claritek Tablets 500	omg against the dissolution	arative Dissolution ne reference product mediums has been	
		Facility) Firm has also subr Claritek Tablets 5	or 25 Korangi Indunitted the Compara	tive Dissoluti eference prod	on Profile studies of uct Klaricid Tablets	
	Analytical method validation/ verification of product				substance and drug	
	Stability studies	accelerated and lo	ong term conditions	s from existinand 3 <sup>rd</sup> month	ree batches at both ng site and stability n time interval (both te.	
	STABILITY STUDY DATA (P					
Man	strate of APIs	M/s. Zhejiang Gu Weiwu Road, Har	obang Pharmaceut	ical Co., Ltd yu Economic	I. located at No. 6, and Technological	
API	Lot No.	0000052047, 0000	0052049, 00000562	31 & 000556	29	
	cription of Pack ntainer closure system)	Alu-PVC blister				
Stab	ility Storage Condition		$2^{\circ}$ C / 75% $\pm$ 5%RI			
Stab	inty Storage Condition		$2 \pm 2^{\circ}$ C / 75% $\pm 5$ %	RH		
Tim	e Period	Real time: 18 mon				
1 11111	e r enou	Accelerated: 6 months				
Frac		Accelerated: 0, 3, 6 (Months)				
rieq	uency	Real Time: 0, 3, 6, 9, 12, 18 (Months				
Batc	h No.	263F02	264F		265F02	
Batc	h Size	450,000 Tablet	s 450,000 T	Γablets	450,000 Tablets	
Man	ufacturing Date	11-2019	12-20		12-2019	
No.	of Batches		03			
	DOCUMENTS / DATA TO BE	PROVIDED ALC	NG WITH STAB	ILITY STU	DY DATA	
1.	Reference of previous approval of applications with stability study data of the firm (if any)	Firm has referred (Ebastine) tablets 2019 and was pres 14 <sup>th</sup> -16 <sup>th</sup> May, 20 confirmed.  • The firm • The firm loggers.	to onsite inspection 10mg & 20mg who ented in 289th meet 1019. According to the has 21 CFR complete has audit trail reports a possesses stability	on report of to ich was concing of Registrathe report fol- iant HPLC so rts available. ty chambers	their product Estine ducted on 06 <sup>th</sup> May, ration Board held on lowing points were ftware	
2.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Copy of GMP cert is valid till 04-09-		DML issued b	Orug Administration by Zhejiang Medical	
3.	Documents for the procurement of API with approval from DRAP (in case	Firm has submitte I&E DRAP, Karad		mmercial inv	oice attested by AD	
	of import).	Batch No.	Invoice No.	Quantity Imported	Date of approval by DRAP	
		0000165717	JC201905019-1	650 Kg	15.07.2019	
		0000166174	JC201904007-1	650 Kg	23.07.2019	
		0000167030	JC201904008-1	650 Kg	26.08.2019	
4.	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.		ents like chromato		along with attested data sheets, COA,	

5.	Compliance Record of HPLC software 21CFR & audit trail	Firm has submitted audi	it trail reports.				
6.	reports on product testing.  Record of Digital data logger for						
	temperature & humidity monitoring of stability chambers	Not available.					
	(real time and accelerated)	(Dlot No. 01 Sector 25 K	Zananai Industrial A	maa Vamaahi)			
	STABILITY STUDY DATA	M/s Zhajiang Guahan	A Dharmacautical Co	I td. located a	t No. 6		
Mar	nufacturer of APIs	M/s. Zhejiang Guobang Pharmaceutical Co., Ltd. located at No. 6, Weiwu Road, Hangzhou Gulf Shangyu Economic and Technological					
		Development Zone, Zhejiang, P. R. China.					
API	Lot No.	128-201272-1	grang, r . re. emna.				
	cription of Pack						
	ntainer closure system)	Alu-PVC blister					
,	<u> </u>	Real time: $30^{\circ}\text{C} \pm 2^{\circ}\text{C}$	75% ± 5%RH				
Stat	oility Storage Condition	Accelerated: $40^{\circ}\text{C} \pm 2^{\circ}\text{C}$					
Tim	e Period	Accelerated: 0, 3 (Mont	hs)				
1 1111	e r eriou	Real Time: 0, 3 (Month					
Fred	quency	Accelerated: Initial, 3 &					
	- · ·	Real Time: Initial, 3, 6,		onths			
	ch No.	029ES01	029ES02	-			
	ch Size	10,000 Tablets	10,000 Tablets	-			
	nufacturing Date	15.09.2021	15.09.2021	-			
	e of initiation	01.10.2021	01.10.2021	-			
No.	of Batches		02				
	DOCUMENTS / DATA TO BE		WITH STABILITY	STUDY DATA			
1.	Reference of previous approval of						
	applications with stability study data of						
2.	the firm (if any)  Approval of API/ DML/GMP	Copy of GMP certificat	a issued by State Foo	d & Dona Admin	istration		
۷.	certificate of API manufacturer	is valid till 04-09-2023					
	issued by concerned regulatory	Products Administration			Micuicai		
	authority of country of origin.	1 Todacts Administration	1 vand till 00-12-202-	r.			
3.	Documents for the procurement of	Copy of invoice in the r	name of <b>Getz Pharm</b> s	(Pvt) Limited			
	API	Plot no. 29 – 30, sector			attested		
	with approval from DRAP (in case	by AD I&E DRAP, Kar					
	of						
	import).			Date of			
		Batch No.	Invoice No.	approval			
				by DRAP			
		128-201272-	JC202011023-1	30.03.2021			
		1	002020110201	30.03.2021			
4.	Data of stability batches will be						
	supported by attested respective	Firm has submitted d					
	documents like chromatograms,	respective documents 1	ike chromatograms,	Raw data sneets	s, COA,		
	Raw data sheets, COA, summary data sheets etc.	ry summary data sheets.					
5.	Compliance Record of HPLC						
٥.	software 21CFR & audit trail						
	reports on product testing.	Firm has submitted audit trail reports.					
6.	Record of Digital data logger for						
0.	temperature & humidity						
	monitoring of stability chambers	Not available.					
	(real time and accelerated)						
-		<u> </u>					

## **Remarks of the Evaluator:**

The firm has submitted the following documents as per WHO TRS 981,2013 ( $47^{th}$  report, Annex 3) and SOP guidelines stated in  $283^{rd}$  DRB meeting minutes:

- Stability Data of 3 batches till shelf life manufactured at their existing facility located at Plot No. 29 30, Sector 27, Korangi Industrial Area.
- Stability Data of 2 stability batches at 0 and 3<sup>rd</sup> point have also been submitted by manufacturer from new facility located at Plot No. 01, Sector 25, Korangi Industrial Area as per Guidance Document for Submission

- of Application on Form 5-F (CTD) for registration of pharmaceutical drug products for human use issued in October, 2021.
- Comparative Dissolution Profile and Pharmaceutical Equivalence studies of the product with the innovator from existing manufacturing facility & also submitted Comparative Dissolution Profile against innovator from new manufacturing facility.
- Comparative batch analysis data on two batches from the new facility and comparative data on the last three batches from the existing facility.
- Firm has submitted Executed Production document of stability batch.
- Firm has submitted Process Validation Protocol.
- Firm has submitted undertakings that process validation, accelerated and real time stability studies on 03 commercial batches at new manufacturing facility will be conducted & in case of any quality complaint / OOS result as a result of this change, the same shall be reported to registration board and all the stock shall be recalled from the market immediately.
- Analytical Method Verification / validation studies of API & Finished product.
- Valid GMP/DML of the API manufacturer submitted.

#### **Remarks of Evaluator:**

• Firm has submitted two sets of stability data from existing plant i.e., M/s Getz Pharma (Pvt) Limited Plot no. 29 – 30, sector 27 Korangi Industrial Area, Karachi., briefed as below:

I. Stability data with analytical record, i.e., chromatograms, raw data sheets etc.....

Batch No.	263F02	264F02	265F02
Batch Size	450,000 Tablets	450,000 Tablets	450,000 Tablets
<b>Manufacturing Date</b>	11-2019	12-2019	12-2019
Duration of Long-	18 months	18 months	18 months
term stability			

II. Stability data without analytical record, i.e., chromatograms, raw data sheets etc.....

Batch No.	090F02	091F02	092F02
Batch Size	450,000 Tablets	450,000 Tablets	450,000 Tablets
<b>Manufacturing Date</b>	19.01.2013	19.01.2013	11.02.2013
<b>Duration of Long-</b>	36 months	36 months	36 months
term stability			

Firm has claimed 36 months shelf life, on the basis of above referred stability data.

4.	Name, address of Applicant /	M/s Getz Pharma (Pvt.) Ltd. Plot No. 01, Sector 25, Korangi		
	Marketing Authorization Holder.	Industrial Area, Karachi Pakistan		
	Name, address of Manufacturing	M/s Getz Pharma (Pvt.) Ltd. Plot No. 01, Sector 25, Korangi		
	site.	Industrial Area, Karachi Pakistan		
	Status of the applicant	Manufacturer		
		☐ Importer		
		☐ Is involved in none of the above (contract giver)		
	GMP Status of the firm	Firm has been granted Drug Manufacturing License (DML 000933)		
		by way of formulation dated 25-05-2021.		
	Evidence of approval of	Firm has been granted Drug Manufacturing License (DML 000933)		
	manufacturing facility	by way of formulation dated 25-05-2021, with approved Tablets,		
		Capsules & Dry Powder Suspension sections.		
	Status of application	☐ New Drug Product (NDP)		
		☐ Generic Drug Product (GDP)		
	Intended use of pharmaceutical	☐ Domestic sale		
	product	☐ Export sale		
		☑ Domestic and Export sales		
	Dy. No. and date of submission	Dy. No.: 6079/R&I dated 04-03-2022		
	Details of fee submitted	PKR 30,000/-: 28-01-2022		
	The proposed proprietary name /	Vilget-M Teblets 50mg ± 500mg		
	brand name	Vilget-M Tablets 50mg + 500mg		
	Strength / concentration of drug of	Each film-coated tablet contains:		
	Active Pharmaceutical ingredient	Vildagliptin 50mg		
	(API) per unit	Metformin HCl USP 500mg		

Pharmaceutical form of applied drug	Film-coated tablet
Pharmacotherapeutic Group of (API)	Combinations of oral blood glucose lowering drugs
Reference to Finished product specifications	Getz Pharma Specifications
Proposed Pack size	2x7 (14's) & 4x7 (28's)
Proposed unit price	Rs.1143.28/- (14's) & Rs. 2286.56/- (28's)
The status in reference regulatory	"Galvumet Tablets 50mg + 500mg" Approved by To
authorities	manufactured by Novartis Pharmaceuticals Australia Pty. Ltd.
For generic drugs (me-too status)	Vilget-M Tablets 50mg + 500mg (Reg. No.: 086937) manufactur by M/s Getz Pharma (Pvt.) Limited Plot No. 29 -30, Sector
	Korangi Industrial Area, Karachi
Name and address of API	Vildagliptin:
manufacturer.	Fuxin Long Rui Pharmaceutical Co., Ltd
	Fluoride Industrial Park, Fumeng County (Yi Ma Tu), Fuxin Ci
	Liaoning Province -123000, China
	Metformin HCl:
	Shouguang Fukang Pharmaceutical Co., Ltd.
	North-East of Dongwaihuan Road, Dongcheng Industrial Area, Ci
	Shouguang, Province: Shandong, Country: the People's Republic
	China
Module-II (Quality Overall	Firm has submitted QOS as per WHO QOS-PD template. Firm l
Summary)	summarized information related to nomenclature, structure, gene
• /	properties, solubilities, physical form, manufacturers, description
	manufacturing process and controls, impurities, specificatio
	analytical procedures and its validation, batch analysis a
	justification of specification, reference standard, container close
	system and stability studies of drug substance and drug product.
Module-III Drug Substance:	Firm has submitted detailed data for drug substance related
č	nomenclature, structure, general properties, solubilities, physic
	form, manufacturers, description of manufacturing proce
	impurities, specifications, analytical procedures and its validation
	batch analysis and justification of specification, reference standa
	container closure system and stability studies of both dr
	substances.
Stability Studies of Drug Substance	Vildagliptin:
(Conditions & duration of Stability	Firm has submitted stability study data of 3 batches of drug substar
studies)	at both accelerated as well as real time conditions. The accelerate
	stability data is conducted at $40^{\circ}\text{C} \pm 2^{\circ}\text{C} / 75\% \pm 5\%$ RH for
	months. The real time stability data is conducted at $30^{\circ}\text{C} \pm 2^{\circ}\text{C}$
	± 5% RH for 36 months.
	Metformin HCl:
	Firm has submitted stability study data of 3 batches of drug substar
	at both accelerated as well as real time conditions. The accelera
	stability data is conducted at $40^{\circ}\text{C} \pm 2^{\circ}\text{C} / 75\% \pm 5\%$ RH for
	months. The real time stability data is conducted at $30^{\circ}\text{C} \pm 2^{\circ}\text{C}$ /
	± 5% RH for 60 months.
Module-III Drug Product:	
Module-III Drug Product:	Firm has submitted data of drug product including its description
Module-III Drug Product:	Firm has submitted data of drug product including its description composition, pharmaceutical development, manufacture
Module-III Drug Product:	Firm has submitted data of drug product including its description composition, pharmaceutical development, manufacturing process and process control, process validation
Module-III Drug Product:	Firm has submitted data of drug product including its description composition, pharmaceutical development, manufacturing process and process control, process validation control of excipients, control of drug product, specification
Module-III Drug Product:	Firm has submitted data of drug product including its description composition, pharmaceutical development, manufacturing process and process control, process validation control of excipients, control of drug product, specification analytical procedures, validation of analytical procedures, bar
Module-III Drug Product:	Firm has submitted data of drug product including its description composition, pharmaceutical development, manufacturing process and process control, process validation control of excipients, control of drug product, specification analytical procedures, validation of analytical procedures, bar
Module-III Drug Product:  Pharmaceutical Equivalence and	Firm has submitted data of drug product including its description composition, pharmaceutical development, manufacturing process and process control, process validation control of excipients, control of drug product, specification analytical procedures, validation of analytical procedures, based analysis, justification of specifications, reference standard materials, container closure system and stability studies.  Getz Pharma (Pvt) Limited
	Firm has submitted data of drug product including its description composition, pharmaceutical development, manufacturing process and process control, process validation control of excipients, control of drug product, specification analytical procedures, validation of analytical procedures, based analysis, justification of specifications, reference standard materials, container closure system and stability studies.
Pharmaceutical Equivalence and	Firm has submitted data of drug product including its description composition, pharmaceutical development, manufactur manufacturing process and process control, process validation control of excipients, control of drug product, specification analytical procedures, validation of analytical procedures, based analysis, justification of specifications, reference standard materials, container closure system and stability studies.  Getz Pharma (Pvt) Limited  Plot no. 29 – 30, sector 27 Korangi Industrial Area, Karachi
Pharmaceutical Equivalence and	Firm has submitted data of drug product including its description composition, pharmaceutical development, manufacturing process and process control, process validation control of excipients, control of drug product, specification analytical procedures, validation of analytical procedures, base analysis, justification of specifications, reference standard materials, container closure system and stability studies.  Getz Pharma (Pvt) Limited
Pharmaceutical Equivalence and	Firm has submitted data of drug product including its descriptic composition, pharmaceutical development, manufactur manufacturing process and process control, process validatic control of excipients, control of drug product, specification analytical procedures, validation of analytical procedures, baranalysis, justification of specifications, reference standard materials, container closure system and stability studies.  Getz Pharma (Pvt) Limited  Plot no. 29 – 30, sector 27 Korangi Industrial Area, Karachi  Pharmaceutical Equivalence Studies & Comparative Dissolution Profile studies of Vilget-M tablet 50mg + 500mg against to the studies of Vilget-M tablet 50mg + 500mg against to the studies of Vilget-M tablet 50mg + 500mg against to the studies of Vilget-M tablet 50mg + 500mg against to the studies of Vilget-M tablet 50mg + 500mg against to the studies of Vilget-M tablet 50mg + 500mg against to the studies of Vilget-M tablet 50mg + 500mg against table
Pharmaceutical Equivalence and	Firm has submitted data of drug product including its descriptic composition, pharmaceutical development, manufactur manufacturing process and process control, process validatic control of excipients, control of drug product, specification analytical procedures, validation of analytical procedures, baranalysis, justification of specifications, reference standard materials, container closure system and stability studies.  Getz Pharma (Pvt) Limited  Plot no. 29 – 30, sector 27 Korangi Industrial Area, Karachi  Pharmaceutical Equivalence Studies & Comparative Dissolution

		Getz Pharma (Pvt) Lir	nited			
		, ,	Korangi Industrial Are	a. Karachi		
			the Comparative Dissolu			
			ng + 500mg against the			
		GalvusMet Tablet 50mg + 500mg, in Routine Release Medium with				
		acceptable level of f2 results.				
	Analytical method validation /	Firm has submitted verification studies of the drug substance & drug				
	verification of product	product.				
		Firm has submitted sta	bility studies data of th	ree batches at both		
	Stability studies		m conditions from existi			
	Stability studies		ches at 0 and 3rd month			
			m conditions) from new			
	STABILITY STUDY DATA (Plo		Korangi Industrial Area	, Karachi)		
		Vildagliptin:				
		Fuxin Long Rui Pharma				
			k, Fumeng County (Yi M	Ia Tu), Fuxin City,		
Man	ufacturer of APIs	Liaoning Province -123	000, China			
		Metformin HCl:				
		Wanbury Limited.		T7 T11' 1 '		
				K. Illindalaparru-		
		Iragavaram, West Godav	vari District Andhra Prad	esh,534 217, India		
ADIA AN		Vildagliptin: 00001421	69			
API	Lot No.	Metformin HCl: 0000144126, 0000144131				
D i i CD 1						
Description of Pack		Alu-Alu blister				
(Container closure system)		Real time: $30^{\circ}\text{C} \pm 2^{\circ}\text{C} / 75\% \pm 5\%\text{RH}$				
Stability Storage Condition		Accelerated: $40^{\circ}\text{C} \pm 2^{\circ}\text{C}$				
		Real time: 6 months	2/ /3/0 ± 3/0KII			
Time	e Period	Accelerated: 36 months				
		Accelerated: 0, 3, 6 (Mo				
Freq	uency	Real Time: 0, 3, 6, 9, 12				
Batc	h No.	001FA8	002FA8	003FA8		
	h Size	100,000 Tablets	100,000 Tablets	100,000 Tablets		
Man	ufacturing Date	12.03.2018	27.03.2018	28.03.2018		
	of initiation	05.07.2018	05.07.2018	30.07.2018		
	of Batches		03			
	DOCUMENTS / DATA TO BE P	PROVIDED ALONG W		DY DATA		
1.	Reference of previous approval of		site inspection report of			
	applications with stability study data		& 20mg which was con-			
	of		in 289 <sup>th</sup> meeting of Reg			
	the firm (if any)		9. According to the repo			
		were confirmed.				
			FR compliant HPLC soft	ware		
			trail reports available.			
		•	stability chambers with	digital data loggers.		
2.	Approval of API/ DML/GMP	<u>Vildagliptin</u>				
	certificate of API manufacturer		of DML (License No.Li			
	issued by concerned regulatory		ministration of Liaoning	Province, valid till		
	authority of country of origin.	December 20, 2022.				
		Metformin HCl	COMP CC C	O. A.C. A. N. MAC		
			by of GMP certificate (			
			ment of India, Ministry			
			Standard Control Organi	zauon vand till July		
		02, 2022.				

3.	Documents for the procurement of API with approval from DRAP (in case	Firm has submitted copy of commercial invoice attested by AD I&E DRAP, Karachi.				
	of	Vildagliptin:				
	import).	Batch No.	Invoice No.	Quantity Imported	Date of approval by DRAP	
		0000142169	SY171109-C	130 Kg	14-11-2017	
		Metformin HC	1•			
		Wiction min 11C	<u>1.</u>		Date of	
		Batch No.	Invoice No.	Quantity Imported	approval by DRAP	
		0000144126	EXP/92001487/1	2000 Kg	03-01-2018	
		0000144131	EXP/92001487/1 18	7- 2000 Kg	03-01-2018	
4.	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Firm has submitted data of stability batches along with attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets.				
5.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing.		tted compliance c s on product testin		PLC software and	
6.	Record of Digital data logger for temperature & humidity monitoring of stability chambers (real time and accelerated)	Firm has submitted record of digital data logger for temperature & humidity monitoring of stability chambers (real time and accelerated)				
	STABILITY STUDY DATA (P	lot No. 01, Secto	r 25 Korangi Indu	strial Area, Ka	arachi)	
Manufacturer of APIs    Vildagliptin: Fuxin Long Rui Pharmaceutical Co., Ltd Fluoride Industrial Park, Fumeng County (Yi Manufacturer of APIs    Manufacturer of APIs   Metformin HCl:			County (Yi Ma l Co., Ltd. Dongcheng Ind	lustrial Area, City:		
API	Lot No.		T-20200328-D02- <u>1</u> : A-32612104081-			
	cription of Pack ntainer closure system)	Alu-Alu blister				
Stab	ility Storage Condition		± 2°C / 75% ± 5%; °C ± 2°C / 75% ± 5			
Tim	e Period	Real time: 0, 3 i Accelerated: 0,	nonths	/VIXII		
Free	quency	Accelerated: 0,		onths		
_	h No.	034ES01		ES02	-	
	ch Size	10,000 Table		) Tablets	-	
	nufacturing Date e of initiation	20.09.202 08-10-202		9.2021 0-2021	=	
	of Batches	06-10-202	02-1		-	
140.	DOCUMENTS / DATA TO BE F	PROVIDED ALC			Y DATA	
1.	Reference of previous approval of applications with stability study data of	312 <sup>th</sup> meeting of Case No.11: Re from M/s Getz	Registration Boar quest for Change i z Pharma (Pvt) I	d dated Septem n Registration 3 td, 29-30, Se	ber 14-16, 2021. Status of Products ctor 27, Korangi	
	the firm (if any)	from M/s Getz Pharma (Pvt) Ltd, 29-30, Sector 27, Korangi Industrial Area, Karachi to M/s Getz Pharma (Pvt) Ltd, Plot No.01, Sector 25, Korangi Industrial Area, Karachi				

_						
3.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.  Documents for the procurement of API with approval from DRAP (in case	Vildagliptin  Firm has submitted copy of DML (License No.Liao20150233) issued by Food and Drug Administration of Liaoning Province, valid till December 20, 2022.  Metformin HCI  Firm has submitted copy of GMP certificate (Certificate No.SD20190888) issued by China Food and Drug Administration, valid till March 12, 2024.  Firm has submitted copy of invoice in the name of Getz Pharma (Pvt) Limited Plot no. 29 – 30, sector 27 Korangi Industrial Area, Karachi attested by AD I&E DRAP, Karachi.				
	of		,	-		
	import).	Vildagliptin:				
		Batch No.	Invoice No.	Date of approval by DRAP		
		WT-20200328- D02-WT03-11C 21ATGZ041 28-04-2021		28-04-2021		
		Metformin HCl:				
		Batch No.	No. Invoice No. Date of approval by DRAP			
		A-32612104081- 0150	JC202105010-1	05-07-2021		
4.	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Firm has submitted data of stability batches along with attested respective documents like chromatograms, Raw data sheets, COA,				
5.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing.	Firm has submitted compliance certificate of HPLC software and audit trail reports on product testing.				
6.	Record of Digital data logger for temperature & humidity monitoring of stability chambers (real time and accelerated)			gger for temperature & al time and accelerated)		

The firm has submitted the following documents as per WHO TRS 981,2013 ( $47^{th}$  report, Annex 3) and SOP for approval of post-registration variations approved in  $283^{rd}$  DRB meeting:

- Stability Data of 03 batches till shelf life plus 01 year manufactured at their existing facility located at Plot No. 29 30, Sector 27, Korangi Industrial Area.
- Stability Data of 2 stability batches at 0 and 3<sup>rd</sup> month time point from new facility located at Plot No. 01, Sector 25, Korangi Industrial Area as per Guidance Document for Submission of Application on Form 5-F (CTD) for registration of pharmaceutical drug products for human use issued in October, 2020.
- Comparative Dissolution Profile and Pharmaceutical Equivalence studies of the product with the innovator from existing manufacturing facility & also submitted Comparative Dissolution Profile against innovator from new manufacturing facility.
- Comparative batch analysis data on two batches from the new facility and comparative data on the last three batches from the existing facility.
- Executed Production document of stability batch.
- Process Validation Protocol from new site.
- Undertakings in accordance with SOP for approval of post-registration variations by DRAP.
- Analytical Method Verification studies of API & Finished product.
- Valid DML/GMP Certificate of the API manufacturers.

5.	Name, address of Applicant /	M/s Getz Pharma (Pvt.) Ltd.		
	Marketing Authorization Holder.	Plot No. 01, Sector 25, Korangi Industrial Area, Karachi Pakistan		
	Name, address of Manufacturing	M/s Getz Pharma (Pvt.) Ltd.		
	site.	Plot No. 01, Sector 25, Korangi Industrial Area, Karachi Pakistan		
	Status of the applicant	☑ Manufacturer		
		☐ Importer		
		☐ Is involved in none of the above (contract giver)		

GMP Status of the firm	Firm has been granted Drug Manufacturing License (DML 000933) by way of formulation dated 25-05-2021.
Evidence of approval of manufacturing facility	Firm has been granted Drug Manufacturing License (DML 000933) by way of formulation dated 25-05-2021, with approved Tablets
manuracturing racinty	Capsules & Dry Powder Suspension sections.
Status of application	□ New Drug Product (NDP)
-	☑ Generic Drug Product (GDP)
Intended use of pharmaceutical	☐ Domestic sale
product	☐ Export sale
	☑ Domestic and Export sales
Dy. No. and date of submission	Dy. No.: 6080/R&I dated 04-03-2022
Details of fee submitted	PKR 30,000/-: 28-01-2022
The proposed proprietary name / brand name	Vilget-M Tablets 50mg + 850mg
Strength / concentration of drug of	Each film-coated tablet contains:
Active Pharmaceutical ingredient	Vildagliptin 50mg
(API) per unit Pharmaceutical form of applied	Metformin HCl USP 850mg
drug	Film coated tablet
Pharmacotherapeutic Group of (API)	Combinations of oral blood glucose lowering drugs
Reference to Finished product specifications	Getz Pharma Specifications
Proposed Pack size	2x7 (14's) & 4x7 (28's)
Proposed unit price	Rs.1204.43/- (14's) & Rs. 2410.45/- (28's)
Claimed shelf life	2 years
The status in reference regulatory authorities	"Galvumet Tablets 50mg/850mg" Approved by TGA manufacture by Novartis Pharmaceuticals Australia Pty. Ltd.
For generic drugs (me-too status)	Vilget-M Tablets 50mg + 850mg (Reg. No.: 073875) manufacture by M/s Getz Pharma (Pvt.) Limited Plot No. 29 -30, Sector 27 Korangi Industrial Area, Karachi
Name and address of API manufacturer.	Vildagliptin: Fuxin Long Rui Pharmaceutical Co., Ltd Fluoride Industrial Park, Fumeng County (Yi Ma Tu), Fuxin City Liaoning Province -123000, China Metformin HCl: Shouguang Fukang Pharmaceutical Co., Ltd. North-East of Dongwaihuan Road, Dongcheng Industrial Area, City Shouguang, Province: Shandong, Country: the People's Republic of China
Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Firm has summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications analytical procedures and its validation, batch analysis an justification of specification, reference standard, container closur system and stability studies of drug substance and drug product.
Module-III Drug Substance:	Firm has submitted detailed data for drug substance related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process impurities, specifications, analytical procedures and its validation batch analysis and justification of specification, reference standard container closure system and stability studies of both drug substances.
Stability Studies of Drug Substance (Conditions & duration of Stability studies)	<b>Vildagliptin:</b> Firm has submitted stability study data of 3 batches of drug substance at both accelerated as well as real time conditions. The accelerate stability data is conducted at $40^{\circ}\text{C} \pm 2^{\circ}\text{C} / 75\% \pm 5\%$ RH for months. The real time stability data is conducted at $30^{\circ}\text{C} \pm 2^{\circ}\text{C} / 75\%$ RH for 36 months. <b>Metformin HCl:</b> Firm has submitted stability study data of 3 batches of drug substance.

		stability data is conduction months. The real time s	at both accelerated as well as real time conditions. The accelerated stability data is conducted at $40^{\circ}\text{C} \pm 2^{\circ}\text{C} / 75\% \pm 5\%$ RH for 6 months. The real time stability data is conducted at $30^{\circ}\text{C} \pm 2^{\circ}\text{C} / 75 \pm 5\%$ RH for 60 months.			
	Module-III Drug Product:	Firm has submitted dat composition, pharm manufacturing process control of excipients, analytical procedures, analysis, justification materials, container close	Firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference standard or			
	Pharmaceutical Equivalence and Comparative Dissolution Profile	Industrial Area, Karac Pharmaceutical Equiva Profile studies of Vil reference product Ga	mited Plot no. 29 – 30, chi lence Studies & Comp get-M tablet 50mg + 3 llvusMet Tablet 50mg as been submitted with ac	arative Dissolution 850mg against the +850mg, in three		
			Limited Plot No. 01, S	Sector 25 Korangi		
		of Vilget-M tablet 50r	the Comparative Dissolution + 850mg against the g+850mg, in Routine Re	e reference product		
	Analytical method validation / verification of product	Firm has submitted veri product.	fication studies of the dru	ig substance & drug		
	Stability studies	Firm has submitted stability studies data of three batches at both accelerated and long term conditions from existing site and stability studies data of two batches till 3 <sup>rd</sup> month time interval (both accelerated and long term conditions) from new site.				
	STABILITY STUDY DATA (Plo	t No. 29-30, Sector 27, Korangi Industrial Area, Karachi)				
Man	ufacturer of APIs	Vildagliptin:  Beijing Huikang Boyuan Chemical Co., Ltd.  No.7 Haiying Road, Science City, Fengtai District, Beijing China.  Metformin HCl:  Wanbury Limited.  Doctors Organic Chemicals, Division. K. Illindalaparru-Iragavaram, West Godavari District Andhra Pradesh,534 217, India				
API	Lot No.	Vildagliptin: 00001101 Metformin HCl: 00001	.60	, mora		
	cription of Pack	Alu-Alu blister	100233, 0000111301			
	ntainer closure system) ility Storage Condition	Real time: $30^{\circ}\text{C} \pm 2^{\circ}\text{C} / 75\% \pm 5\%\text{RH}$				
	e Period	Accelerated: $40^{\circ}\text{C} \pm 2^{\circ}\text{C} / 75\% \pm 5\%\text{RH}$ Real time: 6 months  Accelerated: 36 months				
Freq	uency	Accelerated: 36 Hollins  Accelerated: 0, 3, 6 (Months)  Real Time: 0, 3, 6, 9, 12, 18, 24, 36 (Months)				
Batc	h No.	001F87	002F87	003F87		
	h Size	70,000 Tablets	70,000 Tablets	70,000 Tablets		
	ufacturing Date	19.12.2015	30.12.2015	30.12.2015		
	of initiation	15.01.2016	15.01.2016	15.01.2016		
No.	of Batches  DOCUMENTS / DATA TO BE B	DOVIDED ALONG W	03 ITH STARII ITV STIII	DV DATA		
1.	Reference of previous approval of applications with stability study data of the firm (if any)					

		• The firm n	nesesses	stability ch	ambers with	digital data loggers
2.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	• The firm possesses stability chambers with digital data loggers.  Vildagliptin  Firm has submitted copy of DML (License No.Liao20150233) of M/s Fuxin Long Rui (formerly known as M/s Beijing Huikang) issued by Food and Drug Administration of Liaoning Province, valid till December 20, 2022.  Metformin HCI  Firm has submitted copy of GMP certificate (Certificate No.WC-122) issued by Government of India, Ministry of Health & Family Welfare, Central Drugs Standard Control Organization valid till July 02, 2022.				
3.	Documents for the procurement of API with approval from DRAP (in case of import).	Firm has submitted copy of commercial invoice in the name of Getz Pharma (Pvt) Limited Plot no. 29 – 30, sector 27 Korangi Industrial Area, Karachi attested by AD I&E DRAP, Karachi.  Vildagliptin:				
		Batch No.		ice No.	Quantity Imported	Date of approval by DRAP
		0000110160	HN15	51026-E	65.00	28-10-2015
		Metformin HC	1.			
		Batch No.		oice No.	Quantit Importe	
		0000111304	EXP/95	5009853/15 16	5- 1,280 kg	g 24-11- 2015
4.	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Firm has submitted data of stability batches along with attested respective documents like chromatograms, Raw data sheets, COA,				
5.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing.	Firm has submi audit trail report				HPLC software and
6.	Record of Digital data logger for temperature & humidity monitoring of stability chambers (real time and accelerated)	Firm has submitted record of digital data logger for temperature & humidity monitoring of stability chambers (real time and accelerated)				
		lot No. 01, Sector	r 25 Kor	angi Indus	strial Area, I	Karachi)
Mar	nufacturer of APIs	STABILITY STUDY DATA (Plot No. 01, Sector 25 Korangi Industrial Area, Karachi)  Vildagliptin: Fuxin Long Rui Pharmaceutical Co., Ltd Fluoride Industrial Park, Fumeng County (Yi Ma Tu), Fuxin C Liaoning Province -123000, China  Metformin HCl: Shouguang Fukang Pharmaceutical Co., Ltd. North-East of Dongwaihuan Road, Dongcheng Industrial Area, C Shouguang, Province: Shandong, Country: the People's Republic China				Ma Tu), Fuxin City,
API	Lot No.	Vildagliptin: W Metformin HC				
	cription of Pack ntainer closure system)	Alu-Alu blister				
Stab	oility Storage Condition	Real time: 30°C Accelerated: 40°	$^{\circ}C \pm 2^{\circ}C$			
Tim	e Period	Real time: 0, 3 r Accelerated: 0, 3	3 months			
Frec	quency	Accelerated: 0, 3, Real Time: 0, 3,			onths	
	ch No.	035ES01			ES02	-
	ch Size	10,000 Table			Tablets	-
Mar	Manufacturing Date 21.09.2021 21.09.2021 -					

Date	of initiation	08.10.2021	08.10.2021	-			
	of Batches		02	1			
	DOCUMENTS / DATA TO BE P	ROVIDED ALONG W	TTH STABILITY ST	UDY DATA			
1.	Reference of previous approval of applications with stability study data of the firm (if any)						
2.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Vildagliptin Firm has submitted copy of DML (License No.Liao20150233) issued by Food and Drug Administration of Liaoning Province, valid till December 20, 2022.  Metformin HCl Firm has submitted copy of GMP certificate (Certificate No.SD20190888) issued by China Food and Drug Administration, valid till March 12, 2024.					
3.	Documents for the procurement of API with approval from DRAP (in case of import).	Firm has submitted copy of invoice in the name of Getz Pharma (Pvt) Limited Plot no. 29 – 30, sector 27 Korangi Industrial Area, Karachi attested by AD I&E DRAP, Karachi.  Vildagliptin:					
	1	Batch No. Invoice No. Date of approval by DRAP					
		WT-20200328- D02-WT03-11C	21ATGZ041	28-04-2021			
		Metformin HCl:					
		Batch No.	Invoice No.	Date of approval by DRAP			
		A-32612104081- 0150	JC202105010-1	05-07-2021			
4.	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Firm has submitted data of stability batches along with attested respective documents like chromatograms, Raw data sheets, COA,					
5.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing.	Firm has submitted compliance certificate of HPLC software and audit trail reports on product testing.					
6.	Record of Digital data logger for temperature & humidity monitoring of stability chambers (real time and accelerated)	Firm has submitted rec humidity monitoring accelerated)					

The firm has submitted the following documents as per WHO TRS 981,2013 (47<sup>th</sup> report, Annex 3) and SOP for approval of post-registration variations approved in 283<sup>rd</sup> DRB meeting:

- Stability Data of 03 batches till shelf life plus 01 year manufactured at their existing facility located at Plot No. 29 30, Sector 27, Korangi Industrial Area.
- Stability Data of 2 stability batches (till 3<sup>rd</sup> month time point) from new facility located at Plot No. 01, Sector 25, Korangi Industrial Area as per Guidance Document for Submission of Application on Form 5-F (CTD) for registration of pharmaceutical drug products for human use issued in October, 2020.
- Comparative Dissolution Profile and Pharmaceutical Equivalence studies of the product with the innovator from existing manufacturing facility & also submitted Comparative Dissolution Profile against innovator from new manufacturing facility.
- Comparative batch analysis data on two batches from the new facility and comparative data on the last three batches from the existing facility.
- Executed Production document of stability batch.
- Process Validation Protocol from new site.
- Undertakings in accordance with SOP for approval of post-registration variations by DRAP.
- Analytical Method Verification studies of API & Finished product.
- Valid DML/GMP Certificate of the API manufacturers.

6.	Name, address of Applicant /	M/s Getz Pharma (Pvt.) Ltd.	
	Marketing Authorization Holder.	Plot No. 01, Sector 25, Korangi Industrial Area, Karachi Pakistan	
	Name, address of Manufacturing	M/s Getz Pharma (Pvt.) Ltd.	
	site.	Plot No. 01, Sector 25, Korangi Industrial Area, Karachi Pakistan	
	Status of the applicant		
		☐ Importer	
		☐ Is involved in none of the above (contract giver)	
	CMD Control Called Control		
	GMP Status of the firm	Firm has been granted Drug Manufacturing License (DML 000933)	
		by way of formulation dated 25-05-2021.	
	Evidence of approval of	Firm has been granted Drug Manufacturing License (DML 000933)	
	manufacturing facility	by way of formulation dated 25-05-2021, with approved Tablets,	
		Capsules & Dry Powder Suspension sections.	
	Status of application	☐ New Drug Product (NDP)	
		☑ Generic Drug Product (GDP)	
	Intended use of pharmaceutical	☐ Domestic sale	
	product		
	Product	☐ Export sale	
		☑ Domestic and Export sales	
	Dy. No. and date of submission	Dy. No.: 6081/R&I dated 04-03-2022	
	Details of fee submitted	PKR 30,000/-: 28-01-2022	
	The proposed proprietary name /	Vilgot M Toblete 50mg + 1000mg	
	brand name	Vilget-M Tablets 50mg + 1000mg	
	Strength / concentration of drug of	Each film-coated tablet contains:	
	Active Pharmaceutical ingredient	Vildagliptin 50mg	
	(API) per unit	Metformin HCl USP 1000mg	
	Pharmaceutical form of applied drug	Film-coated tablet	
	Pharmacotherapeutic Group of		
	(API)	Combinations of oral blood glucose lowering drugs	
	Reference to Finished product specifications	Getz Pharma Specifications	
	Proposed Pack size	2x7 (14's) & 4x7 (28's)	
		Rs.1210.80/- (14's) & Rs. 2421.59/- (28's)	
	Proposed unit price		
	The status in reference regulatory	"Galvumet Tablets 50mg/1000mg" Approved by TGA manufactured	
	authorities	by Novartis Pharmaceuticals Australia Pty. Ltd.	
	For generic drugs (me-too status)	Vilget-M Tablets 50mg + 1000mg (Reg. No.: 073876) manufactured	
		by M/s Getz Pharma (Pvt.) Limited Plot No. 29 -30, Sector 27,	
		Korangi Industrial Area, Karachi	
	Name and address of API	Vildagliptin:	
	manufacturer.	Fuxin Long Rui Pharmaceutical Co., Ltd	
		Fluoride Industrial Park, Fumeng County (Yi Ma Tu), Fuxin City,	
		Liaoning Province -123000, China	
		Metformin HCl:	
		Shouguang Fukang Pharmaceutical Co., Ltd.	
		North-East of Dongwaihuan Road, Dongcheng Industrial Area, City:	
		Shouguang, Province: Shandong, Country: the People's Republic of	
		China	
	Module-II (Quality Overall	Firm has submitted QOS as per WHO QOS-PD template. Firm has	
	Summary)	summarized information related to nomenclature, structure, general	
		properties, solubilities, physical form, manufacturers, description of	
		manufacturing process and controls, impurities, specifications,	
		analytical procedures and its validation, batch analysis and	
		justification of specification, reference standard, container closure	
		system and stability studies of drug substance and drug product.	
	Module-III Drug Substance:	Firm has submitted detailed data for drug substance related to	
1	<u> </u>	nomenclature, structure, general properties, solubilities, physical	
1		form, manufacturers, description of manufacturing process,	
		impurities, specifications, analytical procedures and its validation,	
		batch analysis and justification of specification, reference standard,	
		container closure system and stability studies of both drug	
		substances.	
	Stability Studies of Drug Substance	Vildagliptin:	
	(Conditions & duration of Stability	Firm has submitted stability study data of 3 batches of drug substance	
1	Conditions & duration of Stability	1 mm has submitted stability study data of 3 datelies of drug substance	

	studies)	stability data is conduct months. The real time is ± 5% RH for 36 months Metformin HCl:  Firm has submitted stab at both accelerated as we stability data is conduct.	ility study data of 3 batch well as real time condition of ted at $40^{\circ}$ C $\pm$ $2^{\circ}$ C / 75 tability data is conducted	$6\% \pm 5\%$ RH for 6 l at $30^{\circ}$ C $\pm 2^{\circ}$ C / 75 es of drug substance ons. The accelerated $6\% \pm 5\%$ RH for 6	
	Module-III Drug Product:	composition, pharm manufacturing process control of excipients, analytical procedures, analysis, justification materials, container clo		nt, manufacture, process validation, uct, specifications, procedures, batch rence standard or	
	Pharmaceutical Equivalence and Comparative Dissolution Profile	materials, container closure system and stability studies.  Getz Pharma (Pvt) Limited  Plot no. 29 – 30, sector 27 Korangi Industrial Area, Karachi  Pharmaceutical Equivalence Studies & Comparative Dissolutio  Profile studies of Vilget-M tablet 50mg + 1000mg against th  reference product GalvusMet Tablet 50mg+1000mg, in thre  dissolution mediums has been submitted with acceptable level of fresults.			
		Firm has also submitted of Vilget-M tablet 50n	Korangi Industrial Are I the Comparative Dissolung + 1000mg against the g+1000mg, in Routine Re	ution Profile studies e reference product	
	Analytical method validation / verification of product	Firm has submitted veri product.	fication studies of the dru	ig substance & drug	
	Stability studies	Firm has submitted sta accelerated and long ter studies data of two b	ability studies data of the rm conditions from existing tatches till 3 <sup>rd</sup> month to rm conditions) from new	ng site and stability time interval (both	
	STABILITY STUDY DATA (Plo				
Manu	afacturer of APIs	Plot No. 29-30, Sector 27, Korangi Industrial Area, Karachi)  Vildagliptin: Beijing Huikang Boyuan Chemical Co., Ltd. No.7 Haiying Road, Science City, Fengtai District, Beijing China.  Metformin HCI: Wanbury Limited. Doctors Organic Chemicals, Division. K. Illindalaparru-Iragavaram, West Godavari District Andhra Pradesh, 534 217, India			
API I	Lot No.	Vildagliptin: 00001101 Metformin HCl: 00001	160 108232, 0000108234, 000	00111304	
	ription of Pack	Alu-Alu blister			
(Cont	ainer closure system)				
Stabi	lity Storage Condition	Real time: $30^{\circ}\text{C} \pm 2^{\circ}\text{C} / \text{Accelerated: } 40^{\circ}\text{C} \pm 2^{\circ}\text{C}$			
Time	Period	Real time: 6 months Accelerated: 36 months			
Frequ	•	Accelerated: 0, 3, 6 (Mo Real Time: 0, 3, 6, 9, 12	2, 18, 24, 36 (Months)	_	
Batch		001F88	002F88	003F88	
Batch		70,000 Tablets	70,000 Tablets	70,000 Tablets	
	facturing Date	27.11.2015	22.12.2015	22.12.2015	
	of initiation	12.01.2016	12.01.2016	12.01.2016	
No. o	No. of Batches 03  DOCUMENTS / DATA TO BE PROVIDED ALONG WITH STABILITY STUDY DATA				
<u> </u>	DOCUMENTS / DATA TO BE 1	PROVIDED ALONG W	<u>ITH STABILITY STUI</u>	DY DATA	

10mg & 20mg v sented in 289 <sup>th</sup> n y, 2019. Accordi s 21 CFR complis audit trail repor	which was conduct neeting of Registrang to the report ant HPLC softwants available.	eted on 06 <sup>th</sup> May, ration Board held following points	
Vildagliptin  Firm has submitted copy of DML (License No.Liao20150233) of M/s Fuxin Long Rui (formerly known as M/s Beijing Huikang) issued by Food and Drug Administration of Liaoning Province, valid till December 20, 2022.  Metformin HCI  Firm has submitted copy of GMP certificate (Certificate No.WC-122) issued by Government of India, Ministry of Health & Family Welfare, Central Drugs Standard Control Organization valid till July 02, 2022.			
ed copy of comm chi.	ercial invoice atte	ested by AD	
Invoice No.	Quantity Imported	Date of approval by DRAP	
HN151026-E	65.00	28-10-2015	
		Date of	
Invoice No.	Quantity Imported	approval by DRAP	
EXP/95009853/1 16	5- 1,280 kg	24-11- 2015	
•		LC software and	
oring of stabil	ity chambers (	(real time and	
25 Korangi Indu	ıstrial Area, Kaı	rachi)	
TA (Plot No. 01, Sector 25 Korangi Industrial Area, Karachi)  Vildagliptin: Fuxin Long Rui Pharmaceutical Co., Ltd Fluoride Industrial Park, Fumeng County (Yi Ma Tu), Fuxin City, Liaoning Province -123000, China  Metformin HCI: Shouguang Fukang Pharmaceutical Co., Ltd. North-East of Dongwaihuan Road, Dongcheng Industrial Area, City: Shouguang, Province: Shandong, Country: the People's Republic of China			
$C \pm 2^{\circ}C / 75\% \pm 5$			
onths months			
	10mg & 20mg vesented in 289th man, 2019. According the sented in 289th man, 2019. According audit trail reports essess stability of the sesses stabili	Rui (formerly known as M/s Ed Drug Administration of Liaonin 2022.  ed copy of GMP certificate (Cerevernment of India, Ministry of Drugs Standard Control Organizate depoys of commercial invoice attechi.  Invoice No.	

		Accelerated: 0, 3, 6 mg	onths		
Freq	luency	Real Time: 0, 3, 6, 9, 1			
Bato	ch No.	033ES01	033ES02	-	
Bato	ch Size	10,000 Tablets	10,000 Tablets	-	
	ufacturing Date	17.09.2021	17.09.2021	-	
	e of initiation	08-10-2021	08-10-2021	-	
No.	of Batches		02		
	DOCUMENTS / DATA TO BE P	PROVIDED ALONG W	TITH STABILITY ST	UDY DATA	
1.	Reference of previous approval of applications with stability study data of the firm (if any)				
2.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Vildagliptin Firm has submitted cop by Food and Drug Ad December 20, 2022.  Metformin HCl Firm has submitted No.SD20190888) issue valid till March 12, 202	ministration of Liaonin copy of GMP ce ed by China Food and 24.	ertificate (Certificate Drug Administration,	
3.	Documents for the procurement of API with approval from DRAP (in case of import).	Firm has submitted copy of invoice in the name of <b>Getz Pharma</b> (Pvt) Limited Plot no. 29 – 30, sector 27 Korangi Industrial Area, Karachi attested by AD I&E DRAP, Karachi.			
	import).	Vildagliptin:  Batch No.	Invoice No.	Date of approval by DRAP	
		WT-20200328- D02-WT03-11C	21ATGZ041	28-04-2021	
		Metformin HCl:			
		Batch No.	Invoice No.	Date of approval by DRAP	
		A-32612104081- 0150	JC202105010-1	05-07-2021	
4.	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Firm has submitted d respective documents summary data sheets.			
5.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing.	Firm has submitted co audit trail reports on pr		HPLC software and	
6.	Record of Digital data logger for temperature & humidity monitoring of stability chambers	Firm has submitted rec humidity monitoring accelerated)			
	(real time and accelerated)				

The firm has submitted the following documents as per WHO TRS 981,2013 (47<sup>th</sup> report, Annex 3) and SOP for approval of post-registration variations approved in 283<sup>rd</sup> DRB meeting:

- Stability Data of 03 batches till shelf life plus 1 year manufactured at their existing facility located at Plot No. 29 30, Sector 27, Korangi Industrial Area.
- Stability Data of 2 stability batches (till 3<sup>rd</sup> month time point) from new facility located at Plot No. 01, Sector 25, Korangi Industrial Area as per Guidance Document for Submission of Application on Form 5-F (CTD) for registration of pharmaceutical drug products for human use issued in October, 2020.
- Comparative Dissolution Profile and Pharmaceutical Equivalence studies of the product with the innovator from existing manufacturing facility & also submitted Comparative Dissolution Profile against innovator from new manufacturing facility.
- Comparative batch analysis data on two batches from the new facility and comparative data on the last three batches from the existing facility.
- Executed Production document of stability batch.

Process Validation Protocol from new site. Undertakings in accordance with SOP for approval of post-registration variations by DRAP. Analytical Method Verification studies of API & Finished product. Valid DML/GMP Certificate of the API manufacturers. M/s Getz Pharma (Pvt.) Ltd. Name, address of Applicant / Plot No. 01, Sector 25, Korangi Industrial Area, Karachi Pakistan Marketing Authorization Holder. Name, address of Manufacturing M/s Getz Pharma (Pvt.) Ltd. Plot No. 01, Sector 25, Korangi Industrial Area, Karachi Pakistan Status of the applicant ☐ Importer ☐ Is involved in none of the above (contract giver) GMP Status of the firm Firm has been granted Drug Manufacturing License (DML 000933) by way of formulation dated 25-05-2021. Firm has been granted Drug Manufacturing License (DML 000933) Evidence of approval of manufacturing facility by way of formulation dated 25-05-2021, with approved Tablets, Capsules & Dry Powder Suspension sections. Status of application ☐ New Drug Product (NDP) ☑ Generic Drug Product (GDP) Intended use of pharmaceutical ☐ Domestic sale product ☐ Export sale □ Domestic and Export sales Dy. No. and date of submission Dy. No.: 5422/R&I dated 25-02-2022 PKR 30,000/-: 28-01-2022 Details of fee submitted The proposed proprietary name / Zetro Tablets 500mg brand name Strength / concentration of drug of Each film-coated tablet contains: Active Pharmaceutical ingredient Azithromycin USP... 500mg (API) per unit (as dihydrate) Pharmaceutical form of applied drug Film-coated Tablets Pharmacotherapeutic Group of (API) Antibacterial for systemic use: Macrolides Reference to Finished product **USP Specifications** specifications Proposed Pack size 3's and 6's 203.67 for 3's and 407.62 for 6's Proposed unit price The status in reference regulatory Zithromax Tablets 500mg approved by US-FDA manufactured by authorities Pfizer USA For generic drugs (me-too status) Zerto Tablets 500mg (Reg. No.: 053120) manufactured by M/s Getz Pharma (Pvt.) Limited Plot No. 29-30, Sector 27, Korangi Industrial Area, Karachi Name and address of API M/s. Zhejiang Guobang Pharmaceutical Co., Ltd. located at No. 6, Weiwu Road, Hangzhou Gulf Shangyu Economic and manufacturer. Technological Development Zone, Zhejiang, P. R. China. Firm has submitted OOS as per WHO OOS-PD template. Firm has Module-II (Quality Overall summarized information related to nomenclature, structure, general Summary) properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product. Module-III Drug Substance: Firm has submitted detailed data for drug substance data related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance. Stability Studies of Drug Substance Firm has submitted stability study data of 3 batches of drug (Conditions & duration of Stability substance at both accelerated as well as real time conditions. The studies) accelerated stability data is conducted at  $40^{\circ}\text{C} \pm 2^{\circ}\text{C} / 75\% \pm 5\%$ RH for 6 months. The real time stability data is conducted at 30°C

		$\pm 2^{\circ}$ C / 75 $\pm 5\%$ RH for	60 months.	
	Module-III Drug Product:  Pharmaceutical Equivalence and Comparative Dissolution Profile	Firm has submitted data composition, pharma manufacturing process protocols, control of specifications, analytic procedures, batch analysistandard or materials, constant of the standard or materials, constant or ma	a of drug product include accutical development and process control, excipients, control all procedures, validates is, justification of speciporation of speciporation of the control in t	nt, manufacture, process validation of drug product, tion of analytical fications, reference and stability.  ial Area, Karachi arative Dissolution be reference product mediums has been
		Plot No. 01, Sector 25 I Facility)	Korangi Industrial Are	a, Karachi (New
		Firm has also submitted	the Comparative Dissolu	ution Profile studies
		of Zetro Tablets 500m	g against the reference	e product Azomax
		Tablets 500mg in routin	e release Medium with	acceptable level of
	Analytical method validation/	f2 results. Firm has submitted veri	ification studies of the	drug substance and
	verification of product	drug product.		arug suesianee and
	Stability studies	Firm has submitted stat		
		accelerated and long term studies data of two bate		
		(both accelerated and los		
	STABILITY STUDY DATA (Plot	No. 29-30, Sector 27, Ko	orangi Industrial Area,	, Karachi)
Man	ufacturer of APIs	M/s. Zhejiang Guobang Weiwu Road, Hang Technological Developr	zhou Gulf Shangyu	Economic and
		M/s. Ningxia Qiyuan F Qiyuan Street, Wangyan	Industrial Area, Yinchu	
	Lot No.	0000138038, 000014217	77	
	cription of Pack ntainer closure system)	Alu-Alu blister		
	ility Storage Condition	Real time: $30^{\circ}\text{C} \pm 2^{\circ}\text{C}$ / Accelerated: $40^{\circ}\text{C} \pm 2^{\circ}\text{C}$		
Time	e Period	Real time: 36 months Accelerated: 6 months		
Frea	uency	Accelerated: 0, 3, 6 (Mo	,	
	h No.	Real Time: 0, 3, 6, 9, 12 118F46	, 18, 24, 36 (Months) 119F46	120F46
	h Size	150,000 Tablets	150,000 Tablets	150,000 Tablets
Man	ufacturing Date	20.12.2017	20.12.2017	18.01.2018
	of initiation	08.03.2018	08.03.2018	08.03.2018
No.	of Batches  DOCUMENTS / DATA TO BE P	 ROVIDED AT ONG WI'	03 TH STARILITY STU	OV DATA
1.	Reference of previous approval of	Firm has referred to ons		
	applications with stability study data	(Ebastine) tablets 10mg	& 20mg which was cond	ducted on 06th May,
	of the firm (if any)	2019 and was presented		
	the firm (if any)	on 14 <sup>th</sup> -16 <sup>th</sup> May, 2019 were confirmed.	. According to the repo	ore following points
		• The firm has 21 CFR c		e
		• The firm has audit trail	•	
2.	Approval of API/ DML/GMP	• The firm possesses stall Copy of GMP certifications		
۷.	certificate of API manufacturer issued	Administration is valid t		

	by concerned regulatory authority of country of origin.	2024. Copy of	Zhejiang Medical Products Administration valid till December 08, 2024. Copy of GMP certificate issued by Ningxia Food and Drug Administration is valid till April 16, 2023. Copy of commercial invoice attested by AD I&E DRAP, Karachi,					
3.	Documents for the procurement of API with approval from DRAP (in case of		comme	ercial invo			EE DRAP, Kai	rachi,
	import).	Azithron	nycin:					
		Batch	No.		ce No.	Quantit Importe	ed approv	al
		000013			017-0940	500 Kg		
		000014	21//	2017	09083	500 Kg	g 05.10.20	)1 /
4.	Data of stability batches will be							
	supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	respectiv	Firm has submitted data of stability batches along with attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets.					
5.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing.	Firm has	submit	tted compl	iance certifi	cate of HI	PLC software.	
6.	Record of Digital data logger for temperature & humidity monitoring of stability chambers (real time and accelerated)		mon				r for temperatus (real time	
	STABILITY STUDY DATA (Pl							
Man	ufacturer of APIs	Weiwu	Road,	Hangzh		Shangyu	td. located at N  Economic  R. China.	No. 6, and
API	Lot No.	129-2101			, ,	J . 87		
	cription of Pack ntainer closure system)	Alu-Alu	blister					
Stab	ility Storage Condition	Accelerat	ted: 40	$^{\circ}$ C $\pm$ 2 $^{\circ}$ C /	5% ± 5%RH 75% ± 5%I			
Time	e Period	Real Tim	ne: 0, 3	3 (Months) (Months)				
Freq	uency	Real Tim	ne: 0, 3,		8, 24, 36 (N			
	h No.		2ES01		032ES		-	
	h Size		00 Tabl		10,000 T		-	
	ufacturing Date of initiation		$\frac{09.202}{10.202}$		17.09.2 05.10.2			
	of Batches	03.	10.202	1	03.10.2	W41		
_ , , ,	DOCUMENTS / DATA TO BE P	ROVIDEI	) ALO	NG WITH		TY STUI	DY DATA	
1.	Reference of previous approval of applications with stability study data of the firm (if any)							
2.	Approval of API/ DML/GMP	Copy of	GMP	certificate	issued by	National	Medical Pro	ducts
	certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Administ	tration	is valid till	29-11-2024	and Cop	y of DML issu d till December	ed by
3.	Documents for the procurement of API with approval from DRAP (in case of import).	Copy of i	29 – 3	30, sector		gi Industr	Pvt) Limited rial Area, Kaubmitted.	rachi
	•		Batc	h No.	Invoice		Date of approval by DRAP	
			129-21	0133-1	21ATGZ		02.03.2021	

4.	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Firm has submitted data of stability batches along with attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets.
5.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing.	Firm has submitted compliance certificate of HPLC software.
6.	Record of Digital data logger for temperature & humidity monitoring of stability chambers (real time and accelerated)	Firm has submitted record of digital data logger for temperature & humidity monitoring of stability chambers (real time and accelerated)

The firm has submitted the following documents as per WHO TRS 981,2013 (47<sup>th</sup> report, Annex 3) and SOP guidelines stated in 283<sup>rd</sup> DRB meeting minutes:

- Stability Data of 03 batches till shelf life manufactured at their existing facility located at Plot No. 29 30, Sector 27, Korangi Industrial Area.
- Stability Data of 02 stability batches at 0 and 3<sup>rd</sup> month interval have also been submitted by manufacturer from new facility located at Plot No. 01, Sector 25, Korangi Industrial Area as per Guidance Document for Submission of Application on Form 5-F (CTD) for registration of pharmaceutical drug products for human use issued in October, 2021.
- Comparative Dissolution Profile and Pharmaceutical Equivalence studies of the product with the innovator from existing manufacturing facility & also submitted Comparative Dissolution Profile against innovator from new manufacturing facility.
- Comparative batch analysis data on two batches from the new facility and comparative data on the last three batches from the existing facility.
- Firm has submitted Executed Production document of stability batch.
- Firm has submitted Process Validation Protocol.
- Firm has submitted undertakings that process validation, accelerated and real time stability studies on 03 commercial batches at new manufacturing facility will be conducted & in case of any quality complaint / OOS result as a result of this change, the same shall be reported to registration board and all the stock shall be recalled from the market immediately.
- Analytical Method Verification / validation studies of API & Finished product.
- Valid GMP/DML of the API manufacturer submitted.

8.	Name, address of Applicant /	M/s Getz Pharma (Pvt.) Ltd. Plot No. 01, Sector 25, Korangi Industrial
	Marketing Authorization Holder.	Area, Karachi Pakistan
	Name, address of Manufacturing	M/s Getz Pharma (Pvt.) Ltd. Plot No. 01, Sector 25, Korangi Industrial
	site.	Area, Karachi Pakistan
	Status of the applicant	✓ Manufacturer
		☐ Importer
		☐ Is involved in none of the above (contract giver)
	GMP Status of the firm	Firm has been granted Drug Manufacturing License (DML 000933) by way of formulation dated 25-05-2021.
	Evidence of approval of manufacturing facility	Firm has been granted Drug Manufacturing License (DML 000933) by way of formulation dated 25-05-2021, with approved Tablets, Capsules & Dry Powder Suspension sections.
	Status of application	☐ New Drug Product (NDP)
		☐ Generic Drug Product (GDP)
	Intended use of pharmaceutical	☐ Domestic sale
	product	☐ Export sale
		☐ Domestic and Export sales
	Dy. No. and date of submission	Dy. No.: 5425/R&I dated 25-02-2022
	Details of fee submitted	PKR 30,000/-: 28-01-2022
	The proposed proprietary name / brand name	Vonozan Tablets 10mg
	Strength / concentration of drug	
	of	Each film-coated tablet contains:
	Active Pharmaceutical ingredient	Vonoprazan Fumarate equivalent to Vonoprazan 10mg
	(API) per unit	
	Pharmaceutical form of applied drug	Film-coated Tablets

	Pharmacotherapeutic Group of (API)	Proton Pump Inhibitor
	Reference to Finished product specifications	Getz Pharma Specifications
	Proposed Pack size	1x7 (7's), 2x7 (14's) & 4x7 (28's)
	Proposed unit price	Rs. 1306.80/-(7's), Rs.2613.80/- (14's) & Rs. 5227.20/- (28's)
•	The status in reference	"Takecab Tablets 10mg" Approved by PMDA - Pharmaceuticals and
	regulatory authorities	Medical Devices Agency
	For generic drugs (me-too status)	Vonozan Tablets 10mg (Reg. No.: 108570) manufactured by M/s Getz Pharma (Pvt.) Limited Plot No. 29 -30, Sector 27, Korangi Industrial Area, Karachi
	Name and address of API	Jiangsu Yongan Pharmaceutical Co., Ltd. – China
	manufacturer.	No. 18,237 provincial highway, Jiangsu Huai'an Economic Development, China.
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Firm has summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and
1		stability studies of drug substance and drug product.
	Module-III Drug Substance:	Firm has submitted detailed data for drug substance related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure
		system and stability studies of both drug substances.
	Stability Studies of Drug	Firm has submitted stability study data of 3 batches of drug substance at
	Substance (Conditions & duration of Stability studies)	both accelerated as well as real time conditions. The accelerated stability data is conducted at $40^{\circ}\text{C} \pm 2^{\circ}\text{C} / 75\% \pm 5\%$ RH for 6 months. The real time stability data is conducted at $30^{\circ}\text{C} \pm 2^{\circ}\text{C} / 65 \pm 5\%$ RH for 24 months.
	Module-III Drug Product:	Firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability studies.
	Pharmaceutical Equivalence and Comparative Dissolution Profile	Getz Pharma (Pvt) Limited Plot no. 29 – 30, Sector 27, Korangi Industrial Area, Karachi Pharmaceutical Equivalence Studies & Comparative Dissolution Profile studies of Vonozan Tablets 10mg against the reference product Vocinti Tablets 10mg, in three dissolution mediums wherein more than 85% of
		drug is released in 15 minutes.  Getz Pharma (Pvt) Limited Plot No. 01, Sector 25 Korangi Industrial Area, Karachi Firm has also submitted the Comparative Dissolution Profile studies of Vonozan Tablets 10mg (new site) against the reference product Vonozan Tablets 10mg (existing site) in Routine Release Medium wherein more than 85% of drug is released in 15 minutes.
	Analytical method validation /	Firm has submitted verification studies of the drug substance & drug
	verification of product	product.
	Stability studies	Firm has submitted stability studies data of three batches at both accelerated and long-term conditions from existing site and stability studies data of two batches till 6 <sup>th</sup> month time interval (both accelerated and long-term conditions) from new site.
	STABILITY STUDY DATA (1	Plot No. 29-30, Sector 27, Korangi Industrial Area, Karachi)
Manu	ifacturer of APIs	Jiangsu Yongan Pharmaceutical Co., Ltd. No. 18,237 provincial highway, Jiangsu Huai'an Economic Development, China.

	Lot No.	182771, 190314	, 191301		
	cription of Pack ntainer closure system)	Alu-PVDC bliste	er		
,	pility Storage Condition		± 2°C / 75% ± 5%RH		
Diac	Shirty Storage Condition		$^{\circ}$ C $\pm$ 2 $^{\circ}$ C / 75% $\pm$ 5%R nths for batch# 001FF		shile only 2 month
Tim	ne Period		ibmitted for batch# 00		mile omy 3 monui
		Accelerated: 6 n			
Free	quency	Accelerated: 0, 3 Real Time: 0, 3,			
Bate	ch No.	001FF8	002F	F8	003FF8
	ch Size	250,000 Tabl			250,000 Tablets
	nufacturing Date e of initiation	03.05.2021 30.06.2021			02.07.2021 14.09.2021
	of Batches	30.00.2021	03	.021	14.09.2021
110.	DOCUMENTS / DATA TO B	E PROVIDED A		ILITY STUD	Y DATA
1.	Reference of previous approval of				
	applications with stability study		ts 10mg & 20mg wh		
	data of the firm (if any)	2019 and was pr	resented in 289 <sup>th</sup> meet 2019. According to	ing of Registra the report follo	owing points were
	the min (n any)	confirmed.	2019. Recording to	ine report for	owing points were
			m has 21 CFR compli		ware
			m has audit trail repor m possesses stability c		digital data laggara
2.	Approval of API/ DML/GMP		tted copy of DML (Ce		
_,	certificate of API manufacturer	by Jiangsu Drug	Administration, issue		
	issued by concerned regulatory authority of country of origin.	December 06, 20	025.		
3.	Documents for the procurement	Copy of comme	ercial invoice attested	by AD I&E D	RAP, Karachi, has
	of API	been submitted.			
	with approval from DRAP (in case of				Date of
	import).	Batch No.	Invoice No.	Quantity Imported	annroval
		20201003	JXCAVIR-200904	17 kg	21-10-2020
4.	Data of stability batches will be				
4.	supported by attested respective	Firm has subm	nitted data of stabili	tv batches al	2.1
	documents like chromatograms,				ong with attested
	Dani data abasta COA ammana	respective docu	ments like chromato		
	Raw data sheets, COA, summary	summary data sh			
5	data sheets etc.	summary data sh	heets.	grams, Raw o	data sheets, COA,
5.		summary data sh Firm has submit	tted compliance certific	grams, Raw o	data sheets, COA,
	data sheets etc.  Compliance Record of HPLC software 21CFR & audit trail reports on product testing.	summary data sh	tted compliance certific	grams, Raw o	data sheets, COA,
<ul><li>5.</li><li>6.</li></ul>	data sheets etc.  Compliance Record of HPLC software 21CFR & audit trail reports on product testing.  Record of Digital data logger for	summary data sh Firm has submit trail reports on p	tted compliance certifications testing.	grams, Raw of	data sheets, COA, software and audit
	data sheets etc.  Compliance Record of HPLC software 21CFR & audit trail reports on product testing.  Record of Digital data logger for temperature & humidity	Firm has submit trail reports on p	tted compliance certification testing.	grams, Raw of cate of HPLC	data sheets, COA, software and audit for temperature &
	data sheets etc.  Compliance Record of HPLC software 21CFR & audit trail reports on product testing.  Record of Digital data logger for temperature & humidity monitoring of stability chambers (real time and accelerated)	Firm has submit trail reports on p  Firm has submit humidity monitor	tted compliance certificated testing.  itted record of digital oring of stability cham	grams, Raw of cate of HPLC data logger bers (real time	software and audit for temperature & and accelerated)
	data sheets etc.  Compliance Record of HPLC software 21CFR & audit trail reports on product testing.  Record of Digital data logger for temperature & humidity monitoring of stability chambers	Firm has submit trail reports on p  Firm has submit humidity monitor	tted compliance certificated testing.  itted record of digitated oring of stability chameter 25 Korangi Indu	grams, Raw of cate of HPLC data logger bers (real time	software and audit for temperature & and accelerated)
6.	data sheets etc.  Compliance Record of HPLC software 21CFR & audit trail reports on product testing.  Record of Digital data logger for temperature & humidity monitoring of stability chambers (real time and accelerated)	Firm has submit trail reports on p  Firm has submit humidity monitor  (Plot No. 01, Sec Jiangsu Yongan No. 18,237	tted compliance certificated record of digital oring of stability chame to the compliance of the complex of the	grams, Raw of cate of HPLC data logger bers (real time strial Area, Kenton Ltd. – China	software and audit for temperature & and accelerated)  Carachi)
6.	data sheets etc.  Compliance Record of HPLC software 21CFR & audit trail reports on product testing.  Record of Digital data logger for temperature & humidity monitoring of stability chambers (real time and accelerated)  STABILITY STUDY DATA nufacturer of APIs	Firm has submit trail reports on p  Firm has submit humidity monitor  (Plot No. 01, Sec Jiangsu Yongan No. 18,237 p Development, C	tted compliance certificated record of digital oring of stability chame to the compliance of the complex of the	grams, Raw of cate of HPLC data logger bers (real time strial Area, Kenton Ltd. – China	software and audit for temperature & and accelerated)  Carachi)
6. Mai	data sheets etc.  Compliance Record of HPLC software 21CFR & audit trail reports on product testing.  Record of Digital data logger for temperature & humidity monitoring of stability chambers (real time and accelerated)  STABILITY STUDY DATA nufacturer of APIs  Lot No.	Firm has submit trail reports on p  Firm has submit humidity monitor  (Plot No. 01, Sec Jiangsu Yongan No. 18,237 p Development, C 20210610	tted compliance certificated record of digital oring of stability chame ctor 25 Korangi Indu Pharmaceutical Co., I provincial highway, China.	grams, Raw of cate of HPLC data logger bers (real time strial Area, Kenton Ltd. – China	software and audit for temperature & and accelerated)  Carachi)
6.  Mai	data sheets etc.  Compliance Record of HPLC software 21CFR & audit trail reports on product testing.  Record of Digital data logger for temperature & humidity monitoring of stability chambers (real time and accelerated)  STABILITY STUDY DATA nufacturer of APIs  Lot No. cription of Pack	Firm has submit trail reports on p  Firm has submit humidity monitor  (Plot No. 01, Sec Jiangsu Yongan No. 18,237 p Development, C	tted compliance certificated record of digital oring of stability chame ctor 25 Korangi Indu Pharmaceutical Co., I provincial highway, China.	grams, Raw of cate of HPLC data logger bers (real time strial Area, Kenton Ltd. – China	software and audit for temperature & and accelerated)  Carachi)
6.  Mai API Des (Co	data sheets etc.  Compliance Record of HPLC software 21CFR & audit trail reports on product testing.  Record of Digital data logger for temperature & humidity monitoring of stability chambers (real time and accelerated)  STABILITY STUDY DATA nufacturer of APIs  Lot No.  cription of Pack ntainer closure system)	Firm has submit trail reports on p  Firm has submit humidity monito  (Plot No. 01, Sec Jiangsu Yongan No. 18,237 p Development, C 20210610  Alu-PVDC blister Real time: 30°C	tted compliance certificated record of digital pring of stability chame to the compliance of the complete of t	grams, Raw of cate of HPLC  data logger bers (real time strial Area, Kanal Langsu Hangsu Hang	software and audit for temperature & and accelerated)  Carachi)
6.  Mai API Des (Co	data sheets etc.  Compliance Record of HPLC software 21CFR & audit trail reports on product testing.  Record of Digital data logger for temperature & humidity monitoring of stability chambers (real time and accelerated)  STABILITY STUDY DATA nufacturer of APIs  Lot No. cription of Pack	Firm has submit trail reports on p  Firm has submit humidity monito  (Plot No. 01, Sec Jiangsu Yongan No. 18,237 p Development, C 20210610  Alu-PVDC blistor Real time: 30°C Accelerated: 40°	tted compliance certificated record of digital pring of stability chame etor 25 Korangi Indu Pharmaceutical Co., I provincial highway, China.	grams, Raw of cate of HPLC  data logger bers (real time strial Area, Kanal Langsu Hangsu Hang	software and audit for temperature & and accelerated)  Carachi)
6.  Man API Des (Co	data sheets etc.  Compliance Record of HPLC software 21CFR & audit trail reports on product testing.  Record of Digital data logger for temperature & humidity monitoring of stability chambers (real time and accelerated)  STABILITY STUDY DATA nufacturer of APIs  Lot No.  cription of Pack ntainer closure system)	Firm has submit trail reports on p  Firm has submit humidity monito  (Plot No. 01, Sec Jiangsu Yongan No. 18,237 p Development, C 20210610  Alu-PVDC blistor Real time: 30°C Accelerated: 40° Real time: 0, 3, 6	tted compliance certificated record of digital pring of stability chame etor 25 Korangi Indu Pharmaceutical Co., I provincial highway, China.  etro 25 Korangi Indu Pharmaceutical Co., I provincial highway, China.	grams, Raw of cate of HPLC  data logger bers (real time strial Area, Kanal Langsu Hangsu Hang	software and audit for temperature & and accelerated)  Carachi)
6.  Man API Des (Co Stab	data sheets etc.  Compliance Record of HPLC software 21CFR & audit trail reports on product testing.  Record of Digital data logger for temperature & humidity monitoring of stability chambers (real time and accelerated)  STABILITY STUDY DATA nufacturer of APIs  Lot No.  cription of Pack ntainer closure system)  bility Storage Condition	Firm has submit trail reports on p  Firm has submit humidity monito  (Plot No. 01, Sec Jiangsu Yongan No. 18,237 p Development, C 20210610  Alu-PVDC blistor Real time: 30°C Accelerated: 40°	tted compliance certificated record of digital pring of stability chame etor 25 Korangi Indu Pharmaceutical Co., I provincial highway, China.  et 2°C / 75% ± 5%RH eC ± 2°C / 75% ± 5%RH foc ± 5%RH fo	grams, Raw of cate of HPLC  data logger bers (real time strial Area, Kanal Langsu Hangsu Hang	software and audit for temperature & and accelerated)  Carachi)

		Real Time: 0, 3, 6, 9,	12, 18, 24 months		
Bate	ch No.	036ES01	036ES02	-	
Bate	ch Size	10,000 Tablets	10,000 Tablets	-	
Mar	nufacturing Date	21.09.2021	21.09.2021	-	
Date	e of initiation	11-10-2021	1-10-2021 11-10-2021 -		
No. of Batches			02		
	DOCUMENTS / DATA TO B	E PROVIDED ALON	G WITH STABILITY	STUDY DATA	
1.	Reference of previous approval of applications with stability study data of the firm (if any)				
2.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Firm has submitted copy of DML (Certificate No. Su 20160324 issued by Jiangsu Drug Administration, issued on December 07, 2020 valid till December 06, 2025.			
3.	Documents for the procurement of API with approval from DRAP (in case of import).	Copy of invoice attested by AD I&E DRAP, Karachi, has been submitted.			
		Batch No.	Invoice No.	Date of approval by DRAP	
		20210610	JXCAVIR-210601	25-06-2021	
4.	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Firm has submitted data of stability batches along with attested respective documents like chromatograms, Raw data sheets, COA,			
5.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing.	Firm has submitted compliance certificate of HPLC software and audit trail reports on product testing.			
6.	Record of Digital data logger for temperature & humidity monitoring of stability chambers	Firm has submitted record of digital data logger for temperature & humidity monitoring of stability chambers (real time and accelerated)			

#### **Miscellaneous documents:**

The firm has submitted the following documents as per WHO TRS 981,2013 ( $47^{th}$  report, Annex 3) and SOP for approval of post-registration variations approved in  $283^{rd}$  DRB meeting:

- Stability Data of 02 batches till 06 months & till month of 1 batch has been submitted, manufactured at their existing facility located at Plot No. 29 30, Sector 27, Korangi Industrial Area.
- Stability Data of 2 stability batches (till 6<sup>th</sup> month time point) from new facility located at Plot No. 01, Sector 25, Korangi Industrial Area as per Guidance Document for Submission of Application on Form 5-F (CTD) for registration of pharmaceutical drug products for human use issued in October, 2020.
- Comparative Dissolution Profile and Pharmaceutical Equivalence studies of the product with the innovator from existing manufacturing facility & also submitted Comparative Dissolution Profile against innovator from new manufacturing facility.
- Comparative batch analysis data on two batches from the new facility and comparative data on the last three batches from the existing facility.
- Executed Production document of stability batch.
- Process Validation Protocol from new site.
- Undertakings in accordance with SOP for approval of post-registration variations by DRAP.
- Analytical Method Verification studies of API & Finished product.
- Valid DML of the API manufacturer.

9.	Name, address of Applicant /	M/s Getz Pharma (Pvt.) Ltd.		
	Marketing Authorization Holder.	Plot No. 01, Sector 25, Korangi Industrial Area, Karachi Pakistan		
	Name, address of Manufacturing	M/s Getz Pharma (Pvt.) Ltd.		
	site.	Plot No. 01, Sector 25, Korangi Industrial Area, Karachi Pakistan		
	Status of the applicant			
		□ Importer		
		☐ Is involved in none of the above (contract giver)		
	GMP Status of the firm	Firm has been granted Drug Manufacturing License (DML 000933)		
		by way of formulation dated 25-05-2021.		

Evidence of approval of	Firm has been granted Drug Manufacturing License (DML 000933
manufacturing facility	by way of formulation dated 25-05-2021, with approved Tablets Capsules & Dry Powder Suspension sections.
Status of application	☐ New Drug Product (NDP)
	☑ Generic Drug Product (GDP)
Intended use of pharmaceutical	☐ Domestic sale
product	□ Export sale
	☐ Domestic and Export sales
Dy. No. and date of submission	Dy. No.: 5426/R&I dated 25-02-2022
Details of fee submitted	PKR 30,000/-: 28-01-2022
The proposed proprietary name / brand name	Vonozan Tablets 20mg
Strength / concentration of drug of	F. 1. Classes de la la contra de la contra del la contra del la contra del la contra de la contra del la contra de la contra de la contra del la contra de la contra del la contra del la contra de la contra del la co
Active Pharmaceutical ingredient	Each film-coated tablet contains:
(API) per unit	Vonoprazan Fumarate equivalent to Vonoprazan 20mg
Pharmaceutical form of applied drug	Film coated Tablets
Pharmacotherapeutic Group of (API)	Proton Pump Inhibitor
Reference to Finished product specifications	Getz Pharma Specifications
Proposed Pack size	1x7 (7's), 2x7 (14's) & 4x7 (28's)
Proposed unit price	Rs. 1902.48/-(7's), Rs.3806.06/- (14's) & Rs. 7612.11/- (28's)
The status in reference regulatory	"Takecab Tablets 20mg" Approved by PMDA - Pharmaceuticals at
authorities	Medical Devices Agency
For generic drugs (me-too status)	Vonozan Tablets 20mg (Reg. No.: 108571) manufactured by M Getz Pharma (Pvt.) Limited Plot No. 29 -30, Sector 27, Koran Industrial Area, Karachi
Name and address of API	Jiangsu Yongan Pharmaceutical Co., Ltd. – China
manufacturer.	No. 18,237 provincial highway, Jiangsu Huai'an Econom
	Development, China.
Module-II (Quality Overall	Firm has submitted QOS as per WHO QOS-PD template. Firm h
Summary)	summarized information related to nomenclature, structure, gener
	properties, solubilities, physical form, manufacturers, description
	manufacturing process and controls, impurities, specification
	analytical procedures and its validation, batch analysis ar
	justification of specification, reference standard, container closu
	system and stability studies of drug substance and drug product.
Module-III Drug Substance:	Firm has submitted detailed data for drug substance related
	nomenclature, structure, general properties, solubilities, physic
	form, manufacturers, description of manufacturing proces
	impurities, specifications, analytical procedures and its validatio
	batch analysis and justification of specification, reference standar
	container closure system and stability studies of both drug substance
Stability Studies of Drug	Firm has submitted stability study data of 3 batches of drug substan-
Substance	at both accelerated as well as real time conditions. The accelerate
(Conditions & duration of Stability	stability data is conducted at $40^{\circ}\text{C} \pm 2^{\circ}\text{C} / 75\% \pm 5\%$ RH for
studies)	months. The real time stability data is conducted at $30^{\circ}\text{C} \pm 2^{\circ}\text{C}$ / 6
	± 5% RH for 24 months.
Module-III Drug Product:	Firm has submitted data of drug product including its description
	composition, pharmaceutical development, manufactur
	manufacturing process and process control, process validation
	control of excipients, control of drug product, specification
	analytical procedures, validation of analytical procedures, bate
	analysis, justification of specifications, reference standard
79	materials, container closure system and stability studies.
Pharmaceutical Equivalence and	Getz Pharma (Pvt) Limited
Comparative Dissolution Profile	Plot no. 29 – 30, Sector 27, Korangi Industrial Area, Karachi
	Pharmaceutical Equivalence Studies & Comparative Dissolution
	Profile studies of Vonozan Tablets 20mg against the reference

			product Vocinti Tablets 20mg, in three dissolution mediums wherein more than 85% of drug is released in 15 minutes.			
		Getz Pharma (Pvt) Limited Plot No. 01, Sector 25 Korangi Industrial Area, Karachi Firm has also submitted the Comparative Dissolution Profile studies of Vonozan Tablets 20mg (new site) against the reference product Vonozan Tablets 20mg (existing site) in Routine Release Medium wherein more than 85% of drug is released in 15 minutes.				
	Analytical method validation / verification of product	Firm has submitted verification studies of the drug substance & drug product.				
	Stability studies	accelerated and lon studies data of ty	Firm has submitted stability studies data of three batches at both accelerated and long term conditions from existing site and stability studies data of two batches till 6 <sup>th</sup> month time interval (both accelerated and long term conditions) from new site.			
	STABILITY STUDY DATA (Plo					
Manı	ufacturer of APIs	Jiangsu Yongan Ph No. 18,237 prov Development, Chin	armaceutical C rincial highwa a.	o., Ltd. – Chi		
	Lot No.	182771, 190314, 19	91302, 191303			
	ription of Pack tainer closure system)	Alu-PVDC blister				
Stabi	lity Storage Condition	Real time: 30°C ± 2 Accelerated: 40°C =	± 2°C / 75% ± 5	%RH		
Time Period		Real time: 6 months for batch# 001FF9 & 002FF9 while only 3-month data has been submitted for batch# 003FF9.  Accelerated: 6 months				
Frequ	uency	Accelerated: 0, 3, 6 (Months) Real Time: 0, 3, 6, 9, 12, 18, 24 (Months)				
Batcl		001FF9		FF9	003FF9	
	n Size	300,000 Tablets		) Tablets	300,000 Tablets	
	ufacturing Date	03.05.2021		5.2021	02.07.2021	
	of initiation	30.06.2021		5.2021	14-09.2021	
No. 0	of Batches	DDOVIDED AT ON	O WITH STA		IDV DATA	
1.	Reference of previous approval of applications with stability study data of the firm (if any)					
2.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Firm has submitted copy of DML (Certificate No. Su 20160324 issued by Jiangsu Drug Administration, issued on December 07, 2020 valid till December 06, 2025.				
3.	Documents for the procurement of API with approval from DRAP (in case	Copy of commercial invoice attested by AD I&E DRAP, Karachi, has been submitted.				
	of import).	Batch No.	Invoice No.	Quantity Imported		
		20201003	JXCAVIR- 200904	17 kg	21-10-2020	
		20201003		17 kg	2	

4.	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Firm has submitted data of stability batches along with attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets.			
5.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing.	Firm has submitted compliance certificate of HPLC software and audit trail reports on product testing.			
6.	Record of Digital data logger for temperature & humidity monitoring of stability chambers (real time and accelerated)	humidity monitoring o	of stability chambers (re	gger for temperature & al time and accelerated)	
	STABILITY STUDY DATA (I				
	ufacturer of APIs	No. 18,237 province Development, China.	naceutical Co., Ltd. – C cial highway, Jiangs	China u Huai'an Economic	
	Lot No.	20210610			
	cription of Pack ntainer Closure System)	Alu-PVDC blister			
	ility Storage Condition	Real time: 30°C ± 2°C Accelerated: 40°C ± 2			
Tim	e Period	Real Time: $0, 3, 6 \text{ mo}$ Accelerated: $0, 3, 6 \text{ mo}$	nths		
Fred	uency	Accelerated: 0, 3, 6 m			
	<u> </u>	Real Time: 0, 3, 6, 9,			
	ch No.	037ES01	037ES02	-	
	ch Size	10,000 Tablets	10,000 Tablets	-	
	ufacturing Date e of initiation	22.09.2021 11.10.2021	22.09.2021 11.10.2021	-	
	of Batches	11.10.2021	02	-	
110.	DOCUMENTS / DATA TO BE	PROVIDED ALONG		TUDY DATA	
1.	Reference of previous approval of applications with stability study data of the firm (if any)				
2.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.		g Administration, issued	cate No. Su 20160324 d on December 07, 2020	
3.	Documents for the procurement of API with approval from DRAP (in case	Copy of invoice attesubmitted.	sted by AD I&E DR.	AP, Karachi, has been	
	of import.	Batch No.	Invoice No.	Date of approval by DRAP	
	•	20210610	JXCAVIR-210601	25-06-2021	
4.	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Firm has submitted data of stability batches along with attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets.			
5.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing.	I firm has submitted compliance certificate of HPLC software and I			
6.	Record of Digital data logger for temperature & humidity monitoring of stability chambers (real time and accelerated)				
	cellaneous documents:				
	firm has submitted the following documents of th			, Annex 3) and SOP for	
appr	approval of post-registration variations approved in 283 <sup>rd</sup> DRB meeting:				

- Stability Data of 02 batches till 06 months & till month of 1 batch has been submitted, manufactured at their existing facility located at Plot No. 29 30, Sector 27, Korangi Industrial Area.
- Stability Data of 2 stability batches (till 6<sup>th</sup> month time point) from new facility located at Plot No. 01, Sector 25, Korangi Industrial Area as per Guidance Document for Submission of Application on Form 5-F (CTD) for registration of pharmaceutical drug products for human use issued in October, 2020.
- Comparative Dissolution Profile and Pharmaceutical Equivalence studies of the product with the innovator from existing manufacturing facility & also submitted Comparative Dissolution Profile against innovator from new manufacturing facility.
- Comparative batch analysis data on two batches from the new facility and comparative data on the last three batches from the existing facility.
- Executed Production document of stability batch.
- Process Validation Protocol from new site.
- Undertakings in accordance with SOP for approval of post-registration variations by DRAP.
- Analytical Method Verification studies of API & Finished product.
- Valid DML of the API manufacturer.

10.	Name, address of Applicant / Marketing	M/s Getz Pharma (Pvt.) Ltd.
	Authorization Holder.	Plot No. 01, Sector 25, Korangi Industrial Area, Karachi Pakistan
	Name, address of Manufacturing site.	M/s Getz Pharma (Pvt.) Ltd.
	_	Plot No. 01, Sector 25, Korangi Industrial Area, Karachi Pakistan
	Status of the applicant	☑ Manufacturer
		☐ Importer
		☐ Is involved in none of the above (contract giver)
	GMP Status of the firm	Firm has been granted Drug Manufacturing License (DML 000933)
		by way of formulation dated 25-05-2021.
	Evidence of approval of manufacturing	Firm has been granted Drug Manufacturing License (DML 000933)
	facility	by way of formulation dated 25-05-2021, with approved Tablets,
		Capsules & Dry Powder Suspension sections.
	Status of application	☐ New Drug Product (NDP)
		☐ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☐ Domestic sale
		☐ Export sale
		☑ Domestic and Export sales
	Dy. No. and date of submission	Dy. No. 5423/R&I dated 25-02-2022
	Details of fee submitted	PKR 30,000/-: 28-01-2022
	The proposed proprietary name / brand name	HCQ 200 Tablets 200mg
	Strength / concentration of drug of	Each film-coated tablet contains:
	Active Pharmaceutical ingredient	Hydroxychloroquine Sulfate BP 200mg
	(API) per unit	
	Pharmaceutical form of applied drug	Film-coated Tablets
	Pharmacotherapeutic Group of (API)	Antimalarial
	Reference to Finished product specifications	BP Specifications
	Proposed Pack size	30's
	Proposed unit price	413.26
	The status in reference regulatory	Hydroxychloroquine Sulfate Tablets 200mg approved by US-FDA
	authorities	manufactured by TEVA PHARMS.
	For generic drugs (me-too status)	HCQ 200 Tablets 200mg (Reg. No.: 045471) manufactured by M/s
		Getz Pharma (Pvt.) Limited Plot No. 29-30, Sector 27, Korangi Industrial Area, Karachi.
	Name and address of API manufacturer.	M/s. Chongqing Kangle Pharmaceutical Co., Ltd. located at No. 4,
	Name and address of ATT manufacturer.	HuaZhong Road, Chongqing (Changshou) Chemical Industrial
		Park, China.
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Firm has summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product.

	Module-III Drug Substance:		etailed data for drug sub	
			description of manufactures,	
			specifications, analytica	
			alysis and justification	
			ntainer closure system a	and stability studies of
	Callia Callia CD a Calarana	drug substance.		C 2 1 . ( . 1 C . 1
	Stability Studies of Drug Substance (Conditions & duration of Stability		stability study data o elerated as well as real	
	studies)		ata is conducted at 40°	
	studies)		real time stability data	
		$30^{\circ}\text{C} \pm 2^{\circ}\text{C} / 65 \pm 5\%$	RH for 24 months.	is come conducted at
	Module-III Drug Product:	Firm has submitted da	ata of drug product included maceutical developm	
			ss and process contro	
			of excipients, control	
			tical procedures, vali	
			lysis, justification of sp	
	Dharmanantiaal Equivalence and		container closure syster	n and stability.
	Pharmaceutical Equivalence and Comparative Dissolution Profile	Getz Pharma (Pvt) L	amnea ctor 27 Korangi Indus	strial Area Karachi
	Comparative Dissolution Frome	(Existing Facility)	tor 27 Korangi maa	striai mica, ixaracin
			valence Studies & Cor	nparative Dissolution
			Q 200 Tablets 200mg	
			lets 200mg, in three dis	
		been submitted with a	cceptable level of f2 res	sults.
		Getz Pharma (Pvt) L	imited	
		, ,	5 Korangi Industrial A	rea, Karachi (New
		Facility)		
			ed the Comparative Diss	
			00mg against the refere	
		Tablets 200mg in routine release Medium with acceptable level of f2 results.		
	Analytical method validation/		erification studies of th	e drug substance and
	verification of product	drug product.		
	Stability studies	Firm has submitted stability studies data of three batches at both		
		accelerated and long term conditions from existing site and stability		
		studies data of two batches at initial and 3 <sup>rd</sup> month time interval (both accelerated and long term conditions) from new site.		
	STABILITY STUDY DATA (Plot N		,	
			tle Pharmaceutical Co.,	
Manuf	acturer of APIs		nongqing (Changshou)	
		Park, China.	81 8 (= 8)	
API L		0000132453, 0000134222, 0000134224		
	ption of Pack iner closure system)	Alu-Alu blister		
Stabili	ty Storage Condition	Real time: $30^{\circ}\text{C} \pm 2^{\circ}\text{C}$		
		Accelerated: $40^{\circ}\text{C} \pm 2$	$^{\circ}$ C / 75% ± 5%RH	
Time I	Period	Real time: 36 months Accelerated: 6 months	•	
		Accelerated: 0, 3, 6 (N		
Freque	ency		12, 18, 24, 36 (Months)	
Batch No.		249F27	250F27	251F27
Batch		400,000 Tablets	400,000 Tablets	400,000 Tablets
	acturing Date	13.06.2017	19.06.2017	19.06.2017
	f initiation	25.08.2017	17.07.2017	17.07.2017
No. of	Batches  DOCUMENTS / DATA TO BE BRO	MIDED ALONG WA	O3	N DATA
	DOCUMENTS / DATA TO BE PRO	DVIDED ALONG WIT	.n Stability Stul	DY DATA

1.	Reference of previous approval of applications with stability study data of the firm (if any)	Firm has referred to onsite inspection report of their product Estine (Ebastine) tablets 10mg & 20mg which was conducted on 06 <sup>th</sup> May, 2019 and was presented in 289 <sup>th</sup> meeting of Registration Board held on 14 <sup>th</sup> -16 <sup>th</sup> May, 2019. According to the report following points were confirmed.  • The firm has 21 CFR compliant HPLC software  • The firm has audit trail reports available.  • The firm possesses stability chambers with digital data loggers.				
2.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Administration va	Copy of GMP certificate issued by China Food and Drug Administration valid till 03-06-2023 and Copy of DML issued by Chongqing Food and Drug Administration valid till October 13, 2025.			
3.	Documents for the procurement of API with approval from DRAP (in case of import).	Copy of recent in been submitted.	nvoice attested	by AD I&E	DRA	P, Karachi, has
		Batch No.	Invoice No	Quant Impor		Date of approval by DRAP
		12-SQKB- 201206 12-SQKB-	TM2021022 11613E TM2021022	3		Ţ.
		201207 12-SQKB- 201203	11613E TM2021022 11613E	1000 1	Kg	06.04.2021
<ol> <li>4.</li> <li>5.</li> </ol>	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.  Compliance Record of HPLC software 21CFR & audit trail reports on product	respective documents like chromatograms, Raw data sheets, COA, summary data sheets.			ta sheets, COA,	
6.	testing.  Record of Digital data logger for temperature & humidity monitoring of stability chambers (real time and accelerated)	Firm has submitted record of digital data logger for temperature &				
	STABILITY STUDY DATA (Plot	No. 01, Sector 25	Korangi Indus	trial Area, Ka	aracl	hi)
Man	ufacturer of APIs	M/s. Chongqing HuaZhong Road Park, 401221, Ch	, Chongqing			
	Lot No.	12-SQKB-210301				
	ription of Pack tainer closure system)	Alu-Alu blister				
	ility Storage Condition	Real time: 30°C ± 2°C / 75% ± 5%RH Accelerated: 40°C ± 2°C / 75% ± 5%RH				
Time	e Period	Accelerated: 0, 3 (Months) Real Time: 0, 3 (Months)				
Freq	uency	Accelerated: 0, 3, 6 (Months) Real Time: 0, 3, 6, 9, 12, 18, 24, 36 (Months)				
Batc	h No.	031ES01		1ES02		-
	h Size	10,000 Tablets		0 Tablets		
	ufacturing Date	16.09.2021		9.2021		-
	of initiation	06.10.2021		0.2021		-
No.	of Batches	WIDED AT CASE		02		TD A
1.	Reference of previous approval of	VIDED ALONG	WITH STABI	LLIY STUD	Υ DA	AIA
1.	applications with stability study data of the firm (if any)	_				

2.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Copy of GMP certificate issued by China Food and Drug Administration valid till 03-06-2023 and Copy of DML issued by Chongqing Food and Drug Administration valid till October 13, 2025.		
3.	Documents for the procurement of API with approval from DRAP (in case of import).	Copy of invoice attested by AD I&E DRAP, Karachi, has been submitted.		
		Batch No. Invoice No. Date of approval by DRAP		
		12-SQKB- 210301 TM210518- 25.06.2021		
4.	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	respective documents like chromatograms. Raw data sheets. COA		
5.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing.			
6.	Record of Digital data logger for temperature & humidity monitoring of stability chambers (real time and accelerated)	Firm has submitted record of digital data logger for temperature & humidity monitoring of stability chambers (real time and accelerated)		

#### **Miscellaneous documents:**

The firm has submitted the following documents as per WHO TRS 981,2013 (47<sup>th</sup> report, Annex 3) and SOP guidelines stated in 283<sup>rd</sup> DRB meeting minutes:

- Stability Data of 03 batches till shelf life manufactured at their existing facility located at Plot No. 29 30, Sector 27, Korangi Industrial Area.
- Stability Data of 2 stability batches at 0 and 3<sup>rd</sup> point have also been submitted by manufacturer from new facility located at Plot No. 01, Sector 25, Korangi Industrial Area as per Guidance Document for Submission of Application on Form 5-F (CTD) for registration of pharmaceutical drug products for human use issued in October, 2021.
- Comparative Dissolution Profile and Pharmaceutical Equivalence studies of the product with the innovator from existing manufacturing facility & also submitted Comparative Dissolution Profile against innovator from new manufacturing facility.
- Comparative batch analysis data on two batches from the new facility and comparative data on the last three batches from the existing facility.
- Firm has submitted Executed Production document of stability batch.
- Firm has submitted Process Validation Protocol.
- Firm has submitted undertakings that process validation, accelerated and real time stability studies on 03 commercial batches at new manufacturing facility will be conducted & in case of any quality complaint / OOS result as a result of this change, the same shall be reported to registration board and all the stock shall be recalled from the market immediately.
- Analytical Method Verification / validation studies of API & Finished product.
- Valid GMP/DML of the API manufacturer submitted.

### **Decision** Registration Board decided as under:

i. Cancelled registration of following products from the name of M/s Getz Pharma (Pvt) Ltd, 29-30, Sector 27, Korangi Industrial Area, Karachi (DML No. 000284).

S. No.	Reg. No.	Product Name
1.	029437	Getryl Tablets 1mg
		Each tablet contains:-
		Glimepiride1mg
2.	019877	Claritek Tablets 250mg
		Each tablet contains:-
		Clarithromycin USP250mg
3.	010640	Claritek Tablets 500mg
		Each tablet contains:-
		Clarithromycin500mg
4.	086937	Vilget-M Tablet 50mg/500mg

		Each film coated tablet contains:
		Vildagliptin50mg
		Metformin HCl USP500mg
		(As per Innovator's Specifications)
5.	073875	Vilget-M Tablet 50mg+850mg
		Each film coated tablet contains:
		Vildagliptin50mg
		Metformin HCl850mg
		(Manufacturer's Specifications)
6.	073876	Vilget-M Tablet 50mg+1000mg
		Each film coated tablet contains:
		Vildagliptin50mg
		Metformin HCl1000mg
		(Manufacturer's Specifications)
7.	053120	Zetro 500mg Tablets
		Each tablet contains:-
		Azithromycin (as Dihydrate)500mg
		(Manufacturer's Specification)
8.	045471	HCQ 200 Tablets
		Each film coated tablet contains:-
		Hydroxychloroquine Sulphate200mg

- ii. Approved registration of following products in the name of M/s Getz Pharma (Pvt) Ltd, Plot No.01, Sector 25, Korangi Industrial Area, Karachi (DML No. 000933) with same registration numbers in the light of legal opinion furnished by Legal Affairs Division, DRAP vide letter F.No. 11-1/2018/DD(LA)-Vol-I dated 05-10-2021.
  - a) Manufacturer will place first three production batches of both products on long term stability studies throughout proposed shelf life and on accelerated studies for six months as per the commitment submitted in the registration application.
  - b) Manufacturer will perform process validation of first three batches of both products as per the commitment submitted in the registration application.

S. No.	Product Name
1.	Getryl Tablets 1mg
	Each tablet contains:-
	Glimepiride1mg
	(USP Specifications)
	Shelf life: 36 Months
2.	Claritek Tablet 250mg
	Each film coated tablet contains:-
	Clarithromycin250mg
	(USP Specifications)
3.	Claritek Tablet 500mg
	Each film coated tablet contains:-
	Clarithromycin500mg
	(USP Specifications)
4.	Vilget-M Tablets 50mg + 500mg
	Each film-coated tablet contains:
	Vildagliptin50mg
	Metformin Hydrochloride 500mg
	(Getz Pharma Specifications)
	Shelf life: 24 Months
5.	Vilget-M Tablets 50mg + 850mg
	Each film-coated tablet contains:
	Vildagliptin50mg
	Metformin Hydrochloride 850mg
	(Getz Pharma Specifications)
	Shelf life: 24 Months
6.	Vilget-M Tablets 50mg + 1000mg

	E. I. Claracter I allowers in the control of the co				
	Each film-coated tablet contains:				
	Vildagliptin50mg				
	Metformin Hydrochloride				
	(Getz Pharma Specifications)				
	Shelf life: 24 Months				
7.	Zetro Tablets 500mg				
	Each film coated tablet contains:-				
	Azithromycin (as dihydrate) 500mg				
	(USP Specifications)				
	Shelf life: 24 Months				
8.	HCQ 200 Tablets 200mg				
	Each film-coated tablet contains:				
	Hydroxychloroquine Sulfate 200mg				
	(BP Specifications)				
	Shelf life: 36 Months				

- iii. For products at S. No. 2 and 3, registration letter will be issued with shelf life of 18 months, since the firm has not submitted stability data of all three batches till claimed shelf life, else while firm shall submit real time stability data upto the claimed shelf life of 36 months before issuance of registration letter.
- iv. With respect to non-pharmacopeial formulations, finished product specifications shall be corrected/ standardized to "As per Innovator's Specifications" after submission of requisite fee by the firm as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021.
- v. Reference will be sent to Costing and Pricing Division for confirmation of maximum retail price (MRP).
- iv. Deferred the following products for further evaluation under WHO TRS 981, 2013 (47th report, Annex 3).

S. No.	Reg. No.	Product Name
1.	108570	Vonozan Tablet 10mg
		Each film coated tablet contains:
		Vonoprazan as Fumarate10mg
		(As per *Innovator's Specifications)
2.	108571	Vonozan Tablet 20mg
		Each film coated tablet contains:
		Vonoprazan as Fumarate20mg
		(As per *Innovator's Specifications)

### Case No. 5. Approved Product of M/s Mediate Pharmaceutical (Pvt) Ltd. Karachi

Registration Board in its  $237^{th}$  meeting (held on 26-02-2013) approved the following products of M/s Mediate Pharmaceutical (Pvt) Ltd. Plot No. 150-151 Sector 24 Korangi Industrial Area Karachi as per details mentioned vide column II & III of below table. The firm has now requested for issuance of registration & submitted requisite fee along-with required documents/ information as per detail recorded vide Column V of below table:

S/ N	Product Name & Composition	Decision of RB/	RB/ mentioned in Column III) to be Met	
		Current Status	Before Consideration by RB	Status/ Remarks
I	II	III	V	
1.	Cal-Vastatin Plus Tablets Each tablet contains:- Atorvastatin Calcium10mg Amlodipine besylate5mg (Calcium Antagonists)	Approved subject to payment of differential fee	<ul> <li>Dy.No.11514/R&amp;I dated 12-05-2022</li> <li>Differential registration fee of Rs.22000/-(DS#9154430511 dated 09-05-2022)</li> <li>Pre-registration variation fee of Rs.30000/- (DS#894999896991 dated 09-05-2022) for correction in composition as per RRA. Correct composition is:  Each film coated tablet contains:- Atorvastatin (as Calcium Trihydrate)10mg Amlodipine (as Besylate)5mg</li> <li>Correct form-5, Master formulation &amp; manufacturing method.</li> <li>FPP Specifications; USP.</li> <li>Last Inspection Report 17-12-2021.(Acceptable Level of Compliance)</li> <li>Renewal of DML issued vide Licensing Division's letter dated 15-09-2021 stating approval of "Tablet (General) Section"</li> </ul>	• USFDA Approved • Lipcal 5mg/10m g Tablets by CCL
2.	Madivantec Tablets Each tablet contains:- Candesartan16mg Hydrochlorothiazide12 .5mg (Angiotensin II Receptor Antagonists)	Approved subject to payment of differential fee	<ul> <li>Dy.No.11516/R&amp;I dated 12-05-2022.</li> <li>Differential registration fee of Rs.22000/-(DS#229829420 dated 10-05-2022)</li> <li>Pre-registration variation fee of Rs.7500/-(DS#323295756354 dated 10-05-2022) for mentioning FPP Specifications.</li> <li>FPP Specifications; USP.</li> <li>Last Inspection Report 17-12-2021 (Acceptable Level of Compliance)</li> <li>Renewal of DML issued vide Licensing Division's letter dated 15-09-2021 stating approval of "Tablet (General) Section"</li> </ul>	USFDA Approved     Dierect-H Tablets by M/s Scottman

3.	Medifenac Capsule 50mg Each capsule contains:- Diclofenac Sodium50mg (Anti rheumatics)	Approved subject to submission of valid GMP COA, Stability data and balance fee for pellets.	•	Dy.No.11517/R&I dated 12-05-2022  Differential registration fee of Rs.22000/-(DS#562594595 dated 10-05-2022)  Pre-registration variation fee of Rs.30000/-(DS#8903987828 dated 10-05-2022) for mentioning complete description of pellets (i.e., enteric coated; Source: M/s Vision Pharma)  Correct form-5, Master formulation & manufacturing method.  FPP Specifications; Manufacturer's.  Last Inspection Report 17-12-2021 (Acceptable Level of Compliance)  Renewal of DML issued vide Licensing Division's letter dated 15-09-2021 stating approval of "Capsule (General) Section	<ul> <li>Difene 50mg         Gastro-         Resistant         Capsule approved by         HPRA,         Ireland.</li> <li>Legofen         Capsule by M/s         Legacy</li> </ul>
4.	M-Tec Tablets Each tablet contains:- Enalapril Maleate .10mg Hydrochlorothiazide25mg (ACE Inhibitor)	Approved subject to payment of differential fee	•	Dy.No.11515/R&I dated 12-05-2022  Differential registration fee of Rs.22000/-(DS#24237433 dated 09-05-2022)  Pre-registration variation fee of Rs.7500/-(DS#762932769 dated 09-05-2022) for mentioning FPP Specifications.  FPP Specifications; USP.  Last Inspection Report 17-12-2021(Acceptable Level of Compliance)  Renewal of DML issued vide Licensing Division's letter dated 15-09-2021 stating approval of "Tablet (General) Section	• USFDA Approved • Acelar Plus 10/25mg Tablet by M/s Pharmev o

Decision: Registration Board approved registration of products at S.No. 1-4 of above table in the name of M/s Mediate Pharmaceutical (Pvt) Ltd. Plot No. 150-151 Sector 24 Korangi Industrial Area Karachi.

Case No: 1 Renewal of Trexam 500mg Injection of M/s Haji Medicine Co., Rawalpindi.

<u> </u>	Renewal of Trexam 300mg injection of M/3 Haji Medicine 00., Rawaipindi.						
Reg. No.	Brand Name & Composition	Initial date of Registration PRV (If any)	Date of application (R&I) Fee submitted	Decision			
069516	Trexam 500mg Injection  Each vial contains: Pemetrexed (as disodium)500mg  Manufacturer: M/s Laboratorios IMA, Argentina License Holder: M/s Laboratorios Richmond S.A., Argentina.	26.02.2011	Dy No.13768 dated 21.05.2021 Rs.90000/-	Renewal is granted w.e.f. 21.05.2021 to 20.05.2026. However, renewal letter shall be after submission of legalized CoPP issued by the regulatory authority of country of origin and as per policy of inspection of manufacturer abroad.			

Above product was referred from QA& LT Division for confirmation of renewal of registration. Accordingly, the above-mentioned details are communicated that the renewal application was submitted after due date but within one year which requires regularization by Registration Board. The firm has now informed that the shipment vide invoice no.0015-00000512 dated 09.03.2022 has been released by QA& LT division with utilization restriction till decision of the Registration Board. Further the firm has provided the copy of COPP of the above product and submitted that the are process of arranging legalized CoPP for Pakistan which will take some time. The firm has requested for regularization of renewal.

## Case No. 2 Renewal application of M/s Medisure Laboratories Pakistan Pvt Limited Karachi.

The below mentioned products were considered in 278<sup>th</sup> meeting of Registration Board under SRO 1005(I)/2017 and deferred for submission of following:

- a) Form 5-B,
- b) Initial Registration Letter
- c) Post Registration Variation (if any),
- d) Last Renewal (if any),
- e) DML Required.

The firm has now submitted the above documents and requested for renewal of registration.

Sr. No.	Reg. No.	Brand Name & Composition	Initial date of Registration PRV (If any)	Renewal application submission details	Decision
1.	048525	Synsma Tablet  Each tablet contains:  Doxofylline400mg	06.03.2008	Rs 10000/- dated: 14.03.2013 Rs. 10000 dated: 12.4.2018	Deferred for submission of differential fee (Rs. 20000/-) as renewal application for the year 2013 and 2018 was submitted late but within sixty days
2.	022547	Nidol Tablets  Each Tablet contains: Nimesulide100mg	28.11.1998  Transfer of Reg: 28.06.2011	Rs. 10000/- dated 13.12.2018 Rs. 10000/- 12.04.2019	Renewal is granted w.e.f. 28.11.2018 to 27.11.2023  The firm shall submit the reference of finished product specifications as per decision of

				Rs. 20000/- dated 28.11.2019	295 <sup>th</sup> meeting of Registration Board.	
3.	055600	Xopra Plus Capsules  Each Capsule contains: Omeprazole (as pellets)40mg (USP Specifications)  Source: M/s EuroAsia Trans	01.04.2009	Rs. 10000/- dated 25.04.2019	Deferred for submission of differential fee (Rs. 30000/-) for following reasons: i. Renewal application for the year 2019 was submitted after due date but within sixty days. ii. Imported source of pellets	
4.	058247	Continental India. Albuterol Syrup Each 5ml contains:	12.08.2009	Rs:10000/- dated 19.08.2019	Deferred for submission of differential fee (Rs. 10000/-) as renewal application for the year	
		Salbutamol as sulphate2mg (BP Specifications)			2019 was submitted late but within sixty days.	
5.	058248	Chewron Syrup  Each 5ml contains: Iron (III) Hydroxide Polymaltose Complex eq. to Elemental Iron50mg (USP Specifications)	12.08.2009	Rs:10000/- dated 19.08.2019	Deferred for submission of differential fee (Rs. 10000/-) as renewal application for the year 2019 was submitted late but within sixty days.	
6.	058249	Pinsure 10mg Tablet  Each film coated tablet contains: Olanzapine10mg	12.08.2009	Rs:10000/- dated 19.08.2019	Deferred for submission of differential fee (Rs. 10000/-) as renewal application for the year 2019 was submitted late but within sixty days.	
7.	058250	Lactusure Syrup 120ml Lactulose3.35gm Source of Bulk: M/s Fresenius Kabi Austria	12-08-2009	Rs:10000/- dated 19.08.2019	Deferred for submission of differential fee (Rs. 30000/-) for following reasons: i. Renewal application for the year 2019 was submitted after due date but within sixty days. ii. Imported source of bulk	
	Remarks:  Product applied under SRO1005(I)/2017 in 278 <sup>th</sup> meeting of Registration Board. Hence cancellation letter was not issued. Further renewal application for the year 2019 was submitted on 19.08.2019 with 10000/- fee which is also after due date but within sixty days. The firm may be advised to submit pending differential fee and case may be placed in forthcoming Registration Board meeting.					
	Keeping in its 312 <sup>th</sup> me	eeting and further advised fee of late renewal submiss	the firm to submit sion (within sixty d	the differential fe	on of cancellation of registration in e for imported source of bulk and 019.	
8.	032639	Diabetal-2 Tablets Each tablet contains: Glimepiride2mg	13.08.2004	Rs.10000/- dated 26.09.2019	Deferred for submission of differential fee (Rs. 10000/-) as renewal application for the year 2019 was submitted late but within sixty days.	
9.	032640	Miosil 5mg Tablet Each tablet contains: Amlodipine besylate eq. to Amlodipine5mg	13.08.2004	Rs.10000/- dated 26.09.2019	Deferred for submission of differential fee (Rs. 10000/-) as renewal application for the year 2019 was submitted late but within sixty days.	

10.	032641	Miosil 10mg Tablet Each tablet contains: Amlodipine besylate eq. to Amlodipine10mg	13.08.2004	Rs.10000/- dated 26.09.2019	Deferred for submission of differential fee (Rs. 10000/-) as renewal application for the year 2019 was submitted late but within sixty days.
11.	032469	Onyfine tablets 125mg Each tablet contains: Terbinafine HCl eq.to Terbinafine125mg	07.08.2004	Rs.10000/- dated 27.09.2019	Deferred for submission of differential fee (Rs. 10000/-) as renewal application for the year 2019 was submitted late but within sixty days.
12.	032740	Arthosure Gel Each 100gm Contains: Diclofenac Diethyl Ammonium salt 1.6gm eq.tp Diclofenac Sodium1.00gm	07.08.2004	Rs.10000/- dated 26.09.2019	Deferred for submission of differential fee (Rs. 10000/-) as renewal application for the year 2019 was submitted late but within sixty days.
13.	032462	Abgenix 20mg tablet Each tablet contains: Citalopram (as Hydrobromide)20mg	06.08.2004	Rs.10000/- dated 27.09.2019	Deferred for submission of differential fee (Rs. 10000/-) as renewal application for the year 2019 was submitted late but within sixty days.
14.	032463	Kovence 60mg Capsule  Each capsule contains Fexofenadine HCI60mg	06.08.2004	Rs.10000/- dated 27.09.2019	Deferred for submission of differential fee (Rs. 10000/-) as renewal application for the year 2019 was submitted late but within sixty days.
15.	034060	Ascorium Sachet Each sachet contains: Calcium Lactate Gluconate1000mg Vitamin C500mg Calcium Carbonate327mg	20.10.2004	Rs.10000/- dated 26.09.2019	Deferred for evidence of approval of formulation in RRA.
16.	034071	Diabetal-1 Tablet Each tablet contains: Glimepiride1mg	20.10.2004	Rs.10000/- dated 26.09.2019	Renewal is granted w.e.f 20.10.2019 to 19.10.2024.  The firm shall submit the reference of finished product specifications as per decision of 295th meeting of Registration Board.
17.	035611	Kevence 60mg Tablet Each tablet contains: Fexofenadine Hydrochloride60m g	30.12.2004	Rs.10000/- dated 19.11.2019	Renewal is granted w.e.f 30.10.2019 to 29.10.2024.  The firm shall submit the reference of finished product specifications as per decision of 295th meeting of Registration Board.
18.	061715	Mal-Anx Dry Suspension Each 5ml contains: Artemether15mg Lumefantrine90mg	19.07.2010	Rs.10000/- dated 12.05.2020	Renewal is granted w.e.f 19.07.2020 to 18.07.2025  The firm shall submit the reference of finished product specifications as per decision of 295th meeting of Registration Board.
19.	061714	Tamlev 250mg Tablet Each tablet contains; Levetiracetam250m g	19.07.2010	Rs.10000/- dated 12.05.2020	Renewal is granted w.e.f 19.07.2020 to 18.07.2025  The formulation shall be corrected as film coated tablet

					further firm shall submit the reference of finished product specifications as per decision of 295 <sup>th</sup> meeting of Registration Board.
20.	042232	Pinsure tablet Each tablet contains: Olanzapine7.5mg	11.03.2006	Rs.10000/- dated 15.02.2021	Renewal is granted w.e.f 15.02.2021 to 14.02.2026  The firm shall submit the reference of finished product specifications as per decision of 295th meeting of Registration Board.
21.	037721	Tolymax Tablet Each film coated tablet contains: Topiramate50mg	04.04.2006	Rs.10000/- dated 08.03.2021	Renewal is granted w.e.f 08.03.2021 to 07.03.2026  The formulation shall be corrected as film coated tablet further firm shall submit the reference of finished product specifications as per decision of 295th meeting of Registration Board.

Case No: 3 Renewal application of M/s Barrett Hodgson Pakistan Pvt Limited Karachi.

Reg. No.	Brand Name & Composition	Initial date of Registration PRV (If any)	Renewal application submission details	Remarks
027279	Soludex-D Injection Each ml contains: Dexamethasone Acetate eq. to Dexamethasone Sodium Phosphate eq.to Dexamethasone2mg	22.06.2002	Dy. No. 9192 Dated:11.04.202 2 Rs.15000/-	As per Licensing Division letter No.F.2-4/97-Lic (Vol-IV) for regarding renewal of DML the firm did not possess injectable steroid.

Decision: Deferred for clarification regarding approval of manufacturing facility for

injectable steroids

Case No: 4 Renewal application of M/s Vantage Laboratories Pvt. Ltd, Faisalabad.

It is submitted that the renewal application of below mentioned registered veterinary products were submitted after due date but within 60 days. Now the firm has submitted the differential

fee Rs.15000/- each and requested for renewal. Reg. No. **Brand Name &** Initial date of Renewal Decision Composition application Registration submission PRV (If any) details 081698 Bromodil Oral Liquid 31.08.2016 Dy No.25617 Renewal is granted w.e.f. Each 100ml contains: Dated 31.08.2021 to 30.08.2026 Tylosin 14.09.2021 Rs.15000/-Tartrate.....10gm shall provide The firm reference in case formulation Doxycycline HCI.....20gm Dy No.8834 Official is included in Bromhexine..... dated Pharmacopeia 1am 06.04.2022 incorporation in renewal letter Rs.15000/-(Manufacturer otherwise "As per Innovator's Specification) Specifications" shall granted. 081699 Micotil 250 Oral Liquid 31.08.2016 Dy No.25617 Renewal is granted w.e.f. Each ml contains: 31.08.2021 to 30.08.2026 Dated Tilmicosin......250mg 14.09.2021

081700	(Manufacturer Specification)	31.08.2016	Rs.15000/-  Dy No.8834 dated 06.04.2022 Rs.15000/-	The firm shall provide reference in case formulation is included in Official Pharmacopeia for incorporation in renewal letter otherwise "As per Innovator's Specifications" shall be granted.  Renewal is granted w.e.f.
	Each ml contains: Enrofloxacin200mg (Manufacturer Specification)		Dated 14.09.2021 Rs.15000/- Dy No.8834 dated 06.04.2022 Rs.15000/-	31.08.2021 to 30.08.2026  The firm shall provide reference in case formulation is included in Official Pharmacopeia for incorporation in renewal letter otherwise "As per Innovator's Specifications" shall be granted.
081701	Foxin Tage Oral Liquid Each ml contains: Florfenicol230mg Colistin Sulphate50 MIU (Manufacturer Specification)	31.08.2016	Dy No.25617 Dated 14.09.2021 Rs.15000/- Dy No.8834 dated 06.04.2022 Rs.15000/-	Renewal is granted w.e.f. 31.08.2021 to 30.08.2026  The firm shall provide reference of finished product specifications in case formulation is included in Official Pharmacopeia for incorporation in renewal letter otherwise "As per Innovator's Specifications" shall be granted.
081702	Tage Tril 10% Oral Liquid Each 100 ml contains:  Enrofloxacin1  Ogm (Manufacturer Specification)	31.08.2016	Dy No.25617 Dated 14.09.2021 Rs.15000/- Dy No.8834 dated 06.04.2022 Rs.15000/-	Renewal is granted w.e.f. 31.08.2021 to 30.08.2026  The firm shall provide reference of finished product specifications in case formulation is included in Official Pharmacopeia for incorporation in renewal letter otherwise "As per Innovator's Specifications" shall be granted.
081703	Sulphadi-Prim Oral Liquid Each ml contains: Sulphadiazine	31.08.2016	Dy No.25617 Dated 14.09.2021 Rs.15000/- Dy No.8834 dated 06.04.2022 Rs.15000/-	Renewal is granted w.e.f. 31.08.2021 to 30.08.2026  The firm shall provide reference of finished product specifications in case formulation is included in Official Pharmacopeia for incorporation in renewal letter otherwise "As per Innovator's Specifications" shall be granted.
081704	Tiverdox Oral Liquid Each 100ml contains: Doxycyclin HCI20gm Tylosin Tartrate10gm (Manufacturer Specification)	31.08.2016	Dy No.25617 Dated 14.09.2021 Rs.15000/- Dy No.8834 dated 06.04.2022	Renewal is granted w.e.f. 31.08.2021 to 30.08.2026  The firm shall provide reference of finished product specifications in case formulation is included in Official Pharmacopeia for

			Rs.15000/-	incorporation in renewal letter otherwise "As per Innovator's Specifications" shall be granted.
081705	Fillicol Oral Liquid Each 100ml contains: Florfenicol	31.08.2016	Dy No.25617 Dated 14.09.2021 Rs.15000/- Dy No.8834 dated 06.04.2022 Rs.15000/-	Renewal is granted w.e.f. 31.08.2021 to 30.08.2026  The firm shall provide reference of finished product specifications in case formulation is included in Official Pharmacopeia for incorporation in renewal letter otherwise "As per Innovator's Specifications" shall be granted.
081706	Micromutin Oral Liquid Each 100ml contains: Tylosin Tartrate10gm Doxycycline HCl20gm Colistin Sulphate50000 IU Bromhexine0.5gm  (Manufacturer Specification)	31.08.2016	Dy No.25617 Dated 14.09.2021 Rs.15000/- Dy No.8834 dated 06.04.2022 Rs.15000/-	Renewal is granted w.e.f. 31.08.2021 to 30.08.2026  The firm shall provide reference of finished product specifications in case formulation is included in Official Pharmacopeia for incorporation in renewal letter otherwise "As per Innovator's Specifications" shall be granted.
081707	Eaflexin Tage Oral Liquid  Each 100ml contains:  Enrofloxacin	31.08.2016	Dy No.25617 Dated 14.09.2021 Rs.15000/- Dy No.8834 dated 06.04.2022 Rs.15000/-	Renewal is granted w.e.f. 31.08.2021 to 30.08.2026  The firm shall provide reference of finished product specifications in case formulation is included in Official Pharmacopeia for incorporation in renewal letter otherwise "As per Innovator's Specifications" shall be granted.
081708	Vantage ESB 30% Oral Powder Each 100gm contains: Sulphaclozine Sodium Monohydrate	31.08.2016	Dy No.25617 Dated 14.09.2021 Rs.15000/- Dy No.8834 dated 06.04.2022 Rs.15000/-	Renewal is granted w.e.f. 31.08.2021 to 30.08.2026  The firm shall provide reference of finished product specifications in case formulation is included in Official Pharmacopeia for incorporation in renewal letter otherwise "As per Innovator's Specifications" shall be granted.
081709	Doxy Tage Oral Powder Each 100gm contains: Tylosin Tartrate10gm Doxycycline HCI20gm (Manufacturer Specification)	31.08.2016	Dy No.25617 Dated 14.09.2021 Rs.15000/- Dy No.8834 dated 06.04.2022 Rs.15000/-	Renewal is granted w.e.f. 31.08.2021 to 30.08.2026  The firm shall provide reference of finished product specifications in case formulation is included in Official Pharmacopeia for incorporation in renewal letter otherwise "As per Innovator's

				Specifications" shall be
081710	Tyl-D 600 Oral Powder Each 100gm contains: Tylosin Tartrate20gm Doxycycline HCl40gm (Manufacturer Specification)	31.08.2016	Dy No.25617 Dated 14.09.2021 Rs.15000/- Dy No.8834 dated 06.04.2022 Rs.15000/-	granted.  Renewal is granted w.e.f. 31.08.2021 to 30.08.2026  The firm shall provide reference of finished product specifications in case formulation is included in Official Pharmacopeia for incorporation in renewal letter otherwise "As per Innovator's Specifications" shall be granted.
081711	Oxytage Oral Powder Each 100gm contains: Oxytetracycline HCI25gm Neomycin Sulphate25gm Colistin Sulphate30MIU (Manufacturer Specification)	31.08.2016	Dy No.25617 Dated 14.09.2021 Rs.15000/- Dy No.8834 dated 06.04.2022 Rs.15000/-	Renewal is granted w.e.f. 31.08.2021 to 30.08.2026  The firm shall provide reference of finished product specifications in case formulation is included in Official Pharmacopeia for incorporation in renewal letter otherwise "As per Innovator's Specifications" shall be granted.
081712	Vantage Asper-C Oral Powder Each 100gm contains: Vitamin C20gm Acetylsalicylic Acid6.7gm (Manufacturer Specification)	31.08.2016	Dy No.25617 Dated 14.09.2021 Rs.15000/- Dy No.8834 dated 06.04.2022 Rs.15000/-	Deferred as formulation is under review by Registration Board
081713	Chlor NEC Oral Powder Each 1000gm contains:- Chlortetracycline	31.08.2016	Dy No.25617 Dated 14.09.2021 Rs.15000/- Dy No.8834 dated 06.04.2022 Rs.15000/-	31.08.2021 to 30.08.2026  The firm shall provide reference of finished product specifications in case formulation is included in Official Pharmacopeia for incorporation in renewal letter otherwise "As per Innovator's Specifications" shall be granted.
081714	Speclinx Oral Powder Each 100gm contains: Lincomycin HCI5gm Spectinomycin HCI7.5gm Spiramycin Adipose2.5gm Bromhexine HCI0.5 gm (Manufacturer Specification)	31.08.2016	Dy No.25617 Dated 14.09.2021 Rs.15000/- Dy No.8834 dated 06.04.2022 Rs.15000/-	Renewal is granted w.e.f. 31.08.2021 to 30.08.2026  The firm shall provide reference of finished product specifications in case formulation is included in Official Pharmacopeia for incorporation in renewal letter otherwise "As per Innovator's Specifications" shall be granted.

Case No: 4 Renewal application of M/s Epla Laboratories (Private) Limited, Karachi

Reg. No.	Brand Name & Composition	Initial date of Registration PRV (If any)	Renewal application submission details	Remarks
002587	Eplazyme Syrup Each 5ml contains: Diastase J.P135mg Pepsin BP50mg Papain BPC50mg Thiamine HCl BP5mg Ribaflavin BP2mg Pyridoxine HCl BP.2mg Cyanocobalamin B.P5mcg Nicotinamide BP20mg Calcium d-pantothenate1mg	22.04.1997	Dy No.9170 dated 11.04.2022 Rs.15000/-	
002587	Eplazyme Capsule Each capsule contains: Bile Extract NF25mg Diastase J.P100mg Pepsin BP60mg Papain BPC60mg Thiamine HCI BP4mg Riboflavin BP0.5mg Pyridoxine HCI BP.0.5mg Cyanocobalamin B.P5mcg Nicotinamide BP10mg	22.04.1997	Dy No.9171 dated 11.04.2022 Rs.15000/-	

Decision: Deferred for submission of evidence of approval of formulation in RRA.

Case No: 4 Renewal application of M/s. Avicenna Laboraoties (Pvt) Ltd, Sheikhupura

Reg. No.	Brand Name & Composition	Initial date of Registration PRV (If any)	Renewal application submission details	Remarks
026530	Gumbotech Injectable Each vial of 250ml contains: 500 does High Antibodies (Against Infectious Bursal Disease)	06.04.2002	Dy No.8277 dated 29.03.2022 Rs.15000/-	
026531	F.M Cenna Injectable Each dose of vaccine contains: Foot and Mouth Disease Vaccine, BHK-21, Strain Titre not less than 106 TCIS50 Viz A.O, & Asia I	06.04.2002	Dy No.8276 dated 29.03.2022 Rs.15000/-	
026532	F.M Cenna-S Injectable Each vial of 250ml contains: 500 doses High Antibodies (Against Cure of FOOT and Mouth disease in Livestock)	06.04.2002	Dy No.8275 dated 29.03.2022 Rs.15000/-	

Decision: Deferred for verification of approval of manufacturing facility for vaccines by the Licensing Division.

Case No: 5 Renewal application of M/s. Alina Combine Pharmaceuticals (Pvt) Ltd, Karachi

Reg. No.	Brand Name & Composition	Initial date of Registration PRV (If any)	Renewal application submission details	Remarks
024596	Strepto-K Injection Each vial contains Streptokinase750,000I U	28.03.2002	Dy No.8795 dated 28.03.2022 Rs.15000/-	
024597	Strepto-K Injection Each vial contains Streptokinase1500,000 IU	28.03.2002	Dy No.8795 dated 28.03.2022 Rs.15000/-	

Decision: Deferred for verification of approval of manufacturing facility for biologicals by the Licensing Division.

Case No: 5 Renewal application of M/s. Popular Chemical Works Ltd, Lahore

Reg. No.	Brand Name & Composition	Initial date of Registration PRV (If any)	Renewal application submission details	Decision
005215- EX	Wingis Ampoule 10ml Each 10ml contains Betaine Flucuronate750mg Diethanolamine Glucuronate200mg Nicotinamide41mg	25.02.2016	Dy No.7006 dated 14.03.2022 Rs.15000/-	Registration is cancelled as renewal application was applied after the prescribed time period i.e. after one year of due date
005216- EX	Wingis Ampoule 2ml Each 2ml contains Betaine Flucuronate150mg Diethanolamine Glucuronate40mg Nicotinamide8.20mg	25.02.2016	Dy No.7006 dated 14.03.2022 Rs.15000/-	Registration is cancelled as renewal application was applied after the prescribed time period i.e. after one year of due date

Case No: 6 Renewal application of M/s. Galaxy Pharma Pvt Ltd, Basemnet Plot No. 28-C Lane No. 09 Ittehad Commercial Phase VI DHA Karachi for Aromek 2.5mg Tablet

Reg. No.	Brand Name & Composition	Initial date of Registration PRV (If any)	Renewal application submission details	Decision
052258	Aromek 10's Tabs Film Coated Tablets Each tablet contains: Letrozole2.5mg  Manufactured by:	11-06-2009	Dy. No. 1613 dated 25-03-2019 Rs. 20000/-	

M/s Celon Pharma S.A. Ogrodova 2A, Kielpin 05- 092 Lomianki Poland.		

### Remarks:

The case was deferred in 4<sup>th</sup> meeting of Renewal Sub-Committee for issuance of Final Reminder for rectification of shortcomings:

- Valid legalized CoPP issued by Chief Pharmaceutical Inspection, Warsaw, Poland dated 08-11-2019. However, the GMP Certificate issued has different site address than manufacturer which is M/s Celon Pharma S.A. ul. Mokra 41A, 05-092 Lomianki/Kielpin, Poland.
- The address of the importer mentioned on Initial Registration Letter is different from the address mentioned on Drug Sale License.

### Reply:

The firm informed that as per GMP there are two addresses, one for head office and other is manufacturer as per GMP.

Further the frim has submitted approval of change of address of DSL vide DRAP letter dated 18.05.2020.

Decision: Deferred for clarification as manufacturer address mentioned on GMP certificate is different from the submitted CoPP.

Case No: 7 Contract Manufacturing of Registered Products of M/s. Novartis Pharma (Pakistan) Ltd., 15-West Wharf Dockyard Road, Karachi at M/s GlaxoSmithKline Consumer Healthcare Pakistan Ltd., Petaro Road Jamshoro.

M/s. Novartis Pharma (Pakistan) Ltd., 15-West Wharf Dockyard Road, Karachi has submitted request for extension in contact manufacturing of below mentioned products registered in their name manufactured at M/s GlaxoSmithKline Consumer Healthcare Pakistan Ltd., Petaro Road Jamshoro. The firm has submitted following documents:

- i. Fee deposit slip of 75000/- each product.
- ii. Copies of DML
- iii. Copies of registration letter
- iv. GMP certificate of M/s GlaxoSmithKline Consumer Healthcare Pakistan Ltd., Petaro Road Jamshoro.
- v. Contract agreement.

The permission was valid for the period of 30months from the date of issuance of registration.

Sr. No.	Reg. No.	Brand Name & Composition	Initial date of Registration PRV (If any)	Date of application (R&I) Fee submitted	Remarks
1.	007823	Mepresor 100mg tablets Each tablet contains: Metoprolol100mg (Manufacturer Specification)	22.01.2020	75000/- dated 21.02.2022	
2.	006144	Mosegor sugar coated tablet Each tablet contains: Pizotifen0.5mg (Manufacturer Specification)	22.01.2020	75000/- dated 21.02.2022	
3.	021529	Tegral 200mg tablets Each tablet contains: Carbamazepine200mg (Manufacturer Specification)	22.01.2020	75000/- dated 21.02.2022	

		T	T	1	1
4.	041184	Trioptal 300mg tablet Each film coated tablet contains: Oxcarbazepin300mg (Manufacturer Specification)	22.01.2020	75000/- dated 21.02.2022	
5.	041185	Trioptal 600mg tablet Each film coated tablet contains: Oxcarbazepin600mg (Manufacturer Specification)	22.01.2020	75000/- dated 21.02.2022	
6.	006282	Mosegor Syrup Each 5ml contains: Pizotifen0.25mg (Manufacturers Specification)	22.01.2020	75000/- dated 21.02.2022	
7.	021528	Caflam 50mg Tablets Each tablet contains: Diclofenac Potassium50mg (Manufacturer's Specification)*	13.02.2020	75000/- dated 21.02.2022	
8.	021525	Voltral 50 Tablets Each enteric coated tablet contains: Diclofenac sodium50mg (Manufacturer's Specification)*	13.02.2020	75000/- dated 21.02.2022	
9.	021524	Voltral 25 Tablets Each enteric coated tablet contains: Diclofenac sodium25mg (Manufacturer's Specification)*	13.02.2020	75000/- dated 21.02.2022	
10.	021526	Voltral SR 100mg Tablets Each tablet contains: Diclofenac Sodium100mg (Manufacturer's Specification)*	13.02.2020	75000/- dated 21.02.2022	
11.	036125	Mepresor SR 200mg Tablets Each sustained release tablet contains: Metoprolol Tartrate200mg (Manufacturer's Specification) *	13.02.2020	75000/- dated 21.02.2022	
12.	070803	Tegral Suspension Each 5ml contains: Carbamazepine100mg (BP Specification)	13.02.2020	75000/- dated 21.02.2022	

### **Decision:** Deferred for following:

- i. Clarification for non-compliance of timelines given by the company and approved by Registration Board i.e. 30months
- ii. Status of products not applied for extension in contact manufacturing in registration letter dated: 22.01.2020 and 13.02.2020

# Case No. 8 Renewal application of Healer 20mg Capsules (038693) of M/s Pulse Pharmaceuticals Pvt Limited Lahore.

Assistant Director PR-I has forwarded the following product registered in name of M/s Pulse Pharmaceuticals Pvt Limited Lahore for confirmation of renewal status. After verification from database it was observed that renewal application for the year 2020 is submitted after due date but within one year. Hence the product is submitted before the Registration Board for renewal under

SRO 1005(I)/ 2017. The firm has submitted the requisite fee.

Reg. No.	Brand Name & Composition	Initial date of Registration PRV (If any)	Date of application (R&I) Fee submitted	Decision
038639	Healer Capsules 20mg Each capsule contains: Omeprazole (Enteric coated pellets)20mg  Source of Pellets: M/s Kola Pharma Pvt Limited, D-No. 2-22- 161/A/401 Plot No. 114 4th Floor Madhavi Nagar Bhagya Nagar Kukatpally Balanagar Mandal Medchal District 5000, 072 Rangareddy District _cirl (Dis) Telangana India On M/s Pelgran Pharma Pvt limited 84-B Phase I IDA Jeedimetla Hyderabad 500 005 Telangana India	09.06.2005  Approval of source of pellets: 29-05-2019	Dy. No. 25380 dated 28.09.2020 Rs. 20000 Rs 45000/- dated: 13.04.2022	Renewal is granted w.e.f 09.06.2020 to 08.06.2025.  The firm shall submit the reference of finished product specifications as per decision of 295th meeting of Registration Board.

Case No: 8 Renewal Applications submitted after prescribed time period

Sr.	Reg.	Product Name &	Date of	Renewal	Renewal	Renewal
No.	No.	Composition	Reg/ PRV	Due Date	Application	Status
					Submissio	
					n Date	
		jo Industries (Pvt) Ltd.,8	849-Pathra Hu	b Chowki Dis	trict Lasbella	Balochistan
•	No.000277	,	00.04.4000	07.04.0045	47.04.0047	T
1.	010699	Trikail Suspension	08-04-1990	07-04-2015	17-01-2017	
		Trimethoprim8%				
		Sulphadiazine4				
		0%				. (01000)
Decis		gistration Board cance				
		newal application was	submitted afte	er prescribed	time period t	inder rule 27 of
B4/- 1		ug (LR&A) Rules 1976.	N 1 05/4 0 /	21 40 0 1		In desertated Assess
		aceutical & Chemical \	Works,25/1-3 3	Sector 12-C i	North Karachi	industriai Area
	hi. (DML N	,	00.07.0040	07.07.0045	00 00 0047	<u> </u>
2.	002488-	Haemo Forte Syrup	08-07-2010	07-07-2015	06-02-2017	
	EX			41 611		(22.122.5)
Decis		gistration Board cance			•	
		newal application was	submitted afte	er prescribed	time period t	inder rule 27 of
B4/- B		ug (LR&A) Rules 1976.	T 1/   /D	MI N - 00044	4\	
		rnational Ltd., F-216 SIT	•			T
3.	011656	Sigel Suspension	02-09-1990	01-09-2015	17-04-2017	
		Each ml contains:				
		Aluminum				
		Hydroxide300mg				
		Magnesium				
		Hydroxide150mg				

		Simethicone125mg				
4.	045211	Salmicort Inhaler Each Actuation contain Salmeterol Xinofoate 25mcg Fluticasone Propionate 250mcg	01-03-2007	28-02-2017	24-10-2017	
5.	045210	Salmicort Inhaler Each Actuation contain Salmeterol Xinofoate 25mcg Fluticasone Propionate 125mcg	01-03-2007	28-02-2017	24-10-2017	
6.	045209	Salmicort Inhaler Each Actuation contain Salmeterol Xinofoate 25mcg Fluticasone Propionate 50mcg	01-03-2007	28-02-2017	24-10-2017	
7.	045208	Inhalon 200mcg Inhaler Each Actuation contain Triamcinolone Acetonide200mcg	01-03-2007	28-02-2017	24-10-2017	
8.	045207	Salmetide 25mcg Inhaler Each Actuation contain Salmeterol Xinofoate 25mcg	01-03-2007	28-02-2017	24-10-2017	
9.	045159	Macticort 250mcg Inhaler Each Actuation contain Beclomethasone Dipropionate250mcg	20-02-2007	19-02-2017	24-10-2017	
10.	045160	Inspirol 100mcg Inhaler Each Actuation contain Salbutamol100mcg	20-02-2007	19-02-2017	24-10-2017	
11.	047267	Macticort 50mcg Inhaler Each Actuation contain Beclomethasone Dipropionate50mcg	30-11-2007	29-11-2017	24-10-2017	
12.	045315	Salnon Inhaler Each Actuation contain Salbutamol	11-04-2007	10-04-2017	24-10-2017	

	]	100mcg				
		Beclomethasone				
		Dipropionate				
		50mcg				
13.	045161	Trupium 40mcg	20-02-2007	19-02-2017	13-11-2017	
		Inhaler				
		Each Actuation				
		contain				
		Ipratropium Bromide				
		40mcg				
Decis	ion: Th	e firm informed that pro	oduct at Sr. No	o. 3 (Sigel Sus	spension Reg	No: 011656)
	w	as applied under SRO	1005(I)/2017 d	on dated 04.1	2.2017 and d	eferred in 278 <sup>th</sup>
		eeting for last renewal.				
		ariation approval grar				
	02	2.07.2014 be considere	d towards ren	ewal w.r.t to	<b>DRAP Circula</b>	ar No. 3-8/2017-
		RR (M-272) dated 12.1	0.2017, hence	e renewal ap	plications for	year 2017 are
		ithin time.				
M/s. S	ami Pharn	naceuticals (Pvt) Ltd., F	-129 SITE Kai			
14.	039782	Sevia-H 80mg +	05-12-2005	04-12-2015	12-05-2017	
		12.5mg Tablet				
		Each film coated	Change of			
		tablet contains:	BN:			
		Valsartan MS 80mg	23.05.2007			
		Hydrochlorothiazide				
		12.5mg				
Decis		e firm submitted appro				
		ter No. F.6-10/2005-Re				
		presaid approval the re				nin time, hence
		gistration of Sevia-H 80				
		International, 10-Km Na			•	/IL NO.000678)
15.		A ala Tablata 40man		00 00 0045	40 05 0047	
	062592	Acio Tablets 40mg	24-02-2010	23-02-2015	12-05-2017	
	002392	Each tablet contains:	24-02-2010	23-02-2015	12-05-2017	
10		Each tablet contains: Famotidine 40mg				
16.	062600	Each tablet contains: Famotidine 40mg Azelab 250mg	24-02-2010	23-02-2015	12-05-2017	
16.		Each tablet contains: Famotidine 40mg Azelab 250mg Capsules				
16.		Each tablet contains: Famotidine 40mg Azelab 250mg Capsules Each Capsule				
16.		Each tablet contains: Famotidine 40mg Azelab 250mg Capsules Each Capsule contains:				
16.		Each tablet contains: Famotidine 40mg Azelab 250mg Capsules Each Capsule contains: Azithromycin (as				
	062600	Each tablet contains: Famotidine 40mg Azelab 250mg Capsules Each Capsule contains: Azithromycin (as Dihydrate)250mg	24-02-2010	23-02-2015	12-05-2017	
16.		Each tablet contains: Famotidine 40mg Azelab 250mg Capsules Each Capsule contains: Azithromycin (as Dihydrate)250mg Azelab 250mg Tablets				
	062600	Each tablet contains: Famotidine 40mg Azelab 250mg Capsules Each Capsule contains: Azithromycin (as Dihydrate)250mg Azelab 250mg Tablets Each tablet contains:	24-02-2010	23-02-2015	12-05-2017	
	062600	Each tablet contains: Famotidine 40mg Azelab 250mg Capsules Each Capsule contains: Azithromycin (as Dihydrate)250mg Azelab 250mg Tablets Each tablet contains: Azithromycin (as	24-02-2010	23-02-2015	12-05-2017	
17.	062600 062599	Each tablet contains: Famotidine 40mg Azelab 250mg Capsules Each Capsule contains: Azithromycin (as Dihydrate)250mg Azelab 250mg Tablets Each tablet contains: Azithromycin (as Dihydrate)250mg	24-02-2010 24-02-2010	23-02-2015	12-05-2017 12-05-2017	
	062600	Each tablet contains: Famotidine 40mg Azelab 250mg Capsules Each Capsule contains: Azithromycin (as Dihydrate)250mg Azelab 250mg Tablets Each tablet contains: Azithromycin (as Dihydrate)250mg Beridal 10mg Tablets	24-02-2010	23-02-2015	12-05-2017	
17.	062600 062599	Each tablet contains: Famotidine 40mg Azelab 250mg Capsules Each Capsule contains: Azithromycin (as Dihydrate)250mg Azelab 250mg Tablets Each tablet contains: Azithromycin (as Dihydrate)250mg Beridal 10mg Tablets Each tablet contains:-	24-02-2010 24-02-2010	23-02-2015	12-05-2017 12-05-2017	
17.	062600 062599	Each tablet contains: Famotidine 40mg Azelab 250mg Capsules Each Capsule contains: Azithromycin (as Dihydrate)250mg Azelab 250mg Tablets Each tablet contains: Azithromycin (as Dihydrate)250mg Beridal 10mg Tablets Each tablet contains: Cetirizine 2HCl	24-02-2010 24-02-2010	23-02-2015	12-05-2017 12-05-2017	
17.	062600 062599 062598	Each tablet contains: Famotidine 40mg Azelab 250mg Capsules Each Capsule contains: Azithromycin (as Dihydrate)250mg Azelab 250mg Tablets Each tablet contains: Azithromycin (as Dihydrate)250mg Beridal 10mg Tablets Each tablet contains: Cetirizine 2HCl 10mg	24-02-2010 24-02-2010 24-02-2010	23-02-2015 23-02-2015 23-02-2015	12-05-2017 12-05-2017	
17.	062600 062599	Each tablet contains: Famotidine 40mg Azelab 250mg Capsules Each Capsule contains: Azithromycin (as Dihydrate)250mg Azelab 250mg Tablets Each tablet contains: Azithromycin (as Dihydrate)250mg Beridal 10mg Tablets Each tablet contains:- Cetirizine 2HCl 10mg Bs Zole 20 mg	24-02-2010 24-02-2010	23-02-2015	12-05-2017 12-05-2017	
17.	062600 062599 062598	Each tablet contains: Famotidine 40mg Azelab 250mg Capsules Each Capsule contains: Azithromycin (as Dihydrate)250mg Azelab 250mg Tablets Each tablet contains: Azithromycin (as Dihydrate)250mg Beridal 10mg Tablets Each tablet contains: Cetirizine 2HCl 10mg Bs Zole 20 mg Each Capsule	24-02-2010 24-02-2010 24-02-2010	23-02-2015 23-02-2015 23-02-2015	12-05-2017 12-05-2017	
17.	062600 062599 062598	Each tablet contains: Famotidine 40mg Azelab 250mg Capsules Each Capsule contains: Azithromycin (as Dihydrate)250mg Azelab 250mg Tablets Each tablet contains: Azithromycin (as Dihydrate)250mg Beridal 10mg Tablets Each tablet contains: Cetirizine 2HCl 10mg Bs Zole 20 mg Each Capsule contains:	24-02-2010 24-02-2010 24-02-2010	23-02-2015 23-02-2015 23-02-2015	12-05-2017 12-05-2017	
17.	062600 062599 062598	Each tablet contains: Famotidine 40mg Azelab 250mg Capsules Each Capsule contains: Azithromycin (as Dihydrate)250mg Azelab 250mg Tablets Each tablet contains: Azithromycin (as Dihydrate)250mg Beridal 10mg Tablets Each tablet contains:- Cetirizine 2HCl 10mg Bs Zole 20 mg Each Capsule contains: Esomeprazole Coated	24-02-2010 24-02-2010 24-02-2010	23-02-2015 23-02-2015 23-02-2015	12-05-2017 12-05-2017	
17.	062600 062599 062598	Each tablet contains: Famotidine 40mg Azelab 250mg Capsules Each Capsule contains: Azithromycin (as Dihydrate)250mg Azelab 250mg Tablets Each tablet contains: Azithromycin (as Dihydrate)250mg Beridal 10mg Tablets Each tablet contains:- Cetirizine 2HCl 10mg Bs Zole 20 mg Each Capsule contains: Esomeprazole Coated pellets of Magnesium	24-02-2010 24-02-2010 24-02-2010	23-02-2015 23-02-2015 23-02-2015	12-05-2017 12-05-2017	
17.	062600 062599 062598	Each tablet contains: Famotidine 40mg Azelab 250mg Capsules Each Capsule contains: Azithromycin (as Dihydrate)250mg Azelab 250mg Tablets Each tablet contains: Azithromycin (as Dihydrate)250mg Beridal 10mg Tablets Each tablet contains:- Cetirizine 2HCl 10mg Bs Zole 20 mg Each Capsule contains: Esomeprazole Coated pellets of Magnesium trihydrate equivalent	24-02-2010 24-02-2010 24-02-2010	23-02-2015 23-02-2015 23-02-2015	12-05-2017 12-05-2017	
17.	062600 062599 062598	Each tablet contains: Famotidine 40mg Azelab 250mg Capsules Each Capsule contains: Azithromycin (as Dihydrate)250mg Azelab 250mg Tablets Each tablet contains: Azithromycin (as Dihydrate)250mg Beridal 10mg Tablets Each tablet contains: Cetirizine 2HCl 10mg Bs Zole 20 mg Each Capsule contains: Esomeprazole Coated pellets of Magnesium trihydrate equivalent to Esomeprazole	24-02-2010 24-02-2010 24-02-2010	23-02-2015 23-02-2015 23-02-2015	12-05-2017 12-05-2017	
17.	062600 062599 062598	Each tablet contains: Famotidine 40mg Azelab 250mg Capsules Each Capsule contains: Azithromycin (as Dihydrate)250mg Azelab 250mg Tablets Each tablet contains: Azithromycin (as Dihydrate)250mg Beridal 10mg Tablets Each tablet contains:- Cetirizine 2HCl 10mg Bs Zole 20 mg Each Capsule contains: Esomeprazole Coated pellets of Magnesium trihydrate equivalent	24-02-2010 24-02-2010 24-02-2010	23-02-2015 23-02-2015 23-02-2015	12-05-2017 12-05-2017	

21.	062594	Each Capsule contains: Esomeprazole Coated pellets of Magnesium trihydrate equivalent to Esomeprazole40mg Byrex 20mg Capsules Each Capsule contains: Piroxicam20mg	24-02-2010	23-02-2015	12-05-2017	
22.	062607	Diclotal 50mg Capsules Each Capsule contains: Diclofenac Sodium 50mg	24-02-2010	23-02-2015	12-05-2017	
23.	062609	Diclotal 100mg SR Capsules Each Capsule contains: Diclofenac Sodium 100mg	24-02-2010	23-02-2015	12-05-2017	
24.	062604	Diclotal SR100mg Tablets Each sustained release tablet contains: Diclofenac Sodium 100mg	24-02-2010	23-02-2015	12-05-2017	
25.	062591	Diclotal-K Tablets 75mg Each tablet contains: Diclofenac Potassium75mg	24-02-2010	23-02-2015	12-05-2017	
26.	062605	Lamizol Capsules 20mg Each Capsule contains: Omeprazole (Pellets) 20mg	24-02-2010	23-02-2015	12-05-2017	
27.	062602	Levobex 250mg Tablets Each tablet contains: Levofloxacin (as hemihydrate)250mg	24-02-2010	23-02-2015	12-05-2017	
28.	062601	Levobex 500mg Tablets Each tablet contains: Levofloxacin (as hemihydrate)500mg	24-02-2010	23-02-2015	12-05-2017	
29.	062597	Mosther Forte Tablets Each tablet contains: Artemether80m g	24-02-2010	23-02-2015	12-05-2017	

		Lumefantrine				
		480mg				
30.	062589	Mosther Tablets	24-02-2010	23-02-2015	12-05-2017	
		Each tablet contains:-				
		Artemether40m				
		g Lumefantrine				
		240mg				
31.	062603	Qubid 200mg Tablets	24-02-2010	23-02-2015	12-05-2017	
	00200	Each tablet contains:-			00 _0	
		Ofloxacin 200mg				
32.	062590	Veoxy 250mg Tablets	24-02-2010	23-02-2015	12-05-2017	
		Each tablet contains:-				
		Ciprofloxacin (as				
	000505	HCI) 250mg	04.00.0040	00 00 0045	40.05.0047	
33.	062595	Veoxy 500mg Tablets	24-02-2010	23-02-2015	12-05-2017	
		Each tablet contains:-				
		Ciprofloxacin (as HCI)500mg				
Decis	ion: Re	gistration Board canc	elled the red	istration of	above produ	cts as renewal
		plications were submit				
		R&A) Rules 1976.	•	•		J
M/s. N	Medisure L	aboratories Pakistan (	Pvt) Ltd., A-1	15 S.I.T.E St	uper Highway	Karachi. (DML
No.00		1	1	T		T
34.	002750-	Glysortin Tablet	05-01-2011	04.01.2016	09-02-2017	
	EX	Each film coated				
		tablet contains:				
		Glucosamine Sulphate 500mg				
		Chondroitin				
		Sulphate 400mg				
Decis	ion: Re	gistration Board cance	lled the regis	tration of Gly	sortin Tablet	(002750-EX) as
		newal application was				
		ug (LR&A) Rules 1976.				
	ledicure La hi. (DML N	aboratories, Plot No. F./	109 Behind K	arachi Polyte	chnic Hub Riv	er Road SITE
35.	007402	Sinodol Tablet	18-12-1984	17-12-2014	14-02-2017	
36.	008167	Meditol Solution	30-04-1985	29-04-2015	10-11-2015	
37.	007145	Carminative Mixture	03-12-1984	02-12-2014	17-11-2015	
Decis		e above products have		ancelled by F		oard in its 313rd
		eeting and letter to this			sued by DRAI	P vide letter No.
		3-6/2021-Reg-I (M-313) (				
		t) Ltd., Plot No.145 Kahu			•	DML No.000296)
38.	043169	Bio-Coccinil Water Soluble Powder	20-05-2006	19-05-2016	24-02-2017	
39.	043174	Spelinamox Water	27-04-2006	26-04-2016	24-02-2017	
		Soluble Powder				
40.	043175	Bio-Tylodox Liquid	27-04-2006	26-04-2016	24-02-2017	
41.	043176	Bio-Reyl Water Soluble Powder	27-04-2006	26-04-2016	24-02-2017	
42.	043177	Bio-Cox Water Soluble Powder	27-04-2006	26-04-2016	24-02-2017	
43.	043178	Bio-Leva CS Oral	20-05-2006	19-05-2016	24-02-2017	
	040470	Powder	00.05.000	40.05.0010	04.00.004=	
44.	043179	Bio-Fursebell Water Soluble Powder	20-05-2006	19-05-2016	24-02-2017	

45.	043180	Trigulphom	20-05-2006	19-05-2016	24-02-2017	
45.	043160	Trisulpham Suspension	20-05-2006	19-05-2016	24-02-2017	
46.	043181	Albende CS	20-05-2006	19-05-2016	24-02-2017	
40.	043101	Suspension	20-03-2000	19-03-2010	24-02-2017	
47.	043182	Bio-Multibiotic Powder	27-04-2006	26-04-2016	24-02-2017	
Decis		egistration Board canc				cts as renewal
		plications were submit				
	-	R&A) Rules 1976.				
M/s. S		oratories (Pvt) Ltd., KLI	Road Share	Colony Sadi	qabad Distric	t Rahim Yar
Khan	(DML No.0	00079)		_	-	
48.	019741	Hepa Wel Syrup	07-08-1996	06-08-2016	09-03-2017	
		Each 5ml contains:				
		L-Ornithine L				
		Aspartate 300mg				
		Vitamin B2-5				
		Phosphate Sodium				
		0.76mg				
40	040740	Nicotinamide 24mg	07.00.4000	00 00 0040	00 00 0047	
49.	019742	Hepa Wel Injection	07-08-1996	06-08-2016	09-03-2017	
		Each 5ml contains: L-Ornithine L-				
		Aspartate 500mg				
Decis	ion Re	egistration Board canc	elled the rec	istration of	above produ	cts as renewal
D00.0		plications were submit				
	•	R&A) Rules 1976.	р. ос	, , , , , , , , , , , , , , , , , , , ,	, , , , , , , , , , , , , , , , , , , ,	· · · · · · · · · · · · · · · · · · ·
M/s. S		zul Éllahie (Pvt) Ltd., E/	46 S.I.T.E Kara	achi (DML No	.000083)	
50.	039341	Ipase Injection	13-07-2005	12-07-2015	19-06-2017	
		Each ml contains:				
		Iron Sucrose eq. to	Change of			
		elemental	BN:			
		Iron100mg	12.07.2007			
Decis		e firm submitted appro				
		o. F.6-10/2005-Reg-II(s) oplication for year 2017				
	-	e.f 12.07.2017 to 11.07.2		s. Negistiatio	ii board graii	ieu tile reliewai
M/s. N		ma (Pvt) Ltd.,17 Km Ferd		hore. (DML N	lo.000444)	
51.	024371	Effidex Cream	03-05-2002	02-05-2017	25-07-2017	
		Betamethasone (as				
		Dipropionate)				
		0.05% w/w				
52.	024372	Effidex Ointment	03-05-2002	02-05-2017	25-07-2017	
		Betamethasone (as				
		Dipropionate)				
		0.05% w/w		22 22 22 4		
53.	071507	Effidex N Ointment	03-05-2002	02-05-2017	29-08-2017	
		Betamethasone				
		Valerate0.05% w/w				
		Neomycin				
		Sulphate3500 Units				
54.	071514	Hyopen Plus Tablet	04-09-2012	03-09-2017	29-08-2017	
J <del>-1</del> .	07 1314	Hyoscine-N Butyl	07-03-2012	00-03-2017	29-00-2017	
		bromide20mg				
55.	071515	C Pride Tablet 0.5mg	04-09-2012	03-09-2017	29-08-2017	
55.		Cintapride (as Acid	0.302012	33 23 7		
		Tartrate0.5mg)				
	•		•	•	•	

56.	046360	Vclor Suspension 125mg Each 5ml Contain: Cefaclor125mg	13-06-2007	12-06-2017	29-08-2017	
	046361	Vclor Suspension 250mg Each 5ml Contain: Cefaclor250mg	13-06-2007	12-06-2017	29-08-2017	
57.	046363	C Zar Tablet Each tablet contains: Topiramate100 mg	13-06-2007	12-06-2017	29-08-2017	
58.	027923	Zoticef Injection	14-06-2002	13-06-2017	29-08-2017	
59.	027324	Zotice injection 1gm Octreotide Acetate20mg	14-06-2002	13-06-2017	29-08-2017	
60.	027921	Nelzim Injection Each vial contains: Cephazolin (as Sodium)250mg	20-06-2002	19-06-2017	29-08-2017	
61.	027922	Nelzim Injection 1gm Each vial contains: Cephazolin (as Sodium)1gm	20-06-2002	19-06-2017	29-08-2017	
62.	027692	Anabact Gel Aminophylline32mg Ammonium Chloride30mg Menthol0.98mg	26-06-2002	25-06-2017	29-08-2017	
Decis	ар	gistration Board canc plications were submit R&A) Rules 1976.				
M/s. C	SH Pharm	aceuticals (Pvt) Ltd.,32	-Km Ferozepu	r Road Lahor	e (DML No.00	0737)
63.	038529	Gastrilax Syrup Each 5ml contains: Lactulose3.35g	22-06-2005	21-06-2015	31-07-2017	
64.	068451	Perindopine tablet Each tablet contains: Perindopril 4mg Amlodipine as Besylate5mg	26-02-2011	25-02-2016	03-05-2016	
65.	068452	Perindopine tablet Each tablet contains: Perindopril 4mg Amlodipine as Besylate10mg	26-02-2011	25-02-2016	03-05-2016	
Decis	ар	gistration Board canc plications were submit R&A) Rules 1976.				
M/s. E		International,10-Km Na	ngshah Chow	k Karachi Ro	ad Multan (DN	/IL No.000678)
66.	065979	Bexelex 30mg Tablet Each tablet contains: Ephedrine HCL30mg	18-10-2010	17-10-2015	31-07-2017	- ,

67.	071444	BS Pram Tablet Each tablet contains: Escitalopram as Oxalate 10mg	18-08-2011	17-08-2016	31-07-2017	
68.	065981	Bercavir 0.5mg Tablet Each tablet contains: Entecavir0.5mg	18-10-2010	17-10-2015	31-07-2017	
69.	071443	Para Tablet Each tablet contains: Paracetamol 450mg Orphenadrine Citrate 35mg	18-08-2011	17-08-2016	31-07-2017	
70.	065983	Diclotal 50mg Tablet Each tablet contains: Diclofenac sodium50mg	18-10-2010	17-10-2015	31-07-2017	
71.	065984	Belex 5mg Tablet Each tablet contains: Levocetirizine 2HCL5mg	18-10-2010	17-10-2015	31-07-2017	
Decis		gistration Board canc				
	-	plications were submit	ted after pres	cribed time	period under	rule 27 of Drug
M/s. \		R&A) Rules 1976. Pharma. International La	ahore.			
72.	019958		27-05-1997	26-05-2017	06-10-2017	
Decis	ion: Re	gistration Board canc	elled the req	istration of	above produ	cts as renewal
	ар	plications were submit R&A) Rules 1976.				
		search Laboratories, Pl	ot No. S/21 SI	TE of Estate /	Avenue Karac	hi. (DML
73.	003510	Bio Quin 650mg Tablet Each tablet contains: Di- lodohydroxyquinolone650mg	11-03-1985	10-03-2015	01-11-2017	
Decis	ion: Re	gistration Board cance	lled the regist	ration of Bio	Quin 650mg T	ablet (003510)
	as	renewal applications w Drug (LR&A) Rules 197	ere submitted			
M/s M		hnologies Services Kar				
74.	045626	Nilisu tablet 30mg Each tablet contains: Nimodipine 30mg	24-04-2007	23-04-2017	06-11-2017	
Decis	rei	egistration Board cance newal applications were ug (LR&A) Rules 1976.				
	Rock Pharn	naceutical Laboratories (DML No.000691)	(Pvt) Ltd., Plo	ot No. 134-B 1	35-B Nowshe	ra Industrial
75.	064256	Ranso 30mg Capsule Each capsule contains: Lansoprazole enteric coated pellets eq. to Lansoprazole 30mg	10-08-2010	09-08-2015	22-11-2017	

76.	024258	Dissium 50mg Capsules Each capsule contains: Diclofenac Sodium pellets eq. to Diclofenac sodium) 50mg Dissium 100mg Capsule	10-08-2010 05-05-2011	09-08-2015	22-11-2017	
		Each capsule contains: Diclofenac Sodium (as sustained release pellets) 100mg				
Decision M/s. A	ap (LF	gistration Board canc plications were submit R&A) Rules 1976. maceuticals, Plot No.	ted after pres	cribed time	period under	rule 27 of Drug
No.000	0608)					`
78.	065392	Monticare 4mg Chewable Tablet Each tablet contains: Montelukast Sodium eq. to Montelukast 4mg	18-08-2010	17-08-2015	19-01-2016	
Decision M/s. A	(06 rul	gistration Board cance §5392) as renewal applice le 27 of Drug (LR&A) Ru armaceuticals (Pvt) Ltd	cation was sul lles 1976.	bmitted after	prescribed tin	ne period under
No.000		aa.ooao(. 11, _1a.	., <b>_</b>		0	aa. (22
79.	054826	Alitox 1000mg Injection Each vial contains: Cefotaxime as sodium1000mg	17-01-2009	16-01-2014	22-01-2016	
80.	054825	Alitox 500mg Injection Each vial contains: Cefotaxime as sodium500mg	17-01-2009	16-01-2014	22-01-2016	
Decisi		gistration Board canc				
M/s. R	(LF	plications were submit R&A) Rules 1976. ma (Pvt) Ltd., Plot No. 2	•	•		
No.000		( <b>,</b>		g		(
81.	066514	Depzac 20mg Tablets Each tablet contains:- Citalopram (as HBr)10mg	03-11-2010	02-11-2015	15-02-2016	_
Decisi	as	gistration Board cance renewal application wa ug (LR&A) Rules 1976.				
		ug (Litan) itules 1370.				
		naceuticals (Pvt) Ltd.,11	2/10 Quaid-e-	Azam Industr	rial Estate Kot	Lakhpat

	1		Т	T	Т	T 1
		Each 5ml contains:				
		Ammonium chloride				
		100mg				
		Sodium				
		Citrate60mg				
		Chlorpheniramine				
		Maleate2mg				
		Ephedrine HCl5mg				
		Menthol5ml				
Decis	ion: Re	gistration Board cancel	led the reaistr	ation of Amm	onium Chloric	de Cough Syrup
	(00	04713) as renewal applic e 27 of Drug (LR&A) Ru	cation was sul			
M/s I		mical & Pharmaceutica		td 137-Shah	rah-e-Moulan	a .lalal Ud din
		DML No.000064)			o moaian	a vaiai va aiii
83.	065976	Neuropath Injection	19-10-2010	18-10-2015	25-02-2016	
00.	0000.0	Each ml contains:	10 10 2010	10 10 2010	20 02 20.0	
		Mecobalamin				
		500mcg				
84.	065977	Neuropath Tablet	19-10-2010	18-10-2015	25-02-2016	
J 1.		Each tablet contains:	10 10 2010	10 10 2010	20 02 2010	
		Mecobalamin				
		500mcg				
Decis	ion: Pe	gistration Board canc	olled the rea	istration of	above produ	rte ae ronowal
Decis		plications were submit				
	-	R&A) Rules 1976.	ted diter pres	onbed time i	scriba ariaci	ruic 27 of Brug
M/s		Pharmaceutical Indu	stries (Pvt)	Itd 18 Km	Multan Road	L Lahore (DMI
No.00	_	i i narmaceuticai muu	onios (i vi.)	_ta., 10 Kill	manan Noac	Landie (DIVIL
85.	022272	Eysul-P Drops	31-08-1998	30-08-2013	30-05-2016	
05.	022212	Each ml contains:-	31-00-1990	30-00-2013	30-03-2010	
		Prednisolone sodium				
		phosphate0.25%				
		Sulphacetamide sodium10%				
Decis	ion: Po	gistration Board cancel	lad the registr	ation of Even	LP Drops (022	(272) as ronowal
Decis		plication was submitte				
		R&A) Rules 1976.	a arter prese	indea time p	eriou unuer i	ule 27 of Drug
M/s. B		t) Ltd., Plot No.145 Kahu	ta Triangle Ind	dustrial Estate	e Islamabad. (I	DML No.000296)
86.	025799	Kerry TS Suspension	07-10-2000	06-10-2015	30-05-2016	
00.	020700	Each 100ml contains:	07 10 2000	00 10 2010	00 00 2010	
		Sulfadiazine 40mg				
		Trimethoprim 8mg				
Decis	ion: Po	gistration Board cance	llad the regist	ration of Kori	y TS Suspans	ion (025700) as
Decis		newal application was				
		ug (LR&A) Rules 1976.	submitted arte	i prescribed	time period t	illuel Tule 21 Of
M/s I		harma, Lahore				
87.	043111	Mycogal 105 Injection	26-04-2006	25-04-2016	27-06-2016	
Ο1.		Each 100ml contains:	20 07 2000	20 07 2010	2, 30 2010	
	1	Spiramycin Adipate				
		105MIU				
Decis	ion: Po	gistration Board cance	lled the regist	ration of Myo	l ogal 105 Injec	tion (043111)
PECIS		renewal application wa				
		Drug (LR&A) Rules 197		itei presenbe	a time period	under ruie 27
M/e N		Pharmaceuticals, Plot N		23 Korangi I	ndustrial Area	Karachi /DMI
No.00		i iiaiiiiaceulicais, riol l	10. 134 366101	23 Noraliyi I	iiuusiiiai Alea	Naiaciii. (DIVIL
88.	042136	Artek 20 Tablet	21-01-2006	20-01-2016	28-06-2016	
00.	042130	Each tablet contains:	21-01-2000	20-01-2010	20-00-2010	
	1					
		Esomeprazole		1		1

		r	Г	T		Т
		Magnesium Trihydrate				
		eq. to Esomeprazole				
		(Pellets) 20mg				
89.	042137	Artek 40 Tablet	21-01-2006	20-01-2016	28-06-2016	
		Each tablet contains:				
		Esomeprazole				
		Magnesium Trihydrate				
		eq. to Esomeprazole				
		(Pellets) 40mg				
Decis	ion· Re	gistration Board canc	elled the rec	istration of	above produ	cts as renewal
200.0	ар	plications were submit			•	
N//o N	•	R&A) Rules 1976.	nana Dood La	horo (DML N	- 000444\	
		na (Pvt) Ltd.,17 Km Ferd				T
90.	026120	Pepzol Capsule	11-09-2000	10-09-2015	22-07-2016	
		Each capsule				
		contains:				
		Omeprazole 20mg				
91.	026123	Favrizole Capsule	11-09-2000	10-09-2015	22-07-2016	
		Each capsule				
		contains:				
		Fluconazole 150mg				
92.	026132	Naprofast Tablet	11-09-2000	10-09-2015	22-07-2016	
		Each tablet contains:				
		Naproxen 275mg				
Decis	ion: Re	gistration Board canc	elled the rec	istration of	above produ	cts as renewal
		plications were submit				
		R&A) Rules 1976.	p	, , , , , , , , , , , , , , , , , , , ,		
M/s N		oratories, Plot No. 24 St	· No. SS-3 Nat	ional Industr	ial Zone Rawa	t (DMI
No.00		514t01165, 1 16t 116. 24 6t	. 110. 00 0 110	ionai maasin	iai zono itawa	a. (DIVIL
93.	043022	Perfan IV Injection	09-06-2006	08-06-2016	15-08-2016	
33.	043022	Each 20ml ampoule	03-00-2000	00-00-2010	13-00-2010	
		contains: -				
Dania	ion. De	Enoximone 100mg	llad tha mania	tration of Da	urfan IV Indaet	ion (042022) ac
Decis		gistration Board cance	_		•	•
		newal application was s	submitted after	er prescribea	time period t	inder rule 21 of
NA/o C		ug (LR&A) Rules 1976.		/DMI No 004	2440\	
		rug Company, E-6-A SI				
94.	067682	Stapirox 20mg Tablet	15-04-2011	14-04-2016	23-08-2016	
		Each tablet contains:				
_		Piroxicam 20mg				
95.	067683	Stamelox 7.5mg	15-04-2011	14-04-2016	23-08-2016	
		Tablet				
		Each tablet contains:				
		Meloxicam 7.5mg				
96.	067684	Stamelox 15mg Tablet	15-04-2011	14-04-2016	23-08-2016	
		Each tablet contains:				
		Meloxicam 15mg				
97.	067685	Stand Inh Syrup	15-04-2011	14-04-2016	23-08-2016	
37.	007000	Each 5ml contains:	10 07-2011	17 07-2010	20 00-2010	
		Isoniazid 50mg				
00	067696	· ·	15 04 0044	14.04.0040	22 00 2042	
98.	067686	Montilu 4mg Tablet	15-04-2011	14-04-2016	23-08-2016	
		Each chewable tablet				
		contains:				
		Montelukast Sodium				
İ		4mg				
99.	067687	Montilu 5mg Tablet	15-04-2011	14-04-2016	23-08-2016	
99.	067687		15-04-2011	14-04-2016	23-08-2016	

	]	contains:				
		Montelukast Sodium 5mg				
100.	067688	Montilu 10mg Tablet Each chewable tablet contains:	15-04-2011	14-04-2016	23-08-2016	
		Montelukast Sodium 10mg				
101.	067689	Netrozole 200mg Tablet	15-04-2011	14-04-2016	23-08-2016	
		Each tablet contains: Metronidazole 200mg				
102.	067690	Netrozole 400mg Tablet Each tablet contains: Metronidazole 400mg	15-04-2011	14-04-2016	23-08-2016	
103.	070547	Septodone 10% Solution Each ml contains: Polyvinylpyrrolidone Iodine 10%	15-06-2011	14-06-2016	23-08-2016	
Decis	ion: Re	gistration Board canc	elled the reg	istration of	above produ	cts as renewal
	•	plications were submit R&A) Rules 1976.	ted after pres	cribed time	period under	rule 27 of Drug
	nvotek Pha 0487)	armaceuticals, Plot No.3	5 Industrial E	state Kahuta	Triangle Islan	nabad. (DML
104.	069849	Polytek Gel Each gm contains:	06-04-2011	05-04-2016	19-09-2016	
		Polyacrylic acid2mg				
Decis	ion: Re	gistration Board cance	lled the regis	tration of Pol	ytek Gel (069	849) as renewal
	•	plication was submitte	ed after presc	ribed time p	eriod under i	rule 27 of Drug
M/s. F		R&A) Rules 1976. ırma (Pvt) Ltd.,5-Km Ma	nga Road Raiv	wind Lahore.	(DML No.0004	169)
105.	027269	Hydrogen Peroxide Each 100ml contains: Hydrogen peroxide 6%	03-07-2001	02-07-2016		
		w/v				
Decis	re Dr	egistration Board cance newal application was s ug (LR&A) Rules 1976.	submitted after	er prescribed	time period (	
	Dnyx Pharr	naceuticals Industries,3	0-A SIE Mans	ehra (DML No	0.000440)	
106.						
	020589	Plaxonyx Syrup Vitamin B13mg Vitamin B22mg Nicotinamide23m	PRV: 14-04-2005	13-04-2015	29-12-2016	

Decision: Registration Board cancelled the registration of above products as renewal applications were submitted after prescribed time period under rule 27 of Drug (LR&A) Rules 1976.

N#1- C	(LR&A) Rules 1976. M/s. Shazal's Pharmaceuticals, Plot No. 41/1-A-1 Phase-I Industrial Estate, Hattar							
	1			1				
108.	043781	Klarid Tablet 250mg Each tablet contains:- Clarithromycin 250mg	04-07-2006	03-07-2016	02-09-2016			
109.	043782	Klarid Tablet 500mg Each tablet contains:- Clarithromycin 500mg	04-07-2006	03-07-2016	02-09-2016			
110.	043784	Dic-50 Tablet Each tablet contains:- Diclofenac Sodium 50mg	04-07-2006	03-07-2016	02-09-2016			
111.	043785	Dikan-50 Tablet Each tablet contains:- Diclofenac Potassium 50mg	04-07-2006	03-07-2016	02-09-2016			
112.	043787	Biocox Tablet 15mg Each tablet contains:- Meloxicam 15mg	04-07-2006	03-07-2016	02-09-2016			
113.	043788	Biocox Tablet 7.5mg Each tablet contains:- Meloxicam 7.5mg	04-07-2006	03-07-2016	02-09-2016			
114.	043789	Zelprox-550 Tablet Each tablet contains:- Naproxen Sodium 550mg	04-07-2006	03-07-2016	02-09-2016			
115.	043790	Frogisic Tablet 100mg Each tablet contains:- Flubiprofen 100mg	04-07-2006	03-07-2016	02-09-2016			
116.	043791	Famocin Tablet 40mg Each tablet contains:- Famotidine 40mg	04-07-2006	03-07-2016	02-09-2016			
117.	043792	Famocin Tablet 20mg Each tablet contains:- Famotidine 20mg	04-07-2006	03-07-2016	02-09-2016			
118.	043793	Cehrin Capsule 500mg Each capsule contains:- Cephradine 500mg	04-07-2006	03-07-2016	02-09-2016			
119.	043794	Cehrin Capsule 250mg Each capsule contains:- Cephradine 250mg	04-07-2006	03-07-2016	02-09-2016			
120.	043795	Cehrin Suspension 125mg/5ml Each 5ml contains:- Cephradine 125mg	04-07-2006	03-07-2016	02-09-2016			
121.	043796	Cehrin Suspension 250mg/5ml Each 5ml contains:- Cephradine 250mg	04-07-2006	03-07-2016	02-09-2016			

122.	043798	Ebison Tablet 10mg Each tablet contains:- Ebastine 10mg	04-07-2006	03-07-2016	02-09-2016	
123.	043799	Esocare Tablet 20mg Each tablet contains:- Esomeprazole (as Magnesium Trihydrate) 20mg	04-07-2006	03-07-2016	02-09-2016	
124.	043800	Esocare Tablet 40mg Each tablet contains:- Esomeprazole (as Magnesium Trihydrate) 40mg	04-07-2006	03-07-2016	02-09-2016	
125.	043806	Voltrec Capsule 50mg Each capsule contains: Diclofenac Sodium 50mg	04-07-2006	03-07-2016	02-09-2016	
126.	043808	Estram Tablet 10mg Each tablet contains: escitalopram as oxalate10mg	04-07-2006	03-07-2016	02-09-2016	
127.	043809	Tinic Tablet 2mg Each tablet contains: Tizanidine as HCl 2mg	04-07-2006	03-07-2016	02-09-2016	
128.	043810	Tinic Tablet 4mg Each tablet contains: Tizanidine as HCI 4mg	04-07-2006	03-07-2016	02-09-2016	
129.	043811	Zytizine Tablet 10mg Each tablet contains: Cetirizine Dihydrochloride 10mg	04-07-2006	03-07-2016	02-09-2016	
130.	043812	Azimal Tablet 250mg Each tablet contains: Azithromycin as Dehydrate 250mg	04-07-2006	03-07-2016	02-09-2016	
131.	044538	Esozole Capsule 40mg Each capsule contains: Esomeprazole Pellets (as Magnesium Trihydrate 40mg	11-08-2006	10-08-2016	21-10-2016	
132.	044539	Esozole Capsule 20mg Each capsule contains: Esomeprazole Pellets (as Magnesium Trihydrate 20mg	11-08-2006	10-08-2016	21-10-2016	
133.	044542	Deslorate 40mg tab Each tablet contains: Desloratadine 5mg	11-06-2006	10-06-2016	21-10-2016	

Registration Board cancelled the registration of above products as renewal Decision: applications were submitted after prescribed time period under rule 27 of Drug (LR&A) Rules 1976. M/s. Hisun Pharmaceutical Industry ,37-A R-02 Industrial Estate Gadoon Amazai District Swabi. (DML No.000624) 134. 052820 Beta-G Cream 18-11-2008 17-11-2013 12-01-2015 Betona-GM Cream. Each tube Contains:-Betamethasone as Valerate.....0.1% Gentamycin as Sulphate......0.1% Miconazole Nitrate......2% (Hisun's Specs) 135. Betona-GM Cream 18-11-2008 17-11-2013 12-01-2015 052818 Betona-GM Cream. Each tube Contains:-Betamethasone as Valerate.....0.1% Gentamycin as Sulphate......0.1% Miconazole Nitrate......2% (Hisun's Specs) Brosun Suspension 01-04-2009 12-01-2015 136. 056480 31-03-2014 Each 5ml contains:-Ibuprofen.....100mg (Hisun Specification) 056477 137. Cetsun Syrup 01-04-2009 31-03-2014 12-01-2015 Each 5ml contains:-Cetirizine 2HCl.....5mg (Hisun Specification) 138. Cetsun 10mg Tablets 12-01-2015 056486 01-04-2009 31-03-2014 Each tablet contains:-Cetirizine 2HCI.....10mg (Hisun Specification) 139. 056491 Dexazole Cream 01-04-2009 31-03-2014 12-01-2015 Each gram contains:-Dexamethasone Acetate......4mg Clotrimazole.....10mg (Hisun Specification) 140. Gentazole Cream. 19-08-2008 051060 18-08-2013 12-01-2015 Each Gram Contains:-Econazole Nitrate .....10mg. Triamcinolone Acetonide......1mg. Gentamycin As Sulphate ......1mg. (Hisun's Specs) 141. Haemonil Capsule 01-04-2009 12-01-2015 056469 31-03-2014 250mg

	]	Each capsule		1		
		contains:-				
		Tranexamic				
		Acid250mg				
		(Hisun Specification)				
142.	056472	Hifexo 60mg Capsule	01-04-2009	31-03-2014	12-01-2015	
		Each capsule				
		contains;:-				
		Fexofenadine				
		HCI60mg				
		(Hisun Specification)				
143.	056479	Higran Suspension	01-04-2009	31-03-2014	12-01-2015	
		Each 5ml contains:-				
		Nalidixic Acid250mg				
		(Hisun Specification)				
144.	051062	Husicort-H Cream.	19-08-2008	18-08-2013	12-01-2015	
		Each Tube Contains:-				
		Fusidic				
		Acid20mg.				
		Hydrocortisone				
		Acetate10mg.				
1.15	054064	(B.P Specs	10.00.2000	40.00.0040	10.01.0015	
145.	051064	Husidin Cream. Each Tube Contains:-	19-08-2008	18-08-2013	12-01-2015	
		Fusidic				
		Acid2%				
		(B.P Specs)				
146.	051065	Likone Cream.	19-08-2008	18-08-2013	12-01-2015	
	00.000	Each Tube Contains:-	.0 00 2000	10 00 2010	.2 0. 20.0	
		Betamethasone				
		Dipropionate0.05%				
		(USP Specs)				
147.	056471	Malrex Capsules	01-04-2009	31-03-2014	12-01-2015	
		Each capsule				
		contains:-				
		Artemether20mg				
		Lumefantrine120mg				
		(Hisun Specification)				
148.	051066	Nitzone Cream.	19-08-2008	18-08-2013	12-01-2015	
		Each Tube Contains:-				
		Nitrofurazone0.2%				
4.40	050470	(USP Specs)	04.04.0000	24 02 2044	40.04.0045	
149.	056473	Phenosun Elixir	01-04-2009	31-03-2014	12-01-2015	
		Each 5ml contains:- Phenobarbitone20				
		mg (Hisun Specification)				
		(i libari opcomoation)				
150.	056474	Pizosun Syrup	01-04-2009	31-03-2014	12-01-2015	
		Each 5ml contains:-				
		Pizotifen (as				
		Hydrogen				
		Maleate)0.				
		25mg				
		(Hisun Specification)				
451	050400	0 : (400 = 111	04.04.000	04.00.0011	10.01.001.7	
151.	056488	Quinof 400mg Tablets	01-04-2009	31-03-2014	12-01-2015	

		Each tablet contains:- Ofloxacin400m g (Hisun Specification)				
152.	056485	Rheuma-T 20mg Tablets Each tablet contains:- Piroxicam (as Beta cyclodextrin)20mg (Hisun Spec) (Anti- rheumatic)	01-04-2009	31-03-2014	12-01-2015	
153.	056494	Samoclor 250mg Capsules Each capsule contains:- Cefaclor250mg (USP Specification)	01-04-2009	31-03-2014	12-01-2015	
154.	056492	Samoclor 125mg Suspension Each 5ml contains:- Cefaclor125mg (USP Specification)	01-04-2009	31-03-2014	12-01-2015	
155.	056493	Samoclor 250mg Suspension Each 5ml contains:- Cefaclor250mg (USP Specification)	01-04-2009	31-03-2014	12-01-2015	
156.	056475	Sucrosun Suspension Each 5ml contains:- Sucralfate1000mg (Hisun Specification)	01-04-2009	31-03-2014	12-01-2015	
157.	056484	Vottsun 75mg Tablets Each enteric coated tablet contains:- Diclofenac Sodium75mg (Hisun Specification)	01-04-2009	31-03-2014	12-01-2015	
158.	056482	X-Pan Tablets Each tablet contains:- Pseudoephedrine (as HCL)60mg Paracetamol 500mg Chlorpheniramine Maleate4mg (Hisun Specification)	01-04-2009	31-03-2014	12-01-2015	
159.	056483	X-Tense10mg Tablets Each tablet contains:- Escitalopram (as Oxalate)10mg	01-04-2009	31-03-2014	12-01-2015	

		(Hisun Specification)				
Decis	ар	egistration Board cance plications were submit R&A) Rules 1976.				
		naceuticals (Pvt) Ltd.,11	12/10 Quaid-e-	Azam Industr	ial Estate Kot	Lakhpat
160.	007873	Aminophylline 100mg Tablet Each tablet contains: Aminophylline100 mg	03-02-1985	02-02-2015	13-04-2015	
161.	007875	Chlorpheniramine Maleate 4mg Tablet Each tablet contains: Chlorpheniramine4 mg	03-02-1985	02-02-2015	13-04-2015	
162.	007874	M.Broplex Tablet Each tablet contains: Thiamine HCI1mg, Riboflavin1mg Nicotinamide15mg	03-02-1985	02-02-2015	13-04-2015	
163.	004712	Calamine Lotion Calamine15% Zinc Oxide15%	27-03-1979	26-03-2014	13-04-2015	
164.	004954	Carminative Mixture Soda Bicarb5% Spt Ammon.Arom6.5%, TR Zingib. Forte0.4%, TR, Card Co6.5%, SPT.Chloroform4 % Aqua Menthpip	05-08-1979	04-08-2014	13-04-2015	
165.	004486	Chloroquine Phosphate Syrup Each ml contains: Chloroquine Base40mg	20-11-1978	19-11-2013	13-04-2015	
166.	004955	Ferrous Gluconate Syrup Ferrous Gluconae300mg	08-09-1979	07-09-2014	13-04-2015	
167.	007794	M.Brozine Elixir Promethazine Hcl5mg Vitamin C10mg Citric Acid50mg	28-01-1985	27-01-2015	13-04-2015	
168.	004953	Mephen Syrup Diphenhydramine HCI13.5mg Ammonium Chloride131.5mg Sodium Citrate Citrate55mg Chloroform22mg	05-08-1979	04-08-2014	13-04-2015	

	]	Menthol1mg				
169.	007877	M.Brovit Syrup	03-02-1985	02-02-2015	13-04-2015	
100.	007077	Vitamin A 25000lu	00 02 1000	02 02 2010	10 01 2010	
		Vitamin D 250IU				
		Thiamine				
		HCl0.55mg				
		Nicotinamide5.5m				
		g   Riboflavin065mg				
		Ascorbic Acid15mg				
170.	004432	Diatrin Suspension	30-09-1985	29-09-2015	13-04-2015	
		Kaolin2.92mg				
		Pectin0.26mg				
		Aluminum				
		Hydroxide0.39mg				
171.	004433	Tr. Benzoine Co	22-11-1978	21-11-2013	13-04-2015	
		Benzoin10%				
		Aloes2%				
		Tolu Balsam2.5%				
		Prepared				
		Storate7.5%				
		Methyl SPT90%				
		TR.Male100ml				
172.	006603	Mandls Paint	23-11-1982	22-11-2012	13-04-2015	
173.	006710	Gum Paint	21-02-1983	20-02-2013	13-04-2015	
174.	007876	Scabicid Lotion	03-02-1985	02-02-2015	13-04-2015	
		Benzyle				
		Benzoate25%				
Decis	ion: Re	Benzoate25% egistration Board canc	elled the reg	istration of	above produ	cts as renewal
Decis	ар	egistration Board canc plications were submit				
	ap (L	egistration Board canc plications were submit R&A) Rules 1976.	ted after pres	cribed time	period under	
M/s. C	ap (L )pal Labor	egistration Board cance plications were submit R&A) Rules 1976. atories (Pvt) Ltd., LC/41	ted after pres	cribed time p	period under No.000046)	
	ap (L	egistration Board cance plications were submit R&A) Rules 1976. atories (Pvt) Ltd., LC/41 Lerit Tablet 5 mg	ted after pres	cribed time	period under	
M/s. C	ap (L )pal Labor	egistration Board cance plications were submit R&A) Rules 1976. atories (Pvt) Ltd., LC/41 Lerit Tablet 5 mg Each tablet contains:	ted after pres	cribed time p	period under No.000046)	
<b>M/s. C</b> 175.	ap (L <b>)pal Labor</b> 035224	egistration Board cance plications were submit R&A) Rules 1976. atories (Pvt) Ltd., LC/41 Lerit Tablet 5 mg Each tablet contains: Ramipril 5mg	SITE Landhi 11-12-2004	Karachi. (DMI 10-12-2014	No.00046) 23-04-2015	
M/s. C	ap (L )pal Labor	egistration Board cance plications were submit R&A) Rules 1976. atories (Pvt) Ltd., LC/41 Lerit Tablet 5 mg Each tablet contains: Ramipril 5mg Lerit Tablet 2.5mg	ted after pres	cribed time p	period under No.000046)	
<b>M/s. C</b> 175.	ap (L <b>)pal Labor</b> 035224	egistration Board cance plications were submit R&A) Rules 1976. atories (Pvt) Ltd., LC/41 Lerit Tablet 5 mg Each tablet contains: Ramipril 5mg Lerit Tablet 2.5mg Each tablet contains:	SITE Landhi 11-12-2004	Karachi. (DMI 10-12-2014	No.00046) 23-04-2015	
<b>M/s. C</b> 175.	ap (L <b>Opal Labor</b> 035224 035223	egistration Board cance plications were submit R&A) Rules 1976. atories (Pvt) Ltd., LC/41 Lerit Tablet 5 mg Each tablet contains: Ramipril 5mg Lerit Tablet 2.5mg Each tablet contains: Ramipril 2.5mg	SITE Landhi 11-12-2004 11-12-2004	Karachi. (DMI 10-12-2014 10-12-2014	No.00046) 23-04-2015 23-04-2015	
<b>M/s. C</b> 175.	ap (L <b>)pal Labor</b> 035224	egistration Board cance plications were submit R&A) Rules 1976. atories (Pvt) Ltd., LC/41 Lerit Tablet 5 mg Each tablet contains: Ramipril 5mg Lerit Tablet 2.5mg Each tablet contains: Ramipril 2.5mg Lerit Tablet 1.25mg	SITE Landhi 11-12-2004	Karachi. (DMI 10-12-2014	No.00046) 23-04-2015	
<b>M/s. C</b> 175.	ap (L <b>Opal Labor</b> 035224 035223	egistration Board cance plications were submit R&A) Rules 1976. atories (Pvt) Ltd., LC/41 Lerit Tablet 5 mg Each tablet contains: Ramipril 5mg Lerit Tablet 2.5mg Each tablet contains: Ramipril 2.5mg Lerit Tablet 1.25mg Each tablet contains:	SITE Landhi 11-12-2004 11-12-2004	Karachi. (DMI 10-12-2014 10-12-2014	No.00046) 23-04-2015 23-04-2015	
<b>M/s.</b> C 175.	035223 035222	egistration Board cance plications were submit R&A) Rules 1976.  atories (Pvt) Ltd., LC/41  Lerit Tablet 5 mg Each tablet contains: Ramipril 5mg Lerit Tablet 2.5mg Each tablet contains: Ramipril 2.5mg Lerit Tablet 1.25mg Each tablet contains: Ramipril 1.25mg	SITE Landhi 11-12-2004 11-12-2004	Karachi. (DMI 10-12-2014 10-12-2014 10-12-2014	23-04-2015 23-04-2015	
<b>M/s. C</b> 175.	ap (L <b>Opal Labor</b> 035224 035223	egistration Board cance plications were submit R&A) Rules 1976. atories (Pvt) Ltd., LC/41 Lerit Tablet 5 mg Each tablet contains: Ramipril 5mg Lerit Tablet 2.5mg Each tablet contains: Ramipril 2.5mg Lerit Tablet 1.25mg Each tablet contains:	SITE Landhi 11-12-2004 11-12-2004	Karachi. (DMI 10-12-2014 10-12-2014	No.00046) 23-04-2015 23-04-2015	
M/s. C 175. 176. 177.	035223 035222 035222	egistration Board cance plications were submit R&A) Rules 1976. atories (Pvt) Ltd., LC/41 Lerit Tablet 5 mg Each tablet contains: Ramipril 5mg Lerit Tablet 2.5mg Each tablet contains: Ramipril 2.5mg Lerit Tablet 1.25mg Each tablet contains: Ramipril 1.25mg Diastop Capsule 2mg	SITE Landhi 11-12-2004 11-12-2004 11-12-2004	Karachi. (DMI 10-12-2014 10-12-2014 10-12-2014 06-05-2015	23-04-2015 23-04-2015 23-04-2015	
<b>M/s.</b> C 175.	035223 035222	egistration Board cance plications were submit R&A) Rules 1976. atories (Pvt) Ltd., LC/41 Lerit Tablet 5 mg Each tablet contains: Ramipril 5mg Lerit Tablet 2.5mg Each tablet contains: Ramipril 2.5mg Lerit Tablet 1.25mg Each tablet contains: Ramipril 1.25mg Diastop Capsule 2mg  Proxim 20 Capsule	SITE Landhi 11-12-2004 11-12-2004	Karachi. (DMI 10-12-2014 10-12-2014 10-12-2014	23-04-2015 23-04-2015	
M/s. C 175. 176. 177.	035223 035222 035222	egistration Board cance plications were submit R&A) Rules 1976. atories (Pvt) Ltd., LC/41 Lerit Tablet 5 mg Each tablet contains: Ramipril 5mg Lerit Tablet 2.5mg Each tablet contains: Ramipril 2.5mg Lerit Tablet 1.25mg Each tablet contains: Ramipril 1.25mg Diastop Capsule 2mg	SITE Landhi 11-12-2004 11-12-2004 11-12-2004	Karachi. (DMI 10-12-2014 10-12-2014 10-12-2014 06-05-2015	23-04-2015 23-04-2015 23-04-2015	
M/s. C 175. 176. 177.	035223 035222 035222	egistration Board cance plications were submit R&A) Rules 1976.  atories (Pvt) Ltd., LC/41  Lerit Tablet 5 mg Each tablet contains: Ramipril 5mg Lerit Tablet 2.5mg Each tablet contains: Ramipril 2.5mg Lerit Tablet 1.25mg Each tablet contains: Ramipril 1.25mg Diastop Capsule 2mg  Proxim 20 Capsule Each Capsule contains:	SITE Landhi 11-12-2004 11-12-2004 11-12-2004	Karachi. (DMI 10-12-2014 10-12-2014 10-12-2014 06-05-2015	23-04-2015 23-04-2015 23-04-2015	
M/s. C 175. 176. 177.	ap (L )pal Labor 035224 035223 035222 009881 017227	egistration Board cance plications were submit R&A) Rules 1976.  atories (Pvt) Ltd., LC/41  Lerit Tablet 5 mg Each tablet contains: Ramipril 5mg  Lerit Tablet 2.5mg Each tablet contains: Ramipril 2.5mg  Lerit Tablet 1.25mg Each tablet contains: Ramipril 1.25mg  Diastop Capsule 2mg  Proxim 20 Capsule Each Capsule contains: Piroxicam 20mg	SITE Landhi 11-12-2004 11-12-2004 11-12-2004 12-05-1988 18-04-1995	Karachi. (DMI 10-12-2014 10-12-2014 10-12-2014 10-12-2014 10-05-2015 17-04-2015	23-04-2015 23-04-2015 23-04-2015 30-07-2015	
M/s. C 175. 176. 177.	035223 035222 035222	egistration Board cance plications were submit R&A) Rules 1976.  atories (Pvt) Ltd., LC/41  Lerit Tablet 5 mg Each tablet contains: Ramipril 5mg  Lerit Tablet 2.5mg Each tablet contains: Ramipril 2.5mg  Lerit Tablet 1.25mg Each tablet contains: Ramipril 1.25mg  Diastop Capsule 2mg  Proxim 20 Capsule Each Capsule contains: Piroxicam 20mg  Camilox Tablet 15mg	SITE Landhi 11-12-2004 11-12-2004 11-12-2004	Karachi. (DMI 10-12-2014 10-12-2014 10-12-2014 06-05-2015	23-04-2015 23-04-2015 23-04-2015	
M/s. C 175. 176. 177.	ap (L )pal Labor 035224 035223 035222 009881 017227	egistration Board cance plications were submit R&A) Rules 1976.  atories (Pvt) Ltd., LC/41  Lerit Tablet 5 mg Each tablet contains: Ramipril 5mg  Lerit Tablet 2.5mg Each tablet contains: Ramipril 2.5mg  Lerit Tablet 1.25mg Each tablet contains: Ramipril 1.25mg  Diastop Capsule 2mg  Proxim 20 Capsule Each Capsule contains: Piroxicam 20mg  Camilox Tablet 15mg Each tablet contains:	SITE Landhi 11-12-2004 11-12-2004 11-12-2004 12-05-1988 18-04-1995	Karachi. (DMI 10-12-2014 10-12-2014 10-12-2014 10-12-2014 10-05-2015 17-04-2015	23-04-2015 23-04-2015 23-04-2015 30-07-2015	
M/s. C 175. 176. 177. 178. 179.	035224 035224 035223 035222 009881 017227	egistration Board cance plications were submit R&A) Rules 1976.  atories (Pvt) Ltd., LC/41  Lerit Tablet 5 mg Each tablet contains: Ramipril 5mg Lerit Tablet 2.5mg Each tablet contains: Ramipril 2.5mg Lerit Tablet 1.25mg Each tablet contains: Ramipril 1.25mg Diastop Capsule 2mg  Proxim 20 Capsule 2mg  Proxim 20 Capsule 2mg  Proxim 20 Capsule 2mg  Camilox Tablet 15mg Each tablet contains: Piroxicam 20mg Camilox Tablet 15mg Each tablet contains: Meloxicam15mg	SITE Landhi 11-12-2004 11-12-2004 11-12-2004 12-05-1988 18-04-1995	Cribed time   Karachi. (DMI   10-12-2014   10-12-2014   10-12-2014   10-12-2015   17-04-2015   07-02-2013	23-04-2015 23-04-2015 23-04-2015 30-07-2015 30-07-2015	
M/s. C 175. 176. 177.	ap (L )pal Labor 035224 035223 035222 009881 017227	egistration Board cance plications were submit R&A) Rules 1976.  atories (Pvt) Ltd., LC/41  Lerit Tablet 5 mg Each tablet contains: Ramipril 5mg  Lerit Tablet 2.5mg Each tablet contains: Ramipril 2.5mg  Lerit Tablet 1.25mg Each tablet contains: Ramipril 1.25mg  Diastop Capsule 2mg  Proxim 20 Capsule Each Capsule contains: Piroxicam 20mg  Camilox Tablet 15mg Each tablet contains: Meloxicam15mg  Camilox Tablet 7.5mg	SITE Landhi 11-12-2004 11-12-2004 11-12-2004 12-05-1988 18-04-1995	Karachi. (DMI 10-12-2014 10-12-2014 10-12-2014 10-12-2014 10-05-2015 17-04-2015	23-04-2015 23-04-2015 23-04-2015 30-07-2015	
M/s. C 175. 176. 177. 178. 179.	035224 035224 035223 035222 009881 017227	egistration Board cance plications were submit R&A) Rules 1976.  atories (Pvt) Ltd., LC/41  Lerit Tablet 5 mg Each tablet contains: Ramipril 5mg  Lerit Tablet 2.5mg Each tablet contains: Ramipril 2.5mg  Lerit Tablet 1.25mg Each tablet contains: Ramipril 1.25mg  Diastop Capsule 2mg  Proxim 20 Capsule 2mg  Proxim 20 Capsule 2mg  Proxim 20 Capsule 2mg  Camilox Tablet 15mg Each tablet contains: Meloxicam 15mg  Camilox Tablet 7.5mg Each tablet contains:	SITE Landhi 11-12-2004 11-12-2004 11-12-2004 12-05-1988 18-04-1995	Cribed time   Karachi. (DMI   10-12-2014   10-12-2014   10-12-2014   10-12-2015   17-04-2015   07-02-2013	23-04-2015 23-04-2015 23-04-2015 30-07-2015 30-07-2015	
M/s. C 175. 176. 177. 178. 179.	035224 035224 035223 035222 009881 017227 029993	egistration Board cance plications were submit R&A) Rules 1976.  atories (Pvt) Ltd., LC/41  Lerit Tablet 5 mg Each tablet contains: Ramipril 5mg  Lerit Tablet 2.5mg Each tablet contains: Ramipril 2.5mg Lerit Tablet 1.25mg Each tablet contains: Ramipril 1.25mg Diastop Capsule 2mg  Proxim 20 Capsule 2mg  Proxim 20 Capsule 2mg  Proxim 20 Capsule 2mg  Camilox Tablet 15mg Each tablet contains: Meloxicam 15mg Camilox Tablet 7.5mg Each tablet contains: Meloxicam 7.5mg	SITE Landhi 11-12-2004 11-12-2004 11-12-2004 12-05-1988 18-04-1995 08-02-2003	Cribed time   Karachi. (DMI   10-12-2014   10-12-2014   10-12-2014   10-12-2015   17-04-2015   17-04-2013   18-06-2013	23-04-2015 23-04-2015 23-04-2015 30-07-2015 30-07-2015 11-08-2015	
M/s. C 175. 176. 177. 178. 179.	035223 035222 035222 035222 009881 017227	egistration Board cance plications were submit R&A) Rules 1976.  atories (Pvt) Ltd., LC/41  Lerit Tablet 5 mg Each tablet contains: Ramipril 5mg Lerit Tablet 2.5mg Each tablet contains: Ramipril 2.5mg Lerit Tablet 1.25mg Each tablet contains: Ramipril 1.25mg Diastop Capsule 2mg  Proxim 20 Capsule 2mg  Proxim 20 Capsule Each Capsule contains: Piroxicam 20mg Camilox Tablet 15mg Each tablet contains: Meloxicam15mg Camilox Tablet 7.5mg Each tablet contains: Meloxicam7.5mg Camilox Dispersible	SITE Landhi 11-12-2004 11-12-2004 11-12-2004 12-05-1988 18-04-1995	Cribed time   Karachi. (DMI   10-12-2014   10-12-2014   10-12-2014   10-12-2015   17-04-2015   07-02-2013	23-04-2015 23-04-2015 23-04-2015 30-07-2015 30-07-2015	
M/s. C 175. 176. 177. 178. 179.	035224 035224 035223 035222 009881 017227 029993	egistration Board cance plications were submit R&A) Rules 1976.  atories (Pvt) Ltd., LC/41  Lerit Tablet 5 mg Each tablet contains: Ramipril 5mg  Lerit Tablet 2.5mg Each tablet contains: Ramipril 2.5mg  Lerit Tablet 1.25mg Each tablet contains: Ramipril 1.25mg  Diastop Capsule 2mg  Proxim 20 Capsule Each Capsule contains: Piroxicam 20mg  Camilox Tablet 15mg Each tablet contains: Meloxicam15mg  Camilox Tablet 7.5mg Each tablet contains: Meloxicam7.5mg  Camilox Dispersible Tablet 15mg	SITE Landhi 11-12-2004 11-12-2004 11-12-2004 12-05-1988 18-04-1995 08-02-2003	Cribed time   Karachi. (DMI   10-12-2014   10-12-2014   10-12-2014   10-12-2015   17-04-2015   17-04-2013   18-06-2013	23-04-2015 23-04-2015 23-04-2015 30-07-2015 30-07-2015 11-08-2015	
M/s. C 175. 176. 177. 178. 179.	035224 035224 035223 035222 009881 017227 029993	egistration Board cance plications were submit R&A) Rules 1976.  atories (Pvt) Ltd., LC/41  Lerit Tablet 5 mg Each tablet contains: Ramipril 5mg Lerit Tablet 2.5mg Each tablet contains: Ramipril 2.5mg Lerit Tablet 1.25mg Each tablet contains: Ramipril 1.25mg Diastop Capsule 2mg  Proxim 20 Capsule 2mg  Proxim 20 Capsule Each Capsule contains: Piroxicam 20mg Camilox Tablet 15mg Each tablet contains: Meloxicam15mg Camilox Tablet 7.5mg Each tablet contains: Meloxicam7.5mg Camilox Dispersible	SITE Landhi 11-12-2004 11-12-2004 11-12-2004 12-05-1988 18-04-1995 08-02-2003	Cribed time   Karachi. (DMI   10-12-2014   10-12-2014   10-12-2014   10-12-2015   17-04-2015   17-04-2013   18-06-2013	23-04-2015 23-04-2015 23-04-2015 30-07-2015 30-07-2015 11-08-2015	

	7	Meloxicam15mg				
183.	029309	Ulcoat Suspension	20-12-2002	19-12-2012	17-12-2014	
		1mg/5ml				
		Each 5ml contains:				
		Sucralfate1gm				
Decis	ion: Re	gistration Board canc	elled the reg	istration of	above produ	cts as renewal
		plications were submit	ted after pres	cribed time	period under	rule 27 of Drug
M/s F		R&A) Rules 1976. atories (Pvt) Ltd., D-12 E	State Avenue	SITE Karac	shi (DML No.0	00071)
184.	010514	Flaren 50 Tablet	06-03-1990	05-03-2015	20-05-2015	
101.	010011	Each tablet contains:	00 00 1000	00 00 2010	20 00 2010	
		Diclofenac Sodium				
		50mg				
Decis	ion: Re	gistration Board canc	elled the reg	istration of	Flaren 50 Tal	olet as renewal
	ар	plication was submitte				
M/c E		R&A) Rules 1976. t) Ltd., Plot No.145 Kahu	ıta Triangla İn	ductrial Estate	a Islamahad //	DMI No 000206)
185. E	023410	Panta Prol 50 Powder		16-05-2014	11-06-2015	
105.	023410	Each gm contains:	17-03-1999	10-03-2014	11-00-2013	
		Amprolium HCl				
		500mg				
Decis		gistration Board cance				
	-	plication was submitted	ed after presc	ribed time p	eriod under i	ule 27 of Drug
34/ 3		R&A) Rules 1976.	/400 D . I I . /	11011		D. LOITE
		aboratories, Plot No. F./ lo.000034).	109 Benina K	aracni Polyte	cnnic Hub Kiv	er Road SIIE
186.	058960	Coli Gold Water	11-08-2009	10-08-2014	18-06-2015	
		Soluble 50,00,000IU				
		Contains:				
		Colistin				
		Sulphate500000IU				
Decis		e above products have				
		eeting and letter to this		•	sued by DRAI	P vide letter No.
M/c E		3-6/2021-Reg-I (M-313) ( ırma (Pvt) Ltd.,5-Km Ma			(DML No 000/	160)
187.	036407	Perfizole Capsule	17-01-2005	16-01-2015	14-07-2015	 
107.	030407	40mg	17-01-2005	10-01-2013	17-01-2013	
		Each capsule				
		contains:				
		Omeprazole				
		(pellets)40mg				
Decis	ion: Re	egistration Board cancel	led the registr	ation of Perfi:	zole Cansule 4	l0mg as renewal
500.0		plication was submitte				
		R&A) Rules 1976.				
M/s M		rma, Lahore	T		T	
188.	059289	Imminoral 100mg	10-04-2010	09-04-2015	03-08-2015	
		Softgel Capsule				
		Each capsule				
		contains:				
		Cyclosporin10mg				
189.	059290	Vitamin D3 Softgel	10-04-2010	09-04-2015	02-09-2015	
		Capsule				
		Each capsule				
		contains:				
		Cholecalciferol5000				
		0IU				

190.	059288	Imminoral 25mg Softgel Capsule Each capsule contains: Cyclosporin25mg	10-04-2010	09-04-2015	31-08-2015	
Decis	ар	egistration Board cand pplications were submit R&A) Rules 1976.				
M/s. F		na (Pvt) Ltd.,A/56 SITE I	Mangopir Kara	chi.(DML No.	.000030)	
191.	002669	Cerelium Tablet 5mg Each tablet contains: Diazepam 5mg	14-06-1977 PRV: <b>21.05.2005</b>	20-05-2015	19-08-2015	
192.	022542	Limera Injection 600mg Each 2ml contains: Lincomycin as HCl 600mg	26-11-1998 PRV: <b>21.05.2005</b>	20-05-2015	19-08-2015	
193.	024440	Oflocin Eye Drops 0.6% Each tablet contains: Ofloxacin 6mg	14-03-2002 PRV: <b>21.05.2005</b>	20-05-2015	19-08-2015	
194.	024441	Ulcerate Tablet Each tablet contains: Sucralfate (Basic Aluminum Sucrose Sulfate) 1000mg	14-03-2002 PRV: <b>21.05.2005</b>	20-05-2015	19-08-2015	
195.	024644	Zavir 600mg Tablet Each tablet contains: Ribavirin 600mg	14-03-2002 PRV: <b>21.05.2005</b>	20-05-2015	19-08-2015	
Decis	ap (L	egistration Board cand polications were submit R&A) Rules 1976. armaceutical Laboratori	ted after pres	scribed time	period under	rule 27 of Drug
196.	039367	Empoir Tablet 500mg Each tablet contains: Ciprofloxacin (as HCI)500mg	05-07-2005	04-07-2015	03-09-2015	140.000131)
197.	039368	Kemyvid Tablet 200mg contains: Ofloxacin200mg	05-07-2005	04-07-2015	03-09-2015	
198.	039369	Zloxpan Suspension 100mg Each 5ml contains: Cefixime USP100mg	05-07-2005	04-07-2015	03-09-2015	
199.	039370	Zloxpan Capsule 400mg Each capsule contains: Cefixime USP400mg	05-07-2005	04-07-2015	03-09-2015	

200.	039365	Zomycin Tablet	05-07-2005	04-07-2015	03-09-2015			
		250mg						
		Each tablet contains: Azithromycin						
		USP250mg						
201.	039366	Empoir Tablet 250mg	05-07-2005	04-07-2015	03-09-2015			
		Each tablet contains:-						
		Ciprofloxacin (as						
	222212	HCI)250mg	10.00.000	1= 00 001=				
202.	039316	Kemyceph Capsule	18-06-2005	17-06-2015	03-09-2015			
		250mg Each capsule						
		contains-						
		Cephradine						
		USP250mg						
	22221=	1, , , ,	10.00.000	1= 00 001=	22 22 22 2			
203.	039317	Kemyceph Capsule 500mg	18-06-2005	17-06-2015	03-09-2015			
		Each capsule						
		contains-						
		Cephradine						
		USP500mg						
204	000506	Manayaan h	12-05-1999	44.05.0044	12-12-2014			
204.	023596	Kemyceph Suspension	12-05-1999	11-05-2014	12-12-2014			
		Odspension						
Decis	ion: Re	gistration Board canc	elled the reg	istration of	above produ	cts as renewal		
applications were submitted after prescribed time period under rule 27 of Drug								
			ted after pres	cribed time	period under	rule 27 of Drug		
	(Ľ	R&A) Rules 1976.				_		
	(Ll Valor Phar	R&A) Rules 1976. maceuticals,124/A Kahu	ıta Triangle In	dustrial Area	Islamabad. (D	_		
<b>M/s.</b> 205.	(Ľ	R&A) Rules 1976. maceuticals,124/A Kahu Pe-King 250mg				_		
	(Ll Valor Phar	R&A) Rules 1976. maceuticals,124/A Kahu Pe-King 250mg Capsule	ıta Triangle In	dustrial Area	Islamabad. (D	_		
	(Ll Valor Phar	R&A) Rules 1976. maceuticals,124/A Kahu Pe-King 250mg	ıta Triangle In	dustrial Area	Islamabad. (D	_		
	(Ll Valor Phar	R&A) Rules 1976. maceuticals,124/A Kahu Pe-King 250mg Capsule Each capsule	ıta Triangle In	dustrial Area	Islamabad. (D	_		
	(Ll Valor Phar	R&A) Rules 1976.  maceuticals,124/A Kahu Pe-King 250mg Capsule Each capsule contains: Ciprofloxacin250mg Pe-King 500mg	ıta Triangle In	dustrial Area	Islamabad. (D	_		
205.	(L) Valor Phar 065101	R&A) Rules 1976. maceuticals,124/A Kahu Pe-King 250mg Capsule Each capsule contains: Ciprofloxacin250mg Pe-King 500mg Capsule	ita Triangle In 15-07-2010	dustrial Area 14-07-2015	Islamabad. (D 14-09-2015	_		
205.	(L) Valor Phar 065101	R&A) Rules 1976. maceuticals,124/A Kahu Pe-King 250mg Capsule Each capsule contains: Ciprofloxacin250mg Pe-King 500mg Capsule Each capsule	ita Triangle In 15-07-2010	dustrial Area 14-07-2015	Islamabad. (D 14-09-2015			
205.	(L) Valor Phar 065101	R&A) Rules 1976. maceuticals,124/A Kahu Pe-King 250mg Capsule Each capsule contains: Ciprofloxacin250mg Pe-King 500mg Capsule Each capsule contains:	ita Triangle In 15-07-2010	dustrial Area 14-07-2015	Islamabad. (D 14-09-2015	_		
205.	(L) Valor Phar 065101	R&A) Rules 1976. maceuticals,124/A Kahu Pe-King 250mg Capsule Each capsule contains: Ciprofloxacin250mg Pe-King 500mg Capsule Each capsule contains: Ciprofloxacin500mg	ita Triangle In 15-07-2010	dustrial Area 14-07-2015	Islamabad. (D 14-09-2015	_		
205.	(L) Valor Phar 065101  065102	R&A) Rules 1976. maceuticals,124/A Kahu Pe-King 250mg Capsule Each capsule contains: Ciprofloxacin250mg Pe-King 500mg Capsule Each capsule contains: Ciprofloxacin500mg Le-sive 250mg Capsule	15-07-2010	dustrial Area 14-07-2015 14-07-2015	Islamabad. (D 14-09-2015 14-09-2015	_		
205.	(L) Valor Phar 065101  065102	R&A) Rules 1976.  maceuticals,124/A Kahu Pe-King 250mg Capsule Each capsule contains: Ciprofloxacin250mg Pe-King 500mg Capsule Each capsule contains: Ciprofloxacin500mg Le-sive 250mg Capsule Levofloxacin (as	15-07-2010	dustrial Area 14-07-2015 14-07-2015	Islamabad. (D 14-09-2015 14-09-2015	_		
205. 206. 207.	065102 065103	R&A) Rules 1976.  maceuticals,124/A Kahu Pe-King 250mg Capsule Each capsule contains: Ciprofloxacin250mg Pe-King 500mg Capsule Each capsule contains: Ciprofloxacin500mg Le-sive 250mg Capsule Levofloxacin (as Hemihydrate)250mg	15-07-2010 15-07-2010	14-07-2015 14-07-2015	14-09-2015 14-09-2015	_		
205.	(L) Valor Phar 065101  065102	R&A) Rules 1976.  maceuticals,124/A Kahu Pe-King 250mg Capsule Each capsule contains: Ciprofloxacin250mg Pe-King 500mg Capsule Each capsule contains: Ciprofloxacin500mg Le-sive 250mg Capsule Levofloxacin (as Hemihydrate)250mg	15-07-2010	dustrial Area 14-07-2015 14-07-2015	Islamabad. (D 14-09-2015 14-09-2015	_		
205. 206. 207.	065102 065103	R&A) Rules 1976. maceuticals,124/A Kahu Pe-King 250mg Capsule Each capsule contains: Ciprofloxacin250mg Pe-King 500mg Capsule Each capsule contains: Ciprofloxacin500mg Le-sive 250mg Capsule Levofloxacin (as Hemihydrate)250mg Le-sive 500mg Capsule	15-07-2010 15-07-2010	14-07-2015 14-07-2015	14-09-2015 14-09-2015	_		
205. 206. 207.	065102 065103	R&A) Rules 1976.  maceuticals,124/A Kahu Pe-King 250mg Capsule Each capsule contains: Ciprofloxacin250mg Pe-King 500mg Capsule Each capsule contains: Ciprofloxacin500mg Le-sive 250mg Capsule Levofloxacin (as Hemihydrate)250mg	15-07-2010 15-07-2010	14-07-2015 14-07-2015	14-09-2015 14-09-2015	_		
205. 206. 207.	(L) Valor Phare 065101  065102  065103	R&A) Rules 1976.  maceuticals,124/A Kahu Pe-King 250mg Capsule Each capsule contains: Ciprofloxacin250mg Pe-King 500mg Capsule Each capsule contains: Ciprofloxacin500mg Le-sive 250mg Capsule Levofloxacin (as Hemihydrate)250mg Capsule Levofloxacin (as Hemihydrate)500mg	15-07-2010 15-07-2010 15-07-2010	dustrial Area 14-07-2015 14-07-2015 14-07-2015 14-07-2015	14-09-2015  14-09-2015  14-09-2015  14-09-2015	oml No.000496)  cts as renewal		
<ul><li>205.</li><li>206.</li><li>207.</li><li>208.</li></ul>	(Li Valor Phar 065101 065102 065103	R&A) Rules 1976.  maceuticals,124/A Kahu Pe-King 250mg Capsule Each capsule contains: Ciprofloxacin250mg Pe-King 500mg Capsule Each capsule contains: Ciprofloxacin500mg Le-sive 250mg Capsule Levofloxacin (as Hemihydrate)250mg Capsule Levofloxacin (as Hemihydrate)250mg Capsule Capsu	15-07-2010 15-07-2010 15-07-2010	dustrial Area 14-07-2015 14-07-2015 14-07-2015 14-07-2015	14-09-2015  14-09-2015  14-09-2015  14-09-2015	oml No.000496)  cts as renewal		
205. 206. 207. 208.	(L) Valor Phan 065101  065102  065104  sion: Re ap (L)	R&A) Rules 1976. maceuticals,124/A Kahu Pe-King 250mg Capsule Each capsule contains: Ciprofloxacin250mg Pe-King 500mg Capsule Each capsule contains: Ciprofloxacin500mg Le-sive 250mg Capsule Levofloxacin (as Hemihydrate)250mg Le-sive 500mg Capsule Levofloxacin (as Hemihydrate)500mg Capsule Levofloxacin (as Hemihydrate)500mg Capsule Levofloxacin (as Hemihydrate)500mg Capsule Levofloxacin (as Hemihydrate)500mg	15-07-2010 15-07-2010 15-07-2010 elled the reged after present	14-07-2015  14-07-2015  14-07-2015  14-07-2015  istration of cribed time p	14-09-2015  14-09-2015  14-09-2015  14-09-2015  above produceriod under in	oml No.000496)  cts as renewal		
206. 207. 208.  Decis	(L) Valor Phan 065101  065102  065104  ion: Re ap (L) Ceicil Labs	R&A) Rules 1976.  maceuticals,124/A Kahu Pe-King 250mg Capsule Each capsule contains: Ciprofloxacin250mg Pe-King 500mg Capsule Each capsule contains: Ciprofloxacin500mg Le-sive 250mg Capsule Levofloxacin (as Hemihydrate)250mg Le-sive 500mg Capsule Levofloxacin (as Hemihydrate)500mg Pegistration Board cance polication were submitter R&A) Rules 1976. (Pvt) Ltd.,21 km Ferozp	15-07-2010 15-07-2010 15-07-2010 15-07-2010 elled the reged after presented after presented the reged that the region that the region that the reged that the region that the regi	14-07-2015  14-07-2015  14-07-2015  14-07-2015  istration of cribed time pare.(DML No.0	14-09-2015  14-09-2015  14-09-2015  14-09-2015  above produceriod under (00384)	oml No.000496)  cts as renewal		
205. 206. 207. 208.	(L) Valor Phan 065101  065102  065104  sion: Re ap (L)	R&A) Rules 1976.  maceuticals,124/A Kahu Pe-King 250mg Capsule Each capsule contains: Ciprofloxacin250mg Pe-King 500mg Capsule Each capsule contains: Ciprofloxacin500mg Le-sive 250mg Capsule Levofloxacin (as Hemihydrate)250mg Le-sive 500mg Capsule Levofloxacin (as Hemihydrate)500mg Pegistration Board cance plication were submitter R&A) Rules 1976. (Pvt) Ltd.,21 km Ferozp Cedin Injection 200mg	15-07-2010 15-07-2010 15-07-2010 elled the reged after present	14-07-2015  14-07-2015  14-07-2015  14-07-2015  istration of cribed time p	14-09-2015  14-09-2015  14-09-2015  14-09-2015  above produceriod under in	oml No.000496)  cts as renewal		
205.  206.  207.  208.  Decis  M/s. 0 209.	(L) Valor Phare 065101  065102  065104  ion: Reap (L) Ceicil Labs 017257	R&A) Rules 1976.  maceuticals,124/A Kahu Pe-King 250mg Capsule Each capsule contains: Ciprofloxacin250mg Pe-King 500mg Capsule Each capsule contains: Ciprofloxacin500mg Le-sive 250mg Capsule Levofloxacin (as Hemihydrate)250mg Le-sive 500mg Capsule Levofloxacin (as Hemihydrate)500mg Pegistration Board cance polication were submitter R&A) Rules 1976. (Pvt) Ltd.,21 km Ferozp	15-07-2010 15-07-2010 15-07-2010 15-07-2010 elled the reged after presented after presented in the reged after presented in the region	14-07-2015  14-07-2015  14-07-2015  14-07-2015  istration of cribed time pore.(DML No.0 30-05-2015	14-09-2015  14-09-2015  14-09-2015  14-09-2015  above produceriod under in the control of the co	oml No.000496)  cts as renewal		

211.	017260	Anagon Injection 30mg	18-04-1995	17-04-2015	10-11-2015	
212.	017261	Cetac Injection 50mg/2ml	31-05-1995	30-05-2015	10-11-2015	
213.	017262	Cecin Injection 2mg	31-05-1995	30-05-2015	10-11-2015	
214.	017684	Temfin Injection 30mg/ml	18-07-1995	17-07-2015	10-11-2015	
215.	065596	Celof Injection 200mg/100ml Ofloxacin as HCI200mg	25-08-2010	24-08-2015	10-11-2015	
216.	065601	Cilmac Injection IM/IV 500mcg/ml Mecobalamin500mc g	25-08-2010	24-08-2015	10-11-2015	
217.	065602	Slay Injection IM/IV 500mg Kanamycin as Sulphate500mg	25-08-2010	24-08-2015	10-11-2015	
218.	065604	Cecyan 1000mg Injection IM/IV Vitamin B12100mcg	25-08-2010	24-08-2015	10-11-2015	
219.	065605	Crimson Injection 300mcg IM/IV Lincomycin as HCI300mg	25-08-2010	24-08-2015	10-11-2015	
220.	065606	Crimson Injection 600mcg IM/IV Lincomycin as HCI600mg	25-08-2010	24-08-2015	10-11-2015	
221.	065607	Ciros Injection 100mg	25-08-2010	24-08-2015	10-11-2015	
222.	065608	Cenac Injection IM Diclofenac Sodium75mg	25-08-2010	24-08-2015	10-11-2015	
223.	065609	Cevitax Injection IM/IV Contains: Thiamine HCI100mg	25-08-2010	24-08-2015	10-11-2015	
224.	065611	Slay Injection 1000mg Contains: Kanamycin as Sulphate1000mg	25-08-2010	24-08-2015	10-11-2015	
Decis	ар	gistration Board canc plications were submit R&A) Rules 1976.				
	liracle Pha	rmaceuticals (Pvt) Ltd., No.000593)	Plot No-8 Str	eet No-5 Natio	onal Industria	I Zone Rawat,
225.	066272	Mevoflox-250 Capsule Each capsule contains: Levofloxacin250mg	20-09-2010	19-09-2015	01-12-2015	
226.	066273	Mevoflox-500 Capsule Each capsule contains: Levofloxacin500mg	20-09-2010	19-09-2015	01-12-2015	
227.	066274	Cipocin-250 Capsule	20-09-2010	19-09-2015	01-12-2015	

	7	l <b>_</b>	İ	l	Ī	Γ
		Each capsule				
		contains:				
000	000075	Ciprofloxacin250mg	00.00.0040	10.00.0015	04 40 0045	
228.	066275	Cipocin-500 Capsule	20-09-2010	19-09-2015	01-12-2015	
		Each capsule				
		contains:				
		Ciprofloxacin500mg		40.00.004=	24 42 224	
229.	066276	Fadal Capsule	20-09-2010	19-09-2015	01-12-2015	
		Each Capsule				
		contains:				
<u> </u>	<u> </u>	Alfacalcidol 0.5mcg				
Decis		gistration Board cand				
	-	plications were submit R&A) Rules 1976.	ted after pres	scribea time	perioa unaer	rule 27 of Drug
M/s. G		narmaceuticals (Pvt) Ltd	Plot No.16/1	Phase No. IV	/ Industrial Es	tate Hattar
		ML No.000454)	,		maadina 20	iato Hattai
230.	002363-	Drotaverine Salveo	20-02-2010	19-02-2015	01-12-2015	
	EX	40mg Tablet				
231.	002365-	Enalapril Salveo 5mg	20-02-2010	19-02-2015	01-12-2015	
	EX	Tablet				
232.	002368- EX	Nitroglycerine Salveo 6.4mg SR Tablet	20-02-2010	19-02-2015	01-12-2015	
Decis		egistration Board cand	elled the red	istration of	above produ	l cts as renewal
Decis		plications were submit				
	•	R&A) Rules 1976.	ica and proc	oribed time	period dilaci	raic 27 or Brag
M/s. F		rmaceuticals (Pvt) Ltd.,	17-Km Ferozr	our Road Lah	ore. (DML No.	000621)
233.	064504	Koartum Suspension	03-06-2010	02-06-2015	16-12-2015	
	00.00.	Contains:	00 00 20.0	02 00 20.0	10 12 2010	
		Artemether15mg				
		Lumefantrine90mg				
Decis	ion: Re	gistration Board cance	lled the regist	ration of Koa	rtum Suspens	ion (064504)
	as	renewal applications w	ere submitted	l after prescri	bed time perio	od under rule 27
		Drug (LR&A) Rules 197				
M/s. / No.00		maceuticals, Plot No.2	291 Industrial	Triangle Ka	huta Road Is	lamabad. (DML
234.	062876	Secnaim 1gm Tablet	27-05-2010	26-05-2015	16-12-2015	
234.	002070	Each tablet contains:	27-03-2010	20-03-2013	10-12-2013	
		Secnidazole1gm				
235.	062875	Mefaim 250mg Tablet	27-05-2010	26-05-2015	16-12-2015	
200.	002073	Each tablet contains:	27-03-2010	20-03-2013	10-12-2013	
		Mefenamic				
		Acid250mg				
Decis	ion. Re	gistration Board canc	elled the red	istration of	above produ	cts as renewal
200.0		plications were submit				
	-	R&A) Rules 1976.				
	lacter Inte	rnational Ltd., F-216 SIT				
236.	003460	Benatus Cough Syrup	PRV:	18-10-2015	18-12-2015	
		Contains:	19.10.2010			
		Phenylephrine				
		HCl5mg				
		Diphenhydramine				
		HCl5mg				
		Dextromethorphan				
		HCI7.5mg				
00=	00015=	Chloroform10mg	<b>55</b> 1.	10.10.5515	40.40.00.00	
237.	000137	Benadryl Cough Syrup Each 5ml contains:-	PRV: 19.10.2010	18-10-2015	18-12-2015	

		Phenobarbitone				
238.	025644	20mg Benylin DM Cough Syrup Contains: Diphenhydramine	PRV: 19.10.2010	18-10-2015	18-12-2015	
		HCI12.50mg Dextromethorphan Hbr12.5mg	2007	10.10.001		
239.	025643	Benylin E Cough Syrup Contains: Dextromethorphan HBr12.50mg Pseudoephedrine HCl30mg Guaifenesin50mg	PRV: 19.10.2010	18-10-2015	18-12-2015	
240.	004851	Gelusil Plus Tablet Each tablet contains: Simethicone25mg Aluminum Hydroxide200mg Magnesium Hydroxide200mg	PRV: 19.10.2010	18-10-2015	18-12-2015	
241.	002430	Listrine Antiseptic Contains: Diphenhydramine HCI12.5mg Dextromethorphan HBR15mg Phenylephrine HCI10mg Ammonium Chloride125mg	PRV: 19.10.2010	18-10-2015	18-12-2015	
242.	007047	Mylenta 2 Liquid Each 5ml contains Aluminum Hydroxide400mg Simethicone30mg Magnesium Hydroxide400mg	PRV: 19.10.2010	18-10-2015	18-12-2015	
243.	019885	Unicap Syrup Each 5ml contains:- Thiamine HCl 1.0mg Pyridoxine HCl 0.5mg Niacinamide 10mg Ascorbic Acid 60mg Riboflavin 1.0mg Dexpanthenol 3.0mg Cyanocobalamin 3.0mcg Vitamin A 1.5mg Cholecalciferol 400IU	PRV: 19.10.2010	18-10-2015	18-12-2015	

244.	001082	Unicap M Tablet Each tablet contains: Thiamine HCl 1.0mg Pyridoxine HCl 0.5mg Niacinamide 10mg Ascorbic Acid 60mg Riboflavin 1.0mg Dexpanthenol 3.0mg Cyanocobalamin 3.0mcg Vitamin A 1.5mg Cholecalciferol 400IU	PRV: 19.10.2010	18-10-2015	18-12-2015	
245.	012302	Unicap T Tablet Each tablet contains: Vitamin A 1.5mg Vitamin D 12.5mcg Thiamine Mononitrate (B-1) 10mg Nicotinamide (B-3) 100mg Vitamin C 300mg Riboflavin (B-2) 10mg Cyanocobalamin (B12) 4.0mcg Pyridoxin HCI (B-6) 2.0mg Calcium Pantothenate 20mg Iron (as Ferrous Fumarate) 10mg Iodine (as Potassium Iodide) 0.15mg Copper (as Sulphate) 1mg Maganese (as Sulphate) 1mg Magnesium (as Oxide) 6mg Potassium (as Oxide) 5mg Calcium (as Carbonate) 50mg	PRV: 19.10.2010	18-10-2015	18-12-2015	
Decis		eferred for confirmation				n by the firm.
		rnational Ltd., F-216 SIT	E Karachi. (Di 10-01-2009	<b>VIL No.00011</b> 1 09-01-2014		
246.	053475	Witin 400mg Capsules Each capsules contains:	10-01-2009	09-01-2014	01-07-2014	
247.	055752	Gabapentin400mg Mac-Mether Plus Each tablet contains Artemether20mg, Lumefantrine120mg	15-04-2009	14-04-2014	19-11-2014	

Decis	ар	gistration Board canc plications were submit R&A) Rules 1976.				
M/s. 7		rmaceuticals (Pvt) Ltd.,	12-Km Bosan	Road Lutafah	ad Multan (DI	VI No.000603)
248.	052321	Speclin Forte Injection Lincomycin50ml Spectinomycin100 mg	19-12-2008	18-12-2013	12-02-2014	
Decis	ion: Re	gistration Board cance	lled the regist	ration of Spe	clin Forte Inje	ction (052321)
	Dr	renewal application wa ug (LR&A) Rules 1976		fter prescribe	d time period	under rule 27 of
		uman Health Limited La		1	T	T
249.	028481	Sorbid Injection Each 10ml ampoule contains: Isosorbide Dinitrate 10mg Sodium Chloride 90mg.	22-08-2003	21-08-2013	02-07-2014	
Decis	(0 rul	egistration Board c 28481) as renewal appli le 27 of Drug (LR&A) Ru		•		rbid Injection ne period under
	_	e Co., Rawalpindi	07.05.4000	00 05 0044	00 07 0044	1
250.	023647	Solu-Hydrocort Injection 500mg (IM/IV) Each vial contains: Hydrocortisone Sodium Succinate500mg	27-05-1999	26-05-2014	28-07-2014	
Decis	(IN un	egistration Board cance M/IV) (023647) as renewa der rule 27 of Drug (LR armaceuticals (Pvt) Lt	al application ( &A) Rules 197	was submitte 6	d after prescri	bed time period
	0565)	illiaceuticais (FVI) Lu	u., 1-vv   111uus	illai Estate	i layatabau P	esilawai. (DiviL
251.	060090	Pranax Tablets Each tablet contains: Alprazolam 0.5mg	12-08-2009	11-08-2014	05-08-2014	
Decis	ion: Re	gistration is valid as re	newal applica	tion was subi	mitted before	due date.
M/s. S		rmaceuticals (Pvt) Ltd		pur Road, La	hore. (DML N	
252.	048358	Maxbon Tablet 70mg Each tablet contains Alendronate as Sodium 70mg	28-01-2008	27-01-2013	28-08-2014	
253.	048349	Isocef-DS Dry Suspension Each 5ml contains Cefixime 200mg	28-01-2008	27-01-2013	03-09-2014	
254.	048357	Silymax Tablet Each tablet contains Silymarin 105mg	28-01-2008	27-01-2013	03-09-2014	
255.	048352	Isocef Capsule 200mg Each Capsule Contains Cefixime 200mg	28-01-2008	27-01-2013	03-09-2014	

Decision: Registration Board cancelled the registration of above products as renewal applications were submitted after prescribed time period under rule 27 of Drug (LR&A) Rules 1976.

		Industries (Pvt) Ltd.,17/2				05)
256.	055579	Stir-Up 10mg/g Oral Drops Solution Each g of solution contains: Memantine HCI10mg	31-03-2009	30-03-2014	27-09-2014	
257.	055580	Aferdoze Tablets Each chewable tablet contains: Iron(III) Hydroxide Polymaltose eq to Elemental Iron100mg	31-03-2009	30-03-2014	27-09-2014	
258.	055581	Aferdoze Syrup Each 5ml contains: Iron(III) Hydroxide Polymaltose eq to Elemental Iron	31-03-2009	30-03-2014	27-09-2014	
259.	055582	Irpo Oral Drops Each ml contains: Iron(III) Hydroxide Polymaltose eq to Elemental Iron50mg	31-03-2009	30-03-2014	27-09-2014	
260.	055583	Romycin 250mg Tablets Each film coated tablet contains: Azithromycin (as dihydrate)250mg	31-03-2009	30-03-2014	27-09-2014	
261.	055584	Romycin 500mg Tablets Each film coated tablet contains: Azithromycin (as dihydrate)500mg	31-03-2009	30-03-2014	27-09-2014	
262.	055585	Diamet 250mg Tablets Each tablet contains: Metformin Hcl250mg	31-03-2009	30-03-2014	27-09-2014	
263.	055586	Diamet 500mg Tablets Each tablet contains: Metformin Hcl500mg	31-03-2009	30-03-2014	27-09-2014	
264.	055587	Fersul 200mg Tablets Each tablet contains: Ferrous Sulphate USP200mg	31-03-2009	30-03-2014	27-09-2014	
265.	055588	Zudic Suspension Each 5ml contains: Fusidic Acid BP250mg	31-03-2009	30-03-2014	27-09-2014	

266.	055589	Probetic G 15/2 tablet Each tablet contains: Pioglitazone (as HCl) 15mg Glimepiride 2mg	31-03-2009	30-03-2014	27-09-2014	
267.	055590	Glanorm 5mg Tablets Each tablet contains: Glibenclamide5mg	31-03-2009	30-03-2014	27-09-2014	
268.	055591	Bacip 500mg Tablets Each film coated tablet contains: Ciprofloxacin HCL eq to Ciprofloxacin USP500m	31-03-2009	04-06-2018	27-09-2014	
269.	055577	Limus 0.03% Ointment Each gm contains: Tacrolimus USP(as Monohydrate)	31-03-2009	30-03-2014	27-09-2014	
270.	055592	Lesprot 20mg Tablet Each enteric coated tablet contains: Pantoprazole (as sodium sesquihydrate)20mg	31-03-2009	30-03-2014	27-09-2014	
271.	055621	Meflox 400mg Tablets Each film coated tablet contains: Moxifloxacin HCL eq to Moxifloxacin400mg	01-04-2009	31-03-2014	27-09-2014	
272.	055622	Eziflo SR 5mg Tablet Each extended release coated tablet contains: Alfuzosin HCL5mg	01-04-2009	31-03-2014	27-09-2014	
273.	055623	Eziflo XL 10mg Tablet Each extended release coated tablet contains: Alfuzosin HCL10mg	01-04-2009	31-03-2014	27-09-2014	
Decis		e firm informed that rer				
	ар	plications are within tin	ne and registr	ations are val	id.	
	Roryan Pha No.000566	rmaceutical industries	(Pvt) Ltd.,85-E	B Hayatabad I	ndustrial Esta	te Peshawar.
274.	060088	Esoyan-40mg Capsule Each Capsule Contains: Esomeprazole (as	12-08-2009	11-08-2014	16-10-2014	

			T	1		1
		Magnesium Trihydrate				
		coated pellets)40mg				
	050400	D :     T	04.00.0000	00 00 0011	10.10.0011	
275.	059422	Rovidol Tablet	04-08-2009	03-08-2014	16-10-2014	
		Each tablet contains:				
		Paracetamol500mg				
		Caffeine65mg				
		Chlorpheniramine				
D ! -	<u> </u>	Maleate2mg	-111 41			-1
Decis		egistration Board cand plications were submit				
		R&A) Rules 1976.	iou unoi proc	oribed time	scriba ariaci	raio Er or Brag
	-Jans Pha	rmaceutical (Pvt) Ltd.,1	48-A Industria	I Estate Haya	tabad Peshaw	ar. (DML
No.00		T	T	1		
276.	059460	Zeporin Injection 1gm	04-08-2009	03-08-2014	11-11-2014	
		Each vial contains:				
		Cephalexin1gm				
277.	059468	Ceforan Injection	04-08-2009	03-08-2014	11-11-2014	
		500mg				
		Each vial contains:				
0=0	050/	Ceforanide500mg	04.00.5555	00.00.00.0	4444	
278.	059452	Ofloxa-Z Infusion 2mg	04-08-2009	03-08-2014	11-11-2014	
		Each ml contains:				
	050450	Ofloxacin2mg	04.00.0000	00 00 0011	11 11 0011	
279.	059459	Zeporin Injection	04-08-2009	03-08-2014	11-11-2014	
		500mg				
		Each vial contains:				
200	050450	Cephalexin500mg	04.00.0000	00.00.0044	44 44 0044	
280.	059458	Zeporin Injection	04-08-2009	03-08-2014	11-11-2014	
		250mg Each vial contains:				
281.	059462	Cephalexin250mg Emexin Injection	04-08-2009	03-08-2014	11-11-2014	
201.	039402	500mg	04-00-2009	03-00-2014	11-11-2014	
		Each vial contains:				
		Cefotaxime(as				
		sodium) 500mg				
282.	059482	Linzee Injection	04-08-2009	03-08-2014	11-11-2014	
202.	000102	Each ml ampoule	01002000	00 00 2011	11 11 2014	
		contains:-				
		Lincomycin (as HCI)				
		300mg				
283.	045948	Zelium Suspension	06-01-2007	05-01-2012	11-11-2014	
		Each 5ml contains:				
		Domperidon5mg				
284.	059477	Triam Injection	04-08-2009	03-08-2014	11-11-2014	
		Each ml contains:-				
		Triamcinolone				
		acetonide 40mg				
285.	059478	Lamin Injection	04-08-2009	03-08-2014	11-11-2014	
		Each ml ampoule				
		contains:-				
		Mecobalamin				
000	050454	500mcg	04.00.000	00.00.001	44.44.004.5	
286.	059474	Zortum 1gm Injection	04-08-2009	03-08-2014	11-11-2014	
	Ì	Each vial contains:	Ī	1		i l

	]	Ceftazidime1gm				
287.	059463	Emexin Injection 1gm Each vial contains:- Cefotaxime(as sodium) 1gm	04-08-2009	03-08-2014	11-11-2014	
288.	059479	Lofsim Injection Each 3ml ampoule contains:- Diclofenac Sodium 75mg	04-08-2009	03-08-2014	11-11-2014	
289.	059467	Cefep 1gm Injection Each vial contains:- Cefepime (as HCI) 1gm	04-08-2009	03-08-2014	11-11-2014	
290.	059473	Zortum 500mg Injection Each vial contains: Ceftazidime500mg	04-08-2009	03-08-2014	11-11-2014	
291.	059464	Lores 500mg Injection Each vial contains: Cefpirome500mg	04-08-2009	03-08-2014	11-11-2014	
292.	059480	Nilvom Injection 50mg Each ml ampoule contains:- Dimenhydrinate 50mg	04-08-2009	03-08-2014	11-11-2014	
293.	059465	Lores 1gm Injection Each vial contains: Cefpirome1gm	04-08-2009	03-08-2014	11-11-2014	
294.	059466	Cefep Injection Each vial contains:- Cefepime (as HCI) 500mg	04-08-2009	03-08-2014	11-11-2014	
295.	059450	Oxirase DS Infusion Each ml contains:- Ciprofloxacin (as Lactate) 4mg	04-08-2009	03-08-2014	11-11-2014	
296.	059451	Oxa-Z infusion Each ml contains:- Levofloxacin 5mg	04-08-2009	03-08-2014	11-11-2014	
297.	059455	Zoclan Injection 500mg Each vial contains:- Ceftriaxone (as sodium) 500mg	04-08-2009	03-08-2014	11-11-2014	
298.	059456	Azosul Injection 1gm Each vial contains:- Cefoperazone (as sodium)500mg, Sulbactam (as sodium) 500mg	04-08-2009	03-08-2014	11-11-2014	
299.	059457	Azosul Injection 500mg Each vial contains:- Cefoperazone (as sodium)250mg	04-08-2009	03-08-2014	11-11-2014	

		Sulbactam (as sodium) 250mg				
		30010111 <i>)</i> 230111g				
300.	059486	Xocrel Capsule 40mg Each capsule contains: Esomeprazole40mg	04-08-2009	03-08-2014	26-12-2014	
301.	059487	Xocrel Capsule 20mg Each capsule contains: Esomeprazole20mg	04-08-2009	03-08-2014	26-12-2014	
Decis		gistration Board canc				
		plications were submit	ted after pres	cribed time	period under	rule 27 of Drug
		R&A) Rules 1976.				
		mical Industries (Pvt) Ltd				DML No.000151
302.	004399	Gastrolon Tablet	15-01-1979	14-01-2014	01-12-2014	
		Each tablet contains:-				
		Metoclopramide10				
Decis	ion. Po	mg	ollad the rea	istration of t	Controlon Tob	lot oo ronowo
Decis	ion: Re	egistration Board canc plication was submitte	elled the reg	istration of t	sastroion Tai	rulo 27 of Drug
		R&A) Rules 1976.	d aller presu	inbed tille p	erioù uriuer i	ule 21 of Diu
M/s C		harma (Pvt) Ltd.,35-Km	Multan Road	lahore (DMI	No 000619)	
303.	049469	Femicure 40mg Tablet	15-07-2008	14-07-2013		
		Each tablet contains:				
		Famotidine40mg				
304.	059468	Femicure 20mg Tablet	15-07-2008	14-07-2013	11-12-2014	
		Each tablet contains:				
		Famotidine20mg				
Decis	ion· Re	l edistration Board cand	elled the rec	istration of	ahove produ	cts as renewa
20013	Decision: Registration Board cancelled the registration of above products as renewal applications were submitted after prescribed time period under rule 27 of Drug					
	-	R&A) Rules 1976.				

# Case No: 9 Renewal application of Ondansetron Normon 8mg Injection of M/s Merixil Pharma Islamabad.

M/s Merixil Pharma Islamabad informed that the Custom Air Freight Unit Islamabad imposed condition of submitting renewal letter for clearance of consignment of Ondansetron Normon 8mg Injection. The firm requested that as application of renewal was submitted within due time hence renewal letter may be issued in order to avoid heavy demurrages and in order to ensure availability of product in market. Accordingly, Custom Air Freight Unit Islamabad was infirmed vide Letter F.No.1-1/2022(RRR) dated 31.03.2022 that under Rule 27 of Drug (Licensing, Registering & Advertising) Rules 1976, the certificate of registration shall, unless earlier suspended or cancelled, be in force for a period of five years for date of registration of drug and may thereafter be renewed for periods not exceeding five years at a time. Provided that if application for renewal is made before the expiry of the period of validity of certificate the certificate shall continue in force until orders are passed on such application. Hence the registration of Ondansetron Normon 8mg Injection registered vide No. 081802 is valid as renewal application is submitted before due date i.e. on 04.08.2021. Further the aforesaid renewal application shall be placed before the Registration Board being Competent Forum for consideration of grant of renewal for further period

Reg. No.	Brand Name & Composition	Initial date of Registration PRV (If any)	Date of application (R&I) Fee submitted	Document details
081802	Ondansetron Normon 8mg Injection	16.09.2016	Dy No.21304 dated 04.08.2021 Rs.30000/-	Valid legalized CoPP No. 2021/ 01614 issued by Head of the Department

Each 4ml vial contains: Ondansetron (as hydrochloride dihydrate)8mg (Manufacturer Specifications)	of Medicines for Human Use of Spanish Agency of Medicines and Health Products dated 23.07.2021.
Product License Holder & Manufacturer M/s Laboratorios Norman, SA Ronda De Valdecarrizo, 6, 28760 Tres Cantos, Madrid, Spain.	

Decision: Registration Board granted renewal to Ondansetron Normon 8mg Injection

(081802) w.e.f. 16.09.2021 to 15.09.2026 as per policy of inspection of

manufacturers abroad.

Case No. 10: Renewal application of M/s. Akson Pharmaceutical Pvt Ltd, Mirpur Azad Kashmir

M/s. Akson Pharmaceutical Pvt Ltd, Mirpur Azad Kashmir has informed that they have been issued Drug Import License for Diclofenac sodium API for their registered product Aksofenac tablet 50mg (Reg no.023738) which is subject to the confirmation of registration/renewal status of aforesaid product. The details are as under:

Reg. No.	Brand Name & Composition	Initial date of Registration	Date of application (R&I)	Remarks
		PRV (If any)	Fee submitted	
023738	Aksofenac tablet	14.09.2001	Rs. 10000/-	Renewal for the
	50mg		dated	year 2019 is
	Each tablet contains:	Approval of Re-	02.04.2014	submitted within
	Diclofenac sodium	registration:	Rs. 20000/-	sixty days.
	50mg	13.04.2009	dated	
			29.04.2019	

Decision: Registration Board while considering above facts granted renewal w.e.f 13.04.2019 to 12.04.2024 to Aksofenac tablet 50mg (023738).

## **Pharmaceutical Evaluation Cell (PEC)**

Sr. No	Name of Evaluator	Title
1.	Mr. Ammar Ashraf Awan	Evaluator PEC-II
2.	Mr. Muhammad Haseeb Tariq	Evaluator PEC-III
3.	Mst.Farzana Raja	Evaluator PEC-IV
4.	Mr. Muhammad Umar Latif	Evaluator PEC-VI
5.	Dr. Sidra Khalid	Evaluator PEC-VII
6.	Dr. Hanif Ullah	Evaluator PEC-IX
7.	Dr. Farhadullah	Evaluator PEC-XI
8.	Mr. Shahid Nawaz	Evaluator PEC-XIII
9.	Mr. Ahsan Hafiz	Evaluator PEC-XIV
10.	Mst. Saima	Evaluator PEC-XV
11.	Mr. Akbar Ali	Evaluator PEC-XVI
12.	Mr. Zia Ullah	Evaluator PEC-XVII
13.	Mr. Syed Ajwad Bukhari	AD PE&R

#### a) Cefixime capsule Specifications:

Registration Board in its 313<sup>th</sup> meeting considered the case for specifications of cefixime capsule and approved the monograph for cefixime capsule and also decided to notify for information of all manufacturers and regulatory laboratories. The monograph was notified vide No. F.14-1/2022-PEC dated 14<sup>th</sup> March, 2022. However, while processing the case for notification few typographic mistakes were identified which were rectified before the final notifications. The mistakes which were corrected are presented below for the information of Registration Board.

#### **CEFIXIME CAPSULES**

Cefixime Capsules contain not less than 90.0% and not more than 105.0% of the labeled potency of cefixime  $(C_{16}H_{15}N_5O_7S_2: 453.45)$ .

## 1. IDENTIFICATION:

Take out the contents of Cefixime Capsules, to a quantity of the contents of Cefixime Capsules, equivalent to 70 mg (potency) of Cefixime Hydrate, add 100 mL of 0.1 mol/L phosphate buffer solution (pH 7.0), shake for 30 minutes, and filter. To 1 mL of the filtrate add 0.1 mol/L phosphate buffer solution (pH 7.0) to make 50 mL. Determine the absorption spectrum of this solution using Ultraviolet-visible Spectrophotometry: it exhibits a maximum between 286 nm and 290 nm.

#### 2. PURITY: Related substances—

Take out the contents of Cefixime Capsules, to a quantity of the contents of Cefixime Capsules, equivalent to 0.1 g (potency) of Cefixime Hydrate, add 100 mL of 0.1 mol/L phosphate buffer solution (pH 7.0), shake for 30 minutes, filter, and use the filtrate as the sample solution. Perform the test with 10 mL µL of the sample solution using Liquid Chromatography according to the following conditions.

Determine each peak area from the sample solution by the automatic integration method, and calculate the amount of them by the area percentage method: the amount of each peak other than cefixime is not more than 1.0%, and the total amount of the peaks other than cefixime is not more than 2.5%.

#### Operating conditions—

**Detector:** An ultraviolet absorption photometer (wavelength: 254 nm).

**Column:** A stainless steel column 4 mm in inside diameter and 125 mm in length, packed with octadecylsilanized silica gel for liquid chromatography (4mm µm in particle diameter).

**Column temperature:** A constant temperature of about 40°C.

*Mobile phase:* To 25 mL of a solution of tetrabutylammonium hydroxide TS (10 in 13) add water to make 1000 mL, adjust to pH 6.5 with diluted phosphoric acid (1 in 10). To 300 mL of this solution add 100 mL of acetonitrile.

*Flow rate:* Adjust so that the retention time of cefixime is about 10 minutes.

**Time span for measurement:** About 3 times as long as the retention time of cefixime beginning after the solvent peak.

#### System suitability—

## Test for required detectability:

Pipet 1 mL of the sample solution, and add 0.1 mol/L phosphate buffer solution (pH 7.0) to make exactly 100 mL, and use this solution as the solution for system suitability test. Pipet 1 mL of the solution for system suitability test, and add 0.1 mol/L phosphate buffer solution (pH 7.0) to make exactly 10 mL. Confirm that the peak area of cefixime obtained from  $10 \frac{\text{mL}}{\text{m}} \frac{\text{m}}{\text{m}} \text{L}$  of this solution is equivalent to 7 to 13% of that obtained from  $10 \frac{\text{m}}{\text{m}} \frac{\text{m}}{\text{m}} \text{L}$  of the solution for system suitability test.

System performance: When the procedure is run with 10mL µL of the solution for system suitability test under the above operating conditions, the number of theoretical plates and the symmetry factor of the peak of cefixime are not less than 4000 and not more than 2.0, respectively.

System repeatability: When the test is repeated 6 times with 10mL µL of the solution for system suitability test under the above operating conditions, the relative standard deviation of the peak area of cefixime is not more than 2.0%.

#### 3. WATER:

Not more than 12.0% (0.1 g of the contents, volumetric titration, direct titration).

## 4. UNIFORMITY OF DOSAGE UNITS:

Perform the Mass variation test, or the Content uniformity test according to the following method *Sample solution:* 

Take out the contents of 1 capsule of Cefixime Capsules, and to the contents and the capsule shells add 7V/10~mL of 0.1~mol/L phosphate buffer solution (pH 7.0), shake for 30minutes, and add 0.1~mol/L phosphate buffer solution (pH 7.0) to make exactly V mL so that each mL contains about 1 mg (potency) of Cefixime Hydrate. Centrifuge this solution, pipet 10~mL of the supernatant liquid, add 0.1~mol/L phosphate buffer solution (pH 7.0) to make exactly 50~mL, and use this solution as the sample solution.

#### Standard solution

Separately, weigh accurately an amount of Cefixime RS, equivalent to about 20 mg (potency), dissolve in 0.1 mol/L phosphate buffer solution (pH 7.0) to make exactly 100 mL, and use this solution as the standard solution.

#### **Procedure**

Perform the test with exactly 10mL  $\mu$ L each of the sample solution and standard solution using Liquid Chromatography according to the following conditions, and determine the peak areas,  $A_T$  and  $A_S$ , of cefixime in each solution.

Amount [ $\mu g \text{ mg (potency)}]$  of Cefixime ( $C_{16}H_{15}N_5O_7S_2$ ) =  $MS \times A_T/A_S \times \frac{10000}{V/20}$ 

MS: Amount [mg (potency)] of Cefixime RS taken

## Operating conditions—

**Detector:** An ultraviolet absorption photometer (wavelength: 254 nm).

**Column:** A stainless steel column 4 mm in inside diameter and 125 mm in length, packed with octadecylsilanized silica gel for liquid chromatography (4mm µm in particle diameter).

**Column temperature:** A constant temperature of about 40°C.

*Mobile phase:* To 25 mL of a solution of tetrabutylammonium hydroxide TS (10 in 13) add water to make 1000 mL, adjust to pH 6.5 with diluted phosphoric acid (1 in 10). To 300 mL of this solution add 100 mL of acetonitrile.

*Flow rate:* Adjust so that the retention time of cefixime is about 10 minutes.

## System suitability—

## System performance:

When the procedure is run with  $10 \text{mL} \, \mu \text{L}$  of the standard solution under the above operating conditions, the number of theoretical plates and the symmetry factor of the peak of cefixime are not less than 4000 and not more than 2.0, respectively.

#### System repeatability:

When the test is repeated 6 times with 10mL µL of the standard solution under the above operating conditions, the relative standard deviation of peak areas of cefixime is not more than 2.0%.

## **5. DISSOLUTION:**

Apparatus: Basket (I) RPM: 100

Medium: 0.05 M Phosphate Buffer, pH 7.2

Volume: 900ml Time: 45 minutes

## Sample solution:

Start the test with 1 capsule of Cefixime Capsules, withdraw not less than 20 mL of the medium 45 minutes after starting the test, and filter through a membrane filter with a pore size not exceeding  $0.5 \frac{1}{10}$  mL. Discard the first 10 mL of the filtrate, pipet V mL of the subsequent filtrate, add the dissolution medium to make exactly V' mL so that each mL contains about 56 µg (potency) of Cefixime Hydrate, and use this solution as the sample solution.

#### Standard solution:

Separately, weigh accurately an amount of Cefixime RS, equivalent to about 28 mg (potency), and dissolve in the dissolution medium to make exactly 100 mL. Pipet 4 mL of this solution, add the dissolution medium to make exactly 20 mL, and use this solution as the standard solution.

## Procedure:

Perform the test with exactly 20  $\mu$ L each of the sample solution and standard solution as directed under Liquid Chromatography according to the following conditions, and determine the peak areas,  $A_T$  and  $A_S$ , of cefixime in each solution.

Dissolution rate (%) with respect to the labeled amount of cefixime ( $C_{16}H_{15}N_5O_7S_2$ )

 $= M_S \times A_T/A_S \times V'/V \times 1/C \times 180$ 

MS: Amount [mg (potency)] of Cefixime RS taken

C: Labeled amount [mg (potency)] of Cefixime Hydrate in 1 capsule

Acceptance criteria: Not Less than 80% in 45 minutes

## Operating conditions—

**Detector:** An ultraviolet absorption photometer (wavelength: 254 nm).

**Column:** A stainless steel column 4 mm in inside diameter and 125 mm in length, packed with octadecylsilanized silica gel for liquid chromatography (4mm um in particle diameter).

**Column temperature:** A constant temperature of about 40°C.

*Mobile phase:* To 25 mL of a solution of tetrabutylammonium hydroxide TS (10 in 13) add water to make 1000 mL, adjust to pH 6.5 with diluted phosphoric acid (1 in 10). To 300 mL of this solution add 100 mL of acetonitrile.

*Flow rate:* Adjust so that the retention time of cefixime is about 10 minutes.

System suitability—

## System performance:

When the procedure is run with 20  $\mu$ L of the standard solution under the above operating conditions, the number of theoretical plates and the symmetry factor of the peak of cefixime are not less than 4000 and not more than 2.0, respectively.

## System repeatability:

When the test is repeated 6 times with 20mL µL of the standard solution under the above operating conditions, the relative standard deviation of the peak area of cefixime is not more than 2.0%.

#### 6. ASSAY:

## Operating conditions—

**Detector:** An ultraviolet absorption photometer (wavelength: 254 nm).

**Column:** A stainless steel column 4 mm in inside diameter and 125 mm in length, packed with octadecylsilanized silica gel for liquid chromatography (4mm µm in particle diameter).

**Column temperature:** A constant temperature of about 40°C.

*Mobile phase:* To 25 mL of a solution of tetrabutylammonium hydroxide TS (10 in 13) add water to make 1000 mL, adjust to pH 6.5 with diluted phosphoric acid (1 in 10). To 300 mL of this solution add 100 mL of acetonitrile.

*Flow rate:* Adjust so that the retention time of cefixime is about 10 minutes.

## Sample solution:

Take out the contents of not less than 20 Cefixime Capsules, weigh accurately the mass of the contents, and powder. Weigh accurately a portion of the powder, equivalent to about 0.1 g (potency) of Cefixime Hydrate, add 70 mL of 0.1 mol/L phosphate buffer solution (pH 7.0) and shake for 30 minutes, add 0.1 mol/L phosphate buffer solution (pH 7.0) to make exactly 100 mL. Centrifuge this solution, pipet 10 mL of the supernatant liquid, add 0.1 mol/L phosphate buffer solution (pH 7.0) to make exactly 50 mL, and use this solution as the sample solution.

## Standard solution:

Separately, weigh accurately an amount of Cefixime RS, equivalent to about 20 mg (potency), dissolve in 0.1 mol/L phosphate buffer solution (pH 7.0) to make exactly 100 mL, and use this solution as the standard solution.

## Procedure:

Perform the test with exactly 10mL  $\mu$ L each of the sample solution and standard solution using Liquid Chromatography and determine the peak areas,  $A_T$  and  $A_S$ , of cefixime in each solution.

Amount [mg (potency)] of cefixime ( $C_{16}H_{15}N_5O_7S_2$ )

 $= M_S \times A_T/A_S \times 5$ 

M<sub>S</sub>: Amount [mg (potency)] of Cefixime RS taken

#### System suitability—

System performance: When the procedure is run with 10<sub>mL</sub> µL of the standard solution under the above operating conditions, the number of theoretical plates and the symmetry factor of the peak of cefixime are not less than 4000 and not more than 2.0, respectively.

System repeatability: When the test is repeated 6 times with 10mL µL of the standard solution under the above operating conditions, the relative standard deviation of peak areas of cefixime is not more than 2.0%. Containers and storage Containers—Tight containers.

Decision: Registration Board noted the correction in the monograph as cited above and endorsed the notification.

## Case No. 01 Registration applications of CTD cases

DRAP Authority in its 129<sup>th</sup> meeting held on 17-02-2022 decided as follows:

## a. Priority cases of new drugs

The Authority appreciated the efforts of PE&R Division for effective and phase wise implementation of CTD and after detailed deliberations approved the out of queue consideration of registration applications of New Chemical Entities on CTD format (Form 5F).

1.	Name, address of Applicant / Marketing Authorization Holder	M/s The Schazoo Pharmaceutical Laboratories (Pvt) Ltd. Kalalwala Stop, 20Km Lahore-Jaranwala Road, District Sheikhupura.	
	Name, address of Manufacturing site.	M/s The Schazoo Pharmaceutical Laboratories (Pvt) Ltd. Kalalwala Stop, 20Km Lahore-Jaranwala Road, District Sheikhupura.	
	Status of the applicant	<ul> <li>✓ Manufacturer</li> <li>☐ Importer</li> <li>☐ Is involved in none of the above (contract giver)</li> </ul>	
	GMP status of the firm	The firm was granted GMP certificate based on inspection dated 30-05-2019. The GMP certificate specifies Tablet (Non antibiotic, antibiotic) section.	
	Evidence of approval of manufacturing facility	The firm was granted GMP certificate based on inspection dated 30-05-2019. The GMP certificate specifies Tablet (Non antibiotic, antibiotic) section.	
	Status of application	<ul><li>☑ New Drug Product (NDP)</li><li>☐ Generic Drug Product (GDP)</li></ul>	
	Intended use of pharmaceutical product	<ul> <li>□ Domestic sale</li> <li>□ Export sale</li> <li>☑ Domestic and Export sales</li> </ul>	
	Dy. No. and date of submission	Dy. No. 24353: 03-09-2021	
	Details of fee submitted	PKR 75,000/-: 20-08-2021	
	The proposed proprietary name / brand name	LOWMINE Tablet 2.5mg	

Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each uncoated tablet Contains: Minoxidil2.5mg
Pharmaceutical form of applied drug	Light pink coloed oblong uncoated tablet with an eye type breakline on one side blistered in (3x10's Alu-PVC blister
Pharmacotherapeutic Group of (API)	Antihypertensive agent (C02DC01)
Reference to Finished product specifications	USP
Proposed Pack size	3 x 10's
Proposed unit price	As per SRO
The status in reference regulatory authorities	USFDA Approved
For generic drugs (me-too status)	Not Applicable
Name and address of API manufacturer.	ICROM Srl. Via Delle Arti, 33, Concorezzo 20863 Italy
Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PI template. Firm has summarized information related to nomenclature, structure, general properties, solubilities, physical form manufacturers, description of manufacturing process and controls, impurities, specifications analytical procedures and its validation, batch analysis and justification of specification reference standard, container closure system and stability studies of drug substance and drug product.
Module-III Drug Substance:	Firm has submitted detailed data for drug substance data related to nomenclature, structure, general properties, solubilities, physical form manufacturers, description of manufacturin process and controls, impurities, specifications analytical procedures and its validation, bate analysis and justification of specification reference standard, container closure system an stability studies of drug substance.
Stability Studies of Drug Substance (Conditions & duration of Stability studies)	Firm has submitted stability study data of 3 batche of drug substance at both accelerated as well as reatime conditions. The accelerated stability data is conducted at $40^{\circ}\text{C} \pm 2^{\circ}\text{C} / 75\% \pm 5\%$ RH for months. The real time stability data is conducted at $30^{\circ}\text{C} \pm 2^{\circ}\text{C} / 65 \pm 5\%$ RH for 60 months.
Module-III Drug Product:	Firm has submitted data of drug product includin its description, composition, pharmaceutica development, manufacture, manufacturing process and process control, process validation protocols control of excipients, control of drug produc specifications, analytical procedures, validation of analytical procedures, batch analysis, justificatio of specifications, reference standard or materials container closure system and stability.
Pharmaceutical Equivalence and Comparative Dissolution Profile	Firm has submitted results of pharmaceutical equivalence for all the quality tests for the product against Loniten Tablet.

			Firm has submitted results of CDP studies in three dissolution medium of their product against Loniten Tablet.		
				rerification studies of the drug ical method validation of the	
		STABILITY S	STU	UDY DATA	
Man	ufacturer of API	ICROM Srl. Via Dell	e A	Arti, 33, Concorezzo 2	20863. Italy
API I	Lot No.	21008			
	ription of Pack tainer closure system)	Alu-PVC blister			
Stabi	ility Storage Condition	Real time : $30^{\circ}\text{C} \pm 2^{\circ}\text{C}$ Accelerated: $40^{\circ}\text{C} \pm 2^{\circ}$			
Time	e Period	Real time: 6 months Accelerated: 6 month	ıS		
Freq	uency	•	Accelerated: 0, 3, 6 (Months) Real Time: 0, 3, 6 (Months)		
Batc	h No.	LNT/LT1/21		LNT/LT2/21	LNT/LT3/21
Batc	h Size	3000 Tablet		3000 Tablet	3000 Tablet
Man	ufacturing Date	03-2021		03-2021	03-2021
Date	of Initiation	20-03-2021		20-03-2021	20-03-2021
No. o	of Batches			03	
	DOCUMENTS / DATA	TO BE PROVIDED	ΑI	LONG WITH STAB	ILITY STUDY DATA
1. Reference of previous approval of applications with stability study data of the firm (if any)			conducted for the conducted on 30th Maby Registration Board Board approved the canoted in the inspectio.  The firm has test real time studies complaint as they HPLC at that time 21CFR compliant remaining studies compliant HPLC's tested on SPD-II SPD-II) and 12, studies tested on PPD). The HPLC manager, QC Man Manager) having and have separate software has been compliance is attaction.	their previous PSI inspection product Valanza Tablet by 2019 which was considered and in its 290th meeting. The ase and following things were in report:  ed 6 months accelerated and on HPLC that is not 21CFR do not have 21CFR complaint be. After that they purchased at HPLC's and conducted the son two different 21CFR is i.e. 9 month real time studies (21 CFR Compliant HPLC-18 and 24 months real time and 24 months real time and 24 group user's (IT ager, Method Developer, QA separate login and password rights of administration. The validated and its certificate of ched with the report.	

from 9 months onwards.

• Related manufacturing area, equipment, personnel and utilities can be rated as compliant.

2.	<del>_</del> _	Firm has submitted copy of GMP certificate (No. IT-API/200/H/2020) issued by Italian Medicine Agency based on the inspection dated 26-07-2019. The certificate is available online at EudraGMP database.
3.	Documents for the procurement of API with approval from DRAP (in case of import).	Firm has also submitted copy of commercial invoice dated 09-03-2021 specifying import of 0.05Kg Minoxidil. The invoice is cleared by AD (I&E) DRAP.
4.	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	all batches along with raw data sheets, COA and
5.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	Firm has submitted HPLC audit trail reports
6.		Firm has submitted record of digital data logger for temperature and humidity monitoring of real time and accelerated stability chambers.

#### **Evaluation by PEC(III):**

• Firm has initially submitted 3 months stability study data. Later the firm has submitted 6 months stability study data conducted on 23-09-2021 along with relevant analytical records.

**Discussion:** Registration Board thoroughly reviewed the innovator drug product approved by USFDA and observed that because of the potential for serious adverse effects, the product is indicated only in the treatment of hypertension that is symptomatic or associated with target organ damage and is not manageable with maximum therapeutic doses of a diuretic plus two other antihypertensive drugs. At the present time use in milder degrees of hypertension is not recommended because the benefit-risk relationship in such patients has not been defined. The Board also reviewed the Risk Management Plan submitted by M/s Schazoo to ensure its use only for the indication as that of the innovator product.

Decision: Registration Board after thorough deliberation and considering the Risk Management Plan submitted by the firm, decided to approve the product with the clinical conditions of the innovator's drug product and approval by USFDA and EMA and same will be incorporated in registration letter.

- Manufacturer will place first three production batches on long term stability studies throughout proposed shelf life and on accelerated studies for six months as per the commitment submitted in the registration application.
- Manufacturer will perform process validation of first three batches as per the commitment submitted in the registration application.

## c. Routine cases of local manufacturing

2.	Name, address of Applicant / Marketing Authorization Holder	M/s Carer Pharmaceuticals Plot # 27, Main Road, Rawat Industrial Estate Rawat.
	Name, address of Manufacturing site.	M/s Global Pharmaceuticals (Pvt) Ltd. Plot No. 204-205, Industrial Triangle Kahuta Road Islamabad.
	Status of the applicant	☐ Manufacturer ☐ Importer ☑ Is involved in none of the above (contract giver) Copy of agreement for contract manufacturing of pharmaceutical products between contract giver and acceptor dated 01-03-2021 is submitted.

GMP status of the firm	<b>Global pharmaceuticals:</b> 11 & 24-10-2018: On the basis of findings, panel unanimously decided to recommend the issuance of GMP certificate.
Evidence of approval of manufacturing facility	Firm has submitted copy of letter of Grant of additional section / amendment under DML No 000417 of M/s Global Pharmaceuticals Islamabad dated 03-02-2016 specifying Capsule (Cephalosporin) section.
Status of application	<ul><li>□ New Drug Product (NDP)</li><li>⊠ Generic Drug Product (GDP)</li></ul>
Intended use of pharmaceutical product	<ul><li>☑ Domestic sale</li><li>☐ Export sale</li><li>☐ Domestic and Export sales</li></ul>
Dy. No. and date of submission	Dy. No. 20651: 29-07-2021
Details of fee submitted	PKR 75,000/-: 09-06-2021
The proposed proprietary name / brand name	BRIAR 400mg Capsule
Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each capsule Contains: Cefixime as trihydrate400mg
Pharmaceutical form of applied drug	Orange / ivory colored hard gelatin capsule shells size 0 filled with almost off white to light yellow colored granular powder
Pharmacotherapeutic Group of (API)	Cephalosporin Antibiotic
Reference to Finished product specifications	USP specification
Proposed Pack size	5's
Proposed unit price	As per SRO
The status in reference regulatory authorities	Cefixime 400mg capsule (MHRA Approved)
For generic drugs (me-too status)	Cefim Capsule by Hilton
Name and address of API manufacturer.	Saakh Pharma (Pvt) Ltd. C-7/1, North Western Industrial Zone, Port Qasim, Karchi.
Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Firm has summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product.
Module-III Drug Substance:	Firm has submitted detailed data for drug substance data related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.

Stability Studies of Dru (Conditions & duration		of drug substance at b time conditions. The conducted at 40°C ± months. The real time	Firm has submitted stability study data of 3 batches of drug substance at both accelerated as well as real time conditions. The accelerated stability data is conducted at $40^{\circ}\text{C} \pm 2^{\circ}\text{C} / 75\% \pm 5\%$ RH for 6 months. The real time stability data is conducted at $30^{\circ}\text{C} \pm 2^{\circ}\text{C} / 65 \pm 5\%$ RH for 24 months.  Firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.		
Module-III Drug Produc	ct:	its description, co development, manufa and process control, control of excipient specifications, analyt analytical procedures			
Pharmaceutical Equiva Dissolution Profile	Pharmaceutical Equivalence and Comparative Dissolution Profile		results of pharmaceutical P for their product against mi Pharma.		
Analytical method va		substance and the dru	erification studies of the drug g product.		
	STABILITY S	TUDY DATA			
Manufacturer of API	Saakh Pharma (Pvt) L Karchi.	td. C-7/1, North Western	Industrial Zone, Port Qasim,		
API Lot No.	18CF101233 17CF101233 17CF101235				
Description of Pack (Container closure system)	Alu-alu blister				
Stability Storage Condition	Real time : $30^{\circ}\text{C} \pm 2^{\circ}\text{C} / 65\% \pm 5\%\text{RH}$ Accelerated: $40^{\circ}\text{C} \pm 2^{\circ}\text{C} / 75\% \pm 5\%\text{RH}$				
Time Period	Real time: 6 months Accelerated: 6 months				
Frequency	Accelerated: 0, 3, 6 (Months) Real Time: 0, 3, 6 (Months)				
Batch No.	18H071	18J084	18M299		
Batch Size	60,000 capsule	60,000 capsule	60,000 capsule		
Manufacturing Date	08-2018	09-2018	12-2018		
Date of Initiation	05-09-2018	17-09-2018	14-12-2018		
No. of Batches		03	03		
	DOCUMENTS / DATA TO BE PROVIDED ALONG WITH STABILITY STUDY DATA				
1. Reference of previous a with stability study data o		s Not submitted			
manufacturer issued by concerned regulatory authority of country of origin.		by Additional Director 06-2020. The GMP ce	Firm has submitted copy of GMP certificate issued by Additional Director DRAP, Karachi dated 23-06-2020. The GMP certificate was granted based on inspection dated 18-06-2020.		
3. Documents for the procapproval from DRAP (in		h Not submitted			

4.	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	
5.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	NA
6.		Firm has submitted record of digital data logger for temperature and humidity monitoring of real time and accelerated stability chambers.

#### **Evaluation by PEC(III)::**

Letter of shortcoming was issued to the firm dated 14-02-2022. Following shortcomings were communicated to the firm.

- Submit module 1 as per the CTD guidance document approved by Registration Board by providing all the information and documents in relevant sections / sub-sections instead of referring to annexures.
- Submit label claim in module 1 as per the reference product along with submission of requisite fee.
- You have mentioned USP specification in section 1.5.6 in module 1 while the drug product monograph is not available in USP. Revise the specifications along with submission of requisite fee.
- Justify the alternate method of assay testing of drug substance by drug product manufacturer which
  is based on UV method, since no such alternate method is recommended in USP or by the API
  manufacturer.
- The drug substance manufacturer has claimed both BP and USP specifications for the drug substance, provide scientific justification in this regard.
- The drug substance manufacturer has claimed USP specifications for the assay method, while the submitted method is different from USP in terms of column specifications including column length and pore size. Justification is required in this regard.
- Submit data in section 3.2.S.4.3 as per the decision of 293<sup>rd</sup> meeting of Registration Board, which states that "Analytical Method Verification studies including specificity, accuracy and repeatability (method precision) performed by the Drug Product manufacturer for both compendial as well as non-compendial drug substance(s) shall be submitted". Further justify how the analysis of drug substance was conducted without performing verification studies of the analytical method of drug substance.
- Justify the use of cefixime drug substance in micronized form for the manufacturing of cefixime capsule, since the compacted form of cefixime is used for manufacturing of capsule dosage form.
- Submit stability study data of the drug substance (cefixime trihydrate in compacted form) from the drug substance manufacturer as per zone IV-A conditions.
- Justify the formulation which is different in terms of qualitative composition from that of innovator product.
- Justify why complete tests are not performed in the pharmaceutical equivalence studies.
- Justify why pharmaceutical equivalence and comparative dissolution profile studies are performed against comparator product instead of performing these studies against innovator product.
- Justify the use of apparatus II with 100rpm using UV method for CDP studies, since HPLC method with apparatus-I has been proposed by the innovator product.
- Justify the drug product specifications in which the assay and dissolution test analytical method and acceptance criteria is completely different from JP monograph as well as innovator's product.
- The peak area of standard solution in analytical method verification is 2940152 while the peak area of standard solution during stability studies is 3659812. Justify how such difference in peak area exists.
- Provide COA of reference standard actually used in the analysis of drug product.
- Provide stability data summary sheets as per the format approved by Registration Board since the submitted data summary sheets are different in format and also does not contain information like batch size, stability testing date of each time point, API lot number used in each batch etc.
- JP monograph for cefixime capsule specifies that assay limit is from 90-105% while in your stability study data the assay limit was 105.44% of batch 18H071 at 3<sup>rd</sup> month time point in accelerated stability, 106.39% and 105.23% for batch 18J084 at 3<sup>rd</sup> month time point during real time and

- accelerated stability respectively and 106.85% for batch 18M299 at 6<sup>th</sup> month time point during real time studies. Justification is required in this regard.
- Submit stability study of three batches of drug product in section 3.2.P.8.3 as per the checklist approved by Registration Board and presented in CTD guidance document in which stability data of three batches of drug product manufactured using batches of drug substance for which COA is attached in section 3.2.S.4.4.

In response, the firm (M/s Carer Pharmaceuticals) dated 30-03-2022 (Dy No. 8298) has submitted a new request for registration of their product on contract manufacturing from M/s Seraph Pharmaceuticals along with submission of full fee.

The details of the newly submitted data are as follows:

DY No. 8298: 30-03-2022 New fee: 75,000/-: 07-03-2022

Name, address of Applicant / Marketing Authorization Holder	M/s Carer Pharmaceuticals Plot # 27, Main Road, Rawat Industrial Estate Rawat.
Name, address of Manufacturing site.	M/s Seraph Pharmaceuticals Plot # 210, Industrial Triangle Kahuta Road Islamabad.
Status of the applicant	☐ Manufacturer ☐ Importer ☑ Is involved in none of the above (contract giver) (Contract manufacturing agreement between both firms dated 05-01-2022 is provided)
GMP status of the firm	<b>Seraph Pharmaceuticals:</b> GMP certificate issued on the basis of inspection conducted on 11/07/2019.
Evidence of approval of manufacturing facility	Firm (M/s Seraph Pharmaceuticals) has submitted copy of Issuance of DML letter dated 12-06-2017 specifying Dry Vial Cephalosporin section.
Status of application	☐ New Drug Product (NDP)  ☑ Generic Drug Product (GDP)
Intended use of pharmaceutical product	<ul><li>□ Domestic sale</li><li>□ Export sale</li><li>☑ Domestic and Export sales</li></ul>
Dy. No. and date of submission	Dy. No 8298: 30-03-2022
Details of fee submitted	Rs. 75,000/-: 07-03-2022
The proposed proprietary name / brand name	BRIAR 400mg Capsule
Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each capsule contains: Cefixime (as trihydrate)400mg
Pharmaceutical form of applied drug	Capsule contained in Alu Alu blister
Pharmacotherapeutic Group of (API)	Cephalosporin antibiotic
Reference to Finished product specifications	JP specs
Proposed Pack size	1x5's
Proposed unit price	As per SRO
The status in reference regulatory authorities	Suprax Capsule 400mg (USFDA Approved)
For generic drugs (me-too status)	Tripsan 400mg capsule by Seraph Pharmaceuticals
Name and address of API manufacturer.	Saakh Pharma (Pvt) Ltd. C-7/1, North Western Industrial Zone Port Qasim Karachi.

Module-II (Quality Overall Summary)		Firm has submitted QOS as per WHO QOS-PD template. Firm has summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.	
Module-III Drug Substance:		Firm has submitted detailed drug substance data related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.	
Stability Studies of Drug Substan (Conditions & duration of Stability		Firm has submitted stability study data of 3 batches of API at accelerated and real time conditions. The real time stability data is conducted as per zone IV-A conditions till 12 months.	
Module-III Drug Product:		Firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.  Firm has also submitted process validation report	
Pharmaceutical Equivalence and Comparative Dissolution Profile			
Analytical method validation/verification of product		Firm has submitted report of validation of analytical method for the drug product. Firm has submitted report of verification studies of analytical	
	QT A D1	method for the drug substance.	
Manufacturer of API		ILITY STUDY DATA  arma (Pvt) Ltd. C-7/1, North Western Industrial Zone Port	
Ivialiuracturer Of AFT	Qasim Kar		
API Lot No. 17CF10172		2	
Description of Pack (Container closure system)  1 x 5's caps		sule in alu-alu blister packed in unit carton	
		30°C ± 2°C / 65% ± 5%RH d: 40°C ± 2°C / 75% ± 5%RH	

		Real time: 6 mc			
1 -			Accelerated: 0, 1, 2, 3, 6 (Months) Real Time: 0, 3, 6 (Months)		
Batc	h No.	001		002	003
Batc	h Size	55,500 capsul	le	55,500 capsule	55,500 capsule
Man	ufacturing Date	01-2018		03-2018	05-2018
Date	of Initiation	19-01-2018		16-03-2018	10-05-2018
No.	of Batches			03	
	DOCUMENTS / DATA T	O BE PROVIDI	ED A	ALONG WITH STABII	LITY STUDY DATA
2.	Approval of API/ DML/O of API manufacturer issue regulatory authority of course	GMP certificate d by concerned untry of origin.	<ul> <li>Dexpro (Dexlansoprazole) 30 and 60mg Capsule. PSI was conducted on 11-09-2018 and the product was approved in 285th meeting of Registration Board.</li> <li>Neovel 800mg Tablet. Its PSI was conducted on 14-12-2018 and the product was approved in 288th meeting of Registration Board.</li> <li>Serbica 20mg Capsule. Its PSI was conducted on 29-10-2018 and the product was approved in 290th meeting of Registration Board.</li> <li>Firm has further submitted that their product Neogene 2g Injection was approved in 293th meeting of Registration Board. That product was applied by AGP and contract manufactured by Seraph and was submitted on Form 5F (CTD) along with complete data.</li> <li>Copy of DML of M/s Saakh Pharma is submitted by the</li> </ul>		
2			01-2018 issued on the basis of inspection dated 16-10-2017 is submitted by the firm. The certificate is issued by Additional Director DRAP Karachi.		
3.	with approval from DRA import).	AP (in case of	Firm has submitted copy of invoice dated 12-01-2018 specifying purchase of 50Kg cefixime from Saakh Pharma (Pvt) Ltd.		
4.	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.		batches along with chromatograms, raw data sheets,		
5.	Compliance Record of I 21CFR & audit trail repotesting	orts on product	prod (Sch we h We t	uct was initiated 2 years imadzu) was not 21 CF ave 21 CFR compliant (F	the the stability study of this ago, at that time our HPLC R compliant. However now Perkin Elmer) HPLC system. e will use 21 CFR compliant ting.
6.	temperature and humidity	ity monitoring of		Firm has submitted that their stability chambers supplied with uninterrupted power supply and have didata logger for monitoring temperature and humidity. digital data logger have been verified by the panel du our onsite inspection as well.	
<b>Eval</b>	uation by PEC(III)::				

- After the notification of monograph of cefixime capsule by Registration Board, the manufacturer firm i.e. Seraph Pharmaceuticals has submitted product testing report of their batches which are tested as per the monograph approved vide No. F.14-1/2022-PEC dated 14<sup>th</sup> March 2022.
- The applied product to be manufactured by M/s Seraph Pharmaceuticals Plot # 210, Industrial Triangle Kahuta Road Islamabad have already been approved by Registration Board in its 297<sup>th</sup> meeting based on the data of same batches of drug product as submitted in the instant case. The details of the already approved product in 297<sup>th</sup> meeting are as follows:

Applicant firm	M/s Moringa Pharmaceuticals 35-A, Sunder Industrial Estate,	
	Lahore.	
Manufacturer firm	M/s Seraph Pharmaceuticals Plot # 210, Industrial Triangle	
	Kahuta Road Islamabad.	
Brand Name	Saf-Xime 400mg Capsule	
Batch No. of drug product	001, 002, 003	
Case No.	278	
BR Meeting	297	

Decision: Approved with Manufacturer's specifications as per the monograph approved in 313<sup>th</sup> meeting of Registration Board and notified vide No. F.14-1/2022-PEC dated 14th March 2022.

- Manufacturer will perform process validation of first three batches as per the commitment submitted in the registration application.
- Firm shall submit the fee of Rs. 7,500 for correction/pre-approval change/ in product specifications, as per notification No.F.7-11/2012-B&A/DRAP dated 13-07-2021.

3.	Name, address of Applicant / Marketing Authorization Holder	M/s Carer Pharmaceuticals Plot # 27, Main Road, Rawat Industrial Estate Rawat.
	Name, address of Manufacturing site.	M/s Global Pharmaceuticals (Pvt) Ltd. Plot No. 204-205, Industrial Triangle Kahuta Road Islamabad.
	Status of the applicant	☐ Manufacturer ☐ Importer ☐ Is involved in none of the above (contract giver) Copy of agreement for contract manufacturing of pharmaceutical products between contract giver and acceptor dated 01-03-2021 is submitted.
	GMP status of the firm	Global pharmaceuticals: 11 & 24-10-2018: On the basis of findings, panel unanimously decided to recommend the issuance of GMP certificate.
	Evidence of approval of manufacturing facility	Not submitted
	Status of application	☐ New Drug Product (NDP) ☐ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	<ul><li>☑ Domestic sale</li><li>☐ Export sale</li><li>☐ Domestic and Export sales</li></ul>
	Dy. No. and date of submission	Dy. No. 17393: 22-06-2021
	Details of fee submitted	PKR 75,000/-: 04-06-2021
	The proposed proprietary name / brand name	BRIAR 200mg/5ml suspension
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each 5ml of reconstituted suspension Contains: Cefixime as trihydrate200mg
	Pharmaceutical form of applied drug	Off white powder filled in amber colored glass bottle

	Pharmacotherapeutic Group	n of (API)	Cephalosporin Antibiotic
	Reference to Finished product specifications		USP
	Proposed Pack size	Special Control of the Control of th	30 ml, 60ml
	Proposed unit price		As per SRO
	The status in reference regu	ulatory authorities	Cefixime suspension (USFDA Approved)
	For generic drugs (me-too s	-	Cefim suspension by Hilton
	Name and address of API manufacturer.		Saakh Pharma (Pvt) Ltd. C-7/1, North Western Industrial Zone Port Qasim Karachi.
	Module-III Drug Substance:		Firm has submitted QOS as per WHO QOS-PD template. Firm has summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product.
			Firm has submitted detailed data for drug substance data related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Stability Studies of Drug St (Conditions & duration of S		Firm has submitted stability study data of 3 batches of drug substance at both accelerated as well as real time conditions. The accelerated stability data is conducted at $40^{\circ}\text{C} \pm 2^{\circ}\text{C} / 75\% \pm 5\%$ RH for 6 months. The real time stability data is conducted at $30^{\circ}\text{C} \pm 2^{\circ}\text{C} / 65 \pm 5\%$ RH for 24 months.
	Module-III Drug Product:  Pharmaceutical Equivalence and Comparative Dissolution Profile		Firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.
			Firm has submitted results of pharmaceutical equivalence for all the quality tests for their product against Cefiget 200mg/5ml dry suspension.
	Analytical method valida product	ation/verification of	Firm has submitted verification studies of the drug substance and the drug product.
		STABILITY ST	UDY DATA
Manufa		nakh Pharma (Pvt) Ltd arachi.	. C-7/1, North Western Industrial Zone Port Qasim

		1			
API Lot No.		18CF10062			
		18CF10068			
		18CF101233			
Desc	cription of Pack	Glass bottle			
(Con	tainer closure system)	Glass bottle			
Stab	ility Storage Condition	Real time : 30°C ± 2°C / 65% ± 5%RH Accelerated: 40°C ± 2°C / 75% ± 5%RH			
			2 C / /3% ± 3% KH		
Time	e Period	Real time: 6 months Accelerated: 6 months			
Freq	uency	Accelerated: 0, 3, 6	(Months)		
		Real Time: 0, 3, 6 (Months)			
Batc	h No.	18D145	18L054	18G104	
Batc	h Size	5000 bottle	5000 bottle	5000 bottle	
Man	ufacturing Date	04-2018	11-2018	07-2018	
Date	of Initiation	18-04-2018	07-11-2018	05-07-2018	
No.	of Batches		03	03	
DOCUMENTS / DATA TO BE PROVIDED A		ALONG WITH STAB	ILITY STUDY DATA		
1.	1. Reference of previous approval of applications with stability study data of the firm (if any)		ns Not submitted		
2.	Approval of API/ DML/	•	PI Firm has submitted or	Firm has submitted copy of GMP certificate issued	
	manufacturer issued by concerned regulatory authority of country of origin.		on the basis of inspection dated 18-06-2020.		
3.	Documents for the pro-	<u> </u>	Not submitted		
	approval from DRAP (in case of import).				
4.				Firm has submitted complete record of testing of	
attested respective documents li chromatograms, Raw data sheets, COA, summa data sheets etc.		e all batches along with chromatograms, raw data			
		sheets, COA and summary data sheets.			
5.			0. Firms had subscribed	oudit tooil magand of man 1	
Э.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing			Firm has submitted audit trail record of product testing of HPLC for all test intervals.	
6.				Firm has submitted record of digital data logger for	
time and accelerated)			and accelerated stabili	and accelerated stability chambers.	

Letter of shortcoming was issued to the firm dated 19-01-2022. Following shortcomings were communicated to the firm.

- Submit GMP certificate / GMP inspection report of the drug product manufacturer within last three years.
- Submit evidence of approval of requisite manufacturing facility / section of the drug product manufacturer approved from Licensing Division DRAP.
- Submit module 1 as per CTD guidance document without referring to annexures.
- Submit label claim as per the innovator product along with submission of fee for revision of label claim.
- Justify the formulation of drug substance manufacturer which is using sodium bicarbonate and water for injection, while the innovator product use edetate disodium dihydrate (EDTA) and sodium citrate as excipients.
- Submit data in section 3.2.S.4.1 and 3.2.S.4.2 as per the guidance document approved by Registration Board which specifies that "Copies of the Drug substance specifications and analytical procedures

used for routine testing of the Drug substance /Active Pharmaceutical Ingredient by both Drug substance & Drug Product manufacturer is required."

- Justify how the drug substance specification complies both USP as well as BP specifications.
- Submit data of verification of analytical procedure of drug substance in section 3.2.S.4.3 as per the guidance document approved by Registration Board which specifies that "Analytical Method Verification studies including specificity, accuracy and repeatability (method precision) performed by the Drug Product manufacturer for both compendial as well as non-compendial drug substance(s) shall be submitted".
- Submit COA of reference standard actually used in the analysis of drug substance and drug product.
- Submit stability study data of the drug substance (cefixime trihydrate in micronized form) from the drug substance manufacturer as per zone IV-A conditions.
- Justify why your formulation is qualitatively different from that of innovator's product.
- Justify how 1383.1mg of cefixime trihydrate is equivalent to 6 doses after reconstitution each having 200mg of cefixime base.
- Justify how your product is equivalent to the innovator's product since the innovator's product is available in 50ml, 75ml and 100ml bottle delivering 10, 15 and 20 doses while your product is available in 30ml bottle which can deliver 6 doses.
- Justify how you are reconstituting your product with 20ml water since the innovator product use 34ml water to reconstitute for 50ml bottle.
- Justify the total fill weight of 14.940gm per bottle, since you have mentioned exactly same quantities of each excipient and have used double quantity of the drug substance as that provided in 100mg/5ml suspension.
- Justify why you have performed pharmaceutical equivalence studies against Cefiget suspension instead of performing studies against the innovator / reference product.
- Justify your pharmaceutical equivalence studies in which only assay and identification test has been
  performed. Justify how you can declare your product as pharmaceutically equivalent just on the basis
  of two tests.
- Provide detailed analytical method verification studies along with interpretation of each test in the light of ICH guidelines. Further also provide exact concentration of each solution tested in each test of the verification studies.
- Provide stability study data of 3 batches of the drug product in section 3.2.P.8.3 as per the 6 points
  checklist approved by Registration Board in CTD guidance document along with submission of
  stability study data of each batch in proper sequence i.e. analytical report, raw data sheet and
  chromatograms of standard and sample preparation at each time point so that further evaluation of
  the data could be carried out.

In response, the firm (M/s Carer Pharmaceuticals) dated 30-03-2022 (Dy No. 8297) has submitted a new request for registration of their product on contract manufacturing from M/s Seraph Pharmaceuticals along with submission of full fee.

The details of the newly submitted data are as follows:

DY No. 8298: 30-03-2022 New fee: 75,000/-: 07-03-2022

New Ice. 75,000/ 07-05-2022		
Name, address of Applicant / Marketing Authorization Holder	M/s Carer Pharmaceuticals Plot # 27, Main Road, Rawat Industrial Estate Rawat.	
Name, address of Manufacturing site.	M/s Seraph Pharmaceuticals Plot # 210, Industrial Triangle Kahuta Road Islamabad.	
Status of the applicant	☐ Manufacturer ☐ Importer ☑ Is involved in none of the above (contract giver) (Contract manufacturing agreement between both firms dated 05-01-2022 is provided)	
GMP status of the firm	<b>Seraph Pharmaceuticals:</b> GMP certificate issued on the basis of inspection conducted on 11/07/2019.	

Evidence of approval of manufacturing facility	Firm (M/s Seraph Pharmaceuticals) has submitted copy of Issuance of DML letter dated 12-06-2017 specifying Dry Vial Cephalosporin section.	
Status of application	<ul><li>□ New Drug Product (NDP)</li><li>☑ Generic Drug Product (GDP)</li></ul>	
Intended use of pharmaceutical product	<ul> <li>□ Domestic sale</li> <li>□ Export sale</li> <li>⋈ Domestic and Export sales</li> </ul>	
Dy. No. and date of submission	Dy. No 4600 dated 01-02-2019 (Form 5) Dy No. 10258 dated 07-05-2020 (Form 5-F)	
Details of fee submitted	Rs.20,000/- Dated 31-01-2019 Rs. 30,000/- dated 06-05-2020	
The proposed proprietary name / brand name	BRIAR 200mg/5ml suspension	
Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each 5ml of reconstituted suspension contains: Cefixime (as trihydrate)100mg	
Pharmaceutical form of applied drug	Amber colored glass bottle containing white to off white powder for reconstitution volume 30ml (after reconstitution)	
Pharmacotherapeutic Group of (API)	Cephalosporin antibiotic	
Reference to Finished product specifications	USP specs	
Proposed Pack size	30ml bottle	
Proposed unit price	As per SRO	
The status in reference regulatory authorities	Suprax suspension 200mg/5ml (USFDA Approved)	
For generic drugs (me-too status)	Tripsan 200mg/5ml dry suspension by Seraph Pharmaceuticals	
Name and address of API manufacturer.	Saakh Pharma (Pvt) Ltd. C-7/1, North Western Industrial Zone Port Qasim Karachi.	
Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Firm has summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.	
Module-III Drug Substance:	Firm has submitted detailed drug substance data related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.	
Stability Studies of Drug Substance (Conditions & duration of Stability studies)	Firm has submitted stability study data of 3 batches of API at accelerated and real time conditions. The real time stability data is conducted as per zone IV-A conditions till 12 months.	
Module-III Drug Product:	Firm has submitted data of drug product including its description, composition, pharmaceutical development,	

	I C V j	proces of dru valida justific materi	ss validation protocols, ag product, specificat tion of analytical p	•
Pharmaceutical Equivalence and Comparative Dissolution Profile		Firm has performed comparative analysis of their developed formulation against the comparator product i.e. "Cefspan Dry powder for suspension 200mg/5ml". Firm has submitted results of pharmaceutical equivalence for all the quality tests for their product against the comparator product. The analysis of all quality tests were performed according to USP monograph. The results depicts that the developed formulation is comparable to the comparator product.  The firm has also performed compatibility studies of the product with diluent i.e. purified (boiled and cooled water). Firm has performed testing of assay pH and other parameters for 7 days at room temperature and 14 days at $2-8$ °C and the results after reconstitution were within the acceptable range specified by the firm.		
Analytical method validation/verification of product		Firm has submitted report of validation of analytical method for the drug product.  Firm has submitted report of verification studies of analytical method for the drug substance.		
			UDY DATA	6
Manufacturer of API	Saakh Pharma (Pvt) Ltd. C-7/1, North Western Industrial Zone Port Qasim Karachi.			
API Lot No.	17CF10172			
Description of Pack (Container closure system)	1's bottle of power	1's bottle of powder for suspension packed in unit carton		
Stability Storage Condition	Real time : $30^{\circ}\text{C} \pm 2^{\circ}\text{C} / 65\% \pm 5\%\text{RH}$ Accelerated: $40^{\circ}\text{C} \pm 2^{\circ}\text{C} / 75\% \pm 5\%\text{RH}$			
Time Period Real time: 6 mo Accelerated: 6 m				
Frequency	Accelerated: 0, 1, Real Time: 0, 3, 6		·	
Batch No.	001		002	003
Batch Size	10,000 bottles		10,000 bottles	10,000 bottles
Manufacturing Date	01-2018		01-2018	03-2018
Date of Initiation 18-01-201			19-01-2018	26-03-2018
No. of Batches		03		
DOCUMENTS / DATA TO BE PROVIDED ALONG V			LONG WITH STABI	ILITY STUDY DATA
1. Reference of previous approval of application with stability study data of the firm (if any)		ations	<ul><li>inspection reports</li><li>Dexpro (Dexlans Capsule. PSI was c</li></ul>	of following product specific oprazole) 30 and 60mg conducted on 11-09-2018 and pproved in 285 <sup>th</sup> meeting of

2.	Approval of API/ DML/GMP certificate of API	**
	manufacturer issued by concerned regulatory authority of country of origin.	the firm.  Copy of GMP certificate of M/s Saakh Pharma dated 15-01-2018 issued on the basis of inspection dated 16-10-2017 is submitted by the firm. The certificate is issued by Additional Director DRAP Karachi.
3.	Documents for the procurement of API with approval from DRAP (in case of import).	Firm has submitted copy of invoice dated 12-01-2018 specifying purchase of 50Kg cefixime from Saakh Pharma (Pvt) Ltd.
4.	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	all batches along with chromatograms, raw data
5.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	Firm has submitted that since the stability study of this product was initiated 2 years ago, at that time our HPLC (Schimadzu) was not 21 CFR compliant. However now we have 21 CFR compliant (Perkin Elmer) HPLC system. We undertake that in future we will use 21 CFR compliant HPLC system for stability testing.
6.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	

• The applied product to be manufactured by M/s Seraph Pharmaceuticals Plot # 210, Industrial Triangle Kahuta Road Islamabad have already been approved by Registration Board in its 297<sup>th</sup> meeting based on the data of same batches of drug product as submitted in the instant case. The details of the already approved product in 297<sup>th</sup> meeting are as follows:

Applicant firm	M/s Moringa Pharmaceuticals 35-A, Sunder Industrial Estate,	
	Lahore.	
Manufacturer firm	M/s Seraph Pharmaceuticals Plot # 210, Industrial Triangle	
	Kahuta Road Islamabad.	
Brand Name	Saf-Xime 200mg/5ml Dry suspension	
Batch No. of drug product	001, 002, 003	
Case No.	280	
BR Meeting	297	

**Decision: Approved.** 

• Manufacturer will perform process validation of first three batches as per the commitment submitted in the registration application.

4.	Name, address of Applicant / Marketing Authorization Holder	M/s Carer Pharmaceuticals Plot # 27, Main Road, Rawat Industrial Estate Rawat.	
	Name, address of Manufacturing site.	M/s Global Pharmaceuticals (Pvt) Ltd. Plot No. 204-205, Industrial Triangle Kahuta Road Islamabad.  □ Manufacturer □ Importer □ Is involved in none of the above (contract giver) Firm has submitted copy of contract manufacturing agreement with applicant firm dated 01-03-2021.	
	Status of the applicant		
	GMP status of the firm	Firm has submitted copy of GMP certificate of M/s Global Pharmaceuticals dated 24-12-2018 based on the inspection dated 24-10-2018. The certificate was valid till 23-10-2021. The GMP certificate specifies dry powder injection (cephalosporin) section.	
	Evidence of approval of manufacturing facility	Firm has submitted copy of GMP certificate of M/s Global Pharmaceuticals dated 24-12-2018 based on the inspection dated 24-10-2018. The certificate was valid till 23-10-2021.  The GMP certificate specifies dry powder injection (cephalosporin) section.	
	Status of application	☐ New Drug Product (NDP)  ☐ Generic Drug Product (GDP)	
	Intended use of pharmaceutical product	<ul><li>☑ Domestic sale</li><li>☐ Export sale</li><li>☐ Domestic and Export sales</li></ul>	
	Dy. No. and date of submission	Dy. No. 16396: 14-06-2021	
	Details of fee submitted	PKR 50,000/-: 04-05-2021	
	The proposed proprietary name / brand name	ACRUX 250mg Injection IV	
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each Vial Contains: Ceftriaxone (as sodium)250mg	
	Pharmaceutical form of applied drug	Sterile white to off white powder filled in transparent glass vials	
	Pharmacotherapeutic Group of (API)	Cephalosporin antibiotic	
	Reference to Finished product specifications	USP	
	Proposed Pack size	1's	
	Proposed unit price	As per SRO	
	The status in reference regulatory authorities	Ceftriaxone sodium Injection (MHRA Approved)	
	For generic drugs (me-too status)	Aczon injection by Vision Pharma	
	Name and address of API manufacturer.	Sinopharm Weiqida Pharmaceutical Co. Ltd. First Medical Zone, Economic and Technological Development Zone, Datong Shanxi. China	
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Firm has summarized information	

		related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product.	
		Firm has submitted detailed data for both drug substance data related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.	
Stability Studies of Dru (Conditions & duration		Firm has submitted stability study data of 3 batches of drug substance at both accelerated as well as real time conditions. The accelerated stability data is conducted at $40^{\circ}\text{C} \pm 2^{\circ}\text{C} / 75\% \pm 5\%$ RH for 6 months. The real time stability data is conducted at $30^{\circ}\text{C} \pm 2^{\circ}\text{C} / 65\% \pm 5\%$ RH for 36 months.	
Module-III Drug Produc	ct:	Firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.	
Pharmaceutical Equiva Dissolution Profile	lence and Comparative	Firm has submitted results of pharmaceutical equivalence for the quality tests for their product against the comparator i.e. Rocephin 250mg Injection.	
Analytical method validation/verification of product		Firm has submitted report of verification of analytical method for the drug substance. Firm has submitted report of verification of analytical method for the drug product.	
STABILITY STUDY DATA			
Manufacturer of API		armaceutical Co. Ltd. First Medical Zone, Economic elopment Zone, Datong Shanxi. China	
API Lot No.	Q011906044 Q011901016 Q011812044		
Description of Pack (Container closure system)	Glass vials		
Stability Storage Condition	Real time : $30^{\circ}\text{C} \pm 2^{\circ}\text{C}$ / Accelerated: $40^{\circ}\text{C} \pm 2^{\circ}\text{C}$		
Time Period Real time: 6 months			

	Accelerated: 6 months		
Frequency	Accelerated: 0, 3, 6 (Months) Real Time: 0, 3, 6 (Months)		
Batch No.	19D319	19E324	19J288
Batch Size	16317 vials	16317 vials	16317 vials
Manufacturing Date	04-2019	05-2019	09-2019
Date of Initiation	13-05-2019	22-05-2019	03-10-2019
No. of Batches 03			
DOCUMENTS / DATA TO BE PROVIDED ALONG WITH STABILITY STUDY DATA			

1.	Reference of previous approval of applications with stability study data of the firm (if any)	Not submitted
2.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	
3.	Documents for the procurement of API with approval from DRAP (in case of import).	Not submitted
4.	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	
5.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	Firm has submitted that their HPLC system is not 21 CFR compliant.
6.		Firm has submitted record of digital data logger for temperature and humidity monitoring of real time and accelerated stability chambers.

Letter of shortcoming was issued to the firm dated 03-01-2022. Following shortcomings were communicated to the firm.

- Submit differential fee for the registration of applied product, since the notification for revision of fee vide SRO No. F.7-11/2012-B&A/DRA was published on 7<sup>th</sup> May 2021 while this application was received in R&I section of DRAP after 7<sup>th</sup> May 2021.
- Provide valid GMP certificate / inspection report of the contract manufacturer since the submitted GMP certificate has been expired.
- The analytical method of the drug substance from the product manufacturer i.e. Global Pharmaceuticals is different in terms of chromatographic conditions, UV wavelength, sample and standard preparation as well as calculation formula and acceptance criteria from both USP monograph as well as drug substance manufacturer's analytical method. Justification is required in this regard.
- Analytical method verification studies (3.2.S.4.3) have been conducted at entirely different chromatographic conditions, UV wavelength, mobile phase. sample and standard preparation as well as calculation formula from that of USP as well as drug substance manufacturer. Justify how routine analysis and verification studies was conducted using a method which is different from USP.
- The peak area of standard solution in verification studies is approximately 515, while the peak area of standard solution at same concentration in stability studies is approximately 13699925. Justify how such significant difference in peak area exist during the analysis of a solution having same concentration.
- Submit COA of relevant batch of drug substance from both drug substance manufacturer as well as drug product manufacturer used in the manufacturing of batches of drug product for which stability study data is submitted in section 3.2.P.8.3, instead of providing complete analysis reports and raw data for various batches.

- Submit COA of reference standard actually used in the analysis of drug substance in section 3.2.S.5.
- Justify how 306.4mg ceftriaxone sodium sterile powder is equivalent to 250mg of ceftriaxone base.
- You have mentioned that the product is filled in 5ml glass vials and that the diluent for reconstitution is 5ml WFI, while in stability studies you have mentioned 10ml WFI. Justification is required in this regard.
- The innovator product Rocephin Injection 250mg have specified that 2.4ml WFI is required to reconstitute the injection for intravenous injection, while you are using 5ml WFI. Justify why you are not using the same volume of diluent as specified by the innovator product.
- Justify why the pharmaceutical equivalence study does not include complete testing of the drug product and the innovator product as per USP specifications. Further also specify the details of innovator product i.e. Rocephin 250mg injection including its batch number, manufacturing site address and expiry date since this product is not registered in Pakistan.
- Justify why you have not performed compatibility studies and submitted its data in section 3.2.P.2.6.
- Justify your process validation protocols and report without any process for optimization of sterilization process and sealing of vials etc.
- Justify why the specifications of the drug product (section 3.2.P.5.1) does not contain important tests as recommended by USP including test for constituted solution, crystallinity and complete assay test. Justify why you are not complying USP monograph and revise your specifications along with submission of fee.
- The standard and sample preparation method for the assay test in your method of analysis is different from USP. Furthermore, USP recommends 2 different tests for assay while you are performing only one type of test. Justification is required in this regard.
- Justify the alternate method of assay which is based on UV method since no such method is recommended by USP.
- In verification studies of the analytical method of drug product, yu have mentioned that retention time of ceftriaxone is 7.2 minutes, while in the stability studies the retention time is above 11 minutes. Justify how your method is specific.
- Specify the exact concentration of the sample solution which is used to perform each test during verification studies instead of mentioning % only.
- Justify how three commercial batches were released for commercial use without performing complete tests as specified in USP monograph.
- Provide COA of reference standard actually used in the analysis of drug product in section 3.2.P.6.
- Justify why in use stability study data is not submitted.
- Batch No. 19J288 is manufactured on 09-2019 while the initial testing was carried out on 22-05-2019. Justification is required in this regard.
- Justify why the test for water contents, constituted solution etc is not performed during stability studies since these tests are very critical and are required to make assessment of the stability profile and shelf life.
- Justify how assay testing was conducted using only 3 analysis of standard solution.
- Provide raw data sheets to justify the calculation of results for assay testing at each time point during the stability testing of each batch. Moreover submit stability study data of each batch with proper separators and raw data sheets in proper sequence starting from initial time point to 6<sup>th</sup> month time point. Since the submitted data is not provided in any sequence.
- Justify the use of completely different formula for calculation of assay results than that specified in USP monograph.
- Submit Reference of previous approval of applications with stability study data of the firm.
- Submit Documents for the procurement of relevant batch of API with approval from DRAP which is actually used in the manufacturing of three batches for which stability study data has been submitted. Since you have submitted commercial invoice for different batches.
- Submit compliance Record of HPLC software 21CFR & audit trail reports on product testing.
- Provide record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated).
- Justify why different volume of vial has been mentioned in different sections of Form 5F, further justify why you are using 15ml vial for 250mg injection as evident from your BMR.

In response, the firm (M/s Carer Pharmaceuticals) dated 30-03-2022 (Dy No. 8293) has submitted a new request for registration of their product on contract manufacturing from M/s Seraph Pharmaceuticals along with submission of full fee.

The details of the newly submitted data are as follows:

DY No. 8293: 30-03-2022 New fee: 75,000/-: 07-03-2022

New fee: 75,000/-: 07-03-2022	
Name, address of Applicant / Marketing Authorization Holder	M/s Carer Pharmaceuticals Plot # 27, Main Road, Rawat Industrial Estate Rawat.
Name, address of Manufacturing site.	M/s Seraph Pharmaceuticals Plot # 210, Industrial Triangle Kahuta Road Islamabad.
Status of the applicant	☐ Manufacturer ☐ Importer ☑ Is involved in none of the above (contract giver) (Contract manufacturing agreement between both firms dated 05-01-2022 is provided)
GMP status of the firm	<b>Seraph Pharmaceuticals:</b> GMP certificate issued on the basis of inspection conducted on 11/07/2019.
Evidence of approval of manufacturing facility	Firm (M/s Seraph Pharmaceuticals) has submitted copy of Issuance of DML letter dated 12-06-2017 specifying Dry Vial Cephalosporin section.
Status of application	<ul><li>□ New Drug Product (NDP)</li><li>☑ Generic Drug Product (GDP)</li></ul>
Intended use of pharmaceutical product	<ul><li>□ Domestic sale</li><li>□ Export sale</li><li>☑ Domestic and Export sales</li></ul>
Dy. No. and date of submission	Dy. No 8293: 30-03-2022
Details of fee submitted	PKR 75,000/-: 07-03-2022
The proposed proprietary name / brand name	ACRUX 250mg Injection IV
Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each vial contains: Ceftriaxone (as sodium)250mg
Pharmaceutical form of applied drug	Sterilized white to off white crystalline dry powder contained in a glass vial with sterilized rubber stopper & aluminium flip seal on it.
Pharmacotherapeutic Group of (API)	Cephalosporin antibiotic
Reference to Finished product specifications	USP specs
Proposed Pack size	As per SRO
Proposed unit price	As per SRO
The status in reference regulatory authorities	Ceftriaxone 250mg powder for solution for injection (MHRA Approved)
For generic drugs (me-too status)	Droncef injection 250mg by Seraph Pharmaceuticals
Name and address of API manufacturer.	Sinopharm Weiqida Pharmaceutical Co. Ltd. First Medical zone, Economic & technological development zone, Datong Shanxi China.
Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Firm has summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities,

		specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product.
Module-III Drug Substance:		Firm has submitted detailed data for drug substance data related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
Stability Studies of Drug Substance (Conditions & duration of Stability studies)		Firm has submitted stability study data of 3 batches of drug substance at both accelerated as well as real time conditions. The accelerated stability data is conducted at $40^{\circ}\text{C} \pm 2^{\circ}\text{C} \: / \: 75\% \: \pm \: 5\% \: \text{RH}$ for 6 months. The real time stability data is conducted at $30^{\circ}\text{C} \pm 2^{\circ}\text{C} \: / \: 65 \pm \: 5\% \: \text{RH}$ for 48 months.
Module-III Drug Product:		Firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.
Pharmaceutical Equivalence and Comparative Dissolution Profile		Firm has submitted results of pharmaceutical equivalence for all the quality tests for their product against the innovator i.e. Rocephin Injection 250mg. The results of all the tests of both products falls within the specifications and are comparable. The firm has also performed compatibility studies of the product with recommended diluent i.e. sterile water for injection. Firm has performed comparative analysis with innovator product after reconstitution as well. The reconstitution studies also demonstrate comparable results with the innovator product.
Analytical method validation product	on/verification of	Firm has submitted report of validation of analytical method for the drug product.
		Firm has submitted report of verification studies of analytical method for the drug substance.
	STABILIT	TY STUDY DATA
Manufacturer of API		da Pharmaceutical Co. Ltd. First Medical zone, Economic evelopment zone, Datong Shanxi China.
API Lot No.	Q011812004	
Description of Pack (Container closure system)	Vials containing powder for reconstitution, packed in unit carton	
Stability Storage Condition		$2^{\circ}C / 65\% \pm 5\% RH$ $\pm 2^{\circ}C / 75\% \pm 5\% RH$
Time Period Real time: 6 month Accelerated: 6 month		

Batch No. 001 002 003  Batch Size 8389 vials 822010 vials 922010 vials 922019 92019 92019 92019 92019 92019 92019 92019 92019 92019 92019 92019 92019 92018 92018 92018 and the product specific proports 928 meeting of Registration Board. 82910-2018 and the product was approved in 288 meeting of Registration Board. 82910-2018 and the product was approved in 289 meeting of Registration Board. 82910-2018 and the product was approved in 299 meeting of Registration Board. 82910-2018 and the product was approved in 299 meeting of Registration Board. 92910-2018 and the product was approved in 299 meeting of Registration Board. 92910-2018 and the product was approved in 299 meeting of Registration Board. 92910-2018 and the product was approved in 299 meeting of Registration Board. 92910-2018 and the product was approved in 299 meeting of Registration Board. 92910-2018 and the product was approved in 299 meeting of Registration Board. 92910-2018 and the product was approved in 299 meeting of Registration Board. 92910-2018 and the product was approved in 29310 meeting of Registration Board. 92910-2018 and the product was approved in 29310 meeting of Registration Board. 92910-2018 and the product was approved in 29310 meeting of Registration Board. 92910-2018 and the product was approved in 29310 meeting of Registration Board. 92910-2018 and the product was approved in 29310 meeting of Registration Board. 92910-2018 and the product was approved in 29310 meeting of Registration Board. 92910-2018 and the product was approved in 29310 meeting of Registration Boa	Frequency Accelerated: 0, 1, 2, 3 Real Time: 0, 3, 6 (M				
Manufacturing Date	Batch No. 001		001	002	003
Date of Initiation 12-02-2019 14-02-2019 10-03-2019  No. of Batches 03  DOCUMENTS / DATA TO BE PROVIDED ALONG WITH STABILITY STUDY DATA  1. Reference of previous approval of applications with stability study data of the firm (if any)  Reference of previous approval of applications with stability study data of the firm (if any)  Power of December 11-09-2018 and the product was approved in 285th meeting of Registration Board.  Neovel 800mg Tablet. Its PSI was conducted and 11-09-2018 and the product was approved in 295th meeting of Registration Board.  Reference of previous approved in 285th meeting of Registration Board.  Neovel 800mg Tablet. Its PSI was conducted and 14-12-2018 and the product was approved in 295th meeting of Registration Board.  Firm has further submitted that their product Neoge 2g Injection was approved in 295th meeting of Registration Board.  Firm has further submitted that their product Neoge 2g Injection was approved in 295th meeting of Registration Board.  Firm has ruther submitted that their product Neoge 2g Injection was approved in 295th meeting of Registration Board.  Firm has further submitted that their product Neoge 2g Injection was approved in 295th meeting of Registration Board.  Firm has ruther submitted that their product Neoge 2g Injection was approved in 295th meeting of Registration Board.  Firm has ruther submitted that their product Neoge 2g Injection was approved in 295th meeting of Registration Board.  Firm has submitted on Form 5F (CTD) along with complete was approved in 295th meeting of Registration Board.  Firm has submitted copy of invoice specifying import of 100Kg ceftriaxone sodium dated 08-01-2019. To invoice is signed by AD (I&E) DRAP Islamabor office.  The product was initiated 2 years ago, at that time of 100Kg ceftriaxone sodium dated 08-01-2019. To invoice is signed by AD (I&E) DRAP Islamabor office.  Data of stability batches will be supported by attested respective documents like chromatograms, raw data sheets.  COA and summary data sheets.  COA and summ	Batch Size 8389 vials		8389 vials	8389 vials	
No. of Batches	Man	ufacturing Date	01-2019	01-2019	02-2019
1. Reference of previous approval of applications with stability study data of the firm (if any)  Reference of previous approval of applications with stability study data of the firm (if any)  Performance of previous approval of applications with stability study data of the firm (if any)  Performance of previous approval of applications with stability study data of the firm (if any)  Performance of previous approval of applications with stability study data of the firm (if any)  Performance of previous approval of applications with stability study data of the firm (if any)  Performance of previous approval of Apply and the product was approved in 285 meeting of Registration Board.  Neovel 800mg Tablet. Its PSI was conducted of 14-12-2018 and the product was approved in 298 meeting of Registration Board.  Serbica 20mg Capsule. Its PSI was conducted of 29-10-2018 and the product was approved in 298 meeting of Registration Board.  Firm has further submitted that their product Neoge 2g Injection was approved in 298 meeting of Registration Board.  Firm has further submitted that their product Neoge 2g Injection was approved in 298 meeting of Registration Board.  Firm has further submitted that their product Neoge 2g Injection was approved in 298 meeting of Registration Board.  Firm has submitted on Form 5F (CTD) along with complet data.  Approval of API/ DML/GMP certificate of API with approval from DRAP (in case of import).  Documents for the procurement of API with approval from DRAP (in case of import).  Firm has submitted copy of invoice specifying import of 100Kg ceftriaxone sodium dated 08-01-2019. To invoice is signed by AD (I&E) DRAP Islamab office.  Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.  Data of stability batches will be supported by attested respective documents like chromatograms, and data sheets of the product was initiated 2 years ago, at that time of HPLC (Schimadzu) was not 21 CFR compliant HPLC s	Date	of Initiation	12-02-2019	14-02-2019	10-03-2019
1. Reference of previous approval of applications with stability study data of the firm (if any)  Reference of previous approval of applications with stability study data of the firm (if any)  PSI was conducted on 11-09-2018 and the product was approved in 285th meeting of Registration Board.  Neovel 800mg Tablet. Its PSI was conducted on 14-12-2018 and the product was approved in 288 meeting of Registration Board.  Neovel 800mg Tablet. Its PSI was conducted on 14-12-2018 and the product was approved in 288 meeting of Registration Board.  Serbica 20mg Capsule. Its PSI was conducted on 29-10-2018 and the product was approved in 293th meeting of Registration Board. That product was approved in 293th meeting of Registration Board. That product was applied by AC and contract manufactured by Seraph and was ubmitted on Form 5F (CTD) along with complet data.  Approval of API/DML/GMP certificate of API with approval from DRAP (in case of import).  Documents for the procurement of API with approval from DRAP (in case of import).  Documents for the procurement of API with approval from DRAP (in case of import).  Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA summary data sheets etc.  Compliance Record of HPLC software 21CFR & audit trail reports on product testing batches along with chromatograms, raw data sheets COA and summary data sheets.  COA and summary data	No.	of Batches		03	
with stability study data of the firm (if any)  Dexpro (Dexlansoprazole) 30 and 60mg Capsul PSI was conducted on 11-09-2018 and the product was approved in 285th meeting of Registration Board.  Neovel 800mg Tablet. Its PSI was conducted of 14-12-2018 and the product was approved in 288 meeting of Registration Board. Serbica 20mg Capsule. Its PSI was conducted of 29-10-2018 and the product was approved in 298 meeting of Registration Board. Firm has further submitted that their product Neoge 2g Injection was approved in 293 meeting of Registration Board. That product was applied by AC and contract manufactured by Seraph and was ubmitted on Form 5F (CTD) along with complete and contract manufactured by Seraph and was ubmitted on Form 5F (CTD) along with complete and contract manufactured by CPDA China is submitted by the firm. To extrificate is valid till 05-06-2023  Documents for the procurement of API with approval from DRAP (in case of import).  Documents for the procurement of API with approval from DRAP (in case of import).  Documents for the procurements like chromatograms, Raw data sheets, COA summary data sheets etc.  Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA summary data sheets etc.  Compliance Record of HPLC software 21CFR & audit trail reports on product testing  Tirm has submitted complete record of testing of all batches along with chromatograms, raw data sheets.  COA and summary data sheets.  COA and summary data sheets.  COA and summary data sheets.  COA and summary data sheets.  Tirm has submitted that since the stability study of the product was initiated 2 years ago, at that time of HPLC (Schimadzu) was not 21 CFR compliant (Perk Elmer) HPLC system. We undertake that in future will use 21 CFR compliant HPLC system for stabilities and humidity monitoring of stability chambers.		DOCUMENTS / DA	TA TO BE PROVIDE	D ALONG WITH STA	BILITY STUDY DATA
manufacturer issued by concerned regulatory authority of country of origin.  3. Documents for the procurement of API with approval from DRAP (in case of import).  4. Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.  5. Compliance Record of HPLC software 21CFR & audit trail reports on product testing  6. Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)  by CFDA China is submitted by the firm. To certificate is valid till 05-06-2023  by CFDA China is submitted by the firm. To certificate is valid till 05-06-2023  by CFDA China is submitted by the firm. To certificate is valid till 05-06-2023  Firm has submitted copy of invoice specifying import of 100Kg ceftriaxone sodium dated 08-01-2019. To invoice is signed by AD (I&E) DRAP Islamaboroffice.  6. Prim has submitted copy of invoice specifying import of 100Kg ceftriaxone sodium dated 08-01-2019. To invoice is signed by AD (I&E) DRAP Islamaboroffice.  6. Prim has submitted copy of invoice specifying import of 100Kg ceftriaxone sodium dated 08-01-2019. To invoice is signed by AD (I&E) DRAP Islamaboroffice.  6. Prim has submitted that since the stability study of the product was initiated 2 years ago, at that time of HPLC (Schimadzu) was not 21 CFR compliant However now we have 21 CFR compliant However will use 21 CFR compliant HPLC system for stability testing.  6. Record of Digital data logger for temperature and humidity monitoring of real time and accelerated)		with stability study dat	a of the firm (if any)	<ul> <li>inspection reports</li> <li>Dexpro (Dexlanson PSI was conducted was approved in Board.</li> <li>Neovel 800mg To 14-12-2018 and the meeting of Regist</li> <li>Serbica 20mg Ca 29-10-2018 and the meeting of Regist Firm has further subsequence 2g Injection was Registration Board. Year and contract manusubmitted on Form data.</li> </ul>	oprazole) 30 and 60mg Capsule. d on 11-09-2018 and the product 285 <sup>th</sup> meeting of Registration ablet. Its PSI was conducted on the product was approved in 288th ration Board.  psule. Its PSI was conducted on the product was approved in 290 <sup>th</sup> ration Board.  mitted that their product Neogene approved in 293 <sup>rd</sup> meeting of That product was applied by AGP afactured by Seraph and was 5F (CTD) along with complete
approval from DRAP (in case of import).  approval from DRAP (in case of import).  of 100Kg ceftriaxone sodium dated 08-01-2019. To invoice is signed by AD (I&E) DRAP Islamable office.  4. Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.  5. Compliance Record of HPLC software 21CFR & audit trail reports on product testing  Firm has submitted complete record of testing of al batches along with chromatograms, raw data sheets.  COA and summary data sheets.  Firm has submitted that since the stability study of the product was initiated 2 years ago, at that time of HPLC (Schimadzu) was not 21 CFR compliant However now we have 21 CFR compliant However now we have 21 CFR compliant However now we have 21 CFR compliant However now we have 21 CFR compliant However now will use 21 CFR compliant HPLC system for stabilitiesting.  6. Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	2.	manufacturer issued b	y concerned regulator	y by CFDA China i	s submitted by the firm. The
attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.  5. Compliance Record of HPLC software 21CFR & audit trail reports on product testing  6. Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)  batches along with chromatograms, raw data sheets COA and summary data sheets.  COA and summary data sheets.  Firm has submitted that since the stability study of the product was initiated 2 years ago, at that time of HPLC (Schimadzu) was not 21 CFR compliant However now we have 21 CFR compliant (Perk Elmer) HPLC system. We undertake that in future will use 21 CFR compliant HPLC system for stability testing.	3.			of 100Kg ceftriaxon invoice is signed b	e sodium dated 08-01-2019. The
& audit trail reports on product testing  Broduct was initiated 2 years ago, at that time of HPLC (Schimadzu) was not 21 CFR compliant However now we have 21 CFR compliant (Perk Elmer) HPLC system. We undertake that in future will use 21 CFR compliant HPLC system for stabilitiesting.  Brooduct was initiated 2 years ago, at that time of HPLC (Schimadzu) was not 21 CFR compliant However now we have 21 CFR compliant (Perk Elmer) HPLC system. We undertake that in future will use 21 CFR compliant HPLC system for stabilitiesting.  Brooduct was initiated 2 years ago, at that time of HPLC (Schimadzu) was not 21 CFR compliant However now we have 21 CFR compliant (Perk Elmer) HPLC system. We undertake that in future will use 21 CFR compliant HPLC system for stabilitiesting.  Brooduct was initiated 2 years ago, at that time of HPLC (Schimadzu) was not 21 CFR compliant However now we have 21 CFR compliant (Perk Elmer) HPLC system. We undertake that in future will use 21 CFR compliant HPLC system for stabilitiesting.  Brooduct was initiated 2 years ago, at that time of HPLC (Schimadzu) was not 21 CFR compliant However now we have 21 CFR compliant (Perk Elmer) HPLC system. We undertake that in future will use 21 CFR compliant HPLC system for stabilities and humidity monitoring of stability chambers (real time and accelerated)	4.	attested respective chromatograms, Raw	documents like data sheets, COA	batches along with c	hromatograms, raw data sheets,
and humidity monitoring of stability chambers (real time and accelerated) temperature and humidity monitoring of real time as accelerated stability chambers.	5.	_		product was initiate HPLC (Schimadzu) However now we 1 Elmer) HPLC syster will use 21 CFR con	ed 2 years ago, at that time our was not 21 CFR compliant. have 21 CFR compliant (Perkin m. We undertake that in future we
Evaluation by DEC(III)	6.	and humidity monitori	ng of stability chamber	rs temperature and hun	nidity monitoring of real time and
Evaluation by PEC(III)::	Eval	uation by PEC(III)::			

• The applied product to be manufactured by M/s Seraph Pharmaceuticals Islamabad have already been approved by Registration Board in its 307<sup>th</sup> meeting based on the data of same batches of drug product

as submitted in the instant case. The details of the already approved product in  $307^{\text{th}}$  meeting are as follows:

Applicant firm M/s CCL Pharmaceuticals (Pvt) Ltd. 62-Industrial Esta		
	Kot Lakhpat Lahore.	
Manufacturer firm	M/s Seraph Pharmaceuticals Plot # 210, Industrial Triangle	
	Kahuta Road Islamabad.	
Brand Name	SNARE Injection 250mg IV	
Batch No. of drug product	001, 002, 003	
Case No.	28	
RB meeting	307	

# **Decision: Approved.**

• Manufacturer will perform process validation of first three batches as per the commitment submitted in the registration application.

5.	Name, address of Applicant / Marketing Authorization Holder	M/s Carer Pharmaceuticals Plot # 27, Main Road, Rawat Industrial Estate Rawat.
	Name, address of Manufacturing site.	M/s Global Pharmaceuticals (Pvt) Ltd. Plot No. 204-205, Industrial Triangle Kahuta Road Islamabad.
	Status of the applicant	☐ Manufacturer ☐ Importer ☑ Is involved in none of the above (contract giver) Firm has submitted copy of contract manufacturing agreement with applicant firm dated 01-03-2021.
	GMP status of the firm	Firm has submitted copy of GMP certificate of M/s Global Pharmaceuticals dated 24-12-2018 based on the inspection dated 24-10-2018. The certificate was valid till 23-10-2021.  The GMP certificate specifies dry powder injection (cephalosporin) section.
	Evidence of approval of manufacturing facility	Firm has submitted copy of GMP certificate of M/s Global Pharmaceuticals dated 24-12-2018 based on the inspection dated 24-10-2018. The certificate was valid till 23-10-2021.  The GMP certificate specifies dry powder injection (cephalosporin) section.
	Status of application	☐ New Drug Product (NDP) ☐ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	<ul><li>☑ Domestic sale</li><li>☐ Export sale</li><li>☐ Domestic and Export sales</li></ul>
	Dy. No. and date of submission	Dy. No. 16397: 14-06-2021
	Details of fee submitted	PKR 50,000/-: 04-05-2021 + PKR 25,000/-: 11-06-2021
	The proposed proprietary name / brand name	ACRUX 500mg Injection IV
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each Vial Contains: Ceftriaxone (as sodium)500mg
	Pharmaceutical form of applied drug	Sterile white to off white powder filled in transparent glass vials

Pharmacotherapeutic Group of (API)	Cephalosporin antibiotic
Reference to Finished product specifications	USP
Proposed Pack size	1's
Proposed unit price	As per SRO
The status in reference regulatory authorities	Ceftriaxone sodium Injection (MHRA Approved)
For generic drugs (me-too status)	Aczon injection by Vision Pharma
Name and address of API manufacturer.	Sinopharm Weiqida Pharmaceutical Co. Ltd. First Medical Zone, Economic and Technological Development Zone, Datong Shanxi. China
Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Firm has summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product.
Module-III Drug Substance:	Firm has submitted detailed data for both drug substance data related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
Stability Studies of Drug Substance (Conditions & duration of Stability studies)	Firm has submitted stability study data of 3 batches of drug substance at both accelerated as well as real time conditions. The accelerated stability data is conducted at $40^{\circ}\text{C} \pm 2^{\circ}\text{C} \ / \ 75\% \pm 5\%$ RH for 6 months. The real time stability data is conducted at $30^{\circ}\text{C} \pm 2^{\circ}\text{C} \ / \ 65\% \pm 5\%$ RH for 36 months.
Module-III Drug Product:	Firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.
Pharmaceutical Equivalence and Comparative Dissolution Profile	Firm has submitted results of pharmaceutical equivalence for the quality tests for their product against the comparator i.e. Rocephin 500mg Injection.
Analytical method validation/verification of product	Firm has submitted report of verification of analytical method for the drug substance. Firm has submitted report of verification of analytical method for the drug product.

		STABILITY	STUDY DATA	
			Pharmaceutical Co. Ltd. levelopment Zone, Daton	First Medical Zone, Economic g Shanxi. China
API Lot No.				
Description of Pack (Container closure s	1 (	Glass vials		
Stability Storage Co		Real time : $30^{\circ}C \pm 2$ Accelerated: $40^{\circ}C \pm 2$		
Time Period		Real time: 6 months Accelerated: 6 mont	hs	
Frequency		Accelerated: 0, 3, 6 (Real Time: 0, 3, 6 (N		
Batch No.		18A101	18B152	18G072
Batch Size		16,806 vials	16,806 vials	16,806 vials
Manufacturing Date	;	01-2018	02-2018	07-2018
Date of Initiation		31-01-2018	07-03-2018	30-07-2018
No. of Batches		03		
DOCUMENT	rs / data t	O BE PROVIDED	ALONG WITH STAB	ILITY STUDY DATA
	Reference of previous approval of applications with stability study data of the firm (if any)		ns Not submitted	
manufacturer	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.			
	Documents for the procurement of API with approval from DRAP (in case of import).		th Not submitted	
attested r	espective s, Raw data s	will be supported documents litheets, COA, summa	ke	
5. Compliance R audit trail repo			& Firm has submitted t 21 CFR compliant.	hat their HPLC system is not
6. Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)			ecord of digital data logger for nidity monitoring of real time ity chambers.	

Letter of shortcoming was issued to the firm dated 03-01-2022. Following shortcomings were communicated to the firm.

- Provide valid GMP certificate / inspection report of the contract manufacturer since the submitted GMP certificate has been expired.
- The analytical method of the drug substance from the product manufacturer i.e. Global Pharmaceuticals is different in terms of chromatographic conditions, UV wavelength, sample and standard preparation as well as calculation formula and acceptance criteria from both USP monograph as well as drug substance manufacturer's analytical method. Justification is required in this regard.
- Analytical method verification studies (3.2.S.4.3) have been conducted at entirely different chromatographic conditions, UV wavelength, mobile phase. sample and standard preparation as well

- as calculation formula from that of USP as well as drug substance manufacturer. Justify how routine analysis and verification studies was conducted using a method which is different from USP.
- The peak area of standard solution in verification studies is approximately 515, while the peak area of standard solution at same concentration in stability studies is approximately 13699925. Justify how such significant difference in peak area exist during the analysis of a solution having same concentration.
- Submit COA of relevant batch of drug substance from both drug substance manufacturer as well as drug product manufacturer used in the manufacturing of batches of drug product for which stability study data is submitted in section 3.2.P.8.3, instead of providing complete analysis reports and raw data for various batches.
- Submit COA of reference standard actually used in the analysis of drug substance in section 3.2.S.5.
- Justify how 595mg ceftriaxone sodium sterile powder is equivalent to 500mg of ceftriaxone base.
- You have mentioned that the product is filled in 5ml glass vials and that the diluent for reconstitution is 5ml WFI, while in stability studies you have mentioned 2ml Lignocaine. Justification is required in this regard.
- The innovator product Rocephin Injection 500mg have specified that 4.8ml WFI is required to reconstitute the injection for intravenous injection, while you are using 5ml WFI. Justify why you are not using the same volume of diluent as specified by the innovator product.
- Justify why the pharmaceutical equivalence study does not include complete testing of the drug product and the innovator product as per USP specifications.
- Justify why you have not performed compatibility studies and submitted its data in section 3.2.P.2.6.
- Justify your process validation protocols and report without any process for optimization of sterilization process and sealing of vials etc.
- Justify why the specifications of the drug product (section 3.2.P.5.1) does not contain important tests as recommended by USP including test for constituted solution, crystallinity and complete assay test. Justify why you are not complying USP monograph and revise your specifications along with submission of fee.
- The standard and sample preparation method for the assay test in your method of analysis is different from USP. Furthermore, USP recommends 2 different tests for assay while you are performing only one type of test. Justification is required in this regard.
- Justify the alternate method of assay which is based on UV method since no such method is recommended by USP.
- In verification studies of the analytical method of drug product, you have mentioned that retention time of ceftriaxone is 7.2 minutes, while in the stability studies the retention time is above 11 minutes. Justify how your method is specific.
- Specify the exact concentration of the sample solution which is used to perform each test during verification studies instead of mentioning % only.
- Justify how three commercial batches were released for commercial use without performing complete tests as specified in USP monograph.
- Provide COA of reference standard actually used in the analysis of drug product in section 3.2.P.6.
- Justify why in use stability study data is not submitted.
- Submit stability study data of ceftriaxone 500mg IV injection since the submitted data is for IM injection.
- Justify why the test for water contents, constituted solution etc is not performed during stability studies since these tests are very critical and are required to make assessment of the stability profile and shelf life.
- Justify how assay testing was conducted using only 3 analysis of standard solution.
- Provide raw data sheets to justify the calculation of results for assay testing at each time point during the stability testing of each batch. Moreover submit stability study data of each batch with proper separators and raw data sheets in proper sequence starting from initial time point to 6<sup>th</sup> month time point. Since the submitted data is not provided in any sequence.
- Submit exact lot of drug substance used for the manufacturing of each batch of drug product.
- Justify the use of completely different formula for calculation of assay results than that specified in USP monograph.
- Submit Reference of previous approval of applications with stability study data of the firm.

- Submit Documents for the procurement of relevant batch of API with approval from DRAP which is
  actually used in the manufacturing of three batches for which stability study data has been submitted.
- Submit compliance Record of HPLC software 21CFR & audit trail reports on product testing.
- Provide record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated).
- Provide copy of Batch Manufacturing Record (BMR) of three batches for which stability study data has been submitted.
- Justify how you are manufacturing ceftriaxone 500mg Injection using a drug substance which is manufactured by Zhuhai United Laboratories, since your complete Form 5F specifies that the drug substance manufacturer is Sinopharm Weiqida Pharmaceutical Co. Ltd.

In response, the firm (M/s Carer Pharmaceuticals) dated 30-03-2022 (Dy No. 8293) has submitted a new request for registration of their product on contract manufacturing from M/s Seraph Pharmaceuticals along with submission of full fee.

The details of the newly submitted data are as follows:

DY No. 8294: 30-03-2022 New fee: 75,000/-: 07-03-2022

New Ice. 75,000/ 07-03-2022	
Name, address of Applicant / Marketing Authorization Holder	M/s Carer Pharmaceuticals Plot # 27, Main Road, Rawat Industrial Estate Rawat.
Name, address of Manufacturing site.	M/s Seraph Pharmaceuticals Plot # 210, Industrial Triangle Kahuta Road Islamabad.
Status of the applicant	☐ Manufacturer ☐ Importer ☑ Is involved in none of the above (contract giver) (Contract manufacturing agreement between both firms dated 05-01-2022 is provided)
GMP status of the firm	<b>Seraph Pharmaceuticals:</b> GMP certificate issued on the basis of inspection conducted on 11/07/2019.
Evidence of approval of manufacturing facility	Firm (M/s Seraph Pharmaceuticals) has submitted copy of Issuance of DML letter dated 12-06-2017 specifying Dry Vial Cephalosporin section.
Status of application	<ul><li>□ New Drug Product (NDP)</li><li>☑ Generic Drug Product (GDP)</li></ul>
Intended use of pharmaceutical product	<ul> <li>□ Domestic sale</li> <li>□ Export sale</li> <li>☑ Domestic and Export sales</li> </ul>
Dy. No. and date of submission	Dy. No 8294: 30-03-2022
Details of fee submitted	PKR 75,000/-: 07-03-2022
The proposed proprietary name / brand name	ACRUX 500mg Injection IV
Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each vial contains: Ceftriaxone (as sodium)500mg
Pharmaceutical form of applied drug	Sterilized white to off white crystalline dry powder contained in a glass vial with sterilized rubber stopper & aluminium flip seal on it.
Pharmacotherapeutic Group of (API)	Cephalosporin antibiotic
Reference to Finished product specifications	USP specs
Proposed Pack size	As per SRO
Proposed unit price	As per SRO

The status in reference regulatory authorities	Ceftriaxone 500mg powder for solution for injection (MHRA Approved)
For generic drugs (me-too status)	Droncef injection 500mg by Seraph Pharmaceuticals
Name and address of API manufacturer.	Sinopharm Weiqida Pharmaceutical Co. Ltd. First Medical zone, Economic & technological development zone, Datong Shanxi China.
Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Firm has summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product.
Module-III Drug Substance:	Firm has submitted detailed data for drug substance data related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
Stability Studies of Drug Substance (Conditions & duration of Stability studies)	Firm has submitted stability study data of 3 batches of drug substance at both accelerated as well as real time conditions. The accelerated stability data is conducted at $40^{\circ}\text{C} \pm 2^{\circ}\text{C} \ / \ 75\% \pm 5\%$ RH for 6 months. The real time stability data is conducted at $30^{\circ}\text{C} \pm 2^{\circ}\text{C} \ / \ 65 \pm 5\%$ RH for 48 months.
Module-III Drug Product:	Firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.
Pharmaceutical Equivalence and Comparative Dissolution Profile	Firm has submitted results of pharmaceutical equivalence for all the quality tests for their product against the innovator i.e. Rocephin Injection 500mg. The results of all the tests of both products falls within the specifications and are comparable. The firm has also performed compatibility studies of the product with recommended diluent i.e. sterile water for injection. Firm has performed comparative analysis with innovator product after reconstitution as well. The reconstitution studies also demonstrate comparable results with the innovator product.
Analytical method validation/verification of product	Firm has submitted report of validation of analytical method for the drug product. Firm has submitted report of verification studies of analytical method for the drug substance.

	STABILITY STUDY DATA			
		Sinopharm Weiqida Pharmaceutical Co. Ltd. First Medical zone, Economic & technological development zone, Datong Shanxi China.		
API I	Lot No.	Q011812004		
	ription of Pack tainer closure system)	Vials containing pov	vder for reconstitution,	packed in unit carton
Stabi	lity Storage Condition	Real time : $30^{\circ}\text{C} \pm 2^{\circ}$ Accelerated: $40^{\circ}\text{C} \pm$		
Time	Period	Real time: 6 months Accelerated: 6 months		
Frequ	uency	Accelerated: 0, 1, 2, Real Time: 0, 3, 6 (M		
Batch	n No.	001	002	003
Batch	n Size	8389 vials	8389 vials	8389 vials
Manu	ufacturing Date	01-2019	01-2019	02-2019
Date	of Initiation	12-02-2019	14-02-2019	10-03-2019
No. c	of Batches		03	
	DOCUMENTS / DATA	A TO BE PROVIDE	ALONG WITH ST	ABILITY STUDY DATA
			PSI was conducte was approved in Board.  Neovel 800mg T 14-12-2018 and the meeting of Regist. Serbica 20mg Ca 29-10-2018 and the meeting of Regist. Firm has further sub 2g Injection was Registration Board. and contract manusubmitted on Form data.	psule. Its PSI was conducted on the product was approved in 290th ration Board.  mitted that their product Neogene approved in 293rd meeting of That product was applied by AGP ifactured by Seraph and was 5F (CTD) along with complete
2.	Approval of API/ DML/ manufacturer issued by authority of country of	concerned regulator	1 0	ficate (No. SX20180229) issued is submitted by the firm. The Il 05-06-2023
3.	Documents for the proapproval from DRAP (i		of 100Kg ceftriaxon	copy of invoice specifying import the sodium dated 08-01-2019. The by AD (I&E) DRAP Islamabad
4.	Data of stability batche attested respective chromatograms, Raw summary data sheets etc	documents lik data sheets, COA		complete record of testing of all chromatograms, raw data sheets, data sheets.
5.	Compliance Record of & audit trail reports on		product was initiate	hat since the stability study of this ed 2 years ago, at that time our was not 21 CFR compliant.

			However now we have 21 CFR compliant (Perkin Elmer) HPLC system. We undertake that in future we will use 21 CFR compliant HPLC system for stability testing.
1	6.		Firm has submitted record of digital data logger for temperature and humidity monitoring of real time and accelerated stability chambers.
١,		· · · · · · · · · · · · · · · · · · ·	

• The applied product to be manufactured by M/s Seraph Pharmaceuticals Islamabad have already been approved by Registration Board in its 316<sup>th</sup> meeting based on the data of same batches of drug product as submitted in the instant case. The details of the already approved product in 316<sup>th</sup> meeting are as follows:

Applicant firm M/s Amson Vaccines and Pharma Pvt Ltd. Plot No. 154		
	Industrial Triangle Kahuta Road Islamabad.	
Manufacturer firm	M/s Seraph Pharmaceuticals Plot # 210, Industrial Triangle	
	Kahuta Road Islamabad.	
Brand Name	CESOD Injection 500mg IV	
Batch No. of drug product	001, 002, 003	
Case No.	784	
RB meeting	316	

Decision: Approved. Manufacturer will perform process validation of first three batches as per the commitment submitted in the registration application.

6.	Name, address of Applicant / Marketing Authorization Holder	M/s Carer Pharmaceuticals Plot # 27, Main Road, Rawat Industrial Estate Rawat.
	Name, address of Manufacturing site.	M/s Global Pharmaceuticals (Pvt) Ltd. Plot No. 204-205, Industrial Triangle Kahuta Road Islamabad.
	Status of the applicant	☐ Manufacturer ☐ Importer ☑ Is involved in none of the above (contract giver) Firm has submitted copy of contract manufacturing agreement with applicant firm dated 01-03-2021.
	GMP status of the firm	Firm has submitted copy of GMP certificate of M/s Global Pharmaceuticals dated 24-12-2018 based on the inspection dated 24-10-2018. The certificate was valid till 23-10-2021.  The GMP certificate specifies dry powder injection (cephalosporin) section.
	Evidence of approval of manufacturing facility	Firm has submitted copy of GMP certificate of M/s Global Pharmaceuticals dated 24-12-2018 based on the inspection dated 24-10-2018. The certificate was valid till 23-10-2021. The GMP certificate specifies dry powder injection (cephalosporin) section.
	Status of application	☐ New Drug Product (NDP) ☐ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	<ul><li>☑ Domestic sale</li><li>☐ Export sale</li><li>☐ Domestic and Export sales</li></ul>

Dy. No. and date of submission	Dy. No. 16398: 14-06-2021
Details of fee submitted	PKR 50,000/-: 04-05-2021 + PKR 25,000/-: 11-06-2021
The proposed proprietary name / brand name	ACRUX 1g Injection IV
Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each Vial Contains: Ceftriaxone (as sodium)1g
Pharmaceutical form of applied drug	Sterile white to off white powder filled transparent glass vials
Pharmacotherapeutic Group of (API)	Cephalosporin antibiotic
Reference to Finished product specifications	USP
Proposed Pack size	1's
Proposed unit price	As per SRO
The status in reference regulatory authorities	Ceftriaxone sodium Injection (MHRA Approved
For generic drugs (me-too status)	Aczon injection by Vision Pharma
Name and address of API manufacturer.	Sinopharm Weiqida Pharmaceutical Co. Ltd. Fi Medical Zone, Economic and Technologic Development Zone, Datong Shanxi. China
Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-I template. Firm has summarized informative related to nomenclature, structure, generoperties, solubilities, physical for manufacturers, description of manufacturic process and controls, impurities, specification analytical procedures and its validation, bat analysis and justification of specification reference standard, container closure system a stability studies of drug substance and drug product.
Module-III Drug Substance:	Firm has submitted detailed data for both dr substance data related to nomenclature, structure general properties, solubilities, physical for manufacturers, description of manufacturing process and controls, impurities, specification analytical procedures and its validation, bat analysis and justification of specification reference standard, container closure system a stability studies of drug substance.
Stability Studies of Drug Substance (Conditions & duration of Stability studies)	Firm has submitted stability study data of 3 batch of drug substance at both accelerated as well as retime conditions. The accelerated stability data conducted at $40^{\circ}\text{C} \pm 2^{\circ}\text{C} / 75\% \pm 5\%$ RH for months. The real time stability data is conducted $30^{\circ}\text{C} \pm 2^{\circ}\text{C} / 65\% \pm 5\%$ RH for 36 months.
Module-III Drug Product:	Firm has submitted data of drug product including its description, composition, pharmaceutic development, manufacture, manufacturing process and process control, process validation protocolocontrol of excipients, control of drug product specifications, analytical procedures, validation analytical procedures, batch analysis, justification

				_	erence standard or materials,
	Pharmaceutical Equivalence and Comparative Dissolution Profile		container closure system and stability.  Firm has submitted results of pharmaceutical equivalence for the quality tests for their product against the comparator i.e. Rocephin 1g Injection.		
	Analytical method validation/verification of product		Firm has submitted report of verification of analytical method for the drug substance.  Firm has submitted report of verification of analytical method for the drug product.		
		STABILITY	ST	UDY DATA	
Man	ufacturer of API	Sinopharm Weiqida Pharmaceutical Co. Ltd. First Medical Zone, Economic and Technological Development Zone, Datong Shanxi. China			
API	Lot No.				
1	ription of Pack tainer closure system)	Glass vials			
Stabi	lity Storage Condition	Real time : $30^{\circ}\text{C} \pm 2^{\circ}\text{C} / 65\% \pm 5\%\text{RH}$ Accelerated: $40^{\circ}\text{C} \pm 2^{\circ}\text{C} / 75\% \pm 5\%\text{RH}$			
Time	e Period	Real time: 6 months Accelerated: 6 months			
Frequ	uency	Accelerated: 0, 3, 6 (Months) Real Time: 0, 3, 6 (Months)			
Batc	h No.	18D132		18D133	18F052
Batc	h Size	33,613 vials		33,613 vials	16,806 vials
Man	ufacturing Date	04-2018		04-2018 06-2018	
Date	of Initiation	07-05-2018		08-05-2018 19-06-2018	
No. o	of Batches	03			
	DOCUMENTS / DATA	TO BE PROVIDED	A	LONG WITH STABI	LITY STUDY DATA
1.	Reference of previous a with stability study data of		ns	Not submitted	
2.	Approval of API/ DML/ manufacturer issued by authority of country of or	concerned regulato			
3.	Documents for the pro approval from DRAP (in		th	Not submitted	
4.	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.				
5.			Firm has submitted that their HPLC system is not 21 CFR compliant.		
6.					
Eval	uation by PEC(III)::				
	r of shortcoming was issue e firm.	ed to the firm dated 03-	01	-2022. Following short	comings were communicated

- Provide valid GMP certificate / inspection report of the contract manufacturer since the submitted GMP certificate has been expired.
- The analytical method of the drug substance from the product manufacturer i.e. Global Pharmaceuticals is different in terms of chromatographic conditions, UV wavelength, sample and standard preparation as well as calculation formula and acceptance criteria from both USP monograph as well as drug substance manufacturer's analytical method. Justification is required in this regard.
- Analytical method verification studies (3.2.S.4.3) have been conducted at entirely different chromatographic conditions, UV wavelength, mobile phase. sample and standard preparation as well as calculation formula from that of USP as well as drug substance manufacturer. Justify how routine analysis and verification studies was conducted using a method which is different from USP.
- The peak area of standard solution in verification studies is approximately 515, while the peak area of standard solution at same concentration in stability studies is approximately 13699925. Justify how such significant difference in peak area exist during the analysis of a solution having same concentration.
- Submit COA of relevant batch of drug substance from both drug substance manufacturer as well as drug product manufacturer used in the manufacturing of batches of drug product for which stability study data is submitted in section 3.2.P.8.3, instead of providing complete analysis reports and raw data for various batches.
- Submit COA of reference standard actually used in the analysis of drug substance in section 3.2.S.5.
- Justify how 1190mg ceftriaxone sodium sterile powder is equivalent to 1g of ceftriaxone base.
- The innovator product Rocephin Injection 500mg have specified that 9.6ml WFI is required to reconstitute the injection for intravenous injection, while you are using 10ml WFI. Justify why you are not using the same volume of diluent as specified by the innovator product.
- Justify why the pharmaceutical equivalence study does not include complete testing of the drug product and the innovator product as per USP specifications.
- Justify why you have not performed compatibility studies and submitted its data in section 3.2.P.2.6.
- Justify your process validation protocols and report without any process for optimization of sterilization process and sealing of vials etc.
- Justify why the specifications of the drug product (section 3.2.P.5.1) does not contain important tests as recommended by USP including test for constituted solution, crystallinity and complete assay test. Justify why you are not complying USP monograph and revise your specifications along with submission of fee.
- The standard and sample preparation method for the assay test in your method of analysis is different from USP. Furthermore, USP recommends 2 different tests for assay while you are performing only one type of test. Justification is required in this regard.
- Justify the alternate method of assay which is based on UV method since no such method is recommended by USP.
- In verification studies of the analytical method of drug product, you have mentioned that retention time of ceftriaxone is 7.2 minutes, while in the stability studies the retention time is above 11 minutes. Justify how your method is specific.
- Specify the exact concentration of the sample solution which is used to perform each test during verification studies instead of mentioning % only.
- Justify how three commercial batches were released for commercial use without performing complete tests as specified in USP monograph.
- Provide COA of reference standard actually used in the analysis of drug product in section 3.2.P.6.
- Justify why in use stability study data is not submitted.
- Justify why the test for water contents, constituted solution etc is not performed during stability studies since these tests are very critical and are required to make assessment of the stability profile and shelf life.
- Justify how assay testing was conducted using only 3 analysis of standard solution.
- Provide raw data sheets to justify the calculation of results for assay testing at each time point during
  the stability testing of each batch. Moreover submit stability study data of each batch with proper
  separators and raw data sheets in proper sequence starting from initial time point to 6<sup>th</sup> month time
  point. Since the submitted data is not provided in any sequence.
- Submit exact lot of drug substance used for the manufacturing of each batch of drug product.

- Justify the use of completely different formula for calculation of assay results than that specified in USP monograph.
- Submit Reference of previous approval of applications with stability study data of the firm.
- Submit Documents for the procurement of relevant batch of API with approval from DRAP which is actually used in the manufacturing of three batches for which stability study data has been submitted.
- Submit compliance Record of HPLC software 21CFR & audit trail reports on product testing.
- Provide record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated).
- Provide copy of Batch Manufacturing Record (BMR) of three batches for which stability study data has been submitted.
- Justify how you are manufacturing ceftriaxone 500mg Injection using a drug substance which is manufactured by Zhuhai United Laboratories, since your complete Form 5F specifies that the drug substance manufacturer is Sinopharm Weiqida Pharmaceutical Co. Ltd.

In response, the firm (M/s Carer Pharmaceuticals) dated 30-03-2022 (Dy No. 8293) has submitted a new request for registration of their product on contract manufacturing from M/s Seraph Pharmaceuticals along with submission of full fee.

The details of the newly submitted data are as follows:

DY No. 8295: 30-03-2022 New fee: 75,000/-: 07-03-2022

Name, address of Applicant / Marketing Authorization Holder	M/s Carer Pharmaceuticals Plot # 27, Main Road, Rawat Industrial Estate Rawat.
Name, address of Manufacturing site.	M/s Seraph Pharmaceuticals Plot # 210, Industrial Triangle Kahuta Road Islamabad.
Status of the applicant	☐ Manufacturer ☐ Importer ☑ Is involved in none of the above (contract giver) (Contract manufacturing agreement between both firms dated 05-01-2022 is provided)
GMP status of the firm	<b>Seraph Pharmaceuticals:</b> GMP certificate issued on the basis of inspection conducted on 11/07/2019.
Evidence of approval of manufacturing facility	Firm (M/s Seraph Pharmaceuticals) has submitted copy of Issuance of DML letter dated 12-06-2017 specifying Dry Vial Cephalosporin section.
Status of application	<ul><li>□ New Drug Product (NDP)</li><li>☑ Generic Drug Product (GDP)</li></ul>
Intended use of pharmaceutical product	<ul><li>□ Domestic sale</li><li>□ Export sale</li><li>☑ Domestic and Export sales</li></ul>
Dy. No. and date of submission	Dy. No 8295: 30-03-2022
Details of fee submitted	PKR 75,000/-: 07-03-2022
The proposed proprietary name / brand name	ACRUX 1g Injection IV
Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each vial contains: Ceftriaxone (as sodium)1g
Pharmaceutical form of applied drug	Sterilized white to off white crystalline dry powder contained in a glass vial with sterilized rubber stopper & aluminium flip seal on it.
Pharmacotherapeutic Group of (API)	Cephalosporin antibiotic
Reference to Finished product specifications	USP specs
Proposed Pack size	As per SRO

Proposed unit price	As per SRO
The status in reference regulatory authorities	Ceftriaxone 1g powder for solution for injection (MHRA Approved)
For generic drugs (me-too status)	Droncef injection 1g by Seraph Pharmaceuticals
Name and address of API manufacturer.	Sinopharm Weiqida Pharmaceutical Co. Ltd. First Medical zone, Economic & technological development zone, Datong Shanxi China.
Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Firm has summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product.
Module-III Drug Substance:	Firm has submitted detailed data for drug substance data related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
Stability Studies of Drug Substance (Conditions & duration of Stability studies)	Firm has submitted stability study data of 3 batches of drug substance at both accelerated as well as real time conditions. The accelerated stability data is conducted at $40^{\circ}\text{C} \pm 2^{\circ}\text{C}  /  75\%  \pm  5\%$ RH for 6 months. The real time stability data is conducted at $30^{\circ}\text{C} \pm 2^{\circ}\text{C}  /  65 \pm  5\%$ RH for 48 months.
Module-III Drug Product:	Firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.
Pharmaceutical Equivalence and Comparative Dissolution Profile	Firm has submitted results of pharmaceutical equivalence for all the quality tests for their product against the innovator i.e. Rocephin Injection 1g. The results of all the tests of both products falls within the specifications and are comparable. The firm has also performed compatibility studies of the product with recommended diluent i.e. sterile water for injection. Firm has performed comparative analysis with innovator product after reconstitution as well. The reconstitution studies also demonstrate comparable results with the innovator product.
Analytical method validation/verification of product	Firm has submitted report of validation of analytical method for the drug product. Firm has submitted report of verification studies of analytical method for the drug substance.

	STABILITY STUDY DATA					
Manu	facturer of API			Pharmaceutical Co. Ltd. First Medical zone, Economic opment zone, Datong Shanxi China.		
API I	Lot No.	Q011812004				
	ription of Pack ainer closure system)	Vials containing po	Vials containing powder for reconstitution, packed in unit carton			
Stabil	ity Storage Condition	Real time : $30^{\circ}\text{C} \pm 2^{\circ}\text{C} / 65\% \pm 5\%\text{RH}$ Accelerated: $40^{\circ}\text{C} \pm 2^{\circ}\text{C} / 75\% \pm 5\%\text{RH}$				
Time	Period	Real time: 6 month Accelerated: 6 mon				
Frequ	ency	Accelerated: 0, 1, 2 Real Time: 0, 3, 6 (				
Batch	No.	001	002	003		
Batch	Size	8389 vials	8389 vials	8389 vials		
Manu	facturing Date	01-2019	01-2019	02-2019		
Date	of Initiation	12-02-2019	14-02-2019	10-03-2019		
No. o	f Batches		03			
	DOCUMENTS / DATA	TO BE PROVIDE	D ALONG WITH ST	ABILITY STUDY DATA		
	with stability study data of the firm (if any)  • Dexpro (Dexlansoprazole) 30 and 60m PSI was conducted on 11-09-2018 and twas approved in 285th meeting of R Board.  • Neovel 800mg Tablet. Its PSI was conducted on 14-12-2018 and the product was approved meeting of Registration Board.  • Serbica 20mg Capsule. Its PSI was conducted 29-10-2018 and the product was approved meeting of Registration Board.  Firm has further submitted that their product 2g Injection was approved in 293rd in Registration Board. That product was a AGP and contract manufactured by Serag submitted on Form 5F (CTD) along with data.					
2.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.  Copy of GMP certificate (No. SX20180229) is by CFDA China is submitted by the firm. certificate is valid till 05-06-2023			s submitted by the firm. The		
3.	Documents for the procurement of API with approval from DRAP (in case of import).  Firm has submitted copy of invoice specifying import of 100Kg ceftriaxone sodium dated 08-01-2019. invoice is signed by AD (I&E) DRAP Islama office.		e sodium dated 08-01-2019. The			
4.	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.  Firm has submitted complete record of testing of batches along with chromatograms, raw data sheets.  COA and summary data sheets.		chromatograms, raw data sheets,			
5.	•	HPLC software 21CF	this product was init	that since the stability study of iated 2 years ago, at that time our ) was not 21 CFR compliant.		

		However now we have 21 CFR compliant (Perkin Elmer) HPLC system. We undertake that in future we will use 21 CFR compliant HPLC system for stability testing.
6.		Firm has submitted record of digital data logger for temperature and humidity monitoring of real time and accelerated stability chambers.
T 1-	4' 1 DEC(III)	

• The applied product to be manufactured by M/s Seraph Pharmaceuticals Islamabad have already been approved by Registration Board in its 316<sup>th</sup> meeting based on the data of same batches of drug product as submitted in the instant case. The details of the already approved product in 316<sup>th</sup> meeting are as follows:

Applicant firm	M/s Amson Vaccines and Pharma Pvt Ltd. Plot No. 154,	
	Industrial Triangle Kahuta Road Islamabad.	
Manufacturer firm	M/s Seraph Pharmaceuticals Plot # 210, Industrial Triangle	
	Kahuta Road Islamabad.	
Brand Name	CESOD Injection 1g IV	
Batch No. of drug product	001, 002, 003	
Case No.	785	
RB meeting	316	

Decision: Approved. Manufacturer will perform process validation of first three batches as per the commitment submitted in the registration application.

7.	Name, address of Applicant / Marketing Authorization Holder	M/s Horizon Healthcare (Pvt) Ltd. Plot No. 35-A, Small Industrial Estate, Taxila.	
	Name, address of Manufacturing site.	M/s Bio-Mark Pharmaceuticals Plot No. 527, Sundar Industrial Estate, Lahore.  □ Manufacturer □ Importer □ Is involved in none of the above (contract giver) Firm has submitted copy of contract manufacturing agreement with applicant firm dated 18-03-2021.	
	Status of the applicant		
	GMP status of the firm	Firm has submitted copy of GMP certificate of M/s Bio-Mark based upon Evaluation conducted on 13-02-2020	
	Evidence of approval of manufacturing facility	Firm has submitted copy of letter for issuance of DML dated 12-06-2017 specifying Oral syrup (General) section.	
	Status of application	☐ New Drug Product (NDP) ☐ Generic Drug Product (GDP)	
	Intended use of pharmaceutical product	<ul><li>□ Domestic sale</li><li>□ Export sale</li><li>☑ Domestic and Export sales</li></ul>	
	Dy. No. and date of submission	Dy. No. 15497: 03-06-2021	
	Details of fee submitted	PKR 50,000/-: 24-03-2021 + PKR 25,000/-: 02-06-2021	
	The proposed proprietary name / brand name	ONDATRO Syrup 4mg/5ml	
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each 5ml Contains: Ondansetron (as HCl)4mg	

Pharmaceutical form of applied drug	Clear to straw coloured syrup filled in amber coloured PET bottle
Pharmacotherapeutic Group of (API)	Antiemetic
Reference to Finished product specifications	USP
Proposed Pack size	As per SRO
Proposed unit price	As per SRO
The status in reference regulatory authorities	Zofran Oral Solution (USFDA Approved)
For generic drugs (me-too status)	Zofran Syrup by GSK
Name and address of API manufacturer.	Anugraha Chemicals, No. D-47 to D-50, C-62 & C-63, KSS DC Industrial Estate, Doddaballapur, Banglore, Karnata India.
Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Firm has summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product.
Module-III Drug Substance:	Firm has submitted detailed data for both drug substance data related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
Stability Studies of Drug Substance (Conditions & duration of Stability studies)	Firm has submitted stability study data of 3 batches of drug substance at both accelerated as well as real time conditions. The accelerated stability data is conducted at $40^{\circ}\text{C} \pm 2^{\circ}\text{C} / 75\% \pm 5\%$ RH for 6 months. The real time stability data is conducted at $30^{\circ}\text{C} \pm 2^{\circ}\text{C} / 65\% \pm 5\%$ RH for 60 months.
Module-III Drug Product:	Firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.
Pharmaceutical Equivalence and Comparative Dissolution Profile	Firm has submitted results of pharmaceutical equivalence for the quality tests for their product against the comparator i.e. Zofran Syrup of GSK
Analytical method validation/verification of product	Firm has submitted report of verification of analytical method for the drug substance.

	Firm has submitted report of verification o analytical method for the drug product.				
	STABILITY STUDY DATA				
Mai	nufacturer of API	_	s, No. D-47 to D-50, C-62 ur, Banglore, Karnata Ind	2 & C-63, KSS DC Industrial ia.	
API	Lot No.	AOND-18006			
	cription of Pack ntainer closure system)	PET Bottle			
Stat	pility Storage Condition		Real time : $30^{\circ}\text{C} \pm 2^{\circ}\text{C} / 65\% \pm 5\%\text{RH}$ Accelerated: $40^{\circ}\text{C} \pm 2^{\circ}\text{C} / 75\% \pm 5\%\text{RH}$		
Tim	ne Period	Real time: 6 months Accelerated: 6 mont			
Free	quency		Accelerated: 0, 3, 6 (Months) Real Time: 0, 3, 6 (Months)		
Bate	ch No.	19A202	19E216	19M244	
Bate	ch Size	10,000 bottles	10,000 bottles	10,000 bottles	
Mai	nufacturing Date	01-2019	01-2019	01-2019	
Date	e of Initiation	02-01-2019	03-01-2019	04-01-2019	
No.	of Batches		03	03	
	DOCUMENTS / DATA	TO BE PROVIDED	ALONG WITH STAB	ILITY STUDY DATA	
1.	Reference of previous a with stability study data of		ons No inspection for veri has been conducted	fication of stability study data	
2.			DCD/SPL.CL-1/CR-1 Drugs Control De Karnataka India da	Drugs Control Department Government of Karnataka India dated 06-02-2021. The GMP certificate is valid for one year from the date of	
3.	3. Documents for the procurement of API with Firm has submitted copy of commercial in		of 5Kg Ondansetron 18-10-2018. The invoice is		
4. Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.		ke all batches along with	omplete record of testing of chromatograms, raw data mary data sheets.		
5.	5. Compliance Record of HPLC software 21CFR & audit trail reports on product testing		Firm has submitted that their HPLC system is not 21 CFR compliant.		
6. Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)		eal temperature and hum			
Eva	Evaluation by PEC(III)::				
Submit GMP certificate / GMP inspection report of the drug product manufacturer.			Response by the firm Firm has submitted cog 26-02-2020 of M/s Evaluation conducted of		

Submit data in section 3.2.S.4.1 and 3.2.S.4.2 as per Firm has submitted copy of specifications and the guidance document approved by Registration analytical method of drug substance from both drug Board which specifies that "Copies of the Drug substance manufacturer as well as drug product substance specifications and analytical procedures manufacturer i.e. M/s Bio Mark Pharmaceuticals. used for routine testing of the Drug substance /Active Pharmaceutical Ingredient by both Drug substance & Drug Product manufacturer is required." Submit data in section 3.2.S.4.3 as per the decision USP monograph for drug substance of 293rd meeting of Registration Board, which Ondansetron is available, so its verification studies states that "Analytical Method Verification studies were performed for the following parameters including specificity, accuracy and repeatability • Specificity, (method precision) performed by the Drug Product Accuracy and manufacturer for both compendial as well as non-• Repeatability (method precision) compendial drug substance(s) shall be submitted". Submit COA of reference standard actually used in Ondansetron is a pharmacopoeial drug substance the analysis of drug substance in section 3.2.S.5 as therefore USP reference standard was used to test per the guidance document approved by and characterize the drug substance. Registration Board which specifies that "COA of COA of reference standard for Ondansetron is primary / secondary reference standard including submitted by the firm. source and lot number shall be provided". Submit data in section 3.2.P.7 as per the guidance Firm has submitted detailed specifications of document approved by Registration Board which primary as well as secondary container closure specifies that "A detail of the container closure system. systems, description of the primary container closure systems, including materials construction, unit count or fill size, container size or volume shall be provided. Specify the exact concentration (mg/ml) of solution **Accuracy** which is used for the accuracy and repeatability Three concentration levels of 70%, 100% and 130% testing during the verification studies of the were Prepared with the concentration of 0.063 analytical method of drug product. mg/ml, 0.09 mg/ml & 0.117 mg/ml respectively, wherein 0.09mg/ml is the concentration specified by USP monograph Repeatability 0.09mg/ml or 90µg/ml was used Provide COA of reference standard actually used in Ondansetron is a pharmacopoeial drug substance the analysis of drug product in section 3.2.P.6 as per therefore USP reference standard was initially used the guidance document approved by Registration to test and characterize the drug substance. Board which specifies that "COA of primary / For continuous use and testing purpose working secondary reference standard including source and standard / secondary reference standard were lot number shall be provided". developed after standardization. COA of USP reference standard (Primary) & working standard (Secondary) is submitted by the firm Firm has submitted record of digital data logger for Provide record of Digital data logger temperature and humidity monitoring of stability temperature and humidity monitoring of the chambers (real time and accelerated). stability chambers. Submit copy of Batch Manufacturing Record for the Firm has submitted copy of BMR of three stability three batches for which stability study data is batches. submitted. Submit copy of blank production document as per Firm has submitted copy of blank BMR as per the requirement of Module 2. requirement of module 2.

Decision: Approved. Manufacturer will perform process validation of first three batches as per the commitment submitted in the registration application.

8.	Name, address of Applicant / Marketing Authorization Holder	M/s Herbion Pakistan Pvt Ltd. Industrial Triangle, Kahuta Road, Islamabad	
	Name, address of Manufacturing site.	M/s Herbion Pakistan Pvt Ltd. Industrial Triangle, Kahuta Road, Islamabad	
	Status of the applicant	<ul> <li>☑ Manufacturer</li> <li>☐ Importer</li> <li>☐ Is involved in none of the above (contract giver)</li> </ul>	
	GMP status of the firm	The firm has submitted copy of GMP certificate dated 17-07-2019. The certificate is valid till 20-05-2022.	
	Evidence of approval of manufacturing facility	Firm has submitted copy of grant of revised / relocated section letter dated 09-04-2020 in which Tablet (general) section is specified.	
	Status of application	☐ New Drug Product (NDP) ☐ Generic Drug Product (GDP)	
	Intended use of pharmaceutical product	☐ Domestic sale ☐ Export sale ☑ Domestic and Export sales	
	Dy. No. and date of submission	Dy. No. 24971: 25-11-2019	
	Details of fee submitted	PKR 20,000/-: 25-11-2019	
	The proposed proprietary name / brand name	DIANCE-MET 5/1000mg Tablet	
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each film coated tablet contains: Empagliflozin5mg Metformin HCl1000mg	
	Pharmaceutical form of applied drug	Beige yellow oblong shaped plain on both sides	
	Pharmacotherapeutic Group of (API)	Antidiabetic	
	Reference to Finished product specifications	Innovator's specs	
	Proposed Pack size	14's (2x7's)	
	Proposed unit price	As per SRO	
	The status in reference regulatory authorities	(USFDA Approved)	
	For generic drugs (me-too status)	Xelglu-Met Tablet by Hilton	
	Name and address of API manufacturer.	Empagliflozin: Fuxin Long Rui Pharmaceutical Co. Ltd. Fluoride Industrial Park, Fumeng County Fuxin City Liaoning Province China.  Metformin: Aarti Drugs Limited Plot No. 211 - 213, Road No.2G.I.D.C., Sarigam, Dist.: Valsad, Gujarat. INDIA.39615	
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Firm has summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product.	

Module-III Drug Subs	stance:	Firm has submitted detailed data for drug substance data related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
Stability Studies of Dr (Conditions & duration	•	<b>Empagliflozin:</b> Firm has submitted stability study data of 3 batches of drug substance at both accelerated as well as real time conditions. The accelerated stability data is conducted at $40^{\circ}\text{C} \pm 2^{\circ}\text{C} / 75\% \pm 5\%$ RH for 6 months. The real time stability data is conducted at $30^{\circ}\text{C} \pm 2^{\circ}\text{C} / 65 \pm 5\%$ RH for 24 months. <b>Metformin:</b> Firm has submitted stability study data of 3 batches of drug substance at both accelerated as well as real time conditions. The accelerated stability data is conducted at $40^{\circ}\text{C} \pm 2^{\circ}\text{C} / 75\% \pm 5\%$ RH for 6 months. The real time stability data is conducted at $30^{\circ}\text{C} \pm 2^{\circ}\text{C} / 65 \pm 5\%$ RH for 48 months.
Module-III Drug Product:		Firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.
Pharmaceutical Equivalence and Comparative Dissolution Profile		Firm has submitted results of pharmaceutical equivalence for all the quality tests for their product against Xenglu-Met Tablet of Hilton Pharma.  Firm has submitted results of CDP for their product against Xenglu-Met Tablet of Hilton Pharma.
Analytical method product	validation/verification of	Firm has submitted verification studies of the drug substance and analytical method validation of the drug product.
	STABILITY ST	UDY DATA
Park, Fumeng County F		ong Rui Pharmaceutical Co. Ltd. Fluoride Industrial xin City Liaoning Province China. ss Limited Plot No. 211-213, Road No.2G.I.D.C., rujarat. INDIA.
API Lot No. <b>Empagliflozin:</b> H-E-202 <b>Metformin:</b> 10010279		01125-D03-E06-01
Description of Pack (Container closure system) Alu-alu blister pack		
Stability Storage Condition Real time: $30^{\circ}\text{C} \pm 2^{\circ}\text{C} / 6$ Accelerated: $40^{\circ}\text{C} \pm 2^{\circ}\text{C}$		
Time Period Real time: 6 months		

		Accelerated: 6 months			
Frequency		Accelerated: 0, 3, 6 (Months) Real Time: 0, 3, 6 (Months)			
Bato	ch No.	DIAM(5/1000)-ST-001	DIAM(5/1000)-ST-002	DIAM(5/1000)-ST-003	
Bato	ch Size	1000 Tablet	1000 Tablet	1000 Tablet	
Mar	nufacturing Date	10-2021	10-2021	10-2021	
Date	e of Initiation	22-10-2021	22-10-2021	22-10-2021	
No.	of Batches		03		
	DOCUMENTS / DAT	A TO BE PROVIDED A	LONG WITH STABILIT	TY STUDY DATA	
1.		Reference of previous approval of applications with stability study data of the firm (if any)  Firm has referred to their previous onsite inspect for Vocab 10 and 20mg tablet which was conducted on 15-11-2021 and was considered by the Board its 313rd meeting. The report cofirms follow points:  FPP testing had been conducted on HP-QC 048 (shimadzu LC-2030) and HP-QCE-C (shimadzu 2080), which were 21 C compliant.  The audit trail report was reproduced at the trail of inspection.  Adequate monitoring and control were availated for stability chamber.			
2.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.				
3.	Documents for the procurement of API with approval from DRAP (in case of import).		Empagliflozin: Firm has also submitted copy of commercial invoice specifying import of 0.38Kg Empagliflozin. The invoice is cleared by AD (I&E) DRAP dated 20-04-2021.  Metformin: Firm has also submitted copy of commercial invoice specifying import of 25Kg Metformin HCl. The invoice is cleared by AD (I&E) DRAP dated 07-10-2020.		
4.	attested respective		Firm has submitted complete record of testing of all batches along with raw data sheets, COA and summary data sheets.		
5.	Compliance Record of laudit trail reports on pro		Firm has submitted HPLC CFR compliance certificat	_	
6.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real temperature and humidity monitoring of real and accelerated)				

time and accelerated)

The application was initially submitted on 25-11-2019 without product development and stability study data. The firm was issued a letter of shortcoming dated 26-12-2019. Later the firm submitted complete data on 18<sup>th</sup> April 2022 and the data was evaluated and following further shortcomings were communicated to the firm. The response of the firm is tabulated below:

and accelerated stability chambers.

Shortcomings communicated	Response by the firm		
Submit drug substance specifications and analytical method from drug product manufacturer for metformin hydrochloride.	The firm has submitted specifications and analytical method of metformin hydrochloride from Herbion Pharma.		
Submit verification studies of analytical method of metformin hydrochloride drug substance.	Firm has submitted verification studies of the analytical method of metformin hydrochloride drug substance.		
Submit stability study data of metformin hydrochloride drug substance as per zone IV-A conditions.	Firm has submitted metformin hydrochloride drug substance stability study data as per zone IV-A conditions.		
Submit GMP certificate for API manufacturer of metformin hydrochloride.	Copy of GMP Certificate (No. 20031933) for M/s Aarti Drugs Limited issued by Food and Drug Control Administration, Gujrat State India is submitted. It is valid till 19-03-2023.		
Clarify the exact source of empaglifloin drug substance, since Beijing Huikang Pharmaceuticals is mentioned in module 1 and 3.	Firm has submitted that Beijing Huikang is the DMF holder / supplier for this drug substance while it is manufactured at Fuxin Long Rui Pharmaceutical Co. Ltd. Fluoride Industrial Park, Fumeng County Fuxin City Liaoning Province China. The commercial invoice and clearance certificate issued by AD (I&E) also specify that the manufacturer is Fuxin Long Rui Pharmaceutical.		
Submit copy of BMR of three stability batches	Firm has submitted copy of BMR of the three batches		

Decision: Deferred for consideration on its turn since the product development and stability study data was submitted in April 2022.

Name, address of Applicant / Marketing	M/s Herbion Pakistan Pvt Ltd. Industrial Triangle, Kahuta Road, Islamabad M/s Herbion Pakistan Pvt Ltd. Industrial Triangle, Kahuta Road, Islamabad	
Authorization Holder  Name, address of Manufacturing site.		
Status of the applicant	<ul> <li>✓ Manufacturer</li> <li>☐ Importer</li> <li>☐ Is involved in none of the above (contract giver)</li> </ul>	
GMP status of the firm	The firm has submitted copy of GMP certificate dated 17-07-2019. The certificate is valid till 20 05-2022.	
Evidence of approval of manufacturing facility	Firm has submitted copy of grant of revised / relocated section letter dated 09-04-2020 in which Tablet (general) section is specified.	
Status of application	☐ New Drug Product (NDP) ☐ Generic Drug Product (GDP)	
Intended use of pharmaceutical product	<ul> <li>□ Domestic sale</li> <li>□ Export sale</li> <li>☑ Domestic and Export sales</li> </ul>	
Dy. No. and date of submission	Dy. No. 24968: 25-11-2019	
Details of fee submitted	PKR 20,000/-: 25-11-2019	
The proposed proprietary name / brand name	DIANCE-MET 12.5/500mg Tablet	
Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each film coated tablet contains: Empagliflozin12.5mg Metformin HCl500mg	

Pharmaceutical form of applied drug	White colored, oblong shaped break line on one side and other side is plain.		
Pharmacotherapeutic Group of (API)	Antidiabetic		
Reference to Finished product specifications	Innovator's specs		
Proposed Pack size	14's (2x7's) As per SRO		
Proposed unit price			
The status in reference regulatory authorities	(USFDA Approved)		
For generic drugs (me-too status)	Xelglu-Met Tablet by Hilton		
Name and address of API manufacturer.	Empagliflozin: Fuxin Long Rui Pharmaceutical Co. Ltd. Fluoride Industrial Park, Fumeng County Fuxin City Liaoning Province China.  Metformin: Aarti Drugs Limited Plot No. 211 - 213, Road No.2G.I.D.C., Sarigam, Dist.: Valsad, Gujarat. INDIA.39615		
Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Firm has summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product.		
Module-III Drug Substance:	Firm has submitted detailed data for drug substance data related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.		
Stability Studies of Drug Substance (Conditions & duration of Stability studies)	dies of Drug Substance Empagliflozin: Firm has submitted stability stud		
Module-III Drug Product:	Firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols, control of excipients, control of drug product,		

	Pharmaceutical Equivalence and Comparative Dissolution Profile		specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.  Firm has submitted results of pharmaceutical equivalence for all the quality tests for their product against Xenglu-Met Tablet of Hilton Pharma.  Firm has submitted results of CDP for their product		
	Analytical method validation/verification of product		against Xenglu-Met Tablet of Hilton Pharma.		
	1		drug product.		
		STABILITY ST	UDY DATA		
Man	Manufacturer of API  Empagliflozin: Fuxin Long Rui Pharmaceutical Co. Ltd. Fluoride Indus Park, Fumeng County Fuxin City Liaoning Province China.  Metformin: Aarti Drugs Limited Plot No. 211-213, Road No.2G.I.I Sarigam, Dist.: Valsad, Gujarat. INDIA.				
API I	API Lot No. <b>Empagliflozin:</b> H-E-20201125-D03-E06-01 <b>Metformin:</b> 10010279				
Description of Pack (Container closure system)  Alu-alu blister pack					
Stabi	Stability Storage Condition Real time: $30^{\circ}\text{C} \pm 2^{\circ}\text{C} / 65\% \pm 5\%\text{RH}$ Accelerated: $40^{\circ}\text{C} \pm 2^{\circ}\text{C} / 75\% \pm 5\%\text{RH}$				
Time	Fime Period Real time: 6 months Accelerated: 6 months				
Frequ	equency Accelerated: 0, 3, 6 (Months) Real Time: 0, 3, 6 (Months)				
Batch No.		DIAM(12.5/500)-ST- 001	DIAM(12.5/500)-ST- 002	DIAM(12.5/500)-ST- 003	
Batcl	n Size	1000 Tablet	1000 Tablet	1000 Tablet	
Manufacturing Date		10-2021	10-2021	10-2021	
Date	of Initiation	22-10-2021	22-10-2021	22-10-2021	
No. o	of Batches		03		
	DOCUMENTS / DAT	A TO BE PROVIDED A	LONG WITH STABILIT	TY STUDY DATA	
1.	Reference of previous approval of applications with stability study data of the firm (if any)		Firm has referred to their previous onsite inspection for Vocab 10 and 20mg tablet which was conducted on 15-11-2021 and was considered by the Board in its 313rd meeting. The report cofirms following points:  • FPP testing had been conducted on HP-QCE-048 (shimadzu LC-2030) and HP-QCE-001 (shimadzu 2080), which were 21 CFR compliant.  • The audit trail report was reproduced at the time of inspection.  • Adequate monitoring and control were available for stability chamber.		

2.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Empagliflozin: Copy of DML certificate No. Liao20150233, dated: 21/12/2017 valid till 20/12/2022, issued by Food & Drug Administration of Liaoning Province- China is submitted.  Metformin: Copy of GMP Certificate (No. 20031933) for M/s Aarti Drugs Limited issued by Food and Drug Control Administration, Gujrat State India is submitted. It is valid till 19-03-2023.
3.	Documents for the procurement of API with approval from DRAP (in case of import).	Empagliflozin: Firm has also submitted copy of commercial invoice specifying import of 0.38Kg Empagliflozin. The invoice is cleared by AD (I&E) DRAP dated 20-04-2021.  Metformin: Firm has also submitted copy of commercial invoice specifying import of 25Kg Metformin HCl. The invoice is cleared by AD (I&E) DRAP dated 07-10-2020.
4.	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	all batches along with raw data sheets, COA and
5.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	Firm has submitted HPLC audit trail reports and 21 CFR compliance certificate
6.		Firm has submitted record of digital data logger for temperature and humidity monitoring of real time and accelerated stability chambers.

# **Evaluation by PEC(III)::**

The application was initially submitted on 25-11-2019 without product development and stability study data. The firm was issued a letter of shortcoming dated 26-12-2019. Later the firm submitted complete data in 18<sup>th</sup> April 2022 and the data was evaluated and following further shortcomings were communicated to the firm. The response of the firm is tabulated below:

Shortcomings communicated	Response by the firm
Submit drug substance specifications and analytical	The firm has submitted specifictations and
method from drug product manufacturer for	analytical method of metformin hydrochloride from
metformin hydrochloride.	Herbion Pharma.
Submit verification studies of analytical method of	Firm has submitted verification studies of the
metformin hydrochloride drug substance.	analytical method of metformin hydrochloride drug
	substance.
Submit stability study data of metformin	Firm has submitted metformin hydrochloride drug
hydrochloride drug substance as per zone IV-A	substance stability study data as per zone IV-A
conditions.	conditions.
Submit GMP certificate for API manufacturer of	Copy of GMP Certificate (No. 20031933) for M/s
metformin hydrochloride.	Aarti Drugs Limited issued by Food and Drug
	Control Administration, Gujrat State India is
	submitted. It is valid till 19-03-2023.
Clarify the exact source of empaglifloin drug	Firm has submitted that Beijing Huikang is the
substance, since Beijing Huikang Pharmaceuticals	DMF holder / supplier for this drug substance while
is mentioned in module 1 and 3.	it is manufactured at Fuxin Long Rui
	Pharmaceutical Co. Ltd. Fluoride Industrial Park,
	Fumeng County Fuxin City Liaoning Province
	China. The commercial invoice and clearance
	certificate issued by AD (I&E) also specify that the
	manufacturer is Fuxin Long Rui Pharmaceutical.
Submit copy of BMR of three stability batches	Firm has submitted copy of BMR of the three
	batches

Decision: Deferred for consideration on its turn since the product development and stability study data was submitted in April 2022. 10. Name, address of Applicant / Marketing M/s Herbion Pakistan Pvt Ltd. **Authorization Holder** Industrial Triangle, Kahuta Road, Islamabad M/s Herbion Pakistan Pvt Ltd. Name, address of Manufacturing site. Industrial Triangle, Kahuta Road, Islamabad Status of the applicant ☐ Importer ☐ Is involved in none of the above (contract giver) GMP status of the firm The firm has submitted copy of GMP certificate dated 17-07-2019. The certificate is valid till 20-05-2022. Firm has submitted copy of grant of revised Evidence of approval of manufacturing facility relocated section letter dated 09-04-2020 in which Tablet (general) section is specified. Status of application ☐ New Drug Product (NDP) ☑ Generic Drug Product (GDP) Intended use of pharmaceutical product ☐ Domestic sale ☐ Export sale ☑ Domestic and Export sales Dy. No. 24976: 25-11-2019 Dy. No. and date of submission Details of fee submitted PKR 20,000/-: 25-11-2019 The proposed proprietary name / brand name DIANCE-MET 12.5/1000mg Tablet Strength / concentration of drug of Active Each film coated tablet contains: Pharmaceutical ingredient (API) per unit Empagliflozin...12.5mg Metformin HCl...1000mg Oblong shaped, blue colored film coated tablets, Pharmaceutical form of applied drug plain on both sides Pharmacotherapeutic Group of (API) Antidiabetic Reference to Finished product specifications Innovator's specs Proposed Pack size 14's (2x7's) Proposed unit price As per SRO The status in reference regulatory authorities (USFDA Approved) For generic drugs (me-too status) Xelglu-Met Tablet by Hilton Name and address of API manufacturer. Empagliflozin: Fuxin Long Rui Pharmaceutical Co. Ltd. Fluoride Industrial Park, Fumeng County Fuxin City Liaoning Province China. Metformin: Aarti Drugs Limited Plot No. 211 213, Road No.2G.I.D.C., Sarigam, Dist.: Valsad, Gujarat. INDIA.39615 Firm has submitted QOS as per WHO QOS-PD Module-II (Quality Overall Summary) template. Firm has summarized information related to nomenclature, structure, general solubilities, properties, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification,

		reference standard, container closure system and stability studies of drug substance and drug product.
Module-III Drug Subs	tance:	Firm has submitted detailed data for drug substance data related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
Stability Studies of Dr (Conditions & duratio		<b>Empagliflozin:</b> Firm has submitted stability study data of 3 batches of drug substance at both accelerated as well as real time conditions. The accelerated stability data is conducted at $40^{\circ}\text{C} \pm 2^{\circ}\text{C} / 75\% \pm 5\%$ RH for 6 months. The real time stability data is conducted at $30^{\circ}\text{C} \pm 2^{\circ}\text{C} / 65 \pm 5\%$ RH for 24 months. <b>Metformin:</b> Firm has submitted stability study data of 3 batches of drug substance at both accelerated as well as real time conditions. The accelerated stability data is conducted at $40^{\circ}\text{C} \pm 2^{\circ}\text{C} / 75\% \pm 5\%$ RH for 6 months. The real time stability data is conducted at $30^{\circ}\text{C} \pm 2^{\circ}\text{C} / 65 \pm 5\%$ RH for 48 months.
Module-III Drug Prod	uct:	Firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.
Pharmaceutical Equiv Dissolution Profile	valence and Comparative	Firm has submitted results of pharmaceutical equivalence for all the quality tests for their product against Xenglu-Met Tablet of Hilton Pharma.  Firm has submitted results of CDP for their product against Xenglu-Met Tablet of Hilton Pharma.
Analytical method validation/verification of product  STABILITY ST		Firm has submitted verification studies of the drug substance and analytical method validation of the drug product.
		UDY DATA
Manufacturer of API	Park, Fumeng County Fu	ong Rui Pharmaceutical Co. Ltd. Fluoride Industrial xin City Liaoning Province China. gs Limited Plot No. 211-213, Road No.2G.I.D.C., Gujarat. INDIA.
API Lot No.	<b>Empagliflozin:</b> H-E-202 <b>Metformin:</b> 10010279	01125-D03-E06-01
Description of Pack (Container closure system)	Alu-alu blister pack	

G. 1.		D 1: 20°G 2°G/6	50/ 50/DII		
Stability Storage Condition		Real time: $30^{\circ}\text{C} \pm 2^{\circ}\text{C} / 6$ Accelerated: $40^{\circ}\text{C} \pm 2^{\circ}\text{C} / 6$			
Time Period		Real time: 6 months Accelerated: 6 months			
Frequ	uency	Accelerated: 0, 3, 6 (Morn Real Time: 0, 3, 6 (Month			
Batc	h No.	DIAM(12.5/1000)-ST- 001	DIAM(12.5/1000)-ST- 002	DIAM(12.5/1000)-ST- 003	
Batc	h Size	1000 Tablet	1000 Tablet	1000 Tablet	
Man	ufacturing Date	10-2021	10-2021	10-2021	
Date	of Initiation	22-10-2021	22-10-2021	22-10-2021	
No. o	of Batches		03	l	
	DOCUMENTS / DATA	A TO BE PROVIDED A	LONG WITH STABILIT	TY STUDY DATA	
2.	Reference of previous approval of applications with stability study data of the firm (if any)  Firm has referred to their previous onsite in for Vocab 10 and 20mg tablet which was considered by the its 313rd meeting. The report cofirms for points:  FPP testing had been conducted on House (shimadzu LC-2030) and HP-C (shimadzu 2080), which were 2 compliant.  The audit trail report was reproduced at of inspection.  Adequate monitoring and control were a for stability chamber.  Approval of API/ DML/GMP certificate of API Empagliflozin: Copy of DML certificate.		blet which was conducted onsidered by the Board in report cofirms following conducted on HP-QCE-030) and HP-QCE-001 which were 21 CFR was reproduced at the time and control were available f DML certificate No. 21/12/2017 valid till ad & Drug Administration		
3.	_	ocurement of API with	Food and Drug Control State India is submitted. I <b>Empagliflozin:</b> Firm has	Administration, Gujrat it is valid till 19-03-2023. also submitted copy of	
	approval from DRAP (in case of import).		commercial invoice specifying import of 0.38Kg Empagliflozin. The invoice is cleared by AD (I&E) DRAP dated 20-04-2021.  Metformin: Firm has also submitted copy of commercial invoice specifying import of 25Kg Metformin HCl. The invoice is cleared by AD (I&E) DRAP dated 07-10-2020.		
4.	attested respective	es will be supported by documents like ta sheets, COA, summary		_	
5.	Compliance Record of I audit trail reports on pro	HPLC software 21CFR & duct testing	Firm has submitted HPLC CFR compliance certificat		
6.	humidity monitoring of time and accelerated)	ogger for temperature and stability chambers (real	Firm has submitted record temperature and humidity and accelerated stability co	monitoring of real time	
Eval	Evaluation by PEC(III)::				

The application was initially submitted on 25-11-2019 without product development and stability study data. The firm was issued a letter of shortcoming dated 26-12-2019. Later the firm submitted complete data in 18<sup>th</sup> April 2022 and the data was evaluated and following further shortcomings were communicated to the firm. The response of the firm is tabulated below:

Shortcomings communicated	Response by the firm
Submit drug substance specifications and analytical method from drug product manufacturer for metformin hydrochloride.	The firm has submitted specifications and analytical method of metformin hydrochloride from Herbion Pharma.
Submit verification studies of analytical method of metformin hydrochloride drug substance.	Firm has submitted verification studies of the analytical method of metformin hydrochloride drug substance.
Submit stability study data of metformin hydrochloride drug substance as per zone IV-A conditions.	Firm has submitted metformin hydrochloride drug substance stability study data as per zone IV-A conditions.
Submit GMP certificate for API manufacturer of metformin hydrochloride.	Copy of GMP Certificate (No. 20031933) for M/s Aarti Drugs Limited issued by Food and Drug Control Administration, Gujrat State India is submitted. It is valid till 19-03-2023.
Clarify the exact source of empaglifloin drug substance, since Beijing Huikang Pharmaceuticals is mentioned in module 1 and 3.	Firm has submitted that Beijing Huikang is the DMF holder / supplier for this drug substance while it is manufactured at Fuxin Long Rui Pharmaceutical Co. Ltd. Fluoride Industrial Park, Fumeng County Fuxin City Liaoning Province China. The commercial invoice and clearance certificate issued by AD (I&E) also specify that the manufacturer is Fuxin Long Rui Pharmaceutical.
Submit copy of BMR of three stability batches	Firm has submitted copy of BMR of the three batches

Decision: Deferred for consideration on its turn since the product development and stability study data was submitted in April 2022.

## Case No. 02 Registration applications of Stability cases

## a) New cases

Sr. No.	Name & Address of Manufacturer / Applicant	Brand Name (Proprietary Name + Dosage Form + Strength), Composition, Pharmacological Group, Finished Product Specification	Type of Form, Initial Diary & Date, Fee (including differential fee), Demanded Price / Pack size	International Availability  GMP Inspection Report Date & Remarks
11.	M/s Genix Pharma Pvt Ltd. 44,45-B, Korangi Creek Road, Karachi.	ERTOZIN-S Tablet 5mg/100mg Each film coated tablet contains: Ertugliflozin (as L-pyroglutamic acid) 5 mg Sitagliptin (as phosphate monohydrate) 100 mg (Antidiabetic) Innovator's specifications	Form 5-D Dy No. 34144 15-10-2018 PKR.50,000/- 15-10-2018 7's, 14's, 28's & 30's As per SRO	Approved by USFDA  The firm is inspected on 02-07-2020 wherein the firm was found to be operating at
12.	M/s Genix Pharma Pvt Ltd. 44,45-B,	ERTOZIN-S Tablet 15mg/100mg Each film coated tablet contains:	Form 5-D Dy No. 34145	good level of GMP compliance.

Korangi Creek Road, Karachi.	Ertugliflozin (as L-pyroglutamic acid) 15 mg Sitagliptin (as phosphate monohydrate) 100 mg (Antidiabetic)	15-10-2018 PKR.50,000/- 15-10-2018 7's, 14's, 28's & 30's As per SRO	
	Innovator's specifications		

Remarks of Evaluator:
 The firm has submitted stability study data along with required documents as per checklist approved in 293<sup>rd</sup> meeting of Registration Board. Details of submitted data are as under:

	(Dy.# 3560 dated 01-02-	2021)			
		STABILITY S	TUDY DATA		
Manufacturer of API			cliflozin: Shanghai Pharma Group Changzhou kony Pharmaceuticals td China Daixi street, Luoyang town, Wujin District, Changzhou, su, China		
		No1 Donghai 4th ave	<b>Sitagliptin:</b> M/s Zheijiang Yengtai Pharmaceutical Co., Ltd, China No1 Donghai 4th avenue zheijiang provincial chemical and medical raw material base Linhai zone, Linhai city Zhejiang province China		
API I	Lot No.	Ertugliflozin: ETG2	0180901		
		Sitagliptin: 1827-00	01-20015		
	ription of Pack tainer closure system)	Alu-Alu blister foil v	vith unit carton		
Stabil	lity Storage Condition	Accelerated: $40^{\circ}\text{C} \pm 2^{\circ}$ Real Time: $30^{\circ}\text{C} \pm 2^{\circ}$			
Time	Period	Accelerated: 6 Months Real Time: 6 Months			
Frequ	iency	Real Time: 0,3 & 6 ( Accelerated: 0,1, 2, 3			
		ERTOZIN-S TABI	LET 5MG/100MG		
Batch	ı No.	20SB-004-01	20SB-005-02	20SB-006-03	
Batch	n Size	1500 Tablets	1500 Tablets	1500 Tablets	
Manu	facturing Date	01-2020	01-2020	01-2020	
Date	of Initiation	24-02-2020	24-02-2020	24-02-2020	
		ERTOZIN-S TABL	ET 15MG/100MG		
Batch	No.	20SB-001-01	20SB-002-02	20SB-003-03	
Batch	n Size	1500 Tablets	1500 Tablets	1500 Tablets	
Manu	facturing Date	01-2020	01-2020	01-2020	
Date	of Initiation	17-02-2020	17-02-2020	17-02-2020	
No. o	f Batches	06			
	DOCUM	MENTS / DATA PROV	IDED BY THE APPLICA	ANT	
	with stability study data of the firm  product Wymly25mg table on 9th April, 2018 and was of Registration Board held According to the report confirmed.		blets which was conducted as presented in 281st meeting eld on 11-13th April, 2018. Our following points were a compliant HPLC software ail reports available.		

		digital data loggers.
2.	Certificate of Analysis of API from both API Manufacturer and Finished Product manufacturer.	Firm has submitted copy of COA of the drug substance from both API Manufacturer and Finished Product manufacturer.
3.	Method used for analysis of API from both API Manufacturer and Finished Product manufacturer	Firm has submitted copy of method used for analysis of API from both API Manufacturer and Finished Product manufacturer
4.	Stability study data of API from API manufacturer	Ertugliflozin: The submitted stability data as per zone IV-A conditions. The real time stability data is till 24 months.  Sitagliptin: Firm has submitted both accelerated (40°C ± 2°C & 75±5%RH) stability studies & long term (30°C ± 2°C & 65±5%RH) stability studies reports of three batches till 24 months.
5.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Ertugliflozin: Firm has submitted copy of GMP certificate (No. JS20170734) issued by CFDA China. The certificate is valid till 25-12-2022.  Sitagliptin: The copy of cGMP Certificate valid up to 28-06-2023 for M/s. Zheijang Yongtai Pharmaceutical Co., Ltd., Zheijiang Province is provided.
6.	Documents for the procurement of API with approval from DRAP (in case of import).	Ertugliflozin: Firm has submitted copy of commercial invoice cleared dated 12-10-2018 specifying import of 500g Ertugliflozin. The invoice is signed by AD (I&E) DRAP Karachi office dated 12-10-2018.  Sitagliptin: Firm has submitted copy of commercial invoice cleared dated 29-10-2019 specifying import of 300kg Sitagliptin phosphate monohydrate. The invoice is signed by AD (I&E) DRAP Karachi.
7.	Protocols followed for conduction of stability study	Firm has submitted protocols followed for conduction of stability study
8.	Method used for analysis of FPP	Firm has provided detailed method for analysis of FPP
9.	Drug-excipients compatibility studies (where applicable)	Firm has used same excipients as that of the innovator's product therefore compatibility studies are not required
10.	Complete batch manufacturing record of three stability batches.	Firm has provided Batch Manufacturing Record for all the batches
11.	Record of comparative dissolution data (where applicable)	<ul> <li>Firm has submitted CDP for 5/100mg with the innovator product Seglujan 5/100mg tablet.</li> <li>Firm has submitted CDP for 15/100mg with the innovator product Seglujan 15/100mg tablet.</li> </ul>
12.	Data of 03 batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Firm has submitted documents like chromatograms, raw data sheets, COA, summary data sheets for the stability studies
13.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing.	Firm has submitted certificate of compliance and audit trail reports for HPLC analysis for all the three batches.
14.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Firm has submitted record of digital data logger for both stability chambers for accelerated as well as real time stability studies.
Eval	uation by PEC(III)::	

Shortcomings communicated	Response by the firm
Submit valid GMP certificate of the API	Ertugliflozin: Firm has submitted copy of GMP
manufacturer of both drug substances issued by	certificate (No. JS20170734) issued by CFDA
relevant regulatory authority of the country of origin.	China. The certificate is valid till 25-12-2022.
	<b>Sitagliptin:</b> The copy of cGMP Certificate valid up
	to 28-06-2023 for M/s. Zheijang Yongtai
	Pharmaceutical Co., Ltd., Zheijiang Province is
	provided.
Submit stability study data of sitagliptin drug	Firm has submitted both accelerated ( $40^{\circ}\text{C} \pm 2^{\circ}\text{C}$ &
substance	$75\pm5\%$ RH) stability studies & long term (30°C $\pm$
	2°C & 65±5%RH) stability studies reports of three
	batches till 24 months for sitagliptin
Specify the dissolution acceptance criteria	The dissolution acceptance criteria is NLT 80%(Q)
	in 15 minutes.

**Decision: Approved with Innovator's specifications.** 

• Manufacturer will place first three production batches on long term stability studies throughout proposed shelf life and on accelerated studies for six months.

## b) Deferred cases

Sr. No.	Name & Address of Manufacturer / Applicant	Brand Name (Proprietary Name + Dosage Form + Strength), Composition, Pharmacological Group, Finished Product Specification	Type of Form, Initial Diary & Date, Fee (including differential fee), Demanded Price / Pack size	International Availability / Local Availability  GMP Inspection Report Date & Remarks
13.	M/s. Macter International Limited, F-216, S.I.T.E, Karachi.	Indamac DPI Capsule 85/43 mcg Each DPI Capsule contains: Indacaterol85 mcg Glycopyrronium43 mcg (Adrenergics in combination with anticholinergic)	Form-5-D Dy. No: 9787 Dated.24-07-2017 Rs.50,000/- (7-7-2017) Rs. 146.73 per DPI Capsule	Approved in US-FDA UltibroBreezhaler 85/ 43 mcg by Novartis Europharm Limited.  Not applicable  The firm was granted GMP certificate based on inspection conducted on 14-03-2017.
		STABILITY S	STUDY DATA	
Drug		Indamac DPI Capsule 85	+ 43 mcg	
Name	of Manufacturer	M/s. Macter International	Limited, F-216, S.I.T.E, Karachi	
Manu	facturer of API	Indacaterol: Inke,S.A. CASTELLBISBAL Barc	Area industrial del Liobregat, C/Agent,108755 celona (Spain)	
			Glycopyrrolate: Harman Finochem Ltd, Plot No: E-7,E-8,E-9,Midc Indl,Area,Chikalthana,Aurangabad 431 006 India.	
API Lot No.		PP-1 PR3 (Indacaterol) GCP/004/2017-2018/A (	Glycopyrrolate USP)	
Descr	iption of Pack	ALU-ALU blister, 10's, 2	20's & 30's Packed In Printe	ed Unit Carton.

(Container closure system)				
Stability Storage Condition		Real time : 30°C ± 2 Accelerated: 40°C ±	2°C / 65% ± 5% RH = 2°C / 75% ± 5% RH	
Time Pe	riod	Real time: 09 month Accelerated: 06 mo		
Frequen	су	Accelerated: 0,1, 3, Real Time: 0,1, 3,6		
Batch N	0.	001P	002P	003P
Batch Si	ze	10,000	10,000	10,000
Manufac	cturing Date	02-2018	02-2018	02-2018
Date of	Initiation	26-Feb 2018	26-Feb 2018	26-Feb 2018
No. of B	atches	03		
Date of	Submission	22-02-19 (Dy. No. 7	7826)	
	DOC	UMENTS / DATA I	PROVIDED BY THE APPLICA	ANT
Sr. No.	<b>Documents T</b>	o Be Provided	Status	5
2.	Approval of API by regulatory authority of country of origin or GMP certificate of API manufacturer issued by regulatory authority of country of origin.		C/Agent,1. Area industrial CASTELLBISBAL Barcelona Government of Catalonia-Spain.  Glycopyrrolate USP: Copy of Common NEW-WHO-GMP/CERT/AD/50769/2017/11. Finochem Ltd, Plot No: E-7,E-8 Chikalthana, Aurangabad 431 00 Drug Administration, M.S. Band to 04-2019.	tificate issued to Inke, SA, del Liobregat, 08755 a (Spain) issued by Validup to 21-06- 2021.  GMP certificate bearing a /18752 issued to Harman A.E-9, Midc Indl, Area, 26 India, issued by Food &
3.	Protocols followed for conduction of stability study and details of tests.		Yes	
4.	Data of 03 batches will be supported by attested respective documents like chromatograms, laboratory reports, data sheets etc.		Yes	
5.	5. Documents confirming import of API etc.		Copy of commercial invoice has *It is not ADC attested. Import quantity: 1gm	been submitted.
			Glycopyrrolate: Copy of commercial invoice has *It is not ADC attested. Import quantity: 1gm	been submitted.

6.	All provided documents will be attested (name, sign and stamp) for ensuring authenticity of data / documents.	
7.	Commitment to continue real time stability study till assigned shelf life of the product.	
8.	Commitment to follow Drug Specification Rules, 1978.	Yes.

## Decision of 290th meeting of Registration Board:

Deferred for confirmation of manufacturing facility for DPIs.

## **Response of the firm:**

Firm has submitted following documents:

• Copy of letter of regularization of layout plan of M/s Macter International Limited dated 10-12-2019 from Secretary Central Licensing Board. According to the letter, CLB in its 272<sup>nd</sup> meeting considered the case of M/s Macter International Ltd., and approved the regularization of building layout on the recommendation of panel of inspectors. The letter contains **Encapsulation (Steroid) including DPI** section.

Firm has also submitted following documents as per the decision of 290<sup>th</sup> meeting of Registration Board regarding Manufacturing Requirements for Rotacaps (Dry Powder Inhaler).

• Evidence of approval of applied formulation in **EMA**. The label claim of EMA approved product **Ultibro Breezhaler 85 micrograms/43 micrograms inhalation powder hard capsules** is as follows: **Each capsule contains** 143 micrograms of indacaterol maleate equivalent to 110 micrograms of indacaterol and 63 micrograms of glycopyrronium bromide equivalent to 50 micrograms of glycopyrronium.

**Each delivered dose** (the dose that leaves the mouthpiece of the inhaler) contains 110 micrograms of indacaterol maleate equivalent to 85 micrograms of indacaterol and 54 micrograms of glycopyrronium bromide equivalent to 43 micrograms of glycopyrronium.

- Firm has also submitted results of aerodynamic particle size distribution by cascade impactors for Indamac DPI.
- Firm has also submitted results of uniformity of delivered dose of Indamac DPI.
- Firm has also submitted results of delivered dose contents of both indacaterol as well as glycopyrronium.

Decision: Deferred for evaluation of complete case along with submitted data for exemption from onsite inspection of submitted stability study data.

**Agenda of Evaluator PEC-II** 

## Case no. 01 New Registration applications on Form 5F (Human)

#### **New Cases (Human)**

14.	Name, address of Applicant / Marketing Authorization Holder	M/s CCL Pharmaceuticals (Pvt.) Ltd, 62-Industrial Estate, Kot Lakhpat, Lahore-54770, Pakistan.					
	Name, address of Manufacturing site.	M/s CCL Pharmaceuticals (Pvt.) Ltd 62-Industrial Estate, Kot Lakhpat, Lahore-54770, Pakistan.					
	Status of the applicant	<ul> <li>✓ Manufacturer</li> <li>☐ Importer</li> <li>☐ Is involved in none of the above (contract giver)</li> </ul>					
	Status of application	☐ New Drug Product (NDP) ☐ Generic Drug Product (GDP)					

Intended use of pharmaceutical product	☐ Domestic sale
	Export sale
	☑ Domestic and Export sales
Dy. No. and date of submission	Dy.No 16908 dated 17-06-2021
Details of fee submitted	Rs.75,000/- dated 07-06-2021
The proposed proprietary name / brand name	Jardy-Met 12.5/850 tablet
Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each film coated tablet contains: Empagliflozin12.5mg Metformin HCI850mg
Pharmaceutical form of applied drug	Dark orange colored, oblong biconvex shaped film coated tablet.
Pharmacotherapeutic Group of (API)	Drugs used in diabetes, combinations of oral blood glucose lowering drugs
Reference to Finished product specifications	Innovator
Proposed Pack size	5's. 10's, 14's,20's,28's,30's, 50's and 100's
Proposed unit price	As per SRO
The status in reference regulatory authorities	Synjardy 12.55/850 Tablet BOEHRINGER INGELHEIM CANADA LTD LTEE
For generic drugs (me-too status)	Xenglu-Met 12.5/850mg by Hilton Pharma.
GMP status of the Finished product manufacturer	New license granted on 26/09/2019 Tablet, Capsule (Antibiotic Non-antibiotics, Cephalosporin), Syrup (Non-Antibiotics), Dry powder suspension (Non-Antibiotics, Antibiotics), Dry Powder Injectable (Cephalosporin) sections approved.
Name and address of API manufacturer.	Empagliflozin: M/s Fuxin Long Rui Pharmaceutical Co. Ltd, Fluoride Industrial park, Fuxin City, Liaoning Province.  Metformin hydrochloride: M/s Wanbury Ltd., Doctors Organic Chemical Division K Illindalaparru-534217 Iragavarum Mandal West Godavari Andhra Pradesh, India.
Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Summarized information related to structure, general properties, Manufacturers, description of manufacturing process and controls, Characterization, Impurities, Specifications, Analytical procedures, Validation of analytical procedure, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product is submitted.
Module III (Drug Substance)	The firm as submitted detail of General information, General properties, Manufacturers, description of manufacturing process and process controls, Characterization, Impurities, Control of drug substance, Reference standard or materials container closure system and stability studies of drug substance.
Stability studies	Empagliflozin:Stability study conditions:Real time: $30^{\circ}C \pm 2^{\circ}C / 65\% \pm 5\%$ RH for 24 monthsAccelerated: $40^{\circ}C \pm 2^{\circ}C / 75\% \pm 5\%$ RH for 6 monthsBatch NoAccelerated  Long Term

		00150505			
		20160606	6 Months	24 Months	
		20161017	6 Months	24 Months	
		20161219	6 Months	24 Months	
		Metformin HCl:	•		
		Stability study conditions:			
		Real time: $30^{\circ}\text{C} \pm 2^{\circ}\text{C} / 65\% \pm 5\%\text{RH for } 72 \text{ months}$			
		Accelerated: $40^{\circ}\text{C} \pm 2^{\circ}\text{C} / 75\% \pm 5\%\text{RH}$ for 6 months			S
		Batch No	Accelerated	Long Term	
		MS-0220601 A	6 Months	72 Months	
		MS-0220601 B	6 Months	72 Months	
		MS-0230601 A	6 Months	72 Months	
		MS-0230601 B	6 Months	72 Months	
		MS-0240601 A	6 Months	72 Months	
		MS-0240601 B	6 Months	72 Months	
	Module-III (Drug Product):	The firm has submit Description and comp			
					lopment,
			0 1	Ianufacturer,	Master
		formulations, Descri	/	*	
		Process Controls, Con			
		Process Validation ar			
		with specification and		•	
		Products including F			
		methods, validation of	•	•	
		Characterization of			
		impurities, Container			
	Pharmaceutical equivalence and	Pharmaceutical Equiv			rainct tha
	comparative dissolution profile				
	comparative dissolution proffic	brand leader that is Synjardy Tablet 12.5/850mg tablet by Boehringer Ingelheim by performing quality tests			
		(Identification, Assay, Dissolution. CDP has been performed			
		against the same brand that is Synjardy Tablet 12.5/850mg			
		tablet by Boehringer	• 5	•	_
		Acetate Buffer (pH 4.			
		•		•	
	•	Method verification			_
	validation/verification of product	Introduction, Verific			
		Accuracy, Precision,	Linearity concer	ntration and pea	k range.
	STABI	LITY STUDY DATA	<u> </u>		
Manu	facturer of API	Empagliflozin: M/s I	Fuxin Long Rui	Pharmaceutical	Co. Ltd,
		Fluoride Industrial pa			
		Metformin hydroch			
			Division K		
		Iragavarum Mandal V	Vest Godavari A	ndhra Pradesh,	India.
ДРІІ	Lot No.	Empagliflozin:		<u> </u>	
1,31,11	200110.	E-20190920-D02-E06	5-01		
		Metformin hydrochl			
		MT01130220			
	dadion of Dodo		1		
	ription of Pack	Alu-Alu in bleach boa	ard with leaflet		
(Con	ainer closure system)				
Stabi	ity Storage Condition	Real time: $30^{\circ}\text{C} \pm 2^{\circ}\text{C}$			
		Accelerated: $40^{\circ}$ C ± 2	$^{\circ}$ C / 75% ± 5% F	RH	
Time	Period	Real time: 6 months			
		Accelerated: 6 month	S		
Encar	onov				
Frequ	chey	Accelerated: 0, 3, 6 (1	violiuis)		

		Real Time: 0, 3, 6 (Months)			
Batch No.		JMF-T2-20	JMF-T3-20	JMF-T4-20	
Batch Size		1000 tab	1000 tab	1000 tab	
Manı	ufacturing Date	07-2020	07-2020	07-2020	
Date	of Initiation	07-2020	07-2020	07-2020	
No. o	of Batches		03		
	Adn	ninistrative Por	tion		
7. Reference of previous approval of		<ul> <li>The firm has referred to on-site inspection report of Ertu tablet range presented in 312 meeting of Registration Board and the applications were approve. Following observations were recorded in the said inspection report;</li> <li>FPP testing had been conducted on HPLC R&amp;D # 19 for Ertu tablet 5mg and Ertu tablet 15mg which were not 21 CFR compliant.</li> <li>FPP testing of 0 and 3rd month testing of Ertu tablet 5mg and Ertu tablet 15mg was conducted on HPLC R&amp;D # 19 which were not 21 CFR compliant and 6th month FPP testing of Ertu tablet 5mg and Ertu tablet 15mg was conducted on HPLC QC# 122 which is 21 CFR compliant.</li> <li>The audit trail was enabled. Log of data was available on the HPLCs and data was also checked through hard copies of chromatograms.</li> <li>Adequate monitoring and control were available for stability chamber.</li> </ul>			
8.		Empagliflozin: Firm had provided valid GMP Certificate of M/s Fuxin Long Rui Pharmaceutical Co., Ltd, China issued by Fuxin Food and Drug Administration, China valid till 23-08-2023.  Metformin HCl: Firm had provided valid GMP Certificate of M/s Wanbury Limited, issued by Drugs Control Administration, Government of Andhra Pardesh, India valid till 06-02-2022.			
9.	Documents for the procurement of API with approval from DRAP (in case of import).	Empagliflozin: The firm has imported Empagliflozin raw			
10.	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.				
11.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	·	rts have been sub		
12.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	temperature and			

	Name, address of Applicant / Marketing Authorization Holder	M/s CCL Pharmaceuticals (Pvt.) Ltd, 62-Industrial Estate, Kot Lakhpat, Lahore-54770, Pakistan.		
	Name, address of Manufacturing site.	M/s CCL Pharmaceuticals (Pvt.) Ltd, 62-Industrial Estate, Kot Lakhpat, Lahore-54770, Pakistan.		
	Status of the applicant	<ul> <li>✓ Manufacturer</li> <li>☐ Importer</li> <li>☐ Is involved in none of the above (contract giver)</li> </ul>		
:	Status of application	☐ New Drug Product (NDP)  ☑ Generic Drug Product (GDP)		
	Intended use of pharmaceutical product	<ul> <li>□ Domestic sale</li> <li>□ Export sale</li> <li>⊠ Domestic and Export sales</li> </ul>		
]	Dy. No. and date of submission	Dy.No 16907 dated 17-06-2021		
	Details of fee submitted	Rs.75,000/- dated 07-06-2021		
	The proposed proprietary name / brand name	Jardy-Met 5/850 tablet		
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each film coated tablet contains: Empagliflozin5mg Metformin HCI850mg		
]	Pharmaceutical form of applied drug	Light orange colored, oblong biconvex shaped film coated tablet.		
	Pharmacotherapeutic Group of (API)	Drugs used in diabetes, combinations of oral blood glucose lowering drugs		
	Reference to Finished product specifications	Innovator		
]	Proposed Pack size	5's. 10's, 14's, 20's, 28's, 30's, 50's and 100's		
	Proposed unit price	As per SRO		
- 1	The status in reference regulatory authorities	Synjardy 5/850 Tablet BOEHRINGER INGELHEIM CANADA LTD LTEE		
]	For generic drugs (me-too status)	Xenglu-Met 5/850mg by Hilton Pharma (Reg.No 093104)		
	GMP status of the Finished product manufacturer	New license granted on 26/09/2019 Tablet, Capsule (Antibiotic Non-antibiotics, Cephalosporin), Syrup (Non-Antibiotics), Dry powder suspension (Non-Antibiotics, Antibiotics), Dry Powder Injectable (Cephalosporin) sections approved.		
	Name and address of API manufacturer.	er. Empagliflozin: M/s Fuxin Long Rui Pharmaceutical Co. L Fluoride Industrial Park, Fuxin City, Liaoning Provin China. Metformin hydrochloride: M/s Wanbury Ltd., Docto Organic Chemical Division K Illindalaparru-5342 Iragavarum Mandal West Godavari Andhra Pradesh, India.		
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Summarized information related to structure, general properties, Manufacturers, description of manufacturing process and controls, Characterization, Impurities, Specifications, Analytical procedures, Validation of analytical		

	procedure, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product is submitted.			
Module III (Drug Substance)	Official monograph of Metformin HCl present in BP and Empagliflozin is Manufacturer. The firm as submitted detail of General information, General properties, Manufacturers, description of manufacturing process and process controls, Characterization, Impurities, Control of drug substance, Reference standard or materials container closure system and stability studies of drug substance.			
Stability studies	Real time: $30^{\circ}\text{C} \pm 2^{\circ}\text{C}$	•		
	Batch No	Accelerated	Long Term	
	20160606	6 Months	24 Months	
	20161017	6 Months	24 Months	
	20161219	6 Months	24 Months	
	<b>Metformin HCl:</b>			
	Stability study condit			
	Real time: $30^{\circ}\text{C} \pm 2^{\circ}\text{C}$			
	Accelerated: $40^{\circ}\text{C} \pm 2$			
	Batch No	Accelerated	Long Term	
	MS-0220601 A MS-0220601 B	6 Months	72 Months 72 Months	
	MS-0230601 A	6 Months	72 Months	
	MS-0230601 A MS-0230601 B	6 Months	72 Months	
	MS-0240601 A	6 Months	72 Months	
	MS-0240601 B	6 Months	72 Months	
Module-III (Drug Product):				lud.
	The firm has submitted detail of Drug Products including Description and composition of drug product, Pharmaceutical Development, Manufacturing process development Microbiological attribution, Manufacturer, Master formulations, Description of Manufacturing Process and Process Controls, Control of Critical Steps and Intermediates Process Validation and/ or Evaluation, Control of Excipient with specification and Analytical methods, Control of Drug Products including Finished product specifications and test methods, validation of Analytical methods, Batch analysis Characterization of impurities, reference standard of impurities, Container closure and stabilities studies.			
Pharmaceutical equivalence and comparative dissolution profile	Pharmaceutical Equivalence have been established against the brand leader that is Synjardy Tablet 5/850mg tablet by Boehringer Ingelheim by performing quality test (Identification, Assay, Dissolution.CDP has been performed against the same brand that is Synjardy Tablet 5/850mg table by Boehringer Ingelheim in Acid media (pH 1.2), Acetat Buffer (pH 4.5) & Phosphate Buffer (pH 6.8)			
Analytical method validation/verification of product	Method verification Introduction, Verific Accuracy, Precision,	cation of assay	y method, Speci	ifici

Manu	FI C M O		Empagliflozin: M/s Fuxin Long Rui Pharmaceutical Co. Ltd, Fluoride Industrial Park, Fuxin City, Liaoning Province, China.  Metformin hydrochloride: M/s Wanbury Ltd., Doctors Organic Chemical Division K Illindalaparru-534217 Iragavarum Mandal West Godavari Andhra Pradesh, India.		
API I	Lot No.	Empagliflozin E-20190920-Do Metformin hy MT01130220	02-E06-01		
	ription of Pack tainer closure system)	Alu-Alu in blea	ach board with leafle	t	
Stabi	lity Storage Condition		$C \pm 2^{\circ}C / 65\% \pm 5\%R$ $0^{\circ}C \pm 2^{\circ}C / 75\% \pm 5\%$		
Time	Period	Real time: 6 mc Accelerated: 6			
Frequ	iency	Accelerated: 0, Real Time: 0, 3			
Batch	n No.	JME-T2-20	JME-T3-20	JME-T4-20	
Batch	ı Size	1000 tab	1000 tab	1000 tab	
Manu	ufacturing Date	07-2020	07-2020	07-2020	
Date	of Initiation	07-2020	07-2020	07-2020	
No. c	of Batches		03		
	Adn	ninistrative Portion			
1.	applications with stability study data of the firm (if any)	<ul> <li>of The firm has referred to on-site inspection report of Ertu table range presented in 312 meeting of Registration Board and the applications were approve. Following observations were recorded in the said inspection report;</li> <li>• FPP testing had been conducted on HPLC R&amp;D # 19 for Ertu tablet 5mg and Ertu tablet 15mg which were not 20 CFR compliant.</li> <li>• FPP testing of 0 and 3rd month testing of Ertu tablet 5m and Ertu tablet 15mg was conducted on HPLC R&amp;D # 11 which were not 21 CFR compliant and 6th month FFD testing of Ertu tablet 5mg and Ertu tablet 15mg was conducted on HPLC QC# 122 which is 21 CFR compliant.</li> <li>• The audit trail was enabled. Log of data was available of the HPLCs and data was also checked through hard copied of chromatograms.</li> <li>• Adequate monitoring and control were available for stability chamber.</li> </ul>		Registration Board and the twing observations were rt;  If on HPLC R&D # 19 for 15mg which were not 21 testing of Ertu tablet 5mg acted on HPLC R&D # 19 diant and 6th month FPP d Ertu tablet 15mg was which is 21 CFR compliant. It is gof data was available on ecked through hard copies introl were available for	
2.	•	Empagliflozin: Firm had provided valid GMP Certificate of M/s Fuxin Long Rui Pharmaceutical Co., Ltd, China issued by Fuxin Food and Drug Administration, China valid till 23-08-2023.			
3.	Documents for the procurement of API with approval from DRAP (in case of import).	M/s Wanbury Administration	Metformin HCl: Firm had provided valid GMP Certificate of		

4.	· · · · · · · · · · · · · · · · · · ·	Empagliflozin: The firm has imported Empagliflozin raw material 15 kg (1 drum) from Beijing Sino Hanson Import & Export Go., Ltd on 16-01-2020.
5.	_	Metformin HCL: The firm has purchased Metformin HCl 8,000 kg from M/s Wanbury Ltd, India on 05.03.2020 through DRAP, Lahore.
6.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	

## Remarks of Evaluator<sup>II</sup>:

Decision: Registration Board approved both "Jardy-Met 5/850 tablet" & "Jardy-Met 12.5/850 tablet" with innovator's specifications.

- Manufacturer will place first three commercial batches on long term stability studies throughout
  proposed shelf life and on accelerated studies for six months as per the commitment submitted
  in the registration application.
- Manufacturer will perform process validation of first three commercial batches as per the commitment submitted in the registration application.

	commitment submitted in the registr	auon application.
16.	Name, address of Applicant / Marketing Authorization Holder	M/s Standard Drug Company, E-6A, S.I.T.E Hyderabad
	Name, address of Manufacturing site.	M/s Inventor Pharma, Plot No. K/196, S.I.T.E. (SHW) Phase II, Karachi
	Status of the applicant	☐ Manufacturer ☐ Importer ☑ Is involved in none of the above (contract giver)
	Status of application	☐ New Drug Product (NDP)  ☐ Generic Drug Product (GDP)
_	Intended use of pharmaceutical product	<ul> <li>□ Domestic sale</li> <li>□ Export sale</li> <li>⊠ Domestic and Export sales</li> </ul>
	Evidence of approval of manufacturing facility	Firm has submitted copy of section approval letter dated 13-07-2017 which specifies Dry Powder Injection (Cephalosporin) for M/s Inventor Pharma
	Dy. No. and date of submission	Dy.No 8049 dated 11-03-2021
	Details of fee submitted	Rs.50,000/- dated 03-02-2021
	The proposed proprietary name / brand name	Staxone IV 1g Injection
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each Vial Contains: Ceftriaxone Sodium Eq. to Ceftriaxone1gm
	Pharmaceutical form of applied drug	Third-generation cephalosporins, Antibiotic
	Pharmacotherapeutic Group of (API)	USP
	Reference to Finished product specifications	1×1Vial

D 1D 1 '	A CDO
Proposed Pack size	As per SRO
Proposed unit price	ROCIPHIN (Ceftriaxone Sodium) by M/s ROCHE Laboratories Inc, USFDA Approved.
The status in reference regulatory authorities	CEFEXONE Powder Injection by M/s Bosch Phrmacuticals (Pvt) Ltd
For generic drugs (me-too status)	Third-generation cephalosporins, Antibiotic
GMP status of the Finished product manufacturer	GMP certificate issued on 13-08-2020.
Name and address of API manufacturer.	M/s. Sinopharm Weiqida Pharmaceuticals Co Ltd, First medical zone, economic and technological development zone, datong, China.
Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Firm has summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, Characterization, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance. The firm has summarized information of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols, control of excipients, control of drug product, specifications, analytical procedures, validation/verification of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.
Module III (Drug Substance)	Firm has submitted detailed data for both drug substance data related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
Stability studies	Firm has submitted stability study data of 3 batches of drug substance at both accelerated as well as real time conditions. The accelerated stability data is conducted at $40^{\circ} \pm 2^{\circ}$ C /75% $\pm$ 5% RH for 6 months. The real time stability data is conducted at $30^{\circ}$ C $\pm$ 2° C / 65% $\pm$ 5% RH for 36 months. (Batch No. 011302001, 011302002, 011302003)
Module-III (Drug Product):	The firm has submitted detail of manufacturers, description of manufacturing process and controls, specifications, analytical procedure (including dissolution testing at acidic and buffer medium) and its verification studies, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug product.
Pharmaceutical equivalence and comparative dissolution profile	Pharmaceutical Equivalence have been established against the brand leader that is Mercefex 1gm Powder Injection by Merck Private Ltd.
Analytical method validation/verification of product	Submitted

	STAI	BILITY STUDY DATA			
z		M/s. Sinopharm Weiqida Pharmaceuticals Co Ltd, First medical zone, economic and technological development zone, datong, China			
API I	Lot No.	Q011910028			
	ription of Pack tainer closure system)	Type III glass vial pack as primary packaging (	•	n a unit carton is used	
Stabi	lity Storage Condition	Real time: $30^{\circ}\text{C} \pm 2^{\circ}\text{C} / \text{Accelerated}$ : $40^{\circ}\text{C} \pm 2^{\circ}\text{C} / \text{C}$			
Time	Period	Real time: 6 months Accelerated: 6 months			
Frequ	nency	Accelerated: 0, 3, 6 (More Real Time: 0, 3, 6 (More			
Batch	n No.	SD-001	SD-002	SD-003	
Batch	n Size	5000 Vials	5000 Vials	5000 Vials	
Manu	afacturing Date	03-2020	03-2020	03-2020	
No. o	f Batches		03		
	Ad	lministrative Portion			
1.	Reference of previous approval of applications with stability study data of the firm (if any)		mitted any documer	nt.	
2.		te GMP certificate of Sinopharm Weiqida Shangxi Food & Dr 2023.	Pharmaceuticals	Co Ltd. issued by	
3.	Documents for the procurement of Al with approval from DRAP (in case of import).	of import of 600Kg Sinopharm. The			
4	Data of stability batches will be supported by attested respective documents like chromatograms, Radata sheets, COA, summary data sheet.	w w	Submitted		
5.	Compliance Record of HPLC softwar 21CFR & audit trail reports on produ- testing				
6.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time an accelerated).	of			
17.	Name, address of Applicant Marketing Authorization Holder	/ M/s Standard Drug	Company, E-6A,	S.I.T.E Hyderabad	
	Name, address of Manufacturing site.	M/s Inventor Pharma II, Karachi	, Plot No. K/196, S	I.T.E. (SHW) Phase	
	Status of the applicant	☐ Manufacturer ☐ Importer ☑ Is involved in non-	e of the above (con	tract giver)	

Status of application	□ New Drug Product (NDP)  ☑ Generic Drug Product (GDP)	
Intended use of pharmaceutical product	☐ Domestic sale ☐ Export sale ☑ Domestic and Export sales	
Evidence of approval of manufacturing facility	Firm has submitted copy of section approval letter dated 1 07-2017 which specifies Dry Powder Injectic (Cephalosporin) for M/s Inventor Pharma	
Dy. No. and date of submission	Dy.No 34339 dated 24-12-2020	
Details of fee submitted	Rs.30,000/- dated 23-12-2020 & Rs.20,000/- dated 13-10-2020	
The proposed proprietary name / brand name	Staxone IV 500mg Injection	
Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each Vial Contains: Ceftriaxone Sodium Eq. to Ceftriaxone500mg	
Pharmaceutical form of applied drug	Third-generation cephalosporins, Antibiotic	
Pharmacotherapeutic Group of (API)	USP	
Reference to Finished product specifications	1×1Vial	
Proposed Pack size	As per SRO	
Proposed unit price	ROCIPHIN (Ceftriaxone Sodium) by M/s ROCHE Laboratories Inc, USFDA Approved.	
The status in reference regulatory authorities	CEFEXONE Powder Injection by M/s Bosch Phrmacuticals (Pvt) Ltd	
For generic drugs (me-too status)	Third-generation cephalosporins, Antibiotic	
GMP status of the Finished product manufacturer	GMP certificate issued on 13-08-2020.	
Name and address of API manufacturer.	M/s. Sinopharm Weiqida Pharmaceuticals Co Ltd, First medical zone, economic and technological development zone, datong, China.	
Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Firm has summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, Characterization, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance. The firm has summarized information of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols, control of excipients, control of drug product, specifications, analytical procedures, validation/verification of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.	
Module III (Drug Substance)	Firm has submitted detailed data for both drug substance data related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of	

		1		1	
		manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.			
	Stability studies	Firm has submitted s substance at both acc The accelerated stabil ± 5% RH for 6 mc conducted at 30°C ± (Batch No. 01130200	elerated as well as r ity data is conducted onths. The real tin $2^{\circ}$ C / 65% $\pm$ 5% Rl	eal time conditions. Lat $40^{\circ} \pm 2^{\circ} \text{ C}/75\%$ the stability data is H for 36 months.	
		manufacturing process procedure (including medium) and its ver justification of speci	The firm has submitted detail of manufacturers, description of manufacturing process and controls, specifications, analytical procedure (including dissolution testing at acidic and buffer medium) and its verification studies, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug product.		
	Pharmaceutical equivalence and comparative dissolution profile	Pharmaceutical Equivorand leader that is Merck Private Ltd.			
	Analytical method validation/verification of product	d Submitted			
	STAB	ILITY STUDY DATA			
ZO			M/s. Sinopharm Weiqida Pharmaceuticals Co Ltd, First medical one, economic and technological development zone, datong, China		
API I	Lot No.	Q011910028			
		Type III glass vial pack as primary packaging (1		a unit carton is used	
Stabil	3 &	Real time: $30^{\circ}\text{C} \pm 2^{\circ}\text{C} / \text{Accelerated}$ : $40^{\circ}\text{C} \pm 2^{\circ}\text{C} / \text{C}$			
Time		Real time: 6 months Accelerated: 6 months			
Frequ	•	Accelerated: 0, 3, 6 (Months) Real Time: 0, 3, 6 (Months)			
Batch	No.	SD-001	SD-002	SD-003	
Batch	Size	3500 Vials	3500 Vials	3500 Vials	
Manu	afacturing Date	01-2020	01-2020	01-2020	
No. o	f Batches		03		
Adm		ministrative Portion			
1.	Reference of previous approval o applications with stability study data o the firm (if any)		mitted any document		
		e GMP certificate ( Sinopharm Weiqida f Shangxi Food & Dr 2023.	Pharmaceuticals C		

3.	Documents for the procurement of API with approval from DRAP (in case of import).	import of 600Kg Ceftriaxone sodium (sterile) from Sinopharm. The invoice specifies multiple batches of Ceftriaxone. AD (I&E) DRAP, Karachi dated 10-11-2019.		
4	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Submitted		
5.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	Not applicable		
6.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated).	Submitted		
18.	Name, address of Applicant / Marketing Authorization Holder	M/s Standard Drug Company, E-6A, S.I.T.E Hyderabad		
	Name, address of Manufacturing site.	M/s Inventor Pharma, Plot No. K/196, S.I.T.E. (SHW) Phase II, Karachi		
	Status of the applicant	<ul> <li>☐ Manufacturer</li> <li>☐ Importer</li> <li>☑ Is involved in none of the above (contract giver)</li> </ul>		
	Status of application	☐ New Drug Product (NDP)  ☑ Generic Drug Product (GDP)		
	Intended use of pharmaceutical product	<ul><li>□ Domestic sale</li><li>□ Export sale</li><li>☑ Domestic and Export sales</li></ul>		
	Evidence of approval of manufacturing facility	Firm has submitted copy of section approval letter dated 13-07-2017 which specifies Dry Powder Injection (Cephalosporin) for M/s Inventor Pharma		
	Dy. No. and date of submission	Dy.No 8055 dated 11-03-2021		
	Details of fee submitted	Rs.50,000/- dated 03-02-2021		
	The proposed proprietary name / brand name	Staxone IM 500mg Injection		
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each Vial Contains: Ceftriaxone Sodium Eq. to Ceftriaxone500mg		
	Pharmaceutical form of applied drug	Third-generation cephalosporins, Antibiotic		
	Pharmacotherapeutic Group of (API)	USP		
	Reference to Finished product specifications	1×1Vial		
	Proposed Pack size	As per SRO		
	Proposed unit price ROCIPHIN (Ceftriaxone Sodium) by M/s F Laboratories Inc, USFDA Approved.			
	The status in reference regulatory authorities	CEFEXONE Powder Injection by M/s Bosch Phrmacuticals (Pvt) Ltd		
	For generic drugs (me-too status)	Third-generation cephalosporins, Antibiotic		

	CMD status of the Einigh of and door	GM (F)
	GMP status of the Finished product nanufacturer	GMP certificate issued on 13-08-2020.
N	Name and address of API manufacturer.	M/s. Sinopharm Weiqida Pharmaceuticals Co Ltd, First medical zone, economic and technological development zone, datong, China.
N	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Firm has summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, Characterization, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance. The firm has summarized information of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols, control of excipients, control of drug product, specifications, analytical procedures, validation/verification of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.
N	Module III (Drug Substance)	Firm has submitted detailed data for both drug substance data related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
S	Stability studies	Firm has submitted stability study data of 3 batches of drug substance at both accelerated as well as real time conditions. The accelerated stability data is conducted at $40^{\circ} \pm 2^{\circ} \text{ C}/75\%$ $\pm$ 5% RH for 6 months. The real time stability data is conducted at $30^{\circ}\text{C} \pm 2^{\circ} \text{ C}/65\% \pm 5\%$ RH for 36 months. (Batch No. 011302001, 011302002, 011302003)
N	Module-III (Drug Product):	The firm has submitted detail of manufacturers, description of manufacturing process and controls, specifications, analytical procedure (including dissolution testing at acidic and buffer medium) and its verification studies, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug product.
	Pharmaceutical equivalence and comparative dissolution profile	Pharmaceutical Equivalence have been established against the brand leader that is Mercefex 500mg Powder Injection by Merck Private Ltd.
	Analytical method validation/verification of product	Submitted
	STABI	LITY STUDY DATA
Manufa	z	M/s. Sinopharm Weiqida Pharmaceuticals Co Ltd, First medical one, economic and technological development zone, datong, China
API Lo	ot No.	2011910028
Descrip	otion of Pack T	Type III glass vial pack in PVC tray then in a unit carton is used

(Con	tainer closure system)	as primary packaging (1	1 x1 vial)		
, , , , , , , , , , , , , , , , , , ,		Real time: $30^{\circ}\text{C} \pm 2^{\circ}\text{C} / 65\% \pm 5\%\text{RH}$ Accelerated: $40^{\circ}\text{C} \pm 2^{\circ}\text{C} / 75\% \pm 5\%\text{RH}$			
Time	Period	Real time: 6 months Accelerated: 6 months			
Frequ	iency	Accelerated: 0, 3, 6 (More Real Time: 0, 3, 6	The state of the s		
Batch	n No.	SD-001	SD-002	SD-003	
Batch	ı Size	5000 Vials	5000 Vials	5000 Vials	
Manı	ufacturing Date	01-2020	01-2020	01-2020	
No. c	of Batches		03		
	Ad	ministrative Portion			
1.	Reference of previous approval of applications with stability study data of the firm (if any)	of	•		
2.		te GMP certificate (Certificate# SX20180229) of M/s Sinopharm Weiqida Pharmaceuticals Co Ltd. issued by Shangxi Food & Drug Administration, valid up to 05-06-2023.		to Ltd. issued by	
3.	Documents for the procurement of Alwith approval from DRAP (in case comport).				
4 Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.		re w	Submitted		
5.	Compliance Record of HPLC softwar 21CFR & audit trail reports on productesting		Not applicable		
6.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time an accelerated).	of	Submitted		
19.	Name, address of Applicant Marketing Authorization Holder	/ M/s Standard Drug	Company, E-6A, S	.I.T.E Hyderabad	
	Name, address of Manufacturing site.	M/s Inventor Pharma II, Karachi	, Plot No. K/196, S.	I.T.E. (SHW) Phase	
	Status of the applicant	☐ Manufacturer ☐ Importer ☑ Is involved in none	e of the above (contr	ract giver)	
	Status of application	☐ New Drug Product (NDP)  ☐ Generic Drug Product (GDP)			
	Intended use of pharmaceutical produc	Domestic sale  □ Export sale  □ Domestic and Exp	ort sales		

Evidence of approval of manufacturing facility	Firm has submitted copy of section approval letter dated 13-07-2017 which specifies Dry Powder Injection (Cephalosporin) for M/s Inventor Pharma
Dy. No. and date of submission	Dy. No 8050 dated 11-03-2021
Details of fee submitted	Rs.50,000/- dated 03-02-2021
The proposed proprietary name / brand name	Staxone IM 250mg Injection
Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each Vial Contains: Ceftriaxone sodium Eq. to Ceftriaxone 250mg
Pharmaceutical form of applied drug	Third-generation cephalosporins, Antibiotic
Pharmacotherapeutic Group of (API)	USP
Reference to Finished product specifications	1×1Vial
Proposed Pack size	As per SRO
Proposed unit price	ROCIPHIN (Ceftriaxone Sodium) by M/s ROCHE Laboratories Inc, USFDA Approved.
The status in reference regulatory authorities	CEFEXONE Powder Injection 250mg by M/s Bosch Phrmacuticals (Pvt) Ltd
For generic drugs (me-too status)	Third-generation cephalosporins, Antibiotic
GMP status of the Finished product manufacturer	GMP certificate issued on 13-08-2020.
Name and address of API manufacturer.	M/s. Sinopharm Weiqida Pharmaceuticals Co Ltd, First medical zone, economic and technological development zone, datong, China.
Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Firm has summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, Characterization, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance. The firm has summarized information of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols, control of excipients, control of drug product, specifications, analytical procedures, validation/verification of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.
Module III (Drug Substance)	Firm has submitted detailed data for both drug substance data related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
Stability studies	Firm has submitted stability study data of 3 batches of drug substance at both accelerated as well as real time conditions.

		$\pm$ 5% RH for 6 m conducted at 30°C $\pm$	onths. The real $2^{\circ}$ C / $65\% \pm 5\%$		
	Module-III (Drug Product):	manufacturing proce procedure (including medium) and its vo	ed detail of manuf ss and controls, sp dissolution testin erification studie ification, referen	facturers, description of becifications, analytical ng at acidic and buffer s, batch analysis and ce standard, container	
	Pharmaceutical equivalence and comparative dissolution profile			established against the g Powder Injection by	
	Analytical method validation/verification of product	od Submitted			
	STAL	BILITY STUDY DATA	1		
Manı	ufacturer of API	M/s. Sinopharm Weiqid zone, economic and te China			
API l	Lot No.	Q011910028			
	ription of Pack tainer closure system)		Type III glass vial pack in PVC tray then in a unit carton is used as primary packaging (1 x1 vial)		
Stabi	lity Storage Condition	Real time: $30^{\circ}\text{C} \pm 2^{\circ}\text{C} / 65\% \pm 5\% \text{RH}$ Accelerated: $40^{\circ}\text{C} \pm 2^{\circ}\text{C} / 75\% \pm 5\% \text{RH}$			
Time	Period	Real time: 6 months Accelerated: 6 months			
Frequ	uency		Accelerated: 0, 3, 6 (Months) Real Time: 0, 3, 6 (Months)		
Batch	n No.	SD-001	SD-002	SD-003	
Batch	n Size	3500 Vials	3500 Vials	3500 Vials	
Manu	ufacturing Date	02-2020	02-2020	02-2020	
Date	of Initiation	12-02-2020	12-02-2020	12-02-2020	
No. c	of Batches		03		
	Ad	Iministrative Portion			
1.	Reference of previous approval applications with stability study data the firm (if any)		mitted any docum	ent.	
2.		y Sinopharm Weiqida	Pharmaceuticals	(20180229) of M/s Co Ltd. issued by on, valid up to 05-06-	
3.	Documents for the procurement of Al with approval from DRAP (in case import).	of import of 600Kg C Sinopharm. The in	Ceftriaxone sodiur voice specifies m		
4	Data of stability batches will be supported by attested respective documents like chromatograms, Ra	ve	Submitted		

	data sheets, COA, summary data sheets etc.			
5.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	Not applicable		
6.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated).	Submitted		
<u> </u>		M/s Standard Drug Company, E-6A, S.I.T.E Hyderabad		
	Name, address of Manufacturing site.	M/s Inventor Pharma, Plot No. K/196, S.I.T.E. (SHW) Phase II, Karachi		
	Status of the applicant	<ul> <li>☐ Manufacturer</li> <li>☐ Importer</li> <li>☑ Is involved in none of the above (contract giver)</li> </ul>		
	Status of application	☐ New Drug Product (NDP)  ☑ Generic Drug Product (GDP)		
Intended use of pharmaceutical product ☐ Domestic sale ☐ Export sale ☐ Domestic and Export sale				
	Evidence of approval of manufacturing facility	Firm has submitted copy of section approval letter dated 13-07-2017 which specifies Dry Powder Injection (Cephalosporin) for M/s Inventor Pharma		
	Dy. No. and date of submission	Dy. No 7313 dated 05-03-2021		
	Details of fee submitted	Rs.50,000/- dated 03-03-2021		
	The proposed proprietary name / brand name	Staxone IV 250mg Injection		
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each Vial Contains: Ceftriaxone sodium Eq. to Ceftriaxone 250mg		
	Pharmaceutical form of applied drug	Third-generation cephalosporins, Antibiotic		
	Pharmacotherapeutic Group of (API)	USP		
	Reference to Finished product specifications	1×1Vial		
	Proposed Pack size	As per SRO		
	Proposed unit price	ROCIPHIN (Ceftriaxone Sodium) by M/s ROCHE Laboratories Inc, USFDA Approved.		
	The status in reference regulatory authorities	CEFEXONE Powder Injection 250mg by M/s Bosch Phrmacuticals (Pvt) Ltd		
	For generic drugs (me-too status)	Third-generation cephalosporins, Antibiotic		
GMP status of the Finished product manufacturer GMP certificate issued on 1		GMP certificate issued on 13-08-2020.		

M/s. Sinopharm Weiqida Pharmaceuticals Co Ltd, First medical zone, economic and technological development zone, datong, China.
Firm has submitted QOS as per WHO QOS-PD template. Firm has summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, Characterization, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance. The firm has summarized information of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols, control of excipients, control of drug product, specifications, analytical procedures, validation/verification of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.
Firm has submitted detailed data for both drug substance data related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
Firm has submitted stability study data of 3 batches of drug substance at both accelerated as well as real time conditions. The accelerated stability data is conducted at $40^{\circ} \pm 2^{\circ}$ C /75% $\pm$ 5% RH for 6 months. The real time stability data is conducted at $30^{\circ}$ C $\pm$ 2° C / 65% $\pm$ 5% RH for 36 months. (Batch No. 011302001, 011302002, 011302003)
The firm has submitted detail of manufacturers, description of manufacturing process and controls, specifications, analytical procedure (including dissolution testing at acidic and buffer medium) and its verification studies, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug product.
Pharmaceutical Equivalence have been established against the Mercefex 250mg Powder Injection by Merck Private Ltd.
Submitted.
LITY STUDY DATA
M/s. Sinopharm Weiqida Pharmaceuticals Co Ltd, First medical zone, economic and technological development zone, datong, China
Q011910028
Type III glass vial pack in PVC tray then in a unit carton is us as primary packaging (1 x1 vial)

Stabil	lity Sto	orage Condition				°C / 65% ± 5%RH 2°C / 75% ± 5%R	Н
Time Period		Real time: 6 months Accelerated: 6 months					
Frequ	iency				Accelerated: 0, 3, 6 (Months) Real Time: 0, 3, 6 (Months)		
Batch	No.			SD-001		SD-002	SD-003
Batch	Size			3500 Vials		3500 Vials	3500 Vials
Manu	ıfactur	ing Date		02-2020		02-2020	02-2020
Date	of Init	ation		12-02-2020		12-02-2020	12-02-2020
No. o	f Batc	hes				03	·
			Adm	inistrative Po	rtion		
1.	applic	ence of previous ap cations with stability stu rm (if any)			ot sub	omitted any docume	ent.
	of conce		ssued by	Sinopharm W	eiqida		(20180229) of M/s Co Ltd. issued by n, valid up to 05-06-
3.		cuments for the procurement of API h approval from DRAP (in case of port).  Firm has submitted copy of commercial invoice import of 600Kg Ceftriaxone sodium (Sinopharm. The invoice specifies multiple Ceftriaxone. AD (I&E) DRAP, Karachi dated		odium (sterile) from multiple batches of			
4 Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.				Submitted			
5.		pliance Record of HPLOR & audit trail reports of				Not available	
6.	tempe stabil	rd of Digital data le erature and humidity mo- ity chambers (real erated).				Submitted	
Rema	arks of	Evaluator(II):					
1	ion#		vations			Firm's re	•
2.3	5.4	administration as product is an IV inj Quality Overall Suprovided in WHO template provided document for subm Form 5-F (CTD pharmaceutical Druse" approved by laggeth meeting, in extracts of Module	IM whe ection. Immary (Q QOS-PD d in the hission of a product Registration stead of p III.	ary (QOS) shall be OS-PD Template or in the "Guidance on of application on for registration of products for human stration Board in its d of presenting the		or the IV injection Revised QOS has b	een submitted.
3.2.	S.4	Copies of the Drug and analytical production	substance		ł	been submitted f	stance analysis have from Drug Product I/s Inventor pharma.

3.2. S.7 3.2. P.5	<ul> <li>testing of the Drug substance /Active Drug Product manufacturer is required.</li> <li>Analytical Method Verification studies including specificity, accuracy and repeatability (method precision) performed by the Drug Product manufacturer for both compendial as well as non-compendial drug substance(s) shall be submitted.</li> <li>Provide results of analysis of relevant batch(es) of Drug Substance performed by Drug Product manufacturer used during product development and stability studies, along with Certificate of Analysis (CoA) of the same batch from Drug Substance / /Active Pharmaceutical Ingredient manufacture.</li> <li>Limits for Assay test submitted in Drug substance specifications, is different between Drug substance manufacturer COA &amp; COA from Drug product manufacturer.</li> <li>Tests of sterility have not been performed during stability studies. Justification shall be submitted in this regard.</li> <li>Justify the specifications of fill weight/vial.</li> <li>Specifications does not include test of "Particulate matter", &amp; "Water determination".</li> <li>Analytical method for Assay does not mentions the wavelength of UV detector in chromatographic conditions.</li> <li>Assay limits mentioned in the analytical procedure for Assay test are not as per USP monograph for "Ceftriaxone for Injection".</li> <li>Sample preparation procedure in the Assay test is not as per the USP monograph for "Ceftriaxone for Injection".</li> <li>As per submitted batch analysis certificates, tests of "Particulate matter", &amp; "Water determination" have not been performed.</li> <li>Submitted COA of batch # SD001 &amp; SD002 declares the strength in conclusion as</li> </ul>	<ul> <li>Analytical method verification studies report has been submitted from M/s Inventor Pharma.</li> <li>Firm has submitted revised COAs with Assay limits as per USP monograph.</li> <li>Firm has submitted sheets for the sterility test during stability studies.</li> <li>Firm has justified the fill weight with salt factor for sodium and water content %age.</li> <li>Firm has submitted revised specifications and analytical procedure as per USP monograph.</li> <li>Firm has performed only one Assay test for "solution 2" as recommended by USP monograph.</li> <li>Firm has submitted corrected COAs of stability batches including test of "Particulate matter", &amp; "Water determination"</li> </ul>
3.2.P.7	<ul><li>500mg.</li><li>COA of working/reference standard, used</li></ul>	Submitted.
J.2.1 ./	for the stability studies analysis, shall be submitted	
3.2. P.8	<ul> <li>Justify the specifications of filled weight/vial applied in the stability studies.</li> <li>Batch size declared in the raw data sheets is different from that mentioned in the stability summary sheets.</li> <li>Batch size mentioned on Stability summary sheet is different from that declared in section 3.2. P.8.1.</li> <li>Tests of "Particulate matter", &amp; "Water determination" have not been performed</li> </ul>	<ul> <li>Firm has justified the fill weight with salt factor for sodium and water content % age.</li> <li>Firm has rectified the raw data sheets for the batch size and details of of column &amp; flow rate.</li> <li>Firm has referred to the analytical method veriofication studies for the system suitability test.</li> <li>Firm has submitted stability summary</li> </ul>

- Details of column & flow rate as declared in the raw data sheets, is different from that recommended by USP monograph of "Ceftriaxone for Injection".
- As per submitted stability analytical record, system suitability test has not been performed during Assay analysis as recommended by USP monograph of "Ceftriaxone for Injection".
- Compete batch manufacturing record for three stability batches shall be submitted.

- particulate matter and water content have been included
- Batchmanufacturing records of all stability batches have been submitted.

Decision: Registration Board decided to defer the applications of Staxone IV 1g Injection, Staxone IV 500mg Injection, Staxone IM 500mg Injection, Staxone IM 250mg Injection & Staxone IV 250mg Injection for onsite investigation of M/s Inventor Pharma, Plot No. K/196, S.I.T.E. (SHW) Phase II, Karachi, for authenticity of submitted product development & stability studies data. Panel will be advised to verify and report following points in addition to the routine checklist:

- Details of the diluent used for the reconstitution of the applied products including its composition, quantity or volume and specifications.
- Availability of TOC analyser for the test of particulate matter.
- Fill weight of each vial for stability batches of each strength.
- Performance of test of "Particulate matter" & "Water determination" during stability studies of drug product.

The Board further advised the firm to perform Pharmaceutical equivalence against the available strengths of Rocephin Injection of M/s Roche and submit data to PE&R Division before above onsite audit.

21.	Name, address of Applicant / Marketing Authorization Holder	M/s Parkar Pharma. Plot No. O/7-A, S.I.T.E Area Kotri, Sindh			
	Name, address of Manufacturing site.	M/s Inventor Pharma, Plot No. K/196, S.I.T.E. (SHW) Phase II, Karachi			
	Status of the applicant	<ul> <li>☐ Manufacturer</li> <li>☐ Importer</li> <li>☑ Is involved in none of the above (contract giver)</li> </ul>			
	Status of application	<ul><li>□ New Drug Product (NDP)</li><li>☑ Generic Drug Product (GDP)</li></ul>			
_	Intended use of pharmaceutical product	t ☐ Domestic sale ☐ Export sale ☐ Domestic and Export sales			
	Evidence of approval of manufacturing facility	Firm has submitted copy of section approval letter dated 13-07-2017 which specifies Dry Powder Injection (Cephalosporin) for M/s Inventor Pharma			
	Dy. No. and date of submission	Dy.No 8051 dated 11-03-2021			
	Details of fee submitted	Rs.50,000/- dated 03-02-2021			
	The proposed proprietary name / brand name	Parxone 1g IV Powder for Injection			
-	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each Vial Contains: Ceftriaxone Sodium Eq. to Ceftriaxone1gm			
	Pharmaceutical form of applied drug	Third-generation cephalosporins, Antibiotic			
	Pharmacotherapeutic Group of (API)	USP			

Reference to Finished product specifications	1×1Vial
Proposed Pack size	As per SRO
Proposed unit price	ROCIPHIN (Ceftriaxone Sodium) by M/s ROCHE Laboratories Inc, USFDA Approved.
The status in reference regulatory authorities	CEFEXONE Powder Injection by M/s Bosch Phrmacuticals (Pvt) Ltd
For generic drugs (me-too status)	Third-generation cephalosporins, Antibiotic
GMP status of the Finished product manufacturer	GMP certificate issued on 13-08-2020.
Name and address of API manufacturer.	M/s. Sinopharm Weiqida Pharmaceuticals Co Ltd, First medical zone, economic and technological development zone, datong, China.
Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Firm has summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, Characterization, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance. The firm has summarized information of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols, control of excipients, control of drug product, specifications, analytical procedures, validation/verification of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.
Module III (Drug Substance)	Firm has submitted detailed data for both drug substance data related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
Stability studies	Firm has submitted stability study data of 3 batches of drug substance at both accelerated as well as real time conditions. The accelerated stability data is conducted at $40^{\circ} \pm 2^{\circ}$ C /75% $\pm$ 5% RH for 6 months. The real time stability data is conducted at $30^{\circ}$ C $\pm$ 2 $^{\circ}$ C / 65% $\pm$ 5% RH for 36 months. (Batch No. 011302001, 011302002, 011302003)
Module-III (Drug Product):	The firm has submitted detail of manufacturers, description of manufacturing process and controls, specifications, analytical procedure (including dissolution testing at acidic and buffer medium) and its verification studies, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug product.
Pharmaceutical equivalence and comparative dissolution profile	Pharmaceutical Equivalence have been established against the brand leader that is Mercefex 1gm Powder Injection by Merck Private Ltd.

	Analytical metho validation/verification of product	od	Submitted			
	*	BII	LITY STUDY DATA			
Manufacturer of API N		ZC	M/s. Sinopharm Weiqida Pharmaceuticals Co Ltd, First medical zone, economic and technological development zone, datong, China			
API Lot No.		Q	Q011910028			
*			Type III glass vial pack in PVC tray then in a unit carton is used as primary packaging (1 x1 vial)			
, ,			Real time: $30^{\circ}\text{C} \pm 2^{\circ}\text{C} / 65\% \pm 5\%\text{RH}$ Accelerated: $40^{\circ}\text{C} \pm 2^{\circ}\text{C} / 75\% \pm 5\%\text{RH}$			
			Real time: 6 months Accelerated: 6 months			
1 1			Accelerated: 0, 3, 6 (Months) Real Time: 0, 3, 6 (Months)			
Batch	No.	P	D-001	PD-002	PD-003	
Batch	Size	35	500 Vials	3500 Vials	3500 Vials	
Manu	facturing Date	03	3-2020	03-2020	03-2020	
No. o	f Batches			03		
	Ad	lm	inistrative Portion			
1.	Reference of previous approval of applications with stability study data of the firm (if any)		The firm has not subn	nitted any document	•	
2.		у	GMP certificate (Sinopharm Weiqida Shangxi Food & Dr 2023.		o Ltd. issued by	
3.	3. Documents for the procurement of API with approval from DRAP (in case of import).		• Firm has submitted copy of commercial invoice specifying import of 600Kg Ceftriaxone sodium (sterile) from Sinopharm. The invoice specifies multiple batches of Ceftriaxone. AD (I&E) DRAP, Karachi dated 10-11-2019.			
4	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.		Submitted			
5.	5. Compliance Record of HPLC software 21CFR & audit trail reports on product testing		Not applicable			
6. Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated).						
22.	Name, address of Applicant Marketing Authorization Holder	/	M/s Parkar Pharma Sindh	. Plot No. O/7-A, S	.I.T.E Area Kotri,	
	Name, address of Manufacturing site.		M/s Inventor Pharma II, Karachi	, Plot No. K/196, S.I	I.T.E. (SHW) Phase	

Status of the applicant	☐ Manufacturer ☐ Importer ☑ Is involved in none of the above (contract giver)
Status of application	☐ New Drug Product (NDP)  ☐ Generic Drug Product (GDP)
Intended use of pharmaceutical product	☐ Domestic sale ☐ Export sale ☑ Domestic and Export sales
Evidence of approval of manufacturing facility	Firm has submitted copy of section approval letter dated 13-07-2017 which specifies Dry Powder Injection (Cephalosporin) for M/s Inventor Pharma
Dy. No. and date of submission	Dy.No 8053 dated 11-03-2021
Details of fee submitted	Rs.50,000/- dated 03-02-2021
The proposed proprietary name / brand name	Parxone 500mg IM Powder for Injection
Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each Vial Contains: Ceftriaxone Sodium Eq. to Ceftriaxone500mg
Pharmaceutical form of applied drug	Third-generation cephalosporins, Antibiotic
Pharmacotherapeutic Group of (API)	USP
Reference to Finished product specifications	1×1Vial
Proposed Pack size	As per SRO
Proposed unit price	ROCIPHIN (Ceftriaxone Sodium) by M/s ROCHE Laboratories Inc, USFDA Approved.
The status in reference regulatory authorities	CEFEXONE Powder Injection by M/s Bosch Phrmacuticals (Pvt) Ltd
For generic drugs (me-too status)	Third-generation cephalosporins, Antibiotic
GMP status of the Finished product manufacturer	GMP certificate issued on 13-08-2020.
Name and address of API manufacturer.	M/s. Sinopharm Weiqida Pharmaceuticals Co Ltd, First medical zone, economic and technological development zone, datong, China.
Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Firm has summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, Characterization, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance. The firm has summarized information of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols, control of excipients, control of drug product, specifications, analytical procedures, validation/verification of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.

Module III (Drug Substance)	related solubilition manufact specificat analysis	to nomencles, physical uring protions, analytimed justificated closure systems.	lature, structure form, manufactocess and coical procedures a stion of specification	oth drug substance data , general properties, cturers, description of controls, impurities, nd its validation, batch ion, reference standard, ility studies of drug	
Stability studies	substance The accel ± 5% R conducte	e at both acc erated stabil H for 6 med d at 30°C ±	elerated as well a ity data is conduct onths. The real	ta of 3 batches of drug as real time conditions. etcd at $40^{\circ} \pm 2^{\circ} \text{ C}/75\%$ time stability data is 6 RH for 36 months. 11302003)	
Module-III (Drug Product):	manufact procedure medium) justificati	The firm has submitted detail of manufacturers, description of manufacturing process and controls, specifications, analytical procedure (including dissolution testing at acidic and buffer medium) and its verification studies, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug product.			
Pharmaceutical equivalence and comparative dissolution profile	brand lea	Pharmaceutical Equivalence have been established against the brand leader that is Mercefex 500mg Powder Injection by Merck Private Ltd.			
Analytical met validation/verification of product	thod Submitte	d			
ST	STABILITY STUDY DATA				
Manufacturer of API	_	M/s. Sinopharm Weiqida Pharmaceuticals Co Ltd, First medical zone, economic and technological development zone, datong, China			
API Lot No.	Q01191002	Q011910028			
Description of Pack (Container closure system)		Type III glass vial pack in PVC tray then in a unit carton is used as primary packaging (1 x1 vial)			
Stability Storage Condition		Real time: $30^{\circ}\text{C} \pm 2^{\circ}\text{C} / 65\% \pm 5\%\text{RH}$ Accelerated: $40^{\circ}\text{C} \pm 2^{\circ}\text{C} / 75\% \pm 5\%\text{RH}$			
Time Period		Real time: 6 months Accelerated: 6 months			
Frequency		Accelerated: 0, 3, 6 (Months) Real Time: 0, 3, 6 (Months)			
Batch No.	PD-001		PD-002	PD-003	
Batch Size	3500 Vials		3500 Vials	3500 Vials	
Manufacturing Date	01-2020		01-2020	01-2020	
No. of Batches		03			
Administrative Portion					
1. Reference of previous approval applications with stability study dat the firm (if any)		has not subr	nitted any docum	ent.	
2. Approval of API/ DML/GMP certification of API manufacturer issued concerned regulatory authority country of origin.	by Sinophar	n Weiqida		X20180229) of M/s Co Ltd. issued by on, valid up to 05-06-	

3.	Documents for the procurement of API with approval from DRAP (in case of import).	<ul> <li>Firm has submitted copy of commercial invoice specifying import of 600Kg Ceftriaxone sodium (sterile) from Sinopharm. The invoice specifies multiple batches of Ceftriaxone. AD (I&amp;E) DRAP, Karachi dated 10-11-2019.</li> </ul>	
4	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Submitted	
5.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	Not applicable	
6.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated).	Submitted	
23.	Name, address of Applicant / Marketing Authorization Holder	M/s Parkar Pharma. Plot No. O/7-A, S.I.T.E Area Kotri, Sindh	
	Name, address of Manufacturing site.	M/s Inventor Pharma, Plot No. K/196, S.I.T.E. (SHW) Phase II, Karachi	
	Status of the applicant	<ul> <li>☐ Manufacturer</li> <li>☐ Importer</li> <li>☑ Is involved in none of the above (contract giver)</li> </ul>	
	Status of application	☐ New Drug Product (NDP)  ☐ Generic Drug Product (GDP)	
	Intended use of pharmaceutical product	<ul><li>□ Domestic sale</li><li>□ Export sale</li><li>☑ Domestic and Export sales</li></ul>	
	Evidence of approval of manufacturing facility	Firm has submitted copy of section approval letter dated 13-07-2017 which specifies Dry Powder Injection (Cephalosporin) for M/s Inventor Pharma	
	Dy. No. and date of submission	Dy.No 8056 dated 11-03-2021	
	Details of fee submitted	Rs.50,000/- dated 03-02-2021	
	The proposed proprietary name / brand name	Parxone 500mg IV Powder for Injection	
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each Vial Contains: Ceftriaxone Sodium Eq. to Ceftriaxone500mg	
	Pharmaceutical form of applied drug	Third-generation cephalosporins, Antibiotic	
	Pharmacotherapeutic Group of (API)	USP	
	Reference to Finished product specifications	1×1Vial	
	Proposed Pack size	As per SRO	
	Proposed unit price	ROCIPHIN (Ceftriaxone Sodium) by M/s ROCHE Laboratories Inc, USFDA Approved.	
	The status in reference regulatory authorities	CEFEXONE Powder Injection by M/s Bosch Phrmacuticals (Pvt) Ltd	
	For generic drugs (me-too status)	Third-generation cephalosporins, Antibiotic	

GMP status of the Finished product manufacturer	GMP certificate issued on 13-08-2020.
Name and address of API manufacturer	. M/s. Sinopharm Weiqida Pharmaceuticals Co Ltd, First medical zone, economic and technological development zone, datong, China.
Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Firm has summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, Characterization, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance. The firm has summarized information of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols, control of excipients, control of drug product, specifications, analytical procedures, validation/verification of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.
Module III (Drug Substance)	Firm has submitted detailed data for both drug substance data related to nomenclature, structure, general properties solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard container closure system and stability studies of drug substance.
Stability studies	Firm has submitted stability study data of 3 batches of drug substance at both accelerated as well as real time conditions. The accelerated stability data is conducted at $40^{\circ} \pm 2^{\circ}$ C /75% $\pm$ 5% RH for 6 months. The real time stability data is conducted at $30^{\circ}$ C $\pm$ 2° C / 65% $\pm$ 5% RH for 36 months. (Batch No. 011302001, 011302002, 011302003)
Module-III (Drug Product):	The firm has submitted detail of manufacturers, description of manufacturing process and controls, specifications, analytical procedure (including dissolution testing at acidic and buffer medium) and its verification studies, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug product.
Pharmaceutical equivalence and comparative dissolution profile	Pharmaceutical Equivalence have been established against the brand leader that is Mercefex 500mg Powder Injection by Merck Private Ltd.
Analytical method validation/verification of product	Submitted
STAB	ILITY STUDY DATA
	M/s. Sinopharm Weiqida Pharmaceuticals Co Ltd, First medical zone, economic and technological development zone, datong, China
Lot No.	Q011910028
cription of Pack	Type III glass vial pack in PVC tray then in a unit carton is used

(Con	tainer closure system)	as primary packaging (1	1 x1 vial)	
Stabi	lity Storage Condition	Real time: $30^{\circ}\text{C} \pm 2^{\circ}\text{C}$ / Accelerated: $40^{\circ}\text{C} \pm 2^{\circ}\text{C}$		
Time	Period	Real time: 6 months Accelerated: 6 months		
Frequ	iency	Accelerated: 0, 3, 6 (MorReal Time: 0, 3, 6 (Mor		
Batch	n No.	PD-001	PD-002	PD-003
Batch	n Size	3500 Vials	3500 Vials	3500 Vials
Manı	nfacturing Date	01-2020	01-2020	01-2020
No. c	of Batches		03	
	Ad	ministrative Portion		
	Reference of previous approval of applications with stability study data of the firm (if any)	of	•	
2.		e GMP certificate ( y Sinopharm Weiqida Shangxi Food & Dr 2023.		to Ltd. issued by
3.	Documents for the procurement of AF with approval from DRAP (in case of import).	of import of 600Kg Sinopharm. The	g Ceftriaxone sodi invoice specifies n	al invoice specifying ium (sterile) from nultiple batches of i dated 10-11-2019.
4	Data of stability batches will be supported by attested respective documents like chromatograms, Raydata sheets, COA, summary data sheet etc.	e w		
5.	Compliance Record of HPLC softwar 21CFR & audit trail reports on productesting		Not applicable	
6.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time an accelerated).	of	Submitted	
24.	Name, address of Applicant Marketing Authorization Holder	/ M/s Parkar Pharma Sindh	a. Plot No. O/7-A, S	S.I.T.E Area Kotri,
	Name, address of Manufacturing site.	M/s Inventor Pharma II, Karachi	, Plot No. K/196, S.	I.T.E. (SHW) Phase
	Status of the applicant	☐ Manufacturer ☐ Importer ☑ Is involved in none	e of the above (contr	ract giver)
	Status of application	☐ New Drug Product ☐ Generic Drug Prod		
	Intended use of pharmaceutical product	□ Domestic sale □ Export sale □ Domestic and Exp	ort sales	

	T
Evidence of approval of manufacturing facility	Firm has submitted copy of section approval letter dated 13-07-2017 which specifies Dry Powder Injection (Cephalosporin) for M/s Inventor Pharma
Dy. No. and date of submission	Dy. No 8054 dated 11-03-2021
Details of fee submitted	Rs.50,000/- dated 03-02-2021
The proposed proprietary name / brand name	Parxone 250mg IM Powder for Injection
Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each Vial Contains: Ceftriaxone sodium Eq. to Ceftriaxone 250mg
Pharmaceutical form of applied drug	Third-generation cephalosporins, Antibiotic
Pharmacotherapeutic Group of (API)	USP
Reference to Finished product specifications	1×1Vial
Proposed Pack size	As per SRO
Proposed unit price	ROCIPHIN (Ceftriaxone Sodium) by M/s ROCHE Laboratories Inc, USFDA Approved.
The status in reference regulatory authorities	CEFEXONE Powder Injection 250mg by M/s Bosch Phrmacuticals (Pvt) Ltd
For generic drugs (me-too status)	Third-generation cephalosporins, Antibiotic
GMP status of the Finished product manufacturer	GMP certificate issued on 13-08-2020.
Name and address of API manufacturer.	M/s. Sinopharm Weiqida Pharmaceuticals Co Ltd, First medical zone, economic and technological development zone, datong, China.
Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Firm has summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, Characterization, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance. The firm has summarized information of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols, control of excipients, control of drug product, specifications, analytical procedures, validation/verification of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.
Module III (Drug Substance)	Firm has submitted detailed data for both drug substance data related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
Stability studies	Firm has submitted stability study data of 3 batches of drug substance at both accelerated as well as real time conditions.

		The accelerated stabil ± 5% RH for 6 m conducted at 30°C ± (Batch No. 01130200	onths. The real tire $2^{\circ} \text{ C} / 65\% \pm 5\% \text{ R}$	ne stability data is H for 36 months.
	Module-III (Drug Product):	The firm has submitted manufacturing process procedure (including medium) and its verification of specification of specification system and st	ss and controls, spec dissolution testing erification studies, ification, reference	ifications, analytical at acidic and buffer batch analysis and standard, container
	Pharmaceutical equivalence and comparative dissolution profile	Pharmaceutical Equivorand leader that is Merck Private Ltd.		
	Analytical metho validation/verification of product	od Submitted		
	STA	BILITY STUDY DATA	1	
Manu	nfacturer of API	M/s. Sinopharm Weiqio zone, economic and te China		
API I	Lot No.	Q011910028		
	ription of Pack tainer closure system)	Type III glass vial pack as primary packaging (1		a unit carton is used
Stabi	lity Storage Condition	Real time: $30^{\circ}\text{C} \pm 2^{\circ}\text{C} / \text{Accelerated}$ : $40^{\circ}\text{C} \pm 2^{\circ}\text{C} / \text{Accelerated}$		
Time	Period	Real time: 6 months Accelerated: 6 months		
Frequ	iency	Accelerated: 0, 3, 6 (More Real Time: 0, 3, 6 (More		
Batch	n No.	PD-001	PD-002	PD-003
Batch	ı Size	3500 Vials	3500 Vials	3500 Vials
Manu	ifacturing Date	02-2020	02-2020	02-2020
No. o	f Batches		03	
	Ad	lministrative Portion		
1.	Reference of previous approval applications with stability study data the firm (if any)		nitted any documen	t.
2.		te GMP certificate (Sinopharm Weiqida Shangxi Food & Dr 2023.		Co Ltd. issued by
3.	Documents for the procurement of Al with approval from DRAP (in case import).	of import of 600Kg C Sinopharm. The in	eftriaxone sodium ( voice specifies mult	
4	Data of stability batches will be supported by attested respective documents like chromatograms, Radata sheets, COA, summary data sheet.	w	Submitted	

5.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	Not applicable
6.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated).	Submitted
25.	Name, address of Applicant / Marketing Authorization Holder	M/s Parkar Pharma. Plot No. O/7-A, S.I.T.E Area Kotri, Sindh
	Name, address of Manufacturing site.	M/s Inventor Pharma, Plot No. K/196, S.I.T.E. (SHW) Phase II, Karachi
	Status of the applicant	☐ Manufacturer ☐ Importer ☑ Is involved in none of the above (contract giver)
	Status of application	☐ New Drug Product (NDP)  ☐ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	<ul><li>□ Domestic sale</li><li>□ Export sale</li><li>⋈ Domestic and Export sales</li></ul>
	Evidence of approval of manufacturing facility	Firm has submitted copy of section approval letter dated 13-07-2017 which specifies Dry Powder Injection (Cephalosporin) for M/s Inventor Pharma
	Dy. No. and date of submission	Dy. No 8052 dated 11-03-2021
	Details of fee submitted	Rs.50,000/- dated 03-02-2021
	The proposed proprietary name / brand name	Parxone 250mg IV Powder for Injection
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each Vial Contains: Ceftriaxone sodium Eq. to Ceftriaxone 250mg
	Pharmaceutical form of applied drug	Third-generation cephalosporins, Antibiotic
	Pharmacotherapeutic Group of (API)	USP
	Reference to Finished product specifications	1×1Vial
	Proposed Pack size	As per SRO
	Proposed unit price	ROCIPHIN (Ceftriaxone Sodium) by M/s ROCHE Laboratories Inc, USFDA Approved.
	The status in reference regulatory authorities	CEFEXONE Powder Injection 250mg by M/s Bosch Phrmacuticals (Pvt) Ltd
	For generic drugs (me-too status)	Third-generation cephalosporins, Antibiotic
	GMP status of the Finished product manufacturer	GMP certificate issued on 13-08-2020.
	Name and address of API manufacturer.	M/s. Sinopharm Weiqida Pharmaceuticals Co Ltd, First medical zone, economic and technological development zone, datong, China.
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template.

	Firm has summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, Characterization, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance. The firm has summarized information of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols, control of excipients, control of drug product, specifications, analytical procedures, validation/verification of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.
Module III (Drug Substance)	Firm has submitted detailed data for both drug substance data related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
Stability studies	Firm has submitted stability study data of 3 batches of drug substance at both accelerated as well as real time conditions. The accelerated stability data is conducted at $40^{\circ} \pm 2^{\circ}$ C /75% $\pm$ 5% RH for 6 months. The real time stability data is conducted at $30^{\circ}$ C $\pm$ 2 $^{\circ}$ C / 65% $\pm$ 5% RH for 36 months. (Batch No. 011302001, 011302002, 011302003)
Module-III (Drug Product):	The firm has submitted detail of manufacturers, description of manufacturing process and controls, specifications, analytical procedure (including dissolution testing at acidic and buffer medium) and its verification studies, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug product.
Pharmaceutical equivalence and comparative dissolution profile	Pharmaceutical Equivalence have been established against the brand leader that is Mercefex 250mg Powder Injection by Merck Private Ltd.
Analytical metho validation/verification of product	d Submitted
STAI	BILITY STUDY DATA
Manufacturer of API	M/s. Sinopharm Weiqida Pharmaceuticals Co Ltd, First medical zone, economic and technological development zone, datong, China
API Lot No.	Q011910028
Description of Pack (Container closure system)	Type III glass vial pack in PVC tray then in a unit carton is used as primary packaging (1 x1 vial)
Stability Storage Condition	Real time: $30^{\circ}\text{C} \pm 2^{\circ}\text{C} / 65\% \pm 5\%\text{RH}$ Accelerated: $40^{\circ}\text{C} \pm 2^{\circ}\text{C} / 75\% \pm 5\%\text{RH}$
Time Period	Real time: 6 months Accelerated: 6 months
Frequency	Accelerated: 0, 3, 6 (Months) Real Time: 0, 3, 6 (Months)

Batch No.		PD-001	PD-002	PD-003
Batch	n Size	3500 Vials	3500 Vials	3500 Vials
Manu	ufacturing Date	02-2020	02-2020	02-2020
No. o	of Batches		03	
	Ad	ministrative Portion		
1.	Reference of previous approval of applications with stability study data of the firm (if any)		mitted any documen	t.
2.		te GMP certificate or Sinopharm Weiqida Shangxi Food & Dr 2023.	Pharmaceuticals C	Co Ltd. issued by
3.	Documents for the procurement of AI with approval from DRAP (in case of import).	of import of 600Kg Sinopharm. The	g Ceftriaxone sod invoice specifies r	al invoice specifying ium (sterile) from multiple batches of ii dated 10-11-2019.
4	Data of stability batches will be supported by attested respective documents like chromatograms, Radata sheets, COA, summary data sheet.	ve w	Submitted	
5.	Compliance Record of HPLC softwar 21CFR & audit trail reports on productesting			
6.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time an accelerated).	of	Submitted	

## **Decision:**

Remarks of Evaluator(II):

Section#	Observations	Firm's response	
2.3	<ul> <li>The introduction table declares route of administration as IM whereas applied product is an IV injection.</li> <li>Quality Overall Summary (QOS) shall be provided in WHO QOS-PD Template or template provided in the "Guidance document for submission of application on Form 5-F (CTD) for registration of pharmaceutical Drug products for human use" approved by Registration Board in its 296th meeting, instead of presenting the extracts of Module III.</li> </ul>	<ul> <li>Firm has revised the introduction table for the IV injection.</li> <li>Revised QOS has been submitted.</li> </ul>	
3.2. S.4	<ul> <li>Copies of the Drug substance specifications and analytical procedures used for routine testing of the Drug substance /Active Drug Product manufacturer is required.</li> <li>Analytical Method Verification studies including specificity, accuracy and repeatability (method precision) performed by the Drug Product manufacturer for both compendial as well as noncompendial drug substance(s) shall be submitted.</li> <li>Provide results of analysis of relevant batch(es) of Drug Substance performed by Drug Product manufacturer used during product development and</li> </ul>		

	stability studies, along with Certificate of Analysis (CoA) of the same batch from Drug Substance / /Active Pharmaceutical Ingredient manufacture.  • Limits for Assay test submitted in Drug substance specifications, is different between Drug substance manufacturer COA & COA from Drug product manufacturer.	
3.2. S.7	Tests of sterility have not been performed during	Firm has submitted sheets for the
0.2. 5.7	stability studies. Justification shall be submitted in this regard.	sterility test during stability studies.
3.2. P.5	<ul> <li>Justify the specifications of fill weight/vial.</li> <li>Specifications does not include test of "Particulate matter", &amp; "Water determination".</li> <li>Analytical method for Assay does not mentions the wavelength of UV detector in chromatographic conditions.</li> <li>Assay limits mentioned in the analytical procedure for Assay test are not as per USP monograph for "Ceftriaxone for Injection".</li> <li>Sample preparation procedure in the Assay test is not as per the USP monograph for "Ceftriaxone for Injection".</li> <li>As per submitted batch analysis certificates, tests of "Particulate matter", &amp; "Water determination" have not been performed.</li> <li>Submitted COA of batch # SD001 &amp; SD002 declares</li> </ul>	<ul> <li>Firm has justified the fill weight with salt factor for sodium and water content %age.</li> <li>Firm has submitted revised specifications and analytical procedure as per USP monograph.</li> <li>Firm has performed only one Assay test for "solution 2" as recommended by USP monograph.</li> <li>Firm has submitted corrected COAs of stability batches including test of "Particulate matter", &amp; "Water</li> </ul>
3.2.P.7	the strength in conclusion as 500mg.  COA of working/reference standard, used for the	determination" Submitted.
3.2. P.8	<ul> <li>stability studies analysis, shall be submitted</li> <li>Justify the specifications of filled weight/vial applied in the stability studies.</li> <li>Batch size declared in the raw data sheets is different from that mentioned in the stability summary sheets.</li> <li>Batch size mentioned on Stability summary sheet is different from that declared in section 3.2. P.8.1.</li> <li>Tests of "Particulate matter", &amp; "Water determination" have not been performed during stability studies.</li> <li>Details of column &amp; flow rate as declared in the raw data sheets, is different from that recommended by USP monograph of "Ceftriaxone for Injection".</li> <li>As per submitted stability analytical record, system suitability test has not been performed during Assay analysis as recommended by USP monograph of "Ceftriaxone for Injection".</li> <li>Compete batch manufacturing record for three stability batches shall be submitted.</li> </ul>	<ul> <li>Firm has justified the fill weight with salt factor for sodium and water content %age.</li> <li>Firm has rectified the raw data sheets for the batch size and details of column &amp; flow rate.</li> <li>Firm has referred to the analytical method verification studies for the system suitability test.</li> <li>Firm has submitted stability summary sheets &amp; COAs, wherein tests of particulate matter and water content have been included</li> <li>Batch manufacturing records of all stability batches have been submitted.</li> </ul>

Decision: Registration Board decided to defer the applications of Parxone 1g IV Powder for Injection, Parxone 500mg IM Powder for Injection, Parxone 500mg IV Powder for Injection, Parxone 250mg IM Powder for Injection, & Parxone 250mg IV Powder for Injection for onsite investigation of M/s Inventor Pharma, Plot No. K/196, S.I.T.E. (SHW) Phase II, Karachi, for authenticity of submitted product development & stability studies data. Panel will be advised to verify and report following points in addition to the routine checklist:

• Details of the diluent used for the reconstitution of the applied products including its composition, quantity or volume and specifications.

- Availability of TOC analyser for the test of particulate matter.
- Fill weight of each vial for stability batches of each strength.
- Performance of test of "Particulate matter" & "Water determination" during stability studies of drug product.

The Board further advised the firm to perform Pharmaceutical equivalence against the available strengths of Rocephin Injection of M/s Roche and submit data to PE&R Division before above onsite audit.

#### **Deferred cases**

26.	Name, address of Applicant / Marketing Authorization Holder	M/s Islam Pharmaceuticals 7KM Pasrur Road Sialkot	
	Name, address of Manufacturing site.	M/s Islam Pharmaceuticals 7KM Pasrur Road Sialkot	
	Status of the applicant	<ul><li>☑ Manufacturer</li><li>☐ Importer</li><li>☐ Is involved in none of the above (contract giver)</li></ul>	
	Status of application  ☐ New Drug Product (NDP)  ☐ Generic Drug Product (GDP)		
	Intended use of pharmaceutical product	<ul><li>☑ Domestic sale</li><li>☐ Export sale</li><li>☐ Domestic and Export sales</li></ul>	
	Dy. No. and date of submission	Dy. No 25698 dated 15-09-2021	
	Details of fee submitted	Rs.30,000/- dated 31-08-2021	
	The proposed proprietary name / brand name	Nalphine 20mg/ml Injection	
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each 1ml ampoule contains: Nalbuphine hydrochloride 20mg	
	Pharmaceutical form of applied drug	Clear and colorless solution filled in clear glass ampoules with blue color breaking ring	
	Pharmacotherapeutic Group of (API)	Opioid agonist-antagonist	
	Reference to Finished product specifications	Innovator	
	Proposed Pack size	1ml×5's	
	Proposed unit price	As per SRO	
	The status in reference regulatory authorities	Nalbuphine Hydrochloride injection 10mg/ml by M/s Hospira Pharmaceuticals, USFDA Approved.	
	For generic drugs (me-too status)	Kinz Injection 10mg/ml by M/s Sami Pharmaceuticals (Pvt) Ltd. Reg. No. 018686	
	GMP status of the Finished product manufacturer	New Section for liquid ampoule (SVP) General was granted after inspection vide letter No.F. 1-19/2014-Lic (Vol-1) Dated: 18/12/2020	
	Name and address of API manufacturer.	M/s Micro orgo-chem, C-1/B-57, LIC Sector, GIDC Vapi-396 195, Gujarat, INDIA.	

Module-II (Quality C	verall Summary)	Firm has submitted QOS template. Summarized in nomenclature, structure, solubilities, physical form, mof manufacturing process and analytical procedures and analysis and justification of standard, container closur studies of drug substance submitted.	nformation related to general properties, nanufacturers, description d controls, specifications, its verification, batch f specification, reference e system and stability
Module III (Drug Sul	ostance)	The firm as submitted of structure, general properties form, manufacturers, descriprocess and controls, supprocedures and its verifical justification of specification container closure system and substance.	es, solubilities, physical iption of manufacturing pecifications, analytical tion, batch analysis and on, reference standard,
Stability studies		Stability study conditions: Real time: 30°C ± 2°C / 65% Accelerated: 40°C ± 2°C / 75° Batches:(MO/NBP/1401, MO/NBP/1403)	
Module-III (Drug Pro	oduct):	The firm has submitted of description of manufacturir impurities, specifications, an verification studies, batch an specification, reference starsystem and stability studies of	ng process and controls, halytical procedure and its halysis and justification of hadrd, container closure
Pharmaceutical equidissolution profile	valence and comparative	Pharmaceutical Equivalence against the Kinz 20mg/s. Pharmaceuticals by per (Appearance, Identification, Variation).	ml injection of Sami forming quality tests
Analytical method product	validation/verification of	Method validation studies ha	ave been submitted.
	STABILITY S	TUDY DATA	
Manufacturer of API	M/s Micro Orgo-chem, OINDIA.	C-1/B-57, LIC Sector, GIDC	Vapi-396 195, Gujarat,
API Lot No.	MO/NBP/2003		
Description of Pack (Container closure system)	USP Type-I Clear Glass a	ampoules in PVC Tray, packe	d in unit carton (1ml×5's)
Stability Storage Condition	Real time: $30^{\circ}\text{C} \pm 2^{\circ}\text{C} / 6$ Accelerated: $40^{\circ}\text{C} \pm 2^{\circ}\text{C}$		
Time Period	Real time: 6 months Accelerated: 6 months		
Frequency	Accelerated: 0, 3, 6 (More Real Time: 0, 3, 6 (Mone	· · · · · · · · · · · · · · · · · · ·	
Batch No.	21ARn027	21ARn028	21ARn029
Batch Size	2500 ampoules	2500 ampoules	2500 ampoules
Manufacturing Date	02-2021	02-2021	02-2021

No. of Batches	O/DRAP-AD-VIII itted wherein the APIs including
1. Reference of previous approval of applications with stability study data of the firm (if any)  2. Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.  3. Documents for the procurement of API with approval from DRAP (in case of import).  4. Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.  5. Compliance Record of HPLC software 21CFR & audit trail reports on product testing  6. Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)  7. Name, address of Applicant / Marketing Authorization Holder  Name, address of Manufacturing site.  8. Name, address of Manufacturing site.  8. Name, address of Manufacturing site.  8. M/s Islam Pharmaceuticals 7KM Pa Sialkot  M/s Islam Pharmaceuticals 7KM Pa Sialkot	O/DRAP-AD-VIII itted wherein the APIs including
with stability study data of the firm (if any)  2. Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.  3. Documents for the procurement of API with approval from DRAP (in case of import).  4. Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.  5. Compliance Record of HPLC software 21CFR & audit trail reports on product testing  6. Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)  7. Name, address of Applicant / Marketing Authorization Holder  Name, address of Manufacturing site.  8. Wis Islam Pharmaceuticals 7KM Pa Sialkot  M/s Islam Pharmaceuticals 7KM Pa Sialkot  M/s Islam Pharmaceuticals 7KM Pa Sialkot	O/DRAP-AD-VIII itted wherein the APIs including
API manufacturer issued by concerned regulatory authority of country of origin.  3. Documents for the procurement of API with approval from DRAP (in case of import).  4. Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.  5. Compliance Record of HPLC software 21CFR & audit trail reports on product testing  6. Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)  7. Name, address of Applicant / Marketing Authorization Holder  Name, address of Manufacturing site.  8. PDCA valid till 23/09/2021.  Copy of letter No.14850/2020 (I&E) dated 16/10/2020 is submited in permission to import different Nalbuphine HCl for the purpose of stability studies is granted.  8. Submitted  Data logger record of HPLC has be submitted in permission to import different Nalbuphine HCl for the purpose of stability studies is granted.  8. Data logger record of HPLC has be submitted in permission to import different Nalbuphine HCl for the purpose of stability studies is granted.  9. Data logger record of HPLC has be submitted in permission to import different Nalbuphine HCl for the purpose of stability studies is granted.  9. Data logger record of HPLC has be submitted in permission to import different Nalbuphine HCl for the purpose of stability studies is granted.  9. Data logger record of HPLC has be submitted in permission to import different Nalbuphine HCl for the purpose of stability studies is granted.  9. Data logger record of HPLC has be submitted in permission to import different Nalbuphine HCl for the purpose of stability studies is granted.  9. Data logger record of HPLC has be submitted in permission to import different Nalbuphine HCl for the purpose of stability studies is granted.  9. Data logger record of HPLC has be submitted in permission to import different Nalbuphine HCl for the purpose of stability studies is granted.  9. Data logger record of HPLC has be submitte	O/DRAP-AD-VIII itted wherein the APIs including
approval from DRAP (in case of import).  (I&E) dated 16/10/2020 is subm permission to import different Nalbuphine HCl for the purpose o stability studies is granted.  4. Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.  5. Compliance Record of HPLC software 21CFR & audit trail reports on product testing  6. Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)  Remarks of Evaluator(II):  27. Name, address of Applicant / Marketing Authorization Holder  Name, address of Manufacturing site.  M/s Islam Pharmaceuticals 7KM Pa Sialkot  Status of the applicant  M/s Islam Pharmaceuticals 7KM Pa Sialkot	itted wherein the APIs including
attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.  5. Compliance Record of HPLC software 21CFR & audit trail reports on product testing  6. Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)  Remarks of Evaluator(II):  27. Name, address of Applicant / Marketing Authorization Holder  Name, address of Manufacturing site.  Name, address of Manufacturing site.  Name, address of Manufacturing site.  M/s Islam Pharmaceuticals 7KM Pa Sialkot  Status of the applicant  M/s Islam Pharmaceuticals 7KM Pa Sialkot	
& audit trail reports on product testing  6. Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)  Remarks of Evaluator(II):  27. Name, address of Applicant / Marketing Authorization Holder  Name, address of Manufacturing site.  Name, address of Manufacturing site.  Status of the applicant  M/s Islam Pharmaceuticals 7KM Pa Sialkot  M/s Islam Pharmaceuticals 7KM Pa Sialkot	
and humidity monitoring of stability chambers (real time and accelerated)  Remarks of Evaluator(II):  27. Name, address of Applicant / Marketing Authorization Holder  Name, address of Manufacturing site.  Name, address of Manufacturing site.  Status of the applicant  M/s Islam Pharmaceuticals 7KM Pa Sialkot  M/s Islam Pharmaceuticals 7KM Pa Sialkot  Status of the applicant	peen submitted.
27. Name, address of Applicant / Marketing Authorization Holder  Name, address of Manufacturing site.  Name, address of Manufacturing site.  M/s Islam Pharmaceuticals 7KM Pasialkot  M/s Islam Pharmaceuticals 7KM Pasialkot  Status of the applicant  Marketing Sialkot  M/s Islam Pharmaceuticals 7KM Pasialkot	
Authorization Holder       Sialkot         Name, address of Manufacturing site.       M/s Islam Pharmaceuticals 7KM Pa Sialkot         Status of the applicant          ☑ Manufacturer	
Authorization Holder       Sialkot         Name, address of Manufacturing site.       M/s Islam Pharmaceuticals 7KM Pa Sialkot         Status of the applicant          ☑ Manufacturer	
Sialkot Status of the applicant	Pasrur Road
	srur Road
$\square$ Is involved in none of the above	(contract giver)
Status of application   ☐ New Drug Product (NDP)  ☐ Generic Drug Product (GDP)	
Intended use of pharmaceutical product  □ Domestic sale □ Export sale □ Domestic and Export sales	
Dy. No. and date of submission Dy. No 25697 Dated: 15/09/2021	
Details of fee submitted PKR 30,000/- Dated: 31/08/2021	
The proposed proprietary name / brand name Nalphine 10mg/ml Injection	
Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit  Each 1ml ampoule contains: Nalbuphine hydrochloride 10:	
Pharmaceutical form of applied drug  Clear and colorless solution fille ampoules with blue color breaking responses to the col	ng
Pharmacotherapeutic Group of (API) Opioid agonist-antagonist	d in clear glass
Reference to Finished product specifications Innovator	d in clear glass
Proposed Pack size 1ml×5's	d in clear glass
Proposed unit price As per SRO	d in clear glass

The status in reference regulatory authorities		e regulatory authorities	Nalbuphine Hydrochloride injection 10mg/ml by M/s Hospira Pharmaceuticals, USFDA Approved.	
For generic drugs (me-too status)		e-too status)	Kinz Injection 10mg/ml by M/s Sami Pharmaceuticals (Pvt) Ltd. Reg. No. 018686	
manufacturer		nished product	New Section for liquid ampoule (SVP) General was granted after inspection vide letter No.F. 1-19/2014-Lic (Vol-1) Dated: 18/12/2020	
	Name and address of	API manufacturer.	M/s Micro orgo-chem, C-1/B-57, LIC Sector, GIDC Vapi-396 195, Gujarat, INDIA.	
Module-II (Quality Overall Summary)		overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product is submitted.	
	Module III (Drug Substance)  Stability studies  Module-III (Drug Product):		The firm as submitted detail of nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.	
			Stability study conditions: Real time: $30^{\circ}\text{C} \pm 2^{\circ}\text{C} / 65\% \pm 5\%$ RH for 48 months Accelerated: $40^{\circ}\text{C} \pm 2^{\circ}\text{C} / 75\% \pm 5\%$ RH for 06 months Batches:(MO/NBP/1401, MO/NBP/1402, MO/NBP/1403)	
			The firm has submitted detail of manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedure and its verification studies, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug product.	
	Pharmaceutical equivalence and comparative dissolution profile		Pharmaceutical Equivalence have been established against the Kinz 10mg/ml injection of Sami Pharmaceuticals by performing quality tests (Appearance, Identification, Assay, pH and Volume Variation).	
	Analytical method validation/verification of product		Method validation studies have been submitted.	
		STABILITY S	TUDY DATA	
Manufa	Manufacturer of API M/s Micro Orgo-cher INDIA.		C-1/B-57, LIC Sector, GIDC Vapi-396 195, Gujarat,	
API Lo	t No.	MO/NBP/2003		
	ner closure system)	USP Type-I Clear Glass	ampoules in PVC Tray, packed in unit carton (1ml×5's)	
Stability	y Storage Condition	Real time: $30^{\circ}\text{C} \pm 2^{\circ}\text{C} / 65\% \pm 5\% \text{RH}$		

		T		
		Accelerated: $40^{\circ}\text{C} \pm 2^{\circ}\text{C}$	/ 75% ± 5%RH	
		Real time: 6 months Accelerated: 6 months		
Freque	ency	Accelerated: 0, 3, 6 (Months) Real Time: 0, 3, 6 (Months)		
Batch	No.	21ARn017	21ARn018	21ARn019
Batch S	Size	2500 ampoules	2500 ampoules	2500 ampoules
Manuf	acturing Date	02-2021	02-2021	02-2021
Date of	f Initiation	10-05-2021	10-05-2021	10-05-2021
No. of	Batches		03	
		Administrat	ive Portion	
1.	1. Reference of previous approval of applications with stability study data of the firm (if any)		Not submitted	
2.	2. Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.		Copy of GMP certificate No. S-GMP/1991608 issued by FDCA valid till 23/09/2021.	
3.	3. Documents for the procurement of API with approval from DRAP (in case of import).		(I&E) dated 16/10/2020 permission to import d	is submitted wherein the lifferent APIs including urpose of test/analysis and
4. Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.		Submi	tted	
5.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing		Data logger record of HPLC has been submitted.	
6.	6. Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)		Submi	tted
Remar	cks of Evaluator(II):			

Section#	Observations	Firm's response
2.3.S.1.1	INN name has been declared as "Nalbuphine hydrochloride dihydrate". Clarification shall be submitted in this regard, since no water molecule is evident in the submitted drug substance structure.	<ul> <li>By a typographic mistake International Non-Proprietary Name (INN) written as "Nalbuphine Hydrochloride dehydrate". However, in CTD under section 1.5.1 Generic name with chemical name &amp; synonyms of the applied drug, INN is declared as "Nalbuphine Hydrochloride".</li> <li>Correction in section 2.3.S.1.1 International Non-Proprietary Name (INN) as "Nalbuphine Hydrochloride" have been made.</li> </ul>
3.2. S.4	<ul> <li>Justification shall be submitted for the performance of Assay test by applying "Titration" method.</li> <li>Analytical method for Assay of drug substance submitted by drug product manufacturer is different form that proposed by drug substance manufacturer.</li> </ul>	violet as indicator instead of • 1-naphtholbenzein because 1-naphtholbenzein was

3.2.S.4.4	Numerical value for the results of Water content test shall be written in the COA of drug substance performed by drug product manufacturer.	Result of water content test in numerical value are added to the CoA of drug substance.
3.2.P.8	<ul> <li>Submit stability studies data for complete till 6<sup>th</sup> month time point for both accelerated and long-term stability conditions.</li> <li>Following shall be submitted:         <ol> <li>Raw data sheets for complete stability studies wherein details of standard solution preparation, sample solution preparation, calculation formula applied.</li> <li>Valid GMP certificate of drug substance issued by the relevant regulatory authority.</li> </ol> </li> </ul>	<ul> <li>Stability study data for 06-month time point for both Accelerated and long-term stability is submitted.</li> <li>Raw data sheets for complete stability studies with details of sample and standard solution preparation and calculation formula applied submitted.</li> <li>Valid GMP certificate of Drug substance issued by relevant regulatory authority is submitted.</li> </ul>
	<ul> <li>Submitted BMRs does not reflect the conditions of terminal sterilization.</li> <li>Dispensing of raw materials for the trial batch manufacturing was performed in February 2021, whereas the compounding was done in April, 2021. Clarification shall be submitted for this delay.</li> </ul>	<ul> <li>Copy of BMR pages containing condition of terminal sterilization are submitted.</li> <li>As it was planned to manufacture the stability batches in Feb-2021 so dispensing was done in Feb-2021 but accidently ampoule filling and sealing machine operator fall ill and was suspected with COVID and was quarantined until fully recovered. Due to his illness the compounding of batches was delayed.</li> </ul>

**Decision of 316**<sup>th</sup> meeting: Registration Board deferred both the applications of "Nalphine 10mg/ml Injection" & "Nalphine 20mg/ml Injection" for the justification of specified pH range of "3.0 – 4.5" for the drug product, since the innovator product i.e., "Nubain injection" approved by U SFDA, specifies the pH range of 3.5 to 3.7.

**Firm's response:** Firm has referred to the nalbuphine hydrochloride injection of m/s hospiraInc., USA, approved by US FDA, wherein the pH range has been specified as 3.0 - 4.5. The firm has also developed the product and conducted stability studies with rthe same ph range of 3.0 - 4.5.

Decision: Registration Board approved both "Nalphine 20mg/ml Injection" & "Nalphine 10mg/ml Injection" with innovator's specifications.

- Manufacturer will place first three commercial batches on long term stability studies throughout
  proposed shelf life and on accelerated studies for six months as per the commitment submitted
  in the registration application.
- Manufacturer will perform process validation of first three commercial batches as per the commitment submitted in the registration application.

28.	Name, address of Applicant / Marketing Authorization Holder	"M/s Sami Pharmaceuticals Pvt Limited. F-95, S.I.T.E, Karachi, Pakistan"
	Name, address of Manufacturing site.	"M/s Sami Pharmaceuticals Pvt Limited. F-95, S.I.T.E, Karachi, Pakistan"
	Status of the applicant	<ul><li>☑ Manufacturer</li><li>☐ Importer</li><li>☐ Is involved in none of the above (contract giver)</li></ul>
	Status of application	<ul><li>□ New Drug Product (NDP)</li><li>☑ Generic Drug Product (GDP)</li></ul>
	Intended use of pharmaceutical product	<ul> <li>□ Domestic sale</li> <li>□ Export sale</li> <li>☑ Domestic and Export sales</li> </ul>

Evidence of approval of manufacturing facility	New license granted on 29/09/2020 Tablet, Capsule, Dry Powder, Liquid Syrup, Cream Ointment (General Sections) Approved
Dy. No. and date of submission	Dy.No 22893 dated 06-11-2019
Details of fee submitted	Rs.50,000 dated 06-11-2019
The proposed proprietary name / brand name	Elezo-BF 150mg/1mg/25mcg Capsule
Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each Capsule Contains: Iron Polysaccharide eq. to elemental Iron150mg Folic Acid1mg Vitamin B1225mcg
Pharmaceutical form of applied drug	Capsule
Pharmacotherapeutic Group of (API)	Mineral, Iron
Reference to Finished product specifications	Innovator's specifications
Proposed Pack size	10's
Proposed unit price	Not submitted
The status in reference regulatory authorities	Firm has referred to the "Ferrex 150 forte capsules" of US, along with its reference from Nation Drug Code list as accessed on 14-09-2021. Firm has also referred to the decision of registration Board regarding Iron containing formulations.
For generic drugs (me-too status)	N/A
GMP status of the Finished product manufacturer	New license granted on 29/09/2020 Tablet, Capsule, Dry Powder, Liquid Syrup, Cream Ointment (General Sections) Approved
Name and address of API manufacturer.	Iron Polysaccharide: M/s Aromatic & Industrial Chemicals Pvt. Ltd.  Address: B-15, Kalyan Badlapu Rd., MIDC Area, Ambarnath- 421S0L D□t. Thane, Thane  Folic Acid:  HEBEi JIHENG {Group) PHARMACEUTICAL Co., Ltd Address: No. 1 Weiwu Street, Henshui Industrial Park, Henshui City, Hebei Province, P.R. China 053000  Vitamin B12 (Cyanocobalamin):  HEBEi HUARONG PHARMACETICAL CO., LTD.  Address: East Road, North Circle, Shijiazhuang, China
Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product is submitted.
Module III (Drug Substance)	The firm has submitted detail of nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, specifications, analytical procedures and its verification, batch analysis and justification of specification,

		reference standard, container studies of drug substance	closure system and stability
Stability studies		Firm has submitted accelerated & long-term stability studies of Iron polysaccharide as per Zone IVa conditions.	
Pharmaceutical equivalence and comparative dissolution profile		The firm has submitted detail of manufacturing process a analytical procedure (including and buffer medium) and its analysis and justification standard, container closure sy drug product.	nd controls, specifications, g dissolution testing at acidic verification studies, batch of specification, reference
		Firm has submitted that Disso dissolution test for this com pharmacopeia and FDA dissolu	bination is not available in
Analytical method of product	validation/verification	Method verification studies linearity, range, accuracy, prec	
	STABIL	ITY STUDY DATA	
Manufacturer of API	Iron Polysaccharide: M/s Aromatic & Industrial Chemicals Pvt. Ltd. Address: B-15, Kalyan Badlapu Rd., MIDC Area, Ambarnath- 421S0L D□t. Thane, Thane Folic Acid: HEBEi JIHENG {Group) PHARMACEUTICAL Co., Ltd Address: No. 1 Weiwu Street, Henshui Industrial Park, Henshui City, Hebei Province, P.R. China 053000 Vitamin B12 (Cyanocobalamin): HEBEi HUARONG PHARMACETICAL CO., LTD. Address: East Road, North Circle, Shijiazhuang, China		
API Lot No. Iron Polysaccharide: Folic Acid: 0218050			
Description of Pack (Container closure system)  Alu-Alu foil			
Stability Storage Condition	Real time: $30^{\circ}\text{C} \pm 2^{\circ}\text{C} / 65\% \pm 5\%\text{RH}$ Accelerated: $40^{\circ}\text{C} \pm 2^{\circ}\text{C} / 75\% \pm 5\%\text{RH}$		
Time Period	Real time: 6 months Accelerated: 6 months		
Frequency	Accelerated: 0, 3 & 6 Real Time: 0, 3, 6 (M		
Batch No.	Lab-01	Lab-02	Lab-03
Batch Size	3000 capsules	3000 capsules	3000 capsules
Manufacturing Date	November-2018	November-2018	November-2018
No. of Batches		03	
Administrative Portion			
		Firm has referred last onsite panel inspection for instant dosage form conducted during last two years- DELANZO DR (Dexlansoprazole) 30mg & 60mg Capsules on 02nd April, 2018, by following panel:  According to the report following points were confirmed.  □ □ The firm has 21 CFR compliant HPLC software	

		☐ The firm has audit trail reports available. ☐ The firm possesses stability chambers with digital data loggers.
regulatory authority of country of origin.		manufacturer issued by concerned (Certificate#6084148) issued by FDA Maharashtra India,
3. Documents for the procurement of API with approval from DRAP (in case of import).		oproval from DRAP (in case of dated 06-06-2018 for the import of Iron (III) hydroxide
4.	by atte	stability batches will be supported sted respective documents like tograms, ata sheets, COA, summary data tc.
5.		ance Record of HPLC software & audit trail reports on product
6.	Record	· ·
Rema	arks of E	Evaluator(II):
Sect	ion#	Observation Firm's response
3.2.9	S.4	<ul> <li>Submit drug substance specifications &amp; analytical method applied by M/s Sami, for all the three drug substances.</li> <li>Submit analytical method verification studies for all three drug substances, performed by M/s Sami</li> <li>Drug substance specifications &amp; analytical method for all three drug substances are submitted</li> <li>Analytical method verification studies for all three drug substances are submitted</li> </ul>

tests (mentioned in	any official	Folic acid	109.64%	119.22%		
pharmacopoeia o						
рпагшасороета о	section	Cyanocobalamin	109.26%	119.71%		
		_		_		
Minutes of 31	7 <sup>th</sup> meeting o	f Registration Board	l (16-17 May, 2	:022)	37	7

Drug substance

Pharmaceutical Equivalence along with the reference

product is submitted. The Assay results of Folic acid &

Sami's

product

Cyanocobalamin have been reported a sunder:

Reference

product

Submitted

Pharmaceuticals.

condition.

Long term stability studies of

Cyanocobalamin & Folic acid are not as per Zone IV a

Pharmaceutical equivalence of

the applied drug shall be

established with the innovator /

reference / comparator product

and results of all the quality

3.2.S.7

3.2.P.2.2.1

	3.2.P.5.1 of this application) of
	the developed formulation and
	the innovator / reference /
	comparator product shall be
	submitted.
3.2. P.2.2.2	Describe the particulars of drug substance on the basis of which 20% overage has been
	claimed for Folic acid & Cyanocobalamin
	The unusual assay limits were due to the overages in Cyanocobalamin and Folic acid. Initially
	the upper limit was set to 150% due to 20% overage. Now, based on stability data, the upper
	limit of assay has been revised to 125% and we will cut down the overages accordingly.
	Revised specifications and testing procedure are submitted.
Reply	Some active pharmaceutical ingredients including several vitamins in certain dosage
	forms or packaging condition may be susceptible to degrade or deteriorate and may not
	remain their native form over the shelf life of product. Degradation or deterioration of
	vitamins is one of the major factors that lead manufacturer to require excess amount of
	vitamins in their products, to ensure the amount of the drug substance meets the
	requirement of 100% of the label claim amount throughout the shelf life of the product.
	(Referred Pharmacopeial Forum Vol.42.42 (3) [May-June 2016], Stimuli to the Revision
	Process, Factors to Consider in Setting Adequate Overages of Vitamins and Minerals in
	Dietary Supplements).
	• ELEZO BF Capsules was developed as per the formulation of reference listed drug (RLD)
	i.e. Ferrex 150 Forte Capsule manufactured by Mis.Contract Pharmacal Corp.
	Hauppauge, NY 11788 USA. During chemical testing of RLD product, assay of Folic
	Acid (Vitamin B9) was observed around 110% and assay of Cyanocobalamin (Vitamin
	B12) was observed around 110%. On the basis of assay results of RLD product,
	formulation of ELEZO BF Capsules was suggested with 20% overage for both Folic Acid
	(Vitamin B9) and Cyanocobalamin (Vitamin B12) to compensate any process loss
	followed by the expected loss in assay during stability studies due to nature of the
	molecules.
	• The stability trending of our product shows about 4.29 to 6.41 % loss in assay of Folic
	Acid (Vitamin 89) under accelerated condition as well as 2.37 to 4.05% loss under long
	term condition, and 9.41 to 13.03% loss in assay of Cyanocobalamin (Vitamin B12) under accelerated condition as well as 2.47 to 4.59% loss under long term condition.
	<ul> <li>Moreover, 20% overage was not fixed, as mentioned above, it is a global practice to take</li> </ul>
	overages for vitamins during development studies and this was also evident in assay results of the RLD product as well.
	<ul> <li>However, after evaluation of the stability data and till the latest time period i.e. 24 months,</li> </ul>
	we recommend to reduce the overage of Folic Acid (Vitamin B9) from 20% to 7% and
	Cyanocobalamin (Vitamin B12) from 20% to 13%.
3.2. P.5.1	<ul> <li>Justify the unusual Assay limits of Cyanocobalamin &amp; Folic acid.</li> </ul>
3.2.1.3.1	<ul> <li>Submitted drug product specifications does not include test of dissolution. Justification</li> </ul>
	shall be submitted in this regard.
Reply	Assay limits were set considering the overage of Cyanocobalamin, folic acid and based
жеріу	on USP specifications for Cyanocobalamin Gel that is 90 to 155 %.
	• On the basis of analysis of stability data, we have revised the Assay limit of
	cyanocobalamin & Folic acid from 90%-150% to 90-125% from 9 <sup>th</sup> month interval to
	onwards.
	<ul> <li>While we have come to conclude that the product is stable till 24 months therefore we</li> </ul>
	will further reduce the overages up to 90 to 120 %, please find submitted revised
	specifications.
	<ul> <li>Dissolution test for cyanocobalamin not performed due to following reasons:</li> </ul>
	"It falls in BCS Class Ill and having a good solubility
	The dissolution of the product is ensured by its Disintegration time which is established within
	10-15 mins during its shelf life through stability studies (stability summaries are attached for
	your reference).
<u> </u>	Jour reconcey.

Label claim of Cyanocobalamin in applied formulation is 25mcg/ capsule and the concentration of the API in dissolution test is about 0.05 PPM which is difficult to detect As per USP general chapters for dissolution of water-soluble multivitamins and mineral tablets, it is recommended to perform dissolution of One index water-soluble vitamin, one index element, and folic acid (if present) Definition of Index Vitamin and Index element as per USP: Index water-soluble vitamin: "Riboflavin is the index vitamin when present in the formulation. For formulations that do not contain riboflavin, pyridoxine is the index vitamin. If neither riboflavin nor pyridoxine is present in the formulation, the index vitamin is niacinamide (or niacin), and in the absence of

niacinamide (or niacin), the index vitamin is thiamine. If none of these four water-soluble

vitamins are present in the formulation, the index vitamin is ascorbic acid." Index element:

"Iron is the index element when present in the formulation. For formulations that do not

contain iron, the index element is calcium. If neither iron nor calcium is present, the index element is zinc. In the absence of all three of these elements, magnesium is the index element." Therefore, we performed dissolution of Folic acid and Iron content only. 3.2. P.5.6 Relevant information shall • The specification of Elezo BF Capsule is developed in-

- be submitted. house based on ICH Q6 "Specifications "as well as based on general chapter of pharmacopeia. The test includes appearance, average weight, disintegration time, Assay and dissolution etc 3.2. P.8 All vitamins are degraded on accelerated conditions due Submitted stability data
  - reflects significant change to heat sensitive, Significant change observed in 06 in the Assay results of months accelerated stability however at long term conditions all results within 3% from initial value and acid Cyanocobalamin, during have no significant change is observed till 24 months. accelerated stability According to ICH Q1E, if significant change occurs
    - between 3 and 6 months testing at accelerated storage condition, the proposed retest period or shelf life should be based on long term data.
    - Currently we have 24th month long term data and have no significant change; See below the statement of ICH O1E:

#### 2.5.1.2 Significant change at accelerated condition

If significant change occurs between 3 and 6 months' testing at the accelerated storage condition, the proposed retest period or shelf life should be based on the longterm data. Extrapolation is not considered appropriate. In addition, a retest period or shelf life shorter than the period covered by long-term data could be called for. If the long-term data show variability, verification of the proposed retest period or shelf life by statistical analysis can be appropriate.

If significant change occurs within the first 3 months' testing at the accelerated storage condition, the proposed retest period or shelf life should be based on long-term data. Extrapolation is not considered appropriate. A retest period or shelf life shorter than the period covered by long-term data could be called for. If the long-term data show variability, verification of the proposed retest period or shelf life by statistical analysis can be appropriate. In addition, a discussion should be provided to address the effect of short-term excursions outside the label storage condition (e.g., during shipping or handling). This discussion can be supported, if appropriate, by further testing on a single batch of the drug substance or product at the accelerated condition for a period shorter than 3 months.

Decision of 316th meeting: Deferred for submission of complete details regarding Pharmacological, Pharmacodynamic & clinical indications of the applied product.

#### Firm's response(II):

Folic

studies. Justification shall

be submitted in this regard.

Firm has submitted screenshots of the reference product packaging i.e., Ferrex -150 forte capsules of M/s Breckridge Pharmaceutical Incorporation., USA wherein following details have been mentioned:

#### • Ferrex 150 Forte Dosage and Administration

Usual adult dosage is 1 capsule daily, or as directed by a physician.

#### • Indications and Usage for Ferrex 150 Forte

Ferrex<sup>TM</sup> 150 Forte is indicated for the dietary management of iron deficiency anemia and/or nutritional megaloblastic anemias.

#### • Contraindications:

Ferrex<sup>TM</sup> 150 Forte is contraindicated in patients with a known hypersensitivity to any of the components of this product. Hemochromatosis and hemosiderosis are contraindications to iron supplementation.

#### • Warning:

Folic Acid alone is improper therapy in the treatment of pernicious anemia and other megaloblastic anemias where vitamin B12 is deficient.

#### Adverse Reactions:

Adverse reactions with iron supplementation may include constipation, diarrhea, nausea, vomiting, dark stools and abdominal pain. Adverse reactions with iron therapy are usually transient.

Allergic sensitization has been reported following both oral and parenteral administration of folic acid

Moreover, firm has submitted following:

## 1. Why cyanocobalamin added in the formulation? as its quantitative assessment is not addressable:

Iron + Folic Acid + Cyanocobalamin belongs to a class of medications called 'haematinics' primarily used to treat anemia (deficiency of iron and hemoglobin). Deficiency occurs mainly due to poor diet, poor absorption of food, or increased folate use in the body (in pregnancy). Anemia is a condition in which the body does not have enough red blood cells for carrying adequate oxygen required to various body tissues.

Vitamin B12 works closely with vitamin B9, also called folate or folic acid, to help make red blood cells and to help iron work better in the body. Folate and B12 work together to produce S-adenosylmethionine (SAMe), a compound involved in immune function and mood.

#### 2. Clinical Indications and its individual role with iron:

Iron + Folic Acid + Cyanocobalamin is a combination drug containing Iron, Folic acid (haematinics combination) and Cyanocobalamin, primarily used to treat anemia. Iron is an important mineral in the body required by red blood cells to carry oxygen to other body cells and tissues. By combining with a protein called hemoglobin, it helps in attracting oxygen in the lugs. Folic acid is a vitamin B that helps the body make more red blood cells and helps the red blood cells carry out more oxygenated blood to other tissues of the body. Cyanocobalamin is known as vitamin B12 that maintains the health of blood cells and nerves. In combination, Iron + Folic Acid + Cyanocobalamin works by boosting red blood cells (RBC) and hemoglobin (Hb) in the body, with a sufficient supply of oxygen to body cells.

Iron + Folic Acid + Cyanocobalamin is a combination drug containing or 'haematinics' primarily used to treat anemia (deficiency of red blood cells and hemoglobin). It acts as a supplement in pregnancy as, during pregnancy, the demand for iron and folic acid in the body is increased. It also helps the body produce and maintain new cells and prevents our DNA from mutating, leading to cancer. Iron + Folic Acid + Cyanocobalamin contains Iron and Folic acid (haematinics combination), and Cyanocobalamin (Vitamin B12) which works by boosting the production of red blood cells (RBC) and hemoglobin in the body. Thus, the use of Iron + Folic Acid + Cyanocobalamin is associated with a reduced risk of iron deficiency and anemia, especially in pregnant women.

#### **Decision:** Approved with Innovator's specifications.

- Manufacturer will place first three commercial batches on long term stability studies throughout
  proposed shelf life and on accelerated studies for six months as per the commitment submitted in the
  registration application.
- Manufacturer will perform process validation of first three commercial batches as per the commitment submitted in the registration application.

29.	11	M/s, Carer Pharmaceuticals Industries Plot # 27, Main Road, Rawat Industrial Estate, Rawat
	,	M/s, Carer Pharmaceuticals Industries Plot # 27, Main Road, Rawat Industrial Estate, Rawat

Status of the applicant	
	☐ Importer
	☐ Is involved in none of the above (contract giver)
Status of application	☐ New Drug Product (NDP)
	☐ Generic Drug Product (GDP)
Intended use of pharmaceutical product	
	☐ Export sale
	☑ Domestic and Export sales
Evidence of section approval	New license granted on 18/03/2021 Tablet (General & General Antibiotic) Dry Powder Suspensio (General), Sachet (General), Ampoule (General), Capsu (General), section approved.
Dy. No. and date of submission	Dy. No 27959 dated 11-10-2021
Details of fee submitted	Rs.30,000/- dated 28-09-2021
proposed proprietary name / brand name	ORS Sachet Lemon flavour
Strength / concentration of drug of	
Active Pharmaceutical ingredient (API) per unit	Sodium Chloride2.6g Sodium Citrate Dihydrate2.9g
per unit	Potassium Chloride1.5g
	Glucose anhydrous13.5g
Pharmaceutical form of applied drug	Sachet
Pharmacotherapeutic Group of (API)	Oral Rehydration Salt
Reference to Finished product specifications	BP Specifications
Proposed Pack size	1 X 20's
Proposed unit price	As per SRO
status in reference regulatory authorities	WHO Approved
For generic drugs (me-too status)	Werisol Sachet of M/s Werrick Pharmaceuticals
GMP status of the Finished product manufacturer	New license granted on 18/03/2021 Tablet (General & General Antibiotic) Dry Powder Suspensio (General), Sachet (General), Ampoule (General), Capsu (General), section approved.
Name and address of API manufacturer.	Nandu Chemicals (Pvt) Ltd. N-12, Industrial Estate, Hub India Sodium Citrate, dihydrate: Nandu Chemicals (Pvt) Ltd. N-12, Industrial Estate, Hub India Potassium Chloride
	Nandu Chemicals (Pvt) Ltd. N-12, Industrial Estate, Hul India Glucose,anhydrous Xiwang Pharmaceutical Co.Ltd.No.237, Tongfu Roa Handian Town, Zouping Country, Binzhou City, Shandor Province China
Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD templa Summarized information related to nomenclature, structure

	general properties, solubilities, physical form, manufacture impurities, specifications, analytical procedures and verification, batch analysis and justification of specificate reference standard, container closure system and stab studies of drug substance and drug product is submitted.
Module III (Drug Substance)	The firm as submitted detail of nomenclature, struct general properties, solubilities, physical form, manufactur specifications, analytical procedures and its verification, be analysis and justification of specification, reference stand container closure system and stability studies of c substance.
Stability studies	Sodium chloride: Firm has submitted stability study data batches of drug substance at both accelerated as well as time conditions. The accelerated stability data is conducted $40^{\circ}\text{C} \pm 2^{\circ}\text{C} / 75\% \pm 5\%$ RH for 6 months. The real tstability data is conducted at $30^{\circ}\text{C} \pm 2^{\circ}\text{C} / 65 \pm 5\%$ RH for months.  Trisodium citrate dihydrate: Firm has submitted stability study data of 3 batches of csubstance at both accelerated as well as real time condition. The accelerated stability data is conducted at $40^{\circ}\text{C} \pm 2^{\circ}\text{C} / 75\%$ the for 6 months. The real time stability data conducted at $30^{\circ}\text{C} \pm 2^{\circ}\text{C} / 65 \pm 5\%$ RH for 60 months.  Potassium chloride: Firm has submitted stability study of 3 batches of drug substance at both accelerated as well real time conditions. The accelerated stability data conducted at $40^{\circ}\text{C} \pm 2^{\circ}\text{C} / 75\% \pm 5\%$ RH for 6 months. real time stability data is conducted at $30^{\circ}\text{C} \pm 2^{\circ}\text{C} / 65 \pm 2\%$ RH for 60 months.  Glucose anhydrous: Firm has submitted stability study of 3 batches of drug substance at both accelerated as well real time conditions. The accelerated stability data conducted at $40^{\circ}\text{C} \pm 2^{\circ}\text{C} / 75\% \pm 5\%$ RH for 6 months. The accelerated at stability data conducted at $40^{\circ}\text{C} \pm 2^{\circ}\text{C} / 75\% \pm 5\%$ RH for 6 months. The accelerated stability data conducted at $40^{\circ}\text{C} \pm 2^{\circ}\text{C} / 75\% \pm 5\%$ RH for 6 months. The accelerated at a submitted stability data conducted at $40^{\circ}\text{C} \pm 2^{\circ}\text{C} / 75\% \pm 5\%$ RH for 6 months. The accelerated at $40^{\circ}\text{C} \pm 2^{\circ}\text{C} / 75\% \pm 5\%$ RH for 6 months. The accelerated at $40^{\circ}\text{C} \pm 2^{\circ}\text{C} / 75\% \pm 5\%$ RH for 6 months. The accelerated at $40^{\circ}\text{C} \pm 2^{\circ}\text{C} / 75\% \pm 5\%$ RH for 6 months. The accelerated at $40^{\circ}\text{C} \pm 2^{\circ}\text{C} / 75\% \pm 5\%$ RH for 6 months. The accelerated at $40^{\circ}\text{C} \pm 2^{\circ}\text{C} / 75\% \pm 5\%$ RH for 6 months.
Module-III (Drug Product):	The firm has submitted detail of manufacturers, description manufacturing process and controls, specifications, analytic procedure and its verification studies, batch analysis justification of specification, reference standard, contactories system and stability studies of drug product.
Pharmaceutical equivalence and comparative dissolution profile	Pharmaceutical Equivalence have been established against Werrisol by Werrick Pharma performing quality tests
Analytical method validation/verification of product	Method verification studies have submitted.

Manufacturer of API	Sodium chloride:
	Nandu Chemicals (Pvt) Ltd. N-12, Industrial Estate, Hubli India.
	Trisodium citrate dihydrate:
	Nandu Chemicals (Pvt) Ltd. N-12, Industrial Estate, Hubli India.
	Potassium chloride:
	Nandu Chemicals (Pvt) Ltd. N-12, Industrial Estate, Hubli India.
	Glucose anhydrous:
	Xiwang Pharmaceutical Co. Ltd. No. 237, Tongfu Road, Handian Town, Zouping
	County, Binzhou City, Shandong Province China.

API I	Lot No.	Sodium chloride: BSCL201112 Trisodium citrate dihydrate: 183 Potassium chloride: 736 Glucose anhydrous: XW20200302			
	ription of Pack rainer closure system)	White to off-whit	e crystalline powder	filled in laminated sachet.(1 x 20's)	
Stabil	lity Storage Condition		$2^{\circ}C / 65\% \pm 5\% RH$ $C \pm 2^{\circ}C / 75\% \pm 5\% R$		
Time	Period	Real time: 6 mont	ths Acc	celerated: 6 months	
Frequ	iency	Accelerated: 0, 2,	4, 6 (Months) Re	al Time: 0, 3, 6 (Months)	
Batch	No.	T001	T002	T003	
Batch	Size	2500 sachet	2500 sachet	2500 sachet	
Manu	facturing Date	03-2021	03-2021	03-2021	
Date	of Initiation	02-2023	02-2023	02-2023	
No. o	f Batches	03	1		
Adm	inistrative Portion	1			
1.	Reference of previous applications with stab the firm (if any)		N/A	N/A	
2. Approval of API/ DML/GMP certificate of API manufacturer issued by		Firm has submitted 21) of M/s Nandu (Control Departmen is valid till 17-11-20 Trisodium citrate Firm has submitted 21) of M/s Nandu (Control Departmen is valid till 17-11-20 Potassium chlorid Firm has submitted 21) of M/s Nandu (Control Departmen is valid till 17-11-20 Glucose anhydrocertificate (No. SD Co. Ltd. Xiwang I Province China issutill 11-01-2023.	dihydrate: copy of GMP certificate (No. 1037/2020) Chemicals (Pvt) Ltd. India issued by Drugst Government of Karnataka. The certificate (021. e: copy of GMP certificate (No. 1037/2020) Chemicals (Pvt) Ltd. India issued by Drugst Government of Karnataka. The certificate (021. us: Firm has submitted copy of GMF (20170644) of M/s Xiwang Pharmaceutical (1001) Industry zone Zouping County, Shandong (1001) Industry zone Zouping County, Shandong (1001) Industry zone Zouping County, Shandong (1001) Industry zone Zouping County, Shandong (1001) Industry zone Zouping County, Shandong (1001) Industry zone Zouping County, Shandong (1001) Industry zone Zouping County, Shandong (1001) Industry zone Zouping County, Shandong (1001) Industry zone Zouping County, Shandong (1001) Industry zone Zouping County (1001) Industry zone Zouping (1001) Industry zone Zouping (1001) Industry zone Zouping (1001) Industry zone Zouping (1001) Industry zone Zouping (1001) Industry zone Zouping (1001) Industry zone Zouping (1001) Industry zone Zouping (1001		
3.	Documents for the procurement of API with approval from DRAP (in case of import).		Copy of commercia	al invoices submitted	
4.	4. Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.		Submitted		
5.					

6.	Record of Digital data logger for	The report of Temperature and humidity log is also attached.
	temperature and humidity monitoring of	
	stability chambers (real time &	
	accelerated)	

#### Remarks of Evaluator(II):

Remarks of Evaluator (11).			
Observations	Firm's response		
Details of the reference product, against which Pharmaceutical equivalence studies have been performed, shall be submitted.	Pharmaceutical studies have been performed against the ORS sachet of M/s Searle.		
Submit evidence of availability of "Atomic emission spectrophotometry/ Flame Photometer", required for the analysis of Potassium & sodium in the applied product.			
Complete batch manufacturing records shall be submitted for stability batches.	Batch manufacturing records of three stability batches have been submitted.		
Submit data in section 3.2.S.4.3 as per the decision of 293 <sup>rd</sup> meeting of Registration Board, which states that "Analytical Method Verification studies including specificity, accuracy and repeatability (method precision) performed by the Drug Product manufacturer for both compendial as well as non-compendial drug substance(s) shall be submitted".	Analytical method verification studies performed by M/s Carer Pharma submitted		
Submit evidence of procurement of each drug substance like ADC attested invoice or DHL slip etc, since only commercial invoice is submitted.	Firm has submitted commercial invoice and courier slips.		

**Decision of 316**<sup>th</sup> **meeting:** Deferred for submission of evidence of availability of "Atomic emission spectrophotometry/ Flame Photometer", required for the analysis of Potassium & sodium in the applied product.

#### Firm's response: Firm has submitted following:

- Commercial invoice from M/s Bio technologies for the Flame Photometer (Model No. 010006) (invoice number 04199) dated 11<sup>th</sup> February 2021.
- Calibration Certificate of the Flame Photometer (Model No. 010006) (Certificate number PME/CAL/CP/025) dated 20<sup>th</sup> February 2021.
- Validation certificate of the Flame Photometer (Model No. 010006) for the Sodium & Potassium element.

#### **Decision: Approved**

- Manufacturer will place first three commercial batches on long term stability studies throughout proposed shelf life and on accelerated studies for six months as per the commitment submitted in the registration application.
- Manufacturer will perform process validation of first three commercial batches as per the commitment submitted in the registration application.

#### Case no. 02 Registration applications of newly granted DML or New section (Human)

#### **New DML**

30.	Name, address of Applicant / Marketing Authorization Holder	M/s JASM PHARMACEUTICALS (PVT) LTD
	Name, address of Manufacturing site.	M/s <b>JASM Pharmaceuticals</b> ( <b>Pvt</b> ) <b>Ltd.</b> Address: Plot # 4A, Export Processing street, Risalpur Industrial Estate, Nowshera. Khyber Pukhtunkhwa.
	Status of the applicant	<ul><li>✓ Manufacturer</li><li>☐ Importer</li></ul>

	☐ Is involved in none of the above (contract giver)
Status of application	□ New Drug Product (NDP)
	☑ Generic Drug Product (GDP)
Intended use of pharmaceutical product	☐ Domestic sale
	☐ Export sale
	☑ Domestic and Export sales
Dy. No. and date of submission	Dy.No 32160 dated 24-11-2021
Details of fee submitted	Rs.30,000/- dated 10-11-2021
The proposed proprietary name / brand name	Zetrozen dry Suspension 200 mg/5ml
Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each 5ml Contains: Azithromycin as dihydrate200 mg
Pharmaceutical form of applied drug	Oral Dry Suspension
Pharmacotherapeutic Group of (API)	Macrolide Antibiotics
Reference to Finished product specifications	USP
Proposed Pack size	15 ml / bottle or as per SRO
Proposed unit price	As per SRO
The status in reference regulatory authorities	Zithromax Suspension (Azithromycin 200mg / 5mL) by M/s Pfizer Registered By UK
For generic drugs (me-too status)	
GMP status of the Finished product manufacturer	New license granted on 29/09/2020 Tablet, Capsule , Dry Powder, Liquid Syrup , Crean Ointment (General Sections) Approved
Name and address of API manufacturer.	M/s <b>Vision Pharmaceuticals (Pvt) Limited.</b> Plot No. 22-23, Industrial Triangle, Kahuta Road, Islamabad- Pakistan
Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PE template. Summarized information related to nomenclature, structure, general properties solubilities, physical form, manufacturers, description of manufacturing process and controls, specifications analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product is submitted.
Module III (Drug Substance)	The firm has submitted detail of nomenclature structure, general properties, solubilities, physica form, manufacturers, description of manufacturing process and controls, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard container closure system and stability studies of drug substance
Stability studies	Stability study conditions: Real time: $30^{\circ}\text{C} \pm 2^{\circ}\text{C} / 65\% \pm 5\%\text{RH}$ for 36 months Accelerated: $40^{\circ}\text{C} \pm 2^{\circ}\text{C} / 75\% \pm 5\%\text{RH}$ for 6 months

			Batches: ( AZI 111, AZI 1	12, AZI 113)
	Module-III (Drug Product):		The firm has submitted detail of manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedure and its verification studies, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug product.	
	Pharmaceutical equivalence and comparative dissolution profile		Firm has submitted refere "Zetamax of M/s Pfizer". Firm has submitted CDP ragainst Zetamax suspension	eport in three mediums
	Analytical method value product	idation/verification of	Method verification studies l linearity, range, accuracy, pr	
		STABILITY S	TUDY DATA	
Manu	facturer of API		ceuticals (Pvt) Limited. rial Triangle, Kahuta Road, Is	lamabad- Pakistan.
API L	ot No.	AZI 148		
	iption of Pack ainer closure system)	30 ml / bottle packed i	n a Unit Carton.	
Stabili	ity Storage Condition		Real time: $30^{\circ}\text{C} \pm 2^{\circ}\text{C} / 65\% \pm 5\%\text{RH}$ Accelerated: $40^{\circ}\text{C} \pm 2^{\circ}\text{C} / 75\% \pm 5\%\text{RH}$	
Time 1	Period	Real time: 6 months Accelerated: 6 months	<b>.</b>	
Freque	ency	Accelerated: 0, 3 & 6 (Real Time: 0, 3, 6 (Mo		
Batch	No.	P06	P11	P17
Batch	Size	500 Bottles	500 Bottles	500 Bottles
Manu	facturing Date	04-2021	04-2021	05-2021
Date of	of Initiation	29-04-2021	30-04-2021	01-05-2021
No. of Batches		03		
Administrat		tive Portion		
1.	Reference of previous apwith stability study data		NA	
2.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.		Copy of GMP certificate No. Addl.Dir.(QA&LT-I) Issued 10/02/2022	
3.	Documents for the procurement of API with approval from DRAP (in case of import).		NA	
4.	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.		Submit	tted
5.	Compliance Record of I & audit trail reports on p			

6.	Record of Digital data logger for temperature
	and humidity monitoring of stability chambers
	(real time and accelerated)

## Remarks of Evaluator(II):

Section#	Observation	Firm's response
3.2.S.4.2	<ul> <li>Analytical procedure applied by the drug substance manufacturer shall be submitted.</li> <li>Justification shall be submitted for applying Titration procedure for the</li> </ul>	Submitted. Firm has followed the substance manufacturer analytical method, validated and then used for the analysis
3.2.S.4.4	Assay test.  • Submitted COA form M/s Vision Pharma. does not clarify whether the declared Assay is on "as is basis" or "on	Firm has submitted revised COA with potency declaration on anhydrous basis and inclusion of
	<ul><li>dried basis".</li><li>Submitted COA does not include test of identification.</li></ul>	
3.2.S.4.5	<ul> <li>The section mentions that the specifications are based upon US Pharmacopoeia, whereas submitted specifications and analytical procedures are not available in USP.</li> </ul>	Firm has submitted that specifications are based on Vision specifications.
3.2.S.5	• Submitted working standard declares the re-test date as 01-01-2021, whereas the drug substance analysis has been performed subsequent to this date.	Frim has submitted that working standard was re-tested on 19-01-2021 and submitted COA & chromatograms for it.
3.2.S.7	• Submitted stability study reports are not readable.	Revised stability reports have been submitted.
3.2.P.2	<ul> <li>Details of the reference product applied for the pharmaceutical equivalence studies shall be submitted.</li> <li>Comparative dissolution profile studies shall be submitted against the innovator product.</li> </ul>	Firm has submitted reference product details as "Zetamax of M/s Pfizer".  Firm has submitted CDP report in three mediums against Zetamax suspension of Pfizer.
3.2.P.2.5	Justification shall be submitted for performing and reporting of preservative effectiveness studies, whereas no preservative has been used in the applied formulation.	
3.2.P.2.6	• Report for compatibility study with diluent shall be submitted.	Firm has submitted compatibility studies after reconstitution.
3.2.P.3.5	<ul> <li>Process validation protocol does not include details of critical process parameters and sampling plan.</li> </ul>	_
3.2.P.5.2	• Submit evidence of availability of HPLC equipped with auto sampler which can maintain temperature upto 10°C.	wherein Peliter tray temperature report has been declared as 10°C.
3.2.P.6	• Submitted working standard declares the re-test date as 01-01-2021, whereas the drug product analysis has been performed subsequent to this date.	re-tested on 19-01-2021 and submitted COA &
3.2.P.8.3	Complete raw data sheets, wherein details of sample and standard dilution	

making is evident, shall be submitted for both assay & dissolution analysis.	
Justify the dispensed quantity of Azithromycin taste masked pellets for each trial batch against the Assay percentage determined during drug substance analysis.	

#### **Decision: Approved.**

- Manufacturer will place first three commercial batches on long term stability studies throughout proposed shelf life and on accelerated studies for six months as per the commitment submitted in the registration application.
- Manufacturer will perform process validation of first three commercial batches as per the commitment submitted in the registration application.

Registration Board further advised M/s Vision Pharmaceuticals to upgrade their method of analysis for "Azithromycin taste masked granules" to HPLC base testing method.

31.	Name, address of Applicant / Marketing Authorization Holder	M/s JASM Pharmaceuticals (Pvt) Ltd Address: Plot # 4A, Export Processing street, Risalpur Industrial Estate, Nowshera. Khyber Pukhtunkhwa.
	Name, address of Manufacturing site.	M/s JASM Pharmaceuticals (Pvt) Ltd Address: Plot # 4A, Export Processing street, Risalpur Industrial Estate, Nowshera. Khyber Pukhtunkhwa.
	Status of the applicant	<ul><li>☑ Manufacturer</li><li>☐ Importer</li><li>☐ Is involved in none of the above (contract giver)</li></ul>
	Status of application	☐ New Drug Product (NDP)  ☑ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	<ul><li>□ Domestic sale</li><li>□ Export sale</li><li>☑ Domestic and Export sales</li></ul>
	Evidence of availability of manufacturing section.	New license granted on 29/09/2020 Tablet, Capsule, Dry Powder, Liquid Syrup, Cream Ointment (General Sections) Approved
	Dy. No. and date of submission	Dy. No 32165 dated 24-11-2021
	Details of fee submitted	Rs.30,000/- dated 10-11-2021
	The proposed proprietary name / brand name	Adovel Tablets 400 mg
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each Film Coated Tablet Contains: Ibuprofen400mg
	Pharmaceutical form of applied drug	Round biconcave film coated <b>Tablets</b>
	Pharmacotherapeutic Group of (API)	NSAID
	Reference to Finished product specifications	USP
	Proposed Pack size	25X10's Tablets or as per SRO
	Proposed unit price	As per SRO
	The status in reference regulatory authorities	Ibuprofen 400mg Tablets by M/s AUROBINDO PHARMA Ltd , USFDA Approved
	For generic drugs (me-too status)	Fenbro tablet of M/s Stanley Pharmaceuticals
_		

GMP status of the Fi manufacturer	nished product	New license granted on 29/09/2020 Tablet, Capsule, Dry Powder, Liquid Syrup, Cream
Name and address of	API manufacturer.	Ointment (General Sections) Approved  M/s Zenith Chemical Industries (Pvt) Limited.  Moza Dhonday, Jia Baga Raiwind Kahna Road
Module-II (Quality C	Overall Summary)	Raiwind Pakistan.  Firm has submitted QOS as per WHO QOS-PD template. Summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product is submitted.
Module III (Drug Su	bstance)	The firm has submitted detail of nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance
Stability studies		Stability study conditions: Real time: $30^{\circ}C \pm 2^{\circ}C / 65\% \pm 5\%$ RH for 36 months Accelerated: $40^{\circ}C \pm 2^{\circ}C / 75\% \pm 5\%$ RH for 6 months Batches: (ZIBU11-001, ZIBU11-002, ZIBU11-003)
Module-III (Drug Pro	oduct):	The firm has submitted detail of manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedure (including dissolution testing at acidic and buffer medium) and its verification studies, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug product.
Pharmaceutical equivalent dissolution profile	valence and comparative	Pharmaceutical Equivalence have been established against the brand leader that is Inflam Tablets 400 mg by AMBROSIA Pharmaceutical by performing quality tests (Identification, Assay, Dissolution, Uniformity of dosage form).  CDP has been performed against the same brand that is INFLAM Tablets 400 mg by AMBROSIA Pharmaceutical in Acetate buffer media (Ph 4.5) & Phosphate Buffer media (pH 6.8). The values for f1 and f2 are in the acceptable range.
Analytical method v	validation/verification of	2 -
	STABILITY S	TUDY DATA
Manufacturer of API	M/s <b>Zenith Chemical In</b> Moza Dhonday, Jia Baga	ndustries (Pvt) Limited. A Raiwind Kahna Road Raiwind Pakistan.
API Lot No.	ZIBU20-032	

Description of Pack (Container closure system) 25 x 10's Tablet		lu blister packed in Unit Cart	on.
Stability Storage Condition	Real time: 30°C ± 2°C / 65% ± 5%RH Accelerated: 40°C ± 2°C / 75% ± 5%RH		
Time Period	Real time: 6 months Accelerated: 6 months		
Frequency	Accelerated: 0, 3 & 6 (Months) Real Time: 0, 3, 6 (Months)		
Batch No.	P04	P04	P04
Batch Size	40 Packs	40 Packs	40 Packs
Manufacturing Date	04-2021	04-2021	04-2021
Date of Initiation	28-04-2021	28-04-2021	28-04-2021
No. of Batches		03	
	Administra	tive Portion	
Reference of previous approval of applications with stability study data of the firm (if any)		NA	
Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.		Copy of GMP certificate Ref No. 141/2019-Drap(AD-813875228) issued by DRAP.	
Documents for the procurement of API with approval from DRAP (in case of import).		NA	
Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.			
	d of HPLC software reports on product testing		Α
Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)			mitted with one reading

# Firm's response: Remarks of Evaluator(II):

Section#	Observation	Firm's response
3.2.S.4.2	Analytical procedure & specifications applied by the drug substance manufacturer shall be submitted.	Submitted.
3.2.P.1	• Submitted composition declares Ibuprofen of USP standard whereas section 3.2.S.4.1 claims BP specifications for the Ibuprofen.	Firm has stated that it was a clerical mistake and has corrected the composition table.
3.2.P.2.2.1	<ul> <li>Details of reference product, against which Pharmaceutical equivalence studies have been performed, shall be submitted.</li> <li>Comparative dissolution profile has been submitted for pH 4.5 &amp; pH 6.8 buffer.</li> </ul>	Firm has submitted details of reference product as "Inflam tablets of M/s Ambrosia Pharmaceuticals". CDP in pH 1.2 medium has also been submitted.

3.2.P.5.3	•	Process validation protocol does not include details of critical process parameters and sampling plan.	Revised process validation protocol has been submitted.
3.2.P.6	•	1 21	Firm has submitted revised COA of USP grade working standard.

### **Decision: Approved.**

- Firm shall submit "Comparative Dissolution Profile" against the "Brufen tablets of M/s Abbott, before issuance of registration letter.
- Manufacturer will place first three commercial batches on long term stability studies throughout
  proposed shelf life and on accelerated studies for six months as per the commitment submitted in
  the registration application.
- Manufacturer will perform process validation of first three commercial batches as per the commitment submitted in the registration application.

Registration Board further advised the firm to increase the frequency of data logging for temperature and humidity monitoring of stability chambers (real time and accelerated) for batches already under stability testing & future batches as well and submit report before issuance of registration letter.

#### Case no. 03 Borrowing of APIs for performing Product Development, R&D & stability Testing:

DRAP Authority in its 133<sup>rd</sup> and 134<sup>th</sup> meeting considered the request of PPMA regarding borrowing of APIs for performing Product Development, R&D & stability Testing. The Authority in its 134<sup>th</sup> meeting decided as under:

The Authority reviewed its earlier decision taken in its 133<sup>rd</sup> meeting and decided as follows:

"The Authority deliberated that for product development / stability studies, the manufacturer need to purchase drug substance from a reliable source, however, in extraordinary circumstances beyond the control of manufacturer, the Authority acceded to the request of Pakistan Pharmaceutical Manufacturers Association (PPMA) to allow borrowing, except controlled drugs, the requisite quantity of drug substance for product development / stability studies only to fulfill pre-requisite for submission of Form 5-F (CTD) from a licensed manufacturer having legitimate purchase evidence. However, all requirements of quality and traceability would be applicable in such cases and will be the responsibility of the borrower of the material. Further, the products so manufactured in NO case shall be allowed for commercial sale."

#### **Decision:**

Registration Board considered decision of Authority and requested for guidance regarding processing of cases for borrowing of drug susbtances/materials for product development / stability studies of drug products on following points:

- a. Parameters to determine "extraordinary circumstances beyond the control of manufacturer".
- b. Whether borrowing will be permisable from manufacturer having registration of the products (containing same material) or will also be permisable for materials imported for experimental/ product development purposes by another manufacturer.
- c. Status of material after commercial import by registration holder (borrower).

Following are the cases which have been previously deferred for deliberation pertaining to subject matter:

32.	Name, address of Applicant / Marketing Authorization Holder	M/s. SAMI Pharmaceuticals (Pvt.) Ltd. F-95, Off Hub River Road, S.I.T.E. Karachi.
	Name, address of Manufacturing site.	M/s Sami Pharmaceuticals (Pvt) Ltd. F-95, Off Hub River Road, S.I.T.E. Karachi.
	Status of the applicant	<ul><li>☑ Manufacturer</li><li>☐ Importer</li><li>☐ Is involved in none of the above (contract giver)</li></ul>
	Status of application	☐ New Drug Product (NDP)

	T
	☑ Generic Drug Product (GDP)
Intended use of pharmaceutical product	☐ Domestic sale
	☐ Export sale
	☑ Domestic and Export sales
Dy. No. and date of submission	Dy. No. 19160 dated :08-07-2021
Details of fee submitted	PKR 30,000/-: Deposit slip #887056162198 PKR 120,000/-: Deposit slip #12835367 dated:20-01 2022
The proposed proprietary name / brand name	Mevulak MR 200mg Capsule
Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each Capsule contains: Modified release Mebeverine HCl Pellets Equivalent to Mebeverine HCl200mg (Innovator's Specifications)
Pharmaceutical form of applied drug	Modified Release Capsule
Pharmacotherapeutic Group of (API)	Synthetic anticholinergics ATC Code: A03AA04
Reference to Finished product specifications	Innovator's Specifications
Proposed Pack size	10's, 20's, & 30's
Proposed unit price	As per SRO
The status in reference regulatory authorities	Colofac® MR. Modified release capsule by M/s MHRA Approved.
For generic drugs (me-too status)	Mebever MR 200mg Capsule by M/s Getz Pharma,Registration No. 050747
GMP status of the Finished product manufacturer	GMP Certificate issued date 11-08-2020 on the basis of inspection conducted on 28-08-2019
Name and address of API manufacturer.	M/s RA Chem Pharma Limited (FDF) Plot No: A-19/C, A-23A 7 A-23B, Road No0 18, IDA Nancharam, Nancharm Village, Uppal Manda, Medchal- malkajgiri district, Hyderabad, Telegana, India.
Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PE template. Summarized information related to nomenclature, structure, general properties, solubilities physical form, manufacturers, description of manufacturing process and controls, specifications analytical procedures and its validation, batch analysis and justification of specification, reference standard container closure system and stability studies of drug substance and drug product is submitted.
Module III (Drug Substance)	The firm as submitted detail of nomenclature, structure general properties, solubilities, physical form manufacturers, description of manufacturing proces and controls, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance
Stability studies of Drug substance	Stability study conditions: Real time: $30^{\circ}C \pm 2^{\circ}C / 75\% \pm 5\%$ RH for 36 months Accelerated: $40^{\circ}C \pm 2^{\circ}C / 75\% \pm 5\%$ RH for 06 months Batches:(MBPJ16007,MBPJ16008,MBPJ16009,)

			The firm has submitted of description of manufacturin impurities, individual impurspecifications, analytical dissolution testing at acidic at validation studies, batch and specification, reference star system and stability studies of	g process and controls, rity and total impurity, procedure (including and buffer medium) and its lysis and justification of adard, container closure
	dissolution profile		Pharmaceutical Equivalence have been established against the Competitor that is Mebever MR® 200mg Tablets by M/s Getz Pharma by performing quality tests (Appearance, average weight, Assay, Dissolution, impurity profiling, Microbiological limit test). CDP has been performed against the same brand that is A Mebever MR® 200mg Tablets by M/s Getz Pharma in Acid media (pH 1.2-4.5) & Phosphate Buffer (pH 6.8). The values for f1 and f2 are in the acceptable range.	
	Analytical method va product	lidation/verification of	Method validation studies have submitted including linearity, accuracy, precision (including intermediate precession, Repeatability), Robustness, specificity	
		STABILITY	STUDY DATA	
Manuf	acturer of API		Limited (FDF) A 7 A-23B, Road No0 18, IDA , Medchal- malkajgiri district,	
API Lo	ot No.	DMBPJ19049		
	ption of Pack iner closure system)	Alu-Alu blister		
Stabilit	ty Storage Condition	Real time: $30^{\circ}\text{C} \pm 2^{\circ}\text{C}$ Accelerated: $40^{\circ}\text{C} \pm 2^{\circ}$		
Time F	Period	Real time: 06 <sup>th</sup> months Accelerated: 6 <sup>th</sup> month		
Freque	ency	Accelerated: 0, 1, 3, 6 Real Time: 0, 3, 6 (Mo		
Batch	No.	Lab-01	Lab-02	Lab-03
Batch	Size	2500 Capsules	2500 Capsules	2500 Capsules
Manuf	facturing Date	07-2020	07-2020	07-2020
Date of	f Initiation	14-07-2020	14-07-2020	14-07-2020
No. of	Batches		03	
		Administra	ative Portion	
1.			Reference of our last onsite p dosage form conducted du DELANZO DR (Dexlansop Capsules which was presente registration board & hence a registration board	ring last two years i.e. orazole) 30mg & 60mg d in 281th meeting of the
			Date of inspection: 02nd Apri report confirms following poi	

		<ul> <li>The HPLC software is 21CFR Compliant</li> <li>Audit trail on the testing reports is available.</li> <li>Adequate monitoring and control are available for stability chamber. Chambers are controlled and monitored through software having alarm system for alerts as well.</li> <li>Related manufacturing area, equipment, personnel and utilities are GMP compliant.</li> </ul>
2.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Copy of DML for M/s RA Chem Pharma Limited (FDF) (License No# 23/RR/AP/2007/F/R/CC, Dt:07/07/2013) issued by Drug Control Administration Government of Telegana, valid upto 26-10-2025 is submitted
3.	Documents for the procurement of API with approval from DRAP (in case of import).	Detail of Loan material from S.J & G Fazul Elahie (Pvt.) Karachi along with the Copy of form 3, form 7 & commercial invoice (Invoice# RATG/19-20/812 02-03- 2020 with received quantity i.e. 250 kg) for the purchase Mebeverine HCl SR Pellets by RA CHEM PHARMA LIMITED (FDF Division) with attestation of DRAP dated: 13-02- 2020
4.	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Submitted
5.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	Submitted.
6.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Submitted

#### **Remarks of Evaluator(II):**

**Fee submitted** PKR 120,000/-: Deposit slip #12835367, Dated: 20-01-2022

S.No	Section	<b>Shortcomings Communicated</b>	Reply
1.	3.2.P.8	Clarify why you take loan of Pellets	Mebeverine HCL pellets of good quality
		from S.J & G Fazul Elahie (Pvt.)	could be sourced from good Indian
		Karachi instead of purchase from direct	manufacturers at reasonable rates.
		pellets maufacturer	In order to conduct Stability Studies, we
			requested few manufacturers to supply
			required quantity of Mebeverine Hcl SR
			pellets to which they agreed.
			Unfortunately no Courier company was
			willing to lift sample quantity from India for
			delivery to us; copies of emails exchanged
			with them are annexed herewith.
			M/s S.J. & G Fazul Ellahie Pvt. Ltd. Karachi
			fortunately had sufficient stock of imported
			Mebeverine Hcl pellets and were willing to
			provide required quantity on loan.
			We accordingly obtained required quantity
			on loan from them.

**Decision of 316<sup>th</sup> meeting:** Deferred for further deliberation regarding regarding use of drug substance pellets by M/s Sami Pharmaceuticals (Pvt.) Ltd, for the manufacturing of stability batches, which had been procured and imported by M/s S.J. & G Fazul Ellahie Pvt. Ltd. Karachi.

Firm's response: Firm has submitted as under:

• Import of all material from India was banned vide SRO. 927 (I)/2019. dated 09-08-2019 issued by Ministry of Commerce & Textile however it was effectively operational only after Oct 2019 when DRAP Legal Affairs Division, vide its letter dated 17-10-2019, requested Ministry of Commerce to issue the following clarification: (Annex A)

#### The words "therapeutic products" and "therapeutic good" carry the same meaning

- Due to this reason, all courier companies and postal authorities were not accepting any type of post and mail including letter, parcels and documents; copies of emails exchanged with FedEx, TCS(*UPS*) are annexed herewith (*Annex B*)
- We contacted many leading USFDA, MHRA and EDQM Certified manufacturers of APIs and Pellets in India from whom we were procuring the material since last 10 years for obtaining samples but due to COVID surge in India, no courier service was accepting samples for delivery to Pakistan (*Annex C*)
- Having been left with no other option, the material was received on "Loan" against an Understanding; as stated on Memo attached; from an established manufacturer viz., M/s. S.J. &G. Fazul Ellahie (Pvt.) Ltd. Karachi who had legally imported these Pellets from the same source viz., RA Chem Pharma Ltd. It was assured to them that on obtaining drug registration, we will import commercial quantities from the same source and then return the material received on loan (Annex D)
- We have learnt that the DRAP Authpority has now allowed to take the material on loan as per following criteria:

Material can be procured from one manufacturer to another for R&D purpose and commercial consignment then shall be obtained from the same source i.e. API supplier

Hence, in the light of above, it is earnestly requested to consider our case for favorable decision.

Moreover, firm has submitted memorandum of understanding between M/s Sami Pharma. & M/s S.J&G Fazul Ellahe regarding loan and return of the said drug substance. Firm has also submitted regarding use of the borrowed material for R&D purpose only.

Decision: Deferred till decision of Authority on borrowing of APIs for performing Product Development, R&D & stability Testing.

33.	Name, address of Applicant / Marketing Authorization Holder	M/s Nabiqasim Industries Pvt Ltd. 17/24, Korangi Industrial Area, Karachi, Pakistan
	Name, address of Manufacturing site.	M/s Nabiqasim Industries Pvt Ltd. 17/24, Korangi Industrial Area, Karachi, Pakistan
	Status of the applicant	<ul><li>☑ Manufacturer</li><li>☐ Importer</li><li>☐ Is involved in none of the above (contract giver)</li></ul>
	GMP status of the firm	GMP certificate issued on basis of inspection conducted on 19-09-2020
	Evidence of approval of manufacturing facility	Firm has submitted copy of DML, declaring "Ear drop/Topical solution" section, whereas submitted GMP certificate mentions the "Cream/Ointment/Lotion section."
	Status of application	☐ New Drug Product (NDP) ☐ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	<ul> <li>□ Domestic sale</li> <li>□ Export sale</li> <li>⋈ Domestic and Export sales</li> </ul>

Dy. No. and date of submission	Dy. No.10088 dated 31-03-2021
Details of fee submitted	Rs.20,000/- dated 31-003-2021
The proposed proprietary name / brand name	Lidogel 2% Jelly
Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each ml Contains: Lidocaine HCl20mg
Pharmaceutical form of applied drug	Topical spray solution
Pharmacotherapeutic Group of (API)	Local Anaesthetic Jelly Sterile. For topical application only <i>ATC Code</i> : N01BB02
Reference to Finished product specifications	USP specification
Proposed Pack size	1gm x 1's
Proposed unit price	MRP as per PRC
The status in reference regulatory authorities	Xylocaine 2% Gel (Lidocaine HCl 2%) is registered and being marketed by OAK Pharms, USA (FDA approved).
For generic drugs (me-too status)	M/s Barrett Hodgson Pakistan (Pvt) Ltd., b. Brand Name: Xylocaine 2% c. Strength: 2% Jelly Reg. No.: 009315
Name and address of API manufacturer.	M/s <b>Gufic Group Testing Laboratories.</b> N.H.No.8, Near Grid AT & PO Kabilpore-39G 42 Navsari, Gujrat, India.
Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-template. Firm has summarized information relato nomenclature, structure, general propert solubilities, physical form, manufacturers, descript of manufacturing process and controls, impurit specifications, analytical procedures and validation, batch analysis and justification specification, reference standard, container closs system and stability studies of drug substance adrug product.
Module-III Drug Substance:	Firm has submitted detailed data for drug substandata related to nomenclature, structure, generoperties, solubilities, physical form, manufacture description of manufacturing process and control impurities, specifications, analytical procedures a its validation, batch analysis and justification specification, reference standard, container closs system and stability studies of drug substance.
Stability Studies of Drug Substance (Conditions duration of Stability studies)	Firm has submitted stability study data of 3 batches drug substance at both accelerated as well as real ti conditions. The accelerated stability data is conduct at $40^{\circ}\text{C} \pm 2^{\circ}\text{C} / 75\% \pm 5\%$ RH for 6 months. The time stability data is conducted at $25^{\circ}\text{C} \pm 2^{\circ}\text{C} / 665\%$ RH for 6 months.
Module-III Drug Product:	Firm has submitted data of drug product including description, composition, pharmaceutidevelopment, manufacture, manufacturing procand process control, process validation protococontrol of excipients, control of drug produspecifications, analytical procedures, validation

			s	analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.			
	Pharmaceutical Equiva Dissolution Profile	lence and Compar	ative F	·			
	Analytical method validation/verification		n of F	Firm 1		l verification	n studies of the drug
	Stability studies		t	batche	s at both acce		studies data of three long-term conditions.
		STABILI	TY ST	UDY	DATA		
	acturer of APIs	Economic Devel					piangjin Street, Jibei
API Lo	ot No.	190305TA					
	ption of Pack iner closure system)	15gm Aluminium	n tube v	with a	n applicator c	cone in a uni	t carton.
	ty Storage Condition	Real time: 30°C Accelerated: 40°					
Time I	Period	Real time: 6 mor	nths				
		Accelerated: 6 m		41 \			
Freque	Frequency Accelerated: 0, 3 Real Time: 0, 3,						
Batch	No.	L001DS		10115)	L001DS02	2	L001DS03
Batch		01 ltr.			01 ltr.		01 ltr.
Manuf	Cacturing Date	12-201				12-2019	
C #			PROVIDED BY THE APPLICANT Status				
Sr.# 1.	<b>Documents To Be Pro</b> Reference of previo		Status	S			
1.	applications with stabil the firm (if any)						
2.	Approval of API/ DMI of API manufactur concerned regulatory country of origin.	rer issued by authority of	Copy of GMP certificate (Certificate# 19081523) issued by Food & Drug Administration Gujarat, valid upto 06-08-2022.				
3.	Documents for the prowith approval from D import).		Copy of commercial invoice issued in the name of M/Surge Laboratories (Pvt.) Ltd. attested by AD I&E DRAP Lahore has been submitted for import of Lidocaine HCl			d by AD I&E DRAP,	
			Invo	oice N	0.	Quantity Imported	Date of approval by DRAP
			NBE	EXBD	2021000188	600Kg	10-11-2020
4.	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.			Firm has submitted data of stability batches along with batch manufacturing record and analytical record.			
5.	Compliance Record of 21CFR & audit trail retesting.		Firm	has s	ubmitted audi	it trail report	s on product testing.
6.	Record of Digital of temperature & humidi		tempe	erature		monitoring	gital data logger for of stability chambers

	Evaluator(II): Observation	Firm's vegonous
Section 2.3		Firm's response Submitted.
	Table for literature references for the drug substance & drug product has not been submitted.	Submitted.
2.3. S.1.2	Submitted molar mass is not correct.	Corrected molar mass has now been submitted.
2.3. S.3.2	List of impurities is as per the USP monograph for Lidocaine HCl, whereas API manufacturer has declared the API of BP grade.	List of impurities as per BP monograph has now been submitted.
2.3. S.4.2	This section declares that "Lidocaine hydrochloride is tested as per the test procedures described in the US Pharmacopoeia", whereas section 2.3.S.4.1 declares the API of BP standard.	Firm has submitted that the drug substance manufacturer has declared the drug substance of standard quality as per both USP & BP monograph.
3.2.S.4.3	Analytical Method Verification studies including specificity, accuracy and repeatability (method precision) performed by the Drug Product manufacturer shall be submitted.	Submitted for the titration method as per BP monograph
3.2.S.4.4	Submit analytical record for the batch analysis of drug substance performed by the M/s Nabiqasim.	Firm has submitted analytical record for the analysis of drug substance according to which analysis has been performed as per BP monograph by way of potentiometric titration.
3.2.P.1	Clarification shall be submitted regarding label claim whether it is in term of "%age w/w" or "%age w/v".	Frim has submitted that the label claim is as per innovator i.e., %age w/v"
3.2.P.2.1.2	Quantities of preservatives used in formulation shall be justified for per unit dose with reference to the relevant guidelines/standards.	Firm has referred to the literature from Hand book of pharmaceutical excipients and reference limits from FDA IID database.
3.2.P.5.1	Test for content of antimicrobial preservative & efficacy of preservative, as recommended by ICH Q1 (R2) guidelines & USP chapter <51>, has not been included in the finished product specifications. You are advised to submit justification in this regard.	Firm has submitted that preservative efficacy test, preservative content test, initial testing and 01-month stability testing and has submitted reports now. Firm has also submitted revised specifications and finished drug product analytical procedure including the test for Methyl paraben & Propyl paraben.
3.2.P.8	<ul> <li>Submitted commercial invoice attested by AD DRAP I&amp;E Karachi has been isuued in the name of M/s Surge Laborartories (Pvt.) Ltd. Justification shall be submitted in this regard.</li> <li>Test for content of antimicrobial preservative &amp; efficacy of preservative, as recommended by ICH Q1 (R2) guidelines, has not been performed during stability studies. You are advised to submit justification in this regard.</li> <li>A white paper titled "Support for Title 21 CFR Part 11" has been submitted from "Agilent open Lab" under the heading of "Compliance record of HPLC software 21 CFR &amp; audit trail report on product testing", whereas submitted</li> </ul>	<ul> <li>With reference to the subjected query, we would like to inform you that "M/s Surge Laboratories (Pvt.) Ltd" is the sister company of "M/s Nabiqasim Industries (Pvt.) Ltd."</li> <li>Commercial invoice of Lidocaine HCl attested by AD DRAP issued in the name of M/s Surge Laboratories (Pvt.) Ltd because material is imported by Surge Laboratories (Pvt.) Limited.</li> <li>Lidocaine HCl supplier to "Nabiqasim Industries (Pvt.) Ltd." is its sister company "Surge Laboratories (Pvt.) Ltd."</li> <li>Moreover, testing of API and stability batches conducted by M/s Nabiqasim Industries (Pvt.) Ltd. and reports are</li> </ul>

enclosed for ready reference. chromatograms establish that the analysis has been performed Firm has submitted that preservative on Schimadzu HPLC. efficacy test, preservative content test, initial testing and 01-month stability testing and has submitted reports now. Firm has also submitted revised specifications and finished drug product analytical procedure including the test for Methyl paraben & Propyl paraben. Firm has now submitted Audit trail

- You are advised to submit scientific rationale for claiming USP specifications for finished drug product while the Drug substance used is of BP specifications.
- Clarification shall be submitted that in which section applied product will be manufactured along with the evidence of approval of required manufacturing facility/section for applied product, from the Licensing Division of DRAP.
- reports.

   We would like to inform that as per dosage form definition in USP chapter (1151). Jelly can also be covered in the definition of Gels and can be manufactured in Semi solid (Gel) manufacturing area.
- Nabiqasim has dedicated semi solid manufacturing area for cream, ointment and gel manufacturing. Nabiqasim has also registered gel dosage form i.e. Chlorhexidine Gluconate Gel for which product specific inspection has been conducted on 27.10.2020. Report of this inspection is attached for your ready reference.
- The Panel has report as follows against the query of required manufacturing facility for manufacturing and filling of gels:

"Firm has well equipped area for manufacturing of ointment, creams and gels. Along with creams and ointments one gel preparation (Acnicot Gel, Reg. No. 080660) is already manufactured in this area. Firm has already applied to the licensing division for the inclusion of gel in their layout vide letter No. NQIL/DRAP/06-20/027, dated 10-06-2020."

**Decision of 316<sup>th</sup> meeting:** Registration Board deferred the case for further deliberation regarding use of drug substance by M/s Nabiqasim Industries (Pvt.) Ltd., for the manufacturing of stability batches, which had been procured and imported by M/s Surge Laboratories (Pvt.) Ltd.

**Firm's response:** We in this regard, would like to clarify that since M/s. Surge Laboratories (Pvt) Ltd., Sheikhupura is our associated company which is under the control of common management. As M/s. Surge Laboratories is importing API "Lidocaine HCl USP" for the manufacturing of their registered drug "Lidoject 2% Injection" Reg # 057348. In order to save time, we had taken a loan of 15Kgs "Lidocaine HCl USP" from M/s. Surge Laboratories to conduct stability for our applied drug "Lidogel Gel 2%". Firm has submitted following documents.

• Mutual agreement between M/s Nabigasim and M/s. Surge Laboratories.

### Undertaking.

34.	Name, address of Applicant / Marketing Authorization Holder	M/s Pacific Pharmaceuticals Ltd. Plot No. 384, Sunder Industrial Estate, Lahore			
	Name, address of Manufacturing site.	M/s Pacific Pharmaceuticals Ltd. Plot No. 384, Sunder Industrial Estate, Lahore			
	Status of the applicant	<ul><li>☑ Manufacturer</li><li>☐ Importer</li><li>☐ Is involved in none of the above (contract giver)</li></ul>			
	GMP status of the firm	GMP certificate issued on 17-07-2020			
	Evidence of approval of manufacturing facility	Firm has submitted copy of section approval letter dated 24-06-2019 which specifies Ophthalmic general section.			
	Status of application	<ul><li>□ New Drug Product (NDP)</li><li>☑ Generic Drug Product (GDP)</li></ul>			
	Intended use of pharmaceutical product	<ul> <li>□ Domestic sale</li> <li>□ Export sale</li> <li>☑ Domestic and Export sales</li> </ul>			
	Dy. No. and date of submission	Dy. No 398 dated 05-01-2022 Rs.30,000/- dated 06-12-2021			
	Details of fee submitted				
	The proposed proprietary name / brand name	Dorzil Eye drop			
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each ml contains 22.26 mg of Dorzolamide hydrochloride equivalent to 20 mg Dorzolamide.			
	Pharmaceutical form of applied drug	Eye Drops, Solution			
	Pharmacotherapeutic Group of (API)	Dorzolamide: Carbonic anhydrase inhibitors ATC Code: S01EC03			
	Reference to Finished product specifications				
	Proposed Pack size	1 x 5 ml			
	Proposed unit price				
	The status in reference regulatory authorities	USFDA Trusopt 20 mg/ml Eye drops, solution Santen pharmaceuticals Co., Ltd Japan			
	For generic drugs (me-too status)	Trusopt Ophthalmic Drops 2% 5ml by OBS Pharma (Pvt) Karachi Ltd, Pakistan Regd. No. 021100 Pack size: 5 ml			
	Name and address of API manufacturer.	Dorzolamide Dorzolamide from Neuland Laboratories Limited, Unit- 1 Sy. No: 347, 473, 474, 490 / 2 Veerabhadraswamy temple road, Bonthapalli Village, Gummadidala Mandal, Sangareddy District - 502 313 Telangana, India			
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Firm has summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product.			

Module-III Drug Substance:		o:	related solubil manuf specifi batch a standa	as submitted detailed data and to nomenclature, structure lities, physical form, manufacturing process and cations, analytical procedurallysis and justification of ard, container closure system substance.	re, general properties, facturers, description of controls, impurities, ares and its validation, specification, reference	
	Stability Studies of Conditions duration of Sta		Long-temper	lamide term stability studies were rature of 30°C±2°C/65%±5 terated stability studies verature of 40±2°C/75%±5%	% RH for 60 months. vere performed at a	
	Module-III Drug Product:		Firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.			
	Pharmaceutical Equi Comparative Dissolution P		Pharmaceutical Equivalence Studies against the reference product of "Trusopt sterile ophthalmic Solution" by Santen pharmaceuticals Co., Ltd. Imported by OBS pharma			
	Analytical method validati product	on/verification of	Firm has submitted verification studies of the drug substance and the drug product.			
	Stability studies		Firm has submitted stability studies data of three batches at both accelerated and long term conditions.			
		STABILITY	Y STUI	DY DATA		
Man	ufacturer of APIs	473, 474, 490 /	2 Veer	uland Laboratories Limited abhadraswamy temple road Sangareddy District - 502 3	d, Bonthapalli Village,	
API	Lot No.	DZ10420013 (D	Oorzolamide)			
	ription of Pack tainer closure system)	cap over a LDPl the bottle cap.	lyethylene bottle with insert-cap assembly, HDPE screw- E nozzle with tamper–evident LDPE dustcover sealing			
Stabi	lity Storage Condition		2 ± 2°C / 35% HR ±5% °C ± 2°C / NMT 25% HR			
Time	Time Period Real time: 3 mo. Accelerated: 3 m					
Frequ	Frequency Accelerated: 0, 3 Real Time: 0, 3					
	Batch No. PDDN00120			PDDN0022021	PDDN0032021	
Batcl	Batch Size 5 liter			5 liter	5 liter	
	Manufacturing Date 07/2021			07/2021	07/2021	
	CUMENTS / DATA PROV		PPLIC	ANT		
#	Documents To Be Provided	Status				

1.	Reference of previous approval of applications with stability study data of the firm (if any)	N/A					
2.	Approval of API/DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Copy of G Unit-1 Sy. Bonthapall 313 Telan	orzolamide opy of GMP certificate in the name of Neuland Laboratories Limited, nit-1 Sy. No: 347, 473, 474, 490 / 2 Veerabhadraswamy temple road, onthapalli Village, Gummadidala Mandal, Sangareddy District - 502 13 Telangana, India, valid upto 28-06-2022 issued by Drug Control dministration, Government of Telangana, India.				
3.	Documents for the procurement of API with	Copy of commercial invoice attested by AD I&E DRAP, Lahore, has been submitted.					
	approval from DRAP (in case of import).		Batch No.	Quantity Imported	Date of approval by DRAP		
		DZ10420	013 (Dorzolamide)	1 kg	08-06-2021		
			ercial invoice is in the na KM, Multan Road, Lahon		Pharmaceuticals		
4.	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Firm has submitted data of stability batches along with batch manufacturing record and analytical record.					
5.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing.	Firm has submitted audit trail reports on product testing.			g.		
6.	Record of Digital data logger for temperature & humidity monitoring of stability chambers (real time and accelerated)		submitted Record of D nonitoring of stability ch				
	arks of Evaluator (II):		T				
Secti			Firm's response				
1.5.6	been referred to as specifications Pharmacopoeial monavailable for applied	rifications have as Innovator's whereas nonographs are			opoe1a		
	1		orzolamide HCl				
3.2. \$	<ul> <li>Drug         manufacturer ha         drug substance as         grade for related         whereas the subm         test is declared a         pharmacopoeia.</li> <li>The analytical a         Assay submitted         product manufal         different form the</li> </ul>	s of Ph. Eur substances hitted Assay as per USP method for I by drug acturer is	assay determinatio for Assay determi equipment than the manufacturer.	ere is potentiometric on while in USP the nation, which is be technique adopted ical procedure sub- arer.	ere is use of HPLC etter technique and by drug substance		
	by the drug manufacturer.	substance					

3.2.P.5.1	<ul> <li>Copies of the Drug substance specifications and analytical procedures used for routine testing of the Drug substance /Active Pharmaceutical Ingredient by Drug Product manufacturer is required.</li> <li>Submitted drug product specifications does not include test of "Preservative Effectiveness testing".</li> <li>COA of primary / secondary</li> </ul>	Microbial report for Preservative testing has been submitted now.
	reference standard including source and lot number shall be provided.	Submitted
3.2. P.8	<ul> <li>Following shall be submitted:</li> <li>Stability studies till 3<sup>rd</sup> month time point has been submitted only.</li> <li>Analytical record i.e., HPLC chromatograms, raw data sheets &amp; COAs shall be submitted for complete stability studies till 6<sup>th</sup> month time point.</li> </ul>	Firm has submitted 6 months stability data along woith analytical record.
2.3.R.1.1	<ul> <li>As per submitted BMRs terminal sterilization has not been performed. Justification shall be submitted in this regard.</li> <li>The proposed batch size shall be justified against the minimum handling capacity of the formulation tank.</li> </ul>	• No terminal sterilization has been performed, for which firm has submitted that aseptic area manufacturing tank under LAF and aseptic blowing, filling/sealing multiple function cartage assembling 0.65µm+0.45µm+0.22µm in manufacturing for filtration of solution and 0.22 in filling BFS machine which already mention in BMR so our product is sterile by filtration and aseptic process.

**Decision of 316<sup>th</sup> meeting:** Registration Board deferred the case for further deliberation regarding use of drug substance by M/s Pacific Pharmaceuticals Ltd. Plot No. 384, Sunder Industrial Estate, Lahore, for the manufacturing of stability batches, which had been procured and imported by M/s Pacific Pharmaceuticals Ltd., 30<sup>th</sup> KM, Multan Road, Lahore.

## Firm's response:

We Pacific pharmaceuticals Ltd. Ravi Lane Plot No. 384, Sundar Industrial Estate, Raiwind Lahore (DML 000902) have borrowed drug substance material used in the following products (Dorzil Eye drops, Glucozole-T Eye Drops, Pacilact-D IV Infusion 500ml, Pacilact-D IV Infusion 1000ml) for stability and validation purpose only from Pacific Pharmaceuticals Ltd. 30th Km Multan Road, Lahore (DML 000295).

The justification for the borrowing was based on the fact that commercial department dealing with procurement was common for both plants operating from the address 30th Km Multan Road, Lahore.

However, we have already started using dedicated procurement for IV plant. We assure that all of our future procurement will be made by Pacific pharmaceuticals Ltd. Ravi Lane Plot No. 384, Sundar Industrial Estate, Raiwind Lahore (DML 000902) separately and dedicatedly.

3	5.	, 11	M/s Pacific Pharmaceuticals Ltd. Plot No. 384, Sunder Industrial Estate, Lahore
			M/s Pacific Pharmaceuticals Ltd. Plot No. 384, Sunder Industrial Estate, Lahore

Status of the applicant	<ul> <li>✓ Manufacturer</li> <li>☐ Importer</li> <li>☐ Is involved in none of the above (contract giver)</li> </ul>
GMP status of the firm	GMP certificate issued on 17-07-2020
Evidence of approval of manufacturing facility	Firm has submitted copy of section approval letter dated 24-06-2019 which specifies Ophthalmic (General) Section
Status of application	☐ New Drug Product (NDP) ☐ Generic Drug Product (GDP)
Intended use of pharmaceutical product	<ul> <li>□ Domestic sale</li> <li>□ Export sale</li> <li>⋈ Domestic and Export sales</li> </ul>
Dy. No. and date of submission	Dy.No 24883 dated 08-09-2021
Details of fee submitted	Rs.30,000/- dated 12-08-2021
The proposed proprietary name / brand name	Glucozole-T 5ml Eye Drops
Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each ml Contains: Dorzolamide as Dorzolamide HCl 20mg Timolol as Timolol Maleate 5mg
Pharmaceutical form of applied drug	Eye drops, solution
Pharmacotherapeutic Group of (API)	Dorzolamide Carbonic anhydrase inhibitors ATC Code: S01EC03 Timolol: nonselective beta-adrenergic receptor blocker ATC Code: S01ED01
Reference to Finished product specifications	Innovator's Specs
Proposed Pack size	5ml
Proposed unit price	As per SRO
The status in reference regulatory authorities	Approved by US FDA
For generic drugs (me-too status)	Cosopt sterile ophthalmic Solution Solution by: Santen pharmaceuticals Co., Ltd. Japan Regd. No. 025294 Pack size: 5 ml
Name and address of API manufacturer.	Dorzolamide HCl: M/sNeuland Laboratories Limited, Unit-1 Sy. No: 347, 473, 474, 490 / 2 Veerabhadraswamy temple road, Bonthapalli Village, Gummadidala Mandal, Sangareddy District – 502 313 Telangana, India Timolol maleate: FDC Limited, 142-48, Swami Vivekananda Road Jogeshwari (West) Mumbai-400 102.
Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Firm has summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product.

Module-III Drug Substance:  Stability Studies of Dr (Conditions duration of Stabil		nce:	Firm has submitted detailed data for related to nomenclature, structure solubilities, physical form, manufacturing process and con analytical procedures and its valid and justification of specification, container closure system and stabsubstance.	e, general properties, cturers, description of trols, specifications, lation, batch analysis, reference standard,	
		C	<b>Dorzolamide HCl:</b> Long-term stream performed at a storage 30°C±2°C/65%±5% RH for 36s stability studies were performed 40±2°C/75%±5% RH for 6 months <b>Timolol maleate:</b> Long-term stream performed at a storage 30°C±2°C/65%±5% RH for 36s stability studies were performed 40±2°C/75%±5% RH for 6 months	temperature of months. Accelerated at a temperature of ability studies were temperature of months. Accelerated at a temperature of	
	Module-III Drug Product:		Firm has submitted data of drug product including i description, composition, pharmaceutical development manufacture, manufacturing process and process control process validation protocols, control of excipient control of drug product, specifications, analytic procedures, validation of analytical procedures, bate analysis, justification of specifications, reference standard or materials, container closure system and stability.		
	Pharmaceutical Equivale Dissolution Profile	nce and Comparative	Pharmaceutical Equivalence Studies against the reference product of "Cosopt" of M/s Santen Pharmaceuticals.		
	Analytical method valid product	lation/verification of	Firm has submitted verification studies of the drug substance and the drug product.		
	Stability studies		Firm has submitted stability studies data of three batches at both accelerated and long-term conditions.		
			Y STUDY DATA		
Man	ufacturer of APIs	473, 474, 490 / 2 Gummadidala Mand	M/s Neuland Laboratories Limited, Unit-1 Sy. No: 347, Veerabhadraswamy temple road, Bonthapalli Village, lal, Sangareddy District – 502 313 Telangana, India FDC Limited, 142-48, Swami Vivekananda Road		
API	Lot No.	Dorzolamide HCl: I	DZI0420013		
	cription of Pack ntainer closure system)	Low Density Polyeth			
		- 2°C / NMT 25% RH			
Time	e Period	Real time: 6 months Accelerated: 6 mont	hs		
_	uency	Accelerated: 0, 3, 6 (Neal Time: 0, 3, 6 (Nea	Months)	MD 0200 C	
	h No.	TD0109O	TD0209O	TD0309O	
	h Size	10 liters	10 liters	10 liters	
Man	ufacturing Date	09/2019	11/2019	11/2019	
			OVIDED BY THE APPLICANT		
#	<b>Documents To Be Prov</b>	rided	Status		

	<u> </u>				
1.	Reference of previous approval of applications with stability study data of the	N/A			
	firm (if any)				
2.	Approval of API/ DML/GMP certificate of	Dorzolamide HCl:			
	API manufacturer issued by concerned	Copy of GMP certifi	icate in the nam	ne of M/s Neuland	
	regulatory authority of country of origin.	Laboratories Limited	valid upto 28-	06-2022 issued by	
		DCA Tealngana.			
		Timolol maleate:			
		Copy of GMP cer			
		GMP/CERT/KD/724		· ·	
		M/s FDC Limited val	id upto 08-08-20	021 issued by FDA	
		Maharashtra.			
3.	Documents for the procurement of API with				
	approval from DRAP (in case of import).	DRAP, Lahore, has b	een submitted.		
			Quantity	Date of	
		Batch No.	Imported	approval	
		011000021	•	by DRAP	
		011909031	5875	03-10-2019	
		T' 1 1 ' 1	1 . T	1.1 11 3.0	
		Firm has submitted to			
		Pacific Pharmaceutic	cais Lia. 30th i	Kin Mullan Road,	
		Lanore			
4.	Data of stability batches will be supported by	Firm has submitted d	lata of stability	batches along with	
	attested respective documents like	batch manufacturing	•	<u> </u>	
	chromatograms, Raw data sheets, COA,		•	,	
	summary data sheets etc.				
5.	Compliance Record of HPLC software				
	21CFR & audit trail reports on product	N/A			
	testing.				
6.	Record of Digital data logger for temperature	Firm has submitted	Record of Digit	tal data logger for	
	& humidity monitoring of stability chambers	temperature & hu	midity monito	ring of stability	
	(real time and accelerated)	chambers (real time a	and accelerated)		

## **Remarks of Evaluator (II):**

In response to the following shortcomings communicated to firm vide letter no. F.1-1/2020/PEC-DRAP (AD PEC-II), firm has submitted that due to some errors in our previous data we have submitted the updated stability batches data along with 6 months stability report. Kindly consider this updated data and withdraw or neglect our previous data at the date of submission of dossier.

Details of revised stability data are as under:

Details of Tevised stability data are as under.						
	STABILITY STUDY	DATA				
	<b>Dorzolamide HCl:</b> M/s Neuland Laboratories Limited, Unit-1 Sy.					
	No: 347, 473, 474	4, 490 / 2 Veerabhad	lraswamy temple road,			
Manufacturer of APIs	Bonthapalli Village	, Gummadidala Manda	l, Sangareddy District –			
	502 313 Telangana,	, India				
	Timolol maleate:	FDC Limited, 142-48	3, Swami Vivekananda			
	Road Jogeshwari (West) Mumbai-400 102.					
API Lot No.	Dorzolamide HCl: l	Dorzolamide HCl: DZI0420013				
AFI Lot No.	Timolol maleate: 02	Timolol maleate: 021D026				
Description of Pack	Low Density Polyet	thylene Bottle				
(Container closure system)						
Stability Storage Condition	Real time: $30^{\circ}\text{C} \pm 2$	Real time: $30^{\circ}\text{C} \pm 2^{\circ}\text{C} / 35\% \pm 5\% \text{RH}$				
Stability Storage Collution	Accelerated: $40^{\circ}\text{C} \pm 2^{\circ}\text{C} / \text{NMT } 25\% \text{ RH}$					
Time Period	Real time: 6 months	Real time: 6 months				
Time Period	Accelerated: 6 months					
Eraguanay	Accelerated: 0, 3, 6	Accelerated: 0, 3, 6 (Months)				
Frequency	Real Time: 0, 3, 6 (Months)					
Batch No.	PDEN0012021	PDEN0022021	PDEN0032021			

Bato	ch Size		5 liters	5 li	ters	5 liters	
Man	nufacturii	C	12-07-2021				
	ı	DOCUMENTS / D		ED BY THE A	PPLICANT	• •	
#		ents to be provided	Status				
1.		nce of previous approval of tions with stability study	N/A				
		the firm (if any)					
2.	Approv	val of API/ DML/GMP	Dorzolamide I				
		ate of API manufacturer				Neuland Laboratories	
		by concerned regulatory ty of country of origin.	Limited valid u Timolol malea		2 issued by D	CA Telangana.	
		of or country or origin.	Copy of		ficate (Ce	ertificate#NEW-WHO-	
					,	the name of M/s FDC	
3.	Docum	ents for the procurement of		_	•	DA Maharashtra.  DI&E DRAP, Lahore,	
٥.		th approval from DRAP (in	has been submi		itested by TH	o lead bleat , Lanoic,	
	case of	import).	API	Batch No.	Quantity Imported	Date of approval by DRAP	
			Dorzolamide	DZT0420 013	1Kg	08-06-2021	
			Timolol	1386/186	0.025gm	08-06-2021	
			Ltd. 30 <sup>th</sup> Km M	Iultan Road, La	hore.	Pacific Pharmaceuticals	
4.		f stability batches will be	Firm has submitted data of stability batches along with batch manufacturing record and analytical record.				
		ted by attested respective ents like chromatograms,	manuracturing	record and anai	yticai record	•	
	Raw da	ata sheets, COA, summary					
5.		eets etc.					
3.		e 21CFR & audit trail	N/A				
		on product testing.					
6.		of Digital data logger for ature & humidity	Firm has submitted Record of Digital data logger for temperature				
		ring of stability chambers		nonitoring of s	stability cha	mbers (real time and	
		me and accelerated)	accelerated)				
C.	otion#	Observations	T	Fium?a uaa	250		
1.5	ction#	Drug product specification	ne have been	Firm's respon		Product is according	
1.3		referred to as Innovator's		• • • •	•	poeial monographs.	
		whereas Pharmacopoeial n		_	_		
		available for applied produc	ct. <b>Dorzolamid</b> e	- HCl			
3 2	2. S.4.1	Drug substance many	ufacturer has		ur there is no	otentiometric titration	
		declared drug substance			_	on while in USP there	
	grade, whereas the sub					determination, which	
	method is as per USP pha		-		_	equipment than the	
	• Copies of the Dru		•	technique manufacture	adopted b	y drug substance	
	specifications and analytic used for routine testing		•			edure submitted from	
		_	Pharmaceutical	_	t manufactur		
		Ingredient by Dr	ug Product				
	0.4.2	manufacturer is required.	anting of 1	Carlana in 1			
3.2	2.S.4.3	Analytical Method Verification including specificity, a	accuracy and	Submitted.			

	repeatability (method precision) performed by the Drug Product	
	manufacturer shall be submitted.	
3.2.S.4.4	Provide results of analysis of relevant	Submitted.
3.2.3.4.4	batch(es) of Drug Substance performed by	Submitted.
	Drug Product manufacturer used during	
	product development and stability studies,	
	along with Certificate of Analysis (CoA)	
	of the same batch from Drug Substance /	
	Active Pharmaceutical Ingredient	
	manufacture.	
3.2. S.7	Drug substance stability data as per Zone	Submitted as per Zone-IVa.
	IV a condition shall be submitted.	
	Timolol ma	aleate
3.2. S.4.1	Copies of the Drug substance	Submitted
	specifications and analytical procedures	
	used for routine testing of the Drug	
	substance /Active Pharmaceutical	
	Ingredient by Drug Product manufacturer	
	is required.	
3.2. S.4.3	Analytical Method Verification studies	Submitted
3.2. 3.4.3	including specificity, accuracy and	Submitted
	repeatability (method precision)	
	performed by the Drug Product	
2.2 G 4.4	manufacturer shall be submitted.	0.1.1.1
3.2. S.4.4	Provide results of analysis of relevant	Submitted.
	batch(es) of Drug Substance performed by	
	Drug Product manufacturer used during	
	product development and stability studies,	
	along with Certificate of Analysis (CoA)	
	of the same batch from Drug Substance /	
	Active Pharmaceutical Ingredient	
	manufacture.	
3.2. S.7	Submitted stability reports are not	Submitted
	readable.	
3.2. P.3.5	Process validation protocol shall be	Submitted
	submitted.	
3.2. P.5.3	Analytical method verification studies	Analytical method verification studies have been
	performed by drug product manufacturer	submitted for Dorzolamide only.
	shall be submitted.	
3.2. P.6	COA of primary / secondary reference	Submitted
	standard including source and lot number	
	shall be provided.	
3.2. P.8	Following shall be submitted:	
	Complete batch manufacturing record	BMR for three trial batches have been
	of stability trial batches.	submitted
	-	
	• Documents for the procurement of API	• No terminal sterilization has been performed,
	with approval from DRAP (in case of	for which firm has submitted that aseptic area
	import).	manufacturing tank under LAF and aseptic
	• Record of Digital data logger for	blowing, filling/sealing multiple function
	temperature & humidity monitoring of	cartage assembling 0.65µm+0.45µm+0.22µm
	stability chambers	in manufacturing for filtration of solution and
	Submitted analytical record reflect that	0.22 in filling BFS machine which already
	7	mention in BMR so our product is sterile by
	chromatographic conditions for the	
	Assay analysis of Dorzolamide have not	filtration and aseptic process.
	been performed as per	

recommendations of USP monograph, • Firm has applied "Solution preparation tank" since the gradient run time as per of 100 litres for the manufacturing of 5 litre monograph is of 30 minutes while the batch size stating that design capacity of active firm has run HPLC chromatogram, for manufacturing tank ranges from 5 litres to 100 about 12 minutes only. litres so, 5 litres batch can be easily processed. • Submitted HPLC chromatograms reflect that the chromatographic conditions for the Assay test have not been complied as per USP monograph in terms of the run time for which firm has replied that although the injection run time is 30minute but the peaks separation of Dorzolamide is about 12 minutes. In the chromatograms sample run time is about 20minute but there is no any further peak found. So, it Is not big issue, in future will follow up to 30minutes.

Firm has submitted fee of Rs. 30,000/- for revision of stability data as per following details:

Rs. 7,500/- vide deposit slip#5349893974 dated 01-03-2022

Rs. 22500/- vide deposit slip#92601467 dated 09-03-2022

**Decision of 316<sup>th</sup> meeting:** Registration Board deferred the case for further deliberation regarding use of drug substance by M/s Pacific Pharmaceuticals Ltd. Plot No. 384, Sunder Industrial Estate, Lahore, for the manufacturing of stability batches, which had been procured and imported by M/s Pacific Pharmaceuticals Ltd., 30<sup>th</sup> KM, Multan Road, Lahore.

# Firm's response:

We Pacific pharmaceuticals Ltd. Ravi Lane Plot No. 384, Sundar Industrial Estate, Raiwind Lahore (DML 000902) have borrowed drug substance material used in the following products (Dorzil Eye drops, Glucozole-T Eye Drops, Pacilact-D IV Infusion 500ml, Pacilact-D IV Infusion 1000ml) for stability and validation purpose only from Pacific Pharmaceuticals Ltd. 30th Km Multan Road, Lahore (DML 000295).

The justification for the borrowing was based on the fact that commercial department dealing with procurement was common for both plants operating from the address 30th Km Multan Road, Lahore.

However, we have already started using dedicated procurement for IV plant. We assure that all of our future procurement will be made by Pacific pharmaceuticals Ltd. Ravi Lane Plot No. 384, Sundar Industrial Estate, Raiwind Lahore (DML 000902) separately and dedicatedly.

36.	Name, address of Applicant / Marketing Authorization Holder	M/s Pacific Pharmaceuticals Ltd. Ravi lane, Plot No., 384, Sundar industrial Estate, Raiwind Road, Lahore
	Name, address of Manufacturing site.	M/s Pacific Pharmaceuticals Ltd. Ravi lane, Plot No., 384, Sunder Industrial Estate, Raiwind Road, Lahore
	Status of the applicant	<ul><li>☑ Manufacturer</li><li>☐ Importer</li><li>☐ Is involved in none of the above (contract giver)</li></ul>
	Status of application	☐ New Drug Product (NDP) ☐ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	<ul><li>☑ Domestic sale</li><li>☐ Export sale</li><li>☐ Domestic and Export sales</li></ul>
	Dy. No. and date of submission	Dy. No 29420 dated 28-10-2021
	Details of fee submitted	Rs.20,000/- dated 25-02-2021

The proposed proprietary	name / brand name	Pacilact-D IV Infusion 500ml
Strength / concentration Pharmaceutical ingredien	of drug of Active	
Pharmaceutical form of a	applied drug	Intravenous Infusion
Pharmacotherapeutic Gre	oup of (API)	Electrolyte
Reference to Finished pr	oduct specifications	USP
Proposed Pack size		500ml
Proposed unit price		As per SRO
The status in reference re	gulatory authorities	Approved by US FDA
For generic drugs (me-to	o status)	Lactated Ringer's and 5% Dextrose Injection of M/s Medipak Limited (Reg.no: 008242)
GMP status of the manufacturer	Finished product	New DML issued on 24-06-2019
Name and address of AP	I manufacturer.	Sodium Chloride: Dominion Salt Limited, 89 Totara Street, Mount Maunganui, New Zealand.  Calcium Chloride Dihydrate: Hebei Huachen Pharmaceuticals. Ltd.  Potassium Chloride: Hebei Huachen Pharmaceuticals Ltd., Economic Devleopment zone. Hebei, China Sodium Lactate: Corbion Purac Bioquimica SA, BarcelonaSpain Dextrose: M/s CSPC Shengxue Glucose Co., Ltd, No.48 Shengxue Road, Luancheng District, China-051430 Shijiazhuang City, Hebei Province.
Module-II (Quality Over	all Summary)	Firm has submitted QOS details as per WHO QOS PD template.
Module-III (Drug Prod	uct):	Firm has submitted relevant information against the Module III, including, Process validation protocol, Finished product analytical method verification report & stability studies data.
		al equivalence studies against the reference product of 5% JECTION of M/s B Braun.
	STABILIT	TY STUDY DATA
Ianufacturer of API	Maunganui, New Z Calcium Chloride Potassium Chlori Devleopment zone. Sodium Lactate: C Dextrose: M/s CS	<b>Dihydrate:</b> Hebei Huachen Pharmaceuticals. Ltd. ide: Hebei Huachen Pharmaceuticals Ltd., Economic
PI Lot No.	Sodium Chloride: Calcium Chloride Potassium Chlorid Sodium Lactate: 1 Dextrose: 2019060	<b>Dihydrate:</b> 20190826 <b>le:</b> 190815 904001735

Description of Pack (Container closure system)		Low Density Polyethylene film bags.			
Stability Storage Condition		Real time: $30^{\circ}\text{C} \pm 2^{\circ}\text{C} / 35\% \pm 5\%\text{RH}$ Accelerated: $40^{\circ}\text{C} \pm 2^{\circ}\text{C} / \text{NMT 25\% RH}$			
Time F	Period	Real time: 6 months Accelerated: 6 month	s		
Freque	ency	Accelerated: 0, 3, 6 (MReal Time: 0, 3, 6 (MReal Ti	*		
Batch	No.	RN01110	RN0211O	RN03110	
Batch	Size	4000 litres	4000 litres 4000 litr		
Manuf	acturing Date	15/10/2019	16/10/2019	17/10/2019	
No. of	Batches	•	03		
		Details of Doc	uments submitted		
1.			ns		
2.	with stability study data of the firm (if any)		Certificate# HE20190013) in the SHENGXUE Glucose Co., Ltd., Road, Luancheng District, Shijian province, China valid upto 02-HEBEI Dug Administration.  Sodium Chloride: Firm has submoderificate in the name of M/s Don totara street, Mount Maunganui, Nupto 29-03-2021 issued by Ministra Newzeland.  Calcium Chloride Dihydrate: Firm GMP certificate (Certificate# HE20 by Hebei food & Drug administrate 2023.  Potassium Chloride: Firm has certificate (Certificate# HE201800 food & Drug administration valid Sodium Lactate: Firm has submit certificate (Certificate# NCF-II/18 valid till April 2021.  Dextrose anhydrous: Firm has GMP certificate (Certificate# Hiname of M/s CSPC SHENGXUE No. 48 Shengxue Road, Lu Shijiazhuang City, Hebei provinc 02-02-2024 issued by HEBEI Dug	name of M/s CSPC No. 48 Shengxue zhuang City, Hebei 02-2024 issued by itted copy of GMP ninion Salt Ltd., 89, IewZeland valid ry of Health, rm has submitted 10180030) issued ition valid till 22-04- s submitted GMP 130) issued by Hebei till 22-04-2023. Ited Eudra GMP 1317/001/CAT) is submitted copy of E20190013) in the Glucose Co., Ltd., Itancheng District, Itanche	
3.	Documents for the papproval from DRAP	orocurement of API with the case of import).	calcium Chloride Dihydrate: It copy of invoice attested by AD DRAP I&E Landard 21-10-2019 specify dated 21-10-2019, M/s Pacific Ltd., Ravi lane, Plot No., 384, Estate, Raiwind Road, Laho quantity of 1MTS.	thore, M/s Pacific in, Multan Road, wing the quantity of Firm has submitted DRAP I&E Lahore in Pharmaceuticals Sundar industrial	

		Potassium Chloride: Firm has submitted copy of invoice attested by AD DRAP I&E Lahore dated 21-10-2019, M/s Pacific Pharmaceuticals Ltd., Ravilane, Plot No., 384, Sundar industrial Estate, Raiwind Road, Lahore specifying the quantity of 1MTS.  Dextrose anhydrous: Firm has submitted copy of commercial invoice (Invoice#. 20ST27003) attested by AD DRAP I&E Lahore, dated 03-10-2019, in the
		name of M/s Pacific Pharmaceuticals Ltd., 30 Km, Multan Road, Lahore specifying the quantity of 5000Kgs of Dextrose anhydrous (Batch# 201906001) from M/s CSPC SHENGXUE Glucose Co., Ltd., No. 48 Shengxue Road, Luancheng District, Shijiazhuang City, Hebei province, China.
4.	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Submitted
5.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	Not applicable
6.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Submitted
Rema	· ·	

Sr.	Section	Deficiencies	Firm's response		
110.	No. #. Calcium Chloride				
1.	3.2. S.2.1	Address of drug substance manufacturer mentioned in this section is different from that mentioned on the COA from drug substance manufacturer.	It was a typographic error, the said section has been revised.		
2.	3.2.S.4.4	• The drug substance COA from drug substance manufacturer declare it of BP grade, whereas COA from drug product manufacturer declare it as of USP grade.	• It was a typographic error, we have rectified the error. Our COA is also as BP grade.		
		Sodium Lactat	te		
3.	3.2.5.4	<ul> <li>The Assay limits in the COA of drug substance manufacturer is 59% -61%, whereas the Assay limits in the COA of drug product manufacturer is 95.0% - 110.0%.</li> <li>The Assay results in the COA of drug substance manufacturer is 60.1%, whereas the Assay limits in the COA of drug product manufacturer is 101.28%.</li> </ul>	According to USP monograph, Sodium Lactate Solution is an aqueous solution containing not less than 50.0 percent, by weight, of monosodium lactate. It contains not less than 98.0 percent and not more than 102.0 percent of labeled amount of C <sub>3</sub> H <sub>5</sub> NaO <sub>3</sub> .We have overlooked the COA of drug substance. This was typographical error from supplier we have intimated the supplier and will provide you correct COA later. However, Assay limits in the COA of drug		

		product manufacturer is 101.28% according
4. 1.5.2	& • The reference product contains	<ul><li>to specifications.</li><li>According to Martindale Anhydrous</li></ul>
3.2. 1	F	glucose 900 mg is equivalent to about 1 g of glucose monohydrate. 50g/litre of glucose monohydrate is (equivalent to about 45 g/litre of anhydrous glucose).
<b>5.</b> 3.2.	Evidence of availability of atomic	Firm has submitted calibration certificate
P.5.2	absorption spectrophotometer and flame photometry, as required by the USP monograph of applied product, shall be submitted	for atomic absorption spectrophotometer. List of equipment including Flame photometer has been submitted.
6. 3.2. P.3.3	You are advised to submit	<ul> <li>We have followed Sterilization process by super-heated water showering at 109°C for 85 minutes.</li> <li>121°C &amp; Time ≥ 15 min, this temperature is used for machine sterilization before running product</li> </ul>
ba pe 17 in Ca La Ju di th 4.: Ju di th in St Po stt qu	the date of manufacturing of three stability tiches i.e., RN0111O, RN0211O, RN0311O, as a submitted BMR is 15/10/2019,16/10/2019 & /10/2019 respectively, whereas commercial voice submitted for Potassium chloride & alcium chloride is attested by AD DRAP I&E thore dated 21-10-2019.  Is stify the quantities of Dextrose anhydrous spensed for batch manufacturing considering to proposed label claim OF Dextrose anhydrous agm/100ml.  Is stify the dispensed quantity of Sodium Lactate spensed for batch manufacturing considering to Assay percentage of drug substance declared the submitted COA from Pacific Pharma.  Idbmit analytical record for the analysis of obtassium, Sodium & Calcium for the stability adies.  Idbmit reconciliation record for the imported antity of 1 MTS each of Potassium chloride & adium chloride.	<ul> <li>We have purchased the material from Medipak Limited for sample. Attested invoice by AD DRAP I&amp;E Lahore dated 21-10-2019 was after manufacturing of RN01110, RN02110, RN03110 batches. This material was imported for commercial manufacturing of other products which is not used in these batches. The Correct invoice is attached.</li> <li>The quantity of dextrose anhydrous dispensed for batch manufacturing considering the proposed label claim of Dextrose anhydrous is 4.5g/100ml.         <ul> <li>(As per submitted BMR Dextrose anhydrous has been dispensed as per 5gm/100ml which is not as per reference product.)</li> </ul> </li> <li>We have used sodium lactate (as sodium lactate solution (60% w/v) as label claim.         <ul> <li>(Dispensed quantity is not as per the percentage purity of sodium lactate determined by the Pacific pharma)</li> <li>We have purchased the material from Medipak Limited for sample. Attested invoice by AD DRAP I&amp;E Lahore dated 21-10-2019 was after manufacturing of RN01110, RN02110, RN03110 batches. This material was imported for commercial manufacturing of other products which is not used in these batches.</li> </ul> </li> </ul>

**Decision of 307**<sup>th</sup> **meeting:** Registration Board deferred the case for submission of following:

- Revised label claim for Dextrose monohydrate as per the innovator's product, along with submission of relevant fee.
- Legal provision of utilizing Drug substances purchased from another DML holder i.e., M/s Medipak Limited.

**Firm's response:** Firm has submitted new stability studies data on 28-10-2021, along with correction in label claim of Dextrose monohydrate. Fee for the submission of new stability data has not been submitted. Details of new stability data are as under:

Name, address of Applicant / Marketing Authorization Holder	M/s Pacific Pharmaceuticals Ltd. Ravi lane, Plot No., 384, Sundar industrial Estate, Raiwind Road, Lahore
Name, address of Manufacturing site.	M/s Pacific Pharmaceuticals Ltd. Ravi lane, Plot No., 384 Sundar industrial Estate, Raiwind Road, Lahore
Status of the applicant	<ul><li>☑ Manufacturer</li><li>☐ Importer</li><li>☐ Is involved in none of the above (contract giver)</li></ul>
GMP status of the firm	GMP certificate issued on 17-07-2020
Evidence of approval of manufacturing facility	Firm has submitted copy of section approval letter dated 24-06-2019 which specifies Large volume parental section.
Status of application	<ul><li>□ New Drug Product (NDP)</li><li>⊠ Generic Drug Product (GDP)</li></ul>
Intended use of pharmaceutical product	<ul> <li>□ Domestic sale</li> <li>□ Export sale</li> <li>☑ Domestic and Export sales</li> </ul>
Dy. No. and date of submission	Dy. No. 29420 dated 28-10-2021
Details of fee submitted	Rs. 30,000/- vide deposit slip# 516358736
The proposed proprietary name / brand name	Pacilact-D IV Infusion 500ml
Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each 100ml Contains: Sodium Chloride0.60g Potassium Chloride0.03g Calcium Chloride Dihydrate0.02g Sodium Lactate 0.31gram Dextrose Monohydrate Eq. to Anhydrous Dextrose5g
Pharmaceutical form of applied drug	Intravenous Infusion
Pharmacotherapeutic Group of (API)	Electrolyte
Reference to Finished product specifications	USP
Proposed Pack size	500ml
Proposed unit price	As per SRO
The status in reference regulatory authorities	Approved by US FDA
For generic drugs (me-too status)	Lactated Ringer's and 5% Dextrose Injection of M/s Medipak Limited (Reg.no: 008242)
Name and address of API manufacturer.	Sodium Chloride: Dominion Salt Limited, 89 Totara Street, Mount Maunganui, New Zealand. Calcium Chloride Dihydrate: Hebei Huachen Pharmaceuticals. Ltd. Potassium Chloride: Hebei Huachen Pharmaceuticals Ltd., Economic Devleopment zone. Hebei, China Sodium Lactate: Corbion Purac Bioquimica SA, BarcelonaSpain Dextrose: M/s CSPC Shengxue Glucose Co., Ltd, No.48 Shengxue Road, Luancheng District, China-051430 Shijiazhuang City, Hebei Province.

		Firm has submitted QOS as per WHO QOS-PD template. Firm has summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product.	
Module-III Drug Substance:		Firm has submitted detailed data for drug substance data related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.	
Stability Studies of Dru (Conditions duration of Stability	•	Real time: 30°C ± 2°C / 35% ± 5%RH Accelerated: 40°C ± 2°C / NMT 25% RH	
Module-III Drug Product:		Firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.	
Pharmaceutical Equivalence and Comparative Dissolution Profile		Firm has submitted Pharmaceutical equivalence studies against the reference product of 5% DEXTROSE in LACTATED RINGER'S INJECTION of M/s B Braun.	
Analytical method validation/verification of product		Firm has submitted verification studies of the drug substance and the drug product.	
Stability studies		Firm has submitted stability studies data of three batches at both accelerated and long term conditions.	
STA		OY DATA (Currently Submitted)	
		ride: Dominion Salt Limited, 89 Totara	
Manufacturer of APIs	Calcium Chlo Pharmaceutica Potassium Ch Ltd., Economi Corbion Purac Dextrose: M/	Maunganui, New Zealand.  Oride Dihydrate: Hebei Huachen  als. Ltd.  Iloride: Hebei Huachen Pharmaceuticals  ic Devleopment zone. Hebei, China Sodium Lactate:  e Bioquimica SA, BarcelonaSpain  s CSPC Shengxue Glucose Co., Ltd, No.48 Shengxue Road,  astrict, China-051430 Shijiazhuang City, Hebei Province.	
API Lot No.	Sodium chlori Potassium chlori Sodium lactate	ide: 08012019 oride: 200413 e: 1909000241 ride: 20200625	
Description of Pack (Container closure system)	Low Density I	Polyethylene film bags.	
Stability Storage Condition Real time: 30°		C ± 2°C / 35% ± 5%RH 40°C ± 2°C / NMT 25% RH	
Time Period Real time: 6 m Accelerated: 6		5 months	
Frequency	Accelerated: 0, 3, 6 (Months)		

		Real Time: 0, 3, 6 (	Months)	
Batch No.		LANB0012020	LANB0022020	LANB0032020
Batch Size		4 liter	4 liter	4 liter
Manufacturing Date		09/2020	09/2020	09/2020
	DOCUM	IENTS / DATA PRO	OVIDED BY THE APPL	ICANT
#	Documents To Be Provided	Status		
1.	Reference of previous approval of applications with stability study data of the firm (if any)  Approval of API/			
2.	DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Sodium Chloride: Firm has submitted copy of GMP certificate in the name of M/s Dominion Salt Ltd., 89, totara street, Mount Maunganui, NewZeland valid upto 29-03-2021 issued by Ministry of Health, Newzeland.  Calcium Chloride Dihydrate: Firm has submitted GMP certificate (Certificate# HE20180030) issued by Hebei food & Drug administration valid till 22-04-2023.  Potassium Chloride: Firm has submitted GMP certificate (Certificate# HE20180030) issued by Hebei food & Drug administration valid till 22-04-2023.  Sodium Lactate: Firm has submitted Eudra GMP certificate (Certificate# NCF-II/1817/001/CAT) is valid till April 2021.  Dextrose anhydrous: Firm has submitted copy of GMP certificate (Certificate# HE20190013) in the name of M/s CSPC SHENGXUE Glucose Co., Ltd., No. 48 Shengxue Road, Luancheng District, Shijiazhuang City, Hebei province, China valid upto 02-02-2024 issued by		
3.	Documents for the procurement of API with approval from DRAP (in case of import).	Bodium Lactate: Firm has submitted copy of invoice attested by AD DRAP I&E Lahore, M/s Pacific Pharmaceuticals Ltd., 30 Km, Multan Road, Lahore dated 07-07-2020 specifying the quantity of 800Kgs of Sodium lactate (60%).  Calcium Chloride Dihydrate: Firm has submitted copy of invoice attested by AD DRAP I&E Lahore dated 09-09-2020, M/s Pacific Pharmaceuticals Ltd., Ravi lane, Plot No., 384, Sundar industrial Estate, Raiwind Road, Lahore specifying the quantity of 1 MTS.  Potassium Chloride: Firm has submitted copy of invoice attested by AD DRAP I&E Lahore dated 09-09-2020, M/s Pacific Pharmaceuticals Ltd., Ravi lane, Plot No., 384, Sundar industrial Estate, Raiwind Road, Lahore specifying the quantity of 1 MTS.  Dextrose anhydrous: Firm has submitted copy of commercial invoice (Invoice#. 20ST27003) attested by AD DRAP I&E Lahore, dated 03-10-2019, in the name of M/s Pacific Pharmaceuticals Ltd., 30 Km, Multan Road, Lahore specifying the quantity of 5000Kgs of Dextrose anhydrous (Batch# 201906001) from M/s CSPC SHENGXUE Glucose Co., Ltd., No. 48 Shengxue Road, Luancheng District, Shijiazhuang City, Hebei province,		
4.	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	China.  Firm has submitted record and analytic	•	ong with batch manufacturing
5.	Compliance Record of HPLC software	Not applicable		

	21CFR & audit trail reports on product testing.				
6.	Record of Digital data logger for temperature & humidity monitoring of stability chambers (real time and accelerated)	Firm has submitted Record of Digital data logger for temperature & humidity monitoring of stability chambers (real time and accelerated)			
Rema	Remarks of Evaluator(II):				

**Decision of 316<sup>th</sup> meeting:** Registration Board deferred the case for further deliberation regarding use of drug substance by M/s Pacific Pharmaceuticals Ltd. Plot No. 384, Sunder Industrial Estate, Lahore, for the manufacturing of stability batches, which had been procured and imported by M/s Pacific Pharmaceuticals Ltd., 30<sup>th</sup> KM, Multan Road, Lahore.

# Firm's response:

We Pacific pharmaceuticals Ltd. Ravi Lane Plot No. 384, Sundar Industrial Estate, Raiwind Lahore (DML 000902) have borrowed drug substance material used in the following products (Dorzil Eye drops, Glucozole-T Eye Drops, Pacilact-D IV Infusion 500ml, Pacilact-D IV Infusion 1000ml) for stability and validation purpose only from Pacific Pharmaceuticals Ltd. 30th Km Multan Road, Lahore (DML 000295).

The justification for the borrowing was based on the fact that commercial department dealing with procurement was common for both plants operating from the address 30th Km Multan Road, Lahore.

However, we have already started using dedicated procurement for IV plant. We assure that all of our future procurement will be made by Pacific pharmaceuticals Ltd. Ravi Lane Plot No. 384, Sundar Industrial Estate, Raiwind Lahore (DML 000902) separately and dedicatedly.

37.	Name, address of Applicant / Marketing Authorization Holder	M/s Pacific Pharmaceuticals Ltd. Ravi lane, Plot No., 384, Sundar industrial Estate, Raiwind Road, Lahore
	Name, address of Manufacturing site.	M/s Pacific Pharmaceuticals Ltd. Ravi lane, Plot No., 384, Sunder Industrial Estate, Raiwind Road, Lahore
	Status of the applicant	<ul> <li>✓ Manufacturer</li> <li>☐ Importer</li> <li>☐ Is involved in none of the above (contract giver)</li> </ul>
	Status of application	☐ New Drug Product (NDP)  ☐ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	<ul><li>☑ Domestic sale</li><li>☐ Export sale</li><li>☐ Domestic and Export sales</li></ul>
	Dy. No. and date of submission	Dy. No 8507 dated 16-03-2021
	Details of fee submitted	Rs.20,000/- dated 25-02-2021
	The proposed proprietary name / brand name	Pacilact-D IV Infusion 1000ml
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each 100ml Contains: Sodium Chloride0.60g Potassium Chloride0.03g Calcium Chloride Dihydrate0.02g Sodium Lactate 0.31gram Dextrose Monohydrate Eq. to Anhydrous Dextrose4.3g

	Pharmaceutical form of applied drug		Intravenous Infusion	
Pharmacotherapeutic Group of (API)		Group of (API)	Electrolyte	
	Reference to Finished product specifications Proposed Pack size Proposed unit price		USP	
			1000ml	
			As per SRO	
	The status in reference	regulatory authorities	Approved by US FDA	
	For generic drugs (me-	too status)	Lactated Ringer's and 5% Dextrose Injection of M/s Medipak Limited	
	GMP status of the manufacturer	ne Finished product	New DML issued on 24-06-2019	
Name and address of API manufacturer.		API manufacturer.	Sodium Chloride: Dominion Salt Limited, 89 Totara Street, Mount Maunganui, New Zealand. Calcium Chloride Dihydrate: Hebei Huachen Pharmaceuticals. Ltd. Potassium Chloride: Hebei Huachen Pharmaceuticals Ltd., Economic Devleopment zone. Hebei, China Sodium Lactate: Corbion Purac Bioquimica SA, BarcelonaSpain Dextrose: M/s CSPC Shengxue Glucose Co., Ltd, No.48 Shengxue Road, Luancheng District, China-051430 Shijiazhuang City, Hebei Province.	
	Module-II (Quality Overall Summary)		Firm has submitted QOS details as per WHO QOS PD template.	
Module-III (Drug Product):		oduct):	Firm has submitted relevant information against the Module III, including, Process validation protocol, Finished product analytical method verification report & stability studies data.	
	<b>Remarks:</b> Firm has submitted Pharmaceutical of DEXTROSE in LACTATED RINGER'S INJECTION.		equivalence studies against the reference product of 5% CTION of M/s B Braun.	
		STABILITY	STUDY DATA	
Manufacturer of API		New Zealand. Calcium Chloride Dih Potassium Chloride: Devleopment zone. Heb Sodium Lactate: Corbi Dextrose: M/s CSPC	· ·	
Calciu Potass Sodiu		Sodium Chloride: 080 Calcium Chloride Dih Potassium Chloride: 1 Sodium Lactate: 19040 Dextrose: 201906001	<b>ydrate:</b> 20190826 90815	
Description of Pack (Container closure system) Low Density Polyethyle		Low Density Polyethyle	ene film bags.	
Stability Storage Condition Real time: $30^{\circ}\text{C} \pm 2^{\circ}\text{C} / \text{Accelerated: } 40^{\circ}\text{C} \pm 2^{\circ}\text{C}$				
Time Period Real time: 6 months Accelerated: 6 months				
Freq	uency	Accelerated: 0, 3, 6 (Mo	onths)	
_				

Real Time: 0, 3, 6 (Mont	hs)			
RD01110	RD0211O	RD03110		
4000 litres	4000 litres	4000 litres		
15/10/2019	14/10/2019	14/10/2019		
	03	-		
Details of Docu	ments submitted			
* * * * * * * * * * * * * * * * * * * *	s			
of Batches  Details of Docum  Reference of previous approval of applications with stability study data of the firm (if any)		Firm has submitted copy of GMP certificate (Certificate# HE20190013) in the name of M/s CSPC SHENGXUE Glucose Co., Ltd., No. 48 Shengxue Road, Luancheng District, Shijiazhuang City, Hebe province, China valid upto 02-02-2024 issued by HEBEI Dug Administration.  Sodium Chloride: Firm has submitted copy of GMP certificate in the name of M/s Dominion Salt Ltd., 89, totara street, Mount Maunganui, NewZeland valid upto 29-03-2021 issued by Ministry of Health, Newzeland.  Calcium Chloride Dihydrate: Firm has submitted GMP certificate (Certificate# HE20180030) issued by Hebei food & Drug administration valid till 22-04-2023.  Potassium Chloride: Firm has submitted GMI certificate# HE20180030) issued by Hebei food & Drug administration valid till 22-04-2023.  Sodium Lactate: Firm has submitted Eudra GMP certificate (Certificate# NCF-II/1817/001/CAT) is valid till April 2021.  Dextrose anhydrous: Firm has submitted copy of GMP certificate (Certificate# HE20190013) in the		
	RD0111O 4000 litres 15/10/2019  Details of Documerous approval of application dy data of the firm (if any) DML/GMP certificate of AP used by concerned regulators	4000 litres   15/10/2019   14/10/2019   03		

3.	Documents for the procurement of API with approval from DRAP (in case of import).	Sodium Lactate: Firm has submitted copy of invoice attested by AD DRAP I&E Lahore, M/s Pacific Pharmaceuticals Ltd., 30 Km, Multan Road, Lahore dated 21-10-2019 specifying the quantity of 800Kgs of Sodium lactate (60%).  Calcium Chloride Dihydrate: Firm has submitted copy of invoice attested by AD DRAP I&E Lahore dated 21-10-2019, M/s Pacific Pharmaceuticals Ltd., Ravi lane, Plot No., 384, Sundar industrial Estate, Raiwind Road, Lahore specifying the quantity of 1MTS.  Potassium Chloride: Firm has submitted copy of invoice attested by AD DRAP I&E Lahore dated 21-10-2019, M/s Pacific Pharmaceuticals Ltd., Ravi lane, Plot No., 384, Sundar industrial Estate, Raiwind Road, Lahore specifying the quantity of 1MTS.  Dextrose anhydrous: Firm has submitted copy of commercial invoice (Invoice#. 20ST27003) attested by AD DRAP I&E Lahore, dated 03-10-2019, in the name of M/s Pacific Pharmaceuticals Ltd., 30 Km, Multan Road, Lahore specifying the quantity of 5000Kgs of Dextrose anhydrous (Batch# 201906001) from M/s CSPC SHENGXUE Glucose Co., Ltd., No. 48 Shengxue Road, Luancheng District, Shijiazhuang City, Hebei province, China.
4.	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Submitted
5.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	Not applicable
6.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Submitted

# Remarks of Evaluator<sup>II</sup>:

Sr. Section No. #.		Deficiencies	Firm's response				
		Calcium Chlo	ride				
1.	3.2. S.2.1	• Address of drug substance manufacturer mentioned in this section is different from that mentioned on the COA from drug substance manufacturer.	It was a typographic error, the said section has been revised.				
2.	3.2.S.4. 4	• The drug substance COA from drug substance manufacturer declare it of BP grade, whereas COA from drug product manufacturer declare it as of USP grade.	• It was a typographic error, we have rectified the error. Our COA is also as BP grade.				
	Sodium Lactate						
3.	3.2.S.4	• The Assay limits in the COA of drug substance manufacturer is 59% -61%, whereas the Assay limits in the COA of	According to USP monograph, Sodium Lactate Solution is an aqueous solution containing not less than 50.0 percent, by				

	_		
		drug product manufacturer is 95.0% - 110.0%.gmail  The Assay results in the COA of drug substance manufacturer is 60.1%, whereas the Assay limits in the COA of drug product manufacturer is 101.28%.	weight, of monosodium lactate. It contains not less than 98.0 percent and not more than 102.0 percent of labeled amount of C <sub>3</sub> H <sub>5</sub> NaO <sub>3</sub> . We have overlooked the COA of drug substance. This was typographical error from supplier we have intimated the supplier and will provide you correct COA later. However, Assay limits in the COA of drug product manufacturer is 101.28% according to specifications.
4.	1.5.2 & 3.2. P.1	<ul> <li>The reference product contains Dextrose monohydrate = 5gm/100ml, while firm has applied for Dextrose anhydrous = 4.3gm/100ml.</li> <li>You are advised to justify the variation in formulation from reference product or else submit revised composition as per reference product along with relevant fee as per Notification No. F.7-11f2012-B&amp;A/DRAP dated 07th May, 2021.</li> </ul>	• According to Martindale Anhydrous glucose 900 mg is equivalent to about 1 g of glucose monohydrate. 50g/litre of glucose monohydrate is (equivalent to about 45 g/litre of anhydrous glucose).
5.	3.2. P.5.2	• Evidence of availability of atomic absorption spectrophotometer and flame photometry, as required by the USP monograph of applied product, shall be submitted	Firm has submitted calibration certificate for atomic absorption spectrophotometer. List of equipment including Flame photometer has been submitted.
6.	3.2. P.3.3	• You are advised to submit justification for applying sterilization conditions other than the standard conditions for terminal sterilization by moist heat i.e., temperature 121oC & Time ≥ 15 min.	<ul> <li>We have followed Sterilization process by super-heated water showering at 109°C for 85 minutes.</li> <li>121°C &amp; Time ≥ 15 min, this temperature is used for machine sterilization before running product</li> </ul>
		N0111O, RN0211O, RN0311O, as per ed BMR is 15/10/2019,16/10/2019 & 019 respectively, whereas commercial submitted for Potassium chloride & n chloride is attested by AD DRAP I&E dated 21-10-2019.  the quantities of Dextrose anhydrous ed for batch manufacturing considering the ed label claim OF Dextrose anhydrous 100ml.  the dispensed quantity of Sodium Lactate ed for batch manufacturing considering the percentage of drug substance declared in the ed COA from Pacific Pharma.  analytical record for the analysis of turn, Sodium & Calcium for the stability reconciliation record for the imported of 1 MTS each of Potassium chloride &	Medipak Limited for sample. Attested invoice by AD DRAP I&E Lahore dated 21-10-2019 was after manufacturing of RN0111O, RN0211O, RN0311O batches. This material was imported for commercial manufacturing of other products which is not used in these batches. The Correct invoice is attached.  • The quantity of dextrose anhydrous dispensed for batch manufacturing considering the proposed label claim of Dextrose anhydrous is 4.5g/100ml.  (As per submitted BMR Dextrose anhydrous has been dispensed as per 5gm/100ml which is not as per reference product.)

	RN01110, RN02110, RN03110 batches. This material was imported for commercial manufacturing of other products which is not used in these batches.	
• Revised label claim for Dextrose monoh relevant fee.	ard deferred the case for submission of following: ydrate as per the innovator's product, along with submission of es purchased from another DML holder i.e., M/s Medipak Limited.	
<u> </u>	stability studies data on 28-10-2021, along with correction in label submission of new stability data has not been submitted. Details	
Name, address of Applicant / Marketing Authorization Holder	M/s Pacific Pharmaceuticals Ltd. Ravi lane, Plot No., 384,Sundar industrial Estate, Raiwind Road, Lahore	
Name, address of Manufacturing site.	M/s Pacific Pharmaceuticals Ltd. Ravi lane, Plot No., 384,Sundar industrial Estate, Raiwind Road, Lahore	
Status of the applicant	<ul><li>☑ Manufacturer</li><li>☐ Importer</li><li>☐ Is involved in none of the above (contract giver)</li></ul>	
GMP status of the firm	GMP certificate issued on 17-07-2020	
Evidence of approval of manufacturing facility	Firm has submitted copy of section approval letter dated 24-06-2019 which specifies Large volume parental section.	
Status of application	☐ New Drug Product (NDP)  ☐ Generic Drug Product (GDP)	
Intended use of pharmaceutical product	☐ Domestic sale ☐ Export sale ☑ Domestic and Export sales	
Dy. No. and date of submission	Dy. No.29421 dated 28-10-2021	
Details of fee submitted	Rs. 30,000 vide deposit slip# 3015188420	
The proposed proprietary name / brand name	Pacilact-D IV Infusion 1000ml	
Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each 100ml Contains: Sodium Chloride0.60g Potassium Chloride0.03g Calcium Chloride Dihydrate0.02g Sodium Lactate 0.31gram Dextrose Monohydrate Eq. to Anhydrous Dextrose5g	
Pharmaceutical form of applied drug	Intravenous Infusion	
Pharmacotherapeutic Group of (API)	Electrolyte	
Reference to Finished product specifications	USP	
Proposed Pack size	1000ml	
Proposed unit price	As per SRO	
The status in reference regulatory authorities	Approved by US FDA	
For generic drugs (me-too status)	Lactated Ringer's and 5% Dextrose Injection of M/s Medipak Limited	

Name and address of API manuf	acturer.	Sodium Chloride: Dominion Salt Limited, 89 Totara Street, Mount Maunganui, New Zealand. Calcium Chloride Dihydrate: Hebei Huachen Pharmaceuticals. Ltd. Potassium Chloride: Hebei Huachen Pharmaceuticals Ltd., Economic Devleopment zone. Hebei, China Sodium Lactate: Corbion Purac Bioquimica SA, BarcelonaSpain Dextrose: M/s CSPC Shengxue Glucose Co., Ltd, No.48 Shengxue Road, Luancheng District, China-051430 Shijiazhuang City, Hebei Province.		
Module-II (Quality Overall Summary)		Firm has submitted QOS as per WHO QOS-PD template. Firm has summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product.		
Module-III Drug Substance:		Firm has submitted detailed data for drug substance data related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.		
Stability Studies of Drug (Conditions duration of Stability		Real time: $30^{\circ}\text{C} \pm 2^{\circ}\text{C} / 35\% \pm 5\%\text{RH}$ Accelerated: $40^{\circ}\text{C} \pm 2^{\circ}\text{C} / \text{NMT } 25\%$ RH		
Module-III Drug Product:		Firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.		
Pharmaceutical Equivalenc Comparative Dissolution Profile		Firm has submitted Pharmaceutical equivalence studies against the reference product of 5% DEXTROSE in LACTATED RINGER'S INJECTION of M/s B Braun.		
Analytical method validation/v of product	verification	Firm has submitted verification studies of the drug substance and the drug product.		
Stability studies		Firm has submitted stability studies data of three batches at both accelerated and long term conditions.		
STA	BILITY ST	TUDY DATA (Currently Submitted)		
	Sodium C	Chloride: Dominion Salt Limited, 89 Totara		
Manufacturer of APIs  Pharmaceu Potassium Ltd., Econ Corbion P Dextrose:		ount Maunganui, New Zealand. Chloride Dihydrate: Hebei Huachen uticals. Ltd. n Chloride: Hebei Huachen Pharmaceuticals nomic Devleopment zone. Hebei, China Sodium Lactate: turac Bioquimica SA, BarcelonaSpain M/s CSPC Shengxue Glucose Co., Ltd, No.48 Shengxue Road, g District, China-051430 Shijiazhuang City, Hebei Province.		
		<u> </u>		

		Codium loctote: 10	00000241		
		Sodium lactate: 19			
		Calcium chloride: 20200625			
Description of Pack		Dextrose: 201906001 Low Density Polyethylene film bags.			
	ainer closure system)				
Stabil	ity Storage Condition		$2^{\circ}$ C / $35\% \pm 5\%$ RH		
- Statistic	nty Storage Condition		± 2°C / NMT 25% RH		
Time	Period	Real time: 6 month Accelerated: 6 mo			
Frequ	ency	Accelerated: 0, 3, Real Time: 0, 3, 6			
Batch	No.	LANA0012020	LANA0022020	LANA0032020	
Batch	Size	4 liter	4 liter	4 liter	
Manu	facturing Date	09/2020	09/2020	09/2020	
DOC	UMENTS / DATA PRO	VIDED BY THE A	PPLICANT		
#	<b>Documents To Be</b>	Status			
	Provided				
1.	Reference of previous	PACILACT-RL 1	000 ml IV INFUSION appro	ove in 297 DRB	
	approval of		11		
	applications with				
	stability study data of				
	the firm (if any)				
2.	Approval of API/	Sodium Chloride	: Firm has submitted copy o	f GMP certificate in the name	
	DML/GMP certificate	of M/s Dominion S	Salt Ltd., 89, totara street, M	lount Maunganui, NewZeland	
	of API manufacturer		021 issued by Ministry of H		
	issued by concerned	Calcium Chloride Dihydrate: Firm has submitted GMP certificate			
	regulatory authority of				
	country of origin.	valid till 22-04-2023.			
		Potassium Chloride: Firm has submitted GMP certificate (Certificate#			
		HE20180030) issued by Hebei food & Drug administration valid till 22-04-2023.			
		<b>Sodium Lactate:</b>	Firm has submitted Eudra C	SMP certificate	
		(Certificate# NCF-II/1817/001/CAT) is valid till April 2021.			
				l copy of GMP certificate	
		(Certificate# HE20	0190013) in the name of M/s	CSPC SHENGXUE Glucose	
		Co., Ltd., No. 48	Shengxue Road, Luanchen	g District, Shijiazhuang City,	
		Hebei province, China valid upto 02-02-2024 issued by HEBEI Dug			
		Admiistration.			
3.	Documents for the		1.0	invoice attested by AD DRAP	
	procurement of API				
	with approval from				
	DRAP (in case of				
	import).	Calcium Chloride Dihydrate: Firm has submitted copy of invoice attested			
		by AD DRAP I&E Lahore dated 09-09-2020, M/s Pacific Pharmaceuticals			
		Ltd., Ravi lane, Plot No., 384, Sundar industrial Estate, Raiwind Road,			
		Lahore specifying the quantity of 1 MTS.			
		Potassium Chloride: Firm has submitted copy of invoice attested by AD			
		DRAP I&E Lahore dated 09-09-2020, M/s Pacific Pharmaceuticals Ltd.,			
		Ravi lane, Plot No., 384, Sundar industrial Estate, Raiwind Road,			
		Lahore specifying the quantity of 1 MTS.  Devtrose aphydrous: Firm has submitted copy of commercial invoice.			
		<b>Dextrose anhydrous:</b> Firm has submitted copy of commercial invoice (Invoice # 20ST27003) attacted by AD DRAP ISE I above dated 03 10			
		(Invoice#. 20ST27003) attested by AD DRAP I&E Lahore, dated 03-10-			
		2019, in the name of M/s Pacific Pharmaceuticals Ltd., 30 Km, Multan			
		Road, Lahore specifying the quantity of 5000Kgs of Dextrose anhydrous			
		(Batch# 201906001) from M/s CSPC SHENGXUE Glucose Co., Ltd., No. 48 Shengxue Road, Luancheng District, Shijiazhuang City, Hebei province,			
		<u> </u>	i, Luancheng District, Shijia	izmuang City, Hebel province,	
		China.			

4.	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Firm has submitted data pf stability batches along with batch manufacturing record and analytical record.
5.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing.	Not applicable
6.	Record of Digital data logger for temperature & humidity monitoring of stability chambers (real time and accelerated)	Firm has submitted Record of Digital data logger for temperature & humidity monitoring of stability chambers (real time and accelerated)

**Decision of 316**<sup>th</sup> **meeting:** Registration Board deferred the case for further deliberation regarding use of drug substance by M/s Pacific Pharmaceuticals Ltd. Plot No. 384, Sunder Industrial Estate, Lahore, for the manufacturing of stability batches, which had been procured and imported by M/s Pacific Pharmaceuticals Ltd., 30<sup>th</sup> KM, Multan Road, Lahore.

## Firm's response:

We Pacific pharmaceuticals Ltd. Ravi Lane Plot No. 384, Sundar Industrial Estate, Raiwind Lahore (DML 000902) have borrowed drug substance material used in the following products (Dorzil Eye drops, Glucozole-T Eye Drops, Pacilact-D IV Infusion 500ml, Pacilact-D IV Infusion 1000ml) for stability and validation purpose only from Pacific Pharmaceuticals Ltd. 30th Km Multan Road, Lahore (DML 000295).

The justification for the borrowing was based on the fact that commercial department dealing with procurement was common for both plants operating from the address 30th Km Multan Road, Lahore.

However, we have already started using dedicated procurement for IV plant. We assure that all of our future procurement will be made by Pacific pharmaceuticals Ltd. Ravi Lane Plot No. 384, Sundar Industrial Estate, Raiwind Lahore (DML 000902) separately and dedicatedly.

Case no. 04 Registration applications of import cases a. Deferred cases

38.	Name, address of Applicant / Importer	M/s Himmel Pharmaceuticals (Pvt.) Ltd 793-D, Block C, Faisal Town Lahore		
	Details of Drug Sale License of importer	License No: 05-352-0065-016174-D Address: 793-D, Block -C, Faisal Town Lahore Address of Godown: NA Validity: 06-02-2022 Status: License to sell drugs as distributor		
	Name and address of marketing authorization holder (abroad)	M/s Beacon Pharmaceuticals Limited Plant address: Kathali Bhaluka Mymensingh Bangladesh Office Address: 9/A Toyenbee Circular Road Motijheel Dhaka Bangladesh		
	Name, address of manufacturer(s)	M/s Beacon Pharmaceuticals Limited Plant address: Kathali Bhaluka Mymensingh Bangladesh Office Address: 9/A Toyenbee Circular Road Motijheel Dhaka Bangladesh		

Name of exporting country	Bangladesh		
Detail of certificates attached (CoPP, Free sale certificate, GMP certificate):  CoPP: Firm has submitted original legalized COPP (DA/6-110/2016/3306) issued on 01-June-2020: Government of the people's republic of Bangladesh, Ministry of Health & Family welfare, Directorat General of Drug Administration Oushad Bhaban, Mohkhali Dhaka-1212, Bangladesh.  GMP: Firm has submitted Legalized GMP certificate (Certificate No. DA/6-110/06/4950) issued by M/Beacon Pharmaceuticals limited valid upto 16-07-2021.			
Details of letter of authorization / sole agency agreement	Firm has submitted copy of letter of distribution certificate from Beacon Pharmaceuticals limited. The letter specifies that the manufacturer appoints M/s Himmel Pharmaceuticals Pvt. Ltd. to register their products in Pakistan. The authorization letter is valid till June, 2025.		
Status of the applicant	<ul> <li>☐ Manufacturer</li> <li>☑ Importer</li> <li>☐ Is involved in none of the above (contract giver)</li> </ul>		
Status of application	<ul><li>☑ New Drug Product (NDP)</li><li>☐ Generic Drug Product (GDP)</li></ul>		
Intended use of pharmaceutical product	<ul><li>☑ Domestic sale</li><li>☐ Export sale</li><li>☐ Domestic and Export sales</li></ul>		
For imported products, specify one the these	<ul> <li>☑ Finished Pharmaceutical product import</li> <li>☐ Buk import and local repackaging</li> <li>☐ Buk import and local repackaging for export purpose only</li> </ul>		
Dy. No. and date of submission	Dy. No 8004 dated 11-03-2021		
Details of fee submitted	Rs.50,000/- dated 01-02-2021		
The proposed proprietary name / brand name	Tofacinix 5mg tablet		
Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each tablet contains Tofacitinib citrate INN equivalent to Tofacitinib 5mg		
Pharmaceutical form of applied drug	Tablet		
Pharmacotherapeutic Group of (API)	Anti-rheumatic, immunosuppressant		
Reference to Finished product specifications	In house		
Proposed Pack size	30's in Alu-Alu Blister		
Proposed unit price	As per current pricing policy of DRAP		
The status in reference regulatory authorities	Xeljanz XR Tablet 5 mg (Pfizer labs)		
For generic drugs (me-too status)	NA		
Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Firm has summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.		

	Name,	address of drug substance manufacturer	Beijing Mesochem Technology Co., Ltd. Floor 23, Building 9, Lippo Plaza Economic and Technological Development Zone Beijing	
	Stability Studies of Drug Substance (Conditions & duration of Stability studies)		Firm has submitted detailed drug substance data for both sources related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.	
			API at accreal time	submitted stability study data of 3 batches of celerated as well as real time conditions. The stability data is conducted at 25±2°C, RH. The stability study data is till 24 months.
	Module-III Drug Product:		Firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.	
		aceutical Equivalence and Comparative ation Profile	Comparative analysis Studies against the reference product Xeljanz XR Tablet 5 mg (Pfizer labs) has been submitted	
	Analyti		Firm has submitted analytical method validation studies for the applied product.	
	Contain	ner closure system of the drug product	Alu-Alu Blister	
		ey study data of drug product, shelf life and conditions	Firm has submitted stability study data of 3 batches. Accelerated stability studies have been conducted at 40°C±2°C and 75%±5% RH for 6 months.	
			Real time stability studies conducted at $30^{\circ}\text{C}\pm2^{\circ}\text{C}$ and $65\% \pm 5\%$ for 24 months.	
Evalu	ation b	y PEC(II):		
Sect	ion #.	Deficiencies		Firm's response
Opies of the Drug substance specific analytical procedures used for routine Drug substance/Active Pharmaceutical by both Drug Product manufacturer is reflected analytical Method Verification studies specificity, accuracy and repeatability precision) performed by Drug manufacturer shall be submitted.  Provide results of analysis of relevant be Drug Substance performed by Drug manufacturer used during product de and stability studies, along with Cere Analysis (CoA) of the same batch for Substance/Active Pharmaceutical		testing of Ingredient equired. including (method Product atch(es) of g Product velopment difficate of	COA s form both drug substance and drug product manufacturer submitted.  Analytical method verification report submitted from M/s Beacon Pharma.  Submitted COA declares the polymorphic form as A.	

manufacture.

	•Submitted COA does not reflect the polymorphic form of the drug substance.	
3.2.P.2	Compatibility studies of the Drug Substance(s) with excipients shall be submitted, since the qualitative composition of the formulation is not similar to innovator / reference product.	We have used Pregelatinized Starch (Starch 1500) BP, Croscarmellose Sodium BP, Magnesium Stearate BP, Colloidal Anhydrous Silica (Aernsil 200) BP, Microcrystalline Cellulose (Avecil PH I 02) BP, Opadry II Blue (85G506t2) in the formulation in Tofacinix 5mg Tablet These excipients are complying with Current Pharmacopoeial Monograph (British Pharmacopoea & United States Pharmacopoea). These excipients are pharmaceutically inert substance and we have used these excipients bellow the IIG limit of FDA Orange Book as well as we have done extensive aldysis of the product after formulation and found satisfactory result of assay, dissolution results & impurity profile.  Also we have done stability study during development stage and found satisfactory result of the product.  So we can conclude that these excipients are not incompatible with API.
3.2.P.2.2.1	<ul> <li>Comparative dissolution studies have been performed against Xeljanz XR tablet, whereas applied product is immediate release tablet.</li> <li>Submitted CDP data declare the extended release profile of the applied drug, whereas the label claim is of immediate release tablet.</li> </ul>	Firm has submitted new CDP study data in three dissolution mediums (i.e., pH 1.2, pH 4.5 & pH 6.8), wherein results of f2 factor are in acceptable range.
3.2.P.5.2	• US FDA review document of the Innovator product, specifies the dissolution limit as "NLT Q in 15 minutes" in 0.1N HCl, whereas submitted specifications declare the dissolution limits as "NLT 75% in 30 minutes" using water as dissolution medium.	

**Decision of 313<sup>rd</sup> meeting:** Registration Board deferred the application for justification for adopting dissolution parameters & specifications for batch release, in variation from that recommended by the US FDA for innovator's product.

**Firm's response:** Firm has submitted comparative dissolution studies for the extended release tablet instead of the applied product.

**Decision of 316<sup>th</sup> meeting:** Deferred for submission of stability studies data of at least two batches at 0 & 1-month timepoint of accelerated and long-term stability studies with revised specification of dissolution of "NLT Q in 15 minutes" in 0.1N HCl dissolution medium.

**Firm's response:** Firm has submitted accelerated and long-term stability studies till 1-month time point, for two batches with revised specifications of dissolution of "NLT Q in 15 minutes" in 0.1N HCl dissolution medium.

Batch#	22012022	22012023
Mfg. date	January 2022	January 2022

Decision: Approved with Innovator's specifications as per Policy for inspection of Manufacturer abroad and verification of local storage facility. Firm shall submit fee of Rs. 7,500 for correction/pre-approval change/ in product specifications, as per notification No.F.7-11/2021-B&A/DRAP dated 13-07-2021.

39.	Name and address of manufacturer /	M/s. Vision Pharmaceuticals, Islamabad.
	Applicant	
	Brand Name +Dosage Form + Strength	ESONAP 375/20mg Tablets
	Diary No. Date of R& I & fee	Dy No. 2335 ,06-04-2017, Rs.20,000/-+Rs. 30,000
	Composition	Each modified release tablet contains:
		Naproxen 375 mg
		Esomeprazole 20 mg
	Pharmacological Group	NSAID / Proton pump inhibitor
	Type of Form	Form-5 D
	Finished Product Specification	In-House
	Pack size & Demanded Price	28's tablets/bottle; As per SRO
	Approval status of product in Reference Regulatory Authorities.	VIMOVOTablet-USFDA approved
	Me-too status	N/A
	GMP status	GMP certificate issued on the basis of inspection conducted on 11- 02-2019

# STABILITY STUDY DATA

Drug	ESONAP 375/20mg Tablets (Naproxen + Esomeprazole)			
Name of Manufacturer	M/s. Vision Pharmaceuticals, Islamabad.			
Manufacturer of API	Naproxen: Zhejiang Charioteer Pharmaceutical Co. Ltd., China. Esomeprazole Magnesium Trihydrate:			
	Everest Organics Limited, India.			
ADLI of No	Naproxen: 156102855	,		
API Lot No.	Esomeprazole Magnesiu	Esomeprazole Magnesium Trihydrate: ESM/E-144/16		
Description of Pack (Container closure system)	Child resistant HDPE bot	ttle.		
Stability Storage Condition	Accelerated: $40^{\circ}\text{C} \pm 2^{\circ}\text{C}$ Real Time: $30^{\circ}\text{C} \pm 2^{\circ}\text{C}$			
Time Period	Accelerated: 06 Months Real Time: 06 Months			
Frequency	Accelerated: 0,3,6 (Month Real Time: 0,3,6 (Month			
Batch No.	NPD609(T-03)	NPD609(T-02)	NPD609(T-01)	
Batch Size	5kg (7,299 Tablets)	5kg (7,299 Tablets)	5kg (7,299 Tablets)	
Manufacturing Date	June 2016	June 2016	June 2016	
Date of Initiation	June 2016	June 2016	June 2016	
No. of Batches 03				
Date of Submission 07-02-2017				

# DOCUMENTS / DATA PROVIDED BY THE APPLICANT

Sr. No.	<b>Documents To Be Provided</b>	Status
1.	COA of API	Yes

2.	Approval of API by regulatory authority of country of origin or GMP certificate of API manufacturer issued by regulatory authority of country of origin.	Yes, Copy of GMP Certificates provided.
3.	Protocols followed for conduction of stability study and details of tests.	Yes
4.	Data of 03 batches will be supported by attested respective documents like chromatograms, laboratory reports, data sheets etc.	Yes
5.	Documents confirming import of API etc.	Copy of AD (Islamabad) attested invoice provided for Naproxen. Copy of Invoice (Dated 01.04.2016) provided for Esomeprazole Magnesium, however AD attestation is missing.
6.	All provided documents will be attested (name, sign and stamp) for ensuring authenticity of data / documents.	Yes
7.	Commitment to continue real time stability study till assigned shelf life of the product.  Yes	
8.	Commitment to follow Drug Specification Rules, 1978.	Yes

## **Previous remarks of Evaluator:**

- Firm has submitted following:
  - i. Report of analytical method validation along with relevant documents i.e. chromatograms & raw data sheets.
  - ii. Stability study data of 12<sup>th</sup> months' time point of real-time of one batch only with dissolution test performed as per recommendations of USFDA.
- Assay analysis has also not been submitted by firm.
- Firm has stated that as dissolution profile as per USFDA for subject product is still in progress so please consider dissolution profile submitted for higher strength of same product i.e. Esonap 500mg/20mg tablet, until then.

According to submitted data firm has withdrawn sample for dissolution analysis one month earlier to its 12<sup>th</sup> month real time stability study time point. When inquired, firm stated that they have performed assay

## **Decision of 271st meeting:**

Deferred for the submission of complete data of three batches for 12<sup>th</sup> month's real time stability study time point. Moreover, registration Board directed the firm to perform Dissolution analysis as per USFDA recommended method at the actual dates of 12<sup>th</sup> months time point of real time stability study and submit the same.

**Firm's response (II):** Firm has submitted complete data of three batches conducted at 12<sup>th</sup> months time-point in the real stability study wherein dissolution analysis as per US-FDA recommended method has been performed.

Firm has further submitted copy of commercial invoice cleared dated 16-05-2016 specifying import of 125Kg esomeprazole magnesium (Batch No. ESM/E-144/16).

	EXEMPTION DATA		
Sr.#	Data requirement	Firm's submission	
1.		Firm has referred to onsite inspection report of their product "Sofovir-V 400/100mg Tablet", which was presented in 286 <sup>th</sup> meeting of Registration Board.  Date of inspection: 5-15 October 2018  According to the report, following points were confirmed:  a) Firm has 1 HPLC dedicated for R&D testing and is 21 CFR II compliant. This HPLC system is used for stability studies of Sofovir-V 400mg/100mg Tablets. The HPLC used for the stability studies is 21CFR compliant. However, the record from	

2. 3. 4.	along with COA.	logbooks, analytical test reports was randomly found verifiable onsite. A complete trail of such testing was available and verifiable.  b) Audit trail on the testing reports are available c) Digital data loggers are available for continuous monitoring for stability chamber.  Submitted  Analytical method for both APIs has been submitted from relevant API manufacturers as well as from M/s Vison Pharma  Firm has submitted both accelerated stability studies & long-term
	manufacturer	stability studies reports of three batches as per Zone IVa conditions from API manufacturers of both APIs.
5.	certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Naorpxen Sodium: Firm has submitted copy of DML of manufacturer "Zhejiang Charioteer Pharmaceutical Co., Ltd. CHINA." (# ZJ 20000308) issued by SFDA, China which is valid till 03/08/2025.  Esomeprazole-Mg: Copy of GMP certificate (Certificate No.L.Dis. No.1221/E1/2019) for M/s Everest Organics Ltd. Aroor Village, Sadasivpet Mandal, Medak District –502291 Telangana India issued by Drug Control Adminstration Government of Telgana issued on 10-09- 2019 and, valid for three years.
6.	_	Copy of ADC (Islamabad) attested invoice provided for Naproxen from M/S. Zhejiang charioteer China vide Invoice letter No. ME 169059 attested by AD DRAP I&E dated 18-05-2016. Copy of ADC (Islamabad) attested invoice provided for Esomeprazole from Everest Organics Ltd vide Invoice No EXP/017/16-17 on May 05 2016 respectively
7.	Authorized Protocols/SOP for the development & stability testing of trial batches.	Firm has submitted SOP for new product development & stability protocol.
8.	Method used for analysis of FPP	Drug product analytical method has been submitted.
9.	Drug-excipients compatibility studies (where applicable)	Firm has referred to the formulation of innovator product for establishing drug-excipient compatibility.
10.	Complete batch manufacturing record of three stability batches.	Firm has provided Batch Manufacturing Record for all the three batches of both strengths.
11.	Record of comparative dissolution data (where applicable)	Comparative dissolution studies have been submitted against the innovator product of Vimovo tablet $375 \text{mg}/20 \text{mg}$ , with acceptable values of $f_2$ .
12.	* *	Firm has submitted analytical record for both accelerated & long-term stability studies, including chromatograms, raw data sheets etc
13.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing.	Audit trail reports have been submitted.
14.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Submitted.

Decision: Approved with Innovator's specifications. Manufacturer will place first three production batches on long term stability studies throughout proposed shelf life and on accelerated studies for six months.

Name and address of manufacturer /	M/s Pharmevo Private Limited., Plot # A-29, North	
Applicant	Western Industrial Zone, Port Qasim, Karachi	
Brand Name +Dosage Form + Strength	IRMAX 100+5MG TABLET	
Composition	Each film coated tablet contains:	
	Irbesartan100mg	
	Amlodipine5mg	
Diary No. Date of R& I & fee	Dy. No 1660 dated 29-Aug-2013, Rs.50,000/-	
Pharmacological Group	Antidiabetic	
Type of Form	Form-5D	
Finished product Specifications	Manufacturer's specifications	
Pack size & Demanded Price	7's, 10's, 14's, 20's, 28's, 30's & As per PRC	
Approval status of product in	AIMIX Approved by JAPAN	
Reference Regulatory Authorities		
Me-too status (with strength and	Not Applicable	
dosage form)		
GMP status	GMP inspection dated 23-02-2018 showed that the firm was	
	considered to be operating at an acceptable level of compliance	
	with GMP standards	
Remarks of the Evaluator:		
n ' 1 ''		

#### **Previous decision:**

The application was initially presented in 260<sup>th</sup> meeting of Registration Board wherein case was deferred for proof of approval status of same formulation in reference countries and Pakistan. Subsequently firm referred to the Aimix tablet approved by PMDA of Japan and submitted stability studies data against which following observations were communicated to firm:

- Valid GMP certificate of M/s Prudence Pharma Chem., Gujarat, India shall be submitted.
- Content Uniformity test has not been performed for Amlodipine. Justification shall be submitted.
- Justification/Clarification needed as in contrary to Japanese Pharmacopoeia monograph for applied formulation firm has submitted different specifications and parameters for the Assay & Dissolution test.
  - Firm had submitted revised stability studies data along with documents as per exemption checklist, detailed as below:

STABILITY STUDY DATA	
Drug	IRMAX 100+5MG TABLET
Name of Manufacturer	M/s Pharmevo Private Limited., Plot # A-29, North Western
	Industrial Zone, Port Qasim, Karachi.
Manufacturer of API	Irbesartan:
	M/s Zhejiang Huahai Pharmaceutical Co. Ltd. Chuannan
	Duqiao, Linhai, Zhejiang
	Amlodipine:
	M/s Prudence Pharma Chem, Plot No 7407, B/H, Lyka Lab,
	GIDC. INDIA.
API Lot No.	Irbesartan: C5055-20-13R
	Amlodpine: AMB/194/10/20
Description of Pack	Alu-Alu Blister
(Container closure system)	Alu-Alu blistei
Stability Storage Condition	Real time : $30^{\circ}$ C ± $2^{\circ}$ C / $75\%$ ± $5\%$ RH
	Accelerated: $40^{\circ}\text{C} \pm 2^{\circ}\text{C} / 75\% \pm 5\% \text{ RH}$
Time Period	Real time: 6 months Accelerated: 6 months
Frequency	Accelerated:0,1,2,3,4,6 (month)

		Real Time: 0,3,6, (mo	onth)			
Batc	h No.	21PD-3572-11-T 21PD-3575-12-T 21PD-3576-13-T				
	ch Size	2500 Tablet	2500 Tablet	2500 Tablet		
	ufacturing Date	3-2021	3-2021	3-2021		
	e of Initiation	4-2021	4-2021	4-2021		
	of Batches	03	1	1		
	CUMENTS / DATA PROVIDED BY TI	HE APPLICANT				
	ıments To Be Provided	Status				
1	Reference of previous approval of applications with stability study data of the firm	<ul> <li>25/1000mg (Empagliflozin + Metformin HCl XR) which was conducted on 05<sup>th</sup> December, 2019 and were presented in 293<sup>rd</sup> meeting of Registration Board held on 6<sup>th</sup> -8<sup>th</sup> Jan, 2020 According to the report following points were confirmed.</li> <li>Firm has 21 CFR compliant HPLC software.</li> <li>Firm has audit trail reports available.</li> <li>Firm possesses stability chambers with digital data</li> </ul>				
2	Certificate of Analysis of API from both API Manufacturer and Finished Product manufacturer.	loggers.  Irbesartan:  M/s Zhejiang Huahai Pharmaceutical Co. Ltd. Chuannan Duqiao, Linhai, Zhejiang.  API COA & FPP COA Provided  Amlodipine:  M/s Prudence Pharma Chem, Plot No 7407, B/H, Lyka Lab, GIDC. INDIA.  API COA & FPP COA Provided				
3	Method used for analysis of API from both API Manufacturer and Finished Product manufacturer	Submitted.				
4	Stability study data of API from API manufacturer	Irbesartan- LPGA: The firm has submitted copy of accelerated, 06 Months (40°C ± 2°C & 75±5%RH) & long term, 24 Months (30°C ± 2°C & 75±5%RH) stability study reports of 03 batches Amlodipine: The firm has submitted copy of accelerated, 06 Months (40°C ± 2°C & 75±5%RH) & long term, 24 Months (30°C ± 2°C & 65±5%RH) stability study reports of 03 batches				
5	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Irbesartan: Copy of I ZJ210061) issued by ADMINISTRATION Amlodipine: Copy of Drug manufa GMP/20051984) for I Estate India, valid up	Drug manufacturing I y ZHEJIANG MED submitted, valid up t acturing license (Licente Food & Drug Adminito 18-05-2022	icense (License no. ICAL PRODUCTS o 09-May-2024.  nse no. S-stration Gujrat		
6	Documents for the procurement of API with approval from DRAP (in case of import).	Irbesartan: Copy of for from M/s Zhejiang H Duqiao, Linhai, Zhejiang H AD(Karachi). Amlodipine: Copy of Commercial Chem, Plot No 7407, submitted attested by	uahai Pharmaceutical ang. is submitted atte Invoice from M/s Pru B/H, Lyka Lab, GID	Co. Ltd. Chuannan sted by		
7	Protocols followed for conduction of stability study	Submitted.				
8	Method used for analysis of FPP	Submitted.				
9	Drug-excipients compatibility studies (where applicable)	Same excipients used	as used by innovator			

10	C1-4-1-4-1	Th. C 1	4 - 1 C.T.: - 1 1	l4 -1
10	Complete batch manufacturing record	The firm has submitted copy of Trial batch manufacturing record. Details are as under:		
	of three stability batches.	Batch no.	Batch Size	Mfg. Started
		21PD-3572-11-T	2500	03-2021
		21PD-3572-11-T	2500	03-2021
		21PD-3572-11-T	2500	03-2021
11	Record of comparative dissolution data	-		lable with the firm & as
	(where applicable)	per Japanese Pharma		
				he firm on their product
		i.e. the product disso		raph. Therefore, 12
12	Data of 03 batches will be supported by	calculations is not no Submitted.	ecessary.	
12	attested respective documents like	Submitted.		
	chromatograms, Raw data sheets, COA,			
	summary data sheets etc.			
13	Compliance Record of HPLC software	Firm has submitted a	audit trail reports	of stability studies of
	21CFR & audit trail reports on product	applied formulation.		
	testing.			
14	Record of Digital data logger for	Submitted.		
	temperature and humidity monitoring			
	of stability chambers (real time and accelerated)			
41.	Name and address of manufacturer /	M/s Pharmevo Priv	rate Limited Plo	at # A - 29 North
71.	Applicant	Western Industrial	•	*
	Brand Name +Dosage Form + Strength	IRMAX 100+10MG		
	Composition	Each film coated tab	let contains:	
		Irbesartan100m	ng	
		Amlodipine10mg		
	Diary No. Date of R& I & fee	Dy. No 1656 dated 2	9-Aug-2013, Rs.5	50,000/-
	Pharmacological Group	Antidiabetic		
	Type of Form	Form-5D	• • • • •	
	Finished product Specifications	Manufacturer's spec		DD C
	Pack size & Demanded Price Approval status of product in Reference	7's, 10's, 14's, 20's, 2		PRC
	Regulatory Authorities	Aliviix Approved by	JAPAN	
	Me-too status (with strength and	Not Applicable		
	dosage form)	Tot ripplicable		
	GMP status	GMP inspection dat	ted 23-02-2018 sl	howed that the firm was
				table level of compliance
		with GMP standards		•
	Remarks of the Evaluator:			
	Now the firm has submitted stability data			
_		ILITY STUDY DAT		
Drug		IRMAX 100+10MG		W A OO NI 11 XXI 1
Nam	e of Manufacturer			# A-29, North Western
Man	ufacturer of API	Industrial Zone, Port Irbesartan:	ı Qasını, Karacılı.	
Ivian	uracturer of Ar I	M/s Zhejiang Huaha	i Pharmaceutical	Co Ltd Chuannan
		Duqiao, Linhai, Zhe		Co. Dia Chamman
		Amlodipine:	<i>y · 6</i>	
		_	na Chem, Plot No	7407, B/H, Lyka Lab,
API	Lot No.	Irbesartan: C5055-20 Amlodpine: AMB/1		
Desc	ription of Pack	•	<u>-</u>	
	tainer closure system)	Alu-Alu Blister		

Stab	ility Storage Condition	Real time : $30^{\circ}\text{C} \pm 2^{\circ}$			
	<i>p</i> : 1	Accelerated: $40^{\circ}\text{C} \pm 2^{\circ}\text{C} / 75\% \pm 5\% \text{ RH}$			
	e Period	Real time: 6 months Accelerated: 6 months			
Freq	uency	Accelerated:0,1,2,3,4 Real Time: 0,3,6, (mo			
Batc	h No.	21PD-3573-13-T	21PD-3577-14-T	21PD-3578-15-T	
	ch Size	2500 Tablet	2500 Tablet	2500 Tablet	
	uufacturing Date	3-2021	3-2021	3-2021	
	e of Initiation	4-2021	4-2021	4-2021	
	of Batches	03	. =		
	CUMENTS / DATA PROVIDED BY TH				
	Documents To Be Provided	Status			
1	Reference of previous approval of applications with stability study data of the firm	Firm has referred to onsite inspection report of their produc			
2	Certificate of Analysis of API from both API Manufacturer and Finished Product manufacturer.	Irbesartan: M/s Zhejiang Huahai Pharmaceutical Co. Ltd. Chuannan Duqiao, Linhai, Zhejiang. API COA & FPP COA Provided Amlodipine: M/s Prudence Pharma Chem, Plot No 7407, B/H, Lyka Lab GIDC. INDIA. API COA & FPP COA Provided			
3	Method used for analysis of API from both API Manufacturer and Finished Product manufacturer	Submitted.			
4	Stability study data of API from API manufacturer	Irbesartan- LPGA: The firm has submitted copy of accelerated, 06 Months (40°C ± 2°C & 75±5%RH) & long term, 24 Months (30°C ± 2°C & 75±5%RH) stability study reports of 03 batches Amlodipine: The firm has submitted copy of accelerated, 06 Months (40°C ± 2°C & 75±5%RH) & long term, 24 Months (30°C ± 2°C & 65±5%RH) stability study reports of 03 batches			
5	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Irbesartan: Copy of Drug manufacturing license (License no.			
6	Documents for the procurement of API with approval from DRAP (in case of import).	Estate India, valid upto 18-05-2022  Irbesartan: Copy of form 6, form 7 & Commercial Invoice from M/s Zhejiang Huahai Pharmaceutical Co. Ltd. Chuannan Duqiao, Linhai, Zhejiang. is submitted attested by AD(Karachi).  Amlodipine: Copy of Commercial Invoice from M/s Prudence Pharma Chem, Plot No 7407, B/H, Lyka Lab, GIDC. INDIA.is submitted attested by AD (Karachi).			

7	Protocols followed for conduction of	Submitted.		
0	stability study	C-1		
8	Method used for analysis of FPP	Submitted.		
9	Drug-excipients compatibility studies (where applicable)	Same excipients used as used by innovator.		
10	Complete batch manufacturing record of three stability batches.	The firm has submitted copy of Trial batch manufacturing record. Details are as under:		
	or times smallery success	Batch no.	Batch Size	Mfg. Started
		21PD-3573-13-T	2500	3-2021
		21PD-3573-13-T	2500	3-2021
		21PD-3573-13-T	2500	3-2021
11	Record of comparative dissolution data (where applicable)	As per literature of the innovator available with the firm & as per Japanese Pharmacopeia.  The same has been demonstrated by the firm on their product i.e. the product dissolve as per monograph. Therefore, f2 calculations is not necessary.		
12	Data of 03 batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	Submitted.		
13	Compliance Record of HPLC software 21CFR & audit trail reports on product testing.	Firm has submitted audit trail reports of stability studies of applied formulation.		
14	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Submitted.		

# REMARKS BY EVALUATOR(II)

Firm has not submitted comparative dissolution data for both strengths while referring to the batch release data performed as per JP monograph.

Decision: Registration Board deferred the applications of IRMAX 100+5mg tablet & IRMAX 100+10mg tablet for submission of Comparative Dissolution Profile data against the relevant strength of Innovator drug product.

42.	Name and address of manufacturer / Applicant	M/s Himont Pharma Pvt Ltd, 17-Km Ferozpur Road, Lahore.
	Brand Name +Dosage Form + Strength	Glipto 10mg Tablet
	Composition	"Each Film Coated Tablet Contains: Empagliflozin10mg"
	Diary No. Date of R& I & fee	Dy. No 13041 dated 12-11-2018 Rs.50,000/-
	Pharmacological Group	Antidiabetic
	Type of Form	Form-5D
	Finished product Specifications	Manufacturer's specifications
	Pack size & Demanded Price	As per PRC
	Approval status of product in Reference Regulatory Authorities	Approved by USFDA
	Me-too status (with strength and dosage form)	Empator of M/s Martin Dow
	GMP status	
	Remarks of the Evaluator <sup>II</sup>	
	S	TABILITY STUDY DATA

Drug	Glipto 10mg Tablet			
Name of Manufacturer	M/s Himont Pharma Pvt Ltd, 17-Km Ferozpur Road, Lahore.			
Manufacturer of API	Empagliflozin: M/s Century Pharmaceuticals Ltd., Panchmahal, Gujarat estate, India.			
API Lot No.	08964005-EMP			
Description of Pack (Container closure system)	Alu-Alu blister with	h unit	carton	
Stability Storage Condition	Real time: 30°C ± 2 Accelerated: 40°C ±			
Time Period	Real time: 6 months Accelerated: 6 mon			
Frequency	Accelerated: 0,1,2,3 Real Time: 0,3,6 m		5 months	
Batch No.	T-411		T-412	T-413
Batch Size	2000 tablets		2000 tablets	2000 tablets
Manufacturing Date	03-2019		03-2019	03-2019
DOC	UMENTS / DATA	PROV	IDED BY THE A	PPLICANT
Documents To Be	Provided			Status
COA of API			Yes	
Approval of API by regulatory authority of country of origin or GMP certificate of API manufacturer issued by regulatory authority of country of origin.		The firm has provided copy of GMP certificate (Certificate# S-GMP/1803664) issued by FOOD 7 Drugs Control Administration for M/s Century Pharmaceuticals Ltd. Valid Up to 04-03-2020.		
Protocols followed for conduction of stability study and details of tests.				Yes
Data of 03 batches will be surespective documents lik laboratory reports, data sheet	e chromatograms,	Yes		
Documents confirming impo	rt of API etc.	Copy of invoice (Invoice No. CPLEXP1800196) for 1.25     Kg of Empagliflozin has been submitted attested by     Assistant Director DRAP, Lahore, dated 24-01-2019.		
All provided documents will be attested (name, sign and stamp) for ensuring authenticity of data / documents.				
Commitment to continue real time stability study till assigned shelf life of the product.		Yes		
Commitment to follow Drug Specification Rules, 1978.		Yes		
	REMARKS OF EVALUATOR			
<ul> <li>Clarification shall be submitted for use of methylene chloride for coating purpose, since it is a banned excipient.</li> <li>Stability summary sheets shall be submitted</li> </ul>				

• Stability summary sheets shall be submitted.

<b>43.</b>	Name and address of	M/s Himont Pharma Pvt Ltd, 17-Km Ferozpur Road, Lahore.
	manufacturer / Applicant	
	Brand Name +Dosage Form +	Glipto 25mg Tablet
	Strength	

Composition			Coated Tablet Con	tains:		
Diary No. Date of R&			Empagliflozin25mg"  Dy. No 13041 dated 12-11-2018 Rs.50,000/-			
		Antidiabetic				
Type of Form	Type of Form F					
Finished product Spe			er's specifications			
Pack size & Demande		As per PRC				
Approval status of Reference Authorities	product in A Regulatory	Approved b	y USFDA			
Me-too status (with st dosage form)	rength and E	Empator of	M/s Martin Dow			
GMP status	. 11					
Remarks of the Evalu		ABILITY	STUDY DATA			
Drug	Glipto 25mg		210212111			
Name of Manufacturer	M/s Himont P	Pharma Pvt	Ltd, 17-Km Ferozp	ur Road, Lahore.		
Manufacturer of API	Empagliflozin India.	n: M/s Cen	tury Pharmaceutica	ls Ltd., Panchmahal, Gujarat estate,		
API Lot No.	08964005-EN	ЛP				
Description of Pack (Container closure system)	Alu-Alu bliste	er with unit	carton			
Stability Storage Condition	Real time : 30 Accelerated: 4		65% ± 5%RH / 75% ± 5%RH			
Time Period	Real time: 6 n Accelerated: 6					
Frequency			1,2,3,4 & 6 months 6,9,12,18,24 months			
Batch No.	T-414		T-415	T-416		
Batch Size	2000 tablets		2000 tablets	2000 tablets		
Manufacturing Date	03-2019		03-2019	03-2019		
Date of Initiation	01-2020		01-2020	01-2020		
No. of Batches	03		1			
DOC	UMENTS / DA	ATA PRO	VIDED BY THE A	APPLICANT		
Documents To Be	Provided			Status		
COA of API			Yes			
Approval of API by regulatory authority of country of origin or GMP certificate of API manufacturer issued by regulatory authority of country of origin.		API S-GI ty of Adm	S-GMP/1803664) issued by FOOD & Drugs Control			
Protocols followed for conduction of stability study and details of tests.		bility	Yes			
Data of 03 batches will be supported by attested respective documents like chromatograms, laboratory reports, data sheets etc.						
Documents confirming impo	ort of API etc.			voice No. CPLEXP1800196) for 1.25 in has been submitted attested by		

	Assistant Director DRAP, Lahore, dated 24-01-2019.
All provided documents will be attested (name, sign and stamp) for ensuring authenticity of data / documents.	
Commitment to continue real time stability study till assigned shelf life of the product.	Yes
Commitment to follow Drug Specification Rules, 1978.	Yes

#### REMARKS OF EVALUATOR

- Clarification shall be submitted for use of methylene chloride for coating purpose, since it is a banned excipient.
- Stability summary sheets shall be submitted.

# Firm's response(II):

Firm has submitted stability data with revised formulation excluding Methylene chloride, details of which are as under:

Drug		Glipto 10mg Tablet			
Batch No.	T-435	T-436	T-437		
Batch Size	2000 tablets	2000 tablets	2000 tablets		
Manufacturing Date	12-2019	12-2019	12-2019		
Date of Initiation	01-2020	01-2020	01-2020		
Drug		Glipto 25mg T	ablet		
Batch No.	T-438	T-439	T-440		
Batch Size	2000 tablets	2000 tablets	2000 tablets		
Manufacturing Date	12-2019	12-2019	12-2019		
Date of Initiation	01-2020	01-2020	01-2020		

Moreover, firm has submitted dissolution data with specifications of NLT 75% within 15 minutes for two batches of each strength.

# Report on Investigation of Authenticity / Genuineness of data submitted for registration of Glipto 10mg & Glipto 25mg tablet of M/s. Himont Pharmaceuticals (Pvt.) Ltd, 17-km Ferozepur Road, Lahore.

Name of Manufacturer	M/s. Himont Pharmaceuticals (Pvt.) Ltd,		
Physical Address	17-km Ferozepur Road, Lahore.		
DML No. and Validity	000231		
Contact Address	17-km Ferozepur Road, Lahore.		
Date of Inspection	08-12-2021		
Purpose of Inspection	Panel inspection for verification of authenticity of stability data		
	for purpose of registration of drugs with reference to DRAP		
	Islamabad letter No. F.1-2/2020-PEC dated, 27-05-2021.		
Name of Inspectors	1. Dr. Munawar Hayat,		
	Director DTL, Lahore.		
	2. Ms. Aisha Irfan,		
	Area Federal Inspector of Drug,		
	DRAP, Lahore.		
	3. Ms. Maham Misbah,		
	Assistant Director, DRAP, Lahore.		
Name of firm representatives	1 Mr. Maqsood Ahmad,		
accompanying during inspection	Technical Director		
	2 Ms. Sammiy Bukhari		
	Production Incharge		

3	Mr. Faizan A. Ansari
	Quality Control Manager
4	Mr. Faisal Javid
	Quality Assurance Manager

# **Focus of Inspection**

The inspection of M/s. Himont Pharmaceuticals (Pvt.) Ltd, 17-km Ferozepur Road, Lahore was conducted with reference to DRAP Islamabad letter No. 1-2/2020-PEC dated 27-05-2021, for verification of authenticity of stability data of products namely Glipto 10mg Tablet and Glipto 25mg Tablet. The panel evaluated the relevant documentation and also visited the required facility and quality control laboratory of the company. The data of both products was evaluated in accordance with the checklist provided as given below.

Q. No.	Contents	Remarks
1.	Do you have documents confirming the import of API including approval from DRAP?	Firm has imported API (1.25 kg) vide Invoice No. CPL EXP1800196 dated 18-01-2019 & DRAP Noc No. 1350/2019 DRAP dated 24-01-2019. Second consignment of 0.6 kg was imported vide Invoice No. CPLEXP2000232 dated 08-01-2021 & DRAP Noc No. 2629/2021-DRAP dated 17-02-2021.
2.	What was the rationale behind selecting the particular manufacturer of API?	M/s. Century Pharmaceuticals, India was selected on the basis of desktop audit and vendor qualification done by M/s. Himont Pharmaceuticals (Pvt.) Ltd, 17- km Ferozepur Road, Lahore.
3.	Do you have documents confirming the import of reference standard and impurity standards?	Firm had imported Empagliflozin working standard from principal manufacturer. Reference standard was not available.
4.	Do you have certificate of Analysis of the API, reference standards and impurity standards?	COAs of API and working standard were available. Impurity standards were not available.
5.	Do you have GMP certificate of API manufacturer issued by regulatory authority of country of origin?	Yes
6.	Do you use API manufacturer method of testing for testing API?	Firm had taken API manufacturer's method of testing from the principal manufacturer. However, the method provided was incomplete and "run time" was not specified in case of analysis on HPLC. API was not tested for Residual solvents because the firm did not have the required QC equipment.
7.	Do you have stability studies reports on API?	Yes
8.	If yes, whether the stability testing has been performed as per SIM method and degradation products have been quantified?	Impurities had been quantified in the API by the principal manufacturer.
9.	Do you have method for quantifying the impurities in the API?	Firm had API manufacturer's method of quantifying the impurities.
10.	Do you have some remaining quantities of the API, its reference standard and impurities standards?	Firm had some remaining quantities of API and working standard.
11.	Have you used pharmaceutical grade excipients?	Yes (as per COAs shown to the panel)

12.	Do you have documents confirming the import of the used excipients?	Excipients were purchased locally, as informed by the firm's management.
13.	Do you have test reports and other records on the excipients used?	In-house COAs of excipients used were available.
14.	Do you have written and authorized protocols for the development of Glipto tablet?	Yes (In-house)
15.	Have you performed Drug-excipient compatibility studies?	Firm had selected excipients based on literature review of compatibility of API and excipients, as informed by the firm's management.
16.	Have you performed comparative dissolution studies?	Firm had used six basket dissolution apparatus for the comparative dissolution study. Reference product used was Diampa tablet 10mg & 25mg of M/s. Getz Pharma.  The comparative dissolution was not per formed at specifications of NLT 75% in 15 minutes.  Further, firm was advised to calculate similarity factor. Comparative dissolution profiling was performed on HPLC HP/QC/E-HPLC-04 on which audit trail was not enabled.
17.	Do you have product development (R&D) section	Firm had used the production equipment of commercial production area for the manufacturing of stability batches.
18.	Do you have necessary equipment available in product development section for development of Glipto tablet?	Yes
19.	Are the equipment in product development section qualified?	Firm had started the process of equipment qualification recently.
20.	Do you have proper maintenance / calibration / re-qualification program for the equipment used in PD section?	Maintenance record was available.
21.	Do you have qualified staff in product development section with proper knowledge and training in product development?	Staff of production was involved in product development as well.
22.	Have you manufactured three stability batches for the stability studies of Glipto tablet as required?	Firm had developed three batches for each strength. For 10mg strength following three batches were manufactured: - T 435, T 436, T437 Mfg 12/19 (Batch size 2000 tablets). For 25mg strength following three batches were manufactured:- T438, T439, T440 (Mfg date 12/19, Batch size 2000 tablets).
23.	Do you have any criteria for fixing the batch size of stability batches?	Batch size of 2000 tablets was fixed on the basis of tablets required for testing during the stability studies, as informed by the firm's management.
24.	Do you have complete record of production of stability batches?	BMRs were shown to the panel.
25.	Do you have protocols for stability	Yes

26.	Do you have developed and validated the method for testing of stability batches?	Yes, as per record shown to the panel.
27.	Do you have method transfer studies in case when the method of testing being used by your firm is given by any other lab?	No
28.	Do you have documents confirming the qualification of equipment / instruments being used in the test and analysis of and API and the finished drug?	Quality control equipment was calibrated and calibration certificates were shown to the panel. However, the firm was advised to procure PDA detector.
29.	Is your method of analysis stability indicating?	Record of forced degradation studies was shown to the panel.
30.	Do your HPLC software 21CFR Compliant?	No
31.	Can you show Audit trail reports on API testing?	Audit trail was not enabled.
32.	Do you have some remaining quantities of degradation products and stability batches?	Firm had some remaining quantities of stability batches.
33.	Do you have stability batches kept on stability testing?	Firm has stability batches Kept on real time stability testing only, at the time of inspection.
34.	Do you have valid calibration status for the equipment used in finished product production and analysis?	Yes
35.	Is proper and continuous monitoring and control are available for stability chamber?	Separate stability chambers were available for accelerated and real time stability studies. Log of conditions was readily available.
36.	Do related manufacturing area, equipment, personnel and utilities be rated as GMP compliant?	Firm had GMP compliance certificate issued by DRAP (78/2020-DRAP (AD-1923986-598) Valid till 16/12/2020.

#### **CONCLUSION**

The following additional point was also verified by the panel: -

"Performance of dissolution date with specifications of NLT 75% within 15 minutes for two batches of each strength."

As verified from documents shown to the panel the firm had developed following four batches from the additional 600gm imported material.

S. No.	Batch No.	Strength	Mfg date	Bach Size
01	T 485	10mg	03/21	2000 tablets
02	T 486	-DO-	-	-
03	T 487	25mg	-DO-	-DO-
04	T 488	-DO-	-	-

The firm had performed dissolution testing on afore mentioned four batches at t=O and t= 1-month testing intervals, for specifications NLT 75% at 15 minutes as communicated to the firm vide DRAP letter No. F. 1-1/2020/PEC-DRAP Islamabad (AD-PEC-11) dated 28/1/2021. Moreover, after January 2021, for t = 18 months firm had started dissolution testing of previously manufactured six stability batches with specifications NLT 75% at 15 minutes, according to documents shown to the panel. Additionally, samples of Glipto tab 10mg and 25mg were tested for dissolution at DTL, Lahore and the results are as follows:

Drug Release Results of Glipto Tablet 10mg & 25 mg			
Glipto Tablet 10mg (15 Min)		Glipto Tablet 2	25mg (15 Mis)
Vessel 1	94.13	Vessel 1	86.87

Tolerance Limit	NLT 75%(Q) at 15 min		
Vessel 2	96.91	Vessel 2	87.45
Vessel 3	86.68	Vessel 3	86.93
Vessel 4	92.59	Vessel 4	84.72
Vessel 5	91.05	Vessel 5	92.99
Vessel 6	99.04	Vessel 6	78.94
Ave.	93.40%	Ave.	86.31%

The dissolution / drug release results for Vessel 6 of Glipto Tab 25mg fall outside the drug dissolution limits i.e. Q+5% at stage 1.

Submitted for further necessary action please.

**Decision of 316**<sup>th</sup> **meeting:** Registration Board deferred the applications of Glipto 25mg & Glipto 10 mg for submission of clarification form the firm upon following observations reported by Inspection panel:

• The dissolution / drug release results Glipto Tab 25mg, analyzed at DTL, Lahore, fall outside the drug dissolution limits i.e. Q+5% at stage 1, for vessel 6.

**Firm's response(II):** Firm has submitted that to clarify the observation, according to Pharmacopoeial reference we have performed stage 2 (S2) for Glipto 25mg with another 6 units and results confirm no unit is less than Q-15%. Hence our product Glipto 25mg complies the USP standard specifications of dissolution.

Firm has also submitted analytical record (Chromatograms & raw data sheets) for the Stage 2 testing.

Decision: Registration Board approved Glipto 10mg Tablet & Glipto 25mg Tablet with Innovator's specifications. Firm shall submit fee of Rs. 7,500 for each strength for correction/pre-approval change/ in product specifications, as per notification No.F.7-11/2021-B&A/DRAP dated 13-07-2021.

- Manufacturer will place first three commercial batches on long term stability studies throughout
  proposed shelf life and on accelerated studies for six months as per the commitment submitted in the
  registration application.
- Manufacturer will perform process validation of first three commercial batches as per the commitment submitted in the registration application.

The Board further decided that the firm shall inform respective FID for taking sample of 1<sup>st</sup> commercial batch for its testing to be performed by CDL and sale of drug product will be done after satisfactory report of CDL.

Case no. 06 Registration applications for local manufacturing of (Human) drugs on Form 5
a. Deferred cases

44.	Name and address of manufacturer /	M/s Zephyr Pharmatec Pvt. Ltd., A-39, S.I.T.E. II, Super
	Applicant	Highway, Karachi. Contract manufacturing by M/s S.J.&G.
		Fazul Ellahie (Pvt.) Ltd. E/46, S.I.T.E. Karachi.
	Brand Name +Dosage Form + Strength	Tikonin injection 200mg
	Composition	Each vial contains:
		Tiecoplanin (lyophilized powder)200mg
	Diary No. Date of R& I & fee	Dy. No.7055; 22-06-2017; Rs.50,000/- (22-06-2017)
	Pharmacological Group	Antibacterial
	Type of Form	Form-5
	Finished product Specification	Innovator's specifications
	Pack size & Demanded Price	1's vial; As per PRC price

Approval status of product in Reference	Targocid 200mg powder for solution for injection/infusion
Regulatory Authorities.	(MHRA approved)
Me-too status	Targocid injection 200mg of M/s Hoechst Pakistan Ltd
GMP status	Last inspection report of M/s Zephyr Pharmatech conducted
	on 30-01-2018 concluding good level of GMP compliance.
	Last GMP Inspection of M/s S.J. & G. Fazul Ellahie
	conducted on 02-05-2018 with conclusive remarks as under:
	"The firm has complied/improved according to the directions
	of the FID. Panel was satisfied for the improvements under
	taken by the firm to comply with the observations dated 12th
	July 2017. Further the panel advised the firm to continue the
Remarks of the Evaluator.	improvements process"  M/s Zephyr Pharmatec has 9 approved sections.
Remarks of the Evaluator.	1 2
	and the firm has no product already registered under the contract manufacturing as confirmed by relevant registration
	section.
	M/s S.J.&G. Fazul Ellahie (Pvt.) Ltd. has approved
	Lyophilization (sterile area) powder injection general section.
Previous Decision:	Registration Board in its 283 <sup>rd</sup> meeting deferred for deferred
Tievious Decision.	for clarification of applied dosage form whether lyophilized
	powder or lyophilized cake.
Evaluation by PEC:	• Firm has submitted that ready to fill powder will be
Evaluation by TEC.	procured and powder filling will be done at sterile powder
	injectable area.
	<ul> <li>Moreover, firm has submitted GMP inspection report dated</li> </ul>
	29-08-2019, wherein following observation has been
	recorded under the section title of "Lyophilization (sterile
	area) powder injectable (general)":
	"Well equipped separate proper lyophilized powder,
	product filling. Packing activity is also carried out under
	the supervision of qualified person. Contour 40mg
	injection (Esomeprazole) was under production process
	with requisite documentation system in place."
Decision of 295th meeting: Deferred for	clarification from Licensing Division whether firm either has
lyophilization or dry powder injection or	both facilities.
	the Incharge PEC letter (No. F.13-11/2017-PEC) dated 08-10-
2020, Assitant Director (Lic) has replied v	vide their letter No.F.2-44/84-Lic(Vol-IV) dated 10-11-2021 has
replied as under:	
"As per record pf Licensing Dicvision, DI	RAP, Islamabad M/s M/s S.J.&G. Fazul Ellahie (Pvt.) Ltd. E/46
	3 (Formulation) possess both licensed sections with the title of
'Dry Powder injection (General) Lyophili	
	l for clarification whether innovator/reference product is
manufactured by way of lyophilization or	
•	"We would like to submit that reference products are being
	hat we have decided to manufacture these products same way as
that of reference product. i.e., vial lyophil	
<u> </u>	ubmission of complete Form-5 as per the revised manufacturing
	Rs.7,500 for correction/pre-approval change in manufacturing
method as per notification No.F.7-11/201	
•	the complete Form-5 as per the revised manufacturing method
along with the fee of Rs. 7,500/- via depo	SIT SIIP NO 396381U49436.

**B&A/DRAP** dated 13-07-2021.

Name and address of manufacturer /

**45.** 

**Applicant** 

approval change in composition to lyophilized injection, as per notification No.F.7-11/2021-

M/s Zephyr Pharmatec Pvt. Ltd., A-39, S.I.T.E. II, Super Highway, Karachi. Contract manufacturing by M/s S.J.&G.

Fazul Ellahie (Pvt.) Ltd. E/46, S.I.T.E. Karachi.

Brand Name +Dosage Form + Strength	Tikonin injection 400mg
Composition	Each vial contains:
•	Tiecoplanin (lyophilized powder)400mg
Diary No. Date of R& I & fee	Dy. No.7054; 22-06-2017; Rs.50,000/- (22-06-2017)
Pharmacological Group	Antibacterial
Type of Form	Form-5
Finished product Specification	Innovator's specifications
Pack size & Demanded Price	1's vial; As per PRC price
Approval status of product in Reference	Targocid 400mg powder for solution for injection/infusion
Regulatory Authorities.	(MHRA approved)
Me-too status	Targocid injection 400mg of M/s Hoechst Pakistan Ltd
GMP status	Last inspection report of M/s Zephyr Pharmatech conducted on 30-01-2018 concluding good level of GMP compliance. Last GMP Inspection of M/s S.J. & G. Fazul Ellahie conducted on 02-05-2018 with conclusive remarks as under: "The firm has complied/improved according to the directions of the FID. Panel was satisfied for the improvements under taken by the firm to comply with the observations dated 12th July 2017. Further the panel advised the firm to continue the improvements process"
Remarks of the Evaluator.	M/s Zephyr Pharmatec has 9 approved sections, and the firm has no product already registered under the contract manufacturing as confirmed by relevant registration section. M/s S.J.&G. Fazul Ellahie (Pvt.) Ltd. has approved Lyophilization (sterile area) powder injection general section.
Previous Decision:	Registration Board in its 283 <sup>rd</sup> meeting deferred for deferred for clarification of applied dosage form whether lyophilized powder or lyophilized cake.
Evaluation by PEC:	<ul> <li>Firm has submitted that ready to fill powder will be procured and powder filling will be done at sterile powder injectable area.</li> <li>Moreover firm has submitted GMP inspection report dated 29-08-2019, wherein following observation has been recorded under the section title of "Lyophilization (sterile area) powder injectable (general)":  "Well equipped separate proper lyophilized powder/product filling. Packing activity is also carried out under the supervision of qualified person. Contour 40mg injection (Esomeprazole) was under production process with requisite documentation system in place."</li> </ul>

**Decision of 295**<sup>th</sup> **meeting:** Deferred for clarification from Licensing Division whether firm either has lyophilization or dry powder injection or both facilities.

**Evaluation by PEC:** In response to the Incharge PEC letter (No. F.13-11/2017-PEC) dated 08-10-2020, Assitant Director (Lic) has replied vide their letter No.F.2-44/84-Lic(Vol-IV) dated 10-11-2021 has replied as under:

"As per record pf Licensing Dicvision, DRAP, Islamabad M/s M/s S.J.&G. Fazul Ellahie (Pvt.) Ltd. E/46, S.I.T.E. Karachi under DML No. 000083 (Formulation) possess both licensed sections with the title of 'Dry Powder injection (General) Lyophilized & Dry Powder Injection (General)"

**Decision of 313r<sup>d</sup> meeting:** Deferred for clarification whether innovator/reference product is manufactured by way of lyophilization or otherwise.

**Firm's response:** Firm has stated that "We would like to submit that reference products are being manufactured by vial lyophilization and that we have decided to manufacture these products same way as that of reference product. i.e., vial lyophilization.

**Decision of 316**<sup>th</sup> **meeting:** Deferred for submission of complete Form-5 as per the revised manufacturing method along with submission of fee of Rs.7,500 for correction/pre-approval change in manufacturing method as per notification No.F.7-11/2012-B&A/DRAP dated 13-07-2021.

Firm's response(II): Firm has submitted the complete Form-5 as per the revised manufacturing method along with the fee of Rs. 7,500/- via deposit slip no 09367970452. Approved. Firm shall submit differential fee of Rs. 67,500/- for correction/pre-approval change in composition to lyophilized injection, as per notification No.F.7-11/2021-B&A/DRAP dated 13-07-Name and address of manufacturer / M/s Zephyr Pharmatec Pvt. Ltd., A-39, S.I.T.E. II, Super 46. **Applicant** Highway, Karachi. Contract manufacturing by M/s S.J.&G. Fazul Ellahie (Pvt.) Ltd. E/46, S.I.T.E. Karachi. Brand Name +Dosage Form + Strength Venko injection 500mg Composition Each vial contains: Vancomycin as hydrochloride......500mg Dy. No.7059; 22-06-2017; Rs.50,000/- (22-06-2017) Diary No. Date of R& I & fee Pharmacological Group Antibacterial Type of Form Form-5 Finished product Specification USP Pack size & Demanded Price 1's vial; As per PRC's price Approval status of product in Reference (USFDA approved) Regulatory Authorities. Me-too status Maparix 500mg Injection of M/s S.J.&G. Fazul Ellahie **GMP** status Last inspection report of M/s Zephyr Pharmatech conducted on 30-01-2018 concluding good level of GMP compliance. Last GMP Inspection of M/s S.J. & G. Fazul Ellahie conducted on 02-05-2018 with conclusive remarks as under: "The firm has complied/improved according to the directions of the FID. Panel was satisfied for the improvements under taken by the firm to comply with the observations dated 12th July 2017. Further the panel advised the firm to continue the improvements process" Remarks of the Evaluator. M/sZephyr Pharmatec has 9 approved and the firm has no product already registered under the contract manufacturing as confirmed by relevant registration section. M/s S.J.&G. Fazul Ellahie (Pvt.) Ltd. has approved Lyophilization (sterile area) powder injection general section. Registration Board in its 283<sup>rd</sup> meeting deferred for deferred Previous Decision: for clarification of applied dosage form whether lyophilized powder or lyophilized cake. Evaluation by PEC: Firm has submitted that ready to fill powder will be procured and powder filling will be done at sterile powder injectable area. Moreover firm has submitted GMP inspection report dated 29-08-2019, wherein following observation has been recorded under the section title of "Lyophilization (sterile area) powder injectable (general)": "Well equipped separate proper lyophilized powder/ product filling. Packing activity is also carried out under the supervision of qualified person. Contour 40mg injection (Esomeprazole) was under production process with requisite documentation system in place." Decision of 295<sup>th</sup> meeting: Deferred for clarification from Licensing Division whether firm either has

lyophilization or dry powder injection or both facilities.

Evaluation by PEC: In response to the Incharge PEC letter (No. F.13-11/2017-PEC) dated 08-10-2020, Assitant Director (Lic) has replied vide their letter No.F.2-44/84-Lic(Vol-IV) dated 10-11-2021 has replied as under:

"As per record pf Licensing Dicvision, DRAP, Islamabad M/s M/s S.J.&G. Fazul Ellahie (Pvt.) Ltd. E/46, S.I.T.E. Karachi under DML No. 000083 (Formulation) possess both licensed sections with the title of 'Dry Powder injection (General) Lyophilized & Dry Powder Injection (General)"

**Decision of 313<sup>rd</sup> meeting:** Deferred for clarification whether innovator/reference product is manufactured by way of lyophilization or otherwise.

**Firm's response:** Firm has stated that "We would like to submit that reference products are being manufactured by vial lyophilization and that we have decided to manufacture these products same way as that of reference product. i.e., vial lyophilization.

**Decision of 316<sup>th</sup> meeting:** Deferred for submission of complete Form-5 as per the revised manufacturing method along with submission of fee of Rs.7,500 for correction/pre-approval change in manufacturing method as per notification No.F.7-11/2012-B&A/DRAP dated 13-07-2021.

**Firm's response(II):** Firm has submitted the complete Form-5 as per the revised manufacturing method along with the fee of Rs. 7,500/- via deposit slip no 57760587932.

Approved. Firm shall submit differential fee of Rs. 67,500/- for correction/pre-approval change in composition to lyophilized injection, as per notification No.F.7-11/2021-B&A/DRAP dated 13-07-2021.

	2021.	s per notification (10.1.7-11/2021-Dec/4/DIA)1 dated 15-07-
47.	Name and address of manufacturer / Applicant	M/s Zephyr Pharmatec Pvt. Ltd., A-39, S.I.T.E. II, Super Highway, Karachi. Contract manufacturing by M/s S.J.&G. Fazul Ellahie (Pvt.) Ltd. E/46, S.I.T.E. Karachi.
	Brand Name +Dosage Form + Strength	Venko injection 1Gm
	Composition	Each vial contains:
		Vancomycin as hydrochloride1gm
	Diary No. Date of R& I & fee	Dy. No.7064; 22-06-2017; Rs.50,000/- (22-06-2017)
	Pharmacological Group	Antibacterial
	Type of Form	Form-5
	Finished product Specification	USP
	Pack size & Demanded Price	1's vial; As per PRC's price
	Approval status of product in Reference Regulatory Authorities.	(USFDA approved)
	Me-too status	Maparix 1gm Injection of M/s S.J.&G. Fazul Ellahie
	GMP status	Last inspection report of M/s Zephyr Pharmatech conducted on 30-01-2018 concluding good level of GMP compliance. Last GMP Inspection of M/s S.J. & G. Fazul Ellahie conducted on 02-05-2018 with conclusive remarks as under: "The firm has complied/improved according to the directions of the FID. Panel was satisfied for the improvements under taken by the firm to comply with the observations dated 12th July 2017. Further the panel advised the firm to continue the improvements process"
	Remarks of the Evaluator.	M/s Zephyr Pharmatec has 9 approved sections, and the firm has no product already registered under the contract manufacturing as confirmed by relevant registration section. M/s S.J.&G. Fazul Ellahie (Pvt.) Ltd. has approved Lyophilization (sterile area) powder injection general section.
	Previous Decision:	Registration Board in its 283 <sup>rd</sup> meeting deferred for deferred for clarification of applied dosage form whether lyophilized powder or lyophilized cake.
	Evaluation by PEC:	<ul> <li>Firm has submitted that ready to fill powder will be procured and powder filling will be done at sterile powder injectable area.</li> <li>Moreover firm has submitted GMP inspection report dated 29-08-2019, wherein following observation has been recorded under the section title of "Lyophilization (sterile area) powder injectable (general)":         "Well equipped separate proper lyophilized powder/product filling. Packing activity is also carried out under the supervision of qualified person. Contour 40mg injection (Esomeprazole) was under production process with requisite documentation system in place."     </li> </ul>

**Decision of 295**<sup>th</sup> **meeting:** Deferred for clarification from Licensing Division whether firm either has lyophilization or dry powder injection or both facilities.

**Evaluation by PEC:** In response to the Incharge PEC letter (No. F.13-11/2017-PEC) dated 08-10-2020, Assitant Director (Lic) has replied vide their letter No.F.2-44/84-Lic(Vol-IV) dated 10-11-2021 has replied as under:

"As per record pf Licensing Dicvision, DRAP, Islamabad M/s S.J.&G. Fazul Ellahie (Pvt.) Ltd. E/46, S.I.T.E. Karachi under DML No. 000083 (Formulation) possess both licensed sections with the title of 'Dry Powder injection (General) Lyophilized & Dry Powder Injection (General)"

**Decision of 313<sup>rd</sup> meeting:** Deferred for clarification whether innovator/reference product is manufactured by way of lyophilization or otherwise.

**Firm's response:** Firm has stated that "We would like to submit that reference products are being manufactured by vial lyophilization and that we have decided to manufacture these products same way as that of reference product. i.e., vial lyophilization.

**Decision of 316**<sup>th</sup> **meeting:** Deferred for submission of complete Form-5 as per the revised manufacturing method along with submission of fee of Rs.7,500 for correction/pre-approval change in manufacturing method as per notification No.F.7-11/2012-B&A/DRAP dated 13-07-2021.

**Firm's response(II):** Firm has submitted the complete Form-5 as per the revised manufacturing method along with the fee of Rs. 7,500/- via deposit slip no 9106158432.

Approved. Firm shall submit differential fee of Rs. 67,500/- for correction/pre-approval change in composition to lyophilized injection, as per notification No.F.7-11/2021-B&A/DRAP dated 13-07-2021.

Case no. 07 Priority Registration applications of New Human drugs on

Name, address of Applicant / Importer	M/s Roche Pakistan Limited, 1 <sup>st</sup> floor, 37-B, Block 6, PECHS, Karachi.		
Details of Drug Sale License of importer	License No: 0171 Address: Roche Pakistan Limited, 1st floor, 37-B Block 6 PECHS, Karachi. Address of Godown:  • R-PI, plot no. 116, sector 15, K.I.A, Karachi Validity: 13-09-2022. Status: Drug License by way of wholesale Renewal: N/A		
Name and address of marketing authorization holder (abroad)	M/s Genentech, Inc. (A member of the Roche group), 1 DNA Way, PDRO building 35, MS 355J, South San Francisco, CA 94080 United States of America.		
Name, address of finished drug product manu	ufacturer(s):		
Name and Address of Site	Activities Occurring at Site		
Catalent CTS, LLC 10245 Hickman Mills Drive Kansas City, Missouri (MO) 64137, United States (USA) Anderson Brecon Inc. (PCI Pharma Services) 4545 Assembly Drive, Rockford,	Pralsetinib Capsules (bulk) Manufacturing Release Testing Stability Testing Bulk Capsules Packaging Primary and Secondary Packaging and Labeling Batch Release		
	e		
Illinois (IL) 61109, United States (USA)  F. Hoffmann-La Roche AG, Contract Organizations, Viaduktstrasse 33, CH-4051 Basel Switzerland	Batch Release  Batch Release		

Detail of certificates attached (CoPP, Free sale	CoPP:
certificate, GMP certificate)	<ul> <li>The firm submitted the copy of the CoPP certificate (No. DUTP-N2ZR) dated 24-02-2021 issued by USFDA (valid till 23-02-2023). The MAH details are "Blueprint medicines corporation, 45 Sidney St, Cambridge, MA 02139 United Staes of America."</li> <li>Later on, the Firm has submitted an original, legalized CoPP on 04-04-2022, certificate (No. TYD4-4GJB) issued by USFDA on 02-08-2021 (valid till 01-08-2023). The applied product is available in the market of exporting countries for free sale. The MAH details are Genentech, Inc (A member of the Roche group), 1 DNA Way, PDRO Building 35, MS 355J, South San Francisco, CA, 94080 United States of America</li> </ul>
Details of letter of authorization / sole agency agreement	Firm has submitted copy of authorization letter for M/s F. Hoffmann-La Roche Ltd., Grenzacherstrasse 124, CH-4070 Basel, Switzerland (authorized M/s Roche Pakistan Limited for marketing and distribution of Gavreto 100mg capsule in Pakistan).
	Firm has submitted copy of letter indicating relationship between M/s F. Hoffmann-La Roche Ltd., Basel, Switzerland and M/s Genentech, Inc. (A member of the Roche group), San Francisco, California, United States of America Firm has also submitted another letter which shows the relationship between M/s F. Hoffmann-La Roche Ltd., Basel, Switzerland and Catalent CTS, LLC, Kansas City, USA
Status of the applicant	<ul> <li>☐ Manufacturer</li> <li>☑ Importer</li> <li>☐ Is involved in none of the above (contract giver)</li> </ul>
Status of application	<ul><li>☑ New Drug Product (NDP)</li><li>☐ Generic Drug Product (GDP)</li></ul>
Intended use of pharmaceutical product	<ul><li>☑ Domestic sale</li><li>☐ Export sale</li><li>☐ Domestic and Export sales</li></ul>
For imported products, specify one the these	<ul> <li>☑ Finished Pharmaceutical product import</li> <li>☐ Buk import and local repackaging</li> <li>☐ Buk import and local repackaging for export purpose only</li> </ul>
Dy. No. and date of submission	Dy.No 22580 dated 17-08-2021
Details of fee submitted	Rs.50,000/- dated 30-06-2021 & Rs.25,000/- dated 23-06-2021
The proposed proprietary name / brand name	Gavreto 100mg capsule
Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each capsule contains: Pralsetinib100mg

Pharmaceutical form of applied drug	Size 0 light blue opaque HPMC capsule, printed in white ink with "BLU-667" on the capsule shell body and "100 mg" on the capsule shell capsule	
Pharmacotherapeutic Group of (API)	Kinase inhibitor	
Reference to Finished product specifications	Innovator's specifications	
Proposed pack size	60 capsules 90 capsules 120 capsules	
Proposed unit price	As per SRO	
The status in reference regulatory authorities	Gavreto 100mg capsule (USFDA Approved)	
For generic drugs (me-too status)	N/A	
Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PI template. Firm has summarized information related to nomenclature, structure, general properties solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its verification studies, batch analysis and justification of specification, reference standard container closure system and stability studies of drug substance.  The firm has summarized information of drug product including its description, composition pharmaceutical development, manufacture manufacturing process and process control, process validation protocols, control of excipients, control of drug product, specifications, analytical procedures verification studies of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability	
Name, address of drug substance manufacturer	Hovione Farmaciencia, S.A. Sete Casas, Loures, 2674-506, Portugal (PRT)	
Module-III Drug Substance:	Firm has submitted detailed drug substance data for both sources related to nomenclature, structure general properties, solubilities, physical form manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard container closure system and stability studies of drug substance.	
Stability Studies of Drug Substance (Conditions & duration of Stability studies)	<ul> <li>12 months real time stability data at 25°C ± 2°C 60% ± 5% RH of 03 batches</li> <li>06 month accelerated stability data 40°C ± 2°C / 75% ± 5% RH of 03 batches</li> </ul>	
Module-III Drug Product:	Firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control,	

	process validation protocols, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.
Pharmaceutical Equivalence and Comparative Dissolution Profile	N/A
Analytical method validation/verification of product	Firm has submitted analytical method validation studies for the applied product.
Container closure system of the drug product	Low-density polyethylene (LDPE) bag
Stability study data of drug product, shelf life and storage conditions	<ul> <li>24 months real time stability data at 30°C ± 2°C / 75% ± 5%RH of 03 batches</li> <li>06 month accelerated stability data 40°C ± 2°C / 75% ± 5%RH of 03 batches</li> </ul>

#### **Evaluation by PEC(II):**

As per section 3.2.P.3.1 the site for Primary and Secondary Packaging has been declared as M/s Anderson Brecon Inc. (PCI Pharma Services) 4545 Assembly Drive, Rockford, Illinois (IL) 61109, United States (USA) whereas the finished drug product stability studies data has been submitted from M/s Catalent CTS, LLC 10245 Hickman Mills Drive Kansas City, Missouri (MO) 64137, United States (USA), which is a site for Capsules (bulk) Manufacturing.

**Discussion:** Registration Board was apprised that the firm has submitted their response that "as per the standard US CPP template, the batch release site is not mentioned in the CPP. However, since the packager is mentioned as Anderson Brecon Inc., Illinois, United States, it also includes the batch release activity from the same site as the part of process"

Decision: Approved with Innovator's specifications as per Policy for inspection of Manufacturer abroad and verification of local storage facility.

49.	Name, address of Applicant / Marketing Authorization Holder	M/s Islam Pharmaceuticals 7KM Pasrur Road Sialkot	
	Name, address of Manufacturing site.	M/s Islam Pharmaceuticals 7KM Pasrur Road Sialkot	
	Status of the applicant	<ul> <li>✓ Manufacturer</li> <li>☐ Importer</li> <li>☐ Is involved in none of the above (contract giver)</li> </ul>	
		☐ New Drug Product (NDP) ☐ Generic Drug Product (GDP)	
	Intended use of pharmaceutical product	<ul><li>☑ Domestic sale</li><li>☐ Export sale</li><li>☐ Domestic and Export sales</li></ul>	
	Dy. No. and date of submission	Dy. No 25696 dated 15-09-2021	
	Details of fee submitted	PKR 30,000/- Dated: 31/08/2021	
	The proposed proprietary name / brand name	Troket 30mg/ml Injection	
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each 1ml ampoule contains: Ketorolac Tromethamine USP30mg	

	Clear and colorless solution filled in clear glass ampoules vered and blue ACF rings and blue color OPC mark
Pharmacotherapeutic Group of (API)	Anti-inflammatory, non-steroid
Reference to Finished product specifications	USP
Proposed Pack size	1ml×5's
Proposed unit price	As per SRO
authorities	Ketorolac Tromethamine injection 30mg/ml by Peckforton Pharmaceuticals Limited Crewe Hall, Cre Cheshire, CW1 6UL, United Kingdom, MHRA Approved.
	Toradol Injection 30mg/ml by M/s Barrett Hodgson Pakis (Pvt.) Ltd. Reg. No. 015000
manufacturer	New Section for liquid ampoule (SVP) General was gran after inspection vide letter No. F. 1-19/2014-Lic (Vol-1) Dated: 18/12/2020
	M/s PERKIN LABORATORIES, plot No. 94 TSIIC, Industrial estate, Medchal Dist. 501401, Telangana, INDIA
	Firm has submitted QOS as per WHO QOS-PD temple. Summarized information related to nomenclature, structure general properties, solubilities, physical form, manufacture description of manufacturing process and controls, impurit specifications, analytical procedures and its verification, bar analysis and justification of specification, reference standar container closure system and stability studies of disubstance and drug product is submitted.
	Official monograph of Ketorolac Tromethamine is present USP. The firm as submitted detail of nomenclature, structure general properties, solubilities, physical form, manufacture description of manufacturing process and controls, tests organic impurities by HPLC (impurity A, impurity B, Impurity C and Impurity D), specifications, analytical procedures its verification, batch analysis and justification specification, reference standard, container closure system a stability studies of drug substance.
	Stability study conditions: Real time: $30^{\circ}\text{C} \pm 2^{\circ}\text{C} / 65\% \pm 5\%\text{RH}$ for 60 months Accelerated: $40^{\circ}\text{C} \pm 2^{\circ}\text{C} / 75\% \pm 5\%\text{RH}$ for 06 months Batches:(KM-1102215, KM-1102315, KM-1102415)
-	The firm has submitted detail of manufacturers, description manufacturing process and controls, impurities, specification analytical procedure and its verification studies, batch analytical procedure and its verification studies, batch analytical justification of specification, reference standard, contain closure system and stability studies of drug product.
comparative dissolution profile	Pharmaceutical Equivalence have been established against brand leader that is Toradol 30mg/ml injection by Sa Pharmaceuticals by performing quality tests (Appearar Identification, Assay, pH and Volume Variation). All parameters results are in the acceptable range.
	Method verification studies have submitted including linear

	STABILITY STUDY DATA				
Manu	ıfacturer of	API	M/s PERKIN LABORATORIES, plot No. 94 TSIIC, Industrial estate, Medchal Dist. 501401, Telangana, INDIA		
API I	Lot No.		KM-1104620		
	ription of Pa		USP Type-I Glass amp	oules in PVC Tray, packe	ed in unit carton (1ml×5's)
Stabi Cond		Storage	Real time: $30^{\circ}\text{C} \pm 2^{\circ}\text{C}$ Accelerated: $40^{\circ}\text{C} \pm 2^{\circ}\text{C}$		
Time	Period		Real time: 06 months Accelerated: 06 month	s	
Frequ	iency		Accelerated: 0, 3, 6 (MoReal Time: 0, 3, 6 (Mo		
Batch	ı No.		21ARn033	21ARn034	21ARn035
Batch	n Size		2500 ampoules	2500 ampoules	2500 ampoules
Manu	ıfacturing D	ate	04-2021	04-2021	04-2021
Date	of Initiation	1	11-05-2021	11-05-2021	11-05-2021
No. c	of Batches			03	
			Admir	nistrative Portion	
13.	Reference application firm (if any	ıs with stal	evious approval of pility study data of the	The firm has not submitted any document. (New Section)	
14.	14. Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.  Copy of GMP certificate No. 3879/Stores/2019 issued by DCA valid till 10/01/2021.			•	
15.		• Copy of letter No.14850/2020/DRAP-AD-VIII (I&E) da 16/10/2020 is submitted wherein the permission to impord different APIs including Ketorolac Tromethamine for the purpose of test/analysis and stability studies is granted.  • AirWay Bill No. 176-26046624 Dated: 21/12/2020		ed wherein the permission to import ng Ketorolac Tromethamine for the s and stability studies is granted.	
16.	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.		Submitted		
17.	17. Compliance Record of HPLC software 21CFR & audit trail reports on product testing				
18.		chambers	humidity monitoring of Submitted ers (real time and		Submitted
-	Remarks of Evaluator(II):				
	Section# Observations Firm's response				
1.6.5		the relevar	P certificate issued by at regulatory authority bmitted for the drug manufacturer.	Copy of GMP certificate No. 77981/TS/2022 issued by DCA Telangana valid till 02/01/2023 has been submitted	

		<del></del>
3.2. S.4.1	Limits for the test of pH are different between the drug substance manufacturer & drug product manufacturer.	As per USP monograph of Ketorolac Tromethamine, Limit for pH is 5.7 – 6.7 which is mentioned in test method and specifications submitted by Drug product manufacturer. Drug substance manufacturer mentioned the pH limit 5.7-6.0 in his specification, However in CoA of drug substance and stability study data submitted by Drug substance manufacturer the limit for pH is mentioned 5.7 – 6.7 (as per USP), copy of CoA provided by Drug substance manufacturer for ketorolac Tromethamine having pH limit as per USP (5.7 – 6.7) is submitted
3.2. S.4.2	Sample and standard solution concentration mentioned in the Assay test method from drug substance manufacturer are different from that recommended by USP monograph of "Ketorolac tromethamine".	USP monograph of Ketorolac Tromethamine recommends concentration of reference and sample solution to be 0.4mg/ml for assay test. For Assay test Drug substance manufacturer referred to related substances sample and standard preparation which is 20mg sample dissolved in 50ml of solvent. The resultant concentration becomes 0.4mg/ml which is same as recommended by USP.
3.2.S.7	Long term stability conditions mentioned in summary & conclusion are different from that declared in the stability data submitted in section 3.2.S.7.3.	Long term stability conditions mentioned in summary and conclusion are different from declared in stability data because in DMF the manufacturer mentioned Zone II conditions and provided stability data for long term stability studies at 25oC/60%RH.  After receiving DMF we asked the drug substance manufacturer to provide Zone-IVA (30oC/65%RH) stability data which is submitted under stability data in section 3.2.S.7.3.
3.2.P.1	<ul> <li>Justify the role of Ethyl alcohol as antimicrobial preservative in the applied formulation.</li> <li>Reference for use of Citric acid as anti-oxidant in the innovator formulation shall be submitted.</li> </ul>	Ethyl alcohol is also used as solvent and penetration enhancer to enhance the solubility of ingredients and it is used as solvent/solubility enhancer in our formulation. By mistake only one function of ethyl alcohol (antimicrobial preservative) was written under section <b>3.2.P.1</b> which is corrected and submitted.
3.2.P.2.2.1	Complete testing has not been performed during Pharmaceutical equivalence studies.	Complete testing was performed during Pharmaceutical equivalence studies (mentioned in finish product reports under batch analysis), sterility and endotoxin test were not reported in pharmaceutical equivalence report which is corrected and revised report containing all test and results are submitted.
3.2.P.3.2	Justify the proposed quantity of drug substance in mg/ml against the label claim.	The quantity of drug substance is written mg per 1.1ml to achieve the deliverable volume (NLT 1ml) per unit in section 3.2.P.3.2. However, to clear the ambiguity, quantity of drug substance is corrected to mg/1ml and submitted
3.2.P.3.3	Justify the performance of terminal sterilization by autoclave while ethyl alcohol is used in the formulation	Firm has referred to a patent wherein terminal sterilization has been performed for Ketorolac injection containing Ethyl alcohol.
2.3.R.1.1	• Justify the performance of terminal sterilization by autoclave while ethyl alcohol is used in the formulation.	<ul> <li>Firm has referred to a patent wherein terminal sterilization has been performed for Ketorolac injection containing Ethyl alcohol.</li> <li>Minimum handling capacity of mixing vessel used in production of trial batches is 1.5 liters.</li> </ul>

Submit the minimum handling	
capacity of the mixing vessel used	
for the production of trial batches.	

Decision: Deferred for scientific rationale of performing terminal sterilization, with reference to the innovator product.

**Firm Response:** After extensive search at product development stage we did not found any innovator document either recommending terminal sterilization or prohibiting from it, so we chose a safe combination of sterilization procedure for applied product i-e **Terminal sterilization along with filtration**.

We performed sterilization of applied product by filtration before filling and sealing (mentioned in BMR provided in CTD) and then terminally sterilized it.

After manufacturing and sterilization of applied product by above mentioned procedure we performed finish product analysis and stability studies (accelerated and long term) for six months on filtered and terminally sterilized drug product and the results were satisfactory (results provided in CTD under Batch analysis and Stability Studies).

**Discussion:** Registration Board deliberated that the innovator product has not recommended terminal sterilization for the applied product and that it is also not recommended when volatile solvents like ethyl alcohol is used in the formulation.

**Decision: Regsitration Board deferred the case for following:** 

- Submission of 3 months stability studies data with frequency of 0,1& 3 months, at both accelerated and long-term conditions, for three new batches, manufactured without terminal sterilization.
- Full fee of registration i.e., Rs. 30,000 for for submission of new stability studies data, as per notification No.F.7-11/2012-B&A/DRAP dated 13-07-2021.

50.	Name, address of Applicant / Marketing Authorization Holder	M/s Islam Pharmaceuticals 7KM Pasrur Road Sialkot	
	Name, address of Manufacturing site.	M/s Islam Pharmaceuticals 7KM Pasrur Road Sialkot	
	Status of the applicant	<ul> <li>☑ Manufacturer</li> <li>☐ Importer</li> <li>☐ Is involved in none of the above (contract giver)</li> </ul>	
	Status of application	☐ New Drug Product (NDP) ☐ Generic Drug Product (GDP)	
	Intended use of pharmaceutical product	<ul><li>☑ Domestic sale</li><li>☐ Export sale</li><li>☐ Domestic and Export sales</li></ul>	
	Dy. No. and date of submission	Dy.No 27960 dated 11-10-2021	
Details of fee submitted PKR 30,000/- Dated: 16/09/202 The proposed proprietary name / brand name Neurone 3ml Injection		PKR 30,000/- Dated: 16/09/2021	
		Neurone 3ml Injection	
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each 3ml ampoule contains: Vitamin B1 (Thiamine HCl) USP100mg Vitamin B6 (Pyridoxine HCl) USP100mg Vitamin B12(Cyanocobalamin)USP1000mcg	
	Pharmaceutical form of applied drug	Red color clear solution filled in amber glass ampoules with white color breaking ring	
	Pharmacotherapeutic Group of (API)	Vitamin B compound	
	Reference to Finished product specifications	Innovator	
	Proposed Pack size	3ml×25's	
	Proposed unit price	As per SRO	
	The status in reference regulatory authorities	Neurobion solution for injection by M/s Merck Selbstmedikation GmbH. Germany Approved	

T		
	Neurobion injection by M/s Martin Dow Marker Ltd. Reg. No. 001485	
manufacturer	New Section for liquid ampoule (SVP) General v granted after inspection vide letter No. F. 1-19/2014-Lic (Vol-1) Dated: 18/12/2020	
	Thiamine HCl & Pyridoxine HCl: M/s Jiangxi Tianxin Pharmaceuticals Co., Ltd Cyanocobalamin: M/s Hebei North China Pharmaceutical Huahang Pharmaceutical Co., Ltd.	
	Firm has submitted QOS as per WHO QOS-PD templ Summarized information related to nomenclate structure, general properties, solubilities, physical formanufacturers, description of manufacturing process controls, impurities, specifications, analytical procedu and its verification, batch analysis and justification specification, reference standard, container closure systand stability studies of drug substance and drug production submitted.	
	Official monograph of Pyridoxine Hydrochlor. Thiamine Hydrochloride and Cyanocobalamin is present USP. The firm as submitted detail of nomenclate structure, general properties, solubilities, physical formanufacturers, description of manufacturing process controls, tests for related compounds by HPLC impurities by Residue on Ignition, specifications, analytic procedures and its verification, batch analysis justification of specification, reference standard, contain closure system and stability studies of drug substance.	
	Thiamine Hydrochloride: Stability study conditions: Real time: $30^{\circ}\text{C} \pm 2^{\circ}\text{C} / 65\% \pm 5\%\text{RH}$ for 36 months Accelerated: $40^{\circ}\text{C} \pm 2^{\circ}\text{C} / 75\% \pm 5\%\text{RH}$ for 06 months Batches:(TH130130130, TH130130131, TH130130132 Pyridoxine Hydrochloride: Stability study conditions: Real time: $30^{\circ}\text{C} \pm 2^{\circ}\text{C} / 65\% \pm 5\%\text{RH}$ for 48 months Accelerated: $40^{\circ}\text{C} \pm 2^{\circ}\text{C} / 75\% \pm 5\%\text{RH}$ for 06 months Batches:(PH2084024, PH2084025, PH2084026) Cyanocobalamin: Stability study conditions: Real time: $30^{\circ}\text{C} \pm 2^{\circ}\text{C} / 65\% \pm 5\%\text{RH}$ for 60 months Batches:(000707, 011013, 020716) Accelerated: $40^{\circ}\text{C} \pm 2^{\circ}\text{C} / 75\% \pm 5\%\text{RH}$ for 06 months Batches:(C190601C, C190602C, C190603C)	
Module-III (Drug Product):	The firm has submitted detail of manufacturers, descript of manufacturing process and controls, impurit specifications, analytical procedure and its validat studies, batch analysis and justification of specification reference standard, container closure system and stabi studies of drug product.	
	Pharmaceutical Equivalence have been established again	

			Marker Ltd. by performing quality tests (Appearance, Identification, Assay, pH and Volume Variation). All parameters results are in the acceptable range.		
	product		Method validation studies have submitted including, Specificity, Limit of Detection, Limit of Quantitation, linearity, range, accuracy, precision, Robustness.		
		STABILITY	Y STUDY DATA		
Manu	ufacturer of API	Thiamine HCl & Pyride M/s Jiangxi Tianxin Phar Cyanocobalamin: M/s Hebei North China I			
API I	Lot No.	Thiamine Hydrochloric Pyridoxine Hydrochlor Cyanocobalamin: C201	hloride: TH20115047 chloride:PH18114018		
	ription of Pack tainer closure system)	USP Type-I amber Glass	ampoules in PVC Tray, pacl	ked in unit carton (3ml×25's)	
Stabi	lity Storage Condition	Real time: $30^{\circ}\text{C} \pm 2^{\circ}\text{C} / 60^{\circ}$ Accelerated: $40^{\circ}\text{C} \pm 2^{\circ}\text{C}$			
Time	Period	Real time: 03 months Accelerated: 03 months			
Frequ	uency	-	Accelerated: 0, 3, 6 (Months) Real Time: 0, 3, 6 (Months)		
Batch	n No.	21ARn051	21ARn052	21ARn053	
Batch	n Size	1500 ampoules	1500 ampoules	1500 ampoules	
Manu	ufacturing Date	04-2021	04-2021	04-2021	
Date	of Initiation	21-05-2021	21-05-2021	21-05-2021	
No. c	of Batches		03		
		Administ	rative Portion		
1.	Reference of previous with stability study da		The firm has not submitted any document. (New Section)		
2.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.				
3.	Documents for the procurement of API with approval from DRAP (in case of import).		<ul> <li>Copy of letter No.14850/2020/DRAP-AD-VIII (I&amp;E) dated 16/10/2020 is submitted wherein the permission to import different APIs including Pyridoxine HCl, Thiamine HCl and Cyanocobalamin for the purpose of test/analysis and stability studies is granted.</li> <li>DHL No.XMLPI 6.2/90-1604 dated 19/11/2020 &amp; DHL No. V4955EL4OKM Dated: 18-12-2020</li> </ul>		
4.	4. Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.		Sub	mitted	

5.		ance Record of HPLC software 21CFR trail reports on product testing	Submitted	
6. Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)		of Digital data logger for temperature midity monitoring of stability chambers ne and accelerated)	Submitted	
Rema	rks of E	Evaluator <sup>II</sup> :		
Section	n#	Observations	Firm's response	
3.2.P.		<ul> <li>Submit the justification for including anti-microbial preservative in applied formulation.</li> <li>Justify the quantities of each API mentioned in composition table against the label claim.</li> </ul>	<ul> <li>Benzyl alcohol is also used as solvent to enhance the solubility of ingredients and it is used as solvent in our formulation. Mistakenly only one function (antimicrobial preservative) was written under section 3.2.P.1.</li> <li>Quantities of each API is written per 3.15ml to achieve the volume NLT 3ml per unit. Quantities of API are corrected to per 3ml.</li> </ul>	
3.2.P.	3.2	<ul> <li>Justify the quantities of each API mentioned in composition table against the label claim.</li> <li>Submit the batch formulation for commercial batch size.</li> </ul>	<ul> <li>Quantities of each API is written per 3.15ml to achieve the volume NLT 3ml per unit. Quantities of API are corrected to per 3ml.</li> <li>Batch formulation for commercial batch size is submitted</li> </ul>	
3.2.P.3.3		Justification shall be submitted for applying UV spectrophotometric method for the analysis of Cyanocobalamin in the finished product.	As applied product is not available in official monographs and USP method of analysis for Cyanocobalamin API and injection is also by UV method, so in-house UV method was developed and validated for analysis of cyanocobalamin.	
3.2. P.5.3		• Justify the performance of specificity parameter for cyanocobalamin, without analyzing the sample solution containing Pyridoxine HCl & Thiamine. • Justify the performance of specificity parameter for Pyridoxine HCl & Thiamine without analyzing the sample solution of injection.	Specificity parameter for cyanocobalamin was performed by preparing a placebo solution including Pyridoxine HCl & Thyamine HCl along with excipients.  Specificity parameter for Pyridoxine HCl & Thyamine HCl was performed by preparing a placebo solution including cyanocobalamin along with excipients.	
3.2. P	.8	• Submit stability studies data till 6th month time point for both accelerated and long-term stability conditions. • Submitted stability studies data does not include test for "Antimicrobial effectiveness", as recommended by USP general chapter <51>. Justify this disparity since proposed formulation contains "benzyl alcohol" as an antimicrobial agent.	6th month stability data has been submitted. Benzyl alcohol is used as solvent in applied product formulation, additionally the said test is recommended for multi dose sterile products while applied product is single dose solution for injection and not stored after opening so test was not performed.	
		•Justify the performance of terminal sterilization by autoclave method for the vitamin containing formulation.	• The applied product was sterilized by filtration method and test of finish product and stability studies are concluded on product sterilized by filtration method, some portion was autoclaved to check the effect of autoclavation on pH and color of product.	

• Firm has submitted machine usage log book of terminal
sterilizer wherein sample portion has been recorded as 25
ampoules for the batches of applied product.
• Revised BMR for commercial manufacturing has been
submitted.

Decision: Deferred for the scientific justification of the claimed role of Benzyl alcohol as solvent and not as preservative in the applied formulation.

#### Firm Response:

- In applied product benzyl alcohol was used to support the solubility of active ingredients (Pyridoxine Hydrochloride, Thiamine Hydrochloride and Cyanocobalamin) which are already soluble in water, so no need to use any additional solvent/solubilizing agent i-e benzyl alcohol.
- Applied product is single dose sterile solution for injection so use of preservative is also not required.
- As benzyl alcohol is not part of innovator formulation and as mentioned above do not have any significant role in applied product formulation so we hereby undertake we will not use benzyl alcohol in our commercial batches formulation.

Discussion: Registration Board deliberated that the firm has used benzyl alcohol as an excipient which is not used by the innovator drug product. The drug product is a single use sterile injection containing water soluble drug substances therefore the use of benzyl alcohol is not justified.

Decision: Regsitration Board deferred the case for following:

- Submission of 3 months stability studies data with frequency of 0,1& 3 months, at both accelerated and long-term conditions, for three new batches, manufactured with revised formulation excluding benzyl alcohol.
- Full fee of registration i.e., Rs. 30,000 for for submission of new stability studies data, as per notification No.F.7-11/2012-B&A/DRAP dated 13-07-2021.

### **Agenda of Evaluator PEC-IV**

#### Case no. 01 Registration applications for local manufacturing of (Human) drugs

**a.** Deferred cases

	a. Deferred cases	
51.	Name and address of manufacturer /	M/s Mediate Pharmaceutical Pvt Ltd.
	Applicant	Plot No. 150-151, Sector 24, Korangi Industrial
		Area, Karchi, Pakistan
	Brand Name +Dosage Form +	Medforge 5/80/12.5mg Tablet
	Strength	
	Composition	Each Film Coated Tablet Contains:
		Amlodipine as besylate5mg
		Valsartan80mg
		Hydrochlorothiazide12.5mg
	Diary No. Date of R& I & fee	Dy.No. 9806 dated 04-03-2019 Rs.20,000/- Dated 04-02-2019
	Pharmacological Group	Anti-hypertension
	Type of Form	Form-5
	Finished product Specifications	USP
	Pack size & Demanded Price	As per SRO
	Approval status of product in	Not found
	Reference Regulatory Authorities	
	Me-too status	Not found
	GMP status	Last GMP inspection conducted on 02-04-2019,
		and report concludes firm was considered to be
		operating at an acceptable level of good compliance with GMP
		guidelines
	Remarks of the Evaluator	Evidence of approval of applied formulation in
		reference regulatory authorities/agencies which were
		declared/approved by the Registration Board in its 275 <sup>th</sup> meeting
·		

	Evidence of applied formulation/drug already approved by DRAP (generic / me-too status) along with registration number, brand name and name of firm.
Previous decision	Deferred for following:
	<ul> <li>Evidence of applied formulation/drug already approved b DRAP (generic / me-too status) along with registratio number, brand name and name of firm.</li> <li>Evidence of approval of applied formulation in reference regulatory authorities/agencies which were adopted by the Registration Board.(M-295)</li> </ul>
Evaluation by PEC: Now firm cha	nge formulations without submission of fee and also firm said that
	rge 5/80/12.5mg Tablet". Formulation is as follows
Brand Name +Dosage Form +	Medforge 5/160/12.5mg Tablet
Strength	
Composition	Each Film Coated Tablet Contains:
-	Amlodipine as besylate5mg
	Valsartan160mg
	Hydrochlorothiazide25mg
Finished product Specifications	USP
Approval status of product in Reference Regulatory Authorities	Exforge HCT 5/160/25 by Novartis (USFDA)
resistance regulatory realistines	

# Case no. 02 Registration applications of newly granted DML or New section (Human)

**a.** New/Additional section(s)

52.	Name, address of Applicant / Marketing Authorization Holder	M/S City Pharmaceuticals Laboratories Plot # 12-A, I-5 Sector 5, New Survey No. 276, Korangi Industrial Area Karachi Pakistan	
	Name, address of Manufacturing site.	M/S City Pharmaceuticals Laboratories Plot # 12-A, I-5 Sector 5, New Survey No. 276, Korangi Industrial Area Karachi Pakistan	
	Status of the applicant	<ul> <li>✓ Manufacturer</li> <li>☐ Importer</li> <li>☐ Is involved in none of the above (contract giver)</li> </ul>	
	Status of application	☐ New Drug Product (NDP)  ☑ Generic Drug Product (GDP)	
	Intended use of pharmaceutical product	<ul><li>☑ Domestic sale</li><li>☐ Export sale</li><li>☐ Domestic and Export sales</li></ul>	
	Dy. No. and date of submission	Dy. No. 1197- dated 13-01/2022	
	Details of fee submitted	PKR 30000/-: dated 03/12/2021	
	The proposed proprietary name / brand name	Tyno 156.25mg/5ml Suspension	
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each reconstituted 5ml contains: Amoxicillin Trihydrate eq. to Amoxicillin 125mg Potassium Clavulanate Eq to Clavulanic Acid31.25mg	
	Pharmaceutical form of applied drug	Powder for Reconstitution for Oral use (Suspension)	
	Pharmacotherapeutic Group of (API)	Penicillin antibiotic	

Reference to Finished product specifications	USP
Proposed Pack size	As per SRO
Proposed unit price	As per SRO
The status in reference regulatory authorities	Augmentin 125/31 Suspension M/s GlaxoSmithKline UK of MHRA approved
For generic drugs (me-too status)	Augmentin 156.25mg/5ml Suspension by M/s GSK, Reg# 009264
GMP status of the Finished product manufacturer	GMP certificate issued on basis of inspection conducted on 18-11-2020.
Evidence of approval of manufacturing facility	Firm has submitted copy of section approval letter dated 22-12-2020, wherein approval for "Sterile dry powder for injection (Penicillin)", Capsule (Penicillin), Dry powder for suspension (Penicillin)."
Name and address of API manufacturer.	Amoxicillin Trihydrate: Pharmagen Limited. Kot Nabi Bukshwala, 34 Km Ferozepur Road, Lahore. Potassium Clavulanate: Sinopharm Weiqida Pharmaceuticals Co., Ltd Economic & Technologies Develpoment Zone, First Zone, Datong, Shanxi, China.
Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product is submitted.
Module III (Drug Substance)	Official monograph of Amoxicillin Trihydrate & Potassium Clavulanate is present in USP. The firm as submitted detail of nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, tests for impurity & related substances, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance
Stability studies	Stability study conditions: <b>Amoxicillin Trihydrate:</b> Real time: $30^{\circ}\text{C} \pm 2^{\circ}\text{C} / 65\% \pm 5\%\text{RH}$ for 48 months Accelerated: $40^{\circ}\text{C} \pm 2^{\circ}\text{C} / 75\% \pm 5\%\text{RH}$ for 6 months <b>Potassium Clavulanate:</b> Real time: $30^{\circ}\text{C} \pm 2^{\circ}\text{C} / 65\% \pm 5\%\text{RH}$ for 36 months Accelerated: $40^{\circ}\text{C} \pm 2^{\circ}\text{C} / 75\% \pm 5\%\text{RH}$ for 6 months
Module-III (Drug Product):	The firm has submitted detail of manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedure and its verification studies, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug product.
Pharmaceutical equivalence and comparative dissolution profile	Pharmaceutical Equivalence have been established against the brand leader that is Augmentin 156.25mg/5ml suspension by

			Assay, pH).	Forming quality tests (Identification, rmed because it is not applicable in this
	Analytical method of product	d validation/verification	Method verification stud range, accuracy, precision	lies have submitted including linearity, on, specificty.
		STABIL	ITY STUDY DATA	
Manufa	acturer of API	Potassium Clavulanat	4 Km Ferozepur Road, L e: Sinopharm Weiqida Ph	
API Lo	t No.	Amoxicillin Trihydrat Potassium Clavulanat		
Descrip (Containsystem)		Glass bottle with PP cap	p (1's)	
Stabilit Conditi	•	Real time: $30^{\circ}\text{C} \pm 2^{\circ}\text{C} / \text{Accelerated}$ : $40^{\circ}\text{C} \pm 2^{\circ}\text{C}$		
Time P	eriod	Real time: 6 months Accelerated: 6 months		
Freque	ncy	Accelerated: 0, 3, 6 (Mo Real Time: 0, 3, 6 (Mor		
Batch N	No.	T-001	T-002	T-003
Batch S	Size	1000 bottles	1000 bottles	1000 bottles
Manufa	acturing Date	02-2021	02-2021	02-2021
Date of	Initiation	26-02-2021	26-02-2021	26-02-2021
No. of	Batches		03	
		Admi	nistrative Portion	
1.		previous approval of tability study data of the	The firm has not submitt	ted any document.
2.	of API manufactu	DML/GMP certificate rer issued by concerned ty of country of origin.	530) issued by DRAP or 08-01-2019	e No. 06/2019-DRAP (AD/607409- n he basis if evaluation conducted on e: Copy of GMP certificate No y China Food and Drug
3.		•	with received quantity i. Batch No# 00078/522/20 source. <b>Potassium Clavulanate</b> EX/3198577 ) Dated: 13 4Kg gm) of <b>Potassium</b> (	ce (Invoice# 321 ) Dated: 03-02-2021 e. 16 Kg) of Amoxicillin Trihydrate 021 without attestation as local e: Copy commercial invoice (Invoice# 8-12-2020 with received quantity i.e.

		Ţ	
4.	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.		Submitted
5.	_	Record of HPLC software dit trail reports on product	We have maintained manual logs of all tests.
6.	temperature a	Digital data logger for and humidity monitoring of ambers (real time and	Submitted
Rema	rks OF Evalua	torIV:	
S.No	Section	<b>Shortcomings Communicated</b>	Reply
1.	1.5.2.	In Label Claim SiO2 mentioned. Clarify.	Innovator also used the silicon dioxide but mentioned as excipients rather than relate with Drug substance. (but label claim not revised)
2.	2.3.R.1.1	Submit complete calculations for Drug substance's quantity dispensed for manufacturing	Submitted.
3.	2.3.R.1.2	For applications of locally manufactured drug product(s), provide blank master production document / batch manufacturing record to be used during the commercial manufacturing of the applied product	Blank master production document / batch manufacturing record to be used during the commercial manufacturing of the applied product submitted.
4.	3.2.S.4.1	<ul> <li>Copies of the Drug substance (Amoxicillin) specifications Drug Product manufacturer is required.</li> <li>Submitted specification of Potassium clavulanate are from USP while Potassium Clavulanate diluted with Syloid 1:1. Clarification is required how on diluted Potassium Clavulanate USP monograph applied.</li> </ul>	<ul> <li>Drug substance (Amoxicillin) specifications by Drug Product manufacturer are submitted.</li> <li>Diluted Potassium Clavulanate is present in BP and the corrected specifications is attached.</li> </ul>
5.	3.2.S.4.2	<ul> <li>Detailed analytical procedures for the testing of drug substance used for routine testing of the Drug substance /Active         Pharmaceutical Ingredient (Amoxicillin) by Drug product manufacturer is required.     </li> <li>Submitted testing method of Potassium clavulanate are from USP while Potassium Clavulanate</li> </ul>	<ul> <li>Detailed analytical procedures for the testing of drug substance used for routine testing of the Drug substance /Active Pharmaceutical Ingredient Amoxicillin) by Drug product manufacture submitted.</li> <li>Testing method of potassium Clavulanate according to BP monograph submitted.</li> </ul>

		diluted with Syloid 1:1.	
		Clarification is required.	
6.	3.2.S.4.3	Analytical Method Verification studies including specificity, accuracy and repeatability (method precision) performed by the Drug Product manufacturer for drug substance(s) (Amoxicillin & Potassium clavulanate) shall be submitted.	Submitted
7.	3.2.S.4.4	<ul> <li>COA of Amoxicillin trihydrate by Drug product manufacturer mentioned Dry powder injection.         Clarification is required.</li> <li>COA of drug substance Potassium Clavulanate by drug product manufacturer claims USP specification while Potassium         Clavulanate is diluted with Syloid 1:1. Clarification is required.</li> </ul>	<ul> <li>Corrected COA of Amoxicillin trihydrate by Drug product manufacturer attached.</li> <li>Corrected COA of Potassium Clavulanate by Drug product manufacturer attached.</li> </ul>
8.	3.2.P.1	Quantity of Amoxicillin trihydrate and Potassium clavulanate is not according to label claim.	It was typographical error made the actual quantity in the formulation. Corrected quantity is attached.
9.	3.2.P.2.1.2	<ul> <li>Compatibility studies with excipients as excipients are different than innovator.</li> <li>Innovator product does not contain preservative while you are adding Sodium benzoate as preservative. Clarification is required.</li> </ul>	<ul> <li>Not submitted</li> <li>No reply submitted</li> </ul>
10.	3.2.P.2.3	Complete manufacturing method of stability batches is required.	Complete manufacturing method is submitted.
11.	3.2.P.5.1	Claimed specification is USP while Deliverable volume and • microbial enumeration tests and Tests for specified microorganism not performed mentioned in USP monograph	Testing according to USP monograph submitted.
12.	3.2.P.5.2	Detailed analytical procedures used for testing the drug product shall be provided.	Detailed analytical procedures used for testing the drug product is submitted.
13.	3.2.P.5.3	Verification studies of Amoxicillin trihydrate is not in line with USP monograph Assay method. Clarification is required.	Submitted.

14.	3.2.P.5.4	Verification studies of     Clavulanic acid not     submitted.  The COA of Drug product mentioned Dry Powder injection mentioned. Clarification is required.	Corrected COA of drug product are attached.
15.	3.2.P.8	<ul> <li>In stability summary sheets 6<sup>th</sup> month mentioned 26-08-2020 while on other months mentioned 2021.         Clarification is required.     </li> <li>Data of stability batches will be supported by attested respective documents like Raw data sheets, COA,</li> <li>Submit Compatibility studies with diluent</li> </ul>	<ul> <li>The year was written as 2020 by typing error. The corrected stability data sheets are attached.</li> <li>The supporting chromatograms are attached.</li> <li>Compatibility studies with diluent not submitted.</li> </ul>

# **Decision: Deferred for following:**

- Revised label claim without Sio2 with submission of applicable fee.
- Compatibility studies with excipients as excipients are different than innovator.
- Innovator product does not contain preservative while firm is adding Sodium benzoate as preservative. Clarification is required.
- Compatibility studies with diluent.

	1 0		
53.	Name, address of Applicant / Marketing Authorization Holder	M/S City Pharmaceuticals Laboratories Plot # 12-A, I-5 Sector 5, New Survey No. 276, Korangi Industrial Area Karachi Pakistan	
	Name, address of Manufacturing site.	M/S City Pharmaceuticals Laboratories Plot # 12-A, I-5 Sector 5, New Survey No. 276, Korangi Industrial Area Karachi Pakistan	
	Status of the applicant	<ul> <li>✓ Manufacturer</li> <li>☐ Importer</li> <li>☐ Is involved in none of the above (contract giver)</li> </ul>	
	Status of application	☐ New Drug Product (NDP)  ☑ Generic Drug Product (GDP)	
	Intended use of pharmaceutical product	<ul><li>☑ Domestic sale</li><li>☐ Export sale</li><li>☐ Domestic and Export sales</li></ul>	
	Dy. No. and date of submission	Dy. No. 401- dated 05-01-2022	
	Details of fee submitted	PKR 30000/-: dated 03/12/2021	
	The proposed proprietary name / brand name	Tyno 312.5mg/5ml Suspension	
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each reconstituted 5ml contains: Amoxicillin Trihydrate eq. to Amoxicillin 250mg Potassium Clavulanate equivalent to Clavulanic Acid 62.50 mg	
	Pharmaceutical form of applied drug	Powder for Reconstitution for Oral use (Suspension)	
	Pharmacotherapeutic Group of (API)	Penicillin antibiotic	

Reference to Finished product specifications	USP
Proposed Pack size	As per SRO
Proposed unit price	As per SRO
The status in reference regulatory authorities	Augmentin 312.5mg/5ml Powder for reconstitution for cuse by M/s <b>GlaxoSmithKline UK</b> , MHRA Approved.
For generic drugs (me-too status)	Augmentin 312.5mg/5ml Suspension by M/s GSK Pakis Reg. No. 0018360
GMP status of the Finished product manufacturer	GMP certificate issued on basis of inspection conducted on 18-11-2020.
Evidence of approval of manufacturing facility	Firm has submitted copy of section approval letter dated 22-12-2020, wherein approval for "Sterile dry powder for injection (Penicillin)", Capsule (Penicillin), Dry powder suspension (Penicillin)."
Name and address of API manufacturer.	Amoxicillin Trihydrate: Pharmagen Limited. Kot Nabi Bukshwala, 34 Km Ferozepur Road, Lahore. Potassium Clavulanate: Sinopharm Weiqida Pharmaceuticals Co., Ltd Economic & Technologies Develpoment Zone, First Zon Datong, Shanxi, China.
Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD tem Summarized information related to nomenclature, stru- general properties, solubilities, physical form, manufact description of manufacturing process and controls, impu- specifications, analytical procedures and its verification, analysis and justification of specification, reference star container closure system and stability studies of substance and drug product is submitted.
Module III (Drug Substance)	Official monograph of Amoxicillin Trihydrate & Pota Clavulanate is present in USP. The firm as submitted de nomenclature, structure, general properties, solub physical form, manufacturers, description of manufacturers and controls, tests for impurity & related subst specifications, analytical procedures and its verification, analysis and justification of specification, reference state container closure system and stability studies of substance
Stability studies	Stability study conditions: <b>Amoxicillin Trihydrate:</b> Real time: $30^{\circ}\text{C} \pm 2^{\circ}\text{C} / 65\% \pm 5\%\text{RH}$ for 48 months Accelerated: $40^{\circ}\text{C} \pm 2^{\circ}\text{C} / 75\% \pm 5\%\text{RH}$ for 6 months <b>Potassium Clavulanate:</b> Real time: $30^{\circ}\text{C} \pm 2^{\circ}\text{C} / 65\% \pm 5\%\text{RH}$ for 36 months Accelerated: $40^{\circ}\text{C} \pm 2^{\circ}\text{C} / 75\% \pm 5\%\text{RH}$ for 6 months
Module-III (Drug Product):	The firm has submitted detail of manufacturers, descript manufacturing process and controls, impurities, specifical analytical procedure and its verification studies, batch are and justification of specification, reference standard, conclosure system and stability studies of drug product.
Pharmaceutical equivalence and comparative dissolution profile	Pharmaceutical Equivalence have been established again brand leader that is Augmentin 312.5mg/5ml suspensi

			GSK Pakistan by performing quality tests (Identification, Assay, pH). CDP has not been performed because it is not applicable in this case.	
	Analytical method validation/verification of product		Method verification studies have submitted including linearity, range, accuracy, precision, specificty.	
			ITY STUDY DATA	
Manufacturer of API		Amoxicillin Trihydrate: Pharmagen Limited. Kot Nabi Bukshwala, 34 Km Ferozepur Road, Lahore. Potassium Clavulanate: Sinopharm Weiqida Pharmaceuticals Co., Ltd Economic & Technologies Develpoment Zone, First Zone, Datong, Shanxi, China.		
API Lot No.		Amoxicillin Trihydrate:00078/522/2021 Potassium Clavulanate:04NB2104013		
Description of Pack (Container closure system)		Glass bottle with PP cap (1's)		
Stability Storage Condition		Real time: 30°C ± 2°C / 65% ± 5%RH Accelerated: 40°C ± 2°C / 75% ± 5%RH		
Time Period		Real time: 6 months Accelerated: 6 months		
Frequency		Accelerated: 0, 3, 6 (Months) Real Time: 0, 3, 6 (Months)		
Batch No.		T-001	T-002	T-003
Batch Size		1000 bottles	1000 bottles	1000 bottles
Manufacturing Date		02-2021	02-2021	02-2021
Date of Initiation		26-02-2021	26-02-2021	26-02-2021
No. of Batches			03	
Administrative Portion				
1.	Reference of previous approval of applications with stability study data of the firm (if any)  The firm has not submitted any document.			ted any document.
2.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.		Amoxicillin Trihydrate: Copy of GMP certificate No. 06/2019-DRAP (AD/607409-530) issued by DRAP on the basis if evaluation conducted on 08-01-2019  Potassium Clavulanate: Copy of GMP certificate No (SX20180229) issued by China Food and Drug Administration valid until 05-06-2023	
3.	Documents for the procurement of API with approval from DRAP (in case of import).		Amoxicillin Trihydrate: Copy commercial invoice (Invoice# 321 ) Dated: 03-02-2021 with received quantity i.e. 16 Kg) of Amoxicillin Trihydrate Batch No# 00078/522/2021 without attestation as local source.  Potassium Clavulanate: Copy commercial invoice (Invoice# EX/3198577 ) Dated: 18-12-2020 with received quantity i.e. 4Kg gm) of Potassium Clavulanate Batch No# 04NB2104013 with attestation of DRAP Karachi dated:01-12-2020.	

	1	1	
4.	by attested chromatogram	ity batches will be supported respective documents like ns, neets, COA, summary data	Submitted
5.		Record of HPLC software dit trail reports on product	We have maintained manual logs of all tests.
6.	temperature a	Digital data logger for and humidity monitoring of ambers (real time and	Submitted
Remai	rks OF Evalua	tor(IV):	
S.No	Section	<b>Shortcomings Communicated</b>	Reply
1.	1.5.2.	In Label Claim SiO2 mentioned. Clarify.	Innovator also used the silicon dioxide but mentioned as excipients rather than relate with Drug substance.  (but label claim not revised)
2.	2.3.R.1.1	Submit complete calculations for Drug substance's quantity dispensed for manufacturing	Submitted.
3.	2.3.R.1.2	For applications of locally manufactured drug product(s), provide blank master production document / batch manufacturing record to be used during the commercial manufacturing of the applied product	Blank master production document / batch manufacturing record to be used during the commercial manufacturing of the applied product submitted.
4.	3.2.S.4.1	<ul> <li>Copies of the Drug substance (Amoxicillin) specifications Drug Product manufacturer is required.</li> <li>Submitted specification of Potassium clavulanate are from USP while Potassium Clavulanate diluted with Syloid 1:1. Clarification is required how on diluted Potassium Clavulanate USP monograph applied.</li> </ul>	and the corrected specifications is attached.
5.	3.2.S.4.2	<ul> <li>Detailed analytical procedures for the testing of drug substance used for routine testing of the Drug substance /Active         Pharmaceutical Ingredient (Amoxicillin) by Drug product manufacturer is required.     </li> <li>Submitted testing method of Potassium clavulanate are from USP while Potassium Clavulanate</li> </ul>	<ul> <li>Detailed analytical procedures for the testing of drug substance used for routine testing of the Drug substance /Active Pharmaceutical Ingredient Amoxicillin) by Drug product manufacture submitted.</li> <li>Testing method of potassium Clavulanate according to BP monograph submitted.</li> </ul>

		11 . 1 . 4 . 6 . 1 . 1 . 1				
		diluted with Syloid 1:1. Clarification is required.				
6.	3.2.S.4.3	Analytical Method Verification studies including specificity, accuracy and repeatability (method precision) performed by the Drug Product manufacturer for drug substance(s) (Amoxicillin & Potassium clavulanate) shall be submitted.	Submitted			
7.	3.2.S.4.4	<ul> <li>COA of Amoxicillin trihydrate by Drug product manufacturer mentioned Dry powder injection.         Clarification is required.</li> <li>COA of drug substance Potassium Clavulanate by drug product manufacturer claims USP specification while Potassium Clavulanate is diluted with Syloid 1:1. Clarification is required.</li> </ul>	<ul> <li>Corrected COA of Amoxicillin trihydrate by Drug product manufacturer attached.</li> <li>Corrected COA of Potassium Clavulanate by Drug product manufacturer attached.</li> </ul>			
8.	3.2.P.1	Quantity of Amoxicillin trihydrate and Potassium clavulanate is not according to label claim.	It was typographical error made the actual quantity in the formulation. Corrected quantity is attached.			
9.	3.2.P.2.1.2	<ul> <li>Compatibility studies with excipients as excipients are different than innovator.</li> <li>Innovator product does not contain preservative while you are adding Sodium benzoate as preservative. Clarification is required.</li> </ul>	<ul><li>Not submitted</li><li>No reply submitted</li></ul>			
10.	3.2.P.2.3	Complete manufacturing method of stability batches is required.	Complete manufacturing method is submitted.			
16.	3.2.P.5.1	Claimed specification is USP while Deliverable volume and • microbial enumeration tests and Tests for specified microorganism not performed mentioned in USP monograph	Testing according to USP monograph submitted.			
17.	3.2.P.5.2	Detailed analytical procedures used for testing the drug product shall be provided.	Detailed analytical procedures used for testing the drug product is submitted.			
18.	3.2.P.5.3	Verification studies of     Amoxicillin trihydrate is     not in line with USP     monograph Assay method.     Clarification is required.	Submitted.			

19.	3.2.P.5.4	Verification studies of     Clavulanic acid not     submitted.  The COA of Drug product mentioned Dry Powder injection mentioned. Clarification is required.	Corrected COA of drug product are attached.
20.	3.2.P.8	<ul> <li>In stability summary sheets 6<sup>th</sup> month mentioned 26-08-2020 while on other months mentioned 2021.         Clarification is required.</li> <li>Data of stability batches will be supported by attested respective documents like Raw data sheets, COA,</li> <li>Submit Compatibility studies with diluent</li> </ul>	<ul> <li>The year was written as 2020 by typing error. The corrected stability data sheets are attached.</li> <li>The supporting chromatograms are attached.</li> <li>Compatibility studies with diluent not submitted.</li> </ul>

# **Decision: Deferred for following:**

- Revised label claim without Sio2 with submission of applicable fee.
- Compatibility studies with excipients as excipients are different than innovator.
- Innovator product does not contain preservative while firm is adding Sodium benzoate as preservative. Clarification is required.
- Compatibility studies with diluent.

# Case no. 03 Registration applications of categories to be considered on priority

a. Import applications of priority categories defined by Registration Board in its 257<sup>th</sup> meeting
 i. Human

54.	Name, address of Applicant / Importer	M/s Titlis Pharmaceuticals., 528-A Industrial Estate, Raiwind Road, Lahore-Pakistan.	
	Details of Drug Sale License of importer	License No: 05-352-0066-035681D  Address: 528-A, Sunder Industrial Estate ,Raiwind Road, Lahore  Validity: 02-Oct-2022  Status: by way of distributor	
	Name and address of marketing authorization holder (abroad)	The Mentholum Company Limited, 1 Redwood Avenue Peel Park campus East Killbride Scotland G74 5PE United Kingdom.	
	Name, address of manufacturer(s)	The Mentholum Company Limited, 1 Redwood Avenue Peel Park campus East Killbride Scotland G74 5PE United Kingdom.	
	Name of exporting country	UK	
	Detail of certificates attached (CoPP, Freesale certificate, GMP certificate)	Detail of certificates attached (CoPP, Free sale certificate, GMP certificate)  • Original legalized COPP (Certificate# PP10165236 ) issued by Medicine and Healthcare Products Regulatory Agency (MHRA) Dated: 19-02-2020	

	Free Sale status: The COPP endorses the free sale status of the applied product in UK.     GMP status: Firm has submitted Legalized copy of GMP certificate (Certificate No. UK MIA 189 Insp GMP/GDP 189/11483-0019) issued by Medicine and Healthcare Products Regulatory Agency (MHRA) in the name of M/s The Mentholatum Company Limited issued on 22-01-2022
Details of letter of authorization / sole agency agreement	Sole agency agreement has been submitted The Mentholum Company Limited, 1 Redwood Avenue Peel Park campus East Killbride Scotland G74 5PE United Kingdom with M/s Titlis Pharmaceuticals., 528-A Industrial Estate, Raiwind Road, Lahore-Pakistan Pakistan. Dated: 18-02-2020
Status of the applicant	<ul> <li>☐ Manufacturer</li> <li>☑ Importer</li> <li>☐ Is involved in none of the above (contract giver)</li> </ul>
Status of application	<ul><li>☑ New Drug Product (NDP)</li><li>☐ Generic Drug Product (GDP)</li></ul>
Intended use of pharmaceutical product	<ul><li>□ Domestic sale</li><li>□ Export sale</li><li>☑ Domestic and Export sales</li></ul>
For imported products, specify one the these	<ul> <li>☑ Finished Pharmaceutical product import</li> <li>☐ Buk import and local repackaging</li> <li>☐ Buk import and local repackaging for export purpose only</li> </ul>
Dy. No. and date of submission	Dy. No. 24081 dated: 01-09-2021
Details of fee submitted	PKR 100,000/- dated :05-10-2020
The proposed proprietary name / brand name	Deep Relief Gel/ Deep Relief Pain Relief Gel
Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each 1g of gel Contains: Ibuprofen50mg (5%) Levomenthol30mg (3%)
Pharmaceutical form of applied drug	Topical gel for external use only.
Pharmacotherapeutic Group of (API)	Non-steroidal anti-inflammatory drug (NSAID)
Reference to Finished product specifications	Manufacturer specifications (In house)
Proposed Pack size	1's x50gm, 1's x100gm,
Proposed unit price	As per PRC
The status in reference regulatory authorities	MHRA Approved
For generic drugs (me-too status)	
Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Firm has summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of

	system and stability studies of drug substance and drug product.
Name, address of drug substance manufacturer	<ul> <li>Levomenthol: M/s BASF SE Carl- Bosch- Straβe 38-67056 Ludwingshafen Feral Republic of Germany Ibuprofen:</li> <li>M/s BASF Corporation, Highway 77 South USA- 78343 bishop Texas</li> <li>Hubei Granules-Biocause Pharmaceutical Co.Ltd/China 122 Yangwan- Biocause China city Hubei Province</li> </ul>
Module-III Drug Substance:	Firm has submitted detailed data for drug substance data related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
Stability Studies of Drug Substance (Conditions & duration of Stability studies)	<b>Levomenthol:</b> Firm has submitted long term stability study data of 3 batches of drug substance at $25^{\circ}C \pm 2^{\circ}C / 60 \pm 5\%$ RH for 24 <b>Ibuprofen:</b> $25^{\circ}C \pm 2^{\circ}C / 60 \pm 5\%$ months. The accelerated stability data is conducted at $40^{\circ}C \pm 2^{\circ}C / 75 \pm 5\%$ RH for 6 months.
Module-III Drug Product:	Firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation report, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.
Pharmaceutical Equivalence and Comparative Dissolution Profile	Firm submitted that Deep Relief Gel (approved by MHRA-UK is an originator's product manufactured by Mentholatum company Limited UK. Therefore pharmaceutical equivalence through comparative dissolution profile is not applicable on it.
Analytical method validation/verification of product	Firm has submitted analytical method verification studies of the drug product.
Container closure system of the drug product	Printed, collapsible aluminium tube with a membrane nozzle.
Stability study data of drug product, shelf life and storage conditions	Accelerated stability studies have been conducted at $40^{\circ}\text{C} \pm 2^{\circ}\text{C} / 75\% \pm 5\%$ RH for 06 months. Real time stability studies conducted at $25^{\circ}\text{C} \pm 2^{\circ}\text{C} / 60\% \pm 5\%$ RH and at $30^{\circ}\text{C} \pm 2^{\circ}\text{C} / 65\% \pm 5\%$ RH for 36months. However stability studies data at & $30^{\circ}\text{C} \pm 2^{\circ}\text{C} / 65\% \pm 5\%$ RH starts from $9^{\text{th}}$ month and in protocols mentioned as Bracketing as per ICH Q1A (R2) employed at the three and six month time points means sample at & $30^{\circ}\text{C} \pm 2^{\circ}\text{C} / 65\% \pm 5\%$ RH were

			only analysed in the event of unsatisfactory results from $40^{\circ}\text{C} \pm 2^{\circ}\text{C} / 75\% \pm 5\%$ RH storage condition.		
Evalua	ation by P	EC IV:	-		
S.No	Section	<b>Shortcomings Communicated</b>	Reply		
1.	1.6.5 Name and address of API manufacturer not mentioned in this section.		Submitted		
2.	3.2.P.8 In Submitted stability studies batches it is not evident that Drug substance Ibuprofen from which source is used.		Firm submitted details that 8 batches stability data submitted out of which in 6 batches source of Ibuprofen was M/s BASF Corporation, Highway 77 South USA-78343 bishop Texas And in 2 batches source of Ibuprofen was Hubei Granules-Biocause Pharmaceutical Co.Ltd/China 122 Yangwan-Biocause China city Hubei Province		
Decisi	on: Deferr	red for Evaluation of stability studies in	the light of ICH Q1-D guidelines.		
55.	Name, a	ddress of Applicant / Importer	M/s Hakimsons Private Limited., Hakimsons House, A-58/B, S.I.T.E, Manghopir Road, Karachi-75700, Pakistan.		
	Details of	of Drug Sale License of importer	License No: 001 No. DHOKW (Drugs)/-0431 Address: A-58/B, S.I.T.E, Karachi Address of Godown: NA Validity: 21-08-2022 Status: Drug license by the way of wholesale		
	Name an holder (a	nd address of marketing authorization abroad)	M/s Eugia Pharma Specialities Limited. Survey No. 550, 551 & 552, Kolthur Village, Shamirpet Mandal, Medchal-Malkajgiri, District Medchal, Telangana, 500101, India.		
	Name, a	ddress of manufacturer(s)	M/s Eugia Pharma Specialities Limited. Survey No. 550, 551 & 552, Kolthur Village, Shamirpet Mandal, Medchal-Malkajgiri, District Medchal, Telangana, 500101, India		
	Name of	f exporting country	India		
	Detail of certificates attached (CoPP, Freesale certificate, GMP certificate)		CoPP: Firm has submitted Original Legalized CoPP (Certificate#2850/STORES/2020-38) issued by Drugs Control Administration, Government of Telangana, India for ENZASTIK Capsules 40mg (Enzalutamide).  CoPP confirms facilities and operations conforming to GMP as recommended by the World Health Organization. The certificate is valid till 28.11.2021.  GMP certificate: The firm has submitted copy of GMP certificate for M/s Eugia Pharma Specialities Ltd. India issued by Drugs control Administration, Government of Telangana, India.  The certificate is valid till 28-11-2021.		
	Details of letter of authorization / sole agency agreement		Firm has submitted a copy of letter of authorization from M/s Aurobindo Pharma Limited, plot No.2, Maitri Vihar, Ameerpet, Hyderabad. According to the letter, the firm has appointed "M/s Hakimsons Pvt. Ltd," with principal place of business at A-58/B, S.I.T.E, Manghopir Road, Karachi as its Exclusive Distributor for the territory of Islamic		

	Republic of Pakistan. The letter was issued on 10-12-2020 and it is valid for a period of five years.  The applicant has submitted notarized copy of letter clarifying the relationship between Eugia pharma specialities Limited and Aurobindo Pharma Ltd.  Eugia pharma specialities Limited is wholly owned subsidiary company of Aurobindo Pharma Limited with registered office address "Plot No.2, Maitrivihar, Ameerpet, Hyderabad, Telanagana State, India.  Eugia pharma specialities Limited, with manufacturing site address "survey no. 550, 551 & 552, kolthur village, shamirpet Mandal, Medchal - Malkagiri District, Telangana, India, manufactures oncology & Hormonal products and is one of the manufacturing facilities associated with Aurobindo Pharma Limited.
Status of the applicant	<ul> <li>☐ Manufacturer</li> <li>☑ Importer</li> <li>☐ Is involved in none of the above (contract giver)</li> </ul>
Status of application	<ul><li>□ New Drug Product (NDP)</li><li>☑ Generic Drug Product (GDP)</li></ul>
Intended use of pharmaceutical product	<ul><li>☑ Domestic sale</li><li>☐ Export sale</li><li>☐ Domestic and Export sales</li></ul>
For imported products, specify one the these	<ul> <li>☑ Finished Pharmaceutical product import</li> <li>☐ Buk import and local repackaging</li> <li>☐ Buk import and local repackaging for export purpose only</li> </ul>
Dy. No. and date of submission	Dy. No. 23873 dated: 31-08-2021
Details of fee submitted	PKR 100,000/- dated :04-02-2021
The proposed proprietary name / brand name	ENZASTIK – 40 Capsules 40mg
Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each Capsule Contains: Enzalutamide40mg
Pharmaceutical form of applied drug	Soft gelatin capsule (Anti-neoplastic Agent)
Pharmacotherapeutic Group of (API)	L02BB; Anti-androgens
Reference to Finished product specifications	In house
Proposed Pack size	4 x 28's
Proposed unit price	As per PRC
The status in reference regulatory authorities	XTANDI (enzalutamide) capsules 40mg (USFDA Approved).
For generic drugs (me-too status)	
Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Firm has summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and

	its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.  The firm has summarized information of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.
Name, address of drug substance manufacturer	M/s Laurus Labs Limited, Plot No. 21, Jawaharlal Nehru Pharma City, Parawada, Visakhapatnam-531021 Andhra Pradesh, India Tel: +91- 891-3061222 Fax: +91-891-3061270
Module-III Drug Substance:	Firm has submitted detailed drug substance data related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
Stability Studies of Drug Substance (Conditions & duration of Stability studies)	Firm has submitted stability study data of 03 batches of API at accelerated as well as real time conditions $40 \pm 2^{\circ}$ C / $75 \pm 5\%$ RH. The real time stability data is conducted at $25 \pm 2^{\circ}$ C/60 $\pm 5\%$ RH. The stability study data is till 24 months.
Module-III Drug Product:	Firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.
Pharmaceutical Equivalence and Comparative Dissolution Profile	The firm has submitted physicochemical evaluation of XTANDI 40 mg Capsules manufactured by Astellas Pharma, Europe B.V, Netherlands (Reference Drug Product) (B.No: EN4017003-B) and also submitted finished product evaluation of Enzalutamide Capsules 40 mg by Eugia Pharma
	Specialties Limited (Proposed Generic Product) (B.No: EN4017003-B).
Analytical method validation/verification of product	(B.No: EN4017003-B).
5	Firm has submitted analytical method validation

Evalua	ntion by PE	C(IV:	$40^{\circ}\text{C} \pm 2^{\circ}\text{C} / 75\% \pm 5\%$ RH for 06 months. The real time stability study data is conducted at $30^{\circ}\text{C} \pm 2^{\circ}\text{C} / 75\% \pm 5\%$ RH. The real time stability study data of 03 batches is for 24months.		
S.No	Section	<b>Shortcomings Communicated</b>	Reply		
1.	3.2.S.4.3	Analytical Method Verification studies including specificity, accuracy and repeatability (method precision) performed by the Drug Product manufacturer drug substance(s) shall be submitted.	Submitted		
2.	3.2.P.3.5	process validation reports including the protocols and results for critical process steps mentioned in 2.3.P.3.4 / 3.2.P.3.4 shall be provided.	All critical quality attributes mentioned 2.3.P.3.4/3.3.P.3.4 are covered in process validation report except "Gelatin shell weight and Gelatin gross weight capsule" are not covered in process validation report However, these are regularly monitored as in proceed checks at initial and every 30 minutes and results a reported in batch manufacturing record		
3.	3.2.P.5.2	US FDA review document of the Innovator product, specifies the dissolution limit as "NLT Q in 15 minutes" 0.1N HCl/ 0.3% CTAB, whereas submitted specifications declare the dissolution limits as "NLT 75% in 30 minutes". Justify the variation in time point of dissolution.	Our product is a dosage form of soft gelatin capsule formulation. Gelatin cross-linking is a common problem of gelatin capsule, which is typically triggered by catalytic amounts of aldehydes and /or from exposure to high temperature and humidity. This impact is commonly seen in stability testing and results in lower and/or incomplete dissolution invitro. Enzymes like pepsin and pancreatin act by cleavage of peptide bonds present in cross- linked gelatin and there by resulting in release of content from capsule  Dissolution method for drug product (Enzalutamide capsule 40mg) includes both Tier-I media (with out enzymes) and Tier-II media [ith inclusion of enzymes i.e., Pepsin added in 0.3% CTAB (cetyl trimethyl ammonium bromide) in 0.1N HCl]. In the instance of drug product failing to meet the acceptance criteria in Tier-I due to gelatin cross-linking, Tier-II method would be adopted.  Since the test product shows the cross linking tendency, we have adopted the dissolution method bot Tier-I and Tier-II in the analytical testing methodology. The tier-II dissolution testing for cross-linked capsules involves two steps:  1) Pre-treatment 2) After Pre-treatment (main treatment)  In first step pre-treatment the cross-linked capsules were subjected to exposure (pre-soaking) to pepsin enriched media (450ml) for 10 minutes. After pre-treatment remaining pre-warmed plain 0.1N HCl/ 0.3% CTAB (without any pepsin) is added to makeup the final volume to 900ml. therefore the representation of dissolution time point [ Q time point in Tier-I media is 30 minutes, which includes 10 minutes of pre-treatment step and remaining 20 minutes of main treatment in final volume.  Hence based on the above dissolution testing discussion and considering the higher disintegration time allowed for soft gelatin capsule, the following dissolution limits are		

		proposed fo Enzalutamic		r release and stability shelf life testing of e capsule.		
			Test	Adopted dissolut	ion Limits	]
				Release	Shelf life	
			Dissolution	NLT 75% Q in	NLT 75% Q in	
			(%)	30 minutes	30 minutes	]
4.	3.2.P.8	From submitted stability data for product it is not evident that dissolution testing conducted either on Tier-1, or Tier-2 or both.	and from 18 r	ere tested with Tier- nonths station bate lity data results ware enclosed.	hes are tested with	n Tier-2

# **Decision: Deferred for following:**

- Details of Reference Drug Product against which pharmaceutical equivalence and CDP studies were performed.
- Clarification that Gelatin shell weight and Gelatin gross weight of capsule" are not monitored in process validation.

# Case no. 04 Registration applications of drugs for which stability study data is submitted

- **a.** Verification of stability study data
  - i. Deferred case

56.	Nome and	addraga of	M/s Zafa Pharmaceutical Laboratories, L-1/B, Block 22, Federal "B"
50.	56. Name and address of manufacturer / Applicant  Brand Name +Dosage Form +		Industrial Area, Karachi.
			Sofosbuvir Tablet 400mg
Strength		Dosage Form +	Solosbuvii Tablet 400ilig
	Composition		Each film coated tablet contains:
	1		Sofosbuvir 400mg
	Diary No. Date	e of R& I & fee	R&I date: 27-08-2018
	·		Fee 20,000/- (20-08-2018) Duplicate dossier
	Pharmacologic	al Group	Anti-viral
	Type of Form		Form-5
	Finished	product	Manufacturer's specifications
	Specifications		
	Pack size & De		28's(HDPE bottle): As per PRC
		s of product in	Approved in US-FDA
	Reference	Regulatory	
	Authorities		
Me-too status (with strength and dosage form)			N/A
			DA DAY AMAY (MATINA) DA MA
		Sil	TABILITY STUDY DATA
Drug		Sofosbuvir Table	et 400mg
Name of Manufacturer M/s Zafa Phari Karachi.			aceutical Laboratories, L-1/B, Block 22, Federal "B" Industrial Area,
Manufactu	irer of API	Optimus Drugs I	PVT Limited.
		Factory, Sy No. 239 & 240 Dothigudam(V) Pochampally(M), Nalgonda Dis	
		Telangana, India	
API Lot No. Batch No. OP-G		Batch No.OP-G	LD/10/15/037
Description of Pack			
(Container closure 28's; HDPE Bo		28's; HDPE Bott	tle
system)			
Stability	Storage	Real Time: 30°C	± 2°C / 65% ± 5%RH
Condition			$C \pm 2^{\circ}C / 75\% \pm 5\% RH$
<u>L</u>			

Time Period	Real time: 6 months	Accelerated: 6 months			
Frequency	Real Time: 0,4,8,12,24 Months Accelerated: 0,4,8,12,24 Months				
Batch No.	Tr-01	Tr-02	Tr-03		
Batch Size	212 tablets	212 tablets	212 tablets		
Manufacturing Date	August, 2017	August, 2017	August, 2017		
Date of Initiation	22th August, 2017	22th August, 2017	22th August, 2017		
No. of Batches	03				
Date of Submission	28-06-18				

DOCUMENTS / DATA PROVIDED BY THE APPLICA	NT
--	----

Sr.#	<b>Documents To Be Provided</b>	Status		
1.	COA of API	Firm has submitted copy of COA stating following information on it:  Product:Sofosbuvir Batch No.OP-GLD/10/15/037 Manufacturer:Optimus Drugs PVT Limited,		
2.	Approval of API by regulatory authority of country of origin or GMP certificate of API manufacturer issued by regulatory authority of country of origin.	Applicant has submitted GMP certificate having following nformation on it:  Certificate No.L.Dis.No.20121/A3/2018		
3.	Protocols followed for conduction of stability study and details of tests.	Yes		
4.	Data of 03 batches will be supported by attested respective documents like chromatograms, laboratory reports, data sheets etc.	Yes		
5.	Documents confirming import of API etc.	Firm has submitted copy of commercial invoice stating following information on it:  Invoice No. 412/EXP  Batch No of API. OP-GLD/10/15/037  Attested by Assistant Director (I & E) DRAP Karachi On: 03-02-2016		
6.	All provided documents will be attested (name, sign and stamp) for ensuring authenticity of data / documents.	Yes		
7.	Commitment to continue real time stability study till assigned shelf life of the product.	Yes		
8.	Commitment to follow Drug Specification Rules, 1978.	Yes		

Evaluation by PEC(**IV**):

# SOFOSBUVIR TABLET 400MG, M/S ZAFA PHARMACEUTICALS LABORATORIES.

Following panel of inspectors visited M/s Zafa Pharmaceuticals Laboratories for verification of authenticity of submitted stability study data for registration of Sofosbuvir 400mg Tablet.

- 1. Syed Adnan Rizvi Director, DTL, Karachi.
- 2. Dr. Najam-us-Saquib Additional Director DRAP, Karachi.

0	. Kirshan, Assistant Director, DRAP, Karachi.			
Q.No.	Question	Observation by panel		
1.	Do you have documents confirming the import of API including approval from DRAP?	The firm has imported Sofosbuvir from Optimus Drug Pvt. Ltd. Hyderabad INDIA, Supplier IRIS Karachi. Invoice No.412/EXP dated 15-11-2015. Batch # OP-GLD/10/15/037. The total quantityofAPI purchased was1.00 kg.The approval from DRAP is available. (Annex-A)		
2.	What was the rationale behind selecting the particular manufacturer of API?	Rationale behind selecting the particular manufacturer of API, as it is GMP compliant and vendor evaluation has been done. (Annex-B).		
3.	Do you have documents confirming the import of reference standard and impurity standards?	The reference standard & impurity standard were imported through Optimus Drug Pvt. Ltd. Hyderabad INDIA. In House Reference standard, Batch # OP-SFS/RS1402, quantity100mg.Impurity standard, Batch # OP-GLD/St-I/Rp-Isomer/A0453/055, with quantity 10.0mg. (Annex-C)		
4.	Do you have certificate of Analysis of the API, reference standards and impurity standards?	The firm has COAs for API, reference standards and impurity.		
5.	Do you have GMP certificate of API manufacturer issued by regulatory authority of country of origin?			
6.	Do you use API manufacturer method of testing for testing API?	The Firm has used manufacturer's method of testing for the testing of API.		
7.	Do you have stability studies reports on API?	The firm has manufacturers Stability studies report of API.		
8.	If yes, whether the stability testing has been performed as per SIM method and degradation products have been quantified?	Stability testing as per SIM method and degradation products has been quantified by the API manufacturer.		
9.	Do you have method for quantifying the impurities in the API.	The firm has used HPLC method for chromatographic impurities that was used for assay purpose.		
10.	Do you have some remaining quantities of the API, its reference standard and impurities standards?	The firm has some quantities of API (As reference), reference standard.		
11.	Have you used pharmaceutical grade excipients?	The firm has used Pharmaceutical grade excipients		
12.	Do you have documents confirming the import of the used excipients?	The firm has necessary documents confirming the import of the used excipients.		
13.	Do you have test reports and other records on the excipients used?			
14.	Do you have written and authorized protocols for the development of applied product?	The firm has written protocol for the development of Sofosbuvir Tablets 400 mg.(Annex-D)		
15.	Have you performed Drug-excipient compatibility studies?	The firm has not performed drug excipient compatibility studies because the composition of their tablets/product is similar to that of the innovator's product (Sovaldi Tablets)		
16.	Have you performed comparative dissolution studies?	The firm has performed comparative dissolution studies and their product show comparable dissolution profile and same were reviewed at time of inspection.		
17.	Do you have product development (R&D) section.	The firm has separate new product development (R&D) section.		

	Do you have necessary equipments available	The firm has used Quality Control Lab instruments for
10	in product development section for	the development of Sofosbuvir Tablets 400 mg. The
18.	development of applied product?	firm has all necessary equipment in QC and Product
		development section.
19.	Are the equipment in product development section qualified?	All the equipment used in the development of product is qualified.
	Do you have proper maintenance / calibration	The firm has proper maintenance and calibration for the
20.	/ requalification program for the equipment	equipment used in quality Control for the development
	used in PD section?	of the product.
	Do you have qualified staff in product	The firm has qualified staff for the development of the
21.	development section with proper knowledge	product with proper knowledge and training in product
	and training in product development?	development. (Annex-E)
	Have you manufactured three stability	The firm has manufactured three stability batches, of
22.	batches for the stability studies of applied	Sofosbuvir Tablets 400 mg, TR01, TR02, TR03.
	products required?  Do you have any criteria for fixing the batch	The criteria for fixing the batch size of stability of
23.	size of stability batches?	batches are the number of tablets as per requirement of
	size of stubility butches.	testing.
	Do you have complete record of production	The firm has complete record of production of stability
24.	of stability batches?	batches. All the log books are properly maintained and
		reviewed at the time of inspection.
25.	Do you have protocols for stability testing of	The firm has protocols for testing of the stability
	stability batches?	batches.
26.	Do you have developed and validated the method for testing of stability batches?	Yes, the firm has used manufacturer's method of testing, the method is validated.
	Do you have method transfer studies in case	Not applicable
27.	when the method of testing being used by	That applicable
	your firm is given by any other lab?	
	Do you have documents confirming the	Yes, the firm has proper documents confirming the
28.	qualification of equipments / instruments	qualification of equipment and instruments being used
	being used in the test and analysis of API and	in the test and analysis of API and the finished product.
	the finished drug?  Do your method of analysis stability	Yes the method of analysis is stability indicating.
29.	indicating?	Tes the method of analysis is stability indicating.
20	Do your HPLC software is 21CFR	HPLC software is 21CFR compliant.
30.	compliant?	I was
31.	Can you show Audit Trail reports on Stability	The firm showed the Audit trail report on API and
51.	study testing?	finished product testing.
32.	Do you have some remaining quantities of	The firm has remaining quantities of stability batches.
	degradation products and stability batches?	
33.	Do you have commitment batches kept on stability testing?	The firm has three commitment batches kept on stability testing for real time stability studies.
	Do you have valid calibration status for the	Yes, the firm has valid calibration status for the
34.	equipment used in Production and analysis?	equipment used in the production and analysis of
	Table 1	Sofosbuvir Tablets 400 mg.
	Do proper and continuous monitoring and	Continuous power supply and monitoring and control
35.	control are available for stability chambers.	are available for the stability chambers.
	Do related manufacturing area, equipment,	The relevant manufacturing facilities are GMP
36.	personal and utilities be used as GMP	complaint.
	compliance	

# **Conclusion:**

M/s Zafa Pharmaceutical Laboratories was inspected as per directions contained in DRAP letter No. 13-11/2017-PEC (Pt) dated 30<sup>th</sup> July, 2019. During inspection, the panel inspected/reviewed the relevant record, data and premises in detail with specific focus on the observations/points made in above referred letter. Following are the current observations:

Criterion/reference for selection of Q Value 70%: - The said molecules was not included in any official monograph, therefore, the firm previously performed the dissolution test as per general requirement for dissolution testing and there was no any specific criteria for the selection of Q value 70%. Now, the firm have performed dissolution test for their product according to US-FDA recommended dissolution method and found it satisfactory at the time of inspection.

- 1. **Valid GMP Certificate** of API Manufacturer is hereby attached for reference.
- 2. On the basis of risk-based approach the genuineness/ authenticity of stability data submitted by the firm for registration of Sofosbuvir Tablets 400mg is verifiable to satisfactory level.
- 3. The related manufacturing area, equipment, personnel and utilities observed in line as per GMP requirements and well suited for manufacturing of the said product.

### **Recommendations:**

Based on the people met, documents reviewed and observations made during inspection including corrective action taken by the firm, the panel unanimously recommends that the firm may kindly be granted necessary registration of Sofosbuvir Tablets 400mg.

Decision(M-294): Registration Board decided to defer the case for following submissions:

- Submit dissolution testing data with specifications of "NLT Q within 15 minutes" at initial and one month time point at both accelerated and real time stability conditions for 2 batches.
- Valid GMP certificate of the API manufacturer.

Now the applicant has submitted following:

Applicant has referred to their Comparative dissolution profile of applied formulation with reference product and submitted results declaring drug release profile of applied formulation is greater than 90 % within 15 minutes.

**Previous Decision:** Registration Board keeping in view its decision taken in 293<sup>rd</sup> meeting decided to defer the case for following submissions:

- Submit dissolution testing data with specifications of "NLT Q within 15 minutes" at initial and one month time point at both accelerated and real time stability conditions for 2 batches.
- Valid GMP certificate of the API manufacturer.(M-296)

### **Evaluation:**

- Firm submitted dissolution testing data with specification of "NLT Q within 15 minutes" according to Accelerated stability studies and real time stability studies conditions of two batches Batch # T-004 and Batch# T-005 for 0, 1, 2 & 3 month data.
- Copy of GMP certificate for M/s Optimus Drugs (P) Ltd, Sy No. 239 & 240 Dothigudam(V) Pochampally(M), Nalgonda Dist., Telangana, India issued by Drug control Administration Government of Telangana issued on 05-07-2019 valid for 3 years.

Decision: Registration Board decided to approve registration of Sofosbuvir Tablet 400mg with Innovator's specifications by M/s Zafa Pharmaceutical Laboratories.

- Manufacturer will place first three production batches of both products on long term stability studies throughout proposed shelf life and on accelerated studies for six months.
- Firm shall submit the fee of Rs. 7,500 for correction/pre-approval change/ in product specifications, as per notification No.F.7-11/2012-B&A/DRAP dated 13-07-2021.
  - **b.** Exemption from onsite verification of stability data
    - i. New Cases

57.	Name and address of manufacturer / Applicant	M/s Horizon Healthcare (Pvt) Ltd. Plot No.33-Sundar Industrial Estate Lahore- Pakistan		
Brand Name +Dosage Form + Strength Rup		Rupri Tablet 1mg		
Composition		Each Film Coated Tablet Contains: Prucalopride Succinate Eq To Prucaloprid1mg		
	Diary No. Date of R& I & fee	Dy.No 14964 dated 07-03-2019 Rs.20,000/- dated 06-03-2019		
	Pharmacological Group	High affinity 5HT4 receptor antagonist (Other drugs for constipation ATC code: A06AX05)_		

	Type of Form		Form 5-D		
	Finished produc	t Specifications	Manufacturers specification		
	Pack size & Der	nanded Price	2 x7's :As per SRO		
	Approval status of product in Reference Regulator Authorities		MOTEGRITY of USFDA appr	oved	
	Me-too status				
	GMP status		cGMP certificate on the basis of evaluation conducted on03-06-2021		
	Remarks of the	Evaluator.			
		STABIL	ITY STUDY DATA		
Drug		Rupri Tablet 1mg			
Name of	Manufacturer	M/s Horizon Healthcar Pakistan	e (Pvt) Ltd. Plot No.33-Sundar Inc	lustrial Estate Lahore-	
Manufact	urer of API		s Limited, (Formerly Known as La Isi Tehsil-Sohna District-Gurgoan		
API Lot 1	No.	KB/PPD/SSP/19/002			
Description (Contained system)	on of Pack er closure	Alu/Alu			
Stability Condition	Storage	Real time : $30^{\circ}\text{C} \pm 2^{\circ}\text{C}$ Accelerated: $40^{\circ}\text{C} \pm 2^{\circ}\text{C}$			
Time Per	Time Period Real time: 06 months Accelerated: 06 months		ns		
Frequenc	Frequency Accelerated:0,1,2,3,4,6 Real Time: 0,3,6 (mon				
Batch No		PL-001	PL-002	PL-003	
Batch Siz	e	1500 Tablets	1500 Tablets	1500 Tablets	
Manufact	turing Date	06-2020	06-2020	06-2020	
Date of In	nitiation	17-06-2020	18-06-2020	19-06-2020	
No. of Ba	atches	03			
Date of S	ubmission	29-01-2021 (3448)			
	D	OCUMENTS / DATA	PROVIDED BY THE APPLICA	ANT	
Sr. No.	Documen	ts To Be Provided	Statu	s	
1.	Reference of previous approval of applications with stability study data of the firm		Firm has referred to onsite inspection report of their product Empazon Tablet 10mg & 25mg which was conducted on 01-06-2021 and was presented in 307th meeting of Registration Board held on 08-10th June, 2021.  According to the report following points were confirmed.  • The firm has 21 CFR compliant HPLC software  • The firm has audit trail reports available.  • The firm possesses stability chambers with digital data loggers.		
2.	Certificate of Analysis of API from both API Manufacturer and Finished Product manufacturer.		Copy of COA of Prucalopride Succinate (Batch# KB/PPD/SSP/19/002.) from M/s Kimia Biosciences Limited, India is submitted.		

		Copy of COA of Prucalopride Succinate (Batch# KB/PPD/SSP/19/002.) from M/s Horizon Healthcare is submitted.				
3.	Method used for analysis of API from both API Manufacturer and Finished Product manufacturer	Yes				
4.	Stability study data of API from API manufacturer	The firm has submitted copy of accelerated, 06 Months (40°C 2°C & 75 $\pm$ 5%RH) & long term, 36 Months (30°C $\pm$ 2°C & 65 $\pm$ 5%RH) stability study reports of 03 batches.				
5.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Copy of GMP certificate for M/s Kimia Biosciences Limited,(Formerly Laurel Organics Ltd.) Village Bhondsi Tehsil-Sohna District-Gurgoan Haryana, India issued by Food and Drug Adminstration Haryana, Panchkula valif from 18- 11-2019 to 17-11-2022			Bhondsi ued by Food	
6.	Documents for the procurement of API with approval from DRAP (in case of import).	Copy of Commercial Invoice No: KBLEXP/19-20/010 Dated: 14-01-2020 from M/s Kimia Biosciences Limited, Village Bhondsi Tehsil-Sohna District-Gurgoan Harryana, India attested by AD DRAP (Lahore) dated; 28-01-2020 for Pruclopride Succinate batch No# KB/PPD/SSP/19/002.Qty .050kg.				
7.	Protocols followed for conduction of stability study	Yes				
8.	Method used for analysis of FPP	Yes				
9.	Drug-excipients compatibility studies (where applicable)	Same excipients used as used by innovator.			or.	
10.	Complete batch manufacturing record of three stability batches.	The firm has submitted copy of Trial batch manufacturing record.  Details are as under:				
		Batch No.		upri Tablet 1mg <b>Bach size</b>	Mfg. Started	-
		PL-001		1500 Tablets	06-2020	-
		PL-002		1500 Tablets	06-2020	-
		PL-003		1500 Tablets	06-2020	
		1 L-003		1300 1401013	00-2020	
11.	Record of comparative dissolution data (where applicable)	Firm has submitted Comparative dissolution study of their product with Innovator's Brand "Rupri".  The details are as follows:				
		Feature Reference Product of Horizon				
		Brand Resolor 1mg Rupri Tablet				
		name 1mg				
		Batch No. JBL2N02 PL-001				
		<ul> <li>Comparative dissolution studies have been performed in following mediums:</li> <li>1. pH 1.2 HCl buffer</li> <li>2. pH 4.5 Acetate buffer</li> <li>3. pH 6.8 Phosphate buffer</li> </ul>			n performed	

by attested rechromatogra COA, summ  13. Compliance software 210 on product to temperature		
software 210 on product to 14. Record of 1 temperature	patches will be supported respective documents like rams, Raw data sheets, mary data sheets etc.	Yes
temperature	Record of HPLC CFR & audit trail reports esting.	Yes
_	Digital data logger for and humidity of stability chambers and accelerated)	Yes

S.No	Shortcomings communicated	Reply
1.	Submit valid Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Submitted.
2.	Submit Real time stability summary sheets.	Real time stability summary sheets submitted.
3.	Submit details of Reference product used for comparative dissolution	Resolor 1mg Tablet Batch No # JBL2N02, Manufactured by Janssen Cilag S.p.A., Latina, Italy
4.	As per submitted calculations for potency adjustment., the salt factor has not been considered for calculating the final quantity to be dispensed, please clarify.	Firm has used the raw material after calculating the quantity with salt factor which can be seen from our warehouse record of material consumption. In the BMR typographical mistake has been done, otherwise quantity was adjusted by salt factor. BMR's and raw material consumption record has been attached for reference. Firm has rectified its mistake by ensuring the correct quantity of API in standard manufacturing procedure which will be followed for commercial scale batches.

### **Decision:**

- Registration Board decided to approve registration of Rupri Tablet 1mg with Innovator's specifications by M/s Horizon Healthcare (Pvt) Ltd. Manufacturer will place first three production batches of both products on long term stability studies throughout proposed shelf life and on accelerated studies for six months.
- Registration letter will be issued after verification of relevant record whether quantity dispensed was with salt factor adjustment or otherwise.

58.	Name and address of manufacturer / Applicant	M/s Horizon Healthcare (Pvt) Ltd. Plot No.33-Sundar Industrial Estate Lahore- Pakistan	
Brand Name +Dosage Form + Strength Rupri Tablet 2mg		Rupri Tablet 2mg	
	Composition	Each Film Coated Tablet Contains: Prucalopride Succinate Eq To Prucaloprid2mg	
	Diary No. Date of R& I & fee	Dy.No 10611 dated 05-03-2019 Rs.20,000/- dated 04-03- 2019	

	Pharmacological Group		High affinity 5HT4 receptor an constipation ATC code: A06AX05)_	tagonist (Other drugs for		
	Type of Form		Form 5-D			
	Finished product Specifications		Manufacturers specification			
	Pack size & Der	nanded Price	2 x7's :As per SRO			
	Approval status Reference Regul		MOTEGRITY of USFDA appr	MOTEGRITY of USFDA approved		
	Me-too status					
	GMP status		cGMP certificate on the basis o on03-06-2021	f evaluation conducted		
	Remarks of the l	Evaluator.				
		STABII	LITY STUDY DATA			
Drug		Rupri Tablet 2mg				
Name of 1	Manufacturer	M/s Horizon Healthcar Pakistan	re (Pvt) Ltd. Plot No.33-Sundar Ind	lustrial Estate Lahore-		
Manufact	urer of API		s Limited, (Formerly Known as Ladsi Tehsil-Sohna District-Gurgoan	C		
API Lot N	lo.	KB/PPD/SSP/19/002				
Description (Container system)	on of Pack r closure	e Alu/Alu				
Stability Condition	Storage	Real time : $25^{\circ}C \pm 2^{\circ}C$ Accelerated: $40^{\circ}C \pm 2^{\circ}$				
Time Peri	od	Real time: 06 months Accelerated: 06 month	18			
Frequenc	À	Accelerated:0, 1, 2, 3, Real Time: 0,3,6 (mon				
Batch No		PH-001	PH-002	PH-003		
Batch Siz	e	1500 Tablets	1500 Tablets	1500 Tablets		
Manufact	uring Date	06-2020	06-2020	06-2020		
Date of Ir	itiation	01-07-2020	02-07-2020	03-07-2020		
No. of Ba	tches	03				
Date of S	ubmission	29-01-2021 (3447)				
	1		PROVIDED BY THE APPLICA	ANT		
Sr. No.	Documen	ts To Be Provided	Status			
15.	5. Reference of previous approval of applications with stability study data of the firm					

16.	Certificate of Analysis of API from both API Manufacturer and Finished Product manufacturer.	A .	/19/0	02.) from M/s	ccinate (Batch# Kimia Bioscienc	es Limited,
		A .		•	ccinate (Batch# Horizon Healthca	are is
17.	Method used for analysis of API from both API Manufacturer and Finished Product manufacturer			Yes		
18.	Stability study data of API from API manufacturer	2°C & 75±5%	6RH)		scelerated, 06 Mo 36 Months (30°C of 03 batches.	
19.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Limited,(For Tehsil-Sohna	merly Distr minstr	Laurel Organio ict-Gurgoan Ha ation Haryana,	Kimia Bioscienc es Ltd.) Village E aryana, India issu Panchkula valif	Bhondsi led by Food
20.	Documents for the procurement of API with approval from DRAP (in case of import).	14-01-2020 the Bhondsi Tehst attested by A	from M sil-Sol D DR	M/s Kimia Bios nna District-Gu AP (Lahore) da	KBLEXP/19-20, sciences Limited, argoan Harryana, ated; 28-01-2020, KB/PPD/SSP/19,	Village India ) for
21.	Protocols followed for conduction of stability study			Yes		
22.	Method used for analysis of FPP			Yes		
23.	Drug-excipients compatibility studies (where applicable)	San	ne exc	ripients used as	used by innovat	or.
24.	Complete batch manufacturing record of three stability batches.	The firm hamanufacturi	ng rec		Γrial batch	
			Rı	ıpri Tablet 2mş	7	
		Batch No.		Bach size	Mfg. Started	
		PH-001		1500 Tablets	06-2020	
		PH-002 PH-003		1500 Tablets 1500 Tablets	06-2020 06-2020	
		FH-003		1300 Tablets	00-2020	
25.	Record of comparative dissolution data (where applicable)		t with	Innovator's B	dissolution stud rand "Rupri".	y of
		Feature	Refe	erence luct	Product of Horizon	
		Brand name		olor 2mg	Rupri Tablet 2mg	
		Batch No.		JBL2L01	PH-001	
		in follow	ing m		studies have been	n performed

			<ul><li>2. pH 4.5 Acetate buffer</li><li>3. pH 6.8 Phosphate buffer</li></ul>
26.	Data of 03 batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.		Yes
27.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing.	Yes	
28.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Yes	
	REMA	RKS	OF EVALUATOR
S.No	<b>Shortcomings communicated</b>		Reply
1.	Submit valid Approval of API/DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.		Submitted.
2.	Submit Real time stability summary sheets.		Real time stability summary sheets submitted.
3.	Submit details of Reference product used for comparative dissolution		Resolor 1mg Tablet Batch No # JBL2L01, Manufactured by Janssen Cilag S.p.A., Latina, Italy
4.	As per submitted calculations for potency adjustment., the salt factor has not been considered for calculating the final quantity to be dispensed, please clarify.		Firm has used the raw material after circulating the quantity with salt factor which can be seen from our warehouse record of material consumption. In the BMR typographical mistake has been done, otherwise quantity was adjusted by salt factor. BMR's and raw material consumption record has been attached for reference. Firm has rectified its mistake by ensuring the correct quantity of API in standard manufacturing procedure which will be

### **Decision:**

• Registration Board decided to approve registration of Rupri Tablet 1mg with Innovator's specifications by M/s Horizon Healthcare (Pvt) Ltd. Manufacturer will place first three production batches of both products on long term stability studies throughout proposed shelf life and on accelerated studies for six months.

followed for commercial scale batches.

• Registration letter will be issued after verification of relevant record whether quantity dispensed was with salt factor adjustment or otherwise.

## ii. Deferred case:

59.	Name and address of manufacturer / Applicant	M/s AGP Limited B-23, S.I.T.E., Karachi
	Brand Name +Dosage Form + Strength	Rigix-D Tablet
	Composition	Each bilayer Sustain release tablet contains: Cetirizine HCl (USP)5mg

		Pseudoephedrine HCl (USP)120mg
Diary No. Date of Ro	& I & fee	Diary No:2197, 08-12-2016, Rs: 50,000/- 08-12-2016
Pharmacological Gro	oup	Histamine antagonist & Adrenergic antagonist
Type of Form		Form 5-D
Finished product Spe	ecifications	BP
Pack size & Demand	ed Price	10's, 30's : As per SRO
Approval status of pr Reference Regulator		ZYRTEC-D 12 HOUR of USFDA approved
Me-too status		
GMP status		cGMP certificate on the basis of evaluation conducted on03-06-2021
Remarks of the Evalu	uator.	• Firm is requesting for change of brand name from Rigix-D to Rigix Plus Via A letter by company dated 11-01-2021.
Details of Pseudoephedrine permission		M/s AGP Limited B-23, S.I.T.E Karachi firm has requested for grant of permission to purchase Pseudoephedrine HCl for Trial Batches/Stability Studies of their following product. The firm has informed that they have acquired the permission to purchase 900gm of Pseudoephedrine from M/s alpha Chemicals (Pvt.) limited on dated 12th February, 2018. As this product is a bilayer tablet having a combination of Pseudoephedrine HCl in sustained release from (Layer 1) and Cetirizine HCl in immediate release form (Layer 2), they are in need of more Pseudoephedrine HCl to produce the large trial batches for stability studies. This will also confirm the reproducibility of trial batches.  Decision of Registration Board: Registration Board decided to recommend allocation of controlled drug substance i.e Pseudoephedrine Hydrochloride for trial/stability batches of Rigix-D Tablet & also acceded to the request for purchase of above mentioned Reference Standards from USP. However, previously acquired material consumption record shall be verified by Area FID.  The Board further advised the firm to maintain records of used substances and waste materials having above API and shall be destroyed after approval of Controlled Drug Division, DRAP (M-290)
	T	Y STUDY DATA
Drug	Rigix-D Tablet	
Name of Manufacturer	M/s AGP Limited B-23	3, S.I.T.E., Karachi
Manufacturer of API	Taluka-Palsana, Dist-S	Praveen Laboratories Limited Block No.206 Moje- Jolwa, urat, Gujrat India  1: M/s alpha Chemicals (Pvt.) limited pakistan
API Lot No.  Cetirizine HCl : N Pseudoephedrine		
Description of Pack (Container closure system)	ALU/PVC/PVDC	
Stability Storage Condition Real time : 30°C		/ 65% ± 5% RH

		Accelerated: $40^{\circ}\text{C} \pm 2^{\circ}\text{Intermediate: }25^{\circ}\text{C} \pm$		
Time Period		Real time: 06 months Accelerated: 06 months		
Frequency		Accelerated:0,3,6 (month) Real Time: 0,6 (month) Intermediate: 0,3,6		
Batch N	lo.	TR-610	TR-611	TR-612
Batch S	lize	8000 Tablets	8000 Tablets	8000 Tablets
Manufa	cturing Date	06-2018	06-2018	06-2018
Date of	Initiation	10-07-2020	10-07-2020	10-07-2020
No. of l	Batches	03		
Date of	Submission	04-01-2021 (336)		
	DOG	CUMENTS / DATA P	ROVIDED BY THE APPLICA	ANT
Sr.	Documents T	To Be Provided	Stat	us
No.				
30.	applications with stability study data of the firm  Glyzia-XR tablets which was conducted on 2 2018 and was presented in 285 <sup>th</sup> meeting Board held on 03-04 <sup>th</sup> October, 2018.  According to the report following points were  The firm has 21 CFR compliant HPL  The firm has audit trail reports availa  The firm possesses stability chambed data loggers.		conducted on 26th September, 35th meeting of Registration , 2018.  In points were confirmed.  In point	
31.	Method used for analysis of API from both API Manufacturer and Finished Product manufacturer		Ye	s
32.	Stability study data of API from API manufacturer		Cetirizine HCl: The firm has 06 Months $(40^{\circ}\text{C} \pm 2^{\circ}\text{C} \& 75\pm 5\%)$ Months $(30^{\circ}\text{C} \pm 2^{\circ}\text{C} \& 75\pm 5\%)$ 03 batches  Pseudoephedrine HCl: The financelerated, 06 Months $(40^{\circ}\text{C} \pm 2^{\circ}\text{C})$ term, 60 Months $(30^{\circ}\text{C} \pm 2^{\circ}\text{C})$ reports of 03 batches	5%RH) & long term, 60 RH) stability study reports of irm has submitted copy of ± 2°C & 75±5%RH) & long
33.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.		Cetirizine HCl (USP): Copy of GMP/21092927 for M/s Praved Block No.206 Moje- Jolwa, Ta Gujrat India issued by Food	en Laboratories Limited luka-Palsana, Dist-Surat,

		Guirat atata indi	a iccurd on 20 00	2021 and valid unto
		19-09-2023		-2021 and, valid upto
		_	ne HCI: Submitte ring also receipt o	d DML No3000373 of f renewal of drug
		manufacturing I	License of dated:	15-10-2020
		•		6/2021-DRAP (DDG) tional director Drug
				Lahore that "The License
		has not been sus office.	pended or cancelle	ed as per record of this
34.	Documents for the procurement of API with approval from DRAP (in case of import).	Invoice No: Ex/0 Laboratories Lin	Dated: 27-12- nited India attest	•
		MK40119138	; 01-01-2020 for C	Cetirizine HCl batch No#
		_	A •	Commercial Invoice No:
				20 from M/s alpha doephedrine HCl batch
			04 mentioning 3.6	•
35.	Protocols followed for conduction of stability study		Yes	
36.	Method used for analysis of FPP		Yes	
37.	Drug-excipients compatibility studies (where applicable)	Same ex	xcipients used as u	ised by innovator.
38.	Complete batch manufacturing record of	The firm has su	ıbmitted copy of T	rial hatch
	three stability batches.	manufacturing		Trui outen
		Details are as u		
		Batch No.	Rigix-D Tablet  Bach size	Mfg. Started
		TR-610	8000 Tablets	24-06-2020
		TR-611	8000 Tablets	24-06-2020
		TR-612	8000 Tablets	24-06-2020
		L		
39.	Record of comparative dissolution data		_	dissolution study of
	(where applicable)	The details are	ith Innovator's Br as follows:	and "Rigix-D".
		Feature	Reference product	Product of AGP
		Brand name	Cirrus Tablet	Rigix-D Tablet
		Batch No.	268988	TR-611
		1. 2.	ative dissolution n following mediu pH 1.2 HCl buffen pH 4.5 Acetate bu pH 6.8 Phosphate	ims: ffer
40.	Data of 03 batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.		Yes	

41.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing.	Yes
42.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	Yes
	REMA	RKS OF EVALUATOR
S.N O	Shortcomings communicated	Reply
1.	Submit Evidence of bilayer tablet machine.	We have already purchased the compression machine for the single/bilayer tablets. An undertaking is enclosed with related documents
2.	Method used for analysis of API's from Finished Product manufacturer.	Method used for analysis of API's from Finished Product manufacturer is attached.
3.	Submit Real time Stability study data of cetirizine HCl According to zone IV-A/B from API manufacturer.	Real time Stability study data of cetirizine HCl According to zone IV-A from API manufacturer is enclosed.
4.	Submit Accelerated Stability study data of Pseudoephedrine HCl from API manufacturer.	Accelerated Stability study data of Pseudoephedrine HCl from API manufacturer is enclosed.
5.	Submit valid Approval of API/ DML/GMP certificate of cetirizine HCl manufacturer issued by concerned regulatory authority of country of origin.	Valid approval of GMP certificate of cetirizine HCl manufacturer is enclosed.
6.	Approval of API/ DML/GMP certificate of Pseudoephedrine HCl issued by concerned regulatory authority of country of origin.	Valid approval of DML certificate of pseudoephedrine HCl is enclosed
7.	Stability condition for Real time stability $25^{\circ}C \pm 2^{\circ}$ C / $60\% \pm 5\%$ RH . Clarification is required.	We would like to clarify that this product is not available in Pakistan and Innovator's storage condition is store at $20^{\circ}\text{C}$ to $25^{\circ}\text{Cn}$ . The product I also complying the USP Specifications and as per USP, the recommended storage condition is "Store below $25^{\circ}\text{C}$ " Therefore, we have conducted the stability studies on the following conditions: $30^{\circ}\text{C} \pm 2^{\circ}\text{C} / 65\% \pm 5\%$ RH $40^{\circ}\text{C} \pm 2^{\circ}\text{C} / 65\% \pm 5\%$ RH $25^{\circ}\text{C} \pm 2^{\circ}\text{C} / 60\% \pm 5\%$ RH As per stability results till 12 months, this product is stable at both temperature conditions i.e $25^{\circ}\text{C} \pm 2^{\circ}\text{C} / 60\% \pm 5\%$ RH and $30^{\circ}\text{C} \pm 2^{\circ}\text{C} / 60\% \pm 5\%$ RH and it is also stable at $40^{\circ}\text{C} \pm 2^{\circ}\text{C} / 75\% \pm 5\%$ RH Evaluation: (Firm submitted conducted on 0,3, 6 <sup>th</sup> month $25^{\circ}\text{C} \pm 2^{\circ}\text{C} / 60\% \pm 5\%$ RH and data submitted. In reply summary sheets of stability at $30^{\circ}\text{C} \pm 2^{\circ}\text{C} / 65\% \pm 5\%$ RH for 0, 6, 9 & $12^{th}$ months are included.)
8.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing.	The audit trail is printed on each chromatogram submitted in the dossier regarding stability studies.

**Previous Decision :** Deferred for justification of not performing long/real term stability studies testing at 3rd month time point. (M-316)

## Reply by firm IV:

We would like to clarify that:

- We have conducted stability studies of our product on Zone IV-A ( $30^{\circ}\text{C} \pm 2^{\circ}\text{C} / 65 \pm 5\%$  RH) and by mistake we have skipped  $3^{\text{rd}}$  month stability testing point but we have performed  $6^{\text{th}}$  month,  $9^{\text{th}}$  month and  $12^{\text{th}}$  months stability studies and results shows that the product is stable.
- We have also performed accelerated stability studies for 0, 3 & 6 months, the results are also in compliance with specifications.
- We assure you that we will continue the stability studies up to the shelf life of 24 months i.e 18<sup>th</sup> months, 24months and submit the data at DRAP.

We would also like to inform you that our product Rigix Plus Tablet contains Pseudoephedrine HCl, the purchasing of this API required QUOTA allocation from DRAP which is a lengthy procedure/ takes time (approximately 3 to 6 months) and we are working on this product since 2016. Therefore, we request you to kindly consider our application for registration sympathetically for approval.

Decision: Registration Board decided to approve registration of Rigix-D Tablet with BP specifications by M/s AGP Limited B-23, S.I.T.E., Karachi.

- Manufacturer will place first three production batches of both products on long term stability studies throughout proposed shelf life and on accelerated studies for six months.
- The Board also directed the manufacturer to update its stability study protocols as per the guidelines approved by Registration Board and international guidelines and follow the same for all products in future.

**Agenda of Evaluator PEC-IX** 

# 1. Item No. 01. Routine cases for registration of human drugs

### a) New cases

Registration Board observed that the drug products are being approved either on the basis of pharmacopoeial specifications or as per innovator's specifications to be followed for drug product development by the applicants. For cases where evaluator has not assessed complete specifications, the Board considered and decided the applications on the basis of aforementioned principles.

60.	Name and address of manufacturer /	M/s Sapient Pharma 123/S, Quaid e Azam Industrial Estate, Kot
	Applicant	Lakhpat, Lahore
		BY
		M/s Bio Labs Pvt Ltd. Plot # 145, Industrial Triangle, Kahuta
		Road, Islamabad
	Brand Name +Dosage Form +	Sapthio Injection 40/0.04mg
	Strength	
	Composition	Each Ampoule Contains:
		Phloroglucinol Dihydrate40mg
		Trimethylhloroglucinol0.04mg
	Diary No. Date of R& I & fee	Dy. No. 12432 dated 06.03.2019
		Rs. 50,000/- dated 04.03.2019
	Pharmacological Group	Drugs for functional gastrointestinal disorders
	Type of Form	Form 5
	Finished Product Specification	The firm has claimed in-house psecifications.
	Pack size & Demanded Price	6'sx4ml; As per SRO
	Approval status of product in	SPASFON, solution injectable en ampoule (4ml). ANSM
	Reference Regulatory Authorities.	approved
	Me-too status	Spadix Injection. Reg. No. 29528
	GMP status	GMP inspection reports required.

	Remarks of the Evaluator.	• The drug product specifications have not been evaluated.			
		<ul> <li>The firm did not submit Form 5.</li> <li>The firm did not submit the requirements /documents as per enclosure of Form 5.</li> </ul>			
		• The firm did not submit copy of contract manufacturing agreement.			
		<ul> <li>The fee has been deposited by M/s Biomarkers</li> <li>Revise the pharmacological group to Drugs for functional gastrointestinal disorders.</li> </ul>			
	Decision: Deferred for submission of Form 5 with requirements /documents	f:			
	<ul> <li>copy of contract manufacturing a</li> <li>Revision of pharmacological grou</li> <li>Application Fee of Rs. 75,000/-</li> </ul>	ngreement. up to Drugs for functional gastrointestinal disorders.			
61.	Name and address of manufacturer / Applicant	M/s Sapient Pharma 123/S, Quaid e Azam Industrial Estate, Kot Lakhpat, Lahore BY			
		M/s Bio Labs Pvt Ltd. Plot # 145, Industrial Triangle, Kahuta Road, Islamabad			
	Brand Name +Dosage Form + Strength	Sapthio Injection 40/0.04mg			
	Composition	Each Ampoule Contains: Phloroglucinol Dihydrate40mg Trimethylhloroglucinol0.04mg			
	Diary No. Date of R& I & fee	Dy. No. 12432 dated 06.03.2019 Rs. 50,000/- dated 04.03.2019			
	Pharmacological Group	Drugs for functional gastrointestinal disorders			
	Type of Form	Form 5			
	Finished Product Specification	The firm has claimed in-house psecifications.			
	Pack size & Demanded Price	6'sx4ml; As per SRO			
	Approval status of product in Reference Regulatory Authorities.	SPASFON, solution injectable en ampoule (4ml). ANSM approved			
	Me-too status	Spadix Injection. Reg. No. 29528			
	GMP status Remarks of the Evaluator.	<ul><li>GMP inspection reports required.</li><li>The drug product specifications have not been evaluated.</li></ul>			
		• The firm did not submit Form 5.			
		• The firm did not submit the requirements /documents as per enclosure of Form 5.			
		• The firm did not submit copy of contract manufacturing agreement.			
		<ul> <li>The fee has been deposited by M/s Biomark Pharmaceuticals.</li> <li>Revise the pharmacological group to Drugs for functional gastrointestinal disorders</li> </ul>			
	Decision: Deferred for submission of Form 5 with requirements /documents	gastrointestinal disorders. mission of: nts /documents as per enclosure of Form 5.			
	<ul> <li>copy of contract manufacturing a</li> <li>revision of pharmacological grou</li> <li>Application Fee of Rs. 75,000/-</li> </ul>	agreement.  p to Drugs for functional gastrointestinal disorders.			
(2)	<del></del>	M/s Coming Discours 122/C Oscilla Association Indicated Free Visit			
62.	Name and address of manufacturer / Applicant	M/s Sapient Pharma 123/S, Quaid e Azam Industrial Estate, Kot Lakhpat, Lahore BY			
		M/s Bio Mark Pharmaceuticals. Plot No. 527, Sundar Industrial Estate, Lahore			

	Brand Name +Dosage Form + Strength	Moseeta Sachet 3g
	Composition	Each Sachet Contains:
	Composition	Dioctahedral Smectite3g
	Diary No. Date of R& I & fee	Dy. No. 12429 dated 06.03.2019
	Blary 140. Bate of Ree 1 ee 1ee	Rs. 50,000/- dated 04.03.2019
	Pharmacological Group	Antidiarrhoeal
	Type of Form	Form 5
	Finished Product Specification	Not submitted.
	Pack size & Demanded Price	30's; As per SRO
	Approval status of product in	Diosmectal 3g powder of Diosmectite for oral suspension,
	Reference Regulatory Authorities.	approved by Italian Medicines Agency
	Me-too status	Semetamed 3.0g Sachets. Reg. No. 61925
	GMP status	GMP inspection reports required.
	Remarks of the Evaluator.	The drug product specifications have not been evaluated.
		• The firm did not submit the requirements /documents as per
		enclosure of Form 5.
		• The firm did not submit copy of contract manufacturing
		agreement.
		• The fee has been deposited by M/s Biomark Pharmaceuticals.
	Decision: Deferred for submission of	* · · ·
	• requirements /documents as per e	
	• copy of contract manufacturing a	
		greement.
(2)	• Application Fee of Rs. 75,000/-	W/ 9
63.	Name and address of manufacturer /	M/s Sapient Pharma 123/S, Quaid e Azam Industrial Estate, Kot
	Applicant	Lakhpat, Lahore BY
		M/s Bio Mark Pharmaceuticals. Plot No. 527, Sundar Industrial
		Estate, Lahore
	Brand Name +Dosage Form +	Sapeso Capsule 20mg
	Strength	
	Composition	Each Capsule Contains:
		Esomeprazole as Esomeprazole Magnesium (Enteric Coated
	Di IV D GDG VG G	Pellets)20mg
	Diary No. Date of R& I & fee	Dy. No. 12430 dated 06.03.2019
	DI 1 1 1 C	Rs. 50,000/- dated 04.03.2019
	Pharmacological Group	Proton pump inhibitor
	Type of Form	Form 5 Not submitted. Available in USP
	Finished Product Specification	
	Pack size & Demanded Price	2x7's; As per SRO Esomeprazole magnesium Capsule 20mg. USFDA Approved
	Approval status of product in Reference Regulatory Authorities.	Esomeprazole magnesium Capsule Zomg. USFDA Approved
	Me-too status	Esorid 20mg Capsules. Reg. No. 33097
	GMP status	GMP inspection reports required.
	Remarks of the Evaluator.	The drug product specifications have not been evaluated.
	Remarks of the Evaluator.	The drug product specifications have not been evaluated.
		• The firm did not submit the requirements /documents as per
		enclosure of Form 5.
		• The firm did not submit copy of contract manufacturing
		agreement.
		• The fee has been deposited by M/s Biomark Pharmaceuticals.
		• The firm did not submit the source of pellets and all required
		data.
	<b>Decision: Deferred for submission of</b>	f:

• requirements /documents as per enclosure of Form 5. • copy of contract manufacturing agreement. • Application Fee of Rs. 75,000/-. • source of pellets, GMP certificate of the source, and CoA and stability data of three batches of the pellets conducted in zone IV-A. Name and address of manufacturer / M/s Sapient Pharma 123/S, Quaid e Azam Industrial Estate, Kot 64. **Applicant** Lakhpat, Lahore BY M/s Bio Mark Pharmaceuticals. Plot No. 527, Sundar Industrial Estate.Lahore Brand Name +Dosage Form + Sapeso Capsule 40mg Strength Composition Each Capsule Contains: Esomeprazole as Esomeprazole Magnesium (Enteric Coated Pellets)...40mg Dy. No. 12431 dated 06.03.2019 Diary No. Date of R& I & fee Rs. 50,000/- dated 04.03.2019 Pharmacological Group Proton pump inhibitor Type of Form Form 5 Finished Product Specification Not submitted. Available in USP Pack size & Demanded Price 2x7's; As per SRO Esomeprazole magnesium Capsule 40mg. USFDA approved Approval status of product in Reference Regulatory Authorities. Me-too status Espra Capsule 40mg. Reg. No. 33051 **GMP** status GMP inspection reports required. Remarks of the Evaluator. • The drug product specifications have not been evaluated. • The firm did not submit the requirements /documents as per enclosure of Form 5. • The firm did not submit copy of contract manufacturing agreement. • The fee has been deposited by M/s Biomark Pharmaceuticals. • The firm did not submit the source of pellets and all required Decision: Deferred for submission of: • requirements /documents as per enclosure of Form 5. • copy of contract manufacturing agreement. • Application Fee of Rs. 75,000/-. • source of pellets, GMP certificate of the source, and CoA and stability data of three batches of the pellets conducted in zone IV-A. 65. Name and address of manufacturer / M/s Sapient Pharma 123/S, Quaid e Azam Industrial Estate, Kot Lakhpat, Lahore **Applicant** BYM/s Bio Mark Pharmaceuticals. Plot No. 527, Sundar Industrial Estate, Lahore Brand Name +Dosage Form + SMP Insta Sachet 20/1680mg Strength Composition **Each Sachet Contains:** Omeprazole Sodium...20mg Sodium Bicarbonate....1680mg Dy. No. 12427 dated 06.03.2019 Diary No. Date of R& I & fee Rs. 50,000/- dated 04.03.2019 Pharmacological Group Proton pump inhibitor and antacid Type of Form

Not submitted. Available in USP

Form 5

Finished Product Specification

	D- 1: 0 D 1- 1 D-:	102 A CDO
	Pack size & Demanded Price	10's; As per SRO
	Approval status of product in	Omeprazole and sodium bicarbonate (Packet) for oral suspension.
	Reference Regulatory Authorities.	approved by US-FDA
	Me-too status	Risek Insta Sachet. Reg. No. 58547
	GMP status	GMP inspection reports required.
	Remarks of the Evaluator.	The drug product specifications have not been evaluated.
		• The firm did not submit the requirements /documents as per enclosure of Form 5.
		• The firm did not submit copy of contract manufacturing agreement.
		• The fee has been deposited by M/s Biomark Pharmaceuticals.
	<b>Decision: Deferred for submission o</b>	
	• requirements /documents as per	
	• copy of contract manufacturing a	agreement.
	• Application Fee of Rs. 75,000/	
66.	Name and address of manufacturer /	M/s Sapient Pharma 123/S, Quaid e Azam Industrial Estate, Kot
	Applicant	Lakhpat, Lahore
		BY
		M/s Bio Mark Pharmaceuticals. Plot No. 527, Sundar Industrial
		Estate, Lahore
	Brand Name +Dosage Form +	SMP Insta Sachet 40/1680mg
	Strength	
	Composition	Each Sachet Contains:
		Omeprazole Sodium40mg
		Sodium Bicarbonate1680mg
	Diary No. Date of R& I & fee	Dy. No. 12428 dated 06.03.2019
		Rs. 50,000/- dated 04.03.2019
	Pharmacological Group	Proton pump inhibitor and antacid
	Type of Form	Form 5
	Finished Product Specification	Not submitted. Available in USP
	Pack size & Demanded Price	10's; As per SRO
	Approval status of product in	Omeprazole and sodium bicarbonate (Packet) for oral suspension.
	Reference Regulatory Authorities.	approved by US-FDA
	Me-too status	Risek Insta Sachet. Reg. No. 58548
	GMP status	GMP inspection reports required.
	Remarks of the Evaluator.	• The drug product specifications have not been evaluated.
		• The firm did not submit the requirements /documents as per
		enclosure of Form 5.
		• The firm did not submit copy of contract manufacturing
		agreement.
		• The fee has been deposited by M/s Biomark Pharmaceuticals.
	Decision: Deferred for submission of	· · ·
	• requirements /documents as per	enclosure of Form 5.
	• copy of contract manufacturing a	
	• Application Fee of Rs. 75,000/	· <del>g</del>
67.	Name and address of manufacturer /	M/s Shrooq Pharmaceuticals Pvt Ltd. 21-km Ferozpur Road,
0/.	Applicant	Lahore, Pakistan
	Brand Name +Dosage Form + Strength	Lacos 50mg Tablet
	Composition	Each Film Coated Tablet Contains:
		Lacosamide50mg
	Diary No. Date of R& I & fee	Dy. No. 13139 dated 06.03.2019
1		Rs. 20,000/- dated 28.02.2019

	Pharmacological Group	The firm has claimed in-house specifications.
	Type of Form	Form 5
	Finished Product Specification	Antiepileptics
	Pack size & Demanded Price	14's, 28's; As per SRO
	Approval status of product in	Lacosamide Accord 50 mg film-coated tablets. MHRA approved.
	Reference Regulatory Authorities.	
	Me-too status	Lacolep 50mg Tablet . Reg. No. 73857
	GMP status	The firm was inspected on 26 & 29.10.2021, where renewal of
		DML was recommended.
	Remarks of the Evaluator.	The drug product specifications have not been evaluated.
	correction/pre-approval change/ in	's specifications. Firm shall submit the fee of Rs. 7,500 for product specifications, as per notification No.F.7-11/2012-
	B&A/DRAP dated 13-07-2021.	
68.	Name and address of manufacturer / Applicant	M/s Shrooq Pharmaceuticals Pvt Ltd. 21-km Ferozpur Road, Lahore, Pakistan
	Brand Name +Dosage Form + Strength	Sarpin H Tablet 5/160/12.5mg
	Composition	Each Film Coated Tablet Contains:
	•	Amlodipine As Besylate5mg
		Valsartan160mg
		Hydrochlorothiazide12.5mg
	Diary No. Date of R& I & fee	Dy. No. 12029 dated 06.03.2019
		Rs. 20,000/- dated 05.03.2019
	Pharmacological Group	Antihypertensive
	Type of Form	Form 5
	Finished Product Specification	The firm has claimed in-house specifications. Available in USP
	Pack size & Demanded Price	28's; As per SRO
	Approval status of product in	EXFORGE HCT® Tablets. US-FDA approved
	Reference Regulatory Authorities.	
	Me-too status	Exforge HCT 5/160/12.5MG film coated tablets. Reg. No. 69548
	GMP status	The firm was inspected on 26 & 29.10.2021, where renewal of DML was recommended.
	Remarks of the Evaluator.	• The drug product specifications have not been evaluated.
		• Revised the specs to USP.
		• The firm had adjusted the weight of amlodipine besylate in
		the master formula as per salt factor. Revised amlodipine
		as besylate to amlodipine besylate in the master formula.
		• Submitted Rs. 7500/- fee (Challan- 7520182900).
	Decision: Approved with HSP specif	fications. The firm shall submit Rs. 22,500 fee for correction in
	formulation before issuance of regist	·
69.	Name and address of manufacturer /	M/s Shrooq Pharmaceuticals Pvt Ltd. 21-km Ferozpur Road,
	Applicant	Lahore, Pakistan
	Brand Name +Dosage Form +	Sarpin H Tablet 10/160/25mg
	Strength	
	Composition	Each Film Coated Tablet Contains:
		Amlodipine As Besylate10mg
		Valsartan160mg
		Hydrochlorothiazide25mg
	Diary No. Date of R& I & fee	Dy. No. 12028 dated 06.03.2019
		Rs. 20,000/- dated 05.03.2019
	Pharmacological Group	Antihypertensive
	Type of Form	Form 5
	Finished Product Specification	The firm has claimed in-house specifications. Available in USP
	Pack size & Demanded Price	28's; As per SRO
		of Posicitation Poord (16, 17 May, 2022)

	Approval status of product in	EXFORGE HCT® Tablets by Novartis Pharmaceuticals
	Reference Regulatory Authorities.	Corporation. US-FDA approved
	Me-too status	Exforge HCT 10/160/25MG film coated tablets by Novatris
		Pharma. Reg. No. 69551
	GMP status	The firm was inspected on 26 & 29.10.2021, where renewal of
		DML was recommended.
	Remarks of the Evaluator.	• The drug product specifications have not been evaluated.
		• Revised the specs to USP.
		• The firm had adjusted the weight of amlodipine besylate in
		the master formula as per salt factor. Revised amlodipine
1		as besylate to amlodipine besylate in the master formula.
		• Submitted Rs. 7500/- fee (Challan- 89999871).
		cations. The firm shall submit Rs. 22,500 fee for correction in
	formulation before issuance of regist	
70.	Name and address of manufacturer /	M/s Shrooq Pharmaceuticals Pvt Ltd. 21-km Ferozpur Road,
	Applicant	Lahore, Pakistan
	Brand Name +Dosage Form +	Sarpin H Tablet 5/160/25mg
	Strength	
	Composition	Each Film Coated Tablet Contains:
		Amlodipine As Besylate5mg
		Valsartan160mg
		Hydrochlorothiazide25mg
	Diary No. Date of R& I & fee	Dy. No. 12026 dated 06.03.2019
		Rs. 20,000/- dated 05.03.2019
	Pharmacological Group	Antihypertensive
	Type of Form	Form 5
	Finished Product Specification	The firm has claimed in-house specifications. Available in USP
	Pack size & Demanded Price	28's; As per SRO
	Approval status of product in	EXFORGE HCT® Tablets by Novartis Pharmaceuticals
	Reference Regulatory Authorities.  Me-too status	Corporation. US-FDA approved
	Me-too status	Exforge HCT 5/160/25MG film coated tablets by Novatris Pharma. Reg. No. 69549
	GMP status	The firm was inspected on 26 & 29.10.2021, where renewal of
	Givir status	DML was recommended.
	Remarks of the Evaluator.	• The drug product specifications have not been evaluated.
		• Revised the specs to USP.
		• The firm had adjusted the weight of amlodipine besylate in
		the master formula as per salt factor. Revised amlodipine
		as besylate to amlodipine besylate in the master formula.
		• Submitted Rs. 7500/- fee (Challan- 394105582).
	Decision: Approved with USP specifi	cations. The firm shall submit Rs. 22,500 fee for correction in
	formulation before issuance of regist	
71.	Name and address of manufacturer /	M/s Shrooq Pharmaceuticals Pvt Ltd. 21-km Ferozpur Road,
	Applicant	Lahore, Pakistan
	Brand Name +Dosage Form +	Dastak Syrup 2.5mg
1	Strength	
1	Composition	Each 5ml Of Oral Solution Contains:
1	*	Desloratadine2.5mg
	Diary No. Date of R& I & fee	Dy. No. 12027 dated 06.03.2019
1		Rs. 20,000/- dated 05.03.2019
	Pharmacological Group	Other antihistamines for systemic use
1	Type of Form	Form 5
1	Finished Product Specification	The firm has claimed in-house specifications.
1	Pack size & Demanded Price	60ml; As per SRO

	Approval status of product in	AERIUS FOR CHILDREN SYRUP desloratadine 2.5mg/5mL
	Reference Regulatory Authorities.	oral liquid bottle. TGA approved
	Me-too status	Neolor 0.5mg/ml Syrup. Reg. No. 82713
	GMP status	The firm was inspected on 26 & 29.10.2021, where renewal of
		DML was recommended.
	Remarks of the Evaluator.	• The drug product specifications have not been evaluated.
		• Revised the pharmacological group from antihistamines to Other antihistamines for systemic use
		• Submitted Rs. 7500/- fee (Challan- 3839950215949).
	Decision: Approved with innovator's	·
72.	Name and address of manufacturer /	M/s Genetics Pharmaceuticals (Pvt) Limited, Plot No. 539-A,
, 2.	Applicant	Sundar Industrial Estate, Lahore
	Brand Name +Dosage Form + Strength	Dopark Plus 150 Tablet
	Composition	Each film-coated tablet contains:
	Composition	Carbidopa (anhydrous bases)37.5mg
		Entacapone200mg
		Levodopa150mg
	Diary No. Date of R& I & fee	Dy. No. 12464 dated 06.03.2019
		Rs.20,000/- dated 06.03.2019
	Pharmacological Group	Antiparkinson's drug
	Type of Form	Form 5
	Finished Product Specification	In-house
	Pack size & Demanded Price	10's, 20's, 30's; As per SRO
	Approval status of product in	Film-coated tablets of:
	Reference Regulatory Authorities.	Stalevo 50 (12.5 mg per 50 mg per 200 mg)
	Therefore Regulatory Transferres.	Stalevo 75 (18.75 mg per 75 mg per 200 mg)
		Stalevo 100 (25 mg per 100 mg per 200 mg)
		Stalevo 125 (31.25 mg per 125 mg per 200 mg)
		Stalevo 150 (37.5 mg per 150 mg per 200 mg)
		Stalevo 200 (50 mg per 200 mg per 200 mg) approved in
		USFDA
	Me-too status	Obsonery 37.5/150/200mg Tablet. Reg. No. 70443 (does not
		show anhydrous eq. of carbidopa)
	GMP status	The firm was inspected on 29.03.2019, wherein the FID
		reported satisfactory level of GMP compliance.
	Remarks of the Evaluator.	The drug product specifications have not been evaluated.
		• The firm has mentioned carbidopa monohydrate in the
		master formula and adjusted the weight as per salt factor
		rounded upto 1.08 from 1.079.
		• The firm revised the address of the firm as per DML along
		with submission of Rs. 10,000/- fee challan
		No.277032440.
	Desisions Approved with innevestor's	
73.	<b>Decision: Approved with innovator's</b> Name and address of manufacturer /	M/s Genetics Pharmaceuticals (Pvt) Limited, Plot No. 539-A,
13.		` '
	Applicant Brand Name +Dosage Form + Strength	Sundar Industrial Estate, Lahore  Dopark Plus 75 Tablet
	Composition	Each film-coated tablet contains:
	Composition	Carbidopa (anhydrous equivalent)18.7.5mg
		Entacapone200mg
		1
	Diary No. Date of R& I & fee	Levodopa75mg  Dy. No. 12461 dated 06.03.2019
	Diary No. Date of K& I & Iee	Rs.20,000/- dated 06.03.2019
	Pharmacological Group	Antiparkinson's drug
	Type of Form	Form 5
	Finished Product Specification	In-house
	ranished Froduct Specification	III-IIOUSC

	Pack size & Demanded Price	10's, 20's, 30's; As per SRO
	Approval status of product in	Film-coated tablets of:
	Reference Regulatory Authorities.	Stalevo 50 (12.5 mg per 50 mg per 200 mg)
		Stalevo 75 (18.75 mg per 75 mg per 200 mg)
		Stalevo 100 (25 mg per 100 mg per 200 mg)
		Stalevo 125 (31.25 mg per 125 mg per 200 mg)
		Stalevo 150 (37.5 mg per 150 mg per 200 mg)
		Stalevo 200 (50 mg per 200 mg per 200 mg) approved in
		USFDA
	Me-too status	Obsonerv 18.75/75/200mg Tablet. Reg. No. 70440 (does not show anhydrous eq. of carbidopa)
	GMP status	The firm was inspected on 29.03.2019, wherein the FID
		reported satisfactory level of GMP compliance.
	Remarks of the Evaluator.	• The drug product specifications have not been evaluated.
		• The firm has mentioned carbidopa monohydrate in the
		master formula and adjusted the weight as per salt factor
		rounded upto 1.08 from 1.079.
		• The firm revised the address of the firm as per DML along
		with submission of Rs. 10,000/- fee challan No.
		3210228063.
		• The firm revised Carbidopa (anhydrous
		equivalent)18.7.5mg to Carbidopa (anhydrous
		equivalent)18.75mg
	Decision: Approved with innovator's s	1 ,
74.	Name and address of manufacturer /	M/s Genetics Pharmaceuticals (Pvt) Limited, Plot No. 539-A,
'	Applicant	Sundar Industrial Estate, Lahore
	Brand Name +Dosage Form + Strength	Dopark Plus 50 Tablet
	Composition	Each film-coated tablet contains:
		Carbidopa (anhydrous equivalent)12.5mg
		Entacapone200mg
		Levodopa50mg
	Diary No. Date of R& I & fee	Dy. No. 12460 dated 06.03.2019
		Rs.20,000/- dated 06.03.2019
	Pharmacological Group	Antiparkinson's drug
	Type of Form	Form 5
	Finished Product Specification	In-house
	Pack size & Demanded Price	10's, 20's, 30's; As per SRO
	Approval status of product in	Film-coated tablets of:
	Reference Regulatory Authorities.	Stalevo 50 (12.5 mg per 50 mg per 200 mg)
		Stalevo 75 (18.75 mg per 75 mg per 200 mg)
		Stalevo 100 (25 mg per 100 mg per 200 mg)
		Stalevo 125 (31.25 mg per 125 mg per 200 mg)
		Stalevo 150 (37.5 mg per 150 mg per 200 mg)
		Stalevo 200 (50 mg per 200 mg per 200 mg) approved in USFDA
	Me-too status	Obsonerv 12.5/50/200mg Tablet. Reg. No. 70442 (does not
		show anhydrous eq. of carbidopa)
	GMP status	The firm was inspected on 29.03.2019, wherein the FID
		reported satisfactory level of GMP compliance.
	Remarks of the Evaluator.	• The drug product specifications have not been evaluated.
		• The firm has mentioned carbidopa monohydrate in the
		master formula and adjusted the weight as per salt factor
1		rounded upto 1.08 from 1.079.

• The firm revised the address of the firm as per DMI with submission of Rs. 10,000/- fee challs 078152840761.  Decision: Approved with innovator's specifications.  Name and address of manufacturer / Applicant	n No.
Decision: Approved with innovator's specifications.   Name and address of manufacturer / Applicant   M/s Genetics Pharmaceuticals (Pvt) Limited, Plot No. 5   Sundar Industrial Estate, Lahore   Brand Name +Dosage Form + Strength   Dopark Plus 100 Tablet   Composition   Each film-coated tablet contains:   Carbidopa (anhydrous equivalent)25mg   Entacapone200mg   Levodopa100mg   Diary No. Date of R& I & fee   Dy. No. 12462 dated 06.03.2019   Rs.20,000/- dated 06.03.2019   Rs.20,000/- dated 06.03.2019   Pharmacological Group   Antiparkinson's drug   Type of Form   Form 5   Finished Product Specification   In-house   Pack size & Demanded Price   10's, 20's, 30's; As per SRO   Film-coated tablets of: Stalevo 50 (12.5 mg per 50 mg per 200 mg)   Stalevo 150 (37.5 mg per 125 mg per 200 mg)   Stalevo 150 (37.5 mg per 125 mg per 200 mg)   Stalevo 125 (31.25 mg per 120 mg)   Stalevo 150 (37.5 mg per 150 mg per 200 mg)   Stalevo 15	
Decision: Approved with innovator's specifications.     75.   Name and address of manufacturer / Applicant	39-A,
Name and address of manufacturer / Applicant   Brand Name +Dosage Form + Strength   Dopark Plus 100 Tablet   Each film-coated tablet contains: Carbidopa (anhydrous equivalent)25mg   Entacapone200mg   Levodopa100mg	39-A,
Applicant Brand Name +Dosage Form + Strength Composition  Each film-coated tablet contains: Carbidopa (anhydrous equivalent)25mg Entacapone200mg Levodopa100mg  Diary No. Date of R& I & fee Dy. No. 12462 dated 06.03.2019 Rs.20,000/- dated 06.03.2019 Pharmacological Group Antiparkinson's drug Type of Form Form 5 Finished Product Specification Pack size & Demanded Price Approval status of product in Reference Regulatory Authorities.  Film-coated tablets of: Stalevo 50 (12.5 mg per 50 mg per 200 mg) Stalevo 100 (25 mg per 100 mg per 200 mg) Stalevo 150 (37.5 mg per 150 mg per 200 mg) Stalevo 150 (37.5 mg per 150 mg per 200 mg) Stalevo 200 (50 mg per 200 mg) approved i USFDA  Me-too status  Obsonerv 25/100/200mg Tablet. Reg. No. 70444 (does show anhydrous eq. of carbidopa)  The firm was inspected on 29.03.2019, wherein the reported satisfactory level of GMP compliance.  Park film-coated tablets of: Stalevo 100 (25 mg per 100 mg per 200 mg) Stalevo 150 (37.5 mg per 150 mg per 200 mg) Stalevo 200 (50 mg per 200 mg) approved i USFDA  Me-too status  Obsonerv 25/100/200mg Tablet. Reg. No. 70444 (does show anhydrous eq. of carbidopa)  The firm was inspected on 29.03.2019, wherein the reported satisfactory level of GMP compliance.	
Brand Name +Dosage Form + Strength Composition  Each film-coated tablet contains: Carbidopa (anhydrous equivalent)25mg Entacapone200mg Levodopa100mg Diary No. Date of R& I & fee Dy. No. 12462 dated 06.03.2019 Rs.20,000/- dated 06.03.2019 Pharmacological Group Type of Form Form 5 Finished Product Specification Pack size & Demanded Price Approval status of product in Reference Regulatory Authorities.  Film-coated tablets of: Stalevo 50 (12.5 mg per 50 mg per 200 mg) Stalevo 75 (18.75 mg per 150 mg per 200 mg) Stalevo 100 (25 mg per 100 mg per 200 mg) Stalevo 150 (37.5 mg per 150 mg per 200 mg) Stalevo 200 (50 mg per 200 mg) approved i USFDA  Me-too status  Obsonerv 25/100/200mg Tablet. Reg. No. 70444 (does show anhydrous eq. of carbidopa)  GMP status  The firm was inspected on 29.03.2019, wherein the reported satisfactory level of GMP compliance.  • The drug product specifications have not been evaluated.	
Composition  Each film-coated tablet contains: Carbidopa (anhydrous equivalent)25mg Entacapone200mg Levodopa100mg  Diary No. Date of R& I & fee  Dy. No. 12462 dated 06.03.2019  Rs.20,000/- dated 06.03.2019  Pharmacological Group  Type of Form  Finished Product Specification Pack size & Demanded Price Approval status of product in Reference Regulatory Authorities.  Film-coated tablets of: Stalevo 50 (12.5 mg per 50 mg per 200 mg) Stalevo 100 (25 mg per 100 mg per 200 mg) Stalevo 125 (31.25 mg per 150 mg per 200 mg) Stalevo 150 (37.5 mg per 150 mg per 200 mg) Stalevo 200 (50 mg per 200 mg) approved in USFDA  Me-too status  Obsonerv 25/100/200mg Tablet. Reg. No. 70444 (does show anhydrous eq. of carbidopa)  GMP status  The firm was inspected on 29.03.2019, wherein the reported satisfactory level of GMP compliance.  • The drug product specifications have not been evaluation.	
Carbidopa (anhydrous equivalent)25mg Entacapone200mg Levodopa100mg  Diary No. Date of R& I & fee  Dy. No. 12462 dated 06.03.2019 Rs.20,000/- dated 06.03.2019  Pharmacological Group  Type of Form  Form 5 Finished Product Specification Pack size & Demanded Price Approval status of product in Reference Regulatory Authorities.  Film-coated tablets of: Stalevo 50 (12.5 mg per 50 mg per 200 mg) Stalevo 75 (18.75 mg per 125 mg per 200 mg) Stalevo 125 (31.25 mg per 125 mg per 200 mg) Stalevo 150 (37.5 mg per 150 mg per 200 mg) Stalevo 200 (50 mg per 200 mg per 200 mg) Stalevo 200 (50 mg per 200 mg per 200 mg) Talevo 200 (50 mg per 200 mg per 200 mg) Stalevo 200 (50 mg per 200 mg per 200 mg) Stalevo 200 (50 mg per 200 mg) The firm was inspected on 29.03.2019, wherein the reported satisfactory level of GMP compliance.  Principal Carbon Compliance of the drug product specifications have not been evaluation.	
Entacapone200mg Levodopa100mg  Diary No. Date of R& I & fee  Dy. No. 12462 dated 06.03.2019 Rs.20,000/- dated 06.03.2019 Rs.20,000/- dated 06.03.2019  Pharmacological Group Antiparkinson's drug Type of Form Form 5 Finished Product Specification Pack size & Demanded Price Approval status of product in Reference Regulatory Authorities. Film-coated tablets of: Stalevo 50 (12.5 mg per 50 mg per 200 mg) Stalevo 75 (18.75 mg per 125 mg per 200 mg) Stalevo 125 (31.25 mg per 125 mg per 200 mg) Stalevo 150 (37.5 mg per 150 mg per 200 mg) Stalevo 150 (37.5 mg per 150 mg per 200 mg) Stalevo 200 (50 mg per 200 mg per 200 mg) Stalevo 200 (50 mg per 200 mg per 200 mg) Talevo 200 (50 mg per 200 mg per 200 mg) Stalevo 200 (50 mg per 200 mg per 200 mg) The firm was inspected on 29.03.2019, wherein the reported satisfactory level of GMP compliance. Remarks of the Evaluator.  • The drug product specifications have not been evaluation.	
Levodopa100mg  Diary No. Date of R& I & fee  Dy. No. 12462 dated 06.03.2019  Rs.20,000/- dated 06.03.2019  Pharmacological Group  Type of Form  Form 5  Finished Product Specification  Pack size & Demanded Price  Approval status of product in  Reference Regulatory Authorities.  Film-coated tablets of:  Stalevo 50 (12.5 mg per 50 mg per 200 mg)  Stalevo 100 (25 mg per 100 mg per 200 mg)  Stalevo 125 (31.25 mg per 125 mg per 200 mg)  Stalevo 150 (37.5 mg per 150 mg per 200 mg)  Stalevo 200 (50 mg per 200 mg) er 200 mg)  Stalevo 200 (50 mg per 200 mg)  The firm was inspected on 29.03.2019, wherein the reported satisfactory level of GMP compliance.  Remarks of the Evaluator.  • The drug product specifications have not been evaluation.	
Diary No. Date of R& I & fee  Dy. No. 12462 dated 06.03.2019  Rs.20,000/- dated 06.03.2019  Antiparkinson's drug  Type of Form  Form 5  Finished Product Specification  Pack size & Demanded Price  Approval status of product in  Reference Regulatory Authorities.  Film-coated tablets of:  Stalevo 50 (12.5 mg per 50 mg per 200 mg)  Stalevo 75 (18.75 mg per 100 mg per 200 mg)  Stalevo 100 (25 mg per 100 mg per 200 mg)  Stalevo 125 (31.25 mg per 125 mg per 200 mg)  Stalevo 150 (37.5 mg per 150 mg per 200 mg)  Stalevo 200 (50 mg per 200 mg) approved in USFDA  Me-too status  Obsonery 25/100/200mg Tablet. Reg. No. 70444 (does show anhydrous eq. of carbidopa)  GMP status  The firm was inspected on 29.03.2019, wherein the reported satisfactory level of GMP compliance.  Parks of the Evaluator.	
Rs.20,000/- dated 06.03.2019  Pharmacological Group Type of Form Finished Product Specification Pack size & Demanded Price Approval status of product in Reference Regulatory Authorities.  Film-coated tablets of: Stalevo 50 (12.5 mg per 50 mg per 200 mg) Stalevo 75 (18.75 mg per 75 mg per 200 mg) Stalevo 100 (25 mg per 100 mg per 200 mg) Stalevo 125 (31.25 mg per 125 mg per 200 mg) Stalevo 150 (37.5 mg per 150 mg per 200 mg) Stalevo 200 (50 mg per 200 mg per 200 mg) Stalevo 200 (50 mg per 200 mg per 200 mg) Tablet. Reg. No. 70444 (does show anhydrous eq. of carbidopa)  GMP status The firm was inspected on 29.03.2019, wherein the reported satisfactory level of GMP compliance.  Remarks of the Evaluator.  • The drug product specifications have not been evaluation.	
Type of Form Finished Product Specification Pack size & Demanded Price Approval status of product in Reference Regulatory Authorities.  Stalevo 50 (12.5 mg per 50 mg per 200 mg) Stalevo 75 (18.75 mg per 75 mg per 200 mg) Stalevo 100 (25 mg per 100 mg per 200 mg) Stalevo 125 (31.25 mg per 125 mg per 200 mg) Stalevo 150 (37.5 mg per 150 mg per 200 mg) Stalevo 200 (50 mg per 200 mg per 200 mg) Stalevo 200 (50 mg per 200 mg per 200 mg) Ametoo status  Obsonerv 25/100/200mg Tablet. Reg. No. 70444 (does show anhydrous eq. of carbidopa)  GMP status  The firm was inspected on 29.03.2019, wherein the reported satisfactory level of GMP compliance.  Remarks of the Evaluator.  • The drug product specifications have not been evaluation.	
Finished Product Specification Pack size & Demanded Price Approval status of product in Reference Regulatory Authorities.  Stalevo 50 (12.5 mg per 50 mg per 200 mg) Stalevo 75 (18.75 mg per 100 mg per 200 mg) Stalevo 100 (25 mg per 100 mg per 200 mg) Stalevo 125 (31.25 mg per 125 mg per 200 mg) Stalevo 150 (37.5 mg per 150 mg per 200 mg) Stalevo 200 (50 mg per 200 mg per 200 mg) Stalevo 200 (50 mg per 200 mg per 200 mg) American Stalevo 200 (50 mg per 200 mg) The firm was inspected on 29.03.2019, wherein the reported satisfactory level of GMP compliance.  Remarks of the Evaluator.  In-house  10's, 20's, 30's; As per SRO Film-coated tablets of: Stalevo 50 (12.5 mg per 50 mg per 200 mg) Stalevo 100 (25 mg per 120 mg per 200 mg) Stalevo 100 (25 mg per 125 mg per 200 mg) Stalevo 150 (37.5 mg per 150 mg per 200 mg) The firm was inspected on 29.03.2019, wherein the reported satisfactory level of GMP compliance.  The drug product specifications have not been evaluation.	
Pack size & Demanded Price  Approval status of product in Reference Regulatory Authorities.  Stalevo 50 (12.5 mg per 50 mg per 200 mg) Stalevo 75 (18.75 mg per 100 mg per 200 mg) Stalevo 100 (25 mg per 100 mg per 200 mg) Stalevo 125 (31.25 mg per 125 mg per 200 mg) Stalevo 150 (37.5 mg per 150 mg per 200 mg) Stalevo 200 (50 mg per 200 mg per 200 mg) Stalevo 200 (50 mg per 200 mg per 200 mg) American Stalevo 200 (50 mg per 200 mg) The firm was inspected on 29.03.2019, wherein the reported satisfactory level of GMP compliance.  Remarks of the Evaluator.  • The drug product specifications have not been evaluation.	
Approval status of product in Reference Regulatory Authorities.  Film-coated tablets of: Stalevo 50 (12.5 mg per 50 mg per 200 mg) Stalevo 75 (18.75 mg per 75 mg per 200 mg) Stalevo 100 (25 mg per 100 mg per 200 mg) Stalevo 125 (31.25 mg per 125 mg per 200 mg) Stalevo 150 (37.5 mg per 150 mg per 200 mg) Stalevo 200 (50 mg per 200 mg per 200 mg) approved i USFDA  Me-too status  Obsonerv 25/100/200mg Tablet. Reg. No. 70444 (does show anhydrous eq. of carbidopa)  GMP status  The firm was inspected on 29.03.2019, wherein the reported satisfactory level of GMP compliance.  Remarks of the Evaluator.  • The drug product specifications have not been evaluation.	
Reference Regulatory Authorities.  Stalevo 50 (12.5 mg per 50 mg per 200 mg) Stalevo 75 (18.75 mg per 75 mg per 200 mg) Stalevo 100 (25 mg per 100 mg per 200 mg) Stalevo 125 (31.25 mg per 125 mg per 200 mg) Stalevo 150 (37.5 mg per 150 mg per 200 mg) Stalevo 200 (50 mg per 200 mg per 200 mg) Stalevo 200 (50 mg per 200 mg per 200 mg) American Stalevo 200 (50 mg per 200 mg per 200 mg)  Me-too status  Obsonerv 25/100/200mg Tablet. Reg. No. 70444 (does show anhydrous eq. of carbidopa)  GMP status  The firm was inspected on 29.03.2019, wherein the reported satisfactory level of GMP compliance.  Remarks of the Evaluator.  • The drug product specifications have not been evaluated.	
Stalevo 75 (18.75 mg per 75 mg per 200 mg) Stalevo 100 (25 mg per 100 mg per 200 mg) Stalevo 125 (31.25 mg per 125 mg per 200 mg) Stalevo 150 (37.5 mg per 150 mg per 200 mg) Stalevo 200 (50 mg per 200 mg per 200 mg) American general gener	
Stalevo 100 (25 mg per 100 mg per 200 mg) Stalevo 125 (31.25 mg per 125 mg per 200 mg) Stalevo 150 (37.5 mg per 150 mg per 200 mg) Stalevo 200 (50 mg per 200 mg per 200 mg) approved i USFDA  Me-too status Obsonerv 25/100/200mg Tablet. Reg. No. 70444 (does show anhydrous eq. of carbidopa)  GMP status The firm was inspected on 29.03.2019, wherein the reported satisfactory level of GMP compliance.  Remarks of the Evaluator.  • The drug product specifications have not been evaluated.	
Stalevo 125 (31.25 mg per 125 mg per 200 mg) Stalevo 150 (37.5 mg per 150 mg per 200 mg) Stalevo 200 (50 mg per 200 mg per 200 mg) approved i USFDA  Me-too status Obsonerv 25/100/200mg Tablet. Reg. No. 70444 (does show anhydrous eq. of carbidopa)  GMP status The firm was inspected on 29.03.2019, wherein the reported satisfactory level of GMP compliance.  Remarks of the Evaluator.  • The drug product specifications have not been evaluated.	
Stalevo 150 (37.5 mg per 150 mg per 200 mg) Stalevo 200 (50 mg per 200 mg per 200 mg) approved i USFDA  Me-too status Obsonerv 25/100/200mg Tablet. Reg. No. 70444 (does show anhydrous eq. of carbidopa)  GMP status The firm was inspected on 29.03.2019, wherein the reported satisfactory level of GMP compliance.  Remarks of the Evaluator.  • The drug product specifications have not been evaluated.	
Stalevo 200 (50 mg per 200 mg per 200 mg) approved i USFDA  Me-too status  Obsonerv 25/100/200mg Tablet. Reg. No. 70444 (does show anhydrous eq. of carbidopa)  GMP status  The firm was inspected on 29.03.2019, wherein the reported satisfactory level of GMP compliance.  Remarks of the Evaluator.  • The drug product specifications have not been evaluated.	
USFDA  Me-too status  Obsonerv 25/100/200mg Tablet. Reg. No. 70444 (does show anhydrous eq. of carbidopa)  GMP status  The firm was inspected on 29.03.2019, wherein the reported satisfactory level of GMP compliance.  Remarks of the Evaluator.  ● The drug product specifications have not been evaluated.	
Me-too status  Obsonery 25/100/200mg Tablet. Reg. No. 70444 (does show anhydrous eq. of carbidopa)  GMP status  The firm was inspected on 29.03.2019, wherein the reported satisfactory level of GMP compliance.  Remarks of the Evaluator.  • The drug product specifications have not been evaluated as the reported satisfactory level.	n
show anhydrous eq. of carbidopa)  GMP status  The firm was inspected on 29.03.2019, wherein the reported satisfactory level of GMP compliance.  Remarks of the Evaluator.  • The drug product specifications have not been evaluated as the reported satisfactory level of GMP compliance.	
GMP status  The firm was inspected on 29.03.2019, wherein the reported satisfactory level of GMP compliance.  Remarks of the Evaluator.  • The drug product specifications have not been evaluated as the complex of the expectation of the expec	not
reported satisfactory level of GMP compliance.  Remarks of the Evaluator.  • The drug product specifications have not been evaluated by the compliance of the Evaluator.	ne FID
Remarks of the Evaluator. • The drug product specifications have not been evaluated as a specific transfer of the Evaluator.	
81	ated
The firm has mentioned caroldopa mononydrate	
master formula and adjusted the weight as per sal	
rounded upto 1.08 from 1.079.	t factor
	-1
• The firm revised the address of the firm as per DMI	_
with submission of Rs. 10,000/- fee challs	ın No.
0233009019.	
Decision: Approved with innovator's specifications.	20. 4
76. Name and address of manufacturer / M/s Genetics Pharmaceuticals (Pvt) Limited, Plot No. 5	39-A,
Applicant Sundar Industrial Estate, Lahore  Brand Name +Dosage Form + Strength Dopark Plus 125 Tablet	
Brand Name +Dosage Form + Strength   Dopark Plus 125 Tablet   Composition   Each film-coated tablet contains:	
Composition Each inin-coated tablet contains.  Carbidopa (anhydrous equivalent)31.25mg	
Entacapone200mg	
Levodopa125mg	
Diary No. Date of R& I & fee Dy. No. 12463 dated 06.03.2019	
Rs.20,000/- dated 06.03.2019	
Pharmacological Group Antiparkinson's drug	
Type of Form Form 5	
Finished Product Specification In-house	
Pack size & Demanded Price 10's, 20's, 30's; As per SRO	
Approval status of product in Film-coated tablets of:	
Reference Regulatory Authorities. Stalevo 50 (12.5 mg per 50 mg per 200 mg)	
Stalevo 75 (18.75 mg per 75 mg per 200 mg)	
Stalevo 100 (25 mg per 100 mg per 200 mg)	
Stalevo 125 (31.25 mg per 125 mg per 200 mg)	

		Stalana 150 (27.5 mg mg 150 mg mg 200 mg)
		Stalevo 150 (37.5 mg per 150 mg per 200 mg)
		Stalevo 200 (50 mg per 200 mg per 200 mg) approved in
		USFDA
	Me-too status	Obsonery 31.5/125/200mg Tablet. Reg. No. 70439 (does not
		show anhydrous eq. of carbidopa)
	GMP status	The firm was inspected on 29.03.2019, wherein the FID
	Own status	reported satisfactory level of GMP compliance.
	Remarks of the Evaluator.	• The drug product specifications have not been evaluated.
		• The firm has mentioned carbidopa monohydrate in the
		master formula and adjusted the weight as per salt factor
		rounded upto 1.08 from 1.079.
		• The firm revised the address of the firm as per DML along
		with submission of Rs. 10,000/- fee challan No.
		65219224322.
	Desisions Annuoved with innevestor's	
	Decision: Approved with innovator's	
77.	Name and address of manufacturer /	M/s Genetics Pharmaceuticals (Pvt) Limited, Plot No. 539-A,
	Applicant	Sundar Industrial Estate, Lahore
	Brand Name +Dosage Form + Strength	Dopark Plus 200 Tablet
	Composition	Each film-coated tablet contains:
		Carbidopa (anhydrous equivalent)50mg
		Entacapone200mg
		Levodopa200mg
	Diary No. Date of R& I & fee	Dy. No. 12465 dated 06.03.2019
	Blary 110. Bate of Rec 1 & 1ce	Rs.20,000/- dated 06.03.2019
	Pharmacological Group	Antiparkinson's drug
		Form 5
	Type of Form	
	Finished Product Specification	In-house
	Pack size & Demanded Price	10's, 20's, 30's; As per SRO
	Approval status of product in	Film-coated tablets of:
	Reference Regulatory Authorities.	Stalevo 50 (12.5 mg per 50 mg per 200 mg)
		Stalevo 75 (18.75 mg per 75 mg per 200 mg)
		Stalevo 100 (25 mg per 100 mg per 200 mg)
		Stalevo 125 (31.25 mg per 125 mg per 200 mg)
		Stalevo 150 (37.5 mg per 150 mg per 200 mg)
		Stalevo 200 (50 mg per 200 mg per 200 mg) approved in
		USFDA
	Me-too status	Obsonery 50/200/200mg Tablet. Reg. No. 70441 (does not
	1110 000 000000	show anhydrous eq. of carbidopa)
	GMP status	The firm was inspected on 29.03.2019, wherein the FID
	OM Status	reported satisfactory level of GMP compliance.
	Remarks of the Evaluator.	
	Remarks of the Evaluator.	• The drug product specifications have not been evaluated.
		• The firm has mentioned carbidopa monohydrate in the
		master formula and adjusted the weight as per salt factor
		rounded upto 1.08 from 1.079.
		• The firm revised the address of the firm as per DML along
		with submission of Rs. 10,000/- fee challan No.
		942780315851.
	Desisions Assessed 1 4 1	
<b>F</b> 0	Decision: Approved with innovator's	
78.	Name and address of manufacturer /	M/s Genetics Pharmaceuticals (Pvt) Limited, Plot No. 539-A,
	Applicant	Sundar Industrial Estate, Lahore
	Brand Name +Dosage Form + Strength	Zomide 25mg Capsule
	Composition	Each capsule contains:
		Zonisamide25mg
	Diary No. Date of R& I & fee	Dy. No. 12465 dated 06.03.2019
		Rs.20,000/- dated 06.03.2019
L	1	

	Pharmacological Group	Antiepileptics
	Type of Form	Form 5
	Finished Product Specification	The firm has claimed In-house specs. Available in USP.
	Pack size & Demanded Price	10's, 14's, 28's; As per SRO
	Approval status of product in	ZONEGRAN® (zonisamide) capsules 25mg. Approved in
	Reference Regulatory Authorities.	USFDA.
	Me-too status	Zonisa 25mg Capsule. Reg. No. 58503
	GMP status	The firm was inspected on 29.03.2019, wherein the FID
		reported satisfactory level of GMP compliance.
	Remarks of the Evaluator.	• The drug product specifications have not been evaluated.
		• The firm revised the address of the firm as per DML along with submission of Rs. 10,000/- fee challan No. 60987063568.
		• The reference product in USFDA contains hydrogenated vegetable oil (from soyabean) and sodium laurilsulfate.  The firm revised the excipients along with submission of Rs. 7,500/- fee challan No.03417327.
	Decision: Approved with USP specific	·
79.	Name and address of manufacturer /	M/s Genetics Pharmaceuticals (Pvt) Limited, Plot No. 539-A,
17.	Applicant	Sundar Industrial Estate, Lahore
	Brand Name +Dosage Form + Strength	Zomide 50mg Capsule
	Composition	Each capsule contains:
		Zonisamide50mg
	Diary No. Date of R& I & fee	Dy. No. 12467 dated 06.03.2019
		Rs.20,000/- dated 06.03.2019
	Pharmacological Group	Antiepileptics
	Type of Form	Form 5
	Finished Product Specification	The firm has claimed In-house specs. Available in USP.
	Pack size & Demanded Price	10's, 14's, 28's; As per SRO
	Approval status of product in	ZONEGRAN® (zonisamide) capsules 50mg. Discontinued not
	Reference Regulatory Authorities.	for safety or efficacy reasons in USFDA.
	Me-too status	Zonisa 50mg Capsule. Reg. No. 58504
	GMP status	The firm was inspected on 29.03.2019, wherein the FID reported satisfactory level of GMP compliance.
	Remarks of the Evaluator.	• The drug product specifications have not been evaluated.
		• The firm revised the address of the firm as per DML along with submission of Rs. 10,000/- fee challan No. 99706260619.
		• The reference product in USFDA contains hydrogenated
		vegetable oil (from soyabean) and sodium laurilsulfate.
		The firm revised the excipients along with submission of
		Rs. 7,500/- fee challan No. 65256445725
	<b>Decision: Approved with USP specific</b>	ations.
80.	Name and address of manufacturer /	M/s Genetics Pharmaceuticals (Pvt) Limited, Plot No. 539-A,
	Applicant	Sundar Industrial Estate, Lahore
	Brand Name +Dosage Form + Strength	Zomide 100mg Capsule
	Composition	Each capsule contains:
		Zonisamide100mg
	Diary No. Date of R& I & fee	Dy. No. 12468 dated 06.03.2019
		Rs.20,000/- dated 06.03.2019
	Pharmacological Group	Antiepileptics
	Type of Form	Form 5
	Finished Product Specification	The firm has claimed In-house specs. Aviable in USP.
	Pack size & Demanded Price	10's, 14's, 28's; As per SRO

	Approval status of product in	ZONEGRAN® (zonisamide) capsules 100mg. Approved in in
	Reference Regulatory Authorities.	USFDA.
	Me-too status	Zonisa 100mg Capsule. Reg. No. 58505
	GMP status	The firm was inspected on 29.03.2019, wherein the FID
		reported satisfactory level of GMP compliance.
	Remarks of the Evaluator.	• The drug product specifications have not been evaluated.
		• The firm revised the address of the firm as per DML along
		with submission of Rs. 10,000/- fee challan No. 5826467376.
		• The reference product in USFDA contains hydrogenated
		vegetable oil (from soyabean) and sodium laurilsulfate.
		The firm revised the excipients along with submission of
		Rs. 7,500/- fee challan No.86030018972.
	<b>Decision: Approved with USP specific</b>	·
81.	Name and address of manufacturer /	M/s Kanel Pharma.
	Applicant	Plot # 6, St # SS-3, National Industrial Zone, Rawat.
		By
		M/s Nicholas Pharmaceuticals.
		Plot # 34, St. # SS-02, National Industrial Zone, Rawat,
		Islamabad
	Brand Name +Dosage Form + Strength	Anzam 1g Injection
	Composition	Each Vial Contains:
		Meropenem As Trihydrate1g
	Diary No. Date of R& I & fee	Dy. No. 13081 dated 06.03.2019
		Rs. 50,000/- dated 05.03.2019
	Pharmacological Group	Carbapenem
	Type of Form	Form 5
	Finished Product Specification	The firm has claimed USP specs.
	Pack size & Demanded Price	1's; As per SRO
	Approval status of product in	Meropenem 1000 mg Powder for Solution for Injection or
	Reference Regulatory Authorities.	Infusion. MHRA Approved
	Me-too status	Meroget Powder for Solution for Infusion or Injection. Reg. No. 83175
	GMP status	Kanel Pharma: GMP certificate issued on the basis of inspection dated 03.06.2020
		Nichloas Pharma: GMP certificate issued on the basis of
		inspection dated 07.04.2021
	Remarks of the Evaluator.	• The drug product specifications have not been evaluated.
		• The firm revised the composition as per the salt factor and
		theoretical quantity of the mixture in the composition /
		master formula per vial along with submission of Rs.
		7,500/- fee challan No.34573370.
	Decision: Approved. The firm shall issuance of registration letter.	submit Rs. 67,500 fee for correction in formulation before
82.	Name and address of manufacturer /	M/s Kanel Pharma.
	Applicant	Plot # 6, St # SS-3, National Industrial Zone, Rawat,
		Islamabad
		By
		M/s Nicholas Pharmaceuticals.
		Plot # 34, St. # SS-02, National Industrial Zone, Rawat,
	D 111 D 5	Islamabad
	Brand Name +Dosage Form + Strength	Anzam 500mg Injection
	Composition	Each Vial Contains:
	D' N D C C C C	Meropenem As Trihydrate500mg
	Diary No. Date of R& I & fee	Dy. No. 13080 dated 06.03.2019

		Rs. 50,000/- dated 05.03.2019
	Pharmacological Group	Carbapenem
	Type of Form	Form 5
	Finished Product Specification	The firm has claimed USP specs.
	Pack size & Demanded Price	1's; As per SRO
	Approval status of product in	Meropenem 500 mg Powder for Solution for Injection or
	Reference Regulatory Authorities.	Infusion. MHRA Approved
	Me-too status	Meroget Powder for Solution for Infusion or Injection. Reg. No. 83174
	GMP status	Kanel Pharma: GMP certificate issued on the basis of inspection dated 03.06.2020 Nichloas Pharma: GMP certificate issued on the basis of inspection dated 07.04.2021
	Remarks of the Evaluator.	• The drug product specifications have not been evaluated.
		• The firm revised the composition as per the salt factor and theoretical quantity of the mixture in the composition / master formula per vial along with submission of Rs. 7,500/- fee challan No. 2395157374.
	<b>Decision: Approved. The firm shall sissuance of registration letter.</b>	submit Rs. 67,500 fee for correction in formulation before
83.	Name and address of manufacturer / Applicant	M/s Reign Pharmaceuticals PCSIR-KLC Pvt Ltd. TBIC Building-1, PCSIR Laboratories Complex, Shahrahe Dr. Salim-us-Zaman Siddiqui, Off University Road, Karachi
	Brand Name +Dosage Form + Strength	Terbin 250mg Tablet
	Composition	Each Uncoated Tablet Contains: Terbinafine as HCl250mg
	Diary No. Date of R& I & fee	Dy. No. 12582 dated 06.03.2019 Rs. 20,000/- dated 05.03.2019
	Pharmacological Group	Antifungal
	Type of Form	Form 5
	Finished Product Specification	Not submitted. Available in USP
	Pack size & Demanded Price	10's; As per SRO
	Approval status of product in Reference Regulatory Authorities.	Lamisil® Tablets 250mg by, MHRA Approved.
	Me-too status	Logirid Tablet 250mg, Reg No. 80847
	GMP status	Show cause issued on 23.08.2019
	Remarks of the Evaluator.	• The drug product specifications have not been evaluated.
		• The address in application is M/s Reign Pharmaceuticals PCSIR-KLC Pvt Ltd. TBIC Building-1, PCSIR Laboratories Complex, Shahrahe Dr. Salim-us-Zaman Siddiqui, Off University Road, Karachi, while it M/s Reign Pharmaceuticals PCSIR-KLC Pvt Ltd. TIBC Building-1,
		PCSIR Laboratories Complex, , Karachi in the DML.
		• Form 5 has not been signed. The firm submitted signed Form
		5.
		• The firm did not submit the composition with list and quantity of excipients. The firm made the necessary revision.
		• The firm added blistering process to the manufacturing outlines
	Decision: Approved with USP spec	• In the revised Form 5, the firm mentioned pack size as 10's. cifications. Firm shall submit the fee of Rs. 7,500 for
		product specifications as per notification No. F.7-11/2012-

B&A/DRAP dated 13-07-2021.

correction/pre-approval change/ in product specifications, as per notification No.F.7-11/2012-

84.	Name and address of manufacturer /	M/s Reign Pharmaceuticals PCSIR-KLC Pvt Ltd.	
	Applicant	TBIC Building-1, PCSIR Laboratories Complex, Shahrahe Dr.	
		Salim-us-Zaman Siddiqui, Off University Road, Karachi	
	Brand Name +Dosage Form + Strength	Febstat 40mg Tablet	
	Composition	Each Film Coated Tablet Contains:	
	Diam. No. Data of D.C. I. C. for	Febuxostat40mg	
	Diary No. Date of R& I & fee	Dy. No. 12614 dated 06.03.2019	
	Pharmacological Group	Rs. 20,000/- dated 05.03.2019  Xynthane oxidase inhibitors	
	Type of Form	Form 5	
	Finished Product Specification	Not submitted.	
	Pack size & Demanded Price	20's; As per SRO	
	Approval status of product in	ULORIC (febuxostat) tablet for oral use. USFDA approved	
	Reference Regulatory Authorities.	ezorte (recursostat) tactet for oral age. Cor zir approved	
	Me-too status	Febulos 40mg Tablet. Reg. No. 82694	
	GMP status	Show cause issued on 23.08.2019	
	Remarks of the Evaluator.	The drug product specifications have not been evaluated.	
		• The address in application is M/s Reign Pharmaceuticals	
		PCSIR-KLC Pvt Ltd. TBIC Building-1, PCSIR	
		Laboratories Complex, Shahrahe Dr. Salim-us-Zaman	
		Siddiqui, Off University Road, Karachi, while it M/s Reign	
		Pharmaceuticals PCSIR-KLC Pvt Ltd. TIBC Building-1,	
		PCSIR Laboratories Complex, , Karachi in the DML.	
		• Form 5 has not been signed. The firm submitted signed Form	
		5.	
		• The firm did not submit the composition with list and	
		quantity of excipients. The firm made the necessary	
		revision.	
		• The firm added blistering process to the manufacturing	
		outlines.	
		• In the revised Form 5, the firm mentioned pack size as 20's.	
		Revised the pharmacological group from Xynthane	
		oxidase inhibitors to preparations inhibiting uric acid	
		production	
	Decision: Approved with innevetor's	specifications. Firm shall submit the fee of Rs. 7,500 for	
		oduct specifications, as per notification No.F.7-11/2012-	
	B&A/DRAP dated 13-07-2021.		
85.	Name and address of manufacturer /	M/s Reign Pharmaceuticals PCSIR-KLC Pvt Ltd.	
	Applicant	TBIC Building-1, PCSIR Laboratories Complex, Shahrahe Dr.	
		Salim-us-Zaman Siddiqui, Off University Road, Karachi	
	Brand Name +Dosage Form + Strength	Rivban 2.5mg Tablet	
	Composition	Each Film Coated Tablet Contains:	
		Rivaroxaban2.5mg	
	Diary No. Date of R& I & fee	Dy. No. 12609 dated 06.03.2019	
		Rs. 20,000/- dated 05.03.2019	
	Pharmacological Group	Factor Xa inhibitor	
	Type of Form	Form 5	
	Finished Product Specification	Not submitted.	
	Pack size & Demanded Price	14's; As per SRO	
	Approval status of product in	Xarelto Film Coated Tablet (2.5mg, 10mg, 15mg, 20mg).	
	Reference Regulatory Authorities.	EMA approved  VARELTO 25MG TABLETS Box no 74704	
	Me-too status GMP status	XARELTO 2.5MG TABLETS. Reg. no. 74794 Show cause issued on 23.08.2019	
	Remarks of the Evaluator.		
	INCINALIS OF THE EVALUATOR.	The drug product specifications have not been evaluated.	

		<ul> <li>The address in application is M/s Reign Pharmaceuticals PCSIR-KLC Pvt Ltd. TBIC Building-1, PCSIR Laboratories Complex, Shahrahe Dr. Salim-us-Zaman Siddiqui, Off University Road, Karachi, while it M/s Reign Pharmaceuticals PCSIR-KLC Pvt Ltd. TIBC Building-1, PCSIR Laboratories Complex, , Karachi in the DML.</li> <li>Form 5 has not been signed. The firm submitted signed Form 5.</li> <li>The firm did not submit the composition with list and quantity of excipients. The firm made the necessary revision.</li> <li>The firm added blistering process to the manufacturing outlines.</li> <li>In the revise Form 5, the firm mentioned pack size as 14's.</li> </ul>
1		• Revised the pharmacological group from antithrombic agent
		to Factor Xa inhibitor.
	Decision: Approved with innovator's	specifications. Firm shall submit the fee of Rs. 7,500 for
		oduct specifications, as per notification No.F.7-11/2012-
	B&A/DRAP dated 13-07-2021.	ound specification, as per nomiculation itself in auta-
86.	Name and address of manufacturer /	M/s Reign Pharmaceuticals PCSIR-KLC Pvt Ltd.
	Applicant	TBIC Building-1, PCSIR Laboratories Complex, Shahrahe Dr.
	TT	Salim-us-Zaman Siddiqui, Off University Road, Karachi
	Brand Name +Dosage Form + Strength	Rivban 10mg Tablet
	Composition	Each Film Coated Tablet Contains:
	1	Rivaroxaban10mg
	Diary No. Date of R& I & fee	Dy. No. 12610 dated 06.03.2019
		Rs. 20,000/- dated 05.03.2019
	Pharmacological Group	Factor Xa inhibitor
	Type of Form	Form 5
	Finished Product Specification	Not submitted.
	Pack size & Demanded Price	10's; As per SRO
	Approval status of product in	Rivaroxaban 10 mg film-coated tablets by Milpharm Limited.
	Reference Regulatory Authorities.	MHRA approved
	Me-too status	Xaroban 10mg Tablet. Reg. No. 76284
	GMP status	Show cause issued on 23.08.2019
	Remarks of the Evaluator.	• The drug product specifications have not been evaluated.
		• The address in application is M/s Reign Pharmaceuticals
		PCSIR-KLC Pvt Ltd. TBIC Building-1, PCSIR
		Laboratories Complex, Shahrahe Dr. Salim-us-Zaman
		Siddiqui, Off University Road, Karachi, while it M/s Reign
		Pharmaceuticals PCSIR-KLC Pvt Ltd. TIBC Building-1,
		PCSIR Laboratories Complex, Karachi in the DML.
		• Form 5 has not been signed. The firm submitted signed Form
		5.
		• The firm did not submit the composition with list and
		quantity of excipients. The firm made the necessary revision.
		• The firm added blistering process to the manufacturing
		outlines.
		• In the revise Form 5, the firm mentioned pack size as 10's.
		<ul> <li>Revise the pharmacological group from antithrombic agent</li> </ul>
		to Factor Xa inhibitor.

		specifications. Firm shall submit the fee of Rs. 7,500 for oduct specifications, as per notification No.F.7-11/2012-	
87.	Name and address of manufacturer / Applicant	M/s Reign Pharmaceuticals PCSIR-KLC Pvt Ltd. TBIC Building-1, PCSIR Laboratories Complex, Shahrahe Dr. Salim-us-Zaman Siddiqui, Off University Road, Karachi	
	Brand Name +Dosage Form + Strength	Urdeoxic 250mg Capsule	
	Composition	Each Capsule Contains: Ursydeoxycholic Acid250mg	
	Diary No. Date of R& I & fee	Dy. No. 12606 dated 06.03.2019 Rs. 20,000/- dated 05.03.2019	
	Pharmacological Group	Bile acids and derivatives.	
	Type of Form	Form 5	
	Finished Product Specification	Not submitted. Available in BP	
	Pack size & Demanded Price	10's; As per SRO	
	Approval status of product in	URSOFALK ursodeoxycholic acid 250mg capsule blister pack.	
	Reference Regulatory Authorities.	TGA approved	
	Me-too status	Rivsa 250mg Capsule. Reg. No. 82263	
	GMP status	Show cause issued on 23.08.2019	
	Remarks of the Evaluator.	<ul> <li>The drug product specifications have not been evaluated.</li> <li>The address in application is M/s Reign Pharmaceuticals</li> </ul>	
		PCSIR-KLC Pvt Ltd. TBIC Building-1, PCSIR Laboratories Complex, Shahrahe Dr. Salim-us-Zaman Siddiqui, Off University Road, Karachi, while it M/s Reign Pharmaceuticals PCSIR-KLC Pvt Ltd. TIBC Building-1, PCSIR Laboratories Complex, Karachi in the DML.	
		<ul> <li>Form 5 has not been signed. The firm submitted signed Form 5.</li> <li>The firm did not submit the composition with list and quantity of excipients. The firm made the necessary revision.</li> </ul>	
		<ul> <li>The firm added blistering process to the manufacturing outlines</li> <li>The firm revised the pharmacological group from antichloelithic to Bile acids and derivatives.</li> <li>The firm revised Ursydeoxycholic acid to Ursodeoxycholic</li> </ul>	
		<ul><li>acid.</li><li>In the revised Form 5, the firm mentioned pack size as 10's</li></ul>	
	Decision: Approved with BP specifications. Firm shall submit the fee of Rs. 7,500 for correction/pre-approval change/ in product specifications, as per notification No.F.7-11/2012-B&A/DRAP dated 13-07-2021.		
88.	Name and address of manufacturer / Applicant	M/s Reign Pharmaceuticals PCSIR-KLC Pvt Ltd. TBIC Building-1, PCSIR Laboratories Complex, Shahrahe Dr. Salim-us-Zaman Siddiqui, Off University Road, Karachi	
	Brand Name +Dosage Form + Strength	Aprant 80mg Capsule	
	Composition	Each Capsule Contains:	
	Diary No. Date of R& I & fee	Aprepitant80mg  Dy. No. 12596 dated 06.03.2019  Rs. 20,000/- dated 05.03.2019	
	Pharmacological Group	Antiemtic	
	Type of Form	Form 5	
	Finished Product Specification	Not submitted. Available in USP	
	Pack size & Demanded Price	2's; As per SRO	
	Approval status of product in Reference Regulatory Authorities.	Emend 80mg hard capsules. USFDA approved.	

	Me-too status	Apritus 80mg Capsule. Reg. No. 74886
	GMP status	Show cause issued on 23.08.2019
	Remarks of the Evaluator.	• The drug product specifications have not been evaluated.
		• The address in application is M/s Reign Pharmaceuticals
		PCSIR-KLC Pvt Ltd. TBIC Building-1, PCSIR
		Laboratories Complex, Shahrahe Dr. Salim-us-Zaman
		Siddiqui, Off University Road, Karachi, while it M/s Reign
		Pharmaceuticals PCSIR-KLC Pvt Ltd. TIBC Building-1,
		PCSIR Laboratories Complex, Karachi in the DML.
		^
		• Form 5 has not been signed. The firm submitted signed Form 5.
		• The firm did not submit the composition with list and
		quantity of excipients. The firm made the necessary
		revision.
		• The firm added blistering process to the manufacturing outlines.
		• In the revised Form 5, the firm mentioned pack size as 2's
		cifications. Firm shall submit the fee of Rs. 7,500 for
		product specifications, as per notification No.F.7-11/2012-
90	B&A/DRAP dated 13-07-2021.	M/s D.: s. Dl. sussessed: all DCCID VI C Ded I d
89.	Name and address of manufacturer /	M/s Reign Pharmaceuticals PCSIR-KLC Pvt Ltd.
	Applicant	TBIC Building-1, PCSIR Laboratories Complex, Shahrahe Dr. Salim-us-Zaman Siddiqui, Off University Road, Karachi
	Brand Name +Dosage Form + Strength	Diarin 50mg Capsule
	Composition	Each Capsule Contains:
	Composition	Diacerein50mg
	Diary No. Date of R& I & fee	Dy. No. 12596 dated 06.03.2019
	Diary No. Date of Ree Lee	Rs. 20,000/- dated 05.03.2019
	Pharmacological Group	Anthraquinones
	Type of Form	Form 5
	Finished Product Specification	Not submitted.
	Pack size & Demanded Price	30's; As per SRO
	Approval status of product in	ART 50 mg capsule. ANSM approved
	Reference Regulatory Authorities.	
	Me-too status	Diora 50mg Capsule. Reg. No. 67631
	GMP status	Show cause issued on 23.08.2019
	Remarks of the Evaluator.	• The drug product specifications have not been evaluated.
		• The address in application is M/s Reign Pharmaceuticals
		PCSIR-KLC Pvt Ltd. TBIC Building-1, PCSIR
		Laboratories Complex, Shahrahe Dr. Salim-us-Zaman
		Siddiqui, Off University Road, Karachi, while it M/s Reign
		Pharmaceuticals PCSIR-KLC Pvt Ltd. TIBC Building-1,
		PCSIR Laboratories Complex, Karachi in the DML.
		• Form 5 has not been signed. The firm submitted signed Form
		5.
		• The firm did not submit the composition with list and
		quantity of excipients. The firm made the necessary
		revision.
		• The firm revised the pharmacological group from
		antiinflammatory agents to anthraquinones.
		• The firm added blistering process to the manufacturing
		outlines.
		• In the revised Form 5, the firm mentioned pack size as 30's

		s specifications. Firm shall submit the fee of Rs. 7,500 for product specifications, as per notification No.F.7-11/2012-
90.	Name and address of manufacturer / Applicant	M/s Reign Pharmaceuticals PCSIR-KLC Pvt Ltd. TBIC Building-1, PCSIR Laboratories Complex, Shahrahe Dr. Salim-us-Zaman Siddiqui, Off University Road, Karachi
	Brand Name +Dosage Form + Strength	Biosoda Sachet (5g)
	Composition	Each Gm Sachet Contains: Sodium Bicarbonate0.429g Sodium Citrate0.153g Citric Acid0.176g Tartaric Acid0.215g
	Diary No. Date of R& I & fee	Dy. No. 12589 dated 06.03.2019 Rs. 20,000/- dated 05.03.2019
	Pharmacological Group	Antacid
	Type of Form	Form 5
	Finished Product Specification	Not submitted.
	Pack size & Demanded Price	5g; As per SRO
	Approval status of product in Reference Regulatory Authorities.	Ural Effervescent powder sachets (4g) approved by TGA
	Me-too status	Citro Soda granules (4g) by Abbott Laboratories. Reg. No. 8749 (citric acid 0.98g instead of 0.89g)
	GMP status Remarks of the Evaluator.	Show cause issued on 23.08.2019
		<ul> <li>The drug product specifications have not been evaluated.</li> <li>The address in application is M/s Reign Pharmaceuticals PCSIR-KLC Pvt Ltd. TBIC Building-1, PCSIR Laboratories Complex, Shahrahe Dr. Salim-us-Zaman Siddiqui, Off University Road, Karachi, while it M/s Reign Pharmaceuticals PCSIR-KLC Pvt Ltd. TIBC Building-1, PCSIR Laboratories Complex, Karachi in the DML.</li> <li>Form 5 has not been signed. The firm submitted signed Form 5.</li> <li>The firm did not submit the composition with list and quantity of excipients. The firm made the necessary revision.</li> <li>The firm added sealing process to the manufacturing outlines</li> <li>Justify the composition of the applied product in line with</li> </ul>
		<ul><li>the international reference product.</li><li>In the revise Form 5, the firm mentioned pack size as 5g.</li></ul>
	Decision: Deferred for evidence of approval of applied formulation in reference regulatory authorities / agencies which were adopted by the Registration Board in its 275th meeting.	
91.	Name and address of manufacturer / Applicant	M/s Reign Pharmaceuticals PCSIR-KLC Pvt Ltd. TBIC Building-1, PCSIR Laboratories Complex, Shahrahe Dr. Salim-us-Zaman Siddiqui, Off University Road, Karachi
	Brand Name +Dosage Form + Strength	Hepren Sachet
	Composition	Each Sachet Contains: L-Ornithine-L-Aspartate3g
	Diary No. Date of R& I & fee	Dy. No. 12596 dated 06.03.2019 Rs. 20,000/- dated 05.03.2019
	Pharmacological Group	Hepatoprotective
	Type of Form	Form 5
	Finished Product Specification	Not submitted.
	Pack size & Demanded Price	As per SRO

	Approval status of product in	Hepa-Merz Sachet containing ornithine aspartate (granules for
	Reference Regulatory Authorities.	solution). AGES approved
	Me-too status	Lolar Sachet. Reg. No. 76499
	GMP status	Show cause issued on 23.08.2019
	Remarks of the Evaluator.	• The drug product specifications have not been evaluated.
		• The address in application is M/s Reign Pharmaceutical
		PCSIR-KLC Pvt Ltd. TBIC Building-1, PCSII
		Laboratories Complex, Shahrahe Dr. Salim-us-Zama
		Siddiqui, Off University Road, Karachi, while it M/s Reig
		Pharmaceuticals PCSIR-KLC Pvt Ltd. TIBC Building-1
		PCSIR Laboratories Complex, Karachi in the DML.
		• Form 5 has not been signed. The firm submitted signed Form
		5.
		• The firm did not submit the composition with list and
		quantity of excipients. The firm made the necessar
		revision.
		• The firm added sealing process to the manufacturing outline
		• In the revised Form 5, the firm mentioned pack size as 5g.
		• The reference product is in the form of granules for solution
		You have applied for powder. Justify.
		ormulation from powder to granules and submission of Rs
_		1/2012-B&A/DRAP dated 13-07-2021.
2.	Name and address of manufacturer /	M/s Reign Pharmaceuticals PCSIR-KLC Pvt Ltd.
	Applicant	TBIC Building-1, PCSIR Laboratories Complex, Shahrahe Di
	D IN D E G	Salim-us-Zaman Siddiqui, Off University Road, Karachi
	Brand Name +Dosage Form + Strength	Citoren Syrup
	Composition	Each ml Contains:
	D' N D ( CD 0 I 0 C	Citicoline as Sodium100mg
	Diary No. Date of R& I & fee	Dy. No. 12596 dated 06.03.2019
	Dhamma a la si sal Crayo	Rs. 20,000/- dated 05.03.2019
	Pharmacological Group	Other psychostimulants and nootropics Form 5
	Type of Form  Finished Product Specification	Not submitted.
	Finished Product Specification	
	Pack size & Demanded Price	30ml; As per SRO
	Approval status of product in Reference Regulatory Authorities.	Somazine 100 mg / ml oral solution. <b>CIMA Spain</b> approved
	Me-too status	Citolin Syrup. Reg. No. 29540
	GMP status	Show cause issued on 23.08.2019
	Remarks of the Evaluator.	
	Remarks of the Evaluator.	• The drug product specifications have not been evaluated.
		• The address in application is M/s Reign Pharmaceutical
		PCSIR-KLC Pvt Ltd. TBIC Building-1, PCSI
		Laboratories Complex, Shahrahe Dr. Salim-us-Zama
		Siddiqui, Off University Road, Karachi, while it M/s Reig
		Pharmaceuticals PCSIR-KLC Pvt Ltd. TIBC Building-
		PCSIR Laboratories Complex, Karachi in the DML.
		• Form 5 has not been signed. The firm submitted signed Form
		5.
		• The firm did not submit the composition with list an
		quantity of excipients. The firm made the necessar
		revision.
		revision.  • In the revised Form 5, the firm mentioned pack size as 30m

B&A/DRAP dated 13-07-2021.

93.	Name and address of manufacturer /	M/s Reign Pharmaceuticals PCSIR-KLC Pvt Ltd.
	Applicant	TBIC Building-1, PCSIR Laboratories Complex, Shahrahe Dr.
		Salim-us-Zaman Siddiqui, Off University Road, Karachi
	Brand Name +Dosage Form + Strength	Dexfen 100mg/5ml Suspension
	Composition	Each 5ml Contains:
	_	Dexibuprofen100mg
	Diary No. Date of R& I & fee	Dy. No. 12634 dated 06.03.2019
		Rs. 20,000/- dated 05.03.2019
	Pharmacological Group	NSAIDs
	Type of Form	Form 5
	Finished Product Specification	Not submitted.
	Pack size & Demanded Price	60ml; As per SRO
	Approval status of product in	Could not be confirmed
	Reference Regulatory Authorities.	Could not be commined
	Me-too status	Dexipro 100mg Suspension. Reg. No. 76869
	GMP status	Show cause issued on 23.08.2019
	Remarks of the Evaluator.	• The drug product specifications have not been evaluated.
	Remarks of the Evaluator.	
		• The address in application is M/s Reign Pharmaceuticals
		PCSIR-KLC Pvt Ltd. TBIC Building-1, PCSIR
		Laboratories Complex, Shahrahe Dr. Salim-us-Zaman
		Siddiqui, Off University Road, Karachi, while it M/s Reign
		Pharmaceuticals PCSIR-KLC Pvt Ltd. TIBC Building-1,
		PCSIR Laboratories Complex, Karachi in the DML.
		• Form 5 has not been signed. The firm submitted signed Form
		5.
		• The firm did not submit the composition with list and
		quantity of excipients. The firm made the necessary
		revision.
		• In the revised Form 5, the firm mentioned pack size as 60ml
		• Provide evidence of approval of applied formulation in
		reference regulatory authorities/agencies which were
		adopted by the Registration Board in its 275th meeting.
	<b>Decision:</b> Deferred for evidence of	approval of applied formulation in reference regulatory
	authorities/agencies which were adopt	ted by the Registration Board in its 275th meeting.
94.	Name and address of manufacturer /	M/s Perfect Pharma Pvt Ltd. 5-Km, Manga Road, Raiwind,
	Applicant	Lahore, Pakistan
	Brand Name +Dosage Form +	Faxa 200mg Tablet
	Strength	
	Composition	Each Tablet Contains:
		Rifaximin200mg
	Diary No. Date of R& I & fee	Dy. No. 11903 dated 06.03.2019
	·	Rs. 20,000/- dated 06.03.2019
	Pharmacological Group	Quinolone antibiotics
	Type of Form	Form 5
	Finished Product Specification	Not submitted
	Pack size & Demanded Price	5's, 10's; As per SRO
	Approval status of product in	XIFAXAN® (rifaximin) 200mg film-coated tablets, for oral
	Reference Regulatory Authorities.	use. USFDA approved
	Me-too status	Nimixa 200mg Tablet film-coated. Reg. No. 70734
	GMP status	The firm was inspected on 22.09.2021 and 08.10.2021, where
	Simi status	satisfactory level of GMP compliance was reported.
	Remarks of the Evaluator.	The drug product specifications have not been evaluated.
	Romains of the Evaluator.	The drug product specifications have not been evaluated.
		• The firm revised "each tablet contains" to "each film-
		coated tablet contains".

	1	
		• Submitted the composition with list and quantity of
		excipients.
		• Submitted Rs. 7500/- fee challan: 97815321
	Decision: Approved with innovator's	
95.	Name and address of manufacturer /	M/s Perfect Pharma Pvt Ltd. 5-Km, Manga Road, Raiwind,
	Applicant	Lahore, Pakistan
	Brand Name +Dosage Form +	Faxa 550mg Tablet
	Strength	T. I. W. I. I. G
	Composition	Each Tablet Contains:
	D' N D ( CD0 I 0 C	Rifaximin550mg
	Diary No. Date of R& I & fee	Dy. No. 11867 dated 06.03.2019
	Dhamas a sha si asl Cuana	Rs. 20,000/- dated 06.03.2019
	Pharmacological Group	Quinolone antibiotics
	Type of Form	Form 5 Not submitted
	Finished Product Specification	
	Pack size & Demanded Price	5's, 10's; As per SRO
	Approval status of product in	XIFAXAN® (rifaximin) 550mg film-coated tablets, for oral
	Reference Regulatory Authorities.	use. USFDA approved
	Me-too status	Nimixa 550mg Tablet film-coated. Reg. No. 70733
	GMP status	The firm was inspected on 22.09.2021 and 08.10.2021, where
	Remarks of the Evaluator.	satisfactory level of GMP compliance was reported.
	Remarks of the Evaluator.	• The drug product specifications have not been evaluated.
		• The firm revised "each tablet contains" to "each film-
		coated tablet contains".
		• Submitted the composition with list and quantity of
		excipients.
		• Submitted Rs. 7500/- fee challan: 524861187
0.6	Decision: Approved with innovator's	
96.	Name and address of manufacturer /	M/s Perfect Pharma Pvt Ltd. 5-Km, Manga Road, Raiwind,
	Applicant  Prond Name   Deceme Form	Lahore, Pakistan Kalgil 50mg/850mg Tablet
	Brand Name +Dosage Form + Strength	Kaigh Johng 630mg Tablet
	Composition	Each Film Coated Tablet Contains:
	Composition	Sitagliptin Phosphate Monohydrate Eq To Sitagliptin50mg
		Metformin850mg
	Diary No. Date of R& I & fee	Dy. No. 11888 dated 06.03.2019
	Blary 110. Bate of fee fee	Rs. 20,000/- dated 06.03.2019
	Pharmacological Group	Antidiabetics
	-	
i	Type of Form	FORM 5
	Type of Form Finished Product Specification	Form 5 Not submitted
	Finished Product Specification Pack size & Demanded Price	Not submitted
	Finished Product Specification	
	Finished Product Specification Pack size & Demanded Price	Not submitted 5's, 10's; As per SRO
	Finished Product Specification Pack size & Demanded Price Approval status of product in	Not submitted 5's, 10's; As per SRO
	Finished Product Specification Pack size & Demanded Price Approval status of product in Reference Regulatory Authorities.	Not submitted 5's, 10's; As per SRO Velmetia 50/850mg film coated tablet, Australia.
	Finished Product Specification Pack size & Demanded Price Approval status of product in Reference Regulatory Authorities. Me-too status	Not submitted 5's, 10's; As per SRO Velmetia 50/850mg film coated tablet, Australia.  S-gliptin plus. Reg # 081619
	Finished Product Specification Pack size & Demanded Price Approval status of product in Reference Regulatory Authorities. Me-too status	Not submitted 5's, 10's; As per SRO Velmetia 50/850mg film coated tablet, Australia.  S-gliptin plus. Reg # 081619 The firm was inspected on 22.09.2021 and 08.10.2021, where
	Finished Product Specification Pack size & Demanded Price Approval status of product in Reference Regulatory Authorities. Me-too status GMP status	Not submitted 5's, 10's; As per SRO Velmetia 50/850mg film coated tablet, Australia.  S-gliptin plus. Reg # 081619 The firm was inspected on 22.09.2021 and 08.10.2021, where satisfactory level of GMP compliance was reported.  • The drug product specifications have not been evaluated.
	Finished Product Specification Pack size & Demanded Price Approval status of product in Reference Regulatory Authorities. Me-too status GMP status	Not submitted 5's, 10's; As per SRO Velmetia 50/850mg film coated tablet, Australia.  S-gliptin plus. Reg # 081619 The firm was inspected on 22.09.2021 and 08.10.2021, where satisfactory level of GMP compliance was reported.  • The drug product specifications have not been evaluated.  • The firm mentioned Metformin HCl in the composition.
	Finished Product Specification Pack size & Demanded Price Approval status of product in Reference Regulatory Authorities. Me-too status GMP status	Not submitted 5's, 10's; As per SRO Velmetia 50/850mg film coated tablet, Australia.  S-gliptin plus. Reg # 081619 The firm was inspected on 22.09.2021 and 08.10.2021, where satisfactory level of GMP compliance was reported.  • The drug product specifications have not been evaluated.
	Finished Product Specification Pack size & Demanded Price Approval status of product in Reference Regulatory Authorities. Me-too status GMP status	Not submitted 5's, 10's; As per SRO  Velmetia 50/850mg film coated tablet, Australia.  S-gliptin plus. Reg # 081619  The firm was inspected on 22.09.2021 and 08.10.2021, where satisfactory level of GMP compliance was reported.  • The drug product specifications have not been evaluated.  • The firm mentioned Metformin HCl in the composition.  The firm revised the Metformin to Metformin HCl in the label claim.
	Finished Product Specification Pack size & Demanded Price Approval status of product in Reference Regulatory Authorities. Me-too status GMP status	Not submitted 5's, 10's; As per SRO Velmetia 50/850mg film coated tablet, Australia.  S-gliptin plus. Reg # 081619 The firm was inspected on 22.09.2021 and 08.10.2021, where satisfactory level of GMP compliance was reported.  • The drug product specifications have not been evaluated.  • The firm mentioned Metformin HCl in the composition. The firm revised the Metformin to Metformin HCl in the
	Finished Product Specification Pack size & Demanded Price Approval status of product in Reference Regulatory Authorities. Me-too status GMP status	Not submitted 5's, 10's; As per SRO Velmetia 50/850mg film coated tablet, Australia.  S-gliptin plus. Reg # 081619 The firm was inspected on 22.09.2021 and 08.10.2021, where satisfactory level of GMP compliance was reported.  • The drug product specifications have not been evaluated.  • The firm mentioned Metformin HCl in the composition. The firm revised the Metformin to Metformin HCl in the label claim.  • Adjusted the weight of sitagliptin phosphate monohydrate
	Finished Product Specification Pack size & Demanded Price Approval status of product in Reference Regulatory Authorities. Me-too status GMP status	Not submitted 5's, 10's; As per SRO Velmetia 50/850mg film coated tablet, Australia.  S-gliptin plus. Reg # 081619 The firm was inspected on 22.09.2021 and 08.10.2021, where satisfactory level of GMP compliance was reported.  • The drug product specifications have not been evaluated.  • The firm mentioned Metformin HCl in the composition. The firm revised the Metformin to Metformin HCl in the label claim.  • Adjusted the weight of sitagliptin phosphate monohydrate in the master formula as per salt factor.

		• Submitted Rs. 7500/- fee challan: 1408744142.	
	Decision: Approved with innovator's	s specifications as:	
	Each Film Coated Tablet Contains:		
	Sitagliptin Phosphate Monohydrate	Eq To Sitagliptin50mg	
	Metformin HCl850mg The firm shall submit Rs 22,500 fee	for correction in formulation before issuance of registration	
	letter.	Tot correction in formation before issuance of registration	
97.	Name and address of manufacturer / Applicant	M/s Perfect Pharma Pvt Ltd. 5-Km, Manga Road, Raiwind, Lahore, Pakistan	
	Brand Name +Dosage Form + Strength	Kalsart CR Tablet 320/10/25mg	
	Composition	Each Film Coated Tablet Contains:	
		Valsartan320mg	
		Amlodipine As Besylate10mg	
		Hydrochlorothiazide25mg	
	Diary No. Date of R& I & fee	Dy. No. 11874 dated 06.03.2019	
		Rs. 20,000/- dated 06.03.2019	
	Pharmacological Group	Antihypertensives	
	Type of Form	Form 5	
	Finished Product Specification	Not submitted. Available in USP	
	Pack size & Demanded Price	5's, 10's, 30's, 14's; As per SRO	
	Approval status of product in	EXFORGE HCT® Tablets by Novartis Pharmaceuticals	
	Reference Regulatory Authorities.	Corporation. US-FDA approved	
	Me-too status	Exforge HCT 10/320/25MG film coated tablets. Reg. No.	
	CMD	69552	
	GMP status	The firm was inspected on 22.09.2021 and 08.10.2021, where satisfactory level of GMP compliance was reported.	
	Remarks of the Evaluator.	• The drug product specifications have not been evaluated.	
		<ul> <li>Submitted the composition with list and quantity of excipients.</li> </ul>	
		• Submitted Rs. 7500/- fee challan: 3216273561.	
	Decision: Approved with USP specif	ications	
98.	Name and address of manufacturer /	M/s Perfect Pharma Pvt Ltd. 5-Km, Manga Road, Raiwind,	
70.	Applicant	Lahore, Pakistan	
	Brand Name +Dosage Form + Strength	Kalsart cr Tablet 160/10/12.5mg	
	Composition	Each Film Coated Tablet Contains:	
		Valsartan160mg	
		Amlodipine As Besylate10mg	
		Hydrochlorothiazide12.5mg	
	Diary No. Date of R& I & fee	Dy. No. 11874 dated 06.03.2019	
		Rs. 20,000/- dated 06.03.2019	
	Pharmacological Group	Antihypertensives	
	Type of Form	Form 5	
	Finished Product Specification	Not submitted. Available in USP	
	Pack size & Demanded Price	5's, 10's, 30's, 14's; As per SRO	
	Approval status of product in	EXFORGE HCT® Tablets by Novartis Pharmaceuticals	
	Reference Regulatory Authorities.	Corporation. US-FDA approved	
	Me-too status	Exforge HCT 10/160/12.5MG film coated tablets by Novatris	
		Pharma. Reg. No. 69550	
	GMP status	The firm was inspected on 22.09.2021 and 08.10.2021, where	
	Damada af the Eq. 1	satisfactory level of GMP compliance was reported.	
	Remarks of the Evaluator.	• The drug product specifications have not been evaluated.	

		Submitted the composition with list and quantity of
		excipients.
		• Submitted Rs. 7500/- fee challan: 987197684.
	<b>Decision: Approved with USP specific</b>	eations.
99.	Name and address of manufacturer /	M/s Perfect Pharma Pvt Ltd. 5-Km, Manga Road, Raiwind,
	Applicant	Lahore, Pakistan
	Brand Name +Dosage Form +	Oxin 250mg Tablet
	Strength	
	Composition	Each Tablet Contains:
	Diama Na Data af D.O. L.O. fac	Levofloxacin250mg
	Diary No. Date of R& I & fee	Dy. No. 11851 dated 06.03.2019 Rs. 20,000/- dated 06.03.2019
	Pharmacological Group	Flurorquinolones
	Type of Form	Form 5
	Finished Product Specification	Not submitted. Available in USP
	Pack size & Demanded Price	10's, 20's, 14's, 100's; As per SRO
	Approval status of product in	Evoxil 250 mg film-coated tablets. MHRA approved
	Reference Regulatory Authorities.	Evokii 250 ing iliin conted molets. Williev approved
	Me-too status	Levolis 250mg Tablets. Reg. No. 85178
	GMP status	The firm was inspected on 22.09.2021 and 08.10.2021, where
		satisfactory level of GMP compliance was reported.
	Remarks of the Evaluator.	The drug product specifications have not been evaluated.
		• The firm applied for levofloxacin250mg and mentioned
		levofloxacin hemihydrate in the master formula. The firm
		revised the label claim to levofloxacin as
		hemihydrate25mg and had already adjusted the weight
		of levofloxacin hemihydrate in the master formula as per
		equivalency factor.
		• Submitted the composition with list and quantity of
		<ul><li>excipients.</li><li>The firm revised the tablet to film-coated tablet and</li></ul>
		mentioned the coating composition and method in the
		manufacturing outlines.
		• Submitted Rs. 7500/- fee challan: 612018465869.
	Decision: Approved with USP specifi	ications as Each film-coated tablet contains: levofloxacin as
		submit Rs. 22,500 fee for correction in formulation before
	issuance of registration letter.	,
100.	Name and address of manufacturer /	M/s Perfect Pharma Pvt Ltd. 5-Km, Manga Road, Raiwind,
	Applicant	Lahore, Pakistan
	Brand Name +Dosage Form +	Kast 10mg Tablet
	Strength	
	Composition	Each Chewable Tablet Contains:
	Di N D (DO VO C	Montelukast Sodium Eq To Montelukast10mg
	Diary No. Date of R& I & fee	Dy. No. 11828 dated 06.03.2019 Rs. 20,000/- dated 06.03.2019
	Pharmacological Group	Bronchodilators
	Type of Form	Form 5
	Finished Product Specification	Not submitted. Available in USP
	Pack size & Demanded Price	10's, 20's, 14's, 100's; As per SRO
	Approval status of product in	SINGULAIR® (montelukast sodium) film-coated tablets.
	Reference Regulatory Authorities.	USFDA approved
	Me-too status	Singulair Tablets 10mg. Reg. No. 25259
	GMP status	The firm was inspected on 22.09.2021 and 08.10.2021, where
		satisfactory level of GMP compliance was reported.

	Remarks of the Evaluator.	• The drug product specifications have not been evaluated.
		Revised the application from chewable tablets to film-
		coated tablet in line with the reference product.
		Adjusted the weight of Montelukast sodium in the master
		formula as per salt factor.
		Submitted the composition with list and quantity of
		excipients.
		• Submitted Rs. 7500/- fee challan: 2858255867.
		Revise the pharmacological group to Leukotriene receptor
		antagonists.
	Decision: Approved with USP specific	eations. The firm shall submit Rs. 22,500 fee for correction in
	formulation before issuance of registr	
101.	Name and address of manufacturer /	M/s Perfect Pharma Pvt Ltd. 5-Km, Manga Road, Raiwind,
1010	Applicant Applicant	Lahore, Pakistan
	Brand Name +Dosage Form +	Oxycam 7.5mg Tablet
	Strength	Onyouth fields Tuesde
	Composition	Each Tablet Contains:
	Composition	Meloxicam7.5mg
	Diary No. Date of R& I & fee	Dy. No. 11868 dated 06.03.2019
	Blary 140. Bate of 182 1 & 166	Rs. 20,000/- dated 06.03.2019
	Pharmacological Group	NSAIDs
	Type of Form	Form 5
	Finished Product Specification	Not submitted. Available in USP
	Pack size & Demanded Price	5's, 10's, 20's, 30's, 14's, 100's; As per SRO
	Approval status of product in	Meloxicam 7.5mg uncoated tablets. MHRA approved
	Reference Regulatory Authorities.	Weloxicam 7.5mg uncoated tablets. Wither approved
	Me-too status	Mexiran Tablets 7.5mg. Reg. No. 20845
	GMP status	The firm was inspected on 22.09.2021 and 08.10.2021, where
	Givii status	satisfactory level of GMP compliance was reported.
	Remarks of the Evaluator.	The drug product specifications have not been evaluated.
	Remarks of the Evaluator.	The drug product specifications have not been evaluated.      The firm applied for uncoated tablet. Removed the coating
		process form the manufacturing outlines.
		<ul> <li>Submitted the composition with list and quantity of</li> </ul>
		excipients.
		• Submitted Rs. 7500/- fee challan: 34575664.
	Decision: Approved with USP specific	,
102.	Name and address of manufacturer /	M/s Perfect Pharma Pvt Ltd. 5-Km, Manga Road, Raiwind,
102.	Applicant	Lahore, Pakistan
	Brand Name +Dosage Form +	Kestec 10mg Tablet
	Strength	Restee Tollig Tablet
	Composition	Each Tablet Contains:
	Composition	Ebastine10mg
	Diary No. Date of R& I & fee	Dy. No. 11896 dated 06.03.2019
	Dialy No. Date of R& 1 & fee	Rs. 20,000/- dated 06.03.2019
	Pharmacological Group	Histamine H1 receptor antagonist
	Type of Form	Form 5
	Finished Product Specification	Not submitted. Available in JP
	Pack size & Demanded Price	5's, 10's, 20's, 30's, 14's, 100's; As per SRO
	Approval status of product in	EBASTINE ARROW 10 mg film-coated tablets
	Reference Regulatory Authorities.	ANSM Approved
	Me-too status	Atmos Tablets 10mg of Scotmann Pharma (Reg# 056116)
	GMP status	The firm was inspected on 22.09.2021 and 08.10.2021, where
	Owir status	satisfactory level of GMP compliance was reported.
	Remarks of the Evaluator.	The drug product specifications have not been evaluated.
	Remarks of the Evaluator.	The drug product specifications have not been evaluated.
	•	·

Submitted the composition with list and quaexcipients.   Submitted Rs. 7500/- fee challan: 41341215     Decision: Approved with JP specifications.	71. ad, Raiwind,
Decision: Approved with JP specifications.  Name and address of manufacturer / Applicant Brand Name +Dosage Form + Strength  Composition Each film-coated tablet Contains: Levosulpride25mg Diary No. Date of R& I & fee Dy. No. 11883 dated 06.03.2019 Rs. 20,000/- dated 06.03.2019 Pharmacological Group Antipsychotic Type of Form Frinished Product Specification Pack size & Demanded Price Approval status of product in Reference Regulatory Authorities. Me-too status GMP status  Me-too status GMP status  Remarks of the Evaluator.  Decision: Approved with innovator's specifications.  Name and address of manufacturer / Applicant Brand Name +Dosage Form + Strength  M/s Perfect Pharma Pvt Ltd. 5-Km, Manga Roz Aphroval Status M/s Perfect Pharma Pvt Ltd. 5-Km, Manga Roz Lahore, Pakistan Peride 50mg Tablet  M/s Perfect Pharma Pvt Ltd. 5-Km, Manga Roz Lahore, Pakistan Peride 50mg Tablet Pride 50mg Tablet Pride 50mg Tablet Pride 50mg Tablet	nd, Raiwind,
Name and address of manufacturer / Applicant   Brand Name +Dosage Form + Strength   Peride 25mg Tablet   Peride 25mg Tablet   Strength   Peride 25mg Tablet   Peride 25mg Table	
Applicant Brand Name +Dosage Form + Strength Composition Each film-coated tablet Contains: Levosulpride25mg Diary No. Date of R& I & fee Dy. No. 11883 dated 06.03.2019 Rs. 20,000/- dated 06.03.2019 Pharmacological Group Antipsychotic Type of Form Form 5 Finished Product Specification Pack size & Demanded Price Approval status of product in Reference Regulatory Authorities. Me-too status Me-too status Me-too status  The firm was inspected on 22.09.2021 and 08.1 satisfactory level of GMP compliance was report Remarks of the Evaluator.  Pecision: Approved with innovator's specifications.  Name and address of manufacturer / Applicant Brand Name +Dosage Form + Strength  Peride 25mg Tablet Syndry Antipsychotic Not submitted. Solvo Tablets 25mg, Reg. No. 31747 The firm was inspected on 22.09.2021 and 08.1 satisfactory level of GMP compliance was reported by AIFA  Revised the label claim from film-coated to Submitted the composition with list and qual excipients.  Submitted Rs. 7500/- fee challan: 64356796  Decision: Approved with innovator's specifications.  M/s Perfect Pharma Pvt Ltd. 5-Km, Manga Rozalahore, Pakistan Peride 50mg Tablet	
Strength Composition Each film-coated tablet Contains: Levosulpride25mg  Diary No. Date of R& I & fee Dy. No. 11883 dated 06.03.2019 Rs. 20,000/- dated 06.03.2019 Rs. 20,000/- dated 06.03.2019 Pharmacological Group Antipsychotic Type of Form Form 5 Finished Product Specification Pack size & Demanded Price Approval status of product in Reference Regulatory Authorities. Me-too status Sulvo Tablets 25mg. Reg. No. 31747 GMP status The firm was inspected on 22.09.2021 and 08.1 satisfactory level of GMP compliance was reported. Remarks of the Evaluator.  Pecision: Approved with innovator's specifications.  Name and address of manufacturer / Applicant Brand Name +Dosage Form + Strength  Strength  Each film-coated tablet Contains: Levosulpride25mg Dy. No. 11883 dated 06.03.2019 Rs. 20,000/- dated 06.03.2019	Srl. Approved
Diary No. Date of R& I & fee  Diary No. Date of R& I & fee  Dy. No. 11883 dated 06.03.2019  Rs. 20,000/- dated 06.03.2019  Pharmacological Group  Antipsychotic  Type of Form  Form 5  Finished Product Specification  Pack size & Demanded Price Approval status of product in  Reference Regulatory Authorities.  Me-too status  GMP status  The firm was inspected on 22.09.2021 and 08.1 satisfactory level of GMP compliance was reported for the drug product specifications have not been excipients.  Pecision: Approved with innovator's specifications.  104.  Name and address of manufacturer / Applicant  Brand Name +Dosage Form +  Strength  Supposed Antipsychotic  Dy. No. 11883 dated 06.03.2019  Dy. No. 11883 dated 06.03.2019  Dy. No. 11883 dated 06.03.2019  Dy. No. 11883 dated 06.03.2019  Dy. No. 11883 dated 06.03.2019  Antipsychotic  Prom 5  Form 5  Not submitted.  Peride 50mg Tablet  Dy. 14, 14, 100's; As per SRO  LEVOPRAID® 25 mg Tablets by TEOFARMA by AIFA  Sulvo Tablets 25mg. Reg. No. 31747  The firm was inspected on 22.09.2021 and 08.1 satisfactory level of GMP compliance was reported in the firm was inspected on 22.09.2021 and 08.1 satisfactory level of GMP compliance was reported in the firm was inspected on 22.09.2021 and 08.1 satisfactory level of GMP compliance was reported in the firm was inspected on 22.09.2021 and 08.1 satisfactory level of GMP compliance was reported in the firm was inspected on 22.09.2021 and 08.1 satisfactory level of GMP compliance was reported in the firm was inspected on 22.09.2021 and 08.1 satisfactory level of GMP compliance was reported in the firm was inspected on 22.09.2021 and 08.1 satisfactory level of GMP compliance was reported in the firm was inspected on 22.09.2021 and 08.1 satisfactory level of GMP compliance was reported in the firm was inspected on 22.09.2021 and 08.1 satisfactory level of GMP compliance was reported in the firm was inspected on 22.09.2021 and 08.1 satisfactory level of GMP compliance was reported in the firm was inspected on 22.09.2021 and 08.1 satisfacto	Srl. Approved
Rs. 20,000/- dated 06.03.2019  Pharmacological Group Antipsychotic  Type of Form Form Form 5  Finished Product Specification Not submitted.  Pack size & Demanded Price 5's, 10's, 30's, 14's, 100's; As per SRO  Approval status of product in Reference Regulatory Authorities. Me-too status Sulvo Tablets 25mg. Reg. No. 31747  GMP status The firm was inspected on 22.09.2021 and 08.1 satisfactory level of GMP compliance was report Remarks of the Evaluator.  • The drug product specifications have not been excipients.  • Revised the label claim from film-coated to submitted the composition with list and qual excipients.  • Submitted Rs. 7500/- fee challan: 64356796  Decision: Approved with innovator's specifications.  104. Name and address of manufacturer / Applicant Brand Name +Dosage Form + Strength  Rs. 20,000/- dated 06.03.2019  Not submitted.  Peride 50mg Tablet	Srl. Approved
Pharmacological Group Type of Form Finished Product Specification Pack size & Demanded Price Approval status of product in Reference Regulatory Authorities. Me-too status GMP status  Remarks of the Evaluator.  Pecision: Approved with innovator's specifications  Not submitted. Silvo Tablets 25 mg Tablets by TEOFARMA by AIFA Sulvo Tablets 25mg. Reg. No. 31747 The firm was inspected on 22.09.2021 and 08.1 satisfactory level of GMP compliance was reported by AIFA  Rewarks of the Evaluator.  Pecision: Approved with innovator's specifications have not been been been been been been been bee	Srl. Approved
Type of Form Finished Product Specification Pack size & Demanded Price Approval status of product in Reference Regulatory Authorities. Me-too status GMP status  The firm was inspected on 22.09.2021 and 08.1 satisfactory level of GMP compliance was repormentations.  Remarks of the Evaluator.  The drug product specifications have not been excipients.  Revised the label claim from film-coated to submitted Rs. 7500/- fee challan: 64356796  Decision: Approved with innovator's specifications.  Name and address of manufacturer / Applicant Brand Name +Dosage Form + Strength  Form 5  Not submitted. Solvo Tablets 25 mg Tablets by TEOFARMA by AIFA  LEVOPRAID® 25 mg Tablets by TEOFARMA by AIFA  LEVOPRAID® 25 mg Tablets by TEOFARMA by AIFA  LEVOPRAID® 25 mg Tablets by TEOFARMA by AIFA  LEVOPRAID® 25 mg Tablets by TEOFARMA by AIFA  LEVOPRAID® 25 mg Tablets by TEOFARMA by AIFA  LEVOPRAID® 25 mg Tablets by TEOFARMA by AIFA  LEVOPRAID® 25 mg Tablets by TEOFARMA by AIFA  LEVOPRAID® 25 mg Tablets by TEOFARMA by AIFA  LEVOPRAID® 25 mg Tablets by TEOFARMA by AIFA  Sulvo Tablets by TEOFARMA by AIFA  LEVOPRAID® 25 mg Tablets by TEOFARMA by AIFA  LEVOPRAID® 25 mg Tablets by TEOFARMA by AIFA  LEVOPRAID® 25 mg Tablets by TEOFARMA by AIFA  LEVOPRAID® 25 mg Tablets by TEOFARMA by AIFA  LEVOPRAID® 25 mg Tablets by TEOFARMA by AIFA  LEVOPRAID® 25 mg Tablets by TEOFARMA by AIFA  LEVOPRAID® 25 mg Tablets by TEOFARMA by AIFA  LEVOPRAID® 25 mg Tablets by TEOFARMA by AIFA  LEVOPRAID® 25 mg Tablets by TEOFARMA by AIFA  LEVOPRAID® 25 mg Tablets by TEOFARMA by AIFA  LEVOPRAID® 25 mg Tablets by TEOFARMA  LEVOPRAID® 26 mg Tablets by TEOFARMA  LEVOPRAID® 26 mg Tablets by TEOFARMA  LEVOPRAID® 26 mg Tablets by TEOFARMA  LEVOPRAID® 26 mg Tablets by TEOFARM	Srl. Approved
Finished Product Specification Pack size & Demanded Price Approval status of product in Reference Regulatory Authorities. Me-too status  GMP status  Remarks of the Evaluator.  Decision: Approved with innovator's specifications  Not submitted.  Silvo Tablets 25 mg Tablets by TEOFARMA by AIFA  Sulvo Tablets 25mg. Reg. No. 31747  The firm was inspected on 22.09.2021 and 08.1 satisfactory level of GMP compliance was reported.  Rewised the label claim from film-coated to Submitted the composition with list and qual excipients.  Submitted Rs. 7500/- fee challan: 64356796  Decision: Approved with innovator's specifications.  Name and address of manufacturer / Applicant Brand Name +Dosage Form + Strength  Not submitted.  S's, 10's, 30's, 14's, 100's; As per SRO  LEVOPRAID® 25 mg Tablets by TEOFARMA by AIFA  Sulvo Tablets 25mg. Reg. No. 31747  The firm was inspected on 22.09.2021 and 08.1 satisfactory level of GMP compliance was reported.  Submitted the composition with list and qual excipients.  Submitted Rs. 7500/- fee challan: 64356796  M/s Perfect Pharma Pvt Ltd. 5-Km, Manga Roa Lahore, Pakistan  Peride 50mg Tablet	Srl. Approved
Pack size & Demanded Price Approval status of product in Reference Regulatory Authorities. Me-too status  Me-too status  GMP status  Remarks of the Evaluator.  Pack size & Decision: Approved with innovator's specifications.  Pack size & Demanded Price  S's, 10's, 30's, 14's, 100's; As per SRO  LEVOPRAID® 25 mg Tablets by TEOFARMA by AIFA  Sulvo Tablets 25mg. Reg. No. 31747  The firm was inspected on 22.09.2021 and 08.1 satisfactory level of GMP compliance was repo  • The drug product specifications have not bed  • Revised the label claim from film-coated to  • Submitted the composition with list and qual excipients.  • Submitted Rs. 7500/- fee challan: 64356796  Decision: Approved with innovator's specifications.  M/s Perfect Pharma Pvt Ltd. 5-Km, Manga Roa Lahore, Pakistan  Brand Name +Dosage Form + Strength  Peride 50mg Tablet	Srl. Approved
Approval status of product in Reference Regulatory Authorities.  Me-too status  Me-too status  GMP status  Remarks of the Evaluator.  Peride Tournel Approved with innovator's specifications.  Name and address of manufacturer / Applicant  Brand Name +Dosage Form +  Sulvo Tablets 25mg. Reg. No. 31747  The firm was inspected on 22.09.2021 and 08.1 satisfactory level of GMP compliance was reported in the firm was inspected on 22.09.2021 and 08.1 satisfactory level of GMP compliance was reported in the firm was inspected on 22.09.2021 and 08.1 satisfactory level of GMP compliance was reported in the firm was inspected on 22.09.2021 and 08.1 satisfactory level of GMP compliance was reported in the firm was inspected on 22.09.2021 and 08.1 satisfactory level of GMP compliance was reported in the firm was inspected on 22.09.2021 and 08.1 satisfactory level of GMP compliance was reported in the firm was inspected on 22.09.2021 and 08.1 satisfactory level of GMP compliance was reported in the firm was inspected on 22.09.2021 and 08.1 satisfactory level of GMP compliance was reported in the firm was inspected on 22.09.2021 and 08.1 satisfactory level of GMP compliance was reported in the firm was inspected on 22.09.2021 and 08.1 satisfactory level of GMP compliance was reported in the firm was inspected on 22.09.2021 and 08.1 satisfactory level of GMP compliance was reported in the firm was inspected on 22.09.2021 and 08.1 satisfactory level of GMP compliance was reported in the firm was inspected on 22.09.2021 and 08.1 satisfactory level of GMP compliance was reported in the firm was inspected on 22.09.2021 and 08.1 satisfactory level of GMP compliance was reported in the firm was inspected on 22.09.2021 and 08.1 satisfactory level of GMP compliance was reported in the firm was inspected on 22.09.2021 and 08.1 satisfactory level of GMP compliance was reported in the firm was inspected on 22.09.2021 and 08.1 satisfactory level of GMP compliance was reported in the firm was inspected on 22.09.2021 and 08.1 satisfactory lev	Srl. Approved
Me-too status  GMP status  Remarks of the Evaluator.  Remarks of the Evaluator.  Pecision: Approved with innovator's specifications.  Name and address of manufacturer / Applicant  Brand Name +Dosage Form +  Sulvo Tablets 25mg. Reg. No. 31747  The firm was inspected on 22.09.2021 and 08.1 satisfactory level of GMP compliance was reported in the firm of the satisfactory level of GMP compliance was reported in the firm of the firm of the satisfactory level of GMP compliance was reported in the firm of the firm of the satisfactory level of GMP compliance was reported in the firm of the firm was inspected on 22.09.2021 and 08.1 satisfactory level of GMP compliance was reported in the firm of the firm was inspected on 22.09.2021 and 08.1 satisfactory level of GMP compliance was reported in the firm was inspected on 22.09.2021 and 08.1 satisfactory level of GMP compliance was reported in the firm was inspected on 22.09.2021 and 08.1 satisfactory level of GMP compliance was reported in the firm was inspected on 22.09.2021 and 08.1 satisfactory level of GMP compliance was reported in the firm was inspected on 22.09.2021 and 08.1 satisfactory level of GMP compliance was reported in the firm was inspected on 22.09.2021 and 08.1 satisfactory level of GMP compliance was reported in the firm was inspected on 22.09.2021 and 08.1 satisfactory level of GMP compliance was reported in the firm was inspected on 22.09.2021 and 08.1 satisfactory level of GMP compliance was reported in the firm was inspected on 22.09.2021 and 08.1 satisfactory level of GMP compliance was reported in the firm was inspected on 22.09.2021 and 08.1 satisfactory level of GMP compliance was reported in the firm was inspected on 22.09.2021 and 08.1 satisfactory level of GMP compliance was reported in the firm was inspected on 22.09.2021 and 08.1 satisfactory level of GMP compliance was reported in the firm was inspected on 22.09.2021 and 08.1 satisfactory level of GMP compliance was reported in the firm was inspected in the firm was reported in the firm was	
GMP status  Remarks of the Evaluator.  Remarks of the Evaluator.  • The drug product specifications have not been excipients.  • Submitted the composition with list and quartexcipients.  • Submitted Rs. 7500/- fee challan: 64356796  Decision: Approved with innovator's specifications.  104.  Name and address of manufacturer / Applicant  Brand Name +Dosage Form + Strength  The firm was inspected on 22.09.2021 and 08.1 satisfactory level of GMP compliance was reposited.  • Revised the label claim from film-coated to excipients.  • Submitted Rs. 7500/- fee challan: 64356796  M/s Perfect Pharma Pvt Ltd. 5-Km, Manga Roa Lahore, Pakistan  Peride 50mg Tablet	
Revised the label claim from film-coated to     Submitted the composition with list and qual excipients.     Submitted Rs. 7500/- fee challan: 64356796      Decision: Approved with innovator's specifications.  104. Name and address of manufacturer / Applicant Lahore, Pakistan  Brand Name +Dosage Form + Strength  Peride 50mg Tablet	
Submitted the composition with list and quarexcipients.     Submitted Rs. 7500/- fee challan: 64356796      Decision: Approved with innovator's specifications.  104. Name and address of manufacturer / Applicant     Brand Name +Dosage Form + Strength  Submitted the composition with list and quarexcipients.  M/s Perfect Pharma Pvt Ltd. 5-Km, Manga Roa Lahore, Pakistan  Peride 50mg Tablet	n evaluated.
excipients.  • Submitted Rs. 7500/- fee challan: 64356796  Decision: Approved with innovator's specifications.  104. Name and address of manufacturer / Applicant Lahore, Pakistan  Brand Name +Dosage Form + Peride 50mg Tablet  Strength	incoated tablet.
Decision: Approved with innovator's specifications.  104. Name and address of manufacturer / Applicant Lahore, Pakistan  Brand Name +Dosage Form + Peride 50mg Tablet  Strength  Decision: Approved with innovator's specifications.  M/s Perfect Pharma Pvt Ltd. 5-Km, Manga Roa Lahore, Pakistan  Peride 50mg Tablet	ntity of
Name and address of manufacturer / Applicant	12.
Applicant Lahore, Pakistan  Brand Name +Dosage Form + Peride 50mg Tablet  Strength	
Brand Name +Dosage Form + Peride 50mg Tablet Strength	d, Raiwind,
Strength	
Levosulpride50mg	
Diary No. Date of R& I & fee Dy. No. 11891 dated 06.03.2019 Rs. 20,000/- dated 06.03.2019	
Pharmacological Group Antipsychotic	
Type of Form Form 5	
Finished Product Specification Not submitted.	
Pack size & Demanded Price 5's, 10's, 30's, 14's, 100's; As per SRO	
Approval status of product in LEVOPRAID® 50 mg Tablets by TEOFARMA	Srl. Approved
Reference Regulatory Authorities. by AIFA	
Me-too status Sulvo Tablets 50mg. Reg. No. 31748	
GMP status  The firm was inspected on 22.09.2021 and 08.1 satisfactory level of GMP compliance was repo	
Remarks of the Evaluator.  • The drug product specifications have not been specifications as a specification of the Evaluator.	rted.
• Revised the label claim from film-coated to	

		Submitted the composition with list and quantity of excipients.
		• Submitted Rs. 7500/- fee challan:040935323563.
	<b>Decision: Approved with innovator's</b>	
105.	Name and address of manufacturer / Applicant	M/s Perfect Pharma Pvt Ltd. 5-Km, Manga Road, Raiwind, Lahore, Pakistan
	Brand Name +Dosage Form + Strength	Perilev 250mg Tablet
	Composition	Each Film Coated Tablet Contains: Levetiracetam250mg
	Diary No. Date of R& I & fee	Dy. No. 11877 dated 06.03.2019 Rs. 20,000/- dated 06.03.2019
	Pharmacological Group	Other antiepileptics
	Type of Form	Form 5
	Finished Product Specification	Not submitted. Available in USP
	Pack size & Demanded Price	5's, 10's, 30's, 14's, 100's; As per SRO
	Approval status of product in	Levetiracetam 250 mg film-coated tablets. MHRA approved
	Reference Regulatory Authorities.	
	Me-too status	Leveticam film-coated 250mg Tablets. Reg. No. 84220
	GMP status	The firm was inspected on 22.09.2021 and 08.10.2021, where
	D 1 64 E 1	satisfactory level of GMP compliance was reported.
	Remarks of the Evaluator.	The drug product specifications have not been evaluated.
		Submitted the composition with list and quantity of excipients.
		• Submitted Rs. 7500/- fee challan: 38735390399.
	<b>Decision: Approved with USP specifi</b>	ications.
106.	Name and address of manufacturer / Applicant	M/s Perfect Pharma Pvt Ltd. 5-Km, Manga Road, Raiwind, Lahore, Pakistan
	Brand Name +Dosage Form +	Perilev 500mg Tablet
		Each Film Coated Tablet Contains:
	Brand Name +Dosage Form + Strength Composition	Each Film Coated Tablet Contains: Levetiracetam500mg
	Brand Name +Dosage Form + Strength	Each Film Coated Tablet Contains: Levetiracetam500mg  Dy. No. 11876 dated 06.03.2019
	Brand Name +Dosage Form + Strength Composition Diary No. Date of R& I & fee	Each Film Coated Tablet Contains: Levetiracetam500mg  Dy. No. 11876 dated 06.03.2019  Rs. 20,000/- dated 06.03.2019
	Brand Name +Dosage Form + Strength Composition Diary No. Date of R& I & fee Pharmacological Group	Each Film Coated Tablet Contains: Levetiracetam500mg  Dy. No. 11876 dated 06.03.2019  Rs. 20,000/- dated 06.03.2019  Other antiepileptics
	Brand Name +Dosage Form + Strength Composition Diary No. Date of R& I & fee  Pharmacological Group Type of Form	Each Film Coated Tablet Contains: Levetiracetam500mg  Dy. No. 11876 dated 06.03.2019  Rs. 20,000/- dated 06.03.2019  Other antiepileptics  Form 5
	Brand Name +Dosage Form + Strength Composition  Diary No. Date of R& I & fee  Pharmacological Group Type of Form Finished Product Specification	Each Film Coated Tablet Contains: Levetiracetam500mg  Dy. No. 11876 dated 06.03.2019  Rs. 20,000/- dated 06.03.2019  Other antiepileptics  Form 5  Not submitted. Available in USP
	Brand Name +Dosage Form + Strength Composition  Diary No. Date of R& I & fee  Pharmacological Group Type of Form Finished Product Specification Pack size & Demanded Price Approval status of product in	Each Film Coated Tablet Contains: Levetiracetam500mg  Dy. No. 11876 dated 06.03.2019  Rs. 20,000/- dated 06.03.2019  Other antiepileptics  Form 5
	Brand Name +Dosage Form + Strength Composition  Diary No. Date of R& I & fee  Pharmacological Group Type of Form Finished Product Specification Pack size & Demanded Price Approval status of product in Reference Regulatory Authorities.	Each Film Coated Tablet Contains: Levetiracetam500mg  Dy. No. 11876 dated 06.03.2019  Rs. 20,000/- dated 06.03.2019  Other antiepileptics  Form 5  Not submitted. Available in USP  5's, 10's, 30's, 14's, 100's; As per SRO  Levetiracetam 500 mg film-coated tablets. MHRA approved
	Brand Name +Dosage Form + Strength Composition  Diary No. Date of R& I & fee  Pharmacological Group Type of Form Finished Product Specification Pack size & Demanded Price Approval status of product in Reference Regulatory Authorities. Me-too status	Each Film Coated Tablet Contains: Levetiracetam500mg  Dy. No. 11876 dated 06.03.2019  Rs. 20,000/- dated 06.03.2019  Other antiepileptics  Form 5  Not submitted. Available in USP  5's, 10's, 30's, 14's, 100's; As per SRO  Levetiracetam 500 mg film-coated tablets. MHRA approved  Leveticam film-coated 500mg Tablets. Reg. No. 84221
	Brand Name +Dosage Form + Strength Composition  Diary No. Date of R& I & fee  Pharmacological Group Type of Form Finished Product Specification Pack size & Demanded Price Approval status of product in Reference Regulatory Authorities.	Each Film Coated Tablet Contains: Levetiracetam500mg  Dy. No. 11876 dated 06.03.2019  Rs. 20,000/- dated 06.03.2019  Other antiepileptics  Form 5  Not submitted. Available in USP  5's, 10's, 30's, 14's, 100's; As per SRO  Levetiracetam 500 mg film-coated tablets. MHRA approved
	Brand Name +Dosage Form + Strength Composition  Diary No. Date of R& I & fee  Pharmacological Group Type of Form Finished Product Specification Pack size & Demanded Price Approval status of product in Reference Regulatory Authorities. Me-too status	Each Film Coated Tablet Contains: Levetiracetam500mg  Dy. No. 11876 dated 06.03.2019  Rs. 20,000/- dated 06.03.2019  Other antiepileptics  Form 5  Not submitted. Available in USP  5's, 10's, 30's, 14's, 100's; As per SRO  Levetiracetam 500 mg film-coated tablets. MHRA approved  Leveticam film-coated 500mg Tablets. Reg. No. 84221  The firm was inspected on 22.09.2021 and 08.10.2021, where
	Brand Name +Dosage Form + Strength Composition  Diary No. Date of R& I & fee  Pharmacological Group Type of Form Finished Product Specification Pack size & Demanded Price Approval status of product in Reference Regulatory Authorities. Me-too status GMP status	Each Film Coated Tablet Contains: Levetiracetam500mg  Dy. No. 11876 dated 06.03.2019  Rs. 20,000/- dated 06.03.2019  Other antiepileptics  Form 5  Not submitted. Available in USP  5's, 10's, 30's, 14's, 100's; As per SRO  Levetiracetam 500 mg film-coated tablets. MHRA approved  Leveticam film-coated 500mg Tablets. Reg. No. 84221  The firm was inspected on 22.09.2021 and 08.10.2021, where satisfactory level of GMP compliance was reported.
	Brand Name +Dosage Form + Strength Composition  Diary No. Date of R& I & fee  Pharmacological Group Type of Form Finished Product Specification Pack size & Demanded Price Approval status of product in Reference Regulatory Authorities. Me-too status GMP status	Each Film Coated Tablet Contains: Levetiracetam500mg  Dy. No. 11876 dated 06.03.2019  Rs. 20,000/- dated 06.03.2019  Other antiepileptics  Form 5  Not submitted. Available in USP  5's, 10's, 30's, 14's, 100's; As per SRO  Levetiracetam 500 mg film-coated tablets. MHRA approved  Leveticam film-coated 500mg Tablets. Reg. No. 84221  The firm was inspected on 22.09.2021 and 08.10.2021, where satisfactory level of GMP compliance was reported.  • The drug product specifications have not been evaluated.  • Submitted the composition with list and quantity of
	Brand Name +Dosage Form + Strength Composition  Diary No. Date of R& I & fee  Pharmacological Group Type of Form Finished Product Specification Pack size & Demanded Price Approval status of product in Reference Regulatory Authorities. Me-too status GMP status  Remarks of the Evaluator.	Each Film Coated Tablet Contains: Levetiracetam500mg  Dy. No. 11876 dated 06.03.2019  Rs. 20,000/- dated 06.03.2019  Other antiepileptics  Form 5  Not submitted. Available in USP  5's, 10's, 30's, 14's, 100's; As per SRO  Levetiracetam 500 mg film-coated tablets. MHRA approved  Leveticam film-coated 500mg Tablets. Reg. No. 84221  The firm was inspected on 22.09.2021 and 08.10.2021, where satisfactory level of GMP compliance was reported.  • The drug product specifications have not been evaluated.  • Submitted the composition with list and quantity of excipients.  • Submitted Rs. 7500/- fee challan: 86992975226.
107.	Brand Name +Dosage Form + Strength Composition  Diary No. Date of R& I & fee  Pharmacological Group Type of Form Finished Product Specification Pack size & Demanded Price Approval status of product in Reference Regulatory Authorities. Me-too status GMP status	Each Film Coated Tablet Contains: Levetiracetam500mg  Dy. No. 11876 dated 06.03.2019  Rs. 20,000/- dated 06.03.2019  Other antiepileptics  Form 5  Not submitted. Available in USP  5's, 10's, 30's, 14's, 100's; As per SRO  Levetiracetam 500 mg film-coated tablets. MHRA approved  Leveticam film-coated 500mg Tablets. Reg. No. 84221  The firm was inspected on 22.09.2021 and 08.10.2021, where satisfactory level of GMP compliance was reported.  • The drug product specifications have not been evaluated.  • Submitted the composition with list and quantity of excipients.  • Submitted Rs. 7500/- fee challan: 86992975226.

	Brand Name +Dosage Form + Strength	Paroxetine 12.5mg Tablet
	Composition	Each Enteric Film Coated controlled release Tablet Contains:
	Composition	Paroxetine As Hcl12.5mg
	Diary No. Date of R& I & fee	Dy. No. 11847 dated 06.03.2019
	Blary 110. Bate of Ree 1 & 1ce	Rs. 20,000/- dated 06.03.2019
	Pharmacological Group	Other antiepileptics
	Type of Form	Form 5
	Finished Product Specification	Not submitted. Available in USP
	Pack size & Demanded Price	5's, 10's, 20's, 30's, 14's, 100's; As per SRO
	Approval status of product in	Paxil CR tablet 12.5mg. USFDA approved
	Reference Regulatory Authorities.	
	Me-too status	Depexil CR Tablet. Reg. No. 84058
	GMP status	The firm was inspected on 22.09.2021 and 08.10.2021, where
		satisfactory level of GMP compliance was reported.
	Remarks of the Evaluator.	The drug product specifications have not been evaluated.
		• The firm submitted the reference wherein it is stated that:
		Each extended-release tablet contains 12.5 mg, 25 mg, or 37.5 mg paroxetine equivalent to 14.25 mg, 28.51 mg, or 42.76 mg of paroxetine hydrochloride, respectively. The factor used is meant for hemihydrate form.
		Revised paroxetine as hydrochloride to paroxetine hydrochloride hemihydrate.
		One layer of the tablet consists of a degradable barrier layer and the other contains the active material in a hydrophilic matrix.
		The firm did not revise the formulation in the light of above.
		➤ In addition to controlling the rate of drug release in vivo, an enteric coat delays the start of drug release until tablets of PAXIL CR have left the stomach.
		The firm did not revise the formulation in the light of above.
		Submitted the composition with list and quantity of excipients.
		• Submitted Rs. 7500/- fee challan: 86992975226.
	<b>Decision: Deferred for revision of form</b>	nulation in line with the reference product.
108.	Name and address of manufacturer /	M/s Perfect Pharma Pvt Ltd. 5-Km, Manga Road, Raiwind,
	Applicant	Lahore, Pakistan
	Brand Name +Dosage Form +	Pramper 15mg Tablet
	Strength	
	Composition	Each Film Coated Tablet Contains:
		Escitalopram As Oxalate15mg
	Diary No. Date of R& I & fee	Dy. No. 11844 dated 06.03.2019
		Rs. 20,000/- dated 06.03.2019
	Pharmacological Group	Antidepressant
	Type of Form	Form 5

	Finished Product Specification	Not submitted. Available in USP
	Pack size & Demanded Price	10's, 20's, 14's, 100's; As per SRO
	Approval status of product in	Escitalopram 15 mg film-coated tablets. MHRA approved
	Reference Regulatory Authorities.	
	Me-too status	Lexopram tablet 15mg. Reg. No. 87696
	GMP status	The firm was inspected on 22.09.2021 and 08.10.2021, where satisfactory level of GMP compliance was reported.
	Remarks of the Evaluator.	The drug product specifications have not been evaluated.
		Submitted the composition with list and quantity of excipients.
		• Submitted Rs. 7500/- fee challan: 1186676400.
	<b>Decision: Approved with USP specifi</b>	
109.	Name and address of manufacturer /	M/s Perfect Pharma Pvt Ltd. 5-Km, Manga Road, Raiwind,
	Applicant	Lahore, Pakistan
	Brand Name +Dosage Form +	Pramper 20mg Tablet
	Strength	
	Composition	Each Film Coated Tablet Contains:
		Escitalopram As Oxalate20mg
	Diary No. Date of R& I & fee	Dy. No. 11855 dated 06.03.2019
		Rs. 20,000/- dated 06.03.2019
	Pharmacological Group	Antidepressant
	Type of Form	Form 5
	Finished Product Specification	Not submitted. Available in USP
	Pack size & Demanded Price	10's, 20's, 14's, 100's; As per SRO
	Approval status of product in	Escitalopram 20 mg film-coated tablets. MHRA approved
	Reference Regulatory Authorities.	
	Me-too status	Neolexa 20mg Tablet . Reg. No. 66978
	GMP status	The firm was inspected on 22.09.2021 and 08.10.2021, where satisfactory level of GMP compliance was reported.
	Remarks of the Evaluator.	The drug product specifications have not been evaluated.
		• Submitted the composition with list and quantity of excipients.
		• Submitted Rs. 7500/- fee challan: 86740179585.
	<b>Decision: Approved with USP specifi</b>	cations.
110.	Name and address of manufacturer / Applicant	M/s Perfect Pharma Pvt Ltd. 5-Km, Manga Road, Raiwind, Lahore, Pakistan
	Brand Name +Dosage Form +	Ristol 2mg Tablet
	Strength	Each Film Coated Tablet Contains:
	Composition	
	Diary No. Date of R& I & fee	Risperidone2mg  Dy. No. 11864 dated 06.03.2019
	Diary No. Date of R& 1 & fee	Rs. 20,000/- dated 06.03.2019
	Pharmacological Group	Antipsychotic
	Type of Form	Form 5
	Finished Product Specification	Not submitted. Available in USP
	Pack size & Demanded Price	5's. 10's, 30's, 14's, 100's; As per SRO
	Approval status of product in	Risperidone 2mg Film-coated Tablets. <b>MHRA</b> approved
	Reference Regulatory Authorities.	Tasportaone Zing I min content rubious. Militar approved
	Me-too status	Genzodin Tablets 2mg. Reg. No. 69992
	GMP status	The firm was inspected on 22.09.2021 and 08.10.2021, where
	Om status	satisfactory level of GMP compliance was reported.
		sansiaciony term of offin compliance was reported.

	Remarks of the Evaluator.	• The drug product specifications have not been evaluated.
		Submitted the composition with list and quantity of excipients.
		• Submitted Rs. 7500/- fee challan: 6701671686.
	<b>Decision: Approved with USP specific</b>	ations.
111.	Name and address of manufacturer / Applicant	M/s Perfect Pharma Pvt Ltd. 5-Km, Manga Road, Raiwind, Lahore, Pakistan
	Brand Name +Dosage Form + Strength	Sova 10mg Tablet
	Composition	Each Tablet Contains: Rosuvastatin as calcium10mg
	Diary No. Date of R& I & fee	Dy. No. 11854 dated 06.03.2019 Rs. 20,000/- dated 06.03.2019
	Pharmacological Group	Lipid lowering agent
	Type of Form	Form 5
	Finished Product Specification	Not submitted.
	Pack size & Demanded Price	10's, 20's, 14's, 100's; As per SRO
	Approval status of product in Reference Regulatory Authorities.	Rosuvastatin 10 mg film-coated tablets. MHRA approved
	Me-too status	Rostor 10mg tablet. Reg. No. 71184
	GMP status	The firm was inspected on 22.09.2021 and 08.10.2021, where satisfactory level of GMP compliance was reported.
	Remarks of the Evaluator.	• The drug product specifications have not been evaluated.
		<ul> <li>Submitted the composition with list and quantity of excipients.</li> </ul>
		Revised rosuvastatin to rosuvastain calcium in the master formula and adjust its weight as per salt factor.
		<ul> <li>Revised rosuvastatin calcium to rosuvastain as calcium in the label claim along with fee of Rs. 7500/- challan: 446051652.</li> </ul>
	Decision: Approved with innovator's s correction in formulation before issua	specifications. The firm shall submit Rs. 22,500 fee for nce of registration letter.
112.	Name and address of manufacturer / Applicant	M/s Welmed Pharmaceuticals Industries (Pvt) Ltd. Plot # 108, R-2, Industrial Estate Gadoon, Swabi
	Brand Name +Dosage Form + Strength	Risper 1mg Tablet
	Composition	Each Film Coated Tablet Contains:
		Risperidone1mg
	Diary No. Date of R& I & fee	Dy. No.12358 dated 06.03.2019 Rs. 20,000/- dated 04.03.2019
	Pharmacological Group	Antipsychotics
	Type of Form	Form 5
	Finished Product Specification	The firm has claimed USP specifications.
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	Risperdal® 1mg film coated Tablets. MHRA approved
	Me-too status	Neo-Risp Tablet 1mg, film-coated. Reg No. 85184
	GMP status	Firm has submitted copy of inspection report dated 17-09-2020
		which confirms fair level of compliance with GMP guidelines.
	Remarks of the Evaluator.	The firm should rectify all observations mentioned in the report.
		• The drug product specifications have not been evaluated.

		•
	Decision: Approved. Registration lettinspection status from QA< Division	ter shall be issued after having updated satisfactory GMP on.
113.	Name and address of manufacturer /	M/s Welmed Pharmaceuticals Industries (Pvt) Ltd. Plot # 108,
	Applicant	R-2, Industrial Estate Gadoon, Swabi
	Brand Name +Dosage Form + Strength	Risper 2mg Tablet
	Composition	Each Film Coated Tablet Contains:
		Risperidone2mg
	Diary No. Date of R& I & fee	Dy. No.12359 dated 06.03.2019
		Rs. 20,000/- dated 04.03.2019
	Pharmacological Group	Antipsychotics
	Type of Form	Form 5
	Finished Product Specification	The firm has claimed USP specifications.
	Pack size & Demanded Price	As per SRO
	Approval status of product in	Risperdal® 2mg film coated Tablets. MHRA approved
	Reference Regulatory Authorities.	
	Me-too status	Neo-Risp Tablet 2mg, film-coated. Reg No. 85185
	GMP status	Firm has submitted copy of inspection report dated 17-09-2020
		which confirms fair level of compliance with GMP guidelines.
		The firm should rectify all observations mentioned in the report.
	Remarks of the Evaluator.	• The drug product specifications have not been evaluated.
		•
	Decision: Approved. Registration lettinspection status from QA< Division	ter shall be issued after having updated satisfactory GMP on.
114.	Name and address of manufacturer /	M/s Welmed Pharmaceuticals Industries (Pvt) Ltd. Plot # 108,
	Applicant	R-2, Industrial Estate Gadoon, Swabi
	Brand Name +Dosage Form + Strength	Risper 3mg Tablet
	Composition	Each Film Coated Tablet Contains:
		Risperidone3mg
	Diary No. Date of R& I & fee	Dy. No.12360 dated 06.03.2019 Rs. 20,000/- dated 04.03.2019
	Pharmacological Group	Antipsychotics
	Type of Form	Form 5
	Finished Product Specification	The firm has claimed USP specifications.
	Pack size & Demanded Price	As per SRO
	Approval status of product in	Risperdal® 3mg film coated Tablets. MHRA approved
	Reference Regulatory Authorities.	
	Me-too status	Neo-Risp Tablet 3mg, film-coated. Reg No. 85186
	GMP status	Firm has submitted copy of inspection report dated 17-09-2020
		which confirms fair level of compliance with GMP guidelines.
		The firm should rectify all observations mentioned in the report.
	Remarks of the Evaluator.	The drug product specifications have not been evaluated.
		•
	Decision: Approved. Registration letter shall be issued after having updated satisfactory GM inspection status from QA< Division.	
115.	Name and address of manufacturer /	M/s Welmed Pharmaceuticals Industries (Pvt) Ltd. Plot # 108,
	Applicant	R-2, Industrial Estate Gadoon, Swabi
	Brand Name +Dosage Form + Strength	Risper 4mg Tablet
	Composition	Each Film Coated Tablet Contains:
		Risperidone4mg
	Diary No. Date of R& I & fee	Dy. No.12361 dated 06.03.2019
	,	Rs. 20,000/- dated 04.03.2019
	Pharmacological Group	Antipsychotics
		·

	Type of Form	Form 5
	Finished Product Specification	The firm has claimed USP specifications.
	Pack size & Demanded Price	As per SRO
	Approval status of product in	Risperdal® 4mg film coated Tablets. MHRA approved
	Reference Regulatory Authorities.	
	Me-too status	Neo-Risp Tablet 4mg, film-coated. Reg No. 85187
	GMP status	Firm has submitted copy of inspection report dated 17-09-2020
		which confirms fair level of compliance with GMP guidelines.
		The firm should rectify all observations mentioned in the report.
	Remarks of the Evaluator.	• The drug product specifications have not been evaluated.
	Decision: Approved. Registration lett	ter shall be issued after having updated satisfactory GMP
	inspection status from QA< Division	on.
116.	Name and address of manufacturer /	M/s Wimits Pharmaceuticals (Pvt.) Ltd. Plot No. 129, Sundar
	Applicant	Industrial Estate, Raiwind Road, Lahore
	Brand Name +Dosage Form + Strength	Difluzim 1% w/w Cream
	Composition	Each Gram Contains:
		Isoconazole Nitrate10mg
	Diary No. Date of R& I & fee	Dy. No.12124 dated 06.03.2019
		Rs. 20,000/- dated 06.03.2019
	Pharmacological Group	Antifungal
	Type of Form	Form 5
	Finished Product Specification	The firm has claimed in-house specifications.
	Pack size & Demanded Price	10g, 15g, 30g, 45g; As per SRO
	Approval status of product in	Travogen Cream (1 g cream contains 10 mg isoconazole
	Reference Regulatory Authorities.	nitrate). AGES Approved
	Me-too status	Conazole –N Cream. Reg. No. 24179
	GMP status	The firm was inspected on 03.11.2017, GMP was reported at satisfactory level.
	Remarks of the Evaluator.	• The drug product specifications have not been evaluated.
	Remarks of the Evaluator.	
		• The firm has been issued explanation / show cause by the
		Division of QA & LT.
	Decision: Registration Board referred updated GMP status and status of sho	the case to QA & LT Division for confirmation of status of
117.	Name and address of manufacturer /	M/s Wimits Pharmaceuticals (Pvt.) Ltd. Plot No. 129, Sundar
117.	Applicant	Industrial Estate, Raiwind Road, Lahore
	Brand Name +Dosage Form + Strength	Trenin 0.05% w/w Cream
	Composition	Each Gram Contains:
	Composition	Tretinoin 0.05%
	Diary No. Date of R& I & fee	Dy. No.12130 dated 06.03.2019
	,	Rs. 20,000/- dated 06.03.2019
	Pharmacological Group	Antiacne
	Type of Form	Form 5
	Finished Product Specification	The firm has claimed USP specifications.
	Pack size & Demanded Price	10g, 15g, 30g, 45g; As per SRO
	Approval status of product in	STIEVA-A Creams 0.025%, 0.05% and 0.1%. TGA
	Reference Regulatory Authorities.	Approved
	Me-too status	Acnecid Cream. Reg. No. 24688
	GMP status	The firm was inspected on 03.11.2017, GMP was reported at
		satisfactory level.
	Remarks of the Evaluator.	• The drug product specifications have not been evaluated.
		•

	Decision: Registration Board referred updated GMP status and status of sho	the case to QA & LT Division for confirmation of status of w cause notice.
118.	Name and address of manufacturer /	M/s Wimits Pharmaceuticals (Pvt.) Ltd. Plot No. 129, Sundar
	Applicant	Industrial Estate, Raiwind Road, Lahore
	Brand Name +Dosage Form + Strength	Fizz 5% w/w Cream
	Composition	Each 100g Contains:
		Permethrin 5g
	Diary No. Date of R& I & fee	Dy. No.12131 dated 06.03.2019
		Rs. 20,000/- dated 06.03.2019
	Pharmacological Group	synthetic pyrethrinoids
	Type of Form	Form 5
	Finished Product Specification	The firm has claimed in-house specifications.
	Pack size & Demanded Price	10g, 15g, 30g, 45g; As per SRO
	Approval status of product in	Permethrin 5% w/w Cream. MHRA Approved
	Reference Regulatory Authorities.	
	Me-too status	Bioscab Cream (Reg#.074773)
	GMP status	The firm was inspected on 03.11.2017, GMP was reported at
		satisfactory level.
	Remarks of the Evaluator.	• The drug product specifications have not been evaluated.
		•
	Decision: Registration Board referred updated GMP status and status of sho	the case to QA & LT Division for confirmation of status of w cause notice.
119.	Name and address of manufacturer /	M/s Semos Pharmaceuticals Pvt Ltd. Plot No. 11, Sector 12-
	Applicant	A, North Karachi, Krachi-75850, Pakistan
		By
		M/s Safe Pharmaceuticals Pvt Ltd. Plot No. C.I-20, Sector 6-
		B, Industrial Area, North Karachi
	Brand Name +Dosage Form + Strength	Semic Injection 250mg/5ml
	Composition	Each 5ml Contains:
		Tranexamic Acid250mg
	Diary No. Date of R& I & fee	Dy. No. 12287 dated 06.03.2019
	Di li la	Rs. 50,000/- dated 05.03.2019
	Pharmacological Group	Antihemorrhagics
	Type of Form	Form 5
	Finished Product Specification	The firm has claimed innovator's specs. available in BP and JP.
	Pack size & Demanded Price	1x10's (5ml ampoule); As per SRO
	Approval status of product in	Could not be confirmed
	Reference Regulatory Authorities.	
	Me-too status	Dravix 250mg/5ml Injection. Reg No. 76446
	GMP status	Semos Pharma: The firm was inspected on 02.09.2021, wherein
		GMP was rated as GOOD>
		Safe Pharma: The firm was inspected on 24.03.2021, wherein GMP was rated as GOOD>
	Remarks of the Evaluator.	• The drug product specifications have not been evaluated.
		• Form 5 shall be submitted by the applicant / contract giver.
		There was no initial sterilization of the ampules and terminal sterilization in the manufacturing outlines. The firm revised it.
		• The firm added filling, sealing and packing process in the manufacturing outlines.
		• The firm revised the oral route of administration to injectable.

- For above revision, submit applicable fee as per notifications
   7-11/2012-B&A/DRAP dated 07.05.2021 and
   13.07.2021.
   Proof of international availability of same formulation and
  - Proof of international availability of same formulation and same strength with filled volume of 5ml in reference regulatory authorities as defined in 275th meeting of the registration board is required.

**Decision: Deferred for submission of:** 

- Form 5 by the applicant.
- Fee of Rs. 75,000.
- Evidence of approval of applied formulation with same fill volum in reference regulatory authorities / agencies which were adopted by the Registration Board in its 275<sup>th</sup> meeting.
- Valid contract manufacturing agreement between the contract giver and contract acceptor.
- Plan & Schedule for capacity enhancement of Quality Control Lab, particularly the capacity in terms of HPLC analysis as per the decision of 316<sup>th</sup> meeting of Registration Board.
- Plan & Schedule for the adoption of Pharmacopoeial specifications and analytical procedures for all registered products as per the decision of 316<sup>th</sup> meeting of Registration Board.

Applicant  A, North Karachi, Krachi-75850, Pakistan By M/s Safe Pharmaceuticals Pvt Ltd. Plot No. C.I-20, Sector 6- B, Industrial Area, North Karachi  Brand Name +Dosage Form + Strength Composition  Each 5ml Contains: Tranexamic Acid500mg  Diary No. Date of R& I & fee Dy. No. 12288 dated 06.03.2019 Rs. 50,000/- dated 05.03.2019 Pharmacological Group Antihemorrhagics Type of Form Finished Product Specification Pack size & Demanded Price Approval status of product in Reference Regulatory Authorities. Me-too status GMP status  GMP status  Dravis 500mg/5ml Injection. Reg No. 76447 Semos Pharma: The firm was inspected on 02.09.2021, wherei GMP was rated as GOOD> Remarks of the Evaluator.  • The drug product specifications have not been evaluated.  • Form 5 shall be submitted by the applicant / contract giver • There was no initial sterilization of the ampules and termins sterilization in the manufacturing outlines. The firm revised it.  • The firm added filling, sealing and packing process in the manufacturing outlines.  • The firm revised the oral route of administration to injectable.  • For above revision, submit applicable fee as per notification 7-11/2012-B&A/DRAP dated 07.05.2021 and		Board.	
Brand Name +Dosage Form + Strength Composition  Brand Name +Dosage Form + Strength Composition  Each 5ml Contains: Tranexamic Acid500mg Diary No. Date of R& I & fee Dy. No. 12288 dated 06.03.2019 Rs. 50,000/- dated 05.03.2019 Pharmacological Group Type of Form Finished Product Specification Pack size & Demanded Price Approval status of product in Reference Regulatory Authorities. Me-too status  GMP status  Brand Name +Dosage Form + Strength  Mrs. Safe Pharmaceuticals Pvt Ltd. Plot No. C.I-20, Sector 6-B, Industrial Area, North Karachi  Semic Injection 500mg/5ml  Each 5ml Contains: Tranexamic Acid500mg Dy. No. 12288 dated 06.03.2019 Rs. 50,000/- dated 05.03.2019  Antihemorrhagics Type of Form Form 5 Finished Product Specification The firm has claimed innovator's specs. available in BP and JI Pack size & Demanded Price Approval status of product in Reference Regulatory Authorities.  Me-too status  Dravix 500mg/5ml Injection. Reg No. 76447  Semos Pharma: The firm was inspected on 02.09.2021, whereif GMP was rated as GOOD> Safe Pharma: The firm was inspected on 24.03.2021, whereif GMP was rated as GOOD>  The drug product specifications have not been evaluated.  Form 5 shall be submitted by the applicant / contract giver there was no initial sterilization of the ampules and termina sterilization in the manufacturing outlines. The firm revised it.  The firm added filling, sealing and packing process in the manufacturing outlines.  The firm revised the oral route of administration to injectable.  For above revision, submit applicable fee as per notification 7-11/2012-B&A/DRAP dated 07.05.2021 and process in the process of the pro	20.		A, North Karachi, Krachi-75850, Pakistan
Composition  Each 5ml Contains: Tranexamic Acid500mg  Diary No. Date of R& I & fee  Dy. No. 12288 dated 06.03.2019  Rs. 50,000/- dated 05.03.2019  Pharmacological Group  Antihemorrhagics  Type of Form  Form 5  Finished Product Specification  Pack size & Demanded Price  Approval status of product in  Reference Regulatory Authorities.  Me-too status  GMP status  GMP status  GMP was rated as GOOD>  Safe Pharma: The firm was inspected on 02.09.2021, wherein GMP was rated as GOOD>  Remarks of the Evaluator.  Perm 5 Shall be submitted by the applicant / contract giver on the manufacturing outlines. The firm revised it.  The firm added filling, sealing and packing process in the manufacturing outlines.  The firm revised the oral route of administration to injectable.  For above revision, submit applicable fee as per notification 7-11/2012-B&A/DRAP dated 07.05.2021 and process in the manufacturing outlines.			M/s Safe Pharmaceuticals Pvt Ltd. Plot No. C.I-20, Sector 6-
Tranexamic Acid500mg  Diary No. Date of R& I & fee  Dy. No. 12288 dated 06.03.2019  Rs. 50,000/- dated 05.03.2019  Antihemorrhagics  Type of Form  Finished Product Specification  Pack size & Demanded Price  Approval status of product in  Reference Regulatory Authorities.  Me-too status  GMP status  Dravix 500mg/5ml Injection. Reg No. 76447  Semos Pharma: The firm was inspected on 02.09.2021, whereif GMP was rated as GOOD>  Remarks of the Evaluator.  Remarks of the Evaluator.  Tranexamic acid 100mg/ml Solution for Injection. MHRA approved  Dravix 500mg/5ml Injection. Reg No. 76447  Semos Pharma: The firm was inspected on 02.09.2021, whereif GMP was rated as GOOD>  Remarks of the Evaluator.  • The drug product specifications have not been evaluated.  • Form 5 shall be submitted by the applicant / contract giver  • There was no initial sterilization of the ampules and terminal sterilization in the manufacturing outlines. The firm revised it.  • The firm added filling, sealing and packing process in the manufacturing outlines.  • The firm revised the oral route of administration to injectable.  • For above revision, submit applicable fee as per notification 7-11/2012-B&A/DRAP dated 07.05.2021 and 1.00 miles 1.00 m		Brand Name +Dosage Form + Strength	Semic Injection 500mg/5ml
Diary No. Date of R& I & fee  Dy. No. 12288 dated 06.03.2019 Rs. 50,000/- dated 05.03.2019  Pharmacological Group  Type of Form Finished Product Specification Pack size & Demanded Price Approval status of product in Reference Regulatory Authorities. Me-too status Dravix 500mg/5ml Injection. Reg No. 76447  GMP status  Semos Pharma: The firm was inspected on 02.09.2021, wherein GMP was rated as GOOD>  Remarks of the Evaluator.  Remarks of the Evaluator.  Porm 5 shall be submitted by the applicant / contract giver There was no initial sterilization of the ampules and termina sterilization in the manufacturing outlines. The firm revised it.  The firm added filling, sealing and packing process in the manufacturing outlines.  The firm revised the oral route of administration to injectable.  For above revision, submit applicable fee as per notification 7-11/2012-B&A/DRAP dated 07.05.2021 and		Composition	
Type of Form Finished Product Specification Pack size & Demanded Price Approval status of product in Reference Regulatory Authorities. Me-too status Dravis 500mg/5ml Injection. Reg No. 76447 GMP status Dravis 500mg/5ml Injection. Reg No. 76447 Semos Pharma: The firm was inspected on 02.09.2021, wherei GMP was rated as GOOD> Remarks of the Evaluator.  The drug product specifications have not been evaluated.  Form 5 shall be submitted by the applicant / contract giver There was no initial sterilization of the ampules and termina sterilization in the manufacturing outlines. The firm revised it.  The firm added filling, sealing and packing process in the manufacturing outlines.  The firm revised the oral route of administration to injectable.  For above revision, submit applicable fee as per notification 7-11/2012-B&A/DRAP dated 07.05.2021 and		Diary No. Date of R& I & fee	Dy. No. 12288 dated 06.03.2019
Finished Product Specification Pack size & Demanded Price Approval status of product in Reference Regulatory Authorities. Me-too status  Me-too status  Meros Safe Pharma: The firm was inspected on 02.09.2021, where GMP was rated as GOOD> Safe Pharma: The firm was inspected on 24.03.2021, where GMP was rated as GOOD>  Remarks of the Evaluator.  Perm 5 shall be submitted by the applicant / contract giver There was no initial sterilization of the ampules and termina sterilization in the manufacturing outlines. The firm revised it.  The firm added filling, sealing and packing process in the manufacturing outlines.  The firm revised the oral route of administration to injectable.  For above revision, submit applicable fee as per notification 7-11/2012-B&A/DRAP dated 07.05.2021 and		Pharmacological Group	Antihemorrhagics
Pack size & Demanded Price Approval status of product in Reference Regulatory Authorities.  Me-too status  Me-too status  Mestatus  Mest		Type of Form	Form 5
Approval status of product in Reference Regulatory Authorities.  Me-too status  Me-too status  Dravix 500mg/5ml Injection. Reg No. 76447  Semos Pharma: The firm was inspected on 02.09.2021, wherein GMP was rated as GOOD>  Remarks of the Evaluator.  Prom 5 shall be submitted by the applicant / contract given or the manufacturing outlines. The firm was inspected it.  The firm added filling, sealing and packing process in the manufacturing outlines.  The firm revised the oral route of administration to injectable.  For above revision, submit applicable fee as per notification 7-11/2012-B&A/DRAP dated 07.05.2021 and packing process in the manufacturing outlines.		Finished Product Specification	The firm has claimed innovator's specs. available in BP and JP.
Reference Regulatory Authorities.  Me-too status  Dravix 500mg/5ml Injection. Reg No. 76447  Semos Pharma: The firm was inspected on 02.09.2021, wherein GMP was rated as GOOD>  Safe Pharma: The firm was inspected on 24.03.2021, wherein GMP was rated as GOOD>  Remarks of the Evaluator.  • The drug product specifications have not been evaluated.  • Form 5 shall be submitted by the applicant / contract given end the terminal sterilization of the ampules and terminal sterilization in the manufacturing outlines. The firm revised it.  • The firm added filling, sealing and packing process in the manufacturing outlines.  • The firm revised the oral route of administration to injectable.  • For above revision, submit applicable fee as per notification 7-11/2012-B&A/DRAP dated 07.05.2021 and		Pack size & Demanded Price	1x10's (5ml ampoule); As per SRO
Me-too status  Dravix 500mg/5ml Injection. Reg No. 76447  Semos Pharma: The firm was inspected on 02.09.2021, wherein GMP was rated as GOOD>  Safe Pharma: The firm was inspected on 24.03.2021, wherein GMP was rated as GOOD>  Remarks of the Evaluator.  • The drug product specifications have not been evaluated.  • Form 5 shall be submitted by the applicant / contract giver  • There was no initial sterilization of the ampules and terminal sterilization in the manufacturing outlines. The firm revised it.  • The firm added filling, sealing and packing process in the manufacturing outlines.  • The firm revised the oral route of administration to injectable.  • For above revision, submit applicable fee as per notification 7-11/2012-B&A/DRAP dated 07.05.2021 and			
Semos Pharma: The firm was inspected on 02.09.2021, wherein GMP was rated as GOOD>  Remarks of the Evaluator.  Prom 5 shall be submitted by the applicant / contract giver on the evaluation of the ampules and terminal sterilization in the manufacturing outlines. The firm revised it.  The firm added filling, sealing and packing process in the manufacturing outlines.  The firm revised the oral route of administration to injectable.  For above revision, submit applicable fee as per notification 7-11/2012-B&A/DRAP dated 07.05.2021 and			* *
<ul> <li>The drug product specifications have not been evaluated.</li> <li>Form 5 shall be submitted by the applicant / contract giver</li> <li>There was no initial sterilization of the ampules and termina sterilization in the manufacturing outlines. The firm revised it.</li> <li>The firm added filling, sealing and packing process in the manufacturing outlines.</li> <li>The firm revised the oral route of administration to injectable.</li> <li>For above revision, submit applicable fee as per notification 7-11/2012-B&amp;A/DRAP dated 07.05.2021 and</li> </ul>		GMP status	Semos Pharma: The firm was inspected on 02.09.2021, wherein GMP was rated as GOOD> Safe Pharma: The firm was inspected on 24.03.2021, wherein
<ul> <li>There was no initial sterilization of the ampules and terminal sterilization in the manufacturing outlines. The first revised it.</li> <li>The firm added filling, sealing and packing process in the manufacturing outlines.</li> <li>The firm revised the oral route of administration to injectable.</li> <li>For above revision, submit applicable fee as per notification 7-11/2012-B&amp;A/DRAP dated 07.05.2021 and</li> </ul>		Remarks of the Evaluator.	
• For above revision, submit applicable fee as per notification 7-11/2012-B&A/DRAP dated 07.05.2021 and			<ul> <li>The firm added filling, sealing and packing process in the manufacturing outlines.</li> <li>The firm revised the oral route of administration to</li> </ul>
Decision: Deferred for submission of:		Decision: Deferred for submission of	• For above revision, submit applicable fee as per notifications

Form 5 by the applicant.

- Fee of Rs. 75,000.
- Valid contract manufacturing agreement between the contract giver and contract acceptor.
- Plan & Schedule for capacity enhancement of Quality Control Lab, particularly the capacity in terms of HPLC analysis as per the decision of 316<sup>th</sup> meeting of Registration Board.
- Plan & Schedule for the adoption of Pharmacopoeial specifications and analytical procedures for all registered products as per the decision of 316<sup>th</sup> meeting of Registration Board.

	Board.	oroducts as per the decision of 510 meeting of Registration
121.	Name and address of manufacturer / Applicant	M/s Semos Pharmaceuticals Pvt Ltd. Plot No. 11, Sector 12-A, North Karachi, Krachi-75850, Pakistan By M/s Safe Pharmaceuticals Pvt Ltd. Plot No. C.I-20, Sector 6-B, Industrial Area, North Karachi
	Brand Name +Dosage Form + Strength	Lizolid Infusion 200mg/100ml
	Composition	Each 100ml Contains: Linezolid200mg
	Diary No. Date of R& I & fee	Dy. No. 12286 dated 06.03.2019 Rs. 50,000/- dated 05.03.2019
	Pharmacological Group	Antihemorrhagics
	Type of Form	Form 5
	Finished Product Specification	The firm has claimed innovator's specs.
	Pack size & Demanded Price	100ml vial; As per SRO
	Approval status of product in Reference Regulatory Authorities.	ZYVOX® (Linezolid) Injection, for Intravenous Use 200mg/100ml, 600mg/300ml. USFDA approved ZYVOX® (Linezolid) Injection, for Intravenous Use 400mg/200ml, discontinued in USFDA not for safety /
		efficacy reasons.
	Me-too status	Linzol Infusion 200mg. Reg No. 81997
	GMP status	Semos Pharma: The firm was inspected on 02.09.2021, wherein GMP was rated as GOOD> Safe Pharma: The firm was inspected on 24.03.2021, wherein
		GMP was rated as GOOD>
	Remarks of the Evaluator.	• The drug product specifications have not been evaluated.
		<ul> <li>Form 5 shall be submitted by the applicant / contract giver.</li> <li>The firm revised the pharmacological group from antibiotics to "antibacterials".</li> </ul>
		• There was no initial sterilization of the ampules and terminal sterilization in the manufacturing outlines. The firm revised it.
		• The firm added filling, sealing and packing process in the manufacturing outlines.
		• The firm mentioned route of administration as injection; later on revised it to infusion, which is not a route of administration.
		• The firm had applied for 200mg/100, while it was 200mg/5ml in the master formula. The firm revised it.
		• For above revision, submit applicable fee as per notifications 7-11/2012-B&A/DRAP dated 07.05.2021 and 13.07.2021.

**Decision: Deferred for submission of:** 

- Form 5 by the applicant.
- Fee of Rs. 75,000.
- Valid contract manufacturing agreement between the contract giver and contract acceptor.

	capacity in terms of HPLC at Board.  • Plan & Schedule for the at	ty enhancement of Quality Control Lab, particularly the nalysis as per the decision of 316 <sup>th</sup> meeting of Registration doption of Pharmacopoeial specifications and analytical products as per the decision of 316 <sup>th</sup> meeting of Registration
122.	Name and address of manufacturer / Applicant	M/s Helix Pharma Pvt Ltd. Hakimsons House, A/56, S.I.T.E Manghopir Road, Karachi, Pakistan By M/s Mediate Pharmaceutical Pvt Ltd. Plot No. 150-151,
	Brand Name +Dosage Form + Strength Composition	Sector 24, Korangi Industrial Area, Karchi, Pakistan Nurosa Injection 10mg/ml Each Vial Contains: Lacosamide10mg
	Diary No. Date of R& I & fee	Dy. No. 13056 dated 06.03.2019 Rs. 50,000/- dated 05.03.2019
	Pharmacological Group Type of Form	Other antiepileptics Form 5
	Finished Product Specification	The firm has claimed in-house specs.
	Pack size & Demanded Price Approval status of product in Reference Regulatory Authorities.	1's (20ml); As per SRO Vimpat 10 mg/ml solution for infusion (20ml). Approved in MHRA.
	Me-too status	Vimpat 10 mg/ml solution for infusion (20ml). Approved in MHRA.
	GMP status	Inspected on 16.06.2020 with the following conclusion: Keeping in view above mentioned rectification status in Liquid Sterile Ampoule/Infusion/Opthalmic/Otic Section of the firm and positive intention towards improvement, panel unanimously "Recommends the Resumption of production in Liquid Sterile Ampoule/Infusion/Opthalmic/Otic Section".
	Remarks of the Evaluator.	<ul> <li>The drug product specifications have not been evaluated.</li> <li>The address in the application is Helix Pharma Pvt Ltd. Hakimsons House, A/56, S.I.T.E Manghopir Road, Karachi, Pakistan, while it is Helix Pharma Pvt Ltd., A/56, S.I.T.E Karachi in the DML.</li> <li>Stamped signatures of qualified persons are placed in the application.</li> <li>The firm added vial washing, vial sterilization and vial sealing, and packing to the manufacturing outlines along with submission of Rs. 25,000/- fee (challan-314211675442)</li> </ul>
	Decision: Deferred for:  • Revision of "Each Vial Contains: Lacosamide10mg" to "Each ml contains: Lacosamide10mg".  • Submission of differential fee of Rs. 50,000.  • Valid contract manufacturing agreement between the contract giver and contract acceptor.	
123.	Name and address of manufacturer / Applicant	M/s Helix Pharma Pvt Ltd. Hakimsons House, A/56, S.I.T.E Manghopir Road, Karachi, Pakistan By M/s Mediate Pharmaceutical Pvt Ltd. Plot No. 150-151, Sector 24, Korangi Industrial Area, Karchi, Pakistan
	Brand Name +Dosage Form + Strength Composition	Protorib Injection 20mg Each Vial Contains: Rabeprazole as Sodium20mg
	Diary No. Date of R& I & fee	Dy. No. 13056 dated 06.03.2019

		Rs. 50,000/- dated 05.03.2019
	Pharmacological Group	Proton pump inhibitors
	Type of Form	Form 5
	Finished Product Specification	The firm has claimed in-house specs.
	Pack size & Demanded Price	1's (vial); As per SRO
	Approval status of product in	Vimpat 10 mg/ml solution for infusion (20ml). Approved in
	Reference Regulatory Authorities.	MHRA.
	Me-too status	Virotab 20mg Injection. Reg. No. 69946
	GMP status	Inspected on 16.06.2020 with the following conclusion:
		Keeping in view above mentioned rectification status in Liquid
		Sterile Ampoule/Infusion/Opthalmic/Otic Section of the firm
		and positive intention towards improvement, panel
		unanimously "Recommends the Resumption of production in
	Domonics of the Evolution	Liquid Sterile Ampoule/Infusion/Opthalmic/Otic Section".
	Remarks of the Evaluator.	• The drug product specifications have not been evaluated.
		• The address in the application is Helix Pharma Pvt Ltd.
		Hakimsons House, A/56, S.I.T.E Manghopir Road,
		Karachi, Pakistan, while it is Helix Pharma Pvt Ltd., A/56,
		S.I.T.E Karachi in the DML.
		• Stamped signatures of qualified persons are placed in the
		application.
		• Provide proof of international availability in the reference
		regulatory agencies as defined by the registration board in
		its 275 <sup>th</sup> meeting.
		• The firm added vial washing, vial sterilization and vial
		sealing, and packing to the manufacturing outlines along
		with submission of Rs. 25,000/- fee (challan-
		999307757318)
		approval of applied formulation in reference regulatory
		oted by the Registration Board in its 275th meeting.
124.	Name and address of manufacturer /	M/s Genome Pharmaceuticals Pvt Ltd.
	Applicant	Plot # 16/I-Phase IV, Industrial Estate, Hattar, KPK
		By My EG Di a di la Di a Na 12 A La di 177 i a
		M/s EG Pharmaceuticals. Plot. No. 13-A, Industrial Triangle,
	Duand Nama   Dagaga Farm   Strongth	Kahuta Road, Islamabad
	Brand Name +Dosage Form + Strength Composition	Gennifer Injection 100mg/5ml (IV) Each 5ml Ampoule Contains:
	Composition	Iron as sucrose100mg
		Eq. to iron100mg
	Diary No. Date of R& I & fee	Dy. No. 12663 dated 06.03.2019
	Blary 110. Bute of the 1 to lee	Rs. 50,000/- dated 06.03.2019
	Pharmacological Group	Iron parenteral preparations
	Type of Form	Form 5
	Finished Product Specification	The firm has claimed USP specs.
	Pack size & Demanded Price	5's (5ml); As per SRO
	Approval status of product in	VENOFER iron 100mg/5mL (as iron(III) hydroxide sucrose
	Reference Regulatory Authorities.	complex) injection ampoule, TGA Approved
	Me-too status	Ferrodin Injection 100mg/5ml. reg. No. 84670
	GMP status	Genome Pharma: The firm was inspected on 12.05.2018
		wherein GMP was rated Good. EG Pharma: The firm was
		inspected on 13.022019, wherein renewal of DML was
		recommnded.
	Remarks of the Evaluator.	• The drug product specifications have not been evaluated.
1		• The TGA has used the term Iron sucrose for the iron(III)
		hydroxide sucrose complex.

	1	
		• Revised the pharmacological group from Iron supplement to
		Iron, parenteral preparations.
		• Applied for Each 5ml Ampoule Contains: iron as
		sucrose100mg Eq. to iron100mg. Revised the label
		claim to iron as iron sucrose100mg in line with the
		reference product and adjust the weight of API as per salt
		factor in master formula.
		No excipients were mentioned. Specified the excipients for
		the pH adjustment.
		• For above revision, submit applicable fee as per notifications
		7-11/2012-B&A/DRAP dated 07.05.2021 and
		13.07.2021.
	Decision: Registration Board delibera	ted the matter and concluded that the innovator product has
	mentioned "Each mL contains 20 m	ng elemental iron as iron sucrose in water for injection".
	Therefore, the product is approved wi	th USP specifications as "Each 5ml Ampoule Contains: Iron
	as sucrose100mg".	
	The firm shall submit Rs. 7,500 fee be	
125.	Name and address of manufacturer /	M/s Genome Pharmaceuticals Pvt Ltd.
	Applicant	Plot # 16/I-Phase IV, Industrial Estate, Hattar, KPK
		By
		M/s EG Pharmaceuticals. Plot. No. 13-A, Industrial Triangle,
		Kahuta Road, Islamabad
	Brand Name +Dosage Form + Strength	Citonome 1g/4ml Injection
	Composition	Each 4ml Ampoule Contains:
		Citicoline As Sodium eq to Citicoline1g
	Diary No. Date of R& I & fee	Dy. No. 12665 dated 06.03.2019
		Rs. 50,000/- dated 06.03.2019
	Pharmacological Group	Other psychostimulants and nootropics
	Type of Form	Form 5
	Finished Product Specification	The firm has claimed in-house specs.
	Pack size & Demanded Price	5's (5ml); As per SRO
	Approval status of product in	CITICOLINA GIT 1000mg / 4ml solution for injection (vial
	Reference Regulatory Authorities.	4ml), AIFA approved
	Me-too status	Coleen Injection.1000mg/4ml. Reg. No. 46760
	GMP status	Genome Pharma: The firm was inspected on 12.05.2018
		wherein GMP was rated Good. EG Pharma: The firm was
		inspected on 13.022019, wherein renewal of DML was
		recommnded.
	Remarks of the Evaluator.	• The drug product specifications have not been evaluated.
		• Revised the pharmacological group from
		neurotonic/nootropic to "Other psychostimulants and
		nootropics".
		_
		• Applied for Each 4ml Ampoule Contains:
		Citicoline As Sodium eq to Citicoline1g. Revised the
		label claim to Each 4ml Ampoule Contains:
		Citicoline As Sodium1g.
		• For above revision, submit applicable fee as per notifications
		7-11/2012-B&A/DRAP dated 07.05.2021 and
		13.07.2021.
	Decision: Approved with innovator	or's specifications as "Each 4ml Ampoule Contains:
	Citicoline as sodium1g".	
	The firm shall submit Rs. 7,500 fee be	
126.	Name and address of manufacturer /	M/s Genome Pharmaceuticals Pvt Ltd.
	Applicant	Plot # 16/I-Phase IV, Industrial Estate, Hattar, KPK

		By M/s EG Pharmaceuticals. Plot. No. 13-A, Industrial
		Triangle, Kahuta Road, Islamabad
	Brand Name +Dosage Form + Strength	Piranome 1g/5ml Injection
	Composition	Each 5ml Ampoule Contains:
		Piracetam1g
	Diary No. Date of R& I & fee	Dy. No. 12659 dated 06.03.2019
		Rs. 50,000/- dated 06.03.2019
	Pharmacological Group	Other psychostimulants and nootropics
	Type of Form	Form 5
	Finished Product Specification	The firm has claimed in-house specs.
	Pack size & Demanded Price	12's (5ml); As per SRO
	Approval status of product in	DIZZITAM 200 mg / ml oral and injectable solution for
	Reference Regulatory Authorities.	intravenous use (5ml, 10ml ampoule), AIFA approved
	Me-too status	Neurotam Injection . Reg. No. 7348
	GMP status	Genome Pharma: The firm was inspected on 12.05.2018 wherein GMP was rated Good. EG Pharma: The firm was inspected on 13.022019, wherein renewal of DML was recommended.
	Remarks of the Evaluator.	• The drug product specifications have not been evaluated.
		• The firm revised the pharmacological group from anticonvulsant to "Other psychostimulants and nootropics".
		• For above revision, submit applicable fee as per notifications 7-11/2012-B&A/DRAP dated 07.05.2021 and 13.07.2021.
	Decision: Approved with innovator's issuance of registration letter.	specifications. The firm shall submit Rs. 7,500 fee before
127.	Name and address of manufacturer /	M/s Genome Pharmaceuticals Pvt Ltd.
	Applicant	Plot # 16/I-Phase IV, Industrial Estate, Hattar, KPK
		By
		M/s EG Pharmaceuticals. Plot. No. 13-A, Industrial Triangle,
		Kahuta Road, Islamabad
	Brand Name +Dosage Form + Strength	Lacgen 30mg/ml Injection
	Composition	Each ml Ampoule Contains:
	_	Ketoralac Tromethamine eq to Ketoralac
		Tromethamine30mg
	Diary No. Date of R& I & fee	Dy. No. 12666 dated 06.03.2019
	-	Rs. 50,000/- dated 06.03.2019
	Pharmacological Group	Acetic acid derivatives and related substances
	Type of Form	Form 5
	Finished Product Specification	The firm has claimed USP specs.
	Pack size & Demanded Price	5's (1ml ampoule); As per SRO
	Approval status of product in	TORADOL ketorolac trometamol 30mg/1mL (ketorolac
	Reference Regulatory Authorities.	trometamol 30mg without equivalency) injection ampoule.
		TGA approved.
	Me-too status	Syntor 30 mg Injection IV/IM. Reg. No. 83365
	GMP status	Genome Pharma: The firm was inspected on 12.05.2018 wherein GMP was rated Good. EG Pharma: The firm was inspected on 13.022019, wherein renewal of DML was recommnded.
	Remarks of the Evaluator.	• The drug product specifications have not been evaluated.
		• Applied for Ketoralac Tromethamine eq to Ketoralac Tromethamine30mg. Revised the label claim to Ketoralac Tromethamine30mg.

		<ul> <li>Revised the pharmacological group from NSAIDs to "Acetic acid derivatives and related substances".</li> <li>For above revision, submit applicable fee as per notifications</li> </ul>
		7-11/2012-B&A/DRAP dated 07.05.2021 and 13.07.2021.
	Decision: Approved with USP	specifications as "Each ml Ampoule Contains:
	Ketoralac Tromethamine30mg". The firm shall submit Rs. 7,500 fee bel	fore issuance of registration letter.
128.	Name and address of manufacturer /	Polyfine Chempharma, 51-Industrial Estate, Hayatabad,
	Applicant	Peshawar, Pakistan
	Brand Name +Dosage Form + Strength	Nodan 4mg tablet
	Composition	Each film-coated tablet contains:
		Ondansetron as HCl dihydrate4mg
	Diary No. Date of R& I & fee	Dy. No. 11698 dated 06.03.2019
	D	Rs. 20,000/- dated 06.03.2019
	Pharmacological Group	Serotonin (5HT3) antagonists
	Type of Form	Form 5
	Finished Product Specification	The firm has claimed USP specifications.
	Pack size & Demanded Price	1x10's; As per SRO
	Approval status of product in Reference Regulatory Authorities.	Ondansetron 4 mg Film-coated Tablets. MHRA approved
	Me-too status	Ondan Tablet film-coated 4mg. Reg No. 82656
	GMP status	Firm has also provided copy of GMP inspection report dated 24-
		04-2019 with conclusion:
		"The firm is considered to be operating at satisfactory level of
		cGMP compliance."
	Remarks of the Evaluator.	• The drug product specifications have not been evaluated.
		• The firm has mentioned in the label claim that 5mg Ondansetron HCl dihydrate eq. to 4mg of Ondansetron, and mentioned the quantity for 100,000 tablets as 0.525kg. the firm revised it 4.99mg per tablet and .499 kg per batch (100,000) in master formula. The factor is 1.247.
		The firm revised Ondansetron HCl dihydrate to Ondansetron HCl, which is against the reference formulation.  The firm revised Ondansetron HCl dihydrate to Ondansetron HCl, which is against the reference formulation.
		• The firm had mentioned the coating process after the blistering. The firm revised it and provided complete coating process.
		• The firm submitted Rs. 7500/- fee (challan- 97554507789).
	Decision: Approved with USP specific	ations. The firm shall submit Rs. 22,500 fee for correction in
		ations. The first shall subside KS. 22,500 fee for correction in ation letter. Registration letter will be issued after submission
		LT Division, valid within last three years.
129.	Name and address of manufacturer /	Polyfine Chempharma, 51-Industrial Estate, Hayatabad,
	Applicant	Peshawar, Pakistan
	Brand Name +Dosage Form + Strength	Nodan 8mg tablet
	Composition	Each film-coated tablet contains:
	T T	Ondansetron as HCl dihydrate8mg
	Diary No. Date of R& I & fee	Dy. No. 11697 dated 06.03.2019
		Rs. 20,000/- dated 06.03.2019
	Pharmacological Group	Serotonin (5HT3) antagonists
	Type of Form	Form 5
	Finished Product Specification	The firm has claimed USP specifications.
	Pack size & Demanded Price	1x10's; As per SRO
	Approval status of product in	Ondansetron 8 mg Film-coated Tablets. MHRA approved
	Reference Regulatory Authorities.	

	Me-too status	Ondan Tablet film-coated 8mg. Reg No. 82657
	GMP status	Firm has also provided copy of GMP inspection report dated 24-
		04-2019 with conclusion:
		"The firm is considered to be operating at satisfactory level of
		cGMP compliance."
	Remarks of the Evaluator.	• The drug product specifications have not been evaluated.
	Tremains of the Evaluation	• Check 5mg eq to 4mg factor 1.11
		• The firm has mentioned in the label claim that 10mg
		Ondansetron HCl dihydrate eq. to 8mg of Ondansetron,
		and mentioned the quantity for 100,000 tablets as 1kg. the
		firm revised it to 9.98mg per tablet and .998 kg per batch
		(100,000) in master formula. The factor is 1.247.
		• The firm revised Ondansetron HCl dihydrate to Ondansetron
		HCl, which is against the reference formulation.
		• The firm had mentioned the coating process after the
		blistering. The firm revised it and provided complete
		coating process.
	D · · · · · · · · · · · · · · · · · · ·	• The firm submitted Rs. 7500/- fee (challan- 5249137243).
		ations. The firm shall submit Rs. 22,500 fee for correction in
		ation letter. Registration letter will be issued after submission
120	Name and address of manufacturer /	LT Division, valid within last three years.
130.		Polyfine Chempharma, 51-Industrial Estate, Hayatabad, Peshawar, Pakistan
	Applicant	· · · · · · · · · · · · · · · · · · ·
	Brand Name +Dosage Form + Strength	Ebas 10mg Tablet
	Composition	Each Film Coated Tablet Contains:
	Diary No. Date of R& I & fee	Ebastine10mg
	Diary No. Date of R& 1 & fee	Dy. No. 11693 dated 06.03.2019 Rs. 20,000/- dated 06.03.2019
	Pharmacological Group	Antihistamine for systemic use
	Type of Form	Form 5
	Finished Product Specification	The firm has claimed JP specifications.
	Pack size & Demanded Price	•
		1x10's; As per SRO EBASTINE ARROW 10 mg film-coated tablets
	Approval status of product in	
	Reference Regulatory Authorities. Me-too status	ANSM Approved Atmos Tablets 10mg of Scotmann Pharma (Reg# 056116)
	GMP status	Firm has also provided copy of GMP inspection report dated 24-
	Givir status	04-2019 with conclusion:
		"The firm is considered to be operating at satisfactory level of
		cGMP compliance."
	Remarks of the Evaluator.	• The drug product specifications have not been evaluated.
	Remarks of the Evaluator.	The drug product specifications have not been evaluated.
		• The firm revised the quantity of API from 0.1kg to 1kg for
		100,000 tablets in the master formula.
		• The firm had mentioned the coating process after the
		blistering. The firm revised it and provided complete
		coating process.
		• The firm submitted Rs. 7500/- fee (challan-92331128).
	Decision: Approved with IP specificat	ions. The firm shall submit Rs. 22,500 fee before issuance of
		will be issued after submission of GMP inspection report from
	QA< Division, valid within last thr	
131.	Name and address of manufacturer /	Polyfine Chempharma, 51-Industrial Estate, Hayatabad,
131.	Applicant	Peshawar, Pakistan
	Brand Name +Dosage Form + Strength	Ebas 20mg Tablet
	Composition	Each Film Coated Tablet Contains:
	Composition	Ebastine20mg
		LoweringLouis

	Diary No. Date of R& I & fee	Dy. No. 11694 dated 06.03.2019
	Dhamasalariad Curun	Rs. 20,000/- dated 06.03.2019
	Pharmacological Group	Antihistamine for systemic use Form 5
	Type of Form  Finished Product Specification	
	Finished Product Specification Pack size & Demanded Price	The firm has claimed JP specifications.  1x10's; As per SRO
	Approval status of product in	
	Reference Regulatory Authorities.	Bactil Forte 20 mg film-coated tablets. CIMA Approved.
	Me-too status	Ebist 20mg Tablets. Reg. No. 77854
	GMP status	Firm has also provided copy of GMP inspection report dated 24-
	Givir status	04-2019 with conclusion:
		"The firm is considered to be operating at satisfactory level of
		cGMP compliance."
	Remarks of the Evaluator.	The drug product specifications have not been evaluated.
		• The firm had mentioned the coating process after the
		blistering. The firm revised it and provided complete
		coating process.
		• The firm submitted Rs. 7500/- fee (challan-46268302742).
	Designary Approved with ID specifies	ations. Registration letter will be issued after submission of
		Division, valid within last three years.
132.	Name and address of manufacturer /	Polyfine Chempharma, 51-Industrial Estate, Hayatabad,
	Applicant	Peshawar, Pakistan
	Brand Name +Dosage Form + Strength	Nodan Injection 4mg/2ml
	Composition	Each 2ml Ampoule Contains:
		Ondansetronas as Hel Dihydrate4mg
	Diary No. Date of R& I & fee	Dy. No. 11696 dated 06.03.2019
		Rs. 20,000/- dated 06.03.2019
	Pharmacological Group	Serotonin (5HT3) antagonists
	Type of Form	Form 5
	Finished Product Specification	The firm has claimed USP specifications.
	Pack size & Demanded Price	5's (2ml); As per SRO
	Approval status of product in	Ondansetron 4 mg / 2 ml Solution for Injection: MHRA
	Reference Regulatory Authorities.	approved
		Ondansetron 8 mg / 4 ml Solution for Injection: MHRA
	Me-too status	approved Duset injection IV/IM 4mg/2ml. Reg. No. 83371
	GMP status	Firm has also provided copy of GMP inspection report dated 24-
	Givir status	04-2019 with conclusion:
		"The firm is considered to be operating at satisfactory level of
		cGMP compliance."
	Remarks of the Evaluator.	• The drug product specifications have not been evaluated.
	Remarks of the Evaluation	• The firm has mentioned Ondansetron as Ondansetron Hel
		Dihydrate 40g for 10.000 ampoules.
		• The firm added filling and packing process and submitted
		Rs. 7500/- fee (challan-932397149668).
		cations. Registration letter will be issued after submission of
122		Division, valid within last three years.
133.	Name and address of manufacturer / Applicant	Polyfine Chempharma, 51-Industrial Estate, Hayatabad, Peshawar, Pakistan
	Brand Name +Dosage Form + Strength	Nodan Injection 8mg/4ml
	Composition	Each 4ml Ampoule Contains:
	Composition	Ondansetron as Hel Dihydrate8mg
	Diary No. Date of R& I & fee	Dy. No. 11695 dated 06.03.2019
	Diary 110. Date of R& 1 & 1cc	Rs. 20,000/- dated 06.03.2019
	Pharmacological Group	Serotonin (5HT3) antagonists
	1 Harmacorogical Group	Derotemm (31113) untagonists

	Type of Form	Form 5
	Finished Product Specification	The firm has claimed USP specifications.
	Pack size & Demanded Price	5's (2ml); As per SRO
	Approval status of product in	Ondansetron 4 mg / 2 ml Solution for Injection: MHRA
	Reference Regulatory Authorities.	approved
		Ondansetron 8 mg / 4 ml Solution for Injection: MHRA
		approved
	Me-too status	Duset injection IV/IM 8mg/4ml. Reg. No. 83372
	GMP status	Firm has also provided copy of GMP inspection report dated 24-
		04-2019 with conclusion:
		"The firm is considered to be operating at satisfactory level of
		cGMP compliance."
	Remarks of the Evaluator.	• The drug product specifications have not been evaluated.
		• The firm has mentioned Ondansetron as Ondansetron Hcl
		Dihydrate 80g for 10.000 ampoules.
		• The firm added filling and packing process and submitted
		Rs. 7500/- fee (challan-09086431779).
	Decision: Approved with USP specific	eations. Registration letter will be issued after submission of
	GMP inspection report from QA<	
134.	Name and address of manufacturer /	Polyfine Chempharma, 51-Industrial Estate, Hayatabad,
	Applicant	Peshawar, Pakistan
	Brand Name +Dosage Form + Strength	Nodan 4mg/5ml Syrup
	Composition	Each 5ml Contains:
		Ondasetron as HCl dihydrate4mg
	Diary No. Date of R& I & fee	Dy. No. 11700 dated 06.03.2019
		Rs. 20,000/- dated 06.03.2019
	Pharmacological Group	Serotonin (5HT3) antagonists
	Type of Form	Form 5
	Finished Product Specification	The firm has claimed USP specifications.
	Pack size & Demanded Price	60ml, 120ml; As per SRO
	Approval status of product in Reference Regulatory Authorities.	Ondansetron 4mg/5ml oral solution: MHRA approved
	Me-too status	Ondan Syrup 4mg/5ml. Reg. No. 82628
	GMP status	Firm has also provided copy of GMP inspection report dated 24-
	Own status	04-2019 with conclusion:
		"The firm is considered to be operating at satisfactory level of
		cGMP compliance."
	Remarks of the Evaluator.	• The drug product specifications have not been evaluated.
		• The firm has mentioned Ondansetron as Ondansetron HCl
		Dihydrate 640g for 800L.
		• Manufacturing outlines had not been submitted. The firm
		submitted that same.
		• Submitted Rs. 7500/- fee (challan-5102160401).
	Decision: Approved with USP specific	eations. Registration letter will be issued after submission of
	GMP inspection report from QA<	
135.	Name and address of manufacturer /	Polyfine Chempharma, 51-Industrial Estate, Hayatabad,
	Applicant	Peshawar, Pakistan
	Brand Name +Dosage Form + Strength	Tvice 100mg/ml Oral Solution
	Composition	Each ml Contains:
		Levetiracetam100mg
	Diary No. Date of R& I & fee	Dy. No. 11699 dated 06.03.2019
		Rs. 20,000/- dated 06.03.2019
	Pharmacological Group	Antiepileptics
	Type of Form	Form 5
	Finished Product Specification	The firm has claimed USP specifications.

136.	Pack size & Demanded Price Approval status of product in Reference Regulatory Authorities. Me-too status GMP status  Remarks of the Evaluator.  Decision: Approved with USP specific GMP inspection report from QA< Name and address of manufacturer /	<ul> <li>60ml, 120ml; As per SRO</li> <li>KEPPRA (levetiracetam) oral solution 100mg/ml. USFD/approved</li> <li>Evic Solution 100mg/ml. Reg. No. 82629</li> <li>Firm has also provided copy of GMP inspection report dated 24 04-2019 with conclusion:</li> <li>"The firm is considered to be operating at satisfactory level of cGMP compliance."</li> <li>The drug product specifications have not been evaluated.</li> <li>The addition of sorbitol, propylene glycol and EDTA had not been mentioned in the manufacturing outlines. The firm revised the manufacturing outlines.</li> <li>Submitted Rs. 7500/- fee (challan-119426418088).</li> <li>cations. Registration letter will be issued after submission of the state of the submission of the state of the submission of the state of the submission of the state of the submission of the state of the submission of the state of the submission of the state of the submission of the state of the submission of the state of the submission of the state of the submission of the state of the submission of t</li></ul>
136. I	Reference Regulatory Authorities.  Me-too status  GMP status  Remarks of the Evaluator.  Decision: Approved with USP specific GMP inspection report from QA<	approved  Evic Solution 100mg/ml. Reg. No. 82629  Firm has also provided copy of GMP inspection report dated 24 04-2019 with conclusion:  "The firm is considered to be operating at satisfactory level of cGMP compliance."  • The drug product specifications have not been evaluated.  • The addition of sorbitol, propylene glycol and EDTA had not been mentioned in the manufacturing outlines. The firm revised the manufacturing outlines.  • Submitted Rs. 7500/- fee (challan-119426418088).
136. I	GMP status  Remarks of the Evaluator.  Decision: Approved with USP specific GMP inspection report from QA<	Evic Solution 100mg/ml. Reg. No. 82629  Firm has also provided copy of GMP inspection report dated 24 04-2019 with conclusion:  "The firm is considered to be operating at satisfactory level of cGMP compliance."  • The drug product specifications have not been evaluated.  • The addition of sorbitol, propylene glycol and EDTA had not been mentioned in the manufacturing outlines. The firm revised the manufacturing outlines.  • Submitted Rs. 7500/- fee (challan-119426418088).
136. I	Remarks of the Evaluator.  Decision: Approved with USP specific GMP inspection report from QA<	<ul> <li>04-2019 with conclusion:     "The firm is considered to be operating at satisfactory level of cGMP compliance."     The drug product specifications have not been evaluated.</li> <li>The addition of sorbitol, propylene glycol and EDTA had not been mentioned in the manufacturing outlines. The firm revised the manufacturing outlines.</li> <li>Submitted Rs. 7500/- fee (challan-119426418088).</li> </ul>
136. I	Decision: Approved with USP specific GMP inspection report from QA<	<ul> <li>"The firm is considered to be operating at satisfactory level of cGMP compliance."</li> <li>The drug product specifications have not been evaluated.</li> <li>The addition of sorbitol, propylene glycol and EDTA had not been mentioned in the manufacturing outlines. The firm revised the manufacturing outlines.</li> <li>Submitted Rs. 7500/- fee (challan-119426418088).</li> </ul>
136. I	Decision: Approved with USP specific GMP inspection report from QA<	<ul> <li>cGMP compliance."</li> <li>The drug product specifications have not been evaluated.</li> <li>The addition of sorbitol, propylene glycol and EDTA had not been mentioned in the manufacturing outlines. The firm revised the manufacturing outlines.</li> <li>Submitted Rs. 7500/- fee (challan-119426418088).</li> </ul>
136. I	Decision: Approved with USP specific GMP inspection report from QA<	<ul> <li>The drug product specifications have not been evaluated.</li> <li>The addition of sorbitol, propylene glycol and EDTA had not been mentioned in the manufacturing outlines. The firm revised the manufacturing outlines.</li> <li>Submitted Rs. 7500/- fee (challan-119426418088).</li> </ul>
136. I	Decision: Approved with USP specific GMP inspection report from QA<	<ul> <li>The addition of sorbitol, propylene glycol and EDTA had not been mentioned in the manufacturing outlines. The firm revised the manufacturing outlines.</li> <li>Submitted Rs. 7500/- fee (challan-119426418088).</li> </ul>
136. I	GMP inspection report from QA<	not been mentioned in the manufacturing outlines. Th firm revised the manufacturing outlines.  • Submitted Rs. 7500/- fee (challan-119426418088).
136. I	GMP inspection report from QA<	firm revised the manufacturing outlines.  • Submitted Rs. 7500/- fee (challan-119426418088).
136. I	GMP inspection report from QA<	• Submitted Rs. 7500/- fee (challan-119426418088).
136. I	GMP inspection report from QA<	· · · · · · · · · · · · · · · · · · ·
136. I	GMP inspection report from QA<	ations. Registration letter will be issued after submission of
136. I		
]	Name and address of manufacturer /	
]		M/s Global Pharmaceuticals Pvt Ltd Plot # 204-205, Industria
	Applicant	Triangle, Kahuta Road, Islamabad
	Brand Name +Dosage Form + Strength	Modfil 200mg Tablet
	Composition	Each Tablet Contains:
,	D' N D ( CD 0 I 0 C	Modafinil200mg
	Diary No. Date of R& I & fee	Dy. No. 13069 dated 06.03.2019
_	DI 1 ' 1 C	Rs. 20,000/- dated 04.03.2019
	Pharmacological Group	Psychostimulants
	Type of Form	Form 5
	Finished Product Specification	The firm has claimed USP specs.
	Pack size & Demanded Price	2x10's; As per SRO
	Approval status of product in	Modafinil 200 mg Tablets. Approved in MHRA.
	Reference Regulatory Authorities.	M. 1 (200 FILL) D. N. (7171
	Me-too status	Monalert 200mg Tablet . Reg. No. 47171
	GMP status Remarks of the Evaluator.	The drug product specifications have not been evaluated.
	-	• Form 5 had not been signed. Signed Form 5 submitted.
	Decision: Approved with USD specific	ations. The firm shall submit Rs. 7,500 fee before issuance of
	registration letter.	ations. The firm shan sublint Rs. 7,300 fee before issuance (
	Name and address of manufacturer /	M/s Global Pharmaceuticals Pvt Ltd Plot # 204-205, Industria
1	Applicant	Triangle, Kahuta Road, Islamabad
]	Brand Name +Dosage Form + Strength	Modfil 100mg Tablet
_	Composition	Each Tablet Contains:
	•	Modafinil100mg
I	Diary No. Date of R& I & fee	Dy. No. 13068 dated 06.03.2019
	•	Rs. 20,000/- dated 04.03.2019
I	Pharmacological Group	Psychostimulants
	Type of Form	Form 5
1	Finished Product Specification	The firm has claimed USP specs.
I	Pack size & Demanded Price	2x10's; As per SRO
1	Approval status of product in	Modafinil 100 mg Tablets. Approved in MHRA.
] ]	Reference Regulatory Authorities.	
	Me-too status	Monalert 100mg Tablet . Reg. No. 47170
	GMP status	
	Remarks of the Evaluator.	• The drug product specifications have not been evaluated.

138.	Name and address of manufacturer /	M/s Rotex Pharma Pvt Ltd. Plot No. 206 & 207. Industrial
	Applicant	Triangle, Kahuta Road, Islamabad
	Brand Name +Dosage Form + Strength	Panatex Extra Tablet
	Composition	Each Tablet Contains:
		Paracetamol500mg
		Caffeine65mg
	Diary No. Date of R& I & fee	Dy. No. 12706 dated 06.03.2019
		Rs. 20,000/- dated 05.03.2019
	Pharmacological Group	Anilide in combination with xanthine derivatives.
	Type of Form	Form 5
	Finished Product Specification	The firm has claimed USP specs.
	Pack size & Demanded Price	100's, 200's; As per SRO
	Approval status of product in	Paracetamol / Caffeine 500mg/65mg Tablets. MHRA approved
	Reference Regulatory Authorities.	
	Me-too status	PANADOL EXTRA TAB. Reg. No. 12437
	GMP status	GMP certificate issued on the basis of inspection dated 12.08.2020
	Remarks of the Evaluator.	The drug product specifications have not been evaluated.
		• Undertaking at the end of Form 5 was missing. The firm submitted signed undertaking.
		• Revised the pharmacological group to anilide in
		combination with xanthine derivatives.
	Decisions Approved with LICD angelie	• Submitted Rs. 7500/- fee (challan- 9906459314).
139.	<b>Decision: Approved with USP specific</b> Name and address of manufacturer /	M/s Rotex Pharma Pvt Ltd. Plot No. 206 & 207. Industrial
139.	Applicant	Triangle, Kahuta Road, Islamabad
	Brand Name +Dosage Form + Strength	Dovin 40mg Tablet
	Composition	Each Uncoated Tablet Contains:
	Composition	Drotaverine Hcl40mg
	Diary No. Date of R& I & fee	Dy. No. 12674 dated 06.03.2019
	Diary 140. Date of Ree 1 & 1ee	Rs. 20,000/- dated 05.03.2019
	Pharmacological Group	Antibiotic
	Type of Form	Form 5
	Finished Product Specification	The firm has claimed in-house specs.
	Pack size & Demanded Price	20's, 100's; As per SRO
	Approval status of product in	Apporved in three EMA states as un-coated tablets in
	Reference Regulatory Authorities.	Hungary (both coated and uncoated), Romania & Solvakia
	reference regulatory readings.	(both coated and uncoated).
	Me-too status	Spasmostar Tablets. Reg. No. 78711
	GMP status	GMP certificate issued on the basis of inspection dated
	5111 511115	12.08.2020
	Remarks of the Evaluator.	• The drug product specifications have not been evaluated.
		• Revised the specs to innovators specs.
		• Undertaking at the end of Form 5 was missing. The firm
		submitted signed undertaking.
		• Revised the pharmacological group to Papaverine and
		derivatives.
	D :: A 1 :/1:	• Submitted Rs. 7500/- fee challan- 77552429096
1.40	Decision: Approved with innovator's s	
140.	Name and address of manufacturer /	M/s Rotex Pharma Pvt Ltd. Plot No. 206 & 207. Industrial
	Applicant  Prond Name   Decora Form   Strongth	Triangle, Kahuta Road, Islamabad
	Brand Name +Dosage Form + Strength	Bamtex 600mg Tablet
	Composition	Each Film Coated Tablet Contains:
		Bamifylline HCl600mg

	Diary No. Date of R& I & fee	Dy. No. 12675 dated 06.03.2019
		Rs. 20,000/- dated 05.03.2019
	Pharmacological Group	Xanthines
	Type of Form	Form 5
	Finished Product Specification	The firm has claimed in-house specs.
	Pack size & Demanded Price	3x10's; As per SRO
	Approval status of product in	BRIOFIL 600mg film-coated tablet. AIFA approved.
	Reference Regulatory Authorities.	
	Me-too status	Bamizine Tablets 600mg. Reg. No. 74539
	GMP status	GMP certificate issued on the basis of inspection dated 12.08.2020
	Remarks of the Evaluator.	• The drug product specifications have not been evaluated.
		• Undertaking at the end of Form 5 was missing. The firm submitted signed undertaking.
		<ul> <li>Revised the pharmacological group from methyl xanthine derivatives (antihistamines) to Xanthines.</li> </ul>
		• Submitted Rs. 7500/- fee challan- 43042076698
	Decision: Approved with innovator's s	
141.	Name and address of manufacturer /	M/s Rotex Pharma Pvt Ltd. Plot No. 206 & 207. Industrial
1111	Applicant	Triangle, Kahuta Road, Islamabad
	Brand Name +Dosage Form + Strength	Rivarox 20mg Tablet
	Composition	Each Film Coated Tablet Contains:
		Rivaroxaban20mg
	Diary No. Date of R& I & fee	Dy. No. 12681 dated 06.03.2019
		Rs. 20,000/- dated 05.03.2019
	Pharmacological Group	Factor Xa inhibitor
	Type of Form	Form 5
	Finished Product Specification	The firm has claimed in-house specs.
	Pack size & Demanded Price	14's; As per SRO
	Approval status of product in	Rivaroxaban 20 mg film-coated tablets by Milpharm Limited.
	Reference Regulatory Authorities.	MHRA approved
	Me-too status	Roxaban 20mg film-coated Tablet. Reg. No. 85120
	GMP status	GMP certificate issued on the basis of inspection dated 12.08.2020
	Remarks of the Evaluator.	• The drug product specifications have not been evaluated.
		<ul> <li>Revised the specs to innovators specs.</li> </ul>
		• Undertaking at the end of Form 5 was missing. The firm
		submitted signed undertaking.
		• Revises the pharmacological group to Factor Xa inhibitor.
		• Submitted Rs. 7500/- fee challan- 01916905
	Decision: Approved with innovator's s	specifications.
142.	Name and address of manufacturer /	M/s Rotex Pharma Pvt Ltd. Plot No. 206 & 207. Industrial
	Applicant	Triangle, Kahuta Road, Islamabad
	Brand Name +Dosage Form + Strength	Rodex 400mg Tablet
	Composition	Each Uncoated Tablet Contains:
		Doxofylline400mg
	Diary No. Date of R& I & fee	Dy. No. 12668 dated 06.03.2019
		Rs. 20,000/- dated 05.03.2019
	Pharmacological Group	Xanthines
	Type of Form	Form 5
	Finished Product Specification	The firm has claimed in-house specs.
	Pack size & Demanded Price	10's; As per SRO
	Approval status of product in	DOXOFILLINA ABC 400mg tablet. AIFA approved
	Reference Regulatory Authorities.	

	MP status emarks of the Evaluator.	Profylline Tablet 400mg. Reg. No. 73744  GMP certificate issued on the basis of inspection dated 12.08.2020  • The drug product specifications have not been evaluated.  • Undertaking at the end of Form 5 was missing. The firm submitted signed undertaking.  • Revised the pharmacological group from bronchodialtor to
Re	emarks of the Evaluator.	<ul> <li>The drug product specifications have not been evaluated.</li> <li>Undertaking at the end of Form 5 was missing. The firm submitted signed undertaking.</li> </ul>
Re	emarks of the Evaluator.	• Undertaking at the end of Form 5 was missing. The firm submitted signed undertaking.
		submitted signed undertaking.
		• Revised the pharmacological group from bronchodialtor to
		Xanthines.
		• Submitted Rs. 7500/- fee challan- 34136797333
D	ecision: Approved with innovator's s	pecifications.
143. Na	ame and address of manufacturer /	M/s Rotex Pharma Pvt Ltd. Plot No. 206 & 207. Industrial
A	pplicant	Triangle, Kahuta Road, Islamabad
Bı	rand Name +Dosage Form + Strength	Ivan 5mg Tablet
Co	omposition	Each Film Coated Tablet Contains:
		Ivabradine As Hcl5mg
Di	iary No. Date of R& I & fee	Dy. No. 12717 dated 06.03.2019
		Rs. 20,000/- dated 05.03.2019
	harmacological Group	Other cardiac preparations
	ype of Form	Form 5
	nished Product Specification	The firm has claimed in-house specs.
l ——	ack size & Demanded Price	10's, 28's, 56's; As per SRO
	pproval status of product in	Ivabradine 5mg Film coated Tablets. MHRA approved
	eference Regulatory Authorities.  le-too status	L. 1. 1. 1. 1. 1. 1. 1. 5 D. N. 02/2/
		Ivabrad Tablet 5mg. Reg. No. 82626
	MP status	GMP certificate issued on the basis of inspection dated 12.08.2020
Re	emarks of the Evaluator.	• The drug product specifications have not been evaluated.
		• Undertaking at the end of Form 5 was missing. The firm submitted signed undertaking.
		• Revised the pharmacological group to Other cardiac
		preparations.
<u> </u>	ecision: Approved with innovator's s	• Submitted Rs. 7500/- fee challan- 14176110
	ame and address of manufacturer /	M/s Rotex Pharma Pvt Ltd. Plot No. 206 & 207. Industrial
	pplicant	Triangle, Kahuta Road, Islamabad
	rand Name +Dosage Form + Strength	Ivan 7.5mg Tablet
	omposition	Each Film Coated Tablet Contains:
	1	Ivabradine As Hcl7.5mg
D	iary No. Date of R& I & fee	Dy. No. 12713 dated 06.03.2019
	•	Rs. 20,000/- dated 05.03.2019
Pł	narmacological Group	Other cardiac preparations.
Ty	ype of Form	Form 5
Fi	inished Product Specification	The firm has claimed in-house specs.
Pa	ack size & Demanded Price	10's, 28's, 56's; As per SRO
	pproval status of product in	Ivabradine 7.5mg Film coated Tablets. MHRA approved
	eference Regulatory Authorities.	
	le-too status	Ivabrad Tablet 7.5mg. Reg. No. 82627
G	MP status	GMP certificate issued on the basis of inspection dated 12.08.2020
Re	emarks of the Evaluator.	• The drug product specifications have not been evaluated.
		• Undertaking at the end of Form 5 was missing. The firm submitted signed undertaking.

		• Revised the pharmacological group to Other cardiac
		preparations.
		• Submitted Rs. 7500/- fee challan- 7779413755
	Decision: Approved with innovator's	
145.	Name and address of manufacturer / Applicant	M/s Rotex Pharma Pvt Ltd. Plot No. 206 & 207. Industrial Triangle, Kahuta Road, Islamabad
	Brand Name +Dosage Form + Strength	Arbex D 150/12.5 mg Tablet
	Composition	Each Film Coated Tablet Contains:
	•	Irbesartan150mg
		Hydrochlorothiazide12.5mg
	Diary No. Date of R& I & fee	Dy. No. 12714 dated 06.03.2019
		Rs. 20,000/- dated 05.03.2019
	Pharmacological Group	Angiotensin II receptor blockers (ARBs) and diuretics.
	Type of Form	Form 5
	Finished Product Specification	The firm has claimed USP specs.
	Pack size & Demanded Price	10's, 28's, 14's; As per SRO
	Approval status of product in	Irbesartan/Hydrochlorothiazide 150 mg/12.5 mg film-coated
	Reference Regulatory Authorities.	tablets. MHRA approved
	Me-too status	Co- Irbisaff Tablet . Reg. No. 77191
	GMP status	GMP certificate issued on the basis of inspection dated 12.08.2020
	Remarks of the Evaluator.	• The drug product specifications have not been evaluated.
		• Undertaking at the end of Form 5 was missing. The firm
		submitted signed undertaking.
		• Revised the pharmacological group from Angiotensin II
		antagonists / diuretics to Angiotensin II receptor blockers
		(ARBs) and diuretics.
		• Submitted Rs. 7500/- fee challan- 3798383304
	<b>Decision: Approved with innovator's s</b>	specifications.
146.	Name and address of manufacturer /	M/s Rotex Pharma Pvt Ltd. Plot No. 206 & 207. Industrial
	Applicant	Triangle, Kahuta Road, Islamabad
	Brand Name +Dosage Form + Strength	Tridon MR 35mg Tablet
	Composition	Each Modified Release Film Coated Tablet Contains:
		Trimetazidine Dihydrochloride35mg
	Diary No. Date of R& I & fee	Dy. No. 12714 dated 06.03.2019
	Di la la C	Rs. 20,000/- dated 05.03.2019
	Pharmacological Group	Other cardiac preparations
	Type of Form	Form 5
	Finished Product Specification	The firm has claimed in-house specs.
	Pack size & Demanded Price	20's; As per SRO
	Approval status of product in	VASTAREL 35 mg film-coated tablet with modified release.
	Reference Regulatory Authorities.	ANSM approved
	Me-too status	Trikat MR Tablet 35mg. Reg. No. 84467
	GMP status	GMP certificate issued on the basis of inspection dated
	Remarks of the Evaluator.	<ul><li>12.08.2020</li><li>The drug product specifications have not been evaluated.</li></ul>
		• Undertaking at the end of Form 5 was missing. The firm
		submitted signed undertaking.
		• Revised the pharmacological group from cytprptective &
		antiischemic agent to Other cardiac preparations.
		• Submitted Rs. 7500/- fee challan- 094525338
	<b>Decision: Approved with innovator's s</b>	specifications.
147.	Name and address of manufacturer /	M/s Rotex Pharma Pvt Ltd. Plot No. 206 & 207. Industrial
	Applicant	Triangle, Kahuta Road, Islamabad

	Brand Name +Dosage Form + Strength	QTP 25mg Tablet		
	Composition	Each Film Coated Tablet Contains:		
	r	Quetiapine Fumarate Eq. To Quetiapine25mg		
	Diary No. Date of R& I & fee	Dy. No. 12697 dated 06.03.2019		
		Rs. 20,000/- dated 05.03.2019		
	Pharmacological Group	Antipsychotics		
	Type of Form	Form 5		
	Finished Product Specification	The firm has claimed USP specs.		
	Pack size & Demanded Price	10's, 20's, 30's, 50's, 100's, 500's; As per SRO		
	Approval status of product in	Quetiapine 25 mg film-coated tablets (MHRA Approved)		
	Reference Regulatory Authorities.	Quotaupino 20 mg min comos morsos (m22222 mppro 100)		
	Me-too status	Quitapin 25mg Tablet by Fynk Pharma		
	GMP status	GMP certificate issued on the basis of inspection dated		
		12.08.2020		
	Remarks of the Evaluator.	The drug product specifications have not been evaluated.		
		• Undertaking at the end of Form 5 was missing. The firm		
		submitted signed undertaking.		
		• Submitted Rs. 7500/- fee challan- 4420568403		
	Decision: Approved.	- Submitted Rs. 7500/ Tee chandi 1120500105		
148.	Name and address of manufacturer /	M/s Rotex Pharma Pvt Ltd. Plot No. 206 & 207. Industrial		
170.	Applicant	Triangle, Kahuta Road, Islamabad		
	Brand Name +Dosage Form + Strength	Amlocor 10mg Tablet		
	Composition	Each Tablet Contains:		
	Composition	Amlodipine Besylate Eq. To Amlodipine10mg		
	Diary No. Date of R& I & fee	Dy. No. 12683 dated 06.03.2019		
	Diary No. Date of R& 1 & fee			
	Dharmagalogical Group	Rs. 20,000/- dated 05.03.2019  Dihydropyridine derivatives.		
-		Form 5		
	Finished Product Specification	The firm has claimed USP specs.		
	Pack size & Demanded Price			
		10's, 20's, 30's, 14's; As per SRO Amlodipine 10mg Tablets. <b>MHRA</b> Approved		
Approval status of product in Reference Regulatory Authorities.		Amiodiphie Tohig Tablets. WHRA Approved		
		Amvasc 10mg Tablets. Reg. No. 73234		
	GMP status	GMP certificate issued on the basis of inspection dated		
		12.08.2020		
	Remarks of the Evaluator.	The drug product specifications have not been evaluated.		
		• Undertaking at the end of Form 5 was missing. The firm		
		submitted signed undertaking.		
		• Revised the pharmacological group from angiotension II		
		antagonist to Dihydropyridine derivatives.		
		• Submitted Rs. 7500/- fee challan- 4720334401.		
	Decision: Approved.	• Submitted Rs. 7500/- fee chanan- 4720354401.		
149.	Name and address of manufacturer /	M/s Rotex Pharma Pvt Ltd. Plot No. 206 & 207. Industrial		
147.	Applicant	Triangle, Kahuta Road, Islamabad		
	Brand Name +Dosage Form + Strength	Ropim 2mg Tablet		
	Composition	Each Film Coated Tablet Contains:		
	Composition	Ropinirole Hcl2mg		
1	Diary No. Date of R& I & fee	Dy. No. 12676 dated 06.03.2019		
	Diary No. Date of R& 1 & fee	Rs. 20,000/- dated 05.03.2019		
1	Pharmacological Group			
	Pharmacological Group	Dopamine agonists. Form 5		
	Type of Form Finished Product Specification			
	Finished Product Specification	The firm has claimed USP specs.		
	Pack size & Demanded Price	10's, 21's; As per SRO		

Reference Regulatory Authorities.  Me-too status  GMP status  Remarks of the Evaluator.  Remarks of the Evaluator.  Remarks of the Evaluator.  Pecision: Approved.  150.  Name and address of manufacturer / Applicant  Brand Name +Dosage Form + Strength  Composition  Diary No. Date of R& I & fee  Dy. No. 12710 dated 06.03.2019  Pharmacological Group  Benzimidazole derivatives.  Form 5  Finished Product Specification  Pack size & Demanded Price  Approval status of product in  Reference Regulatory Authorities.  Me-too status  GMP certificate issued on the basis of inspectic 12.08.2020  • The drug product specifications have not been eval	1mg.	
GMP status  GMP certificate issued on the basis of inspection 12.08.2020  Remarks of the Evaluator.  • The drug product specifications have not been eval  • Undertaking at the end of Form 5 was missing. In Submitted signed undertaking.  • Revised the pharmacological group from antipark Dopamine agonists.  • Submitted Rs. 7500/- fee challan- 316315314953  Decision: Approved.  150.  Name and address of manufacturer / Applicant  Brand Name +Dosage Form + Strength  Composition  Each 5ml Contains: Albendazole100mg  Diary No. Date of R& I & fee  Dy. No. 12710 dated 06.03.2019  Rs. 20,000/- dated 05.03.2019  Pharmacological Group  Pharmacological Group  Benzimidazole derivatives.  Type of Form  Form 5  Finished Product Specification  Pack size & Demanded Price  Approval status of product in Reference Regulatory Authorities.  Me-too status  GMP status  GMP certificate issued on the basis of inspectic 12.08.2020		
Remarks of the Evaluator.    The drug product specifications have not been eval	n doted	
• Undertaking at the end of Form 5 was missing. submitted signed undertaking.     • Revised the pharmacological group from antipark Dopamine agonists.     • Submitted Rs. 7500/- fee challan- 316315314953    Decision: Approved.	n dated	
submitted signed undertaking.  Revised the pharmacological group from antipark Dopamine agonists.  Submitted Rs. 7500/- fee challan- 316315314953  Decision: Approved.  150. Name and address of manufacturer / Applicant Triangle, Kahuta Road, Islamabad Triangle, Kah	uated.	
Dopamine agonists.  Submitted Rs. 7500/- fee challan- 316315314953  Decision: Approved.  150. Name and address of manufacturer / Applicant	The firm	
Dopamine agonists.  Submitted Rs. 7500/- fee challan- 316315314953  Decision: Approved.  150. Name and address of manufacturer / Applicant	inson to	
Decision: Approved.  150. Name and address of manufacturer / Applicant Triangle, Kahuta Road, Islamabad Triangle, Kahuta Road, Islamabad Alenza 100mg/5ml Liquid Suspension  Composition Each 5ml Contains: Albendazole100mg  Diary No. Date of R& I & fee Dy. No. 12710 dated 06.03.2019  Rs. 20,000/- dated 05.03.2019  Pharmacological Group Benzimidazole derivatives.  Type of Form Form 5  Finished Product Specification The firm has claimed USP specs.  Pack size & Demanded Price 10ml; As per SRO  Approval status of product in Reference Regulatory Authorities.  Me-too status Nenzole Suspension. Reg. No. 25891  GMP status GMP certificate issued on the basis of inspection 12.08.2020		
Name and address of manufacturer / Applicant		
Applicant  Brand Name +Dosage Form + Strength  Composition  Composition  Diary No. Date of R& I & fee  Dy. No. 12710 dated 06.03.2019  Rs. 20,000/- dated 05.03.2019  Pharmacological Group  Pharmacological Group  Benzimidazole derivatives.  Type of Form  Form 5  Finished Product Specification  Pack size & Demanded Price  Approval status of product in  Reference Regulatory Authorities.  Me-too status  Meroo status  Meroo status  Triangle, Kahuta Road, Islamabad  Alenza 100mg/5ml Liquid Suspension  Each 5ml Contains:  Albendazole100mg  Dy. No. 12710 dated 06.03.2019  Benzimidazole derivatives.  The firm has claimed USP specs.  10ml; As per SRO  Zentel, 400 mg/20 ml. EMA approved in Poland.  Reference Regulatory Authorities.  Me-too status  Nenzole Suspension. Reg. No. 25891  GMP certificate issued on the basis of inspection 12.08.2020		
Brand Name +Dosage Form + Strength Alenza 100mg/5ml Liquid Suspension  Composition Each 5ml Contains:     Albendazole100mg  Diary No. Date of R& I & fee Dy. No. 12710 dated 06.03.2019     Rs. 20,000/- dated 05.03.2019  Pharmacological Group Benzimidazole derivatives.  Type of Form Form 5  Finished Product Specification The firm has claimed USP specs.  Pack size & Demanded Price 10ml; As per SRO  Approval status of product in Reference Regulatory Authorities.  Me-too status Nenzole Suspension. Reg. No. 25891  GMP status GMP certificate issued on the basis of inspection 12.08.2020	trial	
Composition  Each 5ml Contains: Albendazole100mg  Diary No. Date of R& I & fee  Dy. No. 12710 dated 06.03.2019  Rs. 20,000/- dated 05.03.2019  Pharmacological Group  Benzimidazole derivatives.  Type of Form  Form 5  Finished Product Specification  Pack size & Demanded Price  Approval status of product in  Reference Regulatory Authorities.  Me-too status  Me-too status  GMP status  GMP certificate issued on the basis of inspection 12.08.2020		
Albendazole100mg  Diary No. Date of R& I & fee  Dy. No. 12710 dated 06.03.2019  Rs. 20,000/- dated 05.03.2019  Pharmacological Group  Benzimidazole derivatives.  Type of Form  Form 5  Finished Product Specification  Pack size & Demanded Price  Approval status of product in  Reference Regulatory Authorities.  Me-too status  Mestoo s		
Diary No. Date of R& I & fee  Dy. No. 12710 dated 06.03.2019  Rs. 20,000/- dated 05.03.2019  Pharmacological Group  Benzimidazole derivatives.  Type of Form  Form 5  Finished Product Specification  Pack size & Demanded Price  Approval status of product in  Reference Regulatory Authorities.  Me-too status  Meroo		
Rs. 20,000/- dated 05.03.2019  Pharmacological Group Benzimidazole derivatives.  Type of Form Form 5  Finished Product Specification The firm has claimed USP specs.  Pack size & Demanded Price 10ml; As per SRO  Approval status of product in Reference Regulatory Authorities.  Me-too status Nenzole Suspension. Reg. No. 25891  GMP status GMP certificate issued on the basis of inspection 12.08.2020		
Pharmacological Group  Type of Form  Finished Product Specification  Pack size & Demanded Price  Approval status of product in  Reference Regulatory Authorities.  Me-too status  GMP status  Pharmacological Group  Benzimidazole derivatives.  Form 5  The firm has claimed USP specs.  10ml; As per SRO  Zentel, 400 mg/20 ml. EMA approved in Poland.  Nenzole Suspension. Reg. No. 25891  GMP certificate issued on the basis of inspection in the basis of insp		
Type of Form Finished Product Specification Pack size & Demanded Price Approval status of product in Reference Regulatory Authorities. Me-too status  Menumber of Form 5 The firm has claimed USP specs.  10ml; As per SRO Zentel, 400 mg/20 ml. EMA approved in Poland.  Nenzole Suspension. Reg. No. 25891 GMP status GMP certificate issued on the basis of inspection 12.08.2020		
Finished Product Specification Pack size & Demanded Price Approval status of product in Reference Regulatory Authorities. Me-too status  Meroo		
Pack size & Demanded Price Approval status of product in Reference Regulatory Authorities.  Me-too status  Menumory		
Pack size & Demanded Price Approval status of product in Reference Regulatory Authorities.  Me-too status  Menumory		
Approval status of product in Reference Regulatory Authorities.  Me-too status  Mentoo Suspension. Reg. No. 25891  GMP certificate issued on the basis of inspection 12.08.2020		
Reference Regulatory Authorities.  Me-too status  Menzole Suspension. Reg. No. 25891  GMP status  GMP certificate issued on the basis of inspection in the b		
Me-too status  Menzole Suspension. Reg. No. 25891  GMP status  GMP certificate issued on the basis of inspection 12.08.2020		
GMP status GMP certificate issued on the basis of inspection 12.08.2020		
12.08.2020	n dated	
Remarks of the Evaluator. • The drug product specifications have not been eval		
	uated.	
• Undertaking at the end of Form 5 was missing. 's submitted signed undertaking.	The firm	
• Revised the pharmacological group from Benzin	nidozolo	
	iliuazole	
anthelmintic to Benzimidazole derivatives.		
• Submitted Rs. 7500/- fee challan- 797325135		
Decision: Approved.	41	
151. Name and address of manufacturer / M/s Rotex Pharma Pvt Ltd. Plot No. 206 & 207. Indus	trial	
Applicant Triangle, Kahuta Road, Islamabad		
Brand Name +Dosage Form + Strength Rodix Liquid Suspension Composition Each 5ml Contains:		
T		
Nalidixic Acid250mg		
Diary No. Date of R& I & fee Dy. No. 12710 dated 06.03.2019		
Rs. 20,000/- dated 05.03.2019 Pharmacological Group Quinolone antibiotic		
Type of Form Form 5		
31		
•		
, , ,		
Approval status of product in Reference Regulatory Authorities.  Could not be confirmed.		
Me-too status  NEGRAM 250MG SUP (does not depict quantity per Reg. No. 5237		
GMP status  GMP certificate issued on the basis of inspection 12.08.2020	5ml).	
Remarks of the Evaluator. • The drug product specifications have not been eval		

		• Undertaking at the end of Form 5 was missing. The firm		
		submitted signed undertaking.		
		<ul> <li>Submitted Rs. 7500/- fee challan- 218089680011.</li> <li>Provide proof of international availability in the reference regulatory agencies as defined by the registration board in</li> </ul>		
		its 275 <sup>th</sup> meeting.		
		national availability in the reference regulatory agencies as		
	defined by the registration board in its			
152.	Name and address of manufacturer /	M/s Rotex Pharma Pvt Ltd. Plot No. 206 & 207. Industrial		
	Applicant	Triangle, Kahuta Road, Islamabad		
	Brand Name +Dosage Form + Strength	Clotex 25mg Tablet		
	Composition	Each Film Coated Tablet Contains:		
	Diama Na Data af D.O. I. O. fara	Clomipramine Hcl25mg		
	Diary No. Date of R& I & fee	Dy. No. 12703 dated 06.03.2019		
	Discourse 1 - 2 - 1 Comme	Rs. 20,000/- dated 05.03.2019		
	Pharmacological Group	Non-selective monoamine reuptake inhibitors		
	Type of Form	Form 5		
	Finished Product Specification	The firm has claimed in-house specs.		
	Pack size & Demanded Price	2x10's, 10x10's; As per SRO		
	Approval status of product in	PLACIL clomipramine hydrochloride 25mg film coated tablet		
	Reference Regulatory Authorities. Me-too status	TGA approved Clomixet-25mg Tablet by M/s FYNK Pharmaceuticals (Reg#		
	Me-too status	065861)		
	GMP status	GMP certificate issued on the basis of inspection dated		
		12.08.2020		
	Remarks of the Evaluator.	• The drug product specifications have not been evaluated.		
		• Revised the pharmacological group from tricyclic		
		antidepressant to Non-selective monoamine reuptake		
		inhibitors.		
		• Submitted Rs. 7500/- fee challan- 078106825310		
	Decision: Approved with innovator's s	specifications.		
153.	Name and address of manufacturer /	M/s Remington Pharmaceuticals Industries Pvt Ltd. 18 km,		
	Applicant	Multan Road, Lahore		
	Brand Name +Dosage Form + Strength	Avirone Cream 0.1%		
	Composition	Each Gram Contains:		
		Methylprednisolone Aceponate1mg		
	Diary No. Date of R& I & fee	Dy. No.11771 dated 06.03.2019		
		Rs. 20,000/- dated 06.03.2019		
	Pharmacological Group	Corticosteroids, potent (group III)		
	Type of Form	Form 5		
	Finished Product Specification	The firm has claimed in-house specs.		
	Pack size & Demanded Price	15g; Leader price		
	Approval status of product in Reference	ADVANTAN methylprednisolone aceponate 1mg/g cream		
	Regulatory Authorities.	tube e. TGA approved		
	Me-too status	Zema 1mg Cream. Reg. No. 81508		
	GMP status	The firm was inspected on 15-16.01.2018, wherein GMP was		
	Remarks of the Evaluator.	<ul><li>rated Good.</li><li>The drug product specifications have not been evaluated.</li></ul>		
		• Mentioned eye ointment form in the manufacturing		
		outlines. Later, revised it.		
		• Submitted Rs. 7500/- fee, challan- 603934211202		
	Decision: Annuaved with innevetor's	specifications. The firm shall submit valid GMP inspection		
	report / certificate before issuance of r	•		

154.	Name and address of manufacturer /	M/s Remington Pharmaceuticals Industries Pvt Ltd. 18 km,		
	Applicant	Multan Road, Lahore		
	Brand Name +Dosage Form + Strength	Deporin Cream 0.1%		
	Composition	Each Gram Contains:		
		Adapalene1mg		
	Diary No. Date of R& I & fee	Dy. No.11764 dated 06.03.2019		
		Rs. 20,000/- dated 06.03.2019		
	Pharmacological Group	Retinoids for topical use in acne		
	Type of Form	Form 5		
	Finished Product Specification	The firm has submitted copy of BP specs.		
	Pack size & Demanded Price	15g; Leader price		
	Approval status of product in Reference Regulatory Authorities.	Differin 0.1% Cream. MHRA approved		
	Me-too status	Adapal Cream 0.1%. Reg. No. 83838		
	GMP status	The firm was inspected on 15-16.01.2018, wherein GMP was rated Good.		
	Remarks of the Evaluator.	• The drug product specifications have not been evaluated.		
		• Revised the pharmacological group from topical		
		dermatological to Retinoids for topical use in acne.		
		• Mentioned eye ointment form in the manufacturing		
		outlines. Later, revised it.		
	• Submitted Rs. 7500/- fee, challan- 0047836021			
	Decision: Approved with innovator's specifications. The firm shall submit valid GMP inspection report / certificate before issuance of registration letter.			
155.	Name and address of manufacturer /	M/s Remington Pharmaceuticals Industries Pvt Ltd. 18 km.		
	Applicant	Multan Road, Lahore		
	Brand Name +Dosage Form + Strength	E Fine Cream 139mg		
	Composition	Each Gram Contains:		
		139mg of Anhydrous Eflornithine HCl as Eflornithine HCl Monohydrate150mg		
	Diary No. Date of R& I & fee	Dy. No.11760 dated 06.03.2019		
	Dialy No. Date of R& 1 & Ice	Rs. 20,000/- dated 06.03.2019		
	Pharmacological Group	Corticosteroids, potent (group III)		
	Type of Form	Form 5		
	Finished Product Specification	The firm has claimed in-house specs.		
	Pack size & Demanded Price	11e firm has claimed in-nouse specs.  15g; Leader price		
	Approval status of product in Reference	Vaniqa 11.5% (Eflornithine as HCl Monohydrate) cream		
	Regulatory Authorities.	MHRA approved and CIMA approved.		
	Me-too status	Hirsunil 11.5 % Cream (Eflornithine (as hydrochloride		
	We-too status	monohydrate) 11.5 %). Reg. No. 79993		
		Hairid Cream (Effornithine hydrochloride (as		
		monohydrate)13.9% w/w). Reg. No. 85721		
	GMP status	The firm was inspected on 15-16.01.2018, wherein GMP was rated Good.		
	Pamarks of the Evaluator			
	Remarks of the Evaluator.	• The drug product specifications have not been evaluated.		
	Remarks of the Evaluator.	<ul> <li>The drug product specifications have not been evaluated.</li> <li>Eflornithine HCl Monohydrate150mg eq. to.</li> </ul>		
	Remarks of the Evaluator.	<ul> <li>The drug product specifications have not been evaluated.</li> <li>Eflornithine HCl Monohydrate150mg eq. to.</li> <li>Eflornithine HCl139mg eq. to Eflornithine115mg</li> </ul>		
	Remarks of the Evaluator.	<ul> <li>The drug product specifications have not been evaluated.</li> <li>Eflornithine HCl Monohydrate150mg eq. to.</li> </ul>		
	Remarks of the Evaluator.	<ul> <li>The drug product specifications have not been evaluated.</li> <li>Eflornithine HCl Monohydrate150mg eq. to.</li> <li>Eflornithine HCl139mg eq. to Eflornithine115mg</li> </ul>		
	Remarks of the Evaluator.	<ul> <li>The drug product specifications have not been evaluated.</li> <li>Eflornithine HCl Monohydrate150mg eq. to. Eflornithine HCl139mg eq. to Eflornithine115mg</li> <li>Revised the pharmacological group from topical</li> </ul>		
	Remarks of the Evaluator.	<ul> <li>The drug product specifications have not been evaluated.</li> <li>Eflornithine HCl Monohydrate150mg eq. to.         Eflornithine HCl139mg eq. to Eflornithine115mg</li> <li>Revised the pharmacological group from topical dermatological to Other dermatologicals.</li> </ul>		
	Remarks of the Evaluator.	<ul> <li>The drug product specifications have not been evaluated.</li> <li>Eflornithine HCl Monohydrate150mg eq. to.         Eflornithine HCl139mg eq. to Eflornithine115mg</li> <li>Revised the pharmacological group from topical dermatological to Other dermatologicals.</li> <li>Applied for 139mg of Anhydrous Eflornithine HCl as</li> </ul>		
	Remarks of the Evaluator.	<ul> <li>The drug product specifications have not been evaluated.</li> <li>Eflornithine HCl Monohydrate150mg eq. to.         Eflornithine HCl139mg eq. to Eflornithine115mg</li> <li>Revised the pharmacological group from topical dermatological to Other dermatologicals.</li> <li>Applied for 139mg of Anhydrous Eflornithine HCl as Eflornithine HCl Monohydrate150mg. then, revised the label claim to Eflornithine as HCl</li> </ul>		
	Remarks of the Evaluator.	<ul> <li>The drug product specifications have not been evaluated.</li> <li>Eflornithine HCl Monohydrate150mg eq. to.         Eflornithine HCl139mg eq. to Eflornithine115mg</li> <li>Revised the pharmacological group from topical dermatological to Other dermatologicals.</li> <li>Applied for 139mg of Anhydrous Eflornithine HCl as Eflornithine HCl Monohydrate150mg. then, revised</li> </ul>		

		• Mentioned eye ointment form in the manufacturing			
		outlines. Later, revised it.			
	• Submitted Rs. 7500/- fee, challan- 38506904				
	Decision: Approved with innovator's specifications. The firm shall submit valid GMP inspection				
	report / certificate before issuance of re				
156.	Name and address of manufacturer /	M/s Remington Pharmaceuticals Industries Pvt Ltd. 18 km,			
150.	Applicant	Multan Road, Lahore			
	Brand Name +Dosage Form + Strength	MMS Cream 0.1%			
	Brand Name +Dosage Form + Strength	WIND Cleam 0.170			
	Composition	Each Gram Contains:			
	Composition	Mometasone Furoate1mg			
	Diary No. Date of R& I & fee	Dy. No.11746 dated 06.03.2019			
	Blary 100. Bute of fee 1 & fee	Rs. 20,000/- dated 06.03.2019			
	Pharmacological Group	Corticosteroids, potent (group III)			
	Type of Form	Form 5			
	Finished Product Specification				
	Finished Floduct Specification	The firm has attached the monograph of BP. The product also available in USP.			
	Park size & Domandad Price				
	Pack size & Demanded Price	5g; Leader price			
	Approval status of product in Reference	ELOCON® (mometasone furoate) Cream, 0.1% for topical			
	Regulatory Authorities.	use by Merck Sharp Dohme. US-FDA approved			
	Me-too status	Hivate Creamby Saffron Pharma. Reg. No. 46432			
	GMP status	The firm was inspected on 15-16.01.2018, wherein GMP was rated Good.			
	Remarks of the Evaluator.	• The drug product specifications have not been evaluated.			
		• Revised the pharmacological group to Corticosteroids,			
		potent (group III).			
		• Submitted Rs. 7500/- fee, challan- 2118281789			
	Decision: Approved with BP specifications. The firm shall submit valid GMP inspection report /				
	certificate before issuance of registration letter.				
157.	Name and address of manufacturer /	M/s Remington Pharmaceuticals Industries Pvt Ltd. 18 km,			
	Applicant	Multan Road, Lahore			
	Brand Name +Dosage Form + Strength	MMS Ointment 0.1%			
	Composition	Each Gram Contains:			
		Mometasone Furoate1mg			
	Diary No. Date of R& I & fee	Dy. No.11745 dated 06.03.2019			
		Rs. 20,000/- dated 06.03.2019			
	Pharmacological Group	Corticosteroids, potent (group III)			
	Type of Form	Form 5			
	Finished Product Specification	The firm has attached the monograph of BP. The product is			
		also available in USP.			
	Pack size & Demanded Price	5g; Leader price			
	Approval status of product in Reference	Mometasone furoate 0.1% w/w Ointment. MHRA approved			
	Regulatory Authorities.				
	Me-too status	Momate 0.1% Ointment. Reg. No. 83745			
	GMP status	The firm was inspected on 15-16.01.2018, wherein GMP was			
		rated Good.			
	Remarks of the Evaluator.	• The drug product specifications have not been evaluated.			
		• Revised the pharmacological group to Corticosteroids,			
		potent (group III).			
		• Mentioned eye ointment form in the manufacturing			
		outlines. Later, revised it.			
		• Submitted Rs. 7500/- fee, challan- 9953161229			
1	Decision: Approved with BP specifications. The firm shall submit valid GMP inspection report / certificate before issuance of registration letter.				
	cartificate hafare iccurance of registration	on letter			

158.	Name and address of manufacturer /	M/s Remington Pharmaceuticals Industries Pvt Ltd. 18 km,		
100.	Applicant Applicant	Multan Road, Lahore		
	Brand Name +Dosage Form + Strength	MMS Lotion 0.1%		
	Composition	Each Gram Contains:		
	Composition	Mometasone Furoate1mg		
	Diary No. Date of R& I & fee	Dy. No.11745 dated 06.03.2019		
	Diary No. Date of R& T& Ice	Rs. 20,000/- dated 06.03.2019		
	Pharmacological Group	Corticosteroids, potent (group III)		
	Type of Form	Form 5		
	Finished Product Specification	The firm has attached the monograph of BP. The product is		
	Timished Troddet Specification	available in BP as Mometasone Scalp Application.		
	Pack size & Demanded Price	30ml; Leader price		
	Approval status of product in Reference	Elocon 0.1% w/w Scalp Lotion. MHRA approved		
	Regulatory Authorities.			
	Me-too status	Momate 0.1% Lotion. Reg. No. 83744		
	GMP status	The firm was inspected on 15-16.01.2018, wherein GMP was		
		rated Good.		
	Remarks of the Evaluator.	• The drug product specifications have not been evaluated.		
		• Mentioned eye ointment form in the manufacturing		
		outlines. Later, revised it.		
		• Submitted Rs. 7500/- fee, challan- 943426384700		
	Desisions Annuaved with DD enseificet			
	Decision: Approved with BP specifications. The firm shall submit valid GMP inspection report / certificate before issuance of registration letter.			
159.	Name and address of manufacturer /	M/s Remington Pharmaceuticals Industries Pvt Ltd. 18 km,		
	Applicant	Multan Road, Lahore		
	Brand Name +Dosage Form + Strength	Terbirem cream 1%		
	Composition	Each Gram Contains:		
		Terbinafine HCl10mg		
	Diary No. Date of R& I & fee	Dy. No.11750 dated 06.03.2019		
		Rs. 20,000/- dated 06.03.2019		
	Pharmacological Group	Antifungals for topical use		
	Type of Form	Form 5		
	Finished Product Specification	Not submitted. Then, claimed in-house specs available in JP.		
	Pack size & Demanded Price	5g; Leader price		
	Approval status of product in Reference	LAMISIL 1% w/w Cream. USFDA Approved		
	Regulatory Authorities.	Tarbidarm Craam 1% (Pag#032004)		
	Me-too status	Terbiderm Cream 1% (Reg#032004)		
	GMP status	The firm was inspected on 15-16.01.2018, wherein GMP was rated Good.		
	Remarks of the Evaluator.	• The drug product specifications have not been evaluated.		
		• Mentioned blistering step and eye ointment form in the		
		manufacturing outlines. Then, revised it.		
		• Submitted Rs. 7500/- fee, challan- 4437097793		
	Decision: Approved with JP specifications. The firm shall submit valid GMP inspection report /			
	certificate before issuance of registration letter.			
160.	Name and address of manufacturer /	M/s Remington Pharmaceuticals Industries Pvt Ltd. 18 km,		
	Applicant	Multan Road, Lahore		
	Brand Name +Dosage Form + Strength	Retaval cream 0.1%		
	Composition	Each Gram Contains:		
	_	Betamethasone as Valerate1mg		
	Diary No. Date of R& I & fee	Dy. No.11754 dated 06.03.2019		
		Rs. 20,000/- dated 06.03.2019		
	Pharmacological Group	Corticosteroids		
	Type of Form	Form 5		

	Finished Product Specification	The firm has submitted copy of BP specs. available in BP.		
	Pack size & Demanded Price	5g, 10g; Leader price		
	Approval status of product in Reference	Betamethasone (as) Valerate 0.1% w/w Cream. MHRA		
	Regulatory Authorities.	Approved		
	Me-too status	Beason Cream 0.1%. Reg. No. 80082		
	GMP status	The firm was inspected on 15-16.01.2018, wherein GMP was		
		rated Good.		
	Remarks of the Evaluator.	• The drug product specifications have not been evaluated.		
		• Mentioned NLT 15g filling, but the applied pack size is 5g		
		and 15g. then, revised it.		
		• Submitted Rs. 7500/- fee challan- 208859634230.		
	Decision: Approved with BP specification certificate before issuance of registration	ions. The firm shall submit valid GMP inspection report / n letter.		
161.	Name and address of manufacturer /	M/s Remington Pharmaceuticals Industries Pvt Ltd. 18 km,		
	Applicant	Multan Road, Lahore		
	Brand Name +Dosage Form + Strength	Retaval Lotion 0.1%		
	Composition	Each Gram Contains:		
		1% lotion contains 1.2mg of Betamethasone Valerate (eq. to		
		1mg Betamethasone)		
	Diary No. Date of R& I & fee	Dy. No.11756 dated 06.03.2019		
		Rs. 20,000/- dated 06.03.2019		
	Pharmacological Group	Corticosteroids		
	Type of Form	Form 5		
	Finished Product Specification	The firm has submitted copy of BP specs. available in BP.		
	Pack size & Demanded Price	60ml; Leader price		
	Approval status of product in Reference	Betnovate Lotion (Betamethasone Valerate 0.122% w/w).		
	Regulatory Authorities.	MHRA Approved		
Me-too status B.M.T Lotion 0.1%/gm. Reg.		B.M.T Lotion 0.1%/gm. Reg. No. 72710		
	GMP status	The firm was inspected on 15-16.01.2018, wherein GMP was		
		rated Good.		
	Remarks of the Evaluator.	• The drug product specifications have not been evaluated.		
		• Applied for w/w, however, the master formula and pack		
		size were mentioned in ml. then, revised it to grams.		
		• Submitted Rs. 7500/- fee challan- 27671491529		
	<b>Decision: Approved with BP specificati</b>	ons. The firm shall submit Rs. 22,500 fee for correction in		
	formulation and valid GMP inspection	report / certificate before issuance of registration letter.		
162.	Name and address of manufacturer /	M/s Remington Pharmaceuticals Industries Pvt Ltd. 18 km,		
	Applicant	Multan Road, Lahore		
	Brand Name +Dosage Form + Strength	Recibet Ointment 50mcg/0.5mg		
	Composition	Each Gram Contains:		
		Calcipotriol As Monohydrate50mcg		
		Betamethasone As Dipropionate0.5mg		
	Diary No. Date of R& I & fee	Dy. No.11757 dated 06.03.2019		
		Rs. 20,000/- dated 06.03.2019		
	Pharmacological Group	Calcipotriol, Combinations		
	Type of Form	Form 5		
	Finished Product Specification	The firm has submitted copy of BP specs. available in BP.		
	Pack size & Demanded Price	15g; Leader price		
	Approval status of product in Reference	Calcipotriol (as monohydrate) /Betamethasone (as		
	Regulatory Authorities.	dipropionate) Sandoz 50 micrograms per g / 500 micrograms		
		per g ointment. MHRA approved		
	Me-too status	Calbet Ointment. Reg. No. 84025		
	GMP status	The firm was inspected on 15-16.01.2018, wherein GMP was		
		rated Good.		

Remarks of the Evaluator.	• The drug product specifications have not been evaluated.
	• Revised the pharmacological group from antipsoriatics to Calcipotriol, Combinations.
	• Mentioned eye ointment form in the manufacturing outlines. Later, revised it.
	• Initially applied for Betamethasone As Dipropionate, then, revised Betamethasone As Dipropionate to Betamethasone in the label claim.
	• Already adjusted the weights of API as per equivalency factors. Then, revised Calcipotriol As Monohydrate to Calcipotriol as Monohydrate 52.2mg eq. to calcipotirol50mcg in master formula and 5.24mg in master formula (100kg).
	• Already adjusted the weights of API as per equivalency factors the, revised Betamethasone As Dipropionate 0.643mg to Betamethasone as Dipropionate eq. to betamethasone 0.5mg in the unit formula and 64g in
Decision: Deferred for:	master formula (100kg).  • Submitted Rs. 7500/- fee, challan- 6877773434

### **Decision: Deferred for:**

- Revision of label claim as per the innovator's product along with submission of Rs.22500/-.
- Submission of valid GMP inspection report onducted within a period of last three years.

,	Name and address of manufacturer /	M/s Remington Pharmaceuticals Industries Pvt Ltd. 18 km,		
•	Applicant	Multan Road, Lahore		
ŀ	Brand Name +Dosage Form + Strength	Nasorem nasal spray 0.25mg		
-	Composition	Each ml Contains:		
	Composition	Flunisolide0.25mg		
-	Diary No. Date of R& I & fee	Dy. No.11748 dated 06.03.2019		
	2102) 1101 2 000 01 100 1 00 100	Rs. 20,000/- dated 06.03.2019		
-	Pharmacological Group	Corticosteroids		
-	Type of Form	Form 5		
-	Finished Product Specification	The firm has claimed USP specs.		
	Pack size & Demanded Price	15ml; Leader price		
	Approval status of product in Reference	Flunisolide Nasal Solution (spray) 0.025%		
	Regulatory Authorities.	(0.025MG/SPRAY). USFDA approved		
	Me-too status	Synex Nasal Spray 0.025% w/v. Reg. No. 33925		
	GMP status	The firm was inspected on 15-16.01.2018, wherein GMP was rated Good.		
	Remarks of the Evaluator.	• The drug product specifications have not been evaluated.		
		• Revised the pharmacological group from glucocorticoids to "corticosteroids".		
		• Applied for 15ml, while it was 25ml in the manufacturing outlines. Then, revised it.		
		• Submitted Rs. 7500/- fee, challan- 25572667290		
		• The firm was asked to demonstrate that the spray will		
		deliver the quantity of API as per the reference produc		
	The frim submitted undertaking that they wil			
spray delivery before marketing the product.				
}	Decision: Approved with USP specifics:	ations. The firm shall submit valid GMP inspection report /		

certificate before issuance of registration letter.

164.	Name and address of manufacturer /	M/s Remington Pharmaceuticals Industries Pvt Ltd. 18 km.			
1010	Applicant Applicant				
	Brand Name +Dosage Form + Strength	<ul> <li>Revised the pharmacological group from dermatologic preparations to "Other dermatologicals".</li> <li>Submitted Rs. 7500/- fee, challan- 980970263</li> <li>pecifications. The firm shall submit valid GMP inspection in the firm shall submit valid GMP inspection in the firm shall submit valid GMP inspection in the firm shall submit valid GMP inspection in the firm shall submit valid GMP inspection in the firm shall submit valid GMP inspection in the firm shall submit valid GMP inspection in the firm shall submit valid GMP inspection in the firm shall submit valid GMP inspection.</li> <li>Revised the pharmacological group from dermatological preparations to "Other dermatologicals".</li> <li>Submitted Rs. 7500/- fee, challan- 60830591584</li> <li>pecifications. The firm shall submit valid GMP inspection.</li> </ul>			
	Composition				
	Composition				
	Diary No. Date of R& I & fee				
	Dialy No. Date of R& 1 & Ice	1 *			
	Pharmacological Group				
	Type of Form				
	31				
	Finished Product Specification				
	Pack size & Demanded Price				
	Approval status of product in Reference				
	Regulatory Authorities.				
	Me-too status	e			
	GMP status	•			
	Remarks of the Evaluator.	• The drug product specifications have not been evaluated.			
		• Revised the pharmacological group from dermatological			
		preparations to "Other dermatologicals".			
		• Submitted Rs. 7500/- fee, challan- 980970263			
	Decision: Approved with innovator's si	I '			
	report / certificate before issuance of re				
165.	Name and address of manufacturer /	<u> </u>			
100.	Applicant				
	Brand Name +Dosage Form + Strength	·			
	Composition				
	Composition				
Diary No. Date of R& I & fee					
	Biany 110. Bate of Rec 1 & 100				
	Pharmacological Group				
	Type of Form				
	Finished Product Specification				
	Pack size & Demanded Price				
	Approval status of product in Reference	•			
	Regulatory Authorities.	· · · · · · · · · · · · · · · · · · ·			
	Regulatory Authornties.	,			
	Me-too status				
	GMP status				
	Givir status				
	Remarks of the Evaluator.	• The drug product specifications have not been evaluated.			
		• Revised the pharmacological group from dermatological			
	T	I.			
	Decision: Approved with innovator's specifications. The firm shall submit valid GMP inspection report / certificate before issuance of registration letter.				
166.	Name and address of manufacturer /	M/s Remington Pharmaceuticals Industries Pvt Ltd. 18 km,			
	Applicant	Multan Road, Lahore			
	Brand Name +Dosage Form + Strength	Tamsiflo Capsules 0.4/0.5mg			
	Composition	Each Capsule Contains:			
	r	Tamsulosin HCl (as modified release pellets)0.4mg			
		Dutasteride (in soft gel capsule)0.5mg			
	Diary No. Date of R& I & fee	Dy. No.11769 dated 06.03.2019			
		Rs. 20,000/- dated 06.03.2019			
	Pharmacological Group	Other dermatologicals			
L	I marmucorogram Group	Care deliminotogram			

Type of Form	Form 5	
Finished Product Specification	The firm has claimed in-house specifications.	
Pack size & Demanded Price	1x10's; Leader price	
Approval status of product in Reference	JALYN (dutasteride and tamsulosin hydrochloride) capsules.	
Regulatory Authorities.	USFDA approved.	
Me-too status	Tamsol-D Capsule. Reg. No. 80305	
GMP status	The firm was inspected on 15-16.01.2018, wherein GMP was	
	rated Good.	
Remarks of the Evaluator.	<ul> <li>The drug product specifications have not been evaluated.</li> </ul>	
	• Revised the pharmacological group from 5-alpha	
	reductase inhibitors and Alpha1A adrenoreceptor	
	antagonists to "tamsulosin and dutasteride".	
	• The firm was asked to provide the source of Tamsulosin	
	HCl (0.2%) pellets along with GMP certificate of the firm, COA and stability summary sheets of three batches	
	of the pellets. The firm submitted the data and the source	
	as "RA Chem Pharma Ltd., Plot No. A-19/C, A-23A &	
	A-23B, Road NO. 18, IDA Nacharam, Nacahram (V),	
	Uppal, Mechal, Malkajgiri, Hyderabad, Telangana, India.	
	The firm was asked to provide COA and stability summary	
	sheets of three batches of the pellets. The firm submitted	
	data accelerated stability data of 03 different batches,	
	while real time stability data for 03 other batches.	
	•	
	• The firm was asked to provide name of excipients used in	
	the Tamsulosin HCl (0.2%) pellets, in the composition /formula. The firm provided the same.	
	_	
	• The firm was asked to provide the source of dutasteride	
	soft gel capsules along with GMP certificate of the firm,	
	COA and stability summary sheets of three batches of	
	the capsules.	
	• The firm was asked to provide the source of dutasteride	
	soft gel capsules along with GMP certificate of the firm.	
	The firm provided the source as "Hubei Gedian	
	Humanwell Pharmaceuticla Co., Ltd., Dedian Economic	
	development district, E-Zhou City, Hubei Proivnce, China.	
	• The firm was asked to provide COA and stability summary	
	sheets of three batches of the dutasteride soft gel	
	capsules. The firm submitted accelerated stability data	
	of 03 batches, while real time stability data is for 25°C±2°C.	
	• The firm was asked to provide name of excipients used in	
	the dutasteride soft gel capsules, in the composition	
	/formula. The firm provided the same.	
	• Submitted Rs. 7500/- fee, challan- 8117678521.	
	• The firm shall adjust the weight of Tamsulosin HCl (0.2%)	
	pellets as per strength of the pellets.	
	• The firm shall adjust the weight of dutasteride as per as per	
	weight of the soft gel capsules in the composition	
	/formula.	
	, TOTHIGIG.	

	• For source of imported	pellets ar	nd imported so	ft gel
	capsules, submit applic	cable fee a	s per notification	ons 7-
	11/2012-B&A/DRAP	dated	07.05.2021	and
	13.07.2021.			

### **Decision: Deferred for submission of following:**

- Original, valid, legalized CoPP for dutasteride soft gelatin capsule.
- Valid sole agency agreement for imort of dutasteride soft gelatin capsule.
- Stability study data of both drug substances as per Zone IV-A conditions.
- Revision of master formulation in line with the innovator product along with submission of requisite fee.
- Evidence of requisite manufacturing facility confirming machine for folling of Tamsulosin pellets and Duterside soft gel capsule.
- Fee 15,0000/- for import of pellets as well as soft gelatin capsule.

	• Fee 15,0000/- for import of pene	ets as wen as soft geraun capsule.	
167.	Name and address of manufacturer /	M/s Remington Pharmaceuticals Industries Pvt Ltd. 18 km,	
	Applicant	Multan Road, Lahore	
	Brand Name +Dosage Form + Strength	Merigon Tablet 50mg	
	Composition	Each Prolonged Release Tablet Contains:	
		Mirabegron50mg	
	Diary No. Date of R& I & fee	Dy. No.11766 dated 06.03.2019	
		Rs. 20,000/- dated 06.03.2019	
	Pharmacological Group	Drugs for urinary frequency and incontinence	
	Type of Form	Form 5	
	Finished Product Specification	The firm has claimed in-house specifications.	
	Pack size & Demanded Price	10's; Leader price	
	Approval status of product in Reference	MYRBETRIQ® extended-release (film-coated) tablet, for	
	Regulatory Authorities.	oral administration contains either 25 mg or 50 mg. USFDA	
		approved	
	Me-too status	New molecule	
	GMP status	The firm was inspected on 15-16.01.2018, wherein GMP was	
		rated Good.	
	Remarks of the Evaluator.	• The drug product specifications have not been evaluated.	
		• Revised the pharmacological group to "Drugs for urinary	
		frequency and incontinence".	
		• Submitted Rs. 7500/- fee, challan- 461519824	
		• The firm was asked to submit stability data as per zone IV-	
		A. the firm submitted commitment.	
	Decision: Deferred for submission of real time and accelerated stability data of 03 batches of pellets		
	conducted in zone IV-A.		
168.	Name and address of manufacturer /	M/s Remington Pharmaceuticals Industries Pvt Ltd. 18 km,	
	Applicant	Multan Road, Lahore	
	Brand Name +Dosage Form + Strength	Terbirem 250mg Tablet	
	Composition	Each Tablet Contains:	
		Terbinafine as HCl250mg	
	Diary No. Date of R& I & fee	Dy. No.11750 dated 06.03.2019	
		Rs. 20,000/- dated 06.03.2019	
	Pharmacological Group	Antifungals for topical use	
	Type of Form	Form 5	
	Finished Product Specification	The firm has claimed USP specs.	
	Pack size & Demanded Price	1x10's; Leader price	
	Approval status of product in Reference	Lamisil® Tablets 250mg. MHRA Approved.	
	Regulatory Authorities.		
	Me-too status	Logirid Tablet 250mg, Reg No. 80847	

	GMP status	The firm was inspected on 15-16.01.2018, wherein GMP was rated Good.
	Remarks of the Evaluator.	• The drug product specifications have not been evaluated.
		• Revised the pharmacological group from other antifungal
		agent to Antifungals for systemic use.
		• Revised the term purified in the first step of the
		manufacturing outlines to purified.
		• Submitted Rs. 7500/- fee, challan- 1131915386
	Decision: Approved.	
169.	Name and address of manufacturer / Applicant	M/s Remington Pharmaceuticals Industries Pvt Ltd. 18 km, Multan Road, Lahore
	Brand Name +Dosage Form + Strength	Renide Tablet 1mg
	Composition	Each Film Coated Tablet Contains:
		Finasteride1mg
	Diary No. Date of R& I & fee	Dy. No.11744 dated 06.03.2019
		Rs. 20,000/- dated 06.03.2019
	Pharmacological Group	Antifungals for topical use
	Type of Form	Form 5
	Finished Product Specification	The firm has claimed USP specs.
	Pack size & Demanded Price	30's; Leader price
	Approval status of product in Reference	Finasteride 1mg Film-coated Tablets. MHRA approved
	Regulatory Authorities.	
	Me-too status	Prosin Tablet film-coated, 1mg. Reg. No. 83852
	GMP status	The firm was inspected on 15-16.01.2018, wherein GMP was
		rated Good.
	Remarks of the Evaluator.	• The drug product specifications have not been evaluated.
		• Revised the pharmacological group from 5-alpha reductase inhibitors to Testosterone-5-alpha reductase inhibitors.
		• Submitted Rs. 7500/- fee, challan- 2922771233
	Decision: Approved.	
170.	Name and address of manufacturer /	M/s Rotex Pharma Pvt Ltd. Plot No. 206 & 207. Industrial
	Applicant	Triangle, Kahuta Road, Islamabad
	Brand Name +Dosage Form + Strength	Soliget 10mg Tablet
	Composition	Each Film Coated Tablet Contains:
		Solifenacin Succinate 10mg Eq. To Solifenacin7.5mg
	Diary No. Date of R& I & fee	Dy. No. 12685 dated 06.03.2019
		Rs. 20,000/- dated 05.03.2019
	Pharmacological Group	Drugs for urinary frequency and incontinence
	Type of Form	Form 5
	Finished Product Specification	The firm has claimed in-house specs.
	Pack size & Demanded Price	10's, 30's; As per SRO
	Approval status of product in	Solifenacin 10 mg film-coated tablets (Each film-coated tablet
	Reference Regulatory Authorities.	contains 10 mg solifenacin succinate, corresponding to 7.5 mg
	26	solifenacin). MHRA approved
	Me-too status	Solcina 10mg Tablet (Solifenacin Succinate 10 mg eq. to Solifenacin7.5mg). Reg. No. 82201
	GMP status	GMP certificate issued on the basis of inspection dated 12.08.2020
	Remarks of the Evaluator.	• The drug product specifications have not been evaluated.
		• Undertaking at the end of Form 5 is missing.
		• Revised the pharmacological group from antimuscarinic to
		Drugs for urinary frequency and incontinence.
-		

		• Submitted Rs. 7500/- fee, challan- 34136797333
	<b>Decision: Approved with innovator's s</b>	
171.	Name and address of manufacturer / Applicant	M/s Rotex Pharma Pvt Ltd. Plot No. 206 & 207. Industrial Triangle, Kahuta Road, Islamabad
	Brand Name +Dosage Form + Strength	Fosvex 500mg Capsule
	Composition	Each Capsule Contains:
		Fosfomycin Calcium Eq. To Fosfomycin500mg
	Diary No. Date of R& I & fee	Dy. No. 12677 dated 06.03.2019 Rs. 20,000/- dated 05.03.2019
	Pharmacological Group	Antibiotic
	Type of Form	Form 5
	Finished Product Specification	The firm has claimed in-house specs.
	Pack size & Demanded Price	10's, 12's, 50's, 100's; As per SRO
	Approval status of product in Reference	Calcium Fosfomycin Solufos 500 mg hard capsules. CIMA
	Regulatory Authorities.	approved
	Me-too status	Cynfo 500mg Capsule. Reg. No. 73702
	GMP status	GMP certificate issued on the basis of inspection dated 12.08.2020
	Remarks of the Evaluator.	• The drug product specifications have not been evaluated.
		<ul> <li>Undertaking at the end of Form 5 is missing. The firm submitted the undertaking.</li> <li>Already adjusted the weight of API in master formula. The</li> </ul>
		firm was asked to revise "Fosfomycin calcium eq. to 500mg Fosfomycin" to "Fosfomycin calcium" with correct adjustment as per salt factor. The firm revised
		Fosfomycin calcium to Fosfomycin calcium monohydrate in the label claim. Later on, the firm
		submitted an undertaking that the master formulation is Fosfomycin calcium eq. to 500mg Fosfomycin is equal to 630mg, the firm requested for withdrawal of the reply
		submitted with monohydrate form.
		• The firm submitted Rs. 7500/- fee, challan- 25606506680
	Decision: Approved with innovator's su	pecifications and submission of differential fee.
172.	Name and address of manufacturer /	M/s Welmed Pharmaceuticals Industries (Pvt) Ltd. Plot #
1,2,	Applicant	108, R-2, Industrial Estate Gadoon, Swabi
	Brand Name +Dosage Form + Strength	Onised 8mg Tablet
	Composition	Each Film Coated Tablet Contains:
	1	Ondansetron as HCl dihydrate8mg
	Diary No. Date of R& I & fee	Dy. No.12357 dated 06.03.2019
		Rs. 20,000/- dated 04.03.2019
	Pharmacological Group	Serotonin (5HT3) antagonists
	Type of Form	Form 5
	Finished Product Specification	The firm has claimed USP specifications.
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities.	Ondansetron 8 mg Film-coated Tablets. MHRA approved
	Me-too status	Ondan Tablet film-coated 8mg. Reg No. 82657
	GMP status	Firm has submitted copy of inspection report dated 17-09-2020 which confirms fair level of compliance with GMP
		guidelines. The firm should rectify all observations mentioned in the report.
	Remarks of the Evaluator.	• The drug product specifications have not been evaluated.
		51

	1	
	Decision: Deferred for:	<ul> <li>Revised the pharmacological group from selective Serotonin (5HT3) receptor antagonists to Serotonin (5HT3) antagonists.</li> <li>Already adjusted the weight of the API in master formulation. But did not revise Ondansetron as HCl dihydrate to Ondansetron HCl dihydrate in master formulation.</li> <li>Submitted Rs. 7500/- fee, challan- 15513550</li> </ul>
	formulation.	Cl dihydrate to Ondansetron HCl dihydrate in master
	<ul> <li>Updated satisfactory GMP inspection</li> </ul>	ection status from QA< Division
173.	Name and address of manufacturer /	M/s Welmed Pharmaceuticals Industries (Pvt) Ltd. Plot #
	Applicant	108, R-2, Industrial Estate Gadoon, Swabi
	Brand Name +Dosage Form + Strength	Zapin 10mg Tablet
	Composition	Each Film Coated Tablet Contains:
	Composition	Olanzapine10mg
	D' N D ( CD 0 I 0 C	
	Diary No. Date of R& I & fee	Dy. No.12392 dated 06.03.2019
		Rs. 20,000/- dated 06.03.2019
	Pharmacological Group	atypical antipsychotics
	Type of Form	Form 5
	Finished Product Specification	The firm has claimed USP specifications.
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference	Olanzapine 10mg Film-coated tablets. MHRA approved
	Regulatory Authorities.	oranzapine roing rimi coated tablets: wirita rapproved
	Me-too status	Olanzpine 10mg tablets. Reg. No. 81661
	GMP status	Firm has submitted copy of inspection report dated 17-09-
	GIVIF status	2020 which confirms fair level of compliance with GMP guidelines. The firm should rectify all observations mentioned in the report.
	Remarks of the Evaluator.	• The drug product specifications have not been evaluated.
		<ul> <li>Revised the Pharmacological Group from atypical antipsychotics to Diazepines, oxazepines, thiazepines and oxepines</li> <li>Revised Olanzapine5mg to Olanzapine10mg in</li> </ul>
		formula/composition.
		• Submitted Rs. 7500/- fee, challan- 50964860715.
		r shall be issued after having updated satisfactory GMP
		. Moreover, firm shall submit fee Rs. 22,500 for correction
15.4	in the formulation.	M/ W/ 1 1 DI
174.	Name and address of manufacturer /	M/s Welmed Pharmaceuticals Industries (Pvt) Ltd. Plot #
	Applicant	108, R-2, Industrial Estate Gadoon, Swabi
	Brand Name +Dosage Form + Strength	Zapin 5mg Tablet
	Composition	Each Film Coated Tablet Contains:
		Olanzapine5mg
	Diary No. Date of R& I & fee	Dy. No.12393 dated 06.03.2019
		Rs. 20,000/- dated 06.03.2019
	Pharmacological Group	atypical antipsychotics
	Type of Form	Form 5
	Finished Product Specification	The firm has claimed USP specifications.
	Pack size & Demanded Price	
		As per SRO
	Approval status of product in Reference Regulatory Authorities.	Olanzapine 5mg Film-coated tablets. MHRA approved
	Me-too status	Olanzpine 5mg tablets. Reg. No. 81660
		r

	GMP status	Firm has submitted copy of inspection report dated 17-09-2020 which confirms fair level of compliance with GMP guidelines. The firm should rectify all observations mentioned in the report.
	Remarks of the Evaluator.	• The drug product specifications have not been evaluated.
		<ul> <li>Revised Olanzapine5.07mg to Olanzapine5mg in formula/composition.</li> <li>Submitted Rs. 7500/- fee, challan- 2411829601</li> </ul>
	Decision: Approved. Registration letter	r shall be issued after having updated satisfactory GMP
	inspection status from QA< Division in the formulation.	. Moreover, firm shall submit fee Rs. 22,500 for correction
175.	Name and address of manufacturer / Applicant	M/s Welmed Pharmaceuticals Industries (Pvt) Ltd. Plot # 108, R-2, Industrial Estate Gadoon, Swabi
	Brand Name +Dosage Form + Strength	Canowel V Cream 2%
	Composition	Each Gram Contains:
	Composition	Clotrimazole20mg
	Diary No. Date of R& I & fee	Dy. No.12354 dated 06.03.2019 Rs. 20,000/- dated 04.03.2019
	Pharmacological Group	Antiinfectives and antiseptics, excl. combinations with corticosteroids
	Type of Form	Form 5
	Finished Product Specification	The firm has claimed USP specifications.
	Pack size & Demanded Price	40g; As per SRO
	Approval status of product in Reference	SOUL PATTINSON ANTIFUNGAL CLOTRIMAZOLE
	Regulatory Authorities.	WOMEN'S TREATMENT 2% w/w vaginal cream tube. <b>TGA</b> approved
	Me-too status	Gytrim-V Cream 2%. Reg. No. 42646
	GMP status	Firm has submitted copy of inspection report dated 17-09-
		2020 which confirms fair level of compliance with GMP
		guidelines. The firm should rectify all observations
		mentioned in the report.
	Remarks of the Evaluator.	• The drug product specifications have not been evaluated.
		<ul> <li>Was asked to revise the pharmacological group from gynecological antifungal to Antiinfectives and antiseptics, excl. combinations with corticosteroids; they revised it to imidazole. However, it is imidazole dervatives in ATC codes.</li> </ul>
		• The firm was asked to justify the use of petroleum jelly in the cream. The firm revised the excipients.
		• Added filling and packing process in the manufacturing outlines.
		• Submitted Rs. 7500/- fee, challan- 3625393050.
	Decision: Approved. Registration letter shall be issued after having updated satisfactory GMP inspection status from QA< Division.	
176.	Name and address of manufacturer /	M/s Welmed Pharmaceuticals Industries (Pvt) Ltd. Plot #
	Applicant	108, R-2, Industrial Estate Gadoon, Swabi
	Brand Name +Dosage Form + Strength	Tacmax 0.1% Ointment
	Composition	Each Gram Contains:
		Tacrolimus as Monohydrate1mg
	Diary No. Date of R& I & fee	Dy. No.12363 dated 06.03.2019
	Di li i c	Rs. 20,000/- dated 04.03.2019
	Pharmacological Group	Immunosuppressant
	Type of Form	Form 5
	Finished Product Specification	The firm has claimed in-house specifications.
	Pack size & Demanded Price	10g; As per SRO

	1	T 1' 1 1010/ ' 1 17TD 1
	Approval status of product in Reference Regulatory Authorities.	Tacrolimus Accord 0.1 % ointment. MHRA approved
	Me-too status	Limus 0.1% Ointment. Reg. No. 45215
	GMP status	Firm has submitted copy of inspection report dated 17-09-2020 which confirms fair level of compliance with GMP guidelines. The firm should rectify all observations mentioned in the report.
	Remarks of the Evaluator.	• The drug product specifications have not been evaluated.
		<ul> <li>Already adjusted the weight of the API in master formulation. Then, revised it from 1.0022 to 1.022mg and revised "Tacrolimus as Monohydrate" to Tacrolimus Monohydrate in master formulation.</li> <li>Added filling and packing process in the manufacturing outlines</li> <li>Submitted Rs. 7500/- fee, challan- 739339183023</li> </ul>
	Desigion: Approved with innevertor's sp	
	updated satisfactory GMP inspection st	ecifications. Registration letter shall be issued after having tatus from QA< Division. Moreover, firm shall submit
	fee Rs. 22,500 for correction in the form	
177.	Name and address of manufacturer /	M/s Welmed Pharmaceuticals Industries (Pvt) Ltd. Plot #
	Applicant	108, R-2, Industrial Estate Gadoon, Swabi
	Brand Name +Dosage Form + Strength	Tacmax 0.03% Ointment
	Composition	Each Gram Contains:
		Tacrolimus as Monohydrate0.3mg
	Diary No. Date of R& I & fee	Dy. No.12364 dated 06.03.2019
		Rs. 20,000/- dated 04.03.2019
	Pharmacological Group	Immunosuppressant
	Type of Form	Form 5
	Finished Product Specification	The firm has claimed in-house specifications.
	Pack size & Demanded Price	
	Approval status of product in Reference	10g; As per SRO Tacrolimus 0.03% Ointment. MHRA approved
	Regulatory Authorities.	1 acronnus 0.05% Omunent. WITKA approved
	Me-too status	Cuslim Cinturent Dec No. 40005
		Crolim Ointment Reg. No. 49005
	GMP status	Firm has submitted copy of inspection report dated 17-09-2020 which confirms fair level of compliance with GMP guidelines. The firm should rectify all observations mentioned in the report.
	Remarks of the Evaluator.	The drug product specifications have not been evaluated.
	Remarks of the Evaluator.	
		<ul> <li>Already adjusted the weight of the API in master formulation. Then, revised "Tacrolimus as Monohydrate" to Tacrolimus Monohydrate in master formulation.</li> <li>Added filling and packing process in the manufacturing outlines</li> </ul>
		• Submitted Rs. 7500/- fee, challan- 7913545650
	Decision: Approved with innovator's specifications. Registration letter shall be issued after having updated satisfactory GMP inspection status from QA< Division. Moreover, firm shall submit	
	fee Rs. 22,500 for correction in the form	
178.	Name and address of manufacturer /	M/s Welmed Pharmaceuticals Industries (Pvt) Ltd. Plot #
	Applicant	108, R-2, Industrial Estate Gadoon, Swabi
	Brand Name +Dosage Form + Strength	Risper 5mg/5ml Syrup
	Composition	Each 5ml Syrup Contains:
		Risperidone5mg
	Diary No. Date of R& I & fee	Dy. No.12362 dated 06.03.2019 Rs. 20,000/- dated 04.03.2019
	Pharmacological Group	
	Pharmacological Group	Antipsychotic

	Type of Form	Form 5
	Finished Product Specification	The firm has claimed USP specifications.
	Pack size & Demanded Price	30ml; As per SRO
	Approval status of product in Reference	Risperidone 1 mg/ml Oral Solution. MHRA Approved
	Regulatory Authorities.	
	Me-too status	Rispenia Oral Solution. Reg. No. 47728.
	GMP status	Firm has submitted copy of inspection report dated 17-09-
		2020 which confirms fair level of compliance with GMP
		guidelines. The firm should rectify all observations
		mentioned in the report.
	Remarks of the Evaluator.	• The drug product specifications have not been evaluated.
		Revised the term glusrine in the excipients to glycerine.
		Added packing process in the manufacturing outlines.
		Attached the tablet monograph.
		• Submitted Rs. 7500/- fee. 41985758355
	Decision: Approved. Registration lette inspection status from QA< Division	r shall be issued after having updated satisfactory GMP 1.
179.	Name and address of manufacturer /	M/s Titlis Pharma. 528-A, Sundar Industrial Estate, Raiwind
	Applicant	Road, Lahore
	Brand Name +Dosage Form + Strength	Duloxit 30mg Capsule
	Composition	Each Capsule Contains:
		176.5 mg of Duloxetine delayed release pellets30mg
	Diary No. Date of R& I & fee	Dy. No.11619 dated 06.03.2019
		Rs. 20,000/- dated 06.03.2019
	Pharmacological Group	Antidepressant
	Type of Form	Form 5
	Finished Product Specification	The firm has claimed USP specifications.
	Pack size & Demanded Price	1x10's; As per SRO
	Approval status of product in Reference	Dutor 30 mg gastro-resistant capsules, hard. MHRA
	Regulatory Authorities.	approved
	Me-too status	Oxcym DR 30 mg Capsule. Reg. No. 53101
	GMP status	GMP Certificate issued on the basis of inspection dated
		30.09.2020
	Remarks of the Evaluator.	• The drug product specifications have not been evaluated.
		• Revised the label claim from 176.5 mg of Duloxetine delayed release pellets (17%)30mg to "Duloxetine HCl delayed release pellets (17%) eq. to doluxetine30mg".
		Adjusted the weight of pelletes in master formula as per salt factor and strength of the pellets.
		Specified the capsule shell material in the master formula.
		Previously mentioned the granulation and compression in the manufacturing outlines. Then, revised it.
		• Previously did not provide the source of pellets along with GMP certificate of the firm, COA and stability summary sheets of three batches of the pellets. Then, provided these documents. The source of pellets is vision pharma, Islamabad

		• For revision, submit the applicable fee as per notifications 7-11/2012-B&A/DRAP dated 07.05.2021 and 13.07.2021.
	Decision: Approved. The firm shall su issuance of registration letter.	bmit Rs. 30,000 fee for correction in formulation before
180.	Name and address of manufacturer / Applicant Brand Name +Dosage Form + Strength	M/s Titlis Pharma. 528-A, Sundar Industrial Estate, Raiwind Road, Lahore Duloxit 60mg Capsule
	Composition	Each Capsule Contains: 353 mg of Duloxetine delayed release pellets60mg
	Diary No. Date of R& I & fee	Dy. No.11618 dated 06.03.2019 Rs. 20,000/- dated 06.03.2019
	Pharmacological Group	Antidepressant
	Type of Form	Form 5
	Finished Product Specification	The firm has claimed USP specifications.
	Pack size & Demanded Price	1x10's; As per SRO
	Approval status of product in Reference Regulatory Authorities.	Duloxetine 60 mg hard gastro-resistant capsules. <b>MHRA</b> approved
	Me-too status	Oxcym DR 60 mg Capsule. Reg. No. 53102
	GMP status	GMP Certificate issued on the basis of inspection dated 30.09.2020
	Remarks of the Evaluator.	• The drug product specifications have not been evaluated.
		• Revised the label claim from 353 mg of Duloxetine delayed release pellets (17%)30mg to "Duloxetine HCl delayed release pellets (17%) eq. to doluxetine30mg".
		• Adjusted the weight of pelletes in master formula as per salt factor and strength of the pellets.
		• Specified the capsule shell material in the master formula.
		• Previously mentioned the granulation and compression in the manufacturing outlines. Then, revised it.
		• Previously did not provide the source of pellets along with GMP certificate of the firm, COA and stability summary sheets of three batches of the pellets. Then, provided these documents. The source of pellets is vision pharma, Islamabad
		• For revision, submit the applicable fee as per notifications 7-11/2012-B&A/DRAP dated 07.05.2021 and 13.07.2021.
	Decision: Approved. The firm shall substitute issuance of registration letter.	mit Rs. 30,000 fee for correction in formulation before
181.	Name and address of manufacturer / Applicant	M/s Titlis Pharma. 528-A, Sundar Industrial Estate, Raiwind Road, Lahore
	Brand Name +Dosage Form + Strength	Sevela 400mg tablet
	Composition Composition	Each Film Coated Tablet Contains: Sevelamer HCl400mg
	Diary No. Date of R& I & fee	Dy. No.11617 dated 06.03.2019 Rs. 20,000/- dated 06.03.2019
	Pharmacological Group	Drugs for treatment of hyperkalemia and hyperphosphatemia
	Type of Form	Form 5

	Finished Product Specification	The firm has claimed in-house specifications.
	Pack size & Demanded Price	30's; As per SRO
	Approval status of product in Reference	RENAGEL tablet 400mg. USFDA approved
	Regulatory Authorities.	
	Me-too status	Renavel 400mg tablet. Reg. No. 073228
	GMP status	GMP Certificate issued on the basis of inspection dated 30.09.2020
	Remarks of the Evaluator.	• The drug product specifications have not been evaluated.
		Revised the pharmacological group from phosphate binder to "Drugs for treatment of hyperkalemia and hyperphosphatemia".
		<ul> <li>Added blistering and packing process in the manufacturing outlines.</li> </ul>
		• For revision, submit the applicable fee as per notifications 7-11/2012-B&A/DRAP dated 07.05.2021 and 13.07.2021.
	<b>Decision: Approved with innovator's sn</b>	ecifications. Firm shall submit fee of Rs. 7,500 for
		duct specifications, as per notification No.F.7-11/2012-
	B&A/DRAP dated 13-07-2021.	•
182.	Name and address of manufacturer /	M/s Titlis Pharma. 528-A, Sundar Industrial Estate, Raiwind
	Applicant	Road, Lahore
	Brand Name +Dosage Form + Strength	Sevela 800mg tablet
	Composition	Each Film Coated Tablet Contains:
	Diam. No. Data of D.C. I. C. for	Sevelamer HC1800mg  Dy. No.11616 dated 06.03.2019
	Diary No. Date of R& I & fee	Rs. 20,000/- dated 06.03.2019
	Pharmacological Group	Drugs for treatment of hyperkalemia and hyperphosphatemia
	Type of Form	Form 5
	Finished Product Specification	The firm has claimed in-house specifications.
	Pack size & Demanded Price	30's; As per SRO
	Approval status of product in Reference Regulatory Authorities.	RENAGEL tablet 800mg. USFDA approved
	Me-too status	Renavel 800mg tablet. Reg. No. 075510
	GMP status	GMP Certificate issued on the basis of inspection dated 30.09.2020
	Remarks of the Evaluator.	• The drug product specifications have not been evaluated.
		• Revised the pharmacological group from phosphate binder to "Drugs for treatment of hyperkalemia and hyperphosphatemia".
		• Added blistering and packing process in the manufacturing outlines.
		• For revision, submit the applicable fee as per notifications 7-11/2012-B&A/DRAP dated 07.05.2021 and 13.07.2021.
		duct specifications, as per notification No.F.7-11/2012-
L		A condo of Evoluctor DEC VI

Agenda of Evaluator PEC-XI

### Case No.01: Registration applications of New DML of human drugs on Form 5F

M/s Carer Pharmaceuticals Industries, Plot # 27, Main Road, Rawat Industrial Estate, Rawat.

The Central Licensing Board in its 278<sup>th</sup> meeting held on 10<sup>th</sup>-11<sup>th</sup> December, 2020 has considered and approved the grant of Drug Manufacturing License by way of formulation with following five sections to M/s, Carer Pharmaceuticals Industries Plot # 27, Main Road, Rawat Industrial Estate, Rawat under Drug Manufacturing License No. 000925 by way of Formulation vide approval letter No. F. 1-32/2016-Lic dated 07<sup>th</sup> June 2021. *The Drug Manufacturing License No. 000925 by way of formulation is hereby issued w.e.f. 18-03-2021*.

S No.	Section	
1.	Capsule Section (General) Section	
2.	Dry Powder Suspension (General) Section	
3.	Sachet (General) Section	
4.	Ampoule (General) Section	
5.	Tablet (General) Section	

Following applications have been submitted for registration by the firm.

183.	Name, address of Applicant / Marketing Authorization Holder	M/s, Carer Pharmaceuticals Industries, Plot # 27, Main Road, Rawat Industrial Estate, Rawat
	Name, address of Manufacturing site.	M/s, Carer Pharmaceuticals Industries. Plot # 27, Main Road, Rawat Industrial Estate, Rawat
	Status of the applicant	<ul><li>☑ Manufacturer</li><li>☐ Importer</li><li>☐ Is involved in none of the above (contract giver)</li></ul>
	Status of application	☐ New Drug Product (NDP) ☐ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	<ul><li>□ Domestic sale</li><li>□ Export sale</li><li>☑ Domestic and Export sales</li></ul>
	Dy. No. and date of submission	Dy. No. 29203 dated 26/10/2021
	Details of fee submitted	PKR 30,000/-: dated 18/10/2021
	The proposed proprietary name / brand name	Capliva 500mg tablet
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each film coated tablet contains: Azithromycin as dihydrate500mg
	Pharmaceutical form of applied drug	Tablet
	Pharmacotherapeutic Group of (API)	Macrolides
	Reference to Finished product specifications	USP Specifications
	Proposed Pack size	6's
	Proposed unit price	As per SRO
	The status in reference regulatory authorities	ZITHROMAX 250mg, 500mg film coated tablets, USFDA Approved

For generic drugs (n	ne-too status)	Azomax 500mg Tablet by M/s Novartis Pharma (Reg# 045415)
GMP status of the Fi	inished product	New license granted on 18/03/2021
Name and address o	f API manufacturer.	M/s Hebei Guolong Pharmaceutical Co, Ltd. No 9 Xingye street, Shijiazhuang Economic and Technological Development Zone, Hebei Province, China. Tel: 0086-575-82736468 Fax: 0086-575-82735575
Module-II (Quality (	Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, impurities, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product is submitted.
Module III (Drug Su	ibstance)	The firm has submitted detail of nomenclature, structure, general properties, solubilities, physical form, manufacturers, tests for impurities, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
Stability studies		Stability study conditions: Real time: $30^{\circ}\text{C} \pm 2^{\circ}\text{C} / 75\% \pm 5\%\text{RH}$ for 60 months
		Accelerated: $40^{\circ}\text{C} \pm 2^{\circ}\text{C} / 75\% \pm 5\%\text{RH}$ for 6 months Batches: (U129-141124-1, U129-141125-1, U129-141126-1)
Module-III (Drug Pr	oduct):	The firm has submitted detail of manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedure and its verification studies, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug product.
Pharmaceutical equi comparative dissolu		Pharmaceutical Equivalence has been performed against Azomax 500mg tablet by M/s Novartis Pharma performing quality tests (Identification, Assay, Dissolution, weight variation).  CDP has been performed against Azomax 500mg tablet by M/s Novartis Pharma in Acid media (pH 1.2), acetate buffer pH 4.5 & Phosphate Buffer (pH 6.8). The values for f1 and f2 are in the acceptable range.
Analytical method validation/verification of product		Method verification studies have submitted.
ABILITY STUDY DA	TA	
Lot No. 210507019		

Description of Pack (Container closure system)			White to off-white film coated tablet containing Azithromycin Dihydrate eq to 500mg Azithromycin Packed in Alu-Alu blister further packed in a printed unit carton along with the package insert.			
Stability Storage Condition		age Condition	Real time: 30°C ± 2°C / 65% ± 5%RH Accelerated: 40°C ± 2°C / 75% ± 5%RH			
Time	Period		Real time: 6 months Accelerated: 6 months			
Frequ	iency		Accelerated: 3, 6 (Months) Real Time: 3, 6, 9, 12, 18, 24 (Months)			
Batcl	n No.		T001	T002		T003
Batcl	n Size		2000 tab	2000	tab	2000 tab
Manı	ufacturin	g Date	16-03-2021	16-03	-2021	16-03-2021
Date	of Initiat	tion	16-03-2021	16-03	-2021	16-03-2021
No. o	of Batche	es .	03			·
Adm	inistrati	ve Portion	1			
7.	application (if	any)	ility study data of the	N/A	N/A	
8.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.		Not submitted			
9.			curement of API with (in case of import).	Not submitted		
Data of stability batch by attested respecti chromatograms, Raw summary data sheets of		ested respecti tograms, Raw	ve documents like data sheets, COA,	Attacl	hed	
11.		Compliance Record of HPLC software 21CFR & audit trail reports on product		The firm has submitted that it is not applicable as our HPLC system is not 21 CFR compliant and audit trail reports on product testing is not submitted by firm.		
12.	12. Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)		Not si	ubmitted		
	arks of f tion	Evaluator XI: Observation	<u> </u>		Response	
1.5.	15 –	Commitment		ithout	=	submitted duly signed commitments
Substance manu		GMP certificate of the Drug manufacturer issued by latory authority of country		The firm has submitted copy of GMP certificate of Hebei Guolong Pharmaceutical Co, Ltd from NMPA C website valid upto 21-10-2024		
	2.3.R.1 Provide copy of Batch Manus Record (BMR) for all the batche product for which stability studing provided in Module 3 section 3		R) for all the batches of hich stability studies of Module 3 section 3.2.P	f drug lata is .8.3>	record (BMR) conducted. H manufactured 03-2021)	s submitted complete batch manufacture of the batches for which stability studies owever, the BMR shows that batches were (16-03-2021) before issuance of DML
	S.4.1 S.4.2	specification	<u> </u>	stance ytical ng of	•	e Drug substance specifications and analy used for routine testing of the Drug substance.

	the Drug substance /Active	/Active Pharmaceutical Ingredient by Drug substance	
	Pharmaceutical Ingredient by Drug	manufacturer is submitted.	
	substance manufacturer is required.	• The firm have submitted analytical procedures used for	
	• Submit signed analytical procedures	routine testing of the Drug substance / Active	
	used for routine testing of the Drug	Pharmaceutical Ingredient by Drug product manufacturer	
	substance /Active Pharmaceutical	• It is to clarify that the potency of API has been calculated	
	Ingredient by Drug product	on anhydrous basis, whereas the term "on dried basis" was	
	manufacturer is required.	inadvertently mentioned considering it a broader term.	
	• Justify the declared potency of drug		
	substance on COA as it is given on		
	dried basis while in pharmacopeia it is		
	given on anhydrous basis?		
3.2.S.4.3	Analytical Method Verification studies	The firm have submitted Analytical Method Verification	
	of drug substance(s) for specificity study	studies of drug substance(s) for specificity study by the	
	by the Drug Product manufacturer shall	Drug Product manufacturer	
2255	be submitted.	COA 6 12 4 1 11 1 1 2 1 2 1	
3.2.S.5	COA of primary including source and lot	COA of working standard has been submitted.	
	number is submitted. However, COA of secondary reference standard is not		
	submitted from Firm.		
3.2.P.5	Specifications and analytical procedures	Specifications and analytical method for impurities will be	
	of impurities by drug product	same as that recommended by USP monograph.	
	manufacturer shall be submitted	, , , ,	
3.2.P.5.3	Analytical Method Verification studies	The firm have submitted Analytical Method Verification	
	for specificity study by the Drug Product	studies for specificity study by the Drug Product	
	manufacturer shall be submitted.	manufacturer	
3.2.P.6	• In reference / working standard you	The said statement was a drafting error. Copy of working	
	have submitted "Not applicable since	standard is hereby submitted	
	reference / working standard is not		
	required during analysis of this drug,		
	although reference / working standard		
	is required for analysis of this drug, clarify?		
3.2.P.8	• Submit Raw data sheets, COA &	• Pays data shoots COA & analytical record for assay and	
3.2.1 .0	analytical record for assay and	• Raw data sheets, COA & analytical record for assay and dissolution test containing detail of sample preparation,	
	dissolution test containing detail of	standard preparation for various performance parameters	
	sample preparation, standard	is submitted	
	preparation for various performance	10 00011111100	
	parameters.		
	• Justify the manufacturing of trial	It is hereby submitted that submitted that panel inspected	
	batches for stability study on 16-03-	our premises on 11-11-2020 and 19-11-2020. The panel was	
	2021 while DML issuance date is 18-	satisfied with the installed facility and gave a go ahead. The	
	03-2021.	report of the panel came for consideration in 278th meeting	
	• Audit trail reports on product testing is	of CLB held on 11-12-2020. Th board accordingly approved	
	not submitted by firm.	the DML however due to non-availability of Director	
	• Submit documents for the procurement	Licensing, the formal DML could not be issued to newly	
	of API with approval from DRAP (in	established firms. As such authority decided to entertain the	
	case of import).	cases of all such firms in which DML were approved in the	
	Submit record of Digital data logger for	meeting dated 11-12 2020.	
	temperature and humidity monitoring		
	of stability chambers (real time and	• Firm has submitted copy of commercial invoice from M/s	
	accelerated)	Hebei Guolong along with DHL receipt. The invoice is not	
		attested by AD (I & E) of DRAP Field office.	
Decision: An	nroved		
Decision: Approved.			

- Manufacturer will place first three production batches on long term stability studies throughout proposed shelf life and on accelerated studies for six months as per the commitment submitted in the registration application.
- Manufacturer will perform process validation of first three batches as per the commitment submitted in the registration application.

Case No. 2: Registration applications for local manufacturing of Human drugs (Form 5)

	/ Applicant Brand Name + Dosage Form and	Industrial Zone, Rawat, Islamabad		
	Brand Nama + Dagaga Form and			
	Dialid Name + Dosage Point and	Clopramed 75mg Tablet		
	Strength			
	Composition	Each Film Coated Tablet Contains:		
		Clomipramine HCl75mg		
	Dairy No. date of R &I fee	Form-5 Dy.No 11035 dated 05-03-2019 Rs.20,000/- dated 04-03-2019		
	Pharmacological Group	Non-selective monoamine reuptake inhibitors		
	Type of form	Form 5		
	Finished product specifications	Manufacturer's specifications		
	Pack size and Demand Price	2x10's; As per SRO		
	Approval status of product in Reference Regulatory Authorities	ANAFRANIL 75mg, film-coated tablet ANSM France approved		
I	Me-too-status	Clomixet-75mg Tablet by M/s FYNK Pharmaceuticals (Reg# 065861)		
	GMP Status	The firm was inspected on 06-11-2018 and conclusion of inspection was:		
		Keeping in view the above facts, overall GMP Compliance is found Good as today.		
	Remark of the Evaluator XI	• The firm have submitted revised master formulation as per label claim "as film coated tablets" instead of SR tablets.		
		• As per our database the applied product is already registered in the name of firm with brand name Clopra Tablet 75mg (Reg#069853), clarification was taken from the firm. However, when verified		
		form registration section the drug was registered in the name of M/s Medera Pharmaceuticals (Pvt) Ltd. 249-A Industrial Triangle Kahuta Road Islamabad. 00051 having different manufacturing site.		
	Decision: Approved with innovator's specifications.  Firm shall submit the fee of Rs. 7,500 for correction/pre-approval change/ in product specifications and master formulation as per notification No.F.7-11/2012-B&A/DRAP dated 13-07-2021.			
	Name and address of manufacture / Applicant	M/s Parkar Pharma. Plot No. O/7-A, S.I.T.E Area Kotri, Sindh <i>Contract Manufactured By:</i> M/s Inventor Pharma. Plot No. K/196, S.I.T.E. (SHW) Phase II, Karachi		
	Brand Name + Dosage Form and Strength	Cefkar DS 200mg/5ml oral Suspension		
	Composition	Each 5ml Contains: Cefixime200mg		
	Dairy No. date of R &I fee	Form-5 Dy.No 11405 dated 05-03-2019 Rs.50,000/- dated 04-03-2019		
	Pharmacological Group	Cephalosporin		
	Type of form	Form 5		
<del> </del>	Finished product specifications	USP		
	Pack size and Demand Price	30ml; As per SRO		
	Approval status of product in	SUPRAX 200mg/5ml powder for oral suspension USFDA		
	Reference Regulatory Authorities	Approved.		

Me-too-status	Regcef 200mg/5ml DS Regal Pharmaceutical (Pvt) Ltd,
	(Reg#098276)
GMP Status	The firm M/s Parkar Pharma was inspected on 07-02-2018 for grant
	of DML and Panel recommends the grant of DML."
	The firm M/s Inventor Pharma was inspected on 05-07-2018 and
	conclusion of inspection was:
	Keeping in view the stated conditions and attitude of the firm
	towards better compliance, their current GMP is rated as GOOD.
Remark of the Evaluator XI	• Fee is submitted by inventor Pharma (manufacturer) which must
	be submitted by the applicant i.e. M/s Parkar Pharma
	• The firm have mentioned the hydrated form of cefixime in label
	claim and adjusted its weight in master formulation considering the
	hydrated form. The revised label claim is as under:
	Each 5ml of reconstituted suspension Contains:
	Cefixime Trihydrate equivalent to Cefixime200mg
	• The firm have submitted revised manufacturing outline for dry
	suspension instead of tablet dosage form.
	• The firm does not provide evidence of required manufacturing
	facility/section approval letter
	• The firm have submitted copy of contract manufacturing
	agreement M/s Parkar Pharma and M/s Inventor Pharma (Pvt.) Ltd

Decision: Registration Board decided to defer for submission of following:

- Contract manufacturing fee Rs. 75000/- by the applicant M/s Parkar Pharma. Plot No. O/7-A, S.I.T.E Area Kotri, Sindh as per notification No.F.7-11/2012-B&A/DRAP dated 13-07-2021.
- Evidence of required manufacturing facility/section approval letter from M/s Inventor Pharma. Plot No. K/196, S.I.T.E. (SHW) Phase II, Karachi.
- Latest GMP inspection report from M/s Parkar Pharma.

	Report of inspection panel decided in instant meeting.		
186.	Name and address of manufacture / Applicant	M/s Parkar Pharma. Plot No. O/7-A, S.I.T.E Area Kotri, Sindh Contract Manufactured By: M/s Inventor Pharma. Plot No. K/196,	
	Brand Name + Dosage Form and Strength	S.I.T.E. (SHW) Phase II, Karachi Cefkar 100mg/5ml oral Suspension	
	Composition	Each 5ml Contains: Cefixime100mg	
	Dairy No. date of R &I fee	Form-5 Dy.No 11404 dated 05-03-2019 Rs.50,000/- dated 04-03-2019	
	Pharmacological Group	Cephalosporin	
	Type of form	Form 5	
	Finished product specifications	USP	
	Pack size and Demand Price	30ml; As per SRO	
	Approval status of product in	SUPRAX 100mg/5ml powder for oral suspension USFDA	
	Reference Regulatory Authorities	Approved.	
		<b>Discontinued</b> **Federal Register determination that product was	
		not discontinued or withdrawn for safety or efficacy reasons**	
	Me-too-status	Regcef 100mg/5ml DS Regal Pharmaceutical (Pvt) Ltd, (Reg#098275)	
	GMP Status	The firm M/s Parkar Pharma was inspected on 07-02-2018 for grant of DML and Panel recommends the grant of DML."	
		The firm M/s Inventor Pharma was inspected on 05-07-2018 and conclusion of inspection was:	
		Keeping in view the stated conditions and attitude of the firm towards better compliance, their current GMP is rated as GOOD.	

Remark of the Evaluator XI	• Fee is submitted by inventor Pharma (manufacturer) which must be submitted by the applicant i.e. M/s Parkar Pharma
	• The firm have mentioned the hydrated form of cefixime in label
	claim and adjusted its weight in master formulation considering the
	hydrated form. The revised label claim is as under:
	Each 5ml of reconstituted suspension Contains:
	Cefixime Trihydrate equivalent to Cefixime100mg
	• The firm have submitted revised manufacturing outline for dry suspension instead of tablet dosage form.
	• The firm does not provide evidence of required manufacturing facility/section approval letter
	• The firm have submitted copy of contract manufacturing agreement M/s Parkar Pharma and M/s Inventor Pharma (Pvt.) Ltd

Decision: Registration Board decided to defer for submission of following:

- Contract manufacturing fee Rs. 75000/- by the applicant M/s Parkar Pharma. Plot No. O/7-A, S.I.T.E Area Kotri, Sindh as per notification No.F.7-11/2012-B&A/DRAP dated 13-07-2021.
- Evidence of required manufacturing facility/section approval letter from M/s Inventor Pharma. Plot No. K/196, S.I.T.E. (SHW) Phase II, Karachi
- Latest GMP inspection report from M/s Parkar Pharma.
- Report of inspection panel decided in instant meeting.

	• Report of inspection panel decided in instant meeting.		
187.	Name and address of manufacture	M/s Parkar Pharma. Plot No. O/7-A, S.I.T.E Area Kotri, Sindh	
	/ Applicant	Contract Manufactured By: M/s Inventor Pharma. Plot No. K/196,	
		S.I.T.E. (SHW) Phase II, Karachi	
	Brand Name + Dosage Form and	Cefkar 400mg Capsule	
	Strength		
	Composition	Each Capsule Contains:	
		Cefixime400mg	
	Dairy No. date of R &I fee	Form-5 Dy.No 11406 dated 05-03-2019 Rs.50,000/- dated 04-03-	
		2019	
	Pharmacological Group	Cephalosporin	
	Type of form	Form 5	
	Finished product specifications	JP	
	Pack size and Demand Price	5's; As per SRO	
	Approval status of product in	SUPRAX capsules 400mg, (USFDA approved)	
	Reference Regulatory Authorities	<b>Discontinued</b> **Federal Register determination that product was	
		not discontinued or withdrawn for safety or efficacy reasons**	
	Me-too-status	Xalfocin 400mg Capsule by Martin Dow Karachi (Reg#80646)	
	GMP Status	The firm M/s Parkar Pharma was inspected on 07-02-2018 for grant	
		of DML and Panel recommends the grant of DML."	
		The firm M/s Inventor Pharma was inspected on 05-07-2018 and	
		conclusion of inspection was:	
		Keeping in view the stated conditions and attitude of the firm	
		towards better compliance, their current GMP is rated as GOOD.	
	Remark of the Evaluator XI	• Form 5 is submitted by manufacturer i.e. inventor pharma instead	
		of applicant i.e. Parkar Pharma	
		• Fee is submitted by inventor Pharma (manufacturer) which must	
		be submitted by the applicant i.e. M/s Parkar Pharma	
		• The firm have mentioned the hydrated form of cefixime in label	
		claim and adjusted its weight in master formulation considering the	
		hydrated form. The revised label claim is as under:	
		Each capsule Contains:	
		Cefixime Trihydrate equivalent to Cefixime400mg	
		• The firm have submitted revised manufacturing outline for the	
		capsule instead of tablet dosage form.	

- The firm does not provide evidence of required manufacturing facility/section approval letter
- The firm have submitted copy of contract manufacturing agreement M/s Parkar Pharma and M/s Inventor Pharma (Pvt.) Ltd

Decision: Registration Board decided to defer the applications for onsite investigation of M/s Inventor Pharma, Plot No. K/196, S.I.T.E. (SHW) Phase II, Karachi, for authenticity of product development & stability studies data. The Board further advised the applicant to submit the following:

- Form 5 by the applicant i.e. M/s Parkar Pharma.
- Contract manufacturing fee Rs. 75000/- by the applicant M/s Parkar Pharma. Plot No. O/7-A, S.I.T.E Area Kotri, Sindh as per notification No.F.7-11/2012-B&A/DRAP dated 13-07-2021.
- Latest GMP inspection report from M/s Parkar Pharma.
- Report of inspection panel decided in instant meeting.

### Case No. 3: Deferred cases:

a. Deferred cases of Human Drugs on form 5

188.	Name and address of manufacture /	M/s Lisko Pakistan Pvt Ltd., L-10-D, Block 21, Shaheed	
	Applicant	Rashid Minhas Road, F.B. Industrial Area, Karachi Telsart Tablet 80mg Each Tablet Contains:	
	Brand Name + Dosage Form and Strength		
	Composition		
	•	Telmisartan80mg	
	Dairy No. date of R &I fee	Form-5 Dy.No 41194 dated 07-12-2018 Rs.20,000/- Dated 07-12-2018	
	Pharmacological Group	Angiotensin II receptor blockers (ARBs) Form 5 USP	
	Type of form		
	Finished product specifications		
	Pack size and Demand Price	As per SRO	
	Approval status of product in Reference Regulatory Authorities	MICARDIS tablets USFDA Approved	
	Me-too-status	Telmi 80mg tablets by M/s Crystolite Pharmaceuticals (Reg#082444)	
	GMP Status	The firm submitted GMP certificate issued on 17 <sup>th</sup> August 2021 based on inspection conducted on 17 <sup>th</sup> August 2021.	
	Previous Remark of Evaluator XI	• The firm did not submit undertaking in form 5.	
	Previous Decision (295-DRB)	• Deferred for submission of undertaking at the end of Form 5.	
	Evaluation by PEC	• The firm submitted undertaking at the end of form 5.	
	Decision: Approved.		
189.	Name and address of manufacture / Applicant	M/s Lisko Pakistan Pvt Ltd., L-10-D, Block 21, Shaheed Rashid Minhas Road, F.B. Industrial Area, Karachi	
	Brand Name + Dosage Form and Strength	Comfort Tablet 250mg/250mg/25mg	
	Composition	Each Tablet Contains:	
	- Constitution of the Cons	Acetaminophen250mg	
		Magnesium salicylate250mg	
		Pamabrom25mg	
	Dairy No. date of R &I fee	Form-5 Dy.No 40742 dated 06-12-2018 Rs.20,000/- Dated 06-12-2018	
	Pharmacological Group	Analgesics & Diuretic combination	
	Type of form	Form 5	
	Finished product specifications	Manufacturer's specifications	
	Pack size and Demand Price	As per SRO	
		1	
	Approval status of product in Reference	Pamprin tablets USFDA (Could not be verified)	
	Regulatory Authorities	Dalari Eutra Tablet by Carin Dharma (Dan#72561)	
<u> </u>	Me-too-status	Dolmi Extra Tablet by Genix Pharma (Reg#73561)	

	1	
	GMP Status	The firm submitted GMP certificate issued on 17 <sup>th</sup> August 2021 based on inspection conducted on 17 <sup>th</sup> August 2021.
	Previous Remark of Evaluator XI	• Evidence of approval of applied formulation in reference regulatory authorities/agencies which were adopted by the Registration Board in its 275 <sup>th</sup> meeting could not be verified
		• The firm submitted revised form 5 duly signed by
		technical person.  • The firm have claimed USP monograph, however the
		monograph is not available in any pharmacopeia.
	Previous Decision (295-DRB)	• Deferred for evidence of approval of applied formulation in reference regulatory authorities/agencies which were adopted by the Registration Board in its
	Evaluation by PEC	<ul> <li>275th meeting</li> <li>The firm provided evidence of applied product in RRA, Pamprin Cramp Menstrual Pain Relief tablet USFDA approved. However, the submitted evidence of applied product in RRA could not be verified.</li> </ul>
		broval of applied formulation in reference regulatory by the Registration Board in its 275th meeting.
190.	Name and address of manufacture /	M/s Lisko Pakistan Pvt Ltd., L-10-D, Block 21, Shaheed
	Applicant	Rashid Minhas Road, F.B. Industrial Area, Karachi
	Brand Name + Dosage Form and Strength	
	Composition	Each Film Coated Tablet Contains:
	Dainy No. data of D. P. I foo	Cefixime Trihydrate eq to Cefixime400mg Form-5 Dy.No 40731 dated 06-12-2018 Rs.20,000/-
	Dairy No. date of R &I fee	Dated 06-12-2018 Rs.20,000/-
	Pharmacological Group	Cephalosporine
	Type of form	Form 5
	Finished product specifications	USP
	Pack size and Demand Price	10's; 20's; 30's; 40's; 50's; 60's; 80's; 90's; 100's; As per SRO
	Approval status of product in Reference	SUPRAX 400mg tablets USFDA Approved
	Regulatory Authorities	Discontinued "Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons"
	Me-too-status	Fixitil-T DS 400mg tablets by Tabros Pharma (Reg.
	GMP Status	083787) The firm submitted GMP certificate issued on 17 <sup>th</sup> August
	GMP Status  Previous Remark of Evaluator XI	083787)
		083787) The firm submitted GMP certificate issued on 17 <sup>th</sup> August 2021 based on inspection conducted on 17 <sup>th</sup> August 2021.  •
	Previous Remark of Evaluator XI	083787) The firm submitted GMP certificate issued on 17 <sup>th</sup> August
	Previous Remark of Evaluator XI Previous Decision (295-DRB) Evaluation by PEC  Decision: Approved.	083787) The firm submitted GMP certificate issued on 17 <sup>th</sup> August 2021 based on inspection conducted on 17 <sup>th</sup> August 2021.  Deferred for confirmation of manufacturing facility  The firm submitted letter No. F. 2-15/85-Lic (Vol-III) dated 8 <sup>th</sup> July 2015 issued by Secretary CLB showing presence of Tablet Cephalosporin section
191.	Previous Remark of Evaluator XI Previous Decision (295-DRB) Evaluation by PEC  Decision: Approved. Name and address of manufacture /	083787)  The firm submitted GMP certificate issued on 17 <sup>th</sup> August 2021 based on inspection conducted on 17 <sup>th</sup> August 2021.  ■  Deferred for confirmation of manufacturing facility  ■ The firm submitted letter No. F. 2-15/85-Lic (Vol-III) dated 8 <sup>th</sup> July 2015 issued by Secretary CLB showing presence of Tablet Cephalosporin section  M/s Lisko Pakistan Pvt Ltd., L-10-D, Block 21, Shaheed
191.	Previous Remark of Evaluator XI Previous Decision (295-DRB) Evaluation by PEC  Decision: Approved.  Name and address of manufacture / Applicant	O83787)  The firm submitted GMP certificate issued on 17 <sup>th</sup> August 2021 based on inspection conducted on 17 <sup>th</sup> August 2021.  Deferred for confirmation of manufacturing facility  The firm submitted letter No. F. 2-15/85-Lic (Vol-III) dated 8 <sup>th</sup> July 2015 issued by Secretary CLB showing presence of Tablet Cephalosporin section  M/s Lisko Pakistan Pvt Ltd., L-10-D, Block 21, Shaheed Rashid Minhas Road, F.B. Industrial Area, Karachi
191.	Previous Remark of Evaluator XI Previous Decision (295-DRB) Evaluation by PEC  Decision: Approved.  Name and address of manufacture / Applicant Brand Name + Dosage Form and Strength	083787) The firm submitted GMP certificate issued on 17 <sup>th</sup> August 2021 based on inspection conducted on 17 <sup>th</sup> August 2021.  Deferred for confirmation of manufacturing facility  The firm submitted letter No. F. 2-15/85-Lic (Vol-III) dated 8 <sup>th</sup> July 2015 issued by Secretary CLB showing presence of Tablet Cephalosporin section  M/s Lisko Pakistan Pvt Ltd., L-10-D, Block 21, Shaheed Rashid Minhas Road, F.B. Industrial Area, Karachi Liskoxime Tablet 200mg
191.	Previous Remark of Evaluator XI Previous Decision (295-DRB) Evaluation by PEC  Decision: Approved.  Name and address of manufacture / Applicant	O83787)  The firm submitted GMP certificate issued on 17 <sup>th</sup> August 2021 based on inspection conducted on 17 <sup>th</sup> August 2021.  ■  Deferred for confirmation of manufacturing facility  ■ The firm submitted letter No. F. 2-15/85-Lic (Vol-III) dated 8 <sup>th</sup> July 2015 issued by Secretary CLB showing presence of Tablet Cephalosporin section  M/s Lisko Pakistan Pvt Ltd., L-10-D, Block 21, Shaheed Rashid Minhas Road, F.B. Industrial Area, Karachi Liskoxime Tablet 200mg  Each Film Coated Tablet Contains:
191.	Previous Remark of Evaluator XI Previous Decision (295-DRB) Evaluation by PEC  Decision: Approved.  Name and address of manufacture / Applicant Brand Name + Dosage Form and Strength	083787) The firm submitted GMP certificate issued on 17 <sup>th</sup> August 2021 based on inspection conducted on 17 <sup>th</sup> August 2021.  Deferred for confirmation of manufacturing facility  The firm submitted letter No. F. 2-15/85-Lic (Vol-III) dated 8 <sup>th</sup> July 2015 issued by Secretary CLB showing presence of Tablet Cephalosporin section  M/s Lisko Pakistan Pvt Ltd., L-10-D, Block 21, Shaheed Rashid Minhas Road, F.B. Industrial Area, Karachi Liskoxime Tablet 200mg
191.	Previous Remark of Evaluator XI Previous Decision (295-DRB) Evaluation by PEC  Decision: Approved.  Name and address of manufacture / Applicant Brand Name + Dosage Form and Strength Composition	The firm submitted GMP certificate issued on 17 <sup>th</sup> August 2021 based on inspection conducted on 17 <sup>th</sup> August 2021.  Deferred for confirmation of manufacturing facility  The firm submitted letter No. F. 2-15/85-Lic (Vol-III) dated 8 <sup>th</sup> July 2015 issued by Secretary CLB showing presence of Tablet Cephalosporin section  M/s Lisko Pakistan Pvt Ltd., L-10-D, Block 21, Shaheed Rashid Minhas Road, F.B. Industrial Area, Karachi Liskoxime Tablet 200mg  Each Film Coated Tablet Contains: Cefixime Trihydrate eq to Cefixime
191.	Previous Remark of Evaluator XI Previous Decision (295-DRB) Evaluation by PEC  Decision: Approved.  Name and address of manufacture / Applicant Brand Name + Dosage Form and Strength Composition  Dairy No. date of R &I fee	The firm submitted GMP certificate issued on 17 <sup>th</sup> August 2021 based on inspection conducted on 17 <sup>th</sup> August 2021.  Deferred for confirmation of manufacturing facility  The firm submitted letter No. F. 2-15/85-Lic (Vol-III) dated 8 <sup>th</sup> July 2015 issued by Secretary CLB showing presence of Tablet Cephalosporin section  M/s Lisko Pakistan Pvt Ltd., L-10-D, Block 21, Shaheed Rashid Minhas Road, F.B. Industrial Area, Karachi Liskoxime Tablet 200mg  Each Film Coated Tablet Contains: Cefixime Trihydrate eq to Cefixime

Pack size and Demand Price	10's; 20's; 30's; 40's; 50's; 60's; 80's; 90's; 100's; As po
	SRO
Approval status of product in Reference	SUPRAX 200mg tablets USFDA Approved
Regulatory Authorities	Discontinued "Federal Register determination that produ
	was not discontinued or withdrawn for safety or efficac
	reasons"
Me-too-status	Wizy 200mg tablets by Zephyr Pharmatec (Reg. 088322
GMP Status	The firm submitted GMP certificate issued on 17 <sup>th</sup> Augu
	2021 based on inspection conducted on 17th August 202
Previous Remark of Evaluator XI	•
Previous Decision (295-DRB)	Deferred for confirmation of manufacturing facility
Evaluation by PEC	• The firm submitted letter No. F. 2-15/85-Lic (Vol-I
	dated 8th July 2015 issued by Secretary CLB showi
	presence of Tablet Cephalosporin section

### **Agenda of Evaluator PEC-XIII**

### A: Registration applications of locally manufactured (Human) drugs on Form 5F.

DRAP Authority in its 129<sup>th</sup> meeting held on 17-02-2022 decided as follows:

The Authority appreciated the efforts of PE&R Division for effective and phase wise implementation of CTD and after detailed deliberations approved the out of queue consideration of registration applications of New Chemical Entities on CTD format (Form 5F).

Accordingly, the following application is evaluated and placed before the Registration Board for consideration.

2.	Name, address of Applicant / Importer	Biocare Pharmaceutica, 807-Shadman 1, Lahore-Pakistan.
	Details of Drug Sale License of importer	DSL NO. 05-352-0063-032069D. Address: M/s Biocare Pharmaceutica, 807-Shadman 1, District Lahore. Go-down address: 8-C, Street No.3, Near LGS School, Shah Jamal, District Lahore. Valid up to 17-04-2022.
	Name and address of marketing authorization holder (abroad)	Wanbang Biopharmaceuticals.  Manufacturing site Address: South of Dongshan, Comprehensive area, Jinshanqiao Development Zone, Xuzhou, Jiangsu China.
	Name, address of manufacturer(s)	Manufactured By: - Wanbang Biopharmaceuticals Manufacturing site Address: South of Dongshan, Comprehensive area, Jinshanqiao Development Zone, Xuzhou, Jiangsu China.
	Name of exporting country	China.
	Detail of certificates attached (CoPP, Free sale certificate, GMP certificate)	<ul> <li>Detail of certificates attached (CoPP, GMP certificate)</li> <li>Original legalized CoPP (certificate No. JS20210074) issued by Jiangsu Drug Administration, China on 20-01-2021. The document also confirms that the applied product strength is actually on the market in exporting country. Valid up to 19-01-2022.</li> <li>Original legalized GMP certificate No. JS20180837 valid till 21/06/2023 issued by China Food and Drug Administration is submitted.</li> </ul>

Details of letter of authorization / sole agency agreement	Copy of product specific sole agency agreement is submitted.
Status of the applicant	<ul> <li>☐ Manufacturer</li> <li>☑ Importer</li> <li>☐ Is involved in none of the above (contract giver)</li> </ul>
Status of application	<ul><li>✓ New Drug Product (NDP)</li><li>☐ Generic Drug Product (GDP)</li></ul>
Intended use of pharmaceutical product	<ul><li>☑ Domestic sale</li><li>☐ Export sale</li><li>☐ Domestic and Export sales</li></ul>
For imported products, specify one the these	<ul> <li>☑ Finished Pharmaceutical product import</li> <li>☐ Buk import and local repackaging</li> <li>☐ Buk import and local repackaging for export purpose only</li> </ul>
Dy. No. and date of submission	Dy. No. 25527: dated 14-09-2021.
Details of fee submitted	PKR 75,000/-: dated 04-08-2021.
The proposed proprietary name / brand name	PARIX, Bio-P, Dynastat 40mg Powder for injection (IV/IM).
Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each vial contains: 42.3 mg of parecoxib sodium equivalent to parecoxib
Pharmaceutical form of applied drug	(Parecoxib Sodium) 40 Mg (IM/IV) freez-dried Powder for Solution for Injection.
Pharmacotherapeutic Group of (API)	Anti-inflammatory and Antirheumatic products, Non-steroids (Coxibs). ATC code: M01AH04.
Reference to Finished product specifications	In House specifications.
Proposed Pack size	10 vials/carton, 50 cartons/box.
Proposed unit price	PKR 500/vial.
The status in reference regulatory authorities	DYNASTAT Injection contains 40 mg parecoxib (as 42.36 mg parecoxib sodium), TGA approved.
For generic drugs (me-too status)	Could not be confirmed.
Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Firm has summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, and controls, impurities, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.  The firm has summarized information of drug product including its description, composition, pharmaceutical development, manufacturer, manufacturing process and process control, process validation protocols, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference

	standard or materials, container closure system and stability.
Name, address of drug substance manufacturer	M/s Zhejiang Haisen Pharmaceutical Co. Ltd., Xiangtan Village, Liushi Street, Dongyang, City Zhejiang Province, China. Validity 24-09-2025.
Module-III Drug Substance:	Firm has submitted detailed drug substance data related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its verification studies, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
Stability Studies of Drug Substance (Conditions & duration of Stability studies)	<ul> <li>36 months real time stability data at 30°± 2°C / 65% RH ± 5% RH of 03 batches (5316110201, 5316110202, 5316120201).</li> <li>06 month accelerated stability data 40°C ± 2°C / 75% RH ± 5% RH of 03 batches (5316110201, 5316110202, 5316120201).</li> </ul>
Module-III Drug Product:	Firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.
Pharmaceutical Equivalence and Comparative Dissolution Profile	Pharmaceutical equivalence has been established against reference product i.e. Dynastat 40mg powder for solution for injection, Batch No. R42343 with Exp. Date of 04/2019 manufactured by the Pfizer Limited by performing the following tests;  Appearance, Identification, pH, Clarity of solution, related compounds, water content, weight variation, particulate matter, sterility, bacterial endotoxin, visible particulates and Assay.
Analytical method validation/verification of product	Submitted.
Container closure system of the drug product	5ml type I clear glass tubular injection vial with brominated butyl rubber stopper sealed with a blue flip-off cap on the aluminum seal.
Stability study data of drug product, shelf life and storage conditions	<ul> <li>12 months real time stability data at 30°C ± 2°C / 65% ± 5% RH of 03 batches (42001403, 42001404, 42001407).</li> <li>06 month accelerated stability data 40°C ± 2°C / 75% ± 5% RH of 03 batches (42001403, 42001404, 42001407).</li> <li>Finished product manufacturer has also submitted a commitment letter wherein they commit/confirm that complete full 24 month till shelf life Zone IVA stability study under 30°C ± 2°C / 65% ± 5% RH condition for their product Parecoxib 40mg powder for injection. They further submitted that they will update 15, 18 &amp; 24-month time</li> </ul>

	point stability data under Zone IVA conditions accordingle as soon as it is completed & tested.	
Evaluation	n by PEC XIII:	
Sr. No.	Observations	Reply by the firm.
1	Notarized agreement shall be submitted.	Firm has again submitted copy of agreement.
2	Valid copy of DSL as the DSL is valid up to 17-04-2022.	Firm has provided provisional receipt of "Application for change in drug sale license 352-98572912-2022" with reference No. 352-98572912-2022 of M/s Biocare Pharmaceutica, 807 Shadman-1, District Lahore.
3	Valid CoPP shall be submitted. 19-01-2022.	Firm has submitted copy of CoPP (certificate No. JS20220091) issued by Jiangsu Drug Administration, China on 04-03-2022. The document also confirms that the applied product strength is actually on the market in exporting country. Valid up to 03-03-2023. <i>Not notarized and countersigned by the embassy of Pakistan.</i>
4	Complete shelf life stability data of the applied formulation shall be submitted.	Firm has submitted 24-month real time stability data at $30^{\circ}\text{C} \pm 2^{\circ}\text{C} / 65\% \pm 5\%$ RH of three batches (42001403, 42001404, 42001407) for the applied formulation and results are within the limits.

Decision: Registration Board after thorough deliberation decided to deferr the case for further incorporations of complete details including approval status of the of the new chemical entity in reference regulatory authorities, indications, warnings etc.

# B: Registration applications of Deferred locally manufactured (Human) drugs on Form 5 with stability data.

102	N	M/- Wilson's Discourse discharge 207 200 TO T 1 (11		
193.	Name and address of manufacturer /	M/s Wilson's Pharmaceuticals, 387-388, I-9, Industrial		
	Applicant	Area, Islamabad.		
	Brand Name +Dosage Form + Strength	Coldene day Tablet		
	Diary No. Date of R& I & fee	Dy. No. 16694, R&I Dated 02.10.2017, Rs. 20,000/-(02.10.2017)		
	Composition	Each film-coated tablet contains:		
		Acetaminophen 500mg		
		Phenylephrine HCl 5mg		
	Pharmacological Group	Analgesic, Non-opioid/ Sympathomimetic Decongestants		
	Type of Form	Form 5.		
	Finished Product Specification	Manufacturers specification		
	Pack size & Demanded Price	1x 10's, 10x 10's & as per SRO		
	Approval status of product in Reference Regulatory Authorities.	Could not be confirmed		
	Me-too status	Could not be confirmed		
	GMP status	The firm was inspected on 24-01-2018 and conclusion of		
		inspection was:		
		Overall the firm was found to be operating at a very good		
		level of CGMP Compliance at the time of inspection."		
	Previous remarks of the Evaluator.	The local and international availability of the applied formulation could not be confirmed.		
	Previous decision	Deferred in 284th DRB meeting as the local and international availability of the applied formulation could not be confirmed.		
		not be commined.		

Decision of 296 <sup>th</sup> meeting of Registration Board.		Cold + Flu Rel (Australia) Pty Li • Me- too submitt Panadol CF Da Phenylephrine Ho • The applied form submit stability s accelerated and re on Registration Board stability study data	<ul> <li>International reference has been verified as Demazin Cold + Flu Relief tablet of iNova Pharmaceuticals (Australia) Pty Ltd TGA; Australia Approved.</li> <li>Me- too submitted by the firm has been verified as: Panadol CF Day Caplet (Paracetamol 500mg and Phenylephrine HCl 5mg of M/s GSK, Karachi 094797.</li> <li>The applied formulation is on stability so firm needs to submit stability studies data of at least three batches at accelerated and real time conditions.</li> <li>Registration Board deferred the case for submission of stability study data as per the guidelines provided in 293<sup>rd</sup></li> </ul>		
	STARI	meeting of Registrat	meeting of Registration Board.		
Drug	Coldene day Tabl				
Name of Manufacturer			-9, Industrial Area, Islamabad.		
Manufacturer of API  Paracetamol: M/s Saakh Pharma ( Phenylephrine Hydro M/s Shenzhen Orien		a (Pvt.) Ltd., C-7/1, NW	Pvt.) Ltd., C-7/1, NWIZ, Port Qasim Karachi. ochloride. ttal Pharmaceutical Co., Ltd., No. 43, Dakeng Road, Tongle		
API Lot No.	Paracetamol: 19GN60173		hrine Hydrochloride.		
Description of Pack (Container closure system)	Alu-Alu strip pac	Alu-Alu strip packed in card box unit carton of 30's.			
Stability Storage Condition		Real time: $30^{\circ}\text{C} \pm 2^{\circ}\text{C} / 65\% \pm 5\%\text{RH}$ Accelerated: $40^{\circ}\text{C} \pm 2^{\circ}\text{C} / 75\% \pm 5\%\text{RH}$			
Time Period	Real time: 6 months Accelerated: 6 months				
Frequency		Real time: 0,3,6 (months) Accelerated: 0,3,6 (months)			
Batch No.	Trial # 01	Trial # 02	Trial # 03		
Batch Size	1500 Tablets	1500 Tablets	1500 Tablet		
Manufacturing Date	08-2019	08-2019	08-2019		
Date of Initiation	01-09-2019	01-09-2019	01-09-2019		
No. of Batches		03			
Date of Submission		11-01-2021 (D	11-01-2021 (Dy. No. 1371)		
DOCUMENTS / DATA PROVIDED			D BY THE APPLICANT FOR EXEMPTION		
DOCUMENTS / DATA PROVIDED BY THE APPLICANT			APPLICANT Status		
S. No. Documents To Be Provided  Reference of previous approval of applications with stability study data of the firm  1.		ta product "saferon tab Registration Board i Registration of "Safe Wilson Pharmaceuti Date of Inspection: I • Software of HP compliant and a	Firm has referred to their last inspection report for their product "saferon tablet" Registration Board in its 278th meeting decided to approve Registration of "Saferon (Sofosbuvir 400mg) tablets by M/s Wilson Pharmaceuticals, I-9 Industrial Area, Islamabad. Date of Inspection: 10-12-2015, 19-04-2017 & 20-01-2018  • Software of HPLC present in the firm is 21CFR compliant and audit trail on the testing reports was available and confirmed.		

	Certificate of Analysis of API from	Paracetamol:
2.	both API Manufacturer and Finished Product manufacturer.	Firm has submitted COA of Paracetamol (Batch # 19GN60173) from M/s Saakh Pharma (Pvt.) Ltd., C-7/1, NWIZ, Port Qasim Karachi. COA from Wilson pharma with Batch No. 19GN60173 has also been been submitted. Phenylephrine Hydrochloride.  Firm has submitted COA of Phenylephrine Hydrochloride (Batch # PEH-180101Y1) from M/s Shenzhen Oriental Pharmaceutical Co., Ltd., No. 43, Dakeng Road, Tongle village, Longgang District, Shenzin China. COA from Wilson pharma with Batch No. PEH-180101Y1 has also been submitted.
3.	Method used for analysis of API from both API Manufacturer and Finished Product manufacturer	Submitted.
4.	Stability study data of API from API manufacturer	The firm has submitted copy of accelerated, 12 Months (40°C ± 2°C & 75±5%RH) & long term, 18 Months (30°C ± 2°C & 65±5%RH) stability study reports of 03 batches. Phenylephrine Hydrochloride.  The firm has submitted copy of accelerated, 06 Months (40°C ± 2°C & 75±5%RH) & long term, 48 Months (30°C ± 2°C & 65±5%RH) stability study reports of 03 batches (PEH-160404, PEH-160405 & PEH-160406).
5.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Paracetamol: Firm has submitted copy of GMP certificate No. 83/2020-DRAP (K) dated 23-06-2020 of M/s Saakh Pharma (Pvt.) Ltd., C-7/1, NWIZ, Port Qasim Karachi. The certificate is valid till 22-06-2022. Phenylephrine Hydrochloride. Firm has submitted copy of GMP certificate No. GD20150448 of M/s Shenzhen Oriental Pharmaceutical Co., Ltd., No. 43, Dakeng Road, Tongle village, Longgang District, Shenzin China issued by China Food and Drug Administration. The certificate is valid till 07-12-2020.
6.	Documents for the procurement of API with approval from DRAP (in case of import).	
7.	Protocols followed for conduction of stability study	Submitted.
8.	Method used for analysis of FPP	Submitted.
9.	Drug-excipients compatibility studies (where applicable)	Firm has submitted that ingredients of Coldene day tablets and Panadol Sinus Pain & Congestion relief day & night (innovator brand) are same and no compatibilities of excipients observed with drug during accelerated and real time stability studies.  However, in active ingredients of the applied formulation and Panadol Sinus Pain & Congestion relief day tablets are different from each other.
10.	Complete batch manufacturing record of three stability batches.	The firm has manufactured three stability batches of Paracetamol + Phenylephrine hydrochloride Tablets (500mg + 5mg) and has submitted copy of complete batch manufacturing. Details are as under:  Coldene day Tablet 500/5mg.

		Batch No.	Bach size	Mfg. Date	
		Trial # 01	1500 Tablets	08-2019	
		Trial # 02	1500 Tablets	08-2019	
		Trial # 03	1500 Tablets	08-2019	
	Record of comparative dissolution	Firm has submit	tted CDP agains	t Panadol CF da	y caplet,
11	data	Batch No. KU7Y	Batch No. KU7Y in three different mediums i.e. 0.1N HCl,		
11.	(where applicable)	Acetate Buffer p	oH 4.5 & Phosph	ate Buffer pH 6.	8 and F2
		values for some	other formulation	n have been subn	nitted.
	Data of 03 batches will be supported				
12	by attested respective documents like	Submitted			
12.	chromatograms, Raw data sheets,	Submitted			
	COA, summary data sheets etc.				
	Compliance Record of HPLC		Submitte	ed	
13.	software 21CFR & audit trail reports				
	on product testing.				
	Record of Digital data logger for	Firm has subm	itted record of	digital data lo	gger for
14.	temperature and humidity monitoring	temperature and humidity monitoring of stability chambers.			
	of stability chambers (real time and				
	accelerated)				

### Remarks of the Evaluator XIII:

Sr. No.	Observations	Submission by the firm.
1	Latest GMP certificate/inspection report conducted within last three years of the finished product manufacturer shall be submitted.	Firm has also submitted GMP inspection report dated 24-01-2018.  Provided GMP inspection report is not within last three years.
2	COA's of the drug substances by Wilson pharma shall be submitted.	Firm has submitted COA of paracetamol with Batch No. 19GN60173 manufacturing date 01-03-2019 manufactured by M/s Saakh Pharma.  Firm also submitted COA of phenylephrine HCl with Batch No. PEH-180101Y1 manufacturing date 27-12-2017 manufactured by M/s Shenzhen Oriental Pharmaceutical Co., Ltd.
3	Approval of API/ DML/ valid GMP certificate of drug substance manufacturer issued by concerned regulatory authority of country of origin for Phenylephrine hydrochloride shall be submitted.	• Firm has submitted Certificate No.GD190014 issued by Guangdong Food and Drug Administration wherein M/s Shenzhen Oriental Pharmaceutical Co., Ltd., No. 43, Dakeng Road, Tongle village, Longgang District, Shenzin, Guangdong, China complies with the requirements of the Chinees Good Manufacturing Practice (= GMP of EU, WHO/ICH Q7). Certificate is valid till 11-09-2022.  However, Title as per Online Link: Shenzhen Woland Pharmaceutical Co., Ltd. No. 43, Dakeng Road, Tongle Community, Longgang Street, Longgang District, Shenzhen.  Title as per submitted GMP: M/s Shenzhen Oriental Pharmaceutical Co., Ltd., No. 43, Dakeng Road, Tongle village, Longgang District, Shenzin, Guangdong, China.  Submitted.
	Analytical method of drug substance from both drug substance manufacturer and Finished Product manufacturer shall be submitted.	Submitted.

4	Stability study data for Phenylephrine Hydrochloride from the concerned manufacturer shall be submitted.  Starch pregelatinized maize, Talc purified and stearic acid are used by the innovator product while the applied formulation does not have the same. Innovator product has no sodium starch glycolate (Primojel) while the applied formulation has used Primojel. Clarification is required.	<ul> <li>Firm has submitted that stearic acid &amp; Talcum is a lubricant/glidant and is used for enhancing the flow properties of the material. As our formulated material already had excellent flow properties so we didn't add any lubricant.</li> <li>Our formulation contains sodium starch glycolate (Primojel) which is derivative of starch and it has excellent disintegrating properties as compared to starch so Primojel was preferred over starch. Moreover, our product is tested and found to be stable chemically and physically with existing formulation.</li> </ul>
5	COA of paracetamol used in the stability studies by both the drug substance manufacturer and the finished product manufacturer shall be submitted.	Submitted.
6	Justification for selection of dissolution parameters including dissolution medium, apparatus, time and limits.	Firm has submitted that parameters for dissolution method were developed /selected for the applied formulation as per DRAP guidelines method mentioned in 293 <sup>rd</sup> meeting of the Registration Board held on 06 <sup>th</sup> – 08 <sup>th</sup> January, 2020.  Furthermore, dissolution method for above mentioned combination is not available in any pharmacopoeia nor it is available publicly. Therefore, in-house method for dissolution testing was developed and validated. All results observed in stability studies were within the limits.
7	F2 values in comparative dissolution profile for some other product have been submitted. Clarification is required.	Firm has submitted new sheets for the comparative dissolution profile wherein the F2 values for the applied product has been submitted.
8	Executed BMR's have shown three percent of overages of the active ingredients. Justification / Clarification is required.	Firm submitted that 3% overage is included to compensate process losses during manufacturing. The batch size is lab scale of 1500 tablets. The amount of active is paracetamol 500mg, and phenylephrine HCl 5mg and 3% overage cause an increase in amount to 515.0 mg and 5.15 mg respectively. The overage ensures a content uniformity within range as per USP 2018.

### **Decision: Deferred for the following reasons;**

- GMP certificate/last inspection report conducted within last three years.
- Scientific justification of 03% overage of the active ingredients in the applied formulation.
- Justification for using different excipients from the innovator product.

## C: Registration applications of Deferred locally manufactured (Human) drugs on Form 5 with capacity assessment.

Following cases of M/s Briell Pharmaceuticals Pvt Ltd. 538-C Sundar Industrial Estate Road, Lahore on contract manufacturing from M/s Medisave Pharmaceuticals, Plot 578-579, Sundar Industrial Estate, Lahore, Pakistan were presented in 296<sup>th</sup> meeting of Registration Board. Registration Board deferred the cases for capacity assessment of M/s Medisave pharmaceuticals, Lahore. The capacity assessment reports of M/s Medisave Pharmaceuticals. Plot 578-579, Sundar Industrial Estate, Lahore are hereby presented before the Board.

### **Inspection report No. 1**

### INSPECTION REPORT OF M/S. MEDISAVE PHARMACEUTICALS, LAHORE.

The inspection of M/s. Medisave Pharmaceuticals – Sunder Industrial Estate Lahore was conducted by the undersigned on 11-03-2022 for verification of surplus Production Capacity with reference to DRAP Islamabad letter No. F. 13-11/2017-PEC (Vol-I), Dated 19<sup>th</sup> September, 2019.

The List of machinery / Equipments in production (Section-wise) along with capacity is as follows.

- 1. Liquid Injection
- 2. Infusion (LVP) Section
- 3. Liquid Syrup Section

### 1. Liquid Injection Section (Ampoules)

Process/Steps	Capacity per day/Shift (8Hrs)	Capacity per Month (22 Days) (8Hrs/day/shift) Calculate with respect to total working days/shifts.
3.51		1
Mixing	500 Liters	11,000 Liter
Filling	1,00,000 ampls.	22,00,000 ampls.
Packaging	60,000 ampls.	13,20,000ampls.

# \*Note: Limiting step in this process is dry heat sterilization. Capacity Calculated with respect to capacity limiting step:

QUARTER WISE CAPACITY UTILIZED				
Quarter	Actual Production	Capacity	Capacity utilize in %	
2 <sup>nd</sup> 2021	766,727 ampls.	66,00,000 ampls.	11.61%	
3 <sup>rd</sup> 2021	749,062 ampls.	66,00,000 ampls.	11.35%	
4 <sup>th</sup> 2021	817,803 ampls.	66,00,000 ampls.	12.4%	
1 <sup>st</sup> 2022 10,89,430 ampls. 66,00,000 ampls. 16.50%				
Average Capacity Utilized is 12.96%				

Manufacturing Capacity Utilized (average): 12.96% Manufacturing Capacity Available (average): 87.04%

### 2. <u>Infusion Section (LVP)</u>

Process/Steps	Capacity per day/Shift (8Hrs)	Capacity per Month (22 Days) (8Hrs/day/shift)
		Calculate with respect to total working days/shifts.
Mixing	1200Lit	26,400lit
Filling	12000 Vials	2,64,000 Vials
Packaging	10,000 Vials	2,20,000 Vials

# \*Note: Limiting step in this process is filling. Capacity Calculated with respect to capacity limiting step:

QUARTER WISE CAPACITY UTILIZED				
Quarter	Actual Production	Capacity	Capacity utilize in %	
2 <sup>nd</sup> 2021	24,190 Vials	7,92,000 Vials	3.054%	
3 <sup>rd</sup> 2021	4800 Vials	7,92,000 Vials	0.60%	
4 <sup>th</sup> 2021	20,400 Vials	7,92,000 Vials	2.57%	
1st 2022	14,4000 Vials	7,92,000 Vials	18.18%	
Average Capacity U	Itilized is 6.1%			

Manufacturing Capacity Utilized (average): 6.1% Manufacturing Capacity Available (average):93.9%

#### 3. Liquid Syrup

Process/Steps	Capacity per day/Shift (8Hrs)	Capacity per Month (22 Days) (8Hrs/day/shift)	
		Calculate with respect to total working	
		days/shifts.	
Mixing	2000Lit	44000 Lit	
Filling	33,333 Bottles	73,3320 Bottles	
Packaging	20,000 Bottles	4,40,000 Bottles	

### \*Note: Limiting step in this process is filling.

Capacity Calculated with respect to capacity limiting step:

QUARTER WISE CAPACITY UTILIZED				
Quarter	Actual Production	Capacity	Capacity utilize in %	
2 <sup>nd</sup> 2021	43,363 Bottle	13,20,000 Bottles	3.28%	
3 <sup>rd</sup> 2021	35000 Bottle	13,20,000 Bottles	2.65%	
4 <sup>th</sup> 2021	35000 Bottle	13,20,000 Bottles	2.65%	
1st 2022 1,19,000 Bottle 13,20,000 Bottles 9.01%				
Average Capacity Utilized is 6.1%				

Manufacturing Capacity Utilized (average): 4.39% Manufacturing Capacity Available (average):95.61%

### CAPACITY OF QUALITY CONTROL DEPARTMENT List of Equipments QC Lab

# HPLC Capacity Calculation Quarter Wise (Max 2 tests/Day) Total 3 HPLCs

Quarter	Average Capacity of	Performed	Capacity Utilized	Capacity
	HPLC			Available
4 <sup>th</sup> 2021	44	17	38.63%	61.37
3 <sup>rd</sup> 2021	44	21	47.72%	52.28
2 <sup>rd</sup> 2022	44	26	59.09%	40.91
1st 2022	44	18	40.90%	59.1

Average Capacity Available = 53.42%

Average capacity utilized = 46.58%

### **UV-Spectrophotometer Capacity Calculation Quarter Wise (Average 20 Tests/Day)**

Quarter	Capacity	Performed	Capacity Utilized	Capacity
				Available
4 <sup>th</sup> 2021	440	96	21.81%	78.18
3 <sup>rd</sup> 2021	440	121	27.5%	72.5
2 <sup>rd</sup> 2022	440	81	18.4%	81.59
1st 2022	440	89	20.22%	79.77

Average Capacity Available = 78.01%

Average capacity utilized = 21.98%

# Capacity Calculation for Sterility testing Quarter wise depending on incubators (Average 5 test/day)

Quarter	Capacity	Performed	Capacity Utilized	Capacity Available
4 <sup>th</sup> 2021	110	22	20%	80%
3 <sup>rd</sup> 2021	110	28	25.45%	74.54%
2 <sup>rd</sup> 2022	110	16	14.54%	85.45%
1st 2022	110	27	24.54%	75.45%

Average Capacity Available 78.86%

Average capacity utilized = 21.13%

# List of Equipments QC Lab

S.NO	NAME OF EQUIPMENT	Manufacturing	Calibration Experts Names
	FTIR (Fourier Transform Infrared		Pharma Analytical Solutions
1	Spectroscopy)	Lambda Scientific	
1.	HPLC with (Isocratic) with auto	Lambda Scientific	
	injector, column oven, system		Pharma Analytical Solutions
	controller, uv-vis detector and built		,
	in software, Computer & Printer		
2.	Columns:	Shimadzu Japan	
	HPLC Kauner		Pharma Analytical Solutions
3.	HPLC Kauner	Germany	
		Germany	Pharma Analytical Solutions
	PerkinElmer		
4.		USA	
	UV VIS. Spectrophotometer Double		Pharma Analytical Solutions
	Beam wave length 190-1100 nm	DC Instance at	
5.	with LCDs & Printer Accessories:	PG Instruments Ltd UK	
<i>J</i> .	UV VIS. Spectrophotometer	Liu OK	
	Dynamic HALO DB-20S UV-VIS	Western	
6.	DOUBLE BEAM.	Instruments	
7.	TOC (Total Organic Carbon)	Membrapure	Pharma Analytical Solutions
8.	Coulter Particle Counter	Beckman coulter	Pharma Analytical Solutions
0	Voul Eighau Tituation	Metrohm	Pharma Analytical Solutions
9.	Karl Fisher Titration Analytical Balance (readability 0.1	Switzerland	Pharma Analytical Solutions
	mg) (Capacity 320Gm) built in	Sartorious	Tharma Anarytical Solutions
10.	calibration	Germany	
	Moisture Analyzer (readability 1	Sartorious	Pharma Analytical Solutions
11.	mg) (Capacity 150 Gm)	Germany	
10	Precision Weighing Balance	Sartorious	Pharma Analytical Solutions
12.	(readability 1 mg) (Capacity 310gm)	Germany	Dhama Analytical Calutions
13.	Melting Point Apparatus Weighing Box with all calibrated	China	Pharma Analytical Solutions Pharma Analytical Solutions
14.	weight	China	Thatma Thary iour Dolutions
15.	Viscometer 100-13000 cps	Fungi Lab Spain	Pharma Analytical Solutions
16.	UPS	-	Pharma Analytical Solutions
	Dissolution Test Apparatus	Pharmatest	Pharma Analytical Solutions
17.	7(Stations)	Germany	
18.	pH Meter	China	Pharma Analytical Solutions
19.	Vernier Caliper (Digital)	China Six holes China	Pharma Analytical Solutions  Pharma Analytical Solutions
20.	Water Bath	Range 180x0.1	Pharma Analytical Solutions Pharma Analytical Solutions
		Model WXG-4	Thatma Thatytical Solutions
21.	Polarimeter (Digital)	China	
	Refractrometer automatic		Pharma Analytical Solutions
	temperature compensation Scale	Thomas Scientific	
22.	range 28-62 %	USA	

Disintegration Test Apparatus (Double basket)    23. (Double basket)	ons ons ons ons ons ons ons ons ons
Curio International Tablet Hardness Tester digital with printer  26. Ultrasonic Bath 2.75 lit Spain Pharma Analytical Soluti Pharma Analytical Soluti Spain Pharma Analytical Soluti Pharma Analytical Soluti Spain Pharma Analytical Soluti Pharma Analytical Soluti Pharma Analytical Soluti Pharma Analytical Soluti Pharma Analytical Soluti Pharma Analytical Soluti Pharma Analytical Soluti Pharma Analytical Soluti Pharma Analytical Soluti Pharma Analytical Soluti Pharma Analytical Soluti Pharma Analytical Soluti India Stability Constant Temperature Stability Constant Temperature Chamber 200 lit 25° +/- RH 75 % India Stability Constant Temperature Tharma Analytical Soluti Pharma Analytical Soluti Digital, heat up to India  Digital, heat up to India Tharma Analytical Soluti Pharma Analytical Soluti International, Pakistan	ons ons ons ons ons ons ons ons
Tablet Hardness Tester digital with printer  Tablet Hardness Tester digital with printer  26. Ultrasonic Bath 2.75 lit  Spain  Pharma Analytical Soluti  Pharma Analytical Soluti  Pharma Analytical Soluti  Stop Watch  Filtration Assembly all glass with 1  29. lit flask  Stability Constant Temperature  Chamber 200 lit 25° +/- RH 75 %  Stability Constant Temperature  31. Chamber 200 lit 25° +/- RH 75 %  Stability Constant Temperature  Other 200 lit 25° +/- RH 75 %  Stability Constant Temperature  Tharma Analytical Soluti  Pharma Analytical Soluti  Pharma Analytical Soluti  Digital, heat up to  Tharma Analytical Soluti  Digital, heat up to  Tharma Analytical Soluti  Pharma Analytical Soluti  Pharma Analytical Soluti  Pharma Analytical Soluti  Tharma Analytical Soluti  Pharma Analytical Soluti  Pharma Analytical Soluti  Tharma Analytical Soluti  Pharma Analytical Soluti  Pharma Analytical Soluti  Pharma Analytical Soluti  Tharma Analytical Soluti  Pharma Analytical Soluti	ons ons ons ons ons ons ons ons
Tablet Hardness Tester digital with printer  26. Ultrasonic Bath 2.75 lit  27. Flask shaker for 6-flask  Stop Watch Filtration Assembly all glass with 1 lit flask  Stability Constant Temperature 30. Chamber 200 lit 25° +/- RH 75 %  Stability Constant Temperature 31. Chamber 200 lit 25° +/- RH 75 %  Stability Constant Temperature 32. Eye wash station  Digital, heat up to 1100 C  Curio International, Pakistan  Pharma Analytical Soluti  Pharma Analytical Soluti  Pharma Analytical Soluti  Pharma Analytical Soluti  Pharma Analytical Soluti  Pharma Analytical Soluti  Pharma Analytical Soluti  Pharma Analytical Soluti  Pharma Analytical Soluti  Pharma Analytical Soluti  Pharma Analytical Soluti	ons ons ons ons
25. printer  26. Ultrasonic Bath 2.75 lit  27. Flask shaker for 6-flask  28. Stop Watch  Filtration Assembly all glass with 1  29. lit flask  Stability Constant Temperature  30. Chamber 200 lit 25° +/- RH 75 %  Stability Constant Temperature  31. Chamber 200 lit 25° +/- RH 75 %  Stability Constant Temperature  32. Eye wash station  Digital, heat up to  1100 C  Curio  International  Pharma Analytical Soluti	ons ons ons ons
26. Ultrasonic Bath 2.75 lit  27. Flask shaker for 6-flask  28. Stop Watch  Filtration Assembly all glass with 1  29. lit flask  Stability Constant Temperature  30. Chamber 200 lit 25° +/- RH 75 %  Stability Constant Temperature  31. Chamber 200 lit 25° +/- RH 75 %  Stability Constant Temperature  32. Eye wash station  Digital, heat up to  1100 C  Curio  International,  Pharma Analytical Soluti  Pharma Analytical Soluti  Pharma Analytical Soluti  Pharma Analytical Soluti  Pharma Analytical Soluti  Pharma Analytical Soluti  Pharma Analytical Soluti  Pharma Analytical Soluti  Pharma Analytical Soluti	ons ons ons
27. Flask shaker for 6-flask  28. Stop Watch  China  Pharma Analytical Soluti  Filtration Assembly all glass with 1  29. It flask  Stability Constant Temperature  Chamber 200 lit 25° +/- RH 75 %  Stability Constant Temperature  31. Chamber 200 lit 25° +/- RH 75 %  Stability Constant Temperature  Chamber 200 lit 25° +/- RH 75 %  India  Pharma Analytical Soluti  Pharma Analytical Soluti  India  Pharma Analytical Soluti  Digital, heat up to  1100 C  Curio  Curio  International,  Pharma Analytical Soluti  Pharma Analytical Soluti  Pharma Analytical Soluti  Pharma Analytical Soluti  Pharma Analytical Soluti  Pharma Analytical Soluti  Pharma Analytical Soluti  Pharma Analytical Soluti  Pharma Analytical Soluti  Pharma Analytical Soluti  Pharma Analytical Soluti  Pharma Analytical Soluti	ons ons ons
28. Stop Watch Filtration Assembly all glass with 1 29. lit flask Stability Constant Temperature 30. Chamber 200 lit 25° +/- RH 75 % Stability Constant Temperature Chamber 200 lit 25° +/- RH 75 % India 31. Chamber 200 lit 25° +/- RH 75 % Stability Constant Temperature Chamber 200 lit 25° +/- RH 75 % India 32. Eye wash station - Pharma Analytical Soluti Digital, heat up to 1100 C Curio International, Pakistan  Pharma Analytical Soluti Pharma Analytical Soluti Pharma Analytical Soluti	ons ons
Filtration Assembly all glass with 1 lit flask  Stability Constant Temperature Chamber 200 lit 25° +/- RH 75 %  Stability Constant Temperature Stability Constant Temperature Chamber 200 lit 25° +/- RH 75 %  India  Stability Constant Temperature Chamber 200 lit 25° +/- RH 75 %  India  22. Eye wash station  Figure 4  Digital, heat up to Digital, heat up to Stability Constant Temperature Chamber 200 lit 25° +/- RH 75 %  Digital, heat up to Stability Constant Temperature Chamber 200 lit 25° +/- RH 75 %  India  Chamber 200 lit 25° +/- RH 75 %  India  Pharma Analytical Solution  Pharma Analytical Solution  Turio International, Pakistan	ons
29. lit flask  Stability Constant Temperature 30. Chamber 200 lit 25° +/- RH 75 %  Stability Constant Temperature 31. Chamber 200 lit 25° +/- RH 75 %  32. Eye wash station  33. Muffle Furnace 129 Cu in  Stability Constant Temperature 31. Chamber 200 lit 25° +/- RH 75 %  Digital, heat up to 1100 C  Curio Pharma Analytical Solution  Curio Pharma Analytical Solution  The stability Constant Temperature 31. Chamber 200 lit 25° +/- RH 75 %  Stability Constant Temperature 32. Eye wash station  Chamber 200 lit 25° +/- RH 75 %  India  Digital, heat up to 1100 C  Curio Pharma Analytical Solution  The stability Constant Temperature Analytical Solution  Pharma Analytical Solution  Analytical Solution  Pharma Analytical Solution  Pharma Analytical Solution  Analytical Solution  Pharma Analytical Solution  Pharma Analytical Solution  Pharma Analytical Solution  Pharma Analytical Solution  Pharma Analytical Solution  Pharma Analytical Solution	ons
Stability Constant Temperature Chamber 200 lit 25° +/- RH 75 %  Stability Constant Temperature 31. Chamber 200 lit 25° +/- RH 75 %  Stability Constant Temperature Chamber 200 lit 25° +/- RH 75 %  Stability Constant Temperature India  Pharma Analytical Soluti  Pharma Analytical Soluti  Digital, heat up to Stability Constant Temperature Chamber 200 lit 25° +/- RH 75 %  Stability Constant Temperature India  Pharma Analytical Soluti  Pharma Analytical Soluti  Pharma Analytical Soluti  Turio International, Pakistan	
30. Chamber 200 lit 25° +/- RH 75 % India  Stability Constant Temperature 31. Chamber 200 lit 25° +/- RH 75 % India  32. Eye wash station  - Pharma Analytical Solution  Digital, heat up to 1100 C  Curio Pharma Analytical Solution  Curio Pharma Analytical Solution  The state of the state of	
Stability Constant Temperature Chamber 200 lit 25° +/- RH 75 %  32. Eye wash station  Digital, heat up to 1100 C  Curio International, Pharma Analytical Soluti Pharma Analytical Soluti Pharma Analytical Soluti Pharma Analytical Soluti Pharma Analytical Soluti International, Pakistan	ons
31. Chamber 200 lit 25° +/- RH 75 % India  32. Eye wash station  33. Muffle Furnace 129 Cu in  33. Muffle Furnace 129 Cu in  34. Fumes hood  35. India  - Pharma Analytical Solution  1100 C  Curio International, Pakistan	ons
32. Eye wash station  - Pharma Analytical Soluti Digital, heat up to 1100 C  Curio International, Pakistan  Pharma Analytical Soluti Pharma Analytical Soluti Pharma Analytical Soluti	
Digital, heat up to 1100 C  Surio International, Pakistan  Digital, heat up to 1100 C  Curio Pharma Analytical Solution International, Pakistan	
33. Muffle Furnace 129 Cu in  Curio International, Pakistan  Pharma Analytical Solution Pharma Analytical Solution Pharma Analytical Solution Pharma Analytical Solution Pharma Analytical Solution Pharma Analytical Solution	
Curio Pharma Analytical Solutional, Pakistan	ons
International, Pakistan	
34. Fumes hood Pakistan	ons
35 Racks S. S. Pharma Analytical Soluti	
· · · · · · · · · · · · · · · · · · ·	
Filteration assembly Pharma Analytical Solution	ons
36. (3 station) -	
37. Colony Counter Suntex Taiwan Pharma Analytical Soluti	ons
Memmert Pharma Analytical Soluti	ons
38. Hot Air Oven 53 lit Germany	
Memmert Pharma Analytical Solution	ons
39. Incubator 53 lit Germany	
40. Cool Incubator Lab. Tech Korean Pharma Analytical Soluti	ons
41. Water Bath Lab. Tech Korean Pharma Analytical Soluti	ons
Pharma Analytical Soluti	ons
Autoclave Desk type fitted with	
gauge moving pressure and	
42. temperature China	
43. Refrigerator (for Media) Pel (Pakistan) Pharma Analytical Solution	ons
44. Microscope Binocular China Pharma Analytical Soluti	one
•	
45. Hot Plate with Stirrer China Pharma Analytical Soluti	
46. Laminar Flow Hood (Vertical) Pharma Analytical Soluti	0118
Pharma Analytical Soluti	ons
Handheld laser particle counter	0110
super thin 3 channel Model HPC-	
47. 300 HAL USA	
Pharma Analytical Soluti	ons
Portable microbiological Air	
48. sampler B30120 AP Buck USA	
Thomas Scientific Pharma Analytical Soluti	ons
49. Annamo meter USA	
50. Tube Incubator Zhanijang Pharma Analytical Soluti	
51. Vortex mixer - Pharma Analytical Soluti	
52. Centrifuge Lab 4 you Pharma Analytical Soluti	
53. Micropipette Shangai Qiu Jing Pharma Analytical Soluti	
53.MicropipetteShangai Qiu JingPharma Analytical Soluti54.TrollyS. SPharma Analytical Soluti	ons
53. Micropipette Shangai Qiu Jing Pharma Analytical Soluti	ons ons

	Computer P4		Pharma Analytical Solutions
	3 in lab		
57.	1 in QCM office	Branded/ China	
58.	Printer	hp	Pharma Analytical Solutions
	Micro=3	-	Pharma Analytical Solutions
	Officers room=7		-
	Instrument room=2		
	Main hall=1		
59.	QCM Office=3	Plastic	
	Hall=1		Pharma Analytical Solutions
	Microbiology=1		
	Instrumentation room=1		
	In process room-=1		
	Retain sample room=1		
	Officers room=1	Split A.C	
60.		Kenwood	
	Officer room =4		Pharma Analytical Solutions
	Officer room =2 side table		
	microbiology=1		
	QCM Office=1		
61.		Wooden	
	Washing area=1		Pharma Analytical Solutions
	Microbiology=5		
62.		Stainless steel	
	Hall=6		Pharma Analytical Solutions
	Microbiology=3		
	Instrumentation room=6		
	In process room=3		
	QCM Office =2(wooden)		
63.	Washing area=1	S.S/wooden	

**Technical Staff List** 

Sr. #	Name	Designation	Qualifications	Experience	Section				
	PLANT OPERATIONS								
1.	Tariq Mahmood	QC/Plant Manager	MSc Chemistry	28 Years	Plant Operations				
		PRODUCTION	ON DEPARTMENT	Γ					
2.	Mr. Abdul Rasheed	Production Manager	B Pharm M.Phil (Pharmaceutics)	17 Years	Production				
3.	Miss Zain un Nisa	Production Pharmacist	Pharm D	04 Years	Production				
4.	Miss Momal Hanan	Production Pharmacist	Pharm D	02 Year	Production				
5.	Mr.Qaisar	Production Pharmacist	Pharm D	03 Years	Production				
6.	Miss Aqsa Nisar	Production Pharmacist	Pharm D	03 Years	Ceph.				
7.	Summiya Sultan	Production Pharmacist	Pharm D	01 Years	Ampoules Section				
8.	Miss Soha Mubeen	Production Pharmacist	Pharm D	1.5 Years	Infusion Section				

		QUAL	TY CON	NTROL					
9.	Tariq Mahmood	QC Manager	MSc.	Chemistry	28 Years	QC			
10.	Miss Mehwish	QC Analyst	MSc B	iochemistry	04 Years	QC			
11.	Miss Maham	QC Analyst	MSc	Chemistry	01 Year	QC			
12.	Sidra Jamil	QC Analyst	Pł	narm D	02 Years	QC			
13.	Muhammad Ameen	Microbiologist	BS Mi	crobiology	01 Years	QC			
	QUALITY ASSURANCE								
14.	Mr. Zahid Sarfraz	Manager Q.A	(Cho MS(TO	M.Phil emistry), QM)Medici ne O Scholar ma. Chem.)	18Years	Quality Assurance			
15.	Miss Ayesha	Q. A Officer	Pł	narm D	03Years	Quality Assurance			
16.	Urfah Ishrat	Q. A Officer	Pł	narm D	02Year	Quality Assurance			
17.	Iqra Riyasat	Q. A Officer	MSc.	Chemistry	01Year	Quality Assurance			
			L MANA	GEMENT		1			
18.	Mr. Rana Asghar Rasheed	Manager		B.Pharm	34 Years	R.M.W.H			
19.	Mr. Imran Ali	Supply chain Incha	arge	F. A	13 Years	Supply Chain			
20.	Mr. Faiz Rasool	Store Officer		B. Com	13 years	FGS			

### **Section wise Product List**

# 1. Liquid Injection

No.	Reg. No.	Brand Name	Generic Name	Dosage Form	Strength	Pack Size
1	084671	Alfasave	Alfacalcidol	Injection	2mcg/ml	10's
2	064749	Diclosave	Diclofenac Sodium	Injection	75mg	3ml x 5's
3	064749	Diclosave	Diclofenac Sodium	Injection	75mg	3ml x 10's
4	064749	Diclosave	Diclofenac Sodium	Injection	75mg	3ml x 100's
5	077166	Dicosun	Diclofenac Sodium + Lignocaine	Injection	75mg + 20mg	2ml x 5's
6	077164	D-Save	Cholecalciferol ( Vitamin D3)	Injection	5mg/1ml	1's

7	077165	Ketosave	Ketorolac Trometamol	Injection	30mg	5's x 1ml
8	064757	Medica	Lignocaine HCL 2%	Injection	10ml	25's
9	077163	Medica	Lignocaine HCL 1%	Injection	2ml	1's
10	064758	Medistil	Water for Injection	Injection	5ml	1's
11	100873	Medistil	Water for Injection	Injection	10ml	1's
12	064748	Nicep	Piroxicam	Injection	20mg	5's
13	064767	Rapir	Iron Sucrose complex	Injection	20mg	5 x 5ml
14	064752	Savemin	Mecobalamin	Injection	500mcg	10's
15	064750	Trisave	Tranexamic Acid	Injection	250mg	10 x 5ml
16	064751	Trisave	Tranexamic Acid	Injection	500mg	10's
17	094591	Thiocol	Thiclochicoside	Injection	4mg/2ml	1's
18	094591	Thiocol	Thiclochicoside	Injection	4mg/2ml	5's
19	094591	Thiocol	Thiclochicoside	Injection	4mg/2ml	6's

# 2. Infusion (LVP) Section

No.	Reg. No.	Brand Name	Generic Name	Dosage Form	Strength	Pack Size
1	084067	Ceta	Paracetamol	Injection	1000mg	100ml
2	098400	Ronisave	Zoledronic	Infusion	5mg	100ml
			Acid			
			Monohydrate			
3	064756	Oflosav	Ofloxacin	Infusion	200mg	100ml
4	101537	Linzrao	Linezolid	Infusion	200mg	100ml
5	094584	Medac	Levofloxacin	Infusion	500mg/100ml	100ml
			(as			
			hemihydrate)			
6	064753	Anata	Metronidazole	Infusion	500mg	100ml
7	092582	Ciprozan	Ciprofloxacin	Infusion	200mg	100ml
			(as lactate)			
8	064755	Moxisave	Moxifloxacin	Infusion	400mg	250ml

# 3. <u>Liquid Syrup</u>

No.	Reg. No.	Brand Name	Generic Name	Dosage Form	Strength	Pack Size
1	078810	Dinsave	Loratadine	Syrup	5mg/5ml	60ml
2	084069	Folifur	Iron (III) hydroxyl	Syrup	50mg+0.35	60ml
			Polymaltose		mg	
			Complex + Folic			
			Acid			
3	062761	Lactosav	Lactulose	Syrup	6.7gm/10ml	120ml
4	094550	P-Fin	Pizotifen	Syrup	0.25mg/5ml	120ml
			hydrogen maleate			
5	078811	Redish	Iron (III) hydroxyl	Syrup	50mg5ml	60ml

			Polymaltose complex			
6	078811	Redish	Iron (III) hydroxyl Polymaltose complex	Syrup	50mg5ml	120ml
7	062563	Sucin	Iron Protin Succinylate	Syrup	800mg/15m 1	60ml
8	062563	Sucin	Iron Protin Succinylate	Syrup	800mg/15m 1	120ml

#### CONCLUSION

Production and quality control capacity available for intended manufacturing sections is summarized in below table.

No.	Section	Medisave	Contract	Manufacturing
		Pharma	Product	Capacity Available
		Registration	Pending	(average)
			applications	
1	Liquid injection			87.04
	Section (Ampoule)	19	05	
2	Infusion section	08	01	93.9
	(LVP)			
3	Liquid Syrup	08	01	95.61%

### **Inspection report No. 2.**

### INSPECTION REPORT OF M/S. MEDISAVE PHARMACEUTICALS, LAHORE.

The inspection of M/s. Medisave Pharmaceuticals – Sunder Industrial Estate Lahore was conducted by the following panel of inspectors on 11-03-2022 for verification of surplus Production Capacity with reference to DRAP Islamabad letter No. F. 1-2/2020-PEC, Dated 28<sup>th</sup> August, 2020.

- Mr. Iftikhar Ch. Member Registration Board,
- 2. Mrs. Majida Mujahid. Area F.I.D/Additional Director (E&M), DRAP, Lahore.

The List of machinery / Equipments in production Cephalosporin (Section-wise) along with capacity is as follows.

- 1. General Tablet Section (General),
- 2. Capsule Section (Cephalosporin)
- 3. Dry Powder Suspension Section (Cephalosporin)
- 4. Dry Powder Injection Section (Cephalosporin)

### **Section Wise capacity calculations**

### 1. General Tablet Section (General)

Process/Steps	Capacity per day/Shift (8Hrs)	Capacity per Month (22 Days) (8Hrs/day/shift) Calculate with respect to total working days/shifts.
Mixing	150kg Tabs	3300kg
Compression	5,00,000 Tabs	11,000,000 Tab
Coating	5,00,000 Tabs	11,000,000 Tabs
Blistering	5,00,000 Tabs	11,000,000 Tabs
Packaging	1,50,000 Tabs	33,00,000 Tabs

# \*Note: Limiting step in this process is compression. Capacity Calculated with respect to capacity limiting step:

QUARTER WISE CAPACITY UTILIZED						
Quarter	Actual Production	Capacity	Capacity utilize in %			
2 <sup>nd</sup> 2021	51,16,971 Tabs	11,000,000 Tabs	46.5%			
3 <sup>rd</sup> 2021	33,94,460 Tabs	11,000,000 Tabs	30.85%			
4 <sup>th</sup> 2021	49,31,171 Tabs	11,000,000 Tabs	44.82%			
1st 2022	19,01,650 Tabs	11,000,000 Tabs	17.28%			
Average Capacity Utilized is 34.86%						

Manufacturing Capacity Utilized (average): 34.86% Manufacturing Capacity Available (average): 65.13%

### 2. <u>Capacity of capsule Section</u> (Cephalosporin)

Process/Steps	Capacity per day/Shift (8Hrs)	Capacity per Month (22 Days) (8Hrs/day/shift) Calculate with respect to total working days/shifts.
Mixing	200kg	4400kg
Filling	80,000 caps	17,60,000 caps
Packaging	1,00,000	22,00,000 caps

\*Note: Limiting step in this process is encapsulation.
Capacity Calculated with respect to capacity limiting step:

QUARTER WISE CAPACITY UTILIZED						
Quarter	Actual Production	Capacity	Capacity utilize in %			
2 <sup>nd</sup> 2021	4,28,042 caps	66,00,000 caps	6.48%			
3 <sup>rd</sup> 2021	3,25,410 caps	66,00,000 caps	4.93%			
4 <sup>th</sup> 2021	2,16,535 caps	66,00,000 caps	3.28%			
1st 2022	3,23,992 caps	66,00,000 caps	4.90%			
Average Capacity Utilized is 4.89%						

Manufacturing Capacity Utilized (average): 4.89% Manufacturing Capacity Available (average): 95.10%

### 3. Capacity of Oral Dry Powder Suspension Section (Cephalosporin).

Process/Steps	Capacity per day/Shift (8Hrs)	Capacity per Month (22 Days) (8Hrs/day/shift)
Mixing	200kg	4400kg
Filling	13,000	2,86,000
Packaging	15000	3,30,000

# \*Note: Limiting step in this process is filling of Product. Capacity Calculated with respect to capacity limiting step:

QUARTER WISE CAPACITY UTILIZED						
Quarter	Actual Production	Capacity	Capacity utilize in %			
2 <sup>nd</sup> 2021	34,984 Bottles	8,58,000 Bottles	4.07%			
3 <sup>rd</sup> 2021	62,600 Bottles	8,58,000 Bottles	7.29%			
4 <sup>th</sup> 2021	20,000 Bottles	8,58,000 Bottles	2.33%			
1 <sup>st</sup> 2022	40,061 Bottles	8,58,000 Bottles	4.66%			
Average Capacity Utilized is 4.58%						

Manufacturing Capacity Utilized (average): 4.58% Manufacturing Capacity Available (average): 95.41%

### 4. Capacity of dry Powder Injection section (Cephalosporin).

	Step wise capacity of each process							
Capacity washing of vials/per 8hour	Capacity washing per month with single shift of 8 hours (22working days)	Capacity dry heat sterilization single shift (load per day)	Capacity dry heat sterilization per month single shift (22 working days (sterilizer)	Capacity filling per day	Capacity filling per month with single shift of 8 working hours (22 working days)	Capacity packing per hour	Capacit y packing per month with single shift of 5 working hours (22 working days	
50,000 vials	11,00,000 Vials	40,000 vials	8,80,000 vials	48,000 vials	10,56,000 vials	1500	2,64,000 vials	

# \*Note: Limiting step in this process is filling of product Capacity calculated with respect to the Filling process being capacity limiting step:

QUARTER WISE CAPACITY UTILIZED						
Quarter	Actual Production	Capacity	Capacity utilize in %			
2 <sup>nd</sup> 2021	3,00,653 Vials	7,92,000 Vials	37.96%			
3 <sup>rd</sup> 2021	2,35,318 Vials	7,92,000 Vials	29.71%			
4 <sup>th</sup> 2021	2,07,710 Vials	7,92,000 Vials	34.98%			
1 <sup>st</sup> 2022 2,26,965 Vials 7,92,000 Vials 28.65%						
Average Capacity Utilized in 32.82%						

Manufacturing Capacity Utilized (average): 32.82% Manufacturing Capacity Available (average): 67.18%

### CAPACITY OF QUALITY CONTROL DEPARTMENT

HPLC Capacity Calculation Quarter Wise (Max 2 tests/Day) Total 3 HPLCs						
Quarter	Quarter Average Capacity of Performed Capacity Utilized Capacity					
	HPLC			Available		
4 <sup>th</sup> 2021	44	17	38.63%	61.37		

3 <sup>rd</sup> 2021	44	21	47.72%	52.28		
2 <sup>rd</sup> 2022	44	26	59.09%	40.91		
1st 2022	44	18	40.90%	59.1		
Average Capa	Average Capacity Available = 53.42%					

Average capacity utilized = 46.58%

UV-Sp	UV-Spectrophotometer Capacity Calculation Quarter Wise (Average 20 Tests/Day)						
Quarter	Capacity	Performed	Capacity Utilized	Capacity			
				Available			
4 <sup>th</sup> 2021	440	96	21.81%	78.18			
3 <sup>rd</sup> 2021	440	121	27.5%	72.5			
2 <sup>rd</sup> 2022	440	81	18.4%	81.59			
1st 2022	440	89	20.22%	79.77			
Average Capa	city Available = 78.01%						

Average capacity utilized = 21.98%

Capacity Calculation for Sterility testing Quarter wise depending on incubators							
		(Average 5 test/day					
Quarter     Capacity     Performed     Capacity Utilized     Capacity       Available							
4 <sup>th</sup> 2021	110	22	20%	80%			
3 <sup>rd</sup> 2021	110	28	25.45%	74.54%			
2 <sup>rd</sup> 2022	110	16	14.54%	85.45%			
1st 2022	110	27	24.54%	75.45%			
Average Capac	city Available 78.86%						

Average capacity utilized = 21.13%

# **List of Equipments QC Lab**

Sr.			Calibration Experts Names
No.	NAME OF EQUIPMENT	Manufacturing	<b>P</b>
	FTIR (Fourier Transform Infrared		Pharma Analytical Solutions
	Spectroscopy)		
1.		Lambda Scientific	
	HPLC with (Isocratic) with auto		
	injector, column oven, system		Pharma Analytical Solutions
	controller, UV-vis detector and		
	built in software, Computer &		
	Printer	Cl.:	
2.	Columns:	Shimadzu Japan	Discours Amelorical Calcricos
	HPLC Kauner		Pharma Analytical Solutions
3.	HPLC Kauner	Germany	
3.		Germany	Pharma Analytical Solutions
	PerkinElmer		Filarina Anaryticai Solutions
4.	1 CIKIIIEIIIICI	USA	
т.	UV VIS. Spectrophotometer	OSA	Pharma Analytical Solutions
	Double Beam wave length 190-		Tharma Tharytical Solutions
	1100 nm with LCDs & Printer		
5.	Accessories:	PG Instruments Ltd UK	
	UV VIS. Spectrophotometer		
	Dynamic HALO DB-20S UV-VIS		
6.	DOUBLE BEAM.	Western Instruments	
7.	TOC (Total Organic Carbon)	Membrapure	Pharma Analytical Solutions
8.	Coulter Particle Counter	Beckman coulter	Pharma Analytical Solutions
9.	Karl Fisher Titration	Metrohm Switzerland	Pharma Analytical Solutions

	Analytical Balance (readability		Pharma Analytical Solutions
	0.1 mg) (Capacity 320Gm) built in		Tharma Analytical Solutions
10.	calibration	Sartorious Germany	
10.	Moisture Analyzer (readability 1	Sartorious Germany	Pharma Analytical Solutions
11.	mg) (Capacity 150 Gm)	Sartorious Germany	Thattha Tharytical Solutions
	Precision Weighing Balance	Surtorious Cermany	Pharma Analytical Solutions
	(readability 1 mg) (Capacity		
12.	310gm)	Sartorious Germany	
13.	Melting Point Apparatus	China	Pharma Analytical Solutions
	Weighing Box with all calibrated		Pharma Analytical Solutions
14.	weight	China	
15.	Viscometer 100-13000 cps	Fungi Lab Spain	Pharma Analytical Solutions
16.	UPS	-	Pharma Analytical Solutions
	Dissolution Test Apparatus		Pharma Analytical Solutions
17.	7(Stations)	Pharma test Germany	•
18.	pH Meter	China	Pharma Analytical Solutions
19.	Vernier Caliper (Digital)	China	Pharma Analytical Solutions
20.	Water Bath	Six holes China	Pharma Analytical Solutions
		Range 180x0.1 Model	Pharma Analytical Solutions
21.	Polarimeter (Digital)	WXG-4 China	
	Refractometer automatic		Pharma Analytical Solutions
	temperature compensation Scale		
22.	range 28-62 %	Thomas Scientific USA	
	Disintegration Test Apparatus		Pharma Analytical Solutions
23.	(Double basket)	Curio International,	
24.	Friabilator	Curio International	Pharma Analytical Solutions
	Tablet Hardness Tester digital		Pharma Analytical Solutions
25.	with printer	Curio International	
26.	Ultrasonic Bath 2.75 lit	Spain	Pharma Analytical Solutions
27.	Flask shaker for 6-flask	Gallen kamp type	Pharma Analytical Solutions
28.	Stop Watch	China	Pharma Analytical Solutions
	Filtration Assembly all glass with		Pharma Analytical Solutions
29.	1 lit flask	ldam Europe	
	Stability Constant Temperature		Pharma Analytical Solutions
30.	Chamber 200 lit 25° +/- RH 75 %	India	
	Stability Constant Temperature		Pharma Analytical Solutions
31.	Chamber 200 lit 25° +/- RH 75 %	India	
32.	Eye wash station	-	Pharma Analytical Solutions
	1.00	Digital, heat up to 1100	Pharma Analytical Solutions
33.	Muffle Furnace 129 Cu in	C	
		Curio International,	Pharma Analytical Solutions
34.	Fumes hood	Pakistan	DI 4 1 1 2 1 2
35.	Racks	S. S	Pharma Analytical Solutions
26	Filtration assembly		Pharma Analytical Solutions
36.	(3 station)	- C	Discuss An 1 C 1 C 1
37.	Colony Counter	Suntex Taiwan	Pharma Analytical Solutions
38.	Hot Air Oven 53 lit	Memmert Germany	Pharma Analytical Solutions
39.	Incubator 53 lit	Memmert Germany	Pharma Analytical Solutions
40.	Cool Incubator	Lab. Tech Korean	Pharma Analytical Solutions
41.	Water Bath	Lab. Tech Korean	Pharma Analytical Solutions
	Autoclave Desk type fitted with		Pharma Analytical Solutions
	gauge moving pressure and		
42.	temperature	China	
	_ ^		Pharma Analytical Solutions
43.	Refrigerator (for Media)	Pel (Pakistan)	<b>y</b>
44.	Microscope Binocular	China	Pharma Analytical Solutions

45.	Hot Plate with Stirrer	China	Pharma Analytical Solutions
			Pharma Analytical Solutions
46.	Laminar Flow Hood (Vertical)	China	·
	Handheld laser particle counter		Pharma Analytical Solutions
	super thin 3 channel Model HPC-		
47.	300	HAL USA	
			Pharma Analytical Solutions
	Portable microbiological Air		
48.	sampler B30120 AP	Buck USA	
40			Pharma Analytical Solutions
49.	Annamo meter	Thomas Scientific USA	DI A 1 1 1 C 1 1
50.	Tube Incubator	Zhanijang	Pharma Analytical Solutions
51.	Vortex mixer	-	Pharma Analytical Solutions
52.	Centrifuge	Lab 4 you	Pharma Analytical Solutions
53.	Micropipette	Shangai Qiu Jing	Pharma Analytical Solutions
54.	Trolly	S. S	Pharma Analytical Solutions
55.	Racks	S. S	Pharma Analytical Solutions
56.	Book Rack (1)	Wooden	Pharma Analytical Solutions
	Computer P4		Pharma Analytical Solutions
57	3 in lab	D 4. 4/ Chi	
57.	1 in QCM office	Branded/ China	Dhamas Analytical Calutions
58.	Printer Micro=3	hp	Pharma Analytical Solutions
	Officers room=7		Pharma Analytical Solutions
	Instrument room=2		
	Main hall=1		
59.	QCM Office=3	Plastic	
37.	Hall=1	Trastic	Pharma Analytical Solutions
	Microbiology=1		Tharma Tharytical Solutions
	Instrumentation room=1		
	In process room-=1		
	Retain sample room=1		
	Officers room=1	Split A.C	
60.	QCM Office =1	Kenwood	
	Officer room =4		Pharma Analytical Solutions
	Officer room =2 side table		
	microbiology=1		
	QCM Office=1		
61.	QCM Office=1 side table	Wooden	
	Washing area=1		Pharma Analytical Solutions
	Microbiology=5		
62.	Fume hood area=1	Stainless steel	
	Hall=6 Microbiology=3		Pharma Analytical Solutions
	Instrumentation room=6		
	In process room=3 QCM Office		
	=2(wooden)		
63.	Washing area=1	S.S/wooden	

# **Technical Staff List**

### **Section wise Product List**

# 1. General Tablet Section

Sr.	Reg. No.	Brand	Generic Name	Dosage	Strength	Pack Size
No.		Name		Form		

58189	Acenil	Sucralfate	Tablet	500mg	2 x 10's
58188	Acenil	Sucralfate	Tablet	1gm	10's
59019	Acesave	Aceclofenac	Tablet	100mg	10's
59019	Acesave	Aceclofenac	Tablet	100mg	20's
68196	Anata	Metronidazole	Tablet	200mg	20 x 10's
58197	Anata	Metronidazole	Tablet	400mg	10 x 10's
58195	Asept	Nalidixic Acid	Tablet	500mg	3 x 10's
59006	Bizin	Cetrizine Dihydrochloride	Tablet	10mg	1 x 10's
84066	Ciferol	Alendronate sodium + Cholecalciferol	Tablet	70mg+7 0mcg	7's
	Closun	Clopidogrel as hydrogen sulphate + Aspirin	Tablet	75mg+ 75mg	10's
58194	Diclosave	Diclofenac Sodium	Tablet	50mg	20's
59034	Diclosave SR	Diclofenac Sodium	Tablet	100mg	20's
84762	Dingo	Desloratadine	Tablet	5mg	10's
52574	Dinsave	Loratadine	Tablet	10mg	10's
59005	Domsave	Domperidone	Tablet	10mg	50's
01551	Dopsave	Doxylamine Succinate + Pyridoxine hydrochloride	Tablet	10mg +10mg	30's
69022	Ecloprost	Diclofenac sodium + Misoprostal	Tablet	50mg +200mc g	2 x 10's
62573	Esmov	Naproxen Sodium	Tablet	550mg	2 x 10's
59018	Esolone	Esomeprazole	Tablet	20mg	2 x 7's
59003	Esolone	Esomeprazole	Tablet	40mg	2 x 7's
77159	Estisave	Escitalopram	Tablet	10mg	2 x 7's
58193	Exacid	Telithromycin	Tablet	400mg	10's
52584	Falcim	Artemether & Lumefantrine	Tablet	20mg +120mg	2 x 8's
62583	Falcim	Artemether & Lumefantrine	Tablet	40mg +240mg	8's
98107	Falcim	Artemether & Lumefantrine	Tablet	80mg+4 80mg	1 x 8's
98107	Falcim	Artemether & Lumefantrine	Tablet	80mg+4 80mg	2 x 8's
62565	Flamot	Meloxicam	Tablet	7.5mg	1 x 10's
62566	Flamot	Meloxicam	Tablet	15mg	1 x 10's
94585	Febusave	Febuxostat	Tablet	40mg	20's
94586	Febusave	Febuxostat	Tablet	80mg	20's
59013	Felip	Citalopram	Tablet	20mg	1X 10'S
59009	Folifur	Iron (III) Hydroxide Polymaltose Complex + Folic Acid	Tablet	100mg + 0.35 mg	10's
5901	3	3 Felip	3 Felip Citalopram	3 Felip Citalopram Tablet	3 Felip Citalopram Tablet 20mg

33	069009	Folifur	Iron (III) Hydroxide Polymaltose Complex +Folic Acid	Tablet	100mg + 0.35 mg	20's
34	069016	Itiosave	Itopride HCl	Tablet	50mg	10's
35	069011	Jocin	Fluoxetine HCL	Tablet	20mg	10's
36	069004	Kenac	Diclofenac Potassium	Tablet	75mg	2 x 10's
37	069017	Kenac	Diclofenac Potassium	Tablet	50mg	2 x 10's
38	092585	Lacosave	Lacosamide	Tablet	100mg	14's
39	069007	Medikast	Montelukast sodium	Tablet	5mg	14's
40	069008	Medikast	Montelukast sodium	Tablet	10mg	14's
41	084064	Misofenac	Diclofenac sodium + Misoprostal	Tablet	75mg+2 00mcg	20's
42	069010	Nefam	Piroxicam Beta cyclodextrin	Tablet	20mg	20's
43	068184	Newam	Escitalopram	Tablet	10mg	2 x 7's
44	068192	Oflosav	Ofloxacin	Tablet	200mg	10's
45	100871	Ondasave	Ondansetron HCl	Tablet	8mg	10's
46	084793	O-save	Olanzapine	Tablet	10mg	10's
47	069014	P- Line	Pantoprazole	Tablet	20mg	14's
48	069015	P- Line	Pantoprazole	Tablet	40mg	14's
49	094551	Rabimed	Rabeprazole (as Sodium)	Tablet	20mg	10's
50	064772	Redish	Iron Polymaltose Complex	Tablet	100mg	10's
51	064772	Redish	Iron Polymaltose Complex	Tablet	100mg	30's
52	084072	Rispolet	Risperidone	Tablet	1mg	10's
53	084073	Rispolet	Risperidone	Tablet	2mg	10's
54	091411	Rosun	Rosuvastatin (as calcium)	Tablet	10mg	10's
55	091419	Rosun	Rosuvastatin	Tablet	40mg	10's
56	069023	Savemin	Mecobalamin	Tablet	500 mcg	20's
57	091415	Sitasun	Sitagliptin (as phosphate monohydrate)	Tablet	100mg	14's
58	091412	Sitasun-M	Sitagliptin (as phosphate monohydrate) + Metformin hydrochloride	Tablet	50mg+ 1000m g	10's
59	091414	Telsun	Telmisartan + Amlodipine as besylate	Tablet	80mg +10m g	14's
60	062571	Terac	Pefloxacin	Tablet	400mg	10's
61	069012	Tresit	Famotidine	Tablet	40mg	10's
62	091420	Vabrasave	Ivabradine	Tablet	5mg	14's

63	077158	Valturna- A	Valsartan + Amoldipine	Tablet	80mg +5mg	2 x 7's
64	100869	Vidasave	Vidagliptin + Metformin Hcl	Tablet	50mg+ 850mg	28's
65	100869	Vidasave	Vidagliptin + Metformin Hcl	Tablet	50mg+ 1000m g	28's
66	098402	Virsave	Tenofovir Disproxil Fumarate	Tablet	300mg	30's

# 2. <u>Capsules (Cephalosporin)</u>

Sr.	Reg. No.	Brand Name	Generic Name	Dosage Form	Strength	Pack Size
No.						
1	062569	Cefusave	Cefuroxime	Capsules	250mg	14's
2	068180	Cesave	Cefixime	Capsule	400mg	5's
3	062588	Medbirox	Cefadroxil	Capsules	500mg	12's
4	062564	Medidoxim	Cefpodoxime	Capsule	100mg	12's
5	068191	Piocef	Cephradine	Capsule	250mg	12's
			Monohydrate			
6	068190	Piocef	Cephradine	Capsule	500mg	12's
			Monohydrate			

# 3. <u>Dry Powder Suspension (Cephalosporin)</u>

Sr. No.	Reg. No.	Brand Name	Generic Name	Dosage Form	Strength	Pack Size
1	06258 5	Cefusave	Cefuroxime	Suspension	125mg/5ml	50ml
2	06817 9	Cesave	Cefixime	Suspension	100mg	30ml
3	06817 8	Cesave	Cefixime	Suspension	200mg	30ml
4	09454 9	Medbirox	Cefadroxil (as monohydrate)	Suspension	125mg/5ml	60ml
5	09810 9	Medbirox	Cefadroxil (as monohydrate)	Suspension	250mg/5ml	60ml
6	06257 0	Medidoxim	Cefpodoxime	Suspension	40mg/5ml	50ml
7	08407 1	Piocef	Cephradine Monohydrate	Suspension	250mg/5ml	60ml

### 4. <u>Dry Powder Injection (Cephalosporin)</u>

Sr. No.	Reg. No.	Brand Name	Generic Name	Dosage Form	Strength	Pack Size
1	069025	Bezone	Cefoperazone Sodium+ Sulbactam Sodium	Injection	1000mg+1000 mg	1's
2	069024	Bezone	Cefoperazone Sodium+	Injection	500mg+500mg	1's

			Sulbactam Sodium			
3	064774	Ceftisav	Cefotaxime	Injection	250mg	1's
4	064773	Ceftisav	Cefotaxime	Injection	500mg	1's
5	064775	Ceftisav	Cefotaxime	Injection	1gm	1's
6	062572	Cefusave	Cefuroxime	Inj. Vial	250mg	5's
7	062581	Cefusave	Cefuroxime	Inj. Vial	750mg	1's
8	062582	Cefusave	Cefuroxime	Inj. Vial	1.5gm.	1's
9	062560	Cexzone	Ceftriaxone	Inj. Vial I.M	250mg	1's
10	062561	Cexzone	Ceftriaxone	Inj. Vial I.M	500mg	1's
11	062567	Cexzone	Ceftriaxone	Inj. Vial I.V	250mg	1's
12	062562	Cexzone	Ceftriaxone	Inj. Vial I.V	500mg	1's
13	062568	Cexzone	Ceftriaxone	Inj. Vial I.V	1gm	1's
14	088603	Neudime	Ceftazidime	Injection	250mg	1's
15	069428	Neudime	Ceftazidime	Injection	500mg	1's
16	069400	Neudime	Ceftazidime	Injection	1gm	1's
17	069028	Pimesave	Cefepime	Injection	1gm	1's
18	069029	Pimesave	Cefepime	Injection	500mg	1's
19	077162	Solara	Ceftriaxone	Inj. Vial I.V	1gm	1's

### **CONCLUSION**

Production and quality control capacity available for intended manufacturing sections is summarized in below table.

No.	Section	Medisave Pharma Registration	Contract Product Pending applications	Manufacturing Capacity Available (average)
1	<ul><li>A. General Tablet</li><li>B. Antibiotic Tablet</li></ul>	66	03 06	65.13
2	Capsules Section (Cephalosporin)	06	02	95.10%
3	Dry Powder susp. (Cephalosporin)	07	04	95.41%
4	Dry Powder Injection (Cephalosporin)	19	15	67.18%

Decision: Registration Board discussed the inspection report in details. Deliberations were made on used and available manufacturing and quality control capacity keeping in view all registered product and currently applied products. After thorough deliberation, the Board decided to allow contract manufacturing from M/s Medisave Pharmaceuticals, Plot 578-579, Sundar Industrial Estate, Lahore for following sections:

- General Tablet Section (General),
- Capsule Section (Cephalosporin)
- Dry Powder Suspension Section (Cephalosporin)
- Dry Powder Injection Section (Cephalosporin)
- Liquid Injection
- Infusion (LVP) Section

### • Liquid Syrup Section

However the Board further advised M/s Medisave to further increase testing capacity especially HPLC, microbilogical testing etc to cater the need of pharmacopeial testing of already registered drug products, products under development and contract manufactured products and submit upgradation plan in 2 months time for consideration of Registration Board.

194.	Name and address of manufacturer/	M/s Briell Pharmaceuticals Pvt Ltd. 538-C Sundar
	Applicant	Industrial Estate Road, Lahore. By M/s Medisave
		Pharmaceuticals. Plot 578-579, Sundar Industrial
		Estate, Lahore, Pakistan
	Brand Name + Dosage Form + Strength	Savix 100mg/5ml Dry Powder Suspension
	Composition	Each 5ml of reconstituted suspension contains:
	T T T	Cefixime Trihydrate eq to Cefixime100mg
	Diary No. Date of R & I & fee	Dy. No. 6996; 19.02.2019
	, , , , , , , , , , , , , , , , , , ,	PKR. 50,000/-; 19.02.2019
	Pharmacological Group	Third-generation cephalosporins
	Type of Form	Form 5
	Finished product Specification	USP
	Pack size & Demanded Price	Powder for 30ml suspension; As per SRO
	Approval status of product in Reference	Cefixime 100 mg/5 ml Powder for Oral Suspension.
	Regulatory Authorities.	MHRA approved
	Me-too status	Elixime Dry Suspension 100mg, Reg. No. 53729
	GMP status	Applicant: The firm was inspected on 24.05.2019 with
	Givii status	the following conclusion: The firm was evaluated for
		facilities like building, HVAC System, quality control,
		quality assurance and production operations. The Briell
		Pharma found to be operating at satisfactory level of
		GMP compliance.
		Manufacturer: GMP Certificate issued on 15-03-2018.
	Remarks of the Evaluator (IX)	The firm submitted 05 approved sections, no approved
	Temans of the Evaluator (11)	products for contract manufacturing and 22 applied
		products for contact manufacturing of the applicant
		(M/s Briell Pharma).
	Decision of 296 <sup>th</sup> meeting of	Deferred for capacity assessment of M/s Medisave
	Registration Board.	pharmaceuticals, Lahore.
	Remarks of the Evaluator.	, — — — — — — — — — — — — — — — — — — —
	Decision: Approved.	
195.	Name and address of manufacturer/	M/s Briell Pharmaceuticals Pvt Ltd. 538-C Sundar
	Applicant	Industrial Estate Road, Lahore. By M/s Medisave
		Pharmaceuticals. Plot 578-579, Sundar Industrial
		Estate, Lahore, Pakistan
	Brand Name + Dosage Form + Strength	Savix 200mg/5ml Dry Powder Suspension
	Composition	Each 5ml of reconstituted suspension contains:
	•	Cefixime Trihydrate eq to Cefixime200mg
	Diary No. Date of R & I & fee	Dy. No. 6989; 19.02.2019
		PKR. 50,000/-; 19.02.2019
	Pharmacological Group	Third-generation cephalosporins
	Type of Form	Form 5
	Finished product Specification	USP
	Pack size & Demanded Price	Powder for 30ml suspension; As per SRO
	Approval status of product in Reference	SUPRAX® (cefixime) for oral suspension. USFDA
	Regulatory Authorities.	approved
	Me-too status	Elixime Dry Suspension 200mg. Reg. No. 53730
	GMP status	Applicant: The firm was inspected on 24.05.2019 with
		the following conclusion: The firm was evaluated for
	1	Programming Pound (16, 17 May, 2022)

Name and address of manufacturer/ Applicant   Applic		Remarks of the Evaluator (IX)  Decision of 296 <sup>th</sup> meeting of Registration Board.  Remarks of the Evaluator.  Decision: Approved.	facilities like building, HVAC System, quality control, quality assurance and production operations. The Briell Pharma found to be operating at satisfactory level of GMP compliance.  Manufacturer: GMP Certificate issued on 15-03-2018.  The firm submitted 05 approved sections, no approved products for contract manufacturing and 22 applied products for contact manufacturing of the applicant (M/s Briell Pharma).  Deferred for capacity assessment of M/s Medisave pharmaceuticals, Lahore.
Applicant    Industrial Estate Road, Lahore. By M/s Medisar Pharmaceuticals. Plot 578-579, Sundar Industri Estate, Lahore, Pakistan   Brand Name + Dosage Form + Strength   Savix 400mg Capsule	196.		M/s Briell Pharmaceuticals Pvt Ltd. 538-C Sundar
Composition  Each Capsule Contains: Cefixime Trihydrate eq to Cefixime		Applicant	Industrial Estate Road, Lahore. By M/s Medisave Pharmaceuticals. Plot 578-579, Sundar Industrial Estate, Lahore, Pakistan
Diary No. Date of R & I & fee  Diary No. Date of R & I & fee  Dy. No. 6990; 19.02.2019  PRR 5.00,000/-; 19.02.2019  PRR 5.00,000/-; 19.02.2019  PRR 5.00,000/-; 19.02.2019  PRR 5.00,000/-; 19.02.2019  Prest form  Type of Form  Finished product Specification  Pack size & Demanded Price  Approval status of product in Reference Regulatory Authorities.  Me-too status  Nowcef 400mg Capsule by Nawan Lab. Karachi. Re No. 82219  GMP status  Applicant: The firm was inspected on 24.05.2019 with the following conclusion: The firm was evaluated for facilities like building, HVAC System, quality control quality assurance and production operations. The Brie Pharma found to be operating at satisfactory level of GMP compliance.  Manufacturer: GMP Certificate issued on 15-03-2018  Remarks of the Evaluator (IX)  The firm submitted 05 approved sections, no approve products for contract manufacturing and 22 applic products for contract manufacturing of the applica (M/s Briell Pharma).  Decision of 296th meeting of Registration Board.  Remarks of the Evaluator.  Firm has claimed JP specifications for their product However, monograph of Japanese pharmacopoe confirms test of dissolution only for cefixime capsu 50mg and 100mg. Dissolution test parameter for cefixime 400mg capsule is not available in JP.  Decision: Approved with Manufacturer's specifications notified vide letter No.F.14-1/202  PEC dated 14th March 2022.  Registration Board further decided that firm will submit fee of Rs. 7,500 fc correction/pre-approval change in product specifications, as per notification No.F.7-11/2012-B&A/DRAP dated 13-07-2021.		Brand Panie + Bosage Form + Strength	
PKR. 50,000/-; 19.02.2019  Pharmacological Group Third generation cephalosporins Type of Form Form 5  Finished product Specification JP  Pack size & Demanded Price 5's; as per SRO  Approval status of product in Reference Regulatory Authorities. Ltd for Lupin Pharma. Approved by US-FDA  Me-too status Nowcef 400mg Capsule by Nawan Lab. Karachi. Re No. 82219  GMP status Applicant: The firm was inspected on 24.05.2019 with the following conclusion: The firm was evaluated for facilities like building, HVAC System, quality contropulative assurance and production operations. The Bric Pharma found to be operating at satisfactory level of GMP compliance.  Manufacturer: GMP Certificate issued on 15-03-2018  Remarks of the Evaluator (IX) The firm submitted 05 approved sections, no approve products for contract manufacturing and 22 applies products for contract manufacturing of the applica (M/s Briell Pharma).  Decision of 296th meeting of Registration Board.  Remarks of the Evaluator. Firm has claimed JP specifications for their product However, monograph of Japanese pharmacopoe confirms test of dissolution only for cefixime capsus 50mg and 100mg. Dissolution test parameter for cefixime 400mg capsule is not available in JP.  Decision: Approved with Manufacturer's specifications notified vide letter No.F.14-1/202 PEC dated 14th March 2022.  Registration Board further decided that firm will submit fee of Rs. 7,500 for correction/pre-approval change in product specifications, as per notification No.F.7-11/2012-B&A/DRAP dated 13-07-2021.		-	Cefixime Trihydrate eq to Cefixime400mg
Pharmacological Group Type of Form Finished product Specification Pack size & Demanded Price Approval status of product in Reference Regulatory Authorities. Me-too status  Me-too status  GMP status  Applicant: The firm was inspected on 24.05.2019 with following conclusion: The firm was evaluated for facilities like building, HVAC System, quality control quality assurance and production operations. The Brie Pharma found to be operating at satisfactory level of GMP compliance.  Manufacturer: GMP Certificate issued on 15-03-2018 Remarks of the Evaluator (IX)  The firm submitted 05 approved sections, no approve products for contact manufacturing and 22 applic products for contact manufacturing of the applica (M/s Briell Pharma).  Decision of 296th meeting of Registration Board.  Remarks of the Evaluator.  Firm has claimed JP specifications for their product However, monograph of Japanese pharmacopoe confirms test of dissolution only for cefixime capsus 50mg and 100mg. Dissolution test parameter for cefixime 400mg capsule is not available in JP.  Decision: Approved with Manufacturer's specifications notified vide letter No.F.14-1/202 PEC dated 14th March 2022.  Registration Board further decided that firm will submit fee of Rs. 7,500 fc correction/pre-approval change in product specifications, as per notification No.F.7-11/2012-B&A/DRAP dated 13-07-2021.		Diary No. Date of R & I & fee	•
Finished product Specification Pack size & Demanded Price Approval status of product in Reference Regulatory Authorities.  Me-too status  Me-too status  Mestoo Status  Applicant: The firm was inspected on 24.05.2019 with following conclusion: The firm was evaluated for facilities like building, HVAC System, quality contropharma found to be operating at satisfactory level of GMP compliance.  Manufacturer: GMP Certificate issued on 15-03-2018  Remarks of the Evaluator (IX)  The firm submitted 05 approved sections, no approve products for contract manufacturing and 22 applies products for contract manufacturing of the applications for contact manufacturing of the applications of Registration Board.  Remarks of the Evaluator.  Perfect of capacity assessment of M/s Medisary pharmaceuticals, Lahore.  Firm has claimed JP specifications for their product However, monograph of Japanese pharmacopoe confirms test of dissolution only for cefixime capsus 50mg and 100mg. Dissolution test parameter for cefixime 400mg capsule is not available in JP.  Decision: Approved with Manufacturer's specifications notified vide letter No.F.14-1/202  PEC dated 14th March 2022.  Registration Board further decided that firm will submit fee of Rs. 7,500 for correction/pre-approval change in product specifications, as per notification No.F.7-11/2012-B&A/DRAP dated 13-07-2021.		Pharmacological Group	
Pack size & Demanded Price Approval status of product in Reference Regulatory Authorities.  Me-too status  Me-too status  GMP status  Applicant: The firm was inspected on 24.05.2019 with the following conclusion: The firm was evaluated for facilities like building, HVAC System, quality control quality assurance and production operations. The Brie Pharma found to be operating at satisfactory level of GMP compliance.  Manufacturer: GMP Certificate issued on 15-03-2018  Remarks of the Evaluator (IX)  The firm submitted 05 approved sections, no approve products for contract manufacturing and 22 applies products for contact manufacturing of the applica (M/s Briell Pharma).  Decision of 296th meeting of Registration Board.  Remarks of the Evaluator.  Firm has claimed JP specifications for their product However, monograph of Japanese pharmacopoe confirms test of dissolution only for cefixime capsus 50mg and 100mg. Dissolution test parameter for cefixime 400mg capsule is not available in JP.  Decision: Approved with Manufacturer's specifications notified vide letter No.F.14-1/202. PEC dated 14th March 2022.  Registration Board further decided that firm will submit fee of Rs. 7,500 for correction/pre-approval change in product specifications, as per notification No.F.7-11/2012-B&A/DRAP dated 13-07-2021.		**	
Approval status of product in Reference Regulatory Authorities.  Me-too status  Me-too status  Mowcef 400mg Capsule by Nawan Lab. Karachi. Re No. 82219  GMP status  Applicant: The firm was inspected on 24.05.2019 with the following conclusion: The firm was evaluated for facilities like building, HVAC System, quality control quality assurance and production operations. The Brie Pharma found to be operating at satisfactory level of GMP compliance.  Manufacturer: GMP Certificate issued on 15-03-2018  Remarks of the Evaluator (IX)  The firm submitted 05 approved sections, no approve products for contract manufacturing and 22 applied products for contract manufacturing of the application (M/s Briell Pharma).  Decision of 296th meeting of Registration Board.  Remarks of the Evaluator.  Firm has claimed JP specifications for their product However, monograph of Japanese pharmacopoe confirms test of dissolution only for cefixime capsus 50mg and 100mg. Dissolution test parameter for cefixime 400mg capsule is not available in JP.  Decision: Approved with Manufacturer's specifications notified vide letter No.F.14-1/202 PEC dated 14th March 2022.  Registration Board further decided that firm will submit fee of Rs. 7,500 for correction/pre-approval change in product specifications, as per notification No.F.7-11/2012-B&A/DRAP dated 13-07-2021.			JP
Regulatory Authorities.  Me-too status  Nowcef 400mg Capsule by Nawan Lab. Karachi. Re No. 82219  GMP status  Applicant: The firm was inspected on 24.05.2019 withe following conclusion: The firm was evaluated for facilities like building, HVAC System, quality control quality assurance and production operations. The Brie Pharma found to be operating at satisfactory level of GMP compliance.  Manufacturer: GMP Certificate issued on 15-03-2018  Remarks of the Evaluator (IX)  The firm submitted 05 approved sections, no approve products for contact manufacturing and 22 applied products for contact manufacturing of the application (M/s Briell Pharma).  Decision of 296th meeting of Registration Board.  Remarks of the Evaluator.  Firm has claimed JP specifications for their product However, monograph of Japanese pharmacopoe confirms test of dissolution only for cefixime capsus 50mg and 100mg. Dissolution test parameter for cefixime 400mg capsule is not available in JP.  Decision: Approved with Manufacturer's specifications notified vide letter No.F.14-1/202.  PEC dated 14th March 2022.  Registration Board further decided that firm will submit fee of Rs. 7,500 for correction/pre-approval change in product specifications, as per notification No.F.7-11/2012-B&A/DRAP dated 13-07-2021.			
Me-too status    Nowcef 400mg Capsule by Nawan Lab. Karachi. Re No. 82219   Applicant: The firm was inspected on 24.05.2019 with following conclusion: The firm was evaluated for facilities like building, HVAC System, quality control quality assurance and production operations. The Brie Pharma found to be operating at satisfactory level of GMP compliance.   Manufacturer: GMP Certificate issued on 15-03-2018			
GMP status  Applicant: The firm was inspected on 24.05.2019 with the following conclusion: The firm was evaluated for facilities like building, HVAC System, quality control quality assurance and production operations. The Brie Pharma found to be operating at satisfactory level of GMP compliance.  Manufacturer: GMP Certificate issued on 15-03-2018  Remarks of the Evaluator (IX)  The firm submitted 05 approved sections, no approve products for contract manufacturing and 22 applic products for contract manufacturing of the applica (M/s Briell Pharma).  Decision of 296th meeting of Registration Board.  Remarks of the Evaluator.  Firm has claimed JP specifications for their product However, monograph of Japanese pharmacopoe confirms test of dissolution only for cefixime capsu 50mg and 100mg. Dissolution test parameter for cefixime 400mg capsule is not available in JP.  Decision: Approved with Manufacturer's specifications notified vide letter No.F.14-1/202 PEC dated 14th March 2022.  • Registration Board further decided that firm will submit fee of Rs. 7,500 for correction/pre-approval change in product specifications, as per notification No.F.7-11/2012-B&A/DRAP dated 13-07-2021.			
the following conclusion: The firm was evaluated for facilities like building, HVAC System, quality control quality assurance and production operations. The Brie Pharma found to be operating at satisfactory level of GMP compliance.  Manufacturer: GMP Certificate issued on 15-03-2018  Remarks of the Evaluator (IX)  The firm submitted 05 approved sections, no approved products for contract manufacturing and 22 applic products for contact manufacturing of the application (M/s Briell Pharma).  Decision of 296th meeting of Registration Board.  Remarks of the Evaluator.  Firm has claimed JP specifications for their product However, monograph of Japanese pharmacopoe confirms test of dissolution only for cefixime capsus 50mg and 100mg. Dissolution test parameter for cefixime 400mg capsule is not available in JP.  Decision: Approved with Manufacturer's specifications notified vide letter No.F.14-1/202 PEC dated 14th March 2022.  • Registration Board further decided that firm will submit fee of Rs. 7,500 for correction/pre-approval change in product specifications, as per notification No.F.7-11/2012-B&A/DRAP dated 13-07-2021.		Me-too status	
Remarks of the Evaluator (IX)  The firm submitted 05 approved sections, no approved products for contract manufacturing and 22 applies products for contact manufacturing of the application (M/s Briell Pharma).  Decision of 296th meeting of Registration Board.  Remarks of the Evaluator.  Remarks of the Evaluator.  Firm has claimed JP specifications for their product However, monograph of Japanese pharmacopoe confirms test of dissolution only for cefixime capsus 50mg and 100mg. Dissolution test parameter for cefixime 400mg capsule is not available in JP.  Decision: Approved with Manufacturer's specifications notified vide letter No.F.14-1/202.  PEC dated 14th March 2022.  Registration Board further decided that firm will submit fee of Rs. 7,500 for correction/pre-approval change in product specifications, as per notification No.F.7-11/2012-B&A/DRAP dated 13-07-2021.		GMP status	_
Registration Board.  Remarks of the Evaluator.  Remarks of the Evaluator.  Firm has claimed JP specifications for their product However, monograph of Japanese pharmacopoe confirms test of dissolution only for cefixime capsus 50mg and 100mg. Dissolution test parameter for cefixime 400mg capsule is not available in JP.  Decision: Approved with Manufacturer's specifications notified vide letter No.F.14-1/202.  PEC dated 14th March 2022.  Registration Board further decided that firm will submit fee of Rs. 7,500 for correction/pre-approval change in product specifications, as per notification No.F.7-11/2012-B&A/DRAP dated 13-07-2021.  197. Name and address of manufacturer/ M/s Briell Pharmaceuticals Pvt Ltd. 538-C Sund		Remarks of the Evaluator (IX)	The firm submitted 05 approved sections, no approved products for contract manufacturing and 22 applied products for contact manufacturing of the applicant
Remarks of the Evaluator.  Firm has claimed JP specifications for their product However, monograph of Japanese pharmacopoe confirms test of dissolution only for cefixime capsu 50mg and 100mg. Dissolution test parameter for cefixime 400mg capsule is not available in JP.  Decision: Approved with Manufacturer's specifications notified vide letter No.F.14-1/2022.  PEC dated 14th March 2022.  Registration Board further decided that firm will submit fee of Rs. 7,500 for correction/pre-approval change in product specifications, as per notification No.F.7-11/2012-B&A/DRAP dated 13-07-2021.  197. Name and address of manufacturer/ M/s Briell Pharmaceuticals Pvt Ltd. 538-C Sund		$\mathcal{E}$	Deferred for capacity assessment of M/s Medisave
However, monograph of Japanese pharmacopoe confirms test of dissolution only for cefixime capsu 50mg and 100mg. Dissolution test parameter for cefixime 400mg capsule is not available in JP.  Decision: Approved with Manufacturer's specifications notified vide letter No.F.14-1/2022 PEC dated 14th March 2022.  Registration Board further decided that firm will submit fee of Rs. 7,500 for correction/pre-approval change in product specifications, as per notification No.F.7-11/2012-B&A/DRAP dated 13-07-2021.  197. Name and address of manufacturer/ M/s Briell Pharmaceuticals Pvt Ltd. 538-C Sund			
Decision: Approved with Manufacturer's specifications notified vide letter No.F.14-1/202.  PEC dated 14 <sup>th</sup> March 2022.  Registration Board further decided that firm will submit fee of Rs. 7,500 for correction/pre-approval change in product specifications, as per notification No.F.7-11/2012-B&A/DRAP dated 13-07-2021.  197. Name and address of manufacturer/ M/s Briell Pharmaceuticals Pvt Ltd. 538-C Sund		Remarks of the Evaluator.	However, monograph of Japanese pharmacopoeia confirms test of dissolution only for cefixime capsule 50mg and 100mg. Dissolution test parameter for
PEC dated 14 <sup>th</sup> March 2022.  • Registration Board further decided that firm will submit fee of Rs. 7,500 for correction/pre-approval change in product specifications, as per notification No.F.7-11/2012-B&A/DRAP dated 13-07-2021.  197. Name and address of manufacturer/ M/s Briell Pharmaceuticals Pvt Ltd. 538-C Sund		Decisions Assessed 1-241 No. 6	
<ul> <li>Registration Board further decided that firm will submit fee of Rs. 7,500 for correction/pre-approval change in product specifications, as per notification No.F.7-11/2012-B&amp;A/DRAP dated 13-07-2021.</li> <li>Name and address of manufacturer/ M/s Briell Pharmaceuticals Pvt Ltd. 538-C Sund</li> </ul>			er's specifications nothied vide letter No.F.14-1/2022-
correction/pre-approval change in product specifications, as per notification No.F.7-11/2012-B&A/DRAP dated 13-07-2021.  197. Name and address of manufacturer/ M/s Briell Pharmaceuticals Pvt Ltd. 538-C Sund			decided that firm will submit fee of Rs. 7.500 for
		correction/pre-approval cha	inge in product specifications, as per notification
	197.		M/s Briell Pharmaceuticals Pvt Ltd. 538-C Sundar Industrial Estate Road, Lahore. By M/s Medisave

		Pharmaceuticals. Plot 578-579, Sundar Industrial
		Estate, Lahore, Pakistan
	Brand Name + Dosage Form + Strength	B-Cef IM Injection 250mg
	Composition	Each Vial Contains:
		Ceftriaxone sodium eq to Ceftriaxone250mg
	Diary No. Date of R & I & fee	Dy. No. 6993; 19.02.2019
		PKR. 50,000/-; 19.02.2019
	Pharmacological Group	Third generation cephalosporins
	Type of Form	Form 5
	Finished product Specification	USP
	Pack size & Demanded Price	as per SRO
	Approval status of product in Reference Regulatory Authorities.	Ceftriaxone 250mg (IM) by Lupin Pharmaceuticals Inc. US-FDA approved
	Me-too status	Unixone Injection (ceftriaxone Sodium) 250mg IM by
	We-too status	Caliph Pharmaceuticals (Pvt.) Ltd. Reg. No. 82556
	GMP status	Applicant: The firm was inspected on 24.05.2019 with
	Givii status	the following conclusion: The firm was evaluated for
		facilities like building, HVAC System, quality control,
		quality assurance and production operations. The Briell
		Pharma found to be operating at satisfactory level of
		GMP compliance.
		Manufacturer: GMP Certificate issued on 15-03-2018.
	Remarks of the Evaluator (IX)	The firm submitted 05 approved sections, no approved
		products for contract manufacturing and 22 applied
		products for contact manufacturing of the applicant
		(M/s Briell Pharma).
	Decision of 296 <sup>th</sup> meeting of	Deferred for capacity assessment of M/s Medisave
	Registration Board.	pharmaceuticals, Lahore.
	Remarks of the Evaluator.	
198.	Decision: Approved.  Name and address of manufacturer/	M/s Briell Pharmaceuticals Pvt Ltd. 538-C Sundar
190.	Applicant	Industrial Estate Road, Lahore. By M/s Medisave
	Applicant	Pharmaceuticals. Plot 578-579, Sundar Industrial
		Estate, Lahore, Pakistan
	Brand Name + Dosage Form + Strength	B-Cef IM Injection 500mg
	Composition	Each Vial Contains:
	Composition	Ceftriaxone sodium eq to Ceftriaxone500mg
	Diary No. Date of R & I & fee	Dy. No. 6986; 19.02.2019
		PKR. 50,000/-; 19.02.2019
	Pharmacological Group	Third generation cephalosporins
	Type of Form	Form 5
	Finished product Specification	USP
	Pack size & Demanded Price	as per SRO
	Approval status of product in Reference	Ceftriaxone 500mg (IM) by Lupin Pharmaceuticals Inc.
	Regulatory Authorities.	US-FDA approved
	Me-too status	Wincef 500 mg (Ceftriaxone sodium) IM injection by Wnsfeild Pharmaceuticals. Reg. No. 68371
	GMP status	Applicant: The firm was inspected on 24.05.2019 with
		the following conclusion: The firm was evaluated for
		facilities like building, HVAC System, quality control,
		quality assurance and production operations. The Briell
		Pharma found to be operating at satisfactory level of
		GMP compliance.
		Manufacturer: GMP Certificate issued on 15-03-2018.
	Remarks of the Evaluator (IX)	The firm submitted 05 approved sections, no approved
		products for contract manufacturing and 22 applied

		products for contact manufacturing of the applicant
		(M/s Briell Pharma).
	Decision of 296 <sup>th</sup> meeting of	1 2
	Registration Board.	pharmaceuticals, Lahore.
	Remarks of the Evaluator.	
	Decision: Approved.	
199.	Name and address of manufacturer/	M/s Briell Pharmaceuticals Pvt Ltd. 538-C Sundar
	Applicant	Industrial Estate Road, Lahore. By M/s Medisave
		Pharmaceuticals. Plot 578-579, Sundar Industrial
		Estate, Lahore, Pakistan
	Brand Name + Dosage Form + Strength	B-Cef IV Injection 250mg
	Composition	Each Vial Contains: Ceftriaxone sodium eq to Ceftriaxone250mg
	Diary No. Date of R & I & fee	Dy. No. 6991; 19.02.2019
	Diary No. Date of R & I & Ice	PKR. 50,000/-; 19.02.2019
	Pharmacological Group	Third generation cephalosporins
	Type of Form	Form 5
	Finished product Specification	USP
	Pack size & Demanded Price	as per SRO
	Approval status of product in Reference	Ceftriaxone 250mg (IV) by Lupin Pharmaceuticals Inc.
	Regulatory Authorities.	US-FDA approved
	Me-too status	Ceftirains 250mg (ceftriaxone Sodium) I.V Injection by
		Sunrise Pharma (Pvt) Ltd. Reg. No. 78655
	GMP status	Applicant: The firm was inspected on 24.05.2019 with
		the following conclusion: The firm was evaluated for
		facilities like building, HVAC System, quality control,
		quality assurance and production operations. The Briell
		Pharma found to be operating at satisfactory level of
		GMP compliance.
		Manufacturer: GMP Certificate issued on 15-03-2018.
	Remarks of the Evaluator (IX)	The firm submitted 05 approved sections, no approved
		products for contract manufacturing and 22 applied products for contact manufacturing of the applicant
		(M/s Briell Pharma).
	Decision of 296 <sup>th</sup> meeting of	
	Registration Board.	pharmaceuticals, Lahore.
	Remarks of the Evaluator.	
	Decision: Approved.	
200.	Name and address of manufacturer/	M/s Briell Pharmaceuticals Pvt Ltd. 538-C Sundar
	Applicant	Industrial Estate Road, Lahore. By M/s Medisave
		Pharmaceuticals. Plot 578-579, Sundar Industrial
		Estate, Lahore, Pakistan
	Brand Name + Dosage Form + Strength	B-Cef IV Injection 500mg
	Composition	Each Vial Contains:
		Ceftriaxone sodium eq to Ceftriaxone500mg
	Diary No. Date of R & I & fee	Dy. No. 6994; 19.02.2019
		PKR. 50,000/-; 19.02.2019
	Pharmacological Group	Third generation cephalosporins
	Type of Form	Form 5
	Finished product Specification	USP
	Pack size & Demanded Price	as per SRO
	Approval status of product in Reference	Ceftriaxone 500mg (IV) by Lupin Pharmaceuticals Inc.
	Regulatory Authorities.	US-FDA approved Winger 500 mg (Coftrious and society) IV by Wel Wink
	Me-too status	Wincef 500 mg (Ceftriaxone sodium) IV by Wel Wink
		Pharmaceuticals. Reg. No. 78097

	Remarks of the Evaluator (IX)  Decision of 296th meeting of Registration Board.	Applicant: The firm was inspected on 24.05.2019 with the following conclusion: The firm was evaluated for facilities like building, HVAC System, quality control, quality assurance and production operations. The Briell Pharma found to be operating at satisfactory level of GMP compliance.  Manufacturer: GMP Certificate issued on 15-03-2018.  The firm submitted 05 approved sections, no approved products for contract manufacturing and 22 applied products for contact manufacturing of the applicant (M/s Briell Pharma).  Deferred for capacity assessment of M/s Medisave pharmaceuticals, Lahore.
	Remarks of the Evaluator.	pharmaceuticals, Lanore.
	Decision: Approved.	
201.	Name and address of manufacturer/ Applicant	M/s Briell Pharmaceuticals Pvt Ltd. 538-C Sundar Industrial Estate Road, Lahore. By M/s Medisave Pharmaceuticals. Plot 578-579, Sundar Industrial Estate, Lahore, Pakistan
	Brand Name + Dosage Form + Strength	B-Cef IV Injection 1g
	Composition	Each Vial Contains:
	D: N D ( CD 0 1 0 C	Ceftriaxone sodium eq to Ceftriaxone1000mg
	Diary No. Date of R & I & fee	Dy. No. 7000; 19.02.2019 PKR. 50,000/-; 19.02.2019
	Pharmacological Group	Third generation cephalosporins
	Type of Form	Form 5
	Finished product Specification	USP
	Pack size & Demanded Price	as per SRO
	Approval status of product in Reference	Ceftriaxone 1 g (IV) by Lupin Pharmaceuticals Inc. US-
	Regulatory Authorities.	FDA approved
	Me-too status	Martixon 1gm (Ceftriaxone sodium) I.V Dry powder
	GMP status	Injection by Alkemy Pharma. Reg. No. 70663  Applicant: The firm was inspected on 24.05.2019 with
	Givii status	the following conclusion: The firm was evaluated for facilities like building, HVAC System, quality control, quality assurance and production operations. The Briell Pharma found to be operating at satisfactory level of GMP compliance.  Manufacturer: GMP Certificate issued on 15-03-2018.
	Remarks of the Evaluator (IX)	The firm submitted 05 approved sections, no approved products for contract manufacturing and 22 applied products for contact manufacturing of the applicant (M/s Briell Pharma).
	Decision of 296 <sup>th</sup> meeting of Registration Board.	Deferred for capacity assessment of M/s Medisave pharmaceuticals, Lahore.
	Remarks of the Evaluator.	
	Decision: Approved.	
202.	Name and address of manufacturer/ Applicant	M/s Briell Pharmaceuticals Pvt Ltd. 538-C Sundar Industrial Estate Road, Lahore. By M/s Medisave Pharmaceuticals. Plot 578-579, Sundar Industrial Estate, Lahore, Pakistan
	Brand Name + Dosage Form + Strength	C Pime 500mg dry powder Injection
	Composition	Each Vial Contains: Cefepime HCL with L arginine sterile eq to Cefepime500mg
	Diary No. Date of R & I & fee	Dy. No. 6992; 19.02.2019 PKR. 50,000/-; 19.02.2019

	Pharmacological Group	Fourth generation cephalosporins
	Type of Form	Form 5
	Finished product Specification	USP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference	MAXIPIME (cefepime hydrochloride) for injection, for
	Regulatory Authorities.	intravenous or intramuscular use (500mg, 1g, 2g).
		USFDA Approved
	Me-too status	Cefevial Injection 500 mg IV Reg. No. 80029
	GMP status	Applicant: The firm was inspected on 24.05.2019 with
		the following conclusion: The firm was evaluated for
		facilities like building, HVAC System, quality control,
		quality assurance and production operations. The Briell
		Pharma found to be operating at satisfactory level of
		GMP compliance.
		Manufacturer: GMP Certificate issued on 15-03-2018.
	Remarks of the Evaluator (IX)	The firm submitted 05 approved sections, no approved
		products for contract manufacturing and 22 applied products for contact manufacturing of the applicant
		(M/s Briell Pharma).
		The firm revised Cefepime HCL with L arginine sterile
		eq to Cefepime500mg to Cefepime as HCl
		monohydrate with L-arginine500mg.
	Decision of 296 <sup>th</sup> meeting of	Deferred for capacity assessment of M/s Medisave
	Registration Board.	pharmaceuticals, Lahore.
	Remarks of the Evaluator.	Fee for revision of label claim shall be submitted.
	Decision: Approved. Registration Boa	ard further decided that firm will submit fee of Rs.
		change in label claim, as per notification No.F.7-
	11/2012-B&A/DRAP dated 13-07-2021	
203.	Name and address of manufacturer/	M/s Briell Pharmaceuticals Pvt Ltd. 538-C Sundar
	Applicant	Industrial Estate Road, Lahore. By M/s Medisave Pharmaceuticals. Plot 578-579, Sundar Industrial
		•
		L'etoto I aboro Delzieten
	Brand Name   Dosage Form   Strength	Estate, Lahore, Pakistan
	Brand Name + Dosage Form + Strength	C Pime 1g dry powder Injection
	Brand Name + Dosage Form + Strength Composition	C Pime 1g dry powder Injection Each Vial Contains:
		C Pime 1g dry powder Injection  Each Vial Contains: Cefepime HCL with L arginine sterile eq to Cefepime
	Composition	C Pime 1g dry powder Injection  Each Vial Contains: Cefepime HCL with L arginine sterile eq to Cefepime1gm
		C Pime 1g dry powder Injection  Each Vial Contains: Cefepime HCL with L arginine sterile eq to Cefepime1gm  Dy. No. 6988; 19.02.2019
	Composition	C Pime 1g dry powder Injection  Each Vial Contains: Cefepime HCL with L arginine sterile eq to Cefepime1gm
	Composition  Diary No. Date of R & I & fee	C Pime 1g dry powder Injection  Each Vial Contains: Cefepime HCL with L arginine sterile eq to Cefepime1gm  Dy. No. 6988; 19.02.2019 PKR. 50,000/-; 19.02.2019
	Composition  Diary No. Date of R & I & fee  Pharmacological Group	C Pime 1g dry powder Injection  Each Vial Contains: Cefepime HCL with L arginine sterile eq to Cefepime
	Composition  Diary No. Date of R & I & fee  Pharmacological Group  Type of Form	C Pime 1g dry powder Injection  Each Vial Contains: Cefepime HCL with L arginine sterile eq to Cefepime
	Composition  Diary No. Date of R & I & fee  Pharmacological Group Type of Form Finished product Specification Pack size & Demanded Price Approval status of product in Reference	C Pime 1g dry powder Injection  Each Vial Contains: Cefepime HCL with L arginine sterile eq to Cefepime
	Composition  Diary No. Date of R & I & fee  Pharmacological Group Type of Form Finished product Specification Pack size & Demanded Price	C Pime 1g dry powder Injection  Each Vial Contains: Cefepime HCL with L arginine sterile eq to Cefepime1gm  Dy. No. 6988; 19.02.2019 PKR. 50,000/-; 19.02.2019 Fourth generation cephalosporins Form 5 USP As per SRO MAXIPIME (cefepime hydrochloride) for injection, for intravenous or intramuscular use (500mg, 1g, 2g).
	Composition  Diary No. Date of R & I & fee  Pharmacological Group Type of Form Finished product Specification Pack size & Demanded Price Approval status of product in Reference Regulatory Authorities.	C Pime 1g dry powder Injection  Each Vial Contains: Cefepime HCL with L arginine sterile eq to Cefepime
	Composition  Diary No. Date of R & I & fee  Pharmacological Group Type of Form Finished product Specification Pack size & Demanded Price Approval status of product in Reference Regulatory Authorities.  Me-too status	C Pime 1g dry powder Injection  Each Vial Contains: Cefepime HCL with L arginine sterile eq to Cefepime
	Composition  Diary No. Date of R & I & fee  Pharmacological Group Type of Form Finished product Specification Pack size & Demanded Price Approval status of product in Reference Regulatory Authorities.	C Pime 1g dry powder Injection  Each Vial Contains: Cefepime HCL with L arginine sterile eq to Cefepime
	Composition  Diary No. Date of R & I & fee  Pharmacological Group Type of Form Finished product Specification Pack size & Demanded Price Approval status of product in Reference Regulatory Authorities.  Me-too status	C Pime 1g dry powder Injection  Each Vial Contains: Cefepime HCL with L arginine sterile eq to Cefepime
	Composition  Diary No. Date of R & I & fee  Pharmacological Group Type of Form Finished product Specification Pack size & Demanded Price Approval status of product in Reference Regulatory Authorities.  Me-too status	C Pime 1g dry powder Injection  Each Vial Contains: Cefepime HCL with L arginine sterile eq to Cefepime
	Composition  Diary No. Date of R & I & fee  Pharmacological Group Type of Form Finished product Specification Pack size & Demanded Price Approval status of product in Reference Regulatory Authorities.  Me-too status	C Pime 1g dry powder Injection  Each Vial Contains: Cefepime HCL with L arginine sterile eq to Cefepime
	Composition  Diary No. Date of R & I & fee  Pharmacological Group Type of Form Finished product Specification Pack size & Demanded Price Approval status of product in Reference Regulatory Authorities.  Me-too status	C Pime 1g dry powder Injection  Each Vial Contains: Cefepime HCL with L arginine sterile eq to Cefepime
	Composition  Diary No. Date of R & I & fee  Pharmacological Group Type of Form Finished product Specification Pack size & Demanded Price Approval status of product in Reference Regulatory Authorities.  Me-too status	C Pime 1g dry powder Injection  Each Vial Contains: Cefepime HCL with L arginine sterile eq to Cefepime
	Composition  Diary No. Date of R & I & fee  Pharmacological Group Type of Form Finished product Specification Pack size & Demanded Price Approval status of product in Reference Regulatory Authorities.  Me-too status GMP status	C Pime 1g dry powder Injection  Each Vial Contains: Cefepime HCL with L arginine sterile eq to Cefepime
	Composition  Diary No. Date of R & I & fee  Pharmacological Group Type of Form Finished product Specification Pack size & Demanded Price Approval status of product in Reference Regulatory Authorities.  Me-too status	C Pime 1g dry powder Injection  Each Vial Contains: Cefepime HCL with L arginine sterile eq to Cefepime
	Composition  Diary No. Date of R & I & fee  Pharmacological Group Type of Form Finished product Specification Pack size & Demanded Price Approval status of product in Reference Regulatory Authorities.  Me-too status GMP status	C Pime 1g dry powder Injection  Each Vial Contains: Cefepime HCL with L arginine sterile eq to Cefepime

		The firm revised Cefepime HCL with L arginine sterile
		eq to Cefepime1g to Cefepime as HCl monohydrate
		with L-arginine1g.
	Decision of 296 <sup>th</sup> meeting of	
	$\mathcal{E}$	<u> </u>
	Registration Board.	pharmaceuticals, Lahore.
	Remarks of the Evaluator.	Fee for revision of label claim shall be submitted.
		ard further decided that firm will submit fee of Rs.
		change in label claim, as per notification No.F.7-
	11/2012-B&A/DRAP dated 13-07-2021	
204.	Name and address of manufacturer/	M/s Briell Pharmaceuticals Pvt Ltd. 538-C Sundar
	Applicant	Industrial Estate Road, Lahore. By M/s Medisave
		Pharmaceuticals. Plot 578-579, Sundar Industrial
		Estate, Lahore, Pakistan
	Brand Name + Dosage Form + Strength	D-Rise 5mg/ml Injection IM/oral
	Composition	Each ml contains:
	r	Cholecalciferol5mg
	Diary No. Date of R & I & fee	Dy. No. 6996; 19.02.2019
		PKR. 50,000/-; 19.02.2019
	Pharmacological Group	Vitamin D and analogues
	Type of Form	Form 5
	Finished product Specification	The firm has claimed in-house specifications
	Pack size & Demanded Price	1ml; As per SRO
	Approval status of product in Reference	VITAMIN D3 GOOD 200 000 IU / 1 ml, oral solution
	Regulatory Authorities.	in ampoule.
		VITAMINE D3 BON 200 000 U.I. / 1 ml, solution
		injectable IM en ampoule. ANSM approved
	Me-too status	Accu-D Injection. Reg. No. 79755
	GMP status	Applicant: The firm was inspected on 24.05.2019 with
		the following conclusion: The firm was evaluated for
		facilities like building, HVAC System, quality control,
		quality assurance and production operations. The Briell
		Pharma found to be operating at satisfactory level of
		GMP compliance.
		Manufacturer: GMP Certificate issued on 15-03-2018.
	Remarks of the Evaluator (IX)	The firm submitted 05 approved sections, no approved
		products for contract manufacturing and 22 applied
		products for contact manufacturing of the applicant
		(M/s Briell Pharma).
	Decision of 296 <sup>th</sup> meeting of	
	Registration Board.	pharmaceuticals, Lahore.
	Remarks of the Evaluator.	pharmaceuteurs, Lanore.
		nosifications Designation Deand further desided that
		pecifications. Registration Board further decided that
		0 for correction/pre-approval change in product
20.5		7-11/2012-B&A/DRAP dated 13-07-2021.
205.	Name and address of manufacturer/	M/s Briell Pharmaceuticals Pvt Ltd. 538-C Sundar
	Applicant	Industrial Estate Road, Lahore. By M/s Medisave
		Pharmaceuticals. Plot 578-579, Sundar Industrial
	B 111 5 5 5	Estate, Lahore, Pakistan
	Brand Name + Dosage Form + Strength	Irolic 100mg/5ml Injection
	Composition	Each 5ml contains:
		Iron sucrose eq to elemental iron100mg
	Diary No. Date of R & I & fee	Dy. No. 6997; 19.02.2019
		PKR. 50,000/-; 19.02.2019
	Pharmacological Group	Iron preparations
	Type of Form	Form 5
	Finished product Specification	USP
L		

	Pack size & Demanded Price	5ml ampule; As per SRO
	Approval status of product in Reference	VENOFER iron 100mg/5mL (as iron (III) hydroxide
	Regulatory Authorities.	sucrose complex) injection ampoule. TGA approved
	Me-too status	Orsec Injection 100mg/5ml. Reg. No.82559
	GMP status	Applicant: The firm was inspected on 24.05.2019 with
	Givii status	the following conclusion: The firm was evaluated for
		facilities like building, HVAC System, quality control,
		quality assurance and production operations. The Briell
		Pharma found to be operating at satisfactory level of
		GMP compliance.
		Manufacturer: GMP Certificate issued on 15-03-2018.
	Remarks of the Evaluator (IX)	The firm submitted 05 approved sections, no approved
	Remarks of the Evaluator (EX)	products for contract manufacturing and 22 applied
		products for contact manufacturing and 22 applied products for contact manufacturing of the applicant
		(M/s Briell Pharma).
		The reference product contains iron (III) hydroxide
		sucrose complex which is equivalent to 20mg/ml
		elemental Iron. Iron sucrose is generic term used for iron
		(III) hydroxide sucrose complex in TGA Australia.
	Decision of 296 <sup>th</sup> meeting of	
	Registration Board.	pharmaceuticals, Lahore.
	Remarks of the Evaluator.	pharmaceuticais, Lanore.
	Decision: Approved with following lab	al alaim:
	Each 5ml contains:	er ciami,
		ose complex) eq to elemental iron100mg
206.	Name and address of manufacturer/	M/s Briell Pharmaceuticals Pvt Ltd. 538-C Sundar
200.	Applicant	Industrial Estate Road, Lahore. By M/s Medisave
	Applicant	Pharmaceuticals. Plot 578-579, Sundar Industrial
		Estate, Lahore, Pakistan
	Brand Name + Dosage Form + Strength	Linstar 600mg/300ml Injection
	Composition	Each 300ml vial contains:
	Composition	Linezolid
	Diary No. Date of R & I & fee	Dy. No. 7006; 19.02.2019
	Diary No. Date of R & T & Ice	PKR. 50,000/-; 19.02.2019
	Pharmacological Group	Antibacterial for systemic use
	Type of Form	Form 5
	Finished product Specification	The firm has claimed manufacturer's specifications
	Pack size & Demanded Price	300ml vial; as per SRO
	Approval status of product in Reference	ZYVOX linezolid 600mg/300mL injection infusion
	Regulatory Authorities.	bag. TGA approved
	Me-too status	Oxalid Infusion 600mg/300ml. Reg. No. 82579
	GMP status	Applicant: The firm was inspected on 24.05.2019 with
	Givii status	the following conclusion: The firm was evaluated for
		facilities like building, HVAC System, quality control,
		quality assurance and production operations. The Briell
		Pharma found to be operating at satisfactory level of
		GMP compliance.
		Manufacturer: GMP Certificate issued on 15-03-2018.
	Remarks of the Evaluator (IX)	The firm submitted 05 approved sections, no approved
	Transmiss of the 2 through (112)	products for contract manufacturing and 22 applied
		products for contact manufacturing of the applicant
		(M/s Briell Pharma).
	Decision of 296 <sup>th</sup> meeting of	Deferred for capacity assessment of M/s Medisave
	Registration Board.	pharmaceuticals, Lahore.
	Remarks of the Evaluator.	<u> </u>
L	Transmitted of the Litherton.	

	firm shall submit fee of Rs. 7,50	pecifications. Registration Board further decided that 0 for correction/pre-approval change in product .7-11/2012-B&A/DRAP dated 13-07-2021.
207.	Name and address of manufacturer/ Applicant	
	Brand Name + Dosage Form + Strength	Tolac 30mg/ml Injection
	Composition	Each ml contains: Ketorolac Trometamol30mg
	Diary No. Date of R & I & fee	Dy. No. 6995; 19.02.2019 PKR. 50,000/-; 19.02.2019
	Pharmacological Group	Acetic acid derivatives and related substances
	Type of Form	Form 5
	Finished product Specification	USP
	Pack size & Demanded Price	1ml x 5's ampule; As per SRO
	Approval status of product in Reference	TORADOL ketorolac trometamol 30mg/1mL injection
	Regulatory Authorities.	ampoule. TGA approved
	Me-too status	Syntor 30 mg Injection IV/IM. Reg. No.83365
	GMP status	Applicant: The firm was inspected on 24.05.2019 with the following conclusion: The firm was evaluated for facilities like building, HVAC System, quality control,
		quality assurance and production operations. The Briell Pharma found to be operating at satisfactory level of GMP compliance.
		Manufacturer: GMP Certificate issued on 15-03-2018.
	Remarks of the Evaluator (IX)	The firm submitted 05 approved sections, no approved products for contract manufacturing and 22 applied products for contact manufacturing of the applicant (M/s Briell Pharma).
	Decision of 296 <sup>th</sup> meeting of Registration Board.	Deferred for capacity assessment of M/s Medisave pharmaceuticals, Lahore.
	Remarks of the Evaluator.	, , , , , , , , , , , , , , , , , , ,
	Decision: Approved.	
208.	Name and address of manufacturer/ Applicant	M/s Briell Pharmaceuticals Pvt Ltd. 538-C Sundar Industrial Estate Road, Lahore. By M/s Medisave Pharmaceuticals. Plot 578-579, Sundar Industrial Estate, Lahore, Pakistan
	Brand Name + Dosage Form + Strength	Ondex 8mg/4ml Injection
	Composition	Each 4ml contains:
		Ondansetron as HCl dihydrate8mg
	Diary No. Date of R & I & fee	Dy. No. 6998; 19.02.2019 PKR. 50,000/-; 19.02.2019
	Pharmacological Group	Serotonin (5HT3) antagonists
	Type of Form	Form 5
	Finished product Specification	USP
	Pack size & Demanded Price	4ml ampule; As per SRO
	Approval status of product in Reference Regulatory Authorities.	Ondansetron 2mg/ml Solution for Injection or Infusion (1ml, 2ml, 4ml ampule). MHRA approved.
	Me-too status	Ondenles 8mg Injection (4ml). Reg. No. 80548 Adosetron 4mg Injection (2ml). Reg. No. 78789
	GMP status	Applicant: The firm was inspected on 24.05.2019 with the following conclusion: The firm was evaluated for facilities like building, HVAC System, quality control, quality assurance and production operations. The Briell

		Pharma found to be operating at satisfactory level of
		GMP compliance.
		Manufacturer: GMP Certificate issued on 15-03-2018.
	Remarks of the Evaluator (IX)	The firm submitted 05 approved sections, no approved
	Tremains of the Evaluator (11)	products for contract manufacturing and 22 applied
		products for contact manufacturing of the applicant
		(M/s Briell Pharma).
		The firm revised Ondansetron HCl dihydrate8mg to
	D : : C 20×th	Ondansetron as HCl dihydrate8mg.
	Decision of 296 <sup>th</sup> meeting of Registration Board.	pharmaceuticals, Lahore.
	Remarks of the Evaluator.	Fee for revision of label claim shall be submitted.
		ard further decided that firm will submit fee of Rs.
	75,000/- for correction/pre-approval 11/2012-B&A/DRAP dated 13-07-2021	change in label claim, as per notification No.F.7-
209.	Name and address of manufacturer/	M/s Briell Pharmaceuticals Pvt Ltd. 538-C Sundar
	Applicant	Industrial Estate Road, Lahore. By M/s Medisave
		Pharmaceuticals. Plot 578-579, Sundar Industrial
		Estate, Lahore, Pakistan
	Brand Name + Dosage Form + Strength	Magnix 1g Injection
	Composition	Each Vial Contains:
	1	Cefoperazone sodium eq to Cefoperazone500mg
		Sulbactam sodium eq to sulbactam500mg
	Diary No. Date of R & I & fee	Dy. No. 7002; 19.02.2019
	, , , , , , , , , , , , , , , , , , ,	PKR. 50,000/-; 19.02.2019
	Pharmacological Group	Third generation cephalosporins and beta-lactamase
		inhibitors
	Type of Form	Form 5
	Finished product Specification	JP
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference	Sulperazon Injection. PMDA Approved
	Regulatory Authorities.	
	Me-too status	Ectafin Injection 1gm IV by Hi-Medic Pharmaceuticals
	CMD	(Pvt) Ltd. Reg. No. 80028
	GMP status	Applicant: The firm was inspected on 24.05.2019 with
		the following conclusion: The firm was evaluated for
		facilities like building, HVAC System, quality control,
		quality assurance and production operations. The Briell
		Pharma found to be operating at satisfactory level of GMP compliance.
		Manufacturer: GMP Certificate issued on 15-03-2018.
	Domorks of the Evaluator (IV)	
	Remarks of the Evaluator (IX)	The firm submitted 05 approved sections, no approved
		products for contract manufacturing and 22 applied
		products for contact manufacturing of the applicant
	Decision of 296 <sup>th</sup> meeting of	(M/s Briell Pharma).  Deferred for capacity assessment of M/s Medisave
	8	
	Registration Board.	pharmaceuticals, Lahore.
	Remarks of the Evaluator.	
210	Decision: Approved.	M/s Briell Pharmaceuticals Pvt Ltd. 538-C Sundar
210.	Name and address of manufacturer/	
	Applicant	Industrial Estate Road, Lahore. By M/s Medisave
		Pharmaceuticals. Plot 578-579, Sundar Industrial
	Brand Name   December 1	Estate, Lahore, Pakistan
	Brand Name + Dosage Form + Strength	Magnix 2g Injection
	Composition	Each Vial Contains:
		Cefoperazone sodium eq to Cefoperazone1g
1		Sulbactam sodium eq to sulbactam1g

Diary No. Date of R & I & fee  Dy. No. 7001; 19.02.2019 PKR. 50,000/-; 19.02.2019  Third generation cephalosporins an inhibitors	
Pharmacological Group Third generation cephalosporins and	
	nd hata lactamaca
	iiu beta-iactailiase
Type of Form Form 5	
71	
Pack size & Demanded Price As per SRO	
Approval status of product in Reference   Approved in 03 European count	tries, i.e., Czech
Regulatory Authorities. Republic, Poland and Slovakia	
Me-too status Ectafin Injection 2gm IV by Hi-Med	ic Pharmaceuticals
(Pvt) Ltd. Reg. No. 80027	
GMP status Applicant: The firm was inspected o	
the following conclusion: The firm	
facilities like building, HVAC System	
quality assurance and production ope	
Pharma found to be operating at sa	itisfactory level of
GMP compliance.	
Manufacturer: GMP Certificate issue	
Remarks of the Evaluator (IX)  The firm submitted 05 approved sectors are the submitted 05 approved sectors.	
products for contract manufacturing	
products for contact manufacturing	g of the applicant
(M/s Briell Pharma).	
Decision of 296 <sup>th</sup> meeting of Deferred for capacity assessment	of M/s Medisave
Registration Board. pharmaceuticals, Lahore.	
Remarks of the Evaluator.	
Decision: Approved.	
211. Name and address of manufacturer/ M/s Briell Pharmaceuticals Pvt Lt	
Applicant Industrial Estate Road, Lahore. B	
Pharmaceuticals. Plot 578-579, S	Sundar Industrial
Estate, Lahore, Pakistan	
Brand Name + Dosage Form + Strength   Zymox 400mg/250ml Infusion	
Composition Each ml contains:	
Moxifloxacin as HCl	
	.1.6mg
Diary No. Date of R & I & fee Dy. No. 7001; 19.02.2019	.1.6mg
Diary No. Date of R & I & fee Dy. No. 7001; 19.02.2019 PKR. 50,000/-; 19.02.2019	.1.6mg
Diary No. Date of R & I & fee  Dy. No. 7001; 19.02.2019  PKR. 50,000/-; 19.02.2019  Pharmacological Group  Fluoroquinolones	.1.6mg
Diary No. Date of R & I & fee  Dy. No. 7001; 19.02.2019 PKR. 50,000/-; 19.02.2019 Pharmacological Group Fluoroquinolones Type of Form Form 5	.1.6mg
Diary No. Date of R & I & fee  Dy. No. 7001; 19.02.2019 PKR. 50,000/-; 19.02.2019 Pharmacological Group Fluoroquinolones Type of Form Form 5 Finished product Specification JP	.1.6mg
Diary No. Date of R & I & fee  Dy. No. 7001; 19.02.2019 PKR. 50,000/-; 19.02.2019 Pharmacological Group Fluoroquinolones Type of Form Form 5 Finished product Specification JP Pack size & Demanded Price  Dy. No. 7001; 19.02.2019 Fluoroquinolones Fluoroquinolones Form 5 Form 5 JP	
Diary No. Date of R & I & fee  Dy. No. 7001; 19.02.2019 PKR. 50,000/-; 19.02.2019 Pharmacological Group Fluoroquinolones Type of Form Form 5 Finished product Specification Pack size & Demanded Price Approval status of product in Reference  Dy. No. 7001; 19.02.2019 PKR. 50,000/-; 19.02.2019 Pluoroquinolones Form 5 Form 5  Approval Status of Product in Reference AVELOX IV 400 moxifloxacin 40	0 mg/250 mL (as
Diary No. Date of R & I & fee  Dy. No. 7001; 19.02.2019 PKR. 50,000/-; 19.02.2019 Pharmacological Group Fluoroquinolones Type of Form Form 5 Finished product Specification Pack size & Demanded Price Approval status of product in Reference Regulatory Authorities.  Dy. No. 7001; 19.02.2019 Pluoroquinolones Form 5 Form 5 Average 250ml ampule; As per SRO Average 40 hydrochloride) Average 40 hydrochloride)	0 mg/250 mL (as
Diary No. Date of R & I & fee  Dy. No. 7001; 19.02.2019 PKR. 50,000/-; 19.02.2019 Pharmacological Group Fluoroquinolones Type of Form Form 5 Finished product Specification Pack size & Demanded Price Approval status of product in Reference Regulatory Authorities.  Dy. No. 7001; 19.02.2019 PKR. 50,000/-; 19.02.2019 Fluoroquinolones Form 5  Form 5  APPROVALED STORY AND APPROVALED STORY AVELOX IV 400 moxifloxacin 40 hydrochloride) intravenous infusion TGA approved	0 mg/250 mL (as n solution bottle.
Diary No. Date of R & I & fee  Dy. No. 7001; 19.02.2019 PKR. 50,000/-; 19.02.2019 Pharmacological Group Fluoroquinolones Type of Form Form 5 Finished product Specification Pack size & Demanded Price Approval status of product in Reference Regulatory Authorities. AVELOX IV 400 moxifloxacin 40 hydrochloride) intravenous infusion TGA approved Me-too status Esobrain Injection 40mg. Reg. No. 8:	0 mg/250 mL (as n solution bottle.
Diary No. Date of R & I & fee  Dy. No. 7001; 19.02.2019 PKR. 50,000/-; 19.02.2019 Pharmacological Group Type of Form Form 5 Finished product Specification Pack size & Demanded Price Approval status of product in Reference Regulatory Authorities.  Me-too status GMP status  Dy. No. 7001; 19.02.2019 PKR. 50,000/-; 19.02.2019  Fluoroquinolones Form 5 Form 5  APPURD As per SRO AVELOX IV 400 moxifloxacin 40 hydrochloride) intravenous infusion TGA approved Esobrain Injection 40mg. Reg. No. 8: Applicant: The firm was inspected or	0 mg/250 mL (as n solution bottle.
Diary No. Date of R & I & fee  Dy. No. 7001; 19.02.2019 PKR. 50,000/-; 19.02.2019 Pharmacological Group Fluoroquinolones Type of Form Form 5 Finished product Specification Pack size & Demanded Price Approval status of product in Reference Regulatory Authorities.  Me-too status  GMP status  Dy. No. 7001; 19.02.2019 PKR. 50,000/-; 19.02.2019 Fluoroquinolones Form 5 Form 5 AVELOX IV 400 moxifloxacin 40 hydrochloride) intravenous infusion TGA approved  Esobrain Injection 40mg. Reg. No. 8 Applicant: The firm was inspected of the following conclusion: The firm	0 mg/250 mL (as n solution bottle. 5072 on 24.05.2019 with was evaluated for
Diary No. Date of R & I & fee  Dy. No. 7001; 19.02.2019  PKR. 50,000/-; 19.02.2019  Pharmacological Group  Type of Form  Form 5  Finished product Specification  Pack size & Demanded Price  Approval status of product in Reference Regulatory Authorities.  Me-too status  GMP status  Dy. No. 7001; 19.02.2019  PKR. 50,000/-; 19.02.2019  Fluoroquinolones  Form 5  APO Status  AVELOX IV 400 moxifloxacin 40  hydrochloride) intravenous infusion  TGA approved  Me-too status  Esobrain Injection 40mg. Reg. No. 8:  Applicant: The firm was inspected of the following conclusion: The firm facilities like building, HVAC System  Total Price Port Status  Applicant: The firm was inspected of the following conclusion: The firm facilities like building, HVAC System  Total Price Port Status  Dy. No. 7001; 19.02.2019  PKR. 50,000/-; 19.02.2019  PKR. 50,000/-; 19.02.2019  Fluoroquinolones  Form 5  AVELOX IV 400 moxifloxacin 40  hydrochloride) intravenous infusion  TGA approved  Me-too status  Applicant: The firm was inspected of the following conclusion: The firm facilities like building, HVAC System	0 mg/250 mL (as n solution bottle.  5072 on 24.05.2019 with was evaluated for m, quality control,
Diary No. Date of R & I & fee  Dy. No. 7001; 19.02.2019  PKR. 50,000/-; 19.02.2019  Pharmacological Group  Fluoroquinolones  Type of Form  Form 5  Finished product Specification  Pack size & Demanded Price  Approval status of product in Reference Regulatory Authorities.  Me-too status  GMP status  Dy. No. 7001; 19.02.2019  PKR. 50,000/-; 19.02.2019  Fluoroquinolones  Form 5  APPLOX IV 400 moxifloxacin 40  hydrochloride) intravenous infusion  TGA approved  Esobrain Injection 40mg. Reg. No. 8:  Applicant: The firm was inspected of the following conclusion: The firm facilities like building, HVAC System quality assurance and production open.	0 mg/250 mL (as n solution bottle.  5072 on 24.05.2019 with was evaluated for m, quality control, erations. The Briell
Diary No. Date of R & I & fee  Dy. No. 7001; 19.02.2019  PKR. 50,000/-; 19.02.2019  Pharmacological Group  Fluoroquinolones  Type of Form  Form 5  Finished product Specification  Pack size & Demanded Price  Approval status of product in Reference Regulatory Authorities.  Perform 5  Finished product Specification  Pack size & Demanded Price  Approval status of product in Reference Regulatory Authorities.  TGA approved  Me-too status  Esobrain Injection 40mg. Reg. No. 8:  Applicant: The firm was inspected of the following conclusion: The firm facilities like building, HVAC System quality assurance and production open Pharma found to be operating at satisfactors.	0 mg/250 mL (as n solution bottle.  5072 on 24.05.2019 with was evaluated for m, quality control, erations. The Briell
Diary No. Date of R & I & fee  Dy. No. 7001; 19.02.2019  PKR. 50,000/-; 19.02.2019  Pharmacological Group  Type of Form  Finished product Specification  Pack size & Demanded Price  Approval status of product in Reference Regulatory Authorities.  Dy. No. 7001; 19.02.2019  PkR. 50,000/-; 19.02.2019  Fluoroquinolones  Form 5  Finished product Specification  JP  250ml ampule; As per SRO  AVELOX IV 400 moxifloxacin 40 hydrochloride) intravenous infusion  TGA approved  Me-too status  Esobrain Injection 40mg. Reg. No. 8:  GMP status  Applicant: The firm was inspected of the following conclusion: The firm facilities like building, HVAC System quality assurance and production open Pharma found to be operating at sa GMP compliance.	0 mg/250 mL (as n solution bottle.  5072 on 24.05.2019 with was evaluated for m, quality control, erations. The Briell trisfactory level of
Diary No. Date of R & I & fee  Dy. No. 7001; 19.02.2019 PKR. 50,000/-; 19.02.2019 Pharmacological Group Fluoroquinolones Type of Form Form 5 Finished product Specification Pack size & Demanded Price Approval status of product in Reference Regulatory Authorities.  Me-too status  GMP status  Dy. No. 7001; 19.02.2019 PKR. 50,000/-; 19.02.2019 Fluoroquinolones Form 5  AVELOX IV 400 moxifloxacin 40 hydrochloride) intravenous infusion TGA approved Esobrain Injection 40mg. Reg. No. 8: Applicant: The firm was inspected of the following conclusion: The firm facilities like building, HVAC System quality assurance and production oper Pharma found to be operating at sa GMP compliance. Manufacturer: GMP Certificate issue	0 mg/250 mL (as n solution bottle.  5072 on 24.05.2019 with was evaluated for m, quality control, erations. The Briell tisfactory level of ed on 15-03-2018.
Diary No. Date of R & I & fee  Dy. No. 7001; 19.02.2019  Pharmacological Group  Fluoroquinolones  Type of Form  Form 5  Finished product Specification  Pack size & Demanded Price  Approval status of product in Reference Regulatory Authorities.  Me-too status  GMP status  GMP status  Dy. No. 7001; 19.02.2019  Fluoroquinolones  Fluoroquinolones  Form 5  Form 5  AVELOX IV 400 moxifloxacin 40 hydrochloride) intravenous infusion  TGA approved  Esobrain Injection 40mg. Reg. No. 8  Applicant: The firm was inspected of the following conclusion: The firm facilities like building, HVAC System quality assurance and production open Pharma found to be operating at sate GMP compliance.  Manufacturer: GMP Certificate issue Remarks of the Evaluator (IX)  The firm submitted 05 approved sectors.	0 mg/250 mL (as n solution bottle.  5072 on 24.05.2019 with was evaluated for m, quality control, erations. The Briell trisfactory level of ed on 15-03-2018. tions, no approved
Diary No. Date of R & I & fee  Dy. No. 7001; 19.02.2019 PKR. 50,000/-; 19.02.2019 Pharmacological Group Fluoroquinolones Type of Form Form 5 Finished product Specification Pack size & Demanded Price Approval status of product in Reference Regulatory Authorities.  Me-too status  GMP status  Applicant: The firm was inspected of the following conclusion: The firm facilities like building, HVAC System quality assurance and production open Pharma found to be operating at sate GMP compliance.  Manufacturer: GMP Certificate issue Remarks of the Evaluator (IX)  The firm submitted 05 approved sect products for contract manufacturing	0 mg/250 mL (as n solution bottle.  5072 on 24.05.2019 with was evaluated for m, quality control, crations. The Briell trisfactory level of ed on 15-03-2018. tions, no approved g and 22 applied
Diary No. Date of R & I & fee  Dy. No. 7001; 19.02.2019 PKR. 50,000/-; 19.02.2019 Pharmacological Group Type of Form Form 5 Finished product Specification Pack size & Demanded Price Approval status of product in Reference Regulatory Authorities.  Me-too status  GMP status  Applicant: The firm was inspected of the following conclusion: The firm facilities like building, HVAC Systet quality assurance and production ope Pharma found to be operating at sa GMP compliance.  Manufacturer: GMP Certificate issue Remarks of the Evaluator (IX)  The firm submitted 05 approved sect products for contract manufacturing products for contact manufacturing	0 mg/250 mL (as n solution bottle.  5072 on 24.05.2019 with was evaluated for m, quality control, crations. The Briell trisfactory level of ed on 15-03-2018. tions, no approved g and 22 applied
Diary No. Date of R & I & fee  Dy. No. 7001; 19.02.2019 PKR. 50,000/-; 19.02.2019 Pharmacological Group Fluoroquinolones Type of Form Finished product Specification Pack size & Demanded Price Approval status of product in Reference Regulatory Authorities.  Me-too status  GMP status  Applicant: The firm was inspected of the following conclusion: The firm facilities like building, HVAC System quality assurance and production open Pharma found to be operating at sate GMP compliance.  Memarks of the Evaluator (IX)  The firm submitted 05 approved sector products for contract manufacturing products for contact manufacturing (M/s Briell Pharma).	0 mg/250 mL (as n solution bottle.) 5072 on 24.05.2019 with was evaluated for m, quality control, erations. The Briell trisfactory level of ed on 15-03-2018. tions, no approved g and 22 applied g of the applicant
Diary No. Date of R & I & fee  Dy. No. 7001; 19.02.2019 PKR. 50,000/-; 19.02.2019 Pharmacological Group Fluoroquinolones Type of Form Form 5 Finished product Specification Pack size & Demanded Price Approval status of product in Reference Regulatory Authorities.  Me-too status  GMP status  Applicant: The firm was inspected of the following conclusion: The firm facilities like building, HVAC System quality assurance and production open Pharma found to be operating at sate GMP compliance.  Manufacturer: GMP Certificate issue Remarks of the Evaluator (IX)  The firm submitted 05 approved sect products for contract manufacturing products for contact manufacturing	0 mg/250 mL (as n solution bottle.) 5072 on 24.05.2019 with was evaluated for m, quality control, erations. The Briell trisfactory level of ed on 15-03-2018. tions, no approved g and 22 applied g of the applicant

	Decision of 296 <sup>th</sup> meeting of	Deferred for capacity assessment of M/s Medisave
	Registration Board.	pharmaceuticals, Lahore.
	Remarks of the Evaluator.	praimacourous, Eurore.
		ard further decided that firm will submit fee of Rs.
		change in label claim, as per notification No.F.7-
	11/2012-B&A/DRAP dated 13-07-2021	
212.	Name and address of manufacturer/	M/s Briell Pharmaceuticals Pvt Ltd. 538-C Sundar
	Applicant	Industrial Estate Road, Lahore. By M/s Medisave
	TT	Pharmaceuticals. Plot 578-579, Sundar Industrial
		Estate, Lahore, Pakistan
	Brand Name + Dosage Form + Strength	Nervex 500mcg/ml Injection
	Composition	Each ml contains:
	1	Mecobalamin500mcg
	Diary No. Date of R & I & fee	Dy. No. 7001; 19.02.2019
		PKR. 50,000/-; 19.02.2019
	Pharmacological Group	Vitamin B12 (cyanocobalamin and analogues)
	Type of Form	Form 5
	Finished product Specification	JP
	Pack size & Demanded Price	1mlx10's (ampule); As per SRO
	Approval status of product in Reference	Mecobalamin injection 500μg (1ml). PMDA approved
	Regulatory Authorities.	
	Me-too status	Balco 500mcg IM/IV Injection (1ml). Reg. No. 81484
	GMP status	Applicant: The firm was inspected on 24.05.2019 with
		the following conclusion: The firm was evaluated for
		facilities like building, HVAC System, quality control,
		quality assurance and production operations. The Briell
		Pharma found to be operating at satisfactory level of
		GMP compliance.
		Manufacturer: GMP Certificate issued on 15-03-2018.
	Remarks of the Evaluator (IX)	The firm submitted 05 approved sections, no approved
		products for contract manufacturing and 22 applied
		products for contact manufacturing of the applicant
	4	(M/s Briell Pharma).
	Decision of 296 <sup>th</sup> meeting of	* •
	Registration Board.	pharmaceuticals, Lahore.
	Remarks of the Evaluator.	
		specifications and container closure system of "amber
		bmit the fee of Rs. 7,500 for correction/pre-approval
		per notification No.F.7-11/2012-B&A/DRAP dated 13-
	07-2021.	

# D: Registration applications of Deferred locally manufactured (Human) drugs on Form 5.

213.	Name and address of manufacturer/	M/s Welborne Pharmachem & Biologicals, Plot # 51/1,
	Applicant	52/2 Phase I & II, Industrial Estate, Hattar.
	Brand Name + Dosage Form +	Simper tablet 50mg/ 0.2mg
	Strength	
	Composition	Each enteric-coated tablet contains:
		Diclofenac Sodium50mg
		Misoprostol0.2mg
	Diary No. Date of R & I & fee	Dy. No. 2106, 09-05-2017; Rs.20,000/- (09-05-2017)
	Pharmacological Group	NSAID/ GI mucosal protective prostaglandin E1 analogue
	Type of Form	Form -5
	Finished product Specification	Not provided.
	Pack size & Demanded Price	2x 10's & as per SRO
	Approval status of product in	Arthrotec 50mg/ 0.2mg modified- release tablet of M/s
	Reference Regulatory Authorities	Pfizer Limited (MHRA Approved)

	Me-too status	Rotec 50mg/0.2mg tablet of M/s Searle (Reg. # 053327)
	GMP status	Last GMP inspection was conducted on 27-06-2018 and the
	OWF status	report concludes good level of GMP compliance.
	Remarks of the Evaluator	
	Remarks of the Evaluator	• 5% overage is added.
		• The official monograph of the applied formulation is available in USP.
	Decision of 284 <sup>th</sup> meeting of	Deferred due to 5% overage addition.
	Registration Board.	
	Submission by the firm.	Firm has submitted that their product was deferred in 284 <sup>th</sup> meeting of Registration Board with some minor deficiency. They submitted new master formula for the applied product wherein they have removed 5% of overage with submission of 7500/- fee vide slip no. 5303044184 dated 18-03-2022.
	Remarks of the Evaluator XIII	Reference product is enteric-coated core containing diclofenac sodium surrounded by an outer mantle containing misoprostol, while, according to the manufacturing method of applied formulation, diclofenac sodium and Misoprostol are mixed together along with other excipients and wet granulation technique is used. Master formulation does not depict any dispersion of Misoprostol and the label claim has also not mentioned any core of diclofenac sodium and outer mantle of the misoprostol.  Evidence of availability of bilayer machine for manufacturing of applied drug product.
	Decision: Deferred for following:	Latest GMP certificate of the manufacturer.
		er reference product with full fee.
	<ul><li>Revision of label claim as po</li><li>Evidence of availability of</li></ul>	
	<ul> <li>Revision of label claim as possible.</li> <li>Evidence of availability of product.</li> </ul>	er reference product with full fee.  f bilayer machine for manufacturing of applied drug
	<ul> <li>Revision of label claim as perioduct.</li> <li>Evidence of availability of product.</li> <li>Latest GMP certificate/insperioduct.</li> </ul>	er reference product with full fee.
214	<ul> <li>Revision of label claim as positive.</li> <li>Evidence of availability of product.</li> <li>Latest GMP certificate/insymanufacturer.</li> </ul>	er reference product with full fee.  To bilayer machine for manufacturing of applied drug pection report conducted within last three years of the
214.	<ul> <li>Revision of label claim as possible.</li> <li>Evidence of availability of product.</li> <li>Latest GMP certificate/insymanufacturer.</li> </ul> Name and address of manufacturer/	er reference product with full fee.  To bilayer machine for manufacturing of applied drug  pection report conducted within last three years of the  M/s Welborne Pharmachem & Biologicals, Plot # 51/1,
214.	<ul> <li>Revision of label claim as possible.</li> <li>Evidence of availability of product.</li> <li>Latest GMP certificate/insymanufacturer.</li> <li>Name and address of manufacturer/Applicant</li> </ul>	er reference product with full fee.  I bilayer machine for manufacturing of applied drug  pection report conducted within last three years of the  M/s Welborne Pharmachem & Biologicals, Plot # 51/1, 52/2 Phase I & II, Industrial Estate, Hattar.
214.	<ul> <li>Revision of label claim as periodic product.</li> <li>Latest GMP certificate/insymanufacturer.</li> <li>Name and address of manufacturer/Applicant</li> <li>Brand Name + Dosage Form +</li> </ul>	er reference product with full fee.  To bilayer machine for manufacturing of applied drug  pection report conducted within last three years of the  M/s Welborne Pharmachem & Biologicals, Plot # 51/1,
214.	<ul> <li>Revision of label claim as periodic.</li> <li>Latest GMP certificate/insymanufacturer.</li> <li>Name and address of manufacturer/Applicant</li> <li>Brand Name + Dosage Form + Strength</li> </ul>	er reference product with full fee.  f bilayer machine for manufacturing of applied drug  pection report conducted within last three years of the  M/s Welborne Pharmachem & Biologicals, Plot # 51/1, 52/2 Phase I & II, Industrial Estate, Hattar.  Simper tablet 75mg/ 0.2mg
214.	<ul> <li>Revision of label claim as periodic product.</li> <li>Latest GMP certificate/insymanufacturer.</li> <li>Name and address of manufacturer/Applicant</li> <li>Brand Name + Dosage Form +</li> </ul>	er reference product with full fee.  If bilayer machine for manufacturing of applied drug pection report conducted within last three years of the  M/s Welborne Pharmachem & Biologicals, Plot # 51/1, 52/2 Phase I & II, Industrial Estate, Hattar.  Simper tablet 75mg/ 0.2mg  Each enteric-coated tablet contains:
214.	<ul> <li>Revision of label claim as periodic.</li> <li>Latest GMP certificate/insymanufacturer.</li> <li>Name and address of manufacturer/Applicant</li> <li>Brand Name + Dosage Form + Strength</li> </ul>	er reference product with full fee.  I bilayer machine for manufacturing of applied drug  pection report conducted within last three years of the  M/s Welborne Pharmachem & Biologicals, Plot # 51/1, 52/2 Phase I & II, Industrial Estate, Hattar.  Simper tablet 75mg/ 0.2mg  Each enteric-coated tablet contains: Diclofenac Sodium
214.	<ul> <li>Revision of label claim as possible.</li> <li>Evidence of availability of product.</li> <li>Latest GMP certificate/insymanufacturer.</li> <li>Name and address of manufacturer/Applicant</li> <li>Brand Name + Dosage Form + Strength</li> <li>Composition</li> </ul>	er reference product with full fee.  I bilayer machine for manufacturing of applied drug  pection report conducted within last three years of the  M/s Welborne Pharmachem & Biologicals, Plot # 51/1, 52/2 Phase I & II, Industrial Estate, Hattar.  Simper tablet 75mg/ 0.2mg  Each enteric-coated tablet contains: Diclofenac Sodium
214.	<ul> <li>Revision of label claim as possible.</li> <li>Evidence of availability of product.</li> <li>Latest GMP certificate/insymanufacturer.</li> <li>Name and address of manufacturer/Applicant</li> <li>Brand Name + Dosage Form + Strength</li> <li>Composition</li> <li>Diary No. Date of R &amp; I &amp; fee</li> </ul>	er reference product with full fee.  I bilayer machine for manufacturing of applied drug  pection report conducted within last three years of the  M/s Welborne Pharmachem & Biologicals, Plot # 51/1, 52/2 Phase I & II, Industrial Estate, Hattar.  Simper tablet 75mg/ 0.2mg  Each enteric-coated tablet contains: Diclofenac Sodium
214.	<ul> <li>Revision of label claim as possible.</li> <li>Evidence of availability of product.</li> <li>Latest GMP certificate/insymanufacturer.</li> <li>Name and address of manufacturer/Applicant</li> <li>Brand Name + Dosage Form + Strength</li> <li>Composition</li> <li>Diary No. Date of R &amp; I &amp; fee</li> <li>Pharmacological Group</li> </ul>	er reference product with full fee.  It bilayer machine for manufacturing of applied drug pection report conducted within last three years of the  M/s Welborne Pharmachem & Biologicals, Plot # 51/1, 52/2 Phase I & II, Industrial Estate, Hattar.  Simper tablet 75mg/ 0.2mg  Each enteric-coated tablet contains:  Diclofenac Sodium
214.	<ul> <li>Revision of label claim as possible.</li> <li>Evidence of availability of product.</li> <li>Latest GMP certificate/insymanufacturer.</li> <li>Name and address of manufacturer/Applicant</li> <li>Brand Name + Dosage Form + Strength</li> <li>Composition</li> <li>Diary No. Date of R &amp; I &amp; fee</li> <li>Pharmacological Group</li> <li>Type of Form</li> </ul>	er reference product with full fee.  I bilayer machine for manufacturing of applied drug pection report conducted within last three years of the  M/s Welborne Pharmachem & Biologicals, Plot # 51/1, 52/2 Phase I & II, Industrial Estate, Hattar.  Simper tablet 75mg/ 0.2mg  Each enteric-coated tablet contains: Diclofenac Sodium
214.	<ul> <li>Revision of label claim as periodic.</li> <li>Latest GMP certificate/insymanufacturer.</li> <li>Name and address of manufacturer/Applicant</li> <li>Brand Name + Dosage Form + Strength</li> <li>Composition</li> <li>Diary No. Date of R &amp; I &amp; fee</li> <li>Pharmacological Group</li> <li>Type of Form</li> <li>Finished product Specification</li> </ul>	er reference product with full fee.  f bilayer machine for manufacturing of applied drug pection report conducted within last three years of the  M/s Welborne Pharmachem & Biologicals, Plot # 51/1, 52/2 Phase I & II, Industrial Estate, Hattar.  Simper tablet 75mg/ 0.2mg  Each enteric-coated tablet contains: Diclofenac Sodium
214.	<ul> <li>Revision of label claim as possible.</li> <li>Evidence of availability of product.</li> <li>Latest GMP certificate/insymanufacturer.</li> <li>Name and address of manufacturer/Applicant</li> <li>Brand Name + Dosage Form + Strength</li> <li>Composition</li> <li>Diary No. Date of R &amp; I &amp; fee</li> <li>Pharmacological Group</li> <li>Type of Form</li> <li>Finished product Specification</li> <li>Pack size &amp; Demanded Price</li> </ul>	er reference product with full fee.  If bilayer machine for manufacturing of applied drug pection report conducted within last three years of the M/s Welborne Pharmachem & Biologicals, Plot # 51/1, 52/2 Phase I & II, Industrial Estate, Hattar.  Simper tablet 75mg/ 0.2mg  Each enteric-coated tablet contains: Diclofenac Sodium
214.	<ul> <li>Revision of label claim as possible.</li> <li>Evidence of availability of product.</li> <li>Latest GMP certificate/insymanufacturer.</li> <li>Name and address of manufacturer/Applicant</li> <li>Brand Name + Dosage Form + Strength</li> <li>Composition</li> <li>Diary No. Date of R &amp; I &amp; fee</li> <li>Pharmacological Group</li> <li>Type of Form</li> <li>Finished product Specification</li> <li>Pack size &amp; Demanded Price</li> <li>Approval status of product in</li> </ul>	er reference product with full fee.  It bilayer machine for manufacturing of applied drug pection report conducted within last three years of the  M/s Welborne Pharmachem & Biologicals, Plot # 51/1, 52/2 Phase I & II, Industrial Estate, Hattar.  Simper tablet 75mg/ 0.2mg  Each enteric-coated tablet contains: Diclofenac Sodium
214.	<ul> <li>Revision of label claim as possible.</li> <li>Evidence of availability of product.</li> <li>Latest GMP certificate/insymanufacturer.</li> <li>Name and address of manufacturer/Applicant</li> <li>Brand Name + Dosage Form + Strength</li> <li>Composition</li> <li>Diary No. Date of R &amp; I &amp; fee</li> <li>Pharmacological Group</li> <li>Type of Form</li> <li>Finished product Specification</li> <li>Pack size &amp; Demanded Price</li> <li>Approval status of product in</li> <li>Reference Regulatory Authorities</li> </ul>	er reference product with full fee.  I bilayer machine for manufacturing of applied drug pection report conducted within last three years of the  M/s Welborne Pharmachem & Biologicals, Plot # 51/1, 52/2 Phase I & II, Industrial Estate, Hattar.  Simper tablet 75mg/ 0.2mg  Each enteric-coated tablet contains: Diclofenac Sodium
214.	<ul> <li>Revision of label claim as possible.</li> <li>Evidence of availability of product.</li> <li>Latest GMP certificate/insymanufacturer.</li> <li>Name and address of manufacturer/Applicant</li> <li>Brand Name + Dosage Form + Strength</li> <li>Composition</li> <li>Diary No. Date of R &amp; I &amp; fee</li> <li>Pharmacological Group</li> <li>Type of Form</li> <li>Finished product Specification</li> <li>Pack size &amp; Demanded Price</li> <li>Approval status of product in Reference Regulatory Authorities</li> <li>Me-too status</li> </ul>	er reference product with full fee.  I bilayer machine for manufacturing of applied drug pection report conducted within last three years of the  M/s Welborne Pharmachem & Biologicals, Plot # 51/1, 52/2 Phase I & II, Industrial Estate, Hattar.  Simper tablet 75mg/ 0.2mg  Each enteric-coated tablet contains: Diclofenac Sodium
214.	<ul> <li>Revision of label claim as possible.</li> <li>Evidence of availability of product.</li> <li>Latest GMP certificate/insymanufacturer.</li> <li>Name and address of manufacturer/Applicant</li> <li>Brand Name + Dosage Form + Strength</li> <li>Composition</li> <li>Diary No. Date of R &amp; I &amp; fee</li> <li>Pharmacological Group</li> <li>Type of Form</li> <li>Finished product Specification</li> <li>Pack size &amp; Demanded Price</li> <li>Approval status of product in</li> <li>Reference Regulatory Authorities</li> </ul>	er reference product with full fee. If bilayer machine for manufacturing of applied drug pection report conducted within last three years of the  M/s Welborne Pharmachem & Biologicals, Plot # 51/1, 52/2 Phase I & II, Industrial Estate, Hattar.  Simper tablet 75mg/ 0.2mg  Each enteric-coated tablet contains: Diclofenac Sodium
214.	<ul> <li>Revision of label claim as possible.</li> <li>Evidence of availability of product.</li> <li>Latest GMP certificate/insymanufacturer.</li> <li>Name and address of manufacturer/Applicant</li> <li>Brand Name + Dosage Form + Strength</li> <li>Composition</li> <li>Diary No. Date of R &amp; I &amp; fee</li> <li>Pharmacological Group</li> <li>Type of Form</li> <li>Finished product Specification</li> <li>Pack size &amp; Demanded Price</li> <li>Approval status of product in Reference Regulatory Authorities</li> <li>Me-too status</li> </ul>	er reference product with full fee.  I bilayer machine for manufacturing of applied drug pection report conducted within last three years of the  M/s Welborne Pharmachem & Biologicals, Plot # 51/1, 52/2 Phase I & II, Industrial Estate, Hattar.  Simper tablet 75mg/ 0.2mg  Each enteric-coated tablet contains: Diclofenac Sodium

Decision of 284th meeting of

Registration Board.

Submission by the firm.

available in USP.

Deferred due to 5% overage addition.

The official monograph of the applied formulation is

Firm has submitted that their product was deferred in 284th

meeting of Registration Board with some minor deficiency.

They submitted new master formula for the applied product
wherein they have removed 5% of overage with submission
of 7500/- fee vide slip no. 4699230753 dated 18-03-2022.
Reference product is enteric-coated core containing
diclofenac sodium surrounded by an outer mantle
containing misoprostol, while, according to the
manufacturing method of applied formulation, diclofenac
sodium and Misoprostol are mixed together along with
other excipients and wet granulation technique is used.
Master formulation does not depict any dispersion of
Misoprostol and the label claim has also not mentioned any
core of diclofenac sodium and outer mantle of the
misoprostol.
Evidence of availability of bilayer machine for
manufacturing of applied drug product.
Latest GMP certificate of the manufacturer.
_

- Revision of label claim as per reference product with full fee.
- Evidence of availability of bilayer machine for manufacturing of applied drug product.
- Latest GMP certificate/inspection report conducted within last three years of the manufacturer.

	manufacturer.	
	Name and address of manufacturer/	M/s Wellborne Pharmachem & Biologicals, Plot # 51/1,
	Applicant	52/2 Phase I & II, Industrial Estate, Hattar.
	Brand Name + Dosage Form +	Serene 50mg tablet
	Strength	
	Composition	Each film- coated tablet contains:
		Lacosamide50mg
	Diary No. Date of R & I & fee	Dy. No. 1773, 05-05-2017; Rs.20,000/- (05-05-2017)
	Pharmacological Group	Anti-epileptic
	Type of Form	Form -5
	Finished product Specification	Not provided.
	Pack size & Demanded Price	2x7's & as per SRO
	Approval status of product in Reference Regulatory Authorities	Vimpat 50mg tablet of M/s UCB Pharma Limited, UK (MHRA Approved)
	Me-too status	Lacolep 50mg tablet of M/s Hilton Pharma
	GMP status	Last GMP inspection was conducted on 27-06-2018 and the
		report concludes good level of GMP compliance.
	Remarks of the Evaluator	• The official monograph of the applied formulation is not available in USP or BP.
		• 5% overage is added.
		• Film- coated tablet is not mentioned in the label claim
		of Form- 5.
Ī	Decision of 284 <sup>th</sup> meeting of	Deferred due to following reasons:
	Registration Board.	• 5% overage is added.
		Film-coated tablet is not mentioned in the label claim
		of Form- 5.
	Submission by the firm.	Firm has submitted that their product was deferred in 284 <sup>th</sup>
		meeting of Registration Board with some minor deficiency.
		They submitted new master formula for the applied product
		wherein they have removed 5% of overage with submission
		of 7500/- fee vide slip no. 1990706202 dated 18-03-2022.
	Remarks of the Evaluator XIII	<ul> <li>Latest GMP certificate of the manufacturer.</li> </ul>
		• Form 5 has not been submitted by the firm.
Ī	<b>Decision: Approved with innovator</b>	's specifications. Registration Board further decided that

registration letter will be issued after submission of valid GMP certificates/last inspection

	claim of "Each film coated tablet co • Firm shall submit the f	years of the manufacturer and Revised form 5 with label ontains. fee of Rs. 7,500 for correction/pre-approval change/ in as per notification No.F.7-11/2012-B&A/DRAP dated 13-
216.	Name and address of manufacturer/ Applicant	M/s Wellborne Pharmachem & Biologicals, Plot # 51/1, 52/2 Phase I & II, Industrial Estate, Hattar.
	Brand Name + Dosage Form + Strength	Serene 100mg tablet
	Composition	Each film- coated tablet contains: Lacosamide100mg
	Diary No. Date of R & I & fee	Dy. No. 1780, 05-05-2017; Rs.20,000/- (05-05-2017)
	Pharmacological Group	Anti-epileptic
	Type of Form	Form -5
	Finished product Specification	Not provided.
	Pack size & Demanded Price	2x7's & as per SRO
	Approval status of product in	Vimpat 100mg tablet of M/s UCB Pharma Limited, UK
	Reference Regulatory Authorities	(MHRA Approved)
	Me-too status	Lacolep 100mg tablet of M/s Hilton Pharma
	GMP status	Last GMP inspection was conducted on 27-06-2018 and the
	Remarks of the Evaluator	report concludes good level of GMP compliance.
	Remarks of the Evaluator	• The official monograph of the applied formulation is not available in USP or BP.
	Decision of 284 <sup>th</sup> meeting of	<ul> <li>5% overage is added.</li> <li>Deferred due to addition of 5% overage.</li> </ul>
	Registration Board.	Deferred due to addition of 5% overage.
	Submission by the firm.	Firm has submitted that their product was deferred in 284 <sup>th</sup>
	~ ####################################	meeting of Registration Board with some minor deficiency.
		They submitted new master formula for the applied product
İ		wherein they have removed 5% of overage with submission
		of 7500/- fee vide slip no. 728790252915 dated 18-03-
	Remarks of the Evaluator XIII	<ul><li>2022.</li><li>Latest GMP certificate of the manufacturer.</li></ul>
217.		's specifications. Registration Board further decided that
217.	report conducted within last three the fee of Rs. 7,500 for correction notification No.F.7-11/2012-B&A/I Name and address of manufacturer/	fter submission of valid GMP certificates/last inspection years of the manufacturer. Moreover, firm shall submit h/pre-approval change/ in product specifications, as per DRAP dated 13-07-2021.  M/s Wellborne Pharmachem & Biologicals, Plot # 51/1,
217.	report conducted within last three the fee of Rs. 7,500 for correction notification No.F.7-11/2012-B&A/I Name and address of manufacturer/ Applicant	fter submission of valid GMP certificates/last inspection years of the manufacturer. Moreover, firm shall submit h/pre-approval change/ in product specifications, as per DRAP dated 13-07-2021.  M/s Wellborne Pharmachem & Biologicals, Plot # 51/1, 52/2 Phase I & II, Industrial Estate, Hattar.
217.	report conducted within last three the fee of Rs. 7,500 for correction notification No.F.7-11/2012-B&A/I  Name and address of manufacturer/ Applicant  Brand Name + Dosage Form +	fter submission of valid GMP certificates/last inspection years of the manufacturer. Moreover, firm shall submit h/pre-approval change/ in product specifications, as per DRAP dated 13-07-2021.  M/s Wellborne Pharmachem & Biologicals, Plot # 51/1,
217.	report conducted within last three the fee of Rs. 7,500 for correction notification No.F.7-11/2012-B&A/I Name and address of manufacturer/ Applicant	fter submission of valid GMP certificates/last inspection years of the manufacturer. Moreover, firm shall submit h/pre-approval change/ in product specifications, as per DRAP dated 13-07-2021.  M/s Wellborne Pharmachem & Biologicals, Plot # 51/1, 52/2 Phase I & II, Industrial Estate, Hattar.  Serene 200mg tablet  Each film- coated tablet contains:
217.	report conducted within last three the fee of Rs. 7,500 for correction notification No.F.7-11/2012-B&A/I  Name and address of manufacturer/ Applicant  Brand Name + Dosage Form + Strength Composition	fter submission of valid GMP certificates/last inspection years of the manufacturer. Moreover, firm shall submit h/pre-approval change/ in product specifications, as per DRAP dated 13-07-2021.  M/s Wellborne Pharmachem & Biologicals, Plot # 51/1, 52/2 Phase I & II, Industrial Estate, Hattar.  Serene 200mg tablet  Each film- coated tablet contains: Lacosamide200mg
217.	report conducted within last three the fee of Rs. 7,500 for correction notification No.F.7-11/2012-B&A/I  Name and address of manufacturer/ Applicant  Brand Name + Dosage Form + Strength Composition  Diary No. Date of R & I & fee	fter submission of valid GMP certificates/last inspection years of the manufacturer. Moreover, firm shall submit a/pre-approval change/ in product specifications, as per DRAP dated 13-07-2021.  M/s Wellborne Pharmachem & Biologicals, Plot # 51/1, 52/2 Phase I & II, Industrial Estate, Hattar.  Serene 200mg tablet  Each film- coated tablet contains: Lacosamide
217.	report conducted within last three the fee of Rs. 7,500 for correction notification No.F.7-11/2012-B&A/I  Name and address of manufacturer/ Applicant  Brand Name + Dosage Form + Strength Composition  Diary No. Date of R & I & fee Pharmacological Group	fter submission of valid GMP certificates/last inspection years of the manufacturer. Moreover, firm shall submit h/pre-approval change/ in product specifications, as per DRAP dated 13-07-2021.  M/s Wellborne Pharmachem & Biologicals, Plot # 51/1, 52/2 Phase I & II, Industrial Estate, Hattar.  Serene 200mg tablet  Each film- coated tablet contains: Lacosamide200mg
217.	report conducted within last three the fee of Rs. 7,500 for correction notification No.F.7-11/2012-B&A/I  Name and address of manufacturer/ Applicant  Brand Name + Dosage Form + Strength Composition  Diary No. Date of R & I & fee	Iter submission of valid GMP certificates/last inspection years of the manufacturer. Moreover, firm shall submit a/pre-approval change/ in product specifications, as per DRAP dated 13-07-2021.  M/s Wellborne Pharmachem & Biologicals, Plot # 51/1, 52/2 Phase I & II, Industrial Estate, Hattar.  Serene 200mg tablet  Each film- coated tablet contains: Lacosamide200mg  Dy. No. 1776, 05-05-2017; Rs.20,000/- (05-05-2017)  Anti-epileptic
217.	report conducted within last three the fee of Rs. 7,500 for correction notification No.F.7-11/2012-B&A/I  Name and address of manufacturer/ Applicant  Brand Name + Dosage Form + Strength Composition  Diary No. Date of R & I & fee Pharmacological Group Type of Form	fter submission of valid GMP certificates/last inspection years of the manufacturer. Moreover, firm shall submit h/pre-approval change/ in product specifications, as per DRAP dated 13-07-2021.  M/s Wellborne Pharmachem & Biologicals, Plot # 51/1, 52/2 Phase I & II, Industrial Estate, Hattar.  Serene 200mg tablet  Each film- coated tablet contains: Lacosamide200mg  Dy. No. 1776, 05-05-2017; Rs.20,000/- (05-05-2017)  Anti-epileptic Form -5
217.	report conducted within last three the fee of Rs. 7,500 for correction notification No.F.7-11/2012-B&A/I  Name and address of manufacturer/ Applicant  Brand Name + Dosage Form + Strength Composition  Diary No. Date of R & I & fee Pharmacological Group Type of Form Finished product Specification	fter submission of valid GMP certificates/last inspection years of the manufacturer. Moreover, firm shall submit h/pre-approval change/ in product specifications, as per DRAP dated 13-07-2021.  M/s Wellborne Pharmachem & Biologicals, Plot # 51/1, 52/2 Phase I & II, Industrial Estate, Hattar.  Serene 200mg tablet  Each film- coated tablet contains: Lacosamide
217.	report conducted within last three the fee of Rs. 7,500 for correction notification No.F.7-11/2012-B&A/I  Name and address of manufacturer/ Applicant  Brand Name + Dosage Form + Strength Composition  Diary No. Date of R & I & fee Pharmacological Group Type of Form Finished product Specification Pack size & Demanded Price	fter submission of valid GMP certificates/last inspection years of the manufacturer. Moreover, firm shall submit a/pre-approval change/ in product specifications, as per DRAP dated 13-07-2021.  M/s Wellborne Pharmachem & Biologicals, Plot # 51/1, 52/2 Phase I & II, Industrial Estate, Hattar.  Serene 200mg tablet  Each film- coated tablet contains: Lacosamide
217.	report conducted within last three the fee of Rs. 7,500 for correction notification No.F.7-11/2012-B&A/I  Name and address of manufacturer/ Applicant Brand Name + Dosage Form + Strength Composition  Diary No. Date of R & I & fee Pharmacological Group Type of Form Finished product Specification Pack size & Demanded Price Approval status of product in	ter submission of valid GMP certificates/last inspection years of the manufacturer. Moreover, firm shall submit a/pre-approval change/ in product specifications, as per DRAP dated 13-07-2021.  M/s Wellborne Pharmachem & Biologicals, Plot # 51/1, 52/2 Phase I & II, Industrial Estate, Hattar.  Serene 200mg tablet  Each film- coated tablet contains: Lacosamide200mg  Dy. No. 1776, 05-05-2017; Rs.20,000/- (05-05-2017)  Anti-epileptic Form -5  Not provided.  2x7's & as per SRO  Vimpat 200mg tablet of M/s UCB Pharma Limited, UK
217.	report conducted within last three the fee of Rs. 7,500 for correction notification No.F.7-11/2012-B&A/I  Name and address of manufacturer/ Applicant  Brand Name + Dosage Form + Strength Composition  Diary No. Date of R & I & fee Pharmacological Group Type of Form Finished product Specification Pack size & Demanded Price Approval status of product in Reference Regulatory Authorities	fter submission of valid GMP certificates/last inspection years of the manufacturer. Moreover, firm shall submit h/pre-approval change/ in product specifications, as per DRAP dated 13-07-2021.  M/s Wellborne Pharmachem & Biologicals, Plot # 51/1, 52/2 Phase I & II, Industrial Estate, Hattar.  Serene 200mg tablet  Each film- coated tablet contains: Lacosamide200mg  Dy. No. 1776, 05-05-2017; Rs.20,000/- (05-05-2017)  Anti-epileptic Form -5  Not provided.  2x7's & as per SRO  Vimpat 200mg tablet of M/s UCB Pharma Limited, UK (MHRA Approved)

	D 1 C.1 E 1 .	
	Remarks of the Evaluator	• The official monograph of the applied formulation is not available in USP or BP.
	D : COOAth : C	• 5% overage is added.
	Decision of 284 <sup>th</sup> meeting of	Deferred due to addition of 5% overage.
	Registration Board. Submission by the firm.	Firm has submitted that their product was deferred in 284 <sup>th</sup>
	Submission by the firm.	<u> </u>
		meeting of Registration Board with some minor deficiency.
		They submitted new master formula for the applied product
		wherein they have removed 5% of overage with submission
	Remarks of the Evaluator XIII	of 7500/- fee vide slip no. 24948056999 dated 18-03-2022.
		Latest GMP certificate of the manufacturer.      Design Continue Provided Broad and Additional Continue Provided Broad Additional Continue Provided Broad Additional Continue Provided Broad Additional Continue Provided Broad Additional Continue Provided Broad Additional Continue Provided Broad Additional Continue Provided Broad Additional Continue Provided Broad Additional Continue Provided Broad Additional Continue Provided Broad Additional Continue Provided Broad Additional Continue Provided Broad Additional Continue Provided Broad Additional Continue
		's specifications. Registration Board further decided that fter submission of valid GMP certificates/last inspection
		e years of the manufacturer. Moreover, the firm shall
	notification No.F.7-11/2012-B&A/E	on/pre-approval change/ in product specifications, as per
218.	Name and address of manufacturer/	M/s High-Q Pharmaceuticals, B-64, KDA, Scheme No. 1,
210.	Applicant	Main Karsaz Road, Karachi, Pakistan.
	Brand Name + Dosage Form +	Meco- Q Capsule 500mcg
	Strength	and Company of the Company
	Composition	Each capsule contains:
		Mecobalamin500mcg
	Diary No. Date of R & I & fee	Dy.No.29492; 03-09-2018; Rs.20,000 (03-09-2018)
	Pharmacological Group	Anti- anaemic/ Vitamin B-12
	Type of Form	Form- 5.
	Finished product Specification	Manufacturers.
	Pack size & Demanded Price	10's, 14's, 20's, 30's & 100's & As per leader price.
	Approval status of product in	Could not be confirmed in the applied strength as 250mcg
	Reference Regulatory Authorities	is available in PMDA, Japan.
	Me-too status	Mecobalamin 500mcg capsules of M/s U.M. Enterprise
		(Reg. # 022643).
	GMP status	Last GMP inspection was conducted on 10/04/18 and the
	D 1 21 D 1 VIII	report concludes an acceptable level of GMP compliance.
	Remarks of the Evaluator XIII	International availability for the applied formulation
		could not be confirmed in the applied strength.
		No official monograph is available in USP, BP, IP or
	D : : Cacard : C	JP for the applied formulation.
	Decision of 293 <sup>rd</sup> meeting of	Deferred for evidence of approval of applied formulation in
	Registration Board.	reference regulatory authorities / agencies which were
	Submission by the firm.	adopted by the Registration Board in its 275th meeting.  Firm has submitted that the applied formulation is available
	Submission by the min.	in in Japan and registered in PMDA in the same strength
		and dosage form. Details are as under;
		Brand Name: Height Cobalamin M capsule 500mcg.
		Approval No. 21800 AMX 10113.
		Trade Mark name: Hitocobamin M capsule.
		Active ingredient: (in 1 capsule) Japan pharmacopoeia
		Mecobalamin 500mcg.
	Remarks of the Evaluator XIII	Availability of the above said product in PMDA, Japan
	Tomaino of the Dymunor	could not be confirmed.
	Decision: Deferred for evidence of	approval of applied formulation in reference regulatory
		dopted by the Registration Board in its 275th meeting.
	and the state of t	

# E: Registration applications of Deferred locally manufactured (Veterinary) drugs on Form 5.

).	Name and address of manufacturer/	
	Applicant	Multan.
	Brand Name + Dosage Form + Strength	
	Composition	Fipronil0.29%
	Diary No. Date of R & I & fee	Dy.No.175, 09-10-2015; Rs.20,000/-, 09-10-2015
	Pharmacological Group	Broad- spectrum insecticide
	Type of Form	Form- 5
	Finished product Specification	Manufacturers
	Pack size & Demanded Price	100ml, 120ml, 150ml, 200ml, 250ml, 500ml &
		Decontrolled
	Me-too status	Could not be confirmed
	GMP status	Latest Not provided
	Remarks of the Evaluator PEC-XIII (a)	<ul> <li>Applied label claim is not complete.</li> </ul>
		<ul> <li>Me- too status could not eb confirmed.</li> </ul>
		GMP status could not be confirmed.
		Section is not verified.
	Decision of 297 <sup>th</sup> meeting of	Deferred for following:
	registration Board.	• Evidence of applied formulation/drug already
		approved by DRAP (generic / me-too status) along
		with registration number, brand name and name of
		firm.
		Label claim.
		GMP Status.
		Required manufacturing facility.
	Submission by the firm:	Firm has submitted the following label claim;
	,	Fiprozak spray:
		Each 100 ml contains:
		Fibronil 0.29gm.
		Pack sizes of 100ml, 250ml & 500ml.
		Z.P. Specifications.
		• Firm has submitted panel inspection report for
		renewal of DML and grant of additional section dated
		15-06-2021 wherein the panel of inspectors
		recommends the approval of newly upgrade (revised)
		Bolus section (veterinary) and renewal of drug
		manufacturing License by way of formulation to M/s
		Zakfas Pharma (Pvt.) Ltd., 12 km Bosan Road,
		Multan.
		• Inspection report has also mentioned Spray section
		(Veterinary) and the firm also provided letter No. F.
		6-1/2013-Lic (M-232) dated 29-08-2013 wherein
		spray section is also mentioned on the said letter.
		• Firm has also submitted packing details of frontline.
		However, no details of Reg. No., Active ingredients
		and their strengths and name of the firm is provided.
	Remarks of the Evaluator PEC-XIII	Firm has revised their label claim without submission
		of applicable fee.
		• Evidence of applied formulation/drug already
		approved by DRAP (generic / me-too status) along
		with registration number, brand name and name of
		firm.
	<b>Decision: Deferred for following;</b>	

### **Decision: Deferred for following;**

- Submission of full fee for revision of label claim.
- Evidence of applied formulation/drug already approved by DRAP (generic / me-too status) along with registration number, brand name and name of firm.

220.	Name and address of manufacturer/	M/s Selmore Pharmaceuticals (Pvt.) Ltd., 36-Km, Multan
,	Applicant	Road Lahore.
	Brand Name + Dosage Form +	Bdex Liquid Injection 100ml.
	Strength	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
	Composition	Each ml Contains:
	1	Benzathine Penicillin G125,000IU
		Benzyl Penicillin Procaine125,000IU
		Dihydro Streptomycin Sulphate0.25gm
		Dexamethasone Sodium Phosphate0.20mg
		Dexamethasone 21 Isonicotinate0.20mg
	Diary No. Date of R & I & fee	Dy. No 10342 dated 02-07-2019; Rs.20,000/- dated 01-07-
	,	2019.
	Pharmacological Group	Natural penicillin/aminoglycosides/corticosteroids.
	Type of Form	Form-5.
	Finished product Specification	Manufacturer's specifications.
	Pack size & Demanded Price	Decontrolled.
	Approval status of product in	
	Reference Regulatory Authorities	
	Me-too status	Bicormicina L.A. Injection, Imported by Prix pharma from Italy, Reg. No. 027477.
	GMP status	Conclusion: (05-03-2018,17-08-2018 & 16-10-2018)
		In the light of the inspection conducted by the panel and
		based on the findings the panel of inspectors recommends
		grant of renewal of drug manufacturing license by way of
		formulation of M/s Selmore Pharma Lahore for following
		sections:
		1- Veterinary Bolus
		2- Veterinary Aerosol
		3- Veterinary Oral powder
		4- Veterinary Oral Liquid
		5- Veterinary Liquid Injection
		6- Veterinary Penicillin oral powder
		7- Veterinary Penicillin dry powder for injection
		8- Veterinary Penicillin liquid injection
		9- Veterinary Hormone Liquid injection
		10- Human Penicillin capsule
		11- Human Penicillin dry powder suspension
		12- Human Penicillin dry powder injection.
	Remarks of the Evaluator	Reference product contain dihydrostreptomycin
		sulphate 0.25gm (equivalent to dihydrostreptomycin
		0.20gm) while the applied formulation contains
		dihydrostreptomycin sulphate 0.25gm.
		Manufacturing facility/section approval could not be
	Decision of 312 <sup>th</sup> meeting of	confirmed.
	Decision of 312 <sup>th</sup> meeting of Registration Board.	Deferred for confirmation of required manufacturing facility / section from Licensing Division.
	Submission by the firm.	Firm has submitted that composition of the applied
	sacringsion by the min.	formulation contains both API (Penicillin and Steroid) and
		the API penicillin is more sensitive. We have already
		manufacturing same formulation (Bdex injection 50ml) in
		penicillin section. Therefore, we manufacturing the above
		said product in penicillin section.
		They further requested to consider their application for
		registration.
	Remarks of the Evaluator.	Latest GMP could not be confirmed.

Decision: Deferred for deliberation with Licensing Division regarding permisability of manufacturing of steroidal preparation in combination penicillin's in Penicillin's section or otherwise.

### **Agenda of Evaluator PEC-XIV**

### Case no. 01 Registration applications for local manufacturing of (Human) drugs

### **a.** Deferred cases

221	None and address of manufactures /	M/o Moon Dhomas continuis (Det.) Ltd
221.	Name and address of manufacturer /	M/s. Moon Pharmaceuticals (Pvt.) Ltd
	Applicant	Plot #5, SS-4 Road, National Industrial Zone, Rawat, Islamabad.
	Brand Name +Dosage Form + Strength	Metrolus ointment 0.1%
	Composition	Each gram contains:
	Composition	Tacrolimus monohydrate eq. to Tacrolimus1.0mg
	Diary No. Date of R& I & fee	Dy.No.1673, 17-10-2016, Rs.20,000/=
	Pharmacological Group	Immunosuppressant
	Type of Form	Form-5
	Finished product Specifications	Manufacturer's specifications
	Pack size & Demanded Price	$1 \times 10$ g / As per SRO
	Approval status of product in Reference	Protopic ointment by Leo Pharma (MHRA Approved)
	Regulatory Authorities	
	Me-too status	Graftil 0.1% Ointment by M/s Biolabs (Pvt) Ltd (Reg#096755)
	GMP status	Inspection report dated 29-12-2015 showing compliance of GMP as good.
	Previous remarks of the Evaluator.	of GMT as good.
	Previous Decision	Deferred for decision regarding separate requirement of
	Tievious Beetsion	manufacturing facility for immunosuppressants (M-270).
	Evaluation by PEC	The firm has submitted that at that time, separate
		manufacturing facility was necessary but now general
		facility may be sufficient for immunosuppressant.
		Copy of inspection report dated 11-12-2019 wherein the
		firm is operating at an acceptable level of GMP.
	correction/pre-approval change in produ B&A/DRAP dated 13-07-2021.	cifications. The firm shall submit fee of Rs. 7,500 for act specifications, as per notification No.F.7-11/2012-
222.	Name and address of manufacturer /	M/s. Surge Laboratories (Pvt.), 10 Km Faisalabad Road,
	Applicant	Bikhi district, Sheikhupura.
	Brand Name +Dosage Form + Strength	Levas Injection 50 mg
	Composition	Each 10ml ampoule contains:
		Labetalol hydrochloride50mg
	Diary No. Date of R& I & fee	Dy No. 1234, 16-6-2014, Rs.20000/-
	Pharmacological Group	Anti-hypertensive agent
	Type of Form	Form-5
	Finished product Specifications	USP specifications
	Pack size & Demanded Price	10 ml x 1's
		As per SRO/10's
	Approval status of product in Reference	Labetalol synchrony 5mg/ml solution for injection of
	Regulatory Authorities	M/s Synchrony (MHRA approved)

	Me-too status	Labetalol HCl 5mg/ ml injection of M/s Zafa Pharmaceutical (Reg # 042155).		
	GMP status	Date: 22-02-2018 & 04-05-2018		
		Recommendations:		
		Based on the physical inspection of the unit, the technical personal met and documents evaluated, the panel		
		concluded that the firm M/s Surge Labs Sheikhupura has		
		maintained a fair level of GMP compliance as per		
		Schedule B-II of Drug (Lic, Reg &		
		Adv) Rules 1976 on the day of inspection.		
	Previous remarks of the Evaluator.			
	Previous Decision	Deferred for clarification of filled volume as reference		
		product is available as 20 ml ampoule whereas firm has		
		applied for 10ml ampoule (M-269).		
	Evaluation by PEC	The firm has submitted reference product approved in		
		MHRA which is available in fill volume of 10ml		
		ampoule.		
		Labetalol synchrony 5mg/ml solution for injection of		
		M/s Synchrony (MHRA approved).		
	Decision: Approved.			
223.	Name and address of manufacturer /	M/s. Surge Laboratories (Pvt.), 10 Km Faisalabad Road,		
	Applicant	Bikhi district, Sheikhupura.		
	Brand Name +Dosage Form + Strength	Lisodim I.M Injection		
	Composition	Each 3ml ampoule contains:		
		Diclofenac Sodium75mg		
	D' N D (CD0 I 0 C	Lidocaine hydrochloride20mg		
	Diary No. Date of R& I & fee	Dairy No. 5 dated 01.01.2013, Rs:20,000/		
	Pharmacological Group	NSAID with local Anaesthetic		
	Type of Form	Form-5		
	Finished product Specifications	Surge specifications		
	Pack size & Demanded Price	As per SRO,		
		3ml x 1's 3ml x 5's		
		3mlx10's		
	Approval status of product in Reference	Diclofenac-Mepha 75 ampoules IM		
	Regulatory Authorities	1 ampoule of 2 ml contains: 75 mg diclofenac sodium,		
	Regulatory Authorities	20 mg Lidocaine hydrochloride (Swiss medics		
		approved).		
	Me-too status	Aram Plus Injection by M/s Bosch Pharma		
		Thair I las injection by 141/5 Doseii I harria		
	GMP status			
	GMP status	Date: 22-02-2018 & 04-05-2018.		
	GMP status	Date: 22-02-2018 & 04-05-2018. Recommendations:		
	GMP status	Date: 22-02-2018 & 04-05-2018. Recommendations: Based on the physical inspection of the unit, the technical		
	GMP status	Date: 22-02-2018 & 04-05-2018. Recommendations: Based on the physical inspection of the unit, the technical personal met and documents evaluated, the panel		
	GMP status	Date: 22-02-2018 & 04-05-2018.  Recommendations:  Based on the physical inspection of the unit, the technical personal met and documents evaluated, the panel concluded that the firm M/s Surge Labs Sheikhupura has		
	GMP status	Date: 22-02-2018 & 04-05-2018.  Recommendations:  Based on the physical inspection of the unit, the technical personal met and documents evaluated, the panel concluded that the firm M/s Surge Labs Sheikhupura has maintained a fair level of GMP compliance as per		
	GMP status	Date: 22-02-2018 & 04-05-2018.  Recommendations:  Based on the physical inspection of the unit, the technical personal met and documents evaluated, the panel concluded that the firm M/s Surge Labs Sheikhupura has maintained a fair level of GMP compliance as per Schedule B-II of Drug (Lic, Reg &		
	Previous remarks of the Evaluator.	Date: 22-02-2018 & 04-05-2018.  Recommendations:  Based on the physical inspection of the unit, the technical personal met and documents evaluated, the panel concluded that the firm M/s Surge Labs Sheikhupura has maintained a fair level of GMP compliance as per		
		Date: 22-02-2018 & 04-05-2018.  Recommendations:  Based on the physical inspection of the unit, the technical personal met and documents evaluated, the panel concluded that the firm M/s Surge Labs Sheikhupura has maintained a fair level of GMP compliance as per Schedule B-II of Drug (Lic, Reg & Adv) Rules 1976 on the day of inspection.		
	Previous remarks of the Evaluator.	Date: 22-02-2018 & 04-05-2018.  Recommendations:  Based on the physical inspection of the unit, the technical personal met and documents evaluated, the panel concluded that the firm M/s Surge Labs Sheikhupura has maintained a fair level of GMP compliance as per Schedule B-II of Drug (Lic, Reg &		
	Previous remarks of the Evaluator.	Date: 22-02-2018 & 04-05-2018.  Recommendations:  Based on the physical inspection of the unit, the technical personal met and documents evaluated, the panel concluded that the firm M/s Surge Labs Sheikhupura has maintained a fair level of GMP compliance as per Schedule B-II of Drug (Lic, Reg & Adv) Rules 1976 on the day of inspection.  Deferred for following (M-262):		
	Previous remarks of the Evaluator.	Date: 22-02-2018 & 04-05-2018.  Recommendations:  Based on the physical inspection of the unit, the technical personal met and documents evaluated, the panel concluded that the firm M/s Surge Labs Sheikhupura has maintained a fair level of GMP compliance as per Schedule B-II of Drug (Lic, Reg & Adv) Rules 1976 on the day of inspection.  Deferred for following (M-262):  Commitments as per 251st meeting of RB are missing.  The reference literature for detailed specification of Finished product is missing.		
	Previous remarks of the Evaluator.	Date: 22-02-2018 & 04-05-2018.  Recommendations:  Based on the physical inspection of the unit, the technical personal met and documents evaluated, the panel concluded that the firm M/s Surge Labs Sheikhupura has maintained a fair level of GMP compliance as per Schedule B-II of Drug (Lic, Reg & Adv) Rules 1976 on the day of inspection.  Deferred for following (M-262):  Commitments as per 251st meeting of RB are missing.  The reference literature for detailed specification of Finished product is missing.  Last inspection report		
	Previous remarks of the Evaluator.	Date: 22-02-2018 & 04-05-2018.  Recommendations:  Based on the physical inspection of the unit, the technical personal met and documents evaluated, the panel concluded that the firm M/s Surge Labs Sheikhupura has maintained a fair level of GMP compliance as per Schedule B-II of Drug (Lic, Reg & Adv) Rules 1976 on the day of inspection.  Deferred for following (M-262):  Commitments as per 251st meeting of RB are missing.  The reference literature for detailed specification of Finished product is missing.  Last inspection report  The revised stability study report performing the 1-(2,6-		
	Previous remarks of the Evaluator.	Date: 22-02-2018 & 04-05-2018.  Recommendations:  Based on the physical inspection of the unit, the technical personal met and documents evaluated, the panel concluded that the firm M/s Surge Labs Sheikhupura has maintained a fair level of GMP compliance as per Schedule B-II of Drug (Lic, Reg & Adv) Rules 1976 on the day of inspection.  Deferred for following (M-262):  Commitments as per 251st meeting of RB are missing.  The reference literature for detailed specification of Finished product is missing.  Last inspection report		

Evaluation by PEC	The firm has submitted the relevant documents.	
	The firm has revised the formulation as per reference	
	formulation:	
	Each 2ml ampoule contains:	
	Diclofenac sodium75mg	
	Lidocaine hydrochloride20mg	
	specifications and with following label claim:	
Each 2ml ampoule contains: Diclofenac sodium75m	σ	
Lidocaine hydrochloride20m		
	30,000/- for correction/pre-approval change in product	
	I change in fill volume of drug product) before issuance of	
letter as per notification No.F.7-11/20		
224. Name and address of manufacture		
Applicant	B & 135-B Nowshera Industrial Estate, Risalpur.	
Brand Name +Dosage Form + Strength	Telmex tablet 5/40mg.	
Composition	Each film coated tablet contains:	
	Amlodipine (as besylate)5 mg	
	Telmisartan40mg	
Diary No. Date of R& I & fee	Dy No.9480; 20-07-2017; Rs.20,000/-	
Pharmacological Group	Calcium antagonist/Angiotensin II Receptor antagonist	
Type of Form	Form-5	
Finished product Specifications	Manufacturer's Specifications	
Pack size & Demanded Price	14's; As per SRO	
Approval status of product in Refere Regulatory Authorities	ence Approved in US-FDA	
Me-too status	Ezitab-AM Tablet 5/40mg of M/s. Werrick Pharmaceuticals	
GMP status	GMP inspection conducted on 08-07-2018 and report concludes GMP compliance.	
Previous remarks of the Evaluator.	Reference product is bilayer uncoated tablet but	
	Applicant has changed the applied formulation from	
	single layer film coated tablet to bilayer film coated tablet without submission of fee.	
Previous Decision	Deferred for the following reasons:	
	Submission of Form 5 in line with reference product i.e.	
	Amlodipine (as besylate) 5mg & Telmisartan 40mg	
	bilayerd uncoated tablet which is different from applied	
	formulation i.e. Amlodipine (as besylate) 5 mg	
	&Telmisartan 40mg bilayerd film coated tablet &	
	submission of fee for revision of foremulation.	
	Evidence of required manufacturing equipment for	
	applied formulation.	
E 1 C 1 PEC	Latest GMP Inspection report.  The firm has submitted that in master formulation we	
Evaluation by PEC		
	have written the procedure of bilayered uncoated tablet please review the registration dossier. In finished product	
	specifications we have also claimed green and white	
	round tablet.	
	Manufacturing equipment i.e., bilayered tablet	
	compression machine is available with us (Goods	
	declaration certificate is attached.	
Decision: Annroyed with innovator's	specifications. The firm shall submit following before	
issuance of registration letter:	specifications, the man shan submit following before	
• Installation qualification, performan	nce qualification and operational qualification of bilayered	
tablet compression machine.		

	<ul> <li>Submission of GMP audit report from QA&lt; Division, valid within last three years.</li> <li>The firm shall submit fee of Rs. 7,500 for correction/pre-approval change/ in product specifications, as per notification No.F.7-11/2021-B&amp;A/DRAP dated 13-07-2021.</li> </ul>					
225	Name and address of manufacturer /					
225.	Applicant	M/s Rock Pharmaceuticals Laboratories (Pvt) Ltd., 134-				
-		B & 135-B Nowshera Industrial Estate, Risalpur.				
-	Brand Name +Dosage Form + Strength	Telmex tablet 5/80mg.				
	Composition	Each film coated tablet contains:				
		Amlodipine (as besylate)5 mg				
-	Diam. No. Data of D.C. I. C. foo	Telmisartan				
-	Diary No. Date of R& I & fee	Dy No.9482; 20-07-2017; Rs.20,000/- Calcium antagonist/Angiotensin II Receptor antagonist				
-	Pharmacological Group	Form-5				
	Type of Form					
-	Finished product Specifications	Manufacturer's Specifications				
-	Pack size & Demanded Price	14's; As per SRO				
-	Approval status of product in Reference Regulatory Authorities	Approved in US-FDA				
	Me-too status	Ezitab-AM Tablet 5/80mg of M/s. Werrick Pharmaceuticals				
	GMP status	GMP inspection conducted on 08-07-2018 and report concludes GMP compliance.				
	Previous remarks of the Evaluator.	Reference product is bilayer uncoated tablet but Applicant has changed the applied formulation from				
		single layer film coated tablet to bilayer film coated				
		tablet without submission of fee.				
-	Previous Decision	Deferred for the following reasons:				
		Submission of Form 5 in line with reference product i.e.				
		Amlodipine (as besylate) 5mg & Telmisartan 40mg				
		bilayered uncoated tablet which is different from applied				
		formulation i.e. Amlodipine (as besylate) 5 mg				
		&Telmisartan 40mg bilayerd film coated tablet &				
		submission of fee for revision of foremulation.				
		Evidence of required manufacturing equipment for				
		applied formulation.				
		Latest GMP Inspection report.				
Ī	Evaluation by PEC	The firm has submitted that in master formulation we				
	•	have written the procedure of bilayered uncoated tablet				
		please review the registration dossier. In finished product				
		specifications we have also claimed green and white				
		round tablet.				
		Manufacturing equipment i.e., bilayered tablet				
		compression machine is available with us (Goods				
		declaration certificate is attached).				
	Decision: Approved with innovator's specifications. The firm shall submit following before					
	issuance of registration letter:					
	• Installation qualification, performance of	• Installation qualification, performance qualification and operational qualification of bilayered				
	tablet compression machine.					
	• Submission of GMP audit report from QA< Division, valid within last three years.					
	• The firm shall submit fee of Rs. 7,500 for correction/pre-approval change/ in product					
	specifications, as per notification No.F.7-11/2021-B&A/DRAP dated 13-07-2021.					
226.	specifications, as per notification No.F./-	-11/2021-D&A/DKAI uateu 13-07-2021.				
	Name and address of manufacturer /					
i l						
	Name and address of manufacturer /	M/s Sunshine Pharmaceuticals, Emanabad, G.T. Road,				
-	Name and address of manufacturer / Applicant	M/s Sunshine Pharmaceuticals, Emanabad, G.T. Road, Gujranwala.				
	Name and address of manufacturer / Applicant Brand Name +Dosage Form + Strength	M/s Sunshine Pharmaceuticals, Emanabad, G.T. Road, Gujranwala.  Cobol 500mcg Tablets  Each tablet contains: Mecobalamin500mcg				
	Name and address of manufacturer / Applicant Brand Name +Dosage Form + Strength	M/s Sunshine Pharmaceuticals, Emanabad, G.T. Road, Gujranwala.  Cobol 500mcg Tablets  Each tablet contains:				

Type of Form	Form-5	
Finished product Specifications	Manufacturer's specifications	
Pack size & Demanded Price	10 x 10's; Rs 75 per 10 tablets	
Approval status of product in Reference	PMDA approved.	
Regulatory Authorities		
Me-too status	Mecovis 500mcg by Global	
GMP status	GMP inspection report dated 20-01-2021 concluded t	
	firm has made lot of improvements and up-gradations	
	per GMP guidelines.	
Previous remarks of the Evaluator.		
Previous Decision	Deferred for confirmation of requirement of	
	monograph regarding storage and testing of d	
	substance and container closure system of drug prod	
	(M-313).	
Evaluation by PEC	The firm has submitted revised master formulation w	
	sugar coating composition as per reference.	
	Each sugar-coated tablet contains:	
	Mecobalamin500mcg	
	Fee challan of Rs. 7,500/- (slip # 60357575581) da	
	13-08-2021 for revision of formulation as per referen	
	The firm has claimed USP specifications and monogra	
	is attached. The monograph is available with USP diet	
	supplement section.	
	Further stated all the requirements of USP monogra	
	regarding storage, closure system and testing for prod	
	mecobalamine 500mcg are available.	

Decision: Approved with JP specifications. The firm shall submit fee of Rs. 7,500 for correction/pre-approval change/ in product specifications, as per notification No.F.7-11/2021-B&A/DRAP dated 13-07-2021.

#### Deferred cases of M/s Obsons Pharmaceuticals 209-S, Industrial Estate, Kotlakhpat, Lahore

The Central Licensing Board in its 280<sup>th</sup> meeting held on 26<sup>th</sup> & 27<sup>th</sup> April 2021 has cancelled the Drug Manufacturing License No. 000416 by way of (formulation) of M/s Obsons Pharmaceuticals, 209-S, Quaid-e-Azam Industrial Estate, Kot lakhpat, Lahore, conveyed vide letter No. F.1-5/84-Lic (Vol-IV) dated 25<sup>th</sup> May 2021 by Secretary Central Licensing Board. Later on, the Appellate Board in its meeting No. 156<sup>th</sup> held on 31<sup>st</sup> August, 2021 decided as: The Board after hearing the arguments and pursuing record of case, decided to give final opportunity of two years period to the firm for submission of new lay out plan for approval of the Central Licensing Board. The decision of cancellation of Drug Manufacturing License by the Central Licensing Board is set aside.

Furthermore, the firm has been granted GMP certificate dated 07-03-2022 based on inspection conducted on 22-02-2022.

227.	Name and address of manufacturer /	M/s. Obsons Pharma, industrial state, Kot Lakhpat,	
<b>Applicant</b> Lahore		Lahore	
Contract manufacturer: M/s. Friend		Contract manufacturer: M/s. Friends Pharma Lahore.	
Brand Name +Dosage Form + Strength		Obpra 40mg Injection (IV)	
Composition Each vial contains: Esomeprazole sodium.		Each vial contains:	
		Esomeprazole sodium40mg	
	Diary No. Date of R& I & fee	Dy.No. 165, 23-2-2015, Rs.50,000/-	

	Pharmacological Group	Proton pump inhibitor		
	Type of Form	Form-5		
	Finished product Specification	As per innovator		
	Pack size & Demanded Price	As per SRO		
	Approval status of product in Reference	Esomeprazole by Astrazeneca (MHRA)		
	Regulatory Authorities.	(		
	Me-too status	Esso-40 by shaigan pharma.		
	GMP status	Last GMP Inspection dated 6-10-2016 with conclusive		
		remarks of cGMP compliance for —export purposes.		
	Previous remarks of the Evaluator.	•		
	Previous decision(s)	Deferred for the confirmation of approved sections and		
		number of already approved products under the contract		
		manufacturing (M-274).		
	Evaluation by PEC	• Friend's pharma has both lyophilized and liquid injection		
		section.		
		• M/s Friends pharma: The firm is granted GMP certificate		
		based on inspection conducted on 25-03-2019.		
		• Revision of formulation from Esomeprazole sodium to		
		Esomeprazole as sodium is required.		
		bmit revised formulation with correct salt factor before		
		with submission fee of Rs. 75,000/- for correction/pre-		
		on (correction/pre-approval change in equivalency factor		
220		o.F.7-11/2012-B&A/DRAP dated 07-05-2021.		
228.	Name and address of manufacturer /	M/s. Obsons Pharma, industrial state, Kot Lakhpat, Lahore		
	Applicant	Contract manufacturer: M/s. Friends Pharma Lahore		
	Brand Name +Dosage Form + Strength	Obsozole 40mg Injection (I.V)		
	Composition	Each vial contains:		
	Composition	Omeprazole sodium eq. to omeprazole40mg		
	Diary No. Date of R& I & fee	Dy.No. 154, 23-2-2015, Rs.50,000/-		
	Pharmacological Group	Proton pump inhibitor		
	Type of Form	Form 5		
	Finished product Specification	As per innovator		
	Pack size & Demanded Price	As per SRO		
	Approval status of product in Reference	Omeprazole Injection by Sandoz Pharma (MHRA		
	Regulatory Authorities.	approved)		
	Me-too status	LOPROT by Surge		
	GMP status	Last GMP Inspection dated 6-10-2016 with conclusive		
		remarks of cGMP compliance for —export purposes.		
	Previous remarks of the Evaluator.	• Latest GMP inspection report (which should have been		
		conducted within the period of last one year)		
		• Evidence of approval of applied formulation in reference		
		regulatory authorities which were approved by		
		Registration Board in its 249 <sup>th</sup> meeting.		
	Previous decision(s)	Deferred for the confirmation of approved sections and		
		number of already approved products under the contract		
	7 1 1 7 7 7	manufacturing (M-274).		
	Evaluation by PEC	• Friend's pharma has both lyophilized and liquid injection		
		section.		
		• M/s Friends pharma: The firm is granted GMP certificate		
	Desigions Approved	based on inspection conducted on 25-03-2019.		
229.	Decision: Approved.  Name and address of manufacturer /	M/s. Obsons Pharma, industrial state, Kot Lakhpat,		
<i>447</i> •	Applicant	Lahore		
	zppncant	Contract manufacturer by M/s Medisave Pharma,		
		Lahore		

	Brand Name +Dosage Form + Strength	OB-Mox IV Infusion	
	Composition	Each ml contains:	
	1	Moxifloxacin HCl1.6mg	
	Diary No. Date of R& I & fee	Dy.No. 164, 23-2-2015, Rs.50,000/-	
	Pharmacological Group	Quinolone antibiotics	
	Type of Form	Form-5	
	Finished product Specification	As per innovator	
	Pack size & Demanded Price	1's / As per SRO	
	Approval status of product in Reference	Avelox by Bayer (USFDA)	
	Regulatory Authorities.		
	Me-too status	Avelox by Bayer	
	GMP status		
	Previous remarks of the Evaluator.	• Latest GMP inspection report (which should have been conducted within the period of last one year)	
	Previous decision(s)	Deferred for the confirmation of approved sections and number of already approved products under the contract manufacturing (M-274).	
	Evaluation by PEC	• The firm M/s Medisave pharma has provided Infusion LVP section.	
		GMP certificate issued to M/s Medisave Pharmaceuticals	
		dated 01-10-2021 based on inspection conducted on 18-	
		09-2021.	
		bmit revised formulation with correct salt factor before	
		with submission fee of Rs. 75,000/- for correction/pre-	
		on (correction/pre-approval change in equivalency factor	
220		O.F.7-11/2012-B&A/DRAP dated 07-05-2021.	
230.	Name and address of manufacturer /	· · · · · · · · · · · · · · · · · · ·	
	Applicant	Lahore	
		Contract manufactures by M/a Madiagra Dharma	
		Contract manufacturer by M/s Medisave Pharma,	
	Rrand Name +Dosage Form + Strength	Lahore	
	Brand Name +Dosage Form + Strength	Lahore Ob-Flox 500mg Infusion (IV)	
	Brand Name +Dosage Form + Strength Composition	Lahore Ob-Flox 500mg Infusion (IV) Each 100ml contains	
	Composition	Lahore Ob-Flox 500mg Infusion (IV) Each 100ml contains Levofloxacin (as hemihydrate)500mg	
	Composition  Diary No. Date of R& I & fee	Lahore Ob-Flox 500mg Infusion (IV) Each 100ml contains Levofloxacin (as hemihydrate)500mg Dy.No. 159, 23-2-2015, Rs.50,000/-	
	Composition  Diary No. Date of R& I & fee  Pharmacological Group	Lahore Ob-Flox 500mg Infusion (IV) Each 100ml contains Levofloxacin (as hemihydrate)500mg Dy.No. 159, 23-2-2015, Rs.50,000/- Fluoroquinolones	
	Composition  Diary No. Date of R& I & fee  Pharmacological Group  Type of Form	Lahore Ob-Flox 500mg Infusion (IV) Each 100ml contains Levofloxacin (as hemihydrate)500mg Dy.No. 159, 23-2-2015, Rs.50,000/- Fluoroquinolones Form 5	
	Composition  Diary No. Date of R& I & fee Pharmacological Group Type of Form Finished product Specification	Lahore Ob-Flox 500mg Infusion (IV) Each 100ml contains Levofloxacin (as hemihydrate)500mg Dy.No. 159, 23-2-2015, Rs.50,000/- Fluoroquinolones Form 5 As per innovator	
	Composition  Diary No. Date of R& I & fee Pharmacological Group Type of Form Finished product Specification Pack size & Demanded Price	Lahore Ob-Flox 500mg Infusion (IV) Each 100ml contains Levofloxacin (as hemihydrate)500mg Dy.No. 159, 23-2-2015, Rs.50,000/- Fluoroquinolones Form 5 As per innovator 1's × 100ml; As per SRO	
	Composition  Diary No. Date of R& I & fee Pharmacological Group Type of Form Finished product Specification Pack size & Demanded Price Approval status of product in Reference	Lahore Ob-Flox 500mg Infusion (IV) Each 100ml contains Levofloxacin (as hemihydrate)500mg Dy.No. 159, 23-2-2015, Rs.50,000/- Fluoroquinolones Form 5 As per innovator	
	Composition  Diary No. Date of R& I & fee Pharmacological Group Type of Form Finished product Specification Pack size & Demanded Price Approval status of product in Reference Regulatory Authorities.	Lahore Ob-Flox 500mg Infusion (IV) Each 100ml contains Levofloxacin (as hemihydrate)500mg Dy.No. 159, 23-2-2015, Rs.50,000/- Fluoroquinolones Form 5 As per innovator 1's × 100ml; As per SRO Levaquin by Janseen (USFDA)	
	Composition  Diary No. Date of R& I & fee Pharmacological Group Type of Form Finished product Specification Pack size & Demanded Price Approval status of product in Reference Regulatory Authorities. Me-too status	Lahore Ob-Flox 500mg Infusion (IV) Each 100ml contains Levofloxacin (as hemihydrate)500mg Dy.No. 159, 23-2-2015, Rs.50,000/- Fluoroquinolones Form 5 As per innovator 1's × 100ml; As per SRO Levaquin by Janseen (USFDA)  Levovis by Global pharma.	
	Composition  Diary No. Date of R& I & fee Pharmacological Group Type of Form Finished product Specification Pack size & Demanded Price Approval status of product in Reference Regulatory Authorities. Me-too status GMP status	Lahore Ob-Flox 500mg Infusion (IV) Each 100ml contains Levofloxacin (as hemihydrate)500mg Dy.No. 159, 23-2-2015, Rs.50,000/- Fluoroquinolones Form 5 As per innovator 1's × 100ml; As per SRO Levaquin by Janseen (USFDA)	
	Diary No. Date of R& I & fee Pharmacological Group Type of Form Finished product Specification Pack size & Demanded Price Approval status of product in Reference Regulatory Authorities. Me-too status GMP status Previous remarks of the Evaluator.	Lahore  Ob-Flox 500mg Infusion (IV)  Each 100ml contains Levofloxacin (as hemihydrate)500mg  Dy.No. 159, 23-2-2015, Rs.50,000/- Fluoroquinolones  Form 5  As per innovator 1's × 100ml; As per SRO Levaquin by Janseen (USFDA)  Levovis by Global pharma.  Last inspection report conducted on 22-07-2013.  ●	
	Composition  Diary No. Date of R& I & fee Pharmacological Group Type of Form Finished product Specification Pack size & Demanded Price Approval status of product in Reference Regulatory Authorities. Me-too status GMP status	Lahore Ob-Flox 500mg Infusion (IV) Each 100ml contains Levofloxacin (as hemihydrate)500mg Dy.No. 159, 23-2-2015, Rs.50,000/- Fluoroquinolones Form 5 As per innovator 1's × 100ml; As per SRO Levaquin by Janseen (USFDA)  Levovis by Global pharma. Last inspection report conducted on 22-07-2013.  ■ Deferred for the confirmation of approved sections and	
	Diary No. Date of R& I & fee Pharmacological Group Type of Form Finished product Specification Pack size & Demanded Price Approval status of product in Reference Regulatory Authorities. Me-too status GMP status Previous remarks of the Evaluator.	Lahore Ob-Flox 500mg Infusion (IV) Each 100ml contains Levofloxacin (as hemihydrate)500mg Dy.No. 159, 23-2-2015, Rs.50,000/- Fluoroquinolones Form 5 As per innovator 1's × 100ml; As per SRO Levaquin by Janseen (USFDA)  Levovis by Global pharma. Last inspection report conducted on 22-07-2013.  ■ Deferred for the confirmation of approved sections and number of already approved products under the contract	
	Composition  Diary No. Date of R& I & fee Pharmacological Group Type of Form Finished product Specification Pack size & Demanded Price Approval status of product in Reference Regulatory Authorities. Me-too status GMP status Previous remarks of the Evaluator. Previous decision(s)	Lahore  Ob-Flox 500mg Infusion (IV)  Each 100ml contains Levofloxacin (as hemihydrate)500mg  Dy.No. 159, 23-2-2015, Rs.50,000/- Fluoroquinolones  Form 5  As per innovator 1's × 100ml; As per SRO Levaquin by Janseen (USFDA)  Levovis by Global pharma. Last inspection report conducted on 22-07-2013.  ●  Deferred for the confirmation of approved sections and number of already approved products under the contract manufacturing (M-274).	
	Diary No. Date of R& I & fee Pharmacological Group Type of Form Finished product Specification Pack size & Demanded Price Approval status of product in Reference Regulatory Authorities. Me-too status GMP status Previous remarks of the Evaluator.	Lahore Ob-Flox 500mg Infusion (IV) Each 100ml contains Levofloxacin (as hemihydrate)500mg Dy.No. 159, 23-2-2015, Rs.50,000/- Fluoroquinolones Form 5 As per innovator 1's × 100ml; As per SRO Levaquin by Janseen (USFDA)  Levovis by Global pharma. Last inspection report conducted on 22-07-2013.  ■ Deferred for the confirmation of approved sections and number of already approved products under the contract	
	Composition  Diary No. Date of R& I & fee Pharmacological Group Type of Form Finished product Specification Pack size & Demanded Price Approval status of product in Reference Regulatory Authorities. Me-too status GMP status Previous remarks of the Evaluator. Previous decision(s)	Lahore Ob-Flox 500mg Infusion (IV) Each 100ml contains Levofloxacin (as hemihydrate)500mg Dy.No. 159, 23-2-2015, Rs.50,000/- Fluoroquinolones Form 5 As per innovator 1's × 100ml; As per SRO Levaquin by Janseen (USFDA)  Levovis by Global pharma. Last inspection report conducted on 22-07-2013.  ■ Deferred for the confirmation of approved sections and number of already approved products under the contract manufacturing (M-274).  ■ The firm M/s Medisave pharma has provided Infusion LVP section.	
	Composition  Diary No. Date of R& I & fee Pharmacological Group Type of Form Finished product Specification Pack size & Demanded Price Approval status of product in Reference Regulatory Authorities. Me-too status GMP status Previous remarks of the Evaluator. Previous decision(s)	Lahore  Ob-Flox 500mg Infusion (IV)  Each 100ml contains Levofloxacin (as hemihydrate)500mg  Dy.No. 159, 23-2-2015, Rs.50,000/- Fluoroquinolones  Form 5  As per innovator 1's × 100ml; As per SRO Levaquin by Janseen (USFDA)  Levovis by Global pharma.  Last inspection report conducted on 22-07-2013.  ■  Deferred for the confirmation of approved sections and number of already approved products under the contract manufacturing (M-274).  ■ The firm M/s Medisave pharma has provided Infusion	
	Composition  Diary No. Date of R& I & fee Pharmacological Group Type of Form Finished product Specification Pack size & Demanded Price Approval status of product in Reference Regulatory Authorities. Me-too status GMP status Previous remarks of the Evaluator. Previous decision(s)	Db-Flox 500mg Infusion (IV)  Each 100ml contains Levofloxacin (as hemihydrate)500mg  Dy.No. 159, 23-2-2015, Rs.50,000/- Fluoroquinolones  Form 5  As per innovator 1's × 100ml; As per SRO  Levaquin by Janseen (USFDA)  Levovis by Global pharma.  Last inspection report conducted on 22-07-2013.  ■  Deferred for the confirmation of approved sections and number of already approved products under the contract manufacturing (M-274).  ■ The firm M/s Medisave pharma has provided Infusion LVP section.  ■ GMP certificate issued to M/s Medisave Pharmaceuticals	
	Composition  Diary No. Date of R& I & fee Pharmacological Group Type of Form Finished product Specification Pack size & Demanded Price Approval status of product in Reference Regulatory Authorities. Me-too status GMP status Previous remarks of the Evaluator. Previous decision(s)	Db-Flox 500mg Infusion (IV)  Each 100ml contains Levofloxacin (as hemihydrate)500mg  Dy.No. 159, 23-2-2015, Rs.50,000/- Fluoroquinolones  Form 5  As per innovator 1's × 100ml; As per SRO  Levaquin by Janseen (USFDA)  Levovis by Global pharma.  Last inspection report conducted on 22-07-2013.  Deferred for the confirmation of approved sections and number of already approved products under the contract manufacturing (M-274).  The firm M/s Medisave pharma has provided Infusion LVP section.  GMP certificate issued to M/s Medisave Pharmaceuticals dated 01-10-2021 based on inspection conducted on 18-09-2021.	
231.	Diary No. Date of R& I & fee Pharmacological Group Type of Form Finished product Specification Pack size & Demanded Price Approval status of product in Reference Regulatory Authorities. Me-too status GMP status Previous remarks of the Evaluator. Previous decision(s)  Evaluation by PEC	Db-Flox 500mg Infusion (IV)  Each 100ml contains Levofloxacin (as hemihydrate)500mg  Dy.No. 159, 23-2-2015, Rs.50,000/- Fluoroquinolones  Form 5  As per innovator 1's × 100ml; As per SRO  Levaquin by Janseen (USFDA)  Levovis by Global pharma.  Last inspection report conducted on 22-07-2013.  Deferred for the confirmation of approved sections and number of already approved products under the contract manufacturing (M-274).  The firm M/s Medisave pharma has provided Infusion LVP section.  GMP certificate issued to M/s Medisave Pharmaceuticals dated 01-10-2021 based on inspection conducted on 18-09-2021.	
231.	Diary No. Date of R& I & fee Pharmacological Group Type of Form Finished product Specification Pack size & Demanded Price Approval status of product in Reference Regulatory Authorities. Me-too status GMP status Previous remarks of the Evaluator. Previous decision(s)  Evaluation by PEC  Decision: Approved with innovator's s	Db-Flox 500mg Infusion (IV) Each 100ml contains Levofloxacin (as hemihydrate)500mg Dy.No. 159, 23-2-2015, Rs.50,000/- Fluoroquinolones Form 5 As per innovator 1's × 100ml; As per SRO Levaquin by Janseen (USFDA)  Levovis by Global pharma. Last inspection report conducted on 22-07-2013.  Deferred for the confirmation of approved sections and number of already approved products under the contract manufacturing (M-274).  The firm M/s Medisave pharma has provided Infusion LVP section. GMP certificate issued to M/s Medisave Pharmaceuticals dated 01-10-2021 based on inspection conducted on 18-09-2021.	
231.	Diary No. Date of R& I & fee Pharmacological Group Type of Form Finished product Specification Pack size & Demanded Price Approval status of product in Reference Regulatory Authorities. Me-too status GMP status Previous remarks of the Evaluator. Previous decision(s)  Evaluation by PEC  Decision: Approved with innovator's s Name and address of manufacturer /	Db-Flox 500mg Infusion (IV) Each 100ml contains Levofloxacin (as hemihydrate)500mg Dy.No. 159, 23-2-2015, Rs.50,000/- Fluoroquinolones Form 5 As per innovator 1's × 100ml; As per SRO Levaquin by Janseen (USFDA)  Levovis by Global pharma. Last inspection report conducted on 22-07-2013.  ■ Deferred for the confirmation of approved sections and number of already approved products under the contract manufacturing (M-274).  ■ The firm M/s Medisave pharma has provided Infusion LVP section.  ■ GMP certificate issued to M/s Medisave Pharmaceuticals dated 01-10-2021 based on inspection conducted on 18-09-2021.  Decifications.  M/s. Obsons Pharma, industrial state, Kot Lakhpat,	

Brand Name +Dosage Form + Strength	Syner-3 injection 5mg/ml		
Composition	Each 1 ml contains:		
	Cholecalciferol5mg		
Diary No. Date of R& I & fee	Dy.No. 156, 23-2-2015, Rs.50,000/-		
Pharmacological Group	Vitamin D3		
Type of Form	Form-5		
Finished product Specification	As per innovator		
Pack size & Demanded Price	Ampoule of 1 ml (As per SRO)		
Approval status of product in Reference	Vitamin D3 Bon 200000IU injection (ANSM France).		
Regulatory Authorities.	•		
Me-too status	Calciferol by Global pharma		
GMP status	Last inspection report conducted on 27-04-2017 with		
	remarks as under:		
	"The management agreed and requested for some time to		
	overcome the shortcomings and will inform to the		
	authorities and the re-inspection will be conducted		
	accordingly."		
Previous remarks of the Evaluator.	•		
Previous decision(s)	Deferred for the confirmation of approved sections and		
	number of already approved products under the contract		
	manufacturing (M-274).		
Evaluation by PEC	• The firm M/s Medisave pharma has provided Liquid		
	Injection section.		
	• GMP certificate issued to M/s Medisave Pharmaceuticals		
	dated 01-10-2021 based on inspection conducted on 18-		
	09-2021.		
Decision: Approved with innovator's s	pecifications.		

# **Case 02. Import applications (Veterinary):**

# **Deferred cases:**

232.	Name and address of Applicant	M/s. Huzaifa International, Commercial Area, Aziz Bhatti Town, Sargodha, Pakistan		
	Detail of Drug Sale License	DSL by way of distribution no. 0011000 0001489 valid upto20-Nov-2019.		
	Name and address of the manufacturer	M/s. Kombipharm International Co. Ltd., 17, Gyeongje-Ro, Siheung-SI, Gyeonggi-DO, South Korea, The Republic of Korea		
	Name and address of marketing authorization holder	M/s. Kombipharm International Co. Ltd., 17, Gyeongje-Ro, Siheung-SI, Gyeonggi-DO, South Korea, The Republic of Korea		
	Name of exporting country	Korea		
	Type of Form	Form 5-A		
	Diary No. & Date of R& I	Dy No. 722; Dated: 25-09-2014		
	Fee including differential fee	Rs.100,000/- Dated: 25-09-2014		
	Brand Name +Dosage Form + Strength	Komi Pink Spray		
	Composition	Each Liter contains:- Florfenicol		

	Isopropanolq.s.		
Finished Product Specification	In-house		
Pharmacological Group	Antibiotic-Peptidyl transferase inhibitor		
Shelf life	36 months (supported by realtime and accelerated		
	stability study data)		
Demanded Price	As per SRO		
Pack size	50ml, 100ml, 250ml, 500ml		
International availability	Available in in korea as per CoPP		
Me-too status	Could not be confirmed		
Detail of certificates attached	1. Original legalized free sale certificate issued by Animal		
	and Plant Quarantine Agency Korea on 09-06-2014		
	confirms free sale availability in Korea		
	2. Original legalized GMP certificate issued by Animal and		
	Plant Quarantine Agency Korea on 09-06-2014 confirms		
	GMP status of manufacturing site		
Remarks of the Evaluator.	1. Firm has claimed in house spec's and the product is not present in BP and USP		
	Letter of shortcoming was issued to the firm on 14 <sup>th</sup> April		
	2015 and the reply received is still deficient for		
	"The drug sale license is to sell drugs in pharmacy and not		
	for distribution"		
Previous Decisions	Decision of 270 <sup>th</sup> meeting:		
	In 270 <sup>th</sup> meeting Registration Board deferred the case as		
	the concerned member of Board (veterinary expert) was		
	not available.		
	Deferred for evidence of approval in reference regulatory		
	authorities (M-272).		

**Evaluation by PEC:** The firm has submitted two references as evidence of international approval of the product.

1. TOPAZONE NF SRAY, Mexico

The reference cannot be verified; Moreover, Mexico is not our reference country.

#### 2. FLOXY-SPRAY, Ukraine

The reference has been verified while the firm is unable to provide evidence of approval in 02 more countries of E.U. Moreover, the product which registered in Ukraine has a strength of 2.5gm/100ml while the applied product has strength of 2gm/100ml.

The firm has submitted reference of formulation approved in USFDA the composition of which as follows:

Claro Solution

Our product Komipink Spray is a similar topical formulation with Florfenicol as an active ingredient and used for treatment of bacterial infection, scabies and wounds.

**Previous Decision:** Deferred for evidence of approval of applied formulation in reference regulatory authorities/agencies which were adopted by the Registration Board in its 275<sup>th</sup> meeting (**M-288**).

**Evaluation by PEC:** The firm has submitted that Florfenicol active ingredient is already being enormously used in livestock and poultry sector of Pakistan because of its high efficacy as an antibiotic. It has been used worldwide as Aerosol spray in registered products of

- 1. Europe (Floxy-Spray ®)- registered in Ukraine and freely sold in all European countries.
- 2. Latin America (Topazone®NF Spray)- registered in Mexico.

The samples of Komipink spray have been **utilized and appreciated by Pakistan Army** and they have demanded this product availability as soon as possible, since the Pakistan Army accommodates a great number of Horses, Dogs and Mules for different defense purposes.

The firm has requested to reconsider the application and acknowledge receipt of reference document.

Decision: Deferred for evidence of approval of applied formulation in reference regulatory

authorities/agencies which were adopted by the Registration Board in its 275th meeting.

# Case No.03: Registration applications of drugs for which stability study data is submitted a. Verification of stability study data

Applicant 1		"M/s Wilshire Laboratories Pvt Ltd., 124/1, Quaid-e-Azam Industrial Estate, Kot Lakhpat,			
			Lahore"		
	Brand Name +Dosage Form + Strength			a 30mg Capsule	
Composition			Each Capsule Contains:		
			Dexlansoprazole (as DDR pellets)30mg Dy No. 21257: date 13-06-18: Rs. 20,000		
	Pharmacological Group				KS. 20,000
	Type of Form		Proton pump inhibitor Form 5		
	Finished product Specific		Manufacturer's specifications		
	Pack size & Demanded P		10's, 20's, 30's, 40's, 50's: As per SRO		
	Approval status of	product in A	Appro	ved in US-FDA	•
	Reference Regulatory Au			nt Capsule	
	Me-too status (with	strength and I	Razod	ex of Getz Pharma	
	dosage form)				
	GMP status				ucted on 06-11-2018 and the
				CONCIUDES SATISTACTORY IN	evel of GMP compliance.
-					
Drug		Dexpra 30mg C	_		
Name	of Manufacturer		Laboratories Pvt Ltd. e-Azam Industrial Estate, KotLakhpat, Lahore"		
Manuf	facturer of API	M/s Vision Pha	harmaceutical (Pvt) Ltd. Islamabad.		
API Lo	ot No.	Dexlansoperazo	zole pellets w/w. (Batch. #)		
Description of Pack (Container closure system)  Alu-Alu bliste		Alu-Alu blister	er		
, ,			0°C ± 2°C / 65% ± 5%RH 0°C ±2°C / 75% ± 5%RH		
Time I	Period	Real Time: 12 M	Month	s Accelera	nted:06Months
Freque	ency		3,6,9,12 Months (on going) 0,1,2,3,4,6 Months		
Batch	No.	T#001		T#002	T#003
Batch	Size	0.200kg Capsul	le	0.200kg Capsule	0.200kg Capsule
Manuf	Cacturing Date	04-2018		04-2018	04-2018
Date o	f Initiation	16-04-18		16-04-18	16-04-18
No. of	Batches	03			
Date o	f Submission	23-12-2019			
DOCUMENTS / DATA			ROV	IDED BY THE APPLI	CANT
Sr. No.	Documents To Be	Provided		Sta	atus
9.	COA of API				
10.	Approval of API by regulatory authority country of origin or GMP certificate of A manufacturer issued by regulatory author of country of origin.		PI foli	plicant has submitted lowing information on it rtificate No. F.3-26/201 ued to: M/s. Vision Phan	: 9-Addl. Dir. (QA&LT-1)

				Validity: 10-02-2022.	
11.	Protocols followed for conduction of stability study and details of tests.		of	Yes	
12.	Data of 03 batches will be supported be attested respective documents like chromatograms, laboratory reports, data sheets etc.		ike	Yes	
13.	. Documents confirming import of API etc.		С.	Applicant has submitted Copy Of Invoice having following information on it: Dexlansoprazole pellets Batch No: DLP363 Quantity: 2kg Manufactured by: M/s Vision Pharmaceuticals	
14.	All provided documents (name, sign and stam authenticity of data / docu	p) for ensuri		Yes	
15.	Commitment to continue study till assigned shelf li		•	Yes	
16.	Commitment to follow D Rules, 1978.	rug Specificati	on	Yes	
Evalua	ation by PEC:				
234.	Name and address of m Applicant	nanufacturer /	12	"M/s Wilshire Laboratories Pvt Ltd. 124/1, Quaid-e-Azam Industrial Estate, Kot Lakhpat, Lahore"	
				expra 60mg Capsule	
	· · ·			ch Capsule Contains:	
				exlansoprazole (as DDR pellets)60mg	
	·			No. 21258: date 13-06-18: Rs. 20,000	
	Pharmacological Group			oton pump inhibitor rm 5	
	Type of Form Finished product Specifications			anufacturer's specifications	
	Pack size & Demanded P		10's, 20's, 30's, 40's, 50's: As per SRO		
	Approval status of product in			proved in US-FDA	
	Reference Regulatory Authorities			••	
	Me-too status (with states dosage form)	strength and		Razodex of Getz Pharma	
	GMP status			st GMP inspection was conducted on 06-11-2018 and the port concludes satisfactory level of GMP compliance.	
		STABIL	IT	Y STUDY DATA	
Drug		Dexerid Capsu	ule (	le 60mg	
Name of Manufacturer "M/s Wilshire				Laboratories Pvt Ltd. e-Azam Industrial Estate, KotLakhpat, Lahore"	
Manu	facturer of API	M/s Vision Ph	narn	narmaceutical (Pvt) Ltd. Islamabad.	
API L	ot No.	Dexlansoperaz	zole	DDR pellets w/w. (Batch. # DLP363)	
Descri	iption of Pack ainer closure system)	Alu-Alu bliste		*	
	ity Storage Condition			± 2°C / 65% ± 5%RH ±2°C / 75% ± 5%RH	
Time	Period	Real Time: 09			
Time renou Real Time. 09					

				9,12 Months (on going) 2,3,4,6 Months		
Batch	No.	T#001		T#002	T#003	
Batch	Batch Size 0.400kg Capsule		psule	0.400kg Capsule	0.400kg Capsule	
Manu	facturing Date	04-2018		04-2018	04-2018	
Date of	of Initiation	05-04-18		05-04-18	05-04-18	
No. of	Batches	03		1	1	
Date of	of Submission	23/12/2019	)			
	DOCUME	NTS / DAT	TA PR	OVIDED BY THE AP	PLICANT	
Sr. No.	Documents To Be	Documents To Be Provided		Status		
1.	Certificate of analysis of A	ΑPI				
2.	Approval of API by regulatory authority of country of origin or GMP certificate of API manufacturer issued by regulatory authority of country of origin.		following information on it:			
3.	Protocols followed for stability study and details		n of		Yes	
4.	Data of 03 batches will be supported by attested respective documents like chromatograms, laboratory reports, data sheets etc.		Yes			
5.	Documents confirming import of API etc.		Applicant has submitted Copy of Invoice having following information on it:  Dexlansoprazole pellets  Batch No: DLP363  Quantity: 2kg  Manufactured by: M/s Vision Pharmaceuticals			
6.	All provided documents will be attested (name, sign and stamp) for ensuring authenticity of data / documents.					
7.	Commitment to continue real time stability study till assigned shelf life of the product.		•	Yes		
8.	Commitment to follow Drug Specification Rules, 1978.		cation	Yes		
Evalua	ation by PEC:					
Name of Manufacturer M/		M/s. V	s. Wilshire Labs (Pvt.) Ltd.			
Physical Address 12		124/1,	4/1, Quaid-e-Azam Industrial Estate, Kot Lakhpat, Lahore			
Drug Manufacturing license No. and Validity (Date of application for DML renewal)		00023	232 valid till 20-07-2025			
Conta	ct Address		124/1,	24/1, Quaid-e-Azam Industrial Estate, Kot Lakhpat, Lahore		
Date of inspection 01-3		01-12-	2-2021			
		for pu	anel inspection for verification of authenticity of stability data or purpose of registration of drugs with reference to DRAP, lamabad letter No. F.1-2/2020-PEC dated 01-09-2020.			

Name of inspector (s)	1. Mr. Zaka-ur-Rehman, COO.		
	2. Ms. Aisha Irfan, Area Federal Inspector of Drugs, DRAP,		
	Lahore.		
	3. Ms. Maham Misbah, Assistant Director, DRAP, Lahore.		
Name of Firm's Representative (s)	Mr. Ghazanfar Ali Jawa (Chief Executive Officer)		
accompanying during inspection	Dr. Aqil Husnain (COO BD & Regulatory)		
	Mr. M. Faisal Javid, Plant Head.		
	Ms. Anita Mehdi (Production Manager)		
	Mr. Usman Shoukat (Quality Assurance Manager).		
	Mr. Akhter Hussain (Quality Control Incharge) and Mr. Ah\$@n		
	Sabir (R&D Manager)		

Panel Inspection of M/s. Wilshire Labs (Pvt) Ltd., was conducted with reference to DRAP Letter No. F.1-2/2020-PEC dated 01-09-2020, for verification of authenticity of stability data of following products. The panel evaluated the relevant documents and also visited the required facility and quality control laboratory of the company.

The data of both products was evaluated in accordance with the checklist provided as given below:

- 1. Dexpra 30mg Capsule
- 2. Dexpra 60mg Capsule

1.	of Dexlansoprazole including approval from DRAP?	The firm has locally purchased 2kg Dexlansoprazole DDR Pellets 22.5% (API) from Vision Pharmaceutical (Pvt) Ltd. Invoice No. 500679 dated: 25.09.2017. (Batch NoDLP363, Mfg 07-17, Expiry 06-20).
2.	<u>C</u>	The rationale behind selecting the particular manufacturer of API is the in-house vender evaluation process.
3.	Do you have documents confirming the import of reference standard and impurity standards?	Firm had locally purchased the working standard from M/s. Vision Pharmaceuticals.
4.	reference standards and impurity standards?	Firm had CoA of API and working standard. Additionally, In house Raw material Testing data is also attached.
5.	Do you have GMP certificate of API manufacturer issued by regulatory authority of country of origin?	
6.	Do you use API manufacturer method of testing for testing API?	Yes, as per method of testing shown to the panel.
7.	Do you have stability studies reports on APIs?	Yes
8.	If yes, whether the stability testing has been performed as per SIM method and degradation products have been quantified?	<del>*</del>
9.	impurities in the API?	Method of quantifying the impurities in API was provided by M/s. Vision Pharmaceuticals (Pvt.) Ltd. However, the firm had not run sample for impurity testing according to the time specified in the method.
10.		The firm informed the panel that they had destroyed
11.	Have you used pharmaceutical grade excipients?	Excipients were not used.

12. Do you have documents confirming the import Not applicable. of the used excipients?  13. Do you have test reports and other records on the Not applicable. excipients used?  14. Do you have written and authorized protocols Yes for the development of Dexpra Capsules?  15. Have you performed Drug-excipient Not applicable compatibility studies?  16. Have you performed comparative dissolution The firm had performed comparat studies?  17. Do you have product development (R&D) Yes section  18. Do you have necessary equipments available in Manual capsule filling machine was product development section for development product development / R&D sectio Dexpra Capsules?  19. Are the equipment in product development Equipment. section qualified?  20. Do you have proper maintenance / calibration / Yes re-qualification program for the equipment used in PD section?  21. Do you have qualified staff in product Yes	as available in tion. The firmel that fill sing the autom		
excipients used?  14. Do you have written and authorized protocols and the development of Dexpra Capsules?  15. Have you performed Drug-excipient Not applicable compatibility studies?  16. Have you performed comparative dissolution The firm had performed comparate studies?  17. Do you have product development (R&D) Yes section  18. Do you have necessary equipments available in Manual capsule filling machine was product development section for development product development/ R&D section Dexpra Capsules?  19. Are the equipment in product development Equipment.  19. Are the equipment in product development Equipment.  20. Do you have proper maintenance / calibration / Yes re-qualification program for the equipment used in PD section?	as available in tion. The firmel that fill sing the autom		
for the development of Dexpra Capsules?  15. Have you performed Drug-excipient Not applicable compatibility studies?  16. Have you performed comparative dissolution The firm had performed comparat studies using Dexilant capsules manu Takeda Pharma Co. Ltd. Japan as reference to you have product development (R&D) Yes section  18. Do you have necessary equipments available in Manual capsule filling machine was product development section for development product development / R&D section Dexpra Capsules?  19. Are the equipment in product development Equipment.  19. Are the equipment in product development Equipment.  20. Do you have proper maintenance / calibration / Yes re-qualification program for the equipment used in PD section?	as available in tion. The firmel that fill sing the autom		
compatibility studies?  Have you performed comparative dissolution The firm had performed comparative studies?  Do you have product development (R&D) Yes section  Do you have necessary equipments available in Manual capsule filling machine was product development section for development product development/ R&D section Dexpra Capsules?  The product development informed the pane dexlansoprazole pellets was done using capsule filling machine in comment section qualified?  The firm had performed comparative dissolution Takeda Pharma Co. Ltd. Japan as reference to the pane of the	as available in tion. The firmel that fill sing the autom		
studies?  Studies using Dexilant capsules manu Takeda Pharma Co. Ltd. Japan as reference 17.  Do you have product development (R&D) Yes section  18.  Do you have necessary equipments available in Manual capsule filling machine was product development section for development product development/ R&D section Dexpra Capsules?  Dexpra Capsules?  Are the equipment in product development Equipment. section qualified?  20.  Do you have proper maintenance / calibration / Yes re-qualification program for the equipment used in PD section?	as available in tion. The firmel that fill sing the autom		
18. Do you have necessary equipments available in Manual capsule filling machine was product development section for development product development/ R&D section Dexpra Capsules?  Dexpra Capsules?  Are the equipment in product development Equipment.  19. Are the equipment in product development Equipment.  20. Do you have proper maintenance / calibration / Yes  re-qualification program for the equipment used in PD section?	tion. The firm nel that fill sing the autom		
product development section for development product development/ R&D section Dexpra Capsules?  Dexpra Capsules?  Management informed the pane dexlansoprazole pellets was done using capsule filling machine in comment capsule filling machine in comment section qualified?  20. Do you have proper maintenance / calibration / Yes re-qualification program for the equipment used in PD section?	tion. The firm nel that fill sing the autom		
<ul> <li>19. Are the equipment in product development Equipment. section qualified?</li> <li>20. Do you have proper maintenance / calibration / Yes re-qualification program for the equipment used in PD section?</li> </ul>			
re-qualification program for the equipment used in PD section?			
21 Do you have qualified staff in productVes			
development section with proper knowledge and training in product development?			
Have you manufactured three stability batches Yes for the stability studies of Dexpra Capsules as required?			
23. Do you have any criteria for fixing the batch Firm had fixed batch size accordance size of stability batches? guidelines, as informed by the firm's	Firm had fixed batch size according to DRAP guidelines, as informed by the firm's management.		
24. Do you have complete record of production of The firm had complete record of stability batches?  Stability batches. Complete Batch records of Dexlansoprazole 30mg & 60 to the Panel.	h Manufactu		
Trial # Mfg date Exp	-		
Dexpra Capsule 30mg			
	3-20 1500 ca		
T002 04-18 03-2	3-20 -do-		
	3-20 -do-		
Dexpra Capsule 60mg			
	3-20 -do-		
	3-20 -do-		
	3-20 -do-		
25. Do you have protocols for stability testing of Yes stability batches? The firm had protocol for stability tes	esting.		

26.		Testing Method was provided by M/s. Vision Pharma was validated in-house by the firm and report was shown to the panel.
27.	Do you have method transfer studies in case when the method of testing being used by your firm is given by any other lab?	
28.	Do you have documents confirming the qualification of equipment / instruments being used in the test and analysis of Dexlansoprazole and the finished drug?	
29.	Do your method of analysis stability indicating?	Impurities could be quantified according to testing method provided by M/s. Vision Pharma. Firm had performed forced degradation studies with reference to the parameters of temperature humidity and photolysis, according to the documents shown to the
30.	Do your HPLC software 21CFR Compliant?	HPLC software was 21CFR Compliant as per documents shown to the panel. However, some of the testing data / results had been transferred to the main server, as informed by the firm's management and could not be retrieved at the time of inspection. However, hard copies of chromatograms were
31.	Can you show Audit trail reports on Dexlansoprazole testing?	Audit trail reports were available for testing of trial batches. The data of assay testing Dexlansoprazole pellets could not be verified from HPLC.
32.	Do you have some remaining quantities of degradation products and stability batches?	No
33.	Do you have stability batches kept on stability testing?	Stability Study had been completed at the time of inspection.
34.	Do you have valid calibration status for the equipment used in Dexpra Capsules production and analysis?	
35.	Do proper and continuous monitoring and control are available for stability chamber?	Yes
36.	Do related manufacturing area, equipment, personnel and utilities be rated as GMP compliant?	

#### **Verification of additional points:**

Firm had used dissolution method provided by M/s. Vision Pharmaceutical at pH 7 and sampling time 120 minutes, according to the in-house analytical test method for Dexpra 60mg capsules shown to the panel at the time of inspection.

In-house dissolution testing data of Dexlansoprazole pellets could not be verified from the HPLC at the time of inspection as the firm's management informed that the testing data/results had been transferred to the main server and hence could not be retrieved at the time of inspection.

Submitted for further necessary action.

**Previous Decision:** Registration Board decided to defer the case for submission of either of the following (M-316):

Documented evidence based upon an IT report, to verify firm's claim regarding transfer of analytical data of assay & dissolution testing of Dexlansoprazole pellets.

Or

Fresh analysis of the Dexlansoprazole pellets performed by M/s Wilshire Laboratories including analytical record i.e, chromatograms, raw data sheets etc. for the assay & dissolution testing

**Evaluation by PEC:** The firm has submitted certificate of analysis of Dexlansoprazole pellets 22.5% (batch # DLP772) performed by M/s Wilshire Pharma. Performance of dissolution test at two pH (5.5 & 7.0) and assay testing were submitted alongwith analytical record i.e., chromatograms and raw data sheets.

**Decision: Approved with Innovator's specifications.** 

- The firm shall submit fee of Rs. 7,500 for each product for correction/pre-approval change in product specifications, as per notification No.F.7-11/2012-B&A/DRAP dated 13-07-2021.
- Manufacturer will place first three commercial batches on long term stability studies throughout proposed shelf life and on accelerated studies for six months as per the commitment submitted in the registration application.

# Case No. 4 Registration applications for local manufacturing of human drugs submitted on CTD format (New License)

The Central Licensing Board in its 271<sup>st</sup> meeting held on 12<sup>th</sup> September, 2019 has considered and approved the grant of Drug Manufacturing License to M/s Himark Laboratories Pvt Ltd. Plot 37-A, Sundar Industrial Estate, Lahore by way of Formulation vide approval letter No. F. 1-67/2005-Lic dated 29<sup>th</sup> Sep, 2019 with following (06) sections.

Name of Section	Considered till 316 <sup>th</sup> RB meeting		Freshly applied	
	No of molecules	No of products	No of molecules	No of products
Tablet (General & General Antibiotic) Section	4	7	3	4
Capsule (General & General Antibiotic)	5	11	-	-
Section				
Dry Powder Suspension (General & General Antibiotic) Section	4	6	-	-
Sachet (General) Section	1	1	1	1
Oral Liquid Syrup Section	4	6	1	1
Cream/Ointment (General) Section	-	-	-	-

235.	Name, address of Applicant / Marketing Authorization Holder	M/s Himark Laboratories Private Limited., Plot 37-A, Sundar Industrial Estate, Lahore.		
	Name, address of Manufacturing site.	M/s Himark Laboratories Private Limited., Plot 37-A, Sundar Industrial Estate, Lahore.		
	Status of the applicant	<ul> <li>✓ Manufacturer</li> <li>☐ Importer</li> <li>☐ Is involved in none of the above (contract giver)</li> </ul>		
	Status of application	☐ New Drug Product (NDP)  ☑ Generic Drug Product (GDP)		
	Intended use of pharmaceutical product	<ul><li>☑ Domestic sale</li><li>☐ Export sale</li><li>☐ Domestic and Export sales</li></ul>		
	Dy. No. and date of submission	Dy. No. 32453 Dated 10-12-2021		
	Details of fee submitted	PKR 30,000/-: Dated 29-11-2021		
	The proposed proprietary name / brand name	Citromark 5 mg film coated tablet		
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each film coated tablet contains: Levocetirizine dihydrochloride		
	Pharmaceutical form of applied drug	White color round shaped film coated tablet		

Pharmacotherapeutic Group of (API)	Anti-histamine	
Reference to Finished product specifications	USP Specifications	
Proposed Pack size	1 × 10's	
Proposed unit price	As per SRO	
The status in reference regulatory authorities	XYZAL Levocetirizine hydrochloride 5 mg film coated tablet by M/s UCB Pharma (Approved in TGA)	
For generic drugs (me-too status)	T-Day 5 mg film coated Tablet by M/s GSK Consumer Healthcare (Reg. No. 083964)	
GMP status of the Finished product manufacturer	New license granted on 26-09-2019. Tablet (General & General Antibiotic) section approved.	
Name and address of API manufacturer.	M/s Metrochem API Private Limited., Factory: Unit-I, Plot No. 62/C/6, Pipeline Road, Phase – I, IDA, Jeedimetla Hyderabad-500 055, India.	
Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product is submitted.	
Module III (Drug Substance)	Official monograph of Levocetirizine dihydrochloride is present in USP. The firm has submitted details of nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, Identification, Assay and specific optical rotation, heavy metals and enantiomeric purity by HPLC, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.	
Stability studies	Stability study conditions: Real time: $30^{\circ}C \pm 2^{\circ}C / 65\% \pm 5\%$ RH for 36 months Accelerated: $40^{\circ}C \pm 2^{\circ}C / 75\% \pm 5\%$ RH for 6 months Batches: (LCZ/A/200801001, LCZ/A/200801002, LCZ/A/200801003)	
Module-III (Drug Product):	The firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.	
Pharmaceutical equivalence and comparative dissolution profile	Pharmaceutical equivalence has been established against comparator product <b>T-day 5 mg tablet</b> by GSK consumer healthcare by performing quality tests (Identification, assay, dissolution, uniformity of dosage form).	

	1		CDP has been performed against the same in acidic media (pH 1.0-1.2) and pH 4.5 & phosphate buffer (pH 6.8). The values for $f_1$ and $f_2$ are in the acceptable range.		
	product		Method verification including linearity, specificity.		
		STABILITY	STUDY DATA		
Manufacturer of API  M/s Metrochem API Priv Factory: Unit-I, Plot No. Hyderabad-500 055, Ind.		o. 62/C/6, Pipeline Road,	Phase – I, IDA, Jeedimetla		
API Lot	No.	LUVPC21027			
	ion of Pack er closure system)	Alu-Alu blister packed	in unit carton (1×10's)		
Stability	Storage Condition	Real time: $30^{\circ}\text{C} \pm 2^{\circ}\text{C} / \text{Accelerated}$ : $40^{\circ}\text{C} \pm 2^{\circ}\text{C}$			
Time Per	riod	Real time: 6 months Accelerated: 6 months			
Frequenc	cy	Accelerated: 0, 2, 4, 6 (Real Time: 0, 3, 6 (Mor	The state of the s		
Batch No	0.	T-01	T-02	T-03	
Batch Siz	ze	1500 tab	1500 tab	1500 tab	
Manufac	turing Date	05-2021	05-2021	05-2021	
Date of I	nitiation	12-05-2021	12-05-2021	12-05-2021	
No. of B	atches		03		
DOCUMENTS / DATA PROV			VIDED BY THE APPL	LICANT	
1.		s approval of applications ata of the firm (if any)	The firm has not submi	tted any document.	
2.	Approval of API/ DML/GMP certificate of		The firm has submitted copy of GMP certificate No. 1296/DD/DCA/VSP/2020 issued by Deputy Director & Certifying Authority drugs control administration Visakhapatnam Region India valid up to 28-09-2021.		
3.	Documents for the procurement of API with approval from DRAP (in case of import).		The firm has submitted copy of letter No.17133/2019/DRAP-AD-CD(I&E) dated 26/12/2019 is submitted wherein the permission to import different APIs including Levocetirizine Dihydrochloride for the purpose of test/analysis and stability studies is granted.		
4.			The firm has submitted data of stability batches including raw data sheets, COAs, summary data sheets etc.		
5.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing		Not submitted.		
6.	6. Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated).		The firm has record of data logger for temperature and humidity monitoring of stability chambers (real time and accelerated).		
Remark	s of Evaluator:				
Sr. No.	Observations		Response by the	firm	

1.	The submitted COA from drug product manufacturer shows pH of sample solution as 4.42 which is not within the limit of 1.2 to 1.8.	The firm has submitted fresh certificate of analysis with revised result of pH as 1.5 and document does not contain date of analysis.
2.	Analytical method verification reports of parameters like specificity, accuracy and repeatability (method precision) performed by the Drug Product manufacturer for both compendial as well as non-compendial drug substance(s) shall be submitted.	The firm has submitted analytical method verification reports of drug substance performed by drug product manufacturer. However, details of standard and sample preparation methods alongwith chromatograms of different tested parameters were not provided.
3.	Details of batch numbers of applicant and comparator product in pharmaceutical equivalence are required to be provided	Applicant batch No: T-01  Comparator product:  T-day 5mg Tablet of M/s GSK  Batch No: HH9T
4.	The submitted CDP data showed less than 75% release in 30 min in all media, therefore, justify CDP data in the light of WHO Recommendations for conducting and assessing CDP wherein it is stated:  "In the case where 85% dissolution cannot be reached due to poor solubility of the API, the dissolution should be conducted until an asymptote (plateau) has been reached".	The firm has revised comparative dissolution studies by adding 45 min time point in the studied dissolution media. The results show initial release of 50% at 30 min while the drug release occurred more than 90% at 45 min time point in all media. <i>Moreover, dissolution studies are not conducted until asymptote as per WHO recommendations.</i>
5.	Analytical method verification reports of each parameter like specificity, accuracy and repeatability (method precision) performed by the Drug Product manufacturer shall be submitted.	The firm has submitted analytical method verification reports of drug substance performed by drug product manufacturer. However, details of standard and sample preparation methods alongwith their concentrations in different tested parameters were not provided.
6.	The submitted copy of GMP certificate of API manufacturer is expired on 28-09-2021. Updated copy of GMP certificate shall be submitted.	The firm has submitted copy of GMP certificate issued by Drugs Control Administration Government of Telangana India valid up to 20-05-2023.
7.	Submitted invoice for the procurement of drug substance is not attested by AD (I & E). Clarification is required.	The firm has submitted copy of letter No.17133/2019/DRAP-AD-CD(I&E) dated 26/12/2019 is submitted wherein the permission to import different APIs including Levocetirizine Dihydrochloride for the purpose of test/analysis and stability studies is granted. However, invoice is not cleared by AD (I&E) DRAP of field office.
8.	The submitted chromatograms do not differentiate between real time or accelerated stability studies time points of different batches.	Not submitted
9.	UV spectra alongwith raw data sheets for dissolution tests in stability study data are required to be submitted.	Not submitted.
10.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing.	Not submitted.

- Analytical method verification report of drug substance performed by drug product manufacturer as
- per requirement of section 3.2.S.4.3 of Form-5F.
- Performance of pharmaceutical equivalence and CDP studies with innovator/reference product.
- Justify comparative dissolution studies in the light of WHO recommendations which recommend conduction of dissolution studies until asymptote if 85% dissolution could not be reached due to poor solubility of API.
- HPLC chromatograms of all time points of real time and accelerated stability studies.

- UV spectra alongwith raw data sheets for dissolution tests in stability study data.
- Analytical method verification reports for testing of drug product as per requirements of section 3.2.P.5.3

Name, address of Applicant / Marketing Authorization Holder	M/s Himark Laboratories Private Limited, Plot 37-A, Sunder Industrial Estate Lahore.		
Name, address of Manufacturing site.	M/s Himark Laboratories Private Limited, Plot 37-A, Sunder Industrial Estate Lahore.		
Status of the applicant	<ul> <li>☑ Manufacturer</li> <li>☐ Importer</li> <li>☐ Is involved in none of the above (contract giver)</li> </ul>		
Status of application	<ul> <li>□ New Drug Product (NDP)</li> <li>☑ Generic Drug Product (GDP)</li> <li>□ Domestic sale</li> <li>□ Export sale</li> <li>☑ Domestic and Export sales</li> </ul>		
Intended use of pharmaceutical product			
GMP status of the Finished product manufacturer	New license granted on 26-09-2019. Tablet (General & General Antibiotic) section approved.		
Dy. No. and date of submission	Dy. No. 33577 Dated: 23-12-2021		
Details of fee submitted	PKR 30,000/-: Dated 29/11/2021		
The proposed proprietary name / brand name	Fexomark 120mg film coated tablet		
Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each film coated tablet contains: Fexofenadine hydrochloride120mg		
Pharmaceutical form of applied drug	Whilte colored round shaped film coated tablet, Packed Alu-Alu Blisters $(1 \times 10^{\circ}s)$ .		
Pharmacotherapeutic Group of (API)	Anti-histamine		
Reference to Finished product specifications	USP specifications		
Proposed Pack size	1 × 10's		
Proposed unit price	As per SRO		
The status in reference regulatory authorities	Telfast 120mg film coated tablet of M/s Aventis Pharma Limited, United Kingdom (MHRA approved).		
For generic drugs (me-too status)	Fexet 120mg film coated tablet of M/s GETZ Pharma		
Name and address of API manufacturer.	M/s VPL Chemicals Pvt. Ltd., Plot # 64, 1st phase Sompura Industrial Area, Dobbespet, Nelamangala (Taluk), Bangalore Rural – 562 111, India.		
Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template Summarized information related to nomenclature structure, general properties, solubilities, physical form manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product is submitted.		
Module III (Drug Substance)	The firm as submitted detail of nomenclature, structure general properties, solubilities, physical form manufacturers, description of manufacturing process and		

			verification, batch as	analytical procedures and its nalysis and justification of tandard, container closure system rug substance.	
	Stability studies		Stability study conditions: Real time: $30^{\circ}C \pm 2^{\circ}C / 65\% \pm 5\%$ RH for 36 months Accelerated: $40^{\circ}C \pm 2^{\circ}C / 75\% \pm 5\%$ RH for 6 months Batches: (FE III 1503013, FE III 1503014, FE III 1503015).		
Module-III (Drug Product):		The firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols and report, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.			
	Pharmaceutical equivalence and comparative dissolution profile		The firm has submitted pharmaceutical equivalence against comparator product <b>Telfast 120 mg tablet</b> by <b>Sanofi-Aventis</b> by performing quality tests (Identification, Assay, Dissolution, Uniformity of dosage unit). CDP has been performed against the comparator product <b>Fexet 120 mg Tablet</b> of <b>M/s GETZ pharma</b> in acidic media (pH 1.0-1.2) and pH 4.5 buffer & phosphate buffer (pH 6.8). The values for $f_1$ and $f_2$ are in the acceptable range.		
	Analytical method validation/verification of product		Analytical method verification reports have not been submitted including linearity, accuracy, precision, specificity.		
		STABILITY	STUDY DATA		
Manufac	turer of API	M/s VPL Chemicals Pvt. Ltd., Plot # 64, 1st Phase, Sompura Industrial area Dobbespet, Neelamangala (Taluk), Bengaluru Rural-562 111, India.			
API Lot	No.	FEX2103012			
	on of Pack er closure system)	Alu-Alu blister packed	l in unit carton (1×10's)		
Stability Storage Condition Real time: 30°C ± 2°C Accelerated: 40°C ± 2°C					
Time Period Real time: 6 months Accelerated: 6 months		,			
Frequency Accelerated: 0, 3, 6 (M) Real Time: 0, 3, 6 (M)					
Batch No. T-01		T-02	T-03		
Batch Siz	Batch Size 1500 Tablets		1500 Tablets	1500 Tablets	
Manufac	Manufacturing Date 05-2021		05-2021	05-2021	
Date of I	nitiation	10-05-2021	10-05-2021	10-05-2021	
No. of B		03			
	DOC	UMENTS / DATA PRO	OVIDED BY THE APPL	ICANT	

1.	Reference of previous approval of applications with stability study data of the firm (if any)	The firm has not submitted any document.		
2.	Approval of API / DML / GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	The firm has submitted copy of GMP certificate No DCD/SPL-1/CR-1207/2020-21 issued by Government o Karnataka, Drugs Control Department India valid up to 05 01-2025.		
3.	Documents for the procurement of API with approval from DRAP (in case of import).	The firm has submitted copy of letter No.17133/2019/DRAP-AD-CD (I&E) dated 26/12/2019 wherein the permission to import different APIs including Fexofenadine hydrochloride for the purpose of test/analysis and stability studies is granted. Copy of invoice for the purchase of API has not submitted.		
4.		The firm has submitted data of stability batches including raw data sheets, COAs, summary data sheets etc.		
5.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing.	Not submitted.		
6.		The firm has submitted record of digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated).		

Sr.	Observations	Response by the firm	
No.	Observations	Response by the III in	
1.	Analytical method verification reports of parameters like specificity, accuracy and repeatability (method precision) performed by the Drug Product manufacturer for both compendial as well as non-compendial drug substance(s) shall be submitted.	The firm has submitted analytical method verification reports of drug substance performed by drug product manufacturer. However, details of standard and sample preparation methods alongwith chromatograms of different tested parameters were not provided.	
2.	Details of batch numbers of applicant and comparator product in pharmaceutical equivalence are required to be provided	Applicant batch No: T-01  Comparator product: T-day 5mg Tablet of M/s Sanofi-Aventis Batch No: AN002	
3.	Justify your acceptance criteria for dissolution test as NLT 60% of the labeled amount of Fexofenadine HCl is dissolved in 10 min; NLT 80% of the labeled amount of Fexofenadine HCl is dissolved in 30 min while USP has specified as NLT 60% (Q) of the labeled amount of Fexofenadine HCl dissolved in 10 min; NLT 80% (Q) of the labeled amount of Fexofenadine HCl dissolved in 30 min.	USP defines quantity Q, is the amount of dissolved active ingredient specified in the individual monograph. When we look at a Q value, we are looking at what percent has dissolved at that time. Thus, there is no difference between NLT 60% in 10 min and NLT 60% (Q) in 10 minutes and NLT 80% in 30 min and NLT 80 (Q) in 30 min.  However, USP general chapter of dissolution <711> defines S1 stage of dissolution as each unit is not less than Q + 5% and did not revise dissolution acceptance criteria as per USP.	
4.	Submit acceptance criteria for release and shelf life specifications.	The firm has submitted acceptance criteria for release and shelf life specifications.	
5.	Justify dissolution results in the submitted batch analysis since results are not complying USP monograph.	The firm has referred to USP definition of Q, as the amount of dissolved active ingredient specified in individual monograph. <i>The firm has</i>	

		not provided justification of dissolution results not
		complying USP monograph.
6.	Analytical method verification reports of each parameter like specificity, accuracy and repeatability (method precision) performed by the Drug Product manufacturer shall be submitted.	The firm has submitted analytical method verification reports of drug product. However, details of standard and sample preparation methods alongwith chromatograms of different tested parameters were not provided. The results of repeatability parameter show absorbance values while rest of the parameter gives values in peak area.
7.	COA of primary / secondary reference standard including source and lot number shall be provided.	The firm has submitted COA of working standard from drug substance manufacturer with lot no. WS-Fex-210209.
8.	Submitted invoice for the procurement of drug substance is not attested by AD (I & E). Clarification is required.	The firm has submitted copy of letter No.17133/2019/DRAP-AD-CD(I&E) dated 26/12/2019 is submitted wherein the permission to import different APIs including Levocetirizine Dihydrochloride for the purpose of test/analysis and stability studies is granted. However, invoice is not cleared by AD (I&E) DRAP of field office.
9.	The submitted chromatograms do not differentiate between real time or accelerated stability studies time points of different batches.	Not submitted
10.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing.	The firm has submitted that audit trail is maintained manually.
11.	Submit copies of Batch Manufacturing Record (BMR) for all the batches of drug product for which stability studies data is provided in Module 3 section 3.2.P.8.3.	The firm has submitted copies of batch manufacturing record of stability batches.
12.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated).	The firm has submitted record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated).

- Analytical method verification report of drug substance performed by drug product manufacturer as
- per requirement of section 3.2.S.4.3 of Form-5F.
- Performance of pharmaceutical equivalence and CDP studies with innovator/reference product.
- Justify acceptance criteria for dissolution test in the light of USP monograph.
- Justify dissolution results in the submitted batch analysis since results are not complying USP specifications.
- HPLC chromatograms of all time points of real time and accelerated stability studies.
- Analytical method verification reports for testing of drug product as per requirements of section 3.2.P.5.3 of Form-5F.

237.	Name, address of Applicant / Marketing Authorization Holder	M/s Himark Laboratories Private Limited, Plot 37-A, Sunder Industrial Estate Lahore.	
	Name, address of Manufacturing site.	M/s Himark Laboratories Private Limited, Plot 37-A, Sunder Industrial Estate Lahore.	
	Status of the applicant	<ul> <li>✓ Manufacturer</li> <li>☐ Importer</li> <li>☐ Is involved in none of the above (contract giver)</li> </ul>	
	Status of application	☐ New Drug Product (NDP)  ☐ Generic Drug Product (GDP)	

Intended use of pharmace	utical product	<ul><li>□ Domestic sale</li><li>□ Export sale</li><li>☑ Domestic and Export sales</li></ul>
GMP status of the Finishe manufacturer	d product	New license granted on 26-09-2019. Tablet (General & General Antibiotic) section approved.
Dy. No. and date of subm	ission	Dy. No. 33578 Dated: 23-12-2021
Details of fee submitted		PKR 30,000/-: Dated 29-11-2021
The proposed proprietary name	name / brand	Fexomark 180mg film coated tablet
Strength / concentration o Pharmaceutical ingredient	_	Each film coated tablet contains: Fexofenadine hydrochloride180mg
Pharmaceutical form of ap	oplied drug	Whilte colored round shaped film coated tablet, Packed in Alu-Alu Blisters $(1 \times 10^{\circ}\text{s})$
Pharmacotherapeutic Grou	up of (API)	Anti-histamine
Reference to Finished pro specifications	duct	USP specifications
Proposed Pack size		1 × 10's
Proposed unit price		As per SRO
The status in reference reg authorities	gulatory	Telfast 180mg film coated tablet of M/s Aventis Pharma Limited, United Kingdome (MHRA approved).
For generic drugs (me-too	status)	Fexet 180mg film coated tablet of M/s GETZ Pharma
Name and address of API	manufacturer.	M/s VPL Chemicals Pvt. Ltd., Plot # 64, 1 <sup>st</sup> phase, Sompura Industrial Area, Dobbespet, Nelamangala (Taluk), Bangalore Rural – 562 111, India.
Module-II (Quality Overa	ll Summary)	Firm has submitted QOS as per WHO QOS-PD template. Summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product is submitted.
Module III (Drug Substan	ce)	The firm as submitted detail of nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
Stability studies		Stability study conditions: Real time: $30^{\circ}\text{C} \pm 2^{\circ}\text{C} / 65\% \pm 5\%$ RH for 60 months Accelerated: $40^{\circ}\text{C} \pm 2^{\circ}\text{C} / 75\% \pm 5\%$ RH for 6 months Batches: (FE III 1503013, FE III 1503014, FE III 1503015).
Module-III (Drug Product	·):	The firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols and report, control of excipients, control of drug product, specifications,

			batch analysis, justificat	lidation of analytical procedures, ion of specifications, reference container closure system and
	comparative dissolution profile		The firm has submitted pharmaceutical equivalence against comparator product <b>Telfast 180 mg tablet</b> by <b>Sanofi-Aventis</b> by performing quality tests (Identification, Assay, Dissolution, Uniformity of dosage form).  CDP has been performed against the same brand that is <b>Telfast 180 mg Tablet</b> by <b>Sanofi-Aventis</b> in Acid media (pH 1.0-1.2) and pH 4.5 & phosphate buffer (pH 6.8). The values for $f_1$ and $f_2$ are in the acceptable range.	
	Analytical method va product	alidation/verification of	Analytical method veriful submitted.	fication reports have not been
		STABILITY	STUDY DATA	
Manufac	cturer of API	M/s VPL Chemicals P Plot # 64, 1 <sup>st</sup> Phase, S Bengaluru Rural-562	ompura Industrial area Do	obbespet, Neelamangala (Taluk),
API Lot	No.	FEX2103012		
	ion of Pack er closure system)	Alu-Alu blister packed in unit carton (1×10's)		
Stability	Storage Condition	Real time: $30^{\circ}\text{C} \pm 2^{\circ}\text{C} / 65\% \pm 5\%\text{RH}$ Accelerated: $40^{\circ}\text{C} \pm 2^{\circ}\text{C} / 75\% \pm 5\%\text{RH}$		
Time Per	riod	Real time: 6 months Accelerated: 6 months		
Frequenc	су	Accelerated: 0, 3, 6 (Macelerated: 0, 3, 6 (		
Batch No	0.	T-01	T-02	T-03
Batch Si	ze	1500 tab	1500 tab	1500 tab
Manufac	cturing Date	05-2021	05-2021	05-2021
Date of I	Initiation	11-05-2021	11-05-2021	11-05-2021
No. of B	atches		03	
	DOCU	JMENTS / DATA PRO	OVIDED BY THE APPL	ICANT
1.	Reference of previous approval of applications with stability study data of the firm (if any)		The firm has not submitte	ed any document.
2.	Approval of API / DML / GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.		The firm has submitted copy of GMP certificate No. DCD/SPL-1/CR-1207/2020-21 issued by Government of Karnataka, Drugs Control Department India valid up to 05-01-2025.	
3.	Documents for the procurement of API with approval from DRAP (in case of import).		The firm has submitted copy of letter No.17133/2019/DRAP-AD-CD (I&E) dated 26/12/2019 wherein the permission to import different APIs including Fexofenadine hydrochloride for the purpose of test/analysis and stability studies is granted. Copy of invoice for the purchase of API has not submitted.	

4.		The firm has submitted data of stability batches including raw data sheets, COAs, summary data sheets etc.
5.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	
6.		The firm has submitted record of digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated).

		,
Sr. No.	Observations	Response by the firm
1.	Analytical method verification reports of parameters like specificity, accuracy and repeatability (method precision) performed by the Drug Product manufacturer for both compendial as well as non-compendial drug substance(s) shall be submitted.	The firm has submitted analytical method verification reports of drug substance performed by drug product manufacturer. However, details of standard and sample preparation methods alongwith chromatograms of different tested parameters were not provided.
2.	Details of batch numbers of applicant and comparator product in pharmaceutical equivalence are required to be provided	Applicant batch No: T-01  Comparator product:  T-day 5mg Tablet of M/s Sanofi-Aventis Batch No: AW 006
3.	Justify your acceptance criteria for dissolution test as NLT 60% of the labeled amount of Fexofenadine HCl is dissolved in 10 min; NLT 80% of the labeled amount of Fexofenadine HCl is dissolved in 30 min while USP has specified as NLT 60% (Q) of the labeled amount of Fexofenadine HCl dissolved in 10 min; NLT 80% (Q) of the labeled amount of Fexofenadine HCl dissolved in 30 min.	USP defines quantity Q, is the amount of dissolved active ingredient specified in the individual monograph. When we look at a Q value, we are looking at what percent has dissolved at that time. Thus, there is no difference between NLT 60% in 10 min and NLT 60% (Q) in 10 minutes and NLT 80% in 30 min and NLT 80 (Q) in 30 min.  However, USP general chapter of dissolution <711> defines S <sub>1</sub> stage of dissolution as each unit is not less than Q + 5% and did not revise dissolution acceptance criteria as per USP.
4.	Submit acceptance criteria for release and shelf life specifications.	The firm has submitted acceptance criteria for release and shelf life specifications.
5.	Justify dissolution results in the submitted batch analysis since results are not complying USP monograph.	The firm has referred to USP definition of Q, as the amount of dissolved active ingredient specified in individual monograph. The firm has not provided justification of dissolution results not complying USP monograph.
6.	Analytical method verification reports of each parameter like specificity, accuracy and repeatability (method precision) performed by the Drug Product manufacturer shall be submitted.	The firm has submitted analytical method verification reports of drug product. However, details of standard and sample preparation methods alongwith chromatograms of different tested parameters were not provided. The results of repeatability parameter show absorbance values while rest of the parameter gives values in peak area.
7.	COA of primary / secondary reference standard including source and lot number shall be provided.	The firm has submitted COA of working standard from drug substance manufacturer with lot no. WS-Fex-210209.

8.	Submitted invoice for the procurement of drug substance is not attested by AD (I & E). Clarification is required.	The firm has submitted copy of letter No.17133/2019/DRAP-AD-CD(I&E) dated 26/12/2019 is submitted wherein the permission to import different APIs including Levocetirizine Dihydrochloride for the purpose of test/analysis and stability studies is granted. However, invoice is not cleared by AD (I&E) DRAP of field office.	
9.	The submitted chromatograms do not differentiate between real time or accelerated stability studies time points of different batches.		
10.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing.	The firm has submitted that audit trail is maintained manually.	
11.	Submit copies of Batch Manufacturing Record (BMR) for all the batches of drug product for which stability studies data is provided in Module 3 section 3.2.P.8.3.	The firm has submitted copies of batch manufacturing record of stability batches.	
12.			

- Analytical method verification report of drug substance performed by drug product manufacturer as
- per requirement of section 3.2.S.4.3 of Form-5F.
- Performance of pharmaceutical equivalence and CDP studies with innovator/reference product.
- Justify acceptance criteria for dissolution test in the light of USP monograph.
- Justify dissolution results in the submitted batch analysis since results are not complying USP specifications.
- HPLC chromatograms of all time points of real time and accelerated stability studies.
- Analytical method verification reports for testing of drug product as per requirements of section 3.2.P.5.3 of Form-5F.

238.	Name, address of Applicant / Marketing Authorization Holder	M/s Himark Laboratories Private Limited., Plot # 37-A, Sundar Industrial Estate Lahore		
	Name, address of Manufacturing site.	M/s Himark Laboratories Private Limited., Plot # 37-A, Sundar Industrial Estate Lahore		
	Status of the applicant	<ul> <li>✓ Manufacturer</li> <li>☐ Importer</li> <li>☐ Is involved in none of the above (contract giver)</li> </ul>		
	Status of application	☐ New Drug Product (NDP) ☐ Generic Drug Product (GDP)		
	Intended use of pharmaceutical product	<ul><li>☑ Domestic sale</li><li>☐ Export sale</li><li>☐ Domestic and Export sales</li></ul>		
	Dy. No. and date of submission	Dy. No. 288: Dated 04-01-2022		
	Details of fee submitted	PKR 20,000/-: Dated 31-12-2020 PKR 10,000/-: Copy of challan not attested.		
	The proposed proprietary name / brand name	Levomark 500 mg film coated tablet		
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each film coated tablet contains: Levofloxacin as hemihydrate500 mg		

Pharmaceutical form of applied drug	Light yellow oblong film coated tablet
Pharmacotherapeutic Group of (API)	Flouroquinolones
Reference to Finished product specifications	USP Specifications
Proposed Pack size	1 × 10's
Proposed unit price	As per SRO
The status in reference regulatory authorities	Levofloxacin 500 mg Film-coated tablets by Accord Healthcare Limited UK (MHRA Approved).
For generic drugs (me-too status)	Leflox 500 mg Tablet by Getz Pharma (Reg. No. 026164).
GMP status of the Finished product manufacturer	New license granted on 26-09-2019 Tablet (General & General Antibiotic) section.
Name and address of API manufacturer.	M/s Zhejiang Apeloa Kangyu Pharmaceutical Co. Ltd., 333 Jiangnan Road, hengdian, Dongyang, Zhejiang Province, 322 118 PR China.
Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product is submitted.
Module III (Drug Substance)	Official monograph of Levofloxacin hemihydrate is present in USP. The firm has submitted details of nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, Identification, Assay and impurities and water content have been performed, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
Stability studies	Stability study conditions: Real time: $30^{\circ}\text{C} \pm 2^{\circ}\text{C} / 65\% \pm 5\%\text{RH}$ for 48 months Accelerated: $40^{\circ}\text{C} \pm 2^{\circ}\text{C} / 75\% \pm 5\%$ RH for 6 months Batches: (LFA-V-20120801ES, LFA-V-20120802ES, LFA-V-20120803ES)
Module-III (Drug Product):	The firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols and report, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.
Pharmaceutical equivalence and comparative dissolution profile	Pharmaceutical equivalence has been established with comparator product <b>Leflox 500 mg Tablet</b> of M/s Getz Pharma by performing quality tests (Identification, Assay, Dissolution, Uniformity of dosage form).

			The firm has submitted comparative dissolution study with comparator product <b>Leflox 500 mg Tablet</b> of Getz Pharma in acidic media (pH 1.0-1.2) and pH 4.5 & phosphate buffer (pH 6.8). The values for f1 and f2 are in the acceptable range.		
	Analytical method va product	lidation/verification of	Analytical method veri submitted.	fication reports have not been	
		STABILITY	STUDY DATA		
Manufac	turer of API		Kangyu Pharmaceutical C engdian, Dongyang, Zhejia	o. Ltd., ang Province, 322118 PR China	
API Lot	No.	KY-LFA-M20190968	E		
	on of Pack er closure system)	Alu-Alu blister packed	l in unit carton (1×10's)		
Stability	Storage Condition	Real time: $30^{\circ}\text{C} \pm 2^{\circ}\text{C}$ Accelerated: $40^{\circ}\text{C} \pm 2^{\circ}$			
Time Per	riod	Real time: 6 months Accelerated: 6 months			
Frequenc	<b>с</b> у	Accelerated: 0, 3, 6 (Moreover) Real Time: 0, 3, 6 (Moreover)			
Batch No	).	T-58	T-59	T-60	
Batch Siz	ze	1500 Tablets	1500 Tablets	1500 Tablets	
Manufac	turing Date	04-2020	04-2020	04-2020	
Date of I	nitiation	22-04-2020	22-04-2020	22-04-2020	
No. of Ba	atches		03		
	DOCU	MENTS / DATA PRO	OVIDED BY THE APPL	ICANT	
1.		evious approval of bility study data of the	The firm has not submitted any document.		
2.	Approval of API/ DML/GMP certificate of		The firm has submitted copy of GMP certificate No. ZJ201190145 issued by China food & Drugs administration is attached and it is valid till 29-11-24.		
3.	Documents for the procurement of API with approval from DRAP (in case of import).		The firm has submitted copy of letter No.17133/2019/DRAP-AD-CD(I&E) dated 26/12/2019 is submitted wherein the permission to import different APIs including Levofloxacin hemihydrate for the purpose of test/analysis and stability studies is granted.		
4.			The firm has submitted data of stability batches including raw data sheets, COAs, summary data sheets etc.		
5.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing				
6.			The firm has submitted record of data logger for temperature and humidity monitoring of stability chambers (real time and accelerated).		
Sr. No.	Observations		Response by the	firm	

1.	Analytical method verification reports of parameters like specificity, accuracy and repeatability (method precision) performed by the Drug Product manufacturer for both compendial as well as non-compendial drug substance(s) shall be submitted.	The firm has submitted analytical method verification reports of drug substance performed by drug product manufacturer. However, details of standard and sample preparation methods alongwith chromatograms in different tested parameters were not provided.
2.	Details of batch numbers of applicant and comparator product in pharmaceutical equivalence are required to be provided	Applicant batch No: T-58  Comparator product:  Leflox 500mg Tablet of M/s GETZ Pharma  Batch No: LF-095
3.	The submitted CDP data showed less than 75% release in 30 min in all media, therefore, justify CDP data in the light of WHO Recommendations for conducting and assessing CDP wherein it is stated:  "In the case where 85% dissolution cannot be reached due to poor solubility of the API, the dissolution should be conducted until an asymptote (plateau) has been reached".	The firm has revised comparative dissolution studies by adding 45 min time point in the studied dissolution media. However, dissolution studies are not conducted until asymptote as per WHO recommendations.
4.	Justify your acceptance criteria for dissolution test as NLT 80% of the labeled amount of Levofloxacin is dissolved in 30 min.	The firm has submitted that there is no difference between NLT 80% in 30 min and NLT 80% (Q) in 30 min.  However, USP general chapter of dissolution $<711>$ defines $S_1$ stage of dissolution as each unit is not less than $Q + 5\%$ and accordingly did not revise dissolution acceptance criteria as per USP.
5.	Analytical method verification reports of each parameter like specificity, accuracy and repeatability (method precision) performed by the Drug Product manufacturer shall be submitted.	The firm has submitted analytical method verification reports of drug substance performed by drug product manufacturer. However, details of standard and sample preparation methods alongwith chromatograms in different tested parameters were not provided.
6.	The submitted copy of GMP certificate of API manufacturer is expired on 28-09-2021. Updated copy of GMP certificate shall be submitted.	The firm has submitted copy of GMP certificate issued by Drugs Control Administration Government of Telangana India valid up to 20-05-2023.
7.	Submitted invoice for the procurement of drug substance is not attested by AD (I & E). Clarification is required.	The firm has submitted copy of letter No.17133/2019/DRAP-AD-CD(I&E) dated 26/12/2019 is submitted wherein the permission to import different APIs including Levocetirizine Dihydrochloride for the purpose of test/analysis and stability studies is granted. However, invoice is not cleared by AD (I&E) DRAP of field office.
8.	The submitted chromatograms do not differentiate between real time or accelerated stability studies time points of different batches.	Not submitted.
9.	UV spectra of dissolution results alongwith raw data sheets for dissolution tests throughout stability data are required to be submitted.	Not submitted.
10.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing.	The firm has submitted that audit trail is maintained manually.
11.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated).	The firm has submitted record of data logger for temperature and humidity monitoring of stability chambers (real time and accelerated).

- Analytical method verification report of drug substance performed by drug product manufacturer as
- per requirement of section 3.2.S.4.3 of Form-5F.
- Performance of pharmaceutical equivalence and CDP studies with innovator/reference product.
- Justify comparative dissolution studies in the light of WHO recommendations which recommend conduction of dissolution studies until asymptote if 85% dissolution could not be reached due to poor solubility of API
- Justify your acceptance criteria for dissolution test in the light of USP specifications.
- HPLC chromatograms of all time points of real time and accelerated stability studies.
- UV spectra alongwith raw data sheets for dissolution tests in stability study data.
- Analytical method verification reports for testing of drug product as per requirements of section 3.2.P.5.3 of Form-5F.

	Name, address of Applicant / Marketing Authorization Holder	M/s Himark Laboratories Private Limited., Plot 37-A, Sundar Industrial Estate Lahore.
	Name, address of Manufacturing site.	M/s Himark Laboratories Private Limited., Plot 37-A, Sundar Industrial Estate Lahore
	Status of the applicant	<ul><li>☑ Manufacturer</li><li>☐ Importer</li><li>☐ Is involved in none of the above (contract giver)</li></ul>
	Status of application	☐ New Drug Product (NDP) ☐ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	<ul><li>☑ Domestic sale</li><li>☐ Export sale</li><li>☐ Domestic and Export sales</li></ul>
	Dy. No. and date of submission	Dy. No. 33576 Dated 10-12-2021
	Details of fee submitted	PKR 30,000/-: Dated 29-11-2021
	The proposed proprietary name / brand name	Citromark 2.5 mg / 5ml oral solution
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each 5 mL oral solution contains: Levocetirizine dihdrochloride 2.5 mg
	Pharmaceutical form of applied drug	Oral solution
	Pharmacotherapeutic Group of API	Anti-histamine
	Reference to Finished product specifications	Manufacturer's specifications
	Proposed Pack size	60 mL
	Proposed unit price	As per SRO
	The status in reference regulatory authorities	XYZAL 0.5 mg / ml oral solution by M/s UCB Pharma (USFDA Approved)
	For generic drugs (me-too status)	T-Day 0.5 mg / mL oral solution by M/s GSK Consumer Healthcare Reg. No. 083990
	GMP status of the Finished product manufacturer	New license granted on 26-09-2019 Oral liquid Syrup Section
	Name and address of API manufacturer.	M/s Metrochem API Private Limited., Factory: Unit-I, Plot No. 62/C/6, Pipeline Road, Phase – I, IDA, Jeedimetla Hyderabad-500 055, India
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Summarized information related to nomenclature,

			manufacturers, descripticontrols, impurities, speand its verification, bar specification, reference s	rties, solubilities, physical form, on of manufacturing process and cifications, analytical procedures tch analysis and justification of tandard, container closure system rug substance and drug product is	
Stability studies		Official monograph of Levocetirizine Dihydrochloride is present in USP. The firm as submitted detail of nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, Identification, Assay and specific optical rotation, heavy metals and enantiomeric purity by HPLC, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance			
			Accelerated: $40^{\circ}\text{C} \pm 2^{\circ}\text{C}$	s: 55% ± 5% RH for 36 months / 75% ± 5% RH for 6 months 0801001, LCZ/A/200801002,	
	Module-III (Drug Product):		The firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols and report, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.		
	Pharmaceutical comparative dissoluti	•	Pharmaceutical Equivalence have been established against the brand leader that is <b>T-day 0.5 mg/mL oral solution</b> by GSK consumer healthcare by performing quality tests (Identification, Assay, and of uniformity of dosage form).		
	Analytical method va product	alidation/verification of	Method verification studies have submitted including linearity, range, accuracy, precision, specificity.		
		STABILITY	STUDY DATA		
Manufac	Manufacturer of API M/s Metrochem API Factory: Unit-I, Plo Hyderabad-500 055		*	oad, Phase – I, IDA, Jeedimetla	
API Lot No. LUVPC21027					
Description of Pack (Container closure system)  Amber color pet bott		Amber color pet bottle	e packed in unit carton (1×60 mL)		
Stability Storage Condition Real time: $30^{\circ}\text{C} \pm 2^{\circ}\text{C}$ Accelerated: $40^{\circ}\text{C} \pm 2^{\circ}$					
Time Period Real time: 6 months Accelerated: 6 months					
Frequenc	- y	Accelerated: 0, 2, 4, 6 Real Time: 0, 3, 6 (Mo			
Batch No	).	T-01	T-02	T-03	
Batch Siz	ze	100 bottles	100 bottles	100 bottles	
		•			

Manufacturing Date		05-2021	05-20	21	05-2021			
Date of Initiation		13-05-2021	13-05-2021		13-05-2021			
No. of Batches		03	1					
	DOCUMENTS / DATA PROVIDED BY THE APPLICANT							
1.	Reference of pre applications with stab firm (if any)	vious approval of ility study data of the	The fi	The firm has not submitted any document.				
2.	API manufacturer issued by concerned regulatory authority of country of origin.		Copy of GMP certificate No. 1296/DD/DCA/VSP/2020 issued by Deputy Director & Certifying Authority drugs control administration Visakhapatnam Region India valid up to 28-09-2021					
3.	Documents for the procurement of API with approval from DRAP (in case of import).		Copy of letter No.17133/2019/DRAP-AD-CD(I&E) dated 26/12/2019 is submitted wherein the permission to import different APIs including Levocetirizine Dihydrochloride for the purpose of test/analysis and stability studies is granted.					
4.				The firm has submitted data of stability batches including raw data sheets, COAs, summary data sheets etc.				
5.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing							
6.	Record of Digital data logger for temperature		The firm has submitted record of data logger for temperature and humidity monitoring of stability chambers (real time and accelerated).					
Sr. No.	Observations			Response by the firm				
1.	parameters like s repeatability (method Drug Product manufac	verification reports pecificity, accuracy precision) performed b cturer for both compend al drug substance(s) sh	and by the lial as	verification reporting by drug product metandard and	submitted analytical method ets of drug substance performed nanufacturer. However, details of sample preparation methods attograms in different parameters d.			
2.	Details of batch numbers of applicant comparator product in pharmaceutical equiva are required to be provided			Applicant batch N <b>Comparator pro</b> T-day 2.5mg / 5 consumer healthc Batch No: HH111	duct: Sml oral solution of M/s GSK are			
3.	Discussion of microbiological attributes o Drug Product (e.g. preservative effective studies to be performed as per recommendation pharmacopoeia) shall be provided.		eness	ess effectiveness studies as recommended b				
4.	Analytical method verification reports of parameter like specificity, accuracy repeatability (method precision) performed b Drug Product manufacturer shall be submitted		and by the d.	verification report details of stand methods alongwing parameters were				
5.	The submitted copy of GMP certificate of manufacturer is expired on 28-09-2021. Upd copy of GMP certificate shall be submitted.			The firm has submitted copy of GMP certificate				

6.	Submitted invoice for the procurement of drug substance is not attested by AD (I & E).	The firm has submitted copy of letter No.17133/2019/DRAP-AD-CD(I&E) dated
	Clarification is required.	26/12/2019 is submitted wherein the permission to import different APIs including Levocetirizine Dihydrochloride for the purpose of test/analysis and stability studies is granted. However, invoice is not cleared by AD (I&E) DRAP of field office.
7.	The submitted chromatograms do not differentiate between real time or accelerated stability studies of prepared batches.	Not submitted
8.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing.	The firm has submitted that audit trail is maintained manually.

- Analytical method verification report of drug substance performed by drug product manufacturer as
- per requirement of section 3.2.S.4.3 of Form-5F.
- Performance of pharmaceutical equivalence and CDP studies with innovator/reference product.
- Preservative effectiveness studies as recommended by Pharmacopoeia.
- HPLC chromatograms of all time points of real time and accelerated stability studies.
- Analytical method verification reports for testing of drug product as per requirements of section 3.2.P.5.3 of Form-5F.

240.	Name, address of Applicant / Marketing Authorization Holder	M/s Himark Laboratories Private Limited., Plot 37-A, Sundar Industrial Estate Lahore		
	Name, address of Manufacturing site.	M/s Himark Laboratories Private Limited., Plot 37-A, Sundar Industrial Estate Lahore		
	Status of the applicant	<ul> <li>✓ Manufacturer</li> <li>☐ Importer</li> <li>☐ Is involved in none of the above (contract giver)</li> </ul>		
	Status of application	☐ New Drug Product (NDP) ☐ Generic Drug Product (GDP)		
	Intended use of pharmaceutical product	<ul> <li>☑ Domestic sale</li> <li>☐ Export sale</li> <li>☐ Domestic and Export sales</li> </ul>		
	Dy. No. and date of submission	Dy. No. 24082 Dated 01-09-2021		
	Details of fee submitted	PKR 30,000/-: Dated 21-06-2021		
	The proposed proprietary name / brand name	Hikast 4 mg Sachet		
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each sachet contains: Montelukast Sodium eq. to Montelukast4 mg		
	Pharmaceutical form of applied drug	Granules in sachet pack		
	Pharmacotherapeutic Group of (API)	Leukotriene receptor antagonist		
	Reference to Finished product specifications	USP		
	Proposed Pack size	1×14's		
	Proposed unit price	As per SRO		

The sta	atus in reference regulatory ities	Singulair® Paediatric 4 mg Granules by Merck Sharp & Dohme Limited Hertford Road, Hoddesdon, Hertfordshire EN11 9BU, UK (MHRA Approved).			
For ge	neric drugs (me-too status)	Montiget powder Sachet 4 mg by M/s Getz Pharma, (Reg. No. 057746)			
GMP s manufa	status of the Finished product acturer	New license granted on 26/09/2019 Sachet (General) section approved.			
Name	and address of API manufacturer.	M/s Dhanuka Laboratories Ltd SP4-4, Industrial Area, Cyber City Keshwana Rajput, Kotputli, Shahpura, Jaipur-303108, Rajasthan, India.			
Modul	e-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product is submitted.			
Modul	e III (Drug Substance)	Official monograph of Montelukast Sodium is present in any United States Pharmacopeia. The firm has submitted details of nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, Identification, Assay and tests for related substances (unspecified and total impurities), specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance			
Stabili	ty studies	Stability study conditions: Real time: $30^{\circ}\text{C} \pm 2^{\circ}\text{C} / 65\% \pm 5\%\text{RH}$ for 24 months Accelerated: $40^{\circ}\text{C} \pm 2^{\circ}\text{C} / 75\% \pm 5\%\text{RH}$ for 6 months Batches: (STRHB 170001, STRHB 170002, STRHB 170003).			
Modul	e-III (Drug Product):	The firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols and report, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.			
	aceutical equivalence and rative dissolution profile	Pharmaceutical equivalence has been established against comparator product <b>Montiget Sachet</b> by M/s Getz Pharma by performing quality tests (Identification, Assay, pH, dissolution test, Uniformity of dosage unit & organic impurities).  CDP – Not applicable			
Analyt produc		Method verification reports have not been submitted.			
		STUDY DATA			
Manufacturer of	Manufacturer of API M/s Dhanuka Laboratories Ltd.,				

		SP4-4, Industrial Area, Cyber City Keshwana Rajput, Kotputli, Shahpura, Jaipur-303108, Rajasthan, India.				
API Lot No.		MTS-2010009				
Description of Pack (Container closure system)		White to off white color suspension with sweet taste filled in sachet pack				
Stability	Storage Condition	Real time: $30^{\circ}\text{C} \pm 2^{\circ}\text{C} / 65\% \pm 5\%\text{RH}$ Accelerated: $40^{\circ}\text{C} \pm 2^{\circ}\text{C} / 75\% \pm 5\%\text{RH}$				
Time Per	riod	Real time: 6 months Accelerated: 6 months				
Frequenc	cy	Accelerated: 0, 3, 6 (Months) Real Time: 0, 3, 6 (Months)				
Batch No	0.	T-103		T-104	T-105	
Batch Si	ze	100 Sachet		100 Sachet	100 Sachet	
Manufac	eturing Date	11-2020		11-2020	11-2020	
Date of 1	Initiation	17-11-2020		17-11-2020	17-11-2020	
No. of B	atches			03		
	DOCUMENT	TS / DATA PRO	OVID	ED BY THE APPL	JCANT	
1.	Reference of previous approval of applications with stability study data of the firm (if any)			ed any document.		
2.	API manufacturer issued by concerned regulatory authority of country of origin.		The firm has submitted copy of GMP certificate No. DC/A-2/WHO GMP/2019/35 issued by Drugs Control Organization Swasthya Bhawan Tilak Marg, Jaipur Rajasthan, India, issued on 17-01-2019 and valid for 3 years.			
3.	Documents for the procurement of API with approval from DRAP (in case of import).		The firm has submitted copy of letter No.17133/2019/DRAP-AD-CD(I&E) dated 26-12-2019 is submitted wherein the permission to import different APIs Montelukast Sodium for the purpose of test/analysis and stability studies is granted.			
4.	Data of stability batches will be supported by		The	The firm has submitted data of stability batches including raw data sheets, COAs, summary data sheets etc.		
5.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing					
6.	and humidity monitoring of stability		The firm has submitted record of data logger for temperature and humidity monitoring of stability chambers (real time and accelerated).			
Sr. No.	Observations		Response by the firm			
1.	Analytical method verification reports of parameters like specificity, accuracy and repeatability (method precision) performed by the Drug Product manufacturer for both compendial as well as non-compendial drug substance(s) shall be submitted.		reports of drug substance performed by drug product manufacturer. <i>However, details of standard and sample</i> preparation methods alongwith chromatograms in			

	B : 11	1 1 1 1 N T 100		
2.	Details of batch numbers of applicant and	Applicant batch No: T-103		
	comparator product in pharmaceutical	Comparator product:		
	equivalence are required to be provided	Montiget 4mg Sachet of M/s GETZ pharma		
		Batch No: B656D03		
3.	The reference formulation states granules for oral suspension for applied formulation. Clarification is required in manufacturing process and process control whether granules will be prepared in-house or otherwise.	The granules are prepared in-house by sieving the materials from appropriate mesh.		
4.	Analytical method verification reports of each parameter like specificity, accuracy and repeatability (method precision) performed by the Drug Product manufacturer shall be submitted.	The firm has submitted analytical method verification reports of drug product. However, details of standard and sample preparation methods alongwith chromatograms in different tested parameters were not provided.		
5.	Submitted invoice for the procurement of drug substance is not attested by AD (I & E). Clarification is required.	The firm has submitted copy of letter No.17133/2019/DRAP-AD-CD(I&E) dated 26-12-2019 is submitted wherein the permission to import different APIs Montelukast Sodium for the purpose of test/analysis and stability studies is granted.		
6.	The submitted chromatograms do not differentiate between real time or accelerated stability studies time points of different batches.	Not submitted.		
7.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing.	The firm has submitted that audit trail is maintained manually.		
8.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated).	The firm has submitted record of data logger for temperature and humidity monitoring of stability chambers (real time and accelerated).		

- Analytical method verification report of drug substance performed by drug product manufacturer as
- per requirement of section 3.2.S.4.3 of Form-5F.
- Performance of pharmaceutical equivalence and CDP studies with innovator/reference product i.e., Singulair® Paediatric 4 mg Granules.
- HPLC chromatograms of all time points of real time and accelerated stability studies.
- Analytical method verification reports for testing of drug product as per requirements of section 3.2.P.5.3 of Form-5F.

# Case No. 05: Registration applications of local manufacturing of human drugs submitted on CTD format (New license)

On the recommendations of panel of experts, the CLB in its 276<sup>th</sup> meeting held on 03<sup>rd</sup> September, 2020 has considered and approved the grant of Drug Manufacturing License in the name of M/s Alpenglow pharmaceuticals (Pvt) Ltd, Plot No. A7, Risalpur Export processing Zone, Risalpur.

Name of Section	Considered till 316 <sup>th</sup> RB		Freshly applied	
	meeting			
	No of molecules	No of products	No of molecules	No of products
Capsule (Cephalosporin)	-	-	-	-
Dry Powder injection section (Cephalosporin)	1	6	-	-
Dry powder suspension section (Cephalosporin)	-	-	1	2

Tablet (Psychotropic)	-	-	-	-	1
-----------------------	---	---	---	---	---

241.	Name, address of Applicant / Marketing Authorization Holder	M/s Alpenglow Pharmaceuticals Plot # A/7, Export Processing Zone Risalpur, District Nowshera (KP) Pakistan.
	Name, address of Manufacturing site.	M/s Alpenglow Pharmaceuticals Plot # A/7, Export Processing Zone Risalpur, District Nowshera (KP) Pakistan.
	Status of the applicant	<ul> <li>✓ Manufacturer</li> <li>☐ Importer</li> <li>☐ Is involved in none of the above (contract giver)</li> </ul>
	Status of Application	<ul><li>□ New Drug Product (NDP)</li><li>☑ Generic Drug Product (GDP)</li></ul>
	Intended use of pharmaceutical product	<ul><li>□ Domestic sale</li><li>□ Export sale</li><li>☑ Domestic and Export sales</li></ul>
	Dy. No. and date of submission	Dy. No. 5229 Dated 24-02-2022
	Details of fee submitted	PKR 30,000/-: Dated 20-10-2021
	The proposed proprietary name / brand name	BACCIL Suspension 100 mg/5ml
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each 5ml after reconstitution contains Cefixime as trihydrate100 mg
	Pharmaceutical form of applied drug	Granules for Oral Suspension
	Pharmacotherapeutic Group of (API)	Anti-bacterials for systemic use, Third-generation cephalosporins.
	Reference to Finished product specifications	USP specifications
	Proposed Pack size	1's
	Proposed unit price	As per SRO
	The status in reference regulatory authorities	SUPRAX ® (cefixime) for oral suspension, 100 mg/5 mL (USFDA Approved)
	For generic drugs (me-too status)	Caricef Suspension 100mg/5ml 30ml
	GMP status of the Finished product manufacturer	New license granted on 22-09-2020.
	Name and address of API manufacturer.	M/s Pharmagen Pvt. Limited, Address: Kot Nabi Bukhsh wala, 34-Km Ferozepur Road, Lahore Pakistan
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product is submitted.

	Module III (Drug Substa	nnce)	present in USP. The firm nomenclature, structure solubilities, physical description of manufactorics, specifications, and its verification, justification of specifica	, analytical procedures
	Stability studies		Stability study condition Real time: 30°C±2°C/65° Accelerated:40°C±2°C/7 months Batches: (120512013, 12	%±5%RH for 72 months 5%±5%RH for 6
	Module-III (Drug Product):		description of manuficontrols, impurities, sprocedure (including distant buffer medium) and batch analysis and justification.	fication of specification, ainer closure system and
	Pharmaceutical equiva	ence and comparative	e N/A	
	Analytical method va product	alidation/verification o		lies have been submitted ge, accuracy, precision,
	1	STABILITY STU	DY DATA	
Manufac	cturer of API	M/s Pharmagen Pvt. Address: Kot Nabi Pakistan	Limited., Bukhsh wala, 34-Km F	erozepur Road, Lahore
API Lot	No.	00243-08/160-2021		
	ion of pack er closure system)	30ml HDPE Bottle w (1's)	vith embossed board unit ca	arton UV coated.
Stability	storage condition	Real time: $30^{\circ}\text{C} \pm 2^{\circ}\text{C}$ Accelerated: $40^{\circ}\text{C} \pm$		
Time per	riod	Real time: 6 months Accelerated: 6 month	18	
Frequenc	су	Accelerated: 0, 2, 4, Real Time: 0, 3, 6 (N		
Batch No	0.	001	002	003
Batch siz	ze	2000 Bottles	2000 Bottles	2000 Bottles
Manufacturing Date 06-2021		06-2021	06-2021	06-2021
Date of i	nitiation	15-06-2021	15-06-2021	15-06-2021
No. of B	atches	03		
	DOCUME	NTS /DATA PROVIDI	ED BY THE APPLICAN	T
1.	Reference of previous with stability study data		The firm has not submitt	ted any document.

2.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	Firm has submitted copy of GMP certificate issued by Additional Director DRAP, Lahore dated 11-01-2019. The GMP certificate was granted based on inspection dated 08-01-2019.
3.	Documents for the procurement of API with approval from DRAP (in case of import).	Firm has submitted copy of delivery note dated 16-08-2021 specifying purchase of 25Kg Cefixime (micronised).
4.	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	The firm has submitted data of stability batches alongwith chromatograms, raw data sheets, COA, summary data sheets etc.
5.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing.	Not submitted.
6.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated).	The firm has submitted record of data logger for temperature and humidity monitoring of stability chambers (real time and accelerated).

## Remarks of Evaluator:

Sr.	Observations	Response by the firm
No.	C COLL THEORY AND	The point of the initial
1.	Copies of the Drug Substance Specifications and Analytical procedures used for routine testing of the drug substance / active Pharmaceutical Ingredient by both Drug Substance & Drug Product Manufacturer are required.	The firm has submitted copies of drug substance specifications and analytical procedures from both drug substance manufacturer and drug product manufacturer.
2.	Analytical method verification studies including specificity, accuracy and repeatability (method precision) performed by the Drug Product manufacturer for both compendial as well as non-compendial drug substance(s) shall be submitted.	Analytical method verification studies were submitted from drug product manufacturer by performing specificity, accuracy and precision studies.
3.	<ul> <li>The assay limit specified by drug substance manufacturer (95% to 102) is different from that specified by drug product manufacturer (95% to 103%). Justification is required.</li> <li>The submitted COA shows that the material used is of compacted nature. Justify the type of drug substance used in cefixime suspension since the same is used in Capsule dosage form.</li> </ul>	As per USP, the assay limit of cefixime trihydrate is 95% to 103%. The specification in CoA was incorrect and revised CoA as per USP is attached.  Mistakenly the CoA of Capsule was submitted. The material used in dry suspension is of micronized nature.  The relevant COA is attached.
4.	Provide COA of reference standard which is actually used in the analysis of drug substance	The firm has submitted USP reference standard with lot no. G01139.
5.	Submit master formulation including theoretical fill weight per bottle.	The firm has submitted qualitative and quantitative formula alongwith calculation of equivalency factor of cefixime trihydrate.
6.	<ul> <li>Details of applicant and reference product used in pharmaceutical equivalence are required.</li> <li>Submit data of compatibility studies of the drug product with recommended diluent in section 3.2.P.2.6.</li> </ul>	The firm has used cefiget 100mg/5ml dry suspension as comparator product. However, details of reference product including batch number, manufacturing date and expiry date were not provided.  Compatibility studies were conducted using purified water since the label recommends reconstituting this product with purified water.
7.	• The developed formulation is available in 30ml bottle, while the innovator product is available in 50ml, 75ml and 100ml bottle size only. Justify how your formulation will deliver equal	The submitted justification is not relevant to the point raised.

	1	1
	number of doses as delivered by the innovator product.	
	Justify why drug release studies / comparative dissolution studies were not performed to justify your formulation development process	As the cefixime suspension is formulated as per USP specifications, and USP does not define the test for dissolution of product, so the dissolution is not considered in specification of finished product. However, in the process of formulation development, comparative dissolution was performed in three different media following the parameters defined in FDA dissolution guidelines. Comparative study report is attached.
8.	• The test for deliverable volume is not added in specifications as recommended in USP monograph. Revise your specifications as per USP monograph along with submission of applicable fee.	The firm has included the test for deliverable volume after reconstitution and revised specifications of finished product are submitted.
	• Provide detailed method of analysis of the drug product in section 3.2.P.5.2 instead of providing copy of USP monograph.	Detailed method of analysis of the drug product is provided.
9.	• Provide standard and sample preparation methods used in analytical method verification studies.	Not submitted.
	<ul> <li>Justify method verification studies of drug without performance of specificity test. Specify the details of the accuracy and specificity test including the details of concentration of 80%, 100% and 120% solutions.</li> <li>Test method for Cefixime as trihydrate Tablet is provided in analytical method verification studies while applied formulation is cefixime as trihydrate suspension.</li> </ul>	The firm has submitted method verification of drug product by performing accuracy, precision and specificity parameters. <i>Details of concentrations of 80%, 100% and 120% were not provided.</i> Method verification report of drug product is attached.
	• The peak area of standard solution concentration in analytical method verification studies is approximately 6609294 while the peak area of the standard solution of same concentration in stability studies is 516942. Clarify the difference in peak areas.	The actual area is near about 516942. The area of approx. 6609294 is that of method verification of cefixime capsule. <i>Mistakenly the area of verification study of capsule was mixed with suspension</i> .
10.	Provide COA of reference standard actually used in the analysis of drug product.	USP reference standard of cefixime with lot no. G01139 has been submitted.
11.	In-use studies for drug products which are to be reconstituted before use, along with proposed in-use storage statement and in-use shelf-life shall be provided.	As defined in the labelling, the in-use stability was tested by keeping the reconstituted suspension at room temperature for 7 days and in refrigerator for 14 days.
12.	• USP monograph specifies that the retention time should be 10 minutes, while the retention time in your submitted results is less than 10 min. Justify how the method can be considered as per USP monograph.	USP defines that the flow rate should be adjusted that the retention time is about 10 min. Our retention is a few seconds less than 10 min which is in the acceptable range.
13.	Provide raw data sheets to justify the calculation of results for assay testing at each time point during the stability testing of each batch.	Not submitted
14.	Submit copy of commercial invoice for evidence of purchase of drug substance that have been used in the development of analysis of each batch of drug product.	The firm has submitted copy of delivery note from M/s pharmagen limited stating purchase of Cefixime micronized 25kg. <i>However, purchase invoice is not submitted</i> .

15.	Submit compliance Record of HPLC software	As our pharma is a new licensee, and we have
	21CFR & audit trail reports on product testing.	not come into production. Now we have HPLC
		(Shimadzu 10AT) which is not 21CFR
		compliance. However, we commit that we will
		soon perform the stability studies on a 21CFR
		compliance HPLC system.

**Decision: Deferred for submission of following:** 

- Performance of pharmaceutical equivalence and CDP studies with innovator/reference product i.e., Cefspan 100mg / 5ml Dry suspension.
- Details of reference product including batch number, manufacturing date and expiry date.
- Analytical method verification reports of drug product including standard and sample preparation methods used in each tested parameter.
- Provide raw data sheets to justify the calculation of results for assay testing at each time point during the stability testing of each batch.

Name, address of Applicant / Marketing Authorization Holder	M/s Alpenglow Pharmaceuticals Plot # A/7, Export Processing Zone Risalpur, District Nowshera (KP) Pakistan.
Name, address of Manufacturing site.	M/s Alpenglow Pharmaceuticals Plot # A/7, Export Processing Zone Risalpur, District Nowshera (KP) Pakistan.
Status of the applicant	<ul><li>☑ Manufacturer</li><li>☐ Importer</li><li>☐ Is involved in none of the above (contract giver)</li></ul>
Status of application	☐ New Drug Product (NDP)  ☐ Generic Drug Product (GDP)
Intended use of pharmaceutical product	<ul><li>☑ Domestic sale</li><li>☐ Export sale</li><li>☐ Domestic and Export sales</li></ul>
Dy. No. and date of submission	Dy. No. dated 24/02/2022
Details of fee submitted	PKR 30,000/-: dated 20/10/2021
The proposed proprietary name / brand name	Baccil Suspension 200 mg/5ml
Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each 5ml after reconstitution contains: Cefixime as trihydrate200 mg
Pharmaceutical form of applied drug	Dry Powder Granules for Oral Suspension
Pharmacotherapeutic Group of (API)	Antibacterials for systemic use, Third-generation cephalosporins.
Reference to Finished product specifications	USP
Proposed Pack size	1's
Proposed unit price	As per SRO
The status in reference regulatory authorities	SUPRAX ® (cefixime) for oral suspension, 200 mg/5 mL (USFDA Approved).
For generic drugs (me-too status)	Caricef Suspension 200mg/5ml 30ml
GMP status of the Finished product manufacturer	New license granted on 22-09-2020.
Name and address of API manufacturer.	M/s Pharmagen Pvt. Limited.,

			Address: Kot nabi Bukhsh Road, Lahore Pakistan Tel: 35751093	•
	Module-II (Quality Ov	verall Summary)	Firm has submitted QOS template. Summarized i	nformation related to general properties, form, manufacturers, ng process and controls, malytical procedures and ysis and justification of ndard, container closure
	Module III (Drug Sub	stance)	Official monograph of cefix in USP. The firm has nomenclature, structure, solubilities, physical description of manufacturi specifications, analytical verification, batch analys specification, reference sta system and stability studies	submitted details of general properties, form, manufacturers, ng process and controls, procedures and its its and justification of ndard, container closure
	Stability studies		Stability study conditions: Real time: 30°C ± 2°C / 65% Accelerated: 40°C ± 2°C months Batches: (120512013, 1205	$/$ 75% $\pm$ 5%RH for 6
	Module-III (Drug Prod	duct):	The firm has submitted of description of manufacturi impurities, specifications (including dissolution test medium) and its verification and justification of standard, container closur studies of drug product.	ng process and controls, , analytical procedure ing at acidic and buffer on studies, batch analysis pecification, reference
	Pharmaceutical equividissolution profile	alence and comparative	N/A.	
	Analytical method viproduct	alidation/verification of	Method verification stuincluding linearity, range specificity.	ndies have submitted e, accuracy, precision,
		STABILITY ST	UDY DATA	
Manufac	turer of API	M/S Pharmagen Pvt. L7	ſD	
API Lot		00243-08/160-2021		
Description of Pack (Container closure system) 30ml HDPE Bottle wit (1's).			n embossed board unit cartor	uV coated
Stability	Stability Storage condition Real time: $30^{\circ}C \pm 2^{\circ}C / Accelerated$ : $40^{\circ}C \pm 2^{\circ}C / Accelerated$			
Time Per	riod	Real time: 6 months Accelerated: 6 months		
Frequency Accelerated: 0, 2, 4, 6 (Real Time: 0, 3, 6 (Mor				
		Kear Time. 0, 3, 0 (Mor	iuns)	

Batch Si	Batch Size 2000 Bottles		2000 Bottles	2000 Bottles
Manufac	Manufacturing Date 06-2021		06-2021	06-2021
Date of 1	Initiation	15-06-2021	15-06-2021	15-06-2021
No. of B	atches		03	
	DOCUM	IENTS/DATA PROVII	DED BY THE APPLICAN	T
1.	Reference of previous with stability study dat	**	The firm has not submitted	l any document.
2.	2. Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.		Firm has submitted copy of by Additional Director DR 2019. The GMP certificatinspection dated 08-01-201	AP, Lahore dated 11-01- te was granted based on
3.	3. Documents for the procurement of API with approval from DRAP (in case of import).		Firm has submitted copy o 08-2021 specifying purcha (micronised).	
4.	attested respective documents like		The firm has submitted alongwith raw data sheet sheets etc.	
5.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing		Not submitted.	
6.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated).			monitoring of stability

## Remarks of Evaluator:

	1	
Sr.	Observations	Response by the firm
No.		
1.	Copies of the Drug Substance Specifications and	The firm has submitted copies of drug substance
	Analytical procedures used for routine testing of	specifications and analytical procedures from
	the drug substance / active Pharmaceutical	both drug substance manufacturer and drug
	Ingredient by both Drug Substance & Drug	product manufacturer.
	Product Manufacturer are required.	
2.	Analytical method verification studies including	Analytical method verification studies were
	specificity, accuracy and repeatability (method	submitted from drug product manufacturer by
	precision) performed by the Drug Product	performing specificity, accuracy and precision
	manufacturer for both compendial as well as non-	studies.
	compendial drug substance(s) shall be submitted.	
3.	• The assay limit specified by drug substance	As per USP, the assay limit of cefixime
	manufacturer (95% to 102) is different from	trihydrate is 95% to 103%. The specification in
	that specified by drug product manufacturer	CoA was incorrect and revised CoA as per USP
	(95% to 103%). Justification is required.	is attached.
	• The submitted COA shows that the material	Mistakenly the CoA of Capsule was submitted.
	used is of compacted nature. Justify the type of	The material used in dry suspension is of
	drug substance used in cefixime suspension	micronized nature.
	since the same is used in Capsule dosage form.	The relevant COA is attached.
4.	Provide COA of reference standard which is	The firm has submitted USP reference standard
	actually used in the analysis of drug substance	with lot no. G01139.
5.	Submit master formulation including theoretical	The firm has submitted qualitative and
	fill weight per bottle.	quantitative formula alongwith calculation of
		equivalency factor of cefixime trihydrate.
6.	• Details of applicant and reference product used	The firm has used cefiget 100mg/5ml dry
	in pharmaceutical equivalence are required.	suspension as reference product. However,
		details of reference product including batch

	• Submit data of compatibility studies of the drug product with recommended diluent in section 3.2.P.2.6.	number, manufacturing date and expiry date were not provided.  Compatibility studies were conducted using purified water since the label recommends reconstituting this product with purified water.
7.	• The developed formulation is available in 30ml bottle, while the innovator product is available in 50ml, 75ml and 100ml bottle size only. Justify how your formulation will deliver equal number of doses as delivered by the innovator product.	The submitted justification is not relevant to the point raised.
	• Justify why drug release studies / comparative dissolution studies were not performed to justify your formulation development process	As the cefixime suspension is formulated as per USP specifications, and USP does not define the test for dissolution of product, so the dissolution is not considered in specification of finished product. However, in the process of formulation development, comparative dissolution was performed in three different media following the parameters defined in FDA dissolution guidelines. Comparative study report is attached.
8.	• The test for deliverable volume is not added in specifications as recommended in USP monograph. Revise your specifications as per USP monograph along with submission of applicable fee.	The firm has included the test for deliverable volume after reconstitution and revised specifications of finished product are submitted.
	• Provide detailed method of analysis of the drug product in section 3.2.P.5.2 instead of providing copy of USP monograph.	Detailed method of analysis of the drug product is provided.
9.	• Provide standard and sample preparation methods used in analytical method verification studies.	Not submitted.
	• Justify method verification studies of drug without performance of specificity test. Specify the details of the accuracy and specificity test including the details of concentration of 80%, 100% and 120% solutions.	The firm has submitted method verification of drug product by performing accuracy, precision and specificity parameters. <i>Details of concentrations of 80%, 100% and 120% were not provided.</i>
	• Test method for Cefixime as trihydrate Tablet is provided in analytical method verification studies while applied formulation is cefixime as trihydrate suspension.	Method verification report of drug product is attached.
	• The peak area of standard solution concentration in analytical method verification studies is approximately 6609294 while the peak area of the standard solution of same concentration in stability studies is 516942. Clarify the difference in peak areas.	The actual area is near about 516942. The area of approx. 6609294 is that of method verification of cefixime capsule. <i>Mistakenly the area of verification study of capsule was mixed with suspension</i> .
10.	Provide COA of reference standard actually used in the analysis of drug product.	USP reference standard of cefixime with lot no. G01139 has been submitted.
11.	In-use studies for drug products which are to be reconstituted before use, along with proposed in-use storage statement and in-use shelf-life shall be provided.	As defined in the labelling, the in-use stability was tested by keeping the reconstituted suspension at room temperature for 7 days and in refrigerator for 14 days.
12.	• USP monograph specifies that the retention time should be 10 minutes, while the retention time in your submitted results is less than 10	USP defines that the flow rate should be adjusted that the retention time is about 10 min.

	min. Justify how the method can be considered	Our retention is a few seconds less than 10 min	
	as per USP monograph.	which is in the acceptable range.	
13.	Provide raw data sheets to justify the calculation	Not submitted	
	of results for assay testing at each time point		
	during the stability testing of each batch.		
14.	Submit copy of commercial invoice for evidence	The firm has submitted copy of delivery note	
	of purchase of drug substance that have been	from M/s pharmagen limited stating purchase of	
	used in the development of analysis of each batch	Cefixime micronized 25kg. <i>However, purchase</i>	
	of drug product.	invoice is not submitted.	
15.	Submit compliance Record of HPLC software	As our pharma is a new licensee, and we have	
	21CFR & audit trail reports on product testing.	not come into production. Now we have HPLC	
		(Shimadzu 10AT) which is not 21CFR	
		compliance. However, we commit that we will	
		soon perform the stability studies on a 21CFR	
		compliance HPLC system.	

**Decision: Deferred for submission of following:** 

- Performance of pharmaceutical equivalence and CDP studies with innovator/reference product i.e., Cefspan 200mg / 5ml Dry suspension.
- Details of reference product including batch number, manufacturing date and expiry date.
- Analytical method verification reports of drug product including standard and sample preparation methods used in each tested parameter.
- Provide raw data sheets to justify the calculation of results for assay testing at each time point during the stability testing of each batch.

## Case no. 06: Registration applications of locally manufacturing drugs (human) submitted on CTD format

#### a. New cases

243.	Name, address of Applicant / Marketing Authorization Holder	M/s Standpharm Pakistan (Pvt) Ltd, 20 Km, Ferozpur Road, Lahore
	Name, address of Manufacturing site.	M/s Standpharm Pakistan (Pvt) Ltd, 20 Km, Ferozpur Road, Lahore
	Status of the applicant	<ul> <li>✓ Manufacturer</li> <li>☐ Importer</li> <li>☐ Is involved in none of the above (contract giver)</li> </ul>
	Status of application	☐ New Drug Product (NDP) ☐ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	<ul><li>□ Domestic sale</li><li>□ Export sale</li><li>☑ Domestic and Export sales</li></ul>
	Dy. No. and date of submission	Dy. No. 20434: Dated 27-07-2021
	Details of fee submitted	PKR 20,000/-: Dated 21-09-2020
	GMP status of the Finished product manufacturer and manufacturing facility	M/s Standpharm Pakistan (Pvt) Ltd: The firm is granted GMP certificate based on inspection conducted on 18-02-2020. The firm has provided Dry powder Injection Cephalosporin.
	The proposed proprietary name / brand name	Neon 2g IV Injection

Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each vial contains: Ceftriaxone (as Sodium)2 g
Pharmaceutical form of applied drug	Sterilized white to yellowish orange powder contained in clear glass vial with rubber stopper having aluminum flip off seal on it.
Pharmacotherapeutic Group of (API)	Third generation cephalosporin
Reference to Finished product specifications	USP
Proposed Pack size	1x 1's Vial.
Proposed unit price	As per SRO
The status in reference regulatory authorities	Rocephin 2g powder for solution for Injection MHRA (UK) Approved.
For generic drugs (me-too status)	Oxidil 2g IV Injection by Healthtek for Sami Pharmaceuticals (Pvt) Ltd (Reg. No. 086609)
Name and address of API manufacturer.	M/s Zuhai United Laboratories Co., Ltd., No. 2428, Anji Road, Sanzao town, jinwan District, Zuhai, Guangdong – 519040, P.R. China.
Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product is submitted.
Module III (Drug Substance)	Official monograph of Ceftriaxone Sodium for Injection is present in USP. The firm has submitted details of nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance
Stability studies	Stability study conditions: Real time:30°C±2°C/65%±5%RH for 36 months Accelerated:40°C±2°C/75%±5%RH for 6 months Batches: 3051408011, 3051408012, 3051408013
Module-III (Drug Product):	The firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation, control of excipients, control of drug product. Specifications, analytical procedures, verification of analytical procedures, batch analysis, justification of

			specifications, reference container closure system	e standard or materials, m and stability.
	dissolution profile		equivalence for their programmer 2g IV Injection (Batch & Healthtek (Pvt) Ltd for (Pvt) Ltd Pakistan.  The results of all the test within the specification Firm has performed comparator's product well.  The reconstitution states.	results of pharmaceutical roduct against the Oxidil # 006E) manufactured by or Sami Pharmaceutical sts of both products falls s and are comparable. Imparative analysis with after reconstitution as audies also demonstrate with the comparator's
	Analytical method val product	idation/verification of	Method verification studing accuracy, repeatability, linearity a	
		STABILITY STUD	Y DATA	
Manufac	eturer of API		oratories Co., Ltd. No. 2 Zhuhai, Guangdong – 51	2428, Anji Road, Sanzao 19040, P.R. China.
API Lot	No.	3051903009		
	ion of Pack er closure system)	Vial containing powder for re-constitution with 2x10cc W.F.I, leaflet and unit carton.		
Stability	Storage Condition	Real time: $30^{\circ}\text{C} \pm 2^{\circ}\text{C} / 65\% \pm 5\%\text{RH}$ Accelerated: $40^{\circ}\text{C} \pm 2^{\circ}\text{C} / 75\% \pm 5\%\text{RH}$		
Time Per	riod	Real time: 6 months Accelerated: 6 months		
Frequenc	су	Accelerated: 0,1,2,3,4,6,8,12,16,20,24, 26 weeks Real Time: 0,1,2,3,4,6,8,12,16,20,24, 26 weeks		
Batch No	О.	TRLN-001	TRLN-002	TRLN-003
Batch Siz	ze	500 vials	500 vials	500 vials
Manufac	turing Date	07-2019	07-2019	07-2019
Date of I	nitiation	19-07-2019	22-07-2019	24-07-2019
No. of B	atches	03		
	DOCUMEN	TS / DATA PROVIDE	D BY THE APPLICAN	T
1.	Reference of previous apwith stability study data of		The firm has not submit	tted any document.
2.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.			copy of GMP certificate ed by CFDA China valid
3.	Documents for the procurement of API with approval from DRAP (in case of import).		CEF190522YZ date 7466/2019 DRAP date import of 20 Kg of Ce	* •
4.	Data of stability batches will be supported by attested respective documents like			romatograms, raw data

	chromatograms, Raw data sheets, COA, summary data sheets etc.	
5.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	The firm has submitted compliance record of HPLC software and audit trail reports on product testing.
6.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	

#### **Remarks of Evaluator:**

Sr. No.	Observations communicated	Response by the applicant
1.	Submit differential fee for the registration of applied product since the application was received in R&I section DRAP after 7 <sup>th</sup> May, 2021.	The firm has submitted differential fee of Rs. 10,000/- (deposit slip # 679037843) dated 18-03-2022.
2.	Copies of the Drug substance specifications and analytical procedures used for routine testing of the drug substance / active pharmaceutical ingredient by both drug substance & drug Product manufacturer.	The firm has submitted copies of drug substance specifications and analytical procedures by both drug substance and drug product manufacturer.
3.	Analytical method verification studies including specificity, accuracy and repeatability (method precision) performed by the Drug Product manufacturer for both compendial as well as non-compendial drug substance(s) shall be submitted. Further justify how the analysis of drug substance was performed without verification studies of analytical method of the drug substance.	The firm has submitted that as finished product contains ready to fill Ceftriaxone sodium, so analytical method verification studies performed for finished product is same for drug substance as well. The same method is applicable to raw material.
4.	Submit date of analysis of pharmaceutical equivalence alongwith chromatograms / spectra.	The firm has submitted relevant details alongwith chromatograms: Analysis date: 24-07-2019 Product: Oxidil Injection 2g IV (Batch#006E)
5.	Justify why pharmaceutical equivalence studies were not conducted against the innovator product.	The strength of 2 g Injection of Innovator Brand "Rocephin 2g IV Injection" by Roche Pharmaceuticals is not available in Pakistan. For this reason, we have selected Brand Leader i.e., Oxidil 2g IV Injection (Registration # 086609) by Sami Pharmaceuticals available in market.
6.	Reference of previous approval of applications with stability study data of the firm.	Not available. The firm replied that they have first time submitted CTD application.
7.	Submit batch manufacturing record of three batches for which stability study data is submitted.	The firm has submitted copies of batch manufacturing record of three batches.
8.	Data of stability batches supported by attested respective documents like chromatograms and raw data sheets of each time point.	The firm has submitted stability data supported by documents like chromatograms, raw data sheets, COA and summary data sheets.

#### **Decision: Approved.**

• Manufacturer will place first three production batches on long term stability studies throughout proposed shelf life and on accelerated studies for six months as per the commitment submitted in the registration application.

	ufacturer will perform process validation of first ergistration application.	st three batches as per the commitment submitted
244.	Name, address of Applicant / Marketing Authorization Holder	M/s Curexa Health (Pvt.) Ltd. Plot 517, Sundar Industrial Estate, Raiwind Road, Lahore
	Name, address of Manufacturing site.	M/s Curexa Health (Pvt.) Ltd. Plot 517, Sundar Industrial Estate, Raiwind Road, Lahore
	Status of the applicant	<ul> <li>✓ Manufacturer</li> <li>☐ Importer</li> <li>☐ Is involved in none of the above (contract giver)</li> </ul>
	Status of application	<ul><li>☑ New Drug Product (NDP)</li><li>☐ Generic Drug Product (GDP)</li></ul>
	Intended use of pharmaceutical product	<ul><li>□ Domestic sale</li><li>□ Export sale</li><li>☑ Domestic and Export sales</li></ul>
	GMP status of the Finished product manufacturer	The firm has been granted GMP certificate based on inspection conducted on 24-05-2019.
	Dy. No. and date of submission	Dy. No.17244: Dated 21-06-2021
	Details of fee submitted	PKR 75,000/-: Dated 03-06-2021
	The proposed proprietary name / brand name	Fortez 2g Injection IV
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each vail contains: Ceftazidime pentahydrate eq. to Ceftazidime2g (with Sodium carbonate)
	Pharmaceutical form of applied drug	Dry Powder for Injection
	Pharmacotherapeutic Group of (API)	Antibacterial for systemic use. Third-generation cephalosporin.
	Reference to Finished product specifications	USP
	Proposed Pack size	1's
	Proposed unit price	As per SRO
	The status in reference regulatory authorities	Fortaz Injection 2g by M/s Teligent Pharma, Inc. Buena, NJ 08310 (USFDA Approved)
	For generic drugs (me-too status)	Not confirmed.
	Name and address of API manufacturer.	M/s Qilu Antibiotics Pharmaceutical Co., Ltd. No.849 Dongjia Town, Licheng District, Jinan, Shandong Province, China
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product is submitted.
	Module III (Drug Substance)	Official monograph of Ceftazidime is present in USP. The firm has submitted details of nomenclature, structure, general properties,

			solubilities, physical description of manufactur tests for impurities, sprocedures and its verific justification of specificate container closure system drug substance	pecifications, analytical ation, batch analysis and tion, reference standard,
	Stability studies		Stability study conditions Real time: 30°C ± 2°C/659 Accelerated: 40°C ± 2°C months Batches: (40670FJ81J-I 40672FJ81J-D)	6 ± 5% RH for 24 months C/75% ± 5% RH for 6
	Module-III (Drug Pro	oduct):	The firm has submitted decomposition of the drug development, manufacture protocol, description of mecontrols, specifications, a its verification studies justification of specificate container closure system drug product.	product, pharmaceutical ire, process validation anufacturing process and analytical procedure and , batch analysis and tion, reference standard,
	Pharmaceutical equivalence		The firm has sub- equivalence data of appli RD-CH-20009 with ref Injection 2g (IV), batch # Pharma, Inc. USA by perf as appearance, fill weigh particulate matter and assi	FZL001 of M/s Teligent forming quality tests such at, pH, Loss on drying,
	Analytical method validation/verification of product		Method verification studies have been submitted including linearity, range, accuracy, precision, specificity.	
		STABILITY STU	JDY DATA	
Manufac	turer of API	M/s Qilu Antibiotics Pharmaceutical Co., Ltd., No.849 Dongjia Town, Licheng District, Jinan, Shandong Province, China.		
API Lot	No.	0078BJ81JD		
	ion of Pack er closure system)	1's (Blister of 1 glass vial 15ml & 1 WFI 10mL, LDPE ampoule), securely packed in carton.		
Stability Storage Condition		Real time: $30^{\circ}\text{C} \pm 2^{\circ}\text{C} / 65\% \pm 5\%\text{RH}$ Accelerated: $40^{\circ}\text{C} \pm 2^{\circ}\text{C} / 75\% \pm 5\%\text{RH}$		
Time Period		Real time: 24 months Accelerated: 6 months		
		Accelerated: 0, 3, 6 (Mo Real Time: 0, 3, 6, 9, 12		
Batch No.		RD-CH-20009	RD-CH-20010	RD-CH-20011
Batch Si	ze	128 Vials	128 Vials	128 Vials
Manufac	cturing Date	09-2020	09-2020	09-2020
Date of l	Initiation	27-10-2020	27-10-2020	27-10-2020
No. of B	atches		03	
	DOCUMENT	S / DATA PROVIDED A	LONGWIH STABILITY	DATA

1.	Reference of previous approval of applications with stability study data of the firm (if any)	The firm has not submitted any document.
2.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.	
3.	Documents for the procurement of API with approval from DRAP (in case of import).	The firm has submitted copy of commercial Invoice No. JTRF20067 MQ dated June 23, 2020 for the import of Ceftazidime pentahydrate (110Kg) attested by AD (I & E) DRAP, Lahore dated 13-07-2020.
4.	4. Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.	
5.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing	The firm has submitted compliance record of HPLC software 21 CFR and audit trail reports on product testing.
6.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	
Sr. No.	Observations communicated	Response by the firm
1.	Analytical procedures for determination of pH, loss on drying, sodium carbonate contents are different from USP method.	The firm has submitted analytical procedures for determination of pH, loss on drying, sodium carbonate contents as per USP.
2.	Provide evidence of atomic absorption spectrophotometer for determination of sodium carbonate content.	The firm submitted evidence of atomic absorption spectrophotometer, mode: 240AA from drug substance manufacturer.
3.	Justification of using Type III clear glass vial 15 ml selected as a primary packaging for Fortez 2g injection.	Type III containers can be used for powders for parenteral use, where suitable stability test data indicate that Type III glass is satisfactory. Refer to USP <660> containers – Glass.
4.	Details of batch numbers of reference product and test formulation used for Pharmaceutical equivalence are required.	The firm has submitted pharmaceutical equivalence data of applied formulation, batch # RD-CH-20009 with reference product Fortaz Injection 2g (IV), batch # FZL001 of M/s Teligent Pharma, Inc. USA by performing quality tests such as appearance, fill weight, pH, Loss on drying, particulate matter and assay.
6.	Compatibility studies for the dry powder for injections shall be performed as per the instructions provided in individual label of the drug product.	The diluent used is sterile water for injection for which compatibility study is performed alongwith in-use stability study.
	Justification/clarification is required regarding	The claim of Fortez 2g is ceftazidime 2.00g and

2595.0 mg in batch formula.

moiety (i.e., pentahydrate with sodium carbonate). The ceftazidime (as pentahydrate with sodium carbonate) used in Fortez 2 g trials was having

7.	-Scientific justification /rational for not performing the test of sodium carbonate content and reporting it from manufacturer's certificate of analysis.	potency of 77.07%. The fill weight calculation is based on this potency to make it 100%.  The role of sodium carbonate is only at the time of reconstitution and is present in stoichiometric ratio required to solubilize ceftazidime.  The firm has performed identification of sodium carbonate through chemical test. For content of sodium carbonate, the firm has relied on CoA of drug substance manufacturer.
8.	Justify the weights taken for ceftazidime in different sets of accuracy parameter in analytical method validation studies. Moreover, basis for setting 100% theoretical contents are required to be clarified.	Accuracy is established across the specified range of the analytical procedure and is determined by using a minimum of 9 determinations covering the specified range for the procedure.  Accuracy in drug product is determined by: a) Variable volume of standard stock solution of ceftazidime (1mg/ml) is added to placebo to obtain the desired concentrations of 60%, 100% & 140%. b) Concentration of ceftazidime (0.1 mg/ml) used in assay is set for evaluation during method validation.
9.	Reference of previous approval of applications with stability study data of the firm (if any).	The firm has not submitted any document.

#### **Decision: Approved.**

- Manufacturer will place first three production batches on long term stability studies throughout proposed shelf life and on accelerated studies for six months as per the commitment submitted in the registration application.
- Manufacturer will perform process validation of first three batches as per the commitment submitted in the registration application.

# ${\bf Case\ No.07:\ Registration\ applications\ of\ local\ manufacturing\ of\ human\ drugs\ submitted\ on\ CTD\ format$

#### a. Deferred Cases

245.	Name, address of Applicant / Marketing Authorization Holder	M/s Kaizen Pharmaceuticals (Pvt.) Ltd., E-127-129, North Western Industrial Zone, Bin Qasim, Karachi-75020, Pakistan.
	Name, address of Manufacturing site.	M/s Kaizen Pharmaceuticals (Pvt.) Ltd., E-127-129, North Western Industrial Zone, Bin Qasim, Karachi-75020, Pakistan.
	Status of the applicant	<ul> <li>☑ Manufacturer</li> <li>☐ Importer</li> <li>☐ Is involved in none of the above (contract giver)</li> </ul>
	Status of application	<ul><li>□ New Drug Product (NDP)</li><li>☑ Generic Drug Product (GDP)</li></ul>
	Intended use of pharmaceutical product	<ul><li>☑ Domestic sale</li><li>☐ Export sale</li><li>☐ Domestic and Export sales</li></ul>
	Dy. No. and date of submission	Dy. No. 16356 Dated 14-06-2021
	Details of fee submitted	PKR 20,000/-: Dated 17-11-2020

GMP status of the Finished product manufacturer	GMP inspection report dated 11-08-2020 concluded that overall GMP compliance of the firm with respect to building, facilities and procedures demonstrated was satisfactory at the time of inspection.
The proposed proprietary name / brand name	Rebamide 100mg tablet
Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each film coated tablet contains Rebamipide100mg
Pharmaceutical form of applied drug	White round biconvex tablet coated plain on both sides.
Pharmacotherapeutic Group of (API)	Gastro-protective drug
Reference to Finished product specifications	JP specifications
Proposed Pack size	10's, 20's, 30's
Proposed unit price	As per SRO
The status in reference regulatory authorities	Mucosta Tablets 100mg of M/s Otsuka Pharmaceutical Co., Ltd (PMDA approved)
For generic drugs (me-too status)	Mucosta 100mg tablet by Otsuka (Reg # 078129)
Name and address of API manufacturer.	M/s Jiangxi synergy pharmaceutical, Co., Ltd Jiangxi fengxin Industrial part, fengxin, Jiangxi province, P.R. China
Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product is submitted.
Module III (Drug Substance)	Official monograph of Rebamipide is present in JP. The firm has submitted details of nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance
Stability studies	Stability study conditions: Real time: $30^{\circ}\text{C} \pm 2^{\circ}\text{C} / 65\% \pm 5\%\text{RH}$ for 60 months Accelerated: $40^{\circ}\text{C} \pm 2^{\circ}\text{C} / 75\% \pm 5\%\text{RH}$ for 6 months Batches: (20100704, 20100705, 20100706)
Module-III (Drug Product):	The firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols and report, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.

	Pharmaceutical equivalence and comparative dissolution profile		against innovator pro- (batch # 7B79MT3) by Ltd by performing appearance, thickness Dissolution, Assay). CDP has been perfor Tablet by otsuka Pharn HCl) & Phosphate Bu	duct Mucosta 100mg tablet Otsuka Pharmaceutical Co., quality tests (Physical Apart of the Apart
	Analytical method valida product	ntion/verification of	Method verification	studies have submitted uracy, precision, LOD, LOQ)
		STABILITY ST	TUDY DATA	
Manufactu	urer of API		y pharmaceutical, Co., I lustrial part, fengxin, Jia	.td, ngxi province, P.R.China
API Lot N	0.	05-20170201C		
Descriptio (Container	n of Pack closure system)	Alu / PVC Blister p	pack (10's, 20's, 30's)	
Stability S	torage Condition	Real time: 30°C ± 2 Accelerated: 40°C =	2°C / 65% ± 5%RH ± 2°C / 75% ± 5%RH	
Time Perio	od	Real time: 24 mont Accelerated: 6 mon		
Frequency	,	Accelerated: 0, 3, 6 (Months) Real Time: 0, 3, 6, 9, 12, 18, 24 (Months)		
Batch No.		TF-01	TF-02	TF-03
Batch Size		700 Tablets	700 Tablets	700 Tablets
Manufactu	ring Date	01-2018	11-2018	11-2018
Date of In	itiation	07-02-2018	07-12-2018	09-12-2018
No. of Bat	ches	03		
	DOCUMEN'	TS / DATA PROVI	DED BY THE APPLI	CANT
1.	Reference of previous approval of applications with stability study data of the firm (if any)		inspection report of Ro	19. The report confirms that: R part II compliant.
2.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.		20160125 issued by Jia 15-02-2021. The firm has submitted	ed copy of DML No. GAN angxi province FDA valid till copy of GMP certificate (No. angxi CCD valid till 23-07-
3.	Documents for the procurement of API with approval from DRAP (in case of import).		The firm has submitted	d copy of Form 6 license no. I & E) DRAP, dated 12-10-e is not attested.
4.			along with chromatog	rams, raw data sheets, COA

5.	21CFR & audit trail reports on product	The firm has submitted compliance Record of HPLC software 21CFR & Audit trail on testing reports of
6.	Record of Digital data logger for temperature	product submitted.  Firm has submitted record of data logger for
		temperature and humidity monitoring of real time and accelerated stability chambers.
Remai	ks of Evaluator:	
Sr. No.	Observations communicated	Response by the firm
1.	Copies of the Drug substance specifications and analytical procedures used for routine testing of the drug substance / active pharmaceutical ingredient by both drug substance & drug Product manufacturer.	The firm has submitted copies of drug substance specifications and analytical procedures from both drug substance manufacturer and drug product manufacturer.
2.	Analytical method verification reports of parameters like specificity, accuracy and repeatability (method precision) performed by the Drug Product manufacturer for both compendial as well as non-compendial drug substance(s) shall be submitted.	The firm has submitted analytical method verification report of Rebamipide by titration method.
3.	COA of primary / secondary reference standard including source and lot number shall be provided.	The firm has submitted copy of CoA of working standard of Rebamipide (lot # 201639).
4.	List of all components of the dosage form, and their amount on a per unit basis, the function of the components, and a reference to their quality standards (e.g. compendial monographs or manufacturer's specifications) shall be submitted.	The firm has submitted qualitative and quantitative composition alongwith function of components and reference to their quality standards.
5.	Details of batch numbers of reference product and test formulation used for Pharmaceutical equivalence are required.	Details of pack of innovator product Mucosta Tablet 100mg (Batch # 7B79MT3) of M/s Otsuka pharmaceutical Co., Ltd have been submitted.
6.	The results of analytical method verification studies need to be summarized in tabulated form for each parameter since only chromatograms are presented for each parameter.	The firm has provided summarized tabulated results for linearity, accuracy, precision and specificity.
7.	The copies of complete analysis of at least two batches shall be provided.	Batch analysis of two batches of Rebamipide tablet 100mg were provided.
8.	Those impurities that are degradation product shall be included in the specifications.	Details of related substances were included in finished product specifications.
9.	Justification of specification of non- pharmacopeial product shall be based on batch analysis results.	Since the monograph of Rebamipide Tablet 100mg is available in Japanese pharmacopoeia. Therefore, no justification of specifications is required.
10.	Description of the primary container closure systems shall be submitted.	The firm has provided specifications of PVC film clear transparent and Aluminium Foil Blister.
11.	The results of stability data of B. No.: 002 (TF-02) are lying borderline limit of 95% at 18 months. Result of 24-month stability time point is not submitted.	The firm has submitted 6-month accelerated and 24-month real time stability study data of applied product. The assay result of 24-month time point is 95.09% for B. No. 002 which is lying at borderline limit of 95% -105%.
12.	Submitted chromatograms do not reflect the UV detector wavelength at which analysis has been conducted.	Details of UVProbe software containing wavelength of 326 nm have been provided.
13.	The submitted copy of DML is expired and submitted copy of GMP certificate is not	The firm has submitted copy of GMP certificate of M/s Jiangxi Synergy Pharmaceutical Co., Ltd, china

	issued by concerned regulatory authority of country of origin.	issued by Jiangxi Food and Drug Administration. The certificate is valid till 23-07-2022.
14.	Documents for the procurement of API with	The firm has submitted copy of invoice for the import of Rebamipide JP17 (260g) dated 18-07-2017 received through DHL courier. The invoice is not cleared by AD (I&E) of field office.

**Previous Decision:** Deferred for submission of any document confirming that material (Rebamipide (260g)) has been imported and cleared by Custom authorities against the submitted invoice.

**Evaluation by PEC:** The firm has submitted copies of Form-6 and invoice for the purchase of Rebamipide JP (Quantity: 260mg, invoice no. JXSS170718) from M/s Jiangxi Fengxin pharmaceutical Co. Ltd., China attested by Assistant Director (I&E) DRAP, Karachi dated 17-10-2017.

Decision: Registration Board decided to defer the case and referred both invoices to DRAP Karachi for verification from record since 1<sup>st</sup> submitted invoice was without attestation/clearance from DRAP Karachi.

Karachi	•	
246.	Name, address of Applicant / Marketing Authorization Holder	M/s Sami Pharmaceuticals (Pvt.) Ltd., F-95, off hub River Road, S.I.T.E, Karachi.
	Name, address of Manufacturing site.	M/s Sami Pharmaceuticals (Pvt.) Ltd., F-95, off hub River Road, S.I.T.E, Karachi.
	Status of the applicant	<ul><li>☑ Manufacturer</li><li>☐ Importer</li><li>☐ Is involved in none of the above (contract giver)</li></ul>
	Status of application	<ul><li>☑ New Drug Product (NDP)</li><li>☐ Generic Drug Product (GDP)</li></ul>
	Intended use of pharmaceutical product	<ul> <li>□ Domestic sale</li> <li>□ Export sale</li> <li>☑ Domestic and Export sales</li> </ul>
	GMP status of the firm	The firm is granted GMP certificate based on inspection conducted on 28-08-2019.
	Dy. No. and date of submission	Dy. No. 20437 dated 27-07-2021
	Details of fee submitted	PKR 50,000/-: dated 08-04-2021
	The proposed proprietary name / brand name	BALOXA 20MG TABLET
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each film coated tablet contains: Baloxavir Marboxil20mg
	Pharmaceutical form of applied drug	White to off-white colored, oval shaped film coated tablets, plain on one side and break line on other side.
	Pharmacotherapeutic Group of (API)	Antiviral (WHO ATC code: J05AX25)
	Reference to Finished product specifications	Innovator's Specifications
	Proposed Pack size	10's
	Proposed unit price	As per SRO
	The status in reference regulatory authorities	XOFLUZA TM (Baloxavir marboxil) Tablets 20mg of M/s Genetech USA, Inc (USFDA approved)
	For generic drugs (me-too status)	Not applicable
	Name and address of API manufacturer.	M/s Fujian Jinshan Zhundian Pharmaceutical Co. Ltd, Address: Jintang Industry Zone, Shaowu City, Fujian Province, China.

	Module-II (Quality Overall Summary)  Module III (Drug Substance)		template. Summarized nomenclature, structure, g physical form, mand impurities, specifications, validation, batch anal specification, reference system and stability studi	OS as per WHO QOS-PD information related to general properties, solubilities, ufacturers, characterization, analytical procedures and its lysis and justification of standard, container closure es of drug substance and drug
			structure, general propert manufacturers, description and controls, tests for impland total impurity, specifiand its verification, batcl	ed details of nomenclature, ties, solubility, physical form, on of manufacturing process urity A, B, individual impurity ications, analytical procedures h analysis and justification of standard, container closure es of drug substance.
	Stability studies			5% ± 5%RH for 24 months 75% ± 5%RH for 6 months
	Module-III (Drug Product):		its description, co development, manufactur process control, process v excipients, control of analytical procedures, procedures, batch	analysis, justification of tandard or materials, container
	Pharmaceutical comparative dissolut	equivalence and ion profile	be performed due to the products, justification reg	ice and CDP studies could not e unavailability of innovator arding the comparative studies rement have been submitted.
	Analytical validation/verification	method on of product	Method validation stu- including precision, accur	dies have been submitted racy and specificity studies.
	TY STUDY DATA	M/ F " Y 1	771 1' 51	Q 1.1
Manufactu	irer of API		Zhundian Pharmaceutical ( dustry Zone, Shaowu City,	
API Lot N	О.	200101	•	
Description of Pack (Container closure system)		Alu-Alu blister packed in unit carton (1×10's)		
Stability Storage Condition		Real time: $30^{\circ}\text{C} \pm 2^{\circ}\text{C} / 65\% \pm 5\%\text{RH}$ Accelerated: $40^{\circ}\text{C} \pm 2^{\circ}\text{C} / 75\% \pm 5\%\text{RH}$		
Time Perio	od	Real time: 6 months Accelerated: 6 months		
Frequency	Frequency Accelerated: 0, Real Time: 0, 3			
BALOXA	20MG TABLET			
Batch No.		Lab-01	Lab-02	Lab-03
Batch Size	:	1000 Tablets	1000 Tablets	1000 Tablets

Manufacturing Date		07-2020	07-2020	07-2020
Date of Initiation		21-08-2020	21-08-2020	21-08-2020
No. of Ba	ntches	03		
DOCUMENTS / DATA PROVIDED BY THE AP		PLICANT		
1. Reference of previous approval of applications with stability study data of the firm (if any)		The firm has submitted inspection for instant dosa two years i.e. EMPOLI (Tablets which was prese registration board & her registration board Date of The inspection report confidence of the Audit trail on the testing Adequate monitoring a stability chamber. Chamonitored through soft alerts as well.	Empagliflozin) 10mg & 25mg ented in 290th meeting of the ace approved & registered by of inspection: 13th June 2019. Compliant.  In greports is available.  In ambers are controlled and ware having alarm system for	
2.	Approval of API/ DI of API manufacturer regulatory authority of	issued by concerned	Food and Drug Admir 22/02/2021.	e No. FJ20160009 issued by histration of china valid till ment website no more GMP ed after December 2019.
3.	3. Documents for the procurement of API with approval from DRAP (in case of import).		(Invoice# WIS200028 M quantity i.e. 300 g) for Marboxil by M/s	copy of commercial invoice MAR 18, 2020 with received rethe purchase of Baloxavir Fujian Jinsahn Zhundian attested by DRAP dated 25-03-
4.	supported by at	tested respective romatograms, Raw		iplete record of testing of all omatograms, raw data sheets, wheets.
5.			The Firm has submitted testing of HPLC for all te	audit trail record of product st intervals.
6. Record of Digital data logger temperature and humidity monitoring stability chambers (real time accelerated).		nidity monitoring of	temperature and humic	lity monitoring of stability
Remarks of Evaluator:			12	
I	Observations communic		Response by the firm	
a	Submit differential fee for the registration of applied product since the applied product since the application was received in R&I section of DRAP after 7 <sup>th</sup> May 2021.		t 25000/- has been subm	it slip # 772863043 of Rs. itted.
till E	The reference product I he structure and absolu Baloxavir marboxil is crystal x-ray determin COA from drug substantot contain this test.	te stereochemistry of verified by single ation. The submitted	f Baloxavir Marboxil is v determination is mention form, i.e: form I. Revise	bsolute stereochemistry of verified by single crystal x-ray oned on COA as polymorphic ed COA and XPRD Spectra is ence.

3.	Give a detailed account on polymorphic form of drug substance used in drug product development since several polymorphic forms of drug substance are possible as per reference literature.	Description of polymorphic form of material is defined in DMF (3.2.S.3.1.9 summary) as material is polymorphic form I.
4.	Elaborate the test of "Microbial limit Test" mentioned in certificate of analysis of Baloxavir Marboxil.	Microbial examination of non-sterile products is performed as per following USP method given in the texts on Microbial Enumeration Test <61>, Tests for Specified Microorganisms <62> and Microbiological examination of non-sterile products (acceptance criteria for pharmaceutical preparations and substances for pharmaceutical use) <1111>.  As per pharmacopeia the acceptance criteria for non-sterile pharmaceutical products based on the total aerobic microbial count (TAMC), total yeast and molds count (TYMC) and objectionable microorganisms which must be absent and these are called as Microbial Limit Tests.  We followed the same practice and set restricted microbiological limits as per SAMI's Specs, that is TAMC: NMT 100 cfu/g, TYMC: NMT 10 cfu/g as well as absence of pathogenic organisms including E. Coli, Salmonella, S. Aureus in our raw material.
5.	The submitted acceptance criteria for release and shelf life specifications are same. Scientific justification is required for adopting such acceptance criteria.	We develop the product specifications according to the general monograph of USP and from the chemistry reviews of USFDA, EMA. In addition, ICH Q6A states that the acceptance criteria are the same from release throughout shelf life of product. Therefore, we have also set the same specification limits for release and shelf life.
6.	The submitted process validation protocol does not describe the critical process steps and controls in defined ranges.	Existing protocol captures the required information and describes critical process parameters along with process controls. However, to make this more elaborative, we have revised these sections and version 2 of protocol is attached.
7.	Since the strategy for product development is planned according to identified QTPP which is based on evaluation of the innovator/reference product therefore, justify the authenticity of product development studies for applied formulation without comparison with innovator/reference product.	The innovator of Baloxavir Marboxil Tablet i.e. XOFLUZA 40mg & 20mg Tablets, already published a detailed characterization of API ( <i>Baloxavir Marboxil</i> ) in FDA chemistry review as well product assessment report of European Medicine Agency ( <i>EMA</i> ). This part of QTPP was derived from FDA chemistry review & EMA assessment report.  Appearance of API, its solubility, pKa, partition coefficient, stereoisomerism and polymorphic form etc. were mentioned in detail by the innovator, therefore, all these required details are gathered from literature data.  As the reference finished product is presented as immediate-release film-coated tablets for oral administration containing 20mg or 40mg of Baloxavir Marboxil as the active substance, therefore, we have designed our product same as reference product to ensure pharmaceutical equivalency.

Product dissolution parameters and other related specification are already disclosed by the manufacturer of the reference product. Due to poor solubility of API, to ensure reproducible dissolution results, we have selected micronized grade of API for development of our product as suggested by the reference brand in FDA chemistry review. Due to unavailability of innovator samples, the dissolution profile in different pH mediums i.e., pH 1.2. 4.5 and 6.8 buffers as recommended in WHO for CDP is checked and the release profile found similar to that of innovator product "Xofluza Tablet" in FDA chemistry review publicly available. Information related to product packaging, storage and labeling were also gathered from the above mentioned product assessment reports i.e. FDA chemistry review as well product assessment report of European Medicine Agency.

**Previous Decision:** Registration Board decided to defer the case for submission of pharmaceutical equivalence and CDP studies with innovator / reference product (M-316).

#### **Evaluation by PEC:**

The firm has submitted following:

- I. As per DRAP decision of 286'h meeting held during 14-16'h November, 2018 and reference letter No. F.G-2/2019-QA dated 25th February 2019 "No Objection Certificate for import of finished products for performing comparative dissolution profile" was taken for import of the innovator samples- (Annex-A)
- II. On obtaining required NOC, we did contact several global on-line pharmacies, as stated on sheet attached-(Annex-8), for providing number of packs required for conducting CDP; since XOFLUZA is a prescription drug and not allowed to be dispensed without the prescription of a Regd.Medical Practitioner, no pharmacy was willing to supply
- Ill. A comparison in tabular form, of dissolution profile of our drugs against the innovator's products, as disclosed by the manufacturer himself in FDA Chemistry Review ,is attached here-with -(Annex-C); it shows that Dissolution Profile Pattern of our drugs correspond to those of the innovator's products

IV. For ensuring safety and quality, regulatory authorities viz. FDA, EMA, MHRA, TGA, PMD etc. publish the following data of every drug approved by them:


- Product Development Data
- Parameters of tests conducted including Dissolution
- Occasionally, complete CDP Data of Innovator's product is published as well;in case of XOFLUZA (Ba/oxavir) 20mg Tablet, complete CDP data has been stated in FDA Chemistry Review Application No. 2108540rig1s000 of Shionogi-(Annex-D).

Dissolution Method and Acceptance Criterion: The proposed dissolution method and the revised acceptance criterion for batch release and stability testing, shown in the table below, are acceptable.

USP	Speed	Madimm	Acceptance
Apparatus	(RPM)		Criterion
II (Paddle)		0.07% w/v (for the 20 mg) or 0.16% w/v (for the 40 mg) CTAB* in phosphate buffer, pH 6.8, 900 mL/37°C	NLT 60 % (Q) at 30 minutes


<sup>\*</sup> CTAB = cetyltrimethylammonium bromide

Figure 10: Comparative Dissolution Profiles with Surfactant (0.07% CTAB) For One Unit-Tablet of 20 mg Vs. One Unit Tablet of 40 mg



Notes:  $f_2 = 65$ , 62, and 62 in 0.1 N HCl, at buffer pH 4.5 and 6.8, respectively.

Figure 11: Comparative Dissolution Profiles Without Surfactant for Two Unit Tablets of 20 mg
Vs. One Unit Tablet of 40 mg



Notes:  $f_2 = 99$ , 75, and 68 in 0.1 N HCl, at buffer pH 4.5 and 6.8, respectively; Use of 2 units of 20 mg tablet is to correct different sink conditions due to limit solubility of baloxavir marboxil.

- V. The innovators are legally bound to disclose detail of the excipients used which help a Generic Manufacturer in using appropriate APIs; sometimes quantities of the excipients used are disclosed as well which provide an additional benefit to the Generic Manufacturer to closely match quality of its drug against the Innovator.
- VI. FDA Chemistry Review and EMA Assessment Report both state the following parameters for selecting an appropriate API.

- Appearance of API
- Solubility pKA
- Partition Coefficient
- Stereoisomerism
- Polymorphic Form

Decision: Deferred for further deliberations regarding cases wherein innovator products could not be procured for CDP studies, however, FDA chemistry review publicly reveals comparative dissolution

	M/s Sami Pharmaceuticals (Pvt.) Ltd., F-95, off hub River Road, S.I.T.E, Karachi.
	M/s Sami Pharmaceuticals (Pvt.) Ltd., F-95, off hub River Road, S.I.T.E, Karachi.
	<ul><li>✓ Manufacturer</li><li>☐ Importer</li><li>☐ Is involved in none of the above (contract giver)</li></ul>
	<ul><li>☑ New Drug Product (NDP)</li><li>☐ Generic Drug Product (GDP)</li></ul>
	<ul><li>□ Domestic sale</li><li>□ Export sale</li><li>☑ Domestic and Export sales</li></ul>
	The firm is granted GMP certificate based on inspection conducted on 28-08-2019.
Dy. No. and date of submission	Dy. No. dated 27-07-2021
Details of fee submitted	PKR 50,000/-: dated 08-04-2021
The proposed proprietary name / brand name	BALOXA 40MG TABLET
Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each film coated tablet contains: Baloxavir Marboxil40mg
	White to off-white colored, oval shaped film coated tablets, plain on one side and break line on other side.
Pharmacotherapeutic Group of (API)	Antiviral (WHO ATC code: J05AX25)
Reference to Finished product specifications	Innovator's Specifications
Proposed Pack size	10's
Proposed unit price	As per SRO
•	XOFLUZA <sup>TM</sup> (baloxavir marboxil) Tablets 40mg of M/s Genetech USA, Inc (USFDA approved)
For generic drugs (me-too status)	Not applicable
	M/s Fujian Jinshan Zhundian Pharmaceutical Co. Ltd, Address: Jintang Industry Zone, Shaowu City, Fujian Province, China
	Firm has submitted QOS as per WHO QOS-PD template. Summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities,

			procedures and its validation, astification of specification, ntainer closure system and substance and drug product is	
Module III (Drug Su	bstance)	general properties, s manufacturers, description and controls, tests for substances (impurity A & analytical procedures and and justification of spe	ails of nomenclature, structure, solubility, physical form, on of manufacturing process impurity D, G & related & unspecified), specifications, its verification, batch analysis cification, working standard, and stability studies of drug	
Stability studies			5% ± 5%RH for 24 months 75% ± 5%RH for 6 months	
Module-III (Drug Pr	Module-III (Drug Product):		The firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.	
Pharmaceutical comparative dissolut	equivalence and ion profile	Pharmaceutical equivalence and CDP studies could not be performed due to the unavailability of innovator products, justification regarding the comparative studies and innovator pack procurement have been submitted.		
Analytical validation/verification	method on of product	Method validation studies have been submitted including Linearity, accuracy, precision, robustness and specificity studies.		
STABILITY STUDY DATA				
Manufacturer of API	_	Zhundian Pharmaceutical dustry Zone, Shaowu City,		
API Lot No.	200101			
Description of Pack (Container closure system)	Alu-Alu blister packed in unit carton (10's)			
Stability Storage Condition	Real time: $30^{\circ}\text{C} \pm 2^{\circ}\text{C} / 65\% \pm 5\%\text{RH}$ Accelerated: $40^{\circ}\text{C} \pm 2^{\circ}\text{C} / 75\% \pm 5\%\text{RH}$			
Time Period	Real time: 6 months	Accelera	ated: 6 months	
Frequency	Accelerated: 0, 3, 6	(Months) Real Tir	me: 0, 3, 6 (Months)	
BALOXA 40MG TABLET				
Batch No.	Lab-01	Lab-02	Lab-03	
Batch Size	1000 Tablets	1000 Tablets	1000 Tablets	
Manufacturing Date	10-2020	10-2020	10-2020	
Date of Initiation	15-10-2020	15-10-2020	15-10-2020	
No. of Batches	03			

DOCUM	MENTS / DATA PROVIDED BY THE AP	PLICANT
1.		The firm has submitted reference of last onsite panel inspection for instant dosage form conducted during last two years i.e. EMPOLI (Empagliflozin) 10mg & 25mg Tablets which was presented in 290th meeting of the registration board & hence approved & registered by registration board Date of inspection: 13th June 2019. The inspection report confirms following points The HPLC software is 21CFR Compliant.  • Audit trail on the testing reports is available.  • Adequate monitoring and control are available for stability chamber. Chambers are controlled and monitored through software having alarm system for alerts as well.
2.		The firm has submitted copy of GMP certificate No. FJ20160009 issued by Food and Drug Administration of china valid till 22-02-2021.  As per Chinese Government website no more GMP certificates are being issued after December 2019.
3.	Documents for the procurement of API with approval from DRAP (in case of import).	The firm has submitted copy of commercial invoice (Invoice# WIS200028 MAR 18, 2020 with received quantity i.e. 300 g) for the purchase of Baloxavir Marboxil by M/s Fujian Jinsahn Zhundian Pharmaceutical Co., Ltd attested by Assistant Director (I & E) DRAP, dated 25-03-2020.
4.		Firm has submitted complete record of testing of all batches along with chromatograms, raw data sheets, COA and summary data sheets.
5.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing.	The Firm has submitted audit trail record of product testing of HPLC for all test intervals.
6.	temperature and humidity monitoring of	The firm has submitted record of data logger for temperature and humidity monitoring of stability chambers (real time and accelerated).
Remarks	s of Evaluator:	
1.	Observations communicated Submit differential fee for the registration of applied product since the applied product since the applied product since the application was received in R&section of DRAP after 7th May 2021.	et 25,000/- has been submitted.
	The reference product literature showed that the structure and absolute stereochemistry of Baloxavir marboxil is verified by single crystal x-ray determination. The submitte COA from drug substance manufacturer does not contain this test.	Baloxavir Marboxil is verified by single crystal x- ray determination is mentioned on COA as d polymorphic form, i.e: form I. Revised COA and
	Give a detailed account on polymorphic form of drug substance used in drug product development since several polymorphi forms of drug substance are possible as pereference literature.	defined in DMF (3.2.S.3.1.9 summary) as material is polymorphic form I.

4.	Elaborate the test of "Microbial limit Test" mentioned in certificate of analysis of Baloxavir Marboxil.	Microbial examination of non-sterile products is performed as per following USP method given in the texts on Microbial Enumeration Test <61>, Tests for Specified Microorganisms <62> and Microbiological examination of non-sterile products (acceptance criteria for pharmaceutical preparations and substances for pharmaceutical use) <1111>.  As per pharmacopeia the acceptance criteria for non-sterile pharmaceutical products based on the total aerobic microbial count (TAMC), total yeast and molds count (TYMC) and objectionable microorganisms which must be absent and these are called as Microbial Limit Tests.  We followed the same practice and set restricted microbiological limits as per SAMI's Specs, that is TAMC: NMT 100 cfu/g, TYMC: NMT 10 cfu/g as well as absence of pathogenic organisms including E. Coli, Salmonella, S. Aureus in our raw material.
5.	The submitted acceptance criteria for release and shelf life specifications are same. Scientific justification is required for adopting such acceptance criteria.	We develop the product specifications according to the general monograph of USP and from the chemistry reviews of USFDA, EMA. In addition, ICH Q6A states that the acceptance criteria are the same from release throughout shelf life of product. Therefore, we have also set the same specification limits for release and shelf life.
6.	The submitted process validation protocol does not describe the critical process steps and controls in defined ranges.	Existing protocol captures the required information and describes critical process parameters along with process controls. However, to make this more elaborative, we have revised these sections and version 2 of protocol is attached.
7.	Since the strategy for product development is planned according to identified QTPP which is based on evaluation of the innovator/reference product therefore, justify the authenticity of product development studies for applied formulation without comparison with innovator/reference product.	The innovator of Baloxavir Marboxil Tablet i.e. XOFLUZA 40mg & 20mg Tablets, already published a detailed characterization of API ( <i>Baloxavir Marboxil</i> ) in FDA chemistry review as well product assessment report of European Medicine Agency ( <i>EMA</i> ). This part of QTPP was derived from FDA chemistry review & EMA assessment report.  Appearance of API, its solubility, pKa, partition coefficient, stereoisomerism and polymorphic form etc. were mentioned in detail by the innovator, therefore, all these required details are gathered from literature data.  As the reference finished product is presented as immediate-release film-coated tablets for oral administration containing 20mg or 40mg of Baloxavir Marboxil as the active substance, therefore, we have designed our product same as reference product to ensure pharmaceutical equivalency.  Product dissolution parameters and other related specification are already disclosed by the manufacturer of the reference product. Due to poor solubility of API, to ensure reproducible dissolution results, we have selected micronized grade of API

for development of our product as suggested by the
reference brand in FDA chemistry review.
Due to unavailability of innovator samples, the
dissolution profile in different pH mediums i.e., pH
1.2, 4.5 and 6.8 buffers as recommended in WHO
for CDP is checked and the release profile found
similar to that of innovator product "Xofluza Tablet"
in FDA chemistry review publicly available.
Information related to product packaging, storage
and labeling were also gathered from the above
mentioned product assessment reports i.e. FDA
chemistry review as well product assessment report
of European Medicine Agency.

**Previous Decision:** Registration Board decided to defer the case for submission of pharmaceutical equivalence and CDP studies with innovator / reference product (M-316).

#### **Evaluation by PEC:**

The reply is same as in the above case.

Decision: Deferred for further deliberations regarding cases wherein innovator products could not be procured for CDP studies, however, FDA chemistry review publicly reveals comparative dissolution profile of innovator product.

248.	Name, address of Applicant / Marketing Authorization Holder	M/s Davis Pharmaceutical, 121 industrial Triangle area, Kahuta Road Islamabad.		
	Name, address of Manufacturing site.	M/s Bio-Labs (Pvt) Ltd. Plot No 145 Industrial Triangle, Kahuta road, Islamabad.		
	Status of the applicant	<ul> <li>☐ Manufacturer</li> <li>☐ Importer</li> <li>☑ Is involved in none of the above (contract giver)</li> </ul>		
	Status of application	<ul><li>□ New Drug Product (NDP)</li><li>☑ Generic Drug Product (GDP)</li></ul>		
	Intended use of pharmaceutical product	<ul><li>□ Domestic sale</li><li>□ Export sale</li><li>☑ Domestic and Export sales</li></ul>		
	GMP status	M/s Davis Pharmaceutical: The firm is granted GMP certificate based on inspection conducted 02-02-2022.  M/s Bio-Labs (Pvt) Ltd. The firm is granted GMP certificate based on inspection conducted 23-04-2019.		
	Dy. No. and date of submission	Dy. No. 7327 Dated 05-03-2021		
	Details of fee submitted	PKR 50,000/-: Dated 26-01-2021		
	The proposed proprietary name / brand name	Esset Injection 40mg IV		
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each vial contains: Esomeprazole as sodium		
	Pharmaceutical form of applied drug	Almost white colored lyophilized, hygroscopic powder filled in glass vial.		
	Pharmacotherapeutic Group of (API)	Proton pump inhibitors		
	Reference to Finished product specifications	Innovator's specifications		

Proposed Pack size	1's	
Proposed unit price	As per SRO	
The status in reference regulatory authorities	Nexium IV 40mg Injection of M/s AstraZeneca (USFDA approved)	
For generic drugs (me-too status)	Esomine 40mg Injection Lawari International (Reg # 069703).	
Name and address of API manufacturer.	M/s. Sterile India Pvt. Ltd., Plot No. 100, Sec-56 Phase -4, Kundli Sonipat (Haryana) India	
Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template.  Firm has summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, Characterization, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance. The firm has summarized information of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols, control of excipients, control of drug product, specifications, analytical procedures, validation/verification of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.	
Module III (Drug Substance)	Firm has submitted detailed data for both drug substance data related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.	
Stability studies	Firm has submitted stability study data of 3 batch of drug substance at both accelerated as well as retime conditions. The accelerated stability data conducted at 40°C±2°C/75%±5% RH for 6 month. The real time stability data is conducted at 30°C±2 / 65% ± 5% RH for 36 months. (Batch N SI/EPZ/0010312, SI/EPZ/0020312)	
Module-III (Drug Product):	Firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols and report, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.	

	Pharmaceutical equivalence and comparative dissolution profile		Firm has submitted pharmaceutical equivalence study report of trial formulation (Batch # L-315) with Nexum 40mg injection (Batch # 137P07) of M/s Getz pharma by performing quality tests (Description, water contents, pH, Sterility, assay).		
	Analytical method validation/verification of product				es have submitted including y, precision, specificity.
		STABILITY S'	TUI	DY DATA	
Manufacturer of API M/s. Sterile India Pvt. Plot No. 100, Sec-56 I			vt. Ltd. 5 Phase -4, Kundli Sonipat (Haryana) India.		
API Lot	No.	SI/EPZ/0006121	7		
	ion of Pack er closure system)	Glass vial			
Stability	Storage Condition			°C / 65% ± 5%RH 2°C / 75% ± 5%RH	
Time Per	riod	Real time: 24 mg	onth	s Accelerated	l: 6 months
Frequenc	су	Accelerated: 0, 3 Real Time: 0, 3,		(Months) , 12, 18 & 24 (Month	is)
		E-Zole 40m	g In	jection	
Batch No	0.	L-315		L-287	L-283
Batch Si	ze	5,000 vials		5,000 vials	5,000 vials
Manufac	turing Date	02-2020		02-2020	02-2020
Date of I	nitiation	26-02-2020		22-02-2020	28-02-2020
No. of B	atches	03			
	DOCUMENTS / DAT	TA TO BE PRO	VID	ED WITH STABIL	ITY STUDY
1.	Reference of previous app with stability study data of	* *	ons	NA	
2.	Approval of API/ DML/GMP certificate of A			GMP certificate of M/s. Sterile India Pvt. Ltd. Plot No. 100, Sec-56 Phase -4, Kundli Sonipat (Haryana) India valid upto 21-5-2021	
3.			vith	Firm has submitted attested copy of invoice (invoice# E/161/SIPL/19-20)	
4.	Data of stability batches will be supported attested respective documents 1		-	Firm has submitted record of testing of all batches along with chromatograms, raw data sheets, COA and summary data sheets.	
5.	Compliance Record of HPLC software 21Cl & audit trail reports on product testing		FR	Audit trail not provided.	
6.	Record of Digital data logger for temperat and humidity monitoring of stability chamb (real time and accelerated)				
Remarks of Evaluator:					
Sr.#				sponse by the firm rm has submitted reports of verification studies of	
1.	2	accuracy and sion) performed acturer for both ompendial drug		m has submitted repo analytical method of	

2.	Provide COA of reference standard which is actually used in the analysis of drug substance in section 3.2.S.5.	Firm has submitted COA of working standard from the API manufacturer which is standardized against USP reference standard.
3.	Pharmaceutical equivalence study does not include complete testing of the drug product and the comparator product including the tests recommended by innovator product as well as the tests recommended in general monographs of official pharmacopoeia.	Firm has submitted pharmaceutical equivalence study report of trial formulation (Batch # L-315) with Nexum 40mg injection (Batch # 137P07) of M/s Getz pharma by performing quality tests (Description, water contents, pH, Sterility, assay).
4.	Pharmaceutical equivalence studies were not conducted against the innovator product.	We are using market lead product Nexum 40mg injection by Getz Pharma Ltd which is approved by DRAP.
5.	Justify the pH of your product between 9 to 12 since the pH of the innovator product is between 9 to 11. Revise your specifications along with submission of requisite fee.	Initially we followed in house specifications wherein the pH limit was 9-12. Now we are following innovator's specifications and accordingly revised specifications.
6.	Justify analytical method based on UV spectrophotometric method for assay testing of E-Zole 40mg Injection IV while that of innovator / reference product is based on HPLC.	The firm has submitted that we have revised our method as per innovator's specifications and adopted HPLC method for the assay testing of the drug product. We have also performed validation studies of the analytical method and therefore the HPLC method has been validated for assay testing.
7.	Justify your validation studies of the drug product in the light of ICH guidelines, since your analysis and reporting of the results is not exactly in line with the ICH recommendations.	Firm has submitted revised validation studies of the analytical method of the drug product using HPLC testing as per the ICH guidelines.
8.	Justify why the stability study data of three different batches is submitted from those for which batch analysis is provided in section 3.2.P.5.4.	Firm has initially submitted stability study data of three batches (Batch No. L-234, L-142, L-180) manufactured in 02-2019, 04-2018 and 09-2018 in which the assay testing of stability batches was carried out through UV method. Now the firm has submitted stability study data of three new batches manufactured in 2020 where the assay testing was conducted using HPLC method.
9.	Tests for water contents, constituted solution etc were not performed during stability studies since these tests are critical and are required to make assessment of the stability profile and shelf life.	These tests have been performed as per revised specifications on the submitted data of the stability batches.
10.	Submit documents for the procurement of API with approval from DRAP for the relevant batch of API which is used in the manufacturing of stability batches.	Firm has submitted copy of commercial invoice specifying import of 5Kg Esomeprazole sodium sterile powder dated 02-12-2019. The invoice is cleared by AD (I&E) DRAP.
11.	Submit Batch Manufacturing Record of three batches for which stability study data is submitted.	Firm has submitted copy of batch manufacturing record of three stability batches.

**Previous Decision:** Deferred for submission of Pharmaceutical equivalence studies against innovator/reference product, manufactured by way of lyophilization. Moreover, firm shall submit the fee of Rs. 7500/- for correction/pre-approval change in product specifications as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021 (M-316).

**Evaluation by PEC:** The firm has submitted pharmaceutical equivalence report of test product (Batch # L-53) with comparator product Esso 40mg Injection I/V (lyophilized powder) (Batch # 379) of M/s Shaigan Pharmaceutical (Pvt.) Limited by performing Identification, pH, Assay, Sterility and Bacterial endotoxin test.

Decision: Approved with innovator's specifications.

- Manufacturer will perform process validation of first three batches as per the commitment submitted in the registration application.
- The firm shall submit fee of Rs. 7,500 for each product for correction/pre-approval change in product specifications, as per notification No.F.7-11/2012-B&A/DRAP dated 13-07-2021.

specifica	ecifications, as per notification No.F.7-11/2012-B&A/DRAP dated 13-07-2021.					
249.	Name, address of Applicant / Marketing Authorization Holder	M/s Cherwel Pharmaceuticals (Pvt) Ltd. plot # 2 Phase 4, Hattar Industrial Estate, Hattar KPK fro M/s Bio-Labs (Pvt) Ltd				
	Name, address of Manufacturing site.	M/s Bio-Labs (Pvt) Ltd. Plot No 145 Industrial Triangle, Kahuta road, Islamabad.  □ Manufacturer □ Importer □ Is involved in none of the above (contract giver) □ New Drug Product (NDP) □ Generic Drug Product (GDP)				
	Status of the applicant					
	Status of application					
	Intended use of pharmaceutical product	<ul><li>□ Domestic sale</li><li>□ Export sale</li><li>☑ Domestic and Export sales</li></ul>				
	GMP status	M/s Cherwel Pharmaceuticals: The firm is granted GMP certificate based on inspection conducted on 04-02-2019.  M/s Bio-Labs (Pvt) Ltd. The firm is granted GMP certificate based on inspection conducted 23-04-2019.				
	Dy. No. and date of submission	Dy. No. 7211 Dated 04-03-2021				
	Details of fee submitted	PKR 50,000/-: Dated 24-02-2021				
	The proposed proprietary name / brand name	Esocare Injection 40mg IV				
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each vial contains: Esomeprazole as sodium				
	Pharmaceutical form of applied drug	Almost white colored lyophilized, hygroscop powder filled in glass vial.				
	Pharmacotherapeutic Group of (API)	Proton pump inhibitor				
	Reference to Finished product specifications	In-house specifications				
	Proposed Pack size	1's				
	Proposed unit price	As per SRO				
	The status in reference regulatory authorities	Nexium IV 40mg Injection of M/s AstraZeneca (USFDA approved)				
	For generic drugs (me-too status)	Esomine 40mg Injection Lawari International (R# 069703)				
	GMP status of the Finished product manufacturer	GMP certificate issued based upon inspection conduct 23-4-2019, valid upto 22-4-2022.				
	Name and address of API manufacturer.	M/s. Sterile India Pvt. Ltd. Plot No. 100, Sec- Phase -4, Kundli Sonipat (Haryana) India				
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-Fitemplate. Firm has summarized information related nomenclature, structure, general properties solubilities, physical form, manufacturers,				

		Characterization, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance. The firm has summarized information of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols, control of excipients, control of drug product, specifications, analytical procedures, validation/verification of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.	
Module III (Drug Substan	ce)	Firm has submitted detailed data for both drug substance data related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.	
Stability studies		Firm has submitted stability study data of 3 batches of drug substance at both accelerated as well as real time conditions. The accelerated stability data is conducted at $40^{\circ}\text{C} \pm 2^{\circ}\text{C}$ /75% $\pm$ 5% RH for 6 months. The real time stability data is conducted at $30^{\circ}\text{C} \pm 2^{\circ}\text{C}$ / 65% $\pm$ 5% RH for 36 months. (Batch No. SI/EPZ/0010312, SI/EPZ/0020312 & SI/EPZ/0030312)	
Module-III (Drug Product	;):	Firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols and report, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.	
Pharmaceutical equivalence dissolution profile	ce and comparative	Firm has submitted pharmaceutical equivalence study report of trial formulation (Batch # L-315) with Nexum 40mg injection (Batch # 137P07) of M/s Getz pharma by performing quality tests (Description, water contents, pH, Sterility, assay).	
product		Method validation studies have submitted including linearity, range, accuracy, precision, specificity.	
STABILITY ST			
Manufacturer of API	M/s. Sterile India I Plot No. 100, Sec-	Pvt. Ltd. 56 Phase -4, Kundli Sonipat (Haryana) India	
API Lot No.	SI/EPZ/00061217		
Description of Pack (Container closure system) Glass vial			

Stability Storage Condition Real time: 30°C ± 2 Accelerated: 40°C ±			$2^{\circ}$ C / 65% ± 5%RH ± $2^{\circ}$ C / 75% ± 5%RH		
Time Period Real time: 24 months Accelerated: 6 months			l: 6 months		
Frequen	•	Accelerated: 0, 3, 6 Real Time: 0, 3, 6,			
		E-Zole 40mg	Injection		
Batch N	0.	L-315	L-287	L-283	
Batch S	ize	5,000 vials	5,000 vials	5,000 vials	
Manufa	cturing Date	02-2020	02-2020	02-2020	
Date of	Initiation	26-02-2020	22-02-2020	28-02-2020	
No. of E	Batches	03	•		
	DOCUMENTS / DA	TA TO BE PROV	IDED WITH STABI	LITY STUDY	
1.	Reference of previou applications with stability firm (if any)		The firm has not sub	mitted any document.	
2.	API manufacturer issue	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.		GMP certificate of M/s. Sterile India Pvt. Ltd. Plot No. 100, Sec-56 Phase -4, Kundli Sonipat (Haryana) India valid upto 21-05-2021.	
3.	Documents for the procure approval from DRAP (in case)		Firm has submitte (invoice# E/161/SIPI	d attested copy of invoice L/19-20)	
4.	•	documents like	along with chromato	rm has submitted record of testing of all batches ong with chromatograms, raw data sheets, COA and summary data sheets.	
5.			The firm has not submitted audit trail reports on product testing.		
6.			Firm has submitted record of data logger for temperature and humidity monitoring of real time and accelerated stability chambers.		
Remark	s of Evaluator:				
Sr. No.	Observations communicate	ed	Response by the firm		
1.	including specificity, repeatability (method preci- by the Drug Product manuf compendial as well as non- substance(s) shall be submitt	accuracy and sion) performed facturer for both compendial drug ed.	the analytical method of drug substance.		
2.	Provide COA of reference standard which is actually used in the analysis of drug substance in section 3.2.S.5.		Firm has submitted COA of working standard from the API manufacturer which is standardized against USP reference standard.		
3.	Pharmaceutical equivalence include complete testing of and the comparator product in recommended by innovator p the tests recommended monographs of official pharmaceutical equivalence.	the drug product including the tests product as well as in general	study report of trial formulation (Batch # L-315) with Nexum 40mg injection (Batch # 137P07) of M/s Getz pharma by performing quality tes		
4.	Pharmaceutical equivalence conducted against the innova	studies were not ator product.	We are using market lead product Nexum 40mg injection by Getz Pharma Ltd which is approved by DRAP.		
5.	Justify the pH of your produ 12 since the pH of the inno		•	in house specifications that's 0-12. Now we are following	

	between 9 to 11. Revise your specifications along with submission of requisite fee.	innovator's specification and accordingly revised our specifications.	
6.	Justify analytical method based on UV spectrophotometric method for assay testing of E-Zole 40mg Injection IV while that of innovator / reference product is based on HPLC.	The firm has submitted that we have revised our method as per innovator's specifications and adopted HPLC method for the assay testing of the drug product. We have also performed validation studies of the analytical method and therefore the HPLC method has been validated.	
7.	Justify your validation studies of the drug product in the light of ICH guidelines, since your analysis and reporting of the results is not exactly in line with the ICH recommendations.	Firm has submitted revised validation studies of the analytical method of the drug product using HPLC testing as per the ICH guidelines.	
8.	Justify why the stability study data of three different batches is submitted from those for which batch analysis is provided in section 3.2.P.5.4.	Firm has initially submitted stability study data of three batches (Batch No. L-234, L-142, L-180) manufactured in 02-2019, 04-2018 and 09-2018 in which the assay testing of stability batches was carried out through UV method. Now the firm has submitted stability study data of three new batches manufactured in 2020 where the assay testing was conducted using HPLC method.	
9.	Tests for water contents, constituted solution etc were not performed during stability studies since these tests are critical and are required to make assessment of the stability profile and shelf life.	These tests have been performed as per revised specifications on the submitted data of the stability batches.	
10.	Submit documents for the procurement of API with approval from DRAP for the relevant batch of API which is used in the manufacturing of stability batches.	Firm has submitted copy of commercial invoice specifying import of 5Kg Esomeprazole sodium sterile powder dated 02-12-2019. The invoice is cleared by AD (I&E) DRAP.	
11.	Submit Batch Manufacturing Record of three batches for which stability study data is submitted.	Firm has submitted copy of batch manufacturing record of three stability batches.	

**Previous decision:** Deferred for submission of Pharmaceutical equivalence studies against innovator/reference product, manufactured by way of lyophilization. Moreover, firm shall submit the fee of Rs. 7500/- for correction/pre-approval change in product specifications as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021 (M-316).

**Evaluation by PEC:** The firm has submitted pharmaceutical equivalence data of test product (Batch # L-53) with comparator product Esso 40mg Injection I/V (lyophilized powder) (Batch # 379) of M/s Shaigan Pharmaceutical (Pvt.) Limited by performing Identification, pH, Assay, Sterility and Bacterial endotoxin test.

Decision: Approved with innovator's specifications.

- Manufacturer will perform process validation of first three batches as per the commitment submitted in the registration application.
- The firm shall submit fee of Rs. 7,500 for each product for correction/pre-approval change in product specifications, as per notification No.F.7-11/2012-B&A/DRAP dated 13-07-2021.

250.	Name, address of Applicant / Marketing Authorization Holder	M/s Munawar Pharma (Pvt) Ltd., 31km, Ferozpur Road Lahore
	Name, address of Manufacturing site.	M/s Bio-Labs (Pvt) Ltd. Plot No 145 Industrial Triangle, Kahuta road, Islamabad.
	Status of the applicant	<ul> <li>☐ Manufacturer</li> <li>☐ Importer</li> <li>☑ Is involved in none of the above (contract giver)</li> </ul>

<b>-</b>	<u></u>
Status of application	<ul><li>□ New Drug Product (NDP)</li><li>☑ Generic Drug Product (GDP)</li></ul>
Intended use of pharmaceutical product	☐ Domestic sale ☐ Export sale
	☑ Domestic and Export sales
GMP status	M/s Bio-Labs (Pvt) Ltd. The firm is granted GMP certificate based on inspection conducted 23-04-2019.  M/s Munawar Pharma: The firm is granted GMP certificate based on inspection conducted 07-11-2017.
Dy. No. and date of submission	Dy. No. 6956 Dated 02-03-2021
Details of fee submitted	PKR 50,000/-: Dated 18-05-2020
The proposed proprietary name / brand name	Someper Injection 40mg IV
Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each vial contains: Esomeprazole as sodium
Pharmaceutical form of applied drug	Almost white colored lyophilized, hygroscopic powder filled in glass vial.
Pharmacotherapeutic Group of (API)	Proton pump inhibitor
Reference to Finished product specifications	Innovator's specifications
Proposed Pack size	1's
Proposed unit price	As per SRO
The status in reference regulatory authorities	Nexium IV 40mg Injection of M/s AstraZeneca (USFDA approved)
For generic drugs (me-too status)	Esomine 40mg Injection Lawari International 069703
GMP status of the Finished product manufacturer	GMP certificate issued based upon inspection conduct 23-4-2019, valid upto 22-4-2022.
Name and address of API manufacturer.	M/s. Sterile India Pvt. Ltd., Plot No. 100, Sec-56 Phase -4, Kundli Sonipat (Haryana) India.
Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Firm has summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, Characterization, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance. The firm has summarized information of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols, control of excipients, control of drug product, specifications, analytical procedures, validation/verification of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.

Module III (Drug Substa	Stability studies  Module-III (Drug Product):  Pharmaceutical equivalence and comparative dissolution profile		Firm has submitted detailed data for both drug substance data related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.	
Stability studies			substance at both acc litions. The accelerated $C \pm 2^{\circ}C$ /75% $\pm$ 5% RE lity data is conducted a	y study data of 3 batches of elerated as well as real time stability data is conducted at I for 6 months. The real time t $30^{\circ}\text{C} \pm 2^{\circ}\text{C} / 65\% \pm 5\%$ RH ch No. SI/EPZ/0010312, /0030312)
Module-III (Drug Produ			ription, composition, pufacture, manufacturing ess validation protocopients, control of drytical procedures, edures, batch analysis,	of drug product including its charmaceutical development, g process and process control, cols and reports, control of trug product, specifications, validation of analytical justification of specifications, ials, container closure system
			rt of trial formulation (g injection (Batch # 13'	naceutical equivalence study (Batch # L-315) with Nexum (7P07) of M/s Getz pharma by Description, water contents,
Analytical method valid of product	ation/verification	Method validation studies have submitted including linearity, range, accuracy, precision, specificity.		
	STABILITY	Y ST	UDY DATA	
Manufacturer of API	M/s. Sterile India Plot No. 100, See		Ltd. Phase -4, Kundli Sonipa	at (Haryana) India
API Lot No.	SI/EPZ/0006121	17		
Description of Pack (Container closure system)	Glass vial			
		$\pm 2^{\circ}\text{C} / 65\% \pm 5\%\text{RH}$ $\text{C} \pm 2^{\circ}\text{C} / 75\% \pm 5\%\text{RH}$		
Time Period	Real time: 24 mg	onths Accelerated: 6 months		
Frequency Accelerated: 0, 3 Real Time: 0, 3,		8, 6 (Months) 6, 9, 12, 18 & 24 (Months)		
	E-Zole 4	0mg	Injection	
Batch No. L-315			L-287	L-283
Batch Size 5,000 vials			5,000 vials	5,000 vials
Manufacturing Date 02-2020			02-2020	02-2020
Date of Initiation	26-02-2020		22-02-2020	28-02-2020
No. of Batches 03				
DOCUMENTS /	DATA TO BE PI	ROV	DED WITH STABIL	ITY STUDY

1.	Reference of previous approval of applications with stability study data of the firm (if any)	of NA ne	
2.	Approval of API/ DML/GMP certificate of	of GMP certificate of M/s. Sterile India Pvt. Ltd. Plot No. 100, Sec-56 Phase -4, Kundli Sonipat (Haryana) India valid upto 21-5-2021	
3.	Documents for the procurement of API wit approval from DRAP (in case of import).	th Firm has submitted attested copy of invoice (invoice# E/161/SIPL/19-20)	
4.	•	Firm has submitted record of testing of all batches along with chromatograms, raw data sheets, COA and summary data sheets.	
5.	Compliance Record of HPLC softwar 21CFR & audit trail reports on product testin		
6.	Record of Digital data logger for temperatur and humidity monitoring of stabilit chambers (real time and accelerated)	Firm has submitted record of data logger for temperature and humidity monitoring of real time and accelerated stability chambers.	
Remar	ks of Evaluator:		
Sr.#	Observations communicated	Response by the firm	
1.	Analytical Method Verification studies including specificity, accuracy and repeatability (method precision) performed by the Drug Product manufacturer for both compendial as well as non-compendial drug substance(s) shall be submitted.	Firm has submitted reports of verification studies of the analytical method of drug substance.	
2.	Provide COA of reference standard which is actually used in the analysis of drug substance in section 3.2.S.5.	Firm has submitted COA of working standard from the API manufacturer which is standardized against USP reference standard	
3.	Pharmaceutical equivalence study does not include complete testing of the drug product and the comparator product including the tests recommended by innovator product as well as the tests recommended in general monographs of official pharmacopoeia.	study report of trial formulation (Batch # L-315 with Nexum 40mg injection (Batch # 137P07) o M/s Getz pharma by performing quality test	
4.	Pharmaceutical equivalence studies were not conducted against the innovator product.	We are using market lead product Nexum 40mg injection by Getz Pharma Ltd which is approved by DRAP.	
5.	Justify the pH of your product between 9 to 12 since the pH of the innovator product is between 9 to 11. Revise your specifications along with submission of requisite fee.	Initially we followed in house specifications that's why pH limit was 9-12. Now we are following innovator's specification and accordingly revised our specifications.	
6.	Justify analytical method based on UV spectrophotometric method for assay testing of E-Zole 40mg Injection IV while that of innovator / reference product is based on HPLC.	The firm has submitted that we have revised our method as per innovator's specifications and adopted HPLC method for the assay testing of the	
7.	Justify your validation studies of the drug product in the light of ICH guidelines, since your analysis and reporting of the results is not exactly in line with the ICH recommendations.	Firm has submitted revised validation studies of the analytical method of the drug product using HPLC testing as per the ICH guidelines.	
8.	Justify why the stability study data of three different batches is submitted from those for	Firm has initially submitted stability study data of three batches (Batch No. L-234, L-142, L-180) manufactured in 02-2019, 04-2018 and 09-2018 in	

	which batch analysis is provided in section 3.2.P.5.4.	which the assay testing of stability batches was carried out through UV method. Now the firm has submitted stability study data of three new batches manufactured in 2020 where the assay testing was conducted using HPLC method.
9.	Tests for water contents, constituted solution etc were not performed during stability studies since these tests are critical and are required to make assessment of the stability profile and shelf life.	These tests have been performed as per revised specifications on the submitted data of the stability batches.
10.	Submit documents for the procurement of API with approval from DRAP for the relevant batch of API which is used in the manufacturing of stability batches.	Firm has submitted copy of commercial invoice specifying import of 5Kg Esomeprazole sodium sterile powder dated 02-12-2019. The invoice is cleared by AD (I&E) DRAP.
11.	Submit Batch Manufacturing Record of three batches for which stability study data is submitted.	Firm has submitted copy of batch manufacturing record of three stability batches.

**Previous Decision:** Deferred for submission of Pharmaceutical equivalence studies against innovator/reference product, manufactured by way of lyophilization. Moroever, firm shall submit the fee of Rs. 7500/- for correction/pre-approval change in product specifications as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021 (M-316).

**Evaluation by PEC:** The firm has submitted pharmaceutical equivalence report of test product (Batch # L-53) with comparator product Esso 40mg Injection I/V (lyophilized powder) (Batch # 379) of M/s Shaigan Pharmaceutical (Pvt.) Limited by performing Identification, pH, Assay, Sterility and Bacterial endotoxin test.

Decision: Approved with innovator's specifications.

- Manufacturer will perform process validation of first three batches as per the commitment submitted in the registration application.
- The firm shall submit fee of Rs. 7,500 for each product for correction/pre-approval change in product specifications, as per notification No.F.7-11/2012-B&A/DRAP dated 13-07-2021.

251.	Name, address of Applicant / Marketing Authorization Holder	M/s Islam Pharmaceuticals, 7 Km Pasrur Road Sialkot.
	Name, address of Manufacturing site.	M/s Bio-Labs (Pvt) Ltd. Plot No 145, Industrial Triangle, Kahuta road, Islamabad.
	Status of the applicant	☐ Manufacturer ☐ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	<ul><li>□ New Drug Product (NDP)</li><li>☑ Generic Drug Product (GDP)</li></ul>
	Intended use of pharmaceutical product	<ul><li>□ Domestic sale</li><li>□ Export sale</li><li>⊠ Domestic and Export sales</li></ul>
	GMP status	M/s Islam Pharmaceutical: The firm is granted GMP certificate based on inspection conducted on 01-02-2020.  M/s Bio-Labs (Pvt) Ltd. The firm is granted GMP certificate based on inspection conducted 23-04-2019.
	Dy. No. and date of submission	Dy. No. 7169 Dated 04-03-2021
	Details of fee submitted	PKR 50,000/-: Dated 03-02-2021
	The proposed proprietary name / brand name	Espharm Injection 40mg IV

Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each vial contains: Esomeprazole as sodium40mg (Lyophilized powder)
Pharmaceutical form of applied drug	Almost white colored lyophilized, hygroscopic powder filled in glass vial.
Pharmacotherapeutic Group of (API)	Proton pump inhibitors
Reference to Finished product specifications	In-house
Proposed Pack size	1's
Proposed unit price	As per SRO
The status in reference regulatory authorities	Nexium IV 40mg Injection of M/s AstraZeneca (USFDA approved).
For generic drugs (me-too status)	Esomine 40mg Injection of M/s Lawari International (Reg # 069703)
GMP status of the Finished product manufacturer	GMP certificate issued based upon inspection conduct 23-4-2019, valid upto 22-4-2022.
Name and address of API manufacturer.	M/s. Sterile India Pvt. Ltd. Plot No. 100, Sec-56 Phase -4, Kundli Sonipat (Haryana) India
Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template.  Firm has summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, Characterization, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance. The firm has summarized information of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols, control of excipients, control of drug product, specifications, analytical procedures, validation/verification of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.
Module III (Drug Substance)	Firm has submitted detailed data for both drug substance data related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
Stability studies	Firm has submitted stability study data of 3 batches of drug substance at both accelerated as well as real time conditions. The accelerated stability data is conducted at $40^{\circ}\text{C} \pm 2^{\circ}\text{C}$ /75% $\pm$ 5% RH for 6 months. The real time stability data

			1	
	Module-III (Drug Product):			$C \pm 2^{\circ}C / 65\% \pm 5\%$ RH for tch No. SI/EPZ/0010312, SI/EPZ/0030312).
			including its pharmaceutical d manufacturing pro process validation p excipients, contr specifications, anal of analytical pr justification of spec	ded data of drug product description, composition, levelopment, manufacture, cess and process control, rotocols and report, control of rol of drug product, ytical procedures, validation ocedures, batch analysis, diffications, reference standard tainer closure system and
	Pharmaceutical equivalence and comparative dissolution profile		study report of trial with Nexum 40mg i M/s Getz pharma	I pharmaceutical equivalence formulation (Batch # L-315) injection (Batch # 137P07) of by performing quality tests contents, pH, Sterility, assay). e
	Analytical method validation/verification of product			g linearity, range, accuracy,
STABILITY STU		DY DATA		
Manufactu	irer of API	M/s. Sterile India Pvt. Ltd. Plot No. 100, Sec-56 Phase -4, Kundli Sonipat (Haryana) India		
API Lot N	0.	SI/EPZ/00061217		
Description of Pack (Container closure system) Glas		Glass vial		
Stability Storage Condition R		Real time: $30^{\circ}\text{C} \pm 2^{\circ}\text{C} / 65\% \pm 5\%\text{RH}$ Accelerated: $40^{\circ}\text{C} \pm 2^{\circ}\text{C} / 75\% \pm 5\%\text{RH}$		
Time Perio	bo	Real time: 24 months		
Frequency		Accelerated: 0, 3, 6 (Months) Real Time: 0, 3, 6, 9, 12, 18 & 24 (Months)		
		E-Zole 40mg In	jection	
Batch No.		L-315	L-287	L-283
Batch Size	· ·	5,000 vials	5,000 vials	5,000 vials
Manufactu	rring Date	02-2020	02-2020	02-2020
Date of In	itiation	26-02-2020	22-02-2020	28-02-2020
No. of Batches		03		
	DOCUMENTS / DAT	TA TO BE PROVID	ED WITH STABIL	ITY STUDY
1.	Reference of previous approval of applications with stability study data of the firm (if any)		NA	_
2.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.			M/s. Sterile India Pvt. Ltd. 56 Phase -4, Kundli Sonipat id upto 21-5-2021
3.	Documents for the procurement of API with approval from DRAP (in case of import).		Firm has submitte (invoice# E/161/SIP	

4.	attested respective documents like	y Firm has submitted record of testing of all batches along with chromatograms, raw data sheets, COA, and summary data sheets.	
	summary data sheets etc.	s, and summary data sheets.	
5.	Compliance Record of HPLC software 21CF & audit trail reports on product testing	R The firm has not submitted audit trail reports on product testing.	
6.	Record of Digital data logger for temperaturand humidity monitoring of stability chamber (real time and accelerated)		
Remar	ks of Evaluator:		
Sr.#	Observations communicated	Response by the firm	
1.	Analytical Method Verification studies including specificity, accuracy and repeatability (method precision) performed by the Drug Product manufacturer for both compendial as well as non-compendial drug substance(s) shall be submitted.	Firm has submitted reports of verification studies of the analytical method of drug substance.	
2.	Provide COA of reference standard which is actually used in the analysis of drug substance in section 3.2.S.5.	Firm has submitted COA of working standard from the API manufacturer which is standardized against USP reference standard.	
3.	Pharmaceutical equivalence study does not include complete testing of the drug product and the comparator product including the tests recommended by innovator product as well as the tests recommended in general monographs of official pharmacopoeia.	Firm has submitted pharmaceutical equivalence study report of trial formulation (Batch # L-315) with Nexum 40mg injection (Batch # 137P07) of M/s Getz pharma by performing quality tests (Description, water contents, pH, Sterility, assay).	
4.	Pharmaceutical equivalence studies were not conducted against the innovator product.	We are using market lead product Nexum 40mg injection by M/s Getz Pharmaceuticals Ltd which is approved by DRAP.	
5.	Justify the pH of your product between 9 to 12 since the pH of the innovator product is between 9 to 11. Revise your specifications along with submission of requisite fee.	Initially we followed in house specifications that's why pH limit was 9-12. Now we are following innovator's specification and accordingly revised our specifications.	
6.	Justify analytical method based on UV spectrophotometric method for assay testing of E-Zole 40mg Injection IV while that of innovator / reference product is based on HPLC.	The firm has submitted that we have revised our method as per innovator's specifications and adopted HPLC method for the assay testing of the drug product. We have also performed validation studies of the analytical method and therefore the HPLC method has been validated.	
7.	Justify your validation studies of the drug product in the light of ICH guidelines, since your analysis and reporting of the results is not exactly in line with the ICH recommendations.	Firm has submitted revised validation studies of the analytical method of the drug product using HPLC testing as per the ICH guidelines.	
8.	Justify why the stability study data of three different batches is submitted from those for which batch analysis is provided in section 3.2.P.5.4.	Firm has initially submitted stability study data of three batches (Batch No. L-234, L-142, L-180) manufactured in 02-2019, 04-2018 and 09-2018 in which the assay testing of stability batches was carried out through UV method. Now the firm has submitted stability study data of three new batches manufactured in 02-2020 where the assay testing was conducted using HPLC method.	
9.	Tests for water contents, constituted solution etc were not performed during stability studies since these tests are critical and are required to make assessment of the stability profile and shelf life.	These tests have been performed as per revised specifications on the submitted data of the stability batches.	

10.	Submit documents for the procurement of API	Firm has submitted copy of commercial invoice
	with approval from DRAP for the relevant	specifying import of 5Kg Esomeprazole sodium
	batch of API which is used in the manufacturing	sterile powder dated 02-12-2019. The invoice is
	of stability batches.	cleared by AD (I&E) DRAP.
11.	Submit Batch Manufacturing Record of three	Firm has submitted copy of batch manufacturing
	batches for which stability study data is	record of three stability batches.
	submitted.	

**Decision:** Deferred for submission of pharmaceutical equivalence studies against innovator/reference product, manufactured by way of lyophilization. Moreover, firm shall submit the fee of Rs. 7500/- for correction/preapproval change in product specifications as per notification No.F.7-11/2012-B&A/DRAP dated 07-05-2021 (M-316).

**Evaluation by PEC:** The firm has submitted pharmaceutical equivalence report of test product (Batch # L-53) with comparator product Esso 40mg Injection I/V (lyophilized powder) (Batch # 379) of M/s Shaigan Pharmaceutical (Pvt.) Limited by performing Identification, pH, Assay, Sterility and Bacterial endotoxin test.

Decision: Approved with innovator's specifications.

- Manufacturer will perform process validation of first three batches as per the commitment submitted in the registration application.
- The firm shall submit fee of Rs. 7,500 for each product for correction/pre-approval change in product specifications, as per notification No.F.7-11/2012-B&A/DRAP dated 13-07-2021.

#### **Agenda of Evaluator PEC-XV**

### a) Registration application on Form 5 F local manufacturing Human

#### 1) New DML cases

252.	Name, address of Applicant / Marketing Authorization Holder	Variant Pharmaceuticals (Pvt.) Ltd.
	Name, address of Manufacturing site.	plot # 5, M-2, pharma zone, 26 km main sharaqpur road district Sheikhupura
	Status of the applicant	<ul> <li>✓ Manufacturer</li> <li>☐ Importer</li> <li>☐ Is involved in none of the above (contract giver)</li> </ul>
	Status of application	☐ New Drug Product (NDP) ☐ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	<ul><li>□ Domestic sale</li><li>□ Export sale</li><li>☑ Domestic and Export sales</li></ul>
	Dy. No. and date of submission	Dy. No.33173 dated 21/12/2021
	Details of fee submitted	PKR 30,000/-: dated 24/11/2021
	The proposed proprietary name / brand name	DIPRANT 5mg Tablet
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each tablet contains Amlodipine Besylate eq. to Amlodipine5mg
	Pharmaceutical form of applied drug	Tablet.
	Pharmacotherapeutic Group of (API)	Calcium channel blocker
	Reference to Finished product specifications	USP specifications

Proposed Pack size	3 x 10's
Proposed unit price	As per SRO
The status in reference regulatory authorities	Amlodipine Besylatet 5mg Tablet by Aurobindo Pharma - Milpharm Ltd, USFDA Approved.
For generic drugs (me-too status)	Norvasc 5mg Tablets by M/s Pfizer Pakistan Ltd., Reg. No. 011825
GMP status of the Finished product manufacturer	New license granted on 13/02/2020 General Tablet, General Capsule, General Sachet and General dry powder injectable (pre-lyophilized)
Name and address of API manufacturer.	CADILA PHARMACEUTICALS LIMITED. 294, GIDC Industrial Estate, Ankleshwar-393 002 Gujarat. INDIA.
Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product is submitted.
Module III (Drug Substance)	Official monograph of Amlodipine Besylate is present in USP/BP. The firm as submitted detail of nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, tests for impurity & related substances, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance
Stability studies	Stability study conditions: Real time: $30^{\circ}C \pm 2^{\circ}C / 65\% \pm 5\%$ RH for 36 months Accelerated: $40^{\circ}C \pm 2^{\circ}C / 75\% \pm 5\%$ RH for 6 months Batches:(6AD031,6AD032, 6AD033)
Module-III (Drug Product):	The firm has submitted detail of manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedure (including dissolution testing at acidic and buffer medium) and its verification studies, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug product.
Pharmaceutical equivalence and comparative dissolution profile	Pharmaceutical Equivalence have been established against the innovator brand that is Norvasc 5mg Tablet by M/s Pfizer Pakistan, Reg. No. 011825 by performing quality tests (Identification, Assay, Dissolution,).  CDP has been performed against the same brand that is Norvasc 5mg Tablet by M/s Pfizer Pakistan, in Acid media (pH 1.2), Acetate buffer (pH 4.5) & Phosphate

		Buffer (pH 6.8 acceptable range		or f1 and f2 are in the
	Analytical method validation/verification of product	Method verification studies have submitted including linearity, range, accuracy, precision, specificity.		
STABILITY	STUDY DATA			
Manufacture	er of API			LS LIMITED. nkleshwar-393 002
API Lot No.		20AD020		
Description (Container c	of Pack closure system)	Alu-Alu blister	packed in unit c	earton (30's)
Stability Sto	orage Condition		$C \pm 2^{\circ}C / 65\% \pm 3^{\circ}C \pm 2^{\circ}C / 75\%$	
Time Period		Real time: 6 m Accelerated: 6		
Frequency		Accelerated: 0, Real Time: 0, 3	2, 4, 6 (Months) 3, 6 (Months)	)
Batch No.		T-001	T-002	T-003
Batch Size		2000 tab	2000 tab	2000 tab
Manufacturi	ng Date	02-2021	02-2021	02-2021
Date of Initi	ation	13-02-2021	17-02-2021	17-02-2021
No. of Batch	nes	03		
Administrati	ive Portion			
a.	Reference of previous approval of applications with stability study data of the firm (if any)	The firm has not submitted any document.		
b.	* *	Copy of GMP certificate No. 18101065 FDA INDIA issued by FDA INDIA valid till 18-10-2021.		
C.	Documents for the procurement of API with approval from DRAP (in case of import).	<ul> <li>Copy of letter No.4111/2020/DRAP-AD-CD(I&amp;E) dated 18/03/2020 is submitted wherein the permission to import different APIs including AMLODIPINE BESYLATE for the purpose of test/analysis and stability studies is granted.</li> <li>Invoice # CPL/BD/SAM/003/20-21 AD date 09-10-2020</li> </ul>		
d.	Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.			
e.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing			
f.	Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)	•		

Remarks OF Evaluator:	
<b>Shortcoming Communicated</b>	Reply of the Firm
Provide detailed analytical procedures for the	Firm submitted the requisite information. However,
testing of drug substance by drug product	the firm claimed that drug substance is of BP grade
manufacturer.	while the procedure mentioned is section 3.2.S.4.2 is
	in accordance with USP. Further, COA of drug
	substance from drug substance manufacturer also
	specified that the raw material complies with BP+ IH.
	Assay procedure is the only difference observed
	between the USP and BP of amlodipine besylate.
Provide analytical Method Verification studies	Firm submitted the assay method verification studies
including specificity, accuracy and repeatability	of drug substance, which includes three parameters
performed by the Drug Product manufacturer.	i.e. selectivity, linearity and precision.
	While as per international guidelines verification
	studies includes accuracy, specificity and precision
	(repeatability) parameters, which has not been
	performed by the firm to verify their analytical
	procedure.
Provide copy of COA of primary / secondary	Firm submitted the COA of working standard
reference standard including source and lot	supplied by the drug substance manufacturer and
number used by drug product manufacturer for	standardized against amlodipine besylate 5.0 EPCRS.
analyzing of drug substance.	standardized against annouipine besylate 3.0 Et eRs.
Justify the choice of excipients in your	Firm submitted the reply that they performed drug-
formulation, since the excipients used are different from that of the innovator / reference	excipient compatibility studies by analyzing the
	stability data.
product. Further justify how the formulation was	Firm has not given any justification for using two
developed without performing drug-excipient	lubricating agents in the formulation.
compatibility studies.	
Scientific justification is required for using two	
lubricating agents in the formulation.	
Provide the data of dissolution profile of 12 unit	Firm has submitted the dissolution profile data of 12
of test product and the innovator / reference	units of reference and test batches at 10 minutes,15
product minimum of three time-points (zero	minutes and 30 minutes time point in all three
excluded). Submit the data of comparative	mediums.
dissolution profile in comply with the decision of	
293rd meeting of Registration Board. Since, you	
have submitted the comparative dissolution	
profile data by submitting only the numerical	
values of one unit without mentioning the time	
point and factor calculation.	
Specify details including batch number and	Firm provide the requisite information. Identification
manufacturing date of the reference / comparator	and the uniformity of dosage units has been
product against which pharmaceutical equivalence	performed while establishing pharmaceutical
is performed.	equivalence against the innovator product.
Specify the critical steps identified during the	Firm has replied that they identified the critical
formulation development and manufacturing of	factors during product development.
the applied product and provide summary of	But the reply did not specify the critical step which
controls performed at the critical steps of the	has been identified during product development nor
manufacturing process as per the requirement of	provide summary of controls performed at the critical
3.2. P.3.4.	steps of the manufacturing process as per the
	requirement of 3.2. P.3.4.
Justify the acceptance criteria of weight variation	In their reply, firm has submitted the copy of general
i.e. 200mg±7.5% along with pharmacoepial	chapters of USP 2091 Weight variation of dietary
reference.	supplements.
Justification is required for not including the test	
of uniformity of dosage units in the specification	

of drug product, as the said test is included in the	
USP monograph of Amlodipine Besylate tablet.	Planether and hadrafulded the defendence of the
Provide the method of identification test as per	Firm has not included the identification test in the
USP monograph of Amlodipine Besylate tablet.	release specification of drug product neither the
	procedure has been mentioned in the section 3.2.
	P.5.2.
According to the USP monograph of Amlodipine	Firm has submitted the clarification that the final
Besylate tablet, the final concentration of standard	concentration of standard solution of amlodipine is
solution should be 0.0275mg/ml for assay and	0.02mg/ml which is equivalent to 0.0275mg/ml
0.0139mg/ml for dissolution, while the final	amlodipine besylate, similarly the final conc. Of
concentration of standard solution as per your	standard solution is 0.01mg/ml amlodipine equal to
submitted method of assay and dissolution is	0.0.1398mg/ml amlodipine besylate.
0.02mg/ml and 0.01mg/ml respectively. Justify	
how the tests performed by your method can be	
considered acceptable under the USP monograph.	
Justify the sample solution preparation method	Firm has not given any justification for using
under the assay test of drug product is different	different method for sample preparation from that
from that mentioned in USP monograph.	specified in USP monograph.
Justify why the calculation formula of assay	According to USP "Place NLT 5 Tablets in a suitable
content of drug product is different from that	volumetric flask, and add sufficient quantity of
specified in USP monograph.	Mobile phase to disintegrate the Tablets. Shake for 30
	min, and dilute with Mobile phase to volume. Pass
	the sample through a syringe tip filter of 0.45-µm
	pore size. Discard the first few mL of the filtrate."
	While as per the applicant "Take NLT 20 tablets and
	grind to powder and take powder equivalent to 5
	tablets (eq. to 50mg amlodipine)."
As per USP dissolution apparatus should be	Firm has not replied regarding this query.
covered with Teflon or made of any inert material	
except stainless steel, any such precautionary	
statement has not been mentioned in the	
dissolution procedure submitted by you in this section, clarification is required in this regard.	
Accuracy can be determined by conducting	Firm has performed accuracy of test method by
recovery studies with the appropriate matrix	spiked placebo method in which 4mg ,5mg and 6mg
spiked with known concentrations of the analyte,	of active spiked in 193mg placebo.
since you have not calculated the percentage	However, the sample has been prepared using
recovery to verify the accuracy of assay method.	different method from that specified in USP.
The accuracy study in verification studies of the	amerent method from that specified in OSF.
drug product is performed by analysing samples	
having 80%, 100% and 120% of active. As per the	
USP method, the standard solution has a	
concentration of 0.0275mg/ml while as per the	
accuracy table the amount of drug added is	
246mg, 200mg and 170mg. Justification /	
clarification is required how 246mg,200mg and	
170mg is equivalent to 80%, 100% and 120%.	
Specificity is ensured by the use of a reference	Firm has not provided any data to ensure the
standard wherever possible and is demonstrated	specificity of analytical method.
by the lack of interference from other components	specificity of analytical friction.
present in the matrix, while you have not	
providing and data which ensure the specificity of	
analytical method.	
As per the data, the value of purity of reference	Firm did not respond the query.
standard of amlodipine besylate is 71.80%. Justify	I im aid not respond the query.
how this reference standard was used in the	
testing of drug product which is very low purity.	
testing of drug product which is very low pullty.	

Scientific justification is required that how the	Firm did not respond the query.
value of standard deviation and relative standard	This are not respond the query.
deviation is same in repeatability data.	
Provide copies of complete analysis of at least	Firm has provided the batch analysis report of two
two batches of drug product.	batches.
Justify, how you can analyze the quality of drug	Firm replied that the raw material is of BP grade that
product of USP grade using working standard of	is why we use BP grade working standard as
BP grade of Amlodipine Besylate.	provided by the manufacturer. For the release of
	finished product, we use USP specification and our
	product meets with USP specification. For
	commercial batches after product registration, we will
	use USP grade reference standard.
As per the results of disintegration test specified	Firm replied that "our product is film coated and
in the stability data, all the tablets are	follows USP spec. The USP stated the criteria for
disintegrated within 10minutes, then justify the	film coated tablet are NMT 30 min. Therefore, our
broader acceptance criteria for disintegration test	specifications limits show the product must be
i.e. NMT 30min.	disintegrate within 30 minutes regardless the product
	may disintegrate before 30 min.
According to the results of dissolution test	Firm replied that "Our product complies with USP
obtained during the stability studies, more than	specifications and USP states that the product must
95% of drug release in 30 minutes then justifies	have NLT 75% release in 30min".
your acceptance criteria of dissolution test with	However, the acceptance criteria specified in USP
reference to the guidelines/decision approved in	"NLT 75% (Q) of the labeled amount of amlodipine
293rd meeting of Registration Board.	is dissolved.
Calculation on dissolution analysis sheet shows	Firm has not provided any justification for obtaining
that the Labeled amount of amlodipine calculated	the result of amount of amlodipine more than 115%.
was more than 115% at every time point in all	Later firm submitted the revised calculation in which
three stability batches, while the data of 6 tablets	it is indicated that the firm first calculated the factor
revealed that the percentage label claim was in the	and then the factor has been for the calculation of
range of 99-110%. Clarification is required in this	percentage drug release.
regard.	Firm has not provided any election in response of
According to raw data sheet content of active calculated is 5.0mg /tablet for amlodipine besylate	Firm has not provided any clarification in response of this query.
tablet containing 10mg of active, justify, how the	uns query.
assay would be more than 100% by getting result	
of 5.0mg/tablet for tablet containing 10mg of	
active content.	
active contell.	

#### **Decision: Approved.**

- Firm shall submit following before issuance of registration letter:
  - i. Performance of accuracy and specificity parameter in the analytical method verification studies of drug substance.
  - ii. Revised analytical procedure of drug product wherein sample preparation method for Assay test shall be in accordance with USP monograph of "Amlodipine Besylate Tablet".
- Manufacturer will place first three commercial batches on long term stability studies throughout proposed shelf life and on accelerated studies for six months as per the commitment submitted in the registration application.
- Manufacturer will perform process validation of first three commercial batches as per the commitment submitted in the registration application.

253.	Name, address of Applicant / Marketing Authorization Holder	Variant Pharmaceuticals (Pvt.) Ltd.
	Name, address of Manufacturing site.	plot # 5, M-2, pharma zone, 26 km main sharaqpur road district Sheikhupura

<u> </u>	
Status of the applicant	
	☐ Is involved in none of the above (contract giver)
Status of application	☐ New Drug Product (NDP)  ☐ Generic Drug Product (GDP)
Intended use of pharmaceutical product	<ul><li>□ Domestic sale</li><li>□ Export sale</li><li>☑ Domestic and Export sales</li></ul>
Dy. No. and date of submission	Dy. No.33174 dated 21/12/2021
Details of fee submitted	PKR 30,000/- dated 24/11/2021
The proposed proprietary name / brand name	DIPRANT 10mg Tablet
Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each tablet contains Amlodipine Besylate eq. to Amlodipine10mg
Pharmaceutical form of applied drug	Tablet
Pharmacotherapeutic Group of (API)	Calcium channel blocker
Reference to Finished product specifications	USP specifications
Proposed Pack size	3 x 10's
Proposed unit price	As per SRO
The status in reference regulatory authorities	Amlodipine Besylatet 10mg Tablet by Aurobindo Pharma - Milpharm Ltd, USFDA Approved.
For generic drugs (me-too status)	Norvasc 10mg Tablets by M/s. Pfizer Pakistan Ltd., Reg. No. 011826
GMP status of the Finished product manufacturer	New license granted on 13/02/2020 General Tablet, General Capsule, General Sachet and General dry powder injectable (pre-lyophilized)
Name and address of API manufacturer.	CADILA PHARMACEUTICALS LIMITED. 294, GIDC Industrial Estate, Ankleshwar-393 002 Gujarat. INDIA.
Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product is submitted.
Module III (Drug Substance)	Official monograph of Amlodipine Besylate is present in USP/BP. The firm as submitted detail of nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, tests for impurity & related substances, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference

		standard, constudies of drug		system and stability
	Stability studies	Accelerated: 40	$C \pm 2^{\circ}C / 65\% \pm 3$	5%RH for 36 months ± 5%RH for 6 months D033)
	Module-III (Drug Product):	description of impurities, sy (including dissemedium) and and justification	manufacturing pecifications, a solution testing its verification son of specification	nil of manufacturers, process and controls, analytical procedure at acidic and buffer tudies, batch analysis on, reference standard, ability studies of drug
	Pharmaceutical equivalence and comparative dissolution profile	against the im Tablet by M/s performing q Dissolution,). CDP has been is Norvasc 10 Acid media (j	novator brand the Pfizer Pakistan, uality tests (Idperformed againing Tablet by Moh 1.2), Acetate (pH 6.8). The	ave been established hat is Norvasc 10mg Reg. No. 011826 by dentification, Assay, st the same brand that I/s Pfizer Pakistan, in e buffer (pH 4.5) & e values for f1 and f2
	Analytical method			ve submitted including
STADII ITV	validation/verification of product STUDY DATA	linearity, range	, accuracy, preci	sion, specificity.
Manufacture		294, GIDC In		LS LIMITED. Ankleshwar-393 002
API Lot No.		Gujarat. INDIA 20AD020	Λ.	
	of Pack			
Description of Pack (Container closure system)		Alu-Alu bliste	packed in unit c	earton (30's)
			$C \pm 2^{\circ}C / 65\% \pm 3^{\circ}C \pm 2^{\circ}C / 75\%$	
Time Period		Real time: 6 m Accelerated: 6		
Frequency		Accelerated: 0, Real Time: 0, 3	2, 4, 6 (Months) 8, 6 (Months)	)
Batch No.		T-001	T-002	T-003
Batch Size		2000 tab	2000 tab	2000 tab
Manufacturing Date		02-2021	02-2021	02-2021
Date of Initia	ation	19-02-2021	22-02-2021	22-02-2021
No. of Batch	es		03	
Administrati	ve Portion			
	Reference of previous approval of applications with stability study data of the firm (if any)		ot submitted any	document.

Approval of API/ DML/GMP certificate of API manufacturer issued by concerner regulatory authority of country of origin	d issued by FDA INDIA valid till 18-10-2021.	
Documents for the procurement of AF with approval from DRAP (in case of import).	<ul> <li>Copy of letter No.4111/2020/DRAP-AD-CD(I&amp;E) dated 18/03/2020 is submitted wherein the permission to import different APIs including AMLODIPINE BESYLATE for the purpose of test/analysis and stability studies is granted.</li> <li>Invoice # CPL/BD/SAM/003/20-21 AD date 09-10-2020</li> </ul>	
Data of stability batches will be supporte by attested respective documents lik chromatograms, Raw data sheets, COA, summary dat sheets etc.	re e	
Compliance Record of HPLC softwar 21CFR & audit trail reports on productesting		
Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time an accelerated)	of	
Remarks OF Evaluator:		
Shortcoming Communicated	Reply of the Firm	
Provide detailed analytical procedures for the	Firm submitted the requisite information. However,	
testing of drug substance by drug product	the firm claimed that drug substance is of BP grade	
manufacturer.	while the procedure mentioned is section 3.2.S.4.2 is	
	in accordance with USP. Further, COA of drug	
	substance from drug substance manufacturer also	
	specified that the raw material complies with BP+ IH.	
	Assay procedure is the only difference observed	
	between the USP and BP of amlodipine besylate.	
Provide analytical Method Verification studies	Firm submitted the assay method verification studies	
including specificity, accuracy and repeatability	of drug substance, which includes three parameters i.e.	
performed by the Drug Product manufacturer.	selectivity, linearity and precision.	
performed by the Drug I roduct manufacturer.	While as per international guidelines verification	
	studies includes accuracy, specificity and precision	
	(repeatability) parameters, which has not been	
	performed by the firm to verify their analytical procedure.	
Provide copy of COA of primary / secondary	Firm submitted the COA of working standard supplied	
reference standard including source and lot	by the drug substance manufacturer and standardized	
number used by drug product manufacturer for	against amlodipine besylate 5.0 EPCRS.	
analyzing of drug substance.		
Justify the choice of excipients in your	Firm submitted the reply that they performed drug-	
formulation, since the excipients used are	excipient compatibility studies by analysing the	
different from that of the innovator / reference	stability data.	
product. Further justify how the formulation was	Firm has not given any justification for using two	
developed without performing drug-excipient	lubricating agents in the formulation.	
compatibility studies.		
Scientific justification is required for using two		
lubricating agents in the formulation.		
Provide the data of dissolution profile of 12 unit	Firm has submitted the dissolution profile data of 12	
of test product and the innovator / reference	units of reference and test batches at 10 minutes,15	
product minimum of three time-points (zero	minutes and 30 minutes time point in all three	
excluded). Submit the data of comparative	mediums.	

dissolution profile in comply with the decision of 293rd meeting of Registration Board. Since, you have submitted the comparative dissolution profile data by submitting only the numerical values of one unit without mentioning the time point and factor calculation.  Specify details including batch number and	Firm provide the requisite information. Test of
manufacturing date of the reference / comparator product against which pharmaceutical equivalence is performed.  Specify the critical steps identified during the formulation development and manufacturing of the applied product and provide summary of controls performed at the critical steps of the manufacturing process as per the requirement of 3.2. P.3.4.	identification and the uniformity of dosage units has been performed while establishing pharmaceutical equivalence against the innovator product.  Firm has replied that they identified the critical factors during product development.  But the reply did not specify the critical step which has been identified during product development nor provide summary of controls performed at the critical steps of the manufacturing process as per the requirement of 3.2. P.3.4.
Justify the acceptance criteria of weight variation i.e. 200mg±7.5% along with pharmacoepial reference.  Justification is required for not including the test of uniformity of dosage units in the specification of drug product, as the said test is included in the USP monograph of Amlodipine Besylate tablet.	In their reply, firm has submitted the copy of general chapters of USP 2091 Weight variation of dietary supplements.
Provide the method of identification test as per USP monograph of Amlodipine Besylate tablet.	Firm has not included the identification test in the release specification of drug product neither the procedure has been mentioned in the section 3.2. P.5.2.
According to the USP monograph of Amlodipine Besylate tablet, the final concentration of standard solution should be 0.0275mg/ml for assay and 0.0278mg/ml for dissolution, while the final concentration of standard solution as per your submitted method of assay and dissolution is 0.02mg/ml. Justify how the tests performed by your method can be considered acceptable under the USP monograph.	Firm has submitted the clarification that the final concentration of standard solution of amlodipine is 0.02mg/ml which is equivalent to 0.0278mg/ml amlodipine besylate.
Justify the sample solution preparation method under the assay test of drug product is different from that mentioned in USP monograph.  Justify why the calculation formula of assay content of drug product is different from that specified in USP monograph.	Firm has not given any justification for using different method for sample preparation from that specified in USP monograph. According to USP "Place NLT 5 Tablets in a suitable volumetric flask, and add sufficient quantity of Mobile phase to disintegrate the Tablets. Shake for 30 min, and dilute with Mobile phase to volume. Pass the sample through a syringe tip filter of 0.45-µm pore size. Discard the first few mL of the filtrate." While as per the applicant "Take NLT 20 tablets and grind to powder and take powder equivalent to 5 tablets (eq. to 50mg amlodipine)."
As per USP dissolution apparatus should be covered with Teflon or made of any inert material except stainless steel, any such precautionary statement has not been mentioned in the dissolution procedure submitted by you in this section, clarification is required in this regard.	Firm has not replied regarding this query.

Accuracy can be determined by conducting recovery studies with the appropriate matrix spiked with known concentrations of the analyte, since you have not calculated the percentage recovery to verify the accuracy of assay method. The accuracy study in verification studies of the drug product is performed by analyzing samples having 80%, 100% and 120% of active. As per the USP method, the standard solution has a concentration of 0.0275mg/ml while as per the accuracy table the amount of drug added is 246mg, 200mg and 170mg. Justification / clarification is required how 246mg,200mg and 170mg is equivalent to 80%, 100% and 120%. Specificity is ensured by the use of a reference	Firm has performed accuracy of test method by spiked placebo method in which 8mg ,10mg and 12mg of active spiked in 186mg placebo.  However, the sample has been prepared using different method from that specified in USP.
specificity is ensured by the use of a reference standard wherever possible and is demonstrated by the lack of interference from other components present in the matrix, while you have not providing and data which ensure the specificity of analytical method.	Firm has not provided any data to ensure the specificity of analytical method.
As per the data, the value of purity of reference standard of amlodipine besylate is 71.80%. Justify how this reference standard was used in the testing of drug product which is very low purity.	Firm did not respond the query.
Scientific justification is required that how the value of standard deviation and relative standard deviation is same in repeatability data.	Firm did not respond the query.
Provide copies of complete analysis of at least two batches of drug product.	Firm has provided the batch analysis report of two batches.
Justify, how you can analyze the quality of drug product of USP grade using working standard of BP grade of Amlodipine Besylate.	Firm replied that the raw material is of BP grade that is why we use BP grade working standard as provided by the manufacturer. For the release of finished product, we use USP specification and our product meet with USP specification. For commercial batches after product registration, we will use USP grade reference standard.
As per the results of disintegration test specified in the stability data, all the tablets are disintegrated within 10minutes, then justify the broader acceptance criteria for disintegration test i.e. NMT 30min.	Firm replied that "our product is film coated and follows USP spec. The USP stated the criteria for film coated tablet are NMT 30 min. Therefore, our specifications limits show the product must be disintegrate within 30 minutes regardless the product may disintegrate before 30 min.
According to the results of dissolution test obtained during the stability studies, more than 95% of drug releases in 30 minutes then justify your acceptance criteria of dissolution test with reference to the guidelines/decision approved in 293rd meeting of Registration Board.  Calculation on dissolution analysis sheet shows that the Labeled amount of amlodipine calculated was more than 115% at every time point in all three stability batches, while the data of 6 tablets revealed that the percentage label claim was in the range of 99-110%. Clarification is required in this regard.	Firm replied that "Our product complies with USP specifications and USP states that the product must have NLT 75% release in 30min".  However, the acceptance criteria specified in USP "NLT 75% (Q) of the labeled amount of amlodipine is dissolved.  Firm has not provided any justification for obtaining the result of amount of amlodipine more than 115%. Later firm submitted the revised calculation in which it is indicated that the firm first calculated the factor and then the factor has been for the calculation of percentage drug release.
According to raw data sheet content of active calculated is 5.0mg /tablet for amlodipine besylate	Firm has not provided any clarification in response of this query.

tablet containing 10mg of active, justify, how the	
assay would be more than 100% by getting result	
of 5.0mg/tablet for tablet containing 10mg of	
active content.	

## **Decision: Approved.**

- Firm shall submit following before issuance of registration letter:
  - i. Performance of accuracy and specificity parameter in the analytical method verification studies of drug substance.
  - ii. Revised analytical procedure of drug product wherein sample preparation method for Assay test shall be in accordance with USP monograph of "Amlodipine Besylate Tablet".
- Manufacturer will place first three commercial batches on long term stability studies throughout
  proposed shelf life and on accelerated studies for six months as per the commitment submitted in the
  registration application.
- Manufacturer will perform process validation of first three commercial batches as per the commitment submitted in the registration application.

254.	Name, address of Applicant / Marketing Authorization Holder	Variant Pharmaceuticals (Pvt.) Ltd.				
	Name, address of Manufacturing site.	plot # 5, M-2, pharma zone, 26 km main sharaqpur road district Sheikhupura				
	Status of the applicant	<ul><li>☑ Manufacturer</li><li>☐ Importer</li><li>☐ Is involved in none of the above (contract giver)</li></ul>				
	Status of application	☐ New Drug Product (NDP) ☐ Generic Drug Product (GDP)				
	Intended use of pharmaceutical product ☐ Domestic sale ☐ Export sale ☐ Domestic and Export sales					
	Dy. No. and date of submission	Dy. No.30771 dated 10/11/2021				
	Details of fee submitted	PKR 30,000/-: dated 15/10/2021				
	The proposed proprietary name / brand name	METVAR 400mg Tablet				
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each Film coated tablet contains Metformin HCl500mg  Film coated tablet.  Biguanide  USP specifications  As per SRO				
	Pharmaceutical form of applied drug					
	Pharmacotherapeutic Group of (API)					
	Reference to Finished product specifications					
	Proposed Pack size					
	Proposed unit price	As per SRO				
	The status in reference regulatory authorities	Metformin Hydrochloride 500mg TABLET Aurobindo Pharma - Milpharm Ltd, USF Approved.				
	For generic drugs (me-too status)	Glucophage 500mg TABLET by M/s Martin Daw. Reg. No. 000552				
	GMP status of the Finished product manufacturer	New license granted on 13/02/2020				

		General Tablet, General Capsule, General Sachet and General dry powder injectable (pre-lyophilized)
	Name and address of API manufacturer.	AARTI DRUGS LIMITED. Plot No. 211-213, Road No. 2 G.I.D.C., Sarigam, Dist.: Valsad-396 155 Gujarat. INDIA.
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product is submitted.
	Module III (Drug Substance)	Official monograph of Metformin HCl is present in USP/BP. The firm as submitted detail of nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, tests for impurity & related substances, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance
	Stability studies	Stability study conditions: Real time: $30^{\circ}\text{C} \pm 2^{\circ}\text{C} / 65\% \pm 5\%\text{RH}$ for 48 months Accelerated: $40^{\circ}\text{C} \pm 2^{\circ}\text{C} / 75\% \pm 5\%\text{RH}$ for 6 months Batches:(MEF/1410027, MEF/1410028, MEF/1410029)
	Module-III (Drug Product):	The firm has submitted detail of manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedure (including dissolution testing at acidic and buffer medium) and its verification studies, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug product.
	Pharmaceutical equivalence and comparative dissolution profile	Pharmaceutical Equivalence have been established against the innovator brand that is Neophage 500mg Tablet by M/s Abbott Pakistan, Reg. No. 025526 by performing quality tests (Identification, Assay, Dissolution,).  CDP has been performed against the same brand that is Neophage 500mg Tablet by M/s Abbott Pakistan, in Acid media (pH 1.2), Acetate buffer (pH 4.5) & Phosphate Buffer (pH 6.8). The values for f1 and f2 are in the acceptable range.
	Analytical method validation/verification of product	Method verification studies have submitted including linearity, range, accuracy, precision, specificity.
-	STUDY DATA	
Manufacture	er of API	AARTI DRUGS LIMITED.

		213, Road No. 96 155 Gujarat	. 2 G.I.D.C., Sarigam,	
API Lot No.	MEF/1101027	MEF/11010279		
Description of Pack (Container closure system)	Alu-Alu blister	Alu-Alu blister packed in unit carton (50's)		
Stability Storage Condition		$C \pm 2^{\circ}C / 65\% \pm 0^{\circ}C \pm 2^{\circ}C / 75\%$		
Time Period		Real time: 6 months Accelerated: 6 months		
Frequency	Accelerated: 0, Real Time: 0, 3	, 2, 4, 6 (Month B, 6 (Months)	s)	
Batch No.	T-001	T-002	T-003	
Batch Size	2000 tab	2000 tab	2000 tab	
Manufacturing Date	02-2021	02-2021	02-2021	
Date of Initiation	04-02-2021	09-02-2021	09-02-2021	
No. of Batches		03		
Administrative Portion				
Reference of previous approval of applications with stability study data of the firm (if any)		ot submitted an	y document.	
Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of original control of the country of the count	d issued by FDA			
Documents for the procurement of AI with approval from DRAP (in case of import).	<ul> <li>Copy of letter No.4111/2020/DRAP-AD-CD(Id dated 18/03/2020 is submitted wherein the permission to import different APIs including METFORMIN HCl for the purpose of test/anal and stability studies is granted.</li> <li>Invoice # EXP/1023/20-21 AD date 23-07-202</li> </ul>		ted wherein the ent APIs including purpose of test/analysis ted.	
Data of stability batches will be supported by attested respective documents like chromatograms, Raw data sheets, COA, summary data sheets etc.				
Compliance Record of HPLC softwar 21CFR & audit trail reports on productesting				
Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time an accelerated)	of	Submitte	ed	
Remarks OF Evaluator:				
Shortcoming Communicated  Clarification is required regarding the assay method of drug substance, as the drug substance manufacturer performed assay of drug substance potentiometrically while as per USP assay should be performed on HPLC.	for the drug subscriteria mentione basis). Furthermorprocedure. Firm claimed and analysis of drug	Firm replied that "we follow the USP specifications for the drug substance and the result complies with criteria mentioned in USP (98.0-102.0% on dried basis). Furthermore, we validate the analytical		

	follow the assay procedure of BP and performed the assay of drug substance potentiometrically with the acceptance criteria NLT 98.50% - NMT 101.0% on the dried substance (as per BP). There is a difference in assay method of USP and BP.
Provide detailed analytical procedures for the testing of drug substance by drug product manufacturer.	Firm has submitted the requisite information. But the assay method submitted by the applicant did not include the system suitability parameter which is the part of USP monograph of metformin hydrochloride.
Provide analytical Method Verification studies including specificity, accuracy and repeatability performed by the Drug Product manufacturer	Firm submitted the assay method verification studies of drug substance, which includes three parameters i.e. selectivity, linearity and precision.  While as per international guidelines verification studies includes accuracy, specificity and precision (repeatability) parameters, which has not been performed by the firm to verify their analytical procedure.
Justify the choice of excipients in your formulation, since the excipients used are different from that of the innovator / reference product. Further justify how the formulation was developed without performing drug-excipient compatibility studies.	Firm submitted the reply that they performed drug- excipient compatibility studies by analyzing the stability data.
Scientific justification is required for using two disintegrating agents in the formulation.	Firm replied that "we use only one disintegrant that is primogel (Sodium starch glycolate) in the master formulation the role of other agent was mentioned as disintegrant that was a typographical mistake.
Scientific justification is required for using 5% overage of active ingredient in the formulation as mentioned in the Quality target product profile data.  Provide the data of dissolution profile of 12 unit of test product and the innovator / reference product minimum of three time-points (zero excluded). Submit the data of comparative dissolution profile in comply with the decision of 293rd meeting of Registration Board. Since, you have submitted the comparative dissolution profile data by submitting only the numerical values of one unit without mentioning the time point and factor calculation.	Firm replied that "we do not use any overage in the formulation of metvar 500mg tablet. The 5% was the weight variation limit that was allowed by the USP. It was a typographical error not an overage.  Firm has submitted the dissolution profile data of 12 units of reference and test batches at 10 minutes,15 minutes and 30 minutes time point in all three mediums.
Clarification is required either the tablet is manufactured using wet granulation technique or dry granulation technique. Provide the manufacturing process along with identify the critical steps and points at which process controls, intermediate tests or final product controls are conducted.	Firm has submitted the manufacturing procedure in which it is indicated that wet granulation technique has been used for the manufacturing of metformin tablet.
Clarification is required regarding the following discrepancies observed in process validation protocol:  Process validation protocol specified that manufacturing procedure is consist of filling of pregabalin capsule with excipient into empty capsule shell.  The quantity of active ingredient used in batch manufacturing formula is different from the master formulation given in section 3.2. P.1.	Firm submitted the revised process validation protocol but it is observed that the assay limit set at 90-110% during the mixing and compression of drug product and later at the time of batch release limits of assay content were changed i.e. 95-105%.

Batch formula specified in section 3.2. P.3.2 is	
qualitatively different from the manufacturing	
formula given in process validation protocol.	
Primojel and white coat is not included in the list	Firm provide the requisite information.
of excipients specified in this section. Provide	
specification and analytical detail of primojel and	
white coat (coating material).	
Clarification is required for not including	Firm revised the specification and add identification
identification test in the specification of drug	test in the specification of drug product.
product.	
Provide detailed procedure of identification test as	Firm submitted the revised analytical procedure for
per USP monograph of Metformin HCl Tablet.	drug product which includes identification test.
For the calculation of assay via UV-Vis	Further, firm corrected the formula for calculation of
Spectrophotometer absorbance and concentration	content of active but the formula is different from that
of solutions are used to calculate the assay results	specified in USP monograph.
as per USP, while you have calculated the content	spoomed in CSI monograpii.
active using average peak area of solutions.	
Clarify, from where you get the average peak area	
by performing the assay via UV-Vis	
Spectrophotometer.	
Justify the calculation of results of assay as well	
dissolution using a different formula as specified in	
USP monograph.	
Accuracy can be determined by conducting	Firm has performed accuracy of test method by spiked
recovery studies with the appropriate matrix spiked	placebo method in which 4mg,5mg and 6mg of active
with known concentrations of the analyte, since	spiked in 193mg placebo.
you have not calculated the percentage recovery to	However, the sample has been prepared using different
verify the accuracy of assay method.	method from that specified in USP.
The accuracy study in verification studies of the	method from that specified in OSI.
drug product is performed by analyzing samples	
having 80%, 100% and 120% of active. As per the	
USP method, the standard solution has a	
concentration of 0.0275mg/ml while as per the	
accuracy table the amount of drug added is 246mg,	
200mg and 170mg. Justification / clarification is	
required how 246mg,200mg and 170mg is	
equivalent to 80%, 100% and 120%.	
Specificity is ensured by the use of a reference	Firm has not provided any data to ensure the
standard wherever possible and is demonstrated by	specificity of analytical method.
the lack of interference from other components	specificity of analytical method.
present in the matrix, while you have not providing	
and data which ensure the specificity of analytical	
method.	
Provide copies of complete analysis of at least two	Firm has provided the batch analysis report of two
batches of drug product.	batches.
Justify, how you can analyze the quality of drug	The raw material is of USP grade and the provided
11	-
product of USP grade using BP grade working standard of Metformin HCl.	working standard by manufacturer is BP grade. For
Standard of Metroffilli fict.	commercial batches after product registration, we will
	use USP grade reference standard and working
Von house menformed the identification test of de-	standard.
You have performed the identification test of drug	Firm replied that the identification test is now
product via UV spectrophotometer technique as	performed as per USP specs.
evident from the stability data but USP monograph	
of Metformin HCl do not recommend the	
identification test of drug product via UV	
spectrophotometer then Justify, how your product	
complies USP specification.	

Incomplete batch manufacturing record has been	Firm	has	not	provided	the	complete	Batch
submitted, since there is no record of how much	manuf	facturi	ng Re	cord.			
active material and excipient has been dispensed							
and calculation of batch manufacturing formula							
keeping in views the potency of active material.							
Submit complete batch manufacturing record.							

# **Decision: Approved.**

- Firm shall submit performance of accuracy and specificity parameter in the analytical method verification studies of drug substance.
- Manufacturer will place first three commercial batches on long term stability studies throughout
  proposed shelf life and on accelerated studies for six months as per the commitment submitted
  in the registration application.
- Manufacturer will perform process validation of first three commercial batches as per the commitment submitted in the registration application.

## b) Registration applications for Finished Import Product Human

255.	Name, address of Applicant / Importer	GlaxoSmithKline Pakistan Limited,35 Dockyard Road, West Wharf, Karachi 74000, Pakistan
	Details of Drug Sale License of	
	importer	Address: F-268 S.I.T.E. Karachi
	•	Validity: 19.02.2022
		Status: License to stock, exhibit for sale, distribute and sell by way of whole-sale.
		Renewal: Firm has submitted an acknowledgement receipt of renewal dated 01.02.2022
	Name and address of marketing authorization holder (abroad)	M/s. Piramal Pharma Limited, Plot No. 67-70, Sector-II, Pithampur, District-Dhar, M.P 454 775
	Name, address of manufacturer(s)	M/s. Piramal Pharma Limited, Plot No. 67-70, Sector-II, Pithampur, District-Dhar, M.P 454 775
	Name of exporting country	India
	Detail of certificates attached	CoPP:
	(CoPP, Free sale certificate,	Firm has submitted original, legalized Export CoPP certificate
	GMP certificate)	(No.04) dated 14.05.2022 issued by Food and Drug Administration, India.
		Firm has also submitted original, legalized Australian CoPP certificate (No.21/1171) dated 21/10/2021 issued by Department of Health, Therapeutic Goods Administration for evidence of product approval in SRA markets and confirmation of Free sale.
		The CoPP confirms GMP status of the manufacturing site through periodic inspection every year.
		According to the CoPP, the exporting country is Australia and the name and address of applicant is GlaxoSmithKline Australia Pty Ltd. 1061 Mountain Highway BORONIA VIC 3155 Australia and importing requesting country is Pakistan.
	Details of letter of	Firm has submitted sole agency confirmation from Piramal Pharma
	authorization / sole agency agreement	Limited. The letter states that the Product License Holder and manufacturer i.e., M/s. Piramal Pharma Limited authorizes
		GlaxoSmithKline Pakistan Limited as their sole agency for supply and distribution of

⊠ Importer		
ver)		
<del>(C1)</del>		
purpose only		
purpose only		
ccinate (equivalent		
gh a supranational		
rement by the		
Approved)		
al in reference		
ai ili icicicicc		
with justification fo		
, 70/1 and 70/2		
7, 70/1 and 70/2 rict 502 321		
rict 502 321		
a comprising of		
a comprising of Characterisation,		
a comprising of		
a comprising of Characterisation, ds or Materials,		
a comprising of Characterisation, ds or Materials,  3 batches of API		
a comprising of Characterisation, ds or Materials,  3 batches of API real time stability da		
a comprising of Characterisation, ds or Materials,  3 batches of API real time stability dated at 40°C/75% R		
a comprising of Characterisation, ds or Materials,  3 batches of API real time stability dated at 40°C/75% Ruding its description		
a comprising of Characterisation, ds or Materials,  3 batches of API real time stability dated at 40°C/75% Ruding its descriptionent, manufacture.		
a comprising of Characterisation, dls or Materials,  3 batches of API real time stability dated at 40°C/75% Ruding its descriptionent, manufactuel, process validati		
a comprising of Characterisation, ds or Materials,  3 batches of API real time stability dated at 40°C/75% Ruding its descriptionent, manufactuel, process validati of drug produ		
a comprising of Characterisation, dls or Materials,  3 batches of API real time stability dated at 40°C/75% Ruding its descriptionent, manufactuel, process validati		

	Pharmaceutical Equivalence	Firm has submitted Clinical Study Reports comprising of Reports of
	and Comparative Dissolution	Biopharmaceutic Studies, Bioavailability (BA) Study Reports,
	Profile	Comparative BA and Bioequivalence (BE) Study Reports, Reports of
		Studies Pertinent to Pharmacokinetics using Human
		Biomaterials.
	Analytical method	Firm has submitted analytical method validation studies for the
	validation/verification of	applied product.
	product	
	Container closure system of the	Child-resistant aluminum foil blister strip
	drug product	
	Stability study data of drug	Firm has submitted stability study data of 3 batches of API at
	product, shelf life and storage	accelerated as well as real time conditions. The real time stability data
	conditions	is conducted at for up to 48 months at
		30°C/75% RH or for up to 6 months and accelerated at 40°C/75% RH.
- 1	d 1 DEG	

Evaluation by PEC:

# **Decision: Deferred for following:**

- Evaluation & presentation of complete details regarding Pharmacological, Pharmacodynamic & clinical indications, contra-indications etc of the applied product.
- Approval and availability status of the product in reference regulatory authorities and other countries with malaria prevalence.
- Opinion of Directorate of Malaria Control regarding tentative rollout plan of the drug product.

## c) Deferred cases of form 5 F

256.	Name, address of Applicant / Marketing Authorization Holder	M/s Novamed Pharmaceuticals (Pvt.) Ltd Lahore		
	Name, address of Manufacturing site.	M/s Novamed Pharmaceuticals (Pvt.) Ltd., 28km Ferozepur Road Lahore		
	Status of the applicant			
	Status of application	<ul><li>☑ New Drug Product (NDP)</li><li>☐ Generic Drug Product (GDP)</li></ul>		
	Intended use of pharmaceutical product	<ul><li>□ Domestic sale</li><li>□ Export sale</li><li>☑ Domestic and Export sales</li></ul>		
	Dy. No. and date of submission	Dy. No.18479 Dated 01/07/2021		
	Details of fee submitted	PKR 50,000/-: dated 30/04/2021 slip no.2070706 PKR 25,000/-: dated 16/06/2021 slip no. 7547639635 Total 75,000/		
	The proposed proprietary name / brand name	Morjesta Tablet 20/20mg		
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each Extended release tablet contains: Doxylamine Succinate20mg Pyridoxine HCl20mg		
	Pharmaceutical form of applied drug	Extended release tablet		
	Pharmacotherapeutic Group of (API)	Doxylamine Succinate (Antihistamines) Pyridoxine HCL (water-soluble vitamin)		

Reference to Finished product specifications	Manufacturer Specifications (In-House)
Proposed Pack size	30's
Proposed unit price	As per SRO
The status in reference regulatory authorities	Bonjesta Tablet 20/20mg, approved in FDA USA Company: Duchesnay Inc, USA
For generic drugs (me-too status)	Not Applicable
GMP status of the Finished product manufacturer	License granted on 08/04/2006 and renewed o 08/04/2021 General tablet section approved and GM certificate on 31/08/2021.
Name and address of API manufacturer.	Pyridoxine HCL Jiangxi Tianxin Pharmaceuticals Co., Ltd : LE' Anjiang Industrial Zone, Leping City, Jiangx Province 333300, CHINA Doxylamine Succeinate; Bioxera Pharma N-57, M.I.D.C., Anand Naga: Additional Ambernath, Dist. Thane 421501 Maharashtra, India
Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-Pl template. Summarized information related to nomenclature, structure, general properties solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities specifications, analytical procedures and inverification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product is submitted.
Module III (Drug Substance)	Official monograph of Doxylamine Succinate an Pyridoxine HCL is present in USP and B respectively. The firm has submitted detail of nomenclature, structure, general properties solubilities, physical form, manufacturers, description of manufacturing process and controls, tests for impurity D, G & related substances (impurity A dunspecified), specifications, analytical procedure and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance
Stability studies	Stability study conditions: Real time: $30^{\circ}\text{C} \pm 2^{\circ}\text{C} / 65\% \pm 5\%\text{RH}$ for 36 months. Accelerated: $40^{\circ}\text{C} \pm 2^{\circ}\text{C} / 75\% \pm 5\%\text{RH}$ for 6 month. Batches: Doxylamine Succinate (DS-200604, DS-200605-DS 200606) Pyridoxine HCl (4-11009,4-11010,4-11011)
Module-III (Drug Product):	The firm has submitted detail of manufacturer description of manufacturing process and control impurities, specifications, analytical procedur (including dissolution testing at acidic and buffer medium) and its verification studies, batch analys and justification of specification, reference standard

			container closure syste product.	m and stability studies of drug	
	dissolution profile  Analytical method validation/verification of		Pharmaceutical Equivalence has been established for all the quality test against the brand leader that is Bonjesta Tablet 20/20mg. Pharmaceuticals by performing quality tests (Identification, Assay, Dissolution, pH).  Comparative dissolution profile data has been submitted against the brand leader that is Bonjesta Tablet 20/20mg.  Method verification studies have submitted including linearity, range, accuracy, precision, specificity.		
	1	STABILITY ST	ΓUDY DATA		
Manufac	cturer of API	Pyridoxine HCL Jiangxi Tianxin Pharmaceuticals Co., Ltd: LE' Anjiang Industrial Zone, Leping City, Jiangxi, Province 333300, CHINA Doxylamine Succinate; Bioxera Pharma N-57, M.I.D.C., Anand Nagar, Additional Ambernath, Dist. Thane 421501, Maharashtra, India			
API Lot No.		Pyridoxine HCL PH19075031 Doxylamine Succinate DOX/008/05/19			
Description of Pack (Container closure system)		An alu-alu blister containing a peach colored round biconvex tablet with an enteric coated core containing 10mg of Doxylamine succinate and 10mg of pyridoxine HCl, and an immediate release coating of 10mg of Doxylamine succinate and 10mg of pyridoxine HCl having both sides plain packed in a specific unit carton containing 3 blisters of 10's.			
Stability	Storage Condition	Real time: 30°C ± 2°C / 65% ± 5%RH Accelerated: 40°C ± 2°C / 75% ± 5%RH			
Time Pe	riod	Real time: 6 months Accelerated: 6 months			
Frequen	су	Accelerated: 0, 3, 6 (Months) Real Time: 0, 3, 6 (Months)			
Batch N	0.	RD/PR20-007/T4/S1	RD/PR20-007/T4/S2	RD/PR20-007/T4/S3	
Batch Si	ze	5000 Tablets	5000 Tablets	5000 Tablets	
Manufac	cturing Date	08-2020	08-2020	08-2020	
Date of 1	Initiation	25-08-2020	25-08-2020	25-08-2020	
No. of B	atches		03		
		Administrati	ive Portion		
1.	Reference of previous approval of applications with stability study data of the firm (if any)		The firm has submitted copy of Last inspection Report conducted on 24/01/2018 (Daclatasvir), 06/03/2017 (Sofosbuvir)		
2.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.		1 7		
3.	Documents for the procurement of API with approval from DRAP (in case of import).		Copy of letter No.8830/2019/DRAP-AD-CD(I&E) dated 25/06/2019 is submitted wherein the permission to import of Doxylamine Succinate for		

			<u></u>	
			the purpose of test/analysis and stability studies is granted.  AD Attested Invoice No EI/018/2019-20 (Doxylamine Succinate) and 19NVT-310 (Pyridoxine HCl) is also submitted.	
4.	4. Data of stability batches will be support attested respective documents chromatograms, Raw data sheets, COA, summary data setc.		Submitted	
5.	Compliance Record of HPLC software & audit trail reports on product testing		Submitted	
6.	Record of Digital data logger for tem and humidity monitoring of stability c (real time and accelerated)		Submitted	
Remarks	s OF Evaluator:			
	Shortcoming/Deficiencies		Response of the Firm	
Provide valid GMP certificate of Bioxera Pharma Pvt. Ltd. Maharashtra, India, since the expired certificate has been submitted.		Firm submitted the GMP certificate of M/s. Bioxera Pharma Pvt. Ltd. Maharashtra, India valid for a period of 11/12/2021-10/11/2022. (certificate no. 6081638) issued by Food & Drugs Administration (Maharashtra State) supplier of Doxylamine succinate.		
• You have submitted the accelerated stability data of drug substance of three batches of Doxylamine succinate that are DS200604, DS200605 & DS200706 and which has been conducted in the year 2020, while the real time stability data of three different batches that has been conducted in year 2015 on the batches that are DS-150901, DS-151002 & DS-151103.		Firm submitted the real time and accelerated stability data of batches DS-150901, DS-151002 & DS-151103.		
Justify the descending trend in percentage of drug release after 15min in phosphate buffer pH 6.8 medium as evident from the data of comparative dissolution profile.		Firm replied that, innovator tablet Bonjesta reflects same trend in Comparative dissolution profile as Morjesta and %age coefficient of variation is less than 10%.  As per the dissolution guideline given by DRAP percentage coefficient of variation at other time points than 10 minutes should be not more than 10%.		
• Please clarify the percentage of drug release in pH 1.2 medium i.e. more than 40% in 30minutes, either it is the percentage of release of drug present only in immediate release film coating part or the percentage of release out of 100 % drug present both in core and coat.		Firm confirmed that, it is the percentage of release out of 100 % drug present both in core and coat.		
• Elab HCl med give buff	porate the dissolution method in 0.1N medium and 6.8 pH phosphate buffer ium, since the given method only in the detail of dissolution in phosphate for medium.	applied dissolut comple Phosph However recomm min, which minutes	nended sampling time in acidic medium is till 120 hile the firm replaced the acidic medium after 60	
_	3.2.P.5.1,0.02mg/ml conc. of sample		are in which it is specified that the final conc. of	

and standard solution should be prepared for the assay of drug product, but the raw data sheet of assay reflects that different conc. of sample and standard solution has been used. Provide justification for variation in conc. of sample and standard solution than specified in section 3.2. P.5.1. standard and sample solution of both actives should be of  $0.005 \, \text{mg/ml}$ .

However, the conc of sample and standard solution set in analytical method verification studies of drug product is 0.02mg/ml for both actives.

Justify the acceptance criteria of dissolution in pH 6.8 phosphate buffer NLT 75% (Q) for 30 minutes keeping in view the result of dissolution test submitted in raw data sheet, in which percentage of drug release is more than 85% in the said medium.

As per the acceptance criteria of dissolution in pH 6.8 phosphate buffer Not Less Than (NLT) 75%(Q) for 30 minutes, accordingly percentage of drug release is above 75% in the said medium. So, more than 85% is from core layer (10mg of each API is present in core layer). So more than 8.5mg (which is 85% of labeled quantity in core layer) is released.

As evident from the raw data sheet more than 95% of both drug release at pH 1.2 acid stage, then justify the acceptance criteria of dissolution test in pH 1.2 acid medium i.e. NLT 75% (Q) in 0.1 N HCl for 1hour.

As per the acceptance criteria of dissolution in pH 1.2 acidic buffer Not Less Than (NLT) 75%(Q) for 1 hour, accordingly percentage of drug release is above 95% in the said medium. So, more than 95% is from IR layer)10mg of each API is present is IR layer).). So more than 9.5mg (which is 95% of labeled quantity in IR layer) is released Firm did not clarify the time point at which drug release of more than 95% is achieved, as 1 hour is the time point till which the core should be intact in acidic medium. Further, justification is still need for setting the acceptance criteria on a broader range despite the release achieved above 95% as stated in the reply.

Specify the time points in the raw data sheet of dissolution test at which the percentage of drug release has been calculated. Firm has not clarified the time point at which the drug release of core and coat of morjesta tablet calculated.

- Scientific justification is required for using 10% overage of both active ingredients in the immediate release coating of drug product.
  - As active are present in coating layer to accommodate the line loss during coating,10% overage was used in executed batches.
- Incomplete Batch manufacturing Record has been submitted, as there is no record of in-process weight control sheet of core tablet, in-process dissolution test, inprocess weight control sheet of coated tablet, in-process dissolution test of coated tablet.
- Complete BMR with all in process sheets are attached.

Decision of 316<sup>th</sup> meeting of Registration Board:

Deferred for the submission of following:

- Justification for performing the analytical verification studies with the conc. of 0.02mg/ml of sample and standard solution while the revised analytical method specified that concentration of both solutions should be 0.005mg/ml.
- Justification for changing the 0.1N HCl medium with phosphate buffer medium of pH6.2 after 1 hour, since according to US FDA dissolution database the recommended sampling time in 0.1N HCl is till 120min.
- Clarification regarding sampling time point of dissolution test in the stability data sheets and present the dissolution results with minimum and maximum value along with time point.

Firm submitted the following reply in response to the above-mentioned decision of Registration Board.  Observations/Shortcomings  Justification for performing the analytical validation studies with the cone. of 0.02mg/ml of sample and standard solution while the revised analytical method specified that concentration of both solutions should be 0.005mg/ml.  We have validated our method taking cone. Eq to 0.02mg, as limit of Quantification for both APIs is up a substance i.e. (0.02mg/ml) that is possible to be determined by means of a given analytical procedure with the established accuracy, precision, and uncertainty was used for AMV. (Copy of AMV report is attached)  As per ICH Guideline Q2 R1:  "The quantitation limit of an individual analytical procedure is the lowest amount of analyte in a sample which can be quantitatively determined with suitable precision and accuracy. The quantitation limit is a parameter of quantitative assays for low levels of compounds in sample matrices.  (Copy of ICH Q2 R1 Attached)  Firm performed the analytical validation studies of drug product with the cone. of 0.005mg/ml of sample and standard solution and submit the data of revised validation studies.  As per BP Dissolution Guidance, "the test may be concluded in a shorter period of time when the minimum amount (i.e. 75%) dissolved is met'. In specification to the commended sampling time in 0.1N HCl is till 120min.  Clarification regarding sampling time point of dissolution regarding sampling time point of dissolution results with minimum and maximum value along with time  Clarification regarding sampling time point of dissolution results with minimum and maximum value along with time  Occupantial transportation of the concentration of a concentration of a concentration of a concentration of a concentration of a concentration of a concentration of a concentration of a concentration of a concentration of a concentration of a concentration of a concentration of a concentration of a concentration of a concentration of a concentra	Degrange of the Eigen					
Observations/Shortcomings Justification for performing the analytical validation studies with the conc. of 0.02mg/ml of sample and standard solution while the revised analytical method specified that concentration of both solutions should be 0.005mg/ml.  We have validated our method taking conc. Eq to 0.02mg, as limit of Quantification for both APIs is up to 0.0027 mcg/ml and 0.0007 mcg/ml for Pyridoxine and doxylamine respectively. To Establish this Validated LOQ limit, lowest concentration of a substance i.e. (0.02mg/ml) that is possible to be determined by means of a given analytical procedure with the established accuracy, precision, and uncertainty was used for AMV. (Copy of AMV report is attached) As per ICH Guideline Q2 R1:  "The quantitation limit of an individual analytical procedure is the lowest amount of analyte in a sample which can be quantitatively determined with suitable precision and accuracy. The quantitative determined which can be quantitatively determined with suitable precision and accuracy. The quantitative determined with suitable precision and accuracy. The quantitative determined with suitable precision and accuracy. The quantitative determined with suitable precision and accuracy. The quantitative of an individual analytical procedure is the lowest amount of analyte in a sample matrices. (Copy of ICH Q2 R1 Attached)  Firm performed the analytical validation studies of drug product with the conc. of 0.005mg/ml of sample and standard solution and submit the data of revised validation studies.  As per BP Dissolution Guidance, "the test may be an advanced accoration of the product of the product of the concluded in a shorter period of time when the minimum amount (i.e. 75%) dissolved is met'. In case of the subject Product more than 75% of the drug present in IR Layer has been released in 1 hour this implies that the optimum drug release obtained in Specified time of 1 hour. (Copy of CDP Report & testing Method is attached for reference.)  Clarification regarding sampling time point of d	Response of the Firm:	have mentioned decision of Pagistration Roard				
Justification for performing the analytical validation studies with the cone. of 0.02mg/ml of sample and standard solution while the revised analytical method specified that concentration of both solutions should be 0.005mg/ml.  We have validated our method taking cone. Eq to 1.02mg, as limit of Quantification for both APIs is up to 0.027 meg/ml and 0.0007 meg/ml for Pyridoxine and doxylamine respectively. To Establish this solutions should be 0.005mg/ml.  Validated LOQ limit, lowest concentration of a substance i.e. (0.02mg/ml) that is possible to be determined by means of a given analytical procedure with the established accuracy, precision, and uncertainty was used for AMV. (Copy of AMV report is attached) As per ICH Guideline Q2 R1:  "The quantitative limit of an individual analytical procedure is the lowest amount of analyte in a sample which can be quantitative assays for low levels of compounds in sample matrices. (Copy of CHQ 2R1 Attached) Firm performed the analytical validation studies of drug product with the cone. of 0.005mg/ml of sample and standard solution and submit the data of revised validation studies.  Justification for changing the 0.1N HCl medium with phosphate buffer medium of pH6.8 after 1 hour, since according to US FDA dissolution database the recommended sampling time in 0.1N HCl is till 120min.  Justification for changing the 0.1N HCl medium with phosphate buffer medium of pH6.8 after 1 hour, since according to US FDA dissolution database the recommended sampling time in 0.1N HCl is till 120min.  Justification for changing the 0.1N HCl medium with phosphate buffer medium of pH6.8 after 1 hour, since according to US FDA dissolution database the recommended sampling time in 0.1N HCl is till 120min.  Justification for changing the 0.1N HCl is till 120min.  Justification for changing the 0.1N HCl is till 120min.  Justification for changing the 0.1N HCl is till 120min.  Justification for changing the 0.1N HCl is till 120min.  Justification for changing the 0.1N HCl is till 120min.  Justif						
studies with the conc. of 0.02mg/ml of sample and standard solution while the revised analytical method specified that concentration of both solutions should be 0.005mg/ml.  9.02mg, as limit of Quantification for both APIs is up to 0.0027 mcg/ml and 0.0007 mcg/ml for Pyridoxine and doxylamine respectively. To Establish this Validated LOQ limit, lowest concentration of a substance i.e. (0.02mg/ml) that is possible to be determined by means of a given analytical procedure with the established accuracy, precision, and uncertainty was used for AMV. (Copy of AMV report is attached) As per ICH Guideline Q2 R1:  "The quantitation limit of an individual analytical procedure is the lowest amount of analyte in a sample which can be quantitatively determined with suitable precision and accuracy. The quantitation limit is a parameter of quantitative assays for low levels of compounds in sample marrices.  (Copy of ICH Q2 R1 Attached) Firm performed the analytical validation studies of drug product with the cone. of 0.005mg/ml of sample and standard solution and submit the data of revised validation studies.  As per BP Dissolution Guidance, "the test may be concluded in a shorter period of time when the recommended sampling time in 0.1N HCl is till 120min.  120min.		•				
standard solution while the revised analytical method specified that concentration of both solutions should be 0.005mg/ml.  10 0.0027 meg/ml and 0.0007 meg/ml for Pyridoxine and doxylamine respectively. To Establish this Validated LOQ limit, lowest concentration of a substance i.e. (0.02mg/ml) that is possible to be determined by means of a given analytical procedure with the established accuracy, precision, and uncertainty was used for AMV. (Copy of AMV report is attached)  As per ICH Guideline Q2 R1:  "The quantitation limit of an individual analytical procedure is the lowest amount of analyte in a sample which can be quantitatively determined with suitable precision and accuracy. The quantitation limit is a parameter of quantitative assays for low levels of compounds in sample matrices.  (Copy of ICH Q2 R1 Attached)  Firm performed the analytical validation studies of drug product with the conc. of 0.005mg/ml of sample and standard solution and submit the data of revised validation studies.  Justification for changing the 0.1N HCl medium with phosphate buffer medium of pH6.8 after 1 hour, since according to US FDA dissolution database the recommended sampling time in 0.1N HCl is till 120min.  Justification for changing the 0.1N HCl is till 120min.  Substance i.e. (0.02mg/ml) that is possible to be determined by means of a given analytical procedure with the conc. of a substance i.e. (0.000 group) of a substance i.e. (0.000 group) of a substance i.e. (0.000 group) of a substance i.e. (0.000 group) of a substance i.e. (0.000 group) of a substance i.e. (0.000 group) of a mucertainty was used for AMV. (Copy of AMV report is a tatched)  Firm performed the analytical validation studies of drug product with the conc. of 0.005mg/ml of sample and standard solution and submit the data of revised validation studies.  Justification for changing the 0.1N HCl is till 120min.  Specification first is NL 2 pH) till 2 hours i.e. 120 mins (as per recommended time points of the FDA) and replaced with buffer after 2 hours, which	1	, , , , , , , , , , , , , , , , , , ,				
method specified that concentration of both solutions should be 0.005mg/ml.  and doxylamine respectively. To Establish this Validated LOQ limit, lowest concentration of a substance i.e. (0.02mg/ml) that is possible to be determined by means of a given analytical procedure with the established accuracy, precision, and uncertainty was used for AMV. (Copy of AMV report is attached)  As per ICH Guideline Q2 R1:  "The quantitation limit of an individual analytical procedure is the lowest amount of analyte in a sample which can be quantitatively determined with suitable precision and accuracy. The quantitation limit is a parameter of quantitatively determined with suitable precision and accuracy. The quantitation limit is a parameter of quantitative assays for low levels of compounds in sample matrices.  (Copy of ICH Q2 R1 Attached)  Firm performed the analytical validation studies of drug product with the conc. of 0.005mg/ml of sample and standard solution and submit the data of revised validation studies.  Justification for changing the 0.1N HCl medium with phosphate buffer medium of pH6.8 after 1 hour, since according to US FDA dissolution database the recommended sampling time in 0.1N HCl is till 120min.  As per BP Dissolution Guidance, "the test may be concluded in a shorter period of time when the minimum amount (i.e. 75%) dissolved is met. In case of the subject Product more than 75% of the drug present in IR Layer has been released in 1 hour this implies that the optimum drug release obtained in Specified time of 1 hour. (Copy of the BP Reference is attached)  However, as per analytical method, for testing of enteric coating integrity we have run the dissolution in acidic media, sampling time point is 60 min where observed at acid resistance stage. (Copy of CDP Report & testing Method is attached for reference.)  In acidic media, sampling time point is 60 min where of the drug has been released from IR layer, while dissolution run for 2 hours to check the integrality of the enteric coating layer. And specific	· · · · · · · · · · · · · · · · · ·					
solutions should be 0.005mg/ml.  Validated LOQ limit, lowest concentration of a substance i.e. (0.02mg/ml) that is possible to be determined by means of a given analytical procedure with the established accuracy, precision, and uncertainty was used for AMV. (Copy of AMV report is attached)  As per ICH Guideline Q2 R1:  "The quantitation limit of an individual analytical procedure is the lowest amount of analyte in a sample which can be quantitatively determined with suitable precision and accuracy. The quantitol limit is a parameter of quantitative assays for low levels of compounds in sample matrices.  (Copy of ICH Q2 R1 Attached)  Firm performed the analytical validation studies of drug product with the cone. of 0.005mg/ml of sample and standard solution and submit the data of revised validation studies.  Justification for changing the 0.1N HCI medium with phosphate buffer medium of pH6.8 after 1 hour, since according to US FDA dissolution database the recommended sampling time in 0.1N HCI is till 120min.  Justification for changing the 0.1N HCI is till 120min.  As per BP Dissolution Guidance, "the test may be concluded in a shorter period of time when the minimum amount (i.e. 75%) dissolved is met. In case of the subject Product more than 75% of the drug present in IR Layer has been released in 1 hour this implies that the optimum drug release obtained in Specified time of 1 hour. (Copy of the BP Reference is attached)  However, as per analytical method, for testing of enteric coating integrity we have run the dissolution in acidic media (at 1.2 pH) till 2 hours i.e. 120 mins (as per recommended time points of the FDA) and replaced with buffer after 2 hours. which is evident from CDP report and testing method and no cracks were observed at acid resistance stage. (Copy of CDP Report & testing Method is attached for reference.)  In acidic media, sampling time point is 60 min where 95% of the drug has been released from IR layer, while dissolution run for 2 hours to check the integrality of the enteric coating	· · · · · · · · · · · · · · · · · ·	•				
substance i.e. (0.02mg/ml) that is possible to be determined by means of a given analytical procedure with the established accuracy, precision, and uncertainty was used for AMV. (Copy of AMV report is attached)  As per ICH Guideline Q2 R1:  "The quantitation limit of an individual analytical procedure is the lowest amount of analyte in a sample which can be quantitatively determined with suitable precision and accuracy. The quantitation limit is a parameter of quantitative assays for low levels of compounds in sample matrices.  (Copy of ICH Q2 R1 Attached)  Firm performed the analytical validation studies of drug product with the conc. of 0.005mg/ml of sample and standard solution and submit the data of revised validation studies.  Justification for changing the 0.1N HCl medium with phosphate buffer medium of pH6.8 after 1 hour, since according to US FDA dissolution database the recommended sampling time in 0.1N HCl is till 120min.  As per BP Dissolution Guidance, "the test may be concluded in a shorter period of time when the minimum amount (i.e. 75%) dissolved is met'. In case of the subject Product more than 75% of the drug present in IR Layer has been released in 1 hour this implies that the optimum drug release obtained in Specified time of 1 hour. (Copy of the BP Reference is attached)  However, as per analytical method, for testing of enteric coating integrity we have run the dissolution in acidic media (at 1.2 pH) til 12 hours i.e. 120 mins (as per recommended time points of the FDA) and replaced with buffer after 2 hours. which is evident from CDP report and testing method and no cracks were observed at acid resistance stage. (Copy of CDP Report & testing Method is attached for reference.)  Clarification regarding sampling time point of dissolution results with minimum and maximum value along with time  Clarification regarding sampling time point of dissolution results with minimum and maximum value along with time	_					
determined by means of a given analytical procedure with the established accuracy, precision, and uncertainty was used for AMV. (Copy of AMV report is attached)  As per ICH Guideline Q2 R1:  "The quantitation limit of an individual analytical procedure is the lowest amount of analyte in a sample which can be quantitatively determined with suitable precision and accuracy. The quantitation limit is a parameter of quantitative assays for low levels of compounds in sample matrices.  (Copy of ICH Q2 R1 Attached)  Firm performed the analytical validation studies of drug product with the conc. of 0.005 mg/ml of sample and standard solution and submit the data of revised validation studies.  Justification for changing the 0.1N HCl medium with phosphate buffer medium of pH6.8 after 1 hour, since according to US FDA dissolution database the recommended sampling time in 0.1N HCl is till 120min.  As per BP Dissolution Guidance, "the test may be concluded in a shorter period of time when the minimum amount (i.e. 75%) dissolved is met'. In case of the subject Product more than 75% of the drug present in IR Layer has been released in 1 hour this implies that the optimum drug release obtained in Specified time of 1 hour. (Copy of the BP Reference is attached)  However, as per analytical method, for testing of enteric coating integrity we have run the dissolution in acidic media (at 1.2 pH) till 2 hours i.e. 120 mins (as per recommended time points of the FDA) and replaced with buffer after 2 hours, which is evident from CDP report and testing method and no cracks were observed at acid resistance stage. (Copy of CDP Report & testing Method) is attached for reference.)  Clarification regarding sampling time point of dissolution results with minimum and maximum value along with time  dissolution results with minimum and maximum value along with time  The author of a procedure in the stability data sheets and present he dissolution run for 2 hours to check the integrality of the enteric coating layer. And specification limit is NL	Solutions should be 0.005mg/mi.					
with the established accuracy, precision, and uncertainty was used for AMV. (Copy of AMV report is attached) As per ICH Guideline Q2 R1: "The quantitation limit of an individual analytical procedure is the lowest amount of analyte in a sample which can be quantitatively determined with suitable precision and accuracy. The quantitation limit is a parameter of quantitative assays for low levels of compounds in sample matrices. (Copy of ICH Q2 R1 Attached) Firm performed the analytical validation studies of drug product with the conc. of 0.005mg/ml of sample and standard solution and submit the data of revised validation studies.  Justification for changing the 0.1N HCl medium with phosphate buffer medium of pH6.8 after 1 hour, since according to US FDA dissolution database the recommended sampling time in 0.1N HCl is till 120min.  As per BP Dissolution Guidance, "the test may be concluded in a shorter period of time when the minimum amount (i.e. 75%) dissolved is met'. In case of the subject Product more than 75% of the drug present in IR Layer has been released in 1 hour this implies that the optimum drug release obtained in Specified time of 1 hour. (Copy of the BP Reference is attached) However, as per analytical method, for testing of enteric coating integrity we have run the dissolution in acidic media (at 1.2 pH) till 2 hours i.e. 120 mins (as per recommended time points of the FDA) and replaced with buffer after 2 hours. which is evident from CDP report and testing method and no cracks were observed at acid resistance stage. (Copy of CDP Report & testing Method is attached for reference.)  In acidic media, sampling time point is 60 min where 95% of the drug has been released from IR layer, while dissolution run for 2 hours to check the integrality of the enteric coating layer. And specification limit is NLT 75% (above 75%) in 0.1N HCL for 1 hour.						
uncertainty was used for AMV. (Copy of AMV report is attached) As per ICH Guideline Q2 R1: "The quantitation limit of an individual analytical procedure is the lowest amount of analyte in a sample which can be quantitatively determined with suitable precision and accuracy. The quantitation limit is a parameter of quantitative assays for low levels of compounds in sample matrices. (Copy of ICH Q2 R1 Attached) Firm performed the analytical validation studies of drug product with the conc. of 0.005mg/ml of sample and standard solution and submit the data of revised validation studies.  As per BP Dissolution Guidance, "the test may be concluded in a shorter period of time when the minimum amount (i.e. 75%) dissolved is met'. In case of the subject Product more than 75% of the drug present in IR Layer has been released in 1 hour this implies that the optimum drug release obtained in Specified time of 1 hour. (Copy of the BP Reference is attached) However, as per analytical method, for testing of enteric coating integrity we have run the dissolution in acidic media (at 1.2 pH) till 2 hours i.e. 120 mins (as per recommended time points of the FDA) and replaced with buffer after 2 hours, which is evident from CDP report and testing method and no cracks were observed at acid resistance stage. (Copy of CDP Report & testing Method is attached for reference.)  In acidic media, sampling time point is 60 min where observed at acid resistance stage. (Copy of CDP Report & testing Method is attached for reference.)  In acidic media, sampling time point is 60 min where observed at acid resistance stage. (Copy of CDP Report & testing Method is attached for reference.)  In acidic media, sampling time point is 60 min where observed at acid resistance stage. (Copy of CDP Report & testing Method is attached for reference.)  In acidic media, sampling time point is 60 min where observed at acid resistance stage. (Copy of CDP Report & testing Method is attached for reference.)						
report is attached) As per ICH Guideline Q2 R1: "The quantitation limit of an individual analytical procedure is the lowest amount of analyte in a sample which can be quantitatively determined with suitable precision and accuracy. The quantitation limit is a parameter of quantitative assays for low levels of compounds in sample matrices. (Copy of ICH Q2 R1 Attached) Firm performed the analytical validation studies of drug product with the cone. of 0.005 mg/ml of sample and standard solution and submit the data of revised validation studies.  As per BP Dissolution Guidance, "the test may be concluded in a shorter period of time when the minimum amount (i.e. 75%) dissolved is met'. In case of the subject Product more than 75% of the drug present in IR Layer has been released in 1 hour this implies that the optimum drug release obtained in Specified time of 1 hour. (Copy of the BP Reference is attached) However, as per analytical method, for testing of enteric coating integrity we have run the dissolution in acidic media (at 1.2 pH) till 2 hours i.e. 120 mins (as per recommended time points of the FDA) and replaced with buffer after 2 hours, which is evident from CDP report and testing method and no cracks were observed at acid resistance stage. (Copy of CDP Report & testing Method is attached for reference.)  In acidic media, sampling time point is 60 min where observed at acid resistance stage. (Copy of CDP Report & testing Method is attached for reference.)  In acidic media, sampling time point is 60 min where observed at acid resistance stage. (Copy of CDP Report & testing method and no cracks were observed at acid resistance stage. (Copy of CDP Report & testing method and no cracks were observed at acid resistance stage. (Copy of CDP Report & testing method and no cracks were observed at acid resistance stage. (Copy of CDP Report & testing method and no cracks were observed at acid resistance stage. (Copy of CDP Report & testing method and no cracks were observed at acid resistance stage. (Copy of CDP Report						
As per ICH Guideline Q2 R1:  "The quantitation limit of an individual analytical procedure is the lowest amount of analyte in a sample which can be quantitatively determined with suitable precision and accuracy. The quantitation limit is a parameter of quantitative assays for low levels of compounds in sample matrices.  (Copy of ICH Q2 R1 Attached)  Firm performed the analytical validation studies of drug product with the cone. of 0.005mg/ml of sample and standard solution and submit the data of revised validation studies.  Justification for changing the 0.1N HCl medium with phosphate buffer medium of pH6.8 after 1 hour, since according to US FDA dissolution database the recommended sampling time in 0.1N HCl is till 120min.  As per BP Dissolution Guidance, "the test may be concluded in a shorter period of time when the minimum amount (i.e. 75%) dissolved is met'. In case of the subject Product more than 75% of the drug present in IR Layer has been released in 1 hour this implies that the optimum drug release obtained in Specified time of 1 hour. (Copy of the BP Reference is attached)  However, as per analytical method, for testing of enteric coating integrity we have run the dissolution in acidic media (at 1.2 pH) till 2 hours i.e. 120 mins (as per recommended time points of the FDA) and replaced with buffer after 2 hours, which is evident from CDP report and testing method and no cracks were observed at acid resistance stage. (Copy of CDP Report & testing Method is attached for reference.)  Clarification regarding sampling time point of dissolution results with minimum and maximum value along with time  Clarification in it is NLT 75% (above 75%) in 0.1N HCL for 1 hour.  In basic media, sampling time point is 30 min where 95% of the drug has been released from core layer, and specification limit is NLT 75% (above 75%) in 0.1N HCL for 1 hour.						
procedure is the lowest amount of analyte in a sample which can be quantitatively determined with suitable precision and accuracy. The quantitation limit is a parameter of quantitative assays for low levels of compounds in sample matrices.  (Copy of ICH Q2 R1 Attached)  Firm performed the analytical validation studies of drug product with the conc. of 0.005mg/ml of sample and standard solution and submit the data of revised validation studies.  Justification for changing the 0.1N HCl medium with phosphate buffer medium of pH6.8 after 1 hour, since according to US FDA dissolution database the recommended sampling time in 0.1N HCl is till 120min.  As per BP Dissolution Guidance, "the test may be concluded in a shorter period of time when the minimum amount (i.e. 75%) dissolved is met'. In case of the subject Product more than 75% of the drug present in IR Layer has been released in 1 hour this implies that the optimum drug release obtained in Specified time of 1 hour. (Copy of the BP Reference is attached)  However, as per analytical method, for testing of enteric coating integrity we have run the dissolution in acidic media (at 1.2 pH) till 2 hours i.e. 120 mins (as per recommended time points of the FDA) and replaced with buffer after 2 hours, which is evident from CDP report and testing method and no cracks were observed at acid resistance stage. (Copy of CDP Report & testing Method is attached for reference.)  In acidic media, sampling time point is 60 min where 95% of the drug has been released from IR layer, while dissolution run for 2 hours to check the integrality of the enteric coating layer. And specification limit is NLT 75% (above 75%) in 0.1N HCL for 1 hour.  In basic media, sampling time point is 30 min where 95% of the drug has been released from core layer, and specification limit is NLT 75% (above 75%) in 0.1N HCL for 1 hour.		As per ICH Guideline Q2 R1:				
which can be quantitatively determined with suitable precision and accuracy. The quantitation limit is a parameter of quantitative assays for low levels of compounds in sample matrices.  (Copy of ICH Q2 R1 Attached) Firm performed the analytical validation studies of drug product with the conc. of 0.005mg/ml of sample and standard solution and submit the data of revised validation studies.  Justification for changing the 0.1N HCl medium with phosphate buffer medium of pH6.8 after 1 hour, since according to US FDA dissolution database the recommended sampling time in 0.1N HCl is till 120min.  As per BP Dissolution Guidance, "the test may be concluded in a shorter period of time when the minimum amount (i.e. 75%) dissolved is met'. In case of the subject Product more than 75% of the drug present in IR Layer has been released in 1 hour this implies that the optimum drug release obtained in Specified time of 1 hour. (Copy of the BP Reference is attached) However, as per analytical method, for testing of enteric coating integrity we have run the dissolution in acidic media (at 1.2 pH) till 2 hours i.e. 120 mins (as per recommended time points of the FDA) and replaced with buffer after 2 hours, which is evident from CDP report and testing method and no cracks were observed at acid resistance stage. (Copy of CDP Report & testing Method is attached for reference.)  In acidic media, sampling time point is 60 min where 95% of the drug has been released from IR layer, while dissolution run for 2 hours to check the integrality of the enteric coating layer. And specification limit is NLT 75% (above 75%) in 0.1N HCL for 1 hour.  In basic media, sampling time point is 30 min where 95% of the drug has been released from core layer, and specification limit is NLT 75% (above 75%) in 0.1N HCL for 1 hour.		"The quantitation limit of an individual analytical				
precision and accuracy. The quantitation limit is a parameter of quantitative assays for low levels of compounds in sample matrices.  (Copy of ICH Q2 R1 Attached) Firm performed the analytical validation studies of drug product with the conc. of 0.005mg/ml of sample and standard solution and submit the data of revised validation studies.  Justification for changing the 0.1N HCl medium with phosphate buffer medium of pH6.8 after 1 hour, since according to US FDA dissolution database the recommended sampling time in 0.1N HCl is till 120min.  As per BP Dissolution Guidance, "the test may be concluded in a shorter period of time when the minimum amount (i.e. 75%) dissolved is met'. In case of the subject Product more than 75% of the drug present in IR Layer has been released in 1 hour this implies that the optimum drug release obtained in Specified time of 1 hour. (Copy of the BP Reference is attached) However, as per analytical method, for testing of enteric coating integrity we have run the dissolution in acidic media (at 1.2 pH) till 2 hours i.e. 120 mins (as per recommended time points of the FDA) and replaced with buffer after 2 hours. which is evident from CDP report and testing method and no cracks were observed at acid resistance stage. (Copy of CDP Report & testing Method is attached for reference.)  Clarification regarding sampling time point of dissolution results with minimum and maximum value along with time  The dissolution results with minimum and maximum value along with time  The dissolution results with minimum and maximum value along with time  The dissolution results with minimum and maximum value along with time		procedure is the lowest amount of analyte in a sample				
parameter of quantitative assays for low levels of compounds in sample matrices.  (Copy of ICH Q2 R1 Attached) Firm performed the analytical validation studies of drug product with the conc. of 0.005mg/ml of sample and standard solution and submit the data of revised validation studies.  Justification for changing the 0.1N HCl medium with phosphate buffer medium of pH6.8 after 1 hour, since according to US FDA dissolution database the recommended sampling time in 0.1N HCl is till 120min.  As per BP Dissolution Guidance, "the test may be concluded in a shorter period of time when the minimum amount (i.e. 75%) dissolved is met'. In case of the subject Product more than 75% of the drug present in IR Layer has been released in 1 hour this implies that the optimum drug release obtained in Specified time of 1 hour. (Copy of the BP Reference is attached) However, as per analytical method, for testing of enteric coating integrity we have run the dissolution in acidic media (at 1.2 pH) till 2 hours i.e. 120 mins (as per recommended time points of the FDA) and replaced with buffer after 2 hours. which is evident from CDP report and testing method and no cracks were observed at acid resistance stage. (Copy of CDP Report & testing Method is attached for reference.)  In acidic media, sampling time point is 60 min where 95% of the drug has been released from IR layer, while dissolution run for 2 hours to check the integrality of the enteric coating layer. And specification limit is NLT 75% (above 75%) in 0.1N HCL for 1 hour.  In basic media, sampling time point is 30 min where 95% of the drug has been released from core layer, and specification limit is NLT 75% (above 75%) in		which can be quantitatively determined with suitable				
compounds in sample matrices.  (Copy of ICH Q2 R1 Attached) Firm performed the analytical validation studies of drug product with the conc. of 0.005mg/ml of sample and standard solution and submit the data of revised validation studies.  Justification for changing the 0.1N HCl medium with phosphate buffer medium of pH6.8 after 1 hour, since according to US FDA dissolution database the recommended sampling time in 0.1N HCl is till 120min.  As per BP Dissolution Guidance, "the test may be concluded in a shorter period of time when the minimum amount (i.e. 75%) dissolved is met'. In case of the subject Product more than 75% of the drug present in IR Layer has been released in 1 hour this implies that the optimum drug release obtained in Specified time of 1 hour. (Copy of the BP Reference is attached) However, as per analytical method, for testing of enteric coating integrity we have run the dissolution in acidic media (at 1.2 pH) till 2 hours i.e. 120 mins (as per recommended time points of the FDA) and replaced with buffer after 2 hours. which is evident from CDP report and testing method and no cracks were observed at acid resistance stage. (Copy of CDP Report & testing Method is attached for reference.)  Clarification regarding sampling time point of dissolution results with minimum and maximum value along with time  Clarification limit is NLT 75% (above 75%) in 0.1N HCL for 1 hour.  In basic media, sampling time point is 30 min where 95% of the drug has been released from core layer, and specification limit is NLT 75% (above 75%) in 0.1N						
(Copy of ICH Q2 R1 Attached) Firm performed the analytical validation studies of drug product with the conc. of 0.005mg/ml of sample and standard solution and submit the data of revised validation studies.  Justification for changing the 0.1N HCl medium with phosphate buffer medium of pH6.8 after 1 hour, since according to US FDA dissolution database the recommended sampling time in 0.1N HCl is till 120min.  As per BP Dissolution Guidance, "the test may be concluded in a shorter period of time when the minimum amount (i.e. 75%) dissolved is met'. In case of the subject Product more than 75% of the drug present in IR Layer has been released in 1 hour this implies that the optimum drug release obtained in Specified time of 1 hour. (Copy of the BP Reference is attached) However, as per analytical method, for testing of enteric coating integrity we have run the dissolution in acidic media (at 1.2 pH) till 2 hours i.e. 120 mins (as per recommended time points of the FDA) and replaced with buffer after 2 hours. which is evident from CDP report and testing method and no cracks were observed at acid resistance stage. (Copy of CDP Report & testing Method is attached for reference.)  Clarification regarding sampling time point of dissolution results with minimum and maximum value along with time  Clarification regarding sampling time point of dissolution results with minimum and maximum value along with time  The providence of the subject Product more than 75% of the drug has been released from IR layer, while dissolution run for 2 hours to check the integrality of the enteric coating layer. And specification limit is NLT 75% (above 75%) in 0.1N HCL for 1 hour.  In basic media, sampling time point is 30 min where 95% of the drug has been released from core layer, and specification limit is NLT 75% (above 75%) in 0.1N HCL for 1 hour.		, · · · · · · · · · · · · · · · · · · ·				
Firm performed the analytical validation studies of drug product with the conc. of 0.005mg/ml of sample and standard solution and submit the data of revised validation studies.  Justification for changing the 0.1N HCl medium with phosphate buffer medium of pH6.8 after 1 hour, since according to US FDA dissolution database the recommended sampling time in 0.1N HCl is till 120min.  As per BP Dissolution Guidance, "the test may be concluded in a shorter period of time when the minimum amount (i.e. 75%) dissolved is met." In case of the subject Product more than 75% of the drug present in IR Layer has been released in 1 hour this implies that the optimum drug release obtained in Specified time of 1 hour. (Copy of the BP Reference is attached)  However, as per analytical method, for testing of enteric coating integrity we have run the dissolution in acidic media (at 1.2 pH) till 2 hours i.e. 120 mins (as per recommended time points of the FDA) and replaced with buffer after 2 hours. which is evident from CDP report and testing method and no cracks were observed at acid resistance stage. (Copy of CDP Report & testing Method is attached for reference.)  Clarification regarding sampling time point of dissolution test in the stability data sheets and present the dissolution results with minimum and maximum value along with time  Clarification regarding sampling time point of dissolution test in the stability data sheets and present the dissolution results with minimum and maximum value along with time  Firm performed the analytical method, for test may be concluded in a shorter period of time when the minimum amount (i.e. 75%) dissolved is met'. In case of the subject Product more than 75% of the drug has been released from I hour this implies that the optimum drug release obtained in Specification limit is NLT 75% (above 75%) in 0.1N HCL for 1 hour.  In basic media, sampling time point is 30 min where 95% of the drug has been released from core layer, and specification limit is NLT 75% (above 75%) in						
drug product with the conc. of 0.005mg/ml of sample and standard solution and submit the data of revised validation studies.  As per BP Dissolution Guidance, "the test may be concluded in a shorter period of time when the minimum amount (i.e. 75%) dissolved is met'. In case of the subject Product more than 75% of the drug present in IR Layer has been released in 1 hour this implies that the optimum drug release obtained in Specified time of 1 hour. (Copy of the BP Reference is attached)  However, as per analytical method, for testing of enteric coating integrity we have run the dissolution in acidic media (at 1.2 pH) till 2 hours i.e. 120 mins (as per recommended time points of the FDA) and replaced with buffer after 2 hours. which is evident from CDP report and testing method and no cracks were observed at acid resistance stage. (Copy of CDP Report & testing Method is attached for reference.)  Clarification regarding sampling time point of dissolution results with minimum and maximum value along with time  Clarification regarding sampling time point of dissolution results with minimum and maximum value along with time  drug present in IR Layer has been released in 1 hour this implies that the optimum drug release obtained in Specified time of 1 hour. (Copy of the BP Reference is attached)  However, as per analytical method, for testing of enteric coating integrity we have run the dissolution in acidic media (at 1.2 pH) till 2 hours. which is evident from CDP report and testing method and no cracks were observed at acid resistance stage. (Copy of CDP Report & testing Method is attached for reference.)  In acidic media, sampling time point is 60 min where 95% of the drug has been released from CDP the integrality of the enteric coating layer. And specification limit is NLT 75% (above 75%) in 0.1N HCL for 1 hour.  In basic media, sampling time point is 30 min where 95% of the drug has been released from core layer, and specification limit is NLT 75% (above 75%) in						
Justification for changing the 0.1N HCl medium with phosphate buffer medium of pH6.8 after 1 hour, since according to US FDA dissolution database the recommended sampling time in 0.1N HCl is till 120min.  As per BP Dissolution Guidance, "the test may be concluded in a shorter period of time when the minimum amount (i.e. 75%) dissolved is met'. In case of the subject Product more than 75% of the drug present in IR Layer has been released in 1 hour this implies that the optimum drug release obtained in Specified time of 1 hour. (Copy of the BP Reference is attached) However, as per analytical method, for testing of enteric coating integrity we have run the dissolution in acidic media (at 1.2 pH) till 2 hours i.e. 120 mins (as per recommended time points of the FDA) and replaced with buffer after 2 hours, which is evident from CDP report and testing method and no cracks were observed at acid resistance stage. (Copy of CDP Report & testing Method is attached for reference.)  In acidic media, sampling time point is 60 min where 95% of the drug has been released from IR layer, while dissolution run for 2 hours to check the integrality of the enteric coating layer. And specification limit is NLT 75% (above 75%) in 0.1N HCL for 1 hour.  In basic media, sampling time point is 30 min where 95% of the drug has been released from core layer, and specification limit is NLT 75% (above 75%) in						
Justification for changing the 0.1N HCl medium with phosphate buffer medium of pH6.8 after 1 hour, since according to US FDA dissolution database the recommended sampling time in 0.1N HCl is till 120min.  As per BP Dissolution Guidance, "the test may be concluded in a shorter period of time when the minimum amount (i.e. 75%) dissolved is met'. In case of the subject Product more than 75% of the drug present in IR Layer has been released in 1 hour this implies that the optimum drug release obtained in Specified time of 1 hour. (Copy of the BP Reference is attached) However, as per analytical method, for testing of enteric coating integrity we have run the dissolution in acidic media (at 1.2 pH) till 2 hours i.e. 120 mins (as per recommended time points of the FDA) and replaced with buffer after 2 hours. which is evident from CDP report and testing method and no cracks were observed at acid resistance stage. (Copy of CDP Report & testing Method is attached for reference.)  Clarification regarding sampling time point of dissolution test in the stability data sheets and present the dissolution results with minimum and maximum value along with time  Clarification regarding sampling time point of dissolution results with minimum and maximum value along with time  The dissolution results with minimum and maximum value along with time  The dissolution results with minimum and maximum value along with time  The dissolution results with minimum and maximum value along with time  The dissolution results with minimum and maximum value along with time  The dissolution results with minimum and maximum value along with time  The dissolution results with minimum and maximum value along with time  The dissolution function Guidance, "the test may be concluded in a shorter period of time minimum amount (i.e. 75%) dissolved is met'. In case of the subject Product more than 75% of the drug present in IR Layer has been released from In lour.  The dissolution function of time function function function from CDP report and testing met						
Justification for changing the 0.1N HCl medium with phosphate buffer medium of pH6.8 after 1 hour, since according to US FDA dissolution database the recommended sampling time in 0.1N HCl is till 120min.  As per BP Dissolution Guidance, "the test may be concluded in a shorter period of time when the minimum amount (i.e. 75%) dissolved is met'. In case of the subject Product more than 75% of the drug present in IR Layer has been released in 1 hour this implies that the optimum drug release obtained in Specified time of 1 hour. (Copy of the BP Reference is attached) However, as per analytical method, for testing of enteric coating integrity we have run the dissolution in acidic media (at 1.2 pH) till 2 hours i.e. 120 mins (as per recommended time points of the FDA) and replaced with buffer after 2 hours. which is evident from CDP report and testing method and no cracks were observed at acid resistance stage. (Copy of CDP Report & testing Method is attached for reference.)  Clarification regarding sampling time point of dissolution results with minimum and maximum value along with time  The dissolution results with minimum and maximum value along with time  As per BP Dissolution Guidance, "the test may be concluded in a shorter period of time when the minimum amount (i.e. 75%) dissolved is met'. In case of the subject Product more than 75% of the drug present in IR Layer has been released on 1 hour this implies that the optimum drug release obtained in Specification limit is NLT 75% (above 75%) in 0.1N HCL for 1 hour.  In basic media, sampling time point is 30 min where 95% of the drug has been released from core layer, and specification limit is NLT 75% (above 75%) in						
phosphate buffer medium of pH6.8 after 1 hour, since according to US FDA dissolution database the recommended sampling time in 0.1N HCl is till 120min.  Concluded in a shorter period of time when the minimum amount (i.e. 75%) dissolved is met'. In case of the subject Product more than 75% of the drug present in IR Layer has been released in 1 hour this implies that the optimum drug release obtained in Specified time of 1 hour. (Copy of the BP Reference is attached)  However, as per analytical method, for testing of enteric coating integrity we have run the dissolution in acidic media (at 1.2 pH) till 2 hours i.e. 120 mins (as per recommended time points of the FDA) and replaced with buffer after 2 hours. which is evident from CDP report and testing method and no cracks were observed at acid resistance stage. (Copy of CDP Report & testing Method is attached for reference.)  Clarification regarding sampling time point of dissolution results with minimum and maximum value along with time  Clarification regarding sampling time point of dissolution results with minimum and maximum value along with time  Clarification regarding sampling time point of dissolution results with minimum and maximum value along with time  Clarification limit is NLT 75% (above 75%) in 0.1N HCL for 1 hour.  In basic media, sampling time point is 30 min where 95% of the drug has been released from core layer, and specification limit is NLT 75% (above 75%) in	Justification for changing the 0.1N HCl madium with					
minimum amount (i.e. 75%) dissolved is met'. In case of the subject Product more than 75% of the drug present in IR Layer has been released in 1 hour this implies that the optimum drug release obtained in Specified time of 1 hour. (Copy of the BP Reference is attached) However, as per analytical method, for testing of enteric coating integrity we have run the dissolution in acidic media (at 1.2 pH) till 2 hours i.e. 120 mins (as per recommended time points of the FDA) and replaced with buffer after 2 hours. which is evident from CDP report and testing method and no cracks were observed at acid resistance stage. (Copy of CDP Report & testing Method is attached for reference.)  Clarification regarding sampling time point of dissolution results with minimum and maximum value along with time  The dissolution results with minimum and maximum value along with time  minimum amount (i.e. 75%) dissolved is met'. In case of the subject Product more than 75% of the drug present in IR Layer has been released in 1 hour this implies that the optimum drug release obtained in Specified time of 1 hour. (Copy of the BP Reference is attached)  However, as per analytical method, for testing of enteric coating integrity we have run the dissolution acidic media (at 1.2 pH) till 2 hours i.e. 120 mins (as per recommended time points of the FDA) and replaced with buffer after 2 hours. which is evident from CDP report and testing method and no cracks were observed at acid resistance stage. (Copy of CDP Report & testing Method is attached for reference.)  In acidic media, sampling time point is 60 min where 95% of the drug has been released from IR layer, while dissolution run for 2 hours to check the integrality of the enteric coating layer. And specification limit is NLT 75% (above 75%) in 0.1N HCL for 1 hour.  In basic media, sampling time point is 30 min where 95% of the drug has been released from core layer, and specification limit is NLT 75% (above 75%) in						
case of the subject Product more than 75% of the drug present in IR Layer has been released in 1 hour this implies that the optimum drug release obtained in Specified time of 1 hour. (Copy of the BP Reference is attached) However, as per analytical method, for testing of enteric coating integrity we have run the dissolution in acidic media (at 1.2 pH) till 2 hours i.e. 120 mins (as per recommended time points of the FDA) and replaced with buffer after 2 hours. which is evident from CDP report and testing method and no cracks were observed at acid resistance stage. (Copy of CDP Report & testing Method is attached for reference.)  Clarification regarding sampling time point of dissolution test in the stability data sheets and present the dissolution results with minimum and maximum value along with time  Clarification regarding sampling time point of dissolution results with minimum and maximum value along with time  The dissolution results with minimum and maximum value along with time  Clarification regarding sampling time point of dissolution results with minimum and maximum value along with time  The drug present in IR Layer has been released in 1 hour this implies that the optimum drug release obtained in Specified time of 1 hour. (Copy of the BP Reference is attached)  However, as per analytical method, for testing of enteric coating integrity we have run the dissolution in acidic media (at 1.2 pH) till 2 hours i.e. 120 mins (as per recommended time points of the FDA) and replaced with buffer after 2 hours. which is evident from CDP report and testing method and no cracks were observed at acid resistance stage. (Copy of CDP Report & testing Method is attached for reference.)  In acidic media, sampling time point is 60 min where 95% of the drug has been released from IR layer, while dissolution run for 2 hours to check the integrality of the enteric coating layer. And specification limit is NLT 75% (above 75%) in 0.1N HCL for 1 hour.  In basic media, sampling time point is 30 min where 95% of the drug has be						
drug present in IR Layer has been released in 1 hour this implies that the optimum drug release obtained in Specified time of 1 hour. (Copy of the BP Reference is attached) However, as per analytical method, for testing of enteric coating integrity we have run the dissolution in acidic media (at 1.2 pH) till 2 hours i.e. 120 mins (as per recommended time points of the FDA) and replaced with buffer after 2 hours, which is evident from CDP report and testing method and no cracks were observed at acid resistance stage. (Copy of CDP Report & testing Method is attached for reference.)  Clarification regarding sampling time point of dissolution test in the stability data sheets and present the dissolution results with minimum and maximum value along with time  Clarification regarding sampling time point of dissolution results with minimum and maximum value along with time  The dissolution results with minimum and maximum value along with time  The dissolution run for 2 hours to check the integrality of the enteric coating layer. And specification limit is NLT 75% (above 75%) in 0.1N HCL for 1 hour.  In basic media, sampling time point is 30 min where 95% of the drug has been released from core layer, and specification limit is NLT 75% (above 75%) in	_					
this implies that the optimum drug release obtained in Specified time of 1 hour. (Copy of the BP Reference is attached) However, as per analytical method, for testing of enteric coating integrity we have run the dissolution in acidic media (at 1.2 pH) till 2 hours i.e. 120 mins (as per recommended time points of the FDA) and replaced with buffer after 2 hours. which is evident from CDP report and testing method and no cracks were observed at acid resistance stage. (Copy of CDP Report & testing Method is attached for reference.)  Clarification regarding sampling time point of dissolution test in the stability data sheets and present the dissolution results with minimum and maximum value along with time  In acidic media, sampling time point is 60 min where 95% of the drug has been released from IR layer, while dissolution run for 2 hours to check the integrality of the enteric coating layer. And specification limit is NLT 75% (above 75%) in 0.1N HCL for 1 hour.  In basic media, sampling time point is 30 min where 95% of the drug has been released from core layer, and specification limit is NLT 75% (above 75%) in						
in Specified time of 1 hour. (Copy of the BP Reference is attached) However, as per analytical method, for testing of enteric coating integrity we have run the dissolution in acidic media (at 1.2 pH) till 2 hours i.e. 120 mins (as per recommended time points of the FDA) and replaced with buffer after 2 hours. which is evident from CDP report and testing method and no cracks were observed at acid resistance stage. (Copy of CDP Report & testing Method is attached for reference.)  Clarification regarding sampling time point of dissolution test in the stability data sheets and present the dissolution results with minimum and maximum value along with time  In acidic media, sampling time point is 60 min where 95% of the drug has been released from IR layer, while dissolution run for 2 hours to check the integrality of the enteric coating layer. And specification limit is NLT 75% (above 75%) in 0.1N HCL for 1 hour.  In basic media, sampling time point is 30 min where 95% of the drug has been released from core layer, and specification limit is NLT 75% (above 75%) in						
Reference is attached) However, as per analytical method, for testing of enteric coating integrity we have run the dissolution in acidic media (at 1.2 pH) till 2 hours i.e. 120 mins (as per recommended time points of the FDA) and replaced with buffer after 2 hours. which is evident from CDP report and testing method and no cracks were observed at acid resistance stage. (Copy of CDP Report & testing Method is attached for reference.)  Clarification regarding sampling time point of dissolution test in the stability data sheets and present the dissolution results with minimum and maximum value along with time  In acidic media, sampling time point is 60 min where 95% of the drug has been released from IR layer, while dissolution run for 2 hours to check the integrality of the enteric coating layer. And specification limit is NLT 75% (above 75%) in 0.1N HCL for 1 hour.  In basic media, sampling time point is 30 min where 95% of the drug has been released from core layer, and specification limit is NLT 75% (above 75%) in						
enteric coating integrity we have run the dissolution in acidic media (at 1.2 pH) till 2 hours i.e. 120 mins (as per recommended time points of the FDA) and replaced with buffer after 2 hours. which is evident from CDP report and testing method and no cracks were observed at acid resistance stage. (Copy of CDP Report & testing Method is attached for reference.)  Clarification regarding sampling time point of dissolution test in the stability data sheets and present the dissolution results with minimum and maximum value along with time  In acidic media (at 1.2 pH) till 2 hours i.e. 120 mins (as per recommended time points of the FDA) and replaced with buffer after 2 hours. Which is evident from CDP report and testing method and no cracks were observed at acid resistance stage. (Copy of CDP Report & testing Method is attached for reference.)  In acidic media, sampling time point is 60 min where 95% of the drug has been released from IR layer, while dissolution run for 2 hours to check the integrality of the enteric coating layer. And specification limit is NLT 75% (above 75%) in 0.1N HCL for 1 hour.  In basic media, sampling time point is 30 min where 95% of the drug has been released from core layer, and specification limit is NLT 75% (above 75%) in						
in acidic media (at 1.2 pH) till 2 hours i.e. 120 mins (as per recommended time points of the FDA) and replaced with buffer after 2 hours. which is evident from CDP report and testing method and no cracks were observed at acid resistance stage. (Copy of CDP Report & testing Method is attached for reference.)  Clarification regarding sampling time point of dissolution test in the stability data sheets and present the dissolution results with minimum and maximum value along with time  In acidic media (at 1.2 pH) till 2 hours i.e. 120 mins (as per recommended time points of the FDA) and replaced with buffer after 2 hours. Which is evident from CDP report and testing method and no cracks were observed at acid resistance stage. (Copy of CDP Report & testing Method is attached for reference.)  In acidic media, sampling time point is 60 min where 95% of the drug has been released from IR layer, while dissolution run for 2 hours to check the integrality of the enteric coating layer. And specification limit is NLT 75% (above 75%) in 0.1N HCL for 1 hour.  In basic media, sampling time point is 30 min where 95% of the drug has been released from core layer, and specification limit is NLT 75% (above 75%) in		However, as per analytical method, for testing of				
(as per recommended time points of the FDA) and replaced with buffer after 2 hours. which is evident from CDP report and testing method and no cracks were observed at acid resistance stage. (Copy of CDP Report & testing Method is attached for reference.)  Clarification regarding sampling time point of dissolution test in the stability data sheets and present the dissolution results with minimum and maximum value along with time  In acidic media, sampling time point is 60 min where 95% of the drug has been released from IR layer, while dissolution run for 2 hours to check the integrality of the enteric coating layer. And specification limit is NLT 75% (above 75%) in 0.1N HCL for 1 hour.  In basic media, sampling time point is 30 min where 95% of the drug has been released from core layer, and specification limit is NLT 75% (above 75%) in						
replaced with buffer after 2 hours. which is evident from CDP report and testing method and no cracks were observed at acid resistance stage. (Copy of CDP Report & testing Method is attached for reference.)  Clarification regarding sampling time point of dissolution test in the stability data sheets and present the dissolution results with minimum and maximum value along with time  In acidic media, sampling time point is 60 min where 95% of the drug has been released from IR layer, while dissolution run for 2 hours to check the integrality of the enteric coating layer. And specification limit is NLT 75% (above 75%) in 0.1N HCL for 1 hour.  In basic media, sampling time point is 30 min where 95% of the drug has been released from core layer, and specification limit is NLT 75% (above 75%) in						
from CDP report and testing method and no cracks were observed at acid resistance stage. (Copy of CDP Report & testing Method is attached for reference.)  Clarification regarding sampling time point of dissolution test in the stability data sheets and present the dissolution results with minimum and maximum value along with time  In acidic media, sampling time point is 60 min where 95% of the drug has been released from IR layer, while dissolution run for 2 hours to check the integrality of the enteric coating layer. And specification limit is NLT 75% (above 75%) in 0.1N HCL for 1 hour.  In basic media, sampling time point is 30 min where 95% of the drug has been released from core layer, and specification limit is NLT 75% (above 75%) in						
were observed at acid resistance stage. (Copy of CDP Report & testing Method is attached for reference.)  Clarification regarding sampling time point of dissolution test in the stability data sheets and present the dissolution results with minimum and maximum value along with time  In acidic media, sampling time point is 60 min where 95% of the drug has been released from IR layer, while dissolution run for 2 hours to check the integrality of the enteric coating layer. And specification limit is NLT 75% (above 75%) in 0.1N HCL for 1 hour.  In basic media, sampling time point is 30 min where 95% of the drug has been released from core layer, and specification limit is NLT 75% (above 75%) in		-				
Report & testing Method is attached for reference.)  Clarification regarding sampling time point of dissolution test in the stability data sheets and present the dissolution results with minimum and maximum value along with time  Report & testing Method is attached for reference.)  In acidic media, sampling time point is 60 min where 95% of the drug has been released from IR layer, while dissolution run for 2 hours to check the integrality of the enteric coating layer. And specification limit is NLT 75% (above 75%) in 0.1N HCL for 1 hour.  In basic media, sampling time point is 30 min where 95% of the drug has been released from core layer, and specification limit is NLT 75% (above 75%) in						
Clarification regarding sampling time point of dissolution test in the stability data sheets and present the dissolution results with minimum and maximum value along with time  In acidic media, sampling time point is 60 min where 95% of the drug has been released from IR layer, while dissolution run for 2 hours to check the integrality of the enteric coating layer. And specification limit is NLT 75% (above 75%) in 0.1N HCL for 1 hour.  In basic media, sampling time point is 60 min where integrality of the enteric coating layer. And specification limit is NLT 75% (above 75%) in 0.1N HCL for 1 hour.  In basic media, sampling time point is 60 min where integrality of the drug has been released from IR layer, while dissolution run for 2 hours to check the integrality of the enteric coating layer. And specification limit is NLT 75% (above 75%) in 0.1N HCL for 1 hour.  In basic media, sampling time point is 60 min where integrality of the enteric coating layer. And specification limit is NLT 75% (above 75%) in 0.1N HCL for 1 hour.  In basic media, sampling time point is 80 min where 95% of the drug has been released from core layer, and specification limit is NLT 75% (above 75%) in						
dissolution test in the stability data sheets and present the dissolution results with minimum and maximum value along with time  95% of the drug has been released from IR layer, while dissolution run for 2 hours to check the integrality of the enteric coating layer. And specification limit is NLT 75% (above 75%) in 0.1N HCL for 1 hour.  In basic media, sampling time point is 30 min where 95% of the drug has been released from core layer, and specification limit is NLT 75% (above 75%) in						
the dissolution results with minimum and maximum value along with time  while dissolution run for 2 hours to check the integrality of the enteric coating layer. And specification limit is NLT 75% (above 75%) in 0.1N HCL for 1 hour.  In basic media, sampling time point is 30 min where 95% of the drug has been released from core layer, and specification limit is NLT 75% (above 75%) in						
value along with time  integrality of the enteric coating layer. And specification limit is NLT 75% (above 75%) in 0.1N HCL for 1 hour.  In basic media, sampling time point is 30 min where 95% of the drug has been released from core layer, and specification limit is NLT 75% (above 75%) in	· · · · · · · · · · · · · · · · · · ·	· ·				
specification limit is NLT 75% (above 75%) in 0.1N HCL for 1 hour. In basic media, sampling time point is 30 min where 95% of the drug has been released from core layer, and specification limit is NLT 75% (above 75%) in						
HCL for 1 hour. In basic media, sampling time point is 30 min where 95% of the drug has been released from core layer, and specification limit is NLT 75% (above 75%) in	value along with time					
In basic media, sampling time point is 30 min where 95% of the drug has been released from core layer, and specification limit is NLT 75% (above 75%) in						
95% of the drug has been released from core layer, and specification limit is NLT 75% (above 75%) in						
and specification limit is NLT 75% (above 75%) in						
		· ·				
Sociality inospilate burier for solutions.		Sodium Phosphate buffer for 30mins.				

Decision: Approved with Innovator's specification. Firm shall submit fee of Rs. 7,500 for correction/preapproval change/ in product specifications, as per notification No.F.7-11/2021-B&A/DRAP dated 13-07-2021.

• Manufacturer will place first three commercial batches on long term stability studies throughout proposed shelf life and on accelerated studies for six months as per the commitment submitted in the registration application.

	Ianufacturer will perform process validation of first three commercial batches as per the ommitment submitted in the registration application.			
257.	Name, address of Applicant / Marketing Authorization Holder			
	Name, address of Manufacturing site.	M/s Scotmann Pharmaceuticals, 5-D, I-10/3, Industrial Area, Islamabad, Pakistan		
	Status of the applicant			
	Status of application	☐ New Drug Product (NDP)  ☐ Generic Drug Product (GDP)		
	Intended use of pharmaceutical product	<ul><li>☑ Domestic sale</li><li>☐ Export sale</li><li>☐ Domestic and Export sales</li></ul>		
	Dy. No. and date of submission	Dy. No. 14886 dated 31/05/2021		
	Details of fee submitted	PKR 20,000/- vide slip no. 2073486 dated 16/03/2021		
	The proposed proprietary name / brand name	Famoscot dry suspension 40mg/5ml		
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each 5ml contains: Famotidine 40mg		
	Pharmaceutical form of applied drug	Off white colored granular powder which on reconstitution gives flavored suspension.		
	Pharmacotherapeutic Group of (API)	Short-term treatment of active duodenal ulcer. Short-term treatment of active benign gastric ulcer. Short-term treatment of gastroesophageal reflux disease. Treatment of pathological hypersecretory conditions		
	Reference to Finished product specifications	USP		
	Proposed Pack size	60ML		
	Proposed unit price	As per SRO		
	The status in reference regulatory authorities	Pepcid manufactured by Salix Pharmaceuticals Inc. MERCK SHARP & DOHME Pty., Ltd. South Granville, NSW, Australia 2142.		
	For generic drugs (me-too status)	Sofem Dry Suspension Manufacture by Roryan pharmaceuticals industries. DRAP Registration no. 082573		
	GMP status of the Finished product manufacturer	New license granted on 17/12/2020 Suspension section approved.		
	Name and address of API manufacturer.	NAME: Vaasavaa Pharmaceuticals Pvt. Limited, SITE OF MANUFACTURE: Plot no. C-216, MIDC-Chincholi, Solapur-413 255, Maharashtra, Ph: 02172357176 Contact person: Mr.K.M.K.Prasad/Mr.P.Narashima Rao Email: vaasavaa@yahoo.com OFFICE ADDRESS:		

			Plot No. 623, Pent House, Vivekananda Nagar, Kukatpally, Hyderabad-500072, Telefax: 040-23061183, Contact Person: Mr. M. Subba Rao, Email: <a href="mailto:vaasavaa@yahoo.com">vaasavaa@yahoo.com</a>		
	Module-II (Quality Overall Summary)		Firm has submitted QOS as per WHO QOS-PD template. Summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product is submitted.		
	Module III (Drug Substance)  Stability studies  Module-III (Drug Product):  Pharmaceutical equivalence and comparative dissolution profile		Official monograph of Famotidine is present in USP. The firm as submitted detail of nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, tests for impurity related substances, specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.		
			Stability study conditions: Long term: $30^{\circ}\text{C} \pm 2^{\circ}\text{C} / 65\% \pm 5\%\text{RH}$ for 6 months Accelerated: $40^{\circ}\text{C} \pm 2^{\circ}\text{C} / 75\% \pm 5\%\text{RH}$ for 60 months Batches: FM-IV/05/001, FM-IV/05/005, FM IV/05/002)		
			The firm has submitted detail of manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedure and its Validation/verification studies, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug product.		
			Pharmaceutical Equivalence have been established against the reference product that is Sofem Dry Suspension by Roryan Pharmaceuticals industries performing quality tests (Identification, Assay, Dissolution, Uniformity of dosage form.) Reg.no.082573		
Analytical method validation/verificatio product		ation/verification of	Method verification studies have submitted including linearity, Robustness, accuracy, precision (Repeatability), specificity.		
STABIL	STABILITY STUDY DATA				
Manufac	SITE OF MANU Plot no. C-216, N Ph: 02172357176		DC-Chincholi, Solapur-413 255, Maharashtra, r.K.M.K. Prasad/Mr. P. Narashima Rao yahoo.com		

500072, Telefax: 040-2306118			House, Vivekananda Nagar, Kukatpally, Hyderabad- 83, M. Subba Rao, Email: <u>vaasavaa@yahoo.com</u>		
API Lot	No.	FAM-0120012 (Batch no.)			
	ion of Pack ner closure system)	Pet bottles			
Stability Conditio		Long term: 30°C ± 2°C / 65% ± 5%RH Accelerated: 40°C ± 2°C / 75% ± 5%RH			
Time Per	riod	Long term: 6 months Accelerated: 6 months			
Frequenc	су	Accelerated: 0,1, 2, 3, 4, 6 (Months) Long term: 0, 3, 6 (Months)			
Batch No	0.	T-01	T-02	T-03	
Batch Si	ze	300 Bottles	300 Bottles	300 Bottles	
Manufac	cturing Date	03/2020	03/2020	03/2020	
Date of l	Initiation	06/03/2020	06/03/2020	06/03/2020	
No. of B	atches		03		
		Administrati	ve Portion		
1.	Reference of previous approval of applications with stability study data of the firm (if any)		Mekolade Tablets containing Metolazone 5mg DRAP Registration no. 108059		
2.	Approval of API/ DML/GMP certificate of API manufacturer issued by concerned regulatory authority of country of origin.		Copy of GMP certificate No. 6094634 issued by Food & Drugs Administration (Maharashtra state) Issue & Valid up to dated :16/07/2020 – 15/07/2021		
3.	Documents for the procurement of API with approval from DRAP (in case of import).		Clearance certificate and commercial invoice attested by concerned officer of (I&E) DRAP dated 18/02/2020.		
4.	attested respective documents like		Firm has submitted stability study data of 3 batches along with water loss test at each time point. Firm has submitted analytical report at each stability testing interval.		
5.	Compliance Record of HPLC software 21CFR & audit trail reports on product testing		Submitted		
6.	6. Record of Digital data logger for temperature and humidity monitoring of stability chambers (real time and accelerated)		Firm has submitted record of digital data logger for temperature and humidity monitoring of real time and accelerated stability chambers.		
Remarks of Evaluator:					
Shortcoming/Deficiencies			Response of the Firm		
Evidence of approval of manufacturing facility / Approved Section from Licensing Authority Dry powder suspension section has not been mentioned in the GMP certificate submitted along with the dossier. Section approval letter of dry powder suspension issued by Licensing Division is required.		Firm submitted the copy of panel inspection report, held for regularization of revised layout and grant of renewal of License on 17-11-2018 & 22-11-2018 in which it was endorsed that firm has Dry powder Suspension (general section).			
Provide copy of Batch Manufacturing Record (BMR) for all the batches of drug product for which stability studies data is provided in Module 3 section 3.2. P.8.3.					

Provide analytical Method Verification studies including Firm has submitted the analytical method verification specificity, accuracy and repeatability performed by the studies data of drug substance performed by drug Drug Product manufacturer. product manufacturer, in which the result of all three parameters has been given. Provide results of analysis of relevant batches of Drug Firm has submitted the Batch analysis report of drug Substance performed by Drug Product manufacturer substance performed by drug product manufacturer, used during product development and stability studies, in which all the quality test has been performed as per along with Certificate of Analysis (CoA) of the same USP. batch from Drug Substance manufacture. Provide information including type of diluent, its Firm has submitted the specimen of label of bottle on composition, quantity or volume which is to be provided which it is mentioned that 46ml of boiled water has along with the applied drug. As it is mentioned in the been added in the bottle for 60ml pack size of method of preparation of suspension written on inner Famotidine for oral suspension containing 480mg carton that "Put the premium hygienic water given in the famotidine per 60ml. While, the innovator product Pepcid (Famotidine) for oral suspension contain pack to reconstitute the suspension". 400mg famotidine per 50ml bottle and for reconstitution, 46ml of purified water is added to obtained the concentration of 40mg/5ml famotidine. Firm has not submitted the data of compatibility Compatibility studies of dry powder for suspension with its diluent shall be performed as per the instructions studies with its diluent. provided in individual label of the drug product and submit the obtained results.

Detailed analytical procedure as per USP monograph of Firm has submitted the analytical procedure of drug famotidine for oral suspension is required.

product as per USP.

Provide certificate of analysis of reference standard Firm provided the certificate of analysis of USP /working standard used for testing of the product.

reference standard of famotidine.

In-use stability studies of reconstituted suspension is required along with proposed in-use storage statement and in-use shelf-life.

Firm performed the in-use stability studies of reconstituted suspension at room temperature for 14 days (proposed shelf life).

Decision of 313th meeting of Registration Board

Discussion:

The Board was apprised that the innovator product i.e. Pepcid for suspension approved by USFDA has used 46ml of purified water for reconstitution of 400mg of Famotidine powder for suspension to attain the final concentration of 40mg/5ml while the applicant has used same volume of diluent (i.e. 46ml) for reconstitution of 480mg of Famotidine. The final reconstituted concentration is 40mg/5ml which cannot be attained by using the volume of diluent used by the applicant.

Decision: Registration Board after thorough deliberation decided to deferred the case for clarification/justification of using 46ml of diluent for reconstitution of the drug product containing 480mg of Famotidine per bottle.

Response of the Firm:

Firm has given following justification/clarification in response to the above-mentioned decision of Registration Board:

The innovator "Pepcid" using 400mg of famotidine per bottle by adding 46ml purified water for reconstitution to make of 50ml to attain 40mg/5ml of famotidine, while, we are using 480mg of famotidine per bottle by adding 46ml purifies water for reconstitution to make of 60ml to attain 40mg/5ml of famotidine.

Moreover, we are using the same excipient, but quantity of excipients may differ per bottle as per recommendations by "Handbook of Pharmaceutical Excipients" because of that, the weight of dry powder may vary per bottle from that of the innovator. The famotidine 480mg per bottle to attain 40mg/5ml after reconstitution by adding 46ml of purified water.

# **Decision: Approved.**

- Manufacturer will place first three commercial batches on long term stability studies throughout proposed shelf life and on accelerated studies for six months as per the commitment submitted in the registration application.
- Manufacturer will perform process validation of first three commercial batches as per the

### d) Deferred Cases of FORM-5

8. Name and address of manufacturer / applicant	M/s Amson Vaccines & Pharma (Pvt) Ltd. Plot No. 154, Industrial Triangle, Kahuta Road, Islamabad Pakistan.
Brand Name + Dosage Form + Strength	Osso-D Suspension 60ml / 120ml
Composition	Each 5ml Contains Ossien Mineral Complex (Microcrystalline Hydroxyapatite complex)400mg Vitamin D 400IU
Diary No. Date of R&1 & fee	Duplicate dossier
Pharmacological Group	Minerals and Electrolytes
Type of Form	Form-5
Finished product and specification	AMSON SPECS
Pack size and demanded price	60ml /120ml in PET bottle/ as per policy of DRAP
Approval status of product in reference regulatory authorities	
Me too status	Osnate D Suspension AGP Limited (Reg.no.070854)
GMP status of the Firm	GMP certificate of M/s. Amson Vaccines & Pharma (Pvt.) Ltd. issued which valid till 14-05-2022.
Remarks of the evaluator	
Previous Decision	Registration Board in its 289 <sup>th</sup> meeting decided as under: Deferred for evidence of approval of applied formulation in reference regulatory authorities/agencies which were adopted by Registration Board in its 275th meeting.
Evaluation by PEC AD(PEC-XII)	Firm provide the evidence of Me-Too product Osnate D suspension by M/s. AGP Limited (Reg.no. 070854)
Previous Decision of 295 <sup>th</sup> meeting of	Deferred for the evidence of purchase of Atomic Absorption
Registration Board	Spectrophotometer.
Response of the Firm	Firm submitted an evidence of invoice no. HAWB No: FPL156498 dated 14-08-2021 according to which firm purchase shimadzu absorption spectrophotometer flame mode with accessories from Shimadzu PTE Ltd.
Decision: Approved. Registration letter absorption spectrophotometer.	er will be issued after submission of IQ, OQ and PQ of atomic

# **Agenda of Evaluator PEC-XVI**

## A. Registration applications Human New

250	N 1 11 C C /	M/ D 1 C C 1 1 71 II 1 1 1 1 1 1 1 1
259.	Name and address of manufacturer/	M/s Polyfine Chempharma,51-Hyatabad Industrial estate,
	Applicant	Peshawar.
	Brand Name + Dosage Form + Strength	ALOZ Eye Drops
	Composition	Each ml contains:
		Brinzolamide10 mg
	Diary No. Date of R & I & fee	Dy. No 11691 dated 6-03-2019; Rs.20,000/- dated 06-03-
		2019
	Pharmacological Group	Antiglaucoma, Miotic
	Type of Form	Form - 5
	Finished product Specification	USP specification
	Pack size & Demanded Price	5ml, As per SRO
	Approval status of product in Reference	Brinzolamide 10mg/ml Eye Drops, Suspension
	Regulatory Authorities	by Teva UK Limited (MHRA Approved)

	Me-too status	Azopt eye drops of Alco	on Pharma
	GMP status		within last 3 years is not provided.
	Remarks of the Evaluator	report within last 3 years is required.  2. Complete method of manufacturing mentioning the process of sterilization of solution and primary packaging bottle along with preregistration	88608353 dated 15-03-2022 for preregistration variation along with revised method of manufacturing mentioning; • Solution is sterilized by filtration through 0.45 and 0.22-micron filter. • Bottles, caps and nozzles
	Decision: Approved. Registration letter of from QA< Division, valid within last		
260.	Name and address of manufacturer/		pharma,51-Hyatabad Industrial
	Applicant	estate,Peshawar.	- •
	Brand Name + Dosage Form + Strength	VOPRO Eye Drops	
	Composition	Each ml contains	40
	Diary No. Date of R & I & fee	Travoprost	40 mcg 03-2019; Rs.20,000/- dated 06-03-
	Pharmacological Group	Antiglaucoma, Miotic	
	Type of Form	Form - 5	
	Finished product Specification	USP specification	
	Pack size & Demanded Price	5ml, As per SRO	
	Approval status of product in Reference	1	rams/ml eye drops, Teva UK
	Regulatory Authorities	Limited, (MHRA Appro	
	Me-too status	081621	ution 0.004% by Alza Reg. #
	GMP status		within last 3 years is not provided.
	Remarks of the Evaluator	1. GMP inspection report within last 3 years is required.	Firm has submitted fee of 7500/= vide fee challan No 58740520469 dated 15-03-2022
		2. Complete method of manufacturing mentioning the process of sterilization of solution and primary packaging bottle along with preregistration	for preregistration variation along with revised method of manufacturing mentioning;  • Solution is sterilized by filtration through 0.45 and

		"The firm is considered to be operating at satisfactory level of cGMP compliance."
	Decision: Approved. Registration letter from QA< Division, valid within last	will be issued after submission of GMP inspection report
261.	Name and address of manufacturer/ Applicant	
	Brand Name + Dosage Form + Strength	MEDISOL I.V Infusion 10 % (500ml)
	Composition	Each 100 ml contains: Dextrose Anhydrous
	Diary No. Date of R & I & fee	Dy. No 12568 dated 06-03-2019; Rs.20,000/- dated 06-03-2019
	Pharmacological Group	Carbohydrates
	Type of Form	Form - 5
	Finished product Specification	BP specification
	Pack size & Demanded Price	500 ml, Polypropylene Bottle with Euro Cap, As per SRO
	Approval status of product in Reference Regulatory Authorities	Not provided
	Me-too status	Not provided
	GMP status	GMP report within 3 years is required
	Remarks of the Evaluator	GMP inspection report conducted within last 3 years is required.
		<ol> <li>Evidence of applied product containing Glucose anhydrous in RRA in applied primary packing of Polypropylene bottle or revise formulation along fee challan.</li> <li>Revised mate formulation as per revised label claim.</li> </ol>
		4. Mee-too reference of applied product with applied
	Decision: Deferred for followings:	primary packaging in Pakistan.
	<ul> <li>alongwith registration number, bran</li> <li>Evidence of approval of applied for which were declared/approved by the</li> </ul>	ug already approved by DRAP (generic / me-too status) nd name and name of firm. ormulation in reference regulatory authorities/agencies ne Registration Board.
262.	<ul> <li>Evidence of applied formulation/drealongwith registration number, brand</li> <li>Evidence of approval of applied for which were declared/approved by the Updated status of GMP of the firm for the f</li></ul>	ug already approved by DRAP (generic / me-too status) nd name and name of firm. ormulation in reference regulatory authorities/agencies ne Registration Board. from QA & LT division.
262.	<ul> <li>Evidence of applied formulation/drealongwith registration number, brane</li> <li>Evidence of approval of applied for which were declared/approved by the Updated status of GMP of the firm the Name and address of manufacturer/</li> </ul>	ug already approved by DRAP (generic / me-too status) nd name and name of firm. ormulation in reference regulatory authorities/agencies ne Registration Board.
262.	<ul> <li>Evidence of applied formulation/dra alongwith registration number, brane</li> <li>Evidence of approval of applied for which were declared/approved by the Updated status of GMP of the firm to Name and address of manufacturer/Applicant</li> </ul>	ug already approved by DRAP (generic / me-too status) and name and name of firm.  ormulation in reference regulatory authorities/agencies are Registration Board.  from QA & LT division.  Medipak Limited,554 sundar Industrial Estate, Lahore.
262.	<ul> <li>Evidence of applied formulation/drealongwith registration number, brance</li> <li>Evidence of approval of applied for which were declared/approved by the Updated status of GMP of the firm to Name and address of manufacturer/Applicant</li> <li>Brand Name + Dosage Form + Strength</li> </ul>	ug already approved by DRAP (generic / me-too status) and name and name of firm.  ormulation in reference regulatory authorities/agencies are Registration Board.  from QA & LT division.  Medipak Limited,554 sundar Industrial Estate, Lahore.  MEDISOL I.V Infusion 10 % (1000ml)
262.	<ul> <li>Evidence of applied formulation/dra alongwith registration number, brane</li> <li>Evidence of approval of applied for which were declared/approved by the Updated status of GMP of the firm to Name and address of manufacturer/Applicant</li> </ul>	ng already approved by DRAP (generic / me-too status) and name and name of firm.  ormulation in reference regulatory authorities/agencies are Registration Board.  from QA & LT division.  Medipak Limited,554 sundar Industrial Estate, Lahore.  MEDISOL I.V Infusion 10 % (1000ml)  Each 100 ml contains:
262.	<ul> <li>Evidence of applied formulation/drealongwith registration number, brance</li> <li>Evidence of approval of applied for which were declared/approved by the Updated status of GMP of the firm to Name and address of manufacturer/Applicant</li> <li>Brand Name + Dosage Form + Strength</li> </ul>	ug already approved by DRAP (generic / me-too status) and name and name of firm.  ormulation in reference regulatory authorities/agencies are Registration Board.  from QA & LT division.  Medipak Limited,554 sundar Industrial Estate, Lahore.  MEDISOL I.V Infusion 10 % (1000ml)  Each 100 ml contains: Dextrose Anhydrous
262.	<ul> <li>Evidence of applied formulation/drealongwith registration number, brance</li> <li>Evidence of approval of applied for which were declared/approved by the Updated status of GMP of the firm to Name and address of manufacturer/Applicant</li> <li>Brand Name + Dosage Form + Strength</li> </ul>	ng already approved by DRAP (generic / me-too status) and name and name of firm.  ormulation in reference regulatory authorities/agencies are Registration Board.  from QA & LT division.  Medipak Limited,554 sundar Industrial Estate, Lahore.  MEDISOL I.V Infusion 10 % (1000ml)  Each 100 ml contains:
262.	<ul> <li>Evidence of applied formulation/dra alongwith registration number, brane</li> <li>Evidence of approval of applied for which were declared/approved by the Updated status of GMP of the firm of Name and address of manufacturer/Applicant</li> <li>Brand Name + Dosage Form + Strength</li> <li>Composition</li> </ul> Diary No. Date of R & I & fee	ng already approved by DRAP (generic / me-too status) and name and name of firm.  ormulation in reference regulatory authorities/agencies are Registration Board.  from QA & LT division.  Medipak Limited,554 sundar Industrial Estate, Lahore.  MEDISOL I.V Infusion 10 % (1000ml)  Each 100 ml contains:  Dextrose Anhydrous
262.	<ul> <li>Evidence of applied formulation/dra alongwith registration number, brane</li> <li>Evidence of approval of applied for which were declared/approved by the Updated status of GMP of the firm to Name and address of manufacturer/Applicant</li> <li>Brand Name + Dosage Form + Strength</li> <li>Composition</li> </ul>	ug already approved by DRAP (generic / me-too status) and name and name of firm.  ormulation in reference regulatory authorities/agencies are Registration Board.  from QA & LT division.  Medipak Limited,554 sundar Industrial Estate, Lahore.  MEDISOL I.V Infusion 10 % (1000ml)  Each 100 ml contains:  Dextrose Anhydrous
262.	<ul> <li>Evidence of applied formulation/dra alongwith registration number, brane</li> <li>Evidence of approval of applied for which were declared/approved by the Updated status of GMP of the firm the Name and address of manufacturer/Applicant</li> <li>Brand Name + Dosage Form + Strength</li> <li>Composition</li> </ul> Diary No. Date of R & I & fee Pharmacological Group	ug already approved by DRAP (generic / me-too status) and name and name of firm.  ormulation in reference regulatory authorities/agencies are Registration Board.  from QA & LT division.  Medipak Limited,554 sundar Industrial Estate, Lahore.  MEDISOL I.V Infusion 10 % (1000ml)  Each 100 ml contains:  Dextrose Anhydrous
262.	<ul> <li>Evidence of applied formulation/dra alongwith registration number, brained in the Evidence of approval of applied for which were declared/approved by the Updated status of GMP of the firm the Name and address of manufacturer/Applicant</li> <li>Brand Name + Dosage Form + Strength</li> <li>Composition</li> <li>Diary No. Date of R &amp; I &amp; fee</li> <li>Pharmacological Group</li> <li>Type of Form</li> </ul>	ug already approved by DRAP (generic / me-too status) and name and name of firm.  ormulation in reference regulatory authorities/agencies are Registration Board.  from QA & LT division.  Medipak Limited,554 sundar Industrial Estate, Lahore.  MEDISOL I.V Infusion 10 % (1000ml)  Each 100 ml contains:  Dextrose Anhydrous
262.	<ul> <li>Evidence of applied formulation/dra alongwith registration number, brained in Evidence of approval of applied for which were declared/approved by the Updated status of GMP of the firm to Name and address of manufacturer/Applicant         Brand Name + Dosage Form + Strength Composition     </li> <li>Diary No. Date of R &amp; I &amp; fee</li> <li>Pharmacological Group</li> <li>Type of Form</li> <li>Finished product Specification</li> </ul>	ng already approved by DRAP (generic / me-too status) and name and name of firm.  ormulation in reference regulatory authorities/agencies are Registration Board.  from QA & LT division.  Medipak Limited,554 sundar Industrial Estate, Lahore.  MEDISOL I.V Infusion 10 % (1000ml)  Each 100 ml contains:  Dextrose Anhydrous
262.	<ul> <li>Evidence of applied formulation/dra alongwith registration number, brained in the Evidence of approval of applied for which were declared/approved by the Updated status of GMP of the firm the Name and address of manufacturer/Applicant</li> <li>Brand Name + Dosage Form + Strength</li> <li>Composition</li> <li>Diary No. Date of R &amp; I &amp; fee</li> <li>Pharmacological Group</li> <li>Type of Form</li> <li>Finished product Specification</li> <li>Pack size &amp; Demanded Price</li> <li>Approval status of product in Reference</li> </ul>	ng already approved by DRAP (generic / me-too status) and name and name of firm.  From QA & LT division.  Medipak Limited,554 sundar Industrial Estate, Lahore.  MEDISOL I.V Infusion 10 % (1000ml)  Each 100 ml contains:  Dextrose Anhydrous
262.	Evidence of applied formulation/dralongwith registration number, braided alongwith registration number, braided alongwith registration number, braided alongwith registration number, braided approval of applied for which were declared/approved by the Updated status of GMP of the firm in Name and address of manufacturer/Applicant  Brand Name + Dosage Form + Strength Composition  Diary No. Date of R & I & fee  Pharmacological Group Type of Form Finished product Specification Pack size & Demanded Price  Approval status of product in Reference Regulatory Authorities	ng already approved by DRAP (generic / me-too status) and name and name of firm.  Formulation in reference regulatory authorities/agencies are Registration Board.  From QA & LT division.  Medipak Limited,554 sundar Industrial Estate, Lahore.  MEDISOL I.V Infusion 10 % (1000ml)  Each 100 ml contains:  Dextrose Anhydrous

		2. Evidence of applied product containing Glucose anhydrous in RRA in applied primary packing of Polypropylene bottle or revise formulation along fee
		challan.
		3. Revised master formulation as per revised label claim.
		4. Mee-too reference of applied product with applied
		primary packaging in Pakistan.
	Decision: Deferred for followings:	
	Evidence of applied formulation/dru alongwith registration number, brai	ug already approved by DRAP (generic / me-too status)
		ormulation in reference regulatory authorities/agencies
	which were declared/approved by the	
	Updated status of GMP of the firm f	=
263.	Name and address of manufacturer/	
	Applicant	Lahore.
	Brand Name + Dosage Form + Strength	MEDISOL MANITOL I.V Infusion (500ml)
	Composition	Each 1000 ml contains:
		Mannitol175 g
		Sorbitol25 g
		Water for Injection1000 ml
	Diary No. Date of R & I & fee	Dy. No 12566 dated 06-03-2019; Rs.20,000/- dated 05-03-
	Dhawa a ala si a al Casura	2019
	Pharmacological Group	Osmotic Diuretic Form - 5
	Type of Form	
	Finished product Specification Pack size & Demanded Price	Manufacturer specification 500 ml, Polypropylene Bottle with Euro Cap, As per SRO
	Approval status of product in Reference	Not provided
	Regulatory Authorities	Not provided
	Me-too status	Not provided
	GMP status	GMP report within 3 years is required
	Remarks of the Evaluator	1. GMP inspection report conducted within last 3 years is
		required.
		2. Label claim and master formulation mentioned water for injection 1000 ml instead of whereas applied pack size is 500 ml, clarification is needed
		3. Evidence of applied product in RRA in applied primary
		packing of Polypropylene bottle or revise formulation
		along fee challan.
		4. Revised master formulation as per revised label claim.
		5. Mee-too reference of applied product with applied
		primary packaging in Pakistan.
	<b>Decision: Deferred for followings:</b>	
		nulation mentioned water for injection 1000 ml whereas
	applied pack size is 500 ml. (	
		tion/drug already approved by DRAP (generic / me-too n number, brand name and name of firm.
		of applied formulation in reference regulatory
	1	vere declared/approved by the Registration Board.
		ne firm from QA & LT division.
264.	Name and address of manufacturer/	
	Applicant	Lahore.
	Brand Name + Dosage Form + Strength	PANAFIN I.V Infusion (100ml)
	Composition	Each ml contains:
		Paracetamol10 mg
	Diary No. Date of R & I & fee	Dy. No 12569 dated 06-03-2019; Rs.20,000/- dated 05-03-2019
	Pharmacological Group	Antipyretic

	Type of Form	Form - 5
	Finished product Specification	Manufacturer specification
	Pack size & Demanded Price	100 ml, Polypropylene Bottle with Euro Cap, As per SRO
	Approval status of product in Reference	MHRA approved with Type I colourless glass vial with
	Regulatory Authorities	bromobutyl stopper and an aluminum /plastic flip-off cap
	Me-too status	Not provided.
	GMP status	GMP report within 3 years is required
	Remarks of the Evaluator	1.GMP inspection report conducted within last 3 years is
	Tentants of the Evaration	required.
		2. Evidence of applied product in RRA in applied primary packing of Polypropylene bottle or revise formulation along with evidence of manufacturing facility and preregistration variation fee challan.
		3. Revised master formulation as per revised label claim.
		4. Mee-too reference of applied product with applied
		primary packaging in Pakistan.
	<b>Decision: Deferred for followings:</b>	primary paragraph in a unistant
	1	ig already approved by DRAP (generic / me-too status)
	alongwith registration number, bran	
		rmulation in reference regulatory authorities/agencies
	which were declared/approved by the	
	• Updated status of GMP of the firm f	e
265.	Name and address of manufacturer/	M/s Nimrall Labortories, Plot No. 24 , Street # SS-
	Applicant	03,Rawat Industrial Zone.,Islamabad.
	Brand Name + Dosage Form + Strength	DEXPRO Suspension 100 mg
	Composition	Each 5 ml Contians:
	Composition	Dexibuprofen100 mg
	Diary No. Date of R & I & fee	Dy. No 13071 dated 06-03-2019; Rs.20,000/- dated 06-03-
		2019
	Pharmacological Group	NSAID
	Type of Form	Form - 5
	Finished product Specification	Innovator's Specification
	Pack size & Demanded Price	60 ml & 120 ml, PET bottle, As per SRO.
	Approval status of product in Reference Regulatory Authorities	Could not be verified
	Me-too status	Tercica 100mg/5ml. of M/s Sami (Reg. No. 061206)
	GMP status	GMP inspection report of last 3 years is not provided.
	Remarks of the Evaluator	1. Evidence of
		approval of applied
		formulation in
		reference regulatory
		authorities /
		agencies which
		were adopted by the
		Registration Board
		in its 275th meeting.
		2. GMP inspection
		report conducted
	Desirione Deferred 1 from fr. 11	within last 3 years.
	Decision: Deferred for followings:	61-4::
	Evidence of approval of applied which were declared/approved by	formulation in reference regulatory authorities/agencies by the Registration Board.
		GMP of the firm from QA & LT division.
266.	Name and address of manufacturer/	Nimrall Labortories, Plot No. 24 , Street # SS-03, Rawat
	Applicant Applicant	Industrial Zone., Islamabad.
	Brand Name + Dosage Form + Strength	DEXPRO Tablet 400 mg
	Diana Tame   Dosage I offit + Buength	DEAT NO THURST TOO MIS

	C::::-:::	Est. Classes de la la Containe
	Composition	Each film coated tablet Contains:
	Diam No Data of D % I % for	Dexibuprofen
	Diary No. Date of R & I & fee	Dy. No 13072 dated 06-03-2019; Rs.20,000/- dated 06-03-
		2019
	Pharmacological Group	NSAID
	Type of Form	Form - 5
	Finished product Specification	Innovator's Specification
	Pack size & Demanded Price	30, As per SRO.
	Approval status of product in Reference	Dexibuprofen 400 mg film-coated tablets MHRA
	Regulatory Authorities	Approved
	Me-too status	Tercica 400mg Tablet. Reg. No. 58446
	GMP status	GMP inspection report of last 3 years is not provided.
	Remarks of the Evaluator	GMP inspection report conducted within last 3 years.
		will be issued after submission of GMP audit report from
	QA< Division, valid within last three	
267.	Name and address of manufacturer/	Macquin's International, F-2/H., P.T.C Industrial
207.	Applicant address of manufacturer	Complex,S.I.T.E,Karachi.
	Brand Name + Dosage Form + Strength	MACOLIN Capsule 300 mg
	Composition	Each Capsule Contains:
	Composition	Pregabalin300 mg
	Diary No. Date of R & I & fee	Dy. No 11992 dated 06-03-2019; Rs.20,000/- dated 05-03-
	Diary No. Date of R & I & Ice	2019
	Pharmacological Group	Anticonvulsant
		Form - 5
	Type of Form  Einished product Specification	
	Finished product Specification	Manufacturer specification / USP specification
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference	Lyrica 300 mg capsule of Upjohn UK limited (MHRA)
	Regulatory Authorities	Approved)
	Me-too status	Newgaba 300mg Capsules, 092105, Biolabs (Pvt) Ltd., Islamabad
	CMD status	
	GMP status  Remarks of the Evaluator	GMP inspection report within last 3 years is not provided.  1. GMP inspection
	Remarks of the Evaluator	1
		report within last 3
		years is required.
		2. Form-5 as per
		prescribed format of
		Drug Registering, Licensing &
		advertising is
		required along with
		preregistration fee
		challan.
		3. Complete method of
		manufacturing is
		required.
		4. Finished product
		specification is
		mentioned as both
		manufacturer and
		USP. Revised
		Finished product
		specification is
		required clearly
		mentioning
		specifications.
	Decision: Deferred for followings	operations.
	Decision. Deterred for followings	

	_	rm from QA & LT division. The method of manufacturing are required. The method of manufacturing are required. The method of manufacturing are required.
268.	Name and address of manufacturer/	M/s Macquin's International, F-2/H., P.T.C Industrial
200.	Applicant	Complex, S.I.T.E, Karachi.
	Brand Name + Dosage Form + Strength	Each Capsule Contains:
	Brand Name + Dosage Form + Strength	MACOLIN Capsule 150 mg
	Composition	Each Capsule Contians:
	Composition	Pregabalin150 mg
	Diary No. Date of R & I & fee	Dy. No 11991 dated 06-03-2019; Rs.20,000/- dated 05-03-
		2019
	Pharmacological Group	Anticonvulsant
	Type of Form	Form - 5
	Finished product Specification	Manufacturer specification / USP specification
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference	Lyrica 150 mg capsule of Upjohn UK limited (MHRA)
	Regulatory Authorities	Approved)
	Me-too status	Freglin Capsule 150 mg, 094034, FYNK Pharmaceuticals,
		Lahore
	GMP status	GMP inspection report within last 3 years is not provided.
	Remarks of the Evaluator	1. GMP inspection
		report within last 3
		years is required.
		2. Form-5 as per
		prescribed format of
		Drug Registering,
		Licensing &
		advertising is
		required along with
		preregistration fee
		challan.
		3. Complete method of
		manufacturing is
		required.
		4. Finished product
		specification is
		mentioned as both
		manufacturer and
		USP. Revised
		Finished product
		specification is
		required clearly
		mentioning
		specifications
	<b>Decision: Deferred for followings</b>	
	Updated status of GMP of the fire	rm from QA & LT division.
	<ul> <li>Submission of Form-5, along with</li> </ul>	th method of manufacturing are required.
	Both In-house and USP specification	ations are mentioned, it is advised to specify the one.
269.	Name and address of manufacturer/	M/s Macquin's International, F-2/H., P.T.C Industrial
	Applicant	Complex,S.I.T.E,Karachi.
	Brand Name + Dosage Form + Strength	MACOLIN Capsule 100 mg
	Composition	Each Capsule Contains:
		Pregabalin100 mg
	Diary No. Date of R & I & fee	Dy. No 11990 dated 06-03-2019; Rs.20,000/- dated 05-03-
		2019

	Pharmacological Group	Anticonvulsant
	Type of Form	Form - 5
	Finished product Specification	Manufacturer specification / USP specification
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference	Lyrica 100 mg capsule of Upjohn UK limited (MHRA)
	Regulatory Authorities	Approved)
	Me-too status	Bargan 100mg Capsule, 094932, CKD Pharmaceuticals
		Pakistan (Pvt) Ltd., Karachi
	GMP status	GMP inspection report within last 3 years is not provided.
	Remarks of the Evaluator	<ol> <li>GMP inspection report within last 3 years is required.</li> <li>Form-5 as per prescribed format of Drug Registering,         Licensing &amp; advertising is required along with         preregistration fee challan.</li> <li>Complete method of manufacturing is required.</li> <li>Finished product specification is mentioned as both         manufacturer and USP. Revised Finished product         specification is required clearly mentioning</li> </ol>
	Decisions Defended for followings	specifications.
	Decision: Deferred for followings	CA R I T 1:-:-:
	Updated status of GMP of the fit  Submission of Form 5 along with	
		th method of manufacturing are required.
270.	Name and address of manufacturer/	ations are mentioned, it is advised to specify the one.  M/s Macquin's International, F-2/H., P.T.C Industrial
270.	Applicant	Complex,S.I.T.E,Karachi.
	Brand Name + Dosage Form + Strength	MACOLIN Capsule 75 mg
	Composition	Each Capsule Contains:
	Composition	Pregabalin75 mg
	Diary No. Date of R & I & fee	Dy. No 11989 dated 06-03-2019; Rs.20,000/- dated 05-03-
	Bury 100. But of 100 100	2019
	Pharmacological Group	Anticonvulsant
	Type of Form	Form - 5
	Finished product Specification	Manufacturer specification / USP specification
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities	Lyrica 75 mg capsule of Upjohn UK limited (MHRA) Approved)
	Me-too status	Bargan 75mg Capsule, 094931, CKD Pharmaceuticals Pakistan (Pvt) Ltd., Karachi
	GMP status	GMP inspection report within last 3 years is not provided.
	Remarks of the Evaluator	1. GMP inspection report within last 3 years is required.
		2. Form-5 as per prescribed format of Drug Registering,
		Licensing & advertising is required along with
		preregistration fee challan.
		3. Complete method of manufacturing is required.
		4. Finished product specification is mentioned as both manufacturer and USP. Revised Finished product
		specification is required clearly mentioning
		specification is required clearly mendoming specifications.
	<b>Decision: Deferred for followings</b>	s pecifications.
	Updated status of GMP of the fit	rm from OA & LT division.
	_	th method of manufacturing are required.
		ntions are mentioned, it is advised to specify the one.
271.	Name and address of manufacturer/	
	Applicant	Complex,S.I.T.E,Karachi.
	Brand Name + Dosage Form + Strength	MACOLIN Capsule 50 mg
	Composition	Each Capsule Contains:
		Pregabalin50 mg
	•	

Diary No. Date of R & I & fee	Dy. No 11988 dated 06-03-2019; Rs.20,000/- dated 05-03-
	2019
Pharmacological Group	Anticonvulsant
Type of Form	Form - 5
Finished product Specification	Manufacturer specification / USP specification
Pack size & Demanded Price	As per SRO
Approval status of product in Reference	Lyrica 50 mg capsule of Upjohn UK limited (MHRA)
Regulatory Authorities	Approved)
Me-too status	Bargan 50mg Capsule, 094933, CKD Pharmaceuticals
	Pakistan (Pvt) Ltd., Karachi
GMP status	GMP inspection report within last 3 years is not provided.
Remarks of the Evaluator	1. GMP inspection report within last 3 years is required.
	2. Form-5 as per prescribed format of Drug Registering,
	Licensing & advertising is required along with preregistration fee challan.
	3. Complete method of manufacturing is required.
	4. Finished product specification is mentioned as both
	manufacturer and USP. Revised Finished product
	specification is required clearly mentioning
	specifications.
Decision: Deferred for followings	

- Updated status of GMP of the firm from QA & LT division.
- Submission of Form-5, along with method of manufacturing are required.
- Both In-house and USP specifications are mentioned, it is advised to specify the one.

272.	Name and address of manufacturer/ Applicant	M/s Neomedix,Plot No. 5 ,N/5 National Industrial Zone ,Rawat , Islamabad.
	Brand Name + Dosage Form + Strength	MACPAR Dry Suspension 250 mg/5 ml
	Composition	Each 5ml after reconstitution contain:
		Clarithromycin250 mg
	Diary No. Date of R & I & fee	Dy. No 12985 dated 06-03-2019; Rs.20,000/- dated 06-03-
		2019
	Pharmacological Group	Macrolide
	Type of Form	Form - 5
	Finished product Specification	USP specification
	Pack size & Demanded Price	, As per SRO
	Approval status of product in Reference	MHRA Approved
	Regulatory Authorities	
	Me-too status	Clarimyth Dry Powder Suspension 250mg/5ml, M/s
		Oakdale Pharmaceuticals, Peshawar ,085047.
	GMP status	GMP inspection report within last 3 years is not provided.
	Remarks of the Evaluator	1. GMP inspection report within last 3 years is required.
		2. Form-5 annexures dully, signed and stamped.
		3. Complete method of manufacturing and finished
		product testing specification dully signed and stamped
		is required along with preregistration variation fee
		challan.
		4. In one submitted document pack is mentioned as 60 ml.
		while in another it is mentioned as 90 ml, clarify the
		applied pack size.
		5. Undertaken to follow innovator product formulation,
		packing, labeling and stability study.

## **Decision: Deferred for followings**

- Updated status of GMP of the firm from QA & LT division.
- Submission of complete Form-5, along with method of manufacturing, finish product testing, specification and commitments as per 251st meeting of Registration Board duly signed and stamped are required.

273.	Name and address of manufacturer/	M/s Neomedix, Plot No. 5 , N/5 National Industrial Zone
	Applicant	,Rawat , Islamabad.
	Brand Name + Dosage Form + Strength	MACPAR Dry Suspension 125 mg/5 ml
	Composition	Each 5ml after reconstitution contain: Clarithromycin125 mg
	Diary No. Date of R & I & fee	Dy. No 12984 dated 06-03-2019; Rs.20,000/- dated 06-03-2019
	Pharmacological Group	Macrolide
	Type of Form	Form - 5
	Finished product Specification	USP specification
	Pack size & Demanded Price	, As per SRO
	Approval status of product in Reference Regulatory Authorities	MHRA Approved
	Me-too status	IB-Clar Dry Suspension 125mg/5ml, M/s Ice Berg Pharmaceuticals, Risalpur, 085051
	GMP status	GMP inspection report within last 3 years is not provided.
	Remarks of the Evaluator	<ol> <li>GMP inspection report within last 3 years is required.</li> <li>Form-5 annexures dully signed and stamped.</li> <li>Complete method of manufacturing and finished product testing specification dully signed and stamped is required along with preregistration variation fee challan.</li> </ol>
		4. In one submitted document pack is mentioned as 60 ml, while in another it is mentioned as 90 ml, clarify the applied pack size.
	Decision: Deferred for followings  • Updated status of GMP of the firm for the firm	5. Undertaken to follow innovator product formulation packing, labeling and stability study.  From QA & LT division.
	<ul> <li>Updated status of GMP of the firm f</li> <li>Submission of complete Form-5, alor specification and commitments as p stamped are required.</li> </ul>	5. Undertaken to follow innovator product formulation, packing, labeling and stability study.  From QA & LT division.  In a with method of manufacturing, finish product testing, er 251st meeting of Registration Board duly signed and
274.	<ul> <li>Updated status of GMP of the firm f</li> <li>Submission of complete Form-5, alor specification and commitments as p stamped are required.</li> <li>Name and address of manufacturer/</li> </ul>	5. Undertaken to follow innovator product formulation, packing, labeling and stability study.  From QA & LT division.  In a with method of manufacturing, finish product testing,
274.	<ul> <li>Updated status of GMP of the firm f</li> <li>Submission of complete Form-5, alor specification and commitments as p stamped are required.</li> <li>Name and address of manufacturer/Applicant</li> </ul>	5. Undertaken to follow innovator product formulation, packing, labeling and stability study.  From QA & LT division.  In with method of manufacturing, finish product testing, er 251st meeting of Registration Board duly signed and M/s Neomedix, Plot No. 5, N/5 National Industrial Zone, Rawat, Islamabad.
274.	<ul> <li>Updated status of GMP of the firm f</li> <li>Submission of complete Form-5, alor specification and commitments as p stamped are required.</li> <li>Name and address of manufacturer/</li> </ul>	5. Undertaken to follow innovator product formulation packing, labeling and stability study.  From QA & LT division.  In a with method of manufacturing, finish product testing, ser 251st meeting of Registration Board duly signed and M/s Neomedix, Plot No. 5, N/5 National Industrial Zone
274.	<ul> <li>Updated status of GMP of the firm f</li> <li>Submission of complete Form-5, alor specification and commitments as p stamped are required.</li> <li>Name and address of manufacturer/Applicant</li> <li>Brand Name + Dosage Form + Strength</li> </ul>	5. Undertaken to follow innovator product formulation, packing, labeling and stability study.  From QA & LT division.  In a with method of manufacturing, finish product testing, er 251st meeting of Registration Board duly signed and M/s Neomedix, Plot No. 5 ,N/5 National Industrial Zone, Rawat, Islamabad.  MOSART Dry Suspension 15/90 mg; 60 ml
274.	<ul> <li>Updated status of GMP of the firm f</li> <li>Submission of complete Form-5, alor specification and commitments as p stamped are required.</li> <li>Name and address of manufacturer/Applicant</li> <li>Brand Name + Dosage Form + Strength</li> </ul>	5. Undertaken to follow innovator product formulation, packing, labeling and stability study.  From QA & LT division.  In with method of manufacturing, finish product testing, er 251st meeting of Registration Board duly signed and M/s Neomedix, Plot No. 5 ,N/5 National Industrial Zone ,Rawat , Islamabad.  MOSART Dry Suspension 15/90 mg; 60 ml  Each 5ml after reconstitution contain:  Artemether
274.	<ul> <li>Updated status of GMP of the firm f</li> <li>Submission of complete Form-5, alor specification and commitments as p stamped are required.</li> <li>Name and address of manufacturer/Applicant</li> <li>Brand Name + Dosage Form + Strength</li> </ul>	5. Undertaken to follow innovator product formulation packing, labeling and stability study.  From QA & LT division.  In with method of manufacturing, finish product testing er 251st meeting of Registration Board duly signed and M/s Neomedix, Plot No. 5 ,N/5 National Industrial Zone ,Rawat , Islamabad.  MOSART Dry Suspension 15/90 mg; 60 ml  Each 5ml after reconstitution contain:  Artemether
274.	Updated status of GMP of the firm f     Submission of complete Form-5, alor specification and commitments as p stamped are required.  Name and address of manufacturer/Applicant  Brand Name + Dosage Form + Strength  Composition	5. Undertaken to follow innovator product formulation packing, labeling and stability study.  From QA & LT division.  In with method of manufacturing, finish product testing er 251st meeting of Registration Board duly signed and M/s Neomedix, Plot No. 5 ,N/5 National Industrial Zone, Rawat , Islamabad.  MOSART Dry Suspension 15/90 mg; 60 ml  Each 5ml after reconstitution contain:  Artemether
274.	Updated status of GMP of the firm f     Submission of complete Form-5, alor specification and commitments as p stamped are required.  Name and address of manufacturer/Applicant  Brand Name + Dosage Form + Strength  Composition  Diary No. Date of R & I & fee  Pharmacological Group	5. Undertaken to follow innovator product formulation packing, labeling and stability study.  From QA & LT division.  In with method of manufacturing, finish product testing er 251st meeting of Registration Board duly signed and manufacturing.  M/s Neomedix,Plot No. 5 ,N/5 National Industrial Zone ,Rawat , Islamabad.  MOSART Dry Suspension 15/90 mg; 60 ml  Each 5ml after reconstitution contain:  Artemether
274.	Updated status of GMP of the firm f     Submission of complete Form-5, alor specification and commitments as p stamped are required.  Name and address of manufacturer/Applicant  Brand Name + Dosage Form + Strength  Composition  Diary No. Date of R & I & fee  Pharmacological Group  Type of Form	5. Undertaken to follow innovator product formulation packing, labeling and stability study.  From QA & LT division.  In with method of manufacturing, finish product testing er 251st meeting of Registration Board duly signed and M/s Neomedix, Plot No. 5 ,N/5 National Industrial Zone, Rawat , Islamabad.  MOSART Dry Suspension 15/90 mg; 60 ml  Each 5ml after reconstitution contain:  Artemether
274.	<ul> <li>Updated status of GMP of the firm f</li> <li>Submission of complete Form-5, alor specification and commitments as p stamped are required.</li> <li>Name and address of manufacturer/Applicant</li> <li>Brand Name + Dosage Form + Strength</li> <li>Composition</li> <li>Diary No. Date of R &amp; I &amp; fee</li> <li>Pharmacological Group</li> <li>Type of Form</li> <li>Finished product Specification</li> </ul>	5. Undertaken to follow innovator product formulation packing, labeling and stability study.  From QA & LT division.  In with method of manufacturing, finish product testing er 251st meeting of Registration Board duly signed and manufacturing.  M/s Neomedix,Plot No. 5 ,N/5 National Industrial Zone ,Rawat , Islamabad.  MOSART Dry Suspension 15/90 mg; 60 ml  Each 5ml after reconstitution contain:  Artemether
274.	Updated status of GMP of the firm f     Submission of complete Form-5, alor specification and commitments as p stamped are required.  Name and address of manufacturer/Applicant  Brand Name + Dosage Form + Strength  Composition  Diary No. Date of R & I & fee  Pharmacological Group  Type of Form  Finished product Specification  Pack size & Demanded Price  Approval status of product in Reference	5. Undertaken to follow innovator product formulation packing, labeling and stability study.  From QA & LT division.  In with method of manufacturing, finish product testing er 251st meeting of Registration Board duly signed and M/s Neomedix, Plot No. 5 ,N/5 National Industrial Zone ,Rawat , Islamabad.  MOSART Dry Suspension 15/90 mg; 60 ml  Each 5ml after reconstitution contain:  Artemether
274.	Updated status of GMP of the firm for Submission of complete Form-5, alor specification and commitments as postamped are required.  Name and address of manufacturer/Applicant  Brand Name + Dosage Form + Strength  Composition  Diary No. Date of R & I & fee  Pharmacological Group  Type of Form  Finished product Specification  Pack size & Demanded Price	5. Undertaken to follow innovator product formulation packing, labeling and stability study.  From QA & LT division.  In with method of manufacturing, finish product testing er 251st meeting of Registration Board duly signed and M/s Neomedix, Plot No. 5 ,N/5 National Industrial Zone ,Rawat , Islamabad.  MOSART Dry Suspension 15/90 mg; 60 ml  Each 5ml after reconstitution contain:  Artemether
274.	Updated status of GMP of the firm f     Submission of complete Form-5, alor specification and commitments as p stamped are required.  Name and address of manufacturer/ Applicant  Brand Name + Dosage Form + Strength Composition  Diary No. Date of R & I & fee  Pharmacological Group Type of Form Finished product Specification Pack size & Demanded Price Approval status of product in Reference Regulatory Authorities	5. Undertaken to follow innovator product formulation packing, labeling and stability study.  From QA & LT division.  In with method of manufacturing, finish product testing er 251st meeting of Registration Board duly signed and manufacturing.  M/s Neomedix, Plot No. 5 ,N/5 National Industrial Zone ,Rawat , Islamabad.  MOSART Dry Suspension 15/90 mg; 60 ml  Each 5ml after reconstitution contain:  Artemether

		T	
			ament pack is mentioned as 60 ml.
		while in another it is	mentioned as 90 ml, clarify the
		applied pack size.	
		5. Undertaken to follow	v innovator product formulation,
		packing, labeling and	
	<b>Decision: Deferred for followings</b>		-
	• Updated status of GMP of the firm f	from OA & LT division.	
	Submission of complete Form-5, alor		facturing, finish product testing.
	specification and commitments as p		
	stamped are required.		201 W 201
275.	Name and address of manufacturer/	(Applicant) M/s Medera	Pharmaceuticals (Pvt) Ltd,plot #
275.	Applicant Applicant		al Zone (RCCI)Rawat, Islamabad.
	rippireum	Contract manufactur	
			#34, street # SS-2, National
		Industrial Zone, Rawat-	
	Brand Name + Dosage Form + Strength	MEDRAPEM Injection	
		Each Vial Contains:	300 mg (1. v )
	Composition		1 C. 1 C. 1
			drate with Anhydrous Sodium
	DiameNa Date CD 0 L 0 C	Carbonate	
	Diary No. Date of R & I & fee	1	03-2019; Rs.50,000/- dated 05-03-
	DI 1 : 1 C	2019.	
	Pharmacological Group	Carbapenem antibiotics.	
	Type of Form	Form-5	
	Finished product Specification	USP specification	
	Pack size & Demanded Price	As per SRO.	
	Approval status of product in Reference		hydrate blended with anhydrous
	Regulatory Authorities	sodium carbonate fo	,
	26	meropenem powder. (US	
	Me-too status	<u> </u>	of M/s Hilton Pharma, Karachi.
	GMP status	1	n last 3 years not provided
	Remarks of the Evaluator	2	Firm has submitted reply vide
		issued to firm and	1
		asked to provide:	2022 as under:
		1 5: 5 1: /	• Primary Packaging /closure is
		1. Primary Packing/	USP-Type 1 molded glass
		closure along with	vial.
		type of glass vial is	• GMP certificate of Contract
		not well mentioned	Manufacturer has been
		in Form-5.	granted on the inspection
		2. Provide GMP	conducted on 07-04-2021.
		inspection report of	• Notarized copy of
		contract	Contract/quality agreement is
		manufacturer	provided. However,
		conducted within	Procurement of API (Raw
		last three years.	material excipients and
		3. Pre-registration	packaging material is not
		variation	mentioned in contact
		differential fee	agreement.
		challan.	• Pre-registration variation fee
		4. Quality Agreement	of 7500/= submitted vide
		required as per	challan No. 7793003338 dated
		Contract	11-4-2022.
		manufacturing SRO	
		No.1347 dated 15	
		October 2021.	
		5. Attested copy of Contract agreement	

Name and address of manufacturer/ Applicant	02,Street # N-4 Industria (Manufacturer) M/s Nic	a Pharmaceuticals (Pvt) Ltd,plot # al Zone (RCCI)Rawat, Islamabad. cholas Pharmaceuticals Plot #34, adustrial Zone, Rawat-Islamabad.,
Brand Name + Dosage Form + Strength Composition	MEDRAPEM Injection Each Vial Contains: Meropenem (as Trihy Carbonate	1g (I.V) drate with Anhydrous Sodium1 g
•	2019.	03-2019; Rs.50,000/- dated 05-03-
Type of Form	Form-5	
Finished product Specification	USP specification	
Pack size & Demanded Price	As per SRO.	
Approval status of product in Reference	MERREM IV (as the tri	hydrate blended with anhydrous
Regulatory Authorities		or re-constitution) of sterile
Me-too status	Mopen 1 g Injection of I	M/s Hilton Pharma,Karachi
GMP status	GMP status/report withi	n last 3 years not provided
Remarks of the Evaluator	Deficiency letter was issued to firm and asked to provide:	Firm has submitted reply vide diary No. 9095 dated 11-04-2022 as under:  • Primary Packaging /closure is
	1. Primary Packing/closure along with type of glass vial is not well mentioned in Form-5.  2. Provide GMP inspection report of contract manufacturer conducted within last three years.  3. Pre-registration variation differential fee challan.  4. Quality Agreement required as per	<ul> <li>USP-Type 1 molded glass vial.</li> <li>GMP certificate of Contract Manufacturer has been granted on the inspection conducted on 07-04-2021.</li> <li>Notarized copy of Contract/quality agreement is provided. However, Procurement of API (Raw material excipients and packaging material is not mentioned in contact agreement.</li> <li>Pre-registration variation fee of 7500/= submitted vide challan No. 061628374857</li> </ul>
	mentioning the responsibility of Procure packaging material by the applicant.  Name and address of manufacturer/ Applicant  Brand Name + Dosage Form + Strength Composition  Diary No. Date of R & I & fee  Pharmacological Group Type of Form Finished product Specification Pack size & Demanded Price Approval status of product in Reference Regulatory Authorities  Me-too status GMP status	procedure and responsibility of procurement of API (raw material / Excipients) and packing materials as required in Contract Manufacturing SRO No. 1347 dated 15-10-2021.  Decision: Approved.Registration letter will be issued after sul mentioning the responsibility of Procurement of drug substance packaging material by the applicant.  Name and address of manufacturer/ Applicant (Applicant) M/s Medera (92,Street # N-4 Industria (Manufacturer) M/s Nit street # SS-2, National In Strand Name + Dosage Form + Strength (Manufacturer) M/s Nit street # SS-2, National In MEDRAPEM Injection Each Vial Contains: Meropenem (as Trihy Carbonate

		manufacturing SRO No.1347 dated 15 October 2021.  5. Attested copy of Contract agreement mentioning the procedure and responsibility of procurement of API (raw material / Excipients) and packing materials as required in Contract Manufacturing SRO No. 1347 dated 15- 10-2021.	
	<b>Decision: Approved.Registration letter</b>		_
	mentioning the responsibility of Procure	ement of drug substance	(Raw materials), excipients and
255	packaging material by the applicant.	(A 1' () NA/ NA 1	DI (1 (D () 1 (1 1 ( ) )
277.	Name and address of manufacturer/ Applicant	02,Street # N-4 Industria	Pharmaceuticals (Pvt) Ltd,plot # al Zone (RCCI)Rawat, Islamabad. Pholas Pharmaceuticals Plot #34,
			ndustrial Zone, Rawat-Islamabad.,
	Brand Name + Dosage Form + Strength	MEDISTEN Injection 50	
	Composition	Each Vial Contains:	
	1	Imipenem (Anhydrous).	500 mg
			Cilastatin500 mg
	Diary No. Date of R & I & fee	Dy. No 13075 dated 06-0 2019.	03-2019; Rs.50,000/- dated 05-03-
	Pharmacological Group	Carbapenem antibiotics.	
	Type of Form	Form-5	
	Finished product Specification	USP specification	
	Pack size & Demanded Price	As per SRO.	
	Approval status of product in Reference		m and cilastatin) for Injection, for
	Regulatory Authorities	intravenous use. USFDA	**
	Me-too status	Karachi.	ns of M/s Bosch Pharmaceuticals,
	GMP status		n last 3 years not provided
	Remarks of the Evaluator	Deficiency letter was issued to firm and asked to provide:	1 2
		1. Primary Packing/ closure along with type of glass vial is not well mentioned in Form-5.  2. As per Form-5 Label Claim "Each Vial contains: Imipenem (Anhydrous)500 mg " Where as in master	<ul> <li>Primary Packaging /closure is USP-Type 1 molded glass vial.</li> <li>GMP certificate of Contract Manufacturer has been granted on the inspection conducted on 07-04-2021.</li> <li>Notarized copy of Contract/quality agreement is provided. However, Procurement of API (Raw material excipients and packaging material is not</li> </ul>
		formulation composition	mentioned in contact
		Composition	agreement.

	Decision: Approved as "Each vial contained to the contain	mentions:" each vial contains: Imipenem (as monohydrate)500mg, which needs clarification along with applicable fee for revision of label claim on form-5.  3. Firm has provided clinical literature, raw material and finished product testing method of ceftriaxone Sodium instead of Imipenem and cilastatin.  4. Provide GMP inspection report of contract manufacturer conducted within last three years.  5. Pre-registration variation differential fee challan.  6. Quality Agreement required as per Contract manufacturing SRO No.1347 dated 15 October 2021.  7. Attested copy of Contract agreement mentioning the procedure and responsibility of procurement of API (raw material sa required in Contract Manufacturing SRO No. 1347 dated 15-10-2021.
	responsibility of Procurement of dru	ns: 500 mg
278.	Name and address of manufacturer/ Applicant	(Applicant) Paramount Pharmaceuticals,36-Industrial Triangle, Kahuta road, Islamabad. (Manufacturer) M/s Nicholas Pharmaceuticals Plot #34, street # SS-2, National Industrial Zone, Rawat-Islamabad.,
	Brand Name + Dosage Form + Strength	PARAPENEM Injection 1g (I.V)

Composition	Each Vial Contains:
	Meropenem (as Trihydrate with Anhydrous Sodium
	Carbonate
Diary No. Date of R & I & fee	Dy. No 13083 dated 06-03-2019; Rs.50,000/- dated 04-03
	2019.
Pharmacological Group	Carbapenem antibiotics.
Гуре of Form	Form-5
Finished product Specification	USP specification
Pack size & Demanded Price	As per SRO.
Approval status of product in Reference	MERREM IV (as the trihydrate blended with anhydrous
Regulatory Authorities	sodium carbonate for re-constitution) of sterile
	meropenem powder. (USFDA approved)
Me-too status	Mopen 1 g Injection of M/s Hilton Pharma, Karachi
GMP status	GMP status/report within last 3 years not provided
Remarks of the Evaluator	Deficiency letter was
	issued to firm and
	asked to provide:
	1. Primary Packing/
	closure along with
	type of glass vial is
	not well mentioned
	in Form-5.
	2. Provide GMP
	inspection report of
	contract
	manufacturer
	conducted within
	last three years.
	3. Pre-registration
	variation
	differential fee
	challan.
	4. Valid copy of DML
	of applicant.
	5. Quality Agreement
	required as per
	Contract
	manufacturing SRO No.1347 dated 15
	October 2021.
	October 2021. 6. Attested copy of
	October 2021. 6. Attested copy of Contract agreement
	October 2021. 6. Attested copy of Contract agreement mentioning the
	October 2021. 6. Attested copy of Contract agreement mentioning the procedure and
	October 2021. 6. Attested copy of Contract agreement mentioning the procedure and responsibility of
	October 2021. 6. Attested copy of Contract agreement mentioning the procedure and responsibility of procurement of API
	October 2021. 6. Attested copy of Contract agreement mentioning the procedure and responsibility of procurement of API (raw material /
	October 2021. 6. Attested copy of Contract agreement mentioning the procedure and responsibility of procurement of API (raw material / Excipients) and
	October 2021.  6. Attested copy of Contract agreement mentioning the procedure and responsibility of procurement of API (raw material / Excipients) and packing materials as
	October 2021.  6. Attested copy of Contract agreement mentioning the procedure and responsibility of procurement of API (raw material / Excipients) and packing materials as required in Contract
	October 2021.  6. Attested copy of Contract agreement mentioning the procedure and responsibility of procurement of API (raw material / Excipients) and packing materials as required in Contract Manufacturing SRO
	October 2021.  6. Attested copy of Contract agreement mentioning the procedure and responsibility of procurement of API (raw material / Excipients) and packing materials as required in Contract

**Decision: Deferred for followings** 

• Updated status of GMP of the contract manufacturer and applicant from QA & LT division.

	specifications and attested copy	ng with method of manufacturing, finish product testing, of Contract agreement as required in Contract 15-10-2021 duly signed and stamped are required.	
279.		(Applicant) Paramount Pharmaceuticals,36-Industrial Triangle, Kahuta road, Islamabad. (Manufacturer) M/s Nicholas Pharmaceuticals Plot #34, street # SS-2, National Industrial Zone, Rawat-Islamabad.,	
	Brand Name + Dosage Form + Strength	PARAPENEM Injection 500 mg (I.V)	
	Composition	Each Vial Contains:	
	r	Meropenem (as Trihydrate with Anhydrous Sodium Carbonate	
	Diary No. Date of R & I & fee	Dy. No 13082 dated 06-03-2019; Rs.50,000/- dated 04-03-2019.	
	Pharmacological Group	Carbapenem antibiotics.	
	Type of Form	Form-5	
	Finished product Specification	USP specification	
	Pack size & Demanded Price	As per SRO.	
	Approval status of product in Reference	MERREM IV (as the trihydrate blended with anhydrous	
	Regulatory Authorities	sodium carbonate for re-constitution) of sterile	
		meropenem powder. (USFDA approved)	
	Me-too status	Mopen 1 g Injection of M/s Hilton Pharma, Karachi	
	GMP status	GMP status/report within last 3 years not provided	
	Remarks of the Evaluator	Deficiency letter was	
		issued to firm and	
		asked to provide:	
		1. Primary Packing/	
		closure along with	
		type of glass vial is	
		not well mentioned	
		in Form-5.	
		2. Provide GMP	
		inspection report of	
		contract	
		manufacturer	
		conducted within	
		last three years.	
		3. Pre-registration	
		variation	
		differential fee	
		challan. 4. Valid copy of DML of applicant.	
		**	
		5. Quality Agreement	
		required as per Contract	
		manufacturing SRO	
		No.1347 dated 15	
		October 2021.	
		6. Attested copy of	
		Contract agreement	
		mentioning the	
		procedure and	
		responsibility of	
		procurement of API	
		(raw material /	
		Excipients) and	
		Excipients) and	

		packing materials as
		required in Contract
		Manufacturing SRO
		No. 1347 dated 15-
		10-2021.
	<b>Decision: Deferred for followings</b>	
	_	act manufacturer and applicant from QA & LT division.
	_	ng with method of manufacturing, finish product testing,
		of Contract agreement as required in Contract
	1	15-10-2021 duly signed and stamped are required.
280.	Name and address of manufacturer/	
200.	Applicant	Industrial Estate, Rawat, Islamabad.
	Brand Name + Dosage Form + Strength	SULI-RIDE Tablet 200 mg
	Composition	Each Tablet Contains:
	Composition	Amisulpride200 mg
	Diary No. Date of R & I & fee	Dy. No 12514 dated 06-03-2019; Rs.50,000/- dated 06-03-
1	Diary 110. Date of R & I & Ice	2019.
	Pharmacological Group	Anti-psychotics
	Type of Form	Form-5
	Finished product Specification	BP specification
	Pack size & Demanded Price	10's, As per SRO.
	Approval status of product in Reference	Amisulpride 200mg Tablets by M/s Accord-UK Ltd
	Regulatory Authorities	(MHRA Approved)
	Me-too status	Amiride Tablet 200mg by M/s Shrooq Pharmaceuticals
	CL CD	(Pvt) Ltd (Reg#063102)
	GMP status	GMP status/report within last 3 years not provided
	Remarks of the Evaluator	Deficiency letter was
		issued to firm and
		asked to provide:
		• Finished Product
		specification not
		provided.
		• All the submitted
		Form-5 Annexures
		are without any
		signature/stamp on
		plain paper.
		• GMP inspection
		report conducted
		within last 3 years is
		not provided.
		Preregistration
		variation fee challan.
	<b>Decision: Deferred for followings</b>	· ····································
	• Updated status of GMP of the firm f	From OA & I.T division
		ng with method of manufacturing, finish product testing, er 251st meeting of Registration Board duly signed and
	1 -	er 251" meeting of Registration board duty signed and
281.	stamped are required.  Name and address of manufacturer/	M/s Paliance Pharms Dlot No 00 street No C 0 DCCI
<b>401.</b>		M/s Reliance Pharma, Plot No.08, street No. S-8, RCCI
	Applicant	Industrial Estate, Rawat, Islamabad.
	Brand Name + Dosage Form + Strength	SULI-RIDE Tablet 100 mg
	Composition	Each Tablet Contains:
		Amisulpride
	Diary No. Date of R & I & fee	Dy. No 12513 dated 06-03-2019; Rs.50,000/- dated 06-03-
		2019.

	Pharmacological Group	Anti-psychotics
	Type of Form	Form-5
	Finished product Specification	BP specification
	Pack size & Demanded Price	10's, As per SRO.
	Approval status of product in Reference	Amisulpride 100 mg Tablets, MHRA Approved.
	Regulatory Authorities	
	Me-too status	Amilia 100mg Tablet, Evolution Pharma, Reg.No.101612.
	GMP status	GMP status/report within last 3 years not provided
	Remarks of the Evaluator	Deficiency letter was
		issued to firm and
		asked to provide:
		• Finished Product
		specification not
		provided.
		• All the submitted
		Form-5 Annexures
		are without any
		signature/stamp on
		plain paper.
		• GMP inspection
		report conducted
		within last 3 years is
		not provided.
		Preregistration  varieties for sheller
	Designer Defermed for followings	variation fee challan.
	Decision: Deferred for followings	nct manufacturer and applicant from QA & LT division.
	<ul> <li>Updated status of GMP of the contra</li> </ul>	ict manufacturer and additiont from OA & L1 division. I
	Submission of complete Form-5, alor	ng with method of manufacturing, finish product testing,
282.	Submission of complete Form-5, alor specifications duly signed and stamp	ng with method of manufacturing, finish product testing, bed are required.
282.	• Submission of complete Form-5, alor specifications duly signed and stamp Name and address of manufacturer/	ng with method of manufacturing, finish product testing, bed are required.  M/s Reliance Pharma, Plot No.08, street No. S-8, RCCI
282.	Submission of complete Form-5, alor specifications duly signed and stamp Name and address of manufacturer/ Applicant	ng with method of manufacturing, finish product testing, bed are required.  M/s Reliance Pharma, Plot No.08, street No. S-8, RCCI Industrial Estate, Rawat, Islamabad.
282.	Submission of complete Form-5, alor specifications duly signed and stamp Name and address of manufacturer/ Applicant     Brand Name + Dosage Form + Strength	ng with method of manufacturing, finish product testing, bed are required.  M/s Reliance Pharma, Plot No.08, street No. S-8, RCCI
282.	Submission of complete Form-5, alor specifications duly signed and stamp Name and address of manufacturer/ Applicant	mg with method of manufacturing, finish product testing, bed are required.  M/s Reliance Pharma, Plot No.08, street No. S-8, RCCI Industrial Estate, Rawat, Islamabad.  SULI-RIDE Tablet 50 mg  Each Tablet Contains: Amisulpride
282.	Submission of complete Form-5, alor specifications duly signed and stamp Name and address of manufacturer/ Applicant     Brand Name + Dosage Form + Strength	ng with method of manufacturing, finish product testing, bed are required.  M/s Reliance Pharma, Plot No.08, street No. S-8, RCCI Industrial Estate, Rawat, Islamabad.  SULI-RIDE Tablet 50 mg
282.	Submission of complete Form-5, alor specifications duly signed and stamp Name and address of manufacturer/ Applicant     Brand Name + Dosage Form + Strength Composition	mg with method of manufacturing, finish product testing, bed are required.  M/s Reliance Pharma, Plot No.08, street No. S-8, RCCI Industrial Estate, Rawat, Islamabad.  SULI-RIDE Tablet 50 mg  Each Tablet Contains: Amisulpride
282.	Submission of complete Form-5, alor specifications duly signed and stamp Name and address of manufacturer/ Applicant     Brand Name + Dosage Form + Strength Composition	mg with method of manufacturing, finish product testing, bed are required.  M/s Reliance Pharma, Plot No.08, street No. S-8, RCCI Industrial Estate, Rawat, Islamabad.  SULI-RIDE Tablet 50 mg  Each Tablet Contains:  Amisulpride
282.	Submission of complete Form-5, alor specifications duly signed and stamp.  Name and address of manufacturer/ Applicant  Brand Name + Dosage Form + Strength  Composition  Diary No. Date of R & I & fee	mg with method of manufacturing, finish product testing, led are required.  M/s Reliance Pharma, Plot No.08, street No. S-8, RCCI Industrial Estate, Rawat, Islamabad.  SULI-RIDE Tablet 50 mg  Each Tablet Contains:  Amisulpride
282.	Submission of complete Form-5, alor specifications duly signed and stamp     Name and address of manufacturer/     Applicant     Brand Name + Dosage Form + Strength     Composition     Diary No. Date of R & I & fee  Pharmacological Group	mg with method of manufacturing, finish product testing, bed are required.  M/s Reliance Pharma, Plot No.08, street No. S-8, RCCI Industrial Estate, Rawat, Islamabad.  SULI-RIDE Tablet 50 mg  Each Tablet Contains:  Amisulpride
282.	Submission of complete Form-5, alor specifications duly signed and stamp Name and address of manufacturer/ Applicant Brand Name + Dosage Form + Strength Composition  Diary No. Date of R & I & fee  Pharmacological Group Type of Form	my with method of manufacturing, finish product testing, bed are required.  M/s Reliance Pharma, Plot No.08, street No. S-8, RCCI Industrial Estate, Rawat, Islamabad.  SULI-RIDE Tablet 50 mg  Each Tablet Contains:  Amisulpride
282.	Submission of complete Form-5, alor specifications duly signed and stamp     Name and address of manufacturer/     Applicant     Brand Name + Dosage Form + Strength     Composition  Diary No. Date of R & I & fee  Pharmacological Group     Type of Form     Finished product Specification	mg with method of manufacturing, finish product testing, bed are required.  M/s Reliance Pharma, Plot No.08, street No. S-8, RCCI Industrial Estate, Rawat, Islamabad.  SULI-RIDE Tablet 50 mg  Each Tablet Contains:  Amisulpride
282.	Submission of complete Form-5, alor specifications duly signed and stamp Name and address of manufacturer/ Applicant Brand Name + Dosage Form + Strength Composition  Diary No. Date of R & I & fee  Pharmacological Group Type of Form Finished product Specification Pack size & Demanded Price Approval status of product in Reference Regulatory Authorities	mg with method of manufacturing, finish product testing, bed are required.  M/s Reliance Pharma, Plot No.08, street No. S-8, RCCI Industrial Estate, Rawat, Islamabad.  SULI-RIDE Tablet 50 mg  Each Tablet Contains:  Amisulpride
282.	Submission of complete Form-5, alor specifications duly signed and stamp Name and address of manufacturer/ Applicant Brand Name + Dosage Form + Strength Composition  Diary No. Date of R & I & fee  Pharmacological Group Type of Form Finished product Specification Pack size & Demanded Price Approval status of product in Reference	mg with method of manufacturing, finish product testing, bed are required.  M/s Reliance Pharma, Plot No.08, street No. S-8, RCCI Industrial Estate, Rawat, Islamabad.  SULI-RIDE Tablet 50 mg  Each Tablet Contains: Amisulpride
282.	Submission of complete Form-5, alor specifications duly signed and stamp Name and address of manufacturer/ Applicant Brand Name + Dosage Form + Strength Composition  Diary No. Date of R & I & fee  Pharmacological Group Type of Form Finished product Specification Pack size & Demanded Price Approval status of product in Reference Regulatory Authorities Me-too status	my with method of manufacturing, finish product testing, bed are required.  M/s Reliance Pharma, Plot No.08, street No. S-8, RCCI Industrial Estate, Rawat, Islamabad.  SULI-RIDE Tablet 50 mg  Each Tablet Contains: Amisulpride
282.	Submission of complete Form-5, alor specifications duly signed and stamp Name and address of manufacturer/ Applicant Brand Name + Dosage Form + Strength Composition  Diary No. Date of R & I & fee  Pharmacological Group Type of Form Finished product Specification Pack size & Demanded Price Approval status of product in Reference Regulatory Authorities Me-too status  GMP status	my with method of manufacturing, finish product testing, bed are required.  M/s Reliance Pharma, Plot No.08, street No. S-8, RCCI Industrial Estate, Rawat, Islamabad.  SULI-RIDE Tablet 50 mg  Each Tablet Contains:  Amisulpride
282.	Submission of complete Form-5, alor specifications duly signed and stamp Name and address of manufacturer/ Applicant Brand Name + Dosage Form + Strength Composition  Diary No. Date of R & I & fee  Pharmacological Group Type of Form Finished product Specification Pack size & Demanded Price Approval status of product in Reference Regulatory Authorities Me-too status	my with method of manufacturing, finish product testing, bed are required.  M/s Reliance Pharma, Plot No.08, street No. S-8, RCCI Industrial Estate, Rawat, Islamabad.  SULI-RIDE Tablet 50 mg  Each Tablet Contains:  Amisulpride
282.	Submission of complete Form-5, alor specifications duly signed and stamp Name and address of manufacturer/ Applicant Brand Name + Dosage Form + Strength Composition  Diary No. Date of R & I & fee  Pharmacological Group Type of Form Finished product Specification Pack size & Demanded Price Approval status of product in Reference Regulatory Authorities Me-too status  GMP status	mg with method of manufacturing, finish product testing, bed are required.  M/s Reliance Pharma, Plot No.08, street No. S-8, RCCI Industrial Estate, Rawat, Islamabad.  SULI-RIDE Tablet 50 mg  Each Tablet Contains:  Amisulpride
282.	Submission of complete Form-5, alor specifications duly signed and stamp Name and address of manufacturer/ Applicant Brand Name + Dosage Form + Strength Composition  Diary No. Date of R & I & fee  Pharmacological Group Type of Form Finished product Specification Pack size & Demanded Price Approval status of product in Reference Regulatory Authorities Me-too status  GMP status	my with method of manufacturing, finish product testing, bed are required.  M/s Reliance Pharma, Plot No.08, street No. S-8, RCCI Industrial Estate, Rawat, Islamabad.  SULI-RIDE Tablet 50 mg  Each Tablet Contains:  Amisulpride
282.	Submission of complete Form-5, alor specifications duly signed and stamp Name and address of manufacturer/ Applicant Brand Name + Dosage Form + Strength Composition  Diary No. Date of R & I & fee  Pharmacological Group Type of Form Finished product Specification Pack size & Demanded Price Approval status of product in Reference Regulatory Authorities Me-too status  GMP status	mg with method of manufacturing, finish product testing, bed are required.  M/s Reliance Pharma, Plot No.08, street No. S-8, RCCI Industrial Estate, Rawat, Islamabad.  SULI-RIDE Tablet 50 mg  Each Tablet Contains: Amisulpride
282.	Submission of complete Form-5, alor specifications duly signed and stamp Name and address of manufacturer/ Applicant Brand Name + Dosage Form + Strength Composition  Diary No. Date of R & I & fee  Pharmacological Group Type of Form Finished product Specification Pack size & Demanded Price Approval status of product in Reference Regulatory Authorities Me-too status  GMP status	mg with method of manufacturing, finish product testing, bed are required.  M/s Reliance Pharma, Plot No.08, street No. S-8, RCCI Industrial Estate, Rawat, Islamabad.  SULI-RIDE Tablet 50 mg  Each Tablet Contains: Amisulpride
282.	Submission of complete Form-5, alor specifications duly signed and stamp Name and address of manufacturer/ Applicant Brand Name + Dosage Form + Strength Composition  Diary No. Date of R & I & fee  Pharmacological Group Type of Form Finished product Specification Pack size & Demanded Price Approval status of product in Reference Regulatory Authorities Me-too status  GMP status	my with method of manufacturing, finish product testing, sed are required.  M/s Reliance Pharma, Plot No.08, street No. S-8, RCCI Industrial Estate, Rawat, Islamabad.  SULI-RIDE Tablet 50 mg  Each Tablet Contains: Amisulpride
282.	Submission of complete Form-5, alor specifications duly signed and stamp Name and address of manufacturer/ Applicant Brand Name + Dosage Form + Strength Composition  Diary No. Date of R & I & fee  Pharmacological Group Type of Form Finished product Specification Pack size & Demanded Price Approval status of product in Reference Regulatory Authorities Me-too status  GMP status	my with method of manufacturing, finish product testing, sed are required.  M/s Reliance Pharma, Plot No.08, street No. S-8, RCCI Industrial Estate, Rawat, Islamabad.  SULI-RIDE Tablet 50 mg  Each Tablet Contains: Amisulpride
282.	Submission of complete Form-5, alor specifications duly signed and stamp Name and address of manufacturer/ Applicant Brand Name + Dosage Form + Strength Composition  Diary No. Date of R & I & fee  Pharmacological Group Type of Form Finished product Specification Pack size & Demanded Price Approval status of product in Reference Regulatory Authorities Me-too status  GMP status	ng with method of manufacturing, finish product testing, sed are required.  M/s Reliance Pharma, Plot No.08, street No. S-8, RCCI Industrial Estate, Rawat, Islamabad.  SULI-RIDE Tablet 50 mg  Each Tablet Contains: Amisulpride
282.	Submission of complete Form-5, alor specifications duly signed and stamp Name and address of manufacturer/ Applicant Brand Name + Dosage Form + Strength Composition  Diary No. Date of R & I & fee  Pharmacological Group Type of Form Finished product Specification Pack size & Demanded Price Approval status of product in Reference Regulatory Authorities Me-too status  GMP status	ng with method of manufacturing, finish product testing, sed are required.  M/s Reliance Pharma, Plot No.08, street No. S-8, RCCI Industrial Estate, Rawat, Islamabad.  SULI-RIDE Tablet 50 mg  Each Tablet Contains: Amisulpride
282.	Submission of complete Form-5, alor specifications duly signed and stamp Name and address of manufacturer/ Applicant Brand Name + Dosage Form + Strength Composition  Diary No. Date of R & I & fee  Pharmacological Group Type of Form Finished product Specification Pack size & Demanded Price Approval status of product in Reference Regulatory Authorities Me-too status  GMP status	ng with method of manufacturing, finish product testing, sed are required.  M/s Reliance Pharma, Plot No.08, street No. S-8, RCCI Industrial Estate, Rawat, Islamabad.  SULI-RIDE Tablet 50 mg  Each Tablet Contains: Amisulpride

		, , , , , , , , , , , , , , , , , , ,
		• GMP inspection report conducted
		report conducted within last 3 years is
		not provided.
		Preregistration variation fee challan.
	Desigions Defensed for followings	variation fee chanan.
	Decision: Deferred for followings	set monerate etunes and applicant from OA & IT division
		act manufacturer and applicant from QA & LT division.
	• Submission of complete Form-5, alor specifications duly signed and stamp	ng with method of manufacturing, finish product testing,
283.	Name and address of manufacturer/	M/s Reliance Pharma, Plot No.08, street No. S-8, RCCI
205.	Applicant Applicant	Industrial Estate, Rawat, Islamabad.
	Brand Name + Dosage Form + Strength	RELI-TRIGINE Tablet 50 mg
	Composition	Each Tablet Contains:
	Composition	Lamotrigine50 mg
	Diary No. Date of R & I & fee	Dy. No 12510 dated 06-03-2019; Rs.50,000/- dated 06-03-
	Diany 140. Date of R & I & I e	2019.
	Pharmacological Group	Anti-convulsant
	Type of Form	Form-5
	Finished product Specification	USP specification
	Pack size & Demanded Price	3*10's, As per SRO.
	Approval status of product in Reference	Approved by MHRA
	Regulatory Authorities	Approved by MITKA
	Me-too status	Sportin 50mg Tablets of M/s Fassgen Pharmaceuticals,
		(Reg.# 070345)
	GMP status	GMP status/report within last 3 years not provided
	Remarks of the Evaluator	Deficiency letter was
		issued to firm and
		asked to provide:
		• Finished Product
		specification not
		provided.
		• All the submitted
		Form-5 Annexures
		are without any
		signature/stamp on
		plain paper.
		• GMP inspection
		report conducted
		within last 3 years is
		not provided.
		Preregistration
		variation fee challan.
	<b>Decision: Deferred for followings</b>	
	<u> </u>	nct manufacturer and applicant from QA & LT division.
		ng with method of manufacturing, finish product testing,
	specifications duly signed and stamp	
284.	Name and address of manufacturer/	Reliance Pharma, Plot No.08, street No. S-8, RCCI
	Applicant	Industrial Estate, Rawat, Islamabad.
	Brand Name + Dosage Form + Strength	RELI-TRIGINE Tablet 25 mg
	Composition	Each Tablet Contains:
		Lamotrigine
	Diary No. Date of R & I & fee	Dy. No 12509 dated 06-03-2019; Rs.50,000/- dated 06-03-2019.
	Pharmacological Group	Anti-convulsant
		Form-5
	Type of Form	TOITH-3

	Finished product Specification	USP specification
	Pack size & Demanded Price	3*10's, As per SRO.
	Approval status of product in Reference Regulatory Authorities	MHRA approved.
	Me-too status	Lamogin Tablets 25mg of M/s Navegal Labs (Reg.# 043972)
	GMP status	GMP status/report within last 3 years not provided
	Remarks of the Evaluator	Deficiency letter was issued to firm and
		asked to provide:  • Finished Product
		specification not provided.  • All the submitted
		Form-5 Annexures are without any
		signature/stamp on plain paper.
		• GMP inspection report conducted
		within last 3 years is not provided.
		Preregistration     variation fee challan.
		act manufacturer and applicant from QA & LT division.  ng with method of manufacturing, finish product testing,  ped are required.
285.		Reliance Pharma, Plot No.08, street No. S-8, RCCI
	Applicant	Industrial Estate, Rawat, Islamabad.
	Brand Name + Dosage Form + Strength	RELI-TRIGINE Tablet 100 mg
	Composition	Each Tablet Contains: Lamotrigine100 mg
	Diary No. Date of R & I & fee	Dy. No 12511 dated 06-03-2019; Rs.50,000/- dated 06-03-2019.
	Pharmacological Group	Dy. No 12511 dated 06-03-2019; Rs.50,000/- dated 06-03-2019.  Anti-convulsant
	Pharmacological Group Type of Form	Dy. No 12511 dated 06-03-2019; Rs.50,000/- dated 06-03-2019.  Anti-convulsant Form-5
	Pharmacological Group Type of Form Finished product Specification	Dy. No 12511 dated 06-03-2019; Rs.50,000/- dated 06-03-2019.  Anti-convulsant Form-5 USP specification
	Pharmacological Group Type of Form Finished product Specification Pack size & Demanded Price	Dy. No 12511 dated 06-03-2019; Rs.50,000/- dated 06-03-2019.  Anti-convulsant Form-5 USP specification 3*10's, As per SRO.
	Pharmacological Group Type of Form Finished product Specification Pack size & Demanded Price Approval status of product in Reference Regulatory Authorities	Dy. No 12511 dated 06-03-2019; Rs.50,000/- dated 06-03-2019.  Anti-convulsant Form-5 USP specification 3*10's, As per SRO. Approved by MHRA of UK
	Pharmacological Group Type of Form Finished product Specification Pack size & Demanded Price Approval status of product in Reference Regulatory Authorities Me-too status	Dy. No 12511 dated 06-03-2019; Rs.50,000/- dated 06-03-2019.  Anti-convulsant Form-5 USP specification 3*10's, As per SRO. Approved by MHRA of UK  Epicta 100mg Tablets of M/s Alina Combine Pakistan, Karachi (Reg.# 039081)
	Pharmacological Group Type of Form Finished product Specification Pack size & Demanded Price Approval status of product in Reference Regulatory Authorities Me-too status GMP status	Dy. No 12511 dated 06-03-2019; Rs.50,000/- dated 06-03-2019.  Anti-convulsant Form-5 USP specification 3*10's, As per SRO. Approved by MHRA of UK  Epicta 100mg Tablets of M/s Alina Combine Pakistan, Karachi (Reg.# 039081) GMP status/report within last 3 years not provided
	Pharmacological Group Type of Form Finished product Specification Pack size & Demanded Price Approval status of product in Reference Regulatory Authorities Me-too status	Dy. No 12511 dated 06-03-2019; Rs.50,000/- dated 06-03-2019.  Anti-convulsant  Form-5  USP specification  3*10's, As per SRO.  Approved by MHRA of UK  Epicta 100mg Tablets of M/s Alina Combine Pakistan, Karachi (Reg.# 039081)  GMP status/report within last 3 years not provided  Deficiency letter was issued to firm and
	Pharmacological Group Type of Form Finished product Specification Pack size & Demanded Price Approval status of product in Reference Regulatory Authorities Me-too status GMP status	Dy. No 12511 dated 06-03-2019; Rs.50,000/- dated 06-03-2019.  Anti-convulsant Form-5  USP specification 3*10's, As per SRO. Approved by MHRA of UK  Epicta 100mg Tablets of M/s Alina Combine Pakistan, Karachi (Reg.# 039081)  GMP status/report within last 3 years not provided  Deficiency letter was issued to firm and asked to provide:  • Finished Product
	Pharmacological Group Type of Form Finished product Specification Pack size & Demanded Price Approval status of product in Reference Regulatory Authorities Me-too status GMP status	Dy. No 12511 dated 06-03-2019; Rs.50,000/- dated 06-03-2019.  Anti-convulsant Form-5 USP specification 3*10's, As per SRO. Approved by MHRA of UK  Epicta 100mg Tablets of M/s Alina Combine Pakistan, Karachi (Reg.# 039081)  GMP status/report within last 3 years not provided  Deficiency letter was issued to firm and asked to provide:  • Finished Product specification not provided.
	Pharmacological Group Type of Form Finished product Specification Pack size & Demanded Price Approval status of product in Reference Regulatory Authorities Me-too status GMP status	Dy. No 12511 dated 06-03-2019; Rs.50,000/- dated 06-03-2019.  Anti-convulsant  Form-5  USP specification  3*10's, As per SRO.  Approved by MHRA of UK  Epicta 100mg Tablets of M/s Alina Combine Pakistan, Karachi (Reg.# 039081)  GMP status/report within last 3 years not provided  Deficiency letter was issued to firm and asked to provide:  • Finished Product specification not provided.  • All the submitted
	Pharmacological Group Type of Form Finished product Specification Pack size & Demanded Price Approval status of product in Reference Regulatory Authorities Me-too status GMP status	Dy. No 12511 dated 06-03-2019; Rs.50,000/- dated 06-03-2019.  Anti-convulsant  Form-5  USP specification  3*10's, As per SRO.  Approved by MHRA of UK  Epicta 100mg Tablets of M/s Alina Combine Pakistan, Karachi (Reg.# 039081)  GMP status/report within last 3 years not provided  Deficiency letter was issued to firm and asked to provide:  • Finished Product specification not provided.  • All the submitted Form-5 Annexures
	Pharmacological Group Type of Form Finished product Specification Pack size & Demanded Price Approval status of product in Reference Regulatory Authorities Me-too status GMP status	Dy. No 12511 dated 06-03-2019; Rs.50,000/- dated 06-03-2019.  Anti-convulsant  Form-5  USP specification  3*10's, As per SRO.  Approved by MHRA of UK  Epicta 100mg Tablets of M/s Alina Combine Pakistan, Karachi (Reg.# 039081)  GMP status/report within last 3 years not provided  Deficiency letter was issued to firm and asked to provide:  • Finished Product specification not provided.  • All the submitted

		• GMP inspection
		report conducted
		within last 3 years is
		not provided.
		Preregistration
		variation fee challan.
	Decision: Deferred for followings	variation for chantain
	_	act manufacturer and applicant from QA & LT division.
		ng with method of manufacturing, finish product testing,
	• Submission of complete Form-5, alo specifications duly signed and stamp	
286.	Name and address of manufacturer/	
200.	Applicant	Industrial Estate, Rawat, Islamabad.
	Brand Name + Dosage Form + Strength	FLURELIZINE Capsule 5 mg
	Composition	Each Capsule Contains:
	Composition	Flunarizine Hcl5 mg
	Diary No. Date of R & I & fee	Dy. No 12506 dated 06-03-2019; Rs.50,000/- dated 06-03-
	Diary No. Date of K & I & Iee	2019.
	Dharmacalagical Group	Selective calcium channel blocker
	Pharmacological Group	
	Type of Form	Form-5
	Finished product Specification	Innovator's Specification
	Pack size & Demanded Price	2*6's, As per SRO.
	Approval status of product in Reference	Flunarizine Hydrochloride Capsules, AA PHARMA
	Regulatory Authorities	INC.Health Canada approved.
	Me-too status	Polyzine Cap.5mg, Polyfine ChemPharma, R#036751
	GMP status	GMP status/report within last 3 years not provided
	Remarks of the Evaluator	Deficiency letter was
		issued to firm and
		asked to provide:
		• Finished Product
		specification not
		provided or
		undertaking to follow
		innovator's
		specification.
		• All the submitted
		Form-5 Annexures
		are without any
		signature/stamp on
		plain paper.
		• Label Claim as per
		form-5 is flunarizine
		Hcl5 mg, whereas
		API in reference
		product contains:
		Flunarizine as Hcl
		5 mg
		•
		report conducted
		within last 3 years is
		not provided.

**De Decision: Deferred for followings** 

• Updated status of GMP of the contract manufacturer and applicant from QA & LT division.

• Preregistration

variation fee challan.

• Submission of complete Form-5, along with method of manufacturing, finish product testing, specifications duly signed and stamped are required.

	Revision of formulation as per refer change of formulation.	rence product along with submission of requisite fee for	
287.	Name and address of manufacturer/	M/s Reliance Pharma, Plot No.08, street No. S-8, RCCI	
207.	Applicant Applicant	Industrial Estate, Rawat, Islamabad.	
	Brand Name + Dosage Form + Strength	RELISONE Tablet 50 mg	
	Composition	Each Film Coated Tablet Contains:	
	Composition	Eperisone Hcl Eq to Eprisoone50 mg	
	Diary No. Date of R & I & fee	Dy. No 12508 dated 06-03-2019; Rs.50,000/- dated 06-03-	
	Biary 110. Bate of R & F & Ice	2019.	
	Pharmacological Group	SSRI	
	Type of Form	Form-5	
	Finished product Specification	Innovator's Specification	
	Pack size & Demanded Price	3*10's, As per SRO.	
	Approval status of product in Reference Regulatory Authorities	Expose 50mg film coated tablet, AIFA approved.	
	Me-too status	Perispa 50mg tablets, Platinum pharma, Reg. No. 039302.	
	GMP status	GMP status/report within last 3 years not provided	
	Remarks of the Evaluator	Deficiency letter was	
		issued to firm and	
		asked to provide:	
		• Finished Product	
		specification not	
		provided or	
		undertaking to follow	
		innovator's	
		specification.	
		• Firm has mentioned	
		Methylene chloride	
		in their master	
		formulation which is	
		prohibited.	
		• All the submitted	
		Form-5 Annexures	
		are without any	
		signature/stamp on	
		plain paper.	
		• GMP inspection	
		report conducted	
		within last 3 years is	
		not provided.	
		Preregistration	
		variation fee challan.	
	<b>Decision: Deferred for followings</b>		
		act manufacturer and applicant from QA & LT division.	
		ng with method of manufacturing, finish product testing,	
	specifications duly signed and stamp	- I	
200		as methylene chloride is banned/discontinued excipient	
288.	Name and address of manufacturer/	M/s Reliance Pharma, Plot No.08, street No. S-8, RCCI	
	Applicant Provide Street	Industrial Estate, Rawat, Islamabad.	
	Brand Name + Dosage Form + Strength	RELIFOXINE CAPSULE 50 mg	
	Composition	Each Capsule Contains: Etifoxine Hel50 mg	
	Diary No. Date of R & I & fee	Dy. No 12507 dated 06-03-2019; Rs.50,000/- dated 06-03-2019.	
	Pharmacological Group	SSRI	
	Type of Form	Form-5	

	Finished product Specification	Manufacturer's Specification	
	Pack size & Demanded Price	3*10's, As per SRO.	
	Approval status of product in Reference	STRESAM, capsule". ANSM, France approved	
	Regulatory Authorities		
	Me-too status	Stresam capsule 50mg of M/s CCL Pharma (Reg#	
	112 400 51111115	024595)	
	GMP status	GMP status/report within last 3 years not provided	
	Remarks of the Evaluator	Deficiency letter was	
	Remarks of the Evaration	issued to firm and	
		asked to firm and asked to provide:	
		• Finished Product	
		*	
		provided or	
		undertaking to follow innovator's	
		specification.	
		• All the submitted	
		Form-5 Annexures	
		are without any	
		signature/stamp on	
		plain paper.	
		• `GMP inspection	
		report conducted	
		within last 3 years is	
		not provided.	
		Preregistration	
		variation fee challan.	
	<b>Decision: Deferred for followings</b>		
	• Updated status of GMP of the contract manufacturer and applicant from QA & LT division.		
	Submission of complete Form-5, alor	•41 41 1 6 6 4 • 6• • 1 1 44 4•	
	Submission of complete Form-5, and	ng with method of manufacturing, finish product testing,	
	-	of Contract agreement as required in Contract	
	specifications and attested copy	S, <b>1</b>	
289.	specifications and attested copy	of Contract agreement as required in Contract 15-10-2021 duly signed and stamped are required.	
289.	specifications and attested copy Manufacturing SRO No. 1347 dated	of Contract agreement as required in Contract 15-10-2021 duly signed and stamped are required.	
289.	specifications and attested copy Manufacturing SRO No. 1347 dated Name and address of manufacturer/	of Contract agreement as required in Contract 15-10-2021 duly signed and stamped are required.  Relizon Pharmaceuticals, plot No. 118, Sundar Industrial	
289.	specifications and attested copy Manufacturing SRO No. 1347 dated Name and address of manufacturer/ Applicant	of Contract agreement as required in Contract 15-10-2021 duly signed and stamped are required.  Relizon Pharmaceuticals, plot No. 118, Sundar Industrial Estate, Raiwind Road, Lahore.	
289.	specifications and attested copy Manufacturing SRO No. 1347 dated Name and address of manufacturer/ Applicant Brand Name + Dosage Form + Strength	of Contract agreement as required in Contract 15-10-2021 duly signed and stamped are required.  Relizon Pharmaceuticals, plot No. 118, Sundar Industrial Estate, Raiwind Road, Lahore.  RELBROF TABLET 400 mg	
289.	specifications and attested copy Manufacturing SRO No. 1347 dated Name and address of manufacturer/ Applicant Brand Name + Dosage Form + Strength	of Contract agreement as required in Contract 15-10-2021 duly signed and stamped are required. Relizon Pharmaceuticals, plot No. 118, Sundar Industrial Estate, Raiwind Road, Lahore. RELBROF TABLET 400 mg Each Film Coated Tablet Contains:	
289.	specifications and attested copy Manufacturing SRO No. 1347 dated Name and address of manufacturer/ Applicant Brand Name + Dosage Form + Strength Composition	of Contract agreement as required in Contract 15-10-2021 duly signed and stamped are required.  Relizon Pharmaceuticals, plot No. 118, Sundar Industrial Estate, Raiwind Road, Lahore.  RELBROF TABLET 400 mg Each Film Coated Tablet Contains: Ibuprofen	
289.	specifications and attested copy Manufacturing SRO No. 1347 dated Name and address of manufacturer/ Applicant Brand Name + Dosage Form + Strength Composition	of Contract agreement as required in Contract 15-10-2021 duly signed and stamped are required.  Relizon Pharmaceuticals, plot No. 118, Sundar Industrial Estate, Raiwind Road, Lahore.  RELBROF TABLET 400 mg  Each Film Coated Tablet Contains: Ibuprofen	
289.	specifications and attested copy Manufacturing SRO No. 1347 dated Name and address of manufacturer/ Applicant Brand Name + Dosage Form + Strength Composition  Diary No. Date of R & I & fee  Pharmacological Group	of Contract agreement as required in Contract 15-10-2021 duly signed and stamped are required.  Relizon Pharmaceuticals, plot No. 118, Sundar Industrial Estate, Raiwind Road, Lahore.  RELBROF TABLET 400 mg  Each Film Coated Tablet Contains: Ibuprofen400 mg  Dy. No 12137 dated 06-03-2019; Rs.20,000/- dated 06-03-2019.	
289.	specifications and attested copy Manufacturing SRO No. 1347 dated Name and address of manufacturer/ Applicant Brand Name + Dosage Form + Strength Composition  Diary No. Date of R & I & fee  Pharmacological Group Type of Form	of Contract agreement as required in Contract 15-10-2021 duly signed and stamped are required.  Relizon Pharmaceuticals, plot No. 118, Sundar Industrial Estate, Raiwind Road, Lahore.  RELBROF TABLET 400 mg  Each Film Coated Tablet Contains: Ibuprofen400 mg  Dy. No 12137 dated 06-03-2019; Rs.20,000/- dated 06-03-2019.  NSAID  Form-5	
289.	specifications and attested copy Manufacturing SRO No. 1347 dated Name and address of manufacturer/ Applicant Brand Name + Dosage Form + Strength Composition  Diary No. Date of R & I & fee  Pharmacological Group Type of Form Finished product Specification	of Contract agreement as required in Contract 15-10-2021 duly signed and stamped are required.  Relizon Pharmaceuticals, plot No. 118, Sundar Industrial Estate, Raiwind Road, Lahore.  RELBROF TABLET 400 mg  Each Film Coated Tablet Contains: Ibuprofen400 mg  Dy. No 12137 dated 06-03-2019; Rs.20,000/- dated 06-03-2019.  NSAID  Form-5  USP Specification	
289.	specifications and attested copy Manufacturing SRO No. 1347 dated Name and address of manufacturer/ Applicant Brand Name + Dosage Form + Strength Composition  Diary No. Date of R & I & fee  Pharmacological Group Type of Form Finished product Specification Pack size & Demanded Price	of Contract agreement as required in Contract 15-10-2021 duly signed and stamped are required.  Relizon Pharmaceuticals, plot No. 118, Sundar Industrial Estate, Raiwind Road, Lahore.  RELBROF TABLET 400 mg  Each Film Coated Tablet Contains: Ibuprofen400 mg  Dy. No 12137 dated 06-03-2019; Rs.20,000/- dated 06-03-2019.  NSAID  Form-5	
289.	specifications and attested copy Manufacturing SRO No. 1347 dated Name and address of manufacturer/ Applicant Brand Name + Dosage Form + Strength Composition  Diary No. Date of R & I & fee  Pharmacological Group Type of Form Finished product Specification Pack size & Demanded Price Approval status of product in Reference	of Contract agreement as required in Contract 15-10-2021 duly signed and stamped are required.  Relizon Pharmaceuticals, plot No. 118, Sundar Industrial Estate, Raiwind Road, Lahore.  RELBROF TABLET 400 mg  Each Film Coated Tablet Contains: Ibuprofen400 mg  Dy. No 12137 dated 06-03-2019; Rs.20,000/- dated 06-03-2019.  NSAID  Form-5  USP Specification	
289.	specifications and attested copy Manufacturing SRO No. 1347 dated Name and address of manufacturer/ Applicant Brand Name + Dosage Form + Strength Composition  Diary No. Date of R & I & fee  Pharmacological Group Type of Form Finished product Specification Pack size & Demanded Price Approval status of product in Reference Regulatory Authorities	of Contract agreement as required in Contract 15-10-2021 duly signed and stamped are required.  Relizon Pharmaceuticals, plot No. 118, Sundar Industrial Estate, Raiwind Road, Lahore.  RELBROF TABLET 400 mg  Each Film Coated Tablet Contains: Ibuprofen400 mg  Dy. No 12137 dated 06-03-2019; Rs.20,000/- dated 06-03-2019.  NSAID  Form-5  USP Specification	
289.	specifications and attested copy Manufacturing SRO No. 1347 dated Name and address of manufacturer/ Applicant Brand Name + Dosage Form + Strength Composition  Diary No. Date of R & I & fee  Pharmacological Group Type of Form Finished product Specification Pack size & Demanded Price Approval status of product in Reference Regulatory Authorities Me-too status	of Contract agreement as required in Contract 15-10-2021 duly signed and stamped are required.  Relizon Pharmaceuticals, plot No. 118, Sundar Industrial Estate, Raiwind Road, Lahore.  RELBROF TABLET 400 mg  Each Film Coated Tablet Contains: Ibuprofen	
289.	specifications and attested copy Manufacturing SRO No. 1347 dated Name and address of manufacturer/ Applicant Brand Name + Dosage Form + Strength Composition  Diary No. Date of R & I & fee  Pharmacological Group Type of Form Finished product Specification Pack size & Demanded Price Approval status of product in Reference Regulatory Authorities Me-too status GMP status	of Contract agreement as required in Contract 15-10-2021 duly signed and stamped are required.  Relizon Pharmaceuticals, plot No. 118, Sundar Industrial Estate, Raiwind Road, Lahore.  RELBROF TABLET 400 mg  Each Film Coated Tablet Contains: Ibuprofen	
289.	specifications and attested copy Manufacturing SRO No. 1347 dated Name and address of manufacturer/ Applicant Brand Name + Dosage Form + Strength Composition  Diary No. Date of R & I & fee  Pharmacological Group Type of Form Finished product Specification Pack size & Demanded Price Approval status of product in Reference Regulatory Authorities Me-too status	of Contract agreement as required in Contract 15-10-2021 duly signed and stamped are required.  Relizon Pharmaceuticals, plot No. 118, Sundar Industrial Estate, Raiwind Road, Lahore.  RELBROF TABLET 400 mg  Each Film Coated Tablet Contains: Ibuprofen	
289.	specifications and attested copy Manufacturing SRO No. 1347 dated Name and address of manufacturer/ Applicant Brand Name + Dosage Form + Strength Composition  Diary No. Date of R & I & fee  Pharmacological Group Type of Form Finished product Specification Pack size & Demanded Price Approval status of product in Reference Regulatory Authorities Me-too status GMP status	of Contract agreement as required in Contract 15-10-2021 duly signed and stamped are required.  Relizon Pharmaceuticals, plot No. 118, Sundar Industrial Estate, Raiwind Road, Lahore.  RELBROF TABLET 400 mg  Each Film Coated Tablet Contains: Ibuprofen400 mg  Dy. No 12137 dated 06-03-2019; Rs.20,000/- dated 06-03-2019.  NSAID Form-5 USP Specification 10's,250's As per SRO.  GMP status/report within last 3 years not provided  Deficiency letter was issued to firm and	
289.	specifications and attested copy Manufacturing SRO No. 1347 dated Name and address of manufacturer/ Applicant Brand Name + Dosage Form + Strength Composition  Diary No. Date of R & I & fee  Pharmacological Group Type of Form Finished product Specification Pack size & Demanded Price Approval status of product in Reference Regulatory Authorities Me-too status GMP status	of Contract agreement as required in Contract 15-10-2021 duly signed and stamped are required.  Relizon Pharmaceuticals, plot No. 118, Sundar Industrial Estate, Raiwind Road, Lahore.  RELBROF TABLET 400 mg  Each Film Coated Tablet Contains: Ibuprofen400 mg  Dy. No 12137 dated 06-03-2019; Rs.20,000/- dated 06-03-2019.  NSAID Form-5  USP Specification 10's,250's As per SRO.  GMP status/report within last 3 years not provided  Deficiency letter was issued to firm and asked to provide:	
289.	specifications and attested copy Manufacturing SRO No. 1347 dated Name and address of manufacturer/ Applicant Brand Name + Dosage Form + Strength Composition  Diary No. Date of R & I & fee  Pharmacological Group Type of Form Finished product Specification Pack size & Demanded Price Approval status of product in Reference Regulatory Authorities Me-too status GMP status	of Contract agreement as required in Contract 15-10-2021 duly signed and stamped are required.  Relizon Pharmaceuticals, plot No. 118, Sundar Industrial Estate, Raiwind Road, Lahore.  RELBROF TABLET 400 mg  Each Film Coated Tablet Contains: Ibuprofen	
289.	specifications and attested copy Manufacturing SRO No. 1347 dated Name and address of manufacturer/ Applicant Brand Name + Dosage Form + Strength Composition  Diary No. Date of R & I & fee  Pharmacological Group Type of Form Finished product Specification Pack size & Demanded Price Approval status of product in Reference Regulatory Authorities Me-too status GMP status	of Contract agreement as required in Contract 15-10-2021 duly signed and stamped are required.  Relizon Pharmaceuticals, plot No. 118, Sundar Industrial Estate, Raiwind Road, Lahore.  RELBROF TABLET 400 mg  Each Film Coated Tablet Contains: Ibuprofen	
289.	specifications and attested copy Manufacturing SRO No. 1347 dated Name and address of manufacturer/ Applicant Brand Name + Dosage Form + Strength Composition  Diary No. Date of R & I & fee  Pharmacological Group Type of Form Finished product Specification Pack size & Demanded Price Approval status of product in Reference Regulatory Authorities Me-too status GMP status	of Contract agreement as required in Contract 15-10-2021 duly signed and stamped are required.  Relizon Pharmaceuticals, plot No. 118, Sundar Industrial Estate, Raiwind Road, Lahore.  RELBROF TABLET 400 mg  Each Film Coated Tablet Contains: Ibuprofen	
289.	specifications and attested copy Manufacturing SRO No. 1347 dated Name and address of manufacturer/ Applicant Brand Name + Dosage Form + Strength Composition  Diary No. Date of R & I & fee  Pharmacological Group Type of Form Finished product Specification Pack size & Demanded Price Approval status of product in Reference Regulatory Authorities Me-too status GMP status	of Contract agreement as required in Contract 15-10-2021 duly signed and stamped are required.  Relizon Pharmaceuticals, plot No. 118, Sundar Industrial Estate, Raiwind Road, Lahore.  RELBROF TABLET 400 mg  Each Film Coated Tablet Contains: Ibuprofen	
289.	specifications and attested copy Manufacturing SRO No. 1347 dated Name and address of manufacturer/ Applicant Brand Name + Dosage Form + Strength Composition  Diary No. Date of R & I & fee  Pharmacological Group Type of Form Finished product Specification Pack size & Demanded Price Approval status of product in Reference Regulatory Authorities Me-too status GMP status	of Contract agreement as required in Contract 15-10-2021 duly signed and stamped are required.  Relizon Pharmaceuticals, plot No. 118, Sundar Industrial Estate, Raiwind Road, Lahore.  RELBROF TABLET 400 mg  Each Film Coated Tablet Contains: Ibuprofen	

T.	
	• Firm has mentioned a
	material "tab-coat" in
	their manufacturing
	out line however tab-
	coat is not mentioned
	in master
	formulation.
	Evidence of applied
	product in RRA and
	me too/generic in
	Pakistan as gelatin
	coated tablets or
	revise formulation
	along fee challan.
	• GMP inspection
	report conducted
	within last 3 years is
	not provided.
	Preregistration
	variation fee challan.
Decision: Deferred for following shorted	minos·

**Decision: Deferred for following shortcomings;** 

- 1. Firm has mentioned film coated tablet in some documents as well as gelatin coated tablet which needs clarification.
- 2. Firm has mentioned a material "tab-coat" in their manufacturing out line however tabcoat is not mentioned in master formulation.
- 3. Evidence of applied product in RRA and me too/generic in Pakistan as gelatin coated tablets or revise formulation along fee challan.
- 4. GMP inspection report conducted within last 3 years is not provided.

5. Preregistration variation fee challan.

290.	Name and address of manufacturer/	Relizon Pharmaceuticals, plot No. 118, Sundar Industrial	
	Applicant	Estate, Raiwind Road, Lahore.	
	Brand Name + Dosage Form + Strength	RELBROF TABLET 200 mg	
	Composition	Each Film Coated Tablet Contains:	
		Ibuprofen200 mg	
	Diary No. Date of R & I & fee	Dy. No 12136 dated 06-03-2019; Rs.20,000/- dated 06-03-	
		2019.	
	Pharmacological Group	NSAID	
	Type of Form	Form-5	
	Finished product Specification	USP Specification	
	Pack size & Demanded Price	10's,250's, as per SRO.	
	Approval status of product in Reference	Brufen 200mg film coated tablets (MHRA Approved)	
	Regulatory Authorities		
	Me-too status	Ibumed 200mg tablets, 074799, Medley Pharmaceuticals,	
		41/A Punjab Small Industries Estate Jhang Bahtar Road	
		Wah Cantt., Wah Cantonment, Pakistan	
	GMP status	GMP status/report within last 3 years not provided	
	Remarks of the Evaluator	Deficiency letter was	
		issued to firm and	
		asked to provide:	
		• Composition of	
		coating material	
		"TabCoat" is not	
		provide for film	
		coating.	
		• GMP inspection	
		report conducted	

		within last 3 years is
		not provided.
		Preregistration
		variation fee challan.
	<b>Decision: Deferred for following shortco</b>	omings:
		'TabCoat" is not provide in master formulation for film
	coating.	The second secon
		l within last 3 years is not provided.
	3. Preregistration variation fee chall	
291.	Name and address of manufacturer/	Relizon Pharmaceuticals, plot No. 118, Sundar Industrial
2/1.	Applicant	Estate, Raiwind Road, Lahore.
	Brand Name + Dosage Form + Strength	ZORIC TABLET 40 mg
		Febuxostat40 mg
	Composition	P. N. 12144 1 4 106 02 2010 P. 20 000 / 1 4 106 02
	Diary No. Date of R & I & fee	Dy. No 12144 dated 06-03-2019; Rs.20,000/- dated 06-03-
		2019.
	Pharmacological Group	Xanthine oxidase Inhibitor
	Type of Form	Form-5
	Finished product Specification	Innovator's Specification
	Pack size & Demanded Price	10's,14's, 20's,28's, As per SRO.
	Approval status of product in Reference	Uloric 40mg Tablet of (USFDA approved)
	Regulatory Authorities	
	Me-too status	Febuxin 40mg Tablet of M/s AGP
	GMP status	GMP status/report within last 3 years not provided
	Remarks of the Evaluator	Sill states, report wrant rast b years not provided
		will be issued after submission of GMP audit report from
	QA< Division, valid within last three years.	
292.	Name and address of manufacturer/	Relizon Pharmaceuticals, plot No. 118, Sundar Industrial
292.	Applicant Applicant	Estate, Raiwind Road, Lahore.
	**	
	Brand Name + Dosage Form + Strength Composition	ZORIC TABLET 80 mg
		Febuxostat80 mg
	Diary No. Date of R & I & fee	Dy. No 12145 dated 06-03-2019; Rs.20,000/- dated 06-03-
	Di la la C	2019.
	Pharmacological Group	Xanthine oxidase Inhibitor
	Type of Form	Form-5
	Finished product Specification	Innovator's Specification
	Pack size & Demanded Price	10's,14's, 20's,28's, As per SRO.
	Approval status of product in Reference	Uloric 40mg Tablet of (USFDA approved)
	Regulatory Authorities	
	Me-too status	Febuxin 80mg Tablet of M/s AGP
	GMP status	GMP status/report within last 3 years not provided
	Remarks of the Evaluator	•
	Decision: Approved, Registration letter v	will be issued after submission of GMP audit report from
	QA< Division, valid within last three	
293.	Name and address of manufacturer/	Relizon Pharmaceuticals, plot No. 118, Sundar Industrial
	Applicant Applicant	Estate, Raiwind Road, Lahore.
	Brand Name + Dosage Form + Strength	OMENATE Capsule 40/1100 mg
	Composition	Each Capsule Contains:
	Composition	*
		Omeprazole
	Diam No Data of D 0 1 0 for	Sodium Bicarbonate
	Diary No. Date of R & I & fee	Dy. No 12149 dated 06-03-2019; Rs.20,000/- dated 06-03-2019.
	Dharmagalagical Crown	
	Pharmacological Group	Proton Pump Inhibitor/ Antacid
	Type of Form	Form-5
	Finished product Specification	Innovator's Specification
	Pack size & Demanded Price	10's,14's, 20's,28's, As per SRO.

	Approval status of product in Reference Regulatory Authorities	Capsule ZAGRID, USFDA approved.		
	Me-too status	INSTACID 40/1100mg Capsule, 084803, Genetics		
	GMP status	Pharmaceuticals (Pvt) Ltd,Lahore.  GMP status/report within last 3 years not provided.		
	Remarks of the Evaluator	Givir status/report within last 3 years not provided.		
		will be issued after submission of CMP audit report from		
Decision: Approved. Registration letter will be issued after submission of GMP QA< Division, valid within last three years.		<u>-</u>		
294.	Name and address of manufacturer/	Relizon Pharmaceuticals, plot No. 118, Sundar Industrial		
	Applicant	Estate, Raiwind Road, Lahore.		
	Brand Name + Dosage Form + Strength	OMENATE Capsule 20/1100 mg		
	Composition	Each Capsule Contains:		
		Omeprazole20 mg		
		Sodium Bicarbonate1100 mg		
	Diary No. Date of R & I & fee	Dy. No 12148 dated 06-03-2019; Rs.20,000/- dated 06-03-2019.		
	Pharmacological Group	Proton Pump Inhibitor/ Antacid		
	Type of Form	Form-5		
	Finished product Specification	Innovator's Specification		
	Pack size & Demanded Price	10's,14's, 20's,28's, As per SRO.		
	Approval status of product in Reference	Capsule ZAGRID, USFDA approved.		
	Regulatory Authorities			
	Me-too status	INSTACID 20/1100mg Capsule, 084804, Genetics		
		Pharmaceuticals (Pvt) Ltd, Lahore.		
	GMP status	GMP status/report within last 3 years not provided.		
	Remarks of the Evaluator			
	Decision: Approved. Registration letter will be issued after submission of GMP audit report from QA< Division, valid within last three years.			
295.	Name and address of manufacturer/	Relizon Pharmaceuticals, plot No. 118, Sundar Industrial		
	Applicant	Estate, Raiwind Road, Lahore.		
	Brand Name + Dosage Form + Strength	RELMOL Tablet 500 mg		
	Composition	Each Film Coated Tablet Contains:		
		Paracetamol500 mg		
	Diary No. Date of R & I & fee	Dy. No 12147 dated 06-03-2019; Rs.20,000/- dated 06-03-		
		2019.		
	Pharmacological Group	NSAID		
	Type of Form	Form-5		
	Finished product Specification	USP specifications		
	Pack size & Demanded Price	100's,200's,1000's, As per SRO.		
	Approval status of product in Reference	TGA approved		
	Regulatory Authorities			
		Donadal tableta of M/a CCV		
	Me-too status	Panadol tablets of M/s GSK		
	GMP status	GMP status/report within last 3 years not provided.		
		GMP status/report within last 3 years not provided.  Deficiency letter was		
	GMP status	GMP status/report within last 3 years not provided.  Deficiency letter was issued to firm and		
	GMP status	GMP status/report within last 3 years not provided.  Deficiency letter was issued to firm and asked to provide:		
	GMP status	GMP status/report within last 3 years not provided.  Deficiency letter was issued to firm and asked to provide:  • Reference product is		
	GMP status	GMP status/report within last 3 years not provided.  Deficiency letter was issued to firm and asked to provide:  • Reference product is uncoated tablet,		
	GMP status	GMP status/report within last 3 years not provided.  Deficiency letter was issued to firm and asked to provide:  • Reference product is uncoated tablet, whereas u have		
	GMP status	GMP status/report within last 3 years not provided.  Deficiency letter was issued to firm and asked to provide:  • Reference product is uncoated tablet, whereas u have mentioned "Film		
	GMP status	GMP status/report within last 3 years not provided.  Deficiency letter was issued to firm and asked to provide:  • Reference product is uncoated tablet, whereas u have mentioned "Film Coated tablet. Please		
	GMP status	GMP status/report within last 3 years not provided.  Deficiency letter was issued to firm and asked to provide:  • Reference product is uncoated tablet, whereas u have mentioned "Film Coated tablet. Please clarify or submit		
	GMP status	GMP status/report within last 3 years not provided.  Deficiency letter was issued to firm and asked to provide:  • Reference product is uncoated tablet, whereas u have mentioned "Film Coated tablet. Please clarify or submit revised dosage form		
	GMP status	GMP status/report within last 3 years not provided.  Deficiency letter was issued to firm and asked to provide:  • Reference product is uncoated tablet, whereas u have mentioned "Film Coated tablet. Please clarify or submit		

		• GMP inspection	
		report conducted	
		within last 3 years is	
		not provided.	
	Decision: Approved as "Each Uncoated Tablet Contains;		
	Paracetamol	e	
	9	ed after submission GMP audit report from QA & LT	
	Division.		
		7,500 for correction/pre-approval change/ in product	
296.		No.F.7-11/2021-B&A/DRAP dated 13-07-2021.	
290.	Name and address of manufacturer/	· *	
	Applicant Brand Name + Dosage Form + Strength	Estate, Raiwind Road, Lahore.  CIPROREL Tablet 750 mg	
	Composition	Each Film Coated Tablet Contains:	
	Composition	Ciprofloxacin as HCl750 mg	
	Diary No. Date of R & I & fee	Dy. No 12142 dated 06-03-2019; Rs.20,000/- dated 06-03-	
	Diary No. Date of K & I & fee	2019.	
	Pharmacological Group	Fluoroquinolones	
	Type of Form	Form-5	
	- V 1	USP specifications	
	Finished product Specification Pack size & Demanded Price		
		10's,100's, As per SRO.	
	Approval status of product in Reference	Ciprofloxacin 750 mg film coated tablets. MHRA	
	Regulatory Authorities  Me-too status	approved	
		CIP Tablets 750 mg. Reg. No. 79347	
	GMP status	GMP status/report within last 3 years not provided.	
	Remarks of the Evaluator		
	Decision: Approved.Registration letter will be issued after submission of GMP audit report from QA< Division, valid within last three years.		
297.	Name and address of manufacturer/	Relizon Pharmaceuticals, plot No. 118, Sundar Industrial	
291.	Applicant Applicant	Estate, Raiwind Road, Lahore.	
	Brand Name + Dosage Form + Strength	RELVO Tablet 750 mg	
	Composition	Each Film Coated Tablet Contains:	
	Composition	Levofloxacin as Hemihydrate750 mg	
	Diary No. Date of R & I & fee	Dy. No 12139 dated 06-03-2019; Rs.20,000/- dated 06-03-	
	Blary 10. Bute of R & I & Iee	2019.	
	Pharmacological Group	Fluoroquinolones	
	Type of Form	Form-5	
	Finished product Specification	USP specifications	
	Pack size & Demanded Price	10's, As per SRO.	
	Approval status of product in Reference	LEVAQUIN® (levofloxacin) tablets (250mg, 500mg,	
	Regulatory Authorities	750mg) film-coated, for oral use. USFDA approved	
	Me-too status	Warior 750mg tablet film-coated. Reg. No. 84744	
	GMP status	GMP status/report within last 3 years not provided.	
	Remarks of the Evaluator	Status/report within last 5 years not provided.	
		will be issued after submission of GMP audit report from	
	QA< Division, valid within last three		
298.	Name and address of manufacturer/	Relizon Pharmaceuticals, plot No. 118, Sundar Industrial	
2>0.	Applicant Applicant	Estate, Raiwind Road, Lahore.	
	Brand Name + Dosage Form + Strength	RELFEN Tablet 500 mg	
	Composition	Each Film Coated Tablet Contains:	
	Composition	Mefenamic Acid500 mg	
	Diary No. Date of R & I & fee	Dy. No 12138 dated 06-03-2019; Rs.20,000/- dated 06-03-	
	Diary 110. Date of R & I & ICC	2019.	
	Pharmacological Group	Anti-inflammatory, Analgesic	
Ī			
	Type of Form	Form-5	

	Finished product Specification	B.P specifications
	Pack size & Demanded Price	100's,200's, As per SRO.
	Approval status of product in Reference	Ponston SF 500 by chemidex (MHRA)
	Regulatory Authorities	,
	Me-too status	Amic by Libra
	GMP status	GMP status/report within last 3 years not provided.
	Remarks of the Evaluator	Deficiency letter was
		issued to firm and
		asked to provide:
		• Firm has mentioned
		as Film coted tablet
		however master
		formulation and
		manufacturing
		method does not
		depict film coating,
		submit revised
		master formulation
		and manufacturing
		method with
		preregistration
		variation fee.
		GMP inspection report conducted
		within last 3 years is
		not provided.
		not provided.
	Decision: Deferred for following following	nge•
	Decision: Deferred for following followings;  • Firm has mentioned as Film coted tablet however master formulation and manufacturing	
		coating, submit revised master formulation and
	manufacturing method with pre	
	_	ed within last 3 years is not provided.
299.	Name and address of manufacturer/	
299.	Applicant address of manufacturer/	Estate, Raiwind Road, Lahore.
	Brand Name + Dosage Form + Strength	LEZIR Tablet 10 mg
	Composition	Each Film Coated Tablet Contains:
	Composition	Cetirizine Hydrochloride
	Diary No. Date of R & I & fee	Dy. No 12141 dated 06-03-2019; Rs.20,000/- dated 06-03-
	Diary No. Date of K & I & fee	2019.
	Pharmacalogical Group	Histamine H1 receptor antagonist
	Pharmacological Group Type of Form	Form-5
	Finished product Specification	B.P specifications
	Pack size & Demanded Price	•
	Pack size & Demanded Price	10's, As per SRO.
	A	MIID 4 77 4 1- 10 61 1 - 1 - 1 - 1
	Approval status of product in Reference	MHRA. Zirtek 10mg film coated tablet
	Regulatory Authorities	Č
	Regulatory Authorities Me-too status	Serzine 10mg Tablets, Qintar Pharma, Reg. No. 030644.
	Regulatory Authorities Me-too status GMP status	Serzine 10mg Tablets, Qintar Pharma, Reg. No. 030644.  GMP status/report within last 3 years not provided.
	Regulatory Authorities Me-too status	Serzine 10mg Tablets, Qintar Pharma, Reg. No. 030644.  GMP status/report within last 3 years not provided.  Deficiency letter was
	Regulatory Authorities Me-too status GMP status	Serzine 10mg Tablets, Qintar Pharma, Reg. No. 030644.  GMP status/report within last 3 years not provided.  Deficiency letter was issued to firm and
	Regulatory Authorities Me-too status GMP status	Serzine 10mg Tablets, Qintar Pharma, Reg. No. 030644.  GMP status/report within last 3 years not provided.  Deficiency letter was issued to firm and asked to provide:
	Regulatory Authorities Me-too status GMP status	Serzine 10mg Tablets, Qintar Pharma, Reg. No. 030644.  GMP status/report within last 3 years not provided.  Deficiency letter was issued to firm and asked to provide:  • Firm-5 Cover letter is
	Regulatory Authorities Me-too status GMP status	Serzine 10mg Tablets, Qintar Pharma, Reg. No. 030644.  GMP status/report within last 3 years not provided.  Deficiency letter was issued to firm and asked to provide:  • Firm-5 Cover letter is not signed. Submit
	Regulatory Authorities Me-too status GMP status	Serzine 10mg Tablets, Qintar Pharma, Reg. No. 030644.  GMP status/report within last 3 years not provided.  Deficiency letter was issued to firm and asked to provide:  • Firm-5 Cover letter is not signed. Submit revised signed Form-
	Regulatory Authorities Me-too status GMP status	Serzine 10mg Tablets, Qintar Pharma, Reg. No. 030644.  GMP status/report within last 3 years not provided.  Deficiency letter was issued to firm and asked to provide:  • Firm-5 Cover letter is not signed. Submit revised signed Form-5 cover letter with
	Regulatory Authorities Me-too status GMP status	Serzine 10mg Tablets, Qintar Pharma, Reg. No. 030644.  GMP status/report within last 3 years not provided.  Deficiency letter was issued to firm and asked to provide:  • Firm-5 Cover letter is not signed. Submit revised signed Form-

		• GMP inspection	
		• GMP inspection report conducted	
		within last 3 years is	
		not provided.	
	<b>Decision: Deferred for following followi</b>		
	• Firm-5 Cover letter is not signed. Submit revised signed Form-5 cover letter with pre-		
	registration variation fee.	r	
		ed within last 3 years is not provided.	
300.	Name and address of manufacturer/	Relizon Pharmaceuticals, plot No. 118, Sundar Industrial	
	Applicant	Estate, Raiwind Road, Lahore.	
	Brand Name + Dosage Form + Strength	TRAMCET Tablet 325/37.5 mg	
	Composition	Each Film Coated Tablet Contains:	
		Paracetamol325 mg	
		Tramadol Hydrochloride37.5 mg	
	Diary No. Date of R & I & fee	Dy. No 12140 dated 06-03-2019; Rs.20,000/- dated 06-03-	
		2019.	
	Pharmacological Group	Opioid Analgesic/Antipyretic	
	Type of Form	Form-5	
	Finished product Specification	USP specifications	
	Pack size & Demanded Price	10's, As per SRO.	
	Approval status of product in Reference	Ultracet Tablet by M/s Janssen Ortho, (USFDA	
	Regulatory Authorities	approved)	
	Me-too status	Forgesil Tablet by M/s Genome Pharmaceutical	
	CMP	(Reg No:080874	
	GMP status	GMP status/report within last 3 years not provided.	
	Remarks of the Evaluator	Deficiency letter was issued to firm and	
		asked to firm and asked to provide:	
		Firm has mentioned	
		as Film coted tablet	
		however master	
		formulation and	
		manufacturing	
		method does not	
		depict film coating,	
		submit revised	
		master formulation	
		and manufacturing	
		method with	
		preregistration	
		variation fee.	
		• GMP inspection	
		report conducted	
		within last 3 years is	
		not provided.	
	Davidson Def. 16 6 P. 1		
	Decision: Deferred for following shortcomings;		
		d tablet however master formulation and manufacturing	
	<del>_</del>	coating, submit revised master formulation and	
	manufacturing method with prer	_	
301.	Name and address of manufacturer/	d within last 3 years is not provided.  Polizon Pharmacouticals, plot No. 118, Sundar Industrial	
301.		7 <b>L</b>	
	Applicant Brand Name + Dosage Form + Strength	Estate, Raiwind Road, Lahore.	
	Composition Composition	ITRAZON Capsule 100 mg	
	Composition	Each Capsule Contains:  Itraconazole100 mg	
		in aconazore100 mg	

	Diary No. Date of R & I & fee	Dy. No 12146 dated 06-03-2019; Rs.20,000/- dated 06-03-		
	Di 1 : 1 C	2019.		
	Pharmacological Group	Triazole Antifungal		
	Type of Form	Form-5		
	Finished product Specification	Innovator's specifications		
	Pack size & Demanded Price	4's,14's, as per SRO.		
	Approval status of product in Reference Regulatory Authorities	Itraconazole 100 mg capsules (MHRA approved)		
	Me-too status	Icon 100 mg Capsule by Ferozsons Laboratories Ltd		
	GMP status	GMP status/report within last 3 years not provided.		
	Remarks of the Evaluator			
	COA and stability study data of 150000/=)	omings; along with GMP of source with requisite documents, i-e three batches. (in case of foreign source, Fee challan of of pellets with applicable full fee challan of 30000/=		
302.	Name and address of manufacturer/	Relizon Pharmaceuticals, plot No. 118, Sundar Industrial		
302.	Applicant	Estate, Raiwind Road, Lahore.		
	Brand Name + Dosage Form + Strength	THALREL Capsule 100 mg		
	Composition			
	Composition	Each Capsule Contains:		
	Diary No. Date of R & I & fee	Thalidomide		
		2019.		
	Pharmacological Group	Other Immunosuppressants		
	Type of Form	Form-5		
	Finished product Specification	USP specifications		
	Pack size & Demanded Price	10's, as per SRO.		
	Approval status of product in Reference Regulatory Authorities	Approved by USFDA		
	Me-too status	Thalido-100 Capsules by M/s Atco Labs, Karachi (Reg#047188)		
	GMP status	GMP status/report within last 3 years not provided.		
	Remarks of the Evaluator			
	Decision: Deferred for further deliberation regarding clinical indications, safety and efficacy			
	profile of applied drug product along with availability status in reference regulatory authorities.			
303.	Name and address of manufacturer/ Applicant	Quaper Pvt.Ltd.,26-A small Industrial Estate, Lahore road, Sargodha.		
	Brand Name + Dosage Form + Strength	XANTEQ Tablet 150 mg		
	Composition	Each Film Coated Tablet Contains:		
	Composition	Ranitidine as Hcl		
	Diary No. Date of R & I & fee	Dy. No 11784 dated 06-03-2019; Rs.20,000/- dated 06-03-		
	Pharmacological Group	2019. H2 Receptor Antagonist		
	Type of Form	Form-5		
	Finished product Specification	USP specifications		
	Pack size & Demanded Price	10's, As per SRO		
	Approval status of product in Reference Regulatory Authorities	suspended		
	Me-too status	Ranitide 150 mg Tab of M/s Siza (Reg. # 011747)		
	GMP status	Firm was granted GMP certificate dated 19-06-2019 on the basis of GMP inspection conducted on 28-01-2019 for Tablet (General).		
		Panel inspection of firm for grant of additional sections was also conducted on 16-06-2020 & 18-06-2020 and firm was recommended for grant of following additional sections as per approved layout plan:		

	T	T	1	
		1. Tablet (Gene	·	
			neral) section	
		3. R&D laboratory		
		4. Sachet (general)		
	Remarks of the Evaluator			
	Decision: Deferred as the Registration Board in its 294 <sup>th</sup> meeting has decided to suspend registration of all ranitidine containing medicinal products, based upon the FDA decision.			
304.	Name and address of manufacturer/		A small Industrial Estate, Lahore road,	
304.	Applicant Applicant	Sargodha.	t sman moustrar Estate, Eanore road,	
	Brand Name + Dosage Form + Strength	Q-DOL FORTE Tab	1 <sub>ot</sub>	
	Composition	Each Tablet Contain		
	Composition			
		Paracetamol		
	Diamy No. Data of D. & J. & foo	Dy. No 11783 dated 06-03-2019; Rs.20,000/- dated 06-03-		
	Diary No. Date of R & I & fee	_	00-03-2019; RS.20,000/- dated 00-03-	
	DI 1 : 1 C		2019.	
	Pharmacological Group	Analgesic, Muscle re	elaxant.	
	Type of Form	Form-5		
	Finished product Specification	USP specifications		
	Pack size & Demanded Price	15's, As per SRO		
	Approval status of product in Reference	Not Available.		
	Regulatory Authorities			
	Me-too status	Nuberol Forte tablet		
	GMP status		MP certificate dated 19-06-2019 on	
		the basis of GMP ins	spection conducted on 28-01-2019	
		for Tablet (General).		
		Panel inspection of firm for grant of additional sections		
		was also conducted on 16-06-2020 & 18-06-2020 and		
		firm was recommended for grant of following additional		
		sections as per approved layout plan:		
		<ol> <li>Tablet (General) section</li> <li>Capsule (general) section</li> <li>R&amp;D laboratory</li> </ol>		
		4. Sachet (general)		
	Remarks of the Evaluator	Deficiency letter was issued to firm for submission of		
		evidence of approval of applied formulation in reference		
		regulatory authorities adopted by registration board. Firm		
		has submitted reply vide dairy No. 1018 (PEC DRAI		
			ong with preregistration fee of 30000	
			341513265 dated 13-05-2022 and	
		submitted revised for	rm -5 mentioning revised label claim	
			r standardization of formulation as	
		under:		
		Composition	Each Tablet Contains:	
		Composition	Paracetamol450 mg	
			Orphenadrine citrate35 mg	
		Pharmacological	Anti-Pyretic/Analgesic	
		Group	Tangaratana angaifi artis a	
		Finished Product specification	Innovators specification	
		Pack size & Demanded Price	10's, As per SRO	
		Approval status of	Norgesic tablet (uncoated)	
		product in	35mg/450mg, TGA Approved	
		Reference		
		Regulatory		
		Authorities		
	1	, , , , , , , , , , , , , , , , , , , ,		

		Me-too status	Nuberol 35/450mg Tablet, Searle Pakistan, Reg. No. 020373.		
	Decision: Approved with Innovators specification with following revised label claim; "Each Tablet Contains: Paracetamol				
305.	Name and address of manufacturer/ Applicant	Quaper Pvt.Ltd.,26-A small Industrial Estate, Lahore road, Sargodha.			
	Brand Name + Dosage Form + Strength		Q-DOL EXTRA Tablet		
	Composition	Each Tablet Conta			
		Paracetamol			
	Diary No. Date of R & I & fee	Dy. No 11782 dated 06-03-2019; Rs.20,000/- dated 06-03-2019.			
	Pharmacological Group	Analgesic, antipyr	Analgesic, antipyretic		
	Type of Form	Form-5			
	Finished product Specification	B.P specifications			
	Pack size & Demanded Price	10's, As per SRO			
	Approval status of product in Reference		vance 500 mg/65 mg Film Coated		
	Regulatory Authorities		č č		
	Tregulatory readmentages	Tablets by M/s GSK, MHRA Approved. Uncoated tablet also approved in MHRA			
	Me-too status	* * *	Paratol Extra tablet by M/s Highnoon (Reg.# 13346)		
	GMP status		GMP certificate dated 19-06-2019 on		
	OM Status	•	inspection conducted on 28-01-2019		
		for Tablet (Genera			
		Panel inspection of firm for grant of additional sections			
		was also conducted on 16-06-2020 & 18-06-2020 and			
		firm was recommended for grant of following additional			
		sections as per approved layout plan:			
		1. Tablet (General) section			
		2. Capsule (general) section			
		1 &			
		3. R&D laboratory			
		4. Sachet (general)			
	Remarks of the Evaluator				
	Decision: Approved.	T			
306.	Name and address of manufacturer/	Quaper Pvt.Ltd.,26-A small Industrial Estate, Lahore road,			
	Applicant	Sargodha.			
	Brand Name + Dosage Form + Strength	CLARISIL Tablet 250 mg			
	Composition	Each film Coated Tablet Contains:			
		Clarithromycin250 mg			
	Diary No. Date of R & I & fee	•	ed 06-03-2019; Rs.20,000/- dated 06-03-		
		2019.			
	Pharmacological Group	Polyene Macrolide /Antibiotic			
	Type of Form	Form-5			
	Finished product Specification	U.S.P specifications			
	Pack size & Demanded Price	10's, As per SRO			
	Approval status of product in Reference Regulatory Authorities	BIAXIN by Abbvie (USFDA Approved)			
	Me-too status	Claritals by Cata			
	GMP status	Claritek by Getz	CMD contificate dated 10.06.2010 an		
	GMP status	the basis of GMP i	GMP certificate dated 19-06-2019 on inspection conducted on 28-01-2019		
		for Tablet (Genera			
			f firm for grant of additional sections		
			d on 16-06-2020 & 18-06-2020 and ended for grant of following additional		
		LITTH WAS TACOMMA	STURE LOT OTATILAT TALIAWING ADDITIONAL		

	1	1 T-1-1-4 (C1)4'	
		1. Tablet (General) section	
		2. Capsule (general) section	
		3. R&D laboratory	
		4. Sachet (general)	
	Remarks of the Evaluator	Firm has submitted preregistration variation fee of 7500 vide fee challan No.928806732994 dated 13-05-2022 for	
		label as 'Film coated Tablet".	
	Decision: Approved.		
307.	Name and address of manufacturer/	Quaper Pvt.Ltd.,26-A small Industrial Estate, Lahore road,	
	Applicant	Sargodha.	
	Brand Name + Dosage Form + Strength	CLARISIL Tablet 500 mg	
	Composition	Each film Coated Tablet Contains:	
		Clarithromycin500 mg	
	Diary No. Date of R & I & fee	Dy. No 11777 dated 06-03-2019; Rs.20,000/- dated 06-03-2019.	
	Pharmacological Group	Polyene Macrolide /Antibiotic	
	Type of Form	Form-5	
	Finished product Specification	U.S.P specifications	
	Pack size & Demanded Price	10's, As per SRO	
	Approval status of product in Reference	Clarithromycin 500mg Film-coated Tablets by M/s	
	Regulatory Authorities	Ranbaxy (UK) Limited, (MHRA approved)	
	Me-too status	CLARION 500MG TABLET by M/s. 'Ferozsons Labs	
		(Reg#0002873)	
	GMP status	Firm was granted GMP certificate dated 19-06-2019 on the basis of GMP inspection conducted on 28-01-2019	
		for Tablet (General).	
		Panel inspection of firm for grant of additional sections	
		was also conducted on 16-06-2020 & 18-06-2020 and	
		firm was recommended for grant of following additional	
		sections as per approved layout plan:	
		1. Tablet (General) section	
		2. Capsule (general) section	
		3. R&D laboratory	
		4. Sachet (general)	
	Remarks of the Evaluator	Firm has submitted preregistration variation fee of 7500	
	Terraine of the Evaration	vide fee challan No.693583651846 dated 13-05-2022 for	
		label as 'Film coated Tablet'.	
	Decision: Approved.	nucer us 1 mm course 1 ucres 1	
308.	Name and address of manufacturer/	Quaper Pvt.Ltd.,26-A small Industrial Estate, Lahore road,	
	Applicant	Sargodha.	
	Brand Name + Dosage Form + Strength	ABESTATIN Tablet 40 mg	
	Composition	Each film Coated Tablet Contains:	
		Atorvastatin calcium Eq to Atorvastatin	
	Diary No. Date of R & I & fee	Dy. No 11800 dated 06-03-2019; Rs.20,000/- dated 06-03-	
		2019.	
	Pharmacological Group	Antilipidemic	
	Type of Form	Form-5	
	Finished product Specification	U.S.P specifications	
	Pack size & Demanded Price	10's, As per SRO	
	Approval status of product in Reference Regulatory Authorities	Lipitor tablets ( USFDA approved).	
	Me-too status	Lipitor of M/s parke-davis	
	GMP status	Firm was granted GMP certificate dated 19-06-2019 on	
		the basis of GMP inspection conducted on 28-01-2019	
		the busis of Givil hispection conducted on 20 of 2019	

		Panel inspection of firm for grant of additional sections was also conducted on 16-06-2020 & 18-06-2020 and firm was recommended for grant of following additional sections as per approved layout plan:  1. Tablet (General) section 2. Capsule (general) section 3. R&D laboratory 4. Sachet (general)	
	Remarks of the Evaluator  Decision: Approved.		
309.	Name and address of manufacturer/	Quaper Pvt.Ltd.,26-A small Industrial Estate, Lahore road,	
	Applicant	Sargodha.	
	Brand Name + Dosage Form + Strength	NYMZE Tablet 100 mg	
	Composition	Each Film Coated Tablet Contains:	
		Nimesulide	
	Diary No. Date of R & I & fee	Dy. No 11781 dated 06-03-2019; Rs.20,000/- dated 06-03-2019.	
	Pharmacological Group	Selective COX-2 Inhibitor	
	Type of Form	Form-5	
	Finished product Specification	Innovator's specifications	
	Pack size & Demanded Price	2*10's, As per SRO	
	Approval status of product in Reference	EMA Approved.	
	Regulatory Authorities Me-too status	Numeral Tablet 100mg, Cibay (Dut) Ltd. Dog. No. 094759	
	GMP status	Nymsel Tablet 100mg, Cibex (Pvt) Ltd., Reg. No. 084758.  Firm was granted GMP certificate dated 19-06-2019 on	
		the basis of GMP inspection conducted on 28-01-2019 for Tablet (General).  Panel inspection of firm for grant of additional sections was also conducted on 16-06-2020 & 18-06-2020 and	
		firm was recommended for grant of following additional sections as per approved layout plan:  1. Tablet (General) section  2. Capsule (general) section  3. R&D laboratory	
		4. Sachet (general)	
	Remarks of the Evaluator	Firm has submitted preregistration variation fee of 7500 vide fee challan No.878531125 dated 13-05-2022 for label as 'Film coated Tablet'.	
	Decision: Approved. Keeping in view the approval status of Nimesulide 100mg tablet in EMA, Registration Board approved the applied formulation of Nimesulide Tablets 100mg with a pack size of 15 tablets as per recommendations of EMA only for the following clinical indications as a second line choice.  • Treatment of acute pain		
	Primary dysmenorrhea		
310.	Name and address of manufacturer/	Quaper Pvt.Ltd.,26-A small Industrial Estate, Lahore road,	
	Applicant	Sargodha.	
	Brand Name + Dosage Form + Strength	ACTIDOL CF Tablet	
	Composition	Each Tablet Contains:	
		Paracetamol500 mg	
		Caffeine30 mg	
	Di V D C C C C C C	Chlorpheniramine Maleate2 mg	
	Diary No. Date of R & I & fee	Dy. No 11793 dated 06-03-2019; Rs.20,000/- dated 06-03-	
	Dhammaalasiss! Crows	2019.	
	Pharmacological Group	Analgesic/Antipyretic	
	Type of Form  Einished product Specification	Form-5	
<u></u>	Finished product Specification	Innovator's specifications	

	Pack size & Demanded Price	10's, As per SRO	
	Approval status of product in Reference	Not found	
	Regulatory Authorities		
	Me-too status		
	GMP status	_	MP certificate dated 19-06-2019 on
			spection conducted on 28-01-2019
		for Tablet (General).	irm for grant of additional sections
			on 16-06-2020 & 18-06-2020 and
			led for grant of following additional
		sections as per appro	
		1. Tablet (Gene	
		2. Capsule (ger	neral) section
		3. R&D laborat	•
		4. Sachet (gene	
	Remarks of the Evaluator		as issued to firm for submission of
			l of applied formulation in reference
			s adopted by registration board. Firm vide dairy No. 1018 (PEC DRAP)
			ong with preregistration fee of 30000
			017563568 dated 13-05-2022 and
			rm -5 mentioning revised label claim
			r standardization of formulation as
		under:	
		Composition	Each Film Coated Tablet
			Contains:
			Paracetamol325 mg
		Dharmaaalaaiaal	Tramadol Hcl37.5mg
		Pharmacological Group	Anti-Pyretic/Analgesic
		Finished Product	Innovators specification
		specification	innovators specification
		Pack size &	10's, As per SRO
		Demanded Price	
		Approval status of	Ultracet Tablet by M/s Janssen
		product in	Ortho, (USFDA approved)
		Reference	
		Regulatory	
		Authorities Me-too status	Forgesil Tablet by M/s Genome
		IVIE-100 status	Pharmaceutical
			(Reg No:080874
	Decision: Deferred for review as firm ha	s changes the ingrdie	
311.	Name and address of manufacturer/	Pulse Pharmaceutica	ls (Pvt) Ltd, Mozay Baddoki Raiwind
	Applicant	Road (Sua Aasil Roa	
	Brand Name + Dosage Form + Strength	PHLORSPAM Table	
	Composition	Each sugar-coated ta	
		Phloroglucinol	Dihydrate eq. to
		•	
	Diary No. Date of R & I & fee		cinol
	Diary 110. Date of K & I & ICC	2019.	50-05-2017, IS.20,000/- uaicu 00-03-
	Pharmacological Group	Antispasmodic	
	Type of Form	Form-5	
	Finished product Specification	Innovator's specifica	tions
	Pack size & Demanded Price	3*10's, As per SRO	
		· · · · · · · · · · · · · · · · · · ·	

Regulatory Authorities	Regulatory Authorities		Approval status of product in Reference	Spasfon, coated tablet by M/s Teva Sante, ANSM France
Me-too status	Me-too status			*
GMP status  Firm was granted GMP certificate dated 14-12-2021 on the basis of GMP inspection conducted on 11-06-2021 for Tablet (General) & (Psychotropic), Capsule (General) & (Cephalosporin), Oral Dry Powder Suspension (Ceph), Dry Powder Suspension (Ceph), Dry Powder Suspension (Ceph), Dry Powder Suspension (Ceph), Dry Powder Suspension (Ceph), Dry Powder Suspension (Ceph), Dry Powder Suspension (Ceph), Dry Powder Suspension (Ceph), Dry Powder Suspension (Ceph), Dry Powder Suspension (Ceph), Dry Powder Suspension (Ceph), San Parmacological Group  Parmacological Group  Parmacological Group  Pack size & Demanded Price  Approval status of product in Reference Regulatory Authorities  GMP status  Firm was granted GMP certificate dated 14-12-2021 on the basis of GMP status  Firm shape and Amer + Dosage Form + Strength  Composition  So's, As per SRO  Approved.  REmarks of the Evaluator  Decision: Approved.  So's, As per SRO  Approved.  Remarks of the Evaluator  Decision: Approved.  Brand Name + Dosage Form + Strength  Composition  Diary No. Date of R & 1 & fee  Dy. No 12517 dated 06-03-2019; Rs. 20,000/- dated 06-03-2019.  Remarks of the Evaluator  Decision: Approved.  So's, As per SRO  ALIONOPIN TABLETS (clonazepam) of Roche Pharma & GMP inspection conducted on 11-06-2021 for Tablet (General) & (Psychotropic), Capsule (General) & (Cephalosporin), Oral Dry Powder Suspension (Ceph), Dry Powder Injection (Ceph), Liquid Injection Ampoule (General) & Liquid Ampoule (General)  Diary No. Date of R & 1 & fee  Prill Tablet 2 mg  Each tablet contains:  Clonazepam.  Diary No. Date of R & 1 & fee  Dy. No 12517 dated 06-03-2019; Rs. 20,000/- dated 06-03-2019; Rs. 20,000/- dated 06-03-2019; Rs. 20,000/- dated 06-03-2019; Rs. 20,000/- dated 06-03-2019; Rs. 20,000/- dated 06-03-2019; Rs. 20,000/- dated 06-03-2019; Rs. 20,000/- dated 06-03-2019; Rs. 20,000/- dated 06-03-2019; Rs. 20,000/- dated 06-03-2019; Rs. 20,000/- dated 06-03-2019; Rs. 20,000/- dated 06-03-2019; Rs. 20,000/- dated 06-03-2019; Rs. 20,000/- dated 06-03-2019; Rs.	GMP status    Firm was granted GMP certificate dated 14-12-2021 not basis of GMP inspection conducted on 11-06-2021 for Tablet (General) & (Psychotropic), Capsule (General) & (Cephalosporin), Oral Dry Powder Suspension (Ceph), Dry Powder Suspensi			Gluwix Tablet 80/80mg by M/s Wnsfield, Reg. No.
Decision: Approved.	Decision: Approved.		GMP status	Firm was granted GMP certificate dated 14-12-2021on the basis of GMP inspection conducted on 11-06-2021 for Tablet (General) & (Psychotropic), Capsule (General) & (Cephalosporin), Oral Dry Powder Suspension (Ceph), Dry Powder Injection (Ceph), Liquid Injection Ampoule
Name and address of manufacturer/ Applicant   Pulse Pharmaceuticals (Pvt) Ltd, Mozay Baddoki Raiwind Road (Sua Aasil Road) Lahore.   PTRIL Tablet 0.5 mg	Name and address of manufacturer/ Applicant   Brand Name + Dosage Form + Strength   Composition   Each tablet contains: Clonazepam		Remarks of the Evaluator	
Applicant Brand Name + Dosage Form + Strength Composition  Each tablet contains: Clonazepam	Applicant Brand Name + Dosage Form + Strength Composition Composition Diary No. Date of R & I & fee Dy. No 12516 dated 06-03-2019; Rs.20,000/- dated 06-03-2019. Pharmacological Group Pharmacological Group Benzodiazepine/ Anticonvulsant Type of Form Form-5 Finished product Specification Pack size & Demanded Price Approval status of product in Reference Regulatory Authorities Me-too status Clonazep 0.5 mg Tablets (Reg. 078588) of Roryan Pharma USA, USFDA approved. Clonazep 0.5 mg Tablets (Reg. 078588) of Roryan Pharma W(Cephalosporin), Oral Dry Powder Suspension (Ceph), Dry Powder Injection (Ceph), Liquid Injection Ampoule (General) & Liquid Ampoule (General)  Remarks of the Evaluator Decision: Approved.  313. Name and address of manufacturer/ Applicant Brand Name + Dosage Form + Strength Composition Diary No. Date of R & I & fee Dy. No 12517 dated 06-03-2019; Rs.20,000/- dated 06-03-2019; Rs.20,000/- dated 06-03-2019. Pharmacological Group Pharmacological Group Benzodiazepine/ Anticonvulsant Type of Form Form-5 Finished product Specification Pack size & Demanded Price Approval status of product in Reference Regulatory Authorities  GMP status Remarks of the Evaluator Decision: Approved.  10 py. No 12517 dated 06-03-2019; Rs.20,000/- dated 06-03-2019. Pharmacological Group Benzodiazepine/ Anticonvulsant Type of Form Form-5 Finished product Specification Pack size & Demanded Price Approval status of product in Reference Regulatory Authorities  GMP status  Clonazepa 2 mg Tablets (Reg. 078589) of Roryan Pharma USA, USFDA approved.  Clonazepa 2 mg Tablets (Reg. 078589) of Roryan Pharma & Composition (General) & Liquid Ampoule (General) & Clonazepa 2 mg Tablets (Reg. 078589) of Roryan Pharma & GMP status  Firm was granted GMP errificate dated (4-12-2021 on the basis of GMP inspection conducted on 11-06-2021 for Tablet (General) & Liquid Ampoule (General) & Clonazepa 2 mg Tablets (Reg. 078589) of Roryan Pharma & Clonazepa 2 mg Tablets (Reg. 078589) of Roryan Pharma & Clonazepa 2 mg Tablets (Reg. 078589) of Roryan Pharma		Decision: Approved.	
Brand Name + Dosage Form + Strength   PTRIL Tablet 0.5 mg	Brand Name + Dosage Form + Strength   PTRIL Tablet 0.5 mg   Composition   Each tablet contains:   Clonazepam	312.	Name and address of manufacturer/	Pulse Pharmaceuticals (Pvt) Ltd, Mozay Baddoki Raiwind
Diary No. Date of R & I & fee	Diary No. Date of R & I & fee		Applicant	Road (Sua Aasil Road) Lahore.
Diary No. Date of R & I & fee  Diary No. Date of R & I & fee  Diary No. Date of R & I & fee  Dy. No 12516 dated 06-03-2019; Rs.20,000/- dated 06-03-2019; Rs	Diary No. Date of R & I & fee Dy. No 12516 dated 06-03-2019; Rs.20,000/- dated 06-03-2019.  Pharmacological Group Benzodiazepine/ Anticonvulsant Type of Form Form-5 Finished product Specification Pack size & Demanded Price Approval status of product in Reference Regulatory Authorities Me-too status Clonazep 0.5 mg Tablets (Reg. 078588) of Roryan Pharma GMP status Firm was granted GMP certificate dated 14-12-2021 on the basis of GMP inspection conducted on 11-06-2021 for Tablet (General) & (Psychotropic), Capsule (General) & (Cephalosporin), Oral Dry Powder Suspension (Ceph), Liquid Injection Ampoule (General) & (Sua Aasil Road) Lahore.  Priral: Tablet 2 mg Diary No. Date of R & I & fee Dy. No 12517 dated 06-03-2019; Rs.20,000/- dated 06-03-2019. Pharmacological Group Type of Form Form-5 Finished product Specification Pack size & Demanded Price Nemarks of the Evaluator Decision: Approved.  Strength Composition Diary No. Date of R & I & fee Dy. No 12517 dated 06-03-2019; Rs.20,000/- dated 06-03-2019. Pharmacological Group Benzodiazepine/ Anticonvulsant Type of Form Form-5 Finished product Specification Pack size & Demanded Price No. 3, As per SRO Approval status of product in Reference Regulatory Authorities Me-too status Clonazepa Tablets (Reg. 078589) of Roryan Pharma GMP status Firm was granted GMP certificate dated 14-12-2021 on the basis of GMP inspection conducted on 11-06-2021 for Tablet (General) & (Psychotropic), Capsule (General) & (Cepha, Liquid Injection Ampoule (General) & (Cepha, Liquid Injection Ampoule (General) & (Cepha), Liquid Injection Ampoule (General)		Brand Name + Dosage Form + Strength	
Diary No. Date of R & I & fee  Pharmacological Group  Pharmacological Group  Type of Form  Form-5  Finished product Specification  Pack size & Demanded Price  Approval status of product in Reference Regulatory Authorities  Me-too status  Obersion: Approved.  Remarks of the Evaluator  Decision: Approved.  Name and address of manufacturer/ Applicant  Brand Name + Dosage Form + Strength  Composition  Diary No. Date of R & I & fee  Dy. No 12516 dated 06-03-2019; Rs.20,000/- dated 06-03-2019.  Pharmacological Group  Pack size & Demanded Price  Regulatory Authorities  Clonazep 0.5 mg Tablets (Reg. 078588) of Roryan Pharma  Firm was granted GMP certificate dated 14-12-2021 on the basis of GMP inspection conducted on 11-06-2021 for Tablet (General) & (Psychotropic), Capsule (General) & (General) & Liquid Ampoule (General)  Remarks of the Evaluator  Decision: Approved.  Name and address of manufacturer/ Applicant  Brand Name + Dosage Form + Strength  Composition  Pack size & Demanded Price  Approval status of product in Reference Regulatory Authorities  Me-too status  Clonazep 2 mg Tablets (Reg. 078588) of Roryan Pharma  USA, USFDA approved.  Solva Aasil Road) Lahore.  PTRIL Tablet 2 mg  Diary No. Date of R & I & fee  Dy. No 12517 dated 06-03-2019; Rs.20,000/- dated 06-03-2019.  Remardado Godo Solva Aasil Road) Lahore.  Form-5  Finished product Specification  Pack size & Demanded Price  Approval status of product in Reference Regulatory Authorities  GMP status  Firm was granted GMP certificate dated 14-12-2021 on the basis of GMP inspection conducted on 11-06-2021 for Tablet (General)  & (Cephalosporin), Oral Dry Powder Suspension (Ceph), Dry Powder Injection (Ceph), Liquid Injection Ampoule	Diary No. Date of R & I & fee  Pharmacological Group  Pharmacological Group  Pharmacological Group  Form-5  Finished product Specification  Pack size & Demanded Price  Approval status of product in Reference Regulatory Authorities  Me-too status  GMP status  GMP status  Form-5  Finished product Specification  Pack size & Demanded Price  Regulatory Authorities  Me-too status  GMP status  Firm was granted GMP certificate dated 14-12-2021 on the basis of GMP inspection conducted on 11-06-2021 for Tablet (General) & (Psychotropic), Capsule (General) & (Cephalosporin), Oral Dry Powder Suspension (Ceph), Dry Powder Injection (Ceph), Liquid Injection Ampoule (General) & Liquid Ampoule (General)  Remarks of the Evaluator  Decision: Approved.  313.  Name and address of manufacturer/ Applicant  Brand Name + Dosage Form + Strength  Composition  Final Mame + Dosage Form + Strength  Composition		Composition	Each tablet contains:
Pharmacological Group Benzodiazepine/ Anticonvulsant Type of Form Finished product Specification Pack size & Demanded Price Sp's, As per SRO Approval status of product in Reference Regulatory Authorities  Me-too status  GMP status  Tirm was granted GMP certificate dated 14-12-2021 on the basis of GMP inspection (Ceph), Liquid Injection Ampoule (General) & (Psychotropic), Capsule (General) & (Conazep 0.5 mg Tight 2 mg Each tablet 2 mg Decision: Approved.  Approved.  Tirm was granted GMP certificate dated 14-12-2021 on the basis of GMP inspection conducted on 11-06-2021 for Tablet (General) & (Psychotropic), Capsule (General) & (Ceph), Dry Powder Suspension (Ceph), Dry Powder Injection (Ceph), Liquid Injection Ampoule (General) & Liquid Ampoule (General)  Remarks of the Evaluator Decision: Approved.  Approved.  Approved.  Pulse Pharmaceuticals (Pvt) Ltd, Mozay Baddoki Raiwind Road (Sua Aasil Road) Lahore.  PTRIL Tablet 2 mg Diary No. Date of R & I & fee Dy. No 12517 dated 06-03-2019; Rs.20,000/- dated 06-03-2019.  Pharmacological Group Benzodiazepine/ Anticonvulsant Type of Form Form-5 Finished product Specification USP specification Pack size & Demanded Price So's, As per SRO KLONOPIN TABLETS (clonazepam) of Roche Pharma USA, USFDA approved.  KLONOPIN TABLETS (clonazepam) of Roche Pharma USA, USFDA approved.  KLONOPIN TABLETS (clonazepam) of Roryan Pharma GMP status  GMP status  GMP status  Firm was granted GMP certificate dated 14-12-2021 on the basis of GMP inspection conducted on 11-06-2021 for Tablet (General) & (Psychotropic), Capsule (General) & (Cephalosporin), Oral Dry Powder Suspension (Ceph), Dry Powder Suspension (Ceph), Dry Powder Suspension (Ceph), Dry Powder Suspension (Ceph), Dry Powder Suspension (Ceph), Dry Powder Suspension (Ceph), Dry Powder Suspension (Ceph), Dry Powder Suspension (Ceph), Dry Powder Suspension (Ceph), Dry Powder Suspension (Ceph), Dry Powder Suspension (Ceph), Dry Powder Suspension (Ceph), Dry Powder Suspension (Ceph)	Pharmacological Group   Benzodiazepine/ Anticonvulsant			
Type of Form Finished product Specification Pack size & Demanded Price Approval status of product in Reference Regulatory Authorities Me-too status GMP status GMP status GMP status GMP status GMP status GMP status GMP status GMP status GMP status GMP status GMP status GMP status GMP status GMP inspection conducted on 11-06-2021 for Tablet (General) & (Psychotropic), Capsule (General) & (Cephalosporin), Oral Dry Powder Suspension (Ceph), Dry Powder Suspension (Ceph), Dry Powder Suspension (Ceph), Liquid Injection Ampoule (General) & Liquid Ampoule (General)  Remarks of the Evaluator Decision: Approved.  313. Name and address of manufacturer/ Applicant Brand Name + Dosage Form + Strength Composition Fach tablet 2 mg Diary No. Date of R & I & fee Dy. No 12517 dated 06-03-2019; Rs.20,000/- dated 06-03-2019. Pharmacological Group Benzodiazepine/ Anticonvulsant Type of Form Finished product Specification Pack size & Demanded Price Approval status of product in Reference Regulatory Authorities Me-too status GMP status GMP inspection conducted on 11-06-2021 for Tablet (General) & (Psychotropic), Capsule (General) & (USA, USFDA approved).  KLONOPIN TABLETS (clonazepam) of Roche Pharma USA, USFDA approved.  KLONOPIN TABLETS (clonazepam) of Roche Pharma GMP status GMP status GMP inspection conducted on 11-06-2021 for Tablet (General) & (Psychotropic), Capsule (General) & (Soft), Dry Powder Suspension (Ceph)	Type of Form Finished product Specification Pack size & Demanded Price Approval status of product in Reference Regulatory Authorities Me-too status GMP status GMP status  Remarks of the Evaluator Decision: Approved.  313. Name and address of manufacturer/Applicant Brand Name + Dosage Form + Strength Composition Diary No. Date of R & 1 & fee Dy. No 12517 dated 06-03-2019; Rs.20,000/- dated 06-03-2019. Pharmacological Group Pharmacological Group Pharmacological Group Repards of the Status  Type of Form Finished product Specification Pack size & Demanded Price Approval status of product in Reference Regulatory Authorities Me-too status Clonazep 2 mg Tablets (Reg. 078588) of Roryan Pharma Clonazepam.  Status Clonazepam. Diary No. Date of R & 1 & fee Dy. No 12517 dated 06-03-2019; Rs.20,000/- dated 06-03-2019.  Pharmacological Group Benzodiazepine/ Anticonvulsant Type of Form Finished product Specification Pack size & Demanded Price Approval status of product in Reference Regulatory Authorities Me-too status Clonazep 2 mg Tablets (Reg. 078589) of Roryan Pharma Clonazep 2 mg Tablets (Reg. 078589) of Roryan Pharma GMP status  Firm was granted GMP certificate dated 14-12-2021 on the basis of GMP inspection conducted on 11-06-2021 for Tablet (General) & Cloph, Dry Powder Injection (Ceph), Liquid Injection Ampoule (General) & Liquid Ampoule (General)		Diary No. Date of R & I & fee	
Finished product Specification Pack size & Demanded Price Approval status of product in Reference Regulatory Authorities  Brand Name + Dosage Form + Strength Composition  Diary No. Date of R & I & fee  Diary No. Date of R & I & fee  Diary No. Date of R & I & fee  Diary No. Date of R & I & fee  Approval status of product in Reference Regulatory Authorities  Brand Sams  Clonazep 0.5 mg Tablets (Reg. 078588) of Roryan Pharma  Firm was granted GMP certificate dated 14-12-2021 on the basis of GMP inspection conducted on 11-06-2021 for Tablet (General) & (Psychotropic), Capsule (General) & (Cephalosporin), Oral Dry Powder Suspension (Ceph), Dry Powder Injection (Ceph), Liquid Injection Ampoule (General) & Liquid Ampoule (General)  Remarks of the Evaluator  Decision: Approved.  313.  Name and address of manufacturer/ Applicant  Brand Name + Dosage Form + Strength Composition  Diary No. Date of R & I & fee  Diary No. Date of R & I & fee  Dy. No 12517 dated 06-03-2019; Rs.20,000/- dated 06-03-2019.  Pharmacological Group  Benzodiazepine/ Anticonvulsant  Type of Form  Form-5  Finished product Specification  Pack size & Demanded Price  Approval status of product in Reference Regulatory Authorities  Me-too status  GMP status  Firm was granted GMP certificate dated 14-12-2021 on the basis of GMP inspection conducted on 11-06-2021 for Tablet (General) & (Psychotropic), Capsule (General) & (Cephalosporin), Oral Dry Powder Suspension (Ceph), Dry Powder Injection (Ceph), Liquid Injection Ampoule	Finished product Specification Pack size & Demanded Price Approval status of product in Reference Regulatory Authorities Me-too status  Clonazep 0.5 mg Tablets (Reg. 078588) of Roryan Pharma GMP status  Firm was granted GMP certificate dated 14-12-2021 on the basis of GMP inspection conducted on 11-06-2021 for Tablet (General) & (Psychotropic), Capsule (General) & (Cephalosporin), Oral Dry Powder Suspension (Ceph), Dry Powder Injection (Ceph), Liquid Injection Ampoule (General) & Liquid Ampoule (General)  Remarks of the Evaluator  Decision: Approved.  313.  Name and address of manufacturer/ Applicant Brand Name + Dosage Form + Strength Composition  Each tablet contains: Clonazepam		Pharmacological Group	Benzodiazepine/ Anticonvulsant
Pack size & Demanded Price Approval status of product in Reference Regulatory Authorities  Me-too status  GMP status  GMP status  GMP status  GMP status  Clonazep 0.5 mg Tablets (Reg. 078588) of Roryan Pharma Firm was granted GMP certificate dated 14-12-2021 on the basis of GMP inspection conducted on 11-06-2021 for Tablet (General) & (Psychotropic), Capsule (General) & (Cephalosporin), Oral Dry Powder Suspension (Ceph), Dry Powder Injection (Ceph), Liquid Injection Ampoule (General) & Liquid Ampoule (General)  Remarks of the Evaluator  Decision: Approved.  313.  Name and address of manufacturer/ Applicant Brand Name + Dosage Form + Strength Composition  Brand Name + Dosage Form + Strength Composition  Diary No. Date of R & I & fee Dy. No 12517 dated 06-03-2019; Rs.20,000/- dated 06-03-2019.  Pharmacological Group Benzodiazepine/ Anticonvulsant Type of Form Finished product Specification Pack size & Demanded Price Approval status of product in Reference Regulatory Authorities  GMP status  GMP status  Firm was granted GMP certificate dated 14-12-2021 on the basis of GMP inspection conducted on 11-06-2021 for Tablet (General) & (Psychotropic), Capsule (General) & (Cephalosporin), Oral Dry Powder Suspension (Ceph), Dry Powder Suspension (Ceph), Liquid Injection Ampoule	Pack size & Demanded Price   50's, As per SRO			Form-5
Approval status of product in Reference Regulatory Authorities  Me-too status  GMP status  Clonazep 0.5 mg Tablets (Reg. 078588) of Roryan Pharma USA, USFDA approved.  Me-too status  GMP status  Firm was granted GMP certificate dated 14-12-2021 on the basis of GMP inspection conducted on 11-06-2021 for Tablet (General) & (Psychotropic), Capsule (General) & (Cephalosporin), Oral Dry Powder Suspension (Ceph), Dry Powder Injection (Ceph), Liquid Injection Ampoule (General) & Liquid Ampoule (General)  Remarks of the Evaluator  Decision: Approved.  Remarks of the Evaluator  Decision: Approved.  Name and address of manufacturer/ Applicant  Brand Name + Dosage Form + Strength  Composition  Composition  Pach tablet contains:  Clonazepam	Approval status of product in Reference Regulatory Authorities  Me-too status  GMP status  Clonazep 0.5 mg Tablets (Reg. 078588) of Roryan Pharma USA, USFDA approved.  Clonazep 0.5 mg Tablets (Reg. 078588) of Roryan Pharma GMP status  Firm was granted GMP certificate dated 14-12-2021 on the basis of GMP inspection conducted on 11-06-2021 for Tablet (General) & (Psychotropic), Capsule (General) & (Cephalosporin), Oral Dry Powder Suspension (Ceph), Dry Powder Injection (Ceph), Liquid Injection Ampoule (General) & Liquid Ampoule (General)  Remarks of the Evaluator  Decision: Approved.  313.  Name and address of manufacturer/ Applicant  Brand Name + Dosage Form + Strength  Composition  Each tablet contains:  Clonazepam		Finished product Specification	USP specification
Regulatory Authorities   USA, USFDA approved.	Regulatory Authorities   USA, USFDA approved.		Pack size & Demanded Price	
Me-too status	Me-too status		Approval status of product in Reference	KLONOPIN TABLETS (clonazepam) of Roche Pharma
GMP status  Firm was granted GMP certificate dated 14-12-2021 on the basis of GMP inspection conducted on 11-06-2021 for Tablet (General) & (Psychotropic), Capsule (General) & (Cephalosporin), Oral Dry Powder Suspension (Ceph), Dry Powder Injection (Ceph), Liquid Injection Ampoule (General) & Liquid Ampoule (General)  Remarks of the Evaluator  Decision: Approved.  313.  Name and address of manufacturer/ Applicant  Brand Name + Dosage Form + Strength  Composition  Each tablet contains: Clonazepam	Firm was granted GMP certificate dated 14-12-2021 on the basis of GMP inspection conducted on 11-06-2021 for Tablet (General) & (Psychotropic), Capsule (General) & (Cephalosporin), Oral Dry Powder Suspension (Ceph), Dry Powder Injection (Ceph), Liquid Injection Ampoule (General) & Liquid Ampoule (General) & Liquid Ampoule (General)    Remarks of the Evaluator   Decision: Approved.		Regulatory Authorities	
basis of GMP inspection conducted on 11-06-2021 for Tablet (General) & (Psychotropic), Capsule (General) & (Cephalosporin), Oral Dry Powder Suspension (Ceph), Dry Powder Injection (Ceph), Liquid Injection Ampoule (General) & Liquid Ampoule (General) & Liquid Ampoule (General) & Liquid Ampoule (General)  Remarks of the Evaluator  Decision: Approved.  313.  Name and address of manufacturer/ Applicant Brand Name + Dosage Form + Strength Composition Each tablet 2 mg Diary No. Date of R & I & fee Dy. No 12517 dated 06-03-2019; Rs.20,000/- dated 06-03-2019.  Pharmacological Group Benzodiazepine/ Anticonvulsant Type of Form Form-5 Finished product Specification Pack size & Demanded Price Approval status of product in Reference Regulatory Authorities Me-too status  Clonazep 2 mg Tablets (Reg. 078589) of Roryan Pharma GMP status  Firm was granted GMP certificate dated 14-12-2021 on the basis of GMP inspection conducted on 11-06-2021 for Tablet (General) & (Psychotropic), Capsule (General) & (Cephalosporin), Oral Dry Powder Suspension (Ceph), Dry Powder Injection (Ceph), Liquid Injection Ampoule	basis of GMP inspection conducted on 11-06-2021 for Tablet (General) & (Psychotropic), Capsule (General) & (Cephalosporin), Oral Dry Powder Suspension (Ceph), Dry Powder Injection (Ceph), Liquid Injection Ampoule (General) & Liquid Ampoule (General) & Liquid Ampoule (General)  Remarks of the Evaluator  Decision: Approved.  313.  Name and address of manufacturer/ Applicant Brand Name + Dosage Form + Strength Composition  Each tablet 2 mg Diary No. Date of R & I & fee Dy. No 12517 dated 06-03-2019; Rs.20,000/- dated 06-03-2019.  Pharmacological Group Benzodiazepine/ Anticonvulsant Type of Form Form-5 Finished product Specification Pack size & Demanded Price Approval status of product in Reference Regulatory Authorities Me-too status  GMP status  Dassis of GMP inspection conducted on 11-06-2021 for Tablet (General) & (Psychotropic), Capsule (General) & (Cephalosporin), Oral Dry Powder Suspension (Ceph), Dry Powder Injection (Ceph), Liquid Injection Ampoule (General) & Liquid Ampoule (General) Remarks of the Evaluator		Me-too status	
Remarks of the Evaluator  Decision: Approved.  313.  Name and address of manufacturer/ Applicant  Brand Name + Dosage Form + Strength  Composition  Diary No. Date of R & I & fee  Pharmacological Group  Pharmacological Group  Pharmacological Group  Penduct Specification  Pack size & Demanded Price  Approval status of product in Reference Regulatory Authorities  Me-too status  GMP status  Remarks of the Evaluator  Pulse Pharmaceuticals (Pvt) Ltd, Mozay Baddoki Raiwind Road (Sua Aasil Road) Lahore.  PTRIL Tablet 2 mg  Dy. No 12517 dated 06-03-2019; Rs.20,000/- dated 06-03-2019.  Benzodiazepine/ Anticonvulsant  Form-5  Finished product Specification  USP specification  Pack size & Demanded Price  Approval status of product in Reference Regulatory Authorities  Me-too status  Clonazep 2 mg Tablets (Reg. 078589) of Roryan Pharma  Firm was granted GMP certificate dated 14-12-2021 on the basis of GMP inspection conducted on 11-06-2021 for Tablet (General) & (Psychotropic), Capsule (General) & (Cephalosporin), Oral Dry Powder Suspension (Ceph), Dry Powder Injection (Ceph), Liquid Injection Ampoule	Remarks of the Evaluator  Decision: Approved.  313.  Name and address of manufacturer/ Applicant  Brand Name + Dosage Form + Strength  Composition  Diary No. Date of R & I & fee Dy. No 12517 dated 06-03-2019; Rs.20,000/- dated 06-03-2019.  Pharmacological Group Pharmacological Group Benzodiazepine/ Anticonvulsant Type of Form Pack size & Demanded Price Approval status of product in Reference Regulatory Authorities  Me-too status  Clonazep 2 mg Tablets (Reg. 078589) of Roryan Pharma GMP status  Firm was granted GMP certificate dated 14-12-2021 on the basis of GMP inspection conducted on 11-06-2021 for Tablet (General) & (Psychotropic), Capsule (General) & (Cephalosporin), Oral Dry Powder Suspension (Ceph), Dry Powder Injection (Ceph), Liquid Injection Ampoule (General) & Liquid Ampoule (General)  Remarks of the Evaluator		GWF status	basis of GMP inspection conducted on 11-06-2021 for Tablet (General) & (Psychotropic), Capsule (General) & (Cephalosporin), Oral Dry Powder Suspension (Ceph), Dry Powder Injection (Ceph), Liquid Injection Ampoule
Name and address of manufacturer/ Applicant Brand Name + Dosage Form + Strength Composition  Composition  Diary No. Date of R & I & fee  Pharmacological Group Pharmacological Group Pharmacological Group Promuse Porms  Finished product Specification Pack size & Demanded Price Approval status of product in Reference Regulatory Authorities  Me-too status  GMP status  Pulse Pharmaceuticals (Pvt) Ltd, Mozay Baddoki Raiwind Road (Sua Aasil Road) Lahore.  PTRIL Tablet 2 mg  Dy. No 12517 dated 06-03-2019; Rs.20,000/- dated 06-03-2019.  Benzodiazepine/ Anticonvulsant  Form-5  Finished product Specification Pack size & Demanded Price S0's, As per SRO  KLONOPIN TABLETS (clonazepam) of Roche Pharma USA, USFDA approved.  Clonazep 2 mg Tablets (Reg. 078589) of Roryan Pharma Firm was granted GMP certificate dated 14-12-2021 on the basis of GMP inspection conducted on 11-06-2021 for Tablet (General) & (Psychotropic), Capsule (General) & (Cephalosporin), Oral Dry Powder Suspension (Ceph), Dry Powder Injection (Ceph), Liquid Injection Ampoule	Name and address of manufacturer/ Applicant  Brand Name + Dosage Form + Strength Composition  Each tablet contains: Clonazepam		Remarks of the Evaluator	
Applicant Brand Name + Dosage Form + Strength Composition Each tablet contains: Clonazepam	Applicant Brand Name + Dosage Form + Strength Composition Each tablet contains: Clonazepam		Decision: Approved.	
Composition  Each tablet contains: Clonazepam	Composition  Each tablet contains: Clonazepam	313.		· · · · · · · · · · · · · · · · · · ·
Clonazepam	Clonazepam		Brand Name + Dosage Form + Strength	PTRIL Tablet 2 mg
Diary No. Date of R & I & fee  Dy. No 12517 dated 06-03-2019; Rs.20,000/- dated 06-03-2019.  Pharmacological Group Benzodiazepine/ Anticonvulsant Type of Form Form-5  Finished product Specification Pack size & Demanded Price Approval status of product in Reference Regulatory Authorities USA, USFDA approved.  Me-too status Clonazep 2 mg Tablets (Reg. 078589) of Roryan Pharma GMP status Firm was granted GMP certificate dated 14-12-2021 on the basis of GMP inspection conducted on 11-06-2021 for Tablet (General) & (Psychotropic), Capsule (General) & (Cephalosporin), Oral Dry Powder Suspension (Ceph), Dry Powder Injection (Ceph), Liquid Injection Ampoule	Diary No. Date of R & I & fee  Dy. No 12517 dated 06-03-2019; Rs.20,000/- dated 06-03-2019.  Pharmacological Group  Benzodiazepine/ Anticonvulsant  Type of Form  Finished product Specification  Pack size & Demanded Price  Approval status of product in Reference Regulatory Authorities  Me-too status  Clonazep 2 mg Tablets (Reg. 078589) of Roryan Pharma  GMP status  Firm was granted GMP certificate dated 14-12-2021on the basis of GMP inspection conducted on 11-06-2021 for Tablet (General) & (Psychotropic), Capsule (General) & (Cephalosporin), Oral Dry Powder Suspension (Ceph), Dry Powder Injection (Ceph), Liquid Injection Ampoule (General) & Liquid Ampoule (General)  Remarks of the Evaluator		Composition	Each tablet contains:
Pharmacological Group Benzodiazepine/ Anticonvulsant Type of Form Form-5 Finished product Specification Pack size & Demanded Price Approval status of product in Reference Regulatory Authorities We-too status GMP status GMP status  Type of Form Form-5 So's, As per SRO KLONOPIN TABLETS (clonazepam) of Roche Pharma USA, USFDA approved. Clonazep 2 mg Tablets (Reg. 078589) of Roryan Pharma Firm was granted GMP certificate dated 14-12-2021 on the basis of GMP inspection conducted on 11-06-2021 for Tablet (General) & (Psychotropic), Capsule (General) & (Cephalosporin), Oral Dry Powder Suspension (Ceph), Dry Powder Injection (Ceph), Liquid Injection Ampoule	Pharmacological Group Benzodiazepine/ Anticonvulsant Type of Form Form-5 Finished product Specification Pack size & Demanded Price Approval status of product in Reference Regulatory Authorities We-too status GMP status GMP status  Firm was granted GMP certificate dated 14-12-2021 on the basis of GMP inspection conducted on 11-06-2021 for Tablet (General) & (Psychotropic), Capsule (General) & (Cephalosporin), Oral Dry Powder Suspension (Ceph), Dry Powder Injection (Ceph), Liquid Injection Ampoule (General) & Liquid Ampoule (General)  Remarks of the Evaluator			Clonazepam2 mg
Type of Form Finished product Specification USP specification Pack size & Demanded Price Approval status of product in Reference Regulatory Authorities We-too status GMP status  GMP status  Firm was granted GMP certificate dated 14-12-2021 on the basis of GMP inspection conducted on 11-06-2021 for Tablet (General) & (Psychotropic), Capsule (General) & (Cephalosporin), Oral Dry Powder Suspension (Ceph), Dry Powder Injection (Ceph), Liquid Injection Ampoule	Type of Form Finished product Specification USP specification Pack size & Demanded Price Approval status of product in Reference Regulatory Authorities USA, USFDA approved. Me-too status Clonazep 2 mg Tablets (Reg. 078589) of Roryan Pharma GMP status Firm was granted GMP certificate dated 14-12-2021 on the basis of GMP inspection conducted on 11-06-2021 for Tablet (General) & (Psychotropic), Capsule (General) & (Cephalosporin), Oral Dry Powder Suspension (Ceph), Dry Powder Injection (Ceph), Liquid Injection Ampoule (General) & Liquid Ampoule (General) Remarks of the Evaluator		Diary No. Date of R & I & fee	
Finished product Specification Pack size & Demanded Price Approval status of product in Reference Regulatory Authorities We-too status GMP status  Firm was granted GMP certificate dated 14-12-2021 on the basis of GMP inspection conducted on 11-06-2021 for Tablet (General) & (Psychotropic), Capsule (General) & (Cephalosporin), Oral Dry Powder Suspension (Ceph), Dry Powder Injection (Ceph), Liquid Injection Ampoule	Finished product Specification Pack size & Demanded Price Approval status of product in Reference Regulatory Authorities We-too status GMP status  Firm was granted GMP certificate dated 14-12-2021 on the basis of GMP inspection conducted on 11-06-2021 for Tablet (General) & (Psychotropic), Capsule (General) & (Cephalosporin), Oral Dry Powder Suspension (Ceph), Dry Powder Injection (Ceph), Liquid Injection Ampoule (General) & Liquid Ampoule (General)  Remarks of the Evaluator			
Pack size & Demanded Price  Approval status of product in Reference Regulatory Authorities  Me-too status  Clonazep 2 mg Tablets (Reg. 078589) of Roryan Pharma  GMP status  Firm was granted GMP certificate dated 14-12-2021 on the basis of GMP inspection conducted on 11-06-2021 for Tablet (General) & (Psychotropic), Capsule (General) & (Cephalosporin), Oral Dry Powder Suspension (Ceph), Dry Powder Injection (Ceph), Liquid Injection Ampoule	Pack size & Demanded Price  Approval status of product in Reference Regulatory Authorities  Me-too status  Clonazep 2 mg Tablets (Reg. 078589) of Roryan Pharma  GMP status  Firm was granted GMP certificate dated 14-12-2021 on the basis of GMP inspection conducted on 11-06-2021 for Tablet (General) & (Psychotropic), Capsule (General) & (Cephalosporin), Oral Dry Powder Suspension (Ceph), Dry Powder Injection (Ceph), Liquid Injection Ampoule (General) & Liquid Ampoule (General)  Remarks of the Evaluator			
Approval status of product in Reference Regulatory Authorities  Me-too status  GMP status  GMP status  Clonazep 2 mg Tablets (Reg. 078589) of Roryan Pharma  Firm was granted GMP certificate dated 14-12-2021 on the basis of GMP inspection conducted on 11-06-2021 for Tablet (General) & (Psychotropic), Capsule (General) & (Cephalosporin), Oral Dry Powder Suspension (Ceph), Dry Powder Injection (Ceph), Liquid Injection Ampoule	Approval status of product in Reference Regulatory Authorities  Me-too status  Clonazep 2 mg Tablets (Reg. 078589) of Roryan Pharma GMP status  Firm was granted GMP certificate dated 14-12-2021 on the basis of GMP inspection conducted on 11-06-2021 for Tablet (General) & (Psychotropic), Capsule (General) &(Cephalosporin), Oral Dry Powder Suspension (Ceph), Dry Powder Injection (Ceph), Liquid Injection Ampoule (General) & Liquid Ampoule (General)			1
Regulatory Authorities  Me-too status  Clonazep 2 mg Tablets (Reg. 078589) of Roryan Pharma  GMP status  Firm was granted GMP certificate dated 14-12-2021 on the basis of GMP inspection conducted on 11-06-2021 for Tablet (General) & (Psychotropic), Capsule (General) & (Cephalosporin), Oral Dry Powder Suspension (Ceph), Dry Powder Injection (Ceph), Liquid Injection Ampoule	Regulatory Authorities  Me-too status  Clonazep 2 mg Tablets (Reg. 078589) of Roryan Pharma  GMP status  Firm was granted GMP certificate dated 14-12-2021 on the basis of GMP inspection conducted on 11-06-2021 for Tablet (General) & (Psychotropic), Capsule (General) & (Cephalosporin), Oral Dry Powder Suspension (Ceph), Dry Powder Injection (Ceph), Liquid Injection Ampoule (General) & Liquid Ampoule (General)  Remarks of the Evaluator			
Me-too status  Clonazep 2 mg Tablets (Reg. 078589) of Roryan Pharma  GMP status  Firm was granted GMP certificate dated 14-12-2021 on the basis of GMP inspection conducted on 11-06-2021 for Tablet (General) & (Psychotropic), Capsule (General)  &(Cephalosporin), Oral Dry Powder Suspension (Ceph), Dry Powder Injection (Ceph), Liquid Injection Ampoule	Me-too status  Clonazep 2 mg Tablets (Reg. 078589) of Roryan Pharma  GMP status  Firm was granted GMP certificate dated 14-12-2021 on the basis of GMP inspection conducted on 11-06-2021 for Tablet (General) & (Psychotropic), Capsule (General) & (Cephalosporin), Oral Dry Powder Suspension (Ceph), Dry Powder Injection (Ceph), Liquid Injection Ampoule (General) & Liquid Ampoule (General)  Remarks of the Evaluator			
GMP status  Firm was granted GMP certificate dated 14-12-2021on the basis of GMP inspection conducted on 11-06-2021 for Tablet (General) & (Psychotropic), Capsule (General) & (Cephalosporin), Oral Dry Powder Suspension (Ceph), Dry Powder Injection (Ceph), Liquid Injection Ampoule	GMP status  Firm was granted GMP certificate dated 14-12-2021 on the basis of GMP inspection conducted on 11-06-2021 for Tablet (General) & (Psychotropic), Capsule (General) & (Cephalosporin), Oral Dry Powder Suspension (Ceph), Dry Powder Injection (Ceph), Liquid Injection Ampoule (General) & Liquid Ampoule (General)  Remarks of the Evaluator			
basis of GMP inspection conducted on 11-06-2021 for Tablet (General) & (Psychotropic), Capsule (General) & (Cephalosporin), Oral Dry Powder Suspension (Ceph), Dry Powder Injection (Ceph), Liquid Injection Ampoule	basis of GMP inspection conducted on 11-06-2021 for Tablet (General) & (Psychotropic), Capsule (General) & (Cephalosporin), Oral Dry Powder Suspension (Ceph), Dry Powder Injection (Ceph), Liquid Injection Ampoule (General) & Liquid Ampoule (General)  Remarks of the Evaluator			
&(Cephalosporin), Oral Dry Powder Suspension (Ceph), Dry Powder Injection (Ceph), Liquid Injection Ampoule	&(Cephalosporin), Oral Dry Powder Suspension (Ceph), Dry Powder Injection (Ceph), Liquid Injection Ampoule (General) & Liquid Ampoule (General)  Remarks of the Evaluator		GMP status	basis of GMP inspection conducted on 11-06-2021 for
	(General) & Liquid Ampoule (General)  Remarks of the Evaluator			&(Cephalosporin), Oral Dry Powder Suspension (Ceph),
(General) & Elquid Ampoule (General)	Remarks of the Evaluator			
	Decision: Approved.		Remarks of the Evaluator	<u> </u>
Decision: Approved.			Decision: Approved.	

314.	Name and address of manufacturer/	Pulse Pharmaceuticals (Pvt) Ltd, Mozay Baddoki Raiwind
	Applicant	Road (Sua Aasil Road) Lahore.
	Brand Name + Dosage Form + Strength	ZINOLID Tablet 600 mg
	Composition	Each Film Coated tablet contains:
		Linezolid600 mg
	Diary No. Date of R & I & fee	Dy. No 12539 dated 06-03-2019; Rs.20,000/- dated 06-03-2019.
	Pharmacological Group	Anitbacterial
	Type of Form	Form-5
	Finished product Specification	Manufacturer specification
	Pack size & Demanded Price	12's, As per SRO
	Approval status of product in Reference	Zyvox 600 mg tablet by Pharmacia and Upjohn Pharma
	Regulatory Authorities	(USFDA)
	Me-too status	Ecasil by M/s Sami Pharma ,Khi
	GMP status	Firm was granted GMP certificate dated 14-12-2021on the basis of GMP inspection conducted on 11-06-2021 for Tablet (General) & (Psychotropic), Capsule (General) & (Cephalosporin), Oral Dry Powder Suspension (Ceph), Dry Powder Injection (Ceph), Liquid Injection Ampoule
		(General) & Liquid Ampoule (General)
	Remarks of the Evaluator	Innovator specifications
		specification. Firm shall submit fee of Rs. 7,500 for
		duct specifications, as per notification No.F.7-11/2021-
	B&A/DRAP dated 13-07-2021.	
315.	Name and address of manufacturer/	Pulse Pharmaceuticals (Pvt) Ltd, Mozay Baddoki Raiwind
	Applicant	Road (Sua Aasil Road) Lahore.
	Brand Name + Dosage Form + Strength	ZINOLID Tablet 400 mg
	Composition	Each Film Coated tablet contains:
		Linezolid400 mg
	Diary No. Date of R & I & fee	Dy. No 12538 dated 06-03-2019; Rs.20,000/- dated 06-03-2019.
	Pharmacological Group	Antibacterial
	Type of Form	Form-5
	Finished product Specification	Manufacturer specification
	Pack size & Demanded Price	12's, As per SRO
	Approval status of product in Reference	Zyvox 400 mg tablet by Pharmacia and Upjohn Pharma
	Regulatory Authorities	(USFDA)
	Me-too status	Ecasil by M/s Sami Pharma ,Khi
	GMP status	Firm was granted GMP certificate dated 14-12-2021on the
		basis of GMP inspection conducted on 11-06-2021 for
		Tablet (General) & (Psychotropic), Capsule (General)
		&(Cephalosporin), Oral Dry Powder Suspension (Ceph),
		Dry Powder Injection (Ceph), Liquid Injection Ampoule
		(General) & Liquid Ampoule (General)
	Remarks of the Evaluator	Innovator specifications
		specification. Firm shall submit fee of Rs. 7,500 for
	correction/pre-approval change/ in pro B&A/DRAP dated 13-07-2021.	duct specifications, as per notification No.F.7-11/2021-
316.	Name and address of manufacturer/	Pulse Pharmaceuticals (Pvt) Ltd, Mozay Baddoki Raiwind
	Applicant	Road (Sua Aasil Road) Lahore.
	Brand Name + Dosage Form + Strength	PULSEID Tablet 100 mg
	Composition	Each Film Coated tablet contains:
	_	Flurbiprofen100 mg
	Diary No. Date of R & I & fee	Dy. No 12531 dated 06-03-2019; Rs.20,000/- dated 06-03-
	,	2019.
	Pharmacological Group	Propionic Acid
_		

	Type of Form	Form-5
	Finished product Specification	Manufacturer specification
	Pack size & Demanded Price	30's, As per SRO
	Approval status of product in Reference	Teva-Flurbiprofen by Teva Canada Pharm (Health
	Regulatory Authorities	Canada Approved)
	Me-too status	Neoflarbi 100mg Tablet by M/s Neomedix
		Pharmaceuticals (Reg#081408)
	GMP status	Firm was granted GMP certificate dated 14-12-2021on the
		basis of GMP inspection conducted on 11-06-2021 for
		Tablet (General) & (Psychotropic), Capsule (General)
		&(Cephalosporin), Oral Dry Powder Suspension (Ceph),
		Dry Powder Injection (Ceph), Liquid Injection Ampoule
		(General) & Liquid Ampoule (General)
	Remarks of the Evaluator	USP specifications
		cification. Firm shall submit fee of Rs. 7,500 for
		duct specifications, as per notification No.F.7-11/2021-
317.	Name and address of manufacturer/	Pulse Pharmaceuticals (Pvt) Ltd, Mozay Baddoki Raiwind
	Applicant	Road (Sua Aasil Road) Lahore.
	Brand Name + Dosage Form + Strength	NITAZONID Tablet 500 mg
	Composition	Each Film Coated tablet contains:
	•	Nitazoxanide500 mg
	Diary No. Date of R & I & fee	Dy. No 12533 dated 06-03-2019; Rs.20,000/- dated 06-03-
		2019.
	Pharmacological Group	Amebicides
	Type of Form	Form-5
	Finished product Specification	Manufacturer specification
	Pack size & Demanded Price	20's, As per SRO
	Approval status of product in Reference	USFDA approved, Tablet Alinia, Romark
	Regulatory Authorities	Collection, 1 words 1 minus, 1 consum
	Me-too status	Izato tablet of M/s Sami Pharmaceuticals (Reg. #
		076308)
	GMP status	Firm was granted GMP certificate dated 14-12-2021on the
		basis of GMP inspection conducted on 11-06-2021 for
		Tablet (General) & (Psychotropic), Capsule (General)
		&(Cephalosporin), Oral Dry Powder Suspension (Ceph),
		Dry Powder Injection (Ceph), Liquid Injection Ampoule
		(General) & Liquid Ampoule (General)
	Remarks of the Evaluator	Innovator specifications
	<b>Decision: Approved with innovator's</b>	specification. Firm shall submit fee of Rs. 7,500 for
	correction/pre-approval change/ in pro	duct specifications, as per notification No.F.7-11/2021-
	B&A/DRAP dated 13-07-2021.	
318.	Name and address of manufacturer/	Pulse Pharmaceuticals (Pvt) Ltd, Mozay Baddoki Raiwind
	Applicant	Road (Sua Aasil Road) Lahore.
	Brand Name + Dosage Form + Strength	PULMOTIL Tablet
	Composition	Each tablet contains:
	_	Diphenoxylate Hcl2.5 mg
		Atropine Sulphate
	Diary No. Date of R & I & fee	Dy. No 12530 dated 06-03-2019; Rs.20,000/- dated 06-03-
		2019.
	Pharmacological Group	Anticholinergic
	Type of Form	Form-5
	Finished product Specification	Manufacturer specification
	Pack size & Demanded Price	20's, As per SRO
	Approval status of product in Reference	USFDA Approved
	Regulatory Authorities	Col Dil Tippiotod
		<u> </u>

GMP status  Firm was granted GMP certificate dated 14-12 basis of GMP inspection conducted on 11- Tablet (General) & (Psychotropic), Capsul &(Cephalosporin), Oral Dry Powder Suspens Dry Powder Injection (Ceph), Liquid Injectio (General) & Liquid Ampoule (General)  Remarks of the Evaluator  The official monograph for the applied formu available in USP  Decision: Approved with USP specification. Firm shall submit fee of Rs. 7,500 for corr approval change/ in product specifications, as per notification No.F.7-11/2021-B&A/E	06-2021 for e (General) sion (Ceph), on Ampoule
Tablet (General) & (Psychotropic), Capsul & (Cephalosporin), Oral Dry Powder Suspens Dry Powder Injection (Ceph), Liquid Injection (General) & Liquid Ampoule (General)  Remarks of the Evaluator  The official monograph for the applied formula available in USP  Decision: Approved with USP specification. Firm shall submit fee of Rs. 7,500 for corrapproval change/ in product specifications, as per notification No.F.7-11/2021-B&A/E	e (General) sion (Ceph), on Ampoule
&(Cephalosporin), Oral Dry Powder Suspens Dry Powder Injection (Ceph), Liquid Injection (General) & Liquid Ampoule (General)  Remarks of the Evaluator The official monograph for the applied formutavailable in USP  Decision: Approved with USP specification. Firm shall submit fee of Rs. 7,500 for correspondent in product specifications, as per notification No.F.7-11/2021-B&A/D	sion (Ceph), on Ampoule
Dry Powder Injection (Ceph), Liquid Injection (General) & Liquid Ampoule (General)  Remarks of the Evaluator  The official monograph for the applied formula available in USP  Decision: Approved with USP specification. Firm shall submit fee of Rs. 7,500 for correspondent of the applied formula available in USP.	on Ampoule
(General) & Liquid Ampoule (General)  Remarks of the Evaluator  The official monograph for the applied formu available in USP  Decision: Approved with USP specification. Firm shall submit fee of Rs. 7,500 for corrapproval change/ in product specifications, as per notification No.F.7-11/2021-B&A/D	
Remarks of the Evaluator  The official monograph for the applied formu available in USP  Decision: Approved with USP specification. Firm shall submit fee of Rs. 7,500 for corr approval change/ in product specifications, as per notification No.F.7-11/2021-B&A/E	lation is
available in USP  Decision: Approved with USP specification. Firm shall submit fee of Rs. 7,500 for corr approval change/ in product specifications, as per notification No.F.7-11/2021-B&A/D	lation is
Decision: Approved with USP specification. Firm shall submit fee of Rs. 7,500 for corrapproval change/ in product specifications, as per notification No.F.7-11/2021-B&A/D	
approval change/ in product specifications, as per notification No.F.7-11/2021-B&A/D	rection/pre-
13-07-2021.	
319. Name and address of manufacturer/ Pulse Pharmaceuticals (Pvt) Ltd, Mozay Badd	oki Raiwind
Applicant Road (Sua Aasil Road) Lahore.	
Brand Name + Dosage Form + Strength NOXIN Tablet 400 mg	
Composition Each Film Coated tablet contains:	
Norfloxacin400 mg	
Diary No. Date of R & I & fee Dy. No 12534 dated 06-03-2019; Rs.20,000/-	dated 06-03-
2019.	
Pharmacological Group Fluoroquinolone	
Type of Form Form-5	
Finished product Specification Manufacturer specification	
Pack size & Demanded Price 10's,14's as per SRO	
Approval status of product in Reference TGA approved. Roxin (Norfloxacin) 400 mg.	
Regulatory Authorities  Regulatory Authorities  Norfloxacin tablets by Ratiopharm (MHRA A	
Me-too status  Bacnor Tablets 400mg of M/s Dysor Laboratories	
GMP status  Firm was granted GMP certificate dated 14-12 basis of GMP inspection conducted on 11- Tablet (General) & (Psychotropic), Capsul & (Cephalosporin), Oral Dry Powder Suspens	06-2021 for e (General) sion (Ceph),
Dry Powder Injection (Ceph), Liquid Injection (General) & Liquid Ampoule (General)	on Ampoule
Remarks of the Evaluator  The official monograph for the applied formula available in USP.	lation is
Decision: Approved with USP specification. Firm shall submit fee of Rs. 7,500 for corr	rection/pre-
approval change/ in product specifications, as per notification No.F.7-11/2021-B&A/E 13-07-2021.	
320. Name and address of manufacturer/ M/s Dynatis Pakistan Pvt Ltd., Plot No.7	10, Sundar
Applicant Industrial Estate, Raiwind Road, Lahore.	•
Brand Name + Dosage Form + Strength ZOLONAF Capsule 150 mg	
Composition Each Capsule Contains:	
Fluconazole150 n	ng
Diary No. Date of R & I & fee Dy. No 12385 dated 06-03-2019; Rs.20,000/-02019.	
Pharmacological Group Antifungal	
Type of Form Form-5	
Finished product Specification	
Pack size & Demanded Price 10's,14's as per SRO	
Approval status of product in Reference Regulatory Authorities Fluconazole 150mg Capsules. MHRA approv	ed.
Me-too status  Conza Capsule, De-Mont Research Labs. 084049.	, Reg. No.
GMP status  Last GMP inspection is conducted on 26-0 GMP certificate has been issued to firm on 01	

	Remarks of the Evaluator	Firm has not provided manufacturing outline. Firm has not provided finished product specification.
	1	on. Firm shall submit fee of Rs. 7,500 for correction/prens, as per notification No.F.7-11/2021-B&A/DRAP dated
321.	Name and address of manufacturer/ Applicant	M/s Dynatis Pakistan Pvt Ltd., Plot No.710, Sundar Industrial Estate, Raiwind Road, Lahore.
	Brand Name + Dosage Form + Strength	PEXOL Tablet
	Composition	Each Film Coated Tablet Contains: Paracetamol
	Diary No. Date of R & I & fee	Dy. No 12384 dated 06-03-2019; Rs.20,000/- dated 06-03-2019.
	Pharmacological Group	Opioid Analgesic/Antipyretic
	Type of Form	Form-5
	Finished product Specification	USP specification
	Pack size & Demanded Price	100's, as per SRO
	Approval status of product in Reference	Ultracet Tablet by M/s Janssen Ortho, (USFDA
	Regulatory Authorities	approved)
	Me-too status	Forgesil Tablet by M/s Genome Pharmaceutical (Reg No:080874
	GMP status	Last GMP inspection is conducted on 26-03-2021 and GMP certificate has been issued to firm on 01-07-2021.
	Remarks of the Evaluator  Decision: Approved with USP specificat	
322.	composition, as per notification No.F.7-2  Name and address of manufacturer/ Applicant	M/s Dynatis Pakistan Pvt Ltd., Plot No.710, Sundar
	Brand Name + Dosage Form + Strength	Industrial Estate, Raiwind Road, Lahore.  TICOL Tablet 90 mg
	Composition	Each Film Coated Tablet Contains: Ticagrelor
	Diary No. Date of R & I & fee	Dy. No 12373 dated 06-03-2019; Rs.20,000/- dated 06-03-2019.
	Pharmacological Group	Antithrombotic agent
	Type of Form	Form-5
	Finished product Specification	Innovator specification.
	Pack size & Demanded Price	30's, as per SRO
	Approval status of product in Reference	BRILINTA 90mg Tablets by M/s AstraZeneca
	Regulatory Authorities	Pharmaceuticals, USFDA Approved.
	Me-too status	Anplag 90mg Tablet, PharmEvo(Pvt) Ltd, R. No. 089382
	GMP status	Last GMP inspection is conducted on 26-03-2021 and GMP certificate has been issued to firm on 01-07-2021.
	Remarks of the Evaluator	Stability study data is required as per the guidelines approved in 293RD meeting of Registration Board
	<b>Decision: Deferred for submission of sta</b>	bility study data as per the guidelines approved in 293 <sup>rd</sup>
323.	meeting of Registration Board.	
	meeting of Registration Board.  Name and address of manufacturer/ Applicant	Macquin's International, F-2/H., P.T.C Industrial Complex,S.I.T.E,Karachi.
	Name and address of manufacturer/	_ ·
	Name and address of manufacturer/ Applicant	Complex,S.I.T.E,Karachi.

Diary No. Date of R & I & fee	Dy. No 11999 dated 06-03-2019; Rs.20,000/- dated 05-03-
-	2019.
Pharmacological Group	Proton pump inhibitor
Type of Form	Form-5
Finished product Specification	Manufacturer specification
Pack size & Demanded Price	30's, as per SRO
Approval status of product in Reference	USFDA approved, Delayed release Dexlansoprazole
Regulatory Authorities	capsule 60 mg
Me-too status	Razodex 60mg Capsule by M/s Getz Pharma.
GMP status	Firm has not provided GMP within last 3 years.
Remarks of the Evaluator	• GMP inspection report within last 3 years is required.
	• Form-5 as per prescribed format of Drug Registering,
	Licensing & advertising is required along with
	preregistration fee challan.
	Complete method of manufacturing is required.
	• Stability study data is required as per the guidelines
	approved in 293RD meeting of Registration Board.

#### Decision: deferred for following shortcomings;

- 1. GMP inspection report within last 3 years is required.
- 2. Form-5 as per prescribed format of Drug Registering, Licensing & advertising is required along with preregistration fee challan.
- 3. Complete method of manufacturing is required.
- 4. Stability study data is required as per the guidelines approved in 293RD meeting of Registration Board.

	registration board.	
324.	Name and address of manufacturer/ Applicant	Macquin's International, F-2/H., P.T.C Industrial Complex,S.I.T.E,Karachi.
	Brand Name + Dosa5ge Form + Strength	D-LAN Capsule 30 mg
	Composition	Each Capsule Contains:
		Dexlansoprazole dual delayed released pellets (enteric
		coated) equivalent to Dexlansoprazole30 mg
	Diary No. Date of R & I & fee	Dy. No 11998 dated 06-03-2019; Rs.20,000/- dated 05-03-2019.
	Pharmacological Group	Proton pump inhibitor
	Type of Form	Form-5
	Finished product Specification	Manufacturer specification
	Pack size & Demanded Price	30's, as per SRO
	Approval status of product in Reference	USFDA approved, Delayed release Dexlansoprazole
	Regulatory Authorities	capsule 30 mg
	Me-too status	Razodex Capsule 30 mg by M/s Getz Pharma. (Reg.#086976)
	GMP status	Firm has not provided GMP within last 3 years.
	Remarks of the Evaluator	• GMP inspection report within last 3 years is required.
		• Form-5 as per prescribed format of Drug Registering,
		Licensing & advertising is required along with
		preregistration fee challan.
		Complete method of manufacturing is required.
		• Stability study data is required as per the guidelines
		approved in 293RD meeting of Registration Board
		•

#### **Decision:** deferred for following shortcomings;

- 1. GMP inspection report within last 3 years is required.
- 2. Form-5 as per prescribed format of Drug Registering, Licensing & advertising is required along with preregistration fee challan.
- 3. Complete method of manufacturing is required.
- 4. Stability study data is required as per the guidelines approved in 293RD meeting of Registration Board.

5.	Name and address of manufacturer/	Macquin's International, F-2/H., P.T.C Industrial
	Applicant	Complex,S.I.T.E,Karachi.
	Brand Name + Dosa5ge Form + Strength	Macopime Injection 1 G (I.V/I.M)
	Composition	Each vial Contain:
		Cefepime Hcl (with Sterile L-Arginine) eq.to
		Cefepime1G
	Diary No. Date of R & I & fee	Dy. No 11997 dated 06-03-2019; Rs.20,000/- dated 05-03-
		2019.
	Pharmacological Group	Antibiotic
	Type of Form	Form-5
	Finished product Specification	U.S.P spesification
	Pack size & Demanded Price	1's Glass Vial (USP type II), as per SRO
	Approval status of product in Reference	Cefipime hydrochloride 1gm Injection M/s Hospira, Inc.
	Regulatory Authorities	(USFDA approved)
	Me-too status	Nuxipim 1gm Injection by M/s Bosch, Reg. No. 44357
	GMP status	Firm has not provided GMP within last 3 years.
	Remarks of the Evaluator	• GMP inspection report within last 3 years is required.
		• Form-5 as per prescribed format of Drug Registering,
		Licensing & advertising is required along with
		preregistration fee challan.
		Complete method of manufacturing is required.
		Section approval letter of Dry Powder Injection
		(cephalosporin) is required.
	<b>Decision: Deferred for following shortco</b>	omings:

#### Deferred for following shortcomings;

- 1. GMP inspection report within last 3 years is required.
- 2. Form-5 as per prescribed format of Drug Registering, Licensing & advertising is required along with preregistration fee challan.
- 3. Complete method of manufacturing is required.
- 4. Section approval letter of Dry Powder Injection (Cephalosporin) from CLB is required.

	" Section approval letter of Bry 1 of	vaci injection (explanosporm) from EED is required:
326.	Name and address of manufacturer/ Applicant	Macquin's International, F-2/H., P.T.C Industrial Complex, S.I.T.E, Karachi.
	Brand Name + Dosa5ge Form + Strength	Macopime Injection 500 Mg (I.V/I.M)
	Composition	Each vial Contain:
		Cefepime Hcl (with Sterile L-Arginine) eq.to Cefipime
	Diary No. Date of R & I & fee	Dy. No 11996 dated 06-03-2019; Rs.20,000/- dated 05-03-2019.
	Pharmacological Group	Antibiotic
	Type of Form	Form-5
	Finished product Specification	U.S.P specification
	Pack size & Demanded Price	1's Glass Vial (USP type II), as per SRO
	Approval status of product in Reference	Cefipime hydrochloride 500mg Injection M/s Hospira,
	Regulatory Authorities	Inc. (USFDA approved)
	Me-too status	Nuxipim 500mg Injection by M/s Bosch, Reg. No. 44356
	GMP status	Firm has not provided GMP within last 3 years.
	Remarks of the Evaluator	• GMP inspection report within last 3 years is required.
		• Form-5 as per prescribed format of Drug Registering,
		Licensing & advertising is required along with preregistration fee challan.
		Complete method of manufacturing is required.
		• Section approval letter of Dry Powder Injection (cephalosporin) is required.

## **Decision: Deferred for following shortcomings;**

- GMP inspection report within last 3 years is required. 1.
- 2. Form-5 as per prescribed format of Drug Registering, Licensing & advertising is required along with preregistration fee challan.

	<ul><li>3. Complete method of manufacturi</li><li>4. Section approval letter of Dry Po</li></ul>	ing is required. wder Injection (Cephalosporin) from CLB is required.	
327.	Name and address of manufacturer/		
	Applicant  Brand Name + Dosa5ge Form + Strength	Macopime Injection 250 Mg (I.V/I.M)	
	Composition	Each vial Contain:	
	Composition	Cefepime Hcl (with Sterile L-Arginine) eq.to Cefipime	
	Diary No. Date of R & I & fee	Dy. No 11995 dated 06-03-2019; Rs.20,000/- dated 05-03-2019.	
	Pharmacological Group	Antibiotic	
	Type of Form	Form-5	
	Finished product Specification	U.S.P specification	
	Pack size & Demanded Price	1's Glass Vial (USP type II), as per SRO	
	Approval status of product in Reference	Approval status of product in Reference Regulatory	
	Regulatory Authorities	Authorities not confirmed.	
	Me-too status		
	GMP status	Firm has not provided GMP within last 3 years.	
	Remarks of the Evaluator	GMP inspection report within last 3 years is required.	
	Temans of the Evaluator	• Form-5 as per prescribed format of Drug Registering,	
		Licensing & advertising is required along with	
		preregistration fee challan.	
		Complete method of manufacturing is required.	
		• Section approval letter of Dry Powder Injection	
		(cephalosporin) is required.	
		Approval status of product in Reference Regulatory	
		Authorities not confirmed.	
	Decision: Deferred for following shortcomings;		
	1. GMP inspection report within last 3 years is required.		
		of Drug Registering, Licensing & advertising is required	
	along with preregistration fee cha		
	3. Complete method of manufacturi		
	4. Section approval letter of Dry Po	wder Injection (Cephalosporin) from CLB is required.	
	5. evidence of approval of applied formulation in reference regulatory authorities/agencies which were adopted by the Registration Board in its 275th meeting.		
328.	Name and address of manufacturer/	1 '	
	Applicant	Complex,S.I.T.E,Karachi.	
	Brand Name + Dosa5ge Form + Strength	ACIZOB Injection 4.5 G	
	Composition	Each 4.5 G vial Contain:	
		Piperacillin Sodium Eq to Piperacillin4 G	
		Tazobactam Sodium Eq to Tazobactam0.5 G	
	Diary No. Date of R & I & fee	Dy. No 11994 dated 06-03-2019; Rs.20,000/- dated 05-03-	
	. ,	2019.	
	Pharmacological Group	Antibiotic	
	Type of Form	Form-5	
	Finished product Specification	U.S.P specification	
	Pack size & Demanded Price	1's Glass Vial (USP type II), as per SRO	
	Approval status of product in Reference	Zosyn Injection USFDA Approved.	
		Zosyn injection OSFDA Approved.	
	Regulatory Authorities  Ma too status	Tooin Injection by Master International (December 2007)	
	Me-too status	Tacip Injection by Macter International (Reg#086976)	
	GMP status	Firm has not provided GMP within last 3 years.	
	Remarks of the Evaluator	• GMP inspection report within last 3 years is required.	
		• Form-5 as per prescribed format of Drug Registering,	
		Licensing & advertising is required along with	
		preregistration fee challan.	
		Complete method of manufacturing is required.	

1		
		• Section approval letter of Dry Powder Injection (cephalosporin) is required.
	<b>Decision: Deferred for following shortco</b>	
	1. GMP inspection report within las	
		of Drug Registering, Licensing & advertising is required
	along with preregistration fee cha	
	3. Complete method of manufacturi	
		wder Injection (Penicillin) from CLB is required.
329.	Name and address of manufacturer/	Macquin's International, F-2/H., P.T.C Industrial
	Applicant	Complex,S.I.T.E,Karachi.
	Brand Name + Dosa5ge Form + Strength	ACIZOB Injection 2.25 G
	Composition	Each 2.25 G vial Contain:
	Composition	Piperacillin Sodium Eq to Piperacillin2 G
		Tazobactam Sodium Eq to Tazobactam0.25 G
	Diary No. Date of R & I & fee	Dy. No 11993 dated 06-03-2019; Rs.20,000/- dated 05-03-
	Blary 100. Bute of R & T & Ice	2019.
	Pharmacological Group	Antibiotic
	Type of Form	Form-5
	Finished product Specification	U.S.P specification
	Pack size & Demanded Price	1's Glass Vial (USP type II), as per SRO
	Approval status of product in Reference	Zosyn Injection USFDA Approved.
	Regulatory Authorities	Takin Initedian 1-1 Martin International (Day #000076)
	Me-too status	Tacip Injection by Macter International (Reg#086976)
	GMP status	Firm has not provided GMP within last 3 years.
	Remarks of the Evaluator	GMP inspection report within last 3 years is required.
		• Form-5 as per prescribed format of Drug Registering,
		Licensing & advertising is required along with
		preregistration fee challan.
		Complete method of manufacturing is required.
		Section approval letter of Dry Powder Injection
		(cephalosporin) is required.
	<b>Decision: Deferred for following shortco</b>	
	1. GMP inspection report within last	
	2. Form-5 as per prescribed format	of Drug Registering, Licensing & advertising is required
	along with preregistration fee cha	
	3. Complete method of manufacturi	
	4. Section approval letter of Dry Po	wder Injection (Penicillin) From CLB is required.
330.	Name and address of manufacturer/	Sharooq Pharmaceuticals (Pvt)Ltd, Lahore
	Applicant	
	Brand Name + Dosage Form + Strength	Piracet Injection IM/IV
	Composition	Each ml contains:
		Piracetam1gm/5ml
	Diary No. Date of R & I & fee	Dy. No 682 dated 11-04-2014; Rs.20,000/-
	Pharmacological Group	Nootropic and psychostimulant
	Type of Form	Form-5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	12's, as per SRO.
	Approval status of product in Reference	Not verified during previous evaluation
	Regulatory Authorities	The following provides a valuation
	Me-too status	Cibrotam Injection 1gm of M/s Vision Pharmaceutical,
	THE too status	Islamabad.
	GMP status	GMP certificate issued to M/s Shrooq Pharma based
	Giii butub	upon evaluationconducted on 29-10-2021.
	Previous Remarks of the Evaluator	1st letter: 09 <sup>th</sup> March, 2018 Reminder letter:17th April,
	110 (10 do Remarks of the Lyaluator	2018• Evidence of approval of applied formulation in
		reference regulatory authorities/agencies which were
		reference regulatory authorities/agencies which were

	declared/approved by the Registration Board in its 275th
	meeting
Previous Decision of 282 <sup>nd</sup> meeting:	The case was presented in 282 <sup>nd</sup> meeting of DRB and Board decided to deferred the case for Evidence of approval of applied formulation in reference regulators authorities/agencies which were declared/approved by the Registration Board in its 275 <sup>th</sup> meeting.
Latest Firm Response:	Firm has submitted reply vide dairy No. 10008 dated 20 4-2022 and submitted international reference: Nootropil g Injection of UCB Pharma S.P.A, Italy
Remarks of Evaluator	

Decision: Deferred for submission of evidence of approval of applied formulation in 5ml ampoule in reference regulatory authorities/agencies which were Adopted by the Registration Board in its 275<sup>th</sup> meeting as the applied formulation is authorized by AIFA Italy as 12g/60ml solution for infusion and 3g/15ml oral and injectable solution for intravenous use.

### **B.** Cases of New section (Human):

### (a) M/s Schazoo Pharmaceutical Laboratories (Pvt) Ltd.

CLB in its 284<sup>th</sup> meeting held on 16<sup>th</sup> December 2021 has considered and approved the grant the following additional sections of the Schazoo Pharmacuticals Labortories (Pvt) Ltd, Kalawala stop, 20 Km,Lahore Jaranwala Road ,sheikhupura under DML No.000019 (Formulation):-

1- Tablet (Psychotropic)-New

SectionNo. Of Product appliedNo. of Molecule appliedTablet (Psychotropic)-New0302

331.	Name and address of manufacturer/ Applicant	M/s Schazoo Pharma, Jaranwala road, Paksitan
	Brand Name + Dosage Form + Strength	Onax 0.5mg Tablet
	Composition	Each film coated tablet contains:
	Diary No. Date of R & I & fee	Alprazolam0.5mg  Dy. No.52 ,9-09-2015, Rs.8,000/- (12-01-2005),  Rs.12,000/- (1-05-2015) <b>Duplicate file</b>
	Pharmacological Group	Sedative and Hypnotic (Tranquilizer)
	Type of Form	Form-5
	Finished product Specification	USP
	Pack size & Demanded Price	3x10's; Rs.162/pack, Rs.5.4/tablet
	Approval status of product in Reference Regulatory Authorities	USFDA
	Me-too status	Medilap by Medicorn Pharmaceuticals
	GMP status	New section
	Previous Remarks of the Evaluator	Fee challan photocopy is attached. Psychotropic tablet section is not confirmed. USFDA product is present without film coating.
	<b>Previous Decision of 273rd meeting:</b>	Deferred for the following reason:
		a) Confirmation for approval of psychotropic section by
		CLB.
		b) Clarification required whether the product is coated or otherwise.
	<b>Latest Firm Response:</b>	Firm has submitted reply vide R&I dairy No. 97774 dated 16-04-2022 along with copy of grant of new additional

		section (Psychotropic) approved by CLB in 284 <sup>th</sup> meeting of CLB.
	Remarks of Evaluator	<ul> <li>Initial application along with fee was submitted in 2005 and differential fee was submitted in 2015 along with duplicate dossier, and the case was placed in 273<sup>rd</sup> meeting of DRB. However, section approval has been granted by CLB in 284<sup>th</sup> meeting and section approval letter No F.1-50/84-Lic (pt) was issued on 10<sup>th</sup> May 2022.</li> <li>Firm has submitted preregistration variation fee of 7500 vide fee challan No.846330112 dated 12-05-2022 for label as 'uncoated Tablet'.</li> </ul>
	Decision: Approved with following revis	sed label Claim;
	Registration Board.	o verify fee challan as per decision of 285th meeting of
332.	Name and address of manufacturer/ Applicant	M/s Schazoo Pharma, Jaranwala road, Paksitan
	Brand Name + Dosage Form + Strength	Onax 0.25mg Tablet
	Composition	Each film coated tablet contains:
	Diaments Date CD 0 L 0 C	Alprazolam0.25mg
	Diary No. Date of R & I & fee	Dy. No.52 ,9-09-2015, Rs.8,000/- (12-01-2005),
	Pharmacological Group	Rs.12,000/- (1-05-2015) <b>Duplicate file</b> Sedative and Hypnotic (Tranquilizer)
	Type of Form	Form-5
	Finished product Specification	USP
	Pack size & Demanded Price	3x10's; Rs.116/pack, Rs.3.86/tablet
	Approval status of product in Reference Regulatory Authorities	USFDA
	Me-too status	Medilap by Medicorn Pharmaceuticals
	GMP status	New section
	Previous Remarks of the Evaluator	Fee challan photocopy is attached. Psychotropic tablet section is not confirmed. USFDA product is present without film coating.
	Previous Decision of 273 <sup>rd</sup> meeting:	Deferred for the following reason:  a) Confirmation for approval of psychotropic section by CLB. b) Clarification required whether the product is coated or otherwise.
	Latest Firm Response:	Firm has submitted reply vide R&I dairy No. 97774 dated 16-04-2022 along with copy of grant of new additional section (Psychotropic) approved by CLB in 284 <sup>th</sup> meeting of CLB.
	Remarks of Evaluator	• Initial application along with fee was submitted in 2005 and differential fee was submitted in 2015 along with duplicate dossier, and the case was placed in 273 <sup>rd</sup> meeting of DRB. However, section approval has been granted by CLB in 284 <sup>th</sup> meeting and section approval letter No F.1-50/84-Lic (pt) was issued on 10 <sup>th</sup> May 2022.

		• Firm has submitted preregistration variation fee of 7500
		vide fee challan No.44728184 dated 12-05-2022 for
		label as 'uncoated Tablet'.
	<b>Decision: Approved with following revis</b>	
	"Each Tablet Contains;	and the state of t
	Alprazolam 0.25 mg".	
	_	o verify fee challan as per decision of 285th meeting of
333.	Name and address of manufacturer/ Applicant	M/s Schazoo Pharma, Jaranwala road, Paksitan
	Brand Name + Dosage Form + Strength	Midolam 7.5 mg Tablets
	Composition	Each film coated tablet contains: Midazolam (as maleate)
	Diary No. Date of R & I & fee	Dy. No. 53, 07-01-2005 & Rs. 8000/- (07-01-2005) Rs. 12000/- (04-05-2015) <b>Duplicate file</b>
	Pharmacological Group	Sedative and Hypnotic (Tranquilizer)
	Type of Form	Form-5
	Finished product Specification	BP
	Pack size & Demanded Price	1 x 10 Tablets: Rs.58
	Approval status of product in Reference	Netherland
	Regulatory Authorities	
	Me-too status	Dormicum 7.5 mg Tablets Martin Dow Pharma
	GMP status	New section
	Previous Remarks of the Evaluator	Fee challan photocopy is attached.
	<b>Previous Decision of 272<sup>nd</sup> meeting:</b>	Deferred for Confirmation for approval of psychotropic section by CLB.
	Latest Firm Response:	Firm has submitted reply vide R&I dairy No. 97774 dated 16-04-2022 along with copy of grant of new additional section (Psychotropic) approved by CLB in 284 <sup>th</sup> meeting of CLB. Firm has also informed that their applied product is "Film Coated Tablet".
	Remarks of Evaluator	<ul> <li>Initial application along with fee was submitted in 2005 and differential fee was submitted in 2015 along with duplicate dossier, and the case was placed in 273<sup>rd</sup> meeting of DRB. However, section approval has been granted by CLB in 284<sup>th</sup> meeting and section approval letter No F.1-50/84-Lic (pt) was issued on 10<sup>th</sup> May 2022.</li> <li>The product in not in B.P, May be approved with</li> </ul>
	Decision: Approved. Registration Board 285 <sup>th</sup> meeting of Registration Board.	innovator specifications.  d further decided to verify fee challan as per decision of
(b) M/		77, Industrial Triangle,Kahuta Road,Islamabad.
		021 has considered and approved the grant the following
	•	a (Pvt.) Ltd. Plot No.206-207, Industrial Triangle, Kahuta
Road,	Islamabad under DML No.000651 (Formulat Gel (Preparation & filling)	
Section Gel (Ame	(Preparation & Filling) 08 anded section)	uct applied No. of Molecule applied 08
334.	Name and address of manufacturer/	Rotex Pharma (Pvt.) Ltd. Plot No.206-207, Industrial
	Applicant	Triangle,Kahuta Road,Islamabad.
	Brand Name + Dosage Form + Strength	KEMEX Gel 0.5 % w/w

	Composition	Each Gm Contains:
	Diama Na Data af D 0 1 0 fee	Piroxicam
	Diary No. Date of R & I & fee	Dy. No 16797 dated 07-03-2019; Rs.20,000/- dated 07-03-2019.
	Pharmacological Group	Analgesic & Anti-Inflammatory
	Type of Form	Form-5
	Finished product Specification	B. P
	Pack size & Demanded Price	25 Gm, As per SRO
	Approval status of product in Reference	Feldene Topical (EMA approved).
	Regulatory Authorities	
	Me-too status	Pcam Gel by Martin Dow (Reg. # 018718).
	GMP status	New section
	Remarks of Evaluator	
	Decision: Approved.	
335.	Name and address of manufacturer/	Rotex Pharma (Pvt.) Ltd. Plot No.206-207, Industrial
	Applicant	Triangle,Kahuta Road,Islamabad.
	Brand Name + Dosage Form + Strength	ISOTEN Gel
	Composition	Each Gm Contains:
		Erythromycin20 mg (2%)
		Tretinoin
	Diary No. Date of R & I & fee	Dy. No 14065 dated 07-03-2019; Rs.20,000/- dated 07-03-2019.
	Pharmacological Group	Antibacterial & Anti-acne
	Type of Form	Form-5
	Finished product Specification	Manufacturer specifications
	Pack size & Demanded Price	10 Gm, As per SRO
	Approval status of product in Reference	Not provided
	Regulatory Authorities	1
	Me-too status	Not Provided
	GMP status	New section
	Remarks of Evaluator	Evidence of applied formulation/drug already approved
		by DRAP (generic / me-too status) along with
		registration number, brand name and name of firm.
		• Evidence of approval of applied formulation in
		reference regulatory authorities/agencies which were
		adopted by the Registration Board
	Decision: Deferred for shortcomings;	adopted by the Registration Board
		g already approved by DRAP (generic / me-too status)
	along with registration number, brai	
	,	rmulation in reference regulatory authorities/agencies
	which were adopted by the Registrat	
	,	
336.	Name and address of manufacturer/	Rotex Pharma (Pvt.) Ltd. Plot No.206-207, Industrial
	Applicant	Triangle,Kahuta Road,Islamabad.
	Brand Name + Dosage Form + Strength	CLINZOL Gel
	Composition	Each Gm Contains:
		Clindamycin (as Phosphate)10 mg (1 %)
		Benzoyl Peroxide
	Diary No. Date of R & I & fee	
1	Dhamma a ala si a al Cuarra	2019.
	Pharmacological Group	Antibacterial / Keratolytic
	Type of Form  Finished product Specification	Form-5
	Finished product Specification	B.P Specifications
	Pack size & Demanded Price	10 & 15 Gm, As per SRO

	Approval status of product in Reference	BENZACLIN Gel by Valeant Pharms
	Regulatory Authorities	(USFDA Approved
	Me-too status	` **
	GMP status	DUAC gel by GSK New section
	Remarks of Evaluator	Innovators specification
		specification. Firm shall submit fee of Rs.7500/= for
	B&A/DRAP dated 13-07-2021.	duct specifications, as per notification No.F.7-11/2021-
337.	Name and address of manufacturer/	Rotex Pharma (Pvt.) Ltd. Plot No.206-207, Industrial
	Applicant	Triangle,Kahuta Road,Islamabad.
	Brand Name + Dosage Form + Strength	KAMOFEN Gel 2.5 %
	Composition	Each Gm Contains:
	•	Ketoprofen25 mg (2.5 %)
	Diary No. Date of R & I & fee	Dy. No 16794 dated 07-03-2019; Rs.20,000/- dated 07-03-
		2019.
	Pharmacological Group	Propanoic Acid
	Type of Form	Form-5
	Finished product Specification	B.P Specifications
	Pack size & Demanded Price	30 Gm, As per SRO
	Approval status of product in Reference	Ketoprofen 2.5% w/w Gel of Pinewood Healthcare
	Regulatory Authorities	(MHRA)
	Me-too status	Profenid 2.5% w/w Gel of Sanofi Aventis
	GMP status	New section
	Remarks of Evaluator	
	Decision: Approved.	
338.	Name and address of manufacturer/	Rotex Pharma (Pvt.) Ltd. Plot No.206-207, Industrial
	Applicant	Triangle,Kahuta Road,Islamabad.
	Brand Name + Dosage Form + Strength	Adzon Gel
	Composition	Each Gm Contains:
		Adapalene1mg (0.1% w/w)
		Benzoyl Peroxide25mg (2.5% w/w)
	Diary No. Date of R & I & fee	Dy.No. 14074 dated 07-03-2019 Rs.20,000/- 07-03-2019
	Pharmacological Group	Retinoids for topical use in acne
	Type of Form	Form-5
	Finished product Specification	manufacturer Specifications
	Pack size & Demanded Price	15gm, 30gm, 45gm, 60gm & 90gm; As per SRO
	Approval status of product in Reference	Epiduo gel of (USFDA Approved)
	Regulatory Authorities	
	Me-too status	Adalen e-B Gel of M/s Pharmatec (Reg#076683)
	GMP status	New section
	Remarks of Previous Evaluator IV	
	Decision of 296 <sup>th</sup> meeting	Deferred for consideration on its turn.
	Remarks of Evaluator	Application was placed before DRB in 296 <sup>th</sup> meeting
		wherein Board deferred the case for consideration on its
		turn, However firm has submitted new section approval
		letter no.F.1-53/2003-Lic (Vol-II) dated 10-03-2021 of
		Gel section approved by CLB in 179 <sup>th</sup> meeting held on 18 <sup>th</sup>
		Feb 2021. (Innovator specification)
		specification. Firm shall submit fee of Rs.7500/= for
	correction/pre-approval change/ in pro B&A/DRAP dated 13-07-2021.	duct specifications, as per notification No.F.7-11/2021-
339.	Name and address of manufacturer/	Rotex Pharma (Pvt.) Ltd. Plot No.206-207, Industrial
	Applicant Applicant	Triangle, Kahuta Road, Islamabad.
	**	Clintek Gel
	Brand Name + Dosage Form + Airengin	i Chillek Gel
	Brand Name + Dosage Form + Strength Composition	Clindamycin Phosphate12mg (1.2 % w/w)

		Tretinoin
	Diary No. Date of R & I & fee	Dy.No. 14070 dated 07-03-2019 Rs.20,000/- 07-03-2019
	Pharmacological Group	Anti-Acne (Treatment of acne vulgaris)
	Type of Form	Form-5
	Finished product Specification	manufacturer Specifications
	Pack size & Demanded Price	20 Gm, As per SRO
	Approval status of product in Reference	ZIANA (Gel) of USFDA approved
	Regulatory Authorities	Ziritiri (Gel) of OSI Div apploved
	Me-too status	Clin Gel 20g Gel of M/s Linta pharmaceuticals
	GMP status	New section
	Remarks of Previous Evaluator IV	
	Decision of 296 <sup>th</sup> meeting	Deferred for consideration on its turn.
	Remarks of Evaluator	Application was placed before DRB in 296 <sup>th</sup> meeting wherein Board deferred the case for consideration on its
		turn, however firm has submitted new section approval
		letter no.F.1-53/2003-Lic (Vol-II) dated 10-03-2021 of Gel section approved by CLB in 179 <sup>th</sup> meeting held on 18 <sup>th</sup>
		Feb 2021. (Innovator Spec)
		specification. Firm shall submit fee of Rs.7500/= for
	correction/pre-approval change/ in pro B&A/DRAP dated 13-07-2021.	duct specifications, as per notification No.F.7-11/2021-
340.	Name and address of manufacturer/	Rotex Pharma (Pvt.) Ltd. Plot No.206-207, Industrial
	Applicant	Triangle,Kahuta Road,Islamabad.
	Brand Name + Dosage Form + Strength	Dekzol 2% w/w Oral Gel
	Composition	Each Gm Contains:
		Miconazole20mg
	Diary No. Date of R & I & fee	Dy.No. 14072 dated 07-03-2019 Rs.20,000/- 07-03-2019
	Pharmacological Group	Anti-infective/ Antiseptic
	Type of Form	Form-5
	Finished product Specification	manufacturer Specifications
	Pack size & Demanded Price	20 Gm, As per SRO
	Approval status of product in Reference	Daktarin Oral Gel of MHRA approved
	Regulatory Authorities	**
	Me-too status	Miconit Oral Gel 2% of M/s Bio-Labs (Reg. # 054776)
	GMP status	New section
	Remarks of Previous Evaluator IV	
	Decision of 296 <sup>th</sup> meeting	Deferred for consideration on its turn.
	Remarks of Evaluator	Application was placed before DRB in 296 <sup>th</sup> meeting
		wherein Board deferred the case for consideration on its
		turn, however firm has submitted new section approval
		letter no.F.1-53/2003-Lic (Vol-II) dated 10-03-2021 of
		Gel section approved by CLB in 179 <sup>th</sup> meeting held on 18 <sup>th</sup>
		Feb 2021. (Innovators Specification)
	Decision: Approved with innovator's	specification. Firm shall submit fee of Rs.7500/= for
	correction/pre-approval change/ in pro B&A/DRAP dated 13-07-2021.	duct specifications, as per notification No.F.7-11/2021-
341.	Name and address of manufacturer/	Rotex Pharma (Pvt.) Ltd. Plot No.206-207, Industrial
	Applicant	Triangle,Kahuta Road,Islamabad.
	Brand Name + Dosage Form + Strength	Clintop Gel
	Composition	Each Gm Contains;
		Clindamycin as phosphate10mg
	Diary No. Date of R & I & fee	Dy.No. 14073 dated 07-03-2019 Rs.20,000/- 07-03-2019
	Pharmacological Group	Anti-infective/ Antiseptic
	Type of Form	Form-5
	Finished product Specification	USP Specifications
	1	1

Pack size & Demanded Price	10 gm,20 Gm, As per SRO
Approval status of product in Reference	RESIDERM 1% w/w GEL (MHRA approved)
Regulatory Authorities	
Me-too status	Sixil 10mg/g Gel of M/s Sigma Pharma (Reg # 079912)
GMP status	New section
Remarks of Previous Evaluator IV	
<b>Decision of 296<sup>th</sup> meeting</b>	Deferred for consideration on its turn.
Remarks of Evaluator	Application was placed before DRB in 296th meeting
	wherein Board deferred the case for consideration on its
	turn, however firm has submitted new section approval
	letter no.F.1-53/2003-Lic (Vol-II) dated 10-03-2021 of
	Gel section approved by CLB in 179 <sup>th</sup> meeting held on 18 <sup>th</sup>
	Feb 2021.
Decision : Approved.	

(c) M/s Welmark Pharmaceuticals, Plot. No. 122, Block B, Phase V, Industrial Estate, Hattar, KPK.

CLB in its 284<sup>th</sup> meeting held on 16<sup>th</sup> December, 2021 has considered and approved the grant the following additional section of M/s Welmark Pharmaceuticals, Plot. No. 122, Block B, Phase V, Industrial Estate, Hattar, KPK. under DML No.000641 (Formulation): -

1- Tablet (Psychotropic)

SectionNo. of ProductsNo. of MoleculesTablet (Psychotropic)33

342.	Name and address of manufacturer/	M/s Welmark Pharmaceuticals, Plot. No. 122, Block B,
	Applicant	Phase V, Industrial Estate, Hattar, KPK.
	Brand Name + Dosage Form + Strength	Diazep 10mg Tablet
	Composition	Each Tablet Contains:
	•	Diazepam10mg
	Diary No. Date of R & I & fee	Dy.No. 16315 dated 07-03-2019 Rs.20,000/- 07-03-2019
	Pharmacological Group	Anti- psychotic
	Type of Form	Form-5
	Finished product Specification	USP Specifications
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities	USFDA Approved
	Me-too status	Diazepam 10mg Tab of M/s Star Labs Lahore 005619
	GMP status	New section
	Remarks of Previous Evaluator XIII	
	Decision of 296 <sup>th</sup> meeting	Deferred for consideration on its turn.
	Remarks of Evaluator	Application was placed before DRB in 296 <sup>th</sup> meeting wherein Board deferred the case for consideration on its turn, however firm has submitted new section approval letter no.F.5-1/2016-Lic dated 5-4-2022 for Tablet (Psychotropic) section approved by CLB in 284th <sup>th</sup> meeting held on 16 <sup>th</sup> December 2022.
	Decision: Approved.	
343.	Name and address of manufacturer/	M/s Welmark Pharmaceuticals, Plot. No. 122, Block B,
	Applicant	Phase V, Industrial Estate, Hattar, KPK.
	Brand Name + Dosage Form + Strength	Clon 2mg Tablet
	Composition	Each Tablet Contains:
		Clonazepam2mg
	Diary No. Date of R & I & fee	Dy.No. 16314 dated 07-03-2019 Rs.20,000/- 07-03-2019

	Pharmacological Group	Anti- epileptic
	Type of Form	Form-5
	Finished product Specification	USP Specifications
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities	USFDA Approved
	Me-too status	Clonatril Tablet of M/s Polyfine Chempharma, Peshawar 024098
	CMD status	
	GMP status  Remarks of Previous Evaluator XIII	New section
		D.C. 1.C. 11 (1)
	Decision of 296 <sup>th</sup> meeting	Deferred for consideration on its turn.
	Remarks of Evaluator	Application was placed before DRB in 296 <sup>th</sup> meeting wherein Board deferred the case for consideration on its turn, however firm has submitted new section approval letter no.F.5-1/2016-Lic dated 5-4-2022 for Tablet (Psychotropic) section approved by CLB in 284th <sup>th</sup> meeting held on 16 <sup>th</sup> December 2022.
	Decision: Approved.	-
344.	Name and address of manufacturer/ Applicant	M/s Welmark Pharmaceuticals, Plot. No. 122, Block B, Phase V, Industrial Estate, Hattar, KPK.
	Brand Name + Dosage Form + Strength	Alap 0.5mg Tablet
	Composition	Each Tablet Contains: Alprazolam0.5mg
	Diary No. Date of R & I & fee	Dy.No. 16313 dated 07-03-2019 Rs.20,000/- 07-03-2019
	Pharmacological Group	Anti- psychotic
	Type of Form	Form-5
	Finished product Specification	Manufacturer Specifications
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities	USFDA Approved
	Me-too status	Alprazolam 0.5 mg Tablets of M/s Heal Pharma Peshawar, 079391
	GMP status	New section
	Remarks of Previous Evaluator XIII	
	Decision of 296 <sup>th</sup> meeting	Deferred for consideration on its turn.
	Remarks of Evaluator	Application was placed before DRB in 296 <sup>th</sup> meeting wherein Board deferred the case for consideration on its turn, however firm has submitted new section approval letter no.F.5-1/2016-Lic dated 5-4-2022 for Tablet (Psychotropic) section approved by CLB in 284th <sup>th</sup> meeting held on 16 <sup>th</sup> December 2022.
		ification. Firm shall submit fee of Rs.7500/= for duct specifications, as per notification No.F.7-11/2021-

#### C. Deferred cases (Human)

### M/s Obsons Pharmaceuticals 209-S, Industrial Estate, Kotlakhpat, Lahore

The Central Licensing Board in its 280th meeting held on 26th & 27th April 2021 has cancelled the Drug Manufacturing License No. 000416 by way of (formulation) of M/s Obsons Pharmaceuticals, 209-S, Quaid-e-Azam Industrial Estate, Kot lakhpat, Lahore, conveyed vide letter No. F.1-5/84-Lic (Vol-IV) dated 25th May 2021 by Secretary Central Licensing Board. Later on, the Appellate Board in its meeting No. 156th held on 31st August, 2021 decided as: The Board after hearing the arguments and pursuing record of case, decided to give final opportunity of two years period to the firm for submission of new lay out plan for approval of the Central Licensing Board. The decision of cancellation of Drug Manufacturing License by the Central Licensing

Board is set aside. Furthermore, the firm has been granted GMP certificate dated 07-03-2022 based on inspection conducted on 22-02-2022.

345.	Name and address of manufacturer/	M/s Obsons Pharmaceuticals. 209-S, Quaid e Azam
	Applicant	Industrial Estate, Kotlakhpat, Lahore, Pakistan
	Brand Name + Dosage Form + Strength	Azaltic Tablet 500mg
	Composition	Each Film Coated Tablet Contains:
		Azithromycin as Dihydrate500mg
	Diary No. Date of R & I & fee	Dy.No 3860 dated 28-01-2019 Rs.20,000/- Dated 28-01-
		2019
	Pharmacological Group	Antibiotic (Macrolide)
	Type of Form	Form-5
	Finished product Specification	USP
	Pack size & Demanded Price	6"s: As per SRO
	Approval status of product in Reference Regulatory Authorities	Azithromycin tablet of (MHRA approved)
	Me-too status	Azic 500mg Tablet by M/s NabiQasim
	GMP status	The firm has been granted GMP certificate based on
		inspection conducted on 22-02-2022.
	Remarks of Previous Evaluator VI	
	Decision of 295 <sup>th</sup> meeting	Registration Board referred the case to QA & LT division for updated status of GMP.
	Remarks of Evaluator	
	Decision: Approved.	
346.	Name and address of manufacturer/	M/s Obsons Pharmaceuticals. 209-S, Quaid e Azam
	Applicant	Industrial Estate, Kotlakhpat, Lahore, Pakistan
	Brand Name + Dosage Form + Strength	Azaltic Suspension 200mg/5ml
	Composition	Each 5ml suspension contains:
		Azithromycin as Dihydrate200mg
	Diary No. Date of R & I & fee	Dy.No 3861 dated 28-01-2019 Rs.20,000/- Dated 28-01-2019
	Pharmacological Group	Antibiotic (Macrolide)
	Type of Form	Form-5
	Finished product Specification	USP
	Pack size & Demanded Price	15 ml: As per SRO
	Approval status of product in Reference	Zithromax Powder for Oral Suspension 200mg/5ml of
	Regulatory Authorities	MHRA approved
	Me-too status	Azomax Dry Suspension by M/s Novartis (Reg#022201),
	GMP status	The firm has been granted GMP certificate based on
		inspection conducted on 22-02-2022.
	Remarks of Previous Evaluator VI	
	Decision of 295 <sup>th</sup> meeting	Registration Board referred the case to QA & LT division for updated status of GMP.
	Remarks of Evaluator	
	Decision: Approved.	
347.	Name and address of manufacturer/	M/s Obsons Pharmaceuticals. 209-S, Quaid e Azam
	Applicant	Industrial Estate, Kotlakhpat, Lahore, Pakistan
	Brand Name + Dosage Form + Strength	Obpride 1mg Tablet
	Composition	Each film coated Tablet Contains:
		Cinitapride (as hydrogen tartrate)1mg
	Diary No. Date of R & I & fee	Dy.No 34723 dated 18-10-2018 Rs.20,000/-
	Pharmacological Group	anti-emetic
		Propulsives
	Type of Form	Form-5
1	Finished product Specification	Manufacturer"s Specification

	Pack size & Demanded Price	10"s: Rs 190/-
	Approval status of product in Reference	Approved in Sweden
	Regulatory Authorities	ripproved in 5 weden
	Me-too status	Sitip 1mg Tablet of Sami Pharma.
	GMP status	The firm has been granted GMP certificate based on
	OMI status	inspection conducted on 22-02-2022.
	Remarks of Previous Evaluator VIII	Inspection conducted on 22 of 2022.
	Decision of 295 <sup>th</sup> meeting	Registration Board referred the case to QA & LT division
	beesson of 250 meeting	for updated status of GMP.
	Remarks of Evaluator	Tor apatitude states of Chir.
	Decision: Approved.	
348.	Name and address of manufacturer/	M/s Obsons Pharmaceuticals. 209-S, Quaid e Azam
	Applicant	Industrial Estate, Kotlakhpat, Lahore, Pakistan
	Brand Name + Dosage Form + Strength	Obiva 5mg Tablet
	Composition	Each Film Coated Tablet Contains:
		Ivabradine as hydrochloride5mg
	Diary No. Date of R & I & fee	Dy. No. 34724 dated 18-10-2018 Rs.20,000/-
	Pharmacological Group	Heart-rate-lowering agent
	Type of Form	Form-5
	Finished product Specification	Manufacturer's Specification
	Pack size & Demanded Price	14"s: Rs 280/-
	Approval status of product in Reference	Approved in US-FDA
	Regulatory Authorities	**
	Me-too status	Iva Tablet 5 mg of CSH, Pharmaceuticals-North (Pvt.)
		Ltd.
	GMP status	The firm has been granted GMP certificate based on
	Sill status	inspection conducted on 22-02-2022.
	Remarks of Previous Evaluator VIII	
	Decision of 295 <sup>th</sup> meeting	Registration Board referred the case to QA & LT division
		registration board referred the case to off & L1 division
	200min of 250 mooning	for updated status of GMP.
	Remarks of Evaluator	
349.	Remarks of Evaluator	
349.	Remarks of Evaluator Decision: Approved.	for updated status of GMP.
349.	Remarks of Evaluator  Decision: Approved.  Name and address of manufacturer/	for updated status of GMP.  M/s Obsons Pharmaceuticals. 209-S, Quaid e Azam
349.	Remarks of Evaluator  Decision: Approved.  Name and address of manufacturer/ Applicant	for updated status of GMP.  M/s Obsons Pharmaceuticals. 209-S, Quaid e Azam Industrial Estate, Kotlakhpat, Lahore, Pakistan
349.	Remarks of Evaluator Decision: Approved.  Name and address of manufacturer/ Applicant  Brand Name + Dosage Form + Strength Composition	for updated status of GMP.  M/s Obsons Pharmaceuticals. 209-S, Quaid e Azam Industrial Estate, Kotlakhpat, Lahore, Pakistan Obprofen Suspension 100mg /5ml Each 5ml contains: Ibuprofen
349.	Remarks of Evaluator  Decision: Approved.  Name and address of manufacturer/ Applicant  Brand Name + Dosage Form + Strength	for updated status of GMP.  M/s Obsons Pharmaceuticals. 209-S, Quaid e Azam Industrial Estate, Kotlakhpat, Lahore, Pakistan  Obprofen Suspension 100mg /5ml  Each 5ml contains: Ibuprofen
349.	Remarks of Evaluator  Decision: Approved.  Name and address of manufacturer/ Applicant  Brand Name + Dosage Form + Strength  Composition  Diary No. Date of R & I & fee	for updated status of GMP.  M/s Obsons Pharmaceuticals. 209-S, Quaid e Azam Industrial Estate, Kotlakhpat, Lahore, Pakistan  Obprofen Suspension 100mg /5ml  Each 5ml contains: Ibuprofen100mg  Duplicate: 04-11-2015 Fee. 20,000/-, 03-11-2015
349.	Remarks of Evaluator  Decision: Approved.  Name and address of manufacturer/ Applicant  Brand Name + Dosage Form + Strength  Composition  Diary No. Date of R & I & fee  Pharmacological Group	for updated status of GMP.  M/s Obsons Pharmaceuticals. 209-S, Quaid e Azam Industrial Estate, Kotlakhpat, Lahore, Pakistan  Obprofen Suspension 100mg /5ml  Each 5ml contains: Ibuprofen
349.	Remarks of Evaluator  Decision: Approved.  Name and address of manufacturer/ Applicant  Brand Name + Dosage Form + Strength  Composition  Diary No. Date of R & I & fee  Pharmacological Group  Type of Form	for updated status of GMP.  M/s Obsons Pharmaceuticals. 209-S, Quaid e Azam Industrial Estate, Kotlakhpat, Lahore, Pakistan  Obprofen Suspension 100mg /5ml  Each 5ml contains: Ibuprofen
349.	Remarks of Evaluator  Decision: Approved.  Name and address of manufacturer/ Applicant  Brand Name + Dosage Form + Strength  Composition  Diary No. Date of R & I & fee  Pharmacological Group  Type of Form  Finished product Specification	for updated status of GMP.  M/s Obsons Pharmaceuticals. 209-S, Quaid e Azam Industrial Estate, Kotlakhpat, Lahore, Pakistan  Obprofen Suspension 100mg /5ml  Each 5ml contains: Ibuprofen100mg  Duplicate: 04-11-2015  Fee. 20,000/-, 03-11-2015  NSAIDs  Form-5  USP specifications
349.	Remarks of Evaluator  Decision: Approved.  Name and address of manufacturer/ Applicant  Brand Name + Dosage Form + Strength Composition  Diary No. Date of R & I & fee  Pharmacological Group Type of Form Finished product Specification Pack size & Demanded Price	for updated status of GMP.  M/s Obsons Pharmaceuticals. 209-S, Quaid e Azam Industrial Estate, Kotlakhpat, Lahore, Pakistan  Obprofen Suspension 100mg /5ml  Each 5ml contains: Ibuprofen100mg  Duplicate: 04-11-2015 Fee. 20,000/-, 03-11-2015  NSAIDs  Form-5  USP specifications As per SRO
349.	Remarks of Evaluator  Decision: Approved.  Name and address of manufacturer/ Applicant  Brand Name + Dosage Form + Strength Composition  Diary No. Date of R & I & fee  Pharmacological Group Type of Form Finished product Specification Pack size & Demanded Price Approval status of product in Reference	for updated status of GMP.  M/s Obsons Pharmaceuticals. 209-S, Quaid e Azam Industrial Estate, Kotlakhpat, Lahore, Pakistan Obprofen Suspension 100mg /5ml Each 5ml contains: Ibuprofen
349.	Remarks of Evaluator  Decision: Approved.  Name and address of manufacturer/ Applicant  Brand Name + Dosage Form + Strength Composition  Diary No. Date of R & I & fee  Pharmacological Group Type of Form Finished product Specification Pack size & Demanded Price Approval status of product in Reference Regulatory Authorities	for updated status of GMP.  M/s Obsons Pharmaceuticals. 209-S, Quaid e Azam Industrial Estate, Kotlakhpat, Lahore, Pakistan  Obprofen Suspension 100mg /5ml  Each 5ml contains: Ibuprofen100mg  Duplicate: 04-11-2015  Fee. 20,000/-, 03-11-2015  NSAIDs  Form-5  USP specifications  As per SRO  IBuprofen 100mg/5ml Oral Suspension of (MHRA Approved)
349.	Remarks of Evaluator  Decision: Approved.  Name and address of manufacturer/ Applicant  Brand Name + Dosage Form + Strength Composition  Diary No. Date of R & I & fee  Pharmacological Group Type of Form Finished product Specification Pack size & Demanded Price Approval status of product in Reference Regulatory Authorities Me-too status	for updated status of GMP.  M/s Obsons Pharmaceuticals. 209-S, Quaid e Azam Industrial Estate, Kotlakhpat, Lahore, Pakistan  Obprofen Suspension 100mg /5ml  Each 5ml contains: Ibuprofen100mg  Duplicate: 04-11-2015  Fee. 20,000/-, 03-11-2015  NSAIDs  Form-5  USP specifications  As per SRO  IBuprofen 100mg/5ml Oral Suspension of (MHRA Approved)  Nuprin 100mg Suspension M/s Reign Pharma
349.	Remarks of Evaluator  Decision: Approved.  Name and address of manufacturer/ Applicant  Brand Name + Dosage Form + Strength Composition  Diary No. Date of R & I & fee  Pharmacological Group Type of Form Finished product Specification Pack size & Demanded Price Approval status of product in Reference Regulatory Authorities	for updated status of GMP.  M/s Obsons Pharmaceuticals. 209-S, Quaid e Azam Industrial Estate, Kotlakhpat, Lahore, Pakistan  Obprofen Suspension 100mg /5ml  Each 5ml contains: Ibuprofen
349.	Remarks of Evaluator  Decision: Approved.  Name and address of manufacturer/ Applicant  Brand Name + Dosage Form + Strength Composition  Diary No. Date of R & I & fee  Pharmacological Group Type of Form Finished product Specification Pack size & Demanded Price Approval status of product in Reference Regulatory Authorities Me-too status	for updated status of GMP.  M/s Obsons Pharmaceuticals. 209-S, Quaid e Azam Industrial Estate, Kotlakhpat, Lahore, Pakistan  Obprofen Suspension 100mg /5ml  Each 5ml contains: Ibuprofen100mg  Duplicate: 04-11-2015  Fee. 20,000/-, 03-11-2015  NSAIDs  Form-5  USP specifications  As per SRO  IBuprofen 100mg/5ml Oral Suspension of (MHRA Approved)  Nuprin 100mg Suspension M/s Reign Pharma  The firm has been granted GMP certificate dated 07-03-2022 based on inspection conducted on 22-02-2022.
349.	Remarks of Evaluator  Decision: Approved.  Name and address of manufacturer/ Applicant  Brand Name + Dosage Form + Strength  Composition  Diary No. Date of R & I & fee  Pharmacological Group  Type of Form  Finished product Specification  Pack size & Demanded Price  Approval status of product in Reference Regulatory Authorities  Me-too status  GMP status	for updated status of GMP.  M/s Obsons Pharmaceuticals. 209-S, Quaid e Azam Industrial Estate, Kotlakhpat, Lahore, Pakistan  Obprofen Suspension 100mg /5ml  Each 5ml contains: Ibuprofen100mg  Duplicate: 04-11-2015  Fee. 20,000/-, 03-11-2015  NSAIDs  Form-5  USP specifications  As per SRO  IBuprofen 100mg/5ml Oral Suspension of (MHRA Approved)  Nuprin 100mg Suspension M/s Reign Pharma  The firm has been granted GMP certificate dated 07-03-2022 based on inspection conducted on 22-02-2022. (Valid for two years)
349.	Remarks of Evaluator  Decision: Approved.  Name and address of manufacturer/ Applicant  Brand Name + Dosage Form + Strength Composition  Diary No. Date of R & I & fee  Pharmacological Group Type of Form Finished product Specification Pack size & Demanded Price Approval status of product in Reference Regulatory Authorities Me-too status	for updated status of GMP.  M/s Obsons Pharmaceuticals. 209-S, Quaid e Azam Industrial Estate, Kotlakhpat, Lahore, Pakistan  Obprofen Suspension 100mg /5ml  Each 5ml contains: Ibuprofen100mg  Duplicate: 04-11-2015  Fee. 20,000/-, 03-11-2015  NSAIDs  Form-5  USP specifications  As per SRO  IBuprofen 100mg/5ml Oral Suspension of (MHRA Approved)  Nuprin 100mg Suspension M/s Reign Pharma  The firm has been granted GMP certificate dated 07-03-2022 based on inspection conducted on 22-02-2022.  (Valid for two years)  The duplicate file was received from section vide letter
349.	Remarks of Evaluator  Decision: Approved.  Name and address of manufacturer/ Applicant  Brand Name + Dosage Form + Strength  Composition  Diary No. Date of R & I & fee  Pharmacological Group  Type of Form  Finished product Specification  Pack size & Demanded Price  Approval status of product in Reference Regulatory Authorities  Me-too status  GMP status  Remarks of Previous Evaluator	for updated status of GMP.  M/s Obsons Pharmaceuticals. 209-S, Quaid e Azam Industrial Estate, Kotlakhpat, Lahore, Pakistan  Obprofen Suspension 100mg /5ml  Each 5ml contains: Ibuprofen100mg  Duplicate: 04-11-2015  Fee. 20,000/-, 03-11-2015  NSAIDs  Form-5  USP specifications  As per SRO  IBuprofen 100mg/5ml Oral Suspension of (MHRA Approved)  Nuprin 100mg Suspension M/s Reign Pharma  The firm has been granted GMP certificate dated 07-03-2022 based on inspection conducted on 22-02-2022. (Valid for two years)  The duplicate file was received from section vide letter No. F. 8-6/2013-Reg-V.
349.	Remarks of Evaluator  Decision: Approved.  Name and address of manufacturer/ Applicant  Brand Name + Dosage Form + Strength  Composition  Diary No. Date of R & I & fee  Pharmacological Group  Type of Form  Finished product Specification  Pack size & Demanded Price  Approval status of product in Reference Regulatory Authorities  Me-too status  GMP status	for updated status of GMP.  M/s Obsons Pharmaceuticals. 209-S, Quaid e Azam Industrial Estate, Kotlakhpat, Lahore, Pakistan  Obprofen Suspension 100mg /5ml  Each 5ml contains: Ibuprofen100mg  Duplicate: 04-11-2015  Fee. 20,000/-, 03-11-2015  NSAIDs  Form-5  USP specifications  As per SRO  IBuprofen 100mg/5ml Oral Suspension of (MHRA Approved)  Nuprin 100mg Suspension M/s Reign Pharma  The firm has been granted GMP certificate dated 07-03-2022 based on inspection conducted on 22-02-2022.  (Valid for two years)  The duplicate file was received from section vide letter No. F. 8-6/2013-Reg-V.  Deferred for updated status of GMP of the firm from QA
349.	Remarks of Evaluator  Decision: Approved.  Name and address of manufacturer/ Applicant  Brand Name + Dosage Form + Strength Composition  Diary No. Date of R & I & fee  Pharmacological Group Type of Form Finished product Specification Pack size & Demanded Price Approval status of product in Reference Regulatory Authorities Me-too status  GMP status  Remarks of Previous Evaluator  Decision of 290th meeting	for updated status of GMP.  M/s Obsons Pharmaceuticals. 209-S, Quaid e Azam Industrial Estate, Kotlakhpat, Lahore, Pakistan  Obprofen Suspension 100mg /5ml  Each 5ml contains: Ibuprofen100mg  Duplicate: 04-11-2015  Fee. 20,000/-, 03-11-2015  NSAIDs  Form-5  USP specifications  As per SRO  IBuprofen 100mg/5ml Oral Suspension of (MHRA Approved)  Nuprin 100mg Suspension M/s Reign Pharma  The firm has been granted GMP certificate dated 07-03-2022 based on inspection conducted on 22-02-2022. (Valid for two years)  The duplicate file was received from section vide letter No. F. 8-6/2013-Reg-V.
349.	Remarks of Evaluator  Decision: Approved.  Name and address of manufacturer/ Applicant  Brand Name + Dosage Form + Strength  Composition  Diary No. Date of R & I & fee  Pharmacological Group  Type of Form  Finished product Specification  Pack size & Demanded Price  Approval status of product in Reference Regulatory Authorities  Me-too status  GMP status  Remarks of Previous Evaluator	for updated status of GMP.  M/s Obsons Pharmaceuticals. 209-S, Quaid e Azam Industrial Estate, Kotlakhpat, Lahore, Pakistan  Obprofen Suspension 100mg /5ml  Each 5ml contains: Ibuprofen100mg  Duplicate: 04-11-2015  Fee. 20,000/-, 03-11-2015  NSAIDs  Form-5  USP specifications  As per SRO  IBuprofen 100mg/5ml Oral Suspension of (MHRA Approved)  Nuprin 100mg Suspension M/s Reign Pharma  The firm has been granted GMP certificate dated 07-03-2022 based on inspection conducted on 22-02-2022.  (Valid for two years)  The duplicate file was received from section vide letter No. F. 8-6/2013-Reg-V.  Deferred for updated status of GMP of the firm from QA

350.	Name and address of manufacturer/	M/s Weather Folds Pharmaceuticals. Plot # 69, Phase-II,
350.	Applicant Applicant	Industrial Estate, Hattar"
	Brand Name + Dosage Form + Strength	Itrafon 100mg Capsule
	Composition	Each Capsule Contains:
	Composition	Itraconazole100mg"
		(as IR Pellets)
	Diary No. Date of R & I & fee	Dy.No 29142 dated 31-08-2018 Rs.20,000/- 31-08-2018
	Pharmacological Group	Antifungal
	Type of Form	Form-5
	Finished product Specification	As per Innovator's Specification
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities	Approved in US-FDA
	Me-too status	Itrax Capsule 100mg of Ferozsons Labs.
	GMP status	GMP inspection conducted on 20-02-2019 recommends grant of GMP.
	Remarks of Previous Evaluator	COA, GMP of pellets manufacturer and stability studies of three batches of pellets conducted in accordance with
	Decision of 292 <sup>nd</sup> meeting	zone IV-A conditions.  Deferred submission of COA, GMP of pellets
	Decision of 292 meeting	Deferred submission of COA, GMP of pellets manufacturer and stability studies of three batches of
		pellets conducted in accordance with zone IV-A
		conditions.
	Remarks of Evaluator	• Firm has submitted letter vide dairy No .6482 dated 09-03-2022 and submitted the documents including Source of pellets as "M/s Vision Pharmaceuticals (Pvt)Ltd.
		<ul> <li>Islamabad" and COA of Itraconazole IR pellets 22 % along with stability data of 03 batches.</li> <li>Last available GMP inspection was conducted on 20-</li> </ul>
		02-2019.
	Decision: Approved.	
351.	Name and address of manufacturer/ Applicant	M/s Iceberg Pharmaceuticals (Pvt) Ltd, Plot # 144, Nowshera Industrial Estate, Risalpur, KPK
	Brand Name + Dosage Form + Strength	Icedol Tablet
	Composition	Each tablet contains:
		Paracetamol500mg
		Caffeine65mg
		Chlorpheniramin02 mg
	Diary No. Date of R & I & fee	diary No 209 dated 05-06-2015 Rs20,000
	Pharmacological Group	Analgesic
	Type of Form	Form-5
	Finished product Specification	Manufacturers Specifications
	Pack size & Demanded Price	10s & 10x20, tablets blister Pack, As per SRO
	Approval status of product in Reference Regulatory Authorities	Not provided
	Me-too status	Amidol by M/s Bloom Pharma
	GMP status	
	Remarks of Previous Evaluator	
	Decision of 253 <sup>rd</sup> meeting	Deferred for the confirmation of approval by reference Regulatory authorities.
	Remarks of Evaluator	Firm has submitted reply vide dairy No. 10596 dated 26-04-2022 and submitted revised form -5 mentioning revised label claim and composition as under:
		Composition Each Tablet Contains:

	Paracetamol500 mg
	Caffeine65 mg
Pharmacological	Anti-Pyretic/Analgesic
Group	
Finished Product	Manufacturer Specification
specification	
Pack size &	10*10's,10*20's, As per SRO
Demanded Price	
Approval status of	MHRA approved, Paracetamol
product in	Extra of Wrafton Labotories,UK.
Reference	
Regulatory	
Authorities	
Me-too status	Acetofeb Extra Tablets of M/s
	Vision Pharmaceuticals
	(Reg.#038900)
GMP status	DML renewal inspection has been
	conducted dated 11-01-22
	concluded that firm is operating at
	satisfactory level of GMP and
	recommends grant of renewal of
	DML.

- Firm has not submitted preregistration fee for change /standardization of composition.
- Undertakings/commitments to follow innovator brands are not provided.

Decision: Approved with following revised label claim;

"Each Tablet Contains:

Paracetamol.....500 mg

Caffeine.....65 mg".

• Firm shall submit fee of Rs.30000/= for correction/pre-approval change/ in composition, as per notification No.F.7-11/2021-B&A/DRAP dated 13-07-2021.

**D.** Registration Applications Veterinary (New)

352.	Name and address of manufacturer/ Applicant	Mylab (Pvt) Ltd. Khanqah sharif, Bahawalpur.
	Brand Name + Dosage Form + Strength	AMPIRO-HI Water Soluble Powder
	Composition	Each Gram Contains:
		Amprolium Hcl600 mg
	Diary No. Date of R & I & fee	Dy. No 820 dated 05-01-2018; Rs.20,000/- dated 22-10-2017
	DI 1 ' 1 C	Dy. No 267 dated 04-01-2022 ( <b>Duplicate Dossier</b> )
	Pharmacological Group	Anticoccidial
	Type of Form	Form - 5
	Finished product Specification	U.S.P Specifications
	Pack size & Demanded Price	100 G,500 G,1000 G,5 kg,100 kg. As per Policy
	Approval status of product in Reference	Not Applicable
	Regulatory Authorities	
	Me-too status	BIO-AMPROL 60 POWDER, 063773, MALLARD
		PHARMACEUTICAL (PVT) LTD. MULTAN.
	GMP status	Panel GMP inspection was conducted on 24-02-2021 and
		25-02-2021 and concluded as " In view of above
		inspection proceedings and facilities verified such as
		company profile, building ,production, in process controls,
		quality control testing, machinery/equipment, material

	Remarks of the Evaluator	management , air handling, water treatment system , personnel and documentation etc. the firm M/s Mylab (pvt) Ltd. Khanqah sharif Bahawalpur , was found to be operating at a satisfactory level of GMP compliance for the following sections only, oral Liquid (General)II and Aerosol section were under maintenance and were not functional at time of inspection":  Liquid Injection Section (General)  Oral Powder Premix Section (General)  Oral Liquid (General)(I)  Liquid Injection (penicillin)  Dry Powder Injection (penicillin)  Oral Powder (penicillin)  Liquid Injection (Steroid)  On Form 5 enclosure, firm has mentioned dosage form as Injection  where as provided route route of administration as
		where as provided route of administration as of administration mentioned as oral route, firm is required to clarify and provide revised form -5 enclosure along with preregistration variation fee challan.  • Complete Outline of manufacturing method.  route of administration as "oral" along with preregistration variation fee of 30000 vide challan No.44276263144 dated 15-05-2022.  • Firm has also submitted manufacturing method/outline and finished good testing
		Complete finished good testing specifications mentioning assay of finished products.      Specifications as USP specification.
	Decision: Approved. Registration Board 285 <sup>th</sup> meeting of Registration Board.	d further decided to verify fee challan as per decision of
353.		Mylab (Pvt) Ltd. Khanqah sharif, Bahawalpur.
	Brand Name + Dosage Form + Strength	VITAMEC Injection
	Composition	Each Injection Contains:
		Ivermectin10.00 mg
		Vitamin A40000 IU
		Vitamin E10 mg
		Selenium500 mcg
	Diary No. Date of R & I & fee	Dy. No 12154 dated 06-03-2019; Rs.20,000/- dated 05-03-2019
	Pharmacological Group	Anthelminthic, Multivitamin and mineral.
	Type of Form	Form - 5
	Finished product Specification	Innovator's Specifications.
	Pack size & Demanded Price	50 ml, As per Policy
	Approval status of product in Reference Regulatory Authorities	Not Applicable
	Me-too status	ARMEC FORTE INJECTION, 063593, ZAKFAS PHARMACEUTICALS (PVT) LTD, MULTAN.
	GMP status	Panel GMP inspection was conducted on 24-02-2021 and 25-02-2021 and concluded as "In view of above inspection proceedings and facilities verified such as company profile, building production, in process controls, quality control testing, machinery/equipment, material

		management, air handling, water treatment system personnel and documentation etc. the firm M/s Myla (pvt) Ltd. Khanqah sharif Bahawalpur, was found to be operating at a satisfactory level of GMP compliance for the following sections only, oral Liquid (General)II and Aerosol section were under maintenance and were not functional at time of inspection":  Liquid Injection Section (General)  Oral Powder Premix Section (General)  Oral Liquid (General)(I)	ab be or ad
		Liquid Injection (penicillin) Dry Powder Injection (penicillin) Oral Powder (penicillin) Liquid Injection (hormone)	
	Remarks of the Evaluator	<ul> <li>Form 5 does not mentioned strength of active ingredients per unit ml of injection.</li> <li>Complete Outline of manufacturing method is required.</li> <li>Complete finished good testing specifications mentioning assay of finished products</li> <li>Firm has submitte revised Form-5 wit annexures along wit preregistration full fe 30000/=vide challa No.87611091351 date 15-04-2022 mentionin composition:         Each mL Contains:         Ivermectin10.00 mg         Vitamin A14,000 IU         Vitamin E10 mg         Sodium         Selenite500 mcg         Firm has also submitte manufacturing method/outline an finished good testin specifications as US specification</li> </ul>	th th th th th thee min ed ing
354.	Name and address of manufacturer/ Applicant	Mylab (Pvt) Ltd. Khanqah sharif, Bahawalpur.	
	Brand Name + Dosage Form + Strength	PEPROXIN Oral Solution	$\dashv$
	Composition Composition	Each liter Contains: Pefloxacin methane Sulfonate as Pefloxaci	
	Diary No. Date of R & I & fee	Dy. No 12314 dated 06-03-20119; Rs.20,000/- dated 06 03-2019	5-
	Pharmacological Group	Quinolone Antibiotic	
	Type of Form	Form - 5	
	Finished product Specification	Not provided	
	Pack size & Demanded Price	1000 ml, As per Policy	
	Approval status of product in Reference Regulatory Authorities	Not Applicable	
	Me-too status	PEPEROXIN SOLUTION, 082807, (Import) "M/S HASSAN BROTHERS, FAISALABAD.	
	GMP status	Panel GMP inspection was conducted on 24-02-2021 and 25-02-2021 and concluded as "In view of above inspection proceedings and facilities verified such a company profile, building production, in process control quality control testing, machinery/equipment, material	as as,

	<del></del>	T	
		management, air handling personnel and documentation (pvt) Ltd. Khanqah sharif Baroperating at a satisfactory let the following sections only, Aerosol section were under functional at time of inspection. Liquid Injection Section (Genoral Powder Premix Section Oral Liquid (General)(I) Liquid Injection (penicillin) Dry Powder Injection (penicil Oral Powder (penicillin) Liquid Injection (hormone) Liquid Injection (Steroid)	on etc. the firm M/s Mylab ahawalpur, was found to be evel of GMP compliance for oral Liquid (General)II and maintenance and were not on": neral) (General)
	Remarks of the Evaluator	<ul> <li>Complete Outline of manufacturing method is required.</li> <li>Complete finished good testing specifications mentioning assay of finished products</li> </ul>	Firm has submitted manufacturing method/outline and finished good testing specifications as innovator's specification along with preregistration variation fee of 7500/= vide challan No.0807752658 dated 15-04-2022.
	Decision: Approved		uated 13-04-2022.
355.	Decision: Approved.  Name and address of manufacturer/ Applicant	Mylab (Pvt) Ltd. Khanqah sh	narif, Bahawalpur.
	Brand Name + Dosage Form + Strength	TRIGER oral dry powder	
	Composition	Each gram of powder contain Amoxicillin trihydrate equiva	
	Diary No. Date of R & I & fee	Dy. No 12312 dated 06-03-20 2019	
	Pharmacological Group	Quinolone Antibiotic	
	Type of Form	Form - 5	
	Finished product Specification	B.P vet Specification	
	Pack size & Demanded Price	100 G, 250 G, 500 G, 1000 C	G. As per SRO
	Approval status of product in Reference	Not Applicable	, ,
	Regulatory Authorities  Me-too status	TRIGER ORAL DRY POW	DED 020052 M/C Colmons
	IVIC-100 status	Pharmaceuticals (Pvt) Ltd, L	
	GMP status	Panel GMP inspection was co	
	Givii status	25-02-2021 and concluded	
		inspection proceedings and	
		company profile, building ,pr	
		quality control testing, made	
		management, air handling	
		personnel and documentation	•
		(pvt) Ltd. Khanqah sharif Ba	ahawalpur, was found to be
		operating at a satisfactory le	evel of GMP compliance for
		the following sections only,	
			maintenance and were not
		functional at time of inspection	
		Liquid Injection Section (Ger	
		Oral Powder Premix Section	(General)
		Oral Liquid (General)(I)	
		Liquid Injection (penicillin)	

	1	,
		Dry Powder Injection (penicillin)
		Oral Powder (penicillin) Liquid Injection (hormone)
		Liquid Injection (Steroid)
	Remarks of the Evaluator	<ul> <li>Form 5 prescribed title page dully signed is not provided.</li> <li>Complete Outline of manufacturing method is required</li> <li>Complete finished good testing specifications mentioning assay of finished products.</li> <li>Enclosure of Form - 5 mentions dosage form as "oral dry powder "whereas mentioned route of administration is "Injectable Solution ", clarify dosage form with</li> <li>Firm has submitted dully signed revised form-5 mentioning route of administration as "Oral ", along with complete manufacturing method and finished drug specification as B.P vet Specifications along with preregistration full fee of 30000 vide challan No.4284145021 dated 15-04-2022.</li> </ul>
		revised form-5 enclosure
		along with preregistration
		variation fee challan.
	Decision: Approved.	
356.	Name and address of manufacturer/	Mylab (Pvt) Ltd. Khanqah sharif, Bahawalpur.
	Applicant  Brand Name + Dosage Form + Strength	DRAVIN Injection
	Composition	Each ml contains:
	_	Tulathromycin100 mg
	Diary No. Date of R & I & fee	Dy. No 12158 dated 06-03-2019; Rs.20,000/- dated 05-03-
	Pharmacological Group	2019 Broad Spectrum Antibiotic
	Type of Form	Form - 5
	Finished product Specification	Innovators specification
	Pack size & Demanded Price	50 ML, As per SRO
	Approval status of product in Reference	Not Applicable
	Regulatory Authorities	THE ATT I SEE COARDON IN THE TAX OF THE PARTY OF THE PART
	Me-too status	TULAT Injection, 044908, Hilton pharma (Pvt) Ltd., Karachi.
	GMP status	Panel GMP inspection was conducted on 24-02-2021 and
		25-02-2021 and concluded as "In view of above
		inspection proceedings and facilities verified such as company profile, building production, in process controls,
		quality control testing, machinery/equipment, material
		management, air handling, water treatment system,
		personnel and documentation etc. the firm M/s Mylab
		(pvt) Ltd. Khanqah sharif Bahawalpur, was found to be operating at a satisfactory level of GMP compliance for
		the following sections only, oral Liquid (General)II and
		Aerosol section were under maintenance and were not
		functional at time of inspection":
		Liquid Injection Section (General) Oral Powder Premix Section (General)
		Oral Liquid (General)(I)
		Liquid Injection (penicillin)
1		Dry Powder Injection (penicillin)

		Oral Powder (penicillin)	
		Liquid Injection (hormone)	
		Liquid Injection (Steroid)	
	Remarks of the Evaluator	• Complete Outline of manufacturing method is required.	Firm has submitted manufacturing method/outline and
		• Complete finished good	finished good testing specifications as
		testing specifications mentioning assay of	specifications as innovator's specification
		finished products.	along with preregistration variation fee of 7500/= vide challan No.023250745129
			dated 15-04-2022.
	Decision: Approved.	I	
<b>'•</b>	Name and address of manufacturer/ Applicant	Mylab (Pvt) Ltd. Khanqah sh	narif, Bahawalpur.
	Brand Name + Dosage Form + Strength	D FLOX Injection	
	Composition	Each ml contains:	
		Danofloxacin Mesylate equiv	
		Danofloxacin	
	Diary No. Date of R & I & fee	2019.	019; Rs.20,000/- dated 05-03-
	Pharmacological Group	Fluoroquinolone	
	Type of Form	Form - 5	
	Finished product Specification	Innovator's specification.	
	Pack size & Demanded Price	50 ML, As per SRO	
	Approval status of product in Reference Regulatory Authorities	Not Applicable	
	Me-too status	ADVOCIN -SOLUBLE PO Karachi.	OWDER, 013243, PFIZER
	GMP status		conducted on 24-02-2021 and l as " In view of above
			facilities verified such as
			roduction, in process controls,
			chinery/equipment, material
			g, water treatment system,
			on etc. the firm M/s Mylab
		_	ahawalpur, was found to be
			evel of GMP compliance for
			oral Liquid (General)II and
			maintenance and were not
		functional at time of inspecti	
			·
			(General)
		1	
			:11:)
			111111)
		_	
-	Remarks of the Evaluator		Firm has submitted dully
	Remarks of the Evaluator		
		•	· ·
		•	
		mentioning assay of	specifications as
	Remarks of the Evaluator	Liquid Injection Section (Ge Oral Powder Premix Section Oral Liquid (General)(I) Liquid Injection (penicillin) Dry Powder Injection (penicillin) Coral Powder (penicillin) Liquid Injection (hormone) Liquid Injection (Steroid)  Complete Outline of manufacturing method is required.  Complete finished good testing specifications	(General)  Firm has submitted dully signed revised form -5 along with manufacturing method/outline and finished good testing

	variation fee of 7500/= vide challan No.0966041743
Decision: Approved.	

## Agenda of Evaluator PEC-XVII

# Case No. 1: Registration applications for local manufacturing of (Human) drugs.

## a; New cases:

<b>358.</b>	Name and address of manufacture /	M/s Biorex Pharmaceuticals. Plot No. 251-A, Industrial		
	Applicant	Triangle, Kahuta Road, Islamabad.		
	Brand Name + Dosage Form and	Lozarex 25mg tablet		
	Strength			
	Composition	Each tablet contains:		
	•	Losartan potassium25mg		
	Dairy No. date of R &I fee	Dy. No 13103 dated 06-03-2019 Rs.20,000/- dated 06-03-		
	•	2019 Challan No.0157547 dated: 05.03.2019		
	Pharmacological Group	Angiotensin-II receptor antagonists		
	Type of form	Form 5		
	Finished product specifications	USP specifications		
	Pack size and Demand Price	2×10's, As per SRO		
	Approval status of product in Reference	COZAAR® 25mg, 50mg, 100mg (Organon) US FDA		
	Regulatory Authorities	approved with box warning as:		
		WARNING: FETAL TOXICITY		
		When pregnancy is detected, discontinue COZAAR as		
		soon as possible. Drugs that act directly on the renin-		
		angiotensin system can cause injury and death to the		
		developing fetus.		
	Me-too-status	Leupo 25mg tablet of M/s City pharmaceutical laboratories,		
		Karachi. Registration No.102996		
	GMP Status	GMP certificate issued on 28-01-2022 based on inspection		
		conducted on 09-12-2021 for renewal of DML and grant of		
	OPPO MUM	additional section.		
	Remarks of the Evaluator (PEC-XVII)	• Firm revised the label claim as:		
		Each film-coated tablet contains:		
		Losartan potassium25mg and submitted fee of Rs: 7500/-		
		vide on-line deposit slip No.39653845.		
		• Tablet Section (General) available as per DML renewal		
		inspection conducted on 09-12-2021.		
	Decision: Approved as per following revised label claim with USP specifications:			
	Each film-coated tablet contains:			
250	Losartan potassium25mg	N/ B: Di di la Di di A A A A A A A A		
359.	Name and address of manufacture /	M/s Biorex Pharmaceuticals. Plot No. 251-A, Industrial		
-	Applicant	Triangle, Kahuta Road, Islamabad.		
	Brand Name + Dosage Form and	Lozarex 50mg tablet		
-	Strength	P. 1 (11 ( ) ( )		
	Composition	Each tablet contains:		
-	D' N 1, CD 01C	Losartan potassium50mg		
	Dairy No. date of R &I fee	Dy. No 13104 dated 06-03-2019 Rs.20,000/- dated 06-03-		
-	Dhamas a la si a l Curre	2019 Challan No.0157548 dated: 05.03.2019		
-	Pharmacological Group	Angiotensin-II receptor antagonists		
	Type of form	Form 5		

	Finished product specifications	USP specifications	
	Pack size and Demand Price	2×10's, As per SRO	
	Approval status of product in Reference	COZAAR® 25mg, 50mg, 100mg (Organon) US FDA	
	Regulatory Authorities	approved with box warning as:	
	Regulatory Tathornies	WARNING: FETAL TOXICITY	
		When pregnancy is detected, discontinue COZAAR as	
		soon as possible. Drugs that act directly on the renin-	
		angiotensin system can cause injury and death to the	
		developing fetus.	
	Martina		
	Me-too-status	Leupo 50mg tablet of M/s City pharmaceutical laboratories, Karachi. Registration No.102997	
	GMP Status	GMP certificate issued on 28-01-2022 based on inspection	
		conducted on 09-12-2021 for renewal of DML and grant of	
	(DEC YVIII)	additional section.	
	Remarks of the Evaluator (PEC-XVII)	• Firm revised the label claim as:	
		Each film-coated tablet contains:	
		Losartan potassium50mg and submitted fee of Rs: 7500/-	
		vide on-line deposit slip No.9695349020.	
		• Tablet Section (General) available as per DML renewal	
		inspection conducted on 09-12-2021.	
	Decision: Approved as per following rev	ised label claim with USP specifications.	
	Each film-coated tablet contains:		
	Losartan potassium50mg		
360.	Name and address of manufacture /	M/s Biorex Pharmaceuticals. Plot No. 251-A, Industrial	
	Applicant	Triangle, Kahuta Road, Islamabad.	
	Brand Name + Dosage Form and Strength	Lozarex 100mg tablet	
	Composition	Each tablet contains:	
	•	Losartan potassium100mg	
	Dairy No. date of R &I fee	Dy. No 13105 dated 06-03-2019 Rs.20,000/- dated 06-03-2019 Challan No.0157549 dated: 05.03.2019	
	Pharmacological Group	Angiotensin-II receptor antagonists	
	Type of form	Form 5	
	Finished product specifications	USP specifications	
	Pack size and Demand Price	2×10's, As per SRO	
	Approval status of product in Reference	COZAAR® 25mg, 50mg, 100mg (Organon) US FDA	
	Regulatory Authorities	approved with box warning as:	
	Regulatory radiiornies	WARNING: FETAL TOXICITY	
		When pregnancy is detected, discontinue COZAAR as	
		soon as possible. Drugs that act directly on the renin-	
		angiotensin system can cause injury and death to the	
		developing fetus.	
	Me-too-status	Leupo 100mg tablet of M/s City pharmaceutical	
		laboratories, Karachi. Registration No.102998	
	GMP Status	GMP certificate issued on 28-01-2022 based on inspection	
		conducted on 09-12-2021 for renewal of DML and grant of	
		additional section.	
	Remarks of the Evaluator (PEC-XVII)	• Firm revised the label claim as:	
		Each film-coated tablet contains:	
		Losartan potassium100mg and submitted fee of Rs:	
		7500/- vide on-line deposit slip No.74007531.	
		• Tablet Section (General) available as per DML renewal	
		inspection conducted on 09-12-2021.	
	Decision: Approved as per following rev		
	Each film-coated tablet contains:		
	Losartan potassium100mg		
	Lusai tan putassiumi uumg		

361.	Name and address of manufacture /	M/s Biorex Pharmaceuticals. Plot No. 251-A, Industrial
	Applicant	Triangle, Kahuta Road, Islamabad.
	Brand Name + Dosage Form and Strength	Levoride 25mg tablet
	Composition	Each tablet contains:
	Composition	Levosulpiride25mg
	Dairy No. date of R &I fee	Dy. No 13099 dated 06-03-2019 Rs.20,000/- dated 06-03-
	Daily 100. date of K &f fee	2019 Challan No.0157543 dated: 05.03.2019
	Pharmacological Group	antipsychotic
	Type of form	Form 5
	Finished product specifications	Manufacturer specifications
	Pack size and Demand Price	1×10's, As per SRO
	Approval status of product in Reference	Levosulpiride Aristo 25 mg tablets, AIFA Italy approved.
	Regulatory Authorities	
	Me-too-status	Arrser 25mg tablet of M/s Arreta pharmaceutical Rawalpindi. Registration No.100676
	GMP Status	GMP certificate issued on 28-01-2022 based on inspection conducted on 09-12-2021 for renewal of DML and grant of additional section.
	Remarks of the Evaluator (PEC-XVII)	
	Remarks of the Evaluator (Leckyn)	• The firm has revised the master formulation and
		manufacturing outlines for un-coated tablet since initially
		coating materials and coating process has been mentioned
		and submitted fee of Rs: 7500/- vide on-line deposit slip No.7736546742.
		• Firm has claimed manufacturer specifications.
		• Tablet Section (General) available as per DML renewal
		inspection conducted on 09-12-2021.
362.	<b>Decision: Approved with Innovator's Sp</b> Name and address of manufacture /	
302.		M/s Biorex Pharmaceuticals. Plot No. 251-A, Industrial
	Applicant Brand Name + Dosage Form and	Triangle, Kahuta Road, Islamabad.  Levoride 50mg tablet
	Strength	Levolide Joing tablet
	Composition	Each tablet contains:
	Composition	Levosulpiride50mg
	Dairy No. date of R &I fee	Dy. No 13100 dated 06-03-2019 Rs.20,000/- dated 06-03-
	Daily No. date of K &f fee	2019 Challan No.0157546 dated: 05.03.2019
	Pharmacological Group	antipsychotic
	Type of form	Form 5
	Finished product specifications	Manufacturer specifications
	Pack size and Demand Price	1×10's, As per SRO
	Approval status of product in Reference	Levosulpiride Aristo 50mg tablets, AIFA Italy approved.
	Regulatory Authorities	S
	Me-too-status	Arrser 50mg tablet of M/s Arreta pharmaceutical Rawalpindi. Registration No.100665
	GMP Status	GMP certificate issued on 28-01-2022 based on inspection
		conducted on 09-12-2021 for renewal of DML and grant of
		additional section.
	Remarks of the Evaluator (PEC-XVII)	• The firm has revised the master formulation and
		manufacturing outlines for un-coated tablet since initially
		coating materials and coating process has been mentioned
		and submitted fee of Rs: 7500/- vide on-line deposit slip
		No.6353431549.
		• Firm has claimed manufacturer specifications.
		Tablet Section (General) available as per DML renewal
		inspection conducted on 09-12-2021.
	Decision: Approved with Innovator's Sp	
	Decision, Expristed with innerator 50	VVV11Vmt1V1101

363.	Name and address of manufacture /	M/s Biorex Pharmaceuticals. Plot No. 251-A, Industrial
	Applicant	Triangle, Kahuta Road, Islamabad.
	Brand Name + Dosage Form and	Clarirex 250mg tablet
	Strength	
	Composition	Each tablet contains:
		Clarithromycin250mg
	Dairy No. date of R &I fee	Dy. No 13101 dated 06-03-2019 Rs.20,000/- dated 06-03-
		2019 Challan No.0511227 dated: 05.03.2019
	Pharmacological Group	Semisynthetic macrolide antibiotic
	Type of form	Form 5
	Finished product specifications	USP specifications
	Pack size and Demand Price	1×10's, As per SRO
	Approval status of product in Reference Regulatory Authorities	MHRA approved
	Me-too-status	Clareta 250mg tablet of M/s Arreta pharmaceuticals, Rawalpindi. Registration No.100669
	GMP Status	GMP certificate issued on 28-01-2022 based on inspection conducted on 09-12-2021 for renewal of DML and grant of
		additional section.
	Remarks of the Evaluator (PEC-XVII)	• Firm revised the label claim as:
		Each film-coated tablet contains:
		Clarithromycin250mg and submitted fee of Rs: 7500/-
		vide on-line deposit slip No.916109449.
		• Tablet Section (General) available as per DML renewal
		inspection conducted on 09-12-2021.
		vised label claim with USP specifications:
	Each film-coated tablet contains:	
264	Clarithromycin250mg	DATA DI CONTRA D
364.	Name and address of manufacture /	M/s Biorex Pharmaceuticals. Plot No. 251-A, Industrial
	Applicant Brand Name + Dosage Form and	Triangle, Kahuta Road, Islamabad.  Clarirex 500mg tablet
	Strength	Clarifex 500ing tablet
	Composition	Each tablet contains:
	Composition	Clarithromycin500mg
	Dairy No. date of R &I fee	Dy. No 13102 dated 06-03-2019 Rs.20,000/- dated 06-03-
	,	2019 Challan No.0157544 dated: 05.03.2019
	Pharmacological Group	Semisynthetic macrolide antibiotic
	Type of form	Form 5
	Finished product specifications	USP specifications
	Pack size and Demand Price	1×10's, As per SRO
	Approval status of product in Reference Regulatory Authorities	MHRA approved
	Me-too-status	Clareta 500mg tablet of M/s Arreta pharmaceuticals, Rawalpindi. Registration No.100659
	GMP Status	GMP certificate issued on 28-01-2022 based on inspection
		conducted on 09-12-2021 for renewal of DML and grant of
		additional section.
	Remarks of the Evaluator (PEC-XVII)	• Firm revised the label claim as:
		Each film-coated tablet contains:
		Clarithromycin500mg and submitted fee of Rs: 7500/-
		vide on-line deposit slip No.030160481.
		• Tablet Section (General) available as per DML renewal
		inspection conducted on 09-12-2021.
		vised label claim with USP specifications:
	Each film-coated tablet contains:	
1	Clarithromycin500mg	

365.	Name and address of manufacture /	M/s Biorex Pharmaceuticals. Plot No. 251-A, Industrial
	Applicant	Triangle, Kahuta Road, Islamabad.
	Brand Name + Dosage Form and	Biopime 250mg Injection (IM/IV)
	Strength	
	Composition	Each vial contains:
		Cefepime (as HCL) with L Aginine250mg
	Dairy No. date of R &I fee	Dy. No 13094 dated 06-03-2019 Rs.20,000/- dated 06-03-
		2019 Challan No.0157550 dated: 05.03.2019
	Pharmacological Group	Antibiotic, 4 <sup>th</sup> generation cephalosporin
	Type of form	Form 5
	Finished product specifications	USP specifications
	Pack size and Demand Price	1×1's, As per SRO
	Approval status of product in Reference	Could not be confirmed. MHRA, USFDA & TGA
	Regulatory Authorities	approved strengths are 500mg, 1gm, 2gm.
	Me-too-status	Cefstar Injection IV/IM 250mg of M/s Barrett Hodgson Pakistan, Karachi. Registration No. 076005
	GMP Status	GMP certificate issued on 28-01-2022 based on inspection conducted on 09-12-2021 for renewal of DML and grant of additional section.
	Remarks of the Evaluator (PEC-XVII)	Provide evidence of approval of applied formulation in
	Remarks of the Evaluator	reference regulatory authorities / agencies which were
		adopted by the Registration Board in its 275 <sup>th</sup> meeting.
		• Dry powder injection (Cephalosporin) Section available as
		per DML renewal inspection conducted on 09-12-2021.
	• Decision: Deferred for evidence of ar	oproval of applied formulation in reference regulatory
		d by the Registration Board in its 275 <sup>th</sup> meeting.
366.	Name and address of manufacture /	M/s Biorex Pharmaceuticals. Plot No. 251-A, Industrial
	Applicant	Triangle, Kahuta Road, Islamabad.
	Brand Name + Dosage Form and	Cefbactam 500mg Injection (IM/IV)
	Strength	
	Composition	Each vial contains:
		Cefoperazone Sodium250mg
		Sulbactum Sodium250mg
	Dairy No. date of R &I fee	Dy. No 13095 dated 06-03-2019 Rs.20,000/- dated 06-03-
		2019 Challan No.0791772 dated: 05.03.2019
	Pharmacological Group	Antibiotic
	Type of form	Form 5
	Finished product specifications	JP specifications
	Pack size and Demand Price	1×1's, As per SRO
	Approval status of product in Reference	PMDA Japan Approved
	Regulatory Authorities	
	Me-too-status	CPS 500mg injection (IM/IV) of M/s Semos Pharmaceuticals, Karachi. Registration No.102880
	GMP Status	GMP certificate issued on 28-01-2022 based on inspection
		conducted on 09-12-2021 for renewal of DML and grant of
		additional section.
	Remarks of the Evaluator (PEC-XVII)	• Firm has revised the label claim as:
		Each vial contains:
		Cefoperazone as Sodium250mg
		Sulbactum as Sodium250mg. However, the firm
		has submitted fee of Rs: 7500/- (Only) vide on-line deposit
		slip No.3558322532.
		• Dry powder injection (Cephalosporin) Section available as
	<b>D</b> • • • • • • • • • • • • • • • • • • •	per DML renewal inspection conducted on 09-12-2021.
	Decision: Approved as per following rev	vised label claim:
	Each vial contains:	

		fee of Rs.22,500 for correction/pre-approval change in orm of the drug substance), as per notification No.F.7-
367.	Name and address of manufacture / Applicant	M/s Biorex Pharmaceuticals. Plot No. 251-A, Industrial Triangle, Kahuta Road, Islamabad.
	Brand Name + Dosage Form and Strength	Rocerex 2gm Injection (IV)
	Composition	Each vial contains: Ceftriaxone (as Sodium) 2gm
	Dairy No. date of R &I fee	Dy. No 13096 dated 06-03-2019 Rs.20,000/- dated 06-03-2019 Challan No.0791773 dated: 05.03.2019
	Pharmacological Group	Antibiotic, 3 <sup>rd</sup> Generation Cephalosporin
	Type of form	Form 5
	Finished product specifications	USP specifications
	Pack size and Demand Price	1×1's, As per SRO
	Approval status of product in Reference Regulatory Authorities	MHRA Approved
	Me-too-status	Markcef Injection 2gm IV of M/s Welmark Pharma, Hattar. Registration No.103076
	GMP Status	GMP certificate issued on 28-01-2022 based on inspection conducted on 09-12-2021 for renewal of DML and grant of additional section.
	Remarks of the Evaluator (PEC-XVII)	<ul> <li>Firm specified the proposed route of administration as Intravenous (I.V) as initially the intended route of administration not mentioned/specified and has submitted fee of Rs: 7500/vide online deposit slip No.251816544.</li> <li>Dry powder injection (Cephalosporin) Section available as per DML renewal inspection conducted on 09-12-2021.</li> </ul>
	Decision: Approved.	
368.	Name and address of manufacturer/ Applicant	Applicant: Winilton pharmaceutical (Pvt) Ltd. Plot No.45, Street S-5, National Industrial Zone, Rawat-Islamabad Manufactured By: M/s EG Pharmaceuticals. Plot. No. 13-A, Industrial Triangle, Kahuta Road, Islamabad.
	Brand Name + Dosage Form + Strength	Wilxime 400mg capsules
	Composition	Each capsule contains: Cefixime (As trihydrate) 400mg
	Diary No. Date of R & I & fee	Dy.No 12407 dated 05-03-2019 Rs.50,000/- dated 04-03-2019
	Pharmacological Group	Antibiotic
	Type of Form	Form 5
	Finished product Specification	JP specifications
	Pack size & Demanded Price	5's, As per SRO
	Approval status of product in Reference Regulatory Authorities	(US FDA approved)
	Me-too status	Isocef 400mg capsule of M/s Shrooq Pharmaceuticals, Lahore. Registration No. 040852
	GMP status Remarks of the Evaluator (PEC-XVII)	Not provided for both contract giver and contract acceptor  The contract acceptor that is M/s EG pharmaceuticals provided letter No. F. 1-26/2004-Lic dated 29-08-2012 as evidence of Capsule section (Cephalosporin) availability.  API and drug product testing methods (assay) provided as per USP, while the firm claimed JP specifications for their drug product.

	<del>-</del>	<del>-</del>		
		• GMP inspection report of the contract acceptor that is M/s EG Pharmaceuticals, Kahuta road, Islamabad is required.		
		• GMP inspection report of the contract giver that is M/s		
		Winilton pharmaceutical (Pvt) Ltd. Plot No.45, Street S-5, National Industrial Zone, Rawat-Islamabad is required.		
	Decision: Approved with Manufacturer S	specifications as approved in 313 <sup>th</sup> meeting of Registration		
	Board and notified vide letter No. No.F.14-112022-PEC dated 14-03-2022. However, Firm shall			
	submit the fee of Rs. 7,500 for correction/pre-approval change/ in product specifications, as per			
	notification No.F.7-11/2012-B&A/DRAP dated 13-07-2021.  Moreover, registration letter shall be issued after submission of valid satisfactory GMP inspection			
	reports for both the contract giver and co	ntract acceptor.		
369.	Name and address of manufacturer/	Applicant: Winilton pharmaceutical (Pvt) Ltd. Plot No.45,		
	Applicant	Street S-5, National Industrial Zone, Rawat-Islamabad Manufactured By:		
		M/s EG Pharmaceuticals. Plot. No. 13-A, Industrial		
		Triangle, Kahuta Road, Islamabad.		
	Brand Name + Dosage Form + Strength	Wilxime suspension 100mg/5ml		
	Composition	Each 5ml of reconstituted suspension contains:		
	Di V D CD 0 V 0 C	Cefixime (as trihydrate) 100mg		
	Diary No. Date of R & I & fee	Dy.No 12406 dated 05-03-2019 Rs.50,000/- dated 04-03-2019		
	Pharmacological Group	Antibiotic		
	Type of Form	Form 5		
	Finished product Specification	USP specifications		
	Pack size & Demanded Price	30ml, As per SRO (US FDA approved)		
	Approval status of product in Reference Regulatory Authorities			
	Me-too status	Cefiget 100mg powder for oral suspension of M/s Getz Pharmaceuticals, Karachi. Registration No. 045119.		
	GMP status	Not provided for both contract giver and contract acceptor		
	Remarks of the Evaluator (PEC-XVII)	• The contract acceptor that is M/s EG pharmaceuticals provided letter No. F. 1-26/2004-Lic dated 29-08-2012 as		
		evidence of Dry powder for suspension section (Cephalosporin) availability.		
		• GMP inspection report of the contract acceptor that is M/s		
		EG Pharmaceuticals, Kahuta road, Islamabad is required.		
		• GMP inspection report of the contract giver that is M/s		
		Winilton pharmaceutical (Pvt) Ltd. Plot No.45, Street S-5, National Industrial Zone, Rawat-Islamabad is required.		
	Decision: Approved, However, registration	n letter shall be issued after submission of valid satisfactory		
	GMP inspection reports for both the contract giver and contract acceptor.			
370.		Applicant: Winilton pharmaceutical (Pvt) Ltd. Plot No.45,		
		Street S-5, National Industrial Zone, Rawat-Islamabad		
		Manufactured By:		
		M/s EG Pharmaceuticals. Plot. No. 13-A, Industrial Triangle, Kahuta Road, Islamabad.		
	Brand Name + Dosage Form + Strength	Wilxime DS suspension 200mg/5ml		
	Composition	Each 5ml of reconstituted suspension contains:		
		Cefixime (as trihydrate) 200mg		
	Diary No. Date of R & I & fee	Dy.No 12408 dated 05-03-2019 Rs.50,000/- dated 04-03-2019		
	Pharmacological Group	Antibiotic		
	Туре of Form	Form 5		
	Finished product Specification	USP specifications		
	Pack size & Demanded Price	30ml, As per SRO		

	Approval status of product in Reference Regulatory Authorities	ce(US FDA approved)
	Me-too status	Cefiget DS powder for suspension of M/s Getz Pharmaceuticals, Karachi. Registration No. 045120
	GMP status	Not provided for both contract giver and contract acceptor
	Remarks of the Evaluator (PEC-XVII)	<ul> <li>The contract acceptor that is M/s EG pharmaceuticals provided letter No. F. 1-26/2004-Lic dated 29-08-2012 as evidence of Dry powder for suspension section (Cephalosporin) availability.</li> <li>GMP inspection report of the contract acceptor that is M/s EG Pharmaceuticals, Kahuta road, Islamabad is required.</li> </ul>
		• GMP inspection report of the contract giver that is M/s Winilton pharmaceutical (Pvt) Ltd. Plot No.45, Street S-5,
	Decision: Approved, However, registration	National Industrial Zone, Rawat-Islamabad is required.  n letter shall be issued after submission of valid satisfactory
	GMP inspection reports for both the cont	
371.	Name and address of manufacturer/ Applican	ht Applicant: Winilton pharmaceutical (Pvt) Ltd. Plot No.45, Street S-5, National Industrial Zone, Rawat-Islamabad Manufactured By:  M/s EG Pharmaceuticals. Plot. No. 13-A, Industrial Triangle, Kahuta Road, Islamabad.
	Brand Name + Dosage Form + Strength	Wilpine 500mg injection
	Composition	Each vial contains: Cefipime (as HCl with L-Arginine)500mg
	Diary No. Date of R & I & fee	Dy.No 12405 dated 05-03-2019 Rs.50,000/- dated 04-03-2019
	Pharmacological Group	4 <sup>th</sup> generation cephalosporin antibiotic Form 5
	Type of Form	
	Finished product Specification Pack size & Demanded Price	USP specifications 1's, As per SRO
	Approval status of product in Reference Regulatory Authorities	
	Me-too status	Nuxipim 500mg Injection of Bosch Pharmaceuticals, Karachi. Registration No. 044356
	GMP status	Not provided for both contract giver and contract acceptor
	Remarks of the Evaluator (PEC-XVII)	• The contract acceptor that is M/s EG pharmaceuticals provided letter No. F. 1-26/2004-Lic dated 29-08-2012 as evidence of Sterile Dry Powder for Injection Section (Cephalosporin) availability.
		<ul> <li>GMP inspection report of the contract acceptor that is M/s EG Pharmaceuticals, Kahuta road, Islamabad is required.</li> <li>GMP inspection report of the contract giver that is M/s Winilton pharmaceutical (Pvt) Ltd. Plot No.45, Street S-5, National Industrial Zone, Rawat-Islamabad is required.</li> </ul>
	Decision: Approved. However, registratio GMP inspection reports for both the cont	n letter shall be issued after submission of valid satisfactory ract giver and contract acceptor.
372.		ntApplicant: Winilton pharmaceutical (Pvt) Ltd. Plot No.45, Street S-5, National Industrial Zone, Rawat-Islamabad Manufactured By: M/s EG Pharmaceuticals. Plot. No. 13-A, Industrial Triangle,
	Brand Name + Dosage Form + Strength	Kahuta Road, Islamabad. Wilpine 1gm injection

	Composition	Cefipime (as HCl with L-Arginine) 1gm
		Dy.No 12404 dated 05-03-2019 Rs.50,000/- dated 04-03-2019
	Pharmacological Group	4 <sup>th</sup> generation cephalosporin antibiotic
		Form 5
	71	USP specifications
	Pack size & Demanded Price	1's, As per SRO
	Approval status of product in Reference	
	Regulatory Authorities	( Tr
	Me-too status	Nuxipim 1gm Injection of Bosch Pharmaceuticals, Karachi. Registration No. 044357
		Not provided for both contract giver and contract acceptor
		• The contract acceptor that is M/s EG pharmaceuticals provided letter No. F. 1-26/2004-Lic dated 29-08-2012 as evidence of Sterile Dry Powder for Injection Section (Cephalosporin) availability.
		<ul> <li>GMP inspection report of the contract acceptor that is M/s EG Pharmaceuticals, Kahuta road, Islamabad is required.</li> <li>GMP inspection report of the contract giver that is M/s Winilton pharmaceutical (Pvt) Ltd. Plot No.45, Street S-5,</li> </ul>
		National Industrial Zone, Rawat-Islamabad is required.
	Decision: Approved. However, registration	letter shall be issued after submission of valid satisfactory
	GMP inspection reports for both the contra	· ·
373.		Applicant: Winilton pharmaceutical (Pvt) Ltd. Plot No.45, Street S-5, National Industrial Zone, Rawat-Islamabad Manufactured By:
		M/s EG Pharmaceuticals. Plot. No. 13-A, Industrial Triangle, Kahuta Road, Islamabad.
	Brand Name + Dosage Form + Strength	Wincef 250mg injection (IV)
	1	Each vial contains: Ceftriaxone (as Ceftriaxone Sodium)250mg
		Dy.No 12399 dated 05-03-2019 Rs.50,000/- dated 04-03-2019
	Pharmacological Group	3 <sup>rd</sup> generation cephalosporin antibiotic
	Type of Form	Form 5
	Finished product Specification	USP specifications
	Pack size & Demanded Price	1's, As per SRO
	Approval status of product in Reference Regulatory Authorities	(MHRA approved)
		Getofin 250mg IV injection Getz Pharma, Karachi. Registration No. 024629
		Not provided for both contract giver and contract acceptor
		<ul> <li>The contract acceptor that is M/s EG pharmaceuticals provided letter No. F. 1-26/2004-Lic dated 29-08-2012 as evidence of Sterile Dry Powder for Injection Section (Cephalosporin) availability.</li> <li>GMP inspection report of the contract acceptor that is M/s EG Pharmaceuticals, Kahuta road, Islamabad is required.</li> <li>GMP inspection report of the contract giver that is M/s Winilton pharmaceutical (Pvt) Ltd. Plot No.45, Street S-5, National Industrial Zone, Rawat-Islamabad is required.</li> </ul>

Each vial contains:

Composition

	all submit the fee of Rs. 7,500 for variation in registration oute of administration, as per notification No.F.7-11/20	
Moreover, registration letter shall be is reports for both the contract giver and contract giver and contract gives are contracted.	sued after submission of valid satisfactory GMP inspecti	
	Ant Applicant: Winilton pharmaceutical (Pvt) Ltd. Plot No. Street S-5, National Industrial Zone, Rawat-Islamabad Manufactured By:  M/s EG Pharmaceuticals. Plot. No. 13-A, Industrial Triang	
Brand Name + Dosage Form + Strength	Kahuta Road, Islamabad. Wincef 500mg injection (IV)	
Brand Name + Dosage Porm + Strength	whice soong injection (1v)	
Composition	Each vial contains: Ceftriaxone (as Ceftriaxone Sodium)500mg	
Diary No. Date of R & I & fee	Dy.No 12400 dated 05-03-2019 Rs.50,000/- dated 04-03-20	
Pharmacological Group	3 <sup>rd</sup> generation cephalosporin antibiotic	
Type of Form	Form 5	
Finished product Specification	USP specifications	
Pack size & Demanded Price	1's, As per SRO	
Approval status of product in Referen	, 1	
Regulatory Authorities Me-too status	Curecef 500mg injection Zesion Pharmaceuticals, Islamab	
	Registration No. 045168	
GMP status  Remarks of the Evaluator (PEC-XVII)	Not provided for both contract giver and contract acceptor	
	<ul> <li>The contract acceptor that is M/s EG pharmaceutic provided letter No. F. 1-26/2004-Lic dated 29-08-2012 evidence of sterile dry powder for injection sect (Cephalosporin) availability.</li> <li>GMP inspection report of the contract acceptor that is M/s Pharmaceuticals, Kahuta road, Islamabad is required.</li> <li>GMP inspection report of the contract giver that is I Winilton pharmaceutical (Pvt) Ltd. Plot No.45, Street S National Industrial Zone, Rawat-Islamabad is required.</li> <li>Firm specified the route of administration as Intra-venous did not submit the requisite fee.</li> </ul>	
Decision: Approved. However, Firm shall submit the fee of Rs. 7,500 for variation in registrati application i.e., correction/change of route of administration, as per notification No.F.7-11/2020 B&A/DRAP dated 13-07-2021.  Moreover, registration letter shall be issued after submission of valid satisfactory GMP inspecti reports for both the contract giver and contract acceptor.		
Name and address of manufacturer/ Applica	<ul> <li>Ant Applicant: Winilton pharmaceutical (Pvt) Ltd. Plot No. Street S-5, National Industrial Zone, Rawat-Islamabad Manufactured By:</li> <li>M/s EG Pharmaceuticals. Plot. No. 13-A, Industrial Triang Kahuta Road, Islamabad.</li> </ul>	
Brand Name + Dosage Form + Strength	Wincef 1gm injection (IV)	
Composition	Each vial contains:	
Diary No. Date of R & I & fee	Ceftriaxone (as Ceftriaxone Sodium)1gm  Dy.No 12401 dated 05-03-2019 Rs.50,000/- dated 04-03-2019	
Pharmacological Group	3 <sup>rd</sup> generation cephalosporin antibiotic	
Type of Form	Form 5	
Finished product Specification	USP specifications	
Pack size & Demanded Price	1's, As per SRO	

Regulatory Authorities	
Me-too status	Curecef 1gm injection Zesion Pharmaceuticals, Islama Registration No. 045169
GMP status	Not provided for both contract giver and contract acceptor
Remarks of the Evaluator (PEC-XVII)	• The contract acceptor that is M/s EG pharmaceuti provided letter No. F. 1-26/2004-Lic dated 29-08-2012 evidence of Sterile Dry Powder for Injection sec (Cephalosporin) availability.
	• GMP inspection report of the contract acceptor that is M/s Pharmaceuticals, Kahuta road, Islamabad is required.
	• GMP inspection report of the contract giver that is Winilton pharmaceutical (Pvt) Ltd. Plot No.45, Street
	National Industrial Zone, Rawat-Islamabad is required.  • Firm specified the route of administration as Intra-venous did not submit the requisite fee.
Dagisjan: Approved Hawayar Firm sh	all submit the fee of Rs. 7,500 for variation in registra
	oute of administration, as per notification No.F.7-11/20
B&A/DRAP dated 13-07-2021.	oute of auministration, as per notification 10.1.7-11/2
	sued after submission of valid satisfactory GMP inspec
reports for both the contract giver and c	
	ant Applicant: Winilton pharmaceutical (Pvt) Ltd. Plot No.
	Street S-5, National Industrial Zone, Rawat-Islamabad
	Manufactured By:
	M/s EG Pharmaceuticals. Plot. No. 13-A, Industrial Trian
	Kahuta Road, Islamabad.
Brand Name + Dosage Form + Strength	Wilbac1gm injection
Composition	Each vial contains:
Composition	Cefoperazon Sodium 500mg
	Sulbactum Sodium 500mg
Diary No. Date of R & I & fee	Dy.No 12402 dated 05-03-2019 Rs.50,000/- dated 04-03-2
Pharmacological Group	3 <sup>rd</sup> generation cephalosporin antibiotic
Type of Form	Form 5
Finished product Specification	Manufacturer Specifications
Pack size & Demanded Price	1's, As per SRO
Regulatory Authorities	nceSulperazon Injection 1g by Pfizer Co. PMDA Japan Appro
Me-too status	Ceone 1gm injection Zesion Pharmaceuticals, Islama Registration No. 045173
GMP status	Not provided for both contract giver and contract acceptor
Remarks of the Evaluator (PEC-XVII)	<ul> <li>The contract acceptor that is M/s EG pharmaceutic provided letter No. F. 1-26/2004-Lic dated 29-08-2011 evidence of Sterile Dry Powder for Injection sec (Cephalosporin) availability.</li> <li>GMP inspection report of the contract acceptor that is M/s</li> </ul>
	Pharmaceuticals, Kahuta road, Islamabad is required.  • GMP inspection report of the contract giver that is Winilton pharmaceutical (Pvt) Ltd. Plot No.45, Street National Industrial Zone, Rawat-Islamabad is required.  • Firm revised the label claim as: Each vial contains:

		Sulbactum (as sodium) 500mg without submission					
	of requisite fee.  Decision: Approved as per following revised label claim with JP specifications:						
	Each vial contains: Cefoperazone (as Sodium)500mg Sulbactum (as Sodium)500mg						
	However, Firm shall submit the fee of Rs. 30,000 for correction/pre-approval change in composition						
	(correction/change of salt form of the drug substance), as per notification No.F.7-11/2012-B&A/DRAP						
	dated 13-07-2021.  Moreover, registration letter shall be is reports for both the contract giver and co	sued after submission of valid satisfactory GMP inspection					
7.		ant Applicant: Winilton pharmaceutical (Pvt) Ltd. Plot No.45					
		Street S-5, National Industrial Zone, Rawat-Islamabad					
		Manufactured By:					
		M/s EG Pharmaceuticals. Plot. No. 13-A, Industrial Triangle					
	Brand Name + Dosage Form + Strength	Kahuta Road, Islamabad. Wilbac 2gm injection					
	Brand Name + Bosage Form + Strength	w noac zgm injection					
	Composition	Each vial contains:					
		Cefoperazon as sodium1gm					
		Sulbactum as sodium1gm					
	Diary No. Date of R & I & fee	Dy.No 12403 dated 05-03-2019 Rs.50,000/- dated 04-03-2019					
	Pharmacological Group	3 <sup>rd</sup> generation cephalosporin antibiotic					
	Type of Form	Form 5					
	Finished product Specification	Manufacturer Specifications					
	Pack size & Demanded Price	1's, As per SRO					
		ce Approved by 3 EMA Member States (Poland, Slovakia, Czec					
	Regulatory Authorities	Republic).					
		(Sulperazone) AIFA (Italy) approved					
	Me-too status	Ceone 2gm injection Zesion Pharmaceuticals, Islamabad Registration No. 045174					
	GMP status	Not provided for both contract giver and contract acceptor					
	Remarks of the Evaluator (PEC-XVII)	• The contract acceptor that is M/s EG pharmaceutical					
		provided letter No. F. 1-26/2004-Lic dated 29-08-2012 a evidence of Sterile Dry Powder for Injection section					
		<ul><li>(Cephalosporin) availability.</li><li>GMP inspection report of the contract acceptor that is M/s E0</li></ul>					
		Pharmaceuticals, Kahuta road, Islamabad is required.					
		• GMP inspection report of the contract giver that is M					
		Winilton pharmaceutical (Pvt) Ltd. Plot No.45, Street S-5					
		National Industrial Zone, Rawat-Islamabad is required.					
	Decision: Approved with JP specifications. However, Firm shall submit the fee of Rs. 7,500 fo correction/pre-approval change/ in product specifications, as per notification No.F.7-11/2012 B&A/DRAP dated 13-07-2021.						
	Moreover, registration letter shall be issued after submission of valid satisfactory GMP inspection						
·	reports for both the contract giver and co						
•	Name and address of manufacture / Applicant	M/s Bio Mark Pharmaceuticals. Plot No. 527, Sundar Industrial Estate, Lahore (Tablet I & II General)					
	Brand Name + Dosage Form and	EVRTRS tablet 5mg					
	Strength	LVKIKS tablet Sing					
	Composition	Each Tablet Contains:					
	Composition	Everolimus 5mg					
	Dairy No. date of R &I fee	Form-5 Dy.No 10309 dated 05-03-2019 Rs.20,000 dated 04					
	y = 2 32 22 23	03-2019					
	Pharmacological Group	Protein kinase inhibitor					

[	Type of form	Form 5
	Finished product specifications	Innovator's specifications
	Pack size and Demand Price	30's, As per SRO
	Approval status of product in Reference	AFINITOR 5mg tablet Novartis Pharmaceuticals ltd. UK
	RegulatoryAuthorities	(Approved MHRA)
	Me-too-status	Afinitor 5mg (M/S Novartis) Reg. # 069519
	GMP Status	GMP certificate valid till 12-02-2022, issued on the basis of inspection conducted on 13-02-2020.
	Remarks of the Evaluator (PEC-XVII)	<ul> <li>Confirmation of cytotoxic facility is required as per decision of 297th meeting of DRB as "Registration Board after thorough deliberation and considering the high-risk classification i.e., "Anticancer (L01)", and reviewing its previous decision decided to allow the manufacturing of such type of drugs which fall in both "Antineoplastic (L01)" &amp; "Immunosuppressants (L04)" class including everolimus and methotrextare etc. in the "Anticancer" section only (being high risk products)."</li> <li>Route of administration mentioned as oral suspension</li> </ul>
	Decision: Deferred for consideration of an	oplied formulation in the "anti-cancer section" since the
		ineoplastic agents) & L04 (Immunosuppressants) class.
379.	Name and address of manufacture /	M/s Bio Mark Pharmaceuticals. Plot No. 527, Sundar
	Applicant	Industrial Estate, Lahore (Tablet I & II General)
	Brand Name + Dosage Form and	EVRTRS Tablet 10mg
	Strength	
	Composition	Each Tablet Contains:
		Everolimus 10mg
	Dairy No. date of R &I fee	Form-5 Dy.No 10310 dated 05-03-2019 Rs.20,000 dated 04-03-2019
	Pharmacological Group	Protein kinase inhibitor
	Type of form	Form 5
	Finished product specifications	Innovator
	Pack size and Demand Price	As per SRO
	Approval status of product in Reference RegulatoryAuthorities	AFINITOR 5mg Novartis UK Approved MHRA (BNF 73, p#865-866)
	Me-too-status	Afinitor 5mg (M/S Novartis) Reg. # 069520
	GMP Status	GMP certificate valid till 12-02-2022, issued on the basis of inspection conducted on 13-02-2020.
	Remarks of the Evaluator (PEC-XVII)	• Confirmation of cytotoxic facility is required as per decision
		of 297th meeting of DRB as
		• "Registration Board after thorough deliberation and
		considering the high-risk classification i.e., "Anticancer (L01)", and reviewing its previous decision decided to allow the manufacturing of such type of drugs which fall in both
		"Antineoplastic (L01)" & "Immunosuppressants (L04)" class including everolimus and methotrextare etc. in the "Anti-
		cancer" section only (being high risk products)."
	_	oplied formulation in the "anti-cancer section" since the ineoplastic agents) & L04 (Immunosuppressants) class.
380.	Name and address of manufacture /	M/s Bio Mark Pharmaceuticals. Plot No. 527, Sundar
	Applicant	Industrial Estate, Lahore (Tablet I & II General)
	Brand Name + Dosage Form and	PARBFN 500/200mg Tablet
	Strength	
	Composition	Each Film Coated Tablet Contains:
		Paracetamol 500mg

	Ibuprofen 200mg
Dairy No. date of R &I fee	Form-5 Dy.No 10337 dated 05-03-2019 Rs.20,000 dated 04- 03-2019
Pharmacological Group	NSAID (Nonsteroidal anti-inflammatory drug)
Type of form	Form 5
Finished product specifications	Innovator's specifications
Pack size and Demand Price	30's, As per SRO
Approval status of product in Reference	NUROMOL 500mg/200mg Reckitt Benckiser Healthcare
Regulatory Authorities	UK
	(Approved MHRA)
Me-too-status	Could not be confirmed
GMP Status	GMP certificate valid till 12-02-2022, issued on the basis of inspection conducted on 13-02-2020.
Remarks of the Evaluator (PEC-XVII)	• Submit application on prescribed format on Form 5D along with submission of Differential fee.
	<ul> <li>Provide stability data as per decision of the DRB in 293<sup>rd</sup> meeting.</li> </ul>
D :: D C IC	<ul> <li>Products with same composition approved in 287<sup>th</sup> and 307<sup>th</sup> meetings of DRB as new drug applications.</li> </ul>

### **Decision: Deferred for:**

- Submission of revised application on prescribed format on Form-D along with differential fee.
- Submission of Stability data as per guidelines approved in 293<sup>rd</sup> meeting of Registration Board.
- Submission of updated master formulation, method of manufacturing and drug product specifications.

specifications.	
Name and address of manufacture /	M/s Bio Mark Pharmaceuticals. Plot No. 527, Sundar
Applicant	Industrial Estate, Lahore (Tablet I & II General)
Brand Name + Dosage Form and	KOFGO Tablet
Strength	
Composition	Each Film Coated Tablet Contains:
	Paracetamol 325mg
	Pseudoephedrine Hcl 30mg
	Chlorpheniramine Maleate 1mg
	Dextromethorphan Hbr 10mg
	Vitamin C 50mg
Dairy No. date of R &I fee	Form-5 Dy.No 10320 dated 05-03-2019 Rs.20,000 dated 04-
	03-2019
Pharmacological Group	Paracetamol: NSAID
	Pseudoephedrine HCl: Sympathomimetic
	Chlorpheniramine maleate: Antihistamine
	Dextromethorphan HBr: Antitussive
	Vitamin C: Vitamin
Type of form	Form 5
Finished product specifications	Innovator specifications
Pack size and Demand Price	As per SRO
Approval status of product in Reference	Could not be confirmed
Regulatory Authorities	
Me-too-status	COFCOL 325mg/30mg/ 1mg/10mg/50mg Abbot
	Reg. # 007279
GMP Status	GMP certificate valid till 12-02-2022, issued on the basis of
	inspection conducted on 13-02-2020.
Remarks of the Evaluator (PEC-XVII)	Provide evidence of approval/availability in reference
	regulatory authorities as approved in 275 <sup>th</sup> meeting of
	Name and address of manufacture / Applicant  Brand Name + Dosage Form and Strength  Composition  Dairy No. date of R &I fee  Pharmacological Group  Type of form  Finished product specifications  Pack size and Demand Price  Approval status of product in Reference Regulatory Authorities  Me-too-status

		DRB.							
	Decision: Deferred for confirmation/evi	dence of approval/availability in reference regulatory							
	authorities as approved in 275th meeting								
382.	Name and address of manufacture /	M/s Barrett Hodgson Pakistan (Pvt) Ltd.							
	Applicant	F/423, S.I.T.E, Karachi.							
	Brand Name + Dosage Form and	Brextec tablet 0.25mg							
	Strength								
	Composition	Each film coated tablet contains:							
		Brexpiprazole0.25mg							
	Dairy No. date of R &I fee	Dy. No 12344 dated 06-03-2019 Rs.50,000/- dated 05-03-							
		2019 Challan No.0840286 dated: 27.02.2019							
	Pharmacological Group	A novel atypical antipsychotic agent							
	Type of form	Form 5D							
	Finished product specifications	Manufacturer specifications							
	Pack size and Demand Price	Pack of 10's, Rs: 60000/-							
		Pack of 14's, Rs: 84000/-							
		Pack of 20's, Rs: 120,000/-							
		Pack of 28's, Rs: 168,000/-							
		Pack of 30's, Rs: 180,000/-							
		or as per DRAP's pricing policy.							
	Approval status of product in Reference	REXULTI (Brexpiprazole 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3							
	Regulatory Authorities	mg and 4 mg) film coated tablets, TGA approved.							
	Me-too-status	Could not be confirmed/ not provided							
	GMP Status	GMP inspection conducted on 16th & 28th August 2018.							
		Conclusion: the firm has complied and addressed all the							
		observations as advised in the last inspection. Overall found							
		satisfactory and progressive towards good level of GMP							
	Remarks of the Evaluator (PEC-XVII)	compliance.							
	Remarks of the Evaluator	• Stability study data as per guidelines provided in 293 <sup>rd</sup>							
		meeting of Registration Board is required.							
		• Provide the updated master formulation, method of							
		manufacturing and drug product specifications along with stability data.							
		• Evidence of section approval from Licensing Division,							
		DRAP Islamabad.							
	<b>Decision: Deferred for:</b>								
	<ul> <li>Submission of Stability data as per guidelines approved in 293<sup>rd</sup> meeting of Registration</li> </ul>								
	Board.								
		ormulation, method of manufacturing and drug product							
	specifications.								
		proval by Licensing Division, DRAP Islamabad.							
383.	Name and address of manufacture /	M/s AGP Ltd., B-23-C, S.I.T.E, Karachi.							
	Applicant	Tablet Section (General)							
	Brand Name + Dosage Form and	Erto-Met 2.5/500mg tablet							
	Strength								
	Composition	Each film coated tablet contains:							
		Ertugliflozin							
		(as Ertugliflozin L-pyroglutamic acid)2.5mg							
	D : N 1 CD 016	Metformin Hydrochloride500mg							
	Dairy No. date of R &I fee	Dy. No. 13000 dated 06-03-2019 Rs.50,000/- dated 06-03-							
	DI 1 1 C	2019 Challan No. 0789315 dated: 02.03.2019							
	Pharmacological Group	Ertugliflozin: Sodium-glucose co-transporter-2 (SGLT2)							
		inhibitor							
	Tours	Metformin hydrochloride: antihyperglycemic agent							
	Type of form	Form 5D							
	Finished product specifications	Innovator specifications							

Pack size and Demand Price	14's, as per SRO
Approval status of product in Reference	SEGLUROMET® 2.5mg/500mg, 2.5mg/1000mg,
Regulatory Authorities	7.5mg/500mg, 7.5mg/1000mg (Merck Sharp Dohme) US FDA
Me-too-status	Could not be confirmed
GMP Status	Routine GMP inspection conducted on 16-10-2018 with conclusion:
	Based on the above observations their overall GMP of plant was noted good.
Remarks of the Evaluator (PEC-XVII)	<ul> <li>Submit revised application on prescribed Form 5D.</li> <li>Provide stability data as per decision of the DRB in 293rd meeting.</li> <li>Provide the updated master formulation, method of manufacturing and drug product specifications along with</li> </ul>
	stability data.  • Title/Management of the firm changed from M/s AGP (Pvt) Ltd. to M/s AGP Limited vide Licensing Division letter No.F.2-3/92-Lic (Vol-II) dated 29-12-2016.

# **Decision: Deferred for:**

- Submission of Stability data as per guidelines approved in 293<sup>rd</sup> meeting of Registration Board.
- Submission of updated master formulation, method of manufacturing and drug product specifications.

• Evidence of relevant section approval by Licensing Division, DRAP Islamabad

• Evidence of relevant section approval by Licensing Division, DRAP Islamabad.					
6-03-					
T2)					
′1000mg,					
hme) US					
018 with					
of plant					
293rd					
g with					
GP (Pvt)					
P · n					

Ltd. to M/s AGP Limited vide Licensing Division le	tter
No.F.2-3/92-Lic (Vol-II) dated 29-12-2016.	

#### **Decision: Deferred for:**

- Submission of Stability data as per guidelines approved in 293<sup>rd</sup> meeting of Registration Board.
- Submission of updated master formulation, method of manufacturing and drug product specifications.

• Evidence of relevant section approval by Licensing Division, DRAP Islamabad.

	Evidence of relevant section app	Toval by Licensing Division, DKAF Islamabau.
385.	Name and address of manufacture /	M/s AGP Ltd., B-23-C, S.I.T.E, Karachi.
	Applicant	Tablet Section (General)
	Brand Name + Dosage Form and	Erto-Met 7.5/1000mg tablet
	Strength	
	Composition	Each film coated tablet contains:
		Ertugliflozin
		(as Ertugliflozin L-pyroglutamic acid)7.5mg
		Metformin Hydrochloride1000mg
	Dairy No. date of R &I fee	Dy. No. 12998 dated 06-03-2019 Rs.50,000/- dated 06-03-
		2019 Challan No. 0789317 dated: 02.01.2019
	Pharmacological Group	Ertugliflozin: Sodium-glucose co-transporter-2 (SGLT2)
		inhibitor
		Metformin hydrochloride: antihyperglycemic agent
	Type of form	Form 5D
	Finished product specifications	Manufacturer specifications
	Pack size and Demand Price	14's, as per SRO
	Approval status of product in Reference	SEGLUROMET® 2.5mg/500mg, 2.5mg/1000mg,
	Regulatory Authorities	7.5mg/500mg, 7.5mg/1000mg
		(Merck Sharp Dohme) US FDA
	Me-too-status	Could not be confirmed
	GMP Status	Routine GMP inspection conducted on 16-10-2018 with
		conclusion:
		Based on the above observations their overall GMP of plant
	ODEC VALUE	was noted good.
	Remarks of the Evaluator (PEC-XVII)	• Submit application on prescribed format on Form 5D.
		• Provide stability data as per decision of the DRB in 293rd
		meeting.
		<ul> <li>Provide the updated master formulation, method of</li> </ul>
		manufacturing and drug product specifications along with
		stability data.
		• Title/Management of the firm changed from M/s AGP
		(Pvt) Ltd. to M/s AGP Limited vide Licensing Division
İ		letter No.F.2-3/92-Lic (Vol-II) dated 29-12-2016.

# **Decision: Deferred for:**

- Submission of Stability data as per guidelines approved in 293<sup>rd</sup> meeting of Registration Roard.
- Submission of updated master formulation, method of manufacturing and drug product specifications.
- Evidence of relevant section approval by Licensing Division, DRAP Islamabad.

## Case No. 2: Registration applications for local manufacturing of (Human) drugs (Differential Fee)

#### a) New cases

386	6.	Name	and	address	of	manufacturer/	Roryan Pharmaceutical Industries (Pvt) Ltd. 85/B, Hayatabad
		Applica	ant				Industrial Estate, Peshawar
		Brand 1	Name	+ Dosage	e Fo	rm + Strength	Dicloyan-P 75mg tablet

Diclofenac potassium75mg  Diary No. Date of R & I & fee  Form-5, Fee: 8,000/-, Date.08-06-2012 (Photo copy)  Differential fee: Rs.12,000/- Dated 27-10-2016	
	Challan
No.0284428, (Original)Duplicate dossier	
Pharmacological Group Phenylacetic acid (NSAID)	
Type of Form Form-5	
Finished product Specification Manufacture specification	
Pack size & Demanded Price 2 × 10 tablets, PKR: 110/- per pack	
Approval status of product in Reference Regulatory Authorities Not available	
Me-too status  Beflam 75mg tablet of M/s Batala pharms Gujranwala. Registration No. 031128	aceuticals,
GMP status  Firm has submitted copy of panel inspection report 01-2022 in which the panel recommends the grant of DML.	
Remarks of the Evaluator (PEC-XVII) Provide evidence of approval of applied formula	ılation in
reference regulatory authorities / agencies which we by the Registration Board in its 275th meeting.	
• Revise the finished drug specification as pe monograph with submission of requisite fee.	r official
• The applied formulation is film coated tablet but in formula/composition, the required excipients for film to mentioned.	
• In the manufacturing outlines, the film coating promentioned. Please clarify.	rocess not
• The USP official monograph for finished drug product photodiode array detector for Identification Test E evidence of availability of required quality contraction facility for applied product. (Gradient HPLC with P array detector).	B. Provide ol testing
Provide evidence of approval of relevant section by division, DRAP Islamabad.	Licensing
Decision: Registration Board decided to reject the application since the applied product approved by any Reference Regulatory Authority nor any safety and efficacy data has been so by the applicant.	submitted
<b>387.</b> Name and address of manufacturer/ Roryan Pharmaceutical Industries (Pvt) Ltd. 85/B, 1	Hayatabad
Applicant Industrial Estate, Peshawar	
Brand Name + Dosage Form + Strength Montelu 5mg chewable tablet	
Composition Each chewable tablet contains:	
Montelukast (as Montelukast sodium)5mg	
Diary No. Date of R & I & fee Form-5, Dy.No. 383 dated 08-06-2012 Fee F	
Date.08-06-2012 (Photo copy), Dy.No.575 dated 27	
Differential fee: Rs.12,000 Dated 27-10-2016,	Challan
No.0284432 (Photocopy)	
"Duplicate dossier, R & I Verified"	
Pharmacological Group Leukotriene receptor antagonist (antiasthmatic)	
Type of Form Form-5	
Finished product Specification Manufacture specification	
Pack size & Demanded Price 2× 10's, PKR 360.00/- per pack	

Approval status of product in Reference	Singulair (4mg, 5 mg) Chewable Tablet
Regulatory Authorities	(US FDA Approved with boxed warning:
Ç	SERIOUS NEUROPSYCHIATRIC EVENTS
Me-too status	Dowkast 5mg chewable tablet of M/s Seatle (Pvt) Ltd. Lahor
	Registration No. 103296
GMP status	Firm has submitted copy of panel inspection report dated 13
	01-2022 in which the panel recommends the grant of renews
	of DML.
Remarks of the Evaluator (PEC-XVII)	<ul> <li>Revise the finished drug product specifications as per offici monograph and submit the requisite fee as the product offici monograph available in USP.</li> </ul>
	<ul> <li>Provide recent/last GMP inspection report conducted with last three years.</li> </ul>
	• Verification of DRAP R & I for initial and differenti submission is required.

# **Decision: Approved with USP Specifications.**

- Firm shall submit the fee of Rs. 7,500 for correction/pre-approval change/ in product specifications, as per notification No.F.7-11/2012-B&A/DRAP dated 13-07-2021.
- Registration Board further decided to verify fee challans as per decision of 285<sup>th</sup> meeting of Registration Board.

	Registration Board.	
388.	Name and address of manufacturer/	Saydon Pharmaceutical Industries (Pvt.) Ltd. 77/A, Hayatabad
	Applicant	Industrial Estate, Peshawar
	Brand Name + Dosage Form + Strength	LGEQUIN 1mg tablet
	Composition	Each uncoated tablet contains:
		Lorazepam1mg
	Diary No. Date of R & I & fee	Form-5, Dy. No.38 dated Fee Rs:8,000/-, Date.11-07-2009,
		Dy. No. Differential fee: Rs.12,000 Dated 25-05-2015 vide
		deposit slip No.0294698.
		"Duplicate dossier, R & I verified"
	Pharmacological Group	Benzodiazepine
	Type of Form	Form-5
	Finished product Specification	BP Specifications
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities	Ativan® (lorazepam) 1mg tablet, (US FDA approved)
	Me-too status	Lorafend 1mg tablet of M/s Friend pharma, Lahore.
		Registration No. 099854
	GMP status	As per cGMP compliance inspection conducted on 28-07-2020
		by the area FID with reference to Pakistan Citizen's Portal
		complaint, mainly about GMP particularly injectable section
		(General & cephalosporin), lack of experienced persons and
		microbiological testing of products. The FID recommendations
		included:
		They are directed to
		1. Provide hand sanitizer after change in both the change
		rooms.
		2. Record the temperature and humidity of the
		warehouses at least 03 times in a day.
		3. Provide dispensing booth in the dispensing area.
		4. Increase the number of pharmacists in the production
		area.

		<ol> <li>Improve the dedication in the general and cephalosporins area of the plant in consultation with Licensing Division of DRAP.</li> <li>Provide ready-made, properly designed optical checking booths.</li> <li>Provide FTIR, more HPLCs columns (at least two), primary reference standards for accurate tests and analysis of their mostly produced products.</li> <li>Repair their out of order stability chamber.</li> <li>Latest official books are advised.</li> <li>Make the QA department independent.</li> <li>As per findings of the inspection recorded and keeping in view the overall cGMP compliance status of the firm in terms of plant, premises, manufacturing, quality control, calibration</li> </ol>
		record evaluation, the firm may be considered at acceptable
		level of cGMP compliance subject to compliance of the
		observations and recommendations. The test results of sampled
		products shall also be analyzed.
	Remarks of the Evaluator (PEC-XVII)	• Approval of tablet Psychotropic section granted vide Licensing
		Division letter No.F.6-1/2009-Lic dated 17-03-2009.
		Firm has revised specifications as per BP monograph and
		submitted fee of Rs: 7500/- vide on-line deposit Slip No.
		75703447.
		er shall be issued after having updated satisfactory GMP
		. Registration Board further decided to verify fee challans as
389.	per decision of 285 <sup>th</sup> meeting of Registra Name and address of manufacturer/	
309.	Applicant	Saydon Pharmaceutical Industries (Pvt.) Ltd. 77/A, Hayatabad Industrial Estate, Peshawar
	Brand Name + Dosage Form + Strength	LGEQUIN 2mg tablet
	Composition	Each uncoated tablet contains:
		Lorazepam2mg
	Diary No. Date of R & I & fee	Form-5, Dy No.39 dated 11-07-2009, Fee Rs:8,000/-, Date.11-
		07-2009, Differential fee: Rs.12,000 Dated 25-05-2015 vide
		deposit slip No.0294699,
		"Duplicate dossier, R & I verified"
	Pharmacological Group	Benzodiazepine
	Type of Form	Form-5
	Finished product Specification	BP specification
	Pack size & Demanded Price Approval status of product in Reference	As per SRO Ativan® (lorazepam) 2mg tablet, US FDA approved
	Regulatory Authorities	Ativan® (lorazepain) Zing tablet, US FDA approved
	Me-too status	Gtvan 2mg tablet of M/s Glitz pharma, Islamabad. Registration
	1.10 000 0.000	No. 081420
	GMP status	As per cGMP compliance inspection conducted on 28-07-2020
	Givii status	by the area FID with reference to Pakistan Citizen's Portal
		complaint, mainly about GMP particularly injectable section
		(General & cephalosporin), lack of experienced persons and
		microbiological testing of products. The FID recommendations
		included:
		They are directed to
		Provide hand constitute attended in both the above
		Provide hand sanitizer after change in both the change rooms
		rooms.
		rooms. 2. Record the temperature and humidity of the
		rooms.

		<ul><li>4. Increase the number of pharmacists in the production area.</li><li>5. Improve the dedication in the general and</li></ul>
		cephalosporins area of the plant in consultation with Licensing Division of DRAP.
		<ol><li>Provide ready-made, properly designed optical checking booths.</li></ol>
		7. Provide FTIR, more HPLCs columns (at least two), primary reference standards for accurate tests and analysis of their mostly produced products.
		<ul><li>8. Repair their out of order stability chamber.</li><li>9. Latest official books are advised.</li><li>10. Make the QA department independent.</li></ul>
		As per findings of the inspection recorded and keeping in view the overall cGMP compliance status of the firm in terms of plant, premises, manufacturing, quality control, calibration
		record evaluation, the firm may be considered at acceptable level of cGMP compliance subject to compliance of the observations and recommendations. The test results of sampled products shall also be analyzed.
	Remarks of the Evaluator (PEC-XVII)	• Approval of tablet Psychotropic section granted vide Licensing Division letter No.F.6-1/2009-Lic dated 17-03- 2009.
		• Firm has revised specifications as per BP monograph and submitted fee of Rs: 7500/- vide on-line deposit slip No. 921008842473.
		• Verification of DRAP R & I of initial submission is required.
	inspection status from QA< Division	r shall be issued after having updated satisfactory GMP a. Registration Board further decided to verify fee challans as ation Board and R&I from DRAP's original record.
390.	Name and address of manufacturer/ Applicant	Saydon Pharmaceutical Industries (Pvt.) Ltd. 77/A, Hayatabad Industrial Estate, Peshawar
	Brand Name + Dosage Form + Strength	ZULIX 200mg/100ml infusion (Intra-venous)
	Composition	Each 100ml contains: Linezolid200mg
	Diary No. Date of R & I & fee	Form-5, Dy No.45 dated 17-01-2011 Fee Rs:8,000/-, Date.17-01-2011, Differential fee: Rs.12,000 Dated 07-01-2015 vide challan No.0036094,
		"Duplicate dossier, R & I verified"
	Pharmacological Group	Oxazolidinone
	Type of Form	Form-5
	Finished product Specification	Manufacturer specification
	Pack size & Demanded Price	1's, As per SRO
	Approval status of product in Reference Regulatory Authorities	ZYVOX® (Pfzier) US FDA approved
	Me-too status	Zoldap 200mg/100ml IV infusion of M/s Getz pharma, Karachi. Registration No. 055431
	GMP status	As per cGMP compliance inspection conducted on 28-07-2020 by the area FID with reference to Pakistan Citizen's Portal
		complaint, mainly about GMP particularly injectable section (General & cephalosporin), lack of experienced persons and microbiological testing of products. The FID recommendations included:

		The same that the
		They are directed to
		1. Provide hand sanitizer after change in both the change
		rooms.
		2. Record the temperature and humidity of the
		warehouses at least 03 times in a day.
		3. Provide dispensing booth in the dispensing area.
		4. Increase the number of pharmacists in the production
		area.
		5. Improve the dedication in the general and
		cephalosporins area of the plant in consultation with
		Licensing Division of DRAP.
		6. Provide ready-made, properly designed optical
		checking booths.
		7. Provide FTIR, more HPLCs columns (at least two),
		primary reference standards for accurate tests and
		analysis of their mostly produced products.
		8. Repair their out of order stability chamber.
		9. Latest official books are advised.
		10. Make the QA department independent.
		As per findings of the inspection recorded and keeping in view
		the overall cGMP compliance status of the firm in terms of
		plant, premises, manufacturing, quality control, calibration
		record evaluation, the firm may be considered at acceptable
		level of cGMP compliance subject to compliance of the
		observations and recommendations. The test results of sampled
		products shall also be analyzed.
	Remarks of the Evaluator (PEC-XVII)	• Firm has revised finished drug product specifications and
		submitted fee of Rs: 7500/- vide on-line deposit slip
		No.26367271.
		• Approval of injectable liquid and infusion (small volume)
		granted vide Licensing division letter No.F.3-5/94-Lic (Vol-II) dated 15-07-2006.
		11) dated 13-07-2000.
	Decision: Approved with Innovator's sp	pecifications. Registration letter shall be issued after having
		status from QA< Division. Registration Board further
		ision of 285 <sup>th</sup> meeting of Registration Board.
391.		Saydon Pharmaceutical Industries (Pvt.) Ltd. 77/A, Hayatabad
	Applicant	Industrial Estate, Peshawar
	Brand Name + Dosage Form + Strength	ONEUROTON 2.5mg tablet
	Composition	Each film-coated tablet contains:
		Letrozole2.5mg
	Diary No. Date of R & I & fee	Form-5, Dy No. 37 dated 17-01-2011 Fee Rs:8,000/-, Date.17-
		01-2011, Differential fee: Rs.12,000 Dated 11-03-2016 vide
		challan No.0306635.
		Duplicate dossier
	Pharmacological Group	Non-steroidal aromatase inhibitor
	Type of Form	Form-5
	Finished product Specification	USP specification
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities	FEMARA (Novartis) US FDA approved
	Me-too status	Oreta 2.5mg tablet of M/s Aries pharma, Peshawar.
		Registration No. 085909
	GMP status	As per cGMP compliance inspection conducted on 28-07-2020
		by the area FID with reference to Pakistan Citizen's Portal

		complaint, mainly about GMP particularly injectable section (General & cephalosporin), lack of experienced persons and microbiological testing of products. The FID recommendations included:  They are directed to  1. Provide hand sanitizer after change in both the change rooms.  2. Record the temperature and humidity of the warehouses at least 03 times in a day.  3. Provide dispensing booth in the dispensing area.
		4. Increase the number of pharmacists in the production area.
		5. Improve the dedication in the general and cephalosporins area of the plant in consultation with Licensing Division of DRAP.
		<ol><li>Provide ready-made, properly designed optical checking booths.</li></ol>
		<ol> <li>Provide FTIR, more HPLCs columns (at least two), primary reference standards for accurate tests and analysis of their mostly produced products.</li> <li>Repair their out of order stability chamber.</li> <li>Latest official books are advised.</li> </ol>
		10. Make the QA department independent.  As per findings of the inspection recorded and keeping in view
		the overall cGMP compliance status of the firm in terms of plant, premises, manufacturing, quality control, calibration record evaluation, the firm may be considered at acceptable level of cGMP compliance subject to compliance of the observations and recommendations. The test results of sampled products shall also be analyzed.
	Remarks of the Evaluator (PEC-XVII)	• Firm revised finished drug product specifications as per official monograph (USP) and submitted requisite fee Rs: 7500/- vide on-line deposit slip No.355003317935
		• R & I need to be verified.
	inspection status from QA< Division	r shall be issued after having updated satisfactory GMP n. Registration Board further decided to verify DRAP R & I ns along with fee challans as per decision of 285 <sup>th</sup> meeting of P's original record
392.	Name and address of manufacturer/	Saydon Pharmaceutical Industries (Pvt.) Ltd. 77/A, Hayatabad
	Applicant	Industrial Estate, Peshawar
	Brand Name + Dosage Form + Strength	TRADON tablet
	Composition	Each film-coated tablet contains:
	-	Paracetamol325mg
		Tramadol Hydrochloride37.5mg
	Diary No. Date of R & I & fee	Form-5, Fee Rs:8,000/-, Date.12-01-2011, Differential fee:
		Rs.12,000 Dated 07-01-2015 deposited vide challan No.0036090. Duplicate dossier
	Pharmacological Group	Opioid analogue/ analgesic
	Type of Form	Form-5
	Finished product Specification	USP specification
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference	Ultracet coated tablet (Janssen Pharma) US FDA approved. In
	Regulatory Authorities	MHRA both coated and uncoated available.

	Me-too status	Tramal plus film coated tablet of M/s The Searle Company,
		Lahore. Registration No. 077129
	GMP status	As per cGMP compliance inspection conducted on 28-07-2020
		by the area FID with reference to Pakistan Citizen's Portal complaint, mainly about GMP particularly injectable section
		(General & cephalosporin), lack of experienced persons and microbiological testing of products. The FID recommendations
		included:
		They are directed to  1. Provide hand sanitizer after change in both the change
		2. Record the temperature and humidity of the
		warehouses at least 03 times in a day.  3. Provide dispensing booth in the dispensing area.
		4. Increase the number of pharmacists in the production area.
		5. Improve the dedication in the general and cephalosporins area of the plant in consultation with Licensing Division of DRAP.
		6. Provide ready-made, properly designed optical checking booths.
		7. Provide FTIR, more HPLCs columns (at least two),
		primary reference standards for accurate tests and analysis of their mostly produced products.
		8. Repair their out of order stability chamber.
		<ul><li>9. Latest official books are advised.</li><li>10. Make the QA department independent.</li></ul>
		As per findings of the inspection recorded and keeping in view
		the overall cGMP compliance status of the firm in terms of plant, premises, manufacturing, quality control, calibration
		record evaluation, the firm may be considered at acceptable
		level of cGMP compliance subject to compliance of the observations and recommendations. The test results of sampled
		products shall also be analyzed.
	Remarks of the Evaluator (PEC-XVII)	• Firm revised the finished drug product specifications from
		Tramadol prolong release tablets BP to USP specifications and submitted fee of Rs: 7500/- vide on-line deposit slip
		No.374748105.
		<ul> <li>DRAP R &amp; I of initial submission could not be verified (Record not found).</li> </ul>
	inspection status from QA< Division for initial and differential fee submission	er shall be issued after having updated satisfactory GMP n. Registration Board further decided to verify DRAP R & I ns along with fee challans as per decision of 285th meeting of
	Registration Board and R&I from DRA	
393.	Name and address of manufacturer/ Applicant	Saydon Pharmaceutical Industries (Pvt.) Ltd. 77/A, Hayatabad Industrial Estate, Peshawar
	Brand Name + Dosage Form + Strength	Industrial Estate, Pesnawar Inj. NEUROTON 250mg
	Composition	Each 2ml ampoule contains:
	Diamy No. Date of D. 9. 1.9. for	Citicoline Sodium equivalent to Citicoline250mg
	Diary No. Date of R & I & fee	Form-5, Dy. No. dated 17-01-2011 Fee Rs:8,000/- Date.17-01-2011(Photocopy), Differential fee: Rs.12,000 Dated 11-03-
		2016 vide challan No. 0906632 (Photocopy).
		Duplicate dossier
	Pharmacological Group	Vasodilator (nootropics & Neurotonic)

	Type of Form	Form-5
	Finished product Specification	Innovator specification
	Pack size & Demanded Price	As per SRO
	Approval status of product in Reference Regulatory Authorities	CITICOLINE PANPHARMA 250 mg / 2 ml solution for injection (IM, IV) ampoule by M/s PANPHARMA (ANSM, France Approved) PMDA Japan approved
	Me-too status	
	Nic-too status	Citocode 250mg/2ml Injection of Rotex Pharma (Pvt) Ltd.
	CMD status	Islamabad. Registration No. 100804
	Remarks of the Evaluator (PEC-XVII)	As per cGMP compliance inspection conducted on 28-07-2020 by the area FID with reference to Pakistan Citizen's Portal complaint, mainly about GMP particularly injectable section (General & cephalosporin), lack of experienced persons and microbiological testing of products. The FID recommendations included:  They are directed to  1. Provide hand sanitizer after change in both the change rooms.  2. Record the temperature and humidity of the warehouses at least 03 times in a day.  3. Provide dispensing booth in the dispensing area.  4. Increase the number of pharmacists in the production area.  5. Improve the dedication in the general and cephalosporins area of the plant in consultation with Licensing Division of DRAP.  6. Provide ready-made, properly designed optical checking booths.  7. Provide FTIR, more HPLCs columns (at least two), primary reference standards for accurate tests and analysis of their mostly produced products.  8. Repair their out of order stability chamber.  9. Latest official books are advised.  10. Make the QA department independent.  As per findings of the inspection recorded and keeping in view the overall cGMP compliance status of the firm in terms of plant, premises, manufacturing, quality control, calibration record evaluation, the firm may be considered at acceptable level of cGMP compliance subject to compliance of the observations and recommendations. The test results of sampled products shall also be analyzed.
		granted vide Licensing division letter No.F.3-5/94-Lic (Vol-II) dated 15-07-2006.
		• DRAP R & I of initial submission could not be verified (Record not found).
	inspection status from QA< Division	r shall be issued after having updated satisfactory GMP a. Registration Board further decided to verify DRAP R & I as along with fee challans as per decision of 285 <sup>th</sup> meeting of P's original record.
394.	Name and address of manufacturer/	Wilshire Laboratories (Pvt) Ltd. 124/1, Quaid-e-Azam
	Applicant	Industrial Estate, Lahore.
	Brand Name + Dosage Form + Strength	IMPIKA CR

	Composition	Each enteric, film-coated, bilayer, controlled-release tablet contains paroxetine (as paroxetine hydrochloride)
	Diary No. Date of R & I & fee	Form-5, Dy.No.2589 dated 22-06-2011 Fee Rs:8,000/-, Date 22-06-2011, Dy.No.305 dated 14-01-2015, Differential fee: Rs.12,000 Dated 14-01-2015,
		"Duplicate dossier, R & I Verified"
-	Pharmacological Group	Anti-depressant
-	Type of Form	Form-5
	Finished product Specification	USP specifications
-	Pack size & Demanded Price	As per SRO 470 (1)93
	Approval status of product in Reference	PAXIL CR Extended-release 37.5 mg tablets.
	Regulatory Authorities	(US FDA approved with boxed warning: SUICIDAL THOUGHTS AND BEHAVIORS
	Me-too status	Peroxa CR 37.5mg tablet of M/s Lisko Pakistan (Pvt) Ltd. Karachi. Registration No.082148
	GMP status	GMP certificate issued on 05-09-2019, on the basis of inspection conducted on 08-08-2019.
	Remarks of the Evaluator (PEC-XVII)	• Firm revised the label claim/composition as per reference product that is:
		Each enteric, film-coated, bilayer, controlled-release tablet contains paroxetine (as paroxetine hydrochloride)
		In MHRA, the plain tablets are registered in strengths of 10mg, 20mg, 30mg, 40mg.  The firm also revised the formulation and manufacturing outlines in line with label claim/composition that is enteric, film-coated, controlled-releasee tablet.
		• Tablet Section (General) available as per Licensing division, DRAP Islamabad letter No.F.1-65/84-Lic (Vol-IV) dated 06-10-2021 for renewal of DML.
	hydrochloride)37.5 mg.	ntrolled-release tablet contains paroxetine (as paroxetine
395.	Name and address of manufacturer/	Masfa Industries (Pvt.) Ltd. 17-Km, Sheikhupura Road,
	Applicant	Lahore.
	Brand Name + Dosage Form + Strength	OTILLION Suspension
	Composition	Each ml contains:
-	Diary No. Date of R & I & fee	Domperidone1mg Form-5, Dy No. 926 Dated: 01-06-2011, Fee Rs: 8,000/-, Dated
		01-06-2011 (photo copy)
		Dy.No. 82 dated 05-01-2016, Differential fee Rs: 12,000/-
		Dated 05-01-2016 (photo copy), "Duplicate descion P. & I. Verified"
	Dharmanalanias! Cross-	"Duplicate dossier, R & I Verified"
	Pharmacological Group	Anti-emetic
	Type of Form	Form-5
	Finished product Specification	Manufacturer specifications
	Pack size & Demanded Price	1 × 120ml, Rs: 85.00/120ml bottle

	Approval status of product in Reference	MHRA approved
	Regulatory Authorities Me-too status	
	Me-too status	Domilium 5mg/5ml suspension of M/s Jinnah Pharmaceuticals,
		Multan. Registration No. 099610
	GMP status	Not provided
	Remarks of the Evaluator (PEC-XVII)	• Firm has claimed manufacturer specifications, while currently the product is non-pharmacopoeial.
		BP monographs for both base and maleate forms of API are available.
		• GMP inspection report conducted within last 3 years is required
		• Panel inspection report dated 14-02-2011 for grant of DML by way of formulation for general oral liquids section is attached.
		• Differential fee of Rs: 24000/- for two products Ecephyl cough syrup and Otillion suspension submitted vide same challan No.0515190 dated 23-12-2015.
		• Verification of R & I for initial and differential fee submission along with challans required.
	Registration Board.	o verify fee challans as per decision of 285th meeting of
	Registration letter will be issued after su firm.	ibmission of valid satisfactory GMP inspection report by the
396.		Bosch Pharmaceuticals (Pvt.) Ltd., Plot No.221-223, Sector 23,
396.	firm.	Bosch Pharmaceuticals (Pvt.) Ltd., Plot No.221-223, Sector 23,
396.	<b>firm.</b> Name and address of manufacturer/	
396.	firm.  Name and address of manufacturer/ Applicant	Bosch Pharmaceuticals (Pvt.) Ltd., Plot No.221-223, Sector 23, Korangi Industrial Area, Karachi. (DML No. 000350, Plant-I)
396.	Name and address of manufacturer/ Applicant  Brand Name + Dosage Form + Strength	Bosch Pharmaceuticals (Pvt.) Ltd., Plot No.221-223, Sector 23, Korangi Industrial Area, Karachi.
396.	firm.  Name and address of manufacturer/ Applicant	Bosch Pharmaceuticals (Pvt.) Ltd., Plot No.221-223, Sector 23, Korangi Industrial Area, Karachi. (DML No. 000350, Plant-I) Orip 500mg injection
396.	Name and address of manufacturer/ Applicant  Brand Name + Dosage Form + Strength	Bosch Pharmaceuticals (Pvt.) Ltd., Plot No.221-223, Sector 23, Korangi Industrial Area, Karachi. (DML No. 000350, Plant-I) Orip 500mg injection Each vial contains:
396.	Name and address of manufacturer/ Applicant  Brand Name + Dosage Form + Strength Composition	Bosch Pharmaceuticals (Pvt.) Ltd., Plot No.221-223, Sector 23, Korangi Industrial Area, Karachi. (DML No. 000350, Plant-I)  Orip 500mg injection  Each vial contains:  Doripenem (as monohydrate)500mg
396.	Name and address of manufacturer/ Applicant  Brand Name + Dosage Form + Strength Composition	Bosch Pharmaceuticals (Pvt.) Ltd., Plot No.221-223, Sector 23, Korangi Industrial Area, Karachi. (DML No. 000350, Plant-I)  Orip 500mg injection  Each vial contains: Doripenem (as monohydrate)500mg  Form-5D, Dy No. dated, Initial Fee Rs:15,000/- Dated 09-05-2012 (Challan Photo copy), Differential Fee Rs: 5000/- vide challan No.0003351 dated 09-09-2013. (Challan photocopy),
396.	Name and address of manufacturer/ Applicant  Brand Name + Dosage Form + Strength Composition	Bosch Pharmaceuticals (Pvt.) Ltd., Plot No.221-223, Sector 23, Korangi Industrial Area, Karachi. (DML No. 000350, Plant-I)  Orip 500mg injection  Each vial contains: Doripenem (as monohydrate)500mg  Form-5D, Dy No. dated, Initial Fee Rs:15,000/- Dated 09-05-2012 (Challan Photo copy), Differential Fee Rs: 5000/- vide challan No.0003351 dated 09-09-2013. (Challan photocopy), Differential fee Dy No. dated 15-02-2016, Rs.30,000/- vide
396.	Name and address of manufacturer/ Applicant  Brand Name + Dosage Form + Strength Composition	Bosch Pharmaceuticals (Pvt.) Ltd., Plot No.221-223, Sector 23, Korangi Industrial Area, Karachi. (DML No. 000350, Plant-I)  Orip 500mg injection  Each vial contains: Doripenem (as monohydrate)500mg  Form-5D, Dy No. dated, Initial Fee Rs:15,000/- Dated 09-05-2012 (Challan Photo copy), Differential Fee Rs: 5000/- vide challan No.0003351 dated 09-09-2013. (Challan photocopy), Differential fee Dy No. dated 15-02-2016, Rs.30,000/- vide challan No. 0542397 Dated 22-01-2016 (Photo copy)
396.	Name and address of manufacturer/ Applicant  Brand Name + Dosage Form + Strength Composition  Diary No. Date of R & I & fee	Bosch Pharmaceuticals (Pvt.) Ltd., Plot No.221-223, Sector 23, Korangi Industrial Area, Karachi. (DML No. 000350, Plant-I)  Orip 500mg injection  Each vial contains: Doripenem (as monohydrate)500mg  Form-5D, Dy No. dated, Initial Fee Rs:15,000/- Dated 09-05-2012 (Challan Photo copy), Differential Fee Rs: 5000/- vide challan No.0003351 dated 09-09-2013. (Challan photocopy), Differential fee Dy No. dated 15-02-2016, Rs.30,000/- vide challan No. 0542397 Dated 22-01-2016 (Photo copy) (Duplicate dossier)
396.	Name and address of manufacturer/ Applicant  Brand Name + Dosage Form + Strength Composition  Diary No. Date of R & I & fee  Pharmacological Group	Bosch Pharmaceuticals (Pvt.) Ltd., Plot No.221-223, Sector 23, Korangi Industrial Area, Karachi. (DML No. 000350, Plant-I)  Orip 500mg injection  Each vial contains: Doripenem (as monohydrate)500mg  Form-5D, Dy No. dated, Initial Fee Rs:15,000/- Dated 09-05-2012 (Challan Photo copy), Differential Fee Rs: 5000/- vide challan No.0003351 dated 09-09-2013. (Challan photocopy), Differential fee Dy No. dated 15-02-2016, Rs.30,000/- vide challan No. 0542397 Dated 22-01-2016 (Photo copy) (Duplicate dossier)  Beta-lactam antibiotic agent carbapenem group
396.	Name and address of manufacturer/ Applicant  Brand Name + Dosage Form + Strength Composition  Diary No. Date of R & I & fee  Pharmacological Group Type of Form	Bosch Pharmaceuticals (Pvt.) Ltd., Plot No.221-223, Sector 23, Korangi Industrial Area, Karachi. (DML No. 000350, Plant-I)  Orip 500mg injection  Each vial contains: Doripenem (as monohydrate)500mg  Form-5D, Dy No. dated, Initial Fee Rs:15,000/- Dated 09-05-2012 (Challan Photo copy), Differential Fee Rs: 5000/- vide challan No.0003351 dated 09-09-2013. (Challan photocopy), Differential fee Dy No. dated 15-02-2016, Rs.30,000/- vide challan No. 0542397 Dated 22-01-2016 (Photo copy) (Duplicate dossier)  Beta-lactam antibiotic agent carbapenem group  Form-5D
396.	Name and address of manufacturer/ Applicant  Brand Name + Dosage Form + Strength Composition  Diary No. Date of R & I & fee  Pharmacological Group  Type of Form Finished product Specification	Bosch Pharmaceuticals (Pvt.) Ltd., Plot No.221-223, Sector 23, Korangi Industrial Area, Karachi. (DML No. 000350, Plant-I)  Orip 500mg injection  Each vial contains: Doripenem (as monohydrate)500mg  Form-5D, Dy No. dated, Initial Fee Rs:15,000/- Dated 09-05-2012 (Challan Photo copy), Differential Fee Rs: 5000/- vide challan No.0003351 dated 09-09-2013. (Challan photocopy), Differential fee Dy No. dated 15-02-2016, Rs.30,000/- vide challan No. 0542397 Dated 22-01-2016 (Photo copy) (Duplicate dossier)  Beta-lactam antibiotic agent carbapenem group  Form-5D  Manufacturer specifications
396.	Name and address of manufacturer/ Applicant  Brand Name + Dosage Form + Strength Composition  Diary No. Date of R & I & fee  Pharmacological Group Type of Form Finished product Specification Pack size & Demanded Price	Bosch Pharmaceuticals (Pvt.) Ltd., Plot No.221-223, Sector 23, Korangi Industrial Area, Karachi. (DML No. 000350, Plant-I)  Orip 500mg injection  Each vial contains: Doripenem (as monohydrate)500mg  Form-5D, Dy No. dated, Initial Fee Rs:15,000/- Dated 09-05-2012 (Challan Photo copy), Differential Fee Rs: 5000/- vide challan No.0003351 dated 09-09-2013. (Challan photocopy), Differential fee Dy No. dated 15-02-2016, Rs.30,000/- vide challan No. 0542397 Dated 22-01-2016 (Photo copy) (Duplicate dossier)  Beta-lactam antibiotic agent carbapenem group  Form-5D  Manufacturer specifications  1 Vial, as per PRC policy
396.	Name and address of manufacturer/ Applicant  Brand Name + Dosage Form + Strength Composition  Diary No. Date of R & I & fee  Pharmacological Group Type of Form Finished product Specification Pack size & Demanded Price Approval status of product in Reference	Bosch Pharmaceuticals (Pvt.) Ltd., Plot No.221-223, Sector 23, Korangi Industrial Area, Karachi. (DML No. 000350, Plant-I)  Orip 500mg injection  Each vial contains: Doripenem (as monohydrate)500mg  Form-5D, Dy No. dated, Initial Fee Rs:15,000/- Dated 09-05-2012 (Challan Photo copy), Differential Fee Rs: 5000/- vide challan No.0003351 dated 09-09-2013. (Challan photocopy), Differential fee Dy No. dated 15-02-2016, Rs.30,000/- vide challan No. 0542397 Dated 22-01-2016 (Photo copy) (Duplicate dossier)  Beta-lactam antibiotic agent carbapenem group  Form-5D  Manufacturer specifications  1 Vial, as per PRC policy  PMDA Japan (Finibax® 0.25g and 0.5g for intravenous drip
396.	Name and address of manufacturer/ Applicant  Brand Name + Dosage Form + Strength Composition  Diary No. Date of R & I & fee  Pharmacological Group Type of Form Finished product Specification Pack size & Demanded Price	Bosch Pharmaceuticals (Pvt.) Ltd., Plot No.221-223, Sector 23, Korangi Industrial Area, Karachi. (DML No. 000350, Plant-I)  Orip 500mg injection  Each vial contains: Doripenem (as monohydrate)500mg  Form-5D, Dy No. dated, Initial Fee Rs:15,000/- Dated 09-05-2012 (Challan Photo copy), Differential Fee Rs: 5000/- vide challan No.0003351 dated 09-09-2013. (Challan photocopy), Differential fee Dy No. dated 15-02-2016, Rs.30,000/- vide challan No. 0542397 Dated 22-01-2016 (Photo copy) (Duplicate dossier)  Beta-lactam antibiotic agent carbapenem group  Form-5D  Manufacturer specifications  1 Vial, as per PRC policy  PMDA Japan (Finibax® 0.25g and 0.5g for intravenous drip infusion: Shionogi Pharmaceutical Co., Ltd)  Ronim Injection 400mg of M/s Genix Pharma, Karachi.
396.	Firm.  Name and address of manufacturer/ Applicant  Brand Name + Dosage Form + Strength Composition  Diary No. Date of R & I & fee  Pharmacological Group  Type of Form  Finished product Specification  Pack size & Demanded Price  Approval status of product in Reference Regulatory Authorities	Bosch Pharmaceuticals (Pvt.) Ltd., Plot No.221-223, Sector 23, Korangi Industrial Area, Karachi. (DML No. 000350, Plant-I)  Orip 500mg injection  Each vial contains:  Doripenem (as monohydrate)500mg  Form-5D, Dy No. dated, Initial Fee Rs:15,000/- Dated 09-05-2012 (Challan Photo copy), Differential Fee Rs: 5000/- vide challan No.0003351 dated 09-09-2013. (Challan photocopy), Differential fee Dy No. dated 15-02-2016, Rs.30,000/- vide challan No. 0542397 Dated 22-01-2016 (Photo copy) (Duplicate dossier)  Beta-lactam antibiotic agent carbapenem group  Form-5D  Manufacturer specifications  1 Vial, as per PRC policy  PMDA Japan (Finibax® 0.25g and 0.5g for intravenous drip infusion: Shionogi Pharmaceutical Co., Ltd)  Ronim Injection 400mg of M/s Genix Pharma, Karachi. Registration No. 088904
396.	Name and address of manufacturer/ Applicant  Brand Name + Dosage Form + Strength Composition  Diary No. Date of R & I & fee  Pharmacological Group Type of Form Finished product Specification Pack size & Demanded Price Approval status of product in Reference Regulatory Authorities Me-too status	Bosch Pharmaceuticals (Pvt.) Ltd., Plot No.221-223, Sector 23, Korangi Industrial Area, Karachi. (DML No. 000350, Plant-I)  Orip 500mg injection  Each vial contains: Doripenem (as monohydrate)500mg  Form-5D, Dy No. dated, Initial Fee Rs:15,000/- Dated 09-05-2012 (Challan Photo copy), Differential Fee Rs: 5000/- vide challan No.0003351 dated 09-09-2013. (Challan photocopy), Differential fee Dy No. dated 15-02-2016, Rs.30,000/- vide challan No. 0542397 Dated 22-01-2016 (Photo copy) (Duplicate dossier)  Beta-lactam antibiotic agent carbapenem group  Form-5D  Manufacturer specifications  1 Vial, as per PRC policy  PMDA Japan (Finibax® 0.25g and 0.5g for intravenous drip infusion: Shionogi Pharmaceutical Co., Ltd)  Ronim Injection 400mg of M/s Genix Pharma, Karachi.
396.	Name and address of manufacturer/ Applicant  Brand Name + Dosage Form + Strength Composition  Diary No. Date of R & I & fee  Pharmacological Group Type of Form Finished product Specification Pack size & Demanded Price Approval status of product in Reference Regulatory Authorities Me-too status	Bosch Pharmaceuticals (Pvt.) Ltd., Plot No.221-223, Sector 23, Korangi Industrial Area, Karachi. (DML No. 000350, Plant-I)  Orip 500mg injection  Each vial contains: Doripenem (as monohydrate)500mg  Form-5D, Dy No. dated, Initial Fee Rs:15,000/- Dated 09-05-2012 (Challan Photo copy), Differential Fee Rs: 5000/- vide challan No.0003351 dated 09-09-2013. (Challan photocopy), Differential fee Dy No. dated 15-02-2016, Rs.30,000/- vide challan No. 0542397 Dated 22-01-2016 (Photo copy) (Duplicate dossier)  Beta-lactam antibiotic agent carbapenem group  Form-5D  Manufacturer specifications  1 Vial, as per PRC policy  PMDA Japan (Finibax® 0.25g and 0.5g for intravenous drip infusion: Shionogi Pharmaceutical Co., Ltd)  Ronim Injection 400mg of M/s Genix Pharma, Karachi. Registration No. 088904  Routine GMP inspection report conducted on 25-11-2021, the firm with conclusion that the firm is considered to be operating at an acceptable level of compliance with good manufacturing
396.	Name and address of manufacturer/ Applicant  Brand Name + Dosage Form + Strength Composition  Diary No. Date of R & I & fee  Pharmacological Group Type of Form Finished product Specification Pack size & Demanded Price Approval status of product in Reference Regulatory Authorities Me-too status	Bosch Pharmaceuticals (Pvt.) Ltd., Plot No.221-223, Sector 23, Korangi Industrial Area, Karachi. (DML No. 000350, Plant-I)  Orip 500mg injection  Each vial contains: Doripenem (as monohydrate)500mg  Form-5D, Dy No. dated, Initial Fee Rs:15,000/- Dated 09-05-2012 (Challan Photo copy), Differential Fee Rs: 5000/- vide challan No.0003351 dated 09-09-2013. (Challan photocopy), Differential fee Dy No. dated 15-02-2016, Rs.30,000/- vide challan No. 0542397 Dated 22-01-2016 (Photo copy) (Duplicate dossier)  Beta-lactam antibiotic agent carbapenem group  Form-5D  Manufacturer specifications 1 Vial, as per PRC policy  PMDA Japan (Finibax® 0.25g and 0.5g for intravenous drip infusion: Shionogi Pharmaceutical Co., Ltd)  Ronim Injection 400mg of M/s Genix Pharma, Karachi. Registration No. 088904  Routine GMP inspection report conducted on 25-11-2021, the firm with conclusion that the firm is considered to be operating

- Firm revised finished drug product specifications from manufacturer to JP but has not submitted the requisite fee.
- Dry Powder Injectable (Carbapenem) section with Warehouse approved vide Licensing Division letter No.F.2-4/91-Lic dated 03-02-2016.
- Provide copy of registration dossier (Form 5) covering letter of initial submission in the year 2012, bearing statistical officer and DRAP R & I stamp.
- Verification of DRAP R & I for initial and differential fee submission along with fee challans required.

#### **Decision: Deferred for submission of following:**

- Stability data as per guidelines approved in 293<sup>rd</sup> meeting of Registration Board.
- Fee of Rs. 7,500 for correction/pre-approval change/ in product specifications, as per notification No.F.7-11/2012-B&A/DRAP dated 13-07-2021 as firm has revised finished drug product specifications from manufacturer to JP.
- Form-5 cover letter copy of initial submission (2012) bearing DRAP R & I stamp.
- Verification of DRAP R & I for initial and differential fee submissions along with fee challans.

	Verification of DRAP R & I for it	nitial and differential fee submissions along with fee challans.
397.	Name and address of manufacturer/	Bosch Pharmaceuticals (Pvt.) Ltd., Plot No.221-223, Sector 23,
	Applicant	Korangi Industrial Area, Karachi. (DML No. 350, Plant-I)
	Brand Name + Dosage Form + Strength	BZAC 500mg injection
	Composition	Each vial contains:
		Aztreonam USP500mg
		(with sterile L-Arginine USP)
	Diary No. Date of R & I & fee	Form-5, Dy No. Dated , Initial Fee Rs:8,000/- Dated 03-
		12-2005 (Challan Photo copy), Dy No. dated 15-02-2016,
		Differential fee Rs.12,000/- vide challan No. 0501296 Dated
		22-01-2016 (Photo copy)
		(Duplicate Dossier)
	Pharmacological Group	Monobactam (Anti-infective)
	Type of Form	Form-5
	Finished product Specification	USP specifications
	Pack size & Demanded Price	1 Vial, as per PRC policy
	Approval status of product in Reference	US FDA approved
	Regulatory Authorities	Azactam (Bristol Myers Squibb)
	Me-too status	Azactam 500gm IM/IV by M/s Glaxosmithkline
		(Reg#009001)
	GMP status	Routine GMP inspection report conducted on 25-11-2021, the
		firm with conclusion that the firm is considered to be operating
		at an acceptable level of compliance with good manufacturing
		practices, as of today.
	Remarks of the Evaluator (PEC-XVII)	• Firm was asked to clarify whether the applied formulation is
		in lyophilized powder form or plain powder since both forms
		are available in reference regulatory authorities (US FDA).
		Generic aztreonam is in the form of lyophilized powder while
		the reference product Azactam is in the form of white powder.
		The form informed that the applied formulation is "ready to
		fill Sterile powder" and filling will be done in Dry powder
		Injectable (Carbapenem) area.
		• Dry Powder Injectable (Carbapenem) section with Warehouse
		approved vide Licensing Division letter No.F.2-4/91-Lic
		dated 03-02-2016.

Provide copy of registration dossier (Form 5) covering letter of initial submission in the year 2005, bearing statistical officer and DRAP R & I stamp.
 Decision of 274<sup>th</sup> meeting of DRB for similar product.
 Deferred for the confirmation of dedicated section and manufacturing requirements of applied formulation
 Decision in 287<sup>th</sup> meeting of DRB for similar product
 Registered Board deferred the application since applied formulation is not a Carbapenem, and firm has applied to manufacture it in Dry Powder Injection (Carbapenem)

Section.

**Decision: Registration Board deferred the application since:** 

- Confirmation of manufacturing facility as applied formulation is not a Carbapenem and firm has applied to manufacture it in Dry Powder Injectable (Carbapenem) Section.
- Form-5 cover letter copy of initial submission (2005) bearing DRAP R & I stamp not provided.
- Verification of DRAP R & I for initial and differential fee submissions along with fee challans required.

	required.	
398.	Name and address of manufacturer/	Bosch Pharmaceuticals (Pvt.) Ltd., Plot No.221-223, Sector 23,
	Applicant	Korangi Industrial Area, Karachi. (DML No. 000350, Plant-I)
	Brand Name + Dosage Form + Strength	BZAC 1gm injection
	Composition	Each vial contains:
		Aztreonam USP1000mg
		(with sterile L-Arginine USP)
	Diary No. Date of R & I & fee	Form-5, Dy No. Dated , Initial Fee Rs:8,000/- Dated 03-
		12-2005 (Challan Photo copy), Dy No. dated 15-02-2016,
		Differential fee Rs.12,000/- vide challan No. 0501295 Dated
		22-01-2016 (Photo copy)
	DI 1 ' 1 C	(Duplicate Dossier)
	Pharmacological Group	Monobactam (Anti-infective)
	Type of Form	Form-5
	Finished product Specification	USP specifications
	Pack size & Demanded Price	1 Vial, as per PRC policy
	Approval status of product in Reference Regulatory Authorities	US FDA approved Azactam (Bristol Myers Squibb)
	Me-too status	· -
	Me-too status	Azactam 1gm IM/IV by M/s Glaxosmithkline
		(Reg# 009002)
	GMP status	Routine GMP inspection report conducted on 25-11-2021, the
		firm with conclusion that the firm is considered to be operating
		at an acceptable level of compliance with good manufacturing
	Remarks of the Evaluator (PEC-XVII)	practices, as of today.
	Remarks of the Evaluator (Feekviii)	• Firm was asked to clarify whether the applied formulation is
		in lyophilized powder form or plain powder since both forms
		are available in reference regulatory authorities (US FDA).
		Generic aztreonam is in the form of lyophilized powder while
		the reference product Azactam is in the form of white powder.
		The form informed that the applied formulation is "ready to
		fill Sterile powder" and filling will be done in Dry powder
		Injectable (Carbapenem) area.
		• Dry Powder Injectable (Carbapenem) section with Warehouse
		approved vide Licensing Division letter No.F.2-4/91-Lic
		dated 03-02-2016.
		• Provide copy of registration dossier (Form 5) covering letter

<ul> <li>Decision of 274<sup>th</sup> meeting of DRB for similar product.</li> <li>"Deferred for the confirmation of dedicated section and manufacturing requirements of applied formulation"</li> <li>Decision in 287<sup>th</sup> meeting of DRB for similar product</li> <li>"Registered Board deferred the application since applied</li> </ul>		of initial submission in the year 2005, bearing statistical officer and DRAP R & I stamp.
manufacturing requirements of applied formulation" • Decision in 287 <sup>th</sup> meeting of DRB for similar product  "Registered Board deferred the application since applied	•	<ul> <li>Decision of 274<sup>th</sup> meeting of DRB for similar product.</li> </ul>
		manufacturing requirements of applied formulation"
manufacture it in Dry Powder Injection (Carbapenem) Section".		formulation is not a Carbapenem, and firm has applied to manufacture it in Dry Powder Injection (Carbapenem)

- Confirmation of manufacturing facility as applied formulation is not a Carbapenem and firm has applied to manufacture it in Dry Powder Injectable (Carbapenem) Section.
- Form-5 cover letter copy of initial submission (2005) bearing DRAP R & I stamp not provided.
- Verification of DRAP R & I for initial and differential fee submissions along with fee challans required.

	1	
399.	Name and address of manufacturer/	M/s Epharm Laboratories, A-40, Road No. 1, S.I.T.E. Super
	Applicant	Highway Industrial Area, North Karachi.
	Brand Name + Dosage Form + Strength	DROVERA 40mg tablets
	Composition	Each uncoated tablet contains:
		Drotaverine Hydrochloride40mg
	Diary No. Date of R & I & fee	Dy. No.182 dated 25-11-2010 Rs.8,000/- dated 25-11-2010
		(Photocopy), Dy. No. dated 21-07-2014 Differential fee
		Rs.12,000/- vide Challan No.0053264, Duplicate dossier
		(Only R & I for initial submission verified)
	Pharmacological Group	Anti-spasmodics
	Type of Form	Form-5
	Finished product Specification	Manufacturer specifications
	Pack size & Demanded Price	$2 \times 10$ 's, as per SRO
	Approval status of product in Reference	Applied formulation is present in different European Economic
	Regulatory Authorities	Area (EEA) states like Hungary, Lithuania & Latvia (both as
		un-coated and coated tablets).
	Me-too status	Dytra 40mg Tablet of M/s. Tabros Pharma, Karachi.
		Registration No. 048766
	GMP status	Updated GMP status required
	Remarks of the Evaluator (PEC-XVII)	• Firm has claimed manufacturer specifications.
		• Verification of R & I for differential fee submission and both
		initial and differential fee challans required.
		midul and differential fee chandin fequiled.

# **Decision: Approved with Innovator's specifications.**

- Firm shall submit the fee of Rs. 7,500 for correction/pre-approval change/ in product specifications, as per notification No.F.7-11/2012-B&A/DRAP dated 13-07-2021.
- Registration Board further decided to verify fee challans as per decision of 285th meeting of Registration Board.
- Registration letter will be issued after submission of valid satisfactory GMP inspection report by the firm.

400.	Name and address of manufacturer/	M/s Pharmedic laboratories (Pvt) Ltd. 16-Km, Multan road,
	Applicant	Lahore-Pakistan.
	Brand Name + Dosage Form + Strength	ZEPAM 0.5mg tablet
	Composition	Each tablet contains:
		Clonazepam0.5mg
	Diary No. Date of R & I & fee	Dy. No.1233 dated 16-04-2012, Rs.8,000/- challan dated 09-
		04-2012 (Photocopy), Dy. No. dated 15-07-2016 Differential

		fee Rs.12,000/- vide challan No. 0559603 dated 27-06-2016
		(Photocopy),
		(Duplicate dossier, R & I of initial submission verified)
	Pharmacological Group	Anti-epileptics
	Type of Form	Form 5
	Finished product Specification	USP specifications
	Pack size & Demanded Price	50's, Rs: 118/- per pack
	Approval status of product in Reference Regulatory Authorities	KLONOPIN tablet 0.5mg (USFDA approved)
	Me-too status	Catier 0.5mg tablet of M/s Medizan laboratories, Islamabad. Registration No. 102750
	GMP status	Panel GMP inspection conducted on 04-02-2020 and concluded as: In the light of the inspection conducted by the panel and based on the people met, documents reviewed and findings during inspection, M/s Pharmedic Laboratories Pvt. Ltd., 16-Km, Multan Road, Lahore was considered to be operating at a satisfactory level of cGMP compliance at the time of
		inspection.  Since the firm had upgraded the layout of the anti-cancer sections, therefore, firm was advised to get the anti-cancer sections regularized and approved by DRAP, Islamabad after fulfillment of al codal formalities.
	Remarks of the Evaluator (PEC-XVII)	• Film coating process is mentioned in manufacturing outlines, while as per label claim, the applied formulation/product is uncoated.
		• DML renewal inspection dated 25-11-2011 and 30-11-2011 provided as evidence of approval of Tablet psychotropic section.
		• Verification of R & I for differential fee submission and fee challans for initial and differential fee challans required.
	Decision: Approved.  • Firm shall submit the fee of Rs.	7,500 for correction/pre-approval change/ in manufacturing
		7,500 for corrections pre-approval change, in manufacturing 7.7-11/2012-B&A/DRAP dated 13-07-2021.
	· •	ded to verify fee challans as per decision of 285 <sup>th</sup> meeting of
	9	ded to verify fee chanans as per decision of 205° meeting of
401	Registration Board.  Name and address of manufacturer/	M/s Discount is 1-1-sectories (Dec) I (1 16 IV to Maleston and
401.		M/s Pharmedic laboratories (Pvt) Ltd. 16-Km, Multan road,
	Applicant	Lahore-Pakistan.
	Brand Name + Dosage Form + Strength	ZEPAM 2mg tablet
	Composition	Each tablet contains:
	D' N D CD 0 1 0 C	Clonazepam2mg
	Diary No. Date of R & I & fee	Dy. No.1231 dated 16-04-2012, Rs.8,000/- challan dated 09-04-2012 (Photocopy), Dy. No. dated 15-07-2016 Differential fee Rs.12,000/- vide challan No. 0559607 dated 27-06-2016 (Photocopy), (Duplicate dossier, R & I of initial submission verified)
	Pharmacological Group	Anti-epileptics
	Type of Form	Form 5
	Finished product Specification	USP specifications
	Pack size & Demanded Price	30's, Rs: 145/- per pack
	Approval status of product in Reference	KLONOPIN tablet 2mg (USFDA approved)
	Regulatory Authorities	TELOTION IN MOTOR ZING (ODI DIT approved)
	Me-too status	Catier 2mg tablet of M/s Medizan laboratories, Islamabad. Registration No. 102751
		10g1stration 100, 102/31

GMP status	Panel GMP inspection conducted on 04-02-2020 and concluded as:  In the light of the inspection conducted by the panel and based on the people met, documents reviewed and findings during inspection, M/s Pharmedic Laboratories Pvt. Ltd., 16-Km, Multan Road, Lahore was considered to be operating at a satisfactory level of cGMP compliance at the time of inspection.  Since the firm had upgraded the layout of the anti-cancer
	sections, therefore, firm was advised to get the anti-cancer sections regularized and approved by DRAP, Islamabad after fulfillment of al codal formalities.
Remarks of the Evaluator (PEC-XVII)	• Film coating process is mentioned in manufacturing outlines, while as per label claim, the applied formulation/product is uncoated.
	• DML renewal inspection dated 25-11-2011 and 30-11-2011 provided as evidence of approval of Tablet psychotropic section.
	• Verification of R & I for differential fee submission and fee challans for initial and differential fee challans required.

# **Decision: Approved.**

- Firm shall submit the fee of Rs. 7,500 for correction/pre-approval change/ in manufacturing outlines, as per notification No.F.7-11/2012-B&A/DRAP dated 13-07-2021.
- Registration Board further decided to verify fee challans as per decision of 285th meeting of Registration Board.

	Registration Board.	
402.	Name and address of manufacturer/	M/s Pharmedic laboratories (Pvt) Ltd. 16-Km, Multan road,
	Applicant	Lahore-Pakistan.
	Brand Name + Dosage Form + Strength	ZELAX 5mg tablet
	Composition	Each tablet contains:
		Nitrazepam5mg
	Diary No. Date of R & I & fee	Dy. No.1228 dated 16-04-2012, Rs.8,000/- challan dated 09-
		04-2012 (Photocopy), Dy. No. dated 15-07-2016 Differential
		fee Rs.12,000/- vide challan No. 0559606 dated 27-06-2016
		(Photocopy),
		(Duplicate dossier, R & I of initial submission verified)
	Pharmacological Group	Non-barbiturates
	Type of Form	Form 5
	Finished product Specification	BP specifications
	Pack size & Demanded Price	50's, Rs: 200/- per pack
	Approval status of product in Reference	Mogadon 5mg tablet (MHRA approved)
	Regulatory Authorities	
	Me-too status	Ozitra 5mg Tablet of M/s Theramed, Lahore. Registration No. 100011
	GMP status	Panel GMP inspection conducted on 04-02-2020 and concluded as:
		In the light of the inspection conducted by the panel and based
		on the people met, documents reviewed and findings during
		inspection, M/s Pharmedic Laboratories Pvt. Ltd., 16-Km,
		Multan Road, Lahore was considered to be operating at a
		satisfactory level of cGMP compliance at the time of
		inspection.
		Since the firm had upgraded the layout of the anti-cancer
		sections, therefore, firm was advised to get the anti-cancer

		sections regularized and approved by DRAP, Islamabad after fulfillment of al Codal formalities.
	Remarks of the Evaluator (PEC-XVII)	• Film coating process is mentioned in manufacturing outlines, while as per label claim, the applied formulation/product is uncoated.
		• DML renewal inspection dated 25-11-2011 and 30-11-2011 provided as evidence of approval of Tablet psychotropic section.
		• Verification of R & I for differential fee submission and fee challans for initial and differential fee challans required.
	<ul><li>outlines, as per notification No.F.</li><li>Registration Board further decid Registration Board.</li></ul>	7,500 for correction/pre-approval change/ in manufacturing 7-11/2012-B&A/DRAP dated 13-07-2021. led to verify fee challans as per decision of 285 <sup>th</sup> meeting of
403.	Name and address of manufacturer/ Applicant	M/s Pharmedic laboratories (Pvt) Ltd. 16-Km, Multan road, Lahore-Pakistan.
	Brand Name + Dosage Form + Strength	SECOLIN Injection (250mg/2ml)
	Composition	Each ampoule contains:
		Citicoline250mg/2ml
	Diary No. Date of R & I & fee	Dy. No.454 dated 03-11-2011, Rs.8,000/- challan dated (Photocopy), Dy. No. dated 15-07-2016 Differential fee Rs.12,000/- vide challan No. 0559602 dated 27-06-2016 (Photocopy),
	Pharmacological Group	(Duplicate dossier, R & I of initial submission verified)  Psychostimulant
	Type of Form	Form 5
	Finished product Specification	Firm has claimed in-house specifications
	Pack size & Demanded Price	5× 2ml ampoule, Rs: 209/- per ampoule
	Approval status of product in Reference Regulatory Authorities	CITICOLINE 250 mg / 2 ml solution for injection (IM, IV) ampoule by M/s PANPHARMA (ANSM, France Approved) PMDA Japan approved
	Me-too status	Citocode 250mg/2ml Injection of Rotex Pharma (Pvt) Ltd. Islamabad. Registration No. 100804
	GMP status	Panel GMP inspection conducted on 04-02-2020 and concluded as: In the light of the inspection conducted by the panel and based on the people met, documents reviewed and findings during inspection, M/s Pharmedic Laboratories Pvt. Ltd., 16-Km, Multan Road, Lahore was considered to be operating at a satisfactory level of cGMP compliance at the time of inspection.  Since the firm had upgraded the layout of the anti-cancer sections, therefore, firm was advised to get the anti-cancer sections regularized and approved by DRAP, Islamabad after fulfillment of al Codal formalities.
	Remarks of the Evaluator (PEC-XVII)	• Revise label claim as per reference product as:
		Each 2ml ampoule contains: Citicoline Sodium equivalent to Citicoline250mg  • DML renewal inspection report dated 27-09-2012 provided as evidence of approval of General Injectable Section.
		• Verification of R & I for differential fee submission and fee challans for initial and differential fee challans required.

Decision: Approved as per following revised label claim:

Each 2ml ampoule contains:

Citicoline Sodium equivalent to Citicoline...250mg

- Firm shall submit the fee of Rs. 30,000 for correction/pre-approval change in composition (correction/change of salt form of the drug substance), as per notification No.F.7-11/2012-B&A/DRAP dated 13-07-2021.
- Registration Board further decided to verify fee challans as per decision of 285<sup>th</sup> meeting of Registration Board.

	Registration Board.	
404.	Name and address of manufacturer/	M/s Pharmedic laboratories (Pvt) Ltd. 16-Km, Multan road,
	Applicant	Lahore-Pakistan.
	Brand Name + Dosage Form + Strength	MIDOLAM Injection (5mg/ml)
	Composition	Each ampoule contains:
	•	Midazolam5mg/ml
	Diary No. Date of R & I & fee	Dy. No.1230 dated 16-04-2012, Rs.8,000/- challan dated 09-
	•	04-2012 (Photocopy), Dy. No. dated 15-07-2016 Differential
		fee Rs.12,000/- vide challan No. 0559604 dated 27-06-2016
		(Photocopy),
		(Duplicate dossier, R & I of initial submission verified)
	Pharmacological Group	Tranquilizers
	Type of Form	Form 5
	Finished product Specification	USP specifications
	Pack size & Demanded Price	
		5× 1ml ampoule, Rs: 88/- per ampoule
	Approval status of product in Reference	MHRA approved
	Regulatory Authorities	Midorosia Impainisation of M/o Venus absence Labora
	Me-too status	Midazocin 1mg injection of M/s Venus pharma, Lahore.
	CMD status	Registration No. 097634
	GMP status	Panel GMP inspection conducted on 04-02-2020 and concluded as:
		In the light of the inspection conducted by the panel and based on the people met, documents reviewed and findings during
		inspection, M/s Pharmedic Laboratories Pvt. Ltd., 16-Km,
		Multan Road, Lahore was considered to be operating at a satisfactory level of cGMP compliance at the time of
		inspection.
		Since the firm had upgraded the layout of the anti-cancer
		sections, therefore, firm was advised to get the anti-cancer
		sections, therefore, fifth was advised to get the anti-cancer sections regularized and approved by DRAP, Islamabad after
		fulfillment of al codal formalities.
	Remarks of the Evaluator (PEC-XVII)	Revise label claim as per reference product as:
	Remarks of the Evaluator	- Revise laber claim as per reference product as.
		Each 1ml ampoule contains:
		Midazolam (as Hydrochloride)5mg
		Provide evidence of approval of relevant section by Licensing
		Division, DRAP Islamabad.
		Durani da masat masant CMD insuranti an manant asan durata durathin
		Provide most recent GMP inspection report conducted within
		last three years.
		• Verification of R & I for differential fee submission and fee
		challans for initial and differential fee challans required.
	Decision: Rejected as firm does not be	ve required manufacturing facility (Pyschotropic Injectable
	Section).	ve required manufacturing facility (1 yschotropic injectable
405.	Name and address of manufacturer/	M/s Pharmedic laboratories (Pvt) Ltd. 16-Km, Multan road,
	Applicant	Lahore-Pakistan.
	Brand Name + Dosage Form + Strength	PENOM Injection (30mg/ml)
	Composition	Each ampoule contains:
	•	Pentazocine30mg/ml
		[ Deviation   Devi

	D' N D CDOIG	D 37 1000 1 115 01 0010 D 00001 1 11 1 100
	Diary No. Date of R & I & fee	Dy. No.1232 dated 16-04-2012, Rs.8,000/- challan dated 09-
		04-2012 (Photocopy), Dy. No. dated 15-07-2016 Differential
		fee Rs.12,000/- vide challan No. 0559605 dated 27-06-2016
		(Photocopy),
		(Duplicate dossier, R & I of initial submission verified)
	Pharmacological Group	Narcotics
	Type of Form	Form 5
	Finished product Specification	
	Finished product Specification	USP (a sterile solution of Pentazocine in Water for Injection,
		prepared with the aid of Lactic Acid).
	Pack size & Demanded Price	5× 1ml ampoule, Rs: 22/- per ampoule
	Approval status of product in Reference	TALWIN (pentazocine) 30 mg/ml injection
	Regulatory Authorities	(Health Canada Approved)
		Each mL contains pentazocine lactate equivalent to 30 mg base
	Me-too status	Pantasyn Injection IM/IV of M/s Synchro Pharmaceuticals,
		Lahore. Registration No. 083383
	GMP status	Panel GMP inspection conducted on 04-02-2020 and
		concluded as:
		In the light of the inspection conducted by the panel and based
		on the people met, documents reviewed and findings during
		inspection, M/s Pharmedic Laboratories Pvt. Ltd., 16-Km,
		Multan Road, Lahore was considered to be operating at a
		satisfactory level of cGMP compliance at the time of
		inspection.
		Since the firm had upgraded the layout of the anti-cancer
		sections, therefore, firm was advised to get the anti-cancer
		sections regularized and approved by DRAP, Islamabad after
		fulfillment of al codal formalities.
	Remarks of the Evaluator (PEC-XVII)	• Revise label claim as per reference product as:
		Each Imlammayla contains
		Each 1ml ampoule contains:
		Pentazocine lactate equivalent to Pentazocine base30mg
		• Provide evidence of approval of relevant section by Licensing
		Division, DRAP Islamabad.
		• Provide most recent GMP inspection report conducted within
		• Provide most recent GMP inspection report conducted within last three years.
		last three years.
		last three years.  • Verification of R & I for differential fee submission and fee
		last three years.
	Decision: Rejected as firm does not ha	last three years.  • Verification of R & I for differential fee submission and fee challans for initial and differential fee challans required.
	Decision: Rejected as firm does not have Section).	last three years.  • Verification of R & I for differential fee submission and fee
406.	•	last three years.  • Verification of R & I for differential fee submission and fee challans for initial and differential fee challans required.  • ve required manufacturing facility (Pyschotropic Injectable)
406.	Section).  Name and address of manufacturer/	last three years.  • Verification of R & I for differential fee submission and fee challans for initial and differential fee challans required.
406.	Name and address of manufacturer/ Applicant	last three years.  • Verification of R & I for differential fee submission and fee challans for initial and differential fee challans required.  • Verification of R & I for differential fee submission and fee challans for initial and differential fee challans required.  • Verification of R & I for differential fee submission and fee challans for initial and differential fee submission and fee challans required.  • Verification of R & I for differential fee submission and fee challans for initial and differential fee submission and fee challans for initial and differential fee submission and fee challans required.  • Verification of R & I for differential fee submission and fee challans for initial and differential fee challans required.  • Verification of R & I for differential fee submission and fee challans for initial and differential fee challans required.  • Verification of R & I for differential fee submission and fee challans required.  • Verification of R & I for differential fee challans required.  • Verification of R & I for differential fee submission and fee challans required.  • Verification of R & I for differential fee submission and fee challans required.  • Verification of R & I for differential fee challans required.  • Verification of R & I for differential fee challans required.  • Verification of R & I for differential fee challans required.  • Verification of R & I for differential fee challans required.  • Verification of R & I for differential fee challans required.  • Verification of R & I for differential fee challans required.  • Verification of R & I for differential fee challans required.  • Verification of R & I for differential fee challans required.  • Verification of R & I for differential fee challans required.  • Verification of R & I for differential fee challans required.  • Verification of R & I for differential fee challans required.  • Verification of R & I for differential fee challans required.  • Verification of R & I for differential fee challans required.  • Verifica
406.	Name and address of manufacturer/ Applicant  Brand Name + Dosage Form + Strength	last three years.  • Verification of R & I for differential fee submission and fee challans for initial and differential fee challans required.  • Verification of R & I for differential fee submission and fee challans for initial and differential fee challans required.  • Verification of R & I for differential fee submission and fee challans for initial and differential fee submission and fee challans required.  • Verification of R & I for differential fee submission and fee challans for initial and differential fee submission and fee challans required.  • Verification of R & I for differential fee submission and fee challans required.  • Verification of R & I for differential fee submission and fee challans required.  • Verification of R & I for differential fee submission and fee challans required.  • Verification of R & I for differential fee submission and fee challans required.  • Verification of R & I for differential fee submission and fee challans required.  • Verification of R & I for differential fee submission and fee challans required.  • Verification of R & I for differential fee submission and fee challans required.  • Verification of R & I for differential fee submission and fee challans required.  • Verification of R & I for differential fee submission and fee challans required.  • Verification of R & I for differential fee challans required.  • Verification of R & I for differential fee challans required.  • Verification of R & I for differential fee challans required.  • Verification of R & I for differential fee challans required.  • Verification of R & I for differential fee challans required.  • Verification of R & I for differential fee challans required.  • Verification of R & I for differential fee challans required.  • Verification of R & I for differential fee challans required.  • Verification of R & I for differential fee challans required.  • Verification of R & I for differential fee challans required.  • Verification of R & I for differential fee challans required.  • Verification
406.	Name and address of manufacturer/ Applicant	last three years.  • Verification of R & I for differential fee submission and fee challans for initial and differential fee challans required.  • Verification of R & I for differential fee submission and fee challans for initial and differential fee challans required.  • Verification of R & I for differential fee submission and fee challans for initial and differential fee challans required.  • Verification of R & I for differential fee submission and fee challans required.  • Verification of R & I for differential fee submission and fee challans required.  • Verification of R & I for differential fee submission and fee challans required.  • Verification of R & I for differential fee submission and fee challans required.  • Verification of R & I for differential fee submission and fee challans required.  • Verification of R & I for differential fee submission and fee challans required.  • Verification of R & I for differential fee submission and fee challans required.  • Verification of R & I for differential fee submission and fee challans required.  • Verification of R & I for differential fee submission and fee challans required.  • Verification of R & I for differential fee submission and fee challans required.  • Verification of R & I for differential fee submission and fee challans required.  • Verification of R & I for differential fee challans required.  • Verification of R & I for differential fee challans required.  • Verification of R & I for differential fee challans required.  • Verification of R & I for differential fee challans required.  • Verification of R & I for differential fee challans required.  • Verification of R & I for differential fee challans required.  • Verification of R & I for differential fee challans required.  • Verification of R & I for differential fee challans required.  • Verification of R & I for differential fee challans required.  • Verification of R & I for differential fee challans required.  • Verification of R & I for differential fee challans required.  • Verifica
406.	Name and address of manufacturer/ Applicant  Brand Name + Dosage Form + Strength  Composition	last three years.  • Verification of R & I for differential fee submission and fee challans for initial and differential fee challans required.  • Verification of R & I for differential fee submission and fee challans for initial and differential fee challans required.  • Verification of R & I for differential fee submission and fee challans for initial and differential fee submission and fee challans required.  • Verification of R & I for differential fee submission and fee challans required.  • Verification of R & I for differential fee submission and fee challans for initial and differential fee submission and fee challans required.  • Verification of R & I for differential fee submission and fee challans required.  • Verification of R & I for differential fee submission and fee challans required.  • Verification of R & I for differential fee submission and fee challans required.  • Verification of R & I for differential fee submission and fee challans required.  • Verification of R & I for differential fee submission and fee challans required.  • Verification of R & I for differential fee submission and fee challans required.  • Verification of R & I for differential fee submission and fee challans required.  • Verification of R & I for differential fee submission and fee challans required.  • Verification of R & I for differential fee challans required.  • Verification of R & I for differential fee challans required.  • Verification of R & I for differential fee challans required.  • Verification of R & I for differential fee challans required.  • Verification of R & I for differential fee challans required.  • Verification of R & I for differential fee challans required.  • Verification of R & I for differential fee challans required.  • Verification of R & I for differential fee challans required.  • Verification of R & I for differential fee challans required.  • Verification of R & I for differential fee challans required.  • Verification of R & I for differential fee challans required.  • Verification
406.	Name and address of manufacturer/ Applicant  Brand Name + Dosage Form + Strength	last three years.  • Verification of R & I for differential fee submission and fee challans for initial and differential fee challans required.  • Verification of R & I for differential fee submission and fee challans for initial and differential fee challans required.  • Verification of R & I for differential fee submission and fee challans for initial and differential fee submission and fee challans required.  • Verification of R & I for differential fee submission and fee challans required.  • Verification of R & I for differential fee submission and fee challans required.  • Verification of R & I for differential fee submission and fee challans required.  • Verification of R & I for differential fee submission and fee challans required.  • Verification of R & I for differential fee submission and fee challans required.  • Verification of R & I for differential fee submission and fee challans required.  • Verification of R & I for differential fee submission and fee challans required.  • Verification of R & I for differential fee submission and fee challans required.  • Verification of R & I for differential fee submission and fee challans required.  • Verification of R & I for differential fee submission and fee challans required.  • Verification of R & I for differential fee challans required.  • Verification of R & I for differential fee challans required.  • Verification of R & I for differential fee challans required.  • Verification of R & I for differential fee challans required.  • Verification of R & I for differential fee challans required.  • Verification of R & I for differential fee challans required.  • Verification of R & I for differential fee challans required.  • Verification of R & I for differential fee challans required.  • Verification of R & I for differential fee challans required.  • Verification of R & I for differential fee challans required.  • Verification of R & I for differential fee challans required.  • Verification of R & I for differential fee challans required.  • Verifica
406.	Name and address of manufacturer/ Applicant  Brand Name + Dosage Form + Strength  Composition	last three years.  • Verification of R & I for differential fee submission and fee challans for initial and differential fee challans required.  • Verification of R & I for differential fee submission and fee challans for initial and differential fee challans required.  • Verification of R & I for differential fee submission and fee challans for initial and differential fee challans required.  • Verification of R & I for differential fee submission and fee challans required.  • Verification of R & I for differential fee submission and fee challans required.  • Verification of R & I for differential fee submission and fee challans required.  • Verification of R & I for differential fee submission and fee challans required.  • Verification of R & I for differential fee submission and fee challans required.  • Verification of R & I for differential fee submission and fee challans required.  • Verification of R & I for differential fee submission and fee challans required.  • Verification of R & I for differential fee submission and fee challans required.  • Verification of R & I for differential fee submission and fee challans required.  • Verification of R & I for differential fee submission and fee challans required.  • Verification of R & I for differential fee challans required.  • Verification of R & I for differential fee challans required.  • Verification of R & I for differential fee challans required.  • Verification of R & I for differential fee challans required.  • Verification of R & I for differential fee challans required.  • Verification of R & I for differential fee challans required.  • Verification of R & I for differential fee challans required.  • Verification of R & I for differential fee challans required.  • Verification of R & I for differential fee challans required.  • Verification of R & I for differential fee challans required.  • Verification of R & I for differential fee challans required.  • Verification of R & I for differential fee challans required.  • Verification of R & I for d
406.	Name and address of manufacturer/ Applicant  Brand Name + Dosage Form + Strength  Composition	last three years.  • Verification of R & I for differential fee submission and fee challans for initial and differential fee challans required.  • Verequired manufacturing facility (Pyschotropic Injectable)  M/s EG Pharmaceuticals, 13-A, Industrial Triangle, Kahuta road, Islamabad.  HIFENAC 100mg tablet  Each film-coated tablet contains:  Aceclofenac100mg/ml  Dy. No. 8258 dated 07-08-2012, Rs.8,000/- challan dated 07-08-2012 (Photocopy), Dy. No. dated 23-08-2016 Differential fee Rs.12,000/- vide challan No. 0505667 dated 23-08-2016
406.	Name and address of manufacturer/ Applicant  Brand Name + Dosage Form + Strength  Composition	last three years.  • Verification of R & I for differential fee submission and fee challans for initial and differential fee challans required.  • Verification of R & I for differential fee submission and fee challans for initial and differential fee challans required.  • Verification of R & I for differential fee submission and fee challans for initial and differential fee challans required.  • Verification of R & I for differential fee submission and fee challans required.  • Verification of R & I for differential fee submission and fee challans required.  • Verification of R & I for differential fee submission and fee challans required.  • Verification of R & I for differential fee submission and fee challans required.  • Verification of R & I for differential fee submission and fee challans required.  • Verification of R & I for differential fee submission and fee challans required.  • Verification of R & I for differential fee submission and fee challans required.  • Verification of R & I for differential fee submission and fee challans required.  • Verification of R & I for differential fee submission and fee challans required.  • Verification of R & I for differential fee submission and fee challans required.  • Verification of R & I for differential fee challans required.  • Verification of R & I for differential fee challans required.  • Verification of R & I for differential fee challans required.  • Verification of R & I for differential fee challans required.  • Verification of R & I for differential fee challans required.  • Verification of R & I for differential fee challans required.  • Verification of R & I for differential fee challans required.  • Verification of R & I for differential fee challans required.  • Verification of R & I for differential fee challans required.  • Verification of R & I for differential fee challans required.  • Verification of R & I for differential fee challans required.  • Verification of R & I for differential fee challans required.  • Verification of R & I for d
406.	Name and address of manufacturer/ Applicant  Brand Name + Dosage Form + Strength  Composition	last three years.  • Verification of R & I for differential fee submission and fee challans for initial and differential fee challans required.  • Verequired manufacturing facility (Pyschotropic Injectable)  M/s EG Pharmaceuticals, 13-A, Industrial Triangle, Kahuta road, Islamabad.  HIFENAC 100mg tablet  Each film-coated tablet contains:  Aceclofenac100mg/ml  Dy. No. 8258 dated 07-08-2012, Rs.8,000/- challan dated 07-08-2012 (Photocopy), Dy. No. dated 23-08-2016 Differential fee Rs.12,000/- vide challan No. 0505667 dated 23-08-2016
406.	Name and address of manufacturer/ Applicant  Brand Name + Dosage Form + Strength  Composition	last three years.  • Verification of R & I for differential fee submission and fee challans for initial and differential fee challans required.  • Verification of R & I for differential fee submission and fee challans for initial and differential fee challans required.  • Verification of R & I for differential fee submission and fee challans for initial and differential fee challans required.  • Verification of R & I for differential fee challans fee A. I for differential fee Rs.12,000/- vide challan No. 0505667 dated 23-08-2016 (Photocopy),
406.	Name and address of manufacturer/ Applicant  Brand Name + Dosage Form + Strength Composition  Diary No. Date of R & I & fee  Pharmacological Group	last three years.  Verification of R & I for differential fee submission and fee challans for initial and differential fee challans required.  Ve required manufacturing facility (Pyschotropic Injectable  M/s EG Pharmaceuticals, 13-A, Industrial Triangle, Kahuta road, Islamabad.  HIFENAC 100mg tablet  Each film-coated tablet contains: Aceclofenac100mg/ml  Dy. No. 8258 dated 07-08-2012, Rs.8,000/- challan dated 07-08-2012 (Photocopy), Dy. No. dated 23-08-2016 Differential fee Rs.12,000/- vide challan No. 0505667 dated 23-08-2016 (Photocopy), (Duplicate dossier, R & I of initial submission verified)
406.	Name and address of manufacturer/ Applicant  Brand Name + Dosage Form + Strength  Composition  Diary No. Date of R & I & fee  Pharmacological Group  Type of Form	• Verification of R & I for differential fee submission and fee challans for initial and differential fee challans required.  • Verequired manufacturing facility (Pyschotropic Injectable)  M/s EG Pharmaceuticals, 13-A, Industrial Triangle, Kahuta road, Islamabad.  HIFENAC 100mg tablet  Each film-coated tablet contains: Aceclofenac100mg/ml  Dy. No. 8258 dated 07-08-2012, Rs.8,000/- challan dated 07-08-2012 (Photocopy), Dy. No. dated 23-08-2016 Differential fee Rs.12,000/- vide challan No. 0505667 dated 23-08-2016 (Photocopy), (Duplicate dossier, R & I of initial submission verified)  NSAID  Form 5
406.	Name and address of manufacturer/ Applicant  Brand Name + Dosage Form + Strength  Composition  Diary No. Date of R & I & fee  Pharmacological Group  Type of Form  Finished product Specification	• Verification of R & I for differential fee submission and fee challans for initial and differential fee challans required.  • Verequired manufacturing facility (Pyschotropic Injectable)  M/s EG Pharmaceuticals, 13-A, Industrial Triangle, Kahuta road, Islamabad.  HIFENAC 100mg tablet  Each film-coated tablet contains:  Aceclofenac100mg/ml  Dy. No. 8258 dated 07-08-2012, Rs.8,000/- challan dated 07-08-2012 (Photocopy), Dy. No. dated 23-08-2016 Differential fee Rs.12,000/- vide challan No. 0505667 dated 23-08-2016 (Photocopy), (Duplicate dossier, R & I of initial submission verified)  NSAID  Form 5  Manufacturer specifications
406.	Name and address of manufacturer/ Applicant  Brand Name + Dosage Form + Strength Composition  Diary No. Date of R & I & fee  Pharmacological Group  Type of Form  Finished product Specification  Pack size & Demanded Price	last three years.  Verification of R & I for differential fee submission and fee challans for initial and differential fee challans required.  Ve required manufacturing facility (Pyschotropic Injectable  M/s EG Pharmaceuticals, 13-A, Industrial Triangle, Kahuta road, Islamabad.  HIFENAC 100mg tablet  Each film-coated tablet contains: Aceclofenac100mg/ml  Dy. No. 8258 dated 07-08-2012, Rs.8,000/- challan dated 07-08-2012 (Photocopy), Dy. No. dated 23-08-2016 Differential fee Rs.12,000/- vide challan No. 0505667 dated 23-08-2016 (Photocopy), (Duplicate dossier, R & I of initial submission verified)  NSAID  Form 5  Manufacturer specifications 10's, 20's, As per SRO
406.	Name and address of manufacturer/ Applicant  Brand Name + Dosage Form + Strength  Composition  Diary No. Date of R & I & fee  Pharmacological Group  Type of Form  Finished product Specification	• Verification of R & I for differential fee submission and fee challans for initial and differential fee challans required.  • Verequired manufacturing facility (Pyschotropic Injectable)  M/s EG Pharmaceuticals, 13-A, Industrial Triangle, Kahuta road, Islamabad.  HIFENAC 100mg tablet  Each film-coated tablet contains:  Aceclofenac100mg/ml  Dy. No. 8258 dated 07-08-2012, Rs.8,000/- challan dated 07-08-2012 (Photocopy), Dy. No. dated 23-08-2016 Differential fee Rs.12,000/- vide challan No. 0505667 dated 23-08-2016 (Photocopy), (Duplicate dossier, R & I of initial submission verified)  NSAID  Form 5  Manufacturer specifications

Me-too status	Ace-100 tablet of M/s Aries pharma, Peshawar. Registration
	No. 084268
GMP status	GMP compliance report within last 03 years not provided.
Remarks of the Evaluator (PEC-XVII)	•Firm has claimed manufacturer specifications. Currently official monograph available in BP for API only.
	• GMP compliance inspection report not provided.
	• Tablet section (General) available as per DML renewal inspection dated 13-02-2019 and DML issuance letter No. F. 1-26/2004-Lic dated 29-08-2012.
	• Verification of R & I for differential fee submission and fee challans for initial and differential fee challans required.

# **Decision: Approved with Innovators specifications.**

- Firm shall submit the fee of Rs. 7,500 for correction/pre-approval change/ in product specifications, as per notification No.F.7-11/2012-B&A/DRAP dated 13-07-2021.
- Registration Board further decided to verify fee challans as per decision of 285th meeting of Registration Board.
- Registration letter will be issued after submission of valid satisfactory GMP inspection report.

	Registration letter will be issued a	after submission of valid satisfactory GMP inspection report.
407.		M/s EG Pharmaceuticals, 13-A, Industrial Triangle, Kahuta
	Applicant	road, Islamabad.
	Brand Name + Dosage Form + Strength	TRANEX 500mg capsule
	Composition	Each capsule contains:
		Tranexamic acid500mg
	Diary No. Date of R & I & fee	Dy. No. 8639 dated 03-09-2012, Rs.8,000/- challan dated 03-
		09-2012 (Photocopy), Dy. No. dated 23-08-2016 Differential
		fee Rs.12,000/- vide challan No. 0505661 dated 23-08-2016
		(Photocopy),
		(Duplicate dossier, R & I of initial submission verified)
	Pharmacological Group	Anti-fibrinolytic agent
	Type of Form	Form 5
	Finished product Specification	Manufacturer specifications
	Pack size & Demanded Price	20's, As per SRO
	Approval status of product in Reference	TRANEX 500 mg capsule, AIFA approved.
	Regulatory Authorities	
	Me-too status	Trenfold Capsule 500mg of M/s Weatherfold, Hattar.
		Registration No. 103157
	GMP status	GMP compliance report within last 03 years not provided.
	Remarks of the Evaluator (PEC-XVII)	Firm has claimed manufacturer specifications, however,
		official monograph available in JP.
		• Most recent GMP compliance inspection report not provided.
		• Capsule section (General) available as per DML renewal inspection dated 13-02-2019 and DML issuance letter No. F. 1-26/2004-Lic dated 29-08-2012.
		• Verification of R & I for differential fee submission and fee challans for initial and differential fee challans required.

# **Decision: Approved with JP Specifications.**

- Firm shall submit the fee of Rs. 7,500 for correction/pre-approval change/ in product specifications, as per notification No.F.7-11/2012-B&A/DRAP dated 13-07-2021.
- Registration Board further decided to verify fee challans as per decision of 285th meeting of Registration Board.
- Registration letter will be issued after submission of valid satisfactory GMP inspection report.

408.	Name and address of manufacturer/	M/s EG Pharmaceuticals, 13-A, Industrial Triangle, Kahuta
100.	Applicant Applicant	road, Islamabad.
	Brand Name + Dosage Form + Strength	PAMID 100mg capsule
	Composition	Each capsule contains:
		Pamidronate Disodium Pentahydrate eq. to Pamidronate
		Disodium100mg
	Diary No. Date of R & I & fee	Dy. No. 8631 dated 03-09-2012, Rs.8,000/- challan dated 03-
	Š	09-2012 (Photocopy), Dy. No. dated 23-08-2016 Differential
		fee Rs.12,000/- vide challan No. 0505668 dated 23-08-2016
		(Photocopy),
		(Duplicate dossier, R & I of initial submission verified)
	Pharmacological Group	Bisphosphonate
	Type of Form	Form 5
	Finished product Specification	Manufacturer specifications
	Pack size & Demanded Price	30's, As per SRO
	Approval status of product in Reference	Could not be confirmed
	Regulatory Authorities	
	Me-too status	AMINOMUX 100mg Capsule, GADOR SA, Argentina.
		Registration No. 018981
		(No other generic available as per data base)
	GMP status	GMP compliance report within last 03 years not provided.
	Remarks of the Evaluator (PEC-XVII)	Provide evidence of approval of applied formulation in
		reference regulatory authorities / agencies which were adopted
		by the Registration Board in its 275th meeting.
		• In cover letters for initial and differential fee submission, the
		firm has mentioned manufacturer specifications for the
		applied product, while in duplicate Form-5 and its enclosures,
		the firm has mentioned Innovators specifications.
		•
		• Most recent GMP compliance inspection report not provided.
		• Capsule section (General) available as per DML renewal
		inspection dated 13-02-2019 and DML issuance letter No. F.
		1-26/2004-Lic dated 29-08-2012.
		Weification of D. 9. I for differential for submission and for
		• Verification of R & I for differential fee submission and fee
		challans for initial and differential fee challans required.
	<b>Decision: Deferred for following:</b>	
	<ul> <li>Confirmation/evidence of approva</li> </ul>	al of applied formulation in reference regulatory authorities
	/ agencies which were adopted by	the Registration Board in its 275th meeting.
	<ul> <li>Verification of fee challans as per</li> </ul>	decision of 285th meeting of Registration Board.
	<ul> <li>GMP inspection report within 3 y</li> </ul>	vears.
	<ul> <li>Confirmation of manufacturing f</li> </ul>	Cacility.
409.	Name and address of manufacturer/	M/s EG Pharmaceuticals, 13-A, Industrial Triangle, Kahuta
	Applicant	road, Islamabad.
	Brand Name + Dosage Form + Strength	ROXIM 20mg/ml Injection (I/M)
	Composition	Each 1ml ampoule contains:
		Piroxicam20mg
	Diary No. Date of R & I & fee	Dy. No. 7492 dated 24-07-2012, Rs.8,000/- challan dated 24-
	-	07-2012 (Photocopy), Dy. No. dated 23-08-2016 Differential
		fee Rs.12,000/- vide challan No. 0505666 dated 23-08-2016
		(Photocopy),
		(Duplicate dossier, R & I of initial submission verified)
	Pharmacological Group	NSAID
	Type of Form	Form 5
	Finished product Specification	Manufacturer specifications
	•	Pogistration Poard (16.17 May 2022)

Dools size & Domandad Drice	Ac man CDO
Pack size & Demanded Price	As per SRO
Approval status of product in Reference	PIROXICAM PFIZER 20 mg/1 ml, solution injectable en
Regulatory Authorities	ampoule (IM) (ANSM approved)
Me-too status	Piroxinor 20mg Injection of M/s Nortech Pharmaceuticals,
	Islamabad. (Reg# 080001)
GMP status	GMP compliance report within last 03 years not provided.
Remarks of the Evaluator (PEC-XVII)	• In cover letters for initial and differential fee submission, the
	firm has mentioned manufacturer specifications for the
	applied product, while in duplicate Form-5 and its enclosures,
	the firm has mentioned Innovators specifications.
	• Most recent GMP compliance inspection report not provided.
	• Ampoules section available as per DML renewal inspection dated 13-02-2019 and DML issuance letter No. F. 1-26/2004-Lic dated 29-08-2012.
	• Verification of R & I for differential fee submission and fee challans for initial and differential fee challans required.

# **Decision: Approved with Innovators Specifications.**

- Firm shall submit the fee of Rs. 7,500 for correction/pre-approval change/ in product specifications, as per notification No.F.7-11/2012-B&A/DRAP dated 13-07-2021.
- Registration Board further decided to verify fee challans as per decision of 285th meeting of Registration Board.
- Registration letter will be issued after submission of valid satisfactory GMP inspection report.

# Form 5 and Form 5D applications requiring submission of Stability data

Registration Board in its 240<sup>th</sup> meeting decided that applications of registration of new drug products and its subsequent generics will be considered on the basis of evaluation of its product development and stability study data. Applicants for new drug products and subsequent generics were submitting product development and stability study data along with their applications submitted on Form 5D and Form 5 respectively.

All such applications were considered on FIFO basis on the basis of submission of product development and stability study data. Registration Board in its 293<sup>rd</sup> meeting provided guidelines for submission of product development and stability study data. Various firm has submitted such applications of new drug product or subsequent generics without stability study data since 2010 and are pending for submission of data. Many of such applications (without product development data / stability data) have also been deferred in various meetings of Registration Board for submission of data. Furthermore, such type of applications without stability data have also been applied on Form 5 on 6-7<sup>th</sup> march, 2019.

#### **Decision:**

Registration Board advised to upload list of these applications on DRAP's website and directed applicants to complete these applications (including product development/stability data) within 6 months time, failing which the Board will decide these applications accordingly.

Item No III: Division of Biological Evaluation & Research

Sr.	Details of application	No. of Cases
No.		
A	Shelf Life Extension of already imported batches of Sputnik V	01
В	Priority Registration of New Molecule	01
В	Imported Human Biologicals from Reference Countries/WHO PQ	02
С	Imported Human Biologicals from Non-Reference Countries	03
D	Imported Veterinary Biologicals from Reference Countries	03
Е	Imported Veterinary Biologicals from Non-Reference Countries	11
F	Locally Manufactured Veterinary Biologicals	01
F	Miscellaneous/ Deferred Cases	22
Total	•	53

Sr. No.	Assistant Director	Designated No.	No. of Cases
1.	Mr. M. Zubair Masood	AD-I	13
2.	Mr. Saadat Ali Khan	AD-II	09
3.	Ms. Haleema Shareef	AD-III	18
4.	Mr. M. Kashif	AD_IV	13

# A: Shelf Life extension of already imported batches of Sputnik V vaccine applied by Federal Directorate of Immunization.

Federal Directorate of Immunization (FDI) had requested for extension in shelf life of already imported following batches of Sputnik V:

Sr. No.	Batch No.	Quantity (Doses)	Old Expiry Date	New Expiry Date
1.	I-560821	455,600	28/02/22	31/05/22
2.	I-530821	44,400	28/02/22	31/05/22
3.	II-610821	290,000	28/02/22	31/05/22
4.	II-540821	210,000	28/02/22	31/05/22
5.	10521G2F2	1000,000	31/03/22	31/06/22
6.	22021G4F2	97,000	31/03/22	31/06/22
7.	II-640821	243,000	28/02/22	31/05/22
8.	II-720821	660,000	28/02/22	31/05/22
9.	I-660821	900,000	28/02/22	31/05/22
10.	I-670821	100,000	28/02/22	31/05/22
11.	20321G4F2	180,480	31/03/22	31/06/22
12.	20721G4F2	819,520	28/02/22	31/05/22
13.	I-670821	680,650	28/02/22	31/05/22
14.	I-700821	319,350	28/02/22	31/05/22
15.	20321G4F2	211,200	31/03/22	31/06/22
16.	II-740821	787,200	28/02/22	31/05/22
17.	II-760821	500,000	28/02/22	31/05/22
18.	20321G4F2	401,800	31/03/22	31/06/22
19.	II-730821	472,860	28/02/22	31/05/22
20.	II-740821	14,870	28/02/22	31/05/22
21.	II-760821	112,070	28/02/22	31/05/22

To facilitate the decision making and to ensure the quality of the batches, Federal Directorate of Immunization was advised to submit the following:

- i. Approval of shelf life extension of all the 21 batches mentioned in your letter from Ministry of Health of Russian Federation. The English translated approval attached with the letter mentioned only 04 batches (I-530821, I-540821, I-670821, I-700821)
- ii. Certificate of Analysis after the expiry/ last COA of all the batches, to confirm quality of the batches, for which extension is requested.
- iii. Updated stability data up to the demanded shelf life as an evidence to ensure quality of the batches.
- iv. Clarification, as the official web site of Ministry of Health of Russian Federation indicates shelf life as 6 & 8 months, while the submitted approvals of Russian Federation are for 9 and 12 months.

Federal Directorate of Immunization, even after more than one month, could not submit the complete documents. Therefore, <u>an email was forwarded to Foreign Office on 18-04-2022 by AD-QMS</u> to contact manufacturer through Embassy of Russian Federation for provision of documents. Meanwhile, FDI submitted the following response through email dated 20-04-2022:

Sr. No.	Documents Required	Documents Provided by FDI
1.	Approval of shelf life extension of all the batches mentioned in your letter from Ministry of Health of Russian Federation. The English translated approval attached with the letter mentioned only 04 batches (I-530821, I-540821, I-670821, I-700821)	Submitted
2.	Certificate of Analysis after the expiry/ last COA of all the batches, to confirm quality of the batches, for which extension is requested.	Not submitted and the firm submitted that Gamaleya issues CoA after production of batches and doesn't reissue after shelf-life extension. They requested to use Russian MOH letters with extended expiry dates.
3.	Updated stability data up to the demanded shelf life as an evidence to ensure quality of the batches.	Submitted stability data is of different batches and not of those batches for which extension is requested.
4.	Clarification, as the official web site of Ministry of Health of Russian Federation indicates shelf life as 6 & 8 months, while the submitted approvals of Russian Federation are for 9 and 12 months.	Updated link submitted.

The response of FDI was evaluated and it was observed that the batches for which extension is requested are in 1mL (2 doses) Ampoule while DRAP has granted EUA to 0.5mL (single dose) Ampoule. Moreover, stability data submitted by FDI was of different batches (I-100521, I-130521, I-200521, II-090521, II-090521 & II-100521)

I&E Section of QA&LT Division confirmed that two of the above batches (10521G2F2 & II-760821) were imported by EPI on Institution Supply basis.

Furthermore, Ministry of Foreign Affairs vide letter dated 22-04-2022 submitted the following in response to email:

- "2. As the vaccines were purchased on commercial basis through supplier from Russia without involvement of our Embassy in Moscow or this Ministry, it will be more efficient and appropriate to take up the issue of documents via same channels.
- 3. This Ministry or our Embassy in Moscow did not have any information/documents on the procurement of vaccine or any contact with the concerned agency from which the vaccine were procured. Hence, it will not be appropriate to involve the Ministry of Foreign Affairs in the process at this stage. However, we have instructed our Embassy in Moscow to write a note verbale to the Ministry of Foreign Affairs of the Russian Federal for help in expediting the matter."

It is further submitted that M/s National Institute of Health forwarded test reports for following batches:

Sr. No.	Batch No.
1.	740821-II
2.	730821-II
3.	720821-II

4.	640821-II
5.	610821-II
6.	540821-II
7.	760821-II
8.	670821-I

The batch (670821-I) of Component-I is failed in terms of specific antibody titer. Moreover, NIH has not performed analysis of specific antibody titer as performed by manufacturer and available in dossier as the limit of specific antibodies to S glycoprotein is different in reports i.e. >0.4/ml while in dossier it is 1:250 for component I and 1:1000 for component II.

#### **Discussion:**

Mr. Muazzam and Mr. Rafiq Channa from M/s National Institute of Health (NIH), Islamabad joined the meeting via zoom link and informed the Board that Federal Directorate of immunization has provided only 8 batches to NIH for testing purpose. Moreover, for the testing of titer of specific antibodies against S glycoprotein for Component-I (Adenovirus 26), neither M/s NIH has the requisite facility and method nor manufacturer has provided them. Hence, only identification of antibodies is done using Western Blot technique in Component-I (Adenovirus 26).

Registration Board discussed that as M/s NIH has informed that manufacturer did not provide them methods of testing and they used their in-house methods for testing, hence, there is difference in limits of specific Antibody titer for both components in quality control reports and finished product specifications submitted by manufacturer to DRAP and M/s NIH has provided no correlation between different methods and their limits to ensure that the titer of specific antibodies produced by each component is sufficient to give the desired efficacy. Moreover, the provided reports clearly indicate that only 1 batch of Component-I is tested and that too has failed in terms of specific antibodies.

#### **Decision:**

Registration Board, in light of above, decided as follows:

- 1. The batches for which extension is requested are in 1ml (2 doses) Ampoule packing while Emergency Use Authorization (EUA) was granted to 0.5ml (1 dose) Ampoule packing, hence, Registration Board is not the competent forum for deciding the instant case.
- 2. However, Registration Board being technical forum, took in sight from available record provided by Federal Directorate of Immunization and considering the risk/benefit analysis & public health impact of shelf life extension of said batches of Sputnik V, opined that these batches may not be used beyond existing expiry dates assigned by the manufacturer based on following deliberation:
  - a. The Certificates of Analysis of these batches by the manufacturer after the expiry dates are not available.
  - b. The updated stability data of these batches upto the demanded shelf life is not available.
  - c. The quality control tests performed by M/s National Institute of Health, Islamabad are limited and are not fully conclusive to ensure stability in terms of efficacy of the product.

#### **B:** Priority Registration of New Formulations

M/s The Schazoo Pharmaceutical Laboratories (Pvt.) Ltd., Sheikhupura applied for priority registration of following product being new molecule. Accordingly, the application was evaluated out of queue on priority as per decision of 257<sup>th</sup> meeting of Registration Board. Details of the application are as under:

1.	Name, address of	M/s The Schazoo Pharmaceutical Laboratories (Pvt.) Ltd.,
	Applicant / Importer	Kalalwala Stop, 20-KM Lahore Jaranwala Road, Tehsil Sharaqpur
		Sharif, Sheikhupura.
	Details of Drug Sale	License No: 06-354-0076-069245D
	License of importer	Address: Kalalwala Stop, 20-KM Lahore Jaranwala Road, Tehsil Sharaqpur
		Sharif, Sheikhupura.
		Validity: 25-09-2022
	Name and address of	M/s Celltrion Healthcare Hungary Kft., Vaci ut 1-3, WestEnd Office Building
	marketing authorization	B torony, 1062, Budapest Hungary.
	holder (abroad)	
	Name, address of	M/s Vetter Pharma-Fertigung GmbH & co. KG, Schuetzenstr. 87 and 99-101,
	manufacturer(s)	88212, Germany.

	Batch Release Site:  M/s Biotec Services International Ltd., Biotec House, Central Park, Western Avenue, Bridgend Industrial Estate, Bridgend CF31 3RT, UK.
Name of exporting country	Kore
Detail of certificates attached (CoPP, Free Sale certificate, GMP certificate)	• Firm has submitted Legalized copy of CoPP (No. 03/20/148158) dated 24-08-2020 issued by EMA. The COPP specifies that the product is licensed for sale in country of origin. The COPP also specifies the GMP status of manufacturer.
Details of letter of authorization / sole agency agreement	<ul> <li>Firm has submitted Original Letter of Authorization from CEO &amp; Vice Chairman of M/s Celltrion Healthcare Co., Ltd., Korea. According to the letter, the firm M/s Celltrion Healthcare Co., Ltd., Korea. exclusively authorizes "M/s The Schazoo Pharmaceutical Laboratories (Pvt.) Ltd., to handle all regulatory and commercial affairs of the product in Pakistan.</li> <li>Firm has submitted Original Letter of Certification CEO &amp; Vice Chairman of M/s Celltrion Healthcare Co., Ltd., Korea certifying relationship between M/s Celltrion Healthcare Co., Ltd., Korea &amp; M/s Celltrion Healthcare Hungary Kft., Hungary.</li> </ul>
Status of the applicant	☐Manufacturer  ☑Importer  ☐It is a selected in the selected (contract size s)
Status of application	☐ Is involved in none of the above (contract giver)  ☐ New Drug Product (NDP)  ☐ Generic Drug Product (GDP)
Intended use of pharmaceutical product	<ul><li>☑Domestic sale</li><li>☐Export sale</li><li>☐Domestic and Export sales</li></ul>
For imported products, specify one the these	⊠Finished Pharmaceutical product import     □Buk import and local repackaging     □Buk import and local repackaging for export purpose only
Dy. No. and date of submission	Form -5F 1746, 9679, 10959 & 11070 (R&I) Dated: 19-01-2022, 15-04-2022, 30-04-2022 & 07-05-2022
Details of fee submitted	Rs: 75,000/- Dated: 11-03-2022 Deposit Slip No. 382964522906
The proposed proprietary name / brand name	Remsima SC Solution for Injection
Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each PFS (1mL) contains: Infliximab120mg
Dosage form of applied drug	Solution for Injection
Pharmacotherapeutic Group of (API)	Monoclonal Antibody
Reference to Finished product specifications	Innovator
Proposed Pack size	1's PFS
Proposed unit price Shelf Life	As per DPC 36 months
Storage Conditions	2-8 °C
The status in reference regulatory authorities	The product is itself approved by EMA & Health Canada.
For generic drugs (me-too	Not Applicable.

ICH guidelines. Firm has summarized properties, manufacturers, description of characterization, specifications, analytical analysis and justification of specification, are system and stability studies of drug rm has also submitted the non-clinical and analysis and justification, Incheon, 22014, substance data related to nomenclature, abilities, physical form, manufacturers, as and controls, impurities, specifications, lation, batch analysis and justification of ontainer closure system and stability studies data of 5 batches at long term conditions. Acted at $-40 \pm 5$ °C for 18 months.
properties, manufacturers, description of characterization, specifications, analytical analysis and justification of specification, are system and stability studies of drug rm has also submitted the non-clinical and $\alpha$ , Academy-ro, Yeonsu-gu, Incheon, 22014, substance data related to nomenclature, ubilities, physical form, manufacturers, ess and controls, impurities, specifications, dation, batch analysis and justification of ontainer closure system and stability studies data of 5 batches at long term conditions. cted at $-40 \pm 5$ °C for 18 months.
substance data related to nomenclature, ubilities, physical form, manufacturers, ess and controls, impurities, specifications, lation, batch analysis and justification of ontainer closure system and stability studies data of 5 batches at long term conditions. cted at $-40 \pm 5$ °C for 18 months.
substance data related to nomenclature, ubilities, physical form, manufacturers, as and controls, impurities, specifications, lation, batch analysis and justification of ontainer closure system and stability studies data of 5 batches at long term conditions. cted at $-40 \pm 5$ °C for 18 months.
substance data related to nomenclature, ubilities, physical form, manufacturers, as and controls, impurities, specifications, lation, batch analysis and justification of ontainer closure system and stability studies data of 5 batches at long term conditions. cted at $-40 \pm 5$ °C for 18 months.
ubilities, physical form, manufacturers, ess and controls, impurities, specifications, lation, batch analysis and justification of ontainer closure system and stability studies data of 5 batches at long term conditions. cted at $-40 \pm 5$ °C for 18 months.
ubilities, physical form, manufacturers, ess and controls, impurities, specifications, lation, batch analysis and justification of ontainer closure system and stability studies data of 5 batches at long term conditions. cted at $-40 \pm 5$ °C for 18 months.
cted at $-40 \pm 5$ °C for 18 months.
1 1 1 1
duct including its description, composition, facture, manufacturing process and process ols, control of excipients, control of drug all procedures, validation of analytical tion of specifications, reference standard or and stability.
alytical method validation.
nge with a ½ inch (1.27 cm) fixed (staked- zed elastomeric plunger stopper and has an
lata of 3 batches of Remsima SC 120mg at
The real time stability data is conducted at s. The accelerated stability data provided is 5±2°C for 06 months.
etics of CT-P13 After a Single Intravenous
ingle-dose, Phase I study to evaluate safety ation
gle-dose, two-arm, parallel-group, Phase I of CT-P13 SC via AI and PFS
hase I/III study to evaluate efficacy, PK and 3 IV
lel- group, Phase I study to evaluate the PK, C and CT-P13 IV
eous formulation should be initiated with may be intravenous or subcutaneous. When
1 C

The recommended maintenance dose for Remsima subcutaneous formulation is 120 mg once every 2 weeks.

#### Moderately to severely active Crohn's disease:

Treatment with Remsima administered subcutaneously should be initiated as maintenance therapy 4 weeks after the last administration of two intravenous infusions of infliximab 5 mg/kg given 2 weeks apart. The recommended dose for Remsima subcutaneous formulation is 120 mg once every 2 weeks. If a patient does not respond after 2 doses of intravenous infusions, no additional treatment with infliximab should be given. Available data do not support further infliximab treatment, in patients not responding within 6 weeks of the initial infusion.

#### Fistulising, active Crohn's disease:

Remsima 120 mg given as a subcutaneous injection 4 weeks after the last administration of two intravenous infusions of infliximab 5 mg/kg given 2 weeks apart. The recommended dose for Remsima subcutaneous formulation is 120 mg once every 2 weeks. If a patient does not respond after 6 doses (i.e. 2 intravenous infusions and 4 subcutaneous injections), no additional treatment with infliximab should be given.

#### **Ulcerative colitis:**

Treatment with Remsima administered subcutaneously should be initiated as maintenance therapy 4 weeks after the last administration of two intravenous infusions of infliximab 5 mg/kg given 2 weeks apart. The recommended dose for Remsima subcutaneous formulation is 120 mg once every 2 weeks.

#### **Ankylosing spondylitis:**

Treatment with Remsima administered subcutaneously should be initiated as maintenance therapy 4 weeks after the last administration of two intravenous infusions of infliximab 5 mg/kg given 2 weeks apart. The recommended dose for Remsima subcutaneous formulation is 120 mg once every 2 weeks. If a patient does not respond by 6 weeks (i.e. after 2 intravenous infusions), no additional treatment with infliximab should be given.

#### **Psoriatic arthritis:**

Treatment with Remsima administered subcutaneously should be initiated as maintenance therapy 4 weeks after the last administration of two intravenous infusions of infliximab 5 mg/kg given 2 weeks apart. The recommended dose for Remsima subcutaneous formulation is 120 mg once every 2 weeks.

#### Penriacie

Treatment with Remsima administered subcutaneously should be initiated as maintenance therapy 4 weeks after the last administration of two intravenous infusions of infliximab 5 mg/kg given 2 weeks apart. The recommended dose for Remsima subcutaneous formulation is 120 mg once every 2 weeks. If a patient shows no response after 14 weeks (i.e. 2 intravenous infusions and 5 subcutaneous injections), no additional treatment with infliximab should be given.

#### Remarks of Evaluator

- i. The osmolality specifications have been revised, however, the firm has submitted that no new accelerated studies for drug product have been conducted for revised specifications.
- ii. The product gets out of specifications at 2<sup>nd</sup> and 3<sup>rd</sup> month of accelerated stability data for which the firm submitted that the shelf life is based on real time stability studies.

Decision: Keeping in view legalized CoPP and approval of EMA (Reference Regulatory Authority); Registration Board approved the product subject to compliance of current Import Policy for finished drugs.

# B: Imported Human Biologicals from Reference countries/WHO PQ

	M/s Amson Vaccines & Pharma (Pvt.) Ltd., Plot No. 115, Industrial Triangle, Kahuta Road, Islamabad.
	Address Plot No. 115, Industrial Triangle, Kahuta Road, Islamabad. Validity: 01-08-2022
Name and address of marketing authorization holder (abroad)	M/s LG Chem, Ltd., 151, Osongsaengmyeong 1-ro, Osong-eup, Heungder gu, Cheongju-si, Chungcheongbuk-do, Republic of Korea
Name, address of manufacturer(s)	M/s LG Chem, Ltd., 151, Osongsaengmyeong 1-ro, Osong-eup, Heungdegu, Cheongju-si, Chungcheongbuk-do, Republic of Korea
Name of exporting country	Korea
Detail of certificates attached (CoPP, Free Sale certificate, GMP certificate)	Firm has submitted original, legalized CoPP (No. 2021-A1-1390) dat 22-10-2021 issued by Ministry of Food and Drug Safety, Korea. The Col specifies that the product is not licensed to be placed on the market for use exporting country.
Details of letter of authorization / sole agency agreement	Firm has submitted legalized original Letter of product specification authorization from VP, head of Clinical & Regulatory Affairs Center, L. Chem Ltd., Korea. According to the letter, the firm <i>M/s LG Chem Ltd.</i> exclusively authorizes "Amson Vaccines & Pharma Pvt. Ltd." to registed import, promotion and marketing of the product in Pakistan. The lett was issued on 21-10-2021.
Status of the applicant	<ul> <li>□ Manufacturer</li> <li>⋈ Importer</li> <li>□ Is involved in none of the above (contract giver)</li> </ul>
Status of application	<ul><li>☑ New Drug Product (NDP)</li><li>☐ Generic Drug Product (GDP)</li></ul>
Intended use of pharmaceutical product	<ul><li>☑ Domestic sale</li><li>☐ Export sale</li><li>☐ Domestic and Export sales</li></ul>
For imported products, specify one the these	<ul> <li>☑ Finished Pharmaceutical product import</li> <li>☐ Buk import and local repackaging</li> <li>☐ Buk import and local repackaging for export purpose only</li> </ul>
Dy. No. and date of submission	Dy. No. 31789 & 11223 (R&I) dated 18-11-2021 & 10-05-2022
Details of fee submitted	PKR 150,000/- dated: 11-11-2021
The proposed proprietary name / brand name	Eupolio Injection (Sabin Inactivated Polio Vaccine)
ingredient (API) per unit	Each dose (0.5ml) contains: Inactivated poliovirus type1 (Sabin strain)5DU Inactivated poliovirus type2 (Sabin strain)8DU Inactivated poliovirus type3 (Sabin strain)16DU
	Injection
Pharmacotherapeutic Group of (API)	Polio Vaccine
Reference to Finished product specifications	Ph. Eur/ WHO Specs
Proposed Pack size	Pack Size is 1's Vial (0.5mL), 10's Vials

Shelf Life	36 months
Storage Conditions	2°C-8°C
The status in reference regulatory authorities	Product is itself WHO PQ.
For generic drugs (me-too status)	Not Registered.
Module-II (Quality Overall Summary)	Firm has submitted QOS as per ICH guidelines. Firm has summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product.
Name, address of drug substance manufacturer	M/s LG Chem, Ltd., 151, Osongsaengmyeong 1-ro, Osong-eup, Heungdeokgu, Cheongju-si, Chungcheongbuk-do, Republic of Korea
Module-III Drug Substance:	Firm has submitted detailed drug substance data related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
Stability Studies of Drug Substance (Conditions & duration of Stability studies)	Firm has submitted stability study data as per following details:  Type 1:  11 batches at real time conditions. The real time stability data conducted at 5°C±2°C is for 36 months for 5 batches and 24 months for 6 batches. The accelerated stability data conducted at 25°C±2°C is for 6 months for 6 batches.  Type 2:  13 batches at real time conditions. The real time stability data conducted at 5°C±2°C is for 36 months for 6 batches and 24 months for 7 batches. The accelerated stability data conducted at 25°C±2°C is for 6 months for 6 batches.  Type 3:  11 batches at real time conditions. The real time stability data conducted at 5°C±2°C is for 36 months for 4 batches and 24 months for 7 batches. The accelerated stability data conducted at 25°C±2°C is for 6 months for 6 batches.
Module-III Drug Product:	Firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.
Analytical method validation/verification of product	Firm has submitted that the data from the PPQ batches demonstrate that the FDC drug product manufacturing process consistently yields drug product that meets the predetermined acceptance criteria for all quality attributes and that the in-process tests are suitable to monitor the manufacturing process.
Container closure system of the drug product	<ul> <li>Siliconized borosilicate glass type I</li> <li>Chlorobutyl elastomer coated with silicone oil</li> <li>Aluminum seal, PP flip-off cap (Pink)</li> </ul>
Stability study data of drug product	Firm has submitted real time stability study data of 7 batches. The accelerated stability study data is conducted at $25\pm2^{\circ}$ C $/60\pm5\%$ RH for 6

	months for 6 batches. The real time stability study data is conducted at $5\pm3^{\circ}$ C for 36 months.
Module-IV Non-Clinical	<ul> <li>Immunogenicity Studies in Wister rats</li> <li>Single-dose toxicity in rats</li> <li>Repeat-dose toxicity in rats</li> <li>Repeat-dose toxicity in rabbits</li> </ul>
Module-V Clinical	<ul> <li>Study to evaluate safety and immunogenicity of sIPV in healthy adults</li> <li>Study to evaluate safety and efficacy of plain sIPV and adjuvanted sIPV in healthy adults.</li> <li>Double blind – Increasing capacity, random allocation, contrast, phase 1/2a study to assess the safety and efficacy of each of the three doses of plain sIPV and adjuvanted sIPV in healthy infants.</li> <li>A prospective, multi-national, multi-center, double-blind, randomized, active controlled, parallel-group, seamless Phase II/III clinical study to evaluate the safety and immunogenicity of 'LBVC (Sabin Poliomyelitis Vaccine (Inactivated))' compared with 'Imovax® Polio (Poliomyelitis Vaccine (Inactivated))' in healthy infants.</li> <li>A prospective, multi-national, multi-center, double-blind, randomized, active controlled, parallel-group, seamless Phase II/III clinical study to evaluate the safety and immunogenicity of 'LBVC (Sabin Poliomyelitis Vaccine (Inactivated))' compared with 'Imovax® Polio (Poliomyelitis Vaccine (Inactivated))' in healthy infants.</li> </ul>

### **Remarks of Evaluator:**

The product is not licensed to be placed in market for use in exporting country, however, the product is WHO PQ and its status is checked on 14-05-2022 @ <a href="https://extranet.who.int/pqweb/content/eupolio-inj-0">https://extranet.who.int/pqweb/content/eupolio-inj-0</a>

Decision: Keeping in view legalized CoPP and WHO Prequalification (Reference Regulatory Authority); Registration Board approved the product subject to compliance of current Import Policy for finished drugs.

egistration Board approved the product subject to compliance of current Import Policy for finished drugs.	
Name, address of Applicant /	M/s Amson Vaccines & Pharma (Pvt.) Ltd.,
Importer	Plot No. 115, Industrial Triangle, Kahuta Road, Islamabad.
Details of Drug Sale License of	License No: 920-ICT/2013
	Address Plot No. 115, Industrial Triangle, Kahuta Road, Islamabad.
	Validity: 01-08-2022
Name and address of marketing authorization holder (abroad)	M/s LG Chem, Ltd., 151, Osongsaengmyeong 1-ro, Osong-eup, Heungdeokgu, Cheongju-si, Chungcheongbuk-do, Republic of Korea
Name, address of manufacturer(s)	M/s LG Chem, Ltd., 151, Osongsaengmyeong 1-ro, Osong-eup, Heungdeokgu, Cheongju-si, Chungcheongbuk-do, Republic of Korea
Name of exporting country	Korea
Detail of certificates attached	Firm has submitted original, legalized CoPP (No. 2021-A1-1208) dated
(CoPP, Free Sale certificate,	22-10-2021 issued by Ministry of Food and Drug Safety, Korea. The CoPP
GMP certificate)	specifies that the product is not licensed to be placed on the market for use in exporting country.
Details of letter of authorization /	Firm has submitted legalized original Letter of product specific
sole agency agreement	authorization from VP, head of Clinical & Regulatory Affairs Center, LG
	Chem Ltd., Korea. According to the letter, the firm M/s LG Chem Ltd.,
	exclusively authorizes "Amson Vaccines & Pharma Pvt. Ltd." to register, import, promotion and marketing of the product in Pakistan. The letter
	was issued on 17-08-2021.
Status of the applicant	☐ Manufacturer
	☑ Importer
	$\square$ Is involved in none of the above (contract giver)

Status of application	<ul><li>☑ New Drug Product (NDP)</li><li>☐ Generic Drug Product (GDP)</li></ul>
Intended use of pharmaceutical product	<ul><li>☑ Domestic sale</li><li>☐ Export sale</li><li>☐ Domestic and Export sales</li></ul>
For imported products, specify one the these	<ul> <li>☑ Finished Pharmaceutical product import</li> <li>☐ Buk import and local repackaging</li> <li>☐ Buk import and local repackaging for export purpose only</li> </ul>
Dy. No. and date of submission	Dy. No. 31788 & 11223 (R&I) dated 18-11-2021 & 10-05-2022
Details of fee submitted	PKR 150,000/- dated: 11-11-2021
The proposed proprietary name / brand name	Eupolio Injection (Sabin Inactivated Polio Vaccine)
Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each dose (0.5ml) contains: Inactivated poliovirus type1 (Sabin strain)5DU Inactivated poliovirus type2 (Sabin strain)8DU Inactivated poliovirus type3 (Sabin strain)16DU
Dosage form of applied drug	Injection
Pharmacotherapeutic Group of (API)	Polio Vaccine
Reference to Finished product specifications	Ph. Eur/ WHO Specs
Proposed Pack size	Pack Size is 1's (2.5mL), 10's (2.5mL)
Proposed unit price	Not Provided.
Shelf Life	36 months
Storage Conditions	2°C-8°C
The status in reference regulatory authorities	Product is itself WHO PQ.
For generic drugs (me-too status)	Not Registered.
Module-II (Quality Overall Summary)	Firm has submitted QOS as per ICH guidelines. Firm has summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product.
Name, address of drug substance manufacturer	M/s LG Chem, Ltd., 151, Osongsaengmyeong 1-ro, Osong-eup, Heungdeokgu, Cheongju-si, Chungcheongbuk-do, Republic of Korea
Module-III Drug Substance:	Firm has submitted detailed drug substance data related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
Stability Studies of Drug Substance (Conditions & duration of Stability studies)	Firm has submitted stability study data as per following details: <b>Type 1:</b> 11 batches at real time conditions. The real time stability data conducted at 5°C±2°C is for 36 months for 5 batches and 24 months for 6 batches. The

	accelerated stability data conducted at $2.5^{\circ}\text{C}\pm2^{\circ}\text{C}$ is for 6 months for 6 batches. <b>Type 2:</b> 13 batches at real time conditions. The real time stability data conducted at $5^{\circ}\text{C}\pm2^{\circ}\text{C}$ is for 36 months for 6 batches and 24 months for 7 batches. The accelerated stability data conducted at $2.5^{\circ}\text{C}\pm2^{\circ}\text{C}$ is for 6 months for 6 batches. <b>Type 3:</b> 11 batches at real time conditions. The real time stability data conducted at $5^{\circ}\text{C}\pm2^{\circ}\text{C}$ is for 36 months for 4 batches and 24 months for 7 batches. The accelerated stability data conducted at $2.5^{\circ}\text{C}\pm2^{\circ}\text{C}$ is for 6 months for 6 batches.
Module-III Drug Product:	Firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.
Analytical method validation/verification of product	Firm has submitted that the data from the PPQ batches demonstrate that the FDC drug product manufacturing process consistently yields drug product that meets the predetermined acceptance criteria for all quality attributes and that the in-process tests are suitable to monitor the manufacturing process.
Container closure system of the drug product	<ul> <li>Siliconized borosilicate glass type I</li> <li>Chlorobutyl elastomer coated with silicone oil</li> <li>Aluminum seal, PP flip-off cap (Pink)</li> </ul>
Stability study data of drug product	Firm has submitted real time stability study data of 6 batches. The accelerated stability study data is conducted at $25\pm2^{\circ}$ C /60±5% RH for 6 months for 6 batches. The real time stability study data is conducted at $5\pm3^{\circ}$ C for 36 months.
Module-IV Non-Clinical	<ul> <li>Immunogenicity Studies in Wister rats</li> <li>Single-dose toxicity in rats</li> <li>Repeat-dose toxicity in rats</li> <li>Repeat-dose toxicity in rabbits</li> </ul>
Module-V Clinical	<ul> <li>Study to evaluate safety and immunogenicity of sIPV in healthy adults</li> <li>Study to evaluate safety and efficacy of plain sIPV and adjuvanted sIPV in healthy adults.</li> <li>Double blind – Increasing capacity, random allocation, contrast, phase 1/2a study to assess the safety and efficacy of each of the three doses of plain sIPV and adjuvanted sIPV in healthy infants.</li> <li>A prospective, multi-national, multi-center, double-blind, randomized, active controlled, parallel-group, seamless Phase II/III clinical study to evaluate the safety and immunogenicity of 'LBVC (Sabin Poliomyelitis Vaccine (Inactivated))' compared with 'Imovax® Polio (Poliomyelitis Vaccine (Inactivated))' in healthy infants.</li> <li>A prospective, multi-national, multi-center, double-blind, randomized, active controlled, parallel-group, seamless Phase II/III clinical study to evaluate the safety and immunogenicity of 'LBVC (Sabin Poliomyelitis Vaccine (Inactivated))' compared with 'Imovax® Polio (Poliomyelitis Vaccine (Inactivated))' compared with 'Imovax® Polio (Poliomyelitis Vaccine (Inactivated))' in healthy infants.</li> </ul>

#### **Remarks of Evaluator:**

The product is not licensed to be placed in market for use in exporting country, however, the product is WHO PQ and its status is checked on 14-05-2022 @ <a href="https://extranet.who.int/pqweb/content/eupolio-inj">https://extranet.who.int/pqweb/content/eupolio-inj</a>

Decision: Keeping in view legalized CoPP and WHO Prequalification (Reference Regulatory Authority); Registration Board approved the product subject to compliance of current Import Policy for finished drugs.

#### C: Imported Human Biologicals from Non-reference countries

Name, address of Applicant / Importer	M/s BF Biosciences Limited, 5-KM Sunder Raiwind Road, Raiwind, Lahore.
Details of Drug Sale License of importer	License No: 05-352-0066-034461D  Address: 5-KM Sunder Raiwind Road, Raiwind, Lahore.  Address of go-down: 5-KM Sunder Raiwind Road, Raiwind, Lahore.  Validity: 29-06-2022  Status: License to sell drugs as a distributor.
Name and address of marketing authorization holder (abroad)	M/s Sinergium Biotech S.A., Route 9 Km 38.7, of the City of Garin, Province of Buenos Aires, Argentine Republic
Name, address of manufacturer(s)	M/s Sinergium Biotech S.A., Route 9 Km 38.7, of the City of Garin, Province of Buenos Aires, Argentine Republic
Name of exporting country	Argentina
Detail of certificates attached (CoPP, Freesale certificate, GMP certificate)	• Firm has submitted legalized CoPP (No. CE-2021-13181178-AF DECBR#ANMAT) dated 15-02-2021 valid for two years issued by Argenti The CoPP specifies free sale status of the product in country of origin all with its availability. The certificate also specifies the GMP status of manufacturer.
Details of letter of authorization / sole agency agreement	Firm has submitted product specific Sole Agent Authorization from Attorney Sinergium Biotech. According to the letter, the firm <i>M/s Sinergium Biotech</i> authorizes "BF Biosciences Limited" to apply for registration. The letter vissued on 04-03-2021 and valid for one year.
Status of the applicant	☐ Manufacturer  ☑ Importer ☐ Is involved in none of the above (contract giver)
Status of application	☐ New Drug Product (NDP)  ☐ Generic Drug Product (GDP)
Intended use of pharmaceutical product	<ul><li>☑ Domestic sale</li><li>☐ Export sale</li><li>☐ Domestic and Export sales</li></ul>
For imported products, specify one the these	<ul> <li>☑ Finished Pharmaceutical product import</li> <li>☐ Buk import and local repackaging</li> <li>☐ Buk import and local repackaging for export purpose only</li> </ul>
Dy. No. and date of submission	Dy. No. 18230 & 9560 (R&I) Dated 29-06-2021 & 14-04-2022
Details of fee submitted	Rs. 75,000/- dated 09-06-2021
The proposed proprietary name / brand name	Viraflu
Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each dose (0.5ml) contains:  A/Victoria/2570/2019 (H1N1)-(like strain: A/Victoria/2570/2019, IVR-215)15 micrograms HA*  A/Hong Kong/2671/2019 (H3N2) - (like strain: A/Hong Kong/2671/2019, IVR-208)15 micrograms HA*

	B/Washington/02/2019 - (B/ Victoria lineage) (like strain: B/Victoria/705/2018, BVR-11)15 micrograms HA* *viral haemagglutinin
Dosage form of applied drug	Suspension for Injection
Pharmacotherapeutic Group of (API)	Seasonal Influenza Vaccine
Reference to Finished product specifications	As per Innovator.
Proposed Pack size	1's PFS, 10's PFS
Proposed unit price	Rs. 870/PFS
Shelf Life	12 months
Storage Conditions	2°C-8°C
The status in reference regulatory authorities	Agriflu of M/s Seqirus Inc., FDA.
For generic drugs (me-too status)	Agrippal S1 vaccine M/s Novartis Pharma.
Module-II (Quality Overall Summary)	Firm has submitted ICH QOS. Firm has summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product. The firm has also submitted the non-clinical and clinical overviews and summaries.
Name, address of drug substance manufacturer	M/s Seqirus Vaccines Ltd., Gaskill Road, Speke Liverpool, L24 9GR, UK.
Module-III Drug Substance:	Firm has submitted detailed drug substance data related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
Stability Studies of Drug Substance (Conditions & duration of Stability studies)	Firm has submitted stability study data of 9 batches of Drug Substance at accelerated and real time conditions. The real time stability data conducted at 5°C±2°C is for 6 months.
Module-III Drug Product:	Firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.
Analytical method validation/verification of product	Firm has submitted Validation of Analytical Procedures.
Container closure system of the drug product	<ul> <li>Syringe barrel         Neutral clear glass, type I, colorless, single dose with a total volume of 1 ml.         Syringe barrels are ethylene oxide sterilized.</li> <li>Silicone Oil         The Silicone oil covers the inside barrel surface, to provide easy and smooth plunger stopper motion and the needle, to reduce needle penetration drag force.</li> <li>Needle         Metal needle of 25G 5/8".</li> </ul>

	Metal needle is ethylene oxide sterilized.  • Needle shield (component not in contact with the product)  The needle shield is a grey colour silicone-butyl protection which function is to protect the needle tip, to seal the cannula opening and maintain sterility.  • Stopper  The rubber stopper for plunger used with the Nuova Ompi and BD syringes, is made of grey colour butyl. It seals the flange end of the barrel and functions as a piston to deliver the drug and maintain sterility.  • Plunger Rod (component not in contact with the product)  Plunger rod is made of plastic material and its function is to impart the movement to the plunger
Stability study data of drug product, shelf life and storage conditions	Firm has submitted stability study data of 3 batches. The accelerated stability study data is conducted at $25\pm2^{\circ}$ C for 6 months. The real time stability study data is conducted at $5\pm3^{\circ}$ C for 36 months.
Module-IV Non-Clinical	<ul> <li>Primary Pharmacodynamics</li> <li>Immunogenicity testing of influenza antigens in mice (Study No. KOE 050601).</li> <li>Study of antibody response with influenza vaccines in young and old mice (Study No. 94-0184).</li> <li>Study of lymphoproliferative response with influenza vaccines in young and old mice (Study No. 94-0184).</li> <li>Study of the antibody response in young and old seropositive mice (Study No. 93-847).</li> <li>Studies of antibody response to various doses of influenza vaccine in mice (Study Nos. 94-0307, 94-0214, and 94-0215).</li> <li>Dose-response Study of Agrippal in 8-week-old and 18-month-old female BALB/c mice (Study No. MF-1/MF-2 2003/04).</li> <li>Study of the relative post-exposure viral load in the lungs of immunized mice (Study Nos. 94-0307, 94-0214 and 94-0215).</li> <li>Mouse exposure model</li> <li>Immunogenicity in rabbits</li> <li>Intramuscular toxicity study of two doses of influenza vaccine formulation in New Zealand White rabbits (Study No. 191-44).</li> <li>Reproductive and developmental intramuscular toxicity study of Agrippal vaccine in rabbits, including a post-natal evaluation (Study No. UBA00040).</li> <li>Reproductive and developmental intramuscular toxicity study of Agrippal vaccine in rabbits, including a post-natal evaluation (Study No. UBA00043).</li> <li>Immunogenicity and exposure in ferrets</li> <li>Determination of the efficacy of an influenza vaccine in the experimental exposure model in ferrets (Study No. CBI-PCS-007)</li> <li>Repeat Dose Toxicity Studies</li> <li>30-Day subacute toxicity study in rabbits by intramuscular route (Study No. 940292).</li> </ul>
Module-V Clinical	<ul> <li>Safety and immunogenicity study of two influenza vaccines in healthy subjects aged 3 to 64 years</li> <li>Safety and immunogenicity of three commercial lots of influenza vaccines in children aged 6-36 months</li> <li>Safety and immunogenicity of three lots of cell-derived subunit influenza vaccines compared with 1 lot of egg-derived subunit influenza vaccine in healthy adults</li> <li>Safety and immunogenicity of influenza vaccine in healthy adults and &gt; older adults</li> <li>Comparison of the safety, tolerability and immunogenicity of influenza vaccines in adults and the elderly</li> </ul>

• To evaluate the safety and immunogenicity of Agrippal without thimerosal and Agrippal authorized without preservatives, when administered to subjects aged 3-60 years, stratified into four age groups (3-5 years, 6-11 years, 12-17 years, 18-60 years) • To test the non-inferiority of the immune response to Agrippal with traces of thimerosal (no preservatives) compared to the conventional formulation (i.e. formulation with preservatives, or full formulation with thimerosal) • To test the non-inferiority of the immune response after complete removal of residual thimerosal (Agrippal without thimerosal) to Agrippal with traces of thimerosal. The study was conducted in elderly patients. • To evaluate the safety and immunogenicity of Fluad and other vaccine formulations with MF59 adjuvant when administered to adult patients aged 50-64 years • To evaluate the safety and immunogenicity of Fluad and other vaccine formulations with MF59 adjuvant when administered to adult patients aged 18-64 years with renal transplantation • To evaluate the immunogenicity and safety of Agrippal in adults aged 18-60 and elderly > 60 years. • Open-label, uncontrolled, multi-site study to evaluate the safety and immunogenicity of trivalent influenza virus vaccine (surface antigen, inactivated) AGRIPPAL S1®, formulation 2005-2006, when administered to adults and older adults. • A Phase II, open-label, uncontrolled, multi-site study to evaluate the safety and immunogenicity of AGRIPPAL S1® surface antigen, inactivated, influenza vaccine, Formulation 2006-2007, when administered to adults and the elderly. • A Phase II, open-label, uncontrolled, multi-site study to evaluate the safety and immunogenicity of AGRIPPAL S1® surface antigen, inactivated, influenza vaccine, Formulation 2007-2008, administered to adults and the elderly. • A Phase II, open-label, uncontrolled, multi-site study to evaluate the safety and immunogenicity of AGRIPPAL S1, inactivated surface antigen influenza vaccine, 2008-2009 formulation, when administered to adult and elderly adult • A Phase II, open-label, uncontrolled, multi-site study to evaluate the safety and immunogenicity of AGRIPPAL® S1 inactivated surface antigen influenza vaccine, Formulation 2009-2010, when administered to adults and older adults. • Phase II, open-label, uncontrolled, multi-site study to evaluate the safety and immunogenicity of AGRIPPAL S1®, trivalent influenza virus vaccine (surface antigen, inactivated), 2010-2011 formulation, when administered to adults and older adults. Remarks of Evaluator • The firm has not analyzed all the parameters as per monograph of the product in accelerated stability studies for which the firm submitted that accelerated stability data is conducted to test if accidental exposures to conditions other than proposed can affect stability of product, leading to loss of potency, hence, only potency test is performed. • The product gets out of specifications at 1<sup>st</sup> and 2<sup>nd</sup> month of accelerated stability studies for which the firm submitted that accelerated stability studies are conducted only for information purpose, hence, an "out of specification" does not require analysis of it. **Decision:** Registration Board deferred the product for submission of details of WHO recommended strains of seasonal Influenza vaccines for Northern Hemisphere for year 2021-2022. Name, address of Applicant / M/s BF Biosciences Limited, **Importer** 5-KM Sunder Raiwind Road, Raiwind, Lahore. Details of Drug Sale License of License No: 05-352-0066-034461D importer Address:

		5-KM Sunder Raiwind Road, Raiwind, Lahore. Address of go-down: 5-KM Sunder Raiwind Road, Raiwind, Lahore. Validity: 29-06-2022 Status: License to sell drugs as a distributor.
	Name and address of marketing authorization holder (abroad)	M/s Sinergium Biotech S.A., Route 9 Km 38.7, of the City of Garin, Province of Buenos Aires, Argentine Republic
	Name, address of manufacturer(s)	M/s Sinergium Biotech S.A., Route 9 Km 38.7, of the City of Garin, Province of Buenos Aires, Argentine Republic
	Name of exporting country	Argentina
	Detail of certificates attached (CoPP, Freesale certificate, GMP certificate)	• Firm has submitted legalized CoPP (No. CE-2021-13184701-APN-DECBR#ANMAT) dated 15-02-2021 valid for two years issued by Argentina. The CoPP specifies free sale status of the product in country of origin along with its availability. The certificate also specifies the GMP status of the manufacturer.
	Details of letter of authorization / sole agency agreement	Firm has submitted product specific Sole Agent Authorization from Attorney of Sinergium Biotech. According to the letter, the firm M/s Sinergium Biotech authorizes "BF Biosciences Limited" to apply for registration. The letter was issued on 04-03-2021 and valid for one year.
	Status of the applicant	<ul> <li>□ Manufacturer</li> <li>☑ Importer</li> <li>□ Is involved in none of the above (contract giver)</li> </ul>
	Status of application	☐ New Drug Product (NDP)  ☐ Generic Drug Product (GDP)
1	Intended use of pharmaceutical product	<ul><li>☑ Domestic sale</li><li>☐ Export sale</li><li>☐ Domestic and Export sales</li></ul>
	For imported products, specify one the these	<ul> <li>☑ Finished Pharmaceutical product import</li> <li>☐ Buk import and local repackaging</li> <li>☐ Buk import and local repackaging for export purpose only</li> </ul>
	Dy. No. and date of submission	Dy. No. 18229 & 9560 (R&I) Dated 29-06-2021 & 14-04-2022
	Details of fee submitted	Rs. 75,000/- dated 09-06-2021
	The proposed proprietary name / brand name	Pediatric Viraflu
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each dose (0.25ml) contains:  A/Victoria/2570/2019 (H1N1)-(like strain: A/Victoria/2570/2019, IVR-215)7.5 micrograms HA*  A/Hong Kong/2671/2019 (H3N2) - (like strain: A/Hong Kong/2671/2019, IVR-208)7.5 micrograms HA*  B/Washington/02/2019 - (B/ Victoria lineage) (like strain: B/Victoria/705/2018, BVR-11)7.5 micrograms HA*  *viral haemagglutinin
	Dosage form of applied drug	Suspension for Injection

Pharmacotherapeutic Group of (API)	Seasonal Influenza Vaccine
Reference to Finished product specifications	As per Innovator.
Proposed Pack size	1's PFS, 10's PFS
Proposed unit price	Rs. 870/PFS
Shelf Life	12 months
Storage Conditions	2°C-8°C
The status in reference regulatory authorities	Agriflu of M/s Seqirus Inc., FDA.
For generic drugs (me-too status)	Agrippal S1 vaccine M/s Novartis Pharma.
Module-II (Quality Overall Summary)	Firm has submitted ICH QOS. Firm has summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product. The firm has also submitted the non-clinical and clinical overviews and summaries.
Name, address of drug substance manufacturer	M/s Seqirus Vaccines Ltd., Gaskill Road, Speke Liverpool, L24 9GR, UK.
Module-III Drug Substance:	Firm has submitted detailed drug substance data related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
Stability Studies of Drug Substance (Conditions & duration of Stability studies)	Firm has submitted stability study data of 9 batches of Drug Substance at accelerated and real time conditions. The real time stability data conducted at 50C±20C is for 6 months.
Module-III Drug Product:	Firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.
Analytical method validation/verification of product	Firm has submitted Validation of Analytical Procedures.
Container closure system of the drug product	<ul> <li>Syringe barrel Neutral clear glass, type I, colorless, single dose with a total volume of 1 ml. Syringe barrels are ethylene oxide sterilized.</li> <li>Silicone Oil The Silicone oil covers the inside barrel surface, to provide easy and smooth plunger stopper motion and the needle, to reduce needle penetration drag force.</li> <li>Needle Metal needle of 25G 5/8". Metal needle is ethylene oxide sterilized.</li> <li>Needle shield (component not in contact with the product)</li> </ul>

	<ul> <li>The needle shield is a grey colour silicone-butyl protection which function is to protect the needle tip, to seal the cannula opening and maintain sterility.</li> <li>Stopper The rubber stopper for plunger used with the Nuova Ompi and BD syringes, is made of grey colour butyl. It seals the flange end of the barrel and functions as a piston to deliver the drug and maintain sterility. </li> <li>Plunger Rod (component not in contact with the product) Plunger rod is made of plastic material and its function is to impart the movement to the plunger.</li> </ul>
Stability study data of drug product, shelf life and storage conditions	Firm has submitted stability study data of 3 batches. The accelerated stability study data is conducted at 25±2oC for 6 months. The real time stability study data is conducted at 5±3oC for 36 months.
Module-IV Non-Clinical	<ul> <li>Primary Pharmacodynamics</li> <li>Immunogenicity testing of influenza antigens in mice (Study No. KOE 050601).</li> <li>Study of antibody response with influenza vaccines in young and old mice (Study No. 94-0184).</li> <li>Study of lymphoproliferative response with influenza vaccines in young and old mice (Study No. 94-0184).</li> <li>Study of the antibody response in young and old seropositive mice (Study No. 93-847).</li> <li>Studies of antibody response to various doses of influenza vaccine in mice (Study Nos. 94-0307, 94-0214, and 94-0215).</li> <li>Dose-response Study of Agrippal in 8-week-old and 18-month-old female BALB/c mice (Study No. MF-1/MF-2 2003/04).</li> <li>Study of the relative post-exposure viral load in the lungs of immunized mice (Study Nos. 94-0307, 94-0214 and 94-0215).</li> <li>Mouse exposure model</li> <li>Immunogenicity in rabbits</li> <li>Intramuscular toxicity study of two doses of influenza vaccine formulation in New Zealand White rabbits (Study No. 191-44).</li> <li>Reproductive and developmental intramuscular toxicity study of Agrippal vaccine in rabbits, including a post-natal evaluation (Study No. UBA00040).</li> <li>Reproductive and developmental intramuscular toxicity study of Agrippal vaccine in rabbits, including a post-natal evaluation (Study No. UBA00043).</li> <li>Immunogenicity and exposure in ferrets</li> <li>Determination of the efficacy of an influenza vaccine in the experimental exposure model in ferrets (Study No. CBI-PCS-007)</li> <li>Repeat Dose Toxicity Studies</li> <li>30-Day subacute toxicity study in rabbits by intramuscular route (Study No. 940292).</li> </ul>
Module-V Clinical	<ul> <li>Safety and immunogenicity study of two influenza vaccines in healthy subjects aged 3 to 64 years</li> <li>Safety and immunogenicity of three commercial lots of influenza vaccines in children aged 6-36 months</li> <li>Safety and immunogenicity of three lots of cell-derived subunit influenza vaccines compared with 1 lot of egg-derived subunit influenza vaccine in healthy adults</li> <li>Safety and immunogenicity of influenza vaccine in healthy adults and &gt; older adults</li> <li>Comparison of the safety, tolerability and immunogenicity of influenza vaccines in adults and the elderly</li> </ul>

• To evaluate the safety and immunogenicity of Agrippal without thimerosal and Agrippal authorized without preservatives, when administered to subjects aged 3-60 years, stratified into four age groups (3-5 years, 6-11 years, 12-17 years, 18-60 years) • To test the non-inferiority of the immune response to Agrippal with traces of thimerosal (no preservatives) compared to the conventional formulation (i.e. formulation with preservatives, or full formulation with thimerosal) • To test the non-inferiority of the immune response after complete removal of residual thimerosal (Agrippal without thimerosal) to Agrippal with traces of thimerosal. The study was conducted in elderly patients. • To evaluate the safety and immunogenicity of Fluad and other vaccine formulations with MF59 adjuvant when administered to adult patients aged 50-64 years • To evaluate the safety and immunogenicity of Fluad and other vaccine formulations with MF59 adjuvant when administered to adult patients aged 18-64 years with renal transplantation • To evaluate the immunogenicity and safety of Agrippal in adults aged 18-60 and elderly > 60 years. • Open-label, uncontrolled, multi-site study to evaluate the safety and immunogenicity of trivalent influenza virus vaccine (surface antigen, inactivated) AGRIPPAL S1®, formulation 2005-2006, when administered to adults and older adults. • A Phase II, open-label, uncontrolled, multi-site study to evaluate the safety and immunogenicity of AGRIPPAL S1® surface antigen, inactivated, influenza vaccine, Formulation 2006-2007, when administered to adults and the elderly. • A Phase II, open-label, uncontrolled, multi-site study to evaluate the safety and immunogenicity of AGRIPPAL S1® surface antigen, inactivated, influenza vaccine, Formulation 2007-2008, administered to adults and the elderly. • A Phase II, open-label, uncontrolled, multi-site study to evaluate the safety and immunogenicity of AGRIPPAL S1, inactivated surface antigen influenza vaccine, 2008-2009 formulation, when administered to adult and elderly adult • A Phase II, open-label, uncontrolled, multi-site study to evaluate the safety and immunogenicity of AGRIPPAL® S1 inactivated surface antigen influenza vaccine, Formulation 2009-2010, when administered to adults and older adults. • Phase II, open-label, uncontrolled, multi-site study to evaluate the safety and immunogenicity of AGRIPPAL S1®, trivalent influenza virus vaccine (surface antigen, inactivated), 2010-2011 formulation, when administered to adults and older adults. Remarks of Evaluator • The firm has not analyzed all the parameters as per monograph of the product in accelerated stability studies for which the firm submitted that accelerated stability data is conducted to test if accidental exposures to conditions other than proposed can affect stability of product, leading to loss of potency, hence, only potency test is performed. • The product gets out of specifications at 1st and 2nd month of accelerated stability studies for which the firm submitted that accelerated stability studies are conducted only for information purpose, hence, an "out of specification" does not require analysis of it. **Decision:** Registration Board deferred the product for submission of details of WHO recommended strains of seasonal Influenza vaccines for Northern Hemisphere for year 2021-2022. Name, address of M/s Amson Vaccines & Pharma (Pvt.) Ltd., **Applicant / Importer** Plot No. 115, Industrial Triangle, Kahuta Road, Islamabad. **Details of Drug Sale** License No: 920-ICT/2013 License of importer Address Plot No. 115, Industrial Triangle, Kahuta Road, Islamabad.

	Validity: 01-08-2022
Name and address of marketing authorization holder (abroad)	M/s Green Cross Corporation, 40 Sandan-gil, Hwasun-eup, Hwasun-gun, Jeollanam-do, Republic of Korea
Name, address of manufacturer(s)	M/s Green Cross Corporation, 40 Sandan-gil, Hwasun-eup, Hwasun-gun, Jeollanam-do, Republic of Korea
Name of exporting country	Republic of Korea
Detail of certificates attached (CoPP, Free Sale certificate, GMP certificate)	<ul> <li>Firm has submitted Legalized CoPP (No. 2021-A1-0638) dated 12-04-2022 issued by Ministry of Food and Drug Safety, Korea. The COPP specifies that the product is licensed for sale but not available in country of origin. The COPP also specifies the GMP ststua of manufacturer.</li> <li>Firm has submitted Legalized FSC (No. 2020-A1-0504) dated 24-03-2022 issued by Ministry of Food and Drug Safety, Korea. The FSC specifies that the product is permitted to be freely sold in country of origin.</li> <li>Firm has submitted legalized GMP certificate (No. 2021-F1-0184) dated 18-05-2021 valid till 25-02-2024 issued by Ministry of Food and Drug Safety, Korea.</li> </ul>
Details of letter of authorization / sole agency agreement	Firm has submitted legalized Sole Agency Certificate from General Manager of M/s Green Cross Corporation. According to the letter, the firm M/s Green Cross Corporation exclusively authorizes "M/s Amson Vaccines & Pharma (Pvt.) Ltd. for the purpose of registration, import, promotion and marketing of the product.
Status of the applicant	☐Manufacturer  ☑Importer  ☐Is involved in none of the above (contract giver)
Status of application	□New Drug Product (NDP)  □Generic Drug Product (GDP)
Intended use of pharmaceutical product	<ul><li>☑Domestic sale</li><li>☐Export sale</li><li>☐Domestic and Export sales</li></ul>
For imported products, specify one the these	<ul> <li>☑Finished Pharmaceutical product import</li> <li>☐Buk import and local repackaging</li> <li>☐Buk import and local repackaging for export purpose only</li> </ul>
Dy. No. and date of submission	32870 & 11223 Dated: 15-12-2021 & 10-05-2022
Details of fee submitted	Rs: 150,000/- Dated: 11-11-2021 Deposit Slip No. 1882973539
The proposed proprietary name / brand name	BARYCELA Inj.
Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Powder Vial: Each vial contains: Live attenuated varicella virus (strain: MAV/06, cell line: MRC-5)≥3800PFU Solvent Vial: Each vial contains: Sterile Water for Injection0.7ml
Dosage form of applied drug	Powder & Solvent for Intramuscular Injection

Pharmacotherapeutic Group of (API)	Human Vaccine
Reference to Finished product specifications	Not Provided
Proposed Pack size	1's Vial (Powder) + 1's Vial (Solvent) 10's Vials (Powder) + 10's Vials (Solvent)
Proposed unit price	As per SRO
Shelf Life	24 months
Storage Conditions	2 °C -8°C
The status in reference regulatory authorities	The firm has submitted Varivax as RRA status
For generic drugs (me-too status)	Varicella vaccine with this strain is not registered.
Module-II (Quality Overall Summary)	Firm has submitted QOS as per ICH guidelines. Firm has summarized information related to general properties, manufacturers, description of manufacturing process and controls, characterization, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product. The firm has also submitted the non-clinical and clinical overviews and summaries.
Name, address of drug substance manufacturer	M/s Green Cross Corp., 586, Gwahaksaneop 2-ro, Ochang-eup, Cheongwon-gu, Cheongju-si, Chungcheongbuk-do, South Korea
Module-III Drug Substance:	Firm has submitted detailed drug substance data related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance
Stability Studies of Drug Substance (Conditions & duration of Stability studies)	Firm has submitted stability study data of 3 batches of Varicella vaccine bulk at real time conditions. The real time stability data is conducted at -80 $\pm$ 10°C for 18 months.
Module-III Drug Product:	Firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.
Analytical method validation/verification of product	Firm has submitted the details of analytical method validation.
Container closure system of the drug product	Powder Vial:  Borosilicate (Type I) Glass Vial  Butyl Rubber Stopper  Aluminum cap Solvent Vial:  Borosilicate (EP Type I) Glass Vial  Chlorobutyl Rubber Stopper  Aluminum cap
Stability study data of drug product, shelf life	Firm has submitted stability study data of 3 batches of Barycela Inj. at accelerated and real time conditions. The real time stability data is conducted at 5

and storage conditions	± 3°C for 24 months and accelerated stability is conducted at 25±2°C for 06
	months.  Firm has submitted stability study data of 3 batches of Diluent at real time
	conditions. The real time stability data is conducted at $5 \pm 3$ °C for 36 months.
Module-IV Non-Clinical	Primary Pharmacodynamics
	<ul> <li>Immune response comparison study by animal species (rabbit, rat, and guinea pig)</li> <li>Efficacy comparison study in rabbits and guinea pigs</li> <li>Efficacy comparison study with commercial vaccines in rabbits and guinea pigs</li> <li>Preliminary local tolerance and efficacy study in rabbits</li> <li>Repeat-dose Toxicity</li> <li>Repeated Subcutaneous Dose Toxicity Study of VZV Vaccine (MG1111) with a Recovery Period in Rabbits.</li> <li>Other Toxicity Study</li> <li>A Neurovirulence Test of Attenuated Varicella-Zoster Virus (VZV) in Male</li> </ul>
Module-V Clinical	<ul> <li>Cynomolgus Monkeys</li> <li>A Single-center, Dose Block-randomized, Single-blind, Active-controlled, Dose Escalation Phase 1 Clinical Trial to Evaluate the Safety and Efficacy (Immunogenicity) of MG1111 in Healthy Adults</li> </ul>
	<ul> <li>A Phase II/III, Single-blind (Stage 1), Double-blinded (Stage 2), Randomized, Active-controlled, Dose-escalation (Stage 1), Non-inferiority (Stage 2) Study to Evaluate Immunogenicity and Safety of MG1111 in Healthy Children</li> </ul>
Remarks of Evaluator	<ul> <li>i. The submitted legalized FSC issued on 24-03-2022 specifies that the product is permitted to be freely sold in country of origin, however, legalized CoPP issued on 12-04-2022 indicates that the product is not actually available in the market in country of origin.</li> <li>ii. RRA status submitted by the firm is of OKA strain while the instant product has a different strain.</li> </ul>
	<ul> <li>iii. The instant strain is not registered in Pakistan.</li> <li>iv. pH is not tested in real time stability studies for which the firm has submitted that initially pH was not included in the studies and later Ministry of Food and Drug Safety, Korea (MFDS) advised them to include. The revised stability studies are not yet complete.</li> </ul>
	v. Limits of virus concentration is different in Specifications (3800-38000PFU) and stability data (2530-25298PFU) for which the firm submitted that clinical trial was conducted with target virus concentration of 8000PFU but at the time of review by MFDS, the target virus concentration was 12000PFU, therefore, the final virus concentration limit is also changed from 2530-25298 PFU to 3800-38000PFU.

#### **Decision:**

Registration Board deferred the product for submission of following by the firm:

- i. Clarification regarding non-availability of product in country of origin as per submitted CoPP.
- ii. Evidence of availability of Varicella vaccine with MAV/06 strain in Reference Regulatory Authorities.
- iii. Immunological relevance of MAV/06 strain with circulating strains of Pakistan.
- iv. Real time stability data including all parameters as per finished product specifications.

#### D: Imported Veterinary Biologicals from Reference countries

1.	Name of Importer	M/s Hipra Pakistan (Private) Limited, 3rd floor, plot no 8, block CCA, Phase 6-C, DHA,
		Lahore
		Go-down:
		2nd Warehouse on Left side, Street No.5, Gajjumata Nadir Chowk
	DSL details	License to sell drug as distributor No. 0011000 0004579 valid till 19-Feb-2022 Renewal
		submitted.

	Name of Manufacturer	Product License Holder & Manufacturer: M/S Laboratorios Hipra, S.A.de La Selva, 135, 17170 Amer (Girona) Spain.			
	Brand Name +Dosage Form +	Hipraviar B1/ H120			
	Strength	Freeze-dried tablet and solvent for suspension 2500 doses *10			
	Composition	Each dose of 0.03ml contains: Live Newcastle disease virus attenuated B1 strain 10 <sup>6.5</sup> – 10 <sup>7.8 EID</sup> 50			
		Live Infectious Bronhitis virus, attenuated H120 strain10 <sup>3</sup> – 10 <sup>5</sup> DIE <sub>50</sub> *50% infectious dose in chicken embryo			
		Solvent for suspension			
		Disodium phosphate dodecahydrate0.087mg			
		Potassium dihydrogen phosphate00006mg Sodium chloride0.24mg			
		Potassium chloride0.006mg			
		Patent blue (E-131)0.003mg			
		Water for injection0.03ml qsd			
	Finished product specifications	European Pharmacopeia			
	Pharmacological Group	Live Veterinary vaccine			
	Shelf life	24 Months (Store at 2 °C – 8°C.)			
	Products already registered in Pakistan	The product is already registered in 1000 dose. This is the additional dose of the same.			
	Type of Form Dy. No & Date of application, Fee submitted	Form 5-A, Dy No. 20696 Dated 20-08-2020 Dy No. 20516, Dated 28-07-2021, Dy No. 13AD(BD), Dated 11-02-2022			
	D 11D: /D 1:	Fee 100,000/- dated 18-08-2020			
	Demanded Price / Pack size	2500 doses vial Decontrolled for Veterinary products			
	General documentation	Legalized Free Sale Certificate issued by Agencia Espanola de Medicamentos y productos sanitarios dated: 16-06-2021.  Legalized GMP certificate No.ES/053HVI/19 dated 16-09-2021			
	Remarks of Evaluator	Deganibus Civil Control (Control		ority); Registration Board app	legalized GMP, Free Sale Certificate & approval of Spain (Reference Regulatory roved the product subject to compliance of current Import Policy for finished drugs.
2.	Name of Importer	M/s Hipra Pakistan (Private) Limited, 3rd floor, plot no 8, block CCA, Phase 6-C, DHA, Lahore Go-down:			
		2nd Warehouse on Left side, Street No.5, Gajjumata Nadir Chowk			
	DSL details	License to sell drug as distributor No. 0011000 0004579 valid till 19-Feb-2022 Renewal submitted.			
	Name of Manufacturer	Product License Holder & Manufacturer: M/S Laboratorios Hipra, S.A.de La Selva, 135, 17170 Amer (Girona) Spain.			
	Brand Name +Dosage Form + Strength	Inmeva,125 dose Suspension injectable			
	Composition	Each dose of 2ml contains:			
		Inactivated Chlamydia abortus strain A22,RP*≥ 1			
		Inactivated Salmonella enterica subsp. Enterica serovar Abortusovis strains Sao,RP*≥ 1 *Relative Potency determined by ELISA, using a reference vaccine demonstrated to be efficacious			
	Finished product specifications	European Pharmacopeia			
	Pharmacological Group	Inactivated veterinary vaccine			

	Shelf life	24 Months (Store at 2 – 8°C.)
	Due du eta alessa di escrito di e	
	Products already registered in Pakistan	Not available as per our record
	Type of Form	Form 5-A, Dy No. 20694 Dated 20-08-2020 Dy No. 17-AD(BD), Dated 11-02-2022
	Dy. No & Date of application, Fee submitted	Fee 100,000/- dated 18-08-2020
		Tee 100,000/ dated 10 00 2020
	Demanded Price / Pack size	125 dose vial
-	General documentation	Decontrolled for Veterinary products  Legalized Free Sale Certificate issued by Agencia Espanola de Medicamentos y productos
		sanitarios dated: 27-03-2020
	Remarks of Evaluator	Legalized GMP certificate No.ES/053HVI/19 dated 16-09-2021
Decis		I referred the product to Ministry of National Food Security & Research, Islamabad for
		ecine, prevalence of disease and immunological relevance of the strains in Pakistan.
3.	Name of Importer	M/s Hipra Pakistan (Private) Limited, 3rd floor, plot no 8, block CCA, Phase 6-C, DHA,
		Lahore Go-down:
		2nd Warehouse on Left side, Street No.5, Gajjumata Nadir Chowk
	DSL details	License to sell drug as distributor No. 0011000 0004579 valid till 19-Feb-2022 Renewal submitted.
	Name of Manufacturer	Product License Holder & Manufacturer:
		M/S Laboratorios Hipra, S.A.de La Selva, 135, 17170 Amer (Girona) Spain
	Brand Name +Dosage Form	Inmeva,125 dose Suspension injectable
	+ Strength	
	Composition	Each dose of 2ml contains:
		Inactivated Chlamydia abortus strain A22,RP*≥ 1
		Inactivated Salmonella enterica subsp. Enterica serovar Abortusovis strains Sao,RP*≥ 1 *Relative Potency determined by ELISA, using a reference vaccine demonstrated to be
		efficacious
	Finished product	European Pharmacopeia
	specifications Pharmacological Group	Inactivated veterinary vaccine
	Shelf life	24 Months (Store at 2 – 8°C.)
	Products already registered in	Not available as per our record
	Pakistan	-
	Type of Form Dy. No & Date of application,	Form 5-A Dated:20-08-2020
	Fee submitted	Fee Submitted: Rs. 100,000 /- dated 20-08-2020
	Demanded Price / Pack size	
	Demanded Price / Pack size	5 dose vial Decontrolled for Veterinary products
	General documentation	Legalized Free Sale Certificate issued by Agencia Espanola de Medicamentos y productos
		sanitarios dated: 27-03-2020
	Remarks of Evaluator	Legalized GMP certificate No.ES/053HVI/19 dated 16-09-2021  The firm has submitted stability study data only for 125 doses vial while they have applied
		for two different doses 125 dose & 25 dose vial with separate fee & application. For stability
		study data the firm has submitted European guidelines "Guideline on data requirements for immunological veterinary medicinal products intended for minor use or minor species
		(MUMS)/limited market." Wherein it has been mentioned that "This guideline is intended
		to reduce data requirements where possible for products classified as MUMS/limited market while still providing assurance of appropriate quality, safety and efficacy and complying with
		the legislation in place and leading to an overall positive benefit-risk balance for such

products, and ultimately leading to an increased availability of IVMPs." The guideline is verified vide below link on 14-04-2022.

 $\frac{https://www.ema.europa.eu/en/data-requirements-immunological-veterinary-medicinal-products-intended-minor-use-minor-species$ 

For stability study the following point is given on Table 1, section 2.G:

"In order to stimulate the development of new veterinary medicines intended for minor uses or minor species (MUMS)/limited market the CVMP developed a guideline on data requirements for MUMS/limited market for immunological veterinary medicinal products (IVMPs)."

Stability data for each final container type should be provided but stability data on one final container size is acceptable provided the selected presentation is justified by the applicant.

Decision: Registration Board referred the product to Ministry of National Food Security & Research, Islamabad for comments regarding the need of vaccine, prevalence of disease and immunological relevance of the strains in Pakistan.

#### E: Imported Veterinary Biologicals from Non-Reference countries

1.	Name of Importer	M/s Hivet Animal Health Business, Lahore
		1 <sup>st</sup> Floor,667-P.M.A, Johar Town, Lahore, Pakistan
	DSL details	License to sell drug as distributor No. 05-352-0066-040985D valid till 23-Feb-2023
	Manufacturer Name	M/s Beijing Sinder-Vet Technology Co., Ltd.
		Address: No.118, Shunyu Road, Beijing Tianzhu Airport Economic Development Zone, Shunyi
		District, Beijing, China.
	Brand Name + Dosage Form + Strength	SINVAC ND + IB + EDS + H9
	Composition	Each dose of 0.5ml contains:
	•	Newcastle disease antigen inactivated (La Sota strain) $\geq 10^{8.5} \text{EID}_{50}$
		Infectious Bronchitis antigen inactivated (M41 strain)≥ 10 <sup>6.5</sup> EID <sub>50</sub>
		Avian influenza antigen inactivated (H9 subtype, WD strain) ≥ 10 <sup>7.5</sup> EID <sub>50</sub>
		Egg Drop Syndrome antigen inactivated (HSH23 strains) ≥1000HA Unit
	Finished product specifications	Veterinary Vaccine
	Pharmacological Group	Inactivated veterinary vaccine
	Shelf life	18 months (2 <sup>o</sup> C -8 <sup>o</sup> C)
	Products already registered in Pakistan	Separately available but the combination of the four (as the applied product) is not available.
	Type of Form	Form-5A
	Dy No & Date:	Dy. No.11187(R&I) Dated 12-Apr-2021, Dy. No.9411(R&I) Dated 13-04-2022
	Fee submitted	Rs.100,000/- dated 12-Apr-2021
	Demanded Price / Pack	Decontrolled for Veterinary products
	size	20x 500 ml/ bottle
	General documentation	i. Legalized Certificate of Free Sale issued by Animl Husbandry and Veterinary Bureau of Zhucheng City, China dated 12 <sup>th</sup> Jan, 2022.
		ii. Legalized Certificate of Good Manufacturing Practices (GMP) having Certificate No.
		(2021)S.Y.GMP Z.Zi, No.01010 valid upto 28 <sup>th</sup> Nov, 2026.
	Remarks of Evaluator	
Ļ		
	9	I deferred the case for confirmation of N subtype of Avian Influenza virus along with valid e indicating said N subtype.
2.	Name of Importer	M/s Hivet Animal Health Business, Lahore
	<b>r</b>	1st Floor,667-P.M.A, Johar Town, Lahore, Pakistan
	DSL details	License to sell drug as distributor No. 05-352-0066-040985D valid till 23-Feb-2023

Manufacturer Name	M/s Beijing Sinder-Vet Technology Co., Ltd.
	Address: No.118, Shunyu Road, Beijing Tianzhu Airport Economic Development Zone, Shunyi
	District, Beijing, China.
Brand Name + Dosage	SINVAC H9
Form + Strength	
Composition	Each dose of 0.5ml contains:
	Avian influenza antigen inactivated (H9 subtype, WD strain) $\geq 5 \times 10^7 \text{EID}$
Finished product	Veterinary Vaccine
specifications	
Pharmacological Group	Veterinary vaccine
Shelf life	24 months (2 <sup>o</sup> C -8 <sup>o</sup> C)
Products already	
registered in Pakistan	
Type of Form	Form-5A
Dy No & Date:	Dy. No.11186(R&I) Dated 12-Apr-2021, Dy. No.9411(R&I) Dated 13-04-2022
Fee submitted	Rs.100,000/- dated 12-Apr-2021
Demanded Price / Pack	Decontrolled for Veterinary products
size	500ml/ vial
General documentation	i. Legalized Certificate of Free Sale issued by Animl Husbandry and Veterinary Bureau of
	Zhucheng City, China dated 12 <sup>th</sup> Jan, 2022.
	ii. Legalized Certificate of Good Manufacturing Practices (GMP) having Certificate
	No.(2021)S.Y.GMP Z.Zi, No.01010 valid upto 28 <sup>th</sup> Nov, 2026.
Remarks of Evaluator	
1	

Decision: Registration Board deferred the case for confirmation of N subtype of Avian Influenza virus along with valid legalized Free Sale Certificate indicating said N subtype.

	N. 1 11	MUZGDIA LA LITTUIG TI
3.	Name and address	M/s ZS Biotech Animal Health Company, Lahore
	of Importer	
	Detail of DSL	M/s ZS Biotech Animal Health Company,
		Address: House No. 22-A, Hidayat Ullah Block, Mustafa Town, Wahdat Road, District
		Lahore.
		Valid till: 20-Jan-2022.
	Name and address of	Product License Holder:
	Manufacturer	M/s Guangdong Wens Dahuanong Biotechnology Co., Ltd.
		Address:
		No. 6, Dongdi North Road, Xincheng Town, Xinxing County, Guangdong Province, China.
	Name of exporting	China
	country	
	Brand Name	Sinovac ND LIVE
	+Dosage Form +	
	Strength	
	Diary No. Date of R&	Dy. No. 15308 R&I Dated 02-06-2021
	I & fee	Rs. 150,000/- Dated 28-05-2021 (Slip No. 115815731046)
	Composition	Each dose freeze- drying vaccine contains:
		Activated antigen, Newcastle Disease virus Lasota strain ≥ 10 <sup>6.0</sup> EID <sub>50</sub> per dose
	Pharmacological	Vaccine
	Group	
	Type of Form	Form-5A
	Finished Product	Eur. Phar Specifications
	Specification	
	Shelf Life	24months(2-8°C)
	Document Details	Following is submitted by the firm:
		Original legalized GMP certificate No. 2020(19020) with its translated copy.
		Original legalized Free Sale Certificate.
		· · · · · · · · · · · · · · · · · · ·

	Original lagalized Cala Agency Agreement	
Original legalized Sole Agency Agreement.		
	Pack size	1ml: Decontrolled
	Products already registered in Pakistan	Live Lentogenic Newcastle Disease Virus, Strain LaSota: ≥10^6 EID50
Dee	Remarks of Evaluator	In response to this division's letter dated 15 <sup>th</sup> December 2021 firm has submitted following:  i. Original copy of sole agency agreement.  ii. Original legalized copy of free sale certificate.  iii. Original legalized GMP certificate with translated copy.  iv. Quantity of virus in applied formulation is in Virus/dose rather than Virus/ml and submitted revised Form 5A.  v. Efficacy studies for eye drop route are also submitted.  vi. Clarification regarding difference in address: In China, province is the largest, followed by the city, and the county is the third. Yunfu City belongs to Guangdong Province and the Xingxing county belongs to Yunfu city, By comparison, you can see that the address of the Free sales Certificate is missing Yunfu City, but the two addresses are indeed the same.  in view legalized GMP & Free Sale Certificate; Registration Board approved the
pre	oduct subject to compli	iance of current Import Policy for finished drugs.
4.	Name and address of Importer	M/s Niraav Pharma (Pvt). Ltd Horizon Tower, Office 204, Block 3 Clifton, karachi.
	Detail of DSL	M/s Niraav Pharma (Pvt). Ltd authorized agent of M/s. Vet Pharma Trading Company. Address: Plot No. A-81, Eastern Industrial Zone, Port Qasim Authority, Karachi. Validity: 23-09-2020, 22-09-2022.
	Name and address of Manufacturer	M/s. Shangqiu Meilan Biological Engineering Co., Ltd. Address: No.9 Zhuzhou Road, High Tech Development Zone, Zhecheng Shangqiu, Henan, China.
	Name of exporting country	China
	Brand Name +Dosage Form + Strength	Meilan L.V ND Clone 30 Live
	Diary No. Date of R& I & fee	Dy. No. 2778 Dated 25-01-2021 Rs. 100,000/- Dated 18-01-2021
	Composition	Each dose contains: New castle disease live virus strain clone $30 \ge 10^6 \text{EID}_{50}$
	Pharmacological Group	Vaccine
	Type of Form	Form-5A
	Finished Product Specification	As per innovator's specifications
	Shelf Life	24months (2 <sup>o</sup> C-8 <sup>o</sup> C) Stability studies of three batches at (2 <sup>o</sup> C-8 <sup>o</sup> C) for months.
	Document Details	Following documents are submitted:  a. Original legalized CoPP dated 12-01-2022.  b. Original legalized Sole agency agreement (validity was five years it is not valid now).
	Pack size	1000 doses vial
	Reference Regulatory Authority Availability	N/A
	Products already registered in Pakistan	Not verifiable.
	Remarks of Evaluator	In response to this division's letter dated 2 <sup>nd</sup> November 2021 firm has submitted following:

sole agency agreement address of head office is mentioned.

i.

Clarification regarding difference in address on sole agency agreement DSL that

		ii. Finished product Specifications; As per Innovator's.
		iii. Safety and efficacy data.
		iv. COPP with composition.
		Following documents are still required:
		i. Evidence of locally registered product for applied product is required.
		ii. Sole agency agreement is not valid now.
De		on Board deferred the product for submission of following by the firm:
		of availability of formulation in Pakistan.
_		e Agency Agreement.
5.	Name and address of Importer	M/s Niraav Pharma (Pvt). Ltd Horizon Tower, Office 204, Block 3 Clifton, karachi.
	Detail of DSL	M/s Niraav Pharma (Pvt). Ltd authorized agent of M/s. Vet Pharma Trading Company. Address: Plot No. A-81, Eastern Industrial Zone, Port Qasim Authority, Karachi.
	None and address of	Validity: 23-09-2020, 22-09-2022.
	Name and address of Manufacturer	M/s. Shangqiu Meilan Biological Engineering Co., Ltd. Address: No.9 Zhuzhou Road, High Tech Development Zone, Zhecheng Shangqiu, Henan, China.
	Name of exporting country	China
	Brand Name	Meilan L.V IB H120 Live
	+Dosage Form + Strength	
	Diary No. Date of R& I & fee	Dy. No. 2778 Dated 25-01-2021 Rs. 100,000/- Dated 18-01-2021
	Composition	Each dose contains: Infectious Bronchitis live virus strain H120 (CVCC AV 1514)≥ 10 <sup>3.5</sup> EID <sub>50</sub>
	Pharmacological Group	Vaccine
	Type of Form	Form-5A
	Finished Product Specification	Manufacturer's specifications
	Shelf Life	12months (2 <sup>o</sup> C-8 <sup>o</sup> C)
	Document Details	Following documents are submitted:
		a. Original legalized CoPP dated 12-01-2022.
		b. Original legalized Sole agency agreement (validity was five years it is not valid now).
	Pack size	1000 doses vial
	Reference Regulatory Authority Availability	N/A
	Products already	(Reg No. 91374) JOVAC IB H120 Vaccine
	registered in Pakistan	Each dose of vaccine contains:
		Infectious Bronchitis Disease Virus strain (Live attenuated) H120at least 10 <sup>3.0</sup> EID <sub>50</sub>
	Remarks of Evaluator	In response to this division's letter dated 2 <sup>nd</sup> November 2021 firm has submitted following:
		i. Clarification regarding difference in address on sole agency agreement DSL that sole agency agreement address of head office is mentioned.
		ii. Finished product Specifications; As per Innovator's.
		iii. Safety and efficacy data.
		Following documents are still required:
		i. Sole agency agreement is not valid now.
		1. Sole agency agreement is not valid now.

		ii. Clarification regarding this number with the strain name "CVCC AV 1514" is required.
De	i. Immunolo	on Board deferred the product for submission of following by the firm: ogical relevance of CVCC AV 1514 strain with circulating strains of Pakistan. e Agency Agreement.
6.	Name and address	M/s Niraav Pharma (Pvt). Ltd Horizon Tower, Office 204, Block 3 Clifton,
	of Importer	karachi.
	Detail of DSL	M/s Niraav Pharma (Pvt). Ltd authorized agent of M/s. Vet Pharma Trading Company. Address: Plot No. A-81, Eastern Industrial Zone, Port Qasim Authority, Karachi. Validity: 23-09-2020, 22-09-2022.
	Name and address of Manufacturer	M/s. Shangqiu Meilan Biological Engineering Co., Ltd. Address: No.9 Zhuzhou Road, High Tech Development Zone, Zhecheng Shangqiu, Henar China.
	Name of exporting country	China
	Brand Name +Dosage Form + Strength	Meilan L.V ND+IB Live
	Diary No. Date of R& I & fee	Dy. No. 2778 Dated 25-01-2021 Rs. 100,000/- Dated 18-01-2021
	Composition	Each dose contains:  New castle disease live virus strain Lasota (CVCC AV1615)≥10 <sup>6</sup> EID <sub>50</sub> Infectious Bronchitis live virus strain H120 (CVCC AV1514)≥10 <sup>3.5</sup> EID <sub>50</sub>
	Pharmacological Group	Vaccine
	Type of Form	Form-5A
	Finished Product Specification	As per innovator's specifications
	Shelf Life	18months (2°C-8°C)
	Document Details	<ul> <li>Following documents are submitted:</li> <li>a. Original legalized CoPP dated 12-01-2022.</li> <li>b. Original legalized Sole agency agreement (validity was five years it is not valinow).</li> </ul>
Ì	Pack size	1000 doses vial
	Reference Regulatory Authority Availability	N/A
	Products already registered in Pakistan	(Reg No. 077560) BIO-VAC LS-H120 Live attenuated virus of New Castle Disease, LaSota strain Titer: Not less than 10 <sup>6.5</sup> EID: Live avian infectious brochitis virus, strain Massachusetts H120: Not less than 10 <sub>3.5</sub> EID <sub>5</sub>
	Remarks of Evaluator	In response to this division's letter dated 2 <sup>nd</sup> November 2021 firm has submitted following
		<ul> <li>i. Clarification regarding difference in address on sole agency agreement DSL that sole agency agreement address of head office is mentioned.</li> <li>ii. Finished product Specifications; As per Innovator's.</li> <li>iii. Safety and efficacy data.</li> </ul>
		Following documents are still required:
		i. Sole agency agreement is not valid now.
De firi		on Board deferred the product for submission of valid Sole Agency Agreement, by th
7.	Name and address of Importer	M/s Niraav Pharma (Pvt). Ltd Horizon Tower, Office 204, Block 3 Clifton, karachi.

	Detail of DSL	M/s Niraav Pharma (Pvt). Ltd authorized agent of M/s. Vet Pharma Trading Company.
		Address: Plot No. A-81, Eastern Industrial Zone, Port Qasim Authority, Karachi.
		Validity: 23-09-2020, 22-09-2022.
	Name and address of	M/s. Shangqiu Meilan Biological Engineering Co., Ltd.
	Manufacturer	Address: No.9 Zhuzhou Road, High Tech Development Zone, Zhecheng Shangqiu, Henan,
	Name of avacating	China. China
	Name of exporting country	Cillia
	Brand Name	Meilan L.V IBD Live
	+Dosage Form +	
	Strength	
	Diary No. Date of R&	Dy. No. 2778 Dated 25-01-2021
	I & fee	Rs. 100,000/- Dated 18-01-2021
	Composition	Each dose contains:
	DI 1 1 1	Infectious Bursal Disease Vaccine, Live virus strain B87 (CVCC AV 140)≥10 <sup>3</sup> ELD <sub>50</sub>
	Pharmacological Group	Vaccine
	Type of Form	Form-5A
	Finished Product	As per innovator's specifications
	Specification 1 Todaet	As per filliovator's specifications
	Shelf Life	12months (2°C-8°C)
	Document Details	Following documents are submitted:
		a. Original legalized CoPP dated 12-01-2022.
		b. Original legalized Sole agency agreement (validity was five years it is not valid
		now).
	Pack size	1000 doses vial
	Reference Regulatory	N/A
	Authority	
	Availability Products already	Not verifiable
	Products already registered in Pakistan	Not verifiable
	Remarks of Evaluator	In response to this division's letter dated 2 <sup>nd</sup> November 2021 firm has submitted following:
		i. Clarification regarding difference in address on sole agency agreement DSL that
		sole agency agreement address of head office is mentioned.
		ii. Finished product Specifications; As per Innovator's.
		iii. Safety and efficacy data.
		Following documents are still required:
		<ul><li>i. Evidence of locally registered product for applied product is required.</li><li>ii. Sole agency agreement is not valid now</li></ul>
		ii. Sole agency agreement is not valid now
De		on Board deferred the product for submission of following by the firm:
		gical relevance of B87 (CVCC AV 140) strain with circulating strains of Pakistan.
		Agency Agreement.
8.	Name and address of Importer	M/s Niraav Pharma (Pvt). Ltd Horizon Tower, Office 204, Block 3 Clifton, karachi.
	Detail of DSL	M/s Niraav Pharma (Pvt). Ltd authorized agent of M/s. Vet Pharma Trading Company.
		Address: Plot No. A-81, Eastern Industrial Zone, Port Qasim Authority, Karachi.
		Validity: 23-09-2020, 22-09-2022.
	Name and address of	M/s. Shangqiu Meilan Biological Engineering Co., Ltd.
	Manufacturer	Address: No.9 Zhuzhou Road, High Tech Development Zone, Zhecheng Shangqiu, Henan,
	Name of avacating	China. China
	Name of exporting country	Cillia
	Country	

+	Brand Name -Dosage Form + Strength	Fowl Pox Vaccine, Live (Quail Attenuated)	
Γ	Diary No. Date of R& & fee	Dy. No. 2778 Dated 25-01-2021 Rs. 100,000/- Dated 18-01-2021	
Composition		Each dose contains:	
		Fowl pox virus strain quail attenuated (CVCC AV 1003)≥10 <sup>3</sup> ELD <sub>50</sub> .	
C	Pharmacological Group	Vaccine	
	Type of Form	Form-5A	
S	Finished Product Specification	As per innovator's specifications	
	Shelf Life	12months (2°C-8°C)	
	Document Details	Following documents are submitted: <ul><li>a. Original legalized CoPP dated 12-01-2022.</li><li>b. Original legalized Sole agency agreement (validity was five years it is not valid now).</li></ul>	
P	Pack size	1000 doses vial	
Α	Reference Regulatory Authority Availability	N/A	
	Products already egistered in Pakistan	Not verifiable with this strain	
R	Remarks of Evaluator	In response to this division's letter dated 2 <sup>nd</sup> November 2021 firm has submitted following:	
		<ul> <li>i. Clarification regarding difference in address on sole agency agreement DSL that sole agency agreement address of head office is mentioned.</li> <li>ii. Finished product Specifications; As per Innovator's.</li> <li>iii. Safety and efficacy data.</li> </ul>	
		Following documents are still required:	
		<ul><li>i. Evidence of locally registered product for applied product is required.</li><li>ii. Sole agency agreement is not valid now.</li></ul>	
Decis	Decision: Registration Board deferred the product for submission of following by the firm:  i. Immunological relevance of CVCC AV 1003 strain with circulating strains of Pakistan.  Valid Sole Agency Agreement.		
<b>9.</b> I	Name and address	M/s Snam Pharma 61-G, Phase-1, Commercial Area, DHA, Lahore	
0	of Importer		
	Detail of DSL	M/s Snam Pharma,	
		Address: 61-Block G, Phase-I, DHA, Lahore Cannt, District Lahore. Valid till: 14 November, 2022.	
N	Name and address of	M/s Sante Animale	
	Manufacturer	Lot 157, zone industrielle Sud	
	Name of exporting country	Morroco	
	Brand Name	Bovivax LSD-N Vaccine	
S	-Dosage Form + Strength	(50 doses)	
	Diary No. Date of R&	Dy. No. 8315R&I Dated 30-03-2022	
	& fee Composition	Rs. 75,000/- (Slip No. 10439736) <b>Lyophilizate:</b>	
		Each dose contains:	
		Attenuated live LSD virus, Neethling strain $\geq 10^{3.5}$ TCID <sub>50</sub>	
		Solvent:	

		Calcium chloride dihydrate 0.132mg
		Disodium phosphate dihydrate1.441mg
		Sodium chloride8mg
		Potassium chloride0.2mg
		Monopotassium phosphate0.2mg
		Magnesium chloride0.1mg
		Water for Injections.q.f1ml
	Pharmacological	Vaccine
	Group	
	Type of Form	Form-5A
	Finished Product	Manufacturer's specifications
	Specification	1
ŀ	Shelf Life	24months (2 <sup>o</sup> C-8 <sup>o</sup> C)
		Stability studies of three batches at (2°C-8°C) for 30months.
ŀ	Document Details	Copy of FSC for Bovivax LSD -N lyophilizate and copy of FSC for MCI solvent.
	Document Details	Notarized copy of marketing authorization letter showing sale of Bovivax LSD-N-
		Lyophilizate vials of 10,25,50 and 100 doses of freeze-dried vaccine+ bottle of 20,50,100
		and 200ml of MCI Solvent for live vaccines respectively.
		For GMP of manufacturer firm has referred to Eudra GMP Certificate No. 118/2020/GMP.
		Which is verifiable from the site.
		which is verifiable from the site.
	Pack size	50 doses
	r ack size	50 doses 50ml solvent
ŀ	Reference Regulatory	N/A
	Authority	IV/A
	Availability	
	Products already	
	registered in Pakistan	
	Remarks of Evaluator	In response to this division's letter firm has submitted following:
	Remarks of Evaluator	•
		i. Notarized copy of product specific sole agency agreement.
		ii. Stability studies of diluent for 20ml and 200ml bottles is submitted.
		For FSC indicating diluent firm has submitted following:
		a. Notarized copy of marketing authorization letter showing sale of Bovivax LSD-N-
		Lyophilizate vials of 10,25,50 and100 doses of freeze-dried vaccine+ bottle of
		20,50,100 and 200ml of MCI Solvent for live vaccines respectively in Morocco.
		b. Copy of registration license of biological product for Bovivax LSD-N with
		following pack vial 10 doses+20ml diluent, 25doses+50ml diluent,
		50doses+100ml diluent and 100doses+200ml diluent (MCI sterile diluent) in
		Egypt.
		Document still required:
		i. FSC indicating free sale status of product in country of origin.
De	cision: Registrati	on Board deferred the product for submission of valid legalized Free Sale Certificate
		bility in country of origin.
10.	Name and address	M/s Snam Pharma 61-G, Phase-1, Commercial Area, DHA, Lahore
	of Importer	
	Detail of DSL	M/s Snam Pharma,
		Address: 61-Block G, Phase-I, DHA, Lahore Cannt, District Lahore.
		Valid till: 14 November, 2022.
	Name and address of	M/s Sante Animale
	Manufacturer	Lot 157, zone industrielle Sud-Ouest B.P.278- C.P 28 810
		Mohammedia-Morocco.
	Name of exporting	Morocco.
	country	

Brand Name Bovivax LSD-N	Vaccine
+Dosage Form + (10 doses) Strength	
	I Dated 19-04-2022
	p No. 6035676445)
Composition Lyophilizate:	·
Each dose contain	ns:
Attenuated live J	LSD virus, Neethling strain $\geq 10^{3.5}$ TCID <sub>50</sub>
	•
Solvent:	
	e dihydrate 0.132mg
	hate dihydrate1.441mg
Sodium chloride	
Potassium chlori	
	phosphate0.2mg
Magnesium chlo	
Water for Injecti	ons.q.I1ml
Pharmacological Vaccine Group	
Type of Form Form-5A	
Finished Product Manufacturer's s	pecifications
Specification	
Shelf Life 24months (2 <sup>o</sup> C-8	
Stability studies	of three batches at (2°C-8°C) for 30months.
	Bovivax LSD -N lyophilizate and copy of FSC for MCI solvent.
	of marketing authorization letter showing sale of Bovivax LSD-N-
	s of 10,25,50 and 100 doses of freeze-dried vaccine+ bottle of 20,50,100
	CI Solvent for live vaccines respectively in Morocco.
	ion license of biological product for Bovivax LSD-N with following pack
	20ml diluent, 25doses+50ml diluent, 50doses+100ml diluent and diluent (MCI sterile diluent) in Egypt.
	ufacturer firm has referred to Eudra GMP Certificate No. 118/2020/GMP.
Which is verifial	
Willeli is verification	Tom the site.
Pack size 10 doses	
20ml solvent	
Reference Regulatory N/A	
Authority	
Availability	
Products already	
registered in Pakistan	
_	is division's letter firm has submitted following:
	d copy of product specific sole agency agreement.
7	studies of diluent for 20ml and 200ml bottles is submitted.
	ng diluent firm has submitted following:
	d copy of marketing authorization letter showing sale of Bovivax LSD-N-
	zate vials of 10,25,50 and100 doses of freeze-dried vaccine+ bottle of
	0 and 200ml of MCI Solvent for live vaccines respectively in Morocco. registration license of biological product for Bovivax LSD-N with
	g pack vial 10 doses+20ml diluent, 25doses+50ml diluent,
	+100ml diluent and 100doses+200ml diluent (MCI sterile diluent) in
Egypt.	
Document still re	equired:
	icating free sale status of product in country of origin.
	ed the product for submission of valid legalized Free Sale Certificate

11.	Name and address of	Ghazi Brothers, Ghazi House, D-35, KDA Scheme No. 1, Miran Muhammad Shah Road,
	Applicant	Karachi 75350, Pakistan
	Detail of Drug Sale	DSL No: 0141
	License	Validity: 29-June-2023
		Status: to sell drugs in a wholesale distribution
	Name and address of	Onderstepoort Biological Products SOC Ltd.
	manufacturer	100 Old Soutpan Road, Onderstepoort 0110, South Africa.
	Type of Form Diary	Form 5-A Dy No. 8808 dated 06-04-2022
	No. & Date of R& I	Dy No. 9677 dated 15-04-2022
		Dy No. 9676 dated 15-04-2022
		Fee 75,000/- dated 13-04-2022
	Brand Name	Lumpy Skin Disease Vaccine for Cattle with Diluent
	+Dosage Form +	15
	Strength	
	Composition	Each dose contains:
	r	Live attenuated Lumpy Skin Disease Virus (Neethling strain) log10 <sup>3.5</sup> TCID <sub>50</sub>
		Enve attendated Earnpy Stain Bisease virus (1 (ceaning stain) logic 1 e1230
	Finished Product	
Specification As per innovator's specifications		As per innovator's specifications
Pharmacological		
	Group	Immunological
	Shelf life	24 Months
	Demanded Price	Decontrolled
	Pack size	25 Dose with 50ml Diluent
	I dek size	25 Bose with 50m British
	Detail of certificates	• Notarized copy of Free Sale certificate No.20.1.4.1/O issued by Department of Agriculture
	attached	forestry & fisheries Republic of South Africa.
		• Notarized copy of ISO 9001:2015 certificate issued by Bureau Veritas Certification (non-
	of authorization)	regulatory body) and GMP is also not confirmed.
		• Notarized copy of certificate of registration renewal.
		• Notarized copy of facility audit report conducted by Department of Agriculture forestry &
		fisheries Republic of South Africa but GMP was not confirmed in the said report instead
		some observation was conveyed.
		<ul> <li>Notarized copy of Product specific Letter of Authorization.</li> </ul>
		1 Notalized copy of Froduct specific Letter of Authorization.

### **Remarks of the Evaluator**

Remakrs	Justification provided by the firm
In submitted Notarized copy of Free Sale certificate & certificate of registration renewal, the diluent is not mentioned while the firm applied for diluent with combo pack.	Lumpy Skin Disease Vaccine for Cattle with Diluent is a freeze-dried vaccine, reconstituted in water for injection (WFI) supplied with the vaccine as combo pack.  On the package, it is labeled as 25 and 50 doses in pack presentation of 50 and 100-ml respectively, which is actually the quantity of diluent (WFI) present in the pack.  As the active substance is in freeze-dried form, it must be reconstituted with WFI to formulate 25 doses with 50 ml diluent and 50 doses with 100 ml diluent, respectively. The same is described in the approved SPC.
GMP certificate is not provided instead Notarized copy of ISO 9001:2015 certificate issued by Bureau Veritas Certification (non-regulatory body) wherein GMP is not confirmed.	Copy of Label, Brochure, and SPC are provided.  According to South African legislation, under FERTILIZERS, FARM FEEDS,    AGRICULTURAL REMEDIES AND STOCK REMEDIES ACT 36 OF 1947,    registration is subjected to;    • Fertilizers, farm feeds, agricultural remedies, stock remedies    • Sterilizing plants    • Pest control operators    Please refer,    Clause 2 (a) under section 3, (For Fertilizers and Stock remedies)    "the fertilizer, farm feed, agricultural remedy or stock remedy in respect of which registration is applied for is suitable and sufficiently effective for the purposes for which

	it is intended, and complies with such requirements as may be prescribed, and that it is not contrary to the public interest that it be registered, and that the establishment where it is manufactured is suitable for such manufacture, he (the registrar) shall register such fertilizer, farm feed, agricultural remedy or stock remedy.  Clause 2 (b) under section 3, (For Sterilizing plant)  the sterilizing plant in respect of which registration is applied for is suitable and sufficiently effective for the purpose for which it is intended and complies with such requirements as may be prescribed, and that it is not contrary to the public interest that such sterilizing plant be registered, he (the registrar) shall register such sterilizing plant.
	Thus, it is concluded that in case of stock remedies, registration of premises does not fall under this act where products are subjected to registration, unlike sterilizing plants and pest control operators.
	Definition of Stock remedies, and sterilizing can be reviewed from Act 36 of 1947. In the light of the above-mentioned facts, Onderstepoort Biological Products Ltd. (OBP) has been granted the manufacturing and marketing authorization for the Lumpy Skin Disease Vaccine for Cattle with diluent, based on the legislation in South Africa and in response to a comprehensive audit report.
	The firm has submitted audit report issued by the Department of Agriculture, Forestry, and Fisheries but the report show ten major observations & concluded as under; "The listed major observations identified at your facility poses a high risk on your product quality and non-compliance to applicable prescripts."
In the stability study, a) pack size (doses) is not mentioned, b) time period is not as per ICH (Only tested on initial & final interval )& c) only potency test is performed.	The firm has submitted that "Submitted Stability data is as per required South African regulatory requirements. At the time of dossier submission, only the potency of the vaccine was required."  We are pleased to inform that Real-time stability with required time intervals has been planned by OBP." The firm has submitted Declaration from OBP and Undertaking for this purpose.
	ard deferred the product for submission of following by the firm: GMP Certificate of manufacturer abroad issued by regulatory authority of country of

- i. Valid Legalized GMP Certificate of manufacturer abroad issued by regulatory authority of country of origin.
- ii. Valid Legalized Free Sale Certificate indicating diluent in combo pack issued by regulatory authority of country of origin.
- iii. Stability study guidelines of country of origin to support the submitted stability data.

### F: Locally Manufactured Veterinary Biologicals

2.	Name and address of	M/S Intervac Pvt. Ltd
	product manufacturer	18 Km Lahore Sheikhupura Road, Sheikhupura Pakistan
(Applicant)		•
	Brand Name +Dosage	Intervac ETV-Plus Multivalent Clostridium Perfringens vaccine
	Form + Strength	
	Compo	Each ml contains:
	sition	Alpha toxoid2019.802048.12 HU/ml
		Beta toxoid980.231022.41TCID <sub>50</sub> /ml
Epsilon toxoid511.98512.23 HU/ml		Epsilon toxoid511.98512.23 HU/ml
Pharmacological Group Veterinary vaccine Finished Product Ph. Eur. Specs		Veterinary vaccine
		Ph. Eur. Specs
Specification		
Type of Form, Diary No. Form-5, Dy No. 3907 dated 21-02-2021,		Form-5, Dy No. 3907 dated 21-02-2021,
Date of R& I & fee Dy. No.4972 Date:22-02-2022 Fee 20,000/- dated 28-01-2021 Shelf Life 1 Year (2-8°C)		Dy. No.4972 Date:22-02-2022
		Fee 20,000/- dated 28-01-2021
		1 Year (2-8 <sup>o</sup> C)
	Document Details	i. Copy of GMP certificate on 26-01-2021 wherein the panel rated the facility good
		and GMP

		ii. Copy of Panel inspection for DML renewal on 19-06-2019 & 28-05-2019 wherein the panel rated the facility good and GMP has been recommended for following Biological sections:  a. Vaccine Section	
		b. Hormone Injectable Section (Veterinary)	
	Pack size & Demanded	50ml vial,	
Price <b>Decontrolled</b>		Decontrolled	
	Products already registered in Pakistan	Toxipra X7 of M/s Hipra	
	Remarks of Evaluator		
De	Decision: Registration Board approved the product.		

#### **G:** Miscellaneous/ Deferred Cases

# 1. Imported veterinary biological applied by M/s Vet Line International, Lahore deferred in 297<sup>th</sup> meeting of Registration Board.

Following product of M/s Vet Line International, Lahore was deferred in 316<sup>th</sup> meeting of Registration Board as per following details:

Name and address of	M/s Vet Line International,	
Importer	Plot No. 939-A,Block-J, Phase-I,LDA Avenue,Lahore	
Detail of DSL	No. 05-352-0066-040712D dated 09-02-2019 renewed upto 09-02-2021	
Name and address of	Product License Holder:	
Manufacturer	M/s Laprovet Hungary Veterinary Pharmaceuticals Ltd., 1107 Budapest Horog u. 32-34. Hungary (the wholly owned subsidiary of Laprovet S.A.S. 7 rue du Tertreau, Arched'Oe 2,37390, Notre Dame D' Oe, France.  Contract Manufacturer:	
	M/s Ceva-Phylaxia Veterinary Biologicals Co. Ltd., 1107 Budapest, Szallass u.5. Hungary.	
Brand Name +Dosage Form + Strength	ITA New Flu H9	
Diary No. Date of R& I & fee	Dy. No. 23585(R&I) dated 09-07-2018 Rs. 100000/- dated 09-07-2018	
Composition	Each dose (0.2ml) of vaccine contains: Inactivated Avian Influenza virus, type A, sub-type H9N2 min. 8log2 HI Inactivated Newcastle disease virus, LaSota strain min. 5log2 HI	
Pharmacological Group	Veterinary Vaccine	
Type of Form	Form-5A	
Finished Product Specification	As per Innovator.	
Shelf Life	24 months (2°C-8°C)	
Document Details	<ul> <li>i. Valid Legalized GMP certificate of M/s Ceva-Phylaxia Veterinary Biologicals Co. Ltd., Hungary No. 02.2/3807-2/2017 dated 17-07-2017 issued by Directorate of Veterinary Medicinal Products, Hungary</li> <li>ii. Valid Legalized FSC No. 02.2/2397-2/2018 dated 20-04-2018 issued by Directorate of Veterinary Medicinal Products, Hungary</li> <li>iii. Contract manufacturing certificate No. 02.2/3281-2/2018 dated 13-06-2018 issued by Directorate of Veterinary Medicinal Products, Hungary</li> </ul>	
Pack size 500ml(2000 doses)		
International Availability	UEMOA (West African community including 8 countrie)	
Products already registered in Pakistan	AI-OLVAC of M/s Forward Solutions.	
Decision of RB in 313 <sup>th</sup> meeting	Registration Board deferred the case for confirmation of Influenza disease status in country of origin and reference regulatory authorities.	

The firm then submitted the references from UK, European Union & Hungary along with weblinks of official websites.

#### UK:

In UK, the vaccination against Avian Influenza is not permitted. Stamping out is the most effective means of controlling an outbreak. In England vaccination is only available for zoo birds. Vaccination of zoo birds against avian influenza is currently not permitted in Scotland or Wales.

#### **European Union & Hungary:**

Vaccination against Avian Influenza is prohibited on their territory, except for following:

#### a. Emergency Vaccination:

A Member state may introduce emergency vaccination in poultry or other captive birds as a short-term measure to contain an outbreak when a risk assessment indicates there is a significant and immediate threat of avian influenza spreading within or into the Member State concerned.

#### **b.** Preventive Vaccination:

Member States may introduce preventive vaccination in poultry or other captive birds as a long-term measure in accordance with this Section where they deem that on the basis of a risk assessment certain areas of their territory, type of poultry husbandry or certain categories of poultry or other captive birds or the poultry or other captive birds' compartments are exposed to the risk of avian influenza.

The case was considered in 316<sup>th</sup> meeting wherein the Board decided as follows:

"Registration Board deferred the case for further deliberation in next meeting as neither product is on Free Sale in country of origin nor formulation is available in RRAs"

The firm has now submitted that vaccines manufactured in reference countries only for export are registered & marketed in Pakistan and the firm requested that if DRAP can't allow them to register their product on the point of non-availability in country of origin & RRAs, DRAP kindly cancel all registration of same products. **Decision:** 

#### Registration Board deferred the product for submission of following by the firm:

- i. Valid legalized CoPP OR Free Sale Certificate issued by regulatory authority of country of origin indicating reason of non-availability of product in country of origin
- ii. Details of last usage of the product in country of origin or in any reference regulatory authority.

#### 2. Resemblance of brand name with already registered Typbar injection.

M/s Amson Vaccines & Pharma (Pvt.) Ltd., Islamabad submitted that TYPBAR Injection 0.5ml (Typhoid vaccine), Registration number 017468 is registered in their name since 2009 and they had submitted the renewal till 2024. The firm further submitted that they had been selling and marketing this product from the year 2009. Lot release certificate from National Control Laboratory for Biological by the brand name of TYPBAR had also been acquired. TYPBAR had also been registered by Trade Mark Registry in favor of Amson Vaccines & Pharma (Pvt.) Ltd under trade mark number 571355. Moreover, in 293<sup>rd</sup> DRB meeting of DRAP, the Board has approved a product with the name of Typbar TCV imported by M/s Vikor Enterprises (Pvt) Ltd. Karachi. The firm requested not to register new Typhoid Vaccine with their brand name as they hold the Brand name Typbar and marketing the product since long so as per DRAP policy a new product with same or similar brand name cannot be registered. The firm further requested that the registration board may ask the importer (Vikor) to get the product registered with a different brand name that should not be similar as they had the right to take up the issue to at appropriate forum in case their request is not considered.

In this context, it is submitted that following products of M/s Vikor Enterprises, Karachi were approved in different meetings of Registration Board as per following details:

Name of	Brand Name & Composition	Decision of RB
Manufacturer		
M/s Bharat Biotech	Typbar TCV 0.5mL	Keeping in view the above discussion, WHO
International Ltd.,	Typhoid Vi Conjugate Vaccine	Prequalification and valid legalized CoPP
Genome Valley,	Each dose of 0.5mL contains:	indicating product availability in country of
Shameerpet Mandal,	Purified Vi Capsular	origin; Registration Board cancelled the
Medchal District-	Polysaccharide of Salmonella	approval of Typbar TCV from the name of
500 078, Telangana,	typhi Ty2 conjugated to	M/s Sind Medical Store, Karachi granted in
India	Tetanus Toxoid25μg	284 <sup>th</sup> meeting and granted approval in name

		of M/s Vikor Enterprises (Pvt.) Ltd., Karachi as per current Import Policy for Finished Drugs. The Registration letter shall be issued after confirmation of cold storage facility of by the area FID and price verification from Pricing Division. (M-293)
M/s Bharat Biotech	Typbar TCV 2.5mL	Keeping in view WHO Prequalification and
International Ltd.,	Typhoid Vi Conjugate Vaccine	valid legalized CoPP indicating product
Genome Valley,	Each dose of 0.5mL contains:	availability in country of origin; Registration
Shameerpet Mandal,	Purified Vi Capsular	Board approved the product subject to
Medchal District-	Polysaccharide of Salmonella	compliance of current Import Policy for
500 078, Telangana,	typhi Ty2 conjugated to	Finished Drugs. (M-297)
India	Tetanus Toxoid25µg	

Moreover, previously M/s Amson Vaccines & Pharma, Islamabad submitted the same request which was considered in 297<sup>th</sup> meeting of Registration Board wherein the Board decided as follows:

Accordingly, the case was forwarded to Legal Affairs Division and they provided the following opinion:

"Reference to pre paras the case filed by M/s Amson Vaccine and Pharma against DRAP and other was fixed for 13.10.2021 before Civil Judge (west) Islamabad, However, stay is not granted to the plaintiff (M/s Amson pharma). The next date of hearing of the case is 16.10.2021. The Drug Registration Board constituted under section 7 of the drugs act, 1976 is competent forum to grant registration of drugs, therefore, the Registration Board in 293rd meeting granted approval of Typbar TCV in the name M/s Vikor Enterprises (Pvt.) Ltd., Karachi. The Registration Board further deliberated on the matter in 296th meeting, the decision is given here for ready reference: -

Decision: Registration Board deliberated that already registered brand name is Typbar which is polysaccharide vaccine. While the said vaccine is conjugated vaccine and has TCV suffix in the brand name, which differentiates it from previously registered brand name. Moreover, Typbar TCV is only international brand of Typhoid Conjugate Vaccine and enlisted in WHO Prequalified list with the same name. The Registration Board endorsed its decision of 293rd meeting of Registration Board with Typbar TCV brand name.

Moreover, the Federal Government under Section 12 of the Drugs Act 1976 has fixed the price of the product which is notified vide S.R.O 1115 (I)/2021 dated 03rd September 2021 at Sr. 13 of the ibid notification. Therefore, it is appropriate to issue registration letter after fulfillment of legal formalities. Till date neither stay order exists while the case is fixed for 16.10.2021. Therefore, all the action taken by either Registration Board or Pricing Committee and Federal Government are valid which are taken before 16.10.2021.

The Honorable court vide order dated 18-10-2021 then dismissed the appeal on the basis of maintainability and in light of the orders of August Supreme Court of Pakistan in HR Case No. 2858/2006 and CMA No. 3968/2018.

Accordingly, Legal Affairs Division again provided the following opinion:

"It is submitted that the application filed by the petitioner for grant of temporary injunction has been dismissed by learned Civil Judge, Islamabad being not maintainable vide order dated 18-10-2021. Hence, there is no bar on issuance of registration letter to M/s Vikor Enterprises (Pvt.) Ltd., Karachi."

In light of above, registration letter of product at sr. no. 1 of above table was issued on **10-12-2021** while for product at sr. no. 2, the firm was asked to submit valid legalized CoPP as it was expired at the time of approval. Now, M/s Amson Vaccines & Pharma (Pvt.) Ltd., Islamabad submitted above request on **13-12-2021**.

<sup>&</sup>quot;Registration Board deferred the case and advised DBER to refer the case to Legal Affairs Division of DRAP for their opinion with complete details of the case."

The firm then submitted the valid legalized CoPP and accordingly, Legal Affairs Division was requested for their opinion and case was included in agenda of 316<sup>th</sup> meeting wherein the Board decided as follows:

Legal Affairs Division has furnished the following opinion in the case:

"Drug Registration Board in 293<sup>rd</sup> meeting held on 8th January, 2020 considered the case of Vikor's Typbar TVC (0.5 ml) vaccine for registration. While M/s Amson Vaccine & Pharma (PVT) Ltd. filled Trade Mark application on 16.06.2020 (i.e after the consideration of the Typbar TVC vaccine by the DRB). Subsequently, it was approved for registration by the DRB and registration letter was issued on 10.12.2021. The Amson's letter intimating registration of Trade Mark Typbar was received in DRAP on 13.12.2021. Hence DRAP's action of issuing registration letter to M/s Vikor for Typbar TVC vaccine is justified.

However, the registration letter for 2.5 ml Typbar TVC vaccine may be withheld till settlement of this dispute between the parties through competent forum."

Decision: Registration Board deliberated that the product is of public health need and Typbar TCV is an international brand name of the product of M/s Bharat Biotech International Ltd. Moreover, the instant product is also WHO Prequalified with the same brand name. Hence, Registration Board decided that withholding the registration letter will deny the access of general public of Pakistan to a WHO PQ Typhoid Conjugate Vaccine and advised Division of Biological Evaluation & Research to issue registration letter of the product with brand name Typbar TCV.

## 3. Withdrawal of registration applications of Human Biologicals applied by M/s Sanofi Aventis Pakistan Limited, Karachi.

M/s Sanofi Aventis Pakistan Limited, Karachi applied to withdraw the applications for registration of following products:

Sr. No.	Name of Product	Decision of RB
1.	Imojev Powder and Solvent for Suspension for Injection	Approved. Registration Board also approved water for injection from same manufacturing site, as firm has submitted registration dossier and requisite fee. Expiry dates of both Imojev Japanese Encephalitis Vaccine and diluent shall be same. (M-240)
2.	Imojev MD Powder and Solvent for Suspension for Injection	Approved. Registration Board also approved water for injection from same manufacturing site, as firm has submitted registration dossier and requisite fee. Expiry dates of both Imojev Japanese Encephalitis Vaccine and diluent shall be same. (M-240)
3. 4.	Dengvaxia Dengvaxia MD	Registration Board considered the expert opinions and based on their recommendations and recommendations of WHO Strategic Advisory Group of experts (SAGE) on 15th April 2016 approved the grant of registration of DENGVAXIA, powder and solvent for suspension for Injection (Dengue tetravalent vaccine (live, attenuated) manufactured by Sanofi Pasteur Parc Industrial Incarville, 27100 Val de Reuil France and final release by M/s Sanofi Pasteur NVL 31-33 quai Armand Barbes 69250 Neuville-sur-Saone France, as per import policy. The firm shall provide the valid legalized CoPP issued by the regulatory body of France. The Chairman Registration Board shll allow the issuance of registration letter, if CoPP provided earlier than the next meeting of Registration Board. (M-260)

<sup>&</sup>quot;Registration Board advised DBE&R to wait till the opinion of Legal Affairs Division."

The firm has submitted that the decision is purely due to commercial reason and is not due to safety, quality or efficacy of the vaccines.

Decision: Registration Board deferred the case for submission, of availability /withdrawal status of these product in reference regulatory authorities.

# 4. Transfer of Registration letter from M/s Eli Lilly Pakistan (Pvt) Limited Karachi to M/s Golden Harvest Karachi

M/s Golden harvest, Karachi applied for registration of following veterinary biologicals in their name from M/s Eli Lilly Pakistan (Pvt.) Ltd., Karachi:

1	Name of Importer	M/s Golden Harvest
		Plot No. 49-C, 24th Commercial Street Phase-II Extt: DHA Karachi
DSL details License to sell dru		License to sell drug as distributor No. 054 valid till 26-02-2023
Name of Lohmann Animal Healt		Lohmann Animal Health Heinz-Lohmann-StraBe 4, 27472 Cuxhaven,
	Manufacturer	Germany
	Brand Name + Dosage	Avipro Salmonella DUO
	Form + Strength	10 x 2000 Dose vial
	Composition	Each dose contains:
		Live Salmonella Enteritidis bacteria, strain Sm24/Rif12/Ssq, Atleast 1 x 10 <sup>8</sup> CFU*
		Live Salmonella Typhimurium bacteria, strain Nal2/Rif9/Rtt,
		Atleast 1 x 10 <sup>8</sup> CFU*
		*CFU = Colony Forming Units
	Finished product	Ph. Eur. specifications
	specifications	
Pharmacological Group		
Shelf life 18 months Months (2°C-8°C)		18 months Months (2°C-8°C)
Products already Already Registered in Pakistan registered in Pakistan		Already Registered in Pakistan
	Type of Form	Form 5-A, Dy No.2542 Dated 21-01-2021,
	Dy. No. Date of	Dy No.6549 Dated 09-03-2022, Dy No.803 Dated 14-05-2022
	Application, Fee	
	submitted	Fee Submitted: Rs. 100000./- dated 20-01-21
	Demanded Price / Pack	10 * 2000 dose vial (Already registered)
	size	
General Legalized Free Sale Certificate (FSC) No. 048/L		Legalized Free Sale Certificate (FSC) No. 048/LAH/2020 dated 10-08-
· · · · · · · · · · · · · · · · · · ·		2020 issued by Niedersachsisches Landesamt für Verbraucherschutz und
· · · · · · · · · · · · · · · · · · ·		Lebensmittelsicherheit (Lower Saxony State Office for Consumer
Protection and Food Safety) Germany.		, ,
		And notarized copy of GMP Certificate No. 075/LAH/2018 dated 02-04-2020.

Registration of Product from One importer to another Importer.			
Requirement as per SOP	Document submitted	Remarks	
Application on Form 5A with required fee as per relevant SRO.	Submitted on 20-01-2021 with fee of 100,000/- & evaluated above		
Copy of registration letter and last renewal status	Initial registration letter dated 10-02-2020.		
Termination letter (original) from manufacturer for previous importer.	Copy of termination letter submitted.		
Authority letter/sole agent letter (original) from manufacturer.	Notarized copy of Letter of Authorization dated 21-12-2020.		
Document confirming NOC (issued within last 6 Months) from existing registration holder	NOC dated 04-01-2022		

permitting for registration of product to another		
importer.		
Original and legalized Certificate of	Legalized Free Sale Certificate (FSC) No.	
Pharmaceutical Product as per WHO format	048/LAH/2020 dated 10-08-2020 issued by	
for new manufacturer's name OR Original	Niedersachsisches Landesamt fur	
and legalized GMP certificate of new	Verbraucherschutz und Lebensmittelsicherheit	
manufacturing site with free sale certificate	(Lower Saxony State Office for Consumer	
from regulatory body of country of origin.	Protection and Food Safety) Germany.	
	And Legalized GMP Certificate No. 075/LAH/2018	
	dated 02-04-2020.	
Undertaking that the provided information/	Submitted	
documents are true/ correct.		

#### **Remarks:**

Copy of termination letter has been submitted.

Only test for bacterial counts of the product have been submitted in the stability study data for three batches for 26 months. And Residual moisture (%) for three batches have been performed at months 0 & 34.

While as per CoA four tests are performed i.e. Identification of active substance, viable testing, purity test, residual moisture.

\*\*As per initial Registration letter shelf life of the product is 18 months while in the current case the firm has requested for 21 months shelf life.

Justification for stability study:

Name of Importer	M/s Golden Harvest	
	Plot No. 49-C, 24th Commercial Street Phase-II Extt: DHA Karachi	
DSL details	License to sell drug as distributor No. 054 valid till 26-02-2023	
Name of Manufacturer	Elanco US Inc., 375 China Road, Winslow Maine 04901 USA	
Brand Name + Dosage Form	Avipro ND-IB Polybanco	
+ Strength	10 * 2500 Dose vial	
Composition	Each_dose contains; Newcastle disease virus B1 type, B1 strain 10 <sup>5.5</sup> EID <sub>50</sub> * infectious bronchitis virus** Mass. type, M-48 and Conn.type Live virus strain 10 <sup>3.1</sup> EID <sub>50</sub>	
Finished product specifications	Ph. Eur.	
Pharmacological Group	Veterinary vaccine	
Shelf life	21 months (Store at 2-8°C)	
Products already registered in Pakistan	Already Registered in Pakistan	
Type of Form Dy. No. Date of Application, Fee submitted	Form 5-A, Dy No.2542 Dated 21-01-2021, Dy No. 10351 Dated 07-04-2021, D No.6549 Dated 09-03-2022 Dy No.803 Dated 14-05-2022  Fee Submitted: Rs. 100000./- dated 20-01-21	
Demanded Price / Pack size 10 * 2500 dose vial (Already registered)		
General Documentation	Legalized Certificate of Licensing & Inspection (CLI) No.2002148 dated 26-02020 issued Center for Veterinary Biologics USDA.	
Decision:		

Registration of Product from One importer to another Importer.			
Requirement as per SOP	Document submitted	Remarks	

Application on Form 5A with required fee as per relevant SRO.  Copy of registration letter and last renewal status	Submitted on 21-01-2021 with fee of 100,000/- & evaluated above  Initial registration letter dated 30-09-2020.	
Termination letter (original) from manufacturer for previous importer.	Copy of termination letter submitted	
Authority letter/sole agent letter (original) from manufacturer.	Legalized Letter of Authorization dated 23-09-2020.	
Document confirming NOC (issued within last 6 Months) from existing registration holder permitting for registration of product to another importer.	NOC dated 04-01-2022	
Original and legalized Certificate of Pharmaceutical Product as per WHO format for new manufacturer's name OR Original and legalized GMP certificate of new manufacturing site with free sale certificate from regulatory body of country of origin.	Legalized Certificate of Licensing & Inspection (CLI) No.2002148 dated 26-08-2020 issued Center for Veterinary Biologics USDA.	
Undertaking that the provided information/documents are true/correct.	Submitted	

#### **Evaluator Remarks:**

Copy of termination letter has been submitted.

Only test for virus titration of the product has been submitted in the stability study data for three batches for 26 months. And time frequency of testing is 0 & 21-26 months which is not as per ICH.

<u>Justification submitted by the firm:</u> The firm has submitted letter from its manufacturer wherein it has been stated that "we hereby confirm that AviPro ND-IB Polybanco is registered in the USA with a 21 months shelf life established by the United States Department of Agriculture Center for Veterinary Biologics after submission & review of same stability data that is attached in Annexure-1. AviPrp ND-IB Polybanco was registered in Pakistan with registration letter no. 101955 on 30<sup>th</sup> September 2020 with same stability data.

**Decision:** Registration Board deferred the case for submission of following by the firm:

- i. Original termination letter from manufacturer abroad for previous importer.
- ii. Valid legalized approval of 21 months shelf life for product at sr. no. 1 issued by regulatory authority of country of origin.
- iii. Real time stability data for both products including all the parameters as mentioned in finished product specifications.

### 5. Cases of Biological Drugs Referred to Ministry of National Food Security & Research, Islamabad For Comments:

Registration Board in its 313<sup>th</sup> meetings referred the following products of below mentioned firms to Ministry of National Food Security & Research, Islamabad for comments regarding the need of vaccine, prevalence of disease, and immunological relevance of the strain in Pakistan as per following details:

Now the comments of Assistant Animal husbandry Commissioner are received quoted in the last column of below mention table for consideration of the Board.

Sr. No.	Importer & Manufacturer	Brand Name & Composition Decision	Previous RB meeting Decisions	Recommendations by Assistant Animal
				husbandry
				Commissioner
1.	Importer:	Nobivac Tricat Trio	M-292:	Feline (cat)vaccine.
		Lyophilisate and solvent for	Registration Board decided to	It is a routine
	M/s. Vety	suspension for injection	refer the case to expert	combination, already
	Care	After Freeze-drying	working group on veterinary	many companies
	(Pvt.) Ltd.	Each dose contains:	drugs regarding the	have this

	Plot No. 77, Street No.6, I- 10/3 Islamabad.  Manufacturer:  M/s. Intervet International B.V. Wim de Korverstraat, 5831 AN Boxmeer, The Netherlands.	Live FCV strain F9at least 4.6 log10 PFU Live FVR strain G2620Aat least 5.2 log10 PFU Live FPLV strain MW-1at least 4.3 log10 TCID50 Nobivac Solvent: Each ml contains: Disodium phosphate dihydrate0.31mg Potassium dihydrogen Phosphate0.21mg Water for injections to999.16 mg	prevalence of strains and advised the firm to submit valid legalized CoPP indicating product availability in country of origin and European Union Guidelines regarding stability studies.  M-313 Referred the product to Ministry of National Food Security & Research, Islamabad for comments regarding the need of vaccine, prevalence of disease and immunological relevance of the strain in Pakistan.	combination, therefore, may be recommended for import.
2.		Innovax ND-IBD Each dose(ml) contains: Live Herpesvirus of turkey strain HPV 360*at least 103.3PFU** * HPV 360 is a HVT-based recombinant encoding the NDV F protein and the IBDV VP2 protein. **Plaque Forming Units	M-292 Registration Board decided to refer the case to expert working group on veterinary drugs regarding the prevalence of strains and advised the firm to submit legalized evidence of product availability in reference regulatory authorities and European Union Guidelines regarding stability studies. M-313 Referred the product to Ministry of National Food Security & Research, Islamabad for comments regarding the need of vaccine, prevalence of disease and immunological relevance of the strain in Pakistan.	This is vector vaccine for gumboro(IBD) already 2 similar vaccine are available in Pakistan. May be recommended for import for making healthy competition.
3.		Nobilis IB Primo QX Lyophilisate for suspension for spray Each dose of reconstituted vaccine contains: Live attenuated avian infectious bronchitis virus, strain D388104.0-105.5 EID50* *50% egg infective dose	M-292 Registration Board decided to refer the case to expert working group on veterinary drugs regarding the prevalence of strains and advised the firm to submit valid legalized CoPP indicating product availability in country of origin and European Union Guidelines regarding stability studies. M-313 Referred the product to Ministry of National Food	Already D274 strain is present which gives protection against D388 because D388 is IB variant equal to QX virus it may be recommended for import but in killed form not in live form

			Security & Research, Islamabad for comments	
			regarding the need of vaccine, prevalence of	
			disease and immunological relevance of the strain in	
			Pakistan.	
4.	Importer:	Poulvac SE-ND-IB Newcastle Bronchitis Vaccine,	M-307: Registration Board	Already no such vaccine is available in
	M/s. Hi-Tech Pharmaceutica	Mass Type, Killed Virus, Salmonella Enteritidis Bacterin	referred the case to Expert Working	Pakistan because this is combination of
	ls,	Each 0.3mL dose contains:	Group on Veterinary	vaccine and bacterin
	, Lahore.	S. Enteritidis – Strain D1758, Phage $4 \ge 5.0 \times 107$ CFU per	Drugs.	(bacterial vaccine). Its efficacy may be
	Manufacturer :	dose at release	M-313 Referred the product to	variable. It may be not recommended for
		S. Enteritidis – Strain Se.ceb.50,	Ministry of National Food	import.
	M/s. Zoetis Inc. 2000,	Phage $8 \ge 5.0 \times 107$ CFU per dose	Security & Research, Islamabad for comments	
	Rockford Road.	at release S. Enteritidis – Strain 52-1, Phage	regarding the need of vaccine, prevalence of disease and	
	Charles City,	$13a \ge 5.0 \times 107$ CFU per dose at	immunological relevance of	
	IA 50616, USA	release Newcastle Disease Virus –	the strain in Pakistan.	
		Bearing Fluids ≥ 107.8 EID50 per dose at release		
		Bronchitis Virus – Bearing Fluids		
5.	Importer:	≥ 106.9 EID50 per dose at release NASYM, Lyophilisate and	M-307:	Bovine Respiratory
	M/s Hipra	solvent for suspension for injection or nasal spray	Registration Board referred the case to Expert Working	syncytial virus disease is not
	Pakistan Pvt.	25 doses vial	Group on Veterinary Drugs.	officially reported
	Limited, Pakistan	Each dose of 2ml contains: : Live attenuated bovine respiratory	M-313 Referred the product to	from Pakistan. Therefore, it may not
	ProductLicen	syncytial virus, strain(BRSV) strain Lym-5610 <b>4.7</b> -10 <b>6.5</b>	Ministry of National Food Security & Research,	be recommended for import.
	se	CCID	Islamabad for comments	ттрогс.
	Holder: M/s	<b>50</b> *	regarding the need of vaccine, prevalence of	
	Laboratorios HIPRA, S.A,	Infectious Dose, 50 % equivalent	disease and immunological relevance of the strain in	
	Avda. La	-	Pakistan.	
6.	Selva, 135 17170 Amer	NASYM, Lyophilisate and solvent for suspension for	M-307: Registration Board referred	Bovine Respiratory syncytial virus
	(Girona) Spain.	injection or nasal spray <b>5 doses vial</b>	the case to Expert Working Group on Veterinary Drugs.	disease is not officially reported
	Manufacturer	Each dose of 2ml contains: :	M-313	from Pakistan.
	: M/s	Live attenuated bovine respiratory syncytial virus, strain(BRSV)	Referred the product to Ministry of National Food	Therefore, it may not be recommended for
	Laboratorios HIPRA, S.A,	strain Lym-5610 <b>4.7</b> -10 <b>6.5</b> CCID	Security & Research, Islamabad for comments	import.
	Carretera	50 *	regarding the need of	
	C-63, Km 48,300,	*CCID50 : Cell Culture Infectious Dose, 50 % equivalent	vaccine, prevalence of disease and immunological	
	Poligono Industrial EI		relevance of the strain in Pakistan.	
	Rieral, 17170			
	Amer (Girona),			
	Spain (Also responsible for			
	primary			
	packaging)			

	T = .	T	T = = ==	T
7.	Importer:	Newcastle Disease, Infectious	M-307:	Already one such
	N#/ X7 . T .	Bronchitis, Egg Drop Syndrome	Registration Board	vaccine is available
	M/s. Vet Line	and Avian Influenza (H9N2	referred the case to	in Pakistan, It's a
	International,	Subtype) Vaccine	Expert Working	good combination
	Lahore.	Each dose (0.5ml) contains:	Group on Veterinary	may be
	M 6 4	Inactivated Newcastle Disease	Drugs.	recommended for
	Manufacturer	Virus La Sota	N/ 212	import to make
	:	Strain≥10 <sup>8.0</sup> EID <sub>50</sub>	M-313	healthy competition.
	<b>N</b> 4/.	Infectious Bronchitis Virus M41	Referred the product to	
	M/s.	Strain	Ministry of National Food	
	Zhengzhou	Egg Drop Syndrome Virus AV-	Security & Research, Islamabad for comments	
	Biopharmaceut	127 Strain≥2000HA Avian Influenza virus H9N2		
	ical		regarding the need of	
	Factory	subtype S2 strain≥10 <sup>7.5</sup> EID <sub>50</sub>	vaccine, prevalence of	
	of QYH		disease and immunological relevance of the strain in	
	BIOTECH			
	COMPANY		Pakistan.	
	LIMITED, , P.R.			
	China.			
8.	Importer:	PoulShot® IB-Castle	M-307:	Routine combination
0.	M/s. ICI	Lyophilized Solution	Registration Board	already many
	Pakistan Ltd,	Each dose contains:	referred the case to	companies have this
	Karachi	Newcastle Disease virus (NDV,	Expert Working	combination,
	Manufacturer	NDRL0901 strain) $\geq 10^{6.0}$ EID <sub>50</sub>	Group on Veterinary	therefore, may be
	·	Infectious bronchitis virus (IBV,	Drugs.	recommended for
	M/s. Choong	AVR1/08 strain) : $\geq 10^{6.0}$ EID <sub>50</sub>	Diugs.	import.
9.	Ang	PoulShot® Gumboro	M-313	It is live virus
7.	Vaccine	Lyophilized Solution	Referred the product to	vaccine. This strain is
	Laboratories	Each dose contains:	Ministry of National Food	not prevalent in
	Co., Ltd.,	Infectious bursal disease virus	Security & Research,	Pakistan and no
	Korea	(IBDV, LZD 228-JAC3 strain) : ≥	Islamabad for comments	vaccine containing
		102.0TCID50	regarding the need of	this strain is being
			vaccine, prevalence of	imported in Pakistan,
			disease and immunological	therefore it may not
			relevance of the strain in	be recommended for
			Pakistan.	import.
10.		PoulShot® Qx Flu-5 Injectable		Already one such
		Solution		vaccine is available
		Each dose contains:		in Pakistan. It's a
		Newcastle disease virus (NDV,		good combination
		LaSota strain) $\geq 10^{8.0} \text{EID}_{50}$		may be
		Infectious bronchitis virus (IBV,		recommended for
		KM91 strain) $\geq 10^{6.0}$ EID <sub>50</sub>		import to make
		Infectious bronchitis virus (IBV,		healthy competition.
		ADL05258 strain) $\geq 10^{6.0} EID_{50}$		
		Egg drop syndrome virus (EDSV,		
		$K11 \text{ strain} \ge 10^{5.5} \text{EID}_{50}$		
		Avian influenza virus (AIV		
		$  H9N2, 01310 \text{ strain}   \ge 10^{8.0} \text{EID}_{50}$		

Decision: Keeping in view the recommendations of M/o National food Security & Research and data submitted by the firm; Registration Board decided as follows:

- i. Deferred S.No. 7, 8 & 10 for confirmation of availability of such combination in reference regulatory authorities.
- ii. Rejected the applications for registration of products at S.No. 4,5,6 and 9.
- iii. Deferred the products at S.No. 1,2 and 3 for submission of valid legalized CoPPs indicating products availability in country of origin and European Union Guidelines regarding stability studies.

### 6. Extension in shelf life of Emergency Use Authorized product Convidecia Vaccine in Vial applied by M/s AJM Pharma:

M/s AJM Pharma has applied for extension in shelf life of their already Emergency Use Authorized product Convidecia Vaccine in Vial as per following details:

Reg No.	Brand Name	Approved shelf life	Demanded shelf life
107886	Convidecia Vaccine in vial	6 months	12 months
		(2°C to 8°C)	(2°C to 8°C)

The application has been evaluated as per SOP approved in 283<sup>rd</sup> and 292<sup>nd</sup> meetings of Registration Board for Change (Extension) of shelf life and tabulated below;

Requirements as per SOP	<b>Documents submitted by the firm</b>	Remarks
Application with required fee as per relevant	Application along with Fee of 10,000/-has been	
SRO.	submitted	
Copy of registration letter and last renewal	Copy of initial Emergency Use Authorization	
status.	letter is submitted (dated 08-03-2021).	
Proposed shelf-life, justification & data of long-term	Submitted.	
stability testing (as per conditions of zone IV-A) including chromatograms for a minimum of 3		
commercial scale batches or development scale		
batches upto the proposed shelf-life.		
Approval of regulatory body of country of	Legalized Copy of Drug Registration certificate	
origin or Original and legalized Certificate of	of vial from China National Medical Products	
Pharmaceutical Product as per WHO format	Association having 12 months of Shelf life.	
Undertaking that the provided information/	Submitted	
documents are true/ correct.		

Decision: Registration Board deferred the case and advised the firm to submit the import data of the product since its Emergency Use Authorization.

### 7. Extension in shelf life of Emergency Use Authorized product Comirnaty (Reg. No. 107932) applied by M/s. Pfizer Pakistan Limited:

M/s. Pfizer Pakistan Limited, has applied for extension of their already Emergency Use Authorized product Comirnaty (Reg. No. 107932) as per following details:

Reg. No.	Brand Name	Packing	Existing Shelf Life	Demanded Shelf Life
107932	Comirnaty	6 doses/Vial	9 Months	12 Months
	-		(-90°C to -60°)	(-90°C to -60°)

The application has been evaluated as per SOP approved in 283<sup>rd</sup> and 292<sup>nd</sup> meetings of Registration Board for Change (Extension) of shelf life and tabulated below;

Requirements as per SOP	Documents submitted by the firm	Remarks
Application with required fee as per relevant	Application along with Fee of 10,000/-has been	
SRO.	submitted	
Copy of registration letter and last renewal	Copy of initial Emergency Use Authorization	
status.	letter is submitted (dated 04-06-2021).	
Proposed shelf-life, justification & data of long-term stability testing (as per conditions of zone IV-A) including chromatograms for a minimum of 3 commercial scale batches or development scale batches upto the proposed shelf-life.	Submitted.	

Approval of regulatory body of country of	Copy of Approval of EMA for the demanded	
origin or Original and legalized Certificate of	shelf life is submitted which has been verified	1
Pharmaceutical Product as per WHO format	from official website of EMA.	1
Undertaking that the provided information/	Submitted	
documents are true/ correct.		

Decision: Keeping in view the approval EMA (Reference Regulatory Authority); Registration Board approved the extension in shelf life of Comirnaty (Reg. No. 107932) from 9 months to 12 months.

8. M/s Pfizer Pakistan Ltd. had applied for Extension in shelf life of their already Emergency Use Authorized product Comirnaty (Reg. No. 107932), which was acceded to by the Chairman Registration Board as per following details:

M/s Pfizer Pakistan Limited, Karachi applied for extension in shelf life of Comirnaty (Reg. No. 107932) from 6 months to 9 months as per SOPs of 283<sup>rd</sup> & 292<sup>nd</sup> meeting of Registration Board. The approval was granted by Chairman Registration Board being authorized for such cases and letter was issued as per following details:

Reg. No.	Brand Name	Packing	Existing Shelf Life	New Approved shelf Life
107932	Comirnaty	6 Doses / Vial	6 months	9 months
			$(-90^{\circ}\text{C to } -60^{\circ}\text{C})$	(-90°C to -60°C)

Submitted for the information of the Board.

Decision: Registration Board acknowledged the above information.

9. Exemption from Urdu Text for already Registered Product Euvichol-Plus (Reg. No. 107916) applied by M/s Amson Vaccine & Pharma (Pvt) Ltd.

M/s Amson Vaccine & Pharma (Pvt) Ltd has applied for the Exemption from Urdu Text for their already Registered Product as per following details:

Reg. No.	Brand Name	Documents submitted by the Firm	Remarks
107916	Euvichol-Plus	1. Fee of Rs. 7500/	
		2. Copy of Registration Letter (dated 15-06-2021).	
		3. Registration Number and MRP will be printed at M/s Amson	
		Vaccines and Pharma (Pvt.) Ltd., 154, Industrial triangle, Kahuta	
		Road, Islamabad, DML# 393.	
		4. Copy of an article published in The News International quoting the	
		advisory issued by the National Institute of health Pakistan for the	
		prevention of Cholera outbreak. The article states that:	
		i. There is report of increase in cases of cholera from	
		February to April in South and Central Sindh.	
		ii. No mortality has been reported so for.	
		iii. No case of Cholera has been reported in Rawalpindi.	
		iv. Studies reveal that nearly 60% of untreated patients die of	
		Cholera.	

Decision: Registration Board acceded to the request of the firm to import Euvichol-Plus (Reg. No. 107916) in Standard Export Packs and to locally print MRP and Registration Number along with Urdu Text and other parameters as per Drugs (Labelling & Packing) Rules, 1978 before sale of drug at M/s Amson Vaccines & Pharma (Pvt.) Ltd., 154, Industrial Triangle, Kahuta Road, Islamabad to comply the requirement as per Drugs (Labelling & Packing) Rules, 1986. This permission shall be valid for one (02) year.

10. Regularization of Renewal of Registration of Eurican DHPPI2-LR (Reg. No. 025310) applied by M/s Saadat International.

M/s Saadat International has applied for Regularization of Renewal of Registration of their already registered biological product as per following details:

#### **Renewal Status**

Reg. No	Brand Name	Initial Reg. Date	Transfer of Registration to M/s Saadat International	Renewal	Last Renewal submission date	Renewal Fee submitted	Remarks
025310	Eurican DHPPI2-LR	03-02-2000	27-03-2010	26-03-2020	i.e. almost 12 months after due date (11 months and 15 days)	Rs. 240,000/- & Rs. 30,000/- i.e. total of Rs. 270,000/-	

Decision: Registration Board regularized the registration of above product w.e.f. 26-03-2020 to 25-03-2025 subject to compliance of Import policy for finished products including submission of valid FSC / CoPP.

11. Regularization of Renewal of Registration of biological product Nexfil 300 mcg Injection (Reg. No. 006183-EX) applied by M/s Nextar pharma.

M/s Nextar pharma has applied for Regularization of Renewal of Registration of their already registered biological product as per following details.

#### Renewal Status

Reg. No	Brand Name	Initial Reg. Date	Renewal granted upto	Last Renewal submission date	Renewal Fee submitted	Remarks
006183-EX	Nexfil 300 mcg Injection	17-03-2017	16-03-2022	30-04-2022 i.e. after due date but within 60 days	Rs. 60,000/-	

Decision: Registration Board regularized the export registration of above product w.e.f. 16-03-2022 to 15-03-2027.

12. Regularization of Renewal of Registration of Marek's Disease Vaccine Serotype 1 (RIS) (Reg. No. 021213) and Marek's Disease Vaccine Serotype 1 & 3 (RIS+Hvt) (Reg. No. 021214) applied by M/s Saadat International.

M/s Saadat International has applied for change of Name of the manufacturing site (Manufacturing site remains the same) and change of Legal entity (Marketing Authorization Holder) for which the firm was advised to change the name of both the products because true name of product was issued to them instead of trade name of product and also regularization of renewal of registration is required for processing the case.

#### **Renewal Status**

Reg. No	Brand	Initial Reg.	Transfer of	Last	Last	Renewal Fee	Remarks
	Name	Date	Registration to	Renewal	Renewal	submitted	
			M/s Saadat	granted	submission		
			International	upto	date		
021213	Marek's	12-05-1998	27-03-2010	26-03-2020	17-04-2020	Rs. 40,000/-	
	Disease						
	Vaccine						
	Serotype 1						
	(RIS)						
021214	Marek's	-do-	-do-	-do-	-do-	-do-	
	Disease						
	Vaccine						
	Serotype 1						

& 3			
(RIS+Hvt)			

Decision: Registration Board regularized the registrations of above products w.e.f. 26-03-2020 to 25-03-2025.

## 13. Change of Brand name of products Marek's Disease Vaccine Serotype 1 (RIS) (Reg. No. 021213) and Marek's Disease Vaccine Serotype 1 & 3 (RIS+Hvt) (Reg. No. 021214) applied by M/s Saadat International.

M/s Saadat International has applied for change of Name of the manufacturing site (Manufacturing site remains the same) and change of Legal entity (Marketing Authorization Holder) for which the firm was advised to change the name of both the products for processing the case because true name of product was issued to them instead of trade name of product and accordingly the firm has applied for change of Brand names as per following details:

S. No.	Reg. No	Existing Brand Name	Demanded Brand Names
1.	021213	Marek's Disease Vaccine Serotype 1 (RIS)	Rispens CVI 988
2.	021214	Marek's Disease Vaccine Serotype 1 & 3 (RIS+Hvt)	Rispens CVI 988 + HVT

The application has been evaluated as per SOP approved in  $283^{\rm rd}$  meetings of Registration Board for Change of brand names of both the products at S.No.1 & 2 and tabulated below:

Requirements as per SOP	Documents submitted by the firm	Remarks
Application with required fee as per relevant SRO (in	Application with required fee of Rs.150,000/- per	
case of similarity / resemblance with drug, fee will not be	product i.e. total of Rs.3,00,000/- is submitted	
required).		
Copy of registration letter and last renewal status.	Copy of Initial registration of both the products	
	at S.No.1 & 2 dated 12-05-1998 is submitted.	
	Copy of Transfer of Registration of both the	
	products at S.No.1 & 2 to M/s Saadat	
	International dated 27-03-2010 is submitted.	
	Copy of last renewal application of both the	
	products at S.No.1 & 2 is submitted dated 17-04-	
	2020 i.e. after due date but within 60 days for	
	which regularization is required (Previous Case).	
	7	
	Copy of Approval of PRV for Change of name of	
	manufacturer from M/s Merial Select Inc. to M/s	
	Merial Inc dated 08 <sup>th</sup> June 2016.	
	Wester the dated of Julie 2010.	
Justification for proposed change	Submitted	
Information regarding previous change of brand name	Submitted that there is no change.	
since registration of drug.		
Details (batch number, date of manufacture, quantity and	Submitted and stock position is zero as per	
stock position) regarding last batch imported	submission	
An undertaking that the proposed names do not resemble	Submitted	
with already registered brands.		
In case of resemblance/similarity with already registered		
drug, the applicant will be liable to change immediately.		
Moreover, no case is pending at any forum / court of law		
regarding this matter.		

Original and legalized Certificate of Pharmaceutical Product as per WHO format for new brand name OR Original and legalized GMP certificate of new brand name with free sale certificate from regulatory body of country of origin	Original and Legalized CLI of both the products at S.No.1 & 2 are submitted confirming the trade names.	
Undertaking that the provided information/ documents are true/ correct	Submitted	

Decision: Keeping in view the approval of USDA (Reference Regulatory Authority); Registration Board approved the change in brand name of above products as per following details:

S. No.	Reg. No	Existing Brand Name	New Brand Names
1.	021213	Marek's Disease Vaccine Serotype 1 (RIS)	Rispens CVI 988
2.	021214	Marek's Disease Vaccine Serotype 1 & 3 (RIS+Hvt)	Rispens CVI 988 + HVT

14. Change of Name of the manufacturing site (Manufacturing site remains the same) and change of Legal entity (Marketing Authorization Holder) of products Rispens CVI 988 (Reg. No. 021213) and Rispens CVI 988+HVT (Reg. No. 021214) applied by M/s Saadat International.

M/s Saadat International has applied for change of Name of the manufacturing site (Manufacturing site remains the same) and change of Legal entity (Marketing Authorization Holder) as per following details:

S. No.	Brand Name &	Existing Name of MAH/	Demanded Name of MAH/ Manufacturer
	Reg. No.	Manufacturer	
1.	Rispens CVI 988	M/s Merial Inc.	MAH:
	(Reg. No. 021213	1168 Airport Parkway,	M/s Boehringer Ingelheim Animal Health USA Inc.,
2.	Rispens CVI 988+HVT (Reg.	SW, Gainesville, GA 30501 USA	2621 North Belt Highway St. Joseph, Missouri 64506 USA.
	No. 021214)		Manufacturer:
			M/s Boehringer Ingelheim Animal Health USA Inc.,
			1168 Airport Parkway, SW, Gainesville, GA 30501 USA

The application has been evaluated as per SOPs approved in 283<sup>rd</sup> and 292<sup>nd</sup> meeting of Registration Board for Change in Name / Title of Manufacturer/Marketing Authorization Holder (MAH) of registered products (Site of Manufacturing Remains the Same) and tabulated below;

Requirements as per SOP	Documents submitted by the firm	Remarks
Application with required fee as per	Application on company letter head	
relevant SRO.	with Fee of 5,000/- each.	
Copy of registration letter and last	Copy of Initial registration of both the products at S.No.1 & 2	
renewal status.	dated 12-05-1998 is submitted.	
	Copy of Transfer of Registration of both the products at S.No.1	
	& 2 to M/s Saadat International dated 27-03-2010 is submitted.	
	Copy of last renewal application of both the products at S.No.1	
	& 2 is submitted dated 17-04-2020 i.e. after due date for which regularization is required (Previous Case).	
	Copy of Approval of PRV for Change of name of	
	manufacturer from M/s Merial Select Inc. to M/s Merial Inc dated 08 <sup>th</sup> June 2016.	
	dated 00 Julie 2010.	
Original and legalized Certificate of	Original and Legalized CLIs of both the products at S.No.1 &	
Pharmaceutical Product as per WHO format for new manufacturer's name	2 are submitted.	
Tormat for new manufacturer's name		

OR Original and legalized GMP certificate of new manufacturing site with free sale certificate from regulatory body of country of origin.	Original and Legalized GMP Certificate No. 19-01069 dated Feb 07, 2019 with same name of the manufacturing site as requested.	
Site master file of new manufacturing site in case of change of manufacturing site/ source.	Not applicable because Manufacturing site remains the same.	
Revised Sole Agency Agreement when there is change in MAH.	Submitted.	
Proof/ evidence of the contract between Product License Holder & manufacturer (with changed/ new name), where the manufacturer and product license holder are different entities.	Not applicable as both are same.	
Undertaking that the provided information/ documents are true/ correct.	Undertaking is submitted that the provided information is true & correct.	

Decision: Keeping in view the approval of USDA (Reference Regulatory Authority); Registration Board approved the change in name of manufacturer and addition of product license holder for above products as per following details:

S. No.	Brand Name &	Existing Name of PLH/	New Name of PLH/ Manufacturer
	Reg. No.	Manufacturer	
1.	Rispens CVI 988	M/s Merial Inc.	MAH:
	(Reg. No. 021213	1168 Airport Parkway,	M/s Boehringer Ingelheim Animal Health USA Inc.,
2.	Rispens CVI 988+HVT (Reg.	SW, Gainesville, GA 30501 USA	2621 North Belt Highway St. Joseph, Missouri 64506 USA.
	No. 021214)		Manufacturer:
	110. 021214)		M/s Boehringer Ingelheim Animal Health USA Inc.,
			1168 Airport Parkway, SW, Gainesville, GA 30501 USA.

### 15. Expansion of age for Booster (3rd dose) from 12 years and older for Emergency Use Authorized product Comirnaty (Reg. No. 107932) applied by M/s Pfizer Pakistan Limited.

M/s. Pfizer Pakistan Limited has applied for Expansion of Age from 12 years and older for Booster (3rd Dose) of Emergency Use Authorized product Comirnaty (Reg. No. 107932) as per following details:

Reg. No.	Brand Name	Packing	Existing Course (12 to 17 years)	Existing Age for Single Booster Dose.	Demanded Age for Single Booster Dose (Expansion of age from 12 years and older).
107932	Comirnaty	6 doses/Vial	2 doses	18 years and above.	A Single Booster dose (3rd dose) in 12 years of age and older where appropriate at least 6 months after the administration of 2-dose primary course.

The firm has submitted the following supporting documents:

- I. Application with required fee of Rs. 10,000/-.
- II. Copy of Initial Emergency Use Authorization letter is submitted (dated 04-06-2021).
- III. EMA Approval of Booster dose (3rd dose) for active immunization for the prevention of COVID-19 caused by SARS-COV-2 in individuals of 12 years of age and older where appropriate at least 6 months after the administration of second dose and the same has been verified online from official website of EMA.

- IV. DRAP Approval letter of Booster (3rd dose) at least 6 months after the completion of the primary series in individuals of 18 years of age and above.
- V. Impacted Sections of CTD

Decision: Registration Board deferred the case for the comments of Committee on evaluation of Clinical trial data of COVID-19 vaccines from Non-reference countries.

#### Item No. IV: Division of Quality Assurance & Laboratory Testing

#### **QUALITY CONTROL CASES**

S No.	Case Title
I.	MANUFACTURE & SALE OF SUB-STANDARD MAPARIX INFUSION, REG.
	NO. 050695, BATCH NO. L-21019 MANUFACTURED BY M/S. S.J.&G. FAZUL
	ELLAHIE (PVT.) LTD., KARACHI.
II.	MANUFACTURE & SALE OF SUB-STANDARD INDOBID CAPSULE, REG.
	NO. 007106, BATCH NO. 386, MANUFACTURED BY M/S ADAMJEE
	PHARMACEUTICALS (PVT) LTD., KARACHI. F.NO.03-26/2021-QC.
III.	MANUFACTURE & SALE OF SUB-STANDARD LEFIN PEDIATRIC
	SUSPENSION, REG. NO. 000404, BATCH NO. 332V, MANUFACTURED BY
	M/S. LEAMA CHEMI PHARMA (PVT) LTD. PESHAWAR.
IV.	MANUFACTURE & SALE OF SUB-STANDARD MELOVETZ INJECTION,
	REG. NO. 102021, BATCH NO. 2199017 MANUFACTURED BY M/S. VETZ
	PHAARMACEUTICALS (PVT.) LTD., KOTRI.
V.	MANUFACTURE & SALE OF SUBSTANDARD KLEVRA ORAL SOLUTION,
	REG. NO. 066831, BATCH NO. 0N152, MFG. DATE DEC. 2020, EXP. DATE
	DEC. 2022, MANUFACTURED BY M/S. PHARMEVO (PVT.) LTD. KARACHI.

Case No. 01: MANUFACTURE & SALE OF SUB-STANDARD MAPARIX INFUSION, REG. NO. 050695, BATCH NO. L-21019 MANUFACTURED BY M/S. S.J.&G. FAZUL ELLAHIE (PVT.) LTD., KARACHI.

The Federal Inspector of Drug Karachi inspected the premises of M/s. National Institute of Child Health (NICH) Rafeeqi Shaheed Road Karachi. on 23-04-2021 wherein the sample of drug along with other drugs were taken for the purpose of test/analysis on prescribed Form-3.

S. No	Name of Drug	Reg; No	Batch No.	Mfg. Date	Exp. Date	Mfg.by	Result of CDL
01	Maparix	050695	L21019	02/2021	11/2022	M/s. S.J&G Fazul	Substan
	Infusion					Ellahi (Pvt) Ltd,	dard
	(Vancomy					Plot No. E-46,	
	cin HCL)					S.I.T.E. Karachi.	

The sealed sample of above drug was sent to Federal Government Analyst, Central Drugs Laboratory, Karachi by FID for the purpose of test/analysis vide memorandum No. NO. DHB-06/2021 to 13/2021-FID-III (K) dated 26<sup>th</sup>, April, 2021.

Portion of Sealed sample was sent to Chairman, Registration Board, DRAP Islamabad by FID vide office letter of even number dated 26<sup>th</sup>, April, 2021.

A portion of sealed sample was sent to M/s. S.J&G Fazul Ellahi (Pvt) Ltd, Plot No. E-46, S.I.T.E. Karachi by FID vide office letter of even number dated 26<sup>th</sup> April 2021.

Pharmacist, National Institute of Child Health, (NICH) Rafeeqi Shaheed Road Karachi vide office letters of even number dated 26<sup>th</sup> April 2021 was asked by FID to provide bill warranty in connection with the purchase of above said drug.

Pharmacist, National Institute of Child Health, (NICH) Rafeeqi Shaheed Road Karachi vide their letter No.nil dated 07<sup>th</sup> June 2021 Provided the warranty of M/s. Parras Enterprises Flat No. 08, P.I.A. Shower Land, Block 01, Gulshan-e-Jauhar Karachi.\_in connection with the purchase of above said drug.

FID vide office letter of even number dated 07<sup>th</sup> June 2021, was asked M/s. Parras Enterprises Flat No. 08, P.I.A. Shower Land, Block 01, Gulshan-e-Jauhar Karachi. to verify the same and provide subsequent bill warranty in connection with purchase of above said drug.

M/s. S.J&G Fazul Ellahi (Pvt) Ltd, Plot No. E-46, S.I.T.E. Karachi. vide their letter SJG/REG/0839/2021 dated 02<sup>nd</sup>, June 2021, confirm the receipt of portion sealed samples of drugs under section 19(3) of drug Act 1976.

The Federal Government Analyst, Central Drugs Laboratory, Karachi declared the above said sample as Sub-Standard" quality vide their test report No.KQ.106/2021 dated 10<sup>th</sup>, June 2021.

Results of CDL on the basis of which sample under reference has been declared as Substandard quality are reproduced as under:-

S.No.	Test	Acceptance Criteria	Result	Reference
1.	Description	Off white powder in clear glass vial.	Complies.	Mfg. Specs.
2.	Identification	The identification test must identify Vancomycin HCl.	Complies.	USP 43
3.	pН	2.5 to 4.5	2.64-Complies.	USP 43
4.	Bacterial Sterility	Must be sterile.	Complies.	USP 43
5.	Bacterial Endotoxin	NMT 0.33 USP Endotoxin unit/mg of Vancomycin	<b>Does not comply</b>	USP 43
6.	Assay	90.0 to 115.0%	103.7% Complies.	USP 43

Vancomycin		
(Label claim 500mg/vial)		
<i>y</i> , , ,		

Remarks: The sample is of "Sub-Standard" quality under the Drugs Act, 1976.

FID issued an explanation letter of even number dated; 11<sup>th</sup> June 2021 to M/s. S.J&G Fazul Ella1hi (Pvt) Ltd, Plot No. E-46, S.I.T.E. Karachi for explaining their position in the matter of manufacturing/selling of above-mentioned Sub-Standard drug.

M/s. S.J&G Fazul Ellahi (Pvt) Ltd, Plot No. E-46, S.I.T.E. Karachi. vide their letter No. SJG/REG/0858/2021 dated 29<sup>th</sup> June 2021 requesting for retesting of Drug Maparix Infusion Batch No. L21019 from National Institute of Health (NIH) Islamabad.

FID stated that in the light of above, submission portion of sample lying with the Board may be got retested from Appellate Laboratory National Institute of Health (N.I.H) Islamabad.

In light of Supreme Court judgement of "C.P.1692-L/2020, C.P.1792-L/2020 and C.P.5-L/2021" and firm's request for appellate testing, the case is submitted for consideration of Board.

#### Proceedings and Decision of 312th Meeting of Registration Board.

The case has been deferred till the finalization of Appellate Testing Guidance Document/Protocol.

The agenda of "Handling requests of Appellate Testing- Guidance document for registration Board" was discussed in 313<sup>th</sup> meeting of Registration Board. The Board after thorough deliberations and considering the facts of the case decided as:

- i. The firm will provide OOS investigation and complete testing record of the concerned batch along with scientific justifications/grounds with the request of Appellate testing under section 22(4) of the Drugs Act 1976.
- ii. Federal Government Analyst, Karachi will provide OOS investigation and complete testing record of such reports.
- iii. Registration Board advised QA&LT Division to present all cases of Appellate Testing with these both set of documents along with technical report of the case.

OOS investigation was asked by firm and CDL vide office letter dated 23-12-2021.

The firm submitted the response dated 29-12-2021. They provided the SOPs and records but did not provide OOS investigation claiming they did not find any OOS.

CDL submitted the response dated 15-03-2021 wherein they mentioned: OOS is validated.

#### **Technical Evaluation of the case:**

- > The product was declared sub-standard on the basis of results of Bacterial endotoxin.
- Endotoxin test performed by Gel Clot method both by firm and CDL as given in USP 43.
- ➤ The method is based on visual inspection of the sample after incubation for presence of gel or otherwise.

#### Proceedings and Decision of 317th Meeting of Registration Board.

Out Of Specification (OOS) investigations and testing records submitted by M/s. S.J&G Fazul Ellahi (Pvt) Ltd, Karachi and CDL, DRAP Karachi was presented before Registration Board. After thorough deliberations and considering the facts of the case, the Board decided and allowed to perform appellate test/analysis of sample (Maparix Infusion Batch no. L21019) to the extent of only that particular test (Endotoxin test) on basis of which the product was declared sub-standard by CDL, Karachi"

Case No. 02: MANUFACTURE & SALE OF SUB-STANDARD INDOBID CAPSULE, REG. NO. 007106, BATCH NO. 386, MANUFACTURED BY M/S ADAMJEE PHARMACEUTICALS (PVT) LTD., KARACHI. F.NO.03-26/2021-QC.

FID Karachi vide letter No. F.ARS-107-109/2021-FID-II (K) dated 02<sup>nd</sup> August 2021 wherein the FID Karachi has informed that the sample was received in CDL, Karachi wherein, the Federal Government Analyst has declared following samples of Indobid Capsule as of "Substandard quality".

Name of	f	Manufactured by	Reg.	Batch	Mfg.	Exp.	Report No. &
Product			no.	no.	Date	Date	Date
Indobid		M/s Adamjee	007106	386	01-	01-	No.KQ.129/2021
Capsule		Pharmaceuticals			2021	2025	dated 06 <sup>th</sup> July
		(Pvt) Ltd., Karachi					2021

Results of CDL on the basis of which sample under reference has been declared as Sub-Standard quality are reproduced as under:-

S.No.	Test	Specification	Result	Reference
1	Description	Hard gelatin capsules consist of white body and blue coloured cap, containing off white powder.	Complies	Mfg. Specs.
2	Identification	The identification test must identify Indomethacin.	Complies	BP 2020
3	Dissolution	Each unit is not less than 70%	<b>Does not Comply.</b>	BP 2020
4	Assay Indomethacin (Lebel claim 25mg/ capsule)	90.0% to 110.0%	103.2%-Complies	BP 2020

Remarks: The sample is "Sub-Standard" quality under the Drugs Act, 1976.

The FID Karachi has further informed that the firm has sent the explanation letter to explain their position dated 13<sup>th</sup> July 2021 regarding the violation of Drug Act 1976 and DRAP Act 2012.

The firm has submitted their reply dated 30<sup>th</sup> July 2021, wherein they requesting for retesting of Drug Indobid Capsules B.No.386 from NIH Islamabad.

In light of Supreme Court judgement of "C.P.1692-L/2020, C.P.1792-L/2020 and C.P.5-L/2021" and firm's request for appellate testing, the case is submitted for consideration of Board.

#### Proceedings and Decision of 312th Meeting of Registration Board.

The case has been deferred till the finalization of Appellate Testing Guidance Document/Protocol.

The agenda of "Handling requests of Appellate Testing- Guidance document for registration Board" was discussed in 313<sup>th</sup> meeting of Registration Board. The Board after thorough deliberations and considering the facts of the case decided as:

- i. The firm will provide OOS investigation and complete testing record of the concerned batch along with scientific justifications/grounds with the request of Appellate testing under section 22(4) of the Drugs Act 1976.
- ii. Federal Government Analyst, Karachi will provide OOS investigation and complete testing record of such reports.
- iii. Registration Board advised QA&LT Division to present all cases of Appellate Testing with these both set of documents along with technical report of the case.

OOS investigation was asked by firm and CDL vide office letter dated 23-12-2021.

The firm submitted the response dated 16-02-2022. They provided the results of initial test, Keeping sample and warrantor portion and request for appellate testing. However, OOS investigation was not provided.

CDL submitted the response dated 15-03-2021 wherein they mentioned: OOS is validated.

#### **Technical Evaluation of the case:**

- i. The product was declared substandard on dissolution.
- ii. CDL performed the test as per BP 2020 while firm performed on manufacturer specs.
- iii. Audit trail was not provided by firm.
- iv. Data is not time stamped hence data integrity cannot be verified.

#### **Proceedings of 317th Meeting of Registration Board:**

Out of Specification (OOS) investigations and testing records submitted by M/s. Adamjee Pharmaceuticals (Pvt) Ltd., Karachi and CDL, DRAP Karachi was presented before Registration Board. The Board deliberated the case in detail as follows:

- i. M/s. Adamjee Pharmaceuticals (Pvt) Ltd., Karachi requested for Appellate testing. In compliance to the decision of 313<sup>th</sup> meeting of Registration Board firm and CDL were asked to submit Out of specification (OOS) investigation vide office letter dated 23-12-2021. The firm submitted the response dated 16-02-2022. They provided the results of initial test, Keeping sample and warrantor portion and request for appellate testing. However, OOS investigation was not provided. While CDL submitted the response dated 15-03-2022 wherein they mentioned that OOS is validated.
- ii. Review of documents revealed that the product "Indobid Capsule" (Reg# 007106) was registered vide letter No.F.3-4/83-Reg(M-51) dated 16-01-1984 and no specification was mentioned in registration letter. Later on the subject product was included in BP specifications

while the firm is still manufacturing and testing the product per manufacturer specifications. Further in 197<sup>th</sup> meeting of Registration Board held on 3-4<sup>th</sup> May 2006, the Board decided as:

"All the firms shall adopt the specifications mentioned in the official pharmacopoeias for all the formulation except those drugs not included in the official pharmacopoeias. For these drugs manufacturers may adopt their own specifications till the inclusion of that formulation in the official pharmacopoeias. after this decision firms will not be allowed to adopt their own specifications for the drugs, which are included in any of the official pharmacopoeias, listed in the Section 3 of Drugs Act, 1976."

**Decision:** 

Keeping in view position narrated above, the Board concluded that the firm is still manufacturing/testing the said product as per manufacturer specifications despite of the fact that it is included in the official pharmacopoeia (BP). Therefore, Board did not accede the firm's request of appellate testing. Thus, the Board decided to issue show cause notice for suspension/cancellation/ prosecution in Drug Court of the subject cited drug to M/s. Adamjee Pharmaceuticals (Pvt) Ltd., Karachi and called them for personal hearing before Registration Board.

# Case No. 03: MANUFACTURE & SALE OF SUB-STANDARD LEFIN PEDIATRIC SUSPENSION, REG. NO. 000404, BATCH NO. 332V, MANUFACTURED BY M/S. LEAMA CHEMI PHARMA (PVT) LTD. PESHAWAR.

The Federal Inspector of Drug Peshawar inspected the premises of M/s. Leama Chemi Pharma (Pvt) Ltd. Peshawar on 12-08-2021 wherein the sample of drug along with other drugs were taken for the purpose of test/analysis on prescribed Form-3.

Name o	of	Manufactured by	Reg.	Batch	Mfg.	Exp.	CDL Results
Product			no.	no.	Date	Date	
Lefin		M/s. Leama Chemi	000404	332V	06/21	05/23	Sub-Standard
Pediatric		Pharma (Pvt) Ltd.					on the basis of
Suspension		Peshawar.					Assay.

02. Results of CDL on the basis of which samples under reference has been declared as Substandard quality are reproduced as under:-

S.No.	Test	Acceptance Criteria	Result	Reference
1.	Description	Pink coloured suspension in ambered glass bottles.	Complies.	Mfg. Specs.
2.	Identification	The identification test must identify Paracetamol.	Complies.	BP 2020
4.	Assay Paracetamol.	95.0% to 105.0%	70.45%- Does not comply.	BP 2020

(Label Claim		
120mg/5ml)		

Remarks: The sample is of "Sub-Standard" quality under the Drugs Act, 1976.

FID has sent the explanation letter to explain their position dated 26-10-2021 regarding the violation of Drug Act 1976 and DRAP Act 2012.

The firm has submitted their reply dated 29-11-2021, wherein they requesting for retesting of product Lefin Pediatric Suspension Batch no. 332V.

The agenda of "Handling requests of Appellate Testing- Guidance document for registration Board" was discussed in 313<sup>th</sup> meeting of Registration Board. The Board after thorough deliberations and considering the facts of the case decided as:

- i. The firm will provide OOS investigation and complete testing record of the concerned batch along with scientific justifications/grounds with the request of Appellate testing under section 22(4) of the Drugs Act 1976.
- ii. Federal Government Analyst, Karachi will provide OOS investigation and complete testing record of such reports.
- iii. Registration Board advised QA&LT Division to present all cases of Appellate Testing with these both set of documents along with technical report of the case.

The firm's response received dated 14-02-2022. Firm has submitted testing method on UV and it seems that assay method on HPLC was added afterwards as document show doesnot show serial No. on HPLC method.

CDL submitted the response dated 15-03-2021 wherein they mentioned: OOS is validated.

#### **Technical Evaluation of the case:**

- i. The product was declared substandard by CDL on the basis of assay.
- ii. CDL performed the test as per BP 2020.
- iii. Testing method of firm was not a control document.
- iv. HPLC was not standard method, they mentioned UV for assay in testing method.
- v. Firm performed assay on HPLC dated 10-12-2021 while the parameters i.e mobile phase, standard preparation, sample preparation, wavelength, flow rate were not as per BP 2020.

Parameters	<b>BP Parameters</b>	CDL parameters	Firm's Parameters
Flow rate	1.5ml/min	1.5ml/min	1ml/min
Column temperature	35	35	-
Detection wavelength	245nm	245nm	256nm
Inject volume	50ul	50ul	10ul

- vi. Audit trail was not provided by firm.
- vii. Data is not time stamped hence data integrity cannot be verified.

#### **Proceedings of 317<sup>th</sup> Meeting of Registration Board.**

Out of Specification (OOS) investigations and testing records submitted by M/s. Leama Chemi Pharma (Pvt) Ltd. Peshawar and CDL, DRAP Karachi was presented before Registration Board. The Board deliberated the case in detail as follows:

- i. Registration Board considered the case of M/s. Leama Chemi Pharma (Pvt) Ltd. Peshawar requested for Appellate testing. In compliance to the decision of 313<sup>th</sup> meeting of Registration Board, the firm and CDL were asked to submit Out of specification (OOS) investigation vide office letter dated 23-12-2021. The firm submitted the response dated 14-02-2022. Firm has submitted testing method on UV and it seems that assay method on HPLC was added afterwards as document does not show serial No. on HPLC method. While CDL submitted the response dated 15-03-2022 wherein they mentioned: OOS is validated.
- ii. Review of documents revealed that the product "Lefin Pedriatic Suspension" (Reg# 015203) was registered vide letter No.F.3-3/97-Reg.II(M-125) dated27th June 1997 and no specification was mentioned in registration letter. Later on the subject product was included in BP specifications while the firm is still manufacturing and testing the product per manufacturer specifications. Further in 197<sup>th</sup> meeting of Registration Board held on 3-4<sup>th</sup> May 2006, the Board decided as:

"All the firms shall adopt the specifications mentioned in the official pharmacopoeias for all the formulation except those drugs not included in the official pharmacopoeias. For these drugs manufacturers may adopt their own specifications till the inclusion of that formulation in the official pharmacopoeias. after this decision firms will not be allowed to adopt their own specifications for the drugs, which are included in any of the official pharmacopoeias, listed in the Section 3 of Drugs Act, 1976."

**Decision:** 

Keeping in view position narrated above the Board concluded that the firm is still manufacturing/testing the said product as per manufacturer specifications despite of the fact that it is included in the official pharmacopoeia (BP). Therefore, Board did not accede the firm's request of appellate testing. Thus, the Board decided to issue show cause notice for suspension/cancellation/ prosecution in Drug Court of the subject cited drug to M/s. Leama Chemi Pharma (Pvt) Ltd. Peshawar.and called them for personal hearing before Registration Board.

## CASE NO. 04: MANUFACTURE & SALE OF SUB-STANDARD MELOVETZ INJECTION, REG. NO. 102021, BATCH NO. 2199017 MANUFACTURED BY M/S. VETZ PHAARMACEUTICALS (PVT.) LTD., KOTRI,

FID-IV, DRAP, Karachi inspected the premises of M/s. Vetz Pharmaceuticals (Pvt.) Ltd., Q-1, S.I.T.E., Kotri, Sindh on 31-05-2021; wherein following sample of drug along with other drugs were taken for the purpose of test/analysis on prescribed Form-3:

S.	Name of	Reg;	Batch	Mfg.	Exp.	Mfg.by	CDL Results
No.	Drug	No	No.	Date	Date		
01	Melovetz	102021	2199017	05-	04-	M/s. Vetz	Sub-Standard
	10			2021	2023	Pharmaceuticals (Pvt.)	on the basis of
	Injection					Ltd., Q-1, S.I.T.E.,	
						Kotri, Sindh	pH.

The sealed sample of above drug was sent to Federal Government Analyst, Central Drugs Laboratory, Karachi for the purpose of test/analysis vide memorandum No.SHM-NTF-35-37/2021-FID (K-IV) dated 03-06-2021

Portion of Sealed sample was sent to Chairman, Registration Board, DRAP Islamabad vide this office letter of even number dated 04-06-2021.

The Federal Government Analyst, Central Drugs Laboratory, Karachi declared the above said sample as "Sub-Standard" quality under the Drugs Act 1976 vide their test report No.KQ.161/2021 dated 27-07-2021.

Results of CDL on the basis of which sample under reference has been declared as Sub-Standard quality are reproduced as under:-

S.No.	Test	Specification	Result	Reference
1	Description	Yellow colored		BP Vet.
	_	oily solution in	Complies	2020
		ambered glass vial.		
2	Identification	The identification		BP Vet.
		test must identify	Complies	2020
		Meloxicam.		
3	pН	7.5 to 9.1	<u>13.45%</u>	BP Vet.
			"Does not Comply.	2020
	Assay			BP Vet.
4	Meloxicam	95.0% to 105.0%	99.8%-Complies	2020
	(Lebel claim 10mg/ml)	75.070 to 105.070	77.070 Complies	

Remarks: The sample is "Sub-Standard" quality under the Drugs Act, 1976.

FID sent an explanation letter of even number dated 03<sup>rd</sup> August 2021 to M/s. Vetz Pharmaceuticals (Pvt) Ltd., Q-1, S.I.T.E, Kotri, Sindh for explain their position in the matter of manufacturing/selling of above-mentioned Sub-Standard drug. M/s Vetz Pharmaceuticals (Pvt) Ltd.; Q-1, S.I.T.E, Kotri, Sindh vide their letter No.Ref-DV- 002dated 16<sup>th</sup> August 2021 explain their position.

FID submitted that in the light of Federal Government Analyst, CDL, Karachi test report No.KQ.161/2021 dated 27<sup>th</sup> July 2021 M/s Vetz Pharmaceuticals (Pvt) Ltd:, Q-1, S.I.T.E, Kotri, Sindh involved in manufacturing & selling of Substandard drug Melovetz 10 Injection batch No.2199017 and violated the section 23(1)(a)(v) of the Drugs Act 1976 and rules framed thereunder. FID recommended action under section 42 of the Drugs Act 1976; reproduced as:

"Where any person has been found to have contravened any of the provisions of this Act, or the rules in respect of any registered drug, the registration Board may, after giving such person an opportunity of being heard, cancel the registration of such drug or suspend such registration for a specified period"

The firm submitted recall log which was sent to area FID for verification and reconcillation of stock. FID submitted the response dated 02-12-2021 where in he verified the stock i.e. 16 cartons each containing 120 injections corresponded to 1920 total quantity as mentioned in reconciliation form by firm.

FID submitted the names of responsible persons dated 20-01-2022 along with the <u>reply of firm</u> dated 10-08-2021 where in firm has mentioned that their product has in-house specifications while CDL test on pharmacopeial specification. The firm submitted to check their product by the method provided by manufacturer.

In view of firm's request of appellate testing and notification issued by Registration Division on subject "Compliance with Pharmacopial Specification" dated 07-02-2022, the case is submitted for consideration of Board.

#### Proceedings and Decision of 317th Meeting of Registration Board.

Registration Board deferred the case and directed to present with the registration status of the product i.e. Melovetz 10 Injection (Registration No. 102021) including approved specification of finished product for consideration of firm's request in next meeting.

CASE NO. 05: MANUFACTURE & SALE OF SUBSTANDARD KLEVRA ORAL SOLUTION, REG. NO. 066831, BATCH NO. 0N152, MFG. DATE DEC. 2020, EXP. DATE DEC. 2022, MANUFACTURED BY M/S. PHARMEVO (PVT.) LTD. KARACHI.

Test/analysis report No.KQ.57/2021 dated 20<sup>th</sup> March, 2021, from the Federal Government Analyst, CDL, Karachi received on 29-04-2021. Wherein, the Federal Government Analyst has declared sample of Klevra Oral Solution as of "**Sub-standard quality**". Details are:

S.	Name of Drug	Reg;	Batch	Mfg.	Exp.	Mfg.by	<b>CDL Results</b>
No.		No	No.	Date	Date		
01	Klevra Oral	066831	0N152	Dec.			Sub-Standard on
	Solution			2020	2022	(Pvt.) Ltd. Karachi	the basis of pH.
	(Levetiracetam)						the subis of pri.

Results of CDL on the basis of which sample under reference has been declared as Substandard quality are reproduced as under:-

S.No.	Test	Specification	Result	Reference
1.	Description	Clear, and transparent solution having cherry flavor.	Complies.	Mfg. Specs.
2.	Identification	The identification test must identify Levetiracetam.	Complies	USP 43
3.	рН	4.8 to 6.3	4.52  Does not Comply.	USP 43
4.	Assay Levetiracetam. (Lebel claim 500mg/5ml)	90.0% to 110.0%	98.4%- Complies.	USP 43

**Note:-** The product is included in USP 32 now; therefore, PharmEvo Specs. Should be removed as printed on the label.

**Remarks**: The sample is "Sub-Standard" under the Drugs Act, 1976.

FID has been asked to submit complete case vide office letter of even number dated 04-05-2021. The recall alert to manufacturer issued dated 04-05-2021.

M/s. PharmEvo (Private) Limited, Karachi submitted that the product is registered with Manufacturer Specification (MS) while CDL declared the product as of substandard quality on USP specification. They further said that as DRAP has under circular no. F.3-5/2020-I&VII (M-297) dated 27-01-2021; the board allowed 6-month time for implementation of the decision. They also requested to withdrawn the Drug recall from website of DRAP.

Registration division confirmed that product is registered on MS and renewed on 06-08-2020. Firm has not applied for change of specification of subject drug till date. Further, Firm has been manufacturing product under consideration with manufacturer's specification despite of inclusion of said formulation in USP which is against the decision of Registration Board and Central Licensing Board communicated vide letter no. F.3-2/2006-Reg-II-South (M-197) dated 05-06-2006 where in it was decided that firms may adopt their own specifications for the drugs which are not included in the official Pharmacopeias, till the inclusion of these formulations in the official pharmacopeias listed in Section-3 of Drug Act 1976.

Furthermore, letter No.F.3-5/2020-I&VII(M-297) dated 27-01-2021 is issued in the context of labeling of specification due to which DTLs/QCLs declaring the products as "Misbranded" after deliberations/ discussion regarding the matter and does not apply if product is declared as Sub-Standard on being tested on official Pharmacopeia.

A letter has been issued to firm w.r.t. above decisions dated 02-08-2022.

M/s. PharmEvo Private Limited, Karachi submitted their reply in response to office letter dated 02-08-2021 wherein firm has mentioned that:

"The instructions of MOH/DRAP with regards to pharmacopoeial specifications stand suspended and have been held in abeyance by DRAP till January 26, 2022 vide notification circular No. F.3-5/2020-I&VII (M-297) dated 26-07-2021."

They further requested to withdraw the Medical product alert from DRAP website.

FID, DRAP, Karachi submitted the case details and recommended that:

"As per Federal Government Analyst, CDL Karachi test report No KQ-57/2021
dated 20-04-2021, M/s. PharmEvo Private Limited, Karachi violated the Section 23(1)(a)(v) of the Drugs Act 1976 and rules framed there under."

The case has been submitted for consideration in light of above-mentioned decision of Registration Board.

#### Proceedings and Decision of 317th Meeting of Registration Board.

Registration Board deferred the case and directed to present with the registration status of the product i.e. Klevra Oral Solution (Registration No. 066831) including approved specification of finished product for consideration of firm's request in next meeting."

#### **Division of Quality Assurance & Laboratory Testing**

## Case No. 01: INFORMATION ON LABELLING ERROR ON ZENTAL SUSPENSION (REG. NO. 006730) MFG. BY M/S. GLAXO SMITH KLINE PAKISTAN LIMITED, KARACHI.

M/s. GSK Pakistan Limited, Karachi vide letter dated 23-09-2020 informed regarding printing error on Packaging of their registered product "Zental Suspension". The company informed that the said product is manufactured as per GSK's own specification since it is not included in any international Pharmacopoeia and inadvertently, in recent manufactured batches of Zental Suspension, "USP Specifications" was printed on the packaging. The company further added that their Medical and QA assessment did not reveal any impact on patient safety or product quality since product assay is well within the acceptable range of 90- 110%

Moreover, the firm also provided the quantity of stocks of product zental suspension present at the distributors and at the premises of M/s. GSK Karachi. Details are as follows:

Stocks present at distributor premises:

Product	Batch Number	Quantity	Expiry Date
ZENTEL	VH8Y	7,099	Aug-23
ZENTEL	2B6X	95,987	Aug-23
ZENTEL	3A2F	114,660	Sep-23
ZENTEL	3A2L	114,800	Sep-23
ZENTEL	4A7N	115,080	Sep-23
ZENTEL	4C2T	114,520	Sep-23
ZENTEL	576M	45,104	Sep-23
ZENTEL	5K2B	420	Nov-22
ZENTEL	CM4R	999	Jun-23
ZENTEL	DJ4U	1,393	Jun-23
ZENTEL	G39M	664	Jun-23
ZENTEL	HG5R	2,148	Jun-23
ZENTEL	HZDBQ	20	Nov-21
ZENTEL	K38N	35,840	Jun-23
ZENTEL	MN3J	6,989	Jul-23
ZENTEL	NL8H	33,288	Jul-23
ZENTEL	P33E	20,864	Jul-23
ZENTEL	RG8G	42,509	Jul-23
ZENTEL	T58R	34,456	Jul-23
ZENTEL	TJ4k	17,555	Jul-23
ZENTEL	UE5J	34,204	Aug-23
ZENTEL	UE5K	41,524	Aug-23
ZENTEL	UX4D	93,291	Aug-23
ZENTEL	UX4E	106,413	Aug-23
ZENTEL	VH8Y	64,392	Aug-23
ZENTEL	VP8A	108,736	Aug-23
ZENTEL	W33U	124,145	Aug-23
ZENTEL	WR7L	75,881	Aug-23
ZENTEL	X47X	112,646	

ZEITTEE	Total Quantity	1,567,277	
ZENTEL	Y38V	1,650	Nov-22

Stocks present at GSK's warehouse/DCs:

DC	Batch Number	Quantity	Expiry Date	
KARACHI	5D4E	102	9/12/2022	
KARACHI	X47X	2000	18/08/2023	
KARACHI	4L2R	114300	7/9/2023	
KARACHI	576M	13300	9/9/2023	
LAHORE(GP)	IZDBS	848	13/05/2022	
LAHORE(GP)	L26A	1015	1/7/2023	
ISLAMABAD	HG5R	12000	19/06/2023	
		<b>Total Quantity:</b>		

Keeping in view of above, a nationwide recall alert was issued by QC Section vide letter F. No. 13-45/2020-QC dated 15-10-2020 along with letter instructing M/s. GSK to complete the product recall and submit a report to QC section.

M/s. GSK vide letter dated 02-02-2021 provided details of the recalled stocks, details of which are as under:

Area FID vide letter F. No. 13-45/2020-QC dated 01-03-2021 was instructed to inspect the premises of M/s. GSK Karachi for verification of data provided by the firm. FID-III Karachi vide letter No. F. 1-1/2021-FID (III) dated 24-03-2021 provided the detailed report of the recalled stocks after reconciliation from BMR and distribution record of the recalled batches as under:

Zentel Suspension 4% W/V 1X10ML Total = 33 Batches Recall – Reconciliation data

Sr.No	<b>Batches Need</b>	Total Stock	<b>Total Stock</b>	<b>Total Stock Quantity</b>	
	to Recall	Quantity	<b>Quantity Recalled</b>	Consumed	
		(Production)			
1	VH8Y	114,800	97,536	17,264	
2	2B6X	114,800	114,800	0	
3	3A2F	115,080	114,460	620	
4	3A2L	114,800	114,800	0	
5	4A7N	115,080	115,080	0	
6	4C2T	114,520	114,520	0	
7	576M	114,800	101,500	13,300	
8	CM4R	114,800	1,098	113,702	
9	DJ4U	114,800	0	114,800	
10	G39M	114,800	840	113,960	
11	HG5R	114,800	14,192	100,608	
12	K38N	114,800	35,928	78,872	
13	MN3J	114,800	10,322	104,478	
14	NL8H	114,800	29,368	85,432	
15	P33E	114,800	18,520	96,280	
16	RG8G	114,800	43,050	71,750	
17	T58R	114,800	36,927	77,873	
18	TJ4K	114,520	17,388	97,132	
19	UE5J	114,240	37,491	76,749	
20	UE5K	114,964	39,306	75,658	
21	UX4D	114,240	97,000	17,240	
22	UX4E	114,800	106,816	7,984	

23	VP8A	114,800	111,426		3,374
24	W33U	114,800	105,012		9,788
25	WR7L	114,800	114,510		290
26	X47X	115,360	114,270		1,090
27	5D4E	114,800	0		114,800
28	4L2R	114,800	114300		500
29	L26A	114,800	1,015		113,785
		3,328,804	1,821,475		1,507,329
30	5K2B	114,800	4	20	Said batches were
31	HZDBQ	114,057		20	manufacture before the
32	Y38V	114,800	1,6	50	execution of USP
33	IZDBS	114,800	8	48	monograph change that is
					why this qty of 2938
					packs already as per
					previous artwork
	ADDITION	AL BATCHES INC	LUDED IN RECAI	LS	STRATEGY
34	LV9U	114,636	0		114636
35	F43C	114,800	0		114636
36	FX9X	114,800	560		114,240
37	VS7F	113,857	0		113857
		458093	560		457369

M/s. GSK Karachi informed that their Medical and QA assessment did not reveal any impact on patient safety or product quality since product assay is well within the acceptable range of 90-110% therefore, M/s. GSK Karachi vide letter dated 29-03-2021 requested to grant the redressing permission of recalled stocks of Zentel Suspension at their licensed premises at F268, SITE Karachi (DML No. 000233).

#### Proceedings and decision of 307<sup>th</sup> meeting of Registration Board:

The Board after considering the facts of the case and after thorough discussion decided to call the firm's representatives for a personal hearing before the Board.

In compliance to the decision of the 307<sup>th</sup> meeting of the Board, the representatives of the firm are called for personal hearing.

#### **Proceedings of 312th meeting:**

Registration Board was apprised that product specifications of "Zental" were revised from Manufacturer specifications to 'USP specifications' according to new Monograph, without considering that the USP new monograph of "Albendazole suspension" is for veterinary Product. Revised specifications were printed on the label, and same testing specifications were submitted to DTL, Faisalabad, Punjab. DTL declared the product Sub-standard (on the basis of pH test) and Misbranded (because of wrong product specifications on label). After this Firm initiated recall of the defected stocks from market

Dr. Gohar Nayab, Regulatory Director of M/s. GSK Pakistan Limited, Karachi along with Mr. Khurram Ahmad, Quality Director and Mr. Kashif Ayub, Production lead appeared before the Board and stated their already submitted stance and requested the Board to allow them to redress by changing the label for specifications "USP Specifications" for the 14 batches recalled batches of their registered product namely Zental Suspension.

The Board deliberated the case in detail and expressed serious concern over such Quality Assurance failure during the revision of the product testing specifications of Zental Suspension without

considering that the new monograph is Albendazole suspension for veterinary use. This incident/casual behavior raises question on QA protocols assuring quality of drug product and could lead to more serious quality defect in drug products.

FID DRAP Karachi inspected GSK on 24.03.2021 and verified the quantities recalled by the firm.

#### Decision of 312<sup>th</sup> meeting of the Registration Board:

The Board after thorough deliberations and considering the facts of the case decided as under:

- i. Suspension of the Registration of the said product for six (06) months or till decision of Registration Board on inspection report of the firm (whichever is later) for verification of root cause analysis causing quality assurance failure, Corrective and Preventive Action (CAPA) by the firm, by the following panel,
  - 1. Dr.Rafique Alam Khan, Member Registration Board
  - 2. Area FID
  - 3. Mr.Krishan AD DRAP Karachi
- ii. Firm is allowed to redress the requested (14) batches by printing relevant specifications and comply Drugs (Labelling & Packing) Rules, 1986 and release of these batches by Quality Assurance Department as per their approved specifications and approved protocols for this work. For quality testing of these batches, Area FID Karachi will take sample from these batches for testing by CDL Karachi on the expense of the manufacturer. Firm will be allowed to to market the stated batches after CDL reports. Details of which are as under:

Sr.No.	Batches Need to		Expiry date	Total Stock	Total Stock Quantity
	Recall	date	• •	Quantity	Recalled
				(Production)	
1	VH8Y	Aug-20	Aug-23	114,800	97,536
2	2B6X	Aug-20	Aug-23	114,800	114,800
3	3A2F	Sep-20	Sep-23	115,080	114,460
4	3A2L	Sep-20	Sep-23	114,800	114,800
5	4A7N	Sep-20	Sep-23	115,080	115,080
6	4C2T	Sep-20	Sep-23	114,520	114,520
7	576M	Sep-20	Sep-23	114,800	101,500
8	UX4D	Aug-20	Aug-23	114,240	97,000
9	UX4E	Aug-20	Aug-23	114,800	106,816
10	VP8A	Aug-20	Aug-23	114,800	111,426
11	W33U	Aug-20	Aug-23	114,800	105,012
12	WR7L	Aug-20	Aug-23	114,800	114,510
13	X47X	Aug-20	Aug-23	115,360	114,270
14	4L2R	Sep-20	Sep-23	114,800	114300

**iii.** The remaining recalled batches for which the firm has not requested for redressing, will be destroyed/disposed off by the firm in the presence of a panel nominated by the Additional Director, DRAP, Karachi.

In compliance to the decision of 312<sup>th</sup> meeting of the Registration Board, Registration of product namely "Zental Suspension" was suspended for (06) months which was communicated to firm on 28-10-2021. Whereas letter to Panel for verification of CAPA was also communicated on 28-10-2021 and letter for destruction of expired stocks was sent to Additional Director DRAP Karachi on 28-10-2021 with subsequent reminders on 06-04-2022 and 26-04-2022.

Panel nominated by the Board inspected the premises of M/s. GSK Pakistan Limited, F-268 SITE Area Karachi on 11-11-2021. Contents of report are given as under:

#### **BRIEF HISTORY OF FAILURE:**

A sample of Zentel suspension Batch No VS7F was declared of Sub-standard and Misbranded quality by DTL Rawalpindi due to their wrong product specification claim. The firm admitted that the Albendazole liquid docs not fall under USP specifications for human use, thus they initiated recall level-II for defective batches of the drug from the market under intimation to DRAP. The firm had recalled & stopped selling the drug and around 33 batches were partially recovered from market and for 14 batches firm is seeking approval for redressing. The firm submitted the recalled records to DRAP Islamabad for redressing. The records provided by the firm at the time of inspection further yielded that around 90 batches were manufactured with wrong specifications and those were consumed into the market until they had come to know the failure only a few %-age was recovered along with some batches in hand that were under release. The firm had started the re-manufacturing of Liquid Zentel with current corrected GSK specifications and the same change was communicated to DRAP Islamabad for necessary approval. The case was discussed at various meetings of Registration Board and it was decided to suspend the registration of Zentel Suspension till the verification of RCA and CAPA that were taken by them.

#### **OBSERVATIONS OF PANEL:**

The panel was briefly informed about the investigations carried out by the firm in this quality failure and actions taken to avoid such failures in future. The panel thoroughly reviewed the relevant documents and observed that the firm had inadvertently changed the product specification from manufactures specification to USP without reviewing relevant labeling information provided therein. However that change had not affected the quality and safety of product at any cost and the same was thoroughly assessed through proper required quality checks. As the case was highlighted the firm halted their production, stopped releasing new batches into the market and had also initiated recall process and communicated the DRAP Islamabad the relevant records in the connection. The production activities were resumed after rectifying the label errors. Their investigation further resulted that the Zental suspension should have been no compendia as it was wrongly picked-up from USP, however proper change control had also been taken while switching over to USP. The initial change was also submitted to DRAP for necessary approval. The firm had thought that as Albendazole was included in USP so the liquid must had also been included. The staff that was engaged in the task had mistakenly picked the wrong specification for liquid. There were certain gaps identified which had to complied while incorporating and approving the changes at some stages.

#### **MEASURES TAKEN BY FIRM AFTER FAILURE:**

The firm had lacked some SOPs and methods for detailed evaluation of pharmacopeia specifications. In short, the frim identified that three were procedural gaps and lapses that had caused failures. After ascertaining the error the firm started to take measures to avoid such failures in future thus all other products manufactured by Ms. GSK Pakistan at this site were reviewed in detail.r.t product specifications, SOPs for inclusion and exclusion of specifications were reevaluated, necessary trainings to cope up such issues in future. Audit plans were also revised and a comprehensive checklist has been kept in place to review, approve and incorporate any change in the labels of products. In short the all

required measures have satisfactorily been carried out to mitigate labeling errors in future.

#### **CONCLUSION:**

During the detail review and investigation, the panel observed that the firm had satisfactorily identified the gaps caused that labeling error and necessary actions had also been taken to avoid such errors in future. Based on the stated facts the panel unanimously recommends the resumption of Zentel liquid production in larger public interest as there may be acute shortage of quality de-worm drug into the market."

#### **Proceedings and Decision of 317th Meeting of Registration Board:**

The report of PSI was discussed and the Board after thorough deliberations and considering the facts of the case decided as follows:

- i. To restore registration of Zental Suspension, Registration No.006730.
- ii. The Board advised to submit the status of 14 batches ordered to be redressed by Registration Board in its 312<sup>th</sup> meeting and the procedure adopted/or to be adopted for redressing.

## Case No. 02: CASE REFERED BY PQCB, PUNJAB REGARDING REGULATORY METHOD OF ANALYSIS OF HEMOROSE-F TABLETS SUBMITTED BY M/S NEOMEDIX PHARMA.

The Secretary, Provincial Quality Control Board, Punjab vide reference No. PQCB/F-Isu-Bwp-05/06/19 dated 20-02-2019 has informed that Director DTL Faisalabad vide letter no. 8054/DTL/FSD dated 26-01-2019 stated that the lab has received sample of Tab. Hemorose-F (iron polymaltose complex + Folic acid) manufactured by M/S Neomedix bearing batch No. 484 from Drug Inspector Aziz Bhatti Shaheed Teaching Hospital Gujrat on 27-12-2018.

That requests for the provision of method was sent to manufacturer vide letter no. 6007/DTL/FSD dated 29-12-2018 and 23-01-2019 respectively. The method of analysis was found to be not workable for folic acid as the mentioned concentration (0.00007 mg/ml) for both sample and standard was below the limit of identification and quantification on UV at 280nm.

#### PROCEEDINGS AND DECISION:

Subject issue was considered by the Committee of the Provincial Quality Control Board, under section 11 of the Drugs Act 1976 in its 6<sup>th</sup> meeting held on 20-02-2019. Secretary PQCB apprised the Committee about background of the subject matter which was discussed at length and directed Drugs Testing Laboratory, Faisalabad to file the above-mentioned case. The Board observed that all the manufacturers/ drug registration certificate holders are legally bound to provide product specification and method of analysis to the Government analyst/Drug Testing Laboratories. The need for product specifications /method of analysis becomes more critical when the drug is not available in official pharmacopoeias and/or the manufacturer has its own customized specifications/method for analysis. In such circumstances it becomes quite challenging and almost impossible for a Government Analyst to conduct testing of the drug sample on such method provided by the firm on which sample as well as standard is not responding. The Board expressed its serious concerns over casual behavior on the part of the firms in this regard.

The Committee after due discussion and deliberation unanimously decided to recommend DRAP for the cancellation of registration of the above-mentioned product as the manufacturer ignored the dissolution criteria of the official monograph and also provided a method to the Govt. Analyst which is full of mistakes.

#### Proceeding and Decision of 291st meeting of Registration Board.

The case was presented before the Registration Board in its 291st meeting held on 04<sup>th</sup> September, 2019 and the Board after detailed discussion decided as under:

"To issue the show cause notice and personal hearing to the firm/ responsible persons as provided by the provincial quality control board (PQCB), Lahore. You failed to fulfill the condition of registration as prescribed under the rules because the method of test/analysis method provided by you was non responsive for test analysis of Folic acid and is defective. (The method of analysis was found to be not workable for folic acid as the mentioned concentration (0.00007 mg/ml) for both sample and standard was below the limit of identification and quantification on UV at 280nm.). You are required to explain your position that why the registration of your product i.e. Tab. Hemorose-F (iron polymaltose complex + Folic acid) should not be suspended/cancelled."

Show cause notice was served to the firm as per decision of the Registration Board vide No.F.03-41/2019-QC (291st RB) dated 25-10-2019.

M/s Neomedix Pharma, Islamabad submitted their reply vide reference No. nil dated 06-11-2019 addressed to the Secretary, Registration Board regarding the subject of RE: Letter No.03-41/2019-QC Dated 25th October, 2019 wherein they have stated that "we would like to thank you for offering us the opportunity to be heard in person. Kindly give us a suitable date and time so we pay appear to your kind office and explain our case in detail."

#### Proceedings of 293rd meeting of the Registration Board.

Malik Shahid GM, (37405-4576435-1) and Ghulam of M/s Neomedix Pharma appeared on behalf of M/s Neomedix Pharma for instant case and stated that Quality Control Manager of the firm at that time submitted the method of analysis to the Provincial Quality Control Board which was not working/responding. Later on they submitted a new & validated method to the Provincial Quality Control Board but they told that it's too late now.

#### Decision of 293rd meeting of Registration Board.

Registration Board in its 293rd meeting after detailed discussion decided as under:

- i. Suspension of the Registration of the said product for six (06) months or till the verification of root cause analysis, Corrective and preventive action (CAPA) by the firm, product development data and verification of aforementioned points and Product Specific Inspection by following panel whichever is later.
  - Dr. Qurban Ali, Member Registration Board
  - Area Federal Inspector of Drugs.
  - Mr. Haseeb Tariq AD PEC

The decision of the Board was communicated to the panel vide letter No. 03-65/219-QC-(293<sup>rd</sup> RB) dated 21-04-2020 wherein the Federal Inspector of Drugs-II Islamabad submitted as under:

"Kindly refer to the subject cited above and letter No.03-65/2019-QC- (293rd RB) dated 21-04-2020. It is submitted that a panel comprising of following members namely Dr. Qurban Ali Member Registration Board area FID and Mr. Haseeb Tariq AD, PEC was constituted with a direction to area FID-II implement the decision of the in letter in spirit and delivery of letter to the firm.

02. The letter has been delivered to the firm and case was discussed with members of the panel who opined that if the firm provides the CAPA then inspection may not be necessary. The firm on 07-08-2020 provided a CAPA report along with all Batch history of batch No. 484 in 2018 and 2020 and same has been forwarded to members with the points raised for PSI. The firm complied with the documentary evidence of CAPA and batch record. The members of the panel in consonance with the member registration Board (Dr. Qurban Ali). The panel in the light of evaluation of submitted documents (CAPA) by the firm is of opinion that the inspection may not be necessary for the said product. The same copy of the CAPA has already been submitted AD QC-II. The firm provided the report (BMR) and the test analysis reports dated May 2020 July 2020 same has been provided and sent to the members for perusal and directions. No directions/comments received from the members so letter is being sent to the Secretary Registration Board for record please."

In the above-mentioned reply, FID-II Islamabad has stated that the firm submitted CAPA to the panel members. The panel members were of opinion that in the light of submitted CAPA, the inspection may not be necessary.

Contrary to the statement of FID-II Islamabad, no such reply/comment/consonance has been received from the other panel members and also as per available record in the section no CAPA has been received from neither the firm nor FID-II Islamabad.

FID-II Islamabad vide letter No. F. 03-13/2005-FID-I(Isd) dated 14-06-2021 submitted the request of firm for resumption of production as under:

"In continuation of this office letter of even No. dated 20th August 2020 (Copy enclosed). The subject matter has been discussed with the members of panel, regarding the product namely Hemorose-F Tablet which had been suspended since more than six months as per decision of Registration Board taken before in its 293rd meeting held on 06-08th January 2020 (Copy enclosed). The firm had not manufactured the subject product since more than six months (copy enclosed). 02. In view of directions of the Registration Board the firm had complied with the decision of the Board and now requesting for resumption of production of Hemorose-F Tablet (Copy enclosed) which had been suspended. The panel members had also been kept on Board and agreed to the decision/directions of Registration Board."

#### Proceedings and Decision of 312<sup>th</sup> meeting:

The Board after thorough deliberations and considering the reply of area Federal Inspector of Drugs discussed the matter with the other panel members i.e. Dr. Qurban Ali and Mr. Haseeb Tariq. Both members were unaware of such communication as stated by area Federal Inspector of Drugs. The Board showed serious concern over the reply of area Federal Inspector of Drugs and decided as under:

- i. Suspension of the Registration of the said product till the verification of root cause analysis, Corrective and preventive action (CAPA) by the firm, product development data and verification of aforementioned points and Product Specific Inspection by following panel whichever is later.
  - a. Dr. Qurban Ali, Member Registration Board
  - b. Ms. Mehwish Tanveer, Assistant Director QA&LT
  - c. Mr. Haseeb Tariq Assistant Director PEC

ii. Refer the case to Chief Executive Officer DRAP for taking disciplinary action against the area FID Islamabad for not complying Registration Board directions and mis-quoting other members of Registration Board.

In compliance to the decision of Registration Board, panel mentioned in para. 14 (i) visited the premises of M/s. Neomedix Pharmaceuticals Islamabad on 06-04-2022 for the purpose of verification of Root cause analysis, Corrective and preventatinve action and product development data for Hemorose-F tablet. Details of report as under:

#### "DETAILS OF INSPECTION

The firm was informed about the schedule of the inspection vide letter No. F. 15-1/2022-PRC dated  $1^{st}$  April 2022 by Assistant Director (PEC-III) after coordination with other panel members.

The panel visited the factory premises of M/s Neomedix located at Plot No. 05, N/5 National Industrial Zone, Islamabad on 06-04-2022. The following representatives / management of the firm were present at the premises:

- 1. Mr. Faisal Muzamal (Partner)
- 2. Mr. Syed Talib Hussain Hashmi (Partner)
- 3. Ghulam Ghaus (QC Manager)
- 4. Muhammad Shoaib (Production Manager)

The management of the firm informed the panel that they have recently purchased this unit and applied for change of management in Licensing Division DRAP in January 2022. The management informed that they have not yet got the complete possession of this unit and therefore no production activities are carried out. The firm also presented copy of letter for change of management of M/s Neomedix dated 4<sup>th</sup> July 2022 submitted to the Secretary Licensing Board (Annexure-I). The management further informed that since they have recently purchased the unit therefore they have not completed Root Cause Analysis, Corrective and Preventive Action (CAPA) and product development data for Hemorose-F tablets.

The management submitted a written request for provision of some time for performing Root Cause Analysis, Corrective and Preventive Action (CAPA) and product development data for Hemorose-F tablets (Annexure-II). The written request of the firm is as below:

Dear sir,

Referring to your letter No. F.15-1/2022-PEC dated 1<sup>st</sup> April 2022 and visit of inspection panel on 6<sup>th</sup> April, 2022, it is submitted that we have purchased this premises and submitted the letter of change of management in Licensing Division DRAP, in first week of January (Letter attached) and according to agreement, we will get complete possession of Neomedix in May 2022.

It is submitted that due to change of management and that till date we have not received full possession of premises, we have not completed Root Cause Analysis, CAPA and product development.

Kindly grant us 90 days after the full possession, so we could complete RCA, CAPA and product development in a better way.

Thanks and best regards,

For Neomedix,

Faisal Muzamal Syed Talib Hussain

(Partner) (Partner)

The management of the firm showed positive attitude for performing Root Cause Analysis, Corrective and Preventive Action (CAPA) and product development data for Hemorose-F tablets. The request of the firm is submitted for consideration by the Registration Board."

#### Proceedings and Decision of 317th Meeting of Registration Board.

Registration Board after thorough discussion and deliberations and considering the report of PSI and firm's request decided to advise panel for inspection of the firm in June 2022 for verification of CAPA and submit a report for consideration of the Board."

#### **I&E Section Islamabad Cases**

Case No: I: IMPORT OF SUB-STANDARD RIVAROXABAN (RAW MATERIAL) MFG. DATE: 09-07-2019, EXP. DATE: 08-07-2023, BATCH NO. 032-190706U, MANUFACTURED BY M/S ZHEJIANG SUPOR PHARMA, CHINA. IMPORTED BY M/S SHAIGAN PHARMACEUTICALS (PVT.) LTD. 14 KM, ADYALA ROAD, POST OFFICE DAHGAL, RAWALPINDI.

The Central Drugs Laboratory / Government Analyst vide Report No. RM.88/2019 dated 20<sup>th</sup> February 2020 on Form 6 (See Rule 16) received in this office on 09-03-2020 declared that the samples Rivaroxaban (Raw Material) (taken by the Assistant Director (I&E), Islamabad from the premises of M/s Shaigan Pharmaceuticals (Pvt.) Ltd. 14 Km, Adyala Road, Post Office Dahgal, Rawalpindi on 18-12-2019 under Rule 9 read with 14(a) of The Drugs (Import & Export) Rules, 1976) having following details have been declared as of "Sub-standard quality" by the CDL, Karachi on the basis of Melting Point and Assay for Rivaroxaban:

Sr.	Name of	Batch /	Mfg.	Manufactured	Finished Products	Registration
No.	Sample	Lot No.	Date /	By	in which Raw	No(s).
			Exp.		Material is to be	
			Date		used	
1.	Rivaroxaban	032-	Mfg: 09-	M/s Zhejiang	Embex Forte Tablets	090009
		190706U	07-2019	Supor Pharma,	Embex DS Tablets	
			Exp: 08-	China.	Embex Tablets	
			07-2023			090010
						090011

The firm vide their letter dated March 24, 2020 Dy. No. 5274 (R&I) dated 25/3/2020 received in this office on 06/04/2020 vide Diary No. 141/AD(I&E) requested for appellate testing and the same was forwarded to appellate laboratory through AD (QC-II) vide F.No. 03-15/2020-QC dated 30-09-2020. The firm's response is reproduced as under: -

With reference to your letter No. F.10-4/19-AD(I&E-1V)Pt dated 16<sup>th</sup> March 2020, received in Shaigan Pharmaceutical on 19.03.2020, wherein, the raw material Rivaroxaban, batch No. 032-190706U mfg. date 09-07-2019 Expiry date 08-07-2023 was declared as substandard vide CDL Karachi test analysis report RM.88/2019 dated 20.02.2020.

SHAIGAN Pharmaceutical is a responsible law-abiding company, which not only maintain cGMP standard but also has an independent well-quipped Testing & Research Quality Control laboratory accredited from PNAC for ISO/IEC 17025:2017. Since inception, SHAIGAN has grown from being a relatively humble contender to being one of the fastest growing companies in the Pakistani Pharmaceutical Arena, the company's aim to become the benchmark in the pharmaceutical industry. The same lot also has been tested in our lab as well and all results are within specifications. (report and Chromatograms are attached). Moreover, equipment used for physical tests bears internationally traceable calibration and

verified frequently with proficiency test standards Pharmassure UK (report attached) to ensure equipment performance.

We have found CDL test report No RM.88/2019 dated 20.02.2020 as vague on the following grounds;

- ➤ Prints of weight taken from analytical balance for sample and working standard are not attached to verify sample and standard concentrations.
- ➤ Chromatograms for assay test are not provided along with CDL Report.
- > System suitability parameters for HPLC analysis such as tailing factor and Relative Standard Deviation (RSD) are compulsory while CDL Report lacking this information

### <u>It is respectfully requested to null and void the CDL Test Report and re-test the said raw material at appropriate forum.</u>

Further we confirm that the said Raw Material has not been utilized and no batch has been manufactured yet as we are waiting for the decision of competent authority.

Subsequently, AD QC-II vides letter F. No. 03-15/2020-(QC) dated 01<sup>st</sup> December 2020, shared the appellate lab's report No. No.019-M/2020 dated 18<sup>th</sup> November 2020 for testing of above Raw Material wherein it is concluded as follows: -

"Conclusion: Complies with Shaigan Specification.

The sample is of **Standard** quality on the basis of tests performed."

The summary of the two reports is reproduced as follows: -

Sr.	sts Performed	Limits	Resi	ults	Remarks	
No			CDL	Appellate	CDL	Appellate
•						
01.	Description	-	White Powder	White powder	The sample is	Complies with
				contained in	of "Sub-	Shaigan
				sealed	Standard"	Specification.
				polythene bag.	quality under	The sample is
02.	Identification	-	Rivaroxaban	Rivaroxaban	the Drugs Act,	of <b>Standard</b>
			identified	identified	1976.	quality on the
03.	Melting Point	228°C	236°C	Not		basis of tests
		to	<b>Does not</b>	performed		performed.
		232°C	comply			
04.	Assay for	98.0%	79.9%	100.67%		
	Rivaroxaban	to	<b>Does not</b>			
		102.0%	comply			

M/s Shaigan Pharmaceuticals (Pvt.) Ltd. 14 Km, Adyala Road, Post Office Dahgal, Rawalpindi vide letter number Nil dated 17<sup>th</sup> December, 2020 (received in this office on 31-12-2020) have referred to the appellate laboratory's test report No.019-M/2020 dated 18<sup>th</sup> November 2020 and requested to remove the condition {of utilization restriction, imposed by the then AD (I&E)} and have requested permission for use of material (Rivaroxaban Batch No. 032-190706U, Mfg: 09-07-2019 Exp: 08-07-2023, Manufactured by M/s Zhejiang Supor Pharma, China) for manufacturing purpose.

The firm's request was referred for perusal / approval of the Competent Authority i.e. CEO, DRAP. The Competent Authority referred the case to Board to decide keeping in view all the Pros and Cons.

#### Proceedings & Decision of 307th Meeting of Registration Board

The case is deferred for next meeting due to paucity of time.

#### Proceedings & Decision of 308th Meeting of Registration Board

The board deferred the case and advised the section to pen down the Pros and Cons.

In compliance to the decision of 308<sup>th</sup> meeting of the Registration Board, Pros and Cons of the matter are given as under:

PRO(s)	CON(s)
Since the product has been passed by the Appellate Lab i.e. NIH Islamabad, therefore, as per relevant rules, the Rivaroxaban API - Batch / Lot No. 032-190706U may be released.	<ul> <li>As evident from the case discussed, CDL Karachi has failed the sample to Rivaroxaban API - Batch / Lot No. 032-190706U as of substandard quality on the basis of Assay and Melting Point. However, Appellate Lab i.e. NIH Islamabad has cleared the said API on the basis of standard assay and has not performed Melting Point Analysis.</li> <li>Also, the Rivaroxaban API - Batch / Lot No. 032-190706U is near to its expiry (Approx. 31% Remaining Shelf Life) therefore, the quality of the said substance is also of concern as no Impurity Profile has been performed during the testing from CDL and Appellate Lab.</li> </ul>

Proceedings and Decision of 317th Meeting of Registration Board.

Registration Board after thorough discussion and deliberations and considering the facts of the case decided to recommend for processing of case as per report of Appellate laboratory.

The meeting ended with the vote of thanks to and from the Chair.

= = = = End of document = = = = =